PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Blanco, J; Bosch, B; Fernandez-Figueras, MT; Barretina, J; Clotet, B; Este, JA				Blanco, J; Bosch, B; Fernandez-Figueras, MT; Barretina, J; Clotet, B; Este, JA			High level of coreceptor-independent HIV transfer induced by contacts between primary CD4 T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1; ENTRY; INFECTION; LYMPHOCYTES; PROTEIN; CYTOSKELETON; ENDOCYTOSIS; RECEPTOR; BINDING	Cell-to-cell virus transmission is one of the most efficient mechanisms of human immunodeficiency virus (HIV) spread, requires CD4 and coreceptor expression in target cells, and may also lead to syncytium formation and cell death. Here, we show that in addition to this classical coreceptor-mediated transmission, the contact between HIV-producing cells and primary CD4 T cells lacking the appropriate coreceptor induced the uptake of HIV particles by target cells in the absence of membrane fusion or productive HIV replication. HIV uptake by CD4 T cells required cellular contacts mediated by the binding of gp120 to CD4 and intact actin cytoskeleton. HIV antigens taken up by CD4 T cells were rapidly endocytosed to trypsin-resistant compartments inducing a partial disappearance of CD4 molecules from the cell surface. Once the cellular contact was stopped, captured HIV were released as infectious particles. Electron microscopy revealed that HIV particles attached to the surface of target cells and accumulated in large (0.5 - 1.0 mum) intracellular vesicles containing 1 - 14 virions, without any evidence for massive clathrin-mediated HIV endocytosis. The capture of HIV particles into trypsin-resistant compartments required the availability of the gp120 binding site of CD4 but was independent of the intracytoplasmic tail of CD4. In conclusion, we describe a novel mechanism of HIV transmission, activated by the contact of infected and uninfected primary CD4 T cells, by which HIV could exploit CD4 T cells lacking the appropriate coreceptor as an itinerant virus reservoir.	Hosp Univ Germans Trias & Pujol, Fdn IrsiCaixa, Lab Retrovirol, Barcelona 08916, Spain; Hosp Univ Germans Trias & Pujol, Dept Pathol, Barcelona 08916, Spain	Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Hospital Germans Trias i Pujol	Blanco, J (corresponding author), Hosp Univ Germans Trias & Pujol, Fdn IrsiCaixa, Lab Retrovirol, Ctra Canyet S-N, Barcelona 08916, Spain.	jblanco@ns.hugtip.scs.es	Este, Jose/B-5509-2008; Blanco, Julià/A-5347-2008; Barretina, Jordi/A-7192-2013	Este, Jose/0000-0002-1436-5823; Blanco, Julià/0000-0002-2225-0217; Barretina, Jordi/0000-0002-3478-4080				Barretina J, 2003, ANTIVIR THER, V8, P155; BEDINGER P, 1988, NATURE, V334, P162, DOI 10.1038/334162a0; Blanco J, 2002, AIDS RES HUM RETROV, V18, P27, DOI 10.1089/088922202753394691; Blanco J, 2001, VIROLOGY, V285, P356, DOI 10.1006/viro.2001.0969; Blanco J, 1999, AIDS, V13, P909, DOI 10.1097/00002030-199905280-00006; Blanco J, 2003, VIROLOGY, V305, P318, DOI 10.1006/viro.2002.1764; Blanco J, 2004, J LEUKOCYTE BIOL, V76, P804, DOI 10.1189/jlb.0204100; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42; Campbell EM, 2004, J VIROL, V78, P5745, DOI 10.1128/JVI.78.11.5745-5755.2004; Carlin LM, 2001, J EXP MED, V194, P1507, DOI 10.1084/jem.194.10.1507; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215; Deschambeault J, 1999, J VIROL, V73, P5010, DOI 10.1128/JVI.73.6.5010-5017.1999; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dustin ML, 2002, SCIENCE, V298, P785, DOI 10.1126/science.1076386; EWING EP, 1983, NEW ENGL J MED, V308, P819, DOI 10.1056/NEJM198304073081407; Fackler OT, 2000, CURR BIOL, V10, P1005, DOI 10.1016/S0960-9822(00)00654-0; FAIS S, 1995, AIDS, V9, P329, DOI 10.1097/00002030-199509040-00003; Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GENDELMAN HE, 1987, VIROLOGY, V160, P323, DOI 10.1016/0042-6822(87)90002-X; Goto T, 1998, MICRON, V29, P123, DOI 10.1016/S0968-4328(98)00002-X; HEALEY D, 1990, J EXP MED, V172, P1233, DOI 10.1084/jem.172.4.1233; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KIELIAN M, 1990, MOL BIOL MED, V7, P17; Lagaye S, 2001, J VIROL, V75, P4780, DOI 10.1128/JVI.75.10.4780-4791.2001; Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002; Llano A, 2003, J VIROL, V77, P4389, DOI 10.1128/JVI.77.7.4389-4395.2003; MADDON PJ, 1988, CELL, V54, P865, DOI 10.1016/S0092-8674(88)91241-X; Marechal V, 1998, J VIROL, V72, P2208; Marechal V, 2001, J VIROL, V75, P11166, DOI 10.1128/JVI.75.22.11166-11177.2001; McDonald D, 2003, SCIENCE, V300, P1295, DOI 10.1126/science.1084238; PEARCEPRATT R, 1994, J VIROL, V68, P2898, DOI 10.1128/JVI.68.5.2898-2905.1994; PELCHENMATTHEWS A, 1993, J EXP MED, V178, P1209, DOI 10.1084/jem.178.4.1209; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; SATO H, 1992, VIROLOGY, V186, P712, DOI 10.1016/0042-6822(92)90038-Q; Schaeffer E, 2004, J VIROL, V78, P1375, DOI 10.1128/JVI.78.3.1375-1383.2004; Sjostrom A, 2001, J EXP MED, V194, P1519, DOI 10.1084/jem.194.10.1519; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; Vidricaire G, 2003, J BIOL CHEM, V278, P15832, DOI 10.1074/jbc.M210470200	45	85	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51305	51314		10.1074/jbc.M408547200	http://dx.doi.org/10.1074/jbc.M408547200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371410	hybrid			2022-12-25	WOS:000225355800080
J	Collis, SJ; Schwaninger, JM; Ntambi, AJ; Keller, TW; Nelson, WG; Dillehay, LE; DeWeese, TL				Collis, SJ; Schwaninger, JM; Ntambi, AJ; Keller, TW; Nelson, WG; Dillehay, LE; DeWeese, TL			Evasion of early cellular response mechanisms following low level radiation-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; HISTONE H2AX PHOSPHORYLATION; DOSE HYPER-RADIOSENSITIVITY; IONIZING-RADIATION; GENOMIC INSTABILITY; ATM ACTIVATION; CELLS; REPAIR; SENSITIVITY; EXPOSURE	DNA damage that is not repaired with high fidelity can lead to chromosomal aberrations or mitotic cell death. To date, it is unclear what factors control the ultimate fate of a cell receiving low levels of DNA damage (i.e. survival at the risk of increased mutation or cell death). We investigated whether DNA damage could be introduced into human cells at a level and frequency that could evade detection by cellular sensors of DNA damage. To achieve this, we exposed cells to equivalent doses of ionizing radiation delivered at either a high dose rate (HDR) or a continuous low dose rate (LDR). We observed reduced activation of the DNA damage sensor ataxia-telangiectasia mutated (ATM) and its downstream target histone H2A variant (H2AX) following LDR compared with HDR exposures in both cancerous and normal human cells. This lack of DNA damage signaling was associated with increased amounts of cell killing following LDR exposures. Increased killing by LDR radiation has been previously termed the "inverse dose rate effect," an effect for which no clear molecular processes have been described. These LDR effects could be abrogated by the preactivation of ATM or simulated in HDR-treated cells by inhibiting ATM function. These data are the first to demonstrate that DNA damage introduced at a reduced rate does not activate the DNA damage sensor ATM and that failure to activate ATM-associated repair pathways contributes to the increased lethality of continuous LDR radiation exposures. This inactivation may reflect one strategy by which cells avoid accumulating mutations as a result of error-prone DNA repair and may have a broad range of implications for carcinogenesis and, potentially, the clinical treatment of solid tumors.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Oncol, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Urol, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	DeWeese, TL (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Dept Radiat Oncol & Mol Radiat Sci, Canc Res Bldg,Rm 144,1650 Orleans St, Baltimore, MD 21231 USA.	deweete@jhmi.edu		Collis, Spencer/0000-0002-7874-1891				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banath JP, 2003, CANCER RES, V63, P4347; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Collis SJ, 2003, CANCER RES, V63, P1550; DEALMODOVAR JMR, 1994, RADIAT RES, V138, pS93, DOI 10.2307/3578771; DeWeese TL, 1997, INT J RADIAT ONCOL, V37, P145, DOI 10.1016/S0360-3016(96)00448-8; Deweese TL, 1998, J UROLOGY, V159, P591, DOI 10.1016/S0022-5347(01)63990-9; Downs JA, 2003, NATURE, V424, P732, DOI 10.1038/424732a; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; HALL EJ, 1994, RADIOBIOLOGY RADIOLO, P45; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; Joiner MC, 2001, INT J RADIAT ONCOL, V49, P379, DOI 10.1016/S0360-3016(00)01471-1; KNOX SJ, 1993, RADIAT RES, V135, P24, DOI 10.2307/3578392; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; MacPhail SH, 2003, INT J RADIAT BIOL, V79, P351, DOI 10.1080/0955300032000093128; MARIN LA, 1991, INT J RADIAT ONCOL, V21, P397, DOI 10.1016/0360-3016(91)90788-6; Marples B, 2003, RADIAT RES, V160, P38, DOI 10.1667/RR3013; Marples B, 2004, RADIAT RES, V161, P247, DOI 10.1667/RR3130; Mitchell CR, 2002, RADIAT RES, V158, P311, DOI 10.1667/0033-7587(2002)158[0311:EOETLD]2.0.CO;2; MITCHELL JB, 1979, RADIAT RES, V79, P520, DOI 10.2307/3575178; NAGASAWA H, 1992, RADIAT RES, V132, P375, DOI 10.2307/3578247; Olive PL, 2004, INT J RADIAT ONCOL, V58, P331, DOI 10.1016/j.ijrobp.2003.09.028; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vilenchik MM, 2000, P NATL ACAD SCI USA, V97, P5381, DOI 10.1073/pnas.090099497; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002	40	112	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49624	49632		10.1074/jbc.M409600200	http://dx.doi.org/10.1074/jbc.M409600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377658	hybrid			2022-12-25	WOS:000225229500012
J	Gomes, AV; Venkatraman, G; Davis, JP; Tikunova, SB; Engel, P; Solaro, RJ; Potter, JD				Gomes, AV; Venkatraman, G; Davis, JP; Tikunova, SB; Engel, P; Solaro, RJ; Potter, JD			Cardiac troponin T isoforms affect the Ca2+ sensitivity of force development in the presence of slow skeletal troponin I - Insights into the role of troponin T isoforms in the fetal heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; MAGNESIUM BINDING-SITES; MUSCLE CONTRACTION; CALCIUM-BINDING; TRANSGENIC MICE; REGULATORY SITES; FAILING HEART; RABBIT HEART; MOUSE HEART; EXPRESSION	In this study we investigated the physiological role of the cardiac troponin T (cTnT) isoforms in the presence of human slow skeletal troponin I (ssTnI). ssTnI is the main troponin I isoform in the fetal human heart. In reconstituted fibers containing the cTnT isoforms in the presence of ssTnI, cTnT1-containing fibers showed increased Ca2+ sensitivity of force development compared with cTnT3- and cTnT4-containing fibers. The maximal force in reconstituted skinned fibers was significantly greater for the cTnT1 (predominant fetal cTnT isoform) when compared with cTnT3 (adult TnT isoform) in the presence of ssTnI. Troponin (Tn) complexes containing ssTnI and reconstituted with cTnT isoforms all yielded different maximal actomyosin ATPase activities. Tn complexes containing cTnT1 and cTnT4 (both fetal isoforms) had a reduced ability to inhibit actomyosin ATPase activity when compared with cTnT3 (adult isoform) in the presence of ssTnI. The rate at which Ca2+ was released from site II of cTnC in the cTnI.cTnC complex (122/s) was 12.5-fold faster than for the ssTnI.cTnC complex (9.8/s). Addition of cTnT3 to the cTnI.cTnC complex resulted in a 3.6-fold decrease in the Ca2+ dissociation rate from site II of cTnC. Addition of cTnT3 to the ssTnI.cTnC complex resulted in a 1.9-fold increase in the Ca2+ dissociation rate from site II of cTnC. The rate at which Ca2+ dissociated from site II of cTnC in Tn complexes also depended on the cTnT isoform present. However, the TnI isoforms had greater effects on the Ca2+ dissociation rate of site II than the cTnT isoforms. These results suggest that the different N-terminal TnT isoforms would produce distinct functional properties in the presence of ssTnI when compared with cTnI and that each isoform would have a specific physiological role in cardiac muscle.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Miami; University of Miami; University System of Ohio; Ohio State University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL067415, P01HL062426, T32HL007692, R01HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR020792] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07692, HL62426, HL 42325, HL67415, HL073600] Funding Source: Medline; NIAMS NIH HHS [AR20792] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDERSON PAW, 1991, CIRC RES, V69, P1226, DOI 10.1161/01.RES.69.5.1226; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; Barton PJR, 2004, MOL CELL BIOCHEM, V263, P91, DOI 10.1023/B:MCBI.0000041851.53074.72; Davis JP, 2004, J BIOL CHEM, V279, P17348, DOI 10.1074/jbc.M314095200; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; Fiske CH, 1925, J BIOL CHEM, V66, P375; GAO LH, 1995, J MOL CELL CARDIOL, V27, P541, DOI 10.1016/S0022-2828(08)80049-1; Gomes AV, 2002, J BIOL CHEM, V277, P35341, DOI 10.1074/jbc.M204118200; GUTH K, 1987, J BIOL CHEM, V262, P13627; Hazard AL, 1998, PROTEIN SCI, V7, P2451, DOI 10.1002/pro.5560071123; HILL LE, 1992, J BIOL CHEM, V267, P16106; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; Huang XP, 1999, CIRC RES, V84, P1; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; Johnson JD, 1996, J BIOL CHEM, V271, P761, DOI 10.1074/jbc.271.2.761; JOHNSON JD, 1978, J BIOL CHEM, V253, P3775; Lehman W, 2000, J MOL BIOL, V302, P593, DOI 10.1006/jmbi.2000.4080; MCAULIFFE JJ, 1990, CIRC RES, V66, P1204, DOI 10.1161/01.RES.66.5.1204; Metzger JM, 2003, J BIOL CHEM, V278, P13118, DOI 10.1074/jbc.M212601200; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Moore DD, 1995, GLOB MOB SURV; Morimoto S, 2000, BIOCHEM BIOPH RES CO, V267, P912, DOI 10.1006/bbrc.1999.2068; NASSAR R, 1991, CIRC RES, V69, P1470, DOI 10.1161/01.RES.69.6.1470; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; Parsons B, 1997, J MUSCLE RES CELL M, V18, P599, DOI 10.1023/A:1018623604365; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; SCHACHAT FH, 1987, J MOL BIOL, V198, P551, DOI 10.1016/0022-2836(87)90300-7; Schaertl S, 1995, BIOCHEMISTRY-US, V34, P15890, DOI 10.1021/bi00049a003; Siedner S, 2003, J PHYSIOL-LONDON, V548, P493, DOI 10.1113/JPHYSIOL.2002.036509; SWEENEY HL, 1990, P NATL ACAD SCI USA, V87, P9538, DOI 10.1073/pnas.87.24.9538; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Tikunova SB, 2004, J BIOL CHEM, V279, P35341, DOI 10.1074/jbc.M405413200; Tikunova SB, 2002, BIOCHEMISTRY-US, V41, P6697, DOI 10.1021/bi011763h; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Westfall MV, 1997, P NATL ACAD SCI USA, V94, P5444, DOI 10.1073/pnas.94.10.5444; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	49	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49579	49587		10.1074/jbc.M407340200	http://dx.doi.org/10.1074/jbc.M407340200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358779	hybrid			2022-12-25	WOS:000225229500007
J	Loschi, L; Brokx, SJ; Hills, TL; Zhang, G; Bertero, MG; Lovering, AL; Weiner, JH; Strynadka, NCJ				Loschi, L; Brokx, SJ; Hills, TL; Zhang, G; Bertero, MG; Lovering, AL; Weiner, JH; Strynadka, NCJ			Structural and biochemical identification of a novel bacterial oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMETHYL-SULFOXIDE REDUCTASE; HUMAN SULFITE OXIDASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ALDEHYDE OXIDOREDUCTASE; XANTHINE DEHYDROGENASE; RHODOBACTER-CAPSULATUS; ANGSTROM RESOLUTION; NITRATE REDUCTASE; ELECTRON-TRANSFER	By using a bioinformatics screen of the Escherichia coli genome for potential molybdenum-containing enzymes, we have identified a novel oxidoreductase conserved in the majority of Gram-negative bacteria. The identified operon encodes for a proposed heterodimer, YedYZ in Escherichia coli, consisting of a soluble catalytic subunit termed YedY, which is likely anchored to the membrane by a heme-containing trans-membrane subunit termed YedZ. YedY is uniquely characterized by the presence of one molybdenum molybdopterin not conjugated by an additional nucleotide, and it represents the only molybdoenzyme isolated from E. coli characterized by the presence of this cofactor form. We have further characterized the catalytic subunit YedY in both the molybdenum- and tungsten-substituted forms by using crystallographic analysis. YedY is very distinct in overall architecture from all known bacterial reductases but does show some similarity with the catalytic domain of the eukaryotic chicken liver sulfite oxidase. However, the strictly conserved residues involved in the metal coordination sphere and in the substrate binding pocket of YedY are strikingly different from that of chicken liver sulfite oxidase, suggesting a catalytic activity more in keeping with a reductase than that of a sulfite oxidase. Preliminary kinetic analysis of YedY with a variety of substrates supports our proposal that YedY and its many orthologues may represent a new type of membrane-associated bacterial reductase.	Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ Alberta, Dept Biochem, Canadian Inst Hlth Res Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of British Columbia; University of Alberta	Strynadka, NCJ (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	natalie@byron.biochem.ubc.ca		Lovering, Andrew/0000-0002-1856-7975; Bertero, Michela/0000-0002-2012-6706				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENZ R, 1978, J BACTERIOL, V135, P1080, DOI 10.1128/JB.135.3.1080-1090.1978; Bertero MG, 2003, NAT STRUCT BIOL, V10, P681, DOI 10.1038/nsb969; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buc J, 1999, MOL MICROBIOL, V32, P159, DOI 10.1046/j.1365-2958.1999.01340.x; COHEN HJ, 1971, J BIOL CHEM, V246, P359; Czjzek M, 1998, J MOL BIOL, V284, P435, DOI 10.1006/jmbi.1998.2156; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELANO WL, 2002, PYMOL MOL GRPAHICS S; Dias JM, 1999, STRUCTURE, V7, P65, DOI 10.1016/S0969-2126(99)80010-0; Dobbek H, 1999, P NATL ACAD SCI USA, V96, P8884, DOI 10.1073/pnas.96.16.8884; Drew D, 2002, P NATL ACAD SCI USA, V99, P2690, DOI 10.1073/pnas.052018199; Ellis PJ, 2001, STRUCTURE, V9, P125, DOI 10.1016/S0969-2126(01)00566-4; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Feng CJ, 2003, BIOCHEMISTRY-US, V42, P12235, DOI 10.1021/bi0350194; Garrett RM, 1998, P NATL ACAD SCI USA, V95, P6394, DOI 10.1073/pnas.95.11.6394; GREENWOOD N, 1984, CHEM ELEMENTS, P170; Hille R, 2002, TRENDS BIOCHEM SCI, V27, P360, DOI 10.1016/S0968-0004(02)02107-2; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Johnson Jean L, 2002, Hum Mutat, V20, P74, DOI 10.1002/humu.9038; Kappler U, 2000, J BIOL CHEM, V275, P13202, DOI 10.1074/jbc.275.18.13202; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KRAULIS PJ, 1991, SCIENCE, V254, P581, DOI 10.1126/science.1658931; Lam CW, 2002, MOL GENET METAB, V75, P91, DOI 10.1006/mgme.2001.3267; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lim D, 2002, NAT STRUCT BIOL, V9, P870, DOI 10.1038/nsb858; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NEU HC, 1965, J BIOL CHEM, V240, P3685; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rebelo JM, 2001, J BIOL INORG CHEM, V6, P791, DOI 10.1007/s007750100255; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Sambrook J, 2001, MOL CLONING LAB MANU; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; Schneider F, 1996, J MOL BIOL, V263, P53, DOI 10.1006/jmbi.1996.0555; Schrader N, 2003, STRUCTURE, V11, P1251, DOI 10.1016/j.str.2003.09.001; SimalaGrant JL, 1996, MICROBIOL-SGM, V142, P3231, DOI 10.1099/13500872-142-11-3231; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; Stewart LJ, 2000, J MOL BIOL, V299, P593, DOI 10.1006/jmbi.2000.3702; STIEFEL EI, 1993, ACS S SERIES, V535; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wilson HL, 2004, J BIOL CHEM, V279, P15105, DOI 10.1074/jbc.M314288200	51	89	93	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50391	50400		10.1074/jbc.M408876200	http://dx.doi.org/10.1074/jbc.M408876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355966	hybrid			2022-12-25	WOS:000225229500104
J	Malygin, EG; Sclavi, B; Zinoviev, VV; Evdokimov, AA; Hattman, S; Buckle, M				Malygin, EG; Sclavi, B; Zinoviev, VV; Evdokimov, AA; Hattman, S; Buckle, M			Bacteriophage T4Dam DNA-(adenine-N-6)-methyltransferase - Comparison of pre-steady state and single turnover methylation of 40-mer duplexes containing two (un)modified target sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA N-6-ADENINE METHYLTRANSFERASE; ESCHERICHIA-COLI; GENE-EXPRESSION; PHAGE-T4 DNA; DAM; RESTRICTION; PURIFICATION; RECOGNITION; ENDONUCLEASE; MUTANTS	We analyzed pre-steady state and single turnover kinetics of bacteriophage T4Dam DNA-(adenine-N-6)methyltransferase- mediated methyl group transfer from S-adenosyl-L-methionine ( AdoMet) to 40-mer duplexes containing native recognition sites (5'-GATC/5'- GATC) or some modified variant(s). The results extend a model from studies with single-site 20-mer duplexes. Under pre-steady state conditions, monomeric T4Dam methyltransferase- AdoMet complexes were capable of rapid methylation of adenine residues in 40-mer duplexes containing two sites. During processive movement of T4Dam to the next site, the rate-limiting step was the exchange of the product S-adenosyl-L-homocysteine ( AdoHcy) for AdoMet without T4Dam dissociating from the duplex. Consequently, instead of a single exponential rate dependence, complex methylation curves were obtained with at least two pre-steady state steps. With 40-mer duplexes containing a single target site, the kinetics were simpler, fitting a single exponential followed by a linear steady state phase. Single turnover methylation of 40-mer duplexes also proceeded in two stages. First, two dimeric T4Dam-AdoMet molecules bound, and each catalyzed a two-step methylation. Instead of processive movement of T4Dam, a conformational adaptation occurred. We propose that following methyl transfer to one strand, dimeric ( T4Dam-AdoMet)-(T4Dam-AdoHcy) was capable of rapidly reorienting itself and catalyzing methyl transfer to the target adenine on the complementary, unmethylated strand. This second stage methyl transfer occurred at a rate about 25-fold slower than in the first step; it was rate-limited by Dam-AdoHcy dissociation or its clearance from the methylated complementary strand. Under single turnover conditions, there was complete methylation of all target adenine residues with each of the two-site 40-mer duplexes.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA; State Res Ctr Virol & Biotechnol Vector, Inst Mol Biol, Novosibirsk 630559, Russia; Ecole Normale Super, CNRS, UMR 8113, Lab Biotechnol & Pharmacol Genet Appl, F-94235 Cachan, France	University of Rochester; State Research Center of Virology & Biotechnology VECTOR; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay	Hattman, S (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.	modDNA@mail.rochester.edu	Evdokimov, Alexey/A-6485-2014; Sclavi, Bianca/AAT-4554-2021; sclavi, bianca/F-8536-2010; Ernst, Malygin/A-6741-2014	Sclavi, Bianca/0000-0002-3883-8592; 	FIC NIH HHS [R03 TW05755] Funding Source: Medline; NIGMS NIH HHS [GM29227] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW005755] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Bae SH, 2003, J BIOL CHEM, V278, P45987, DOI 10.1074/jbc.M306038200; Bheemanaik S, 2003, J BIOL CHEM, V278, P7863, DOI 10.1074/jbc.M211458200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELACAMPA AG, 1987, J MOL BIOL, V196, P457, DOI 10.1016/0022-2836(87)90024-6; Dong AP, 2004, BIOL CHEM, V385, P373, DOI 10.1515/bchm.385.13.373.57208; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P1579, DOI 10.1093/nar/20.7.1579; DUBEY AK, 1992, NUCLEIC ACIDS RES, V20, P31657; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goodsell DS, 2000, ANNU REV BIOPH BIOM, V29, P105, DOI 10.1146/annurev.biophys.29.1.105; Hattman S, 2004, PROG NUCLEIC ACID RE, V77, P67, DOI 10.1016/S0079-6603(04)77003-8; HATTMAN S, 1970, VIROLOGY, V42, P359, DOI 10.1016/0042-6822(70)90279-5; Heithoff DM, 1999, SCIENCE, V284, P967, DOI 10.1126/science.284.5416.967; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; KASZUBSKA W, 1992, GENE, V118, P5, DOI 10.1016/0378-1119(92)90242-H; KOSSYKH VG, 1995, J BIOL CHEM, V270, P14389, DOI 10.1074/jbc.270.24.14389; KURGANOV BI, 1982, ALLOSTERIC ENZYMES K, P151; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; Lobner-Olesen A, 2003, P NATL ACAD SCI USA, V100, P4672, DOI 10.1073/pnas.0538053100; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Malygin EG, 2003, J BIOL CHEM, V278, P41749, DOI 10.1074/jbc.M306397200; Malygin EG, 2001, NUCLEIC ACIDS RES, V29, P2361, DOI 10.1093/nar/29.11.2361; MINER Z, 1988, J BACTERIOL, V170, P5177, DOI 10.1128/jb.170.11.5177-5184.1988; Minko I, 2001, NUCLEIC ACIDS RES, V29, P1484, DOI 10.1093/nar/29.7.1484; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1982, CRC CR REV BIOCH MOL, V13, P287, DOI 10.3109/10409238209114231; Oshima T, 2002, MOL MICROBIOL, V45, P673, DOI 10.1046/j.1365-2958.2002.03037.x; REVEL HR, 1971, VIROLOGY, V45, P484, DOI 10.1016/0042-6822(71)90348-5; SANTOS ME, 1994, GENETICS, V138, P553; SCHLAGMAN SL, 1989, NUCLEIC ACIDS RES, V17, P9101, DOI 10.1093/nar/17.22.9101; Shier VK, 2001, J BIOL CHEM, V276, P14744, DOI 10.1074/jbc.M010688200; Thielking V, 1997, BIOL CHEM, V378, P407, DOI 10.1515/bchm.1997.378.5.407; WYATT GR, 1952, NATURE, V170, P1072, DOI 10.1038/1701072a0; Yang Z, 2003, NAT STRUCT BIOL, V10, P849, DOI 10.1038/nsb973; YOO H, 1987, J BIOL CHEM, V262, P8066; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481; Zinoviev VV, 2003, J BIOL CHEM, V278, P7829, DOI 10.1074/jbc.M210769200	37	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50012	50018		10.1074/jbc.M409786200	http://dx.doi.org/10.1074/jbc.M409786200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375160	hybrid			2022-12-25	WOS:000225229500058
J	Woods, YL; Xirodimas, DP; Prescott, AR; Sparks, A; Lane, DP; Saville, MK				Woods, YL; Xirodimas, DP; Prescott, AR; Sparks, A; Lane, DP; Saville, MK			p14 arf promotes small ubiquitin-like modifier conjugation of Werners helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO E3 LIGASE; TUMOR-SUPPRESSOR; SYNDROME PROTEIN; IN-VIVO; NUCLEAR-LOCALIZATION; STABILIZES P53; YEAST SEPTINS/; GENE-PRODUCT; DNA-DAMAGE; MDM2	Here we demonstrate a novel p53-independent interaction between the nucleolar tumor suppressors, p14 Arf and Werners helicase (WRN). Binding of p14 Arf to WRN is multivalent and resembles the binding of p14 Arf to Mdm2. Residues 2 - 14 and 82 - 101 of p14 Arf and residues in the central region and C terminus of WRN have particular importance for binding. p14 Arf promotes small ubiquitin-like modifier ( SUMO) modification of WRN in a synergistic manner with the SUMO-conjugating enzyme, UBCH9. p14 Arf causes redistribution of WRN within the nucleus, and this effect is reversed by expression of a SUMO-specific protease, thus implicating the SUMO conjugation pathway in WRN re-localization. We establish that the ability to promote SUMO conjugation is a general property of the p14 Arf tumor suppressor.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp, Dundee DD1 9SY, Scotland; Univ Dundee, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee; University of Dundee	Woods, YL (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, CR UK Cell Transformat Res Grp, Ninewells Ave, Dundee DD1 9SY, Scotland.	y.l.woods@dundee.ac.uk	Lane, David P/C-4920-2008; Prescott, Alan/Y-5956-2018	Prescott, Alan/0000-0002-0747-7317; Xirodimas, Dimitris/0000-0001-9275-1140; Lane, David/0000-0003-0551-3545				Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baynton K, 2003, J BIOL CHEM, V278, P36476, DOI 10.1074/jbc.M303885200; Blander G, 1999, J BIOL CHEM, V274, P29463, DOI 10.1074/jbc.274.41.29463; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851; Chen Lishan, 2002, Journal of Biomedicine & Biotechnology, V2, P46, DOI 10.1155/S1110724302201011; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558; Duprez E, 1999, J CELL SCI, V112, P381; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kuo ML, 2003, CANCER RES, V63, P1046; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Matsumoto T, 1998, INT J MOL MED, V1, P71; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; O'Leary KA, 2004, MOL CELL BIOL, V24, P186, DOI 10.1128/MCB.24.1.186-191.2004; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stelter P, 2003, NATURE, V425, P188, DOI 10.1038/nature01965; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Yarbrough WG, 2002, CANCER RES, V62, P1171; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	54	52	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50157	50166		10.1074/jbc.M405414200	http://dx.doi.org/10.1074/jbc.M405414200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355988	hybrid			2022-12-25	WOS:000225229500075
J	Bhat, GJ; Samikkannu, T; Thomas, JJ; Thekkumkara, TJ				Bhat, GJ; Samikkannu, T; Thomas, JJ; Thekkumkara, TJ			alpha-Thrombin rapidly induces tyrosine phosphorylation of a novel, 74-78-kDa stress response protein(s) in lung fibroblast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; JAK-STAT PATHWAY; RECEPTOR ACTIVATION; MITOCHONDRIAL HSP70; COUPLED RECEPTORS; HUMAN PLATELETS; ANGIOTENSIN-II; CLONING; FAMILY; KINASE	We demonstrated previously that exposure of CCL39 lung fibroblasts to alpha-thrombin rapidly inhibits interleukin 6-induced tyrosine phosphorylation of signal transducers and activators of transcription 3 (Stat3). While studying the cross-talk between alpha-thrombin and interleukin 6, we observed that the phospho-specific (tyrosine) anti-Stat3 antibody specifically cross-reacted with a 74-78-kDa protein(s) in alpha-thrombin-treated cells. In this study, we demonstrate that in alpha-thrombin-treated CCL39 cells, the 74-78-kDa protein(s) rapidly undergoes tyrosine phosphorylation. The phosphorylation by alpha-thrombin was detected as early as 5 min and reached a maximum at 15 min; however, low levels were present at 2 h. alpha-Thrombin receptor agonist peptide (SFLLRN) induced its tyrosine phosphorylation, suggesting that alpha-thrombin mediates the effects via protease-activated receptor type 1. Anti-Stat3 antibodies specific to different regions of Stat3 failed to recognize the 74-78-kDa protein(s), suggesting that it is unrelated to Stat3. Cell fractionation experiments showed that it is localized to the cytoplasm. Mass spectrometric analysis of the immunoprecipitated protein showed that the 74-78-kDa protein(s) is related to glucose-regulated protein 75 (GRP75), a member of the heat shock/stress-response protein family. Consistent with these data, we observed tyrosine phosphorylation of GRP-75 in alpha-thrombin-treated cells. Exposure of cells to pervanadate, a stress-inducing agent, stimulated its tyrosine phosphorylation; however, cytokines and growth factors were ineffective. This is the first report of tyrosine phosphorylation of GRP-75-related stress protein(s) by alpha-thrombin and suggests that this pathway may contribute to the ability of alpha-thrombin to prevent apoptosis in cells exposed to stress or in the injured tissue.	Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Bhat, GJ (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.	Jayarama.gunaje@ttuhsc.edu		Thekkumkara, Thomas/0000-0001-8865-1446	NHLBI NIH HHS [HL061356, R01 HL66000] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061356, R01HL066000] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adinolfi E, 2003, J BIOL CHEM, V278, P37344, DOI 10.1074/jbc.M301508200; BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; Bhat GJ, 1998, ARCH BIOCHEM BIOPHYS, V350, P307, DOI 10.1006/abbi.1997.0520; Bhat GJ, 1996, J BIOL CHEM, V271, P22447, DOI 10.1074/jbc.271.37.22447; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Chalmers CJ, 2003, BIOCHEM J, V375, P99, DOI 10.1042/BJ20030346; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHEN YH, 1994, J BIOL CHEM, V269, P27372; Cottrell CS, 2002, ESSAYS BIOCHEM, V38, P169, DOI 10.1042/bse0380169; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; DOMANICO SZ, 1993, MOL CELL BIOL, V13, P3598, DOI 10.1128/MCB.13.6.3598; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Hadari YR, 1997, J BIOL CHEM, V272, P657; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; Kaul SC, 1998, ONCOGENE, V17, P907, DOI 10.1038/sj.onc.1202017; Kaul SC, 2000, FEBS LETT, V474, P159, DOI 10.1016/S0014-5793(00)01594-5; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; MASSA SM, 1995, J NEUROSCI RES, V40, P807, DOI 10.1002/jnr.490400612; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MICHIKAWA Y, 1993, FEBS LETT, V336, P27, DOI 10.1016/0014-5793(93)81602-V; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MIZZEN LA, 1991, CELL REGUL, V2, P165, DOI 10.1091/mbc.2.2.165; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Pelletier S, 2003, MOL CELL BIOL, V23, P1316, DOI 10.1128/MCB.23.4.1316-1333.2003; Polanowska-Grabowska R, 2000, PLATELETS, V11, P6; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P228, DOI 10.1111/j.1749-6632.1986.tb34585.x; SILVER IA, 1994, J NEUROSCI, V14, P5068; Singh B, 1997, EXP CELL RES, V234, P205, DOI 10.1006/excr.1997.3609; TANAKO S, 2001, BIOCHEM J, V357, P393; Tibbles HE, 2001, J BIOL CHEM, V276, P17815, DOI 10.1074/jbc.M011405200; VASSALLO RR, 1992, J BIOL CHEM, V267, P6081; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	46	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48915	48922		10.1074/jbc.M409043200	http://dx.doi.org/10.1074/jbc.M409043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364938	hybrid			2022-12-25	WOS:000225098100053
J	Inoue, M; Digman, MA; Cheng, M; Breusegem, SY; Halaihel, N; Sorribas, V; Mantulin, WW; Gratton, E; Barry, NP; Levi, M				Inoue, M; Digman, MA; Cheng, M; Breusegem, SY; Halaihel, N; Sorribas, V; Mantulin, WW; Gratton, E; Barry, NP; Levi, M			Partitioning of NaPi cotransporter in cholesterol-, sphingomyelin-, and glycosphingolipid-enriched membrane domains modulates NaPi protein diffusion, clustering, and activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; 2-PHOTON FLUORESCENCE MICROSCOPY; LIPID RAFTS; BRUSH-BORDER; MODEL MEMBRANES; CELL-SURFACE; CORRELATION SPECTROSCOPY; TARGETED DISRUPTION; PLASMA-MEMBRANE; MICRODOMAINS	In dietary potassium deficiency there is a decrease in the transport activity of the type IIa sodium/phosphate cotransporter protein (NaPi) despite an increase in its apical membrane abundance. This novel posttranslational regulation of NaPi activity is mediated by the increased glycosphingolipid content of the potassium-deficient apical membrane. However, the mechanisms by which these lipids modulate NaPi activity have not been determined. We determined if in potassium deficiency NaPi is increasingly partitioned in cholesterol-, sphingomyelin-, and glycosphingolipid-enriched microdomains of the apical membrane and if the increased presence of NaPi in these microdomains modulates its activity. By using a detergent-free density gradient flotation technique, we found that 80% of the apical membrane NaPi partitions into the low density cholesterol-, sphingomyelin-, and GM1-enriched fractions characterized as "lipid raft" fractions. In potassium deficiency, a higher proportion of NaPi was localized in the lipid raft fractions. By combining fluorescence correlation spectroscopy and photon counting histogram methods for control and potassium-deficient apical membranes reconstituted into giant unilamellar vesicles, we showed a 2-fold decrease in lateral diffusion of NaPi protein and a greater than 2-fold increase in size of protein aggregates/clusters in potassium deficiency. Our results indicate that NaPi protein is localized in membrane microdomains, that in potassium deficiency a larger proportion of NaPi protein is present in these microdomains, and that NaPi lateral diffusion is slowed down and NaPi aggregation/clustering is increased in potassium deficiency, both of which could be associated with the decreased Na/P-i cotransport activity in potassium deficiency.	Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biophys, Div Renal Dis & Hypertens, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80262 USA; Univ Illinois, Dept Phys, Fluorescence Dynam Lab, Urbana, IL 61801 USA; Univ Zaragoza, Dept Toxicol, E-50013 Zaragoza, Spain	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Illinois System; University of Illinois Urbana-Champaign; University of Zaragoza	Levi, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Renal Dis & Hypertens, 4200 E 9th Ave, Denver, CO 80262 USA.	Moshe.Levi@UCHSC.edu	Halaihel, Nabil/J-2973-2016	Sorribas, Victor/0000-0003-3457-323X; Levi, Moshe/0000-0002-6225-946X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR003155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062209] Funding Source: NIH RePORTER; NCRR NIH HHS [5 P41-RRO3155] Funding Source: Medline; NIDDK NIH HHS [5R01 DK062209-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akhter S, 2002, AM J PHYSIOL-CELL PH, V283, pC927, DOI 10.1152/ajpcell.00613.2001; Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1; Bagatolli LA, 1999, BIOPHYS J, V77, P2090, DOI 10.1016/S0006-3495(99)77050-5; BERLAND KM, 1995, BIOPHYS J, V68, P694, DOI 10.1016/S0006-3495(95)80230-4; Blasco T, 2003, AM J PHYSIOL-RENAL, V285, pF799, DOI 10.1152/ajprenal.00149.2003; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brown DA, 2001, TRAFFIC, V2, P668, DOI 10.1034/j.1600-0854.2001.20909.x; Chen Y, 1999, METHODS, V19, P234, DOI 10.1006/meth.1999.0854; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Chen Y, 2002, BIOPHYS J, V82, P133, DOI 10.1016/S0006-3495(02)75380-0; Dietrich C, 2002, BIOPHYS J, V82, P274, DOI 10.1016/S0006-3495(02)75393-9; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Draeger A, 2003, DEV BIOL, V262, P324, DOI 10.1016/S0012-1606(03)00398-1; Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439; Elkjaer ML, 2002, AM J PHYSIOL-RENAL, V283, pF1376, DOI 10.1152/ajprenal.00186.2002; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gisler SM, 2003, KIDNEY INT, V64, P1733, DOI 10.1046/j.1523-1755.2003.00266.x; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; He XX, 2002, ANAL BIOCHEM, V306, P115, DOI 10.1006/abio.2002.5686; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; Huber TB, 2003, J BIOL CHEM, V278, P13417, DOI 10.1074/jbc.C200678200; Kahya N, 2003, J BIOL CHEM, V278, P28109, DOI 10.1074/jbc.M302969200; Kahya N, 2002, J BIOL CHEM, V277, P39304, DOI 10.1074/jbc.M202635200; Kenworthy AK, 2004, J CELL BIOL, V165, P735, DOI 10.1083/jcb.200312170; Khan TK, 2003, BIOCHEMISTRY-US, V42, P4780, DOI 10.1021/bi0265877; Kocher O, 2003, MOL CELL BIOL, V23, P1175, DOI 10.1128/MCB.23.4.1175-1180.2003; Kokubo H, 2003, BRAIN RES, V965, P83, DOI 10.1016/S0006-8993(02)04140-9; Kwik J, 2003, P NATL ACAD SCI USA, V100, P13964, DOI 10.1073/pnas.2336102100; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ledoux S, 2003, CIRC RES, V92, P848, DOI 10.1161/01.RES.0000069022.95401.FE; LEVI M, 1990, J CLIN INVEST, V85, P231, DOI 10.1172/JCI114417; LEVI M, 1995, J CLIN INVEST, V96, P207, DOI 10.1172/JCI118022; LEVI M, 1993, PHOTOCHEM PHOTOBIOL, V57, P420, DOI 10.1111/j.1751-1097.1993.tb02312.x; LEVI M, 1989, AM J PHYSIOL, V256, pF85, DOI 10.1152/ajprenal.1989.256.1.F85; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; Li XH, 2001, J PHYSIOL-LONDON, V537, P537, DOI 10.1111/j.1469-7793.2001.00537.x; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Lippincott-Schwartz J, 2003, NAT CELL BIOL, pS7, DOI 10.1038/ncb1032; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Magnani F, 2004, J BIOL CHEM, V279, P38770, DOI 10.1074/jbc.M400831200; MOLITORIS BA, 1985, AM J PHYSIOL, V249, pF12, DOI 10.1152/ajprenal.1985.249.1.F12; Muller JD, 2000, BIOPHYS J, V78, P474, DOI 10.1016/S0006-3495(00)76610-0; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Parasassi T, 1997, BIOPHYS J, V72, P2413, DOI 10.1016/S0006-3495(97)78887-8; Pike LJ, 2004, BIOCHEM J, V378, P281, DOI 10.1042/BJ20031672; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Pribanic S, 2003, AM J PHYSIOL-RENAL, V285, pF784, DOI 10.1152/ajprenal.00109.2003; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Ruan QQ, 2004, BIOPHYS J, V87, P1260, DOI 10.1529/biophysj.103.036483; Ruan QQ, 2002, BIOPHYS J, V83, P3177, DOI 10.1016/S0006-3495(02)75320-4; Runembert I, 2002, J CELL SCI, V115, P713; Salzer U, 2001, BLOOD, V97, P1141, DOI 10.1182/blood.V97.4.1141; Sharma P, 2004, CELL, V116, P577, DOI 10.1016/S0092-8674(04)00167-9; Shenolikar S, 2002, P NATL ACAD SCI USA, V99, P11470, DOI 10.1073/pnas.162232699; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Smith WJ, 2003, J BIOL CHEM, V278, P4949, DOI 10.1074/jbc.M210601200; Sorribas V, 2001, KIDNEY INT, V59, P1024, DOI 10.1046/j.1523-1755.2001.0590031024.x; Tenenhouse HS, 2003, J AM SOC NEPHROL, V14, P240, DOI 10.1097/01.ASN.0000045045.47494.71; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Zajicek HK, 2001, KIDNEY INT, V60, P694, DOI 10.1046/j.1523-1755.2001.060002694.x	70	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49160	49171		10.1074/jbc.M408942200	http://dx.doi.org/10.1074/jbc.M408942200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355967	hybrid, Green Submitted			2022-12-25	WOS:000225098100081
J	Mutka, AL; Lusa, S; Linder, MD; Jokitalo, E; Kopra, O; Jauhiainen, M; Ikonen, E				Mutka, AL; Lusa, S; Linder, MD; Jokitalo, E; Kopra, O; Jauhiainen, M; Ikonen, E			Secretion of sterols and the NPC2 protein from primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PICK C1-DEFICIENT NEURONS; C DISEASE; CHOLESTEROL-METABOLISM; RAT-BRAIN; SYNTHESIZED CHOLESTEROL; DOCOSAHEXAENOIC ACID; HUMAN EPIDIDYMIS; BINDING-PROTEIN; DISTAL AXONS; MOUSE-BRAIN	Astrocytes secrete cholesterol in lipoprotein particles. Here we show that primary murine embryonic astrocytes secrete endogenously synthesized cholesterol but also the cholesterol precursors desmosterol and lathosterol. In astrocyte membranes, desmosterol and cholesterol were the predominant sterols. Astrocytes derived from Niemann-Pick type C lipidosis (NPC1(-/-)) mice displayed late endosomal cholesterol deposits, but the secretion of biosynthetic sterols from the cells was not inhibited. Both wild-type and NPC1(-/-) astrocytes secreted the NPC2 protein. Size-exclusion chromatography combined with electron microscopy showed that the majority of sterols were secreted separately from NPC2 in heterogeneous spherical particles with an average diameter of 20 nm. These data suggest that NPC2 and the majority of sterols secreted from astrocytes are not released together and that the secretion of neither sterols nor NPC2 requires NPC1 function. In addition, the findings reveal a complexity of sterol species in astrocytes and bring up the possibility that some of the effects assigned to astrocyte cholesterol may be attributed to its penultimate precursors.	Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Biomedicum Helsinki, Natl Publ Hlth Inst, Helsinki 00251, Finland	University of Helsinki; Finland National Institute for Health & Welfare; University of Helsinki	Ikonen, E (corresponding author), Univ Helsinki, Inst Biotechnol, Viikinkaari 9, FIN-00014 Helsinki, Finland.	elina.ikonen@helsinki.fi	Jokitalo, Eija/C-8375-2009	Jokitalo, Eija/0000-0002-4159-6934; Ikonen, Elina/0000-0001-8382-1135				Aula N, 2004, NEUROBIOL DIS, V15, P251, DOI 10.1016/j.nbd.2003.11.017; Blom TS, 2003, HUM MOL GENET, V12, P257, DOI 10.1093/hmg/ddg025; Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Connor WE, 1998, J LIPID RES, V39, P1404; Danik M, 1999, CRIT REV NEUROBIOL, V13, P357, DOI 10.1615/CritRevNeurobiol.v13.i4.20; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Fagan AM, 1999, J BIOL CHEM, V274, P30001, DOI 10.1074/jbc.274.42.30001; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; German DC, 2002, NEUROSCIENCE, V109, P437, DOI 10.1016/S0306-4522(01)00517-6; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; HINSE CH, 1971, J NEUROCHEM, V18, P1989, DOI 10.1111/j.1471-4159.1971.tb09604.x; Holtta-Vuori M, 2002, MOL BIOL CELL, V13, P3107, DOI 10.1091/mbc.E02-01-0025; Holtta-Vuori M, 2000, CURR BIOL, V10, P95, DOI 10.1016/S0960-9822(99)99991-8; Ikonen E, 2004, SEMIN CELL DEV BIOL, V15, P445, DOI 10.1016/j.semcdb.2004.03.001; Karten B, 2002, J NEUROCHEM, V83, P1154, DOI 10.1046/j.1471-4159.2002.01220.x; Karten B, 2003, J BIOL CHEM, V278, P4168, DOI 10.1074/jbc.M205406200; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; Ko DC, 2003, P NATL ACAD SCI USA, V100, P2518, DOI 10.1073/pnas.0530027100; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KRITCHEVSKY D, 1962, BIOCHEM BIOPH RES CO, V7, P128, DOI 10.1016/0006-291X(62)90160-2; Laitinen S, 2002, J LIPID RES, V43, P245; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LIN DS, 1993, J LIPID RES, V34, P491; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Lusa S, 2003, J BIOL CHEM, V278, P19844, DOI 10.1074/jbc.M212503200; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Moore SA, 2001, J MOL NEUROSCI, V16, P195, DOI 10.1385/JMN:16:2-3:195; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Patterson MC, 2003, NEUROLOGIST, V9, P301, DOI 10.1097/01.nrl.0000094627.78754.5b; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; Reid PC, 2004, J LIPID RES, V45, P582, DOI 10.1194/jlr.D300032-JLR200; Reid PC, 2003, J LIPID RES, V44, P1010, DOI 10.1194/jlr.M300009-JLR200; SHAH SN, 1986, NEUROCHEM RES, V11, P813, DOI 10.1007/BF00965206; Sleat DE, 2004, P NATL ACAD SCI USA, V101, P5886, DOI 10.1073/pnas.0308456101; Snipes G J, 1997, Subcell Biochem, V28, P173; Suresh S, 1998, J NEUROCHEM, V70, P242; VOLPE JJ, 1977, BIOCHIM BIOPHYS ACTA, V486, P408, DOI 10.1016/0005-2760(77)90090-X; Waterham HR, 2000, BBA-MOL CELL BIOL L, V1529, P340, DOI 10.1016/S1388-1981(00)00159-1; Wechsler A, 2003, SCIENCE, V302, P2087, DOI 10.1126/science.1090776	45	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48654	48662		10.1074/jbc.M405345200	http://dx.doi.org/10.1074/jbc.M405345200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355983	hybrid			2022-12-25	WOS:000225098100022
J	Veljkovic, E; Bacconi, A; Stetak, A; Hajnal, A; Stasiuk, S; Skelly, PJ; Forster, I; Shoemaker, CB; Verrey, F				Veljkovic, E; Bacconi, A; Stetak, A; Hajnal, A; Stasiuk, S; Skelly, PJ; Forster, I; Shoemaker, CB; Verrey, F			Aromatic amino acid transporter AAT-9 of Caenorhabditis elegans localizes to neurons and muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/P-I COTRANSPORTER; CHANNEL; RESIDUES; GENETICS; BIOLOGY; CLONING	The Caenorhabditis elegans genome encodes nine homologues of mammalian glycoprotein-associated amino acid transporters. Two of these C. elegans proteins (AAT-1 and AAT-3) have been shown to function as catalytic subunits (light chains) of heteromeric amino acid transporters. These proteins need to associate with a glycoprotein heavy chain subunit (ATG-2) to reach the cell surface in a manner similar to that of their mammalian homologues. AAT-1 and AAT-3 contain a cysteine residue in the second putative extracellular loop through which a disulfide bridge can form with a heavy chain. In contrast, six C. elegans members of this family (AAT-4 to AAT-9) lack such a cysteine residue. We show here that one of these transporter proteins, AAT-9, reaches the cell surface in Xenopus oocytes without an exogenous heavy chain and that it functions as an exchanger of aromatic amino acids. Two-electrode voltage clamp experiments demonstrate that AAT-9 displays a substrate-activated conductance. Immunofluorescence shows that it is expressed close to the pharyngeal bulbs within C. elegans neurons. The selective expression of an aat-9 promoter-green fluorescent protein construct in several neurons of this region and in wall muscle cells around the mouth supports and extends these localization data. Taken together, the results show that AAT-9 is expressed in excitable cells of the nematode head and pharynx in which it may provide a pathway for aromatic amino acid transport.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; AgRes Anim Hlth, Wallaceville Anim Res Ctr, Upper Hutt, New Zealand; Tufts Univ, Sch Vet Med, Dept Biomed Sci, Grafton, MA 01536 USA	University of Zurich; University of Zurich; AgResearch - New Zealand; Tufts University	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	verrey@access.unizh.ch		Forster, Ian/0000-0003-3087-9952; Hajnal, Alex/0000-0002-4098-3721; Verrey, Francois/0000-0003-3250-9824				BRENNER S, 1974, GENETICS, V77, P71; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; Harlow E., 1988, ANTIBODIES LAB MANUA; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanai Y, 2001, CURR DRUG METAB, V2, P339, DOI 10.2174/1389200013338324; Kim DK, 2002, GENOMICS, V79, P95, DOI 10.1006/geno.2001.6678; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kohler K, 2002, J GEN PHYSIOL, V120, P693, DOI 10.1085/jgp.20028645; MADURO M, 1995, GENETICS, V141, P977; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Meier C, 2002, EMBO J, V21, P580, DOI 10.1093/emboj/21.4.580; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Pfeiffer R, 1999, MOL BIOL CELL, V10, P4135, DOI 10.1091/mbc.10.12.4135; Pfeiffer R, 1998, FEBS LETT, V439, P157, DOI 10.1016/S0014-5793(98)01359-3; Puoti A, 1997, P NATL ACAD SCI USA, V94, P5949, DOI 10.1073/pnas.94.11.5949; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Strange K, 2003, PHYSIOL REV, V83, P377, DOI 10.1152/physrev.00025.2002; Veljkovic E, 2004, J BIOL CHEM, V279, P7655, DOI 10.1074/jbc.M309528200; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	25	5	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49268	49273		10.1074/jbc.M404470200	http://dx.doi.org/10.1074/jbc.M404470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364921	Green Accepted, hybrid			2022-12-25	WOS:000225098100094
J	Walerych, D; Kudla, G; Gutkowska, M; Wawrzynow, B; Muller, L; King, FW; Helwak, A; Boros, J; Zylicz, A; Zylicz, M				Walerych, D; Kudla, G; Gutkowska, M; Wawrzynow, B; Muller, L; King, FW; Helwak, A; Boros, J; Zylicz, A; Zylicz, M			Hsp90 chaperones wild-type p53 tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; C-TERMINAL DOMAIN; MUTANT P53; DNA-BINDING; MOLECULAR CHAPERONE; ATP HYDROLYSIS; RNA-POLYMERASE; CORE DOMAIN; MUTATED P53; IN-VIVO	Immortalized human fibroblasts were used to investigate the putative interactions of the Hsp90 molecular chaperone with the wild-type p53 tumor suppressor protein. We show that geldanamycin or radicicol, specific inhibitors of Hsp90, diminish specific wild-type p53 binding to the p21 promoter sequence. Consequently, these inhibitors decrease p21 mRNA levels, which lead to a reduction in cellular p21/Waf1 protein, known to induce cell cycle arrest. In control experiments, we show that neither geldanamycin nor radicicol affect p53 mRNA levels. A minor decrease in p53 protein level following the treatment of human fibroblasts with the inhibitors suggests the potential involvement of Hsp90 in the stabilization of wild-type p53. To support our in vivo findings, we used a reconstituted system with highly purified recombinant proteins to examine the effects of Hsp90 on wildtype p53 binding to the p21 promoter sequence. The human recombinant Hsp90 alpha-isoform as well as bovine brain Hsp90 were purified to homogeneity. Both of these molecular chaperones displayed ATPase activity and the ability to refold heat-inactivated luciferase in a geldanamycin- and radicicol-sensitive manner, suggesting that post-translational modifications are not involved in the modulation of Hsp90alpha activity. We show that the incubation of recombinant p53 at 37degreesC decreases the level of its wildtype conformation and strongly inhibits the in vitro binding of p53 to the p21 promoter sequence. Interestingly, Hsp90 in an ATP-dependent manner can positively modulate p53 DNA binding after incubation at physiological temperature of 37degreesC. Other recombinant human chaperones from Hsp70 and Hsp40 families were not able to efficiently substitute Hsp90 in this reaction. Consistent with our in vivo results, geldanamycin can suppress Hsp90 ability to regulate in vitro p53 DNA binding to the promoter sequence. In summary, the results presented in this article state that chaperone activity of Hsp90 is important for the transcriptional activity of genotypically wild-type p53.	Int Inst Mol & Cell Biol Warsaw, PL-02109 Warsaw, Poland; Polish Acad Sci, M Nencki Inst Expt Biol, PL-02093 Warsaw, Poland; Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; Inst Biochem & Biophys, PL-02106 Warsaw, Poland	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Technical University of Munich; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Zylicz, M (corresponding author), Int Inst Mol & Cell Biol Warsaw, Trojdena 4 St, PL-02109 Warsaw, Poland.	zylicz@iimcb.gov.pl	Walerych, Dawid/I-2517-2016	Gutkowska, Malgorzata/0000-0001-6584-7964; Zylicz, Alicja/0000-0003-4174-3073; Kudla, Grzegorz/0000-0002-7924-2744; Walerych, Dawid/0000-0002-8440-1375				Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Asher G, 2002, P NATL ACAD SCI USA, V99, P3099, DOI 10.1073/pnas.052706799; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Burch L, 2004, J MOL BIOL, V337, P129, DOI 10.1016/j.jmb.2004.01.017; Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; HAINAUT P, 1995, ONCOGENE, V10, P27; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1990, ONCOGENE, V5, P1683; Minami Y, 1999, GENES CELLS, V4, P721, DOI 10.1046/j.1365-2443.1999.00299.x; Muller L, 2004, J BIOL CHEM, V279, P48846, DOI 10.1074/jbc.M407687200; Nichols NM, 2002, BIOCHEMISTRY-US, V41, P170, DOI 10.1021/bi011736r; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Picard D, 2002, CELL MOL LIFE SCI, V59, P1640, DOI 10.1007/PL00012491; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Terada K, 2000, J BIOL CHEM, V275, P24728, DOI 10.1074/jbc.M002021200; Terada K, 1997, J CELL BIOL, V139, P1089, DOI 10.1083/jcb.139.5.1089; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadhwa R, 2002, EXP CELL RES, V274, P246, DOI 10.1006/excr.2002.5468; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Workman P, 2004, CANCER LETT, V206, P149, DOI 10.1016/j.canlet.2003.08.032; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	65	119	122	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48836	48845		10.1074/jbc.M407601200	http://dx.doi.org/10.1074/jbc.M407601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358769	hybrid			2022-12-25	WOS:000225098100045
J	Begenisich, T; Nakamoto, T; Ovitt, CE; Nehrke, K; Brugnara, C; Alper, SL; Melvin, JE				Begenisich, T; Nakamoto, T; Ovitt, CE; Nehrke, K; Brugnara, C; Alper, SL; Melvin, JE			Physiological roles of the intermediate conductance, Ca2+-activated potassium channel Kcnn4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANDIBULAR SECRETORY-CELLS; PAROTID ACINAR-CELLS; K+ CHANNEL; ERYTHROCYTE DEHYDRATION; GARDOS CHANNEL; FUNCTIONAL-CHARACTERIZATION; CATION CHANNELS; T-LYMPHOCYTES; SAD MICE; CALCIUM	Three broad classes of Ca2+-activated potassium channels are defined by their respective single channel conductances, i.e. the small, intermediate, and large conductance channels, often termed the SK, IK, and BK channels, respectively. SK channels are likely encoded by three genes, Kcnn1- 3, whereas IK and most BK channels are most likely products of the Kcnn4 and Slo (Kcnma1) genes, respectively. IK channels are prominently expressed in cells of the hematopoietic system and in organs involved in salt and fluid transport, including the colon, lung, and salivary glands. IK channels likely underlie the K+ permeability in red blood cells that is associated with water loss, which is a contributing factor in the pathophysiology of sickle cell disease. IK channels are also involved in the activation of T lymphocytes. The fluid-secreting acinar cells of the parotid gland express both IK and BK channels, raising questions about their particular respective roles. To test the physiological roles of channels encoded by the Kcnn4 gene, we constructed a mouse deficient in its expression. Kcnn4 null mice were of normal appearance and fertility, their parotid acinar cells expressed no IK channels, and their red blood cells lost K+ permeability. The volume regulation of T lymphocytes and erythrocytes was severely impaired in Kcnn4 null mice but was normal in parotid acinar cells. Despite the loss of IK channels, activated fluid secretion from parotid glands was normal. These results confirm that IK channels in red blood cells, T lymphocytes, and parotid acinar cells are indeed encoded by the Kcnn4 gene. The role of these channels in water movement and the subsequent volume changes in red blood cells and T lymphocytes is also confirmed. Surprisingly, Kcnn4 channels appear to play no required role in fluid secretion and regulatory volume decrease in the parotid gland.	Univ Rochester, Med Ctr, Aab Inst Biomed Sci, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Mol & Vasc Med Unit, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Renal, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	University of Rochester; University of Rochester; University of Rochester; Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Aab Inst Biomed Sci, Ctr Oral Biol, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.	james_melvin@urmc.rochester.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Nehrke, Keith/0000-0001-9697-726X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921, R01DE009692, P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034854, R21DK061051, R01DK050422, R01DK057662] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73112] Funding Source: Medline; NIDCR NIH HHS [DE013539, DE08921, DE09692] Funding Source: Medline; NIDDK NIH HHS [DK61051, DK34854, DK50422, DK57662] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; Brugnara C, 1996, J CLIN INVEST, V97, P1227, DOI 10.1172/JCI118537; Brugnara C, 2001, DRUG NEWS PERSPECT, V14, P208, DOI 10.1358/dnp.2001.14.4.858404; DEFRANCESCHI L, 1994, J CLIN INVEST, V93, P1670, DOI 10.1172/JCI117149; Elliott JL, 2003, EMBO REP, V4, P189, DOI 10.1038/sj.embor.embor722; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; HALPERIN JA, 1989, J CLIN INVEST, V83, P1466, DOI 10.1172/JCI114039; Hayashi T, 1996, J MEMBRANE BIOL, V151, P19, DOI 10.1007/s002329900054; Hayashi T, 1996, J MEMBRANE BIOL, V152, P253, DOI 10.1007/s002329900103; Hoffman JF, 2003, P NATL ACAD SCI USA, V100, P7366, DOI 10.1073/pnas.1232342100; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; ISHIKAWA T, 1994, PFLUG ARCH EUR J PHY, V428, P516, DOI 10.1007/BF00374573; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Krane CM, 2001, J BIOL CHEM, V276, P23413, DOI 10.1074/jbc.M008760200; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MARUYAMA Y, 1986, JPN J PHYSIOL, V36, P219, DOI 10.2170/jjphysiol.36.219; MEREDITH AL, J BIOL CHEM, V279, P36746; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; Park K, 2001, ARCH ORAL BIOL, V46, P801, DOI 10.1016/S0003-9969(01)00047-4; Rivera A, 1999, AM J PHYSIOL-CELL PH, V277, pC746, DOI 10.1152/ajpcell.1999.277.4.C746; SCHMUKLER BE, 2001, BIOCHIM BIOPHYS ACTA, V1518, P36; Stocker JW, 2003, BLOOD, V101, P2412, DOI 10.1182/blood-2002-05-1433; Takahata T, 2003, AM J PHYSIOL-CELL PH, V284, pC127, DOI 10.1152/ajpcell.00250.2002; Vandorpe DH, 1998, J BIOL CHEM, V273, P21542, DOI 10.1074/jbc.273.34.21542; Warth R, 1999, PFLUG ARCH EUR J PHY, V438, P437, DOI 10.1007/s004240051059; WEGMAN EA, 1992, AM J PHYSIOL, V263, pG786, DOI 10.1152/ajpgi.1992.263.5.G786; Wulff H, 2003, CURR OPIN DRUG DI DE, V6, P640; Zhang BM, 2001, BIOCHEMISTRY-US, V40, P3189, DOI 10.1021/bi001675h	30	155	163	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47681	47687		10.1074/jbc.M409627200	http://dx.doi.org/10.1074/jbc.M409627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347667	Green Published, hybrid			2022-12-25	WOS:000224957000033
J	Hou, BK; Lim, EK; Higgins, GS; Bowles, DJ				Hou, BK; Lim, EK; Higgins, GS; Bowles, DJ			N-glucosylation of cytokinins by glycosyltransferases of Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZEATIN O-GLUCOSYLTRANSFERASE; TRANSGENIC TOBACCO; MULTIGENE FAMILY; GENE; METABOLISM; IDENTIFICATION; BIOSYNTHESIS; MAIZE; ENZYMES; INHIBITORS	Cytokinins are plant hormones that can be glucosylated to form O-glucosides and N-glucosides. The glycoconjugates are inactive and are thought to play a role in homeostasis of the hormones. Although O-glucosyltransferases have been identified that recognize cytokinins, the enzymes involved in N-glucosylation have not been identified even though the process has been recognized for many years. This study utilizes a screening strategy in which 105 recombinant glycosyltransferases (UGTs) of Arabidopsis have been analyzed for catalytic activity toward the classical cytokinins: trans-zeatin, dihydrozeatin, N-6-benzyladenine, N-6-isopentenyladenine, and kinetin. Five UGTs were identified in the screen. UGT76C1 and UGT76C2 recognized all cytokinins and glucosylated the hormones at the N-7 and N-9 positions. UGT85A1, UGT73C5, and UGT73C1 recognized trans-zeatin and dihydrozeatin, which have an available hydroxyl group for glucosylation and formed the O-glucosides. The biochemical characteristics of the N-glucosyltransferases were analyzed, and highly effective inhibitors of their activities were identified. Constitutive overexpression of UGT76C1 in transgenic Arabidopsis confirmed that the recombinant enzyme functioned in vivo to glucosylate cytokinin applied to the plant. The role of the N-glucosyltransferases in cytokinin metabolism is discussed.	Univ York, Dept Biol, CNAP, York YO10 5DD, N Yorkshire, England	University of York - UK	Bowles, DJ (corresponding author), Univ York, Dept Biol, CNAP, York YO10 5DD, N Yorkshire, England.	djb32@york.ac.uk		Higgins, Gillian/0000-0003-2963-1597				Auer CA, 2002, J PLANT GROWTH REGUL, V21, P24, DOI 10.1007/s003440010044; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BINNS AN, 1994, ANNU REV PLANT PHYS, V45, P173, DOI 10.1146/annurev.pp.45.060194.001133; Broo A, 1996, CHEM PHYS, V211, P147, DOI 10.1016/0301-0104(96)00184-X; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CAMPOS N, 1992, PLANT J, V2, P675, DOI 10.1111/j.1365-313X.1992.tb00136.x; Chang HS, 2003, PLANT PHYSIOL, V132, P2174, DOI 10.1104/pp.103.023945; Coenen C, 1997, TRENDS PLANT SCI, V2, P351, DOI 10.1016/S1360-1385(97)84623-7; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; COWLEY DE, 1978, AUST J CHEM, V31, P1095, DOI 10.1071/CH9781095; DIXON SC, 1989, PLANT PHYSIOL, V90, P1316, DOI 10.1104/pp.90.4.1316; Eklof S, 1996, PHYSIOL PLANTARUM, V98, P333, DOI 10.1034/j.1399-3054.1996.980215.x; ENTSCH B, 1979, BIOCHIM BIOPHYS ACTA, V570, P124, DOI 10.1016/0005-2744(79)90207-9; ENTSCH B, 1979, PLANT SCI LETT, V14, P205, DOI 10.1016/0304-4211(79)90061-0; Gaspar T, 1996, IN VITRO CELL DEV-PL, V32, P272; Haberer G, 2002, PLANT PHYSIOL, V128, P354, DOI 10.1104/pp.010773; HOCART CH, 1991, PHYTOCHEMISTRY, V30, P2477, DOI 10.1016/0031-9422(91)85086-F; Hutchison CE, 2002, PLANT CELL, V14, pS47, DOI 10.1105/tpc.010444; Jackson RG, 2002, PLANT J, V32, P573, DOI 10.1046/j.1365-313X.2002.01445.x; Jackson RG, 2001, J BIOL CHEM, V276, P4350, DOI 10.1074/jbc.M006185200; Jones P, 2003, J BIOL CHEM, V278, P43910, DOI 10.1074/jbc.M303523200; Jones RJ, 1997, PLANT GROWTH REGUL, V23, P123, DOI 10.1023/A:1005913311266; Kakimoto T, 2003, ANNU REV PLANT BIOL, V54, P605, DOI 10.1146/annurev.arplant.54.031902.134802; Kakimoto T, 2003, J PLANT RES, V116, P233, DOI 10.1007/s10265-003-0095-5; Kakimoto T, 2001, PLANT CELL PHYSIOL, V42, P677, DOI 10.1093/pcp/pce112; LETHAM DS, 1983, ANNU REV PLANT PHYS, V34, P163, DOI 10.1146/annurev.pp.34.060183.001115; LETHAM DS, 1978, PHYTOHORMONES RELATE, V1, P29; Li Y, 2001, J BIOL CHEM, V276, P4338, DOI 10.1074/jbc.M007447200; Lim EK, 2004, EMBO J, V23, P2915, DOI 10.1038/sj.emboj.7600295; Lim EK, 2003, BIOCHEM J, V373, P987, DOI 10.1042/BJ20021453; Lim EK, 2003, GLYCOBIOLOGY, V13, P139, DOI 10.1093/glycob/cwg017; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; Lim EK, 2001, J BIOL CHEM, V276, P4344, DOI 10.1074/jbc.M007263200; Martin RC, 1999, P NATL ACAD SCI USA, V96, P284, DOI 10.1073/pnas.96.1.284; Martin RC, 2001, P NATL ACAD SCI USA, V98, P5922, DOI 10.1073/pnas.101128798; Martin RC, 2001, IN VITRO CELL DEV-PL, V37, P354, DOI 10.1007/s11627-001-0063-5; Martin RC, 1999, PLANT PHYSIOL, V120, P553, DOI 10.1104/pp.120.2.553; MILLER CO, 1955, J AM CHEM SOC, V77, P1392, DOI 10.1021/ja01610a105; Mok DWS, 2001, ANNU REV PLANT PHYS, V52, P89, DOI 10.1146/annurev.arplant.52.1.89; Mok DWS, 2000, PLANT GROWTH REGUL, V32, P285, DOI 10.1023/A:1010712102890; PARKER CW, 1986, PHYTOCHEMISTRY, V25, P303, DOI 10.1016/S0031-9422(00)85471-0; Poppenberger B, 2003, J BIOL CHEM, V278, P47905, DOI 10.1074/jbc.M307552200; Rashotte AM, 2003, PLANT PHYSIOL, V132, P1998, DOI 10.1104/pp.103.021436; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Schmulling T, 2003, J PLANT RES, V116, P241, DOI 10.1007/s10265-003-0096-4; Sheen J, 2002, SCIENCE, V296, P1650, DOI 10.1126/science.1071883; SKOOG F, 1970, ANN REV PLANT PHYSIO, V21, P359, DOI 10.1146/annurev.pp.21.060170.002043; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; SUMMONS RE, 1977, FEBS LETT, V82, P211, DOI 10.1016/0014-5793(77)80586-3; Sun JQ, 2003, PLANT PHYSIOL, V131, P167, DOI 10.1104/pp.011494; Takei K, 2001, J BIOL CHEM, V276, P26405, DOI 10.1074/jbc.M102130200; TAO GQ, 1991, J PLANT GROWTH REGUL, V10, P179, DOI 10.1007/BF02279331; Veach YK, 2003, PLANT PHYSIOL, V131, P1374, DOI 10.1104/pp.017210; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; Vogel JP, 1998, GENETICS, V149, P417; Vogt T, 2000, TRENDS PLANT SCI, V5, P380, DOI 10.1016/S1360-1385(00)01720-9; Werner T, 2003, PLANT CELL, V15, P2532, DOI 10.1105/tpc.014928	58	219	252	4	67	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47822	47832		10.1074/jbc.M409569200	http://dx.doi.org/10.1074/jbc.M409569200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342621	hybrid			2022-12-25	WOS:000224957000051
J	Kosta, A; Roisin-Bouffay, C; Luciani, MF; Otto, GP; Kessin, RH; Golstein, P				Kosta, A; Roisin-Bouffay, C; Luciani, MF; Otto, GP; Kessin, RH; Golstein, P			Autophagy gene disruption reveals a non-vacuolar cell death pathway in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SACCHAROMYCES-CEREVISIAE; SLIME-MOLD; DISCOIDEUM; MUTANTS; DIFFERENTIATION; MECHANISMS; APOPTOSIS; MACROAUTOPHAGY; MITOCHONDRIA	Types of cell death include apoptosis, necrosis, and autophagic cell death. The latter can be defined as death of cells containing autophagosomes, autophagic bodies, and/or vacuoles. Are autophagy and vacuolization causes, consequences, or side effects in cell death with autophagy? Would control of autophagy suffice to control this type of cell death? We disrupted the atg1 autophagy gene in Dictyostelium discoideum, a genetically tractable model for developmental autophagic vacuolar cell death. The procedure that induced autophagy, vacuolization, and death in wild-type cells led in atg1 mutant cells to impaired autophagy and to no vacuolization, demonstrating that atg1 is required for vacuolization. Unexpectedly, however, cell death still took place, with a non-vacuolar and centrally condensed morphology. Thus, a cell death mechanism that does not require vacuolization can operate in this cell death model showing conspicuous vacuolization. The revelation of non-vacuolar cell death in this protist by autophagy gene disruption is reminiscent of caspase inhibition revealing necrotic cell death in animal cells. Thus, hidden alternative cell death pathways may be found across kingdoms and for diverse types of cell death.	Univ Mediterranee Marseille Luminy, Ctr Immunol, INSERM, CNRS, F-13288 Marseille 9, France; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Columbia University	Golstein, P (corresponding author), Univ Mediterranee Marseille Luminy, Ctr Immunol, INSERM, CNRS, Case 906,Campus Luminy,Ave Luminy, F-13288 Marseille 9, France.	golstein@ciml.univ-mrs.fr	Golstein, Pierre/A-4954-2014	Golstein, Pierre/0000-0003-1750-3483; Otto, Grant/0000-0001-8709-3366; Kosta, Artemis/0000-0001-7115-4566				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Al-Saffar NMS, 2002, BRIT J CANCER, V86, P963, DOI 10.1038/sj/bjc/6600188; Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; BEAULATION J, 1977, J MORPHOL, V154, P39, DOI 10.1002/jmor.1051540104; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CORNILLON S, 1994, J CELL SCI, V107, P2691; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Dementhon K, 2003, EUKARYOT CELL, V2, P238, DOI 10.1128/EC.2.2.238-246.2003; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Fukuda H, 2004, NAT REV MOL CELL BIO, V5, P379, DOI 10.1038/nrm1364; GEORGE RP, 1972, J GEN MICROBIOL, V70, P477, DOI 10.1099/00221287-70-3-477; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; Gorski SM, 2003, CURR BIOL, V13, P358, DOI 10.1016/S0960-9822(03)00082-4; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Hall DH, 1997, J NEUROSCI, V17, P1033; Harris E, 2002, MOL BIOL CELL, V13, P656, DOI 10.1091/mbc.01-09-0454; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; KAY RR, 1987, METHOD CELL BIOL, V28, P433; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Levraud JP, 2003, J CELL BIOL, V160, P1105, DOI 10.1083/jcb.200212104; LOCKSHIN RICHARD A., 1965, J INSECT PHYSIOL, V11, P123, DOI 10.1016/0022-1910(65)90099-5; MAEDA Y, 1969, DEV GROWTH DIFFER, V11, P232; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Olie RA, 1998, CURR BIOL, V8, P955, DOI 10.1016/S0960-9822(98)70395-1; Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200; Otto GP, 2004, MOL MICROBIOL, V51, P63, DOI 10.1046/j.1365-2958.2003.03826.x; Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; Pinan-Lucarre R, 2003, MOL MICROBIOL, V47, P321, DOI 10.1046/j.1365-2958.2003.03208.x; QUIVIGER B, 1980, BIOL CELLULAIRE, V37, P241; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Roisin-Bouffay C, 2004, J BIOL CHEM, V279, P11489, DOI 10.1074/jbc.M312741200; RYTER A, 1977, J CELL BIOL, V75, P200, DOI 10.1083/jcb.75.1.200; SCHAAP P, 1981, BIOL CELL, V41, P133; SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; Thomas WD, 2000, J IMMUNOL, V165, P5612, DOI 10.4049/jimmunol.165.10.5612; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Weeks JC, 2003, PROG NEUROBIOL, V70, P421, DOI 10.1016/S0301-0082(03)00102-3; WHITTINGHAM WF, 1960, P NATL ACAD SCI USA, V46, P642, DOI 10.1073/pnas.46.5.642; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	56	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48404	48409		10.1074/jbc.M408924200	http://dx.doi.org/10.1074/jbc.M408924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358773	hybrid			2022-12-25	WOS:000224957000116
J	Murriel, CL; Churchill, E; Inagaki, K; Szweda, LI; Mochly-Rosen, D				Murriel, CL; Churchill, E; Inagaki, K; Szweda, LI; Mochly-Rosen, D			Protein kinase C delta activation induces apoptosis in response to cardiac ischemia and reperfusion damage - A mechanism involving bad and the mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PKC-DELTA; PROMOTES SURVIVAL; IN-VITRO; EPSILON; INJURY; MYOCYTES; HYPOXIA; BCL-2; VIVO	Heart attacks caused by occlusion of coronary arteries are often treated by mechanical or enzymatic removal of the occlusion and reperfusion of the ischemic heart. It is now recognized that reperfusion per se contributes to myocardial damage, and there is a great interest in identifying the molecular basis of this damage. We recently showed that inhibiting protein kinase Cdelta (PKCdelta) protects the heart from ischemia and reperfusion-induced damage. Here, we demonstrate that PKCdelta activity and mitochondrial translocation at the onset of reperfusion mediates apoptosis by facilitating the accumulation and dephosphorylation of the pro-apoptotic BAD ( (B) under bar cl- 2-(a) under bar ssociated death promoter), (d) under bar ephosphorylation of Akt, cytochrome c release, PARP (poly(ADPribose) polymerase) cleavage, and DNA laddering. Our data suggest that PKCdelta activation has a critical proapoptotic role in cardiac responses following ischemia and reperfusion.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Stanford University; Case Western Reserve University	Mochly-Rosen, D (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	mochly@stanford.edu		Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL52141] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Anversa P, 1998, BASIC RES CARDIOL, V93, P8; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Buja LM, 1998, LAB INVEST, V78, P1345; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200; Cerda SR, 2001, GASTROENTEROLOGY, V120, P1700, DOI 10.1053/gast.2001.24843; Chen L, 2001, P NATL ACAD SCI USA, V98, P11114, DOI 10.1073/pnas.191369098; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen ZY, 2001, AM J PHYSIOL-HEART C, V280, pH2313, DOI 10.1152/ajpheart.2001.280.5.H2313; Clerk A, 2003, PHARMACOL THERAPEUT, V97, P223, DOI 10.1016/S0163-7258(02)00339-X; Cook SA, 1999, J MOL CELL CARDIOL, V31, P1429, DOI 10.1006/jmcc.1999.0979; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Moissac D, 2000, J MOL CELL CARDIOL, V32, P53, DOI 10.1006/jmcc.1999.1057; Dong JW, 2003, CELL RES, V13, P385, DOI 10.1038/sj.cr.7290184; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Freude B, 2000, J MOL CELL CARDIOL, V32, P197, DOI 10.1006/jmcc.1999.1066; Fryer RM, 2001, AM J PHYSIOL-HEART C, V280, pH1346, DOI 10.1152/ajpheart.2001.280.3.H1346; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Hawkins HK, 1996, AM J PATHOL, V148, P1957; Heidkamp MC, 2001, CIRC RES, V89, P882, DOI 10.1161/hh2201.099434; Imahashi K, 2004, CIRC RES, V95, P734, DOI 10.1161/01.RES.0000143898.67182.4c; Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36; Inagaki K, 2003, CIRCULATION, V108, P869, DOI 10.1161/01.CIR.0000081943.93653.73; Jayakumar J, 2001, CIRCULATION, V104, pI303; Jeremias I, 2000, CIRCULATION, V102, P915; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; Mackay K, 1999, J BIOL CHEM, V274, P6272, DOI 10.1074/jbc.274.10.6272; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Masters SC, 2002, BIOCHEM SOC T, V30, P360, DOI 10.1042/bst0300360; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Matsui T, 2001, CIRCULATION, V104, P330; Mochly-Rosen D, 2000, CIRC RES, V86, P1173; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Paz Y, 2003, J AM COLL CARDIOL, V42, P1299, DOI 10.1016/S0735-1097(03)00992-6; Pozzi S, 2002, CELL PHYSIOL BIOCHEM, V12, P39, DOI 10.1159/000047825; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Schimmer AD, 2001, LEUKEMIA LYMPHOMA, V42, P429, DOI 10.3109/10428190109064600; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; Takemura G, 2001, J PATHOL, V193, P546; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yamamoto S, 2001, J MOL CELL CARDIOL, V33, P1829, DOI 10.1006/jmcc.2001.1446; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Yellon DM, 2000, HEART, V83, P381, DOI 10.1136/heart.83.4.381; Zhang JL, 2002, MECH AGEING DEV, V123, P613, DOI 10.1016/S0047-6374(01)00412-2	66	172	187	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47985	47991		10.1074/jbc.M405071200	http://dx.doi.org/10.1074/jbc.M405071200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339931	hybrid			2022-12-25	WOS:000224957000069
J	Takasaki, J; Saito, T; Taniguchi, M; Kawasaki, T; Moritani, Y; Hayashi, K; Kobori, M				Takasaki, J; Saito, T; Taniguchi, M; Kawasaki, T; Moritani, Y; Hayashi, K; Kobori, M			A novel G alpha(q/11)-selective inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN ANTAGONISTS; G(Q/11) INHIBITOR; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; GTP HYDROLYSIS; ADP RECEPTORS; IN-VIVO; CELLS; ACTIVATION; YM-254890	YM-254890, which was isolated from the culture broth of Chromobacterium sp., inhibits ADP-induced platelet aggregation and has antithrombotic and thrombolytic effects. YM-254890 blocks Galpha(q/11)-coupled ADP receptor P2Y1-mediated Ca2+ mobilization. Here we report that YM-254890 is a selective Galpha(q/11) inhibitor. YM-254890 blocked Ca2+ mobilization mediated by several Galpha(q/11)-coupled receptors but not by Galpha(i)- or Galpha(15)-coupled receptor, indicating that phospholipase Cbeta activation and subsequent signaling molecules are not the target of YM-254890. YM-254890 completely prevented the serum response factor (SRF)-mediated gene transcription induced by Galpha(q)R183C, which is constitutively active in a receptor-dependent manner because of its reduced k(cat) of GTP hydrolysis. Conversely, YM-254890 had only a modest effect on the SRF-mediated gene transcription by Galpha(q)Q209L, which is GTPase-deficient (activated) Galpha(q). These suggested that the acting point of YM-254890 is receptor-Galpha(q) interaction or the subsequent guanine nucleotide exchange step. The fact that YM-254890 (i) inhibited the SRF-mediated gene transcription by Galpha(qi5), which interacts with Galpha(i)-coupled receptor and possesses the effector function of Galpha(q), and (ii) had no effect on the K-d value of high affinity [H-3]2MeSADP binding to P2Y1, which reflects the agonist-receptor-Galpha ternary complex, suggested that receptor-Galpha(q/11) interaction is not the target of YM-254890. On the other hand, specific [S-35]GTPgammaS binding to Galpha(q/11) stimulated by the M1 muscarinic acetylcholine receptor and P2Y1 were inhibited by YM-254890. These data indicate that YM-254890 blocks the exchange of GDP for GTP in Galpha(q/11) activation. This novel Galpha(q/11)-selective inhibitor is a promising and powerful tool for studying Galpha(q/11) protein activation, Galpha(q/11)-coupled receptor signaling, and Galpha(q/11)-mediated biological events.	Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Astellas Pharmaceuticals	Takasaki, J (corresponding author), Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.	takasaki@yamanouchi.co.jp		Saito, Tetsu/0000-0002-9045-6743				Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; BENKA ML, 1995, FEBS LETT, V363, P49, DOI 10.1016/0014-5793(95)00278-H; Bianchi BR, 1999, EUR J PHARMACOL, V376, P127, DOI 10.1016/S0014-2999(99)00350-7; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Boyer JL, 1998, BRIT J PHARMACOL, V124, P1, DOI 10.1038/sj.bjp.0701837; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CHUEH SH, 1994, BRAIN RES, V660, P81, DOI 10.1016/0006-8993(94)90841-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; COWEN DS, 1990, J BIOL CHEM, V265, P16181; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Gachet C, 2001, THROMB HAEMOSTASIS, V86, P222; Hechler B, 2003, J EXP MED, V198, P661, DOI 10.1084/jem.20030144; Hohenegger M, 1998, P NATL ACAD SCI USA, V95, P346, DOI 10.1073/pnas.95.1.346; Jantzen HM, 1999, THROMB HAEMOSTASIS, V81, P111; Kawasaki T, 2003, THROMB HAEMOSTASIS, V90, P406, DOI 10.1160/TH03-02-0115; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; KLEUSS C, 1994, P NATL ACAD SCI USA, V91, P9828, DOI 10.1073/pnas.91.21.9828; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; Lukyanetz EA, 1998, NEUROSCIENCE, V87, P265, DOI 10.1016/S0306-4522(98)00057-8; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; Milligan G, 2003, TRENDS PHARMACOL SCI, V24, P87, DOI 10.1016/S0165-6147(02)00027-5; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUKAI H, 1992, J BIOL CHEM, V267, P16237; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neves SR, 2002, SCIENCE, V296, P1636, DOI 10.1126/science.1071550; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Ralevic V, 1998, PHARMACOL REV, V50, P413; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; Takasaki J, 2001, MOL PHARMACOL, V60, P432; Taniguchi M, 2003, TETRAHEDRON, V59, P4533, DOI 10.1016/S0040-4020(03)00680-X; Taniguchi M, 2003, J ANTIBIOT, V56, P358, DOI 10.7164/antibiotics.56.358; WU DQ, 1992, J BIOL CHEM, V267, P1811	33	288	295	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47438	47445		10.1074/jbc.M408846200	http://dx.doi.org/10.1074/jbc.M408846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339913	hybrid			2022-12-25	WOS:000224957000005
J	Tucker, WC; Schwarz, A; Levine, T; Du, ZY; Gromet-Elhanan, Z; Richter, ML; Haran, G				Tucker, WC; Schwarz, A; Levine, T; Du, ZY; Gromet-Elhanan, Z; Richter, ML; Haran, G			Observation of calcium-dependent unidirectional rotational motion in recombinant photosynthetic F-1-ATPase molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SUBUNIT OLIGOMER; BINDING CHANGE MECHANISM; F0F1 ATP SYNTHASE; GAMMA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; COUPLING FACTOR; WILD-TYPE; HYDROLYSIS; BETA; DICYCLOHEXYLCARBODIIMIDE	ATP hydrolysis and synthesis by the F0F1-ATP synthase are coupled to proton translocation across the membrane in the presence of magnesium. Calcium is known, however, to disrupt this coupling in the photosynthetic enzyme in a unique way: it does not support ATP synthesis, and CaATP hydrolysis is decoupled from any proton translocation, but the membrane does not become leaky to protons. Understanding the molecular basis of these calcium-dependent effects can shed light on the as yet unclear mechanism of coupling between proton transport and rotational catalysis. We show here, using an actin filament gamma-rotation assay, that CaATP is capable of sustaining rotational motion in a highly active hybrid photosynthetic F-1-ATPase consisting of alpha and beta subunits from Rhodospirillum rubrum and gamma subunit from spinach chloroplasts (alpha(3)(R)beta(3)(R)gamma(C)). The rotation was found to be similar to that induced by MgATP in Escherichia coli F-1-ATPase molecules. Our results suggest a possible long range pathway that enables the bound CaATP to induce full rotational motion of gamma but might block transmission of this rotational motion into proton translocation by the F-0 part of the ATP synthase.	Weizmann Inst Sci, Dept Chem Phys, IL-71600 Rehovot, Israel; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA; Weizmann Inst Sci, Dept Biol Chem, IL-71600 Rehovot, Israel	Weizmann Institute of Science; University of Kansas; Weizmann Institute of Science	Haran, G (corresponding author), Weizmann Inst Sci, Dept Chem Phys, IL-71600 Rehovot, Israel.	gilad.haran@weizmann.ac.il	HARAN, GILAD/K-1489-2012		NIGMS NIH HHS [GM08545] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bald D, 2001, J BIOL CHEM, V276, P39505, DOI 10.1074/jbc.C100436200; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Du ZY, 1999, EUR J BIOCHEM, V263, P430, DOI 10.1046/j.1432-1327.1999.00512.x; Du ZY, 2001, J BIOL CHEM, V276, P11517, DOI 10.1074/jbc.M007568200; Gromet-Elhanan Z., 1995, ANOXYGENIC PHOTOSYNT, P807; GROMETELHANAN Z, 1989, BIOCHEMISTRY-US, V28, P3645, DOI 10.1021/bi00435a004; Hisabori T, 1999, FEBS LETT, V463, P35, DOI 10.1016/S0014-5793(99)01602-6; HOCHMAN Y, 1976, FEBS LETT, V61, P255, DOI 10.1016/0014-5793(76)81051-4; Hochman Y, 2000, INDIAN J BIOCHEM BIO, V37, P459; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; Itoh H, 2004, NATURE, V427, P465, DOI 10.1038/nature02212; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNOYAGI A, 1993, J BIOL CHEM, V268, P1539; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; MIKI J, 1988, FEBS LETT, V232, P221, DOI 10.1016/0014-5793(88)80421-6; Muller M, 2002, J BIOL CHEM, V277, P23308, DOI 10.1074/jbc.M201998200; Nathanson L, 2000, J BIOL CHEM, V275, P901, DOI 10.1074/jbc.275.2.901; Nathanson L, 1998, J BIOL CHEM, V273, P10933, DOI 10.1074/jbc.273.18.10933; NELSON N, 1972, J BIOL CHEM, V247, P6506; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Nowak KF, 2004, BIOCHEMISTRY-US, V43, P3273, DOI 10.1021/bi035820d; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Oster G, 2000, BBA-BIOENERGETICS, V1458, P482, DOI 10.1016/S0005-2728(00)00096-7; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PENEFSKY HS, 1985, P NATL ACAD SCI USA, V82, P1589, DOI 10.1073/pnas.82.6.1589; PICK U, 1988, EUR J BIOCHEM, V173, P623, DOI 10.1111/j.1432-1033.1988.tb14044.x; Richter ML, 2000, BBA-BIOENERGETICS, V1458, P326, DOI 10.1016/S0005-2728(00)00084-0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sokolov M, 1999, J BIOL CHEM, V274, P13824, DOI 10.1074/jbc.274.20.13824; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Tucker WC, 2001, EUR J BIOCHEM, V268, P2179, DOI 10.1046/j.1432-1327.2001.02110.x; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	42	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47415	47418		10.1074/jbc.C400269200	http://dx.doi.org/10.1074/jbc.C400269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15377671	hybrid			2022-12-25	WOS:000224957000002
J	Zang, MW; Zuccollo, A; Hou, XY; Nagata, D; Walsh, K; Herscovitz, H; Brecher, P; Ruderman, NB; Cohen, RA				Zang, MW; Zuccollo, A; Hou, XY; Nagata, D; Walsh, K; Herscovitz, H; Brecher, P; Ruderman, NB; Cohen, RA			AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; MALONYL-COA DECARBOXYLASE; CELLULAR-ENERGY; SKELETAL-MUSCLE; GENE-EXPRESSION; GLUCOSE; PHOSPHORYLATION; CASCADE; SECRETION; LKB1	The antidiabetic drug metformin stimulates AMP-activated protein kinase (AMPK) activity in the liver and in skeletal muscle. To better understand the role of AMPK in the regulation of hepatic lipids, we studied the effect of metformin on AMPK and its downstream effector, acetyl-CoA carboxylase (ACC), as well as on lipid content in cultured human hepatoma HepG2 cells. Metformin increased Thr-172 phosphorylation of the alpha subunit of AMPK in a dose- and time-dependent manner. In parallel, phosphorylation of ACC at Ser-79 was increased, which was consistent with decreasing ACC activity. Intracellular triacylglycerol and cholesterol contents were also decreased. These effects of metformin were mimicked or completely abrogated by adenoviral-mediated expression of a constitutively active AMPKalpha or a kinase-inactive AMPKalpha, respectively. An insulin-resistant state was induced by exposing cells to 30 mM glucose as indicated by decreased phosphorylation of Akt and its downstream effector, glycogen synthase kinase 3alpha/beta. Under these conditions, the phosphorylation of AMPK and ACC was also decreased, and the level of hepatocellular triacylglycerols increased. The inhibition of AMPK and the accumulation of lipids caused by high glucose concentrations were prevented either by metformin or by expressing the constitutively active AMPKalpha. The kinase-inactive AMPKalpha increased lipid content and blocked the ability of metformin to decrease lipid accumulation caused by high glucose concentrations. Taken together, these results indicate that AMPKalpha negatively regulates ACC activity and hepatic lipid content. Inhibition of AMPK may contribute to lipid accumulation induced by high concentrations of glucose associated with insulin resistance. Metformin lowers hepatic lipid content by activating AMPK, thereby mediating beneficial effects in hyperglycemia and insulin resistance.	Boston Univ, Sch Med, Vasc Biol Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Boston Univ, Sch Med, Diabet & Metab Unit, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Cohen, RA (corresponding author), Boston Univ, Sch Med, Vasc Biol Unit, X708,650 Albany St, Boston, MA 02118 USA.	racohen@bu.edu		Herscovitz, Haya/0000-0001-8067-6091; /0000-0002-1070-6408; Brecher, Peter/0000-0002-9347-6643; Ruderman, Neil/0000-0002-6589-6587; Zang, Mengwei/0000-0002-2502-2586	NHLBI NIH HHS [P01 HL68758] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Anurag P, 2002, DIABETES OBES METAB, V4, P36, DOI 10.1046/j.1463-1326.2002.00178.x; Buhl ES, 2002, DIABETES, V51, P2199, DOI 10.2337/diabetes.51.7.2199; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Davidson MB, 1997, AM J MED, V102, P99, DOI 10.1016/S0002-9343(96)00353-1; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; FEDELE D, 1976, DIABETES METAB, V2, P127; Foretz M, 1998, J BIOL CHEM, V273, P14767, DOI 10.1074/jbc.273.24.14767; Gerich JE, 1998, ENDOCR REV, V19, P491, DOI 10.1210/er.19.4.491; Hardie DG, 2003, FEBS LETT, V546, P113, DOI 10.1016/S0014-5793(03)00560-X; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HERMANN LS, 1979, DIABETES METAB, V5, P233; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kefas BA, 2004, BIOCHEM PHARMACOL, V68, P409, DOI 10.1016/j.bcp.2004.04.003; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; MIKOKOSHI Y, 2004, NATURE, V428, P569; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783; Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; Payne KL, 1997, EUR J ENDOCRINOL, V137, P415, DOI 10.1530/eje.0.1370415; Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476; Ruderman N, 2004, NAT REV DRUG DISCOV, V3, P340, DOI 10.1038/nrd1344; Ruderman N, 2001, SCIENCE, V291, P2558, DOI 10.1126/science.1060277; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; Sambandam N, 2004, EUR J BIOCHEM, V271, P2831, DOI 10.1111/j.1432-1033.2004.04218.x; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Winder WW, 1997, J APPL PHYSIOL, V82, P219, DOI 10.1152/jappl.1997.82.1.219; Winder WW, 1999, AM J PHYSIOL-ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1; WITTERS LA, 1988, P NATL ACAD SCI USA, V85, P5473, DOI 10.1073/pnas.85.15.5473; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xavier GD, 2003, BIOCHEM J, V371, P761; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yu-Poth S, 2004, J NUTR, V134, P68, DOI 10.1093/jn/134.1.68; Yuan L, 2003, ACTA PHARMACOL SIN, V24, P55; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zou MH, 2002, J BIOL CHEM, V277, P32552, DOI 10.1074/jbc.M204512200	49	368	385	2	60	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47898	47905		10.1074/jbc.M408149200	http://dx.doi.org/10.1074/jbc.M408149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15371448	hybrid			2022-12-25	WOS:000224957000060
J	Kuhn, FJP; Luckhoff, A				Kuhn, FJP; Luckhoff, A			Sites of the NUDT9-H domain critical for ADP-ribose activation of the cation channel TRPM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUDIX HYDROLASES; FAMILY; PYROPHOSPHATASE; LTRPC2; PROTEINS; REVEALS; GENE	TRPM2 is a cation channel unique within the transient receptor potential family because of its gating by ADP-ribose (ADPR). ADPR gating is enabled by a cytosolic C-terminal Nudix box sequence motif embedded into a region homologous to the NUDT9 ADPR pyrophosphatase. A recently discovered splice variant of TRPM2 (TRPM2-DeltaC) lacks 34 amino acid residues in the NUDT9 domain and is insensitive to ADPR. To analyze in detail which parts of the deleted sequence (DeltaC-stretch) are critical for ADPR gating, we tested mutants that lacked 19, 25, and 29 amino acid residues in the N-terminal part or had amino acid residues substituted in the remaining C-terminal part of the DeltaC-stretch. All of these mutants displayed typical ADPR-induced currents. However, the deletion or substitution of the amino acid residue Asn-1326 immediately downstream of the DeltaC-stretch abrogated ADPR gating. We furthermore analyzed the mutation I1405E/L1406F in the Nudix box of TRPM2, because a considerably decreased ADPRase activity of the TRPM2 NUDT9-H protein in comparison to the NUDT9 pyrophosphatase has been attributed to the reverse exchange EF --> IL. The I1405E/L1406F variant of TRPM2 failed to respond to ADPR even at concentrations up to 10 mM. We concluded that the DeltaC-stretch contains no individual amino acid residues essential for ADPR gating but may act as a spacer segment stabilizing a conformation necessary for the essential residue Asn-1326 to interact with other channel regions. Enhancing the enzymatic activity of the Nudix box abolishes the ADPR gating of TRPM2, pointing to the requirement of prolonged binding rather than degradation.	Rhein Westfal TH Aachen, Inst Physiol, Fak Med, D-52057 Aachen, Germany	RWTH Aachen University	Luckhoff, A (corresponding author), Rhein Westfal TH Aachen, Inst Physiol, Fak Med, Pauwelsstr 30, D-52057 Aachen, Germany.	luckhoff@physiology.rwth-aachen.de	Kuehn, Frank JP/H-5889-2018					Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Birnbaumer L, 2003, CELL CALCIUM, V33, P419, DOI 10.1016/S0143-4160(03)00068-X; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; GUSE AH, 2002, CURR MOL MED, V2, P272; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heiner I, 2003, BIOCHEM J, V371, P1045, DOI 10.1042/BJ20021975; Inamura K, 2003, J MEMBRANE BIOL, V191, P201, DOI 10.1007/s00232-002-1057-x; McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Perraud AL, 2003, CELL CALCIUM, V33, P519, DOI 10.1016/S0143-4160(03)00057-5; Perraud AL, 2003, J BIOL CHEM, V278, P1794, DOI 10.1074/jbc.M205601200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Shen BW, 2003, J MOL BIOL, V332, P385, DOI 10.1016/S0022-2836(03)00954-9; Wehage E, 2002, J BIOL CHEM, V277, P23150, DOI 10.1074/jbc.M112096200; Zitt C, 2002, PROG NEUROBIOL, V66, P243, DOI 10.1016/S0301-0082(02)00002-3	21	102	106	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46431	46437		10.1074/jbc.M407263200	http://dx.doi.org/10.1074/jbc.M407263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347676	hybrid			2022-12-25	WOS:000224832400013
J	Kobayashi, T; Funakoshi, Y; Hoshino, S; Katada, T				Kobayashi, T; Funakoshi, Y; Hoshino, S; Katada, T			The GTP-binding release factor eRF3 as a key mediator coupling translation termination to mRNA decay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; FACTOR EF-TU; CRYSTAL-STRUCTURE; POLY(A)-BINDING PROTEIN; IN-VIVO; YEAST; DOMAIN; COMPLEX; ASSOCIATION; SPECIFICITY	GTP is essential for eukaryotic translation termination, where the release factor 3 (eRF3) complexed with eRF1 is involved as the guanine nucleotide-binding protein. In addition, eRF3 regulates the termination-coupled events, eRF3 interacts with poly(A)-binding protein (Pab1) and the surveillance factor Upf1 to mediate normal and nonsense-mediated mRNA decay. However, the roles of GTP binding to eRF3 in these processes remain largely unknown. Here, we showed in yeast that GTP is essentially required for the association of eRF3 with eRF1, but not with Pab1 and Upf1. A mutation in the GTP-binding motifs of eRF3 impairs the eRF1-binding ability without altering the Pab1- or Upf1-binding activity. Interestingly, the mutation causes not only a defect in translation termination but also delay of normal and nonsense-mediated mRNA decay, suggesting that GTP/eRF3-dependent termination exerts its influence on the subsequent mRNA degradation. The termination reaction itself is not sufficient, but eRF3 is essential for triggering mRNA decay. Thus, eRF3 is a key mediator that transduces termination signal to mRNA decay.	Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Hoshino, S (corresponding author), Univ Tokyo, Dept Physiol Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	hoshino@mol.f.u-tokyo.ac.jp		Hoshino, Shinichi/0000-0001-6135-7896				Araki Y, 2001, EMBO J, V20, P4684, DOI 10.1093/emboj/20.17.4684; BEAUDET AL, 1971, P NATL ACAD SCI USA, V68, P619, DOI 10.1073/pnas.68.3.619; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; Bertram G, 2001, MICROBIOL-SGM, V147, P255, DOI 10.1099/00221287-147-2-255; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Cosson B, 2002, BIOL CELL, V94, P205, DOI 10.1016/S0248-4900(02)01194-2; Cosson B, 2002, MOL CELL BIOL, V22, P3301, DOI 10.1128/MCB.22.10.3301-3315.2002; Czaplinski K, 1998, GENE DEV, V12, P1665, DOI 10.1101/gad.12.11.1665; Drugeon G, 1997, NUCLEIC ACIDS RES, V25, P2254, DOI 10.1093/nar/25.12.2254; Ebihara K, 1999, RNA, V5, P739, DOI 10.1017/S135583829998216X; Eurwilaichitr L, 1999, MOL MICROBIOL, V32, P485, DOI 10.1046/j.1365-2958.1999.01346.x; Frolova L, 1996, RNA, V2, P334; FROLOVA L, 1994, NATURE, V372, P701, DOI 10.1038/372701a0; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; Hoshino S, 1999, J BIOL CHEM, V274, P16677, DOI 10.1074/jbc.274.24.16677; Hosoda N, 2003, J BIOL CHEM, V278, P38287, DOI 10.1074/jbc.C300300200; HWANG YW, 1987, J BIOL CHEM, V262, P13081; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Inagaki Y, 2000, MOL BIOL EVOL, V17, P882, DOI 10.1093/oxfordjournals.molbev.a026368; Inagaki Y, 2003, NUCLEIC ACIDS RES, V31, P4227, DOI 10.1093/nar/gkg440; Inge-Vechtomov S, 2003, BIOL CELL, V95, P195, DOI 10.1016/S0248-4900(03)00035-2; Ito K, 1998, RNA, V4, P958, DOI 10.1017/S1355838298971874; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; KIKUCHI Y, 1988, EMBO J, V7, P1175, DOI 10.1002/j.1460-2075.1988.tb02928.x; Kisselev L, 2003, EMBO J, V22, P175, DOI 10.1093/emboj/cdg017; Kisselev LL, 2000, TRENDS BIOCHEM SCI, V25, P561, DOI 10.1016/S0968-0004(00)01669-8; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KONECKI DS, 1977, J BIOL CHEM, V252, P4514; Kong CG, 2004, MOL CELL, V14, P233, DOI 10.1016/S1097-2765(04)00206-0; Kozlov G, 2001, P NATL ACAD SCI USA, V98, P4409, DOI 10.1073/pnas.071024998; Merkulova TI, 1999, FEBS LETT, V443, P41, DOI 10.1016/S0014-5793(98)01669-X; Merrick WC, 2000, COLD SPRING HARBOR M, V39, P89; Nakamura Y, 2000, CELL, V101, P349, DOI 10.1016/S0092-8674(00)80845-4; Nakamura Y, 2003, TRENDS BIOCHEM SCI, V28, P99, DOI 10.1016/S0968-0004(03)00006-9; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAHA SK, 1986, J BIOL CHEM, V261, P2599; Schwartz DC, 2000, COLD SPRING HARBOR M, V39, P807; Song HW, 2000, CELL, V100, P311, DOI 10.1016/S0092-8674(00)80667-4; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; Wang WR, 2001, EMBO J, V20, P880, DOI 10.1093/emboj/20.4.880; Welch EM, 2000, COLD SPRING HARBOR M, V39, P467; Zavialov AV, 2001, CELL, V107, P115, DOI 10.1016/S0092-8674(01)00508-6; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	50	50	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45693	45700		10.1074/jbc.M405163200	http://dx.doi.org/10.1074/jbc.M405163200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15337765	hybrid			2022-12-25	WOS:000224694900050
J	Azriel-Tamir, H; Sharir, H; Schwartz, B; Hershfinkel, M				Azriel-Tamir, H; Sharir, H; Schwartz, B; Hershfinkel, M			Extracellular zinc triggers ERK-dependent activation of Na+/H+ exchange in colonocytes mediated by the zinc-sensing receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR RECEPTOR; GLOMERULAR MESANGIAL CELLS; SIGNAL-REGULATED KINASE; PH REGULATION; INTRACELLULAR CA2+; COLONIC CRYPTS; T-84 CELLS; CROSS-TALK; CALCIUM	Extracellular zinc promotes cell proliferation and its deficiency leads to impairment of this process, which is particularly important in epithelial cells. We have recently characterized a zinc-sensing receptor (ZnR) linking extracellular zinc to intracellular release of calcium. In the present study, we addressed the role of extracellular zinc, acting via the ZnR, in regulating the MAP kinase pathway and Na+/H+ exchange in colonocytes. We demonstrate that Ca2+ release, mediated by the ZnR, induces phosphorylation of ERK1/2, which is highly metal-specific, mediated by physiological concentrations of extracellular Zn2+ but not by Cd2+, Fe2+, Ni2+, or Mn2+. Desensitization of the ZnR by Zn2+, is followed by similar to90% inhibition of the Zn2+-dependent ERK1/2 phosphorylation, indicating that the ZnR is a principal link between extracellular Zn2+ and ERK1/2 activation. Application of both the IP3 pathway and PI 3-kinase antagonists largely inhibited Zn2+-dependent ERK1/2 phosphorylation. The physiological significance of the Zn2+-dependent activation of ERK1/2 was addressed by monitoring Na+/H+ exchanger activity in HT29 cells and in native colon epithelium. Preincubation of the cells with zinc was followed by robust activation of Na+/H+ exchange, which was eliminated by cariporide (0.5 muM); indicating that zinc enhances the activity of NHE1. Activation of NHE1 by zinc was totally blocked by the ERK1/2 inhibitor, U0126. Prolonged acidification, in contrast, stimulates NHE1 by a distinct pathway that is not affected by extracellular Zn2+ or inhibitors of the MAP kinase pathway. Desensitization of ZnR activity eliminates the Zn2+-dependent, but not the prolonged acidification-dependent activation of NHE1, indicating that Zn2+-dependent activation of H+ extrusion is specifically mediated by the ZnR. Our results support a role for extracellular zinc, acting through the ZnR, in regulating multiple signaling pathways that affect pH homeostasis in colonocytes. Furthermore activation of both, ERK and NHE1, by extracellular zinc may provide the mechanism linking zinc to enhanced cell proliferation.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, Zlotowski Ctr Neurosci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Dept Physiol, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Canc Res Ctr, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Fac Agr, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel	Ben Gurion University; Ben Gurion University; Ben Gurion University; Hebrew University of Jerusalem	Hershfinkel, M (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Morphol, Zlotowski Ctr Neurosci, Box 653, IL-84105 Beer Sheva, Israel.	hmichal@bgu.ac.il	Hershfinkel, Michal/F-1548-2012	Hershfinkel, Michal/0000-0003-1652-1989				Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; ATAR D, 1995, J BIOL CHEM, V270, P2473, DOI 10.1074/jbc.270.6.2473; Bachmann O, 2004, AM J PHYSIOL-GASTR L, V287, pG125, DOI 10.1152/ajpgi.00332.2003; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC857, DOI 10.1152/ajpcell.1988.255.6.C857; BOYARSKY G, 1988, AM J PHYSIOL, V255, pC844, DOI 10.1152/ajpcell.1988.255.6.C844; Busche R, 1997, COMP BIOCHEM PHYS A, V118, P395, DOI 10.1016/S0300-9629(96)00327-1; Cammarota M, 2002, CELL MOL NEUROBIOL, V22, P259, DOI 10.1023/A:1020763716886; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHEN SM, 2004, NEPHRON PHYSIOL, V96, P113; Chimienti F, 2003, CURR DRUG TARGETS, V4, P323, DOI 10.2174/1389450033491082; Chu JS, 2002, AM J PHYSIOL-CELL PH, V283, pC358, DOI 10.1152/ajpcell.01380.2000; CHU SY, 1995, P NATL ACAD SCI USA, V92, P3303, DOI 10.1073/pnas.92.8.3303; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dudeja PK, 1996, AM J PHYSIOL-GASTR L, V271, pG483, DOI 10.1152/ajpgi.1996.271.3.G483; Duvillard C, 2004, ANTI-CANCER DRUG, V15, P295, DOI 10.1097/00001813-200403000-00015; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Elgersma Y, 2002, NEURON, V36, P493, DOI 10.1016/S0896-6273(02)01007-3; Ginnan R, 2002, AM J PHYSIOL-CELL PH, V282, pC754, DOI 10.1152/ajpcell.00335.2001; Gonda T, 1999, AM J PHYSIOL-GASTR L, V276, pG259, DOI 10.1152/ajpgi.1999.276.1.G259; Hasselblatt P, 2000, PFLUG ARCH EUR J PHY, V441, P118, DOI 10.1007/s004240000377; Haworth RS, 2003, J BIOL CHEM, V278, P31676, DOI 10.1074/jbc.M304400200; Hazan-Halevy I, 2000, J BIOL CHEM, V275, P12416, DOI 10.1074/jbc.275.17.12416; Hershfinkel M, 2001, P NATL ACAD SCI USA, V98, P11749, DOI 10.1073/pnas.201193398; Kaiser GC, 1999, EXP CELL RES, V249, P349, DOI 10.1006/excr.1999.4488; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Keely SJ, 2000, J BIOL CHEM, V275, P12619, DOI 10.1074/jbc.275.17.12619; Keely SJ, 1999, J BIOL CHEM, V274, P33449, DOI 10.1074/jbc.274.47.33449; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kiss Z, 1997, FEBS LETT, V415, P71, DOI 10.1016/S0014-5793(97)01095-8; KNUDSEN E, 1995, J NUTR, V125, P1274; Koh SD, 1999, J PHYSIOL-LONDON, V517, P75, DOI 10.1111/j.1469-7793.1999.0075z.x; Krishnan S, 2003, AM J PHYSIOL-CELL PH, V285, pC1246, DOI 10.1152/ajpcell.00598.2002; LAWSON MJ, 1988, BIOL TRACE ELEM RES, V18, P115, DOI 10.1007/BF02917495; MacDonald RS, 2000, J NUTR, V130, p1500S, DOI 10.1093/jn/130.5.1500S; Maouyo D, 2000, AM J PHYSIOL-CELL PH, V278, pC973, DOI 10.1152/ajpcell.2000.278.5.C973; Maret W, 2001, P NATL ACAD SCI USA, V98, P12325, DOI 10.1073/pnas.231481398; Maret W, 2001, BIOMETALS, V14, P187, DOI 10.1023/A:1012945110820; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Masereel B, 2003, EUR J MED CHEM, V38, P547, DOI 10.1016/S0223-5234(03)00100-4; MCKEARN TJ, 1993, CANCER, V71, P4302, DOI 10.1002/1097-0142(19930615)71:12+<4302::AID-CNCR2820711820>3.0.CO;2-M; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; Montrose MH, 1997, COMP BIOCHEM PHYS A, V118, P389, DOI 10.1016/S0300-9629(96)00326-X; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Park KS, 2003, AM J PHYSIOL-GASTR L, V19, P19; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Philp AJ, 2001, CANCER RES, V61, P7426; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Praskova M, 2002, ARCH DERMATOL RES, V294, P198, DOI 10.1007/s00403-002-0312-4; Praskova M, 2002, EXP DERMATOL, V11, P344, DOI 10.1034/j.1600-0625.2002.110408.x; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; ROBINSON NC, 2004, J PHYSL, V30, P30; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; SANDSTROM B, 1995, ANALYST, V120, P913, DOI 10.1039/an9952000913; SANDSTROM B, 1986, AM J CLIN NUTR, V44, P501, DOI 10.1093/ajcn/44.4.501; Schultheiss Gerhard, 2002, Biological Procedures Online, V3, P70, DOI 10.1251/bpo25; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sheng H, 2003, GUT, V52, P1472, DOI 10.1136/gut.52.10.1472; Szapiro G, 2003, HIPPOCAMPUS, V13, P53, DOI 10.1002/hipo.10043; TAKEWAKI S, 1995, J MOL CELL CARDIOL, V27, P729, DOI 10.1016/S0022-2828(08)80063-6; Thamilselvan V, 2003, J SURG RES, V110, P255, DOI 10.1016/S0022-4804(03)00028-3; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; Velazquez OC, 1997, ADV EXP MED BIOL, V427, P123; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang YG, 2003, CIRC RES, V93, P776, DOI 10.1161/01.RES.0000094746.24774.DC; Wapnir RA, 2000, J NUTR, V130, p1388S, DOI 10.1093/jn/130.5.1388S; Winter DC, 2000, BRIT J SURG, V87, P1684, DOI 10.1046/j.1365-2168.2000.01584.x; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877; WU FYH, 1987, ANNU REV NUTR, V7, P251, DOI 10.1146/annurev.nu.07.070187.001343; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0	78	86	88	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					51804	51816		10.1074/jbc.M406581200	http://dx.doi.org/10.1074/jbc.M406581200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15355987	hybrid			2022-12-25	WOS:000225493400013
J	Kessi, J; Hanselmann, KW				Kessi, J; Hanselmann, KW			Similarities between the abiotic reduction of selenite with glutathione and the dissimilatory reaction mediated by Rhodospirillum rubrum and Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENTAL SELENIUM; SUPEROXIDE; SELENODIGLUTATHIONE; THIOREDOXIN; DISULFIDES; MECHANISMS; TOXICITY; SELENATE	Various mechanisms have been proposed to explain the biological dissimilatory reduction of selenite (SeO32-) to elemental selenium (Se-o), although none is without controversy. Glutathione, the most abundant thiol in the eukaryotic cells, the cyanobacteria, and the alpha, beta, and gamma groups of the proteobacteria, has long been suspected to be involved in selenium metabolism. Experiments with the phototrophic alpha proteobacterium Rhodospirillum rubrum showed that the rate of selenite reduction was decreased when bacteria synthesized lower than normal levels of glutathione, and in Rhodobacter sphaeroides and Escherichia coli the reaction was reported to induce glutathione reductase. In the latter organism superoxide dismutase was also induced in cells grown in the presence of selenite, indicating that superoxide anions (O-2(-)) were produced. These observations led us to investigate the abiotic ( chemical) reduction of selenite by glutathione and to compare the features of this reaction with those of the reaction mediated by R. rubrum and E. coli. Our findings imply that selenite was first reduced to selenodiglutathione, which reached its maximum concentration within the 1st min of the reaction. Formation of selenodiglutathione was paralleled by a rapid reduction of cytochrome c, a known oxidant for superoxide anions. Cytochrome c reduction was inhibited by superoxide dismutase, indicating that O-2(-) was the source of electrons for the reduction. These results demonstrated that superoxide was produced in the abiotic reduction of selenite with glutathione, thus lending support to the hypothesis that glutathione may be involved in the reaction mediated by R. rubrum and E. coli. The second phase of the reaction, which led to the formation of elemental selenium (Se-o), developed more slowly. Se-o precipitation reached a maximum within 2 h after the beginning of the reaction. Secondary reactions leading to the degradation of the superoxide significantly decreased the yield of Se-o in the abiotic reaction compared with that of the bacterially mediated selenite reduction. Abiotically formed selenium particles showed the same characteristic orange-red color, spherical structure, and size as particles produced by R. rubrum, again providing support for the hypothesis that glutathione is involved in the reduction of selenite to elemental selenium in this organism.	Univ Zurich, Inst Plant Biol, Microbial Ecol Grp, CH-8008 Zurich, Switzerland	University of Zurich	Kessi, J (corresponding author), Univ Zurich, Inst Plant Biol, Microbial Ecol Grp, Zollikerstr 107, CH-8008 Zurich, Switzerland.	Janine.kessi@access.unizh.ch		Kessi, Janine/0000-0002-9414-4050				APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P1, DOI 10.1016/0304-4165(75)90205-6; Bebien M, 2001, APPL ENVIRON MICROB, V67, P4440, DOI 10.1128/AEM.67.10.4440-4447.2001; Bebien M, 2002, J BACTERIOL, V184, P1556, DOI 10.1128/JB.184.6.1556-1564.2002; Beveridge TJ, 1999, J BACTERIOL, V181, P4725, DOI 10.1128/JB.181.16.4725-4733.1999; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BJORNSTEDT M, 1995, METHOD ENZYMOL, V252, P209; Dungan RS, 2003, ENVIRON MICROBIOL, V5, P287, DOI 10.1046/j.1462-2920.2003.00410.x; FREW JE, 1983, ANAL CHIM ACTA, V155, P139, DOI 10.1016/S0003-2670(00)85587-7; GANTHER HE, 1971, BIOCHEMISTRY-US, V10, P4089, DOI 10.1021/bi00798a013; Garbisu C, 1995, BIOFACTORS, V5, P29; Garbisu C, 1999, BIOFACTORS, V10, P311, DOI 10.1002/biof.5520100401; Gates B, 2002, ADV FUNCT MATER, V12, P219, DOI 10.1002/1616-3028(200203)12:3<219::AID-ADFM219>3.0.CO;2-U; HESS WM, 1966, STAIN TECHNOL, V41, P27, DOI 10.3109/10520296609116276; KESSI J, 1994, BIOCHEMISTRY-US, V33, P10825, DOI 10.1021/bi00201a033; Kessi J, 1999, APPL ENVIRON MICROB, V65, P4734; KRAMER GF, 1988, MUTAT RES, V201, P169, DOI 10.1016/0027-5107(88)90123-6; LAPAGE SP, 1968, J APPL BACTERIOL, V31, P568, DOI 10.1111/j.1365-2672.1968.tb00407.x; LAUCHLI A, 1993, BOT ACTA, V106, P455; LORTIE L, 1992, APPL ENVIRON MICROB, V58, P4042, DOI 10.1128/AEM.58.12.4042-4044.1992; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; NEWTON GL, 1989, GLUTATHIONE METABOLI, P69; O'Toole D, 1998, BOOK SOIL P, V64, P355; OHLENDORF H M, 1989, SSSA Special Publication, P133; Oremland RS, 2004, APPL ENVIRON MICROB, V70, P52, DOI 10.1128/AEM.70.1.52-60.2004; Painter EP, 1941, CHEM REV, V28, P179, DOI 10.1021/cr60090a001; Roux M, 2001, APPL ENVIRON MICROB, V67, P769, DOI 10.1128/AEM.67.2.769-773.2001; SINGH R, 1991, J ORG CHEM, V56, P6931, DOI 10.1021/jo00024a041; SWERDLOW RD, 1983, J BACTERIOL, V153, P475, DOI 10.1128/JB.153.1.475-484.1983; WATKINSON JH, 1966, ANAL CHEM, V38, P92; WINTERBOURN CC, 1995, METHOD ENZYMOL, V251, P81, DOI 10.1016/0076-6879(95)51112-1	30	150	165	5	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50662	50669		10.1074/jbc.M405887200	http://dx.doi.org/10.1074/jbc.M405887200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371444	hybrid			2022-12-25	WOS:000225355800006
J	Ahn, HJ; Kim, KH; Lee, J; Ha, JY; Lee, HH; Kim, D; Yoon, HJ; Kwon, AR; Suh, SW				Ahn, HJ; Kim, KH; Lee, J; Ha, JY; Lee, HH; Kim, D; Yoon, HJ; Kwon, AR; Suh, SW			Crystal structure of agmatinase reveals structural conservation and inhibition mechanism of the ureohydrolase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINUCLEAR MANGANESE CLUSTER; ELECTRON-DENSITY MAPS; ESCHERICHIA-COLI AGMATINASE; TRANSITION-STATE ANALOG; CATALYTIC-ACTIVITY; PHYSIOLOGICAL-ROLE; ERECTILE FUNCTION; LIVER ARGINASE; NITRIC-OXIDE; RAT-BRAIN	Agmatine is the product of arginine decarboxylation and can be hydrolyzed by agmatinase to putrescine, the precursor for biosynthesis of higher polyamines, spermidine, and spermine. Besides being an intermediate in polyamine metabolism, recent findings indicate that agmatine may play important regulatory roles in mammals. Agmatinase is a binuclear manganese metalloenzyme and belongs to the ureohydrolase superfamily that includes arginase, formiminoglutamase, and proclavaminate amidinohydrolase. Compared with a wealth of structural information available for arginases, no three-dimensional structure of agmatinase has been reported. Agmatinase from Deinococcus radiodurans, a 304-residue protein, shows similar to 33% of sequence identity to human mitochondrial agmatinase. Here we report the crystal structure of D. radiodurans agmatinase in Mn2+-free, Mn2+-bound, and Mn2+-inhibitor-bound forms, representing the first structure of agmatinase. It reveals the conservation as well as variation in folding, oligomerization, and the active site of the ureohydrolase superfamily. D. radiodurans agmatinase exists as a compact homohexamer of 32 symmetry. Its binuclear manganese cluster is highly similar but not identical to the clusters of arginase and proclavaminate amidinohydrolase. The structure of the inhibited complex reveals that inhibition by 1,6-diaminohexane arises from the displacement of the metal-bridging water.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU)	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Suh, Won/H-8306-2013; Kim, Do Jin/I-7675-2014	Suh, Won/0000-0002-1768-4635; 				Baggio R, 1997, J AM CHEM SOC, V119, P8107, DOI 10.1021/ja971312d; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bewley MC, 1999, STRUCT FOLD DES, V7, P435, DOI 10.1016/S0969-2126(99)80056-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cama E, 2004, BIOCHEMISTRY-US, V43, P8987, DOI 10.1021/bi0491705; Cama E, 2003, BIOCHEMISTRY-US, V42, P7748, DOI 10.1021/bi030074y; Cama E, 2003, BIOCHEMISTRY-US, V42, P8445, DOI 10.1021/bi034340j; Carvajal N, 1999, BIOCHEM BIOPH RES CO, V264, P196, DOI 10.1006/bbrc.1999.1505; Carvajal N, 1999, BIOCHEM BIOPH RES CO, V258, P808, DOI 10.1006/bbrc.1999.0709; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Cox JD, 2001, BIOCHEMISTRY-US, V40, P2689, DOI 10.1021/bi002318+; Cox JD, 1999, NAT STRUCT BIOL, V6, P1043; Elkins JM, 2002, BIOCHEM J, V366, P423, DOI 10.1042/BJ20020125; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Gilad GM, 1996, NEUROREPORT, V7, P1730, DOI 10.1097/00001756-199607290-00007; Iyer RK, 2002, MOL GENET METAB, V75, P209, DOI 10.1006/mgme.2001.3277; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANYO Z, 1996, THESIS U PENNSYLVANI; Kanyo ZF, 1996, NATURE, V383, P554, DOI 10.1038/383554a0; KHANGULOV SV, 1995, BIOCHEMISTRY-US, V34, P2015, DOI 10.1021/bi00006a023; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P8539, DOI 10.1021/bi972874c; KHRAMOV V A, 1976, Biokhimiya, V41, P553; Kim NN, 2001, BIOCHEMISTRY-US, V40, P2678, DOI 10.1021/bi002317h; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JA, 2004, ACTA CRYSTALLOGR D, V60, P1890, DOI 10.1107/S0907444904018761; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LOTRIE MJ, 1996, J CLIN INVEST, V97, P413; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mistry SK, 2002, AM J PHYSIOL-GASTR L, V282, pG375, DOI 10.1152/ajpgi.00386.2001; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUZOUNIS CA, 1994, J MOL EVOL, V39, P101; RAASCH W, 1995, LIFE SCI, V56, P2319, DOI 10.1016/0024-3205(95)00226-V; REGUNATHAN S, 1995, NEUROREPORT, V6, P1897, DOI 10.1097/00001756-199510020-00018; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; Reis DJ, 1999, ANN NY ACAD SCI, V881, P65, DOI 10.1111/j.1749-6632.1999.tb09343.x; Sastre M, 1996, J NEUROCHEM, V67, P1761; Sastre M, 1998, BIOCHEM J, V330, P1405, DOI 10.1042/bj3301405; SATISHCHANDRAN C, 1986, J BACTERIOL, V165, P843, DOI 10.1128/jb.165.3.843-848.1986; Sekowska A, 2000, MICROBIOL-SGM, V146, P1815, DOI 10.1099/00221287-146-8-1815; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001	44	40	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50505	50513		10.1074/jbc.M409246200	http://dx.doi.org/10.1074/jbc.M409246200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355972	hybrid			2022-12-25	WOS:000225229500116
J	Lee, HH; Kim, DJ; Ahn, HJ; Ha, JY; Suh, SW				Lee, HH; Kim, DJ; Ahn, HJ; Ha, JY; Suh, SW			Crystal structure of T-protein of the glycine cleavage system - Cofactor binding, insights into H-protein recognition, and molecular basis for understanding nonketotic hyperglycinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEA LEAF MITOCHONDRIA; ESCHERICHIA-COLI; DECARBOXYLASE COMPLEX; TETRAHYDROFOLATE POLYGLUTAMATES; SERINE HYDROXYMETHYLTRANSFERASE; TERMINAL REGION; GENE; CRYSTALLIZATION; PURIFICATION; ASSOCIATION	The glycine cleavage system catalyzes the oxidative decarboxylation of glycine in bacteria and in mitochondria of animals and plants. Its deficiency in human causes nonketotic hyperglycinemia, an inborn error of glycine metabolism. T-protein, one of the four components of the glycine cleavage system, is a tetrahydrofolate-dependent aminomethyltransferase. It catalyzes the transfer of the methylene carbon unit to tetrahydrofolate from the methylamine group covalently attached to the lipoamide arm of H-protein. To gain insight into the T-protein function at the molecular level, we have determined the first crystal structure of T-protein from Thermotoga maritima by the multiwavelength anomalous diffraction method of x-ray crystallography and refined four structures: the apoform; the tetrahydrofolate complex; the folinic acid complex; and the lipoic acid complex. The overall fold of T-protein is similar to that of the C-terminal tetrahydrofolate-binding region ( residues 421 - 830) of Arthrobacter globiformis dimethylglycine oxidase. Tetrahydrofolate ( or folinic acid) is bound near the center of the tripartite T-protein. Lipoic acid is bound adjacent to the tetrahydrofolate binding pocket, thus defining the interaction surface for H-protein binding. A homology model of the human T-protein provides the structural framework for understanding the molecular mechanisms underlying the development of nonketotic hyperglycinemia due to missense mutations of the human T-protein.	Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU)	Suh, SW (corresponding author), Seoul Natl Univ, Coll Nat Sci, Dept Chem, Seoul 151742, South Korea.	sewonsuh@snu.ac.kr	Suh, Won/H-8306-2013; Kim, Do Jin/I-7675-2014	Suh, Won/0000-0002-1768-4635; 				BESSON V, 1993, BIOCHEM J, V292, P425, DOI 10.1042/bj2920425; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen-Addad C, 1997, BIOCHIMIE, V79, P637, DOI 10.1016/S0300-9084(97)83496-7; COHENADDAD C, 1995, NAT STRUCT BIOL, V2, P63, DOI 10.1038/nsb0195-63; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Guilhaudis L, 2000, BIOCHEMISTRY-US, V39, P4259, DOI 10.1021/bi992674w; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kure S, 1998, J HUM GENET, V43, P135, DOI 10.1007/s100380050055; Kure S, 1998, HUM GENET, V102, P430, DOI 10.1007/s004390050716; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leys D, 2003, EMBO J, V22, P4038, DOI 10.1093/emboj/cdg395; Lokanath NK, 2004, ACTA CRYSTALLOGR D, V60, P1450, DOI 10.1107/S0907444904012910; Macherel D, 1996, EUR J BIOCHEM, V236, P27, DOI 10.1111/j.1432-1033.1996.00027.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOTOKAWA Y, 1995, BIOTHIOLS HLTH DIS, P389; Nakai T, 2003, ACTA CRYSTALLOGR D, V59, P1610, DOI 10.1107/S0907444903014975; Nakai T, 2003, ACTA CRYSTALLOGR D, V59, P554, DOI 10.1107/S090744490300043X; NANAO K, 1994, HUM GENET, V93, P655; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okamura-Ikeda K, 1999, EUR J BIOCHEM, V264, P446, DOI 10.1046/j.1432-1327.1999.00637.x; Okamura-Ikeda K, 2003, J BIOL CHEM, V278, P10067, DOI 10.1074/jbc.M210853200; OKAMURAIKEDA K, 1993, EUR J BIOCHEM, V216, P539, DOI 10.1111/j.1432-1033.1993.tb18172.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARES S, 1994, P NATL ACAD SCI USA, V91, P4850, DOI 10.1073/pnas.91.11.4850; REBEILLE F, 1994, BIOCHEM J, V302, P223, DOI 10.1042/bj3020223; Sakata Y, 2001, MOL BRAIN RES, V94, P119, DOI 10.1016/S0169-328X(01)00225-X; TADA K, 1993, J INHERIT METAB DIS, V16, P691, DOI 10.1007/BF00711901; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P38, DOI 10.1107/S0907444902018036; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toone JR, 2001, HUM MUTAT, V17, DOI 10.1002/1098-1004(2001)17:1<76::AID-HUMU17>3.0.CO;2-0; Toone JR, 2000, MOL GENET METAB, V70, P116, DOI 10.1006/mgme.2000.3000; Toone JR, 2003, MOL GENET METAB, V79, P272, DOI 10.1016/S1096-7192(03)00115-X; Toone JR, 2001, MOL GENET METAB, V72, P322, DOI 10.1006/mgme.2001.3158	40	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50514	50523		10.1074/jbc.M409672200	http://dx.doi.org/10.1074/jbc.M409672200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355973	hybrid			2022-12-25	WOS:000225229500117
J	Fu, DC; Wen, Y; Ma, J				Fu, DC; Wen, Y; Ma, J			The co-activator CREB-binding protein participates in enhancer-dependent activities of bicoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENERAL TRANSCRIPTION FACTORS; DROSOPHILA EMBRYO; DNA-BINDING; ACETYLTRANSFERASE ACTIVITY; ACTIVATION; CBP; RECRUITMENT; REPRESSION; EXPRESSION; PROMOTER	Bicoid (Bcd) is a transcriptional activator required for early embryonic patterning in Drosophila. Despite extensive studies, it currently remains unclear how Bcd activates transcription and what proteins participate in its activation process. In this report, we describe experiments to analyze the role of the Drosophila co-activator dCBP in Bcd-mediated activation. In Drosophila S2 cells, the Bcd activity is increased by the co-transfection of plasmids expressing dCBP and reduced by double-stranded RNA-mediated interference against dCBP. We further show that Bcd and dCBP can interact with each other and that Bcd-interacting domains of dCBP can cause dominant negative effects on Bcd activity in S2 cells. Our comparison of two Bcd-responsive enhancers, hunchback (hb) and knirps (kni), reveals a differential role of dCBP in facilitating Bcd activation. A dCBP mutant defective in its histone acetyltransferase activity exhibits a reduced, but not abolished, co-activator function for Bcd. Our chromatin immunoprecipitation experiments show that dCBP can increase not only the occupancy of Bcd itself at the enhancers but also the recruitment of general transcription factors to the promoter. Together, these experiments suggest that dCBP is an enhancer-dependent co-activator of Bcd, facilitating its activation through multiple mechanisms.	Univ Cincinnati, Coll Med, Grad Program Mol & Dev Biol, Cincinnati Childrens Hosp Res Fdn,Div Dev Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Ma, J (corresponding author), Univ Cincinnati, Coll Med, Grad Program Mol & Dev Biol, Cincinnati Childrens Hosp Res Fdn,Div Dev Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jun.ma@cchmc.org	Ma, Jun/GLT-4809-2022	Ma, Jun/0000-0002-1609-3294				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Breiling A, 2001, NATURE, V412, P651, DOI 10.1038/35088090; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; Chan HM, 2001, J CELL SCI, V114, P2363; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1989, NATURE, V342, P149, DOI 10.1038/342149a0; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Driever W., 1992, TRANSCRIPTIONAL REGU, P1221; Ephrussi A, 2004, CELL, V116, P143, DOI 10.1016/S0092-8674(04)00037-6; Florence B, 1998, GENETICS, V150, P1497; Fu DC, 2003, MOL CELL BIOL, V23, P4439, DOI 10.1128/MCB.23.13.4439-4448.2003; Gao Q, 1996, MECH DEVELOP, V56, P3, DOI 10.1016/0925-4773(96)00504-7; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hatzis P, 2002, MOL CELL, V10, P1467, DOI 10.1016/S1097-2765(02)00786-4; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; Ludlam WH, 2002, MOL CELL BIOL, V22, P3832, DOI 10.1128/MCB.22.11.3832-3841.2002; Ma XG, 1996, DEVELOPMENT, V122, P1195; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pile LA, 2003, J BIOL CHEM, V278, P37840, DOI 10.1074/jbc.M305996200; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RiveraPomar R, 1996, TRENDS GENET, V12, P478, DOI 10.1016/0168-9525(96)10044-5; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; Schaeffer V, 1999, P NATL ACAD SCI USA, V96, P4461, DOI 10.1073/pnas.96.8.4461; Sekinger EA, 2001, CELL, V105, P403, DOI 10.1016/S0092-8674(01)00329-4; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Waltzer L, 1999, EMBO J, V18, P1630, DOI 10.1093/emboj/18.6.1630; Yuan D, 1999, J BIOCHEM-TOKYO, V125, P809, DOI 10.1093/oxfordjournals.jbchem.a022353; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhao C, 2000, MOL CELL BIOL, V20, P8112, DOI 10.1128/MCB.20.21.8112-8123.2000; Zhao C, 2003, J BIOL CHEM, V278, P43901, DOI 10.1074/jbc.M302714200; Zhao C, 2002, DEVELOPMENT, V129, P1669; ZHAO C, 2003, RRD MOLEC CELL BIOL, V4, P115	52	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48725	48733		10.1074/jbc.M407066200	http://dx.doi.org/10.1074/jbc.M407066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358774	hybrid			2022-12-25	WOS:000225098100030
J	Fahnert, B; Veijola, J; Roel, G; Karkkainen, MK; Railo, A; Destree, O; Vainio, S; Neubauer, P				Fahnert, B; Veijola, J; Roel, G; Karkkainen, MK; Railo, A; Destree, O; Vainio, S; Neubauer, P			Murine Wnt-1 with an internal c-myc tag recombinantly produced in Escherichia coli can induce intracellular signaling of the canonical Wnt pathway in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-MODIFIED PROTEINS; TRANSCRIPTION FACTOR; XENOPUS EMBRYOS; BETA-CATENIN; SPEMANN ORGANIZER; AXIS FORMATION; EXPRESSION; KIDNEY; IDENTIFICATION; LIPOPROTEINS	Wnt-1 belongs to the Wnt family of secreted glycoproteins inducing an intracellular signaling pathway involved in cell proliferation, differentiation, and pattern formation. The canonical branch is one of three known branches. This is also valid in vitro, and Wnts can be considered beneficial for culturing primary cells from organs, provided Wnts are available and applicable even with cells of different species. It was shown here that internally c-myc-tagged murine Wnt-1 produced in the heterologous host Escherichia coli was appropriate for inducing intracellular signaling of the canonical Wnt pathway in eukaryotic cells via stabilization of cytosolic beta-catenin. The pioneering injection of the protein into the blastocoels of Xenopus laevis embryos led to axis duplication and suppression of head formation. Applying the recombinant murine Wnt-1 to metanephric mesenchyme activated the tubulogenic program. The signal-inducing activity of the recombinant protein was also positively demonstrated in the TOPflash reporter assay. Although Wnts were purified recently from the growth media of stably transfected eukaryotic cell lines, the production of active Wnt proteins in pro- or eukaryotic microorganisms reportedly has never been successful. Here soluble production in E. coli and translocation into the oxidizing environment of the periplasm were achieved. The protein was purified using the internal c-myc tag. The effect on the eukaryotic cells implies that activity was retained. Thus, this approach could make recombinant murine Wnt-1 available as a good starting point for other Wnts needed, for example, for maintaining and differentiating stem cells, organ restoration therapy, and tissue engineering.	Univ Oulu, Dept Proc & Environm Engn, Bioproc Engn Lab, FIN-90014 Oulu, Finland; Bioctr Oulu, FIN-90014 Oulu, Finland; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	University of Oulu; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Finland National Institute for Health & Welfare; University of Oulu	Fahnert, B (corresponding author), Univ Oulu, Dept Proc & Environm Engn, Bioproc Engn Lab, POB 4300, FIN-90014 Oulu, Finland.	beatrix.fahnert@oulu.fi	Neubauer, Peter/N-8146-2013; Neubauer, Peter/W-4518-2019; Fahnert, Beatrix/A-6852-2010	Neubauer, Peter/0000-0002-1214-9713; Fahnert, Beatrix/0000-0002-1768-6702; Vainio, Seppo/0000-0001-9319-3566				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; Carroll TJ, 2000, J AM SOC NEPHROL, V11, pS116; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DAVIES JA, 1995, DEV BIOL, V167, P50, DOI 10.1006/dbio.1995.1006; Dihlmann S, 2003, MOL CANCER THER, V2, P509; DU SJ, 1995, MOL CELL BIOL, V15, P2625; FAHNERT B, 2001, THESIS F SCHILLER U; Fukuda A, 2002, J BIOL CHEM, V277, P43512, DOI 10.1074/jbc.M206816200; Godin RE, 1998, DEVELOPMENT, V125, P3473; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Kuure S, 2000, MECH DEVELOP, V92, P31, DOI 10.1016/S0925-4773(99)00323-8; LaBonne C, 2002, CURR BIOL, V12, pR743, DOI 10.1016/S0960-9822(02)01254-X; Landesman Y, 1997, MECH DEVELOP, V63, P199, DOI 10.1016/S0925-4773(97)00041-5; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MORRISON TG, 1970, J BACTERIOL, V103, P81, DOI 10.1128/JB.103.1.81-88.1970; Mullegger J, 2002, MOL REPROD DEV, V61, P312, DOI 10.1002/mrd.10097; Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168-9525(99)01767-9; Niehrs C, 2001, EMBO J, V20, P631, DOI 10.1093/emboj/20.4.631; Nieuwkoop P.D., 1976, NORMAL TABLE XENOPUS; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; PENG HB, 1991, METHOD CELL BIOL, V36, P657; *PROM CORP, 2004, ENOTES REM END CONT, P21; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; SANKARAN K, 1994, J BIOL CHEM, V269, P19701; Schein Catherine H., 1993, Current Opinion in Biotechnology, V4, P456, DOI 10.1016/0958-1669(93)90012-L; SCHLEGEL HG, 1992, ALLGEMEINE MIKROBIOL, P58; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; WOLDA SL, 1993, DEV BIOL, V155, P46, DOI 10.1006/dbio.1993.1005; WOLPERT L, 1998, PRINCIPLES DEV, P28; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681	46	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47520	47527		10.1074/jbc.M403207200	http://dx.doi.org/10.1074/jbc.M403207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337757	hybrid			2022-12-25	WOS:000224957000015
J	Siljander, PRM; Hamaia, S; Peachey, AR; Slatter, DA; Smethurst, PA; Ouwehand, WH; Knight, CG; Farndale, RW				Siljander, PRM; Hamaia, S; Peachey, AR; Slatter, DA; Smethurst, PA; Ouwehand, WH; Knight, CG; Farndale, RW			Integrin activation state determines selectivity for novel recognition sites in fibrillar collagens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED THROMBUS FORMATION; PLATELET GLYCOPROTEIN-VI; FLOW CONDITIONS; I-DOMAIN; ALPHA(2)BETA(1) INTEGRIN; SEQUENCE DEPENDENCE; STRUCTURAL BASIS; BINDING-SITES; A-DOMAIN; ADHESION	Only three recognition motifs, GFOGER, GLOGER, and GASGER, all present in type I collagen, have been identified to date for collagen-binding integrins, such as alpha(2)beta(1). Sequence alignment was used to investigate the occurrence of related motifs in other human fibrillar collagens, and located a conserved array of novel GER motifs within their triple helical domains. We compared the integrin binding properties of synthetic triple helical peptides containing examples of such sequences (GLSGER, GMOGER, GAOGER, and GQRGER) or the previously identified motifs. Recombinant inserted (I) domains of integrin subunits alpha(1), alpha(2), and alpha(11) bound poorly to all motifs other than GFOGER and GLOGER. Similarly, alpha(2)beta(1)-containing resting platelets adhered well only to GFOGER and GLOGER, while ADP-activated platelets, HT1080 cells and two active alpha(2)I domain mutants (E318W, locked open) bound all motifs well, indicating that affinity modulation determines the sequence selectivity of integrins. GxO/SGER peptides inhibited platelet adhesion to collagen monomers with order of potency F greater than or equal to L greater than or equal to M > A. These results establish GFOGER as a high affinity sequence, which can interact with the alpha(2)I domain in the absence of activation and suggest that integrin reactivity of collagens may be predicted from their GER content.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Dept Haematol, Cambridge CB2 1QW, England	University of Cambridge; University of Cambridge	Siljander, PRM (corresponding author), Univ Cambridge, Dept Biochem, Main Bldg,Downing Site,Tennis Court Rd, Cambridge CB2 1QW, England.	prms2@mole.bio.cam.ac.uk	Slatter, David/AAW-6938-2021; Slatter, David/AAV-5771-2020	Siljander, Pia/0000-0003-2326-5821				Ackerman MS, 1999, J BIOL CHEM, V274, P7668, DOI 10.1074/jbc.274.12.7668; Aquilina A, 2002, EUR J BIOCHEM, V269, P1136, DOI 10.1046/j.0014-2956.2001.02740.x; Asselin J, 1999, BIOCHEM J, V339, P413, DOI 10.1042/0264-6021:3390413; Ball S, 2003, J BIOL CHEM, V278, P15326, DOI 10.1074/jbc.M209977200; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Chan W, 1999, FMOC SOLID PHASE PEP, V222; Chen JC, 2002, AM J PATHOL, V161, P337, DOI 10.1016/S0002-9440(10)64185-5; Chen JF, 2003, NAT STRUCT BIOL, V10, P995, DOI 10.1038/nsb1011; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; Edelson BT, 2004, BLOOD, V103, P2214, DOI 10.1182/blood-2003-08-2978; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Farndale RW, 2003, BIOCHEM SOC SYMP, V70, P81, DOI 10.1042/bss0700081; FITZSIMMONS C, 2002, PAN VASCULAR MED, P217; FITZSIMMONS CM, 1986, THROMB HAEMOSTASIS, V56, P95; Guidetti GF, 2003, BBA-MOL CELL RES, V1640, P43, DOI 10.1016/S0167-4889(02)00401-9; GULLBERG D, 1992, EMBO J, V11, P3865, DOI 10.1002/j.1460-2075.1992.tb05479.x; Gullberg DE, 2002, PROG HISTOCHEM CYTO, V37, P9; He L, 2003, BLOOD, V102, P3652, DOI 10.1182/blood-2003-04-1323; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 2000, TRENDS CARDIOVAS MED, V10, P285, DOI 10.1016/S1050-1738(01)00064-0; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Kuijpers MJE, 2003, FASEB J, V17, P685, DOI 10.1096/fj.02-0381fje; Kunicki TJ, 2001, CURR OPIN HEMATOL, V8, P277, DOI 10.1097/00062752-200109000-00003; Lahav J, 2003, BLOOD, V102, P2085, DOI 10.1182/blood-2002-06-1646; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; Nieswandt B, 2001, EMBO J, V20, P2120, DOI 10.1093/emboj/20.9.2120; Nishiya T, 2002, BLOOD, V100, P136, DOI 10.1182/blood.V100.1.136; Onley DJ, 2000, J BIOL CHEM, V275, P24560, DOI 10.1074/jbc.M004111200; Perret S, 2003, J BIOL CHEM, V278, P29873, DOI 10.1074/jbc.M304073200; Persikov AV, 2000, BIOPOLYMERS, V55, P436, DOI 10.1002/1097-0282(2000)55:6<436::AID-BIP1019>3.0.CO;2-D; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAELMAN EUM, 1993, BLOOD, V82, P3029; Salas A, 2002, J BIOL CHEM, V277, P50255, DOI 10.1074/jbc.M209822200; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Savage B, 1999, BLOOD, V94, P2704, DOI 10.1182/blood.V94.8.2704.420k41_2704_2715; Shah NK, 1996, BIOCHEMISTRY-US, V35, P10262, DOI 10.1021/bi960046y; Siljander P, 1999, ARTERIOSCL THROM VAS, V19, P3033, DOI 10.1161/01.ATV.19.12.3033; Siljander PRM, 2004, BLOOD, V103, P1333, DOI 10.1182/blood-2003-03-00869; SILJANDER PRM, 2002, PLATELETS THROMBOTIC, P158; Smethurst PA, 2004, BLOOD, V103, P903, DOI 10.1182/blood-2003-01-0308; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; Tuckwell DS, 1995, COMPUT APPL BIOSCI, V11, P627; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; Verkleij MW, 1998, BLOOD, V91, P3808; Vilaseca M, 1998, TETRAHEDRON, V54, P15273, DOI 10.1016/S0040-4020(98)00954-5; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xu Y, 2000, J BIOL CHEM, V275, P38981, DOI 10.1074/jbc.M007668200; Zhang WM, 2003, J BIOL CHEM, V278, P7270, DOI 10.1074/jbc.M210313200	58	127	133	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47763	47772		10.1074/jbc.M404685200	http://dx.doi.org/10.1074/jbc.M404685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15345717	hybrid			2022-12-25	WOS:000224957000044
J	Wei, HJ; Ahn, S; Barnes, WG; Lefkowitz, RJ				Wei, HJ; Ahn, S; Barnes, WG; Lefkowitz, RJ			Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; PROTEIN-KINASE; II RECEPTOR; DEPENDENT DEGRADATION; INTRACELLULAR DOMAINS; GENE-EXPRESSION; ERK ACTIVATION; PHOSPHORYLATION; LOOP; DESENSITIZATION	receptors (7MSRs) not only leads to receptor desensitization and endocytosis but also elicits additional signaling processes. We recently proposed that stimulation of the angiotensin type 1A (AT(1A)) receptor results in independent beta-arrestin 2- and G protein-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation. Here we utilize two AT(1A) mutant receptors to study these independent pathways, one truncated at residue 324, thus removing all potential carboxyl-terminal phosphorylation sites, and the other bearing four mutations in the serine/threonine-rich clusters in the carboxyl terminus. As assessed by confocal microscopy, the two mutant receptors interacted with beta-arrestin 2- green fluorescent protein with much lower affinity than did the wild-type receptor. In addition, the mutant receptors more robustly stimulated G protein-mediated inositol phosphate production. Approximately one-half of the wild-type AT(1A) receptor-stimulated ERK1/2 activation was via a beta-arrestin 2-dependent pathway ( suppressed by beta-arrestin 2 small interfering RNA), whereas the rest was mediated by a G protein-dependent pathway ( suppressed by protein kinase C inhibitor). ERK1/2 activation by the mutant receptors was insensitive to beta-arrestin 2 small interfering RNA but was reduced more than 80% by a protein kinase C inhibitor. The biochemical consequences of ERK activation by the G protein and beta-arrestin 2-dependent pathways were also distinct. G-protein-mediated ERK activation enhanced the transcription of early growth response 1, whereas beta-arrestin 2- dependent ERK activation did not. In addition, stimulation of the truncated AT(1A) mutant receptor caused significantly greater early growth response 1 transcription than did the wild-type receptor. These findings demonstrate how the ability of receptors to interact with beta-arrestins determines both the mechanism of ERK activation as well as the physiological consequences of this activation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Box 3821, Durham, NC 27710 USA.	lefko001@receptor-biol.duke.edu	Lefkowitz, Robert/AAW-2649-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070631, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL70631, R01 HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn S, 2004, J BIOL CHEM, V279, P7807, DOI 10.1074/jbc.C300443200; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; Angulo E, 2003, BRAIN PATHOL, V13, P440; Bhaskaran RS, 2003, BIOCHEMISTRY-US, V42, P13950, DOI 10.1021/bi034907w; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Day FL, 1999, J BIOL CHEM, V274, P23726, DOI 10.1074/jbc.274.34.23726; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Guillemot L, 2001, J BIOL CHEM, V276, P39394, DOI 10.1074/jbc.M103862200; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Mukherjee S, 2002, J BIOL CHEM, V277, P17916, DOI 10.1074/jbc.M110479200; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Qian HW, 2001, MOL ENDOCRINOL, V15, P1706, DOI 10.1210/me.15.10.1706; Qian HW, 1999, BIOCHEM J, V343, P637, DOI 10.1042/0264-6021:3430637; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Thomas WG, 1999, REGUL PEPTIDES, V79, P9, DOI 10.1016/S0167-0115(98)00140-2; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Wei HJ, 2003, P NATL ACAD SCI USA, V100, P10782, DOI 10.1073/pnas.1834556100	29	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48255	48261		10.1074/jbc.M406205200	http://dx.doi.org/10.1074/jbc.M406205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355986	hybrid			2022-12-25	WOS:000224957000101
J	Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J				Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J			Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer	ONCOGENE			English	Article						Chk2 kinase; truncating mutation; DNA damage; tumour suppressor; p53; urinary bladder carcinomas	DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; BREAST-CANCER; IN-VIVO; PROSTATE-CANCER; CHEK2 VARIANTS; KINASE CHK2; LUNG-CANCER; P53; MUTATIONS	Checkpoint kinase 2 (Chk2) is a tumour suppressor and signal transducer in genome integrity checkpoints that coordinate cell-cycle progression with DNA repair or cell death in response to DNA damage. Defects of Chk2 occur in subsets of diverse sporadic malignancies and predispose to several types of hereditary carcinomas. However, the status of Chk2 in tumours of the urinary bladder remains unknown. Here, we report that among 58 advanced ( grade T2 - T4) human bladder carcinomas, immunohistochemical analysis revealed tumour-specific reduction or lack of Chk2 protein in 6 ( 10.3%) cases. Genetic analysis of the latter subset showed that a Chk2-negative carcinoma # 668 harboured a truncating mutation 1100delC, in one Chk2 allele and loss of the corresponding second allele. The 1100delC mutation was also found in the germ line of this patient. Sequencing of TP53 in tumour # 668 identified two missense mutations. Furthermore, the vast majority of the tumours showed 'unscheduled' activatory phosphorylation on Thr68 of Chk2 in the absence of any DNA-damaging treatment. Our results indicate that the otherwise dormant DNA damage signal transducer Chk2 is aberrantly and constitutively activated in invasive urinary bladder carcinomas, and that such likely proapoptotic checkpoint signalling can be disabled by inactivation of Chk2 and/or p53 tumour suppressors in subsets of these tumours.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Clin Biochem, DK-8200 Aarhus, Denmark	Danish Cancer Society; Aarhus University	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Gronbaek, Kirsten/0000-0002-1535-9601				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lee SB, 2001, CANCER RES, V61, P8062; Lukas C, 2001, CANCER RES, V61, P4990; LUKAS C, 2003, NAT CELL BIOL, V421, P952; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	48	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8545	8551		10.1038/sj.onc.1207878	http://dx.doi.org/10.1038/sj.onc.1207878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361851				2022-12-25	WOS:000224870700015
J	Gong, P; Esposito, EA; Martin, CT				Gong, P; Esposito, EA; Martin, CT			Initial bubble collapse plays a key role in the transition to elongation in T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC UV5 PROMOTER; RIBONUCLEIC-ACID POLYMERASE; TRANSCRIPTION INITIATION; T7-RNA POLYMERASE; COMPLEX STABILITY; STRUCTURAL BASIS; TEMPLATE STRAND; BACTERIOPHAGE-T7; DNA; BINDING	RNA polymerases bind to specific sequences in DNA, melt open duplex DNA around the start site, and start transcription within the initially melted bubble. The initially transcribing complex is relatively unstable, releasing short abortive products. After synthesis of a minimal length of RNA (similar to10-12 bases in the T7 system), RNA polymerases complete the transition to a processive ( highly stable) elongation phase and lose the initial promoter contacts. The current study strongly supports a model for T7 RNA polymerase in which initial bubble collapse from position -4 to position +3 is responsible for initiating RNA displacement in the transition process. More specifically, collapse of the bubble from position -4 to position -1 indirectly and energetically facilitates the direct strand invasion offered by collapse at positions +1 to +3. Parallel work shows that promoter release, another key event occurring during this stage of transcription, begins after translocation to position +8 and is largely complete upon translocation to about position +12. The timing of promoter release agrees with the timing of initial bubble collapse determined by our previous fluorescence studies, suggesting that these two events are closely related.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Martin, CT (corresponding author), Univ Massachusetts, Dept Chem, 701 N Pleasant St,LGRT 701, Amherst, MA 01003 USA.	cmartin@chem.umass.edu	Gong, Peng/ABD-6333-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055002, T32GM008515] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM55002, T32 GM08515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Brieba LG, 2001, J BIOL CHEM, V276, P10306, DOI 10.1074/jbc.M009866200; CAI H, 1987, MOL CELL BIOL, V7, P3371, DOI 10.1128/MCB.7.10.3371; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; Esposito EA, 2004, J BIOL CHEM, V279, P44270, DOI 10.1074/jbc.M407688200; FURUICHI Y, 1981, J BIOL CHEM, V256, P483; Gopal V, 1999, J MOL BIOL, V290, P411, DOI 10.1006/jmbi.1999.2836; GRACHEV MA, 1980, FEBS LETT, V115, P23, DOI 10.1016/0014-5793(80)80718-6; GRALLA JD, 1980, BIOCHEMISTRY-US, V19, P5864, DOI 10.1021/bi00566a031; He B, 1997, PROTEIN EXPRES PURIF, V9, P142, DOI 10.1006/prep.1996.0663; He B, 1997, J MOL BIOL, V265, P275, DOI 10.1006/jmbi.1996.0741; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; Jung YW, 2003, J BIOL CHEM, V278, P52084, DOI 10.1074/jbc.M310120200; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MACDONALD LE, 1994, J MOL BIOL, V238, P145, DOI 10.1006/jmbi.1994.1277; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MCALLISTER WT, 1993, CELL MOL BIOL RES, V39, P385; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; Mukherjee S, 2002, CELL, V110, P81, DOI 10.1016/S0092-8674(02)00815-2; MULLER DK, 1989, BIOCHEMISTRY-US, V28, P3306, DOI 10.1021/bi00434a028; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SCHICK C, 1993, BIOCHEMISTRY-US, V32, P4275, DOI 10.1021/bi00067a016; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STROTHKAMP RE, 1980, BIOCHEMISTRY-US, V19, P1074, DOI 10.1021/bi00547a005; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2002, J BIOL CHEM, V277, P47035, DOI 10.1074/jbc.M208923200; THEIS K, 2004, IN PRESS BIOCHEMISTR; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	44	34	35	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44277	44285		10.1074/jbc.M409118200	http://dx.doi.org/10.1074/jbc.M409118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15337752	hybrid			2022-12-25	WOS:000224505600008
J	Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL				Gartel, AL; Radhakrishnan, SK; Serfas, MS; Kwon, YH; Tyner, AL			A novel p21(WAF1/CIP1) transcript is highly dependent on p53 for its basal expression in mouse tissues	ONCOGENE			English	Article						p21; p53; alternate transcript	KINASE INHIBITOR; CELL-CYCLE; GENE; P21; ARREST; CLONING; WAF1	p21(WAF1/CIP1) is an important transcriptional target of p53 and it plays a critical role in growth arrest after DNA damage. Here, we report the identification of a novel alternate mouse p21 transcript that is conserved in evolution. It differs from the classical p21(WAF1/CIP1) transcript in the first exon, which is located at approximately 2.8 kb upstream of transcriptional start site of p21(WAF1/CIP1) and is sandwiched between two p53 binding sites. This novel p21 transcript is present in most mouse tissues with highest levels of expression in the spleen. In contrast to the classical p21(WAF1/CIP1) transcript, this new transcript is highly dependent on p53 for its basal expression, as evidenced by its absence in nearly all of p53(-/-) mouse tissues. This transcript is also absent at nonpermissive temperature in a 10-1 mouse cell line lacking endogenous p53 and harboring temperature-sensitive p53 mutant. However, this novel transcript is induced to appreciable levels in the presence of high p53 activity at the permissive temperature. Our data suggest that p53-dependent induction of p21 may be an additive effect conferred by individual increases in the alternate and classical p21 transcripts.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, 840 S Wood St, Chicago, IL 60612 USA.	atyner@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498; Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [R21CA091146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NCI NIH HHS [CA91146-01A1] Funding Source: Medline; NIDDK NIH HHS [DK56283, R01 DK056283-05, R01 DK056283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Couronne O, 2003, GENOME RES, V13, P73, DOI 10.1101/gr.762503; DURO D, 1995, ONCOGENE, V11, P21; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gribnau J, 2000, MOL CELL, V5, P377, DOI 10.1016/S1097-2765(00)80432-3; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hogga I, 2002, DEVELOPMENT, V129, P4915; HUPPI K, 1994, ONCOGENE, V9, P3017; Landry JR, 2003, TRENDS GENET, V19, P640, DOI 10.1016/j.tig.2003.09.014; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAO L, 1995, CANCER RES, V55, P2995; Nozell S, 2002, ONCOGENE, V21, P1285, DOI 10.1038/sj.onc.1205191; Nunez F, 2000, FASEB J, V14, P1073, DOI 10.1096/fasebj.14.9.1073; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; QUELLE DE, 1995, CELL, V83, P993; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Tsubari M, 1997, CANCER RES, V57, P2966; Wang XD, 2004, NAT GENET, V36, P231, DOI 10.1038/ng1301; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	23	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8154	8157		10.1038/sj.onc.1207820	http://dx.doi.org/10.1038/sj.onc.1207820			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361845				2022-12-25	WOS:000224692500013
J	Park, KM; Kim, JI; Ahn, Y; Bonventre, AJ; Bonventre, JV				Park, KM; Kim, JI; Ahn, Y; Bonventre, AJ; Bonventre, JV			Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; INDUCED FUNCTIONAL INJURY; MAPK KINASE ACTIVATION; REPERFUSION INJURY; SEX-HORMONES; L-ARGININE; IN-VITRO; MYOCARDIAL-ISCHEMIA; MONOCYTE ADHESION	Female mice are much more resistant to ischemia/reperfusion (I/R)-induced kidney injury when compared with males. Although estrogen administration can partially reduce kidney injury associated with I/R, we demonstrated that the presence of testosterone, more than the absence of estrogen, plays a critical role in gender differences in susceptibility of the kidney to ischemic injury. Testosterone administration to females increases kidney susceptibility to ischemia. Dihydrotestosterone, which can not be aromatized to estrogen, has effects equal to those of testosterone. Castration reduces the I/R-induced kidney injury. In contrast, ovariectomy does not affect kidney injury induced by ischemia in females. Testosterone reduces ischemia-induced activation of nitric oxide synthases (NOSs) and Akt and the ratio of extracellular signal related kinase (ERK) to c-jun N-terminal kinase (JNK) phosphorylation. Pharmacological (N-omega-nitro-L-arginine) or genetic ( endothelial NOS or inducible NOS) inhibition of NOSs in females enhances kidney susceptibility to ischemia. Nitric oxide increases Akt phosphorylation and protects Madin-Darby canine kidney epithelial cells from oxidant stress. Antagonists of androgen or estrogen receptors do not affect the gender differences. In conclusion, testosterone inhibits the post-ischemic activation of NOSs and Akt and the ratio of ERK to JNK phosphorylation through non-androgen receptor-medicated mechanisms, leading to increased inflammation and increased functional injury to the kidney. These findings provide a new paradigm for the design of therapies for ischemia/reperfusion injury and may be important to our understanding of the pathophysiology of acute renal failure in pregnancy where plasma androgen levels are elevated.	Harvard Mit Div Hlth Sci & Technol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Kyungpook Natl Univ, Sch Med, Dept Anat, Taegu 700422, South Korea; Harvard Univ, Sch Med, Dept Med, Brigham & Womens Hosp,Renal Div, Boston, MA 02115 USA	Harvard University; Harvard University; Massachusetts General Hospital; Kyungpook National University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Bonventre, JV (corresponding author), Harvard Inst Med, 4 Blackfan Circle, Boston, MA 02115 USA.	joseph_bonventre@hms.harvard.edu			NIDDK NIH HHS [DK 39773, DK 38452, DK46267] Funding Source: Medline; NINDS NIH HHS [NS 10828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, R37DK039773, P01DK038452, R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander BT, 2002, HYPERTENSION, V39, P586, DOI 10.1161/hy0202.103288; Alvarez A, 2002, CIRC RES, V91, P1142, DOI 10.1161/01.RES.0000046018.23605.3E; Andreucci M, 2003, KIDNEY INT, V64, P1189, DOI 10.1046/j.1523-1755.2003.00204.x; BAKER PJ, 1978, AM J PHYSIOL, V235, pH242, DOI 10.1152/ajpheart.1978.235.2.H242; Camper-Kirby D, 2001, CIRC RES, V88, P1020, DOI 10.1161/hh1001.090858; Chao W, 2003, J GENE MED, V5, P277, DOI 10.1002/jgm.347; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIMARI J, 1999, AM J PHYSIOL, pF195; Fernandez M, 2001, J AM SOC NEPHROL, V12, P1900, DOI 10.1681/ASN.V1291900; Friedl R, 2000, LIFE SCI, V68, P417, DOI 10.1016/S0024-3205(00)00953-X; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Goligorsky MS, 2002, KIDNEY INT, V61, P855, DOI 10.1046/j.1523-1755.2002.00233.x; Guo ZY, 2002, J BIOL CHEM, V277, P7044, DOI 10.1074/jbc.M109808200; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hirschberg R, 1998, MINER ELECTROL METAB, V24, P211, DOI 10.1159/000057373; Hung CC, 2003, J BIOL CHEM, V278, P29317, DOI 10.1074/jbc.M302368200; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Kelly KJ, 1996, J CLIN INVEST, V97, P1056, DOI 10.1172/JCI118498; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Ling SH, 2002, ENDOCRINOLOGY, V143, P1119, DOI 10.1210/en.143.3.1119; Maestri M, 1997, TRANSPLANTATION, V64, P185, DOI 10.1097/00007890-199707270-00001; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; McCrohon JA, 1999, CIRCULATION, V99, P2317, DOI 10.1161/01.CIR.99.17.2317; McNeill AM, 1999, STROKE, V30, P2186, DOI 10.1161/01.STR.30.10.2186; Medina A, 2002, PEDIATR NEPHROL, V17, P1005, DOI 10.1007/s00467-002-0979-y; MILEWICH L, 1982, J STEROID BIOCHEM, V17, P61, DOI 10.1016/0022-4731(82)90592-1; Mori M, 2004, LIFE SCI, V75, P599, DOI 10.1016/j.lfs.2003.12.023; Muller V, 2002, KIDNEY INT, V62, P1364, DOI 10.1111/j.1523-1755.2002.kid590.x; Neugarten J, 1997, J AM SOC NEPHROL, V8, P1240; Park KM, 2003, J BIOL CHEM, V278, P27256, DOI 10.1074/jbc.M301778200; Park KM, 2002, J BIOL CHEM, V277, P2040, DOI 10.1074/jbc.M107525200; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; PARK KM, 2000, J AM SOC NEPHROL, V11, P594; Pasceri V, 2000, CIRCULATION, V101, P235, DOI 10.1161/01.CIR.101.3.235; RABB H, 1995, BIOCHEM BIOPH RES CO, V211, P67, DOI 10.1006/bbrc.1995.1779; Rodriguez E, 2002, LIFE SCI, V71, P2181, DOI 10.1016/S0024-3205(02)01999-9; Schramm L, 2002, KIDNEY INT, V61, P1423, DOI 10.1046/j.1523-1755.2002.00268.x; Serin IS, 2001, ACTA OBSTET GYN SCAN, V80, P1009, DOI 10.1034/j.1600-0412.2001.801107.x; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Squadrito F, 1997, EUR J PHARMACOL, V335, P185, DOI 10.1016/S0014-2999(97)01201-6; Sugden PH, 2001, CIRC RES, V88, P975, DOI 10.1161/hh1001.091864; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Vos IHC, 2001, J AM SOC NEPHROL, V12, P361, DOI 10.1681/ASN.V122361; WAKASUGI M, 1989, PROSTAG OTH LIPID M, V37, P401, DOI 10.1016/0090-6980(89)90090-7; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WEYRICH AS, 1992, CIRCULATION, V86, P279, DOI 10.1161/01.CIR.86.1.279; Wunderlich F, 2002, STEROIDS, V67, P535, DOI 10.1016/S0039-128X(01)00175-1; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195	50	232	247	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52282	52292		10.1074/jbc.M407629200	http://dx.doi.org/10.1074/jbc.M407629200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15358759	hybrid			2022-12-25	WOS:000225493400069
J	Kawai, Y; Morinaga, H; Kondo, H; Miyoshi, N; Nakamura, Y; Uchida, K; Osawa, T				Kawai, Y; Morinaga, H; Kondo, H; Miyoshi, N; Nakamura, Y; Uchida, K; Osawa, T			Endogenous formation of novel halogenated 2 '-deoxycytidine - Hypohalous acid-mediated DNA modification at the site of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; LUNG-CANCER RISK; HYPOCHLORITE-INDUCED DAMAGE; HUMAN NEUTROPHILS EMPLOY; CALF THYMUS DNA; HUMAN PHAGOCYTES; EOSINOPHIL PEROXIDASE; BROMINATING OXIDANTS; GENERATED OXIDANTS; REACTIVE OXYGEN	A potential role of DNA damage by leukocyte-derived reactive species in carcinogenesis has been suggested. Leukocyte-derived peroxidases, such as myeloperoxidase and eosinophil peroxidase, use hydrogen peroxide and halides (Cl- and Br-) to generate hypohalous acids (HOCl and HOBr), halogenating intermediates. It has been suggested that these oxidants lead to the formation of halogenated products upon reaction with nucleobases. To verify the consequences of phagocyte-mediated DNA damage at the site of inflammation, we developed a novel monoclonal antibody (mAb2D3) that recognizes the hypohalous acid-modified DNA and found that the antibody most significantly recognized HOCl/HOBr-modified 2'-deoxycytidine residues. The immunoreactivity of HOCl-treated oligonucleotide was attenuated by excess methionine, suggesting that chloramine-like species may be the plausible epitopes of the antibody. On the basis of further characterization combined with mass spectrometric analysis, the epitopes of mAb2D3 were determined to be novel N-4,5-dihalogenated 2'-deoxycytidine residues. The formation of the dihalogenated 2'-deoxycytidine in vivo was immunohistochemically demonstrated in the lung and liver nuclei of mice treated with lipopolysaccharides, an experimental inflammatory model. These results strongly suggest that phagocyte-derived oxidants, hypohalous acids, endogenously generate the halogenated DNA bases such as a novel dihalogenated 2'-deoxycytidine in vivo. Halogenation ( chlorination and/or bromination) of DNA therefore may constitute one mechanism for oxidative DNA damage at the site of inflammation.	Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi 4648601, Japan	Nagoya University	Kawai, Y (corresponding author), Univ Tokushima, Grad Sch Nutr & Biosci, Dept Food Sci, Tokushima 7708503, Japan.	y-kawai@nutr.med.tokushima-u.ac.jp	Miyoshi, Noriyuki/F-4554-2010; Kawai, Yoshichika/G-3231-2011	Uchida, Koji/0000-0003-3894-5299; Miyoshi, Noriyuki/0000-0002-4233-4282				Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Carr AC, 1997, BIOCHEM J, V327, P275, DOI 10.1042/bj3270275; Cascorbi I, 2000, CANCER RES, V60, P644; Chen HJC, 2002, CHEM RES TOXICOL, V15, P262, DOI 10.1021/tx015578g; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; GOULD JP, 1984, WATER RES, V18, P205, DOI 10.1016/0043-1354(84)90070-8; GOULD JP, 1984, WATER RES, V18, P991, DOI 10.1016/0043-1354(84)90250-1; Hawkins CL, 2002, CHEM RES TOXICOL, V15, P83, DOI 10.1021/tx015548d; Hawkins CL, 2001, ARCH BIOCHEM BIOPHYS, V395, P137, DOI 10.1006/abbi.2001.2581; Hawkins CL, 2001, CHEM RES TOXICOL, V14, P1071, DOI 10.1021/tx010071r; HAYATSU H, 1971, CHEM PHARM BULL, V19, P2189; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; Henderson JP, 2003, J BIOL CHEM, V278, P23522, DOI 10.1074/jbc.M303928200; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; Henderson JP, 2001, P NATL ACAD SCI USA, V98, P1631, DOI 10.1073/pnas.041146998; HEWETT JA, 1993, PHARMACOL REV, V45, P381; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; Huang X, 2001, FREE RADICAL BIO MED, V31, P1341, DOI 10.1016/S0891-5849(01)00681-5; ISHII A, 1994, MUTAT RES, V305, P273, DOI 10.1016/0027-5107(94)90247-X; Jiang Q, 2003, J BIOL CHEM, V278, P32834, DOI 10.1074/jbc.M304021200; Kato Y, 1997, J AGR FOOD CHEM, V45, P3004, DOI 10.1021/jf960865p; Kawai Y, 2002, CARCINOGENESIS, V23, P485, DOI 10.1093/carcin/23.3.485; KISSANE JM, 1958, J BIOL CHEM, V233, P184; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; London SJ, 1997, CANCER RES, V57, P5001; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; Masuda M, 2001, J BIOL CHEM, V276, P40486, DOI 10.1074/jbc.M102700200; Nakamura Y, 1998, CANCER RES, V58, P4832; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; Shen ZZ, 2000, BIOCHEMISTRY-US, V39, P5474, DOI 10.1021/bi992809y; Shen ZZ, 2001, BIOCHEMISTRY-US, V40, P2041, DOI 10.1021/bi001961t; SUEOKA NOBORU, 1962, JOUR MOLECULAR BIOL, V4, P161; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEITZMAN SA, 1990, BLOOD, V76, P655; Whiteman M, 1997, CHEM RES TOXICOL, V10, P1240, DOI 10.1021/tx970086i; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V257, P572, DOI 10.1006/bbrc.1999.0448; Whiteman M, 1999, BIOMARKERS, V4, P303, DOI 10.1080/135475099230831; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702	53	55	56	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51241	51249		10.1074/jbc.M408210200	http://dx.doi.org/10.1074/jbc.M408210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15364942	hybrid			2022-12-25	WOS:000225355800072
J	Fritz, DT; Liu, DL; Xu, JW; Jiang, S; Rogers, MB				Fritz, DT; Liu, DL; Xu, JW; Jiang, S; Rogers, MB			Conservation of Bmp2 post-transcriptional regulatory mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; EMBRYONAL CARCINOMA-CELLS; 3' UNTRANSLATED REGION; ACID RECEPTOR-ALPHA; MESSENGER-RNA DECAY; RETINOIC ACID; PROCESSING EFFICIENCY; DECAPENTAPLEGIC GENE; SITE SELECTION; MOUSE	Bone morphogenetic protein (BMP) orthologs from diverse species like flies and humans are functionally interchangeable and play key roles in fundamental processes such as dorso-ventral axis formation in metazoans. Because both transcriptional and post-transcriptional mechanisms play central roles in modulating developmental protein levels, we have analyzed the 3'-untranslated region (3'UTR) of the Bmp 2 gene. This 3' UTR is unusually long and is alternatively polyadenylated. Mouse, human, and dog mRNAs are 83 - 87% identical within this region. A 265-nucleotide sequence, conserved between mammals, birds, frogs, and fish, is present in Bmp2 but not Bmp4. The ability of AmphiBMP2/4, a chordate ortholog to Bmp2 and Bmp4, to align with this sequence suggests that its function may have been lost in Bmp4. Activation of reporter genes by the conserved region acts by a post-transcriptional mechanism. Mouse, human, chick, and zebrafish Bmp2 synthetic RNAs decay rapidly in extracts from cells not expressing Bmp2. In contrast, these RNAs are relatively stable in extracts from Bmp2-expressing cells. Thus, Bmp2 RNA half-lives in vitro correlate with natural Bmp2 mRNA levels. The fact that non-murine RNAs interact appropriately with the mouse decay machinery suggests that the function of these cis-regulatory regions has been conserved for 450 million years since the fish and tetrapod lineages diverged. Overall, our results suggest that the Bmp2 3' UTR contains essential regulatory elements that act post-transcriptionally.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rogers, MB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, MSB E627,185 S Orange Ave,POB 1709, Newark, NJ 07101 USA.	rogersmb@umdnj.edu	Jiang, Shan/F-9770-2010		NICHD NIH HHS [HD31117] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD031117, R01HD031117] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abrams KL, 2004, J BIOL CHEM, V279, P15916, DOI 10.1074/jbc.M313531200; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAGGA PS, 1995, NUCLEIC ACIDS RES, V23, P1625, DOI 10.1093/nar/23.9.1625; Bakheet T, 2003, NUCLEIC ACIDS RES, V31, P421, DOI 10.1093/nar/gkg023; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Baur ST, 2000, DEVELOPMENT, V127, P605; Beppu H, 2000, DEV BIOL, V221, P249, DOI 10.1006/dbio.2000.9670; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; Canestro C, 2003, EVOL DEV, V5, P157, DOI 10.1046/j.1525-142X.2003.03022.x; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Chen F, 1998, NUCLEIC ACIDS RES, V26, P2891, DOI 10.1093/nar/26.12.2891; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Davidson E. H., 1986, GENE ACTIVITY EARLY; DENOME RM, 1988, MOL CELL BIOL, V8, P4829, DOI 10.1128/MCB.8.11.4829; Deutsch M, 1999, NUCLEIC ACIDS RES, V27, P3219, DOI 10.1093/nar/27.15.3219; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; Feng JQ, 2003, J BIOL CHEM, V278, P29130, DOI 10.1074/jbc.M212296200; Ford LP, 1999, METHODS, V17, P21, DOI 10.1006/meth.1998.0703; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; Frazer KA, 2003, GENOME RES, V13, P1, DOI 10.1101/gr.222003; Fritz DT, 2004, CELL BIOCHEM BIOPHYS, V41, P265, DOI 10.1385/CBB:41:2:265; Fritz DT, 2000, SCI STKE, V2000, P11; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; GIL A, 1984, NATURE, V312, P473, DOI 10.1038/312473a0; GIL A, 1987, CELL, V49, P399, DOI 10.1016/0092-8674(87)90292-3; Glozak MA, 1996, DEV BIOL, V179, P458, DOI 10.1006/dbio.1996.0275; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; Heller LC, 1999, J BIOL CHEM, V274, P1394, DOI 10.1074/jbc.274.3.1394; Helvering LM, 2000, GENE, V256, P123, DOI 10.1016/S0378-1119(00)00364-4; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; HOGAN BLM, 1995, NATURE, V376, P210, DOI 10.1038/376210a0; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JONES CM, 1991, DEVELOPMENT, V111, P531; Kakoki M, 2004, DEV CELL, V6, P597, DOI 10.1016/S1534-5807(04)00094-2; Keene JD, 2003, MOL CELL, V12, P1347, DOI 10.1016/S1097-2765(03)00496-9; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kuersten S, 2003, NAT REV GENET, V4, P626, DOI 10.1038/nrg1125; Lelong C, 2001, BIOCHIMIE, V83, P423, DOI 10.1016/S0300-9084(01)01260-3; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1989, GENE DEV, V3, P1657, DOI 10.1101/gad.3.11.1657; MacDonald CC, 2002, MOL CELL ENDOCRINOL, V190, P1, DOI 10.1016/S0303-7207(02)00044-8; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Mukherjee Devi, 2004, Methods Mol Biol, V257, P193, DOI 10.1385/1-59259-750-5:193; Natalizio BJ, 2002, J BIOL CHEM, V277, P42733, DOI 10.1074/jbc.M208070200; Newfeld SJ, 1997, GENETICS, V145, P297; Nohara M, 2004, ZOOL SCI, V21, P203, DOI 10.2108/zsj.21.203; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; Panopoulou G, 2003, GENOME RES, V13, P1056, DOI 10.1101/gr.874803; Panopoulou GD, 1998, DEV DYNAM, V213, P130, DOI 10.1002/(SICI)1097-0177(199809)213:1<130::AID-AJA13>3.0.CO;2-6; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rajagopalan LE, 1997, PROG NUCLEIC ACID RE, V56, P257, DOI 10.1016/S0079-6603(08)61007-7; Reddi AH, 2001, J BONE JOINT SURG AM, V83A, pS1, DOI 10.2106/00004623-200100001-00001; Richter B, 1997, GENETICS, V145, P311; ROGERS MB, 1992, MOL BIOL CELL, V3, P189, DOI 10.1091/mbc.3.2.189; Rogers MB, 1996, CELL GROWTH DIFFER, V7, P115; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SanchezSalazar J, 1996, DEV GENES EVOL, V206, P237, DOI 10.1007/s004270050049; Shabalina SA, 2004, NUCLEIC ACIDS RES, V32, P1774, DOI 10.1093/nar/gkh313; Shabalina SA, 2003, NUCLEIC ACIDS RES, V31, P5433, DOI 10.1093/nar/gkg751; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; Spicher A, 1998, MOL CELL BIOL, V18, P7371, DOI 10.1128/MCB.18.12.7371; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRIJKER R, 1989, EMBO J, V8, P2669, DOI 10.1002/j.1460-2075.1989.tb08407.x; Sugiura T, 1999, BIOCHEM J, V338, P433, DOI 10.1042/0264-6021:3380433; Tremblay KD, 2001, DEVELOPMENT, V128, P3609; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yang X, 1999, DEVELOPMENT, V126, P1571; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Yi SE, 2000, DEVELOPMENT, V127, P621; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhou SH, 2003, MOL ENDOCRINOL, V17, P56, DOI 10.1210/me.2002-0210; Zile MH, 1998, J NUTR, V128, p455S, DOI 10.1093/jn/128.2.455S; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	95	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48950	48958		10.1074/jbc.M409620200	http://dx.doi.org/10.1074/jbc.M409620200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358784	hybrid			2022-12-25	WOS:000225098100057
J	Linder, T; Gustafsson, CM				Linder, T; Gustafsson, CM			The Soh1/MED31 protein is an ancient component of Schizosaccharomyces pombe and Saccharomyces cerevisiae mediator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; SEQUENCE ALIGNMENT; COFACTOR COMPLEX; TERMINAL DOMAIN; REPEAT DOMAIN; SUBUNITS; YEAST; PURIFICATION; MUTATIONS	We here demonstrated that the Soh1/MED31 protein is a stable component of Mediator complex isolated from Schizosaccharomyces pombe and Saccharomyces cerevisiae. Bioinformatic analysis traces the Soh1/MED31 family of Mediator subunits to the point of major eukaryotic divergence, before the appearance of the canonical heptapeptide repeat structure of the RNA polymerase II C-terminal domain.	Karolinska Inst, Novum, Karolinska Univ Hosp, Dept Med Nutr, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Gustafsson, CM (corresponding author), Karolinska Inst, Novum, Karolinska Univ Hosp, Dept Med Nutr, SE-14186 Stockholm, Sweden.	claes.gustafsson@mednut.ki.se	Linder, Tomas/AAN-3433-2020; Linder, Tomas/B-2492-2009	Linder, Tomas/0000-0001-5365-0494; Linder, Tomas/0000-0001-5365-0494; Gustafsson, Claes/0000-0003-3531-8468				BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; Borggrefe T, 2001, J BIOL CHEM, V276, P47150, DOI 10.1074/jbc.M109581200; Bourbon HM, 2004, MOL CELL, V14, P553, DOI 10.1016/j.molcel.2004.05.011; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Fan HY, 1996, GENETICS, V142, P749; FAN HY, 1994, GENETICS, V137, P945; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Grallert A, 1999, YEAST, V15, P669, DOI 10.1002/(SICI)1097-0061(19990615)15:8<669::AID-YEA411>3.0.CO;2-K; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Gustafsson CM, 1998, J BIOL CHEM, V273, P30851, DOI 10.1074/jbc.273.47.30851; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Malagon F, 2004, GENETICS, V166, P1215, DOI 10.1534/genetics.166.3.1215; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; NONET ML, 1989, GENETICS, V123, P715; Park JM, 2001, MOL CELL BIOL, V21, P2312, DOI 10.1128/MCB.21.7.2312-2323.2001; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Samuelsen CO, 2003, P NATL ACAD SCI USA, V100, P6422, DOI 10.1073/pnas.1030497100; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Spahr H, 2000, J BIOL CHEM, V275, P1351, DOI 10.1074/jbc.275.2.1351; Spahr H, 2001, P NATL ACAD SCI USA, V98, P11985, DOI 10.1073/pnas.211253898; Stiller JW, 2002, P NATL ACAD SCI USA, V99, P6091, DOI 10.1073/pnas.082646199; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Szilagyi Z, 2002, MOL GENET GENOMICS, V268, P553, DOI 10.1007/s00438-002-0773-3; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876	35	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49455	49459		10.1074/jbc.M409046200	http://dx.doi.org/10.1074/jbc.M409046200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15356001	hybrid			2022-12-25	WOS:000225098100115
J	Hernandez, JM; Heine, GF; Irani, NG; Feller, A; Kim, MG; Matulnik, T; Chandler, VL; Grotewold, E				Hernandez, JM; Heine, GF; Irani, NG; Feller, A; Kim, MG; Matulnik, T; Chandler, VL; Grotewold, E			Different mechanisms participate in the R-dependent activity of the R2R3 MYB transcription factor C1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; REGULATORY GENE; MYB DOMAIN; MAIZE C1; PROTEIN; ANTHOCYANIN; ARABIDOPSIS; PROMOTER; ACTIVATION; FAMILY	The R2R3 MYB transcription factor C1 requires the basic helix-loop-helix factor R as an essential co-activator for the transcription of maize anthocyanin genes. In contrast, the R2R3 MYB protein P1 activates a subset of the C1-regulated genes independently of R. Substitution of six amino acids in P1 with the C1 amino acids results in P1*, whose activity on C1-regulated and P1-regulated genes is R-dependent or R-enhanced, respectively. We have used P1* in combination with various promoters to uncover two mechanisms for R function. On synthetic promoters that contain only C1/P1 binding sites, R is an essential co-activator of C1. This function of R is unlikely to simply be the result of an increase in the C1 DNA-binding affinity, since transcriptional activity of a C1 mutant that binds DNA at a higher affinity, comparable with P1, remains R-dependent. The differential transcriptional activity of C1 fusions with the yeast Gal4 DNA-binding domain in yeast and maize cells suggests that part of the function of R is to relieve C1 from a plant-specific inhibitor. A second function of R requires cis-regulatory elements in addition to the C1/P1 DNA-binding sites for R-enhanced transcription of a1. We hypothesize that R functions in this mode by binding or recruiting additional factors to the anthocyanin regulatory element conserved in the promoters of several anthocyanin genes. Together, these findings suggest a model in which combinatorial interactions with co-activators enable R2R3 MYB factors with very similar DNA binding preferences to discriminate between target genes in vivo.	Ohio State Univ, Dept Plant Cellular & Mol Biol, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Plant Biotechnol, Columbus, OH 43210 USA; Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Arizona	Grotewold, E (corresponding author), Ohio State Univ, Dept Plant Cellular & Mol Biol, 206 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	grotewold.1@osu.edu	Feller, Antje C/B-8188-2011	Irani, Niloufer/0000-0003-3252-4493; Grotewold, Erich/0000-0002-4720-7290				Abe H, 1997, PLANT CELL, V9, P1859, DOI 10.1105/tpc.9.10.1859; Aharoni A, 2001, PLANT J, V28, P319, DOI 10.1046/j.1365-313X.2001.01154.x; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; Buck MJ, 2003, J MOL EVOL, V56, P742, DOI 10.1007/s00239-002-2449-3; Burr FA, 1996, PLANT CELL, V8, P1249, DOI 10.1105/tpc.8.8.1249; Carey CC, 2004, PLANT CELL, V16, P450, DOI 10.1105/tpc.018796; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DOSEFF AI, 1995, GENETICS, V141, P857; Elomaa P, 2003, PLANT PHYSIOL, V133, P1831, DOI 10.1104/pp.103.026039; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF SA, 1991, GENE DEV, V5, P298, DOI 10.1101/gad.5.2.298; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; Grotewold E, 2000, P NATL ACAD SCI USA, V97, P13579, DOI 10.1073/pnas.250379897; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; Grotewold E, 1998, PLANT CELL, V10, P721, DOI 10.1105/tpc.10.5.721; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; Heim MA, 2003, MOL BIOL EVOL, V20, P735, DOI 10.1093/molbev/msg088; Irani NG, 2003, RECENT ADV PHYTOCHEM, V37, P59; James P, 1996, GENETICS, V144, P1425; Jiang CH, 2004, GENE, V326, P13, DOI 10.1016/j.gene.2003.09.049; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kroon A., 2004, THESIS VRIJE U AMSTE; Lesnick M.L., 1997, THESIS U OREGON EUGE, P32; Lesnick ML, 1998, PLANT PHYSIOL, V117, P437, DOI 10.1104/pp.117.2.437; LUDWIG SR, 1990, CELL, V62, P849, DOI 10.1016/0092-8674(90)90259-H; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Payne CT, 2000, GENETICS, V156, P1349; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; Pooma W, 2002, GENETICS, V161, P793; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Rabinowicz PD, 1999, GENETICS, V153, P427; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; SABLOWSKI RWM, 1994, EMBO J, V13, P128, DOI 10.1002/j.1460-2075.1994.tb06242.x; Sainz MB, 1997, MOL CELL BIOL, V17, P115, DOI 10.1128/MCB.17.1.115; Sainz MB, 1997, PLANT CELL, V9, P611, DOI 10.1105/tpc.9.4.611; SAINZ MB, 1997, THESIS U OREGON EUGE, P144; Schellmann S, 2002, EMBO J, V21, P5036, DOI 10.1093/emboj/cdf524; Selinger DA, 1999, PLANT CELL, V11, P5, DOI 10.1105/tpc.11.1.5; SHIEH MW, 1993, PLANT PHYSIOL, V101, P353, DOI 10.1104/pp.101.2.353; Stracke R, 2001, CURR OPIN PLANT BIOL, V4, P447, DOI 10.1016/S1369-5266(00)00199-0; Suzuki A, 1998, PLANT CELL PHYSIOL, V39, P555, DOI 10.1093/oxfordjournals.pcp.a029404; Toledo-Ortiz G, 2003, PLANT CELL, V15, P1749, DOI 10.1105/tpc.013839; TUERCK JA, 1994, PLANT CELL, V6, P1655, DOI 10.1105/tpc.6.11.1655; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; Williams CE, 1997, J BIOL CHEM, V272, P563, DOI 10.1074/jbc.272.1.563; Zhang F, 2003, DEVELOPMENT, V130, P4859, DOI 10.1242/dev.00681	49	102	129	4	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48205	48213		10.1074/jbc.M407845200	http://dx.doi.org/10.1074/jbc.M407845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347654	hybrid			2022-12-25	WOS:000224957000095
J	Lam, AKM; Ko, BCB; Tam, S; Morris, R; Yang, JY; Chung, SK; Chung, SSM				Lam, AKM; Ko, BCB; Tam, S; Morris, R; Yang, JY; Chung, SK; Chung, SSM			Osmotic response element-binding protein (OREBP) is an essential regulator of the urine concentrating mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UREA TRANSPORTER; VASOPRESSIN ANTAGONIST; TRANSCRIPTION FACTOR; WATER PERMEABILITY; EXPRESSION; GENE; AQUAPORIN-2; KIDNEY; MOUSE; NFAT5	OREBP (osmotic response element-binding protein), also called TonEBP or NFAT5, is thought to induce the expression of genes that increase the accumulation of organic osmolytes to protect cells against a hypertonic environment. To investigate the consequences of lacking OREBP activity, transgenic (Tg) mice that overexpress OREBPdn (dominant negative form of OREBP) specifically in the epithelial cells of the renal collecting tubules were generated. These mice showed impairment in their urine concentrating mechanism, most likely due to reduced expression of the aquaporin AQP2 and the urea transporter UT-A1 and UT-A2 mRNAs. When deprived of water or after the administration of a vasopressin analogue, urine osmolality of the Tg mice was significantly increased but not to the same extent as that of the wild type mice. The expression of AQP2 and UT-A1, but not UT-A2 mRNAs, was increased to the same level as that of the wild type mice in the water deprivation state, indicating that the vasopressin regulatory mechanism was not affected by OREBPdn. These data indicate that in addition to vasopressin, OREBP is another essential regulator of the urine concentrating mechanism. Furthermore, the OREBPdn Tg mice developed progressive hydronephrosis soon after weaning, confirming the osmoprotective function of OREBP implicated by the in vitro experiments.	Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Div Clin Biochem, Hong Kong, Hong Kong, Peoples R China; NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ko, BCB (corresponding author), Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China.	cbko@hkucc.hku.hk; smchung@hkucc.hku.hk	Lam, Alfred/C-1652-2008; Ko, Chi-bun/ACH-7514-2022	Lam, Alfred/0000-0003-2771-564X; Ko, Ben Chi Bun/0000-0003-2027-5899				Bagnasco SM, 2001, AM J PHYSIOL-RENAL, V281, pF400, DOI 10.1152/ajprenal.2001.281.3.F400; Burdmann EA, 2003, SEMIN NEPHROL, V23, P465, DOI 10.1016/S0270-9295(03)00090-1; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Cha JH, 2001, J AM SOC NEPHROL, V12, P2221, DOI 10.1681/ASN.V12112221; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; ECELBARGER CA, 1995, AM J PHYSIOL-RENAL, V269, pF663, DOI 10.1152/ajprenal.1995.269.5.F663; Fenton RA, 2002, AM J PHYSIOL-RENAL, V282, pF630, DOI 10.1152/ajprenal.00264.2001; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; Ho HTB, 2000, MOL CELL BIOL, V20, P5840, DOI 10.1128/MCB.20.16.5840-5846.2000; HOLTHOFER H, 1987, CELL TISSUE RES, V249, P481; Igarashi P, 1999, AM J PHYSIOL-RENAL, V277, pF599, DOI 10.1152/ajprenal.1999.277.4.F599; Kihara M, 1998, KIDNEY INT, V53, P548, DOI 10.1046/j.1523-1755.1998.00801.x; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; LANKFORD SP, 1991, AM J PHYSIOL, V261, pF554, DOI 10.1152/ajprenal.1991.261.3.F554; Leroy C, 2000, BIOCHEM BIOPH RES CO, V271, P368, DOI 10.1006/bbrc.2000.2640; Lim SW, 2004, AM J PHYSIOL-RENAL, V287, pF139, DOI 10.1152/ajprenal.00240.2003; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Marples D, 1998, AM J PHYSIOL-RENAL, V275, pF400, DOI 10.1152/ajprenal.1998.275.3.F400; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nakayama Y, 2001, BBA-GENE STRUCT EXPR, V1518, P19, DOI 10.1016/S0167-4781(00)00311-0; Nakayama Y, 2000, J BIOL CHEM, V275, P38275, DOI 10.1074/jbc.M004678200; Nielsen S, 1996, P NATL ACAD SCI USA, V93, P5495, DOI 10.1073/pnas.93.11.5495; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; Promeneur D, 1998, J AM SOC NEPHROL, V9, P1359; SANDS JM, 1987, J CLIN INVEST, V79, P138, DOI 10.1172/JCI112774; SCHULTE BA, 1983, AM J ANAT, V168, P345, DOI 10.1002/aja.1001680308; Sheikh-Hamad D, 2001, J AM SOC NEPHROL, V12, P2732, DOI 10.1681/ASN.V12122732; Storm R, 2003, AM J PHYSIOL-RENAL, V284, pF189, DOI 10.1152/ajprenal.00245.2002; Terris J, 1996, AM J PHYSIOL-RENAL, V271, pF414, DOI 10.1152/ajprenal.1996.271.2.F414; Trama J, 2002, J IMMUNOL, V169, P5477, DOI 10.4049/jimmunol.169.10.5477; TSUBOI Y, 1994, J ENDOCRINOL, V143, P227, DOI 10.1677/joe.0.1430227; YAMAMURA Y, 1992, BRIT J PHARMACOL, V105, P787, DOI 10.1111/j.1476-5381.1992.tb09058.x; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200; Zhang Z, 2002, AM J PHYSIOL-RENAL, V283, pF302, DOI 10.1152/ajprenal.00038.2002	38	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48048	48054		10.1074/jbc.M407224200	http://dx.doi.org/10.1074/jbc.M407224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347663	hybrid			2022-12-25	WOS:000224957000076
J	Sathish, JG; Walters, J; Luo, JC; Johnson, KG; LeRoy, FG; Brennan, P; Kim, KP; Gygi, SP; Neel, BG; Matthews, RJ				Sathish, JG; Walters, J; Luo, JC; Johnson, KG; LeRoy, FG; Brennan, P; Kim, KP; Gygi, SP; Neel, BG; Matthews, RJ			CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR SIGNAL-TRANSDUCTION; IG-LIKE RECEPTOR-1; ANTIGEN RECEPTOR; PROLIFERATIVE RESPONSE; CD22-DEFICIENT MICE; NEGATIVE REGULATION; B-CELLS; SHP-1; ACTIVATION; SELECTION	The intracellular Src homology 2 (SH2) domain-containing protein-tyrosine phosphatase (SHP-1) has been characterized as a negative regulator of T cell function, contributing to the definition of T cell receptor signaling thresholds in developing and peripheral mouse T lymphocytes. The activation of SHP-1 is achieved through the engagement of its tandem SH2 domains by tyrosine-phosphorylated proteins; however, the identity of the activating ligand(s) for SHP-1, within mouse primary T cells, is presently unresolved. The identification of SHP-1 ligand( s) in primary T cells would provide crucial insight into the molecular mechanisms by which SHP-1 contributes to in vivo thresholds for T cell activation. Here we present a combination of biochemical and yeast genetic analyses indicating CD22 to be a T cell ligand for the SHP-1 SH2 domains. Based on these observations we have confirmed that CD22 is indeed expressed on mouse primary T cells and capable of associating with SHP-1. Significantly, CD22-deficient T cells demonstrate enhanced proliferation in response to anti-CD3 or allogeneic stimulation. Furthermore, the co-engagement of CD3 and CD22 results in a raising of TCR signaling thresholds hence demonstrating a previously unsuspected functional role for CD22 in primary T cells.	Cardiff Univ, Sect Infect & Immun, Cardiff CF14 4XX, S Glam, Wales; Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Cardiff University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Matthews, RJ (corresponding author), Cardiff Univ, Sect Infect & Immun, Henry Wellcome Bldg Biomed Res Wales, Cardiff CF14 4XX, S Glam, Wales.	matthewsrj@cardiff.ac.uk	Brennan, Paul/ABB-9196-2021; Jin Cai, Luo/A-7900-2011; Brennan, Paul/B-9210-2009	Brennan, Paul/0000-0001-8792-0499; Brennan, Paul/0000-0001-8792-0499; Kim, Kwang Pyo/0000-0003-0095-3787; Sathish, Jean/0000-0002-5605-6957	NIDDK NIH HHS [R01 DK66600] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066600] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blery M, 1999, CLIN CHEM LAB MED, V37, P187, DOI 10.1515/CCLM.1999.035; Carter JD, 1999, INT IMMUNOL, V11, P1999, DOI 10.1093/intimm/11.12.1999; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gorham JD, 1996, P NATL ACAD SCI USA, V93, P12467, DOI 10.1073/pnas.93.22.12467; Guler ML, 1999, MICROBES INFECT, V1, P79, DOI 10.1016/S1286-4579(99)80018-5; Havelkova H, 1999, IMMUNOGENETICS, V49, P235, DOI 10.1007/s002510050485; Jin L, 2002, J EXP MED, V195, P1199, DOI 10.1084/jem.20011796; Johnson KG, 1999, J IMMUNOL, V162, P3802; Krulova M, 1997, GENOMICS, V42, P11, DOI 10.1006/geno.1997.4694; Lebbink RJ, 2004, J IMMUNOL, V172, P5535, DOI 10.4049/jimmunol.172.9.5535; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; NAKAYAMA E, 1989, P NATL ACAD SCI USA, V86, P1352, DOI 10.1073/pnas.86.4.1352; Nitschke L, 1997, CURR BIOL, V7, P133, DOI 10.1016/S0960-9822(06)00057-1; OKeefe TL, 1996, SCIENCE, V274, P798, DOI 10.1126/science.274.5288.798; Otipoby KL, 1996, NATURE, V384, P634, DOI 10.1038/384634a0; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Peng JM, 2001, J MASS SPECTROM, V36, P1083, DOI 10.1002/jms.229; Plas DR, 1999, J IMMUNOL, V162, P5680; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Robinson WH, 1997, IMMUNOGENETICS, V45, P195, DOI 10.1007/s002510050189; Sathish JG, 2001, J IMMUNOL, V166, P1763, DOI 10.4049/jimmunol.166.3.1763; Sato S, 1996, IMMUNITY, V5, P551, DOI 10.1016/S1074-7613(00)80270-8; SCOTT D, 1991, IMMUNOGENETICS, V33, P54, DOI 10.1007/BF00211696; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TORRES RM, 1992, J IMMUNOL, V149, P2641; Williams O, 1996, EUR J IMMUNOL, V26, P532, DOI 10.1002/eji.1830260305; Yang J, 2003, J BIOL CHEM, V278, P6516, DOI 10.1074/jbc.M210430200; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47783	47791		10.1074/jbc.M402354200	http://dx.doi.org/10.1074/jbc.M402354200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364920	hybrid			2022-12-25	WOS:000224957000046
J	Shajahan, AN; Tiruppathi, C; Smrcka, AV; Malik, AB; Minshall, RD				Shajahan, AN; Tiruppathi, C; Smrcka, AV; Malik, AB; Minshall, RD			G beta gamma activation of Src induces caveolae-mediated endocytosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PROTEIN SUBUNIT DISSOCIATION; TYROSINE PHOSPHORYLATION; PLASMALEMMAL VESICLES; MICROVASCULAR ENDOTHELIUM; CAPILLARY ENDOTHELIUM; ALBUMIN TRANSCYTOSIS; TRANSPORT VESICLES; MEMBRANE-PROTEIN; BINDING PROTEIN	Caveolae-mediated endocytosis in endothelial cells is stimulated by the binding of albumin to gp60, a specific albumin-binding protein localized in caveolae. The activation of gp60 induces its cell surface clustering and association with caveolin-1, the caveolar-scaffolding protein. This interaction leads to G(i)-induced Src kinase activation, which in turn signals dynamin-2-mediated fission and directed migration of caveolae-derived vesicles from apical to basal membrane. In this study, we investigated the possible role of the Gbetagamma heterodimer in signaling G(i)-induced Src activation and subsequent caveolae-mediated endocytosis. We observed using rat lung microvascular endothelial cells that expression of the C terminus of beta-adrenergic receptor kinase (ct-betaARK), an inhibitor Gbetagamma signaling, prevented gp60-dependent Src activation as well as caveolae-mediated endocytosis and transcellular transport of albumin and uptake of cholera toxin subunit B, a specific marker of caveolae internalization. Expression of ct-betaARK also prevented Src-mediated tyrosine phosphorylation of caveolin-1 and dynamin-2 and the resultant phosphorylation-dependent association of dynamin-2 and caveolin-1. Also, the direct activation of Gbetagamma using a specific cell-permeant activating peptide (myristoylated-SIRKALNILGYPDYD) simulated the effects of gp60 in inducing Src activation, caveolin-1, and dynamin-2 phosphorylation as well as caveolae-mediated endocytosis of cholera toxin subunit B. The myristoylated-SIRKALNILGYPDYD peptide-induced responses were inhibited by the expression of ct-betaARK. Taken together, our results demonstrate that Gbetagamma activation of Src signals caveolae-mediated endocytosis and transendothelial albumin transport via transcytosis.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Rochester	Minshall, RD (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	rminsh@uic.edu		Malik, Asrar/0000-0002-8205-7128; Shajahan-Haq, Ayesha/0000-0001-7616-320X	NHLBI NIH HHS [T32 HL07239, HL60678, HL71626] Funding Source: Medline; NIGMS NIH HHS [GM58531] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL060678, R01HL071626] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; ANTOHE F, 1993, EUR J CELL BIOL, V60, P268; Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Cao H, 2003, MOL CELL BIOL, V23, P2162, DOI 10.1128/MCB.23.6.2162-2170.2003; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; Chen YZ, 1999, EXP CELL RES, V246, P83, DOI 10.1006/excr.1998.4301; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; Ghosh M, 2003, J BIOL CHEM, V278, P34747, DOI 10.1074/jbc.C300271200; Goubaeva F, 2003, J BIOL CHEM, V278, P19634, DOI 10.1074/jbc.M300052200; Henley JR, 1999, FASEB J, V13, pS243, DOI 10.1096/fasebj.13.9002.S243; John TA, 2003, AM J PHYSIOL-LUNG C, V284, pL187, DOI 10.1152/ajplung.00152.2002; John TA, 2001, J PHYSIOL-LONDON, V533, P547, DOI 10.1111/j.1469-7793.2001.0547a.x; Kim J, 2003, BIOCHEMISTRY-US, V42, P2887, DOI 10.1021/bi026942t; Kim YN, 2002, ENDOCRINOLOGY, V143, P1726, DOI 10.1210/en.143.5.1726; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Li SW, 1996, J BIOL CHEM, V271, P3863; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1999, BIOCHEM BIOPH RES CO, V261, P695, DOI 10.1006/bbrc.1999.1082; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MILICI AJ, 1987, J CELL BIOL, V105, P2603, DOI 10.1083/jcb.105.6.2603; Minshall RD, 2002, HISTOCHEM CELL BIOL, V117, P105, DOI 10.1007/s00418-001-0367-x; Minshall RD, 2000, J CELL BIOL, V150, P1057, DOI 10.1083/jcb.150.5.1057; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Niles WD, 1999, J MEMBRANE BIOL, V167, P85, DOI 10.1007/s002329900474; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2002, SCIENCE, V296, P535, DOI 10.1126/science.1069784; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; PREDESCU D, 1988, J CELL BIOL, V107, P1729, DOI 10.1083/jcb.107.5.1729; Razani B, 2001, J BIOL CHEM, V276, P38121; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246; Shajahan AN, 2004, J BIOL CHEM, V279, P20392, DOI 10.1074/jbc.M308710200; Sharma DK, 2004, MOL BIOL CELL, V15, P3114, DOI 10.1091/mbc.E04-03-0189; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIMIONESCU M, 1991, CELL BIOL REV, V25, P5; Singh RD, 2003, MOL BIOL CELL, V14, P3254, DOI 10.1091/mbc.E02-12-0809; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Tiruppathi C, 1997, J BIOL CHEM, V272, P25968, DOI 10.1074/jbc.272.41.25968; Tuma PL, 2003, PHYSIOL REV, V83, P871, DOI 10.1152/physrev.00001.2003; Vogel SM, 2001, MICROVASC RES, V61, P87, DOI 10.1006/mvre.2000.2274; Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799	66	76	78	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48055	48062		10.1074/jbc.M405837200	http://dx.doi.org/10.1074/jbc.M405837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15345719	hybrid			2022-12-25	WOS:000224957000077
J	Young, GD; Murphy-Ullrich, JE				Young, GD; Murphy-Ullrich, JE			The tryptophan-rich motifs of the thrombospondin type 1 repeats bind VLAL motifs in the latent transforming growth factor-beta complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA CELL-ADHESION; TGF-BETA; IN-VIVO; PANCREATIC-CANCER; HEPARIN-BINDING; PRO REGION; ACTIVATION; TGF-BETA-1; EXPRESSION; PEPTIDES	Transforming growth factor-beta (TGF-beta) is secreted as a latent complex of the latency-associated peptide (LAP) and the mature domain, which must be activated for TGF-beta to signal. We previously identified thrombospondin 1 (TSP1) as a physiologic activator of TGF-beta in vitro and in vivo. The WSXW sequences in the type 1 repeats of TSP1 interact with the mature domain of TGF-beta, and WSXW peptides inhibit TSP1-mediated activation by blocking TSP1 binding to the TGF-beta latent complex. However, the binding site for the WSXW sequence was not identified. In this report, we show that the WSXW sequences bind the (61)VLAL sequence in mature TGF-beta and also bind (77)VLAL in LAP. A glutathione S-transferase (GST) fusion protein of the second TSP1 type 1 repeat (GST-TSR2) binds immobilized VLAL peptide. VLAL peptides inhibit binding of LAP and mature TGF-beta to soluble GST-TSR2 and immobilized WSXW peptide. VLAL peptide inhibits TSP1-mediated activation of recombinant and endothelial cell-derived latent TGF-beta. Furthermore, TGF-beta or LAP deleted in the VLAL sequence fails to bind immobilized WSXW or soluble GST-TSR2, indicating that binding to both VLAL sequences is important for association of TSP1 and the latent complex. Additionally, TSP1 is unable to activate latent TGF-beta when VLAL is deleted from the mature domain. These data show that the WSXW motif binds VLAL on both LAP and mature TGF-beta, and these interactions are critical for TSP1-mediated activation of the TGF-beta latent complex.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Med Scientist Training Program, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Volker Hall 668,1670 Univ Blvd, Birmingham, AL 35294 USA.	murphy@path.uab.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050061] Funding Source: NIH RePORTER; NCRR NIH HHS [C06RR15490] Funding Source: Medline; NHLBI NIH HHS [HL50061] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; Albo D, 1998, J SURG RES, V76, P86, DOI 10.1006/jsre.1998.5299; Albo D, 1999, J GASTROINTEST SURG, V3, P411, DOI 10.1016/S1091-255X(99)80058-4; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BRUNNER AM, 1989, J BIOL CHEM, V264, P13660; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Dumont N, 2002, DIFFERENTIATION, V70, P574, DOI 10.1046/j.1432-0436.2002.700910.x; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hugo CPM, 1999, KIDNEY INT, V55, P2236, DOI 10.1046/j.1523-1755.1999.00459.x; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Janssens K, 2003, J BIOL CHEM, V278, P7718, DOI 10.1074/jbc.M208857200; Kawataki T, 2000, NEUROPATHOLOGY, V20, P161, DOI 10.1046/j.1440-1789.2000.00327.x; Koch RM, 2000, WOUND REPAIR REGEN, V8, P179, DOI 10.1046/j.1524-475x.2000.00179.x; Kondou H, 2003, J HEPATOL, V39, P742, DOI 10.1016/S0168-8278(03)00377-5; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; MOSHER DF, 1990, ANNU REV MED, V41, P85; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Sasaki A, 2001, NEUROL MED-CHIR, V41, P253, DOI 10.2176/nmc.41.253; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SHA X, 1991, J CELL BIOL, V114, P827, DOI 10.1083/jcb.114.4.827; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; Tan KM, 2002, J CELL BIOL, V159, P373, DOI 10.1083/jcb.200206062; WAKEFIELD LM, 1988, ANN NY ACAD SCI, V551, P290, DOI 10.1111/j.1749-6632.1988.tb22355.x; Wolfraim LA, 2002, J IMMUNOL METHODS, V266, P7, DOI 10.1016/S0022-1759(02)00090-X	39	72	81	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47633	47642		10.1074/jbc.M404918200	http://dx.doi.org/10.1074/jbc.M404918200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342643	hybrid			2022-12-25	WOS:000224957000028
J	Tippin, B; Kobayashi, S; Bertram, JG; Goodman, MF				Tippin, B; Kobayashi, S; Bertram, JG; Goodman, MF			To slip or skip, visualizing frameshift mutation dynamics for error-prone DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU POL-MU; ESCHERICHIA-COLI; NUCLEOTIDE MISINCORPORATION; TRANSIENT MISALIGNMENT; TRANSLESION SYNTHESIS; CRYSTAL-STRUCTURES; ADAPTIVE MUTATION; KINETIC-ANALYSIS; 2-AMINOPURINE; BETA	Three models describing frameshift mutations are "classical" Streisinger slippage, proposed for repetitive DNA, and "misincorporatation misalignment" and "dNTP-stabilized misalignment," proposed for non-repetitive DNA. We distinguish between models using pre-steady state fluorescence kinetics to visualize transiently misaligned DNA intermediates and nucleotide incorporation products formed by DNA polymerases adept at making small frameshift mutations in vivo. Human polymerase (pol) mu catalyzes Streisinger slippage exclusively in repetitive DNA, requiring as little as a dinucleotide repeat. Escherichia coli pol IV uses dNTP-stabilized misalignment in identical repetitive DNA sequences, revealing that pol mu and pol IV use different mechanisms in repetitive DNA to achieve the same mutational end point. In non-repeat sequences, pol mu switches to dNTP-stabilized misalignment. pol beta generates -1 frameshifts in "long" repeats and base substitutions in "short" repeats. Thus, two polymerases can use two different frameshift mechanisms on identical sequences, whereas one polymerase can alternate between frameshift mechanisms to process different sequences.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, SHS172,Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@usc.edu			NIEHS NIH HHS [ES012259] Funding Source: Medline; NIGMS NIH HHS [GM21422] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bertocci B, 2003, IMMUNITY, V19, P203, DOI 10.1016/S1074-7613(03)00203-6; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; Bloom LB, 1996, J BIOL CHEM, V271, P30699, DOI 10.1074/jbc.271.48.30699; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Delarue M, 2002, EMBO J, V21, P427, DOI 10.1093/emboj/21.3.427; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Efrati E, 1997, J BIOL CHEM, V272, P2559; ERITJA R, 1986, NUCLEIC ACIDS RES, V14, P5869, DOI 10.1093/nar/14.14.5869; FAZAKERLEY GV, 1987, BIOCHEMISTRY-US, V26, P5641, DOI 10.1021/bi00392a009; Foster PL, 2000, COLD SPRING HARB SYM, V65, P21, DOI 10.1101/sqb.2000.65.21; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; HOCHSTRASSER RA, 1994, BIOCHEMISTRY-US, V33, P11971, DOI 10.1021/bi00205a036; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Kobayashi S, 2002, J BIOL CHEM, V277, P34198, DOI 10.1074/jbc.M204826200; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; Otto MR, 1998, BIOCHEMISTRY-US, V37, P10156, DOI 10.1021/bi9800754; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; Reha-Krantz LJ, 1998, J BIOL CHEM, V273, P22969, DOI 10.1074/jbc.273.36.22969; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; WARD DC, 1969, J BIOL CHEM, V244, P1228; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	36	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45360	45368		10.1074/jbc.M408600200	http://dx.doi.org/10.1074/jbc.M408600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15339923	hybrid			2022-12-25	WOS:000224694900011
J	Ayrault, O; Andrique, L; Larsen, CJ; Seite, P				Ayrault, O; Andrique, L; Larsen, CJ; Seite, P			Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes	ONCOGENE			English	Article						p14(ARF); Topo I; chromatin; ChIP; rRNA genes	DNA TOPOISOMERASE-I; NUCLEAR-MATRIX; CELL-LINES; P53; TRANSCRIPTION; P19(ARF); MDM2; PROTEINS; STABILIZATION; BIOGENESIS	The tumor suppressor Arf (Alternative Reading Frame) protein (p14(ARF) in human and p19(ARF) in mouse) is mainly located in the nucleolus consistent with its subcellular localization, the protein has been shown to specifically interact with 5.8S rRNA and with B23/Nucleophosmin and to regulate ribosome biogenesis. Here, we show that the p14(ARF) protein interacts with chromatin and is recovered by chromatin immunoprecipitation (ChIP) in a fraction that contains a DNA sequence of the rRNA gene promoter. In addition, topoisomerase I (Topo I) that has been shown to interact with p14(ARF) coprecipitates with p14(ARF) containing chromatin. These data, in view of the function for Topo I in rRNA transcription, are consistent with a role for the p14(ARF)-Topo I complex in rRNA transcription and/or maturation.	Lab Oncol Mol EA 3805, F-86022 Poitiers, France		Seite, P (corresponding author), Lab Oncol Mol EA 3805, Pole Biol SAnte 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr		Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Arnan C, 2003, J BIOL CHEM, V278, P31319, DOI 10.1074/jbc.M305560200; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Gladden AB, 2003, J BIOL CHEM, V278, P9754, DOI 10.1074/jbc.M212088200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; JACKSON DA, 1985, EMBO J, V4, P919, DOI 10.1002/j.1460-2075.1985.tb03719.x; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Pourquier Philippe, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P303; QUELLE DE, 1995, CELL, V83, P993; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rossi F, 1996, NATURE, V381, P80, DOI 10.1038/381080a0; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SMITH HC, 1987, BIOCHEM GENET, V25, P863, DOI 10.1007/BF00502606; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Wadhwa R, 2002, J BIOL CHEM, V277, P36665, DOI 10.1074/jbc.M203222200; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	34	40	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8097	8104		10.1038/sj.onc.1207968	http://dx.doi.org/10.1038/sj.onc.1207968			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361825				2022-12-25	WOS:000224692500007
J	Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F				Bergonzini, V; Delbue, S; Wang, JY; Reiss, K; Prisco, M; Amini, S; Khalili, K; Peruzzi, F			HIV-Tat promotes cellular proliferation and inhibits NGF-induced differentiation through mechanisms involving Id1 regulation	ONCOGENE			English	Article						HIV-1 TAT; NGF; neuronal signaling; Id1	LOOP-HELIX PROTEIN; NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; DNA-BINDING; MYELOID DIFFERENTIATION; NEURONAL APOPTOSIS; SIGNALING PATHWAYS; ACTIVATION; RECEPTOR	Id1 is a helix - loop - helix transcriptional factor that controls growth and survival of neuronal cells. Downregulation of Id1 expression is required to initiate differentiation and cell-cycle withdrawal in primary neuronal culture as well as in PC12 cells. The HIV-1 transactivating factor, Tat, has been suspected of causing neuronal dysfunction that often leads to the development of HIV-associated dementia in AIDS patients. We found that the expression of Tat in PC12 cells promotes serum-independent growth, formation of large colonies in soft agar, and the acceleration of tumor growth in nude mice. In addition, Tat showed the ability to inhibit the nerve growth factor (NGF)-induced neuronal differentiation of PC12 cells. Our results show that the Tat-mediated signaling events, which lead to serum-independent growth and the inhibition of NGF-induced differentiation, have a common cellular target: the upregulation of Id1 expression. In the absence of NGF, expression of Id1 is required to promote serum-independent proliferation of PC12/Tat cells, as the inhibition of Id1 by antisense DNA restored the serum-dependent growth of PC12/Tat cells. In the presence of NGF, Tat utilizes an additional pathway that involves phosphorylation of Stat5a, to upregulate Id1 expression and block neuronal cell differentiation. Suppression of Stat5a by use of its dominant-negative mutant reversed the transient expression of Id1 and the blockage of NGF-mediated differentiation in PC12/Tat cells. Finally, the treatment of PC12 cells with recombinant Tat also enhanced the NGF-induced Id1 expression, further pointing to Id1 as a target for Tat. Taken together, these studies suggest additional targets for Tat action in neuronal cells and provide new insights into the mechanisms involved in the dysregulation of neuronal functions.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA; Fdn Don C Gnocchi, Milan, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; IRCCS Fondazione Don Carlo Gnocchi Onlus	Peruzzi, F (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 12th North St, Philadelphia, PA 19122 USA.	fperuzzi@temple.edu	Peruzzi, Francesca/M-9804-2014; delbue, serena/A-1145-2010	Delbue, Serena/0000-0002-3199-9369				Belletti B, 2002, EXP CELL RES, V277, P107, DOI 10.1006/excr.2002.5542; BENEZRA R, 1990, ANN NY ACAD SCI, V599, P1, DOI 10.1111/j.1749-6632.1990.tb42359.x; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Borgatti P, 1998, BIOCHEM BIOPH RES CO, V242, P332, DOI 10.1006/bbrc.1997.7877; Bovolenta C, 1999, BLOOD, V94, P4202, DOI 10.1182/blood.V94.12.4202.424k22_4202_4209; Bovolenta C, 2002, J IMMUNOL, V169, P4443, DOI 10.4049/jimmunol.169.8.4443; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Cai L, 2000, DEVELOPMENT, V127, P3021; Caldenhoven E, 1998, STEM CELLS, V16, P397, DOI 10.1002/stem.160397; Cantaluppi V, 2001, AIDS RES HUM RETROV, V17, P965, DOI 10.1089/088922201750290087; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; de la Fuente C, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-14; De-Fraja C, 2000, INT J DEV NEUROSCI, V18, P439, DOI 10.1016/S0736-5748(00)00007-1; Desprez PY, 1998, MOL CELL BIOL, V18, P4577, DOI 10.1128/MCB.18.8.4577; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; EINARSON MB, 1995, MOL CELL BIOL, V15, P4175; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI F, 1994, VIROLOGY, V200, P668, DOI 10.1006/viro.1994.1230; GAYNOR RB, 1995, CURR TOP MICROBIOL, V193, P51; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; Israel MA, 1999, CANCER RES, V59, p1726S; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Klesse LJ, 1999, ONCOGENE, V18, P2055, DOI 10.1038/sj.onc.1202524; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958; Lin CQ, 2000, CANCER RES, V60, P1332; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MERRILL JE, 1992, J VIROL, V66, P2217, DOI 10.1128/JVI.66.4.2217-2225.1992; Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008; MIN X, 2003, EMBO J, V22, P893; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; NAGATA Y, 1994, BIOCHEM BIOPH RES CO, V199, P1355, DOI 10.1006/bbrc.1994.1380; Nath A, 1996, J VIROL, V70, P1475, DOI 10.1128/JVI.70.3.1475-1480.1996; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nguyen KB, 2002, SCIENCE, V297, P2063, DOI 10.1126/science.1074900; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x; Recio JA, 1997, J BIOL CHEM, V272, P26807, DOI 10.1074/jbc.272.43.26807; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, CLIN CANCER RES, V7, P2134; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; Seve M, 1999, ARCH BIOCHEM BIOPHYS, V361, P165, DOI 10.1006/abbi.1998.0942; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; Wang JY, 2003, VIROLOGY, V305, P66, DOI 10.1006/viro.2002.1690; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; ZAULI G, 1993, CANCER RES, V53, P4481; ZAULI G, 1995, BLOOD, V86, P3823, DOI 10.1182/blood.V86.10.3823.bloodjournal86103823; Zhong HY, 2001, LIFE SCI, V68, P2269, DOI 10.1016/S0024-3205(01)01015-3	59	19	19	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7701	7711		10.1038/sj.onc.1207828	http://dx.doi.org/10.1038/sj.onc.1207828			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361847				2022-12-25	WOS:000224306700011
J	Xu, WL; Kaneko, FT; Zheng, S; Comhair, SAA; Janocha, AJ; Goggans, T; Thunnissen, FBJM; Farver, C; Hazen, SL; Jennings, C; Dweik, RA; Arroliga, AC; Erzurum, SC				Xu, WL; Kaneko, FT; Zheng, S; Comhair, SAA; Janocha, AJ; Goggans, T; Thunnissen, FBJM; Farver, C; Hazen, SL; Jennings, C; Dweik, RA; Arroliga, AC; Erzurum, SC			Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension	FASEB JOURNAL			English	Article						arginine; lung; pulmonary vasodilation	NITRIC-OXIDE SYNTHASE; HUMAN AIRWAY EPITHELIUM; SMOOTH-MUSCLE-CELLS; HYDROXY-L-ARGININE; ALVEOLAR MACROPHAGES; MOLECULAR-MECHANISMS; GENE-EXPRESSION; INHIBITION; PURIFICATION; METABOLISM	Pulmonary arterial hypertension (PAH), a fatal disease of unknown etiology characterized by impaired regulation of pulmonary hemodynamics and vascular growth, is associated with low levels of pulmonary nitric oxide (NO). Based upon its critical role in mediating vasodilation and cell growth, decrease of NO has been implicated in the pathogenesis of PAH. We evaluated mechanisms for low NO and pulmonary hypertension, including NO synthases ( NOS) and factors regulating NOS activity, i.e. the substrate arginine, arginase expression and activity, and endogenous inhibitors of NOS in patients with PAH and healthy controls. PAH lungs had normal NOS I-III expression, but substrate arginine levels were inversely related to pulmonary artery pressures. Activity of arginase, an enzyme that regulates NO biosynthesis through effects on arginine, was higher in PAH serum than in controls, with high-level arginase expression localized by immunostaining to pulmonary endothelial cells. Further, pulmonary artery endothelial cells derived from PAH lung had higher arginase II expression and produced lower NO than control cells in vitro. Thus, substrate availability affects NOS activity and vasodilation, implicating arginase II and alterations in arginine metabolic pathways in the pathophysiology of PAH.	Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Canisius Wihelmina Ziekenhuis, Dept Pathol, Nijmegen, Netherlands	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Erzurum, SC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Pathobiol, 9500 Euclid Ave,NB40, Cleveland, OH 44195 USA.	erzurus@ccf.org	Arroliga, Alejandro/AAX-3933-2021; Hazen, Stanley L/ABD-5845-2021	Thunnissen, Erik/0000-0001-5355-8508	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL060917, R01HL060917, K24HL004265, P01HL076491] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR018390] Funding Source: Medline; NHLBI NIH HHS [HL076491, HL 60917, HL 04265] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albina JE, 2003, WOUND REPAIR REGEN, V11, P445, DOI 10.1046/j.1524-475X.2003.11619.x; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Archer S, 2000, CIRCULATION, V102, P2781, DOI 10.1161/01.CIR.102.22.2781; ARNAL JF, 1995, J CLIN INVEST, V95, P2565, DOI 10.1172/JCI117957; Arrigoni FI, 2003, CIRCULATION, V107, P1195, DOI 10.1161/01.CIR.0000051466.00227.13; Arroliga AC, 2000, CLEV CLIN J MED, V67, P175, DOI 10.3949/ccjm.67.3.175; Azeka E, 2002, PEDIATR CARDIOL, V23, P20, DOI 10.1007/s00246-001-0006-2; Berka V, 1996, J BIOL CHEM, V271, P33293, DOI 10.1074/jbc.271.52.33293; Berkels R, 2001, J APPL PHYSIOL, V90, P317, DOI 10.1152/jappl.2001.90.1.317; Berkowitz DE, 2003, CIRCULATION, V108, P2000, DOI 10.1161/01.CIR.0000092948.04444.C7; Bogle RG, 1996, J PHYSIOL-LONDON, V490, P229, DOI 10.1113/jphysiol.1996.sp021138; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; Chang CI, 2000, J IMMUNOL, V165, P2134, DOI 10.4049/jimmunol.165.4.2134; Chicoine LG, 2004, AM J PHYSIOL-LUNG C, V287, pL60, DOI 10.1152/ajplung.00194.2003; Clarkson P, 1996, J CLIN INVEST, V97, P1989, DOI 10.1172/JCI118632; Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324; Cooke JP, 1997, CIRCULATION, V96, P379; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; Dweik RA, 1999, LUNG BIOL HEALTH DIS, V131, P333; Dweik RA, 2001, AM J RESP CELL MOL, V24, P414, DOI 10.1165/ajrcmb.24.4.4127; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256, DOI 10.1152/jappl.1993.75.3.1256; Fagan KA, 1999, AM J PHYSIOL-LUNG C, V277, pL472, DOI 10.1152/ajplung.1999.277.3.L472; Fagan KA, 2000, PHYSIOL RES, V49, P539; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; Fishman AP, 2000, PHYSIOL RES, V49, P485; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; Ghamra Ziad W, 2003, Cleve Clin J Med, V70 Suppl 1, pS2; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gorenflo M, 2001, J CARDIOVASC PHARM, V37, P489, DOI 10.1097/00005344-200104000-00016; Gotoh T, 1997, BIOCHEM BIOPH RES CO, V233, P487, DOI 10.1006/bbrc.1997.6473; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970, DOI 10.4049/jimmunol.164.11.5970; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; Hey C, 1997, BRIT J PHARMACOL, V121, P395, DOI 10.1038/sj.bjp.0701143; Ignarro LJ, 2001, P NATL ACAD SCI USA, V98, P4202, DOI 10.1073/pnas.071054698; Jeffery TK, 2002, PROG CARDIOVASC DIS, V45, P173, DOI 10.1053/pcad.2002.130041; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917, DOI 10.1164/ajrccm.158.3.9802066; Khangulov SV, 1998, BIOCHEMISTRY-US, V37, P8539, DOI 10.1021/bi972874c; Leiper J, 1999, CARDIOVASC RES, V43, P542, DOI 10.1016/S0008-6363(99)00162-5; Leiper JM, 1999, BIOCHEM J, V343, P209, DOI 10.1042/0264-6021:3430209; Li H, 2001, AM J PHYSIOL-ENDOC M, V280, pE75, DOI 10.1152/ajpendo.2001.280.1.E75; Louis CA, 1998, AM J PHYSIOL-REG I, V274, pR775, DOI 10.1152/ajpregu.1998.274.3.R775; Mason NA, 1998, J PATHOL, V185, P313, DOI 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8; MEHTA S, 1995, CIRCULATION, V92, P1539, DOI 10.1161/01.CIR.92.6.1539; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; Morris CR, 2003, AM J RESP CRIT CARE, V168, P63, DOI 10.1164/rccm.200208-967OC; Nagaya N, 2001, AM J RESP CRIT CARE, V163, P887, DOI 10.1164/ajrccm.163.4.2007116; Nuszkowski A, 2001, J BIOL CHEM, V276, P14212, DOI 10.1074/jbc.M007659200; Ozkan M, 2001, LUNG, V179, P233, DOI 10.1007/s004080000064; Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565; Pearson DL, 2001, NEW ENGL J MED, V344, P1832, DOI 10.1056/NEJM200106143442404; Que LG, 1998, AM J PHYSIOL-LUNG C, V275, pL96, DOI 10.1152/ajplung.1998.275.1.L96; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; Trummer G, 2002, ANN THORAC SURG, V73, P1299, DOI 10.1016/S0003-4975(01)03265-9; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; VALLANCE P, 1992, LANCET, V339, P572; Veyssier-Belot C, 1999, CARDIOVASC RES, V44, P274, DOI 10.1016/S0008-6363(99)00230-8; Wei LH, 2001, P NATL ACAD SCI USA, V98, P9260, DOI 10.1073/pnas.161294898; Wei LH, 2000, AM J PHYSIOL-CELL PH, V279, pC248, DOI 10.1152/ajpcell.2000.279.1.C248; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Xu WL, 2003, AM J PHYSIOL-LUNG C, V285, pL137, DOI 10.1152/ajplung.00441.2002; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	74	282	294	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1746	+		10.1096/fj.04-2317fje	http://dx.doi.org/10.1096/fj.04-2317fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364894				2022-12-25	WOS:000224243200029
J	Freie, BW; Ciccone, SLM; Li, XX; Plett, PA; Orschell, CM; Srour, EF; Hanenberg, H; Schindler, D; Lee, SH; Clapp, DW				Freie, BW; Ciccone, SLM; Li, XX; Plett, PA; Orschell, CM; Srour, EF; Hanenberg, H; Schindler, D; Lee, SH; Clapp, DW			A role for the Fanconi anemia C protein in maintaining the DNA damage-induced G(2) checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; CELL-CYCLE; ATAXIA-TELANGIECTASIA; HOMOLOGOUS RECOMBINATION; NUCLEAR-COMPLEX; IONIZING-RADIATION; VERTEBRATE CELLS; KINASE-ACTIVITY; HISTONE H3; G2 ARREST	Fanconi anemia ( FA) is a complex, heterogeneous genetic disorder composed of at least 11 complementation groups. The FA proteins have recently been found to functionally interact with the cell cycle regulatory proteins ATM and BRCA1; however, the function of the FA proteins in cell cycle control remains incompletely understood. Here we show that the Fanconi anemia complementation group C protein (Fancc) is necessary for proper function of the DNA damage-induced G(2)/M checkpoint in vitro and in vivo. Despite apparently normal induction of the G(2)/M checkpoint after ionizing radiation, murine and human cells lacking functional FANCC did not maintain the G(2) checkpoint as compared with wild-type cells. The increased rate of mitotic entry seen in Fancc -/- mouse embryo fibroblasts correlated with decreased inhibitory phosphorylation of cdc2 kinase on tyrosine 15. An increased inability to maintain the DNA damage-induced G(2) checkpoint was observed in Fancc -/-; Trp53 -/- cells compared with Fancc -/- cells, indicating that Fancc and p53 cooperated to maintain the G(2) checkpoint. In contrast, genetic disruption of both Fancc and Atm did not cooperate in the G(2) checkpoint. These data indicate that Fancc and p53 in separate pathways converge to regulate the G(2) checkpoint. Finally, fibroblasts lacking FANCD2 were found to have a G(2) checkpoint phenotype similar to FANCC-deficient cells, indicating that FANCD2, which is activated by the FA complex, was also required to maintain the G(2) checkpoint. Because a proper checkpoint function is critical for the maintenance of genomic stability and is intricately related to the function and integrity of the DNA repair process, these data have implications in understanding both the function of FA proteins and the mechanism of genomic instability in FA.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem, Indianapolis, IN 46202 USA; Univ Dusseldorf, Dept Pediat, D-40225 Dusseldorf, Germany; Univ Wurzburg, Biozentrum, Inst Humangenet, D-97074 Wurzburg, Germany	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Heinrich Heine University Dusseldorf; University of Wurzburg	Clapp, DW (corresponding author), Canc Res Inst, 1044 W Walnut St,Rm 408, Indianapolis, IN 46202 USA.	dclapp@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055716, R01HL063219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NCI NIH HHS [CA92111] Funding Source: Medline; NHLBI NIH HHS [R01 HL063219-04, R01 HL55716] Funding Source: Medline; NIDDK NIH HHS [P50 DK49218] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Centurion SA, 2000, EXP CELL RES, V260, P216, DOI 10.1006/excr.2000.4995; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Digweed M, 2002, CARCINOGENESIS, V23, P1121, DOI 10.1093/carcin/23.7.1121; Donahue SL, 2003, J BIOL CHEM, V278, P29487, DOI 10.1074/jbc.M213251200; DUCKWORTHRYSIECKI G, 1985, CANCER RES, V45, P416; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Haneline LS, 1998, BLOOD, V91, P4092; Hanenberg H, 2002, EXP HEMATOL, V30, P410, DOI 10.1016/S0301-472X(02)00782-8; Heinrich MC, 2000, BLOOD, V95, P3970; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; ISHIDA R, 1982, CANCER RES, V42, P4000; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Juan G, 1998, CYTOMETRY, V32, P71, DOI 10.1002/(SICI)1097-0320(19980601)32:2<71::AID-CYTO1>3.0.CO;2-H; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; LOCK RB, 1990, CANCER RES, V50, P3761; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAULES RS, 1995, CANCER RES, V55, P1763; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2002, INT J HEMATOL, V75, P123, DOI 10.1007/BF02982016; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TUCKER JD, 1991, MUTAT RES, V254, P143, DOI 10.1016/0921-8777(91)90005-A; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Winters ZE, 1998, ONCOGENE, V17, P673, DOI 10.1038/sj.onc.1201991; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435	69	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50986	50993		10.1074/jbc.M407160200	http://dx.doi.org/10.1074/jbc.M407160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15377654	hybrid			2022-12-25	WOS:000225355800043
J	Zhang, M; Hu, PR; Napoli, JL				Zhang, M; Hu, PR; Napoli, JL			Elements in the N-terminal signaling sequence that determine cytosolic topology of short-chain dehydrogenases/reductases Studies with retinol dehydrogenase type 1 and cis-retinol/androgen dehydrogenase type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGENIC 17-BETA-HYDROXYSTEROID DEHYDROGENASE; ENDOPLASMIC-RETICULUM MEMBRANE; DELAYED DARK-ADAPTATION; ALL-TRANS-RETINOL; BINDING-PROTEIN; ALCOHOL-DEHYDROGENASE; VITAMIN-A; 11-BETA-HYDROXYSTEROID DEHYDROGENASE; FUNDUS-ALBIPUNCTATUS; PIGMENT EPITHELIUM	High affinity, retinoid-specific binding proteins chaperone retinoids to manage their transport and metabolism. Proposing mechanisms of retinoid transfer between these binding proteins and membrane-associated retinoid-metabolizing enzymes requires insight into enzyme topology. We therefore determined the topology of mouse retinol dehydrogenase type 1 (Rdh1) and cis-retinoid androgen dehydrogenase type 1 (Crad1) in the endoplasmic reticulum of intact mammalian cells. The properties of Rdh1 were compared with a chimera with a luminal signaling sequence (11beta-hydroxysteroid dehydrogenase ( 11beta-HSD1)( 1 - 41)/Rdh1( 23 - 317); the green fluorescent protein (GFP) fusion proteins Rdh1( 1 - 22)/ GFP, Crad1( 1 - 22)/ GFP, and 11beta-HSD1( 1 - 41)/ GFP; and signaling sequence charge difference mutants using confocal immunofluorescence, antibody access, proteinase K sensitivity, and deglycosylation assays. An N-terminal signaling sequence of 22 residues, consisting of a hydrophobic helix ending in a net positive charge, anchors Rdh1 and Crad1 in the endoplasmic reticulum facing the cytoplasm. Mutating arginine to glutamine in the signaling sequence did not affect topology. Inserting one or two arginine residues near the N terminus of the signaling sequence caused 28-95% inversion from cytoplasmic to luminal, depending on the net positive charge remaining at the C terminus of the signaling sequence; e. g. the mutant L3R, L5R, R16Q, R19Q, R21Q faced the lumen. Experiments with N- and C-terminal epitope-tagged Rdh1 and molecular modeling indicated that a hydrophobic helix-turn-helix near the C terminus of Rdh1 ( residues 289 - 311) projects into the cytoplasm. These data provide insight into the features necessary to orient type III ( reverse signal-anchor) proteins and demonstrate that Rdh1, Crad1, and other short-chain dehydrogenases/reductases, which share similar N- terminal signaling sequences such as human Rdh5 and mouse Rdh4, orient with their catalytic domains facing the cytoplasm.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC 3104, Berkeley, CA 94720 USA.	jna@nature.berkeley.edu			NIDDK NIH HHS [DK047839, DK36870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870, R01DK047839] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; DELUCA LM, 1993, BASIC LIFE SCI, V61, P17; E XP, 2002, J BIOL CHEM, V277, P36617, DOI 10.1074/jbc.M205519200; Eusebio A, 1998, EXP CELL RES, V241, P181, DOI 10.1006/excr.1998.4042; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; Frick C, 2004, J BIOL CHEM, V279, P31131, DOI 10.1074/jbc.M313666200; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; Gollapalli DR, 2003, BIOCHEMISTRY-US, V42, P11824, DOI 10.1021/bi035227w; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; Hegde RS, 1998, CELL, V92, P621, DOI 10.1016/S0092-8674(00)81130-7; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Kedishvili NY, 1998, BIOCHEM BIOPH RES CO, V249, P191, DOI 10.1006/bbrc.1998.9105; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r; Liden M, 2003, MOL ASPECTS MED, V24, P403, DOI 10.1016/S0098-2997(03)00036-0; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Palmer M, 1998, BIOCHEMISTRY-US, V37, P2378, DOI 10.1021/bi9720890; Quadro L, 1999, EMBO J, V18, P4633, DOI 10.1093/emboj/18.17.4633; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Romert A, 2000, EXP CELL RES, V256, P338, DOI 10.1006/excr.2000.4817; Rosch K, 2000, J BIOL CHEM, V275, P14916, DOI 10.1074/jbc.M000456200; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Simon A, 1999, J CELL SCI, V112, P549; Song MS, 2003, J BIOL CHEM, V278, P40079, DOI 10.1074/jbc.M304910200; Tryggvason K, 2001, J BIOL CHEM, V276, P19253, DOI 10.1074/jbc.M100215200; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	59	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51482	51489		10.1074/jbc.M409051200	http://dx.doi.org/10.1074/jbc.M409051200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15355969	hybrid			2022-12-25	WOS:000225355800101
J	Liao, YF; Wang, BJ; Cheng, HT; Kuo, LH; Wolfe, MS				Liao, YF; Wang, BJ; Cheng, HT; Kuo, LH; Wolfe, MS			Tumor necrosis factor-alpha, interleukin-1 beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ALZHEIMERS-DISEASE; SIGNAL-TRANSDUCTION; DIFFERENTIAL ACTIVATION; BETA-APP; PRESENILIN; COMPLEX; NICASTRIN; RECEPTOR; DOMAIN	The deposition of the amyloid beta (Abeta) peptide in neuritic plaques plays a critical role in the pathogenesis of Alzheimer's disease (AD). Abeta is generated through the proteolysis of amyloid precursor protein (APP) by the sequential actions of beta- and gamma-secretases. Although recent evidence has unveiled much about the biochemical identity and characteristics of gamma-secretase, the mechanism regulating endogenous gamma-secretase activity remains elusive. To identify possible extracellular signals and associated signaling cascades that could regulate APP proteolysis by gamma-secretase activity, we have developed a cell-based reporter gene assay by stably cotransfecting HEK293 cells with the Gal4-driven luciferase reporter gene and the Gal4/VP16-tagged C-terminal fragment of APP (C99-GV), the immediate substrate of gamma-secretase. The cleavage of C99-GV by gamma-secretase releases the transcription factor that activates luciferase expression, providing a quantitative measurement of gamma-secretase activity. Using this reporter assay, we have demonstrated that interferon-gamma, interleukin-1beta, and tumor necrosis factor-alpha can specifically stimulate gamma-secretase activity, concomitant with increased production of Abeta and the intracellular domain of APP (AICD). The gamma-secretase-dependent cleavage of Notch is also enhanced upon the stimulation of these cytokines. The cytokine-enhanced gamma-secretase activity can be suppressed by a potent inhibitor of c-Jun N-terminal kinase (JNK). Furthermore, cells transfected with dominant-positive MEKK1, one of the most potent activators of the JNK cascade, exhibit increased gamma-secretase activity, suggesting that the JNK-dependent mitogen-activated protein kinase pathway could mediate the cytokine-elicited regulation of gamma-secretase. Our studies provide direct evidence that cytokine-elicited signaling cascades control Abeta production by modulating gamma-secretase activity.	Acad Sinica, Inst Zool, Mol Neurobiol Lab, Taipei 115, Taiwan; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Academia Sinica - Taiwan; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liao, YF (corresponding author), Acad Sinica, Inst Zool, Mol Neurobiol Lab, 129 Sec 2 Acad Rd,Rm 328, Taipei 115, Taiwan.	yliao@sinica.edu.tw	Liao, Yung-Feng/A-9761-2011					Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Bamberger ME, 2003, J NEUROSCI, V23, P2665; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blasko I, 1999, FASEB J, V13, P63, DOI 10.1096/fasebj.13.1.63; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Chen FS, 2002, J BIOL CHEM, V277, P36521, DOI 10.1074/jbc.M205093200; Combs CK, 2001, J NEUROSCI, V21, P1179; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Griffin WST, 2002, J LEUKOCYTE BIOL, V72, P233; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Kim JW, 2001, J CELL BIOL, V153, P457, DOI 10.1083/jcb.153.3.457; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Nyabi O, 2003, J BIOL CHEM, V278, P43430, DOI 10.1074/jbc.M306957200; PETRY RP, 2001, NEUROBIOL AGING, V22, P873; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Rogers J., 1998, NEUROINFLAMMATION ME, P177; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; Savage MJ, 2002, J NEUROSCI, V22, P3376; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; Siow YL, 1997, J BIOL CHEM, V272, P7586, DOI 10.1074/jbc.272.12.7586; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tang J, 2003, J MOL NEUROSCI, V20, P299, DOI 10.1385/JMN:20:3:299; Weidemann A, 2002, BIOCHEMISTRY-US, V41, P2825, DOI 10.1021/bi015794o; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolozin B, 1998, NEUROBIOL AGING, V19, pS23, DOI 10.1016/S0197-4580(98)00041-4; Xia WM, 2003, J CELL SCI, V116, P2839, DOI 10.1242/jcs.00651; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhao WQ, 2002, NEUROBIOL DIS, V11, P166, DOI 10.1006/nbdi.2002.0520; Zhu XW, 2003, J NEUROCHEM, V86, P136, DOI 10.1046/j.1471-4159.2003.01820.x; Zhu XW, 2003, J NEUROCHEM, V85, P87, DOI 10.1046/j.1471-4159.2003.01645.x; Zhu XW, 2001, MECH AGEING DEV, V123, P39, DOI 10.1016/S0047-6374(01)00342-6	53	268	276	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49523	49532		10.1074/jbc.M402034200	http://dx.doi.org/10.1074/jbc.M402034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347683	hybrid			2022-12-25	WOS:000225098100123
J	Swindle, EJ; Metcalfe, DD; Coleman, JW				Swindle, EJ; Metcalfe, DD; Coleman, JW			Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; HISTAMINE-RELEASE; IFN-GAMMA; GENERATION; DIPHENYLENEIODONIUM; DEGRANULATION; SUPEROXIDE; PHOSPHORYLATION; INHIBITION; INFECTION	In immunity, reactive oxygen species (ROS) and nitric oxide (NO) are important antimicrobial agents and regulators of cell signaling and activation pathways. However, the cellular sources of ROS and NO are much debated. Particularly, there is contention over whether mast cells, key secretory cells in allergy and immunity, can generate these chemical species, and if so, whether they are of functional significance. We therefore examined directly by flow cytometry the capacity of mast cells to generate intracellular ROS and NO using the respective cell-permeable fluorescent probes dichlorodihydrofluorescein and diaminofluorescein and evaluated the effects of inhibitors of ROS and NO synthesis on cell degranulation. For each of three mast cell types ( rat peritoneal mast cells, mouse bone marrow-derived mast cells, and human blood-derived mast cells), degranulation stimulated by IgE/antigen was accompanied by production of intracellular ROS but not NO. Inhibition of ROS production led to reduced degranulation, indicating a facilitatory role for ROS, whereas NO synthase inhibitors were without effect. Likewise, bacterial lipopolysaccharide and interferon-gamma over a wide range of conditions failed to generate intracellular NO in mast cells, whereas these agents readily induced intracellular NO in macrophages. NO synthase protein, as assessed by Western blotting, was readily induced in macrophages but not mast cells. We conclude that rodent and human mast cells generate intracellular ROS but not NO and that intracellular ROS but not intracellular NO are functionally linked to mast cell degranulation.	NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Liverpool, Dept Pharmacol, Liverpool L69 3GE, Merseyside, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Liverpool	Swindle, EJ (corresponding author), NIAID, Lab Allerg Dis, NIH, Bldg 10,Rm 11C 209, Bethesda, MD 20892 USA.	ejswindle@niaid.nih.gov		Swindle, Emily/0000-0003-3644-7747	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000607] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bidri M, 1997, EUR J IMMUNOL, V27, P2907, DOI 10.1002/eji.1830271124; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; Brooks AC, 1999, BRIT J PHARMACOL, V128, P585, DOI 10.1038/sj.bjp.0702838; Brooks B, 2000, J IMMUNOL, V164, P573, DOI 10.4049/jimmunol.164.2.573; Chen SS, 2000, IMMUNOLOGY, V100, P471, DOI 10.1046/j.1365-2567.2000.00045.x; Deschoolmeester ML, 1999, IMMUNOLOGY, V96, P138; Eastmond NC, 1997, J IMMUNOL, V159, P1444; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; FORMAN HJ, 1986, ANNU REV PHYSIOL, V48, P669; Fukuishi N, 1997, BIOCHEM MOL MED, V61, P107, DOI 10.1006/bmme.1997.2594; Gilchrist M, 2003, J BIOL CHEM, V278, P50607, DOI 10.1074/jbc.M307777200; Gilchrist M, 2002, J LEUKOCYTE BIOL, V71, P618; Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990; Guerin-Marchand C, 2001, INFLAMM RES, V50, P341, DOI 10.1007/PL00000254; GUSHCHIN IS, 1990, AGENTS ACTIONS, V30, P85, DOI 10.1007/BF01969005; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HENDERSON WR, 1978, J CLIN INVEST, V61, P187, DOI 10.1172/JCI108917; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; Kirshenbaum AS, 1999, BLOOD, V94, P2333, DOI 10.1182/blood.V94.7.2333.419k30_2333_2342; KUROSAWA M, 1990, ARZNEIMITTEL-FORSCH, V40-2, P767; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Matsui T, 2000, BIOCHEM BIOPH RES CO, V276, P742, DOI 10.1006/bbrc.2000.3545; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; PEDERSEN UB, 1994, EUR J PHARM-MOLEC PH, V267, P85, DOI 10.1016/0922-4106(94)90228-3; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; SALVEMINI D, 1990, BIOCHEM BIOPH RES CO, V169, P596, DOI 10.1016/0006-291X(90)90372-T; Suzuki Y, 2003, J IMMUNOL, V171, P6119, DOI 10.4049/jimmunol.171.11.6119; Swindle EJ, 2002, J IMMUNOL, V169, P5866, DOI 10.4049/jimmunol.169.10.5866; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Tkaczyk C, 2002, J IMMUNOL METHODS, V268, P239, DOI 10.1016/S0022-1759(02)00210-7; TSINKALOVSKY OR, 1994, APMIS, V102, P474, DOI 10.1111/j.1699-0463.1994.tb04901.x; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wolfreys K, 1997, EUR J IMMUNOL, V27, P297, DOI 10.1002/eji.1830270143; Yoshimaru T, 2002, CLIN EXP ALLERGY, V32, P612, DOI 10.1046/j.0954-7894.2002.01263.x	40	81	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48751	48759		10.1074/jbc.M409738200	http://dx.doi.org/10.1074/jbc.M409738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15361524	hybrid			2022-12-25	WOS:000225098100033
J	Barriault, D; Sylvestre, M				Barriault, D; Sylvestre, M			Evolution of the biphenyl dioxygenase BphA from Burkholderia xenovorans LB400 by random mutagenesis of multiple sites in region III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENASE COMPONENT; STRAIN; DEGRADATION; REGIOSPECIFICITY; 2,3-DIOXYGENASE; METABOLISM; PATHWAY; DNA	It is now established that several amino acids of region III of the biphenyl dioxygenase (BPDO) alpha subunit are involved in substrate recognition and regiospecificity toward chlorobiphenyls. However, the sequence pattern of the amino acids of that segment of seven amino acids located in the C-terminal portion of the alpha subunit is rather limited in BPDOs of natural occurrence. In this work, we have randomly mutated simultaneously four residues (Thr(335)-Phe(336)-Ile(338)-Ile(341)) of region III of Burkholderia xenovorans LB400 BphA. The library was screened for variants able to oxygenate 2,2'-dichlorobiphenyl (2,2'-CB). Replacement of Phe(336) with Met or Ile with a concomitant change of Thr(335) to Ala created new variants that transformed 2,2'-CB into 3,4-dihydro-3,4-dihydroxy-2,2'-dichlorobiphenyl, which is a dead end metabolite that was not cleaved by BphC. Replacement of Thr(335)- Phe(336) with Ala(335)-Leu(336) did not cause this type of phenotypic change. Regiospecificity toward congeners other than 2,2'-CB that were oxygenated more efficiently by variant Ala(335)-Met(336) than by LB400 BPDO was similar for both enzymes. Thus structural changes that altered the regiospecificity toward 2,2'-CB did not affect the metabolite profile of other congeners, although it affected the rate of conversion of these congeners. It was especially noteworthy that both LB400 BPDO and the Ala(335)-Met(336) variant generated 2,3-dihydroxy-2',4,4'-trichlorobiphenyl as the sole metabolite from 2,4,2', 4'-CB and 4,5-dihydro-4,5-dihydroxy-2,3,2', 3'-tetrachlorobiphenyl as the major metabolite from 2,3,2', 3'-CB. This shows that 2,4,2', 4'-CB is oxygenated principally onto vicinal ortho-meta carbons 2 and 3 and that 2,3,2', 3'-CB is oxygenated onto meta-para carbons 4 and 5 by both enzymes. The data suggest that interactions between the chlorine substitutes on the phenyl ring and specific amino acid residues of the protein influence the orientation of the phenyl ring inside the catalytic pocket.	Inst Natl Rech Sci, Inst Armand Frappier, Pointe Claire, PQ H9R 1G6, Canada	University of Quebec; Institut national de la recherche scientifique (INRS)	Sylvestre, M (corresponding author), Inst Natl Rech Sci, Inst Armand Frappier, 245 Blvd Hymus, Pointe Claire, PQ H9R 1G6, Canada.	Michel.Sylvestre@inrs-iaf.uquebec.ca		Sylvestre, Michel/0000-0002-6942-3373				Arnett CM, 2000, APPL ENVIRON MICROB, V66, P2928, DOI 10.1128/AEM.66.7.2928-2933.2000; Barriault D, 2004, J BIOL CHEM, V279, P47489, DOI 10.1074/jbc.M406808200; Barriault D, 1999, BIOCHEM BIOPH RES CO, V260, P181, DOI 10.1006/bbrc.1999.0706; Barriault D, 2002, J BACTERIOL, V184, P3794, DOI 10.1128/JB.184.14.3794-3800.2002; Barriault D, 2001, CAN J MICROBIOL, V47, P1025, DOI 10.1139/cjm-47-11-1025; BEDARD DL, 1987, APPL ENVIRON MICROB, V53, P1103, DOI 10.1128/AEM.53.5.1103-1112.1987; Bruhlmann F, 1999, BIOTECHNOL BIOENG, V63, P544, DOI 10.1002/(SICI)1097-0290(19990605)63:5<544::AID-BIT4>3.0.CO;2-6; Chebrou H, 1999, J BACTERIOL, V181, P4805, DOI 10.1128/JB.181.16.4805-4811.1999; Denef VJ, 2004, APPL ENVIRON MICROB, V70, P4961, DOI 10.1128/AEM.70.8.4961-4970.2004; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; Fain MG, 2001, CURR MICROBIOL, V42, P269, DOI 10.1007/s002840010216; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; Hurtubise Y, 1996, J BIOL CHEM, V271, P8152, DOI 10.1074/jbc.271.14.8152; Hurtubise Y, 1998, J BACTERIOL, V180, P5828, DOI 10.1128/JB.180.22.5828-5835.1998; Imbeault NYR, 2000, J BIOL CHEM, V275, P12430, DOI 10.1074/jbc.275.17.12430; Kumamaru T, 1998, NAT BIOTECHNOL, V16, P663, DOI 10.1038/nbt0798-663; LIN JJ, 1992, BIOTECHNIQUES, V12, P718; LOIDA PJ, 1995, J BIOL CHEM, V270, P5326, DOI 10.1074/jbc.270.10.5326; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; SAMBROOK J, 1989, MOL CLON LAB MANUAL; Seeger M, 2001, J BACTERIOL, V183, P3548, DOI 10.1128/JB.183.12.3548-3555.2001; Seeger M, 1999, APPL ENVIRON MICROB, V65, P3614; SEEGER M, 1995, APPL ENVIRON MICROB, V61, P2654, DOI 10.1128/AEM.61.7.2654-2658.1995; SONDOSSI M, 1992, APPL ENVIRON MICROB, V58, P485, DOI 10.1128/AEM.58.2.485-495.1992; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; Suenaga H, 2002, J BACTERIOL, V184, P3682, DOI 10.1128/JB.184.13.3682-3688.2002; Sylvestre M, 1996, GENE, V174, P195, DOI 10.1016/0378-1119(96)00039-X; TAIRA K, 1992, J BIOL CHEM, V267, P4844	29	43	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47480	47488		10.1074/jbc.M406805200	http://dx.doi.org/10.1074/jbc.M406805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342624	hybrid			2022-12-25	WOS:000224957000010
J	Chen, SU; Cho, M; Karlsberg, K; Zhou, DJ; Yuan, YC				Chen, SU; Cho, M; Karlsberg, K; Zhou, DJ; Yuan, YC			Biochemical and biological characterization of a novel anti-aromatase coumarin derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; RECONSTITUTED BASEMENT-MEMBRANE; BREAST-CANCER; ISOFLAVONE PHYTOESTROGENS; ACCEPTOR OXIDOREDUCTASE; ESTROGEN BIOSYNTHESIS; STEROID SULFATASE; EPITHELIAL-CELLS; MOLECULAR-BASIS; TUMOR-CELLS	Estrogen stimulates the proliferation of estrogen receptor (ER)-positive breast cancer cells. Aromatase is the enzyme responsible for the conversion of androgens into estrogens, and synthetic aromatase inhibitors such as letrozole, anastrozole, and exemestane have proven to be effective endocrine regimens for ER-positive breast cancer. In a recent study, we have found that 4-benzyl-3(4'-chlorophenyl)-7-methoxycoumarin is a potent competitive inhibitor of aromatase with respect to the androgen substrate. Its K-i value was determined to be 84 nM, significantly more potent than several known aromatase inhibitors. The specific interaction of this compound with aromatase was further demonstrated by the reduction of its binding by several mutations at the active site region of aromatase and evaluated by computer modeling analysis. The structure-activity studies have revealed that three functional groups (i.e. 3-(4'-chlorophenyl), 4-benzyl, and 7-methoxyl) of this coumarin are important in its inhibition of aromatase. In addition, through a matrigel thread three-dimensional cell culture, this compound was shown to behave like known aromatase inhibitors that suppress the proliferation of aromatase and estrogen receptor positive MCF-7aro breast cancer cells. This coumarin has been shown not to be cytotoxic at up to 40 muM. It was found not to be an inhibitor of steroid 5alpha-reductase that also utilizes androgen as the substrate and not to be a ligand of ERalpha, ERbeta, estrogen-related receptors, or androgen receptor. These results demonstrate that coumarins (a common type of phytochemical) or their derivatives can be potent inhibitors of aromatase and may be useful in suppressing aromatase- and ER-positive breast tumors.	City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg Res, Duarte, CA 91010 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Informat Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Chen, SU (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Surg Res, Duarte, CA 91010 USA.	schen@coh.org			NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER; NCI NIH HHS [CA44735] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam L, 2001, CANCER RES, V61, P81; ALBINI A, 1987, CANCER RES, V47, P3239; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; CASCIARI JJ, 1995, IN VITRO CELL DEV-AN, V31, P582, DOI 10.1007/BF02634310; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; CHEN S, 1993, ARCH BIOCHEM BIOPHYS, V302, P72, DOI 10.1006/abbi.1993.1182; DALY PF, 1988, FASEB J, V2, P2596, DOI 10.1096/fasebj.2.10.3384239; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Eng ET, 2003, CANCER RES, V63, P8516; ESTEBAN JM, 1992, AM J PATHOL, V140, P337; Fang MZ, 2003, CANCER RES, V63, P7563; Hoult JRS, 1996, GEN PHARMACOL-VASC S, V27, P713, DOI 10.1016/0306-3623(95)02112-4; Johnston SRD, 2001, AROMATASE INHIBITION AND BREAST CANCER, P29; Kao YC, 2001, EUR J BIOCHEM, V268, P243, DOI 10.1046/j.1432-1033.2001.01886.x; Kao YC, 1996, CANCER RES, V56, P3451; Kao YC, 1998, ENVIRON HEALTH PERSP, V106, P85, DOI 10.1289/ehp.9810685; Kinoshita Y, 2003, CANCER RES, V63, P3546; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lemmen C, 1998, J MED CHEM, V41, P4502, DOI 10.1021/jm981037l; LIU XF, 1990, MOL PHARMACOL, V37, P911; Lu Q, 1996, ENDOCRINOLOGY, V137, P3061, DOI 10.1210/en.137.7.3061; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; PEARLMAN RS, 1998, CONCORD VERSION 4 0; Purohit A, 2003, J STEROID BIOCHEM, V86, P423, DOI 10.1016/S0960-0760(03)00353-4; SANTEN RJ, 1994, J CLIN ENDOCR METAB, V79, P627, DOI 10.1210/jc.79.2.627; Shields-Botella J, 2003, J STEROID BIOCHEM, V84, P327, DOI 10.1016/S0960-0760(03)00046-3; Suetsugi M, 2003, MOL CANCER RES, V1, P981; Sun XZ, 1997, J STEROID BIOCHEM, V63, P29, DOI 10.1016/S0960-0760(97)00068-X; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; *SYB, 2002, VERS 6 9; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TERRANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465, DOI 10.1073/pnas.83.2.465; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; *TRIP INC, 2003, FORC FIELD MAN; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; Yang C, 1998, CANCER RES, V58, P5695; ZHOU D, 1990, CANCER RES, V50, P6949; ZHOU DJ, 1994, J BIOL CHEM, V269, P19501; Zhou DJ, 2001, NUCLEIC ACIDS RES, V29, P3939, DOI 10.1093/nar/29.19.3939	42	64	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48071	48078		10.1074/jbc.M406847200	http://dx.doi.org/10.1074/jbc.M406847200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358790	hybrid			2022-12-25	WOS:000224957000079
J	Pierrel, F; Douki, T; Fontecave, M; Atta, M				Pierrel, F; Douki, T; Fontecave, M; Atta, M			MiaB protein is a bifunctional radical-S-adenosylmethionine enzyme involved in thiolation and methylation of tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III RIBONUCLEOTIDE REDUCTASE; PYRUVATE FORMATE-LYASE; IRON-SULFUR CENTER; ESCHERICHIA-COLI; BIOTIN SYNTHASE; CYSTEINE DESULFURASE; LYSINE 2,3-AMINOMUTASE; CRYSTAL-STRUCTURE; SULFANE SULFUR; 2FE-2S CLUSTER	The last biosynthetic step for 2-methylthio-N-6-isopentenyl-adenosine (ms(2)i(6)A), present at position 37 in some tRNAs, consists of the methylthiolation of the isopentenyladenosine (i(6)A) precursor. In this work we have reconstituted in vitro the conversion of i(6)A to ms(2)i(6)A within a tRNA substrate using the iron-sulfur MiaB protein, S-adenosylmethionine (AdoMet), and a reducing agent. We show that a synthetic i(6)A-containing RNA corresponding to the anticodon stem loop of tRNAPhe is also a substrate. This study demonstrates that MiaB protein is a bifunctional system, involved in both thiolation and methylation of i(6)A. In this process, one molecule of AdoMet is converted to 5'-deoxyadenosine, probably through reductive cleavage and intermediate formation of a 5'-deoxyadenosyl radical as observed in other "Radical-AdoMet" enzymes, and a second molecule of AdoMet is used as a methyl donor as shown by labeling experiments. The origin of the sulfur atom is discussed.	Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DRDC CB,CEA,CNRS,UMR 5047, F-38054 Grenoble 09, France; CEA Grenoble, Dept Rech Fondamentale Mat Condensee, DSM,CEA, Serv Chim Inorgan & Biol,Lab Les Acides Nucleique, F-38054 Grenoble 09, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Fontecave, M (corresponding author), Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DRDC CB,CEA,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr; mohamed.atta@cea.fr	PIERREL, Fabien/M-6016-2014; Thierry, Douki/H-2108-2018	PIERREL, Fabien/0000-0003-2083-3002; Thierry, Douki/0000-0002-5022-071X				Agris PF, 1996, PROG NUCLEIC ACID RE, V53, P79, DOI 10.1016/S0079-6603(08)60143-9; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Bjork Glenn R., 1995, P165; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK M, 1982, NUCLEIC ACIDS RES, V10, P2609, DOI 10.1093/nar/10.8.2609; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Cabello-Villegas J, 2002, J MOL BIOL, V319, P1015, DOI 10.1016/S0022-2836(02)00382-0; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Chen DW, 2003, J AM CHEM SOC, V125, P11788, DOI 10.1021/ja036120z; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Fontecave M, 2003, CHEM REV, V103, P2149, DOI 10.1021/cr020427j; Fontecave M, 2002, PROG NUCLEIC ACID RE, V72, P95, DOI 10.1016/S0079-6603(02)72068-0; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; FREY M, 1994, J BIOL CHEM, V269, P12432; Frey PA, 1999, ADV FR RAD, V2, P1; Frey PA, 2003, CHEM REV, V103, P2129, DOI 10.1021/cr020422m; GEFTER ML, 1969, BIOCHEM BIOPH RES CO, V36, P435, DOI 10.1016/0006-291X(69)90583-X; GEHRKE CW, 1990, CHROMATOGRAPHY MOD A, pA3; GROSJEAN H, 1985, NUCLEIC ACIDS RES, V13, P5697, DOI 10.1093/nar/13.15.5697; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; Jameson GNL, 2004, BIOCHEMISTRY-US, V43, P2022, DOI 10.1021/bi035666v; Junemann R, 1996, NUCLEIC ACIDS RES, V24, P907, DOI 10.1093/nar/24.5.907; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 2003, BIOCHEMISTRY-US, V42, P1109, DOI 10.1021/bi026536+; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; LIPSETT MN, 1966, P NATL ACAD SCI USA, V55, P1169, DOI 10.1073/pnas.55.5.1169; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; MEYER J, 1981, BIOCHEM BIOPH RES CO, V103, P667, DOI 10.1016/0006-291X(81)90502-7; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Mulliez E, 2001, BIOCHEMISTRY-US, V40, P3730, DOI 10.1021/bi001746c; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; PETERKOFSKY A, 1965, BIOCHEM BIOPH RES CO, V20, P780, DOI 10.1016/0006-291X(65)90086-0; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; Pierrel F, 2003, J BIOL CHEM, V278, P29515, DOI 10.1074/jbc.M301518200; Pierrel F, 2002, J BIOL CHEM, V277, P13367, DOI 10.1074/jbc.C100609200; ROSENBERG AH, 1969, J MOL BIOL, V46, P581, DOI 10.1016/0022-2836(69)90197-1; Shaw NM, 1998, BIOCHEM J, V330, P1079; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; TABOR S, 1990, CURRENT PROTOCOLS MO; TUI BTS, 2003, BIOCHEMISTRY-US, V42, P8791; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Walsby CJ, 2002, J AM CHEM SOC, V124, P11270, DOI 10.1021/ja027078v; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	55	130	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47555	47563		10.1074/jbc.M408562200	http://dx.doi.org/10.1074/jbc.M408562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339930	hybrid			2022-12-25	WOS:000224957000019
J	Simard, CF; Daigle, ND; Bergeron, MJ; Brunet, GM; Caron, L; Noel, M; Montminy, V; Isenring, P				Simard, CF; Daigle, ND; Bergeron, MJ; Brunet, GM; Caron, L; Noel, M; Montminy, V; Isenring, P			Characterization of a novel interaction between the secretory Na+-K+-Cl(-)cotransporter and the chaperone hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-CL COTRANSPORTER; SHARK RECTAL GLAND; HEAT-SHOCK PROTEINS; NA+-K+-2CL(-) COTRANSPORTER; FUNCTIONAL EXPRESSION; MOLECULAR CHARACTERIZATION; CHLORIDE COTRANSPORTER; BUMETANIDE BINDING; ION-TRANSPORT; CELL-VOLUME	The first isoform of the Na+-K+-Cl- cotransporter (NKCC1) is of central importance for the control of cellular ion concentration and epithelium-mediated salt secretion. Several studies have established that a change in intracellular [Cl-] (Cl-i(-)) represents a key signaling mechanism by which NKCC1-induced Cl- movement is autoregulated and by which Cl- entry and exit on opposite sides of polarized cells are coordinated. Although this signaling mechanism is coupled to a pathway that leads to post-translational modification of the carrier, no unifying model currently accounts for the ion dependence of NKCC1 regulation. In this paper, evidence is presented for the first time that hsp90 associates with the cytosolic C terminus of NKCC1, probably when the carrier is predominantly in its unfolded form during early biogenesis. Evidence is also presented that the Cl-i(-)-dependent regulatory pathway can be activated by a thermal stress but that it is no longer operational if NKCC1-expressing cells are pretreated with geldanamycin, an antibiotic that inhibits hsp90, albeit nonspecifically. Taken together, our data indicate that binding of hsp90 to NKCC1 may be required for Na+-K+-Cl- cotransport to occur at the cell surface and that it could play an important role in ion-dependent signaling mechanisms, insofar as the maneuvers that were used to alter the expression or activity of the chaperone do not exert their main effect by inducing other cellular events such as the unfolded protein response. Further studies will be required to elucidate the functional relevance of this novel interaction.	Univ Laval, Dept Med, Nephrol Res Grp, Fac Med, Quebec City, PQ G1R 2J6, Canada	Laval University	Isenring, P (corresponding author), Hotel Dieu Quebec Res Ctr, 10 Rue McMahon,Rm 3852, Quebec City, PQ G1R 2J6, Canada.	paul.isenring@crhdq.ulaval.ca						Bachmann O, 2003, J PHYSIOL-LONDON, V549, P525, DOI 10.1113/jphysiol.2002.030205; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Caplan Avrom J., 2003, EMBO Reports, V4, P126, DOI 10.1038/sj.embor.embor742; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Dowd BFX, 2003, J BIOL CHEM, V278, P27347, DOI 10.1074/jbc.M301899200; Evans RL, 2000, J BIOL CHEM, V275, P26720; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; FORBUSH B, 1994, RENAL PHYSIOL BIOCH, V17, P201; Fuller W, 2000, J BIOL CHEM, V275, P37462, DOI 10.1074/jbc.M006278200; Gagnon E, 2002, AM J PHYSIOL-RENAL, V283, pF1046, DOI 10.1152/ajprenal.00107.2002; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1998, J GEN PHYSIOL, V112, P549, DOI 10.1085/jgp.112.5.549; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Isenring P, 2001, COMP BIOCHEM PHYS A, V130, P487, DOI 10.1016/S1095-6433(01)00420-2; ISENRING P, 1997, INT SOC NEPHR; Jacoby SC, 1999, AM J PHYSIOL-CELL PH, V277, pC684, DOI 10.1152/ajpcell.1999.277.4.C684; Kinard TA, 2001, DIABETES, V50, P992, DOI 10.2337/diabetes.50.5.992; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUDT J, 1993, J MEMBRANE BIOL, V134, P143; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Malhotra V, 2001, AM J RESP CELL MOL, V25, P92, DOI 10.1165/ajrcmb.25.1.4384; MANABE KI, 2004, IN PRESS PFLUGERS AR; Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Oehler R, 1998, FASEB J, V12, P553, DOI 10.1096/fasebj.12.7.553; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Piechotta K, 2003, J BIOL CHEM, V278, P52848, DOI 10.1074/jbc.M309436200; Piechotta K, 2002, J BIOL CHEM, V277, P50812, DOI 10.1074/jbc.M208108200; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J BIOL CHEM, V268, P21455; Race JE, 1999, AM J PHYSIOL-CELL PH, V277, pC1210, DOI 10.1152/ajpcell.1999.277.6.C1210; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Shillingford JM, 2002, MOL ENDOCRINOL, V16, P1309, DOI 10.1210/me.16.6.1309; Shin JH, 2004, J BIOL CHEM, V279, P18567, DOI 10.1074/jbc.M400639200; Shumaker H, 1999, AM J PHYSIOL-CELL PH, V277, pC1100, DOI 10.1152/ajpcell.1999.277.6.C1100; Simard CF, 2004, J BIOL CHEM, V279, P40769, DOI 10.1074/jbc.M406458200; Solit DB, 2003, CANCER RES, V63, P2139; Suffia I, 1997, INT J PARASITOL, V27, P1547, DOI 10.1016/S0020-7519(97)00142-2; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	55	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48449	48456		10.1074/jbc.M407012200	http://dx.doi.org/10.1074/jbc.M407012200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347682	hybrid			2022-12-25	WOS:000224957000122
J	Beglopoulos, V; Sun, XY; Saura, CA; Lemere, CA; Kim, RD; Shen, J				Beglopoulos, V; Sun, XY; Saura, CA; Lemere, CA; Kim, RD; Shen, J			Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL FRAGMENT; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CATHEPSIN-S; SYNAPTIC PLASTICITY; TRANSGENIC MICE; BRAIN; EXPRESSION; NOTCH; DEGENERATION	Mutations in presenilins ( PS) 1 and 2 are the major cause of familial Alzheimer's disease. Conditional double knock-out mice lacking both presenilins in the postnatal forebrain (PS cDKO mice) exhibit memory and synaptic plasticity impairments followed by progressive neurodegeneration in the cerebral cortex. Here we further investigate the molecular events that may underlie the observed phenotypes and identify additional neuropathological markers in the PS cDKO brain. Enzyme-linked immunosorbent assay analysis showed reduced levels of the toxic beta-amyloid (Abeta) peptides in the cerebral cortex of PS cDKO mice. Interestingly, the reduction in Abeta40 and Abeta42 peptides is similar in PS1 conditional knock-out and PS cDKO mice. We further examined the gene expression profile by oligonucleotide microarrays in the PS cDKO cerebral cortex and found that a high number of genes are differentially expressed, most notably a group of upregulated inflammatory genes. Quantitative real-time reverse transcription PCR and Western analyses confirmed the elevated levels of glial fibrillary acidic protein, complement component C1q, and cathepsin S, up-regulation of which has been associated with inflammatory responses in various neurodegenerative processes. Immunohistochemical analysis revealed that the increase in complement component C1q is confined to the hippocampal formation, whereas glial fibrillary acidic protein and cathepsin S are up-regulated throughout the entire neocortex and hippocampus. In addition, strong microglial activation occurs in the hippocampus and the deeper cortical layers of PS cDKO mice. These results indicate that the memory impairment and neurodegeneration in PS cDKO mice are not caused by Abeta accumulation and that loss of PS function leads to differential up-regulation of inflammatory markers in the cerebral cortex.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis,Program Neurosci, Boston, MA 02115 USA; Harvard PArtners Ctr Genet & Genom, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University	Shen, J (corresponding author), Ctr Neurol Dis, Harvard New Res Bldg 636E,77 Ave Louis Pasteur, Boston, MA 02115 USA.	jshen@rics.bwh.harvard.edu	Saura, Carlos A/D-2727-2011; Shen, Jie/GXH-9449-2022; Saura, Carlos A/AFM-9239-2022	Saura, Carlos A/0000-0003-3692-5657; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041783] Funding Source: NIH RePORTER; NINDS NIH HHS [NS41783] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DICKSON DW, 1988, AM J PATHOL, V132, P86; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Handler M, 2000, DEVELOPMENT, V127, P2593; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; KAMMESHEIDT A, 1992, P NATL ACAD SCI USA, V89, P10857, DOI 10.1073/pnas.89.22.10857; Kawarabayashi T, 1996, NEUROBIOL AGING, V17, P215, DOI 10.1016/0197-4580(95)02061-6; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; LEMERE CA, 1995, AM J PATHOL, V146, P848; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MANDYBUR TI, 1990, NEUROLOGY, V40, P635, DOI 10.1212/WNL.40.4.635; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; Nalbantoglu J, 1997, NATURE, V387, P500, DOI 10.1038/387500a0; OCALLAGHAN JP, 1992, NEUROTOXICOLOGY, V13, P113; OsterGranite ML, 1996, J NEUROSCI, V16, P6732; Overmyer M, 1999, DEMENT GERIATR COGN, V10, P252, DOI 10.1159/000017128; Petanceska S, 1996, J BIOL CHEM, V271, P4403; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; Song DK, 1998, J NEUROCHEM, V71, P875; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Sun X, 2002, NEUROSCI LETT, V321, P61, DOI 10.1016/S0304-3940(01)02583-6; Tenner AJ, 2001, NEUROBIOL AGING, V22, P849, DOI 10.1016/S0197-4580(01)00301-3; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Yu HK, 2001, NEURON, V31, P713, DOI 10.1016/S0896-6273(01)00417-2; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	36	127	133	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46907	46914		10.1074/jbc.M409544200	http://dx.doi.org/10.1074/jbc.M409544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15345711	hybrid			2022-12-25	WOS:000224832400073
J	Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S				Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S			Expression of the NF-kappa B-responsive gene BTG2 is aberrantly regulated in breast cancer	ONCOGENE			English	Article						BTG2; breast cancer; cell cycle; cyclin D1; NF-kappa B	MULLERIAN-INHIBITING SUBSTANCE; CYCLIN D1 TRANSCRIPTION; NERVE GROWTH-FACTOR; CELL-GROWTH; DOWN-REGULATION; TIS21 PROTEIN; DNA-DAMAGE; IN-VIVO; CARCINOMA; PC3	BTG2, a p53-inducible antiproliferative gene, is stimulated in breast cancer cells by activation of nuclear factor kappa B (NF-kappaB). In rat mammary glands, BTG2 is expressed in epithelial cells and levels decreased during pregnancy and lactation but recovered during involution. Estrogen and progestin suppress BTG2 expression, suggesting that these steroids, which stimulate proliferation and lobuloalveolar development of mammary epithelial cells, may downregulate BTG2 in the mammary gland during pregnancy. Consistent with the report that BTG2 inhibits cyclin D1 expression, suppression of BTG2 mRNA in the mammary gland during gestation, and by estrogen and progestin, correlated with stimulation of cyclin D1. Ectopic expression of BTG2 inhibited breast cancer cell growth by arresting cells in the G1 phase, an effect reversed by cyclin D1. BTG2 expression was very low or undetectable in human breast cancer cell lines compared with nontumorigenic mammary epithelial cells, and nuclear expression of BTG2 was absent in 65% of human breast tumors compared with adjacent matched normal glands. Spontaneous mammary tumors arising in a mouse model with targeted expression of the early region of the SV40 large tumor Ag demonstrated loss of BTG2 protein very early during the tumorigenic process. Thus deregulation of BTG2 may be an important step in the development of mammary tumors.	Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NYU Med Ctr, Dept Urol, New York, NY 10016 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; New York University	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Dept Surg Oncol, Jackson 904,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu			NCI NIH HHS [CA84441, CA89138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740, R01CA089138, R01CA084441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CMARIK JL, 1994, MOL CARCINOGEN, V11, P115, DOI 10.1002/mc.2940110209; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kuo ML, 2003, CANCER RES, V63, P1046; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, BIOCHEM MOL BIOL INT, V45, P871; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; NANDI S, 1958, J NATL CANCER I, V21, P1039; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sakaguchi T, 2001, MECH DEVELOP, V104, P113, DOI 10.1016/S0925-4773(01)00374-4; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2002, P NATL ACAD SCI USA, V99, P239, DOI 10.1073/pnas.221599298; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	44	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8310	8319		10.1038/sj.onc.1208008	http://dx.doi.org/10.1038/sj.onc.1208008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378000				2022-12-25	WOS:000224749500013
J	Wang, ZX; Fukuda, S; Pelus, LM				Wang, ZX; Fukuda, S; Pelus, LM			Survivin regulates the p53 tumor suppressor gene family	ONCOGENE			English	Article						survivin; apoptosis; p53; p63; p73	CELL-CYCLE ENTRY; MDM2 ONCOPROTEIN; APOPTOSIS; P73; P21(CIP1/WAF1); EXPRESSION; PROTEIN; CANCER; P63; CLEAVAGE	Survivin regulates cell division and inhibits apoptosis by blocking caspase activation. The tumor suppressor p53 inhibits cell cycle progression and induces apoptosis. Since Survivin overexpression and loss of wild-type p53 expression/function occur in most cancers, we investigated whether Survivin regulates p53. Stable overexpression of Survivin protects BaF3 cells from Adriamycin-induced apoptosis, while dominant-negative (T34A) and antisense (AS) Survivin accelerate apoptosis. In BaF3 cells and transiently transfected MCF7 breast cancer cells, elevation of total and phospho-Ser(15)-p53 in response to Adriamycin is blocked by Survivin and enhanced by Survivin disruption. Furthermore, in Adriamycin-treated MCF7 cells, ectopic Survivin decreased p53 mRNA and increased mRNA and protein of the p53 homologues DeltaNp63 and TAp73 and mRNA for DeltaNp73, suggesting that Survivin may differentially regulate p53 family transcription. Concomitant with decreasing p53 mRNA, Survivin decreased Mdm2 mRNA. Survivin disruption by T34A or AS Survivin resulted in reduced Mdm2 protein. The caspase inhibitor, Z-VAD-FMK, blocked the decrease in Mdm2 as well as the increase in p53 resulting from Survivin disruption, indicating that Survivin regulates Mdm2 at the post-translational level. Proteosome inhibition confirmed that reduced p53 protein observed in cells overexpressing Survivin is due to enhanced p53 degradation resulting from Survivin-mediated inhibition of Mdm2 cleavage by caspases. In summary, our results identify regulatory interactions between Survivin and p53 at the mRNA and protein levels, and suggest that the p53 homologues DeltaNp63, TAp73 and DeltaNp73 may also be regulated by Survivin.	Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Pelus, LM (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, 950 W Walnut St, Indianapolis, IN 46202 USA.	lpelus@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079654] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL079654] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Chumakov PM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P28; Erhardt P, 1997, J BIOL CHEM, V272, P15049, DOI 10.1074/jbc.272.24.15049; Freebern WJ, 2003, J BIOL CHEM, V278, P2249, DOI 10.1074/jbc.M208517200; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Fukuda S, 2004, BLOOD, V103, P120, DOI 10.1182/blood-2003-05-1756; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Goetz AW, 2001, CANCER RES, V61, P7635; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hayashibara T, 2002, NUTR CANCER, V44, P192, DOI 10.1207/S15327914NC4402_12; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kostrouchova M, 2003, P NATL ACAD SCI USA, V100, P5240, DOI 10.1073/pnas.0730770100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; McKay TR, 2003, ONCOGENE, V22, P3539, DOI 10.1038/sj.onc.1206417; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Novak U, 2001, ANN ONCOL, V12, P981, DOI 10.1023/A:1011153206003; NYLANDER K, 2003, J PATHOL, V198, P5686; Okada H, 2004, J EXP MED, V199, P399, DOI 10.1084/jem.20032092; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2004, ONCOGENE, V23, P386, DOI 10.1038/sj.onc.1207071; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Waltermann A, 2003, ONCOGENE, V22, P5686, DOI 10.1038/sj.onc.1206859; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	48	69	80	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8146	8153		10.1038/sj.onc.1207992	http://dx.doi.org/10.1038/sj.onc.1207992			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361831				2022-12-25	WOS:000224692500012
J	Liu, F; Shollenberger, LM; Huang, L				Liu, F; Shollenberger, LM; Huang, L			Non-immunostimulatory nonviral vectors	FASEB JOURNAL			English	Article						gene therapy; cytokines; CpG motif	NF-KAPPA-B; PLASMID DNA; BACTERIAL-DNA; GENE-TRANSFER; IN-VIVO; INFLAMMATORY RESPONSE; CATIONIC LIPOSOMES; CPG MOTIFS; LUNG; COMPLEXES	The vectors for gene delivery are usually classified as viral and nonviral vectors. While the viral vectors are very efficient in transducing cells, safety concerns regarding their use in humans make nonviral vectors an attractive alternative. Among the nonviral vectors, the lipoplexes ( complexes of cationic liposome/pDNA) are the most studied and represent the most promising approaches for human clinical trials. However, an inflammatory response is invariably associated with administration of the lipoplexes, which must be avoided in the clinical application. Here, we have successfully developed a nonimmunostimulatory vector for gene therapy. The vector possesses dual functions of: 1) efficiently delivering a gene to target cells and 2) codelivering DNA and inflammatory suppressors into the immune cells where the released suppressor can inhibit cytokine production. The inflammatory suppressors successfully delivered by the vector included glucocorticoids, a nonsteroidal anti-inflammatory drug ( NSAID), an NF-kappaB inhibitor, and a natural compound from an herbal medicine. Intravenous injection of the vector dramatically suppressed the cytokine production induced by CpG motif pDNA, including TNF-alpha, IL-12 and IFN-gamma. This new gene vector has a great potential in clinical gene therapy. Another potential use of the vector is codelivery of an enhancer candidate, acting at the transcriptional and translational levels to improve the efficiency of gene transfer by the nonviral vector. Moreover, the unique feature of this vector is that it can be used as an easy and powerful tool for in vivo screening of anti-inflammatory drugs.	Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Liu, F (corresponding author), Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, 718 Salk Hall, Pittsburgh, PA 15261 USA.	fliu@pitt.edu; leafh+@pitt.edu	Shollenberger, Lisa/A-1826-2009; Shollenberger, Lisa/ABA-7393-2021	Shollenberger, Lisa/0000-0002-0943-0838; Shollenberger, Lisa/0000-0002-0943-0838				Alton EWFW, 1998, GENE THER, V5, P291, DOI 10.1038/sj.gt.3300655; Audouy SAL, 2002, PHARM RES-DORDR, V19, P1599, DOI 10.1023/A:1020989709019; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Chen F, 1997, BIOCHEM BIOPH RES CO, V231, P99, DOI 10.1006/bbrc.1997.6057; Davis HL, 1998, J IMMUNOL, V160, P870; Elouahabi A, 2003, MOL THER, V7, P81, DOI 10.1016/S1525-0016(02)00032-1; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Freimark BD, 1998, J IMMUNOL, V160, P4580; GILKESON GS, 1989, J IMMUNOL, V142, P1482; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hofman CR, 2001, GENE THER, V8, P71, DOI 10.1038/sj.gt.3301373; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Li DG, 2001, WORLD J GASTROENTERO, V7, P627; Li S, 1999, AM J PHYSIOL-LUNG C, V276, pL796, DOI 10.1152/ajplung.1999.276.5.L796; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Niidome T, 2002, GENE THER, V9, P1647, DOI 10.1038/sj.gt.3301923; Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Rao MR, 2002, ACTA PHARMACOL SIN, V23, P1075; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sakurai F, 2002, GENE THER, V9, P1120, DOI 10.1038/sj.gt.3301784; Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689; Tan YD, 1999, HUM GENE THER, V10, P2153, DOI 10.1089/10430349950017149; Tan YD, 2001, MOL THER, V3, P673, DOI 10.1006/mthe.2001.0311; Tousignant JD, 2000, HUM GENE THER, V11, P2493, DOI 10.1089/10430340050207984; Yew NS, 2000, MOL THER, V1, P255, DOI 10.1006/mthe.2000.0036; Yew NS, 1999, HUM GENE THER, V10, P223, DOI 10.1089/10430349950019011; Zingarelli B, 2003, CRIT CARE MED, V31, pS105, DOI 10.1097/00003246-200301001-00015; Zuhorn IS, 2002, BBA-BIOMEMBRANES, V1560, P25, DOI 10.1016/S0005-2736(01)00448-5	30	72	75	2	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1779	+		10.1096/fj.04-2187fje	http://dx.doi.org/10.1096/fj.04-2187fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364893				2022-12-25	WOS:000224243200030
J	Chung, WL; Carrington, M; Field, MC				Chung, WL; Carrington, M; Field, MC			Cytoplasmic targeting signals in transmembrane invariant surface glycoproteins of trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORMS; AFRICAN TRYPANOSOMES; ENDOCYTIC APPARATUS; ANCHORED PROTEIN; RAB5 ISOFORMS; BRUCEI; STAGE; EXPRESSION; SYSTEM; KINETOPLASTIDA	Protein targeting mechanisms in flagellated protozoan parasites have received considerable interest because of a huge bias in these organisms toward the glycosylphosphatidylinositol anchor as a mechanism for the membrane attachment of cell surface macromolecules. In this study, the trafficking of invariant surface glycoprotein 65 (ISG65), a family of type I transmembrane proteins, was examined. Analysis of the C-terminal domains of ISG65 family members demonstrated a high level of conservation and, in particular, the presence of three lysine residues contained within the cytoplasmic tails of all ISG65s. ISG65 was expressed on the cell surface, in agreement with earlier work, but an intracellular pool of ISG65 was also detected within a Rab5A early endosome. Transplantation of the C-terminal 74 amino acids of ISG65 ( encompassing the 23 C-terminal residues of the extracellular domain, the transmembrane peptide, and the cytoplasmic domain) onto the N-terminal domain of BiP (BiPN) was sufficient to target the chimera to the same internal compartments as native ISG65. Further, site-directed mutagenesis indicated that the cytoplasmic tail was required for endoplasmic reticulum exit and that at least two of the cytoplasmic domain lysine residues are needed for endosomal targeting, as removal of all three led to surface expression. Kinetic measurements demonstrate that the BiPN fusion protein ( containing the ISG65 C terminus) has a short half-life, indicating rapid turnover. In contrast, BiPN fusion proteins containing a glycosylphosphatidylinositol anchor instead of the ISG65 C-terminal region are stably expressed on the surface, confirming the requirement for the ISG65 sequence for endosomal targeting. We suggest that the lack of surface expression of the BiPN-ISG65 fusion protein is likely due to more efficient internalization compared with ISG65. Taken together, these data demonstrate the presence of a lysine-dependent endocytosis signal in the ISG65 family.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge	Field, MC (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	mfield@mac.com	Carrington, Mark/N-4892-2018; Field, Mark/AAD-6455-2021; Carrington, Mark/N-3653-2019	Carrington, Mark/0000-0002-6435-7266; Carrington, Mark/0000-0002-6435-7266; Field, Mark/0000-0002-4866-2885				Allen CL, 2003, EMBO J, V22, P4991, DOI 10.1093/emboj/cdg481; Ausubel FM, 2003, CURRENT PROTOCOLS MO; BANGS JD, 1986, J CELL BIOL, V103, P255, DOI 10.1083/jcb.103.1.255; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Burchmore RJS, 2003, J BIOL CHEM, V278, P23502, DOI 10.1074/jbc.M301252200; Butikofer P, 1997, BIOCHEM J, V326, P415; Carrington M, 1996, MOL BIOCHEM PARASIT, V81, P119, DOI 10.1016/0166-6851(96)02706-5; ElSayed NMA, 1997, J BIOL CHEM, V272, P26742, DOI 10.1074/jbc.272.42.26742; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; FIELD MC, 1994, J BIOL CHEM, V269, P10830; Grunfelder CG, 2003, MOL BIOL CELL, V14, P2029, DOI 10.1091/mbc.E02-10-0640; Grunfelder CG, 2002, TRAFFIC, V3, P547, DOI 10.1034/j.1600-0854.2002.30805.x; Harley CA, 1998, J BIOL CHEM, V273, P24963, DOI 10.1074/jbc.273.38.24963; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; Jeffries TR, 2001, J CELL SCI, V114, P2617; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Mehlert A, 2002, GLYCOBIOLOGY, V12, P607, DOI 10.1093/glycob/cwf079; Morgan GW, 2004, J BIOL CHEM, V279, P10692, DOI 10.1074/jbc.M312178200; Morgan GW, 2002, TRENDS PARASITOL, V18, P540, DOI 10.1016/S1471-4922(02)02392-9; Morgan GW, 2002, TRENDS PARASITOL, V18, P491, DOI 10.1016/S1471-4922(02)02391-7; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nolan DP, 1997, J BIOL CHEM, V272, P29212, DOI 10.1074/jbc.272.46.29212; O'Beirne C, 1998, MOL BIOCHEM PARASIT, V91, P165, DOI 10.1016/S0166-6851(97)00191-6; Overath P, 1997, TRENDS CELL BIOL, V7, P27, DOI 10.1016/S0962-8924(97)10046-0; Pal A, 2002, J BIOL CHEM, V277, P9529, DOI 10.1074/jbc.M110055200; Pinheiro CB, 2003, ACTA CRYSTALLOGR D, V59, P405, DOI 10.1107/S090744490202111X; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SEYFANG A, 1990, J PROTOZOOL, V37, P546, DOI 10.1111/j.1550-7408.1990.tb01263.x; Strous GJ, 2002, FEBS LETT, V529, P102, DOI 10.1016/S0014-5793(02)03187-3; Yang H, 2000, MOL CELL BIOL, V20, P5149, DOI 10.1128/MCB.20.14.5149-5163.2000; ZIEGELBAUER K, 1995, MOL BIOCHEM PARASIT, V69, P53, DOI 10.1016/0166-6851(94)00194-R; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797; Zitzmann N, 2000, GLYCOBIOLOGY, V10, P243, DOI 10.1093/glycob/10.3.243	39	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 24	2004	279	52					54887	54895		10.1074/jbc.M409311200	http://dx.doi.org/10.1074/jbc.M409311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	880MJ	15342636	hybrid			2022-12-25	WOS:000225793600118
J	Anderson, SP; Howroyd, P; Liu, J; Qian, X; Bahnemann, R; Swanson, C; Kwak, MK; Kensler, TW; Corton, JC				Anderson, SP; Howroyd, P; Liu, J; Qian, X; Bahnemann, R; Swanson, C; Kwak, MK; Kensler, TW; Corton, JC			The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-ALPHA; NULL MICE; DIFFERENTIAL EXPRESSION; PROTEASOME ACTIVITY; 20S PROTEASOME; PROTECTION; PROTEINS; DITHIOLETHIONES; CLOFIBRATE; APOPTOSIS	The nuclear receptor peroxisome proliferator-activated receptor alpha(PPARalpha), in addition to regulating lipid homeostasis, controls the level of tissue damage after chemical or physical stress. To determine the role of PPARalpha in oxidative stress responses, we examined damage after exposure to chemicals that increase oxidative stress in wild-type or PPARalpha-null mice. Primary hepatocytes from wild-type but not PPARalpha-null mice pretreated with the PPAR pan-agonist WY-14,643 (WY) were protected from damage to cadmium and paraquat. The livers from intact wild-type but not PPARalpha-null mice were more resistant to damage after carbon tetrachloride treatment. To determine the molecular basis of the protection by PPARalpha, we identified by transcript profiling genes whose expression was altered by a 7-day exposure to WY in wild-type and PPARalpha-null mice. Of the 815 genes regulated by WY in wild-type mice ( p less than or equal to 0.001; greater than or equal to 1.5-fold or less than or equal to - 1.5-fold), only two genes were regulated similarly by WY in PPARalpha-null mice. WY increased expression of stress modifier genes that maintain the health of the proteome, including those that prevent protein aggregation (heat stress-inducible chaperones) and eliminate damaged proteins ( proteasome components). Although the induction of proteasomal genes significantly overlapped with those regulated by 1,2-dithiole-3-thione, an activator of oxidant-inducible Nrf2, WY increased expression of proteasomal genes independently of Nrf2. Thus, PPARalpha controls the vast majority of gene expression changes after exposure to WY in the mouse liver and protects the liver from oxidant-induced damage, possibly through regulation of a distinct set of proteome maintenance genes.	ToxicoGenom, Chapel Hill, NC 27514 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; BASF AG, D-67056 Ludwigshafen, Germany; NCI, NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Chem Ind Inst Toxicol, Ctr Hlth Res, Res Triangle Pk, NC 27709 USA; Expt Pathol Labs Inc, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline Res & Dev Ltd, Invest Toxicol & Pathol Grp, Safety Assessment, Res Triangle Pk, NC 27709 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; BASF; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS); GlaxoSmithKline	Corton, JC (corresponding author), ToxicoGenom, 209 Silver Creek Tr, Chapel Hill, NC 27514 USA.	ccorton@msn.com	Kensler, Thomas W/D-8686-2014	Kensler, Thomas W/0000-0002-6676-261X	NIEHS NIH HHS [ES09775-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES009775] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDERSON SA, 2004, IN PRESS MOL PHARM; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chen C, 2000, TOXICOL SCI, V57, P338, DOI 10.1093/toxsci/57.2.338; Conconi M, 1998, BIOCHEM J, V333, P407, DOI 10.1042/bj3330407; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; DeLuca JG, 2000, MOL PHARMACOL, V58, P470, DOI 10.1124/mol.58.3.470; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hatayama T, 2001, BIOCHEM BIOPH RES CO, V288, P528, DOI 10.1006/bbrc.2001.5802; Hihi AK, 2002, CELL MOL LIFE SCI, V59, P790, DOI 10.1007/s00018-002-8467-x; Hill CP, 2002, CURR TOP MICROBIOL, V268, P73; Howroyd P, 2004, TOXICOL PATHOL, V32, P591, DOI 10.1080/01926230490515283; Kedderis GL, 1996, TOXICOL APPL PHARM, V140, P124, DOI 10.1006/taap.1996.0205; Klaunig JE, 2003, CRIT REV TOXICOL, V33, P655, DOI 10.1080/713608372; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lee MW, 2001, BIOCHEM BIOPH RES CO, V284, P261, DOI 10.1006/bbrc.2001.4938; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Mehendale HM, 2000, TOXICOL SCI, V57, P187, DOI 10.1093/toxsci/57.2.187; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; O'Brien ML, 2002, TOXICOL SCI, V69, P139, DOI 10.1093/toxsci/69.1.139; Oh HJ, 1997, J BIOL CHEM, V272, P31636, DOI 10.1074/jbc.272.50.31636; Peters JM, 2003, BBA-MOL CELL BIOL L, V1632, P80, DOI 10.1016/S1388-1981(03)00065-9; Plaa GL, 2000, ANNU REV PHARMACOL, V40, P43, DOI 10.1146/annurev.pharmtox.40.1.43; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Shankar K, 2003, FASEB J, V17, P1748, DOI 10.1096/fj.02-1186fje; Stulnig TM, 2002, MOL PHARMACOL, V62, P1299, DOI 10.1124/mol.62.6.1299	38	67	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52390	52398		10.1074/jbc.M409347200	http://dx.doi.org/10.1074/jbc.M409347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15375163	hybrid			2022-12-25	WOS:000225493400083
J	Hayashi, F; Itoh, N; Uzumaki, T; Iwase, R; Tsuchiya, Y; Yamakawa, H; Moirishita, M; Onai, K; Itoh, S; Ishiura, M				Hayashi, F; Itoh, N; Uzumaki, T; Iwase, R; Tsuchiya, Y; Yamakawa, H; Moirishita, M; Onai, K; Itoh, S; Ishiura, M			Roles of two ATPase-motif-containing domains in cyanobacterial circadian clock protein KaiC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; GENE	Cyanobacterial clock protein KaiC has a hexagonal, pot-shaped structure composed of six identical dumb-bell-shaped subunits. Each subunit has duplicated domains, and each domain has a set of ATPase motifs. The two spherical regions of the dumbbell are likely to correspond to two domains. We examined the role of the two sets of ATPase motifs by analyzing the in vitro activity of ATPgammaS binding, AMPPNP-induced hexamerization, thermostability, and phosphorylation of KaiC and by in vivo rhythm assays both in wild type KaiC (KaiC(WT)) and KaiCs carrying mutations in either Walker motif A or deduced catalytic Glu residues. We demonstrated that 1) the KaiC subunit had two types of ATP-binding sites, a high affinity site in N-terminal ATPase motifs and a low affinity site in C-terminal ATPase motifs, 2) the N-terminal motifs were responsible for hexamerization, and 3) the C-terminal motifs were responsible for both stabilization and phosphorylation of the KaiC hexamer. We proposed the following reaction mechanism. ATP preferentially binds to the N-terminal high affinity site, inducing the hexamerization of KaiC. Additional ATP then binds to the C-terminal low affinity site, stabilizing and phosphorylating the hexamer. We discussed the effect of these KaiC mutations on circadian bioluminescence rhythm in cells of cyanobacteria.	Nagoya Univ, Ctr Gene Res, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Biooriented Technol Res Adv Inst, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Div Mat Sci, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Ishiura, M (corresponding author), Nagoya Univ, Ctr Gene Res, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	ishiura@gene.nagoya-u.ac.jp		Onai, Kiyoshi/0000-0001-9062-2548				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Hayashi F, 2004, BIOCHEM BIOPH RES CO, V316, P195, DOI 10.1016/j.bbrc.2004.02.034; Hayashi F, 2003, GENES CELLS, V8, P287, DOI 10.1046/j.1365-2443.2003.00633.x; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Iwasaki H, 1999, EMBO J, V18, P1137, DOI 10.1093/emboj/18.5.1137; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; Leipe DD, 2002, J MOL BIOL, V317, P41, DOI 10.1006/jmbi.2001.5378; Onai M, 2004, J BACTERIOL, V186, P4972, DOI 10.1128/JB.186.15.4972-4977.2004; Pattanayek R, 2004, MOL CELL, V15, P375, DOI 10.1016/j.molcel.2004.07.013; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; Uzumaki T, 2004, NAT STRUCT MOL BIOL, V11, P623, DOI 10.1038/nsmb781; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168	16	36	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52331	52337		10.1074/jbc.M406604200	http://dx.doi.org/10.1074/jbc.M406604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15377674	hybrid			2022-12-25	WOS:000225493400075
J	Nadauld, LD; Sandoval, IT; Chidester, S; Yost, HJ; Jones, DA				Nadauld, LD; Sandoval, IT; Chidester, S; Yost, HJ; Jones, DA			Adenomatous polyposis coli control of retinoic acid biosynthesis is critical for zebrafish intestinal development and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; NULL MUTANT MICE; BETA-CATENIN; COLORECTAL-CANCER; GENE-EXPRESSION; CARCINOMA-CELLS; POSTERIOR AXIS; EMBRYONIC AXIS; DEHYDROGENASE; APC	Mutations in the APC ( adenomatous polyposis coli) tumor suppressor gene cause uncontrolled proliferation and impaired differentiation of intestinal epithelial cells. Recent studies indicate that human colon adenomas and carcinomas lack retinol dehydrogenases (RDHs) and that APC regulates the expression of human RDHL. These data suggest a model wherein APC controls enterocyte differentiation by controlling retinoic acid production. However, the importance of APC and retinoic acid in mediating control of normal enterocyte development and differentiation remains unclear. To examine the relationship between APC and retinoic acid biosynthesis in normal enterocytes, we have identified two novel zebrafish retinol dehydrogenases, termed zRDHA and zRDHB, that show strong expression within the gut of developing zebrafish embryos. Morpholino knockdown of either APC or zRDHB in zebrafish embryos resulted in defects in structures known to require retinoic acid. These defects included cardiac abnormalities, pericardial edema, failed jaw and pectoral fin development, and the absence of differentiated endocrine and exocrine pancreas. In addition, APC or zRDHB morphant fish developed intestines that lacked columnar epithelial cells and failed to express the differentiation marker intestinal fatty acid-binding protein. Treatment of either APC or zRDHB morphant embryos with retinoic acid rescued the defective phenotypes. Downstream of retinoic acid production, we identified hoxc8 as a retinoic acid-induced gene that, when ectopically expressed, rescued phenotypes of APC- and zRDHB-deficient zebrafish. Our data establish a genetic link supporting a critical role for retinoic acid downstream of APC and confirm the importance of retinoic acid in enterocyte differentiation.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Jones, DA (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope,Rm 5262, Salt Lake City, UT 84112 USA.	david.jones@hci.utah.edu		Chidester, Stephanie/0000-0003-4163-3480	NCI NIH HHS [CA073992-06A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA073992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andre M, 2000, INT J DEV BIOL, V44, P249; Begemann G, 2001, DEVELOPMENT, V128, P3081; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bisgrove BW, 2000, DEVELOPMENT, V127, P3567; BLANER WS, 1999, RETINOIDS BIOCH MOL, P117; Chetyrkin SV, 2001, J BIOL CHEM, V276, P22278, DOI 10.1074/jbc.M102076200; Davidson AJ, 2003, NATURE, V425, P300, DOI 10.1038/nature01973; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Draper BW, 2001, GENESIS, V30, P154, DOI 10.1002/gene.1053; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Grandel H, 2002, DEVELOPMENT, V129, P2851; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoier EF, 2000, GENE DEV, V14, P874; Houle VM, 2003, AM J PHYSIOL-GASTR L, V284, pG722, DOI 10.1152/ajpgi.00458.2002; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200; Kallberg Y, 2002, EUR J BIOCHEM, V269, P4409, DOI 10.1046/j.1432-1033.2002.03130.x; KELLY GM, 1995, MECH DEVELOP, V53, P261, DOI 10.1016/0925-4773(95)00442-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; Mic FA, 2002, DEVELOPMENT, V129, P2271; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NARISAWA T, 1976, CANCER RES, V36, P1379; NZEGWU H, 1991, GUT, V32, P1324, DOI 10.1136/gut.32.11.1324; NZEGWU HC, 1992, GUT, V33, P794, DOI 10.1136/gut.33.6.794; Pack M, 1996, DEVELOPMENT, V123, P321; Perz-Edwards A, 2001, DEV BIOL, V229, P89, DOI 10.1006/dbio.2000.9979; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; Samowitz WS, 1999, CANCER RES, V59, P1442; Shah S, 2002, J BIOL CHEM, V277, P25313, DOI 10.1074/jbc.M203158200; Sparks AB, 1998, CANCER RES, V58, P1130; Stafford D, 2002, CURR BIOL, V12, P1215, DOI 10.1016/S0960-9822(02)00929-6; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Traber PG, 1999, ADV EXP MED BIOL, V470, P1; Wallace KN, 2003, DEV BIOL, V255, P12, DOI 10.1016/S0012-1606(02)00034-9; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Yashiro K, 2004, DEV CELL, V6, P411, DOI 10.1016/S1534-5807(04)00062-0; ZILE M, 1977, J NUTR, V107, P552, DOI 10.1093/jn/107.4.552	46	51	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51581	51589		10.1074/jbc.M408830200	http://dx.doi.org/10.1074/jbc.M408830200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358764	hybrid			2022-12-25	WOS:000225355800114
J	Liu, SJ; Zhang, JY; Li, HL; Fang, ZY; Wang, Q; Deng, HM; Gong, CX; Grundke-Iqbal, I; Iqbal, K; Wang, JZ				Liu, SJ; Zhang, JY; Li, HL; Fang, ZY; Wang, Q; Deng, HM; Gong, CX; Grundke-Iqbal, I; Iqbal, K; Wang, JZ			Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; ALZHEIMER-LIKE PHOSPHORYLATION; ABNORMAL PHOSPHORYLATION; BIOLOGICAL-ACTIVITY; FETAL TAU; DISEASE; SITES; BINDING	Microtubule-associated protein tau is abnormally hyperphosphorylated in Alzheimer's disease ( AD) and other tauopathies and is believed to lead to neurodegeneration in this family of diseases. Here we show that infusion of forskolin, a specific cAMP-dependent protein kinase A (PKA) activator, into the lateral ventricle of brain in adult rats induced activation of PKA by several-fold and concurrently enhanced the phosphorylation of tau at Ser-214, Ser-198, Ser-199, and or Ser-202 (Tau-1 site) and Ser-396 and or Ser-404 (PHF-1 site), which are among the major abnormally hyperphosphorylated sites seen in AD. PKA activation positively correlated to the extent of tau phosphorylation at these sites. Infusion of forskolin together with PKA inhibitor or glycogen synthase kinase-3 (GSK-3) inhibitor revealed that the phosphorylation of tau at Ser-214 was catalyzed by PKA and that the phosphorylation at both the Tau-1 and the PHF-1 sites is induced by basal level of GSK-3, because forskolin activated PKA and not GSK-3 and inhibition of the latter inhibited the phosphorylation at Tau-1 and PHF-1 sites. Inhibition of cdc2, cdk5, or MAPK had no significant effect on the forskolin-induced hyperphosphorylation of tau. Forskolin inhibited spatial memory in a dose-dependent manner in the absence but not in the presence of Rp-adenosine 3', 5'-cyclic monophosphorothioate triethyl ammonium salt, a PKA inhibitor. These results demonstrate for the first time that phosphorylation of tau by PKA primes it for phosphorylation by GSK-3 at the Tau-1 and the PHF-1 sites and that an associated loss in spatial memory is inhibited by inhibition of the hyperphosphorylation of tau. These data provide a novel mechanism of the hyperphosphorylation of tau and identify both PKA and GSK-3 as promising therapeutic targets for AD and other tauopathies.	Hua Zhong Univ Sci & Technol, Tongji Med Coll, Inst Neurosci, Dept Pathophysiol, Wuhan 430030, Peoples R China; New York State Inst Basic Res Dev Disabil, Dept Neurochem, Staten Isl, NY 10314 USA	Huazhong University of Science & Technology; Institute for Basic Research in Developmental Disabilities	Wang, JZ (corresponding author), Hua Zhong Univ Sci & Technol, Tongji Med Coll, Inst Neurosci, Dept Pathophysiol, Wuhan 430030, Peoples R China.	wangjz@mails.tjmu.edu.cn		Zhang, jiayu/0000-0003-0137-746X	NIA NIH HHS [AG19158] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019158] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADASHI EY, 1986, J CELL BIOCHEM, V31, P217, DOI 10.1002/jcb.240310304; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Avila J, 2002, MOL NEUROBIOL, V25, P213, DOI 10.1385/MN:25:3:213; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Bennecib M, 2000, ALZHEIMERS REP, V3, P295; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; Clare PM, 2001, J BIOL CHEM, V276, P48292, DOI 10.1074/jbc.M102034200; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Godemann R, 1999, FEBS LETT, V454, P157, DOI 10.1016/S0014-5793(99)00741-3; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; IQBAL K, 1986, LANCET, V2, P421; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; IQBAL K, 1995, NEUROBIOL AGING, V16, P375, DOI 10.1016/0197-4580(95)00033-B; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jicha GA, 1999, J NEUROSCI, V19, P7486, DOI 10.1523/JNEUROSCI.19-17-07486.1999; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Johnson G V, 1999, J Alzheimers Dis, V1, P329; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Lau Lit-Fui, 2002, Current Topics in Medicinal Chemistry, V2, P395, DOI 10.2174/1568026024607526; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEW J, 1992, J BIOL CHEM, V267, P13383; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Lovestone S, 1997, NEUROSCIENCE, V78, P309; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MORISHIMAKAWASHIMA M, 1995, NEUROBIOL AGING, V16, P365, DOI 10.1016/0197-4580(95)00027-C; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Pei JJ, 1997, J NEUROPATH EXP NEUR, V56, P70, DOI 10.1097/00005072-199701000-00007; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; ROBERTSON J, 1993, DEMENTIA, V4, P256, DOI 10.1159/000107331; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; Singh TJ, 1996, MOL CELL BIOCHEM, V154, P143, DOI 10.1007/BF00226782; SINGH TJ, 1995, FEBS LETT, V358, P267, DOI 10.1016/0014-5793(94)01445-7; SONG JS, 1995, J PROTEIN CHEM, V14, P95, DOI 10.1007/BF01888367; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Tolnay M, 1999, NEUROPATH APPL NEURO, V25, P171; Tsujio I, 2000, FEBS LETT, V469, P111, DOI 10.1016/S0014-5793(00)01234-5; Wang JZ, 1996, NAT MED, V2, P871, DOI 10.1038/nm0896-871; Wang JZ, 1998, FEBS LETT, V436, P28, DOI 10.1016/S0014-5793(98)01090-4; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; YANG SD, 1994, J NEUROCHEM, V63, P1416; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x	64	140	162	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50078	50088		10.1074/jbc.M406109200	http://dx.doi.org/10.1074/jbc.M406109200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375165	hybrid			2022-12-25	WOS:000225229500066
J	Meinild, AK; Sitte, HH; Gether, U				Meinild, AK; Sitte, HH; Gether, U			Zinc potentiates an uncoupled anion conductance associated with the dopamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN SEROTONIN TRANSPORTER; CARRIER-MEDIATED RELEASE; ACID GABA TRANSPORTER-1; MONOAMINE TRANSPORTERS; CHARGE-TRANSFER; AMPHETAMINE; ZN2+; COCAINE; MECHANISM; BINDING	Binding of Zn2+ to an endogenous binding site in the dopamine transporter (DAT) leads to inhibition of dopamine (DA) uptake and enhancement of carrier-mediated substrate efflux. To elucidate the molecular mechanism for this dual effect, we expressed the DAT and selected mutants in Xenopus laevis oocytes and applied the two-electrode voltage clamp technique together with substrate flux studies employing radiolabeled tracers. Under voltage clamp conditions we found that Zn2+ (10 muM) enhanced the current induced by both DA and amphetamine. This was not accompanied by a change in the uptake rate but by a marked increase in the charge/DA flux coupling ratio as assessed from concomitant measurements of [H-3] DA uptake and currents in voltage-clamped oocytes. These data suggest that Zn2+ facilitates an uncoupled ion conductance mediated by DAT. Whereas this required substrate in the wild type (WT), we observed that Zn2+ by itself activated such a conductance in a previously described mutant (Y335A). This signifies that the conductance is not strictly dependent on an active transport process. Ion substitution experiments in Y335A, as well as in WT, indicated that the uncoupled conductance activated by Zn2+ was mainly carried by Cl-. Experiments in oocytes under non-voltage-clamped conditions revealed furthermore that Zn2+ could enhance the depolarizing effect of substrates in oocytes expressing WT. The data suggest that by potentiating an uncoupled Cl- conductance, Zn2+ is capable of modulating the membrane potential of cells expressing DAT and as a result cause simultaneous inhibition of uptake and enhancement of efflux.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, DK-2200 Copenhagen N, Denmark; Med Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria	University of Copenhagen; Medical University of Vienna	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Neuropharmacol Grp, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.	gether@neuropharm.ku.dk	Sitte, Harald/O-7025-2019; Sitte, Harald/N-2681-2013	Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Gether, Ulrik/0000-0002-0020-3807	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA 12408] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Accardi A, 2004, NATURE, V427, P803, DOI 10.1038/nature02314; Adams SV, 2003, BIOPHYS J, V85, P1548, DOI 10.1016/S0006-3495(03)74587-1; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; Diez-Sampedro A, 2003, P NATL ACAD SCI USA, V100, P11753, DOI 10.1073/pnas.1733027100; Falkenburger BH, 2001, SCIENCE, V293, P2465, DOI 10.1126/science.1060645; Galli A, 1996, P NATL ACAD SCI USA, V93, P8671, DOI 10.1073/pnas.93.16.8671; Goldberg NR, 2003, EUR J PHARMACOL, V479, P3, DOI 10.1016/j.ejphar.2003.08.052; GU H, 1994, J BIOL CHEM, V269, P7124; Ingram SL, 2002, NAT NEUROSCI, V5, P971, DOI 10.1038/nn920; JARDETZK.O, 1966, NATURE, V211, P969, DOI 10.1038/211969a0; Jones SR, 1998, J NEUROSCI, V18, P1979; Ju PC, 2004, J BIOL CHEM, V279, P22983, DOI 10.1074/jbc.M312484200; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; LEVI G, 1993, TRENDS NEUROSCI, V16, P415, DOI 10.1016/0166-2236(93)90010-J; Li Y, 2001, J NEUROPHYSIOL, V86, P2597, DOI 10.1152/jn.2001.86.5.2597; Li Y, 2001, J NEUROSCI, V21, P8015, DOI 10.1523/JNEUROSCI.21-20-08015.2001; Loland CJ, 2004, J BIOL CHEM, V279, P3228, DOI 10.1074/jbc.M304755200; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; MacAulay N, 2002, J PHYSIOL-LONDON, V544, P447, DOI 10.1113/jphysiol.2002.022897; MacAulay N, 2001, J BIOL CHEM, V276, P40476, DOI 10.1074/jbc.M105578200; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Mayfield RD, 2001, J NEUROCHEM, V79, P1070, DOI 10.1046/j.1471-4159.2001.00656.x; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; Meinild AK, 2001, BIOCHEMISTRY-US, V40, P11897, DOI 10.1021/bi011026l; Norregaard L, 2001, Curr Opin Drug Discov Devel, V4, P591; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Norregaard L, 2000, BIOCHEMISTRY-US, V39, P15836, DOI 10.1021/bi0018335; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Pifl C, 2004, NEUROPHARMACOLOGY, V46, P223, DOI 10.1016/j.neuropharm.2003.09.007; PIFL C, 1995, MOL PHARMACOL, V47, P368; Prasad BM, 2001, J NEUROSCI, V21, P7561, DOI 10.1523/JNEUROSCI.21-19-07561.2001; Quick M, 2001, J BIOL CHEM, V276, P1728, DOI 10.1074/jbc.M005521200; Quick MW, 2003, NEURON, V40, P537, DOI 10.1016/S0896-6273(03)00605-6; RICHFIELD EK, 1993, MOL PHARMACOL, V43, P100; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Scholze P, 2002, J BIOL CHEM, V277, P21505, DOI 10.1074/jbc.M112265200; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Torres GE, 2003, J BIOL CHEM, V278, P2731, DOI 10.1074/jbc.M201926200; Vogt K, 2000, NEURON, V26, P187, DOI 10.1016/S0896-6273(00)81149-6; WALL SC, 1995, MOL PHARMACOL, V47, P544	50	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49671	49679		10.1074/jbc.M407660200	http://dx.doi.org/10.1074/jbc.M407660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358780	hybrid			2022-12-25	WOS:000225229500017
J	Olmo-Mira, MF; Gavira, M; Richardson, DJ; Castillo, F; Moreno-Vivian, C; Roldan, MD				Olmo-Mira, MF; Gavira, M; Richardson, DJ; Castillo, F; Moreno-Vivian, C; Roldan, MD			NapF is a cytoplasmic iron-sulfur protein required for Fe-S cluster assembly in the periplasmic nitrate reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; SPHAEROIDES DSM 158; RHODOBACTER-SPHAEROIDES; GENE-EXPRESSION; RHODOPSEUDOMONAS-CAPSULATA; POLYACRYLAMIDE GELS; EXPORT PATHWAY; MEMBRANE; SYSTEM; SITES	The periplasmic nitrate reductase (Nap) is widespread in proteobacteria. NapA, the nitrate reductase catalytic subunit, contains a Mo-bisMGD cofactor and one [4Fe-4S] cluster. The nap gene clusters in many bacteria, including Rhodobacter sphaeroides DSM158, contain an napF gene, disruption of which drastically decreases both in vitro and in vivo nitrate reductase activities. In spite its importance in the Nap system, NapF has never been characterized biochemically, and its role remains unknown. The NapF protein has four polycysteine clusters that suggest that it is an iron-sulfur-containing protein. In the present study, a His(6)-tagged NapF protein was overproduced in Escherichia coli and purified anaerobically. The purified NapF protein was used to obtain polyclonal antibodies raised in rabbit, and cellular fractionation of R. sphaeroides followed by immunoprobing with anti-NapF antibodies revealed that the native NapF protein is located in the cytoplasm. This contrasts with the periplasmic location of the mature NapA. However, NapA could not be detected in an isogenic napF(-) strain of R. sphaeroides. The His(6)-tagged NapF protein displayed spectral properties indicative of Fe-S clusters, but these features were rapidly lost, suggesting cluster lability. However, reconstitution of the Fe-S centers into the apo-NapF protein was achieved in the presence of Azotobacter vinelandii cysteine desulfurase (NifS), and this allowed the recovery of nitrate reductase activity in NapA protein that had previously been treated with 2,2'-dipyridyl to remove the [4Fe-4S] cluster. This activity was not recovered in the absence of NapF. Taking into account the cytoplasmic localization of NapF, the presence of labile Fe-S clusters in the protein, the napF(-) strain phenotype, and the NapF-dependent reactivation of the 2,2'-dipyridyltreated NapA, we propose a role for NapF in assembling the [4Fe-4S] center of the catalytic subunit NapA.	Univ Cordoba, Dept Bioquim & Biol Mol, Edificio Severo Ochoa, E-14071 Cordoba, Spain; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	Universidad de Cordoba; University of East Anglia	Roldan, MD (corresponding author), Univ Cordoba, Dept Bioquim & Biol Mol, Edificio Severo Ochoa, Campus Rabanales,1a Planta, E-14071 Cordoba, Spain.	bb2rorum@uco.es	Richardson, David J/E-2275-2011; Moreno, Conrado/K-3976-2014; Roldán Ruiz, María Dolores/K-4370-2014	Roldán Ruiz, María Dolores/0000-0001-7173-8641				ARNOLD W, 1988, GENE, V70, P171, DOI 10.1016/0378-1119(88)90115-1; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Brondijk THC, 2002, MOL MICROBIOL, V44, P245, DOI 10.1046/j.1365-2958.2002.02875.x; Buc J, 1995, EUR J BIOCHEM, V234, P766, DOI 10.1111/j.1432-1033.1995.766_a.x; CARITHERS RP, 1977, J BIOL CHEM, V252, P7461; Delgado MJ, 2003, MICROBIOL-SGM, V149, P3395, DOI 10.1099/mic.0.26620-0; DIEZ J, 1989, ARCH BIOCHEM BIOPHYS, V268, P707, DOI 10.1016/0003-9861(89)90339-1; FOGO JK, 1949, ANAL CHEM, V21, P732, DOI 10.1021/ac60030a028; FRANCIS RT, 1984, ANAL BIOCHEM, V136, P509, DOI 10.1016/0003-2697(84)90253-7; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gavira M, 2002, J BACTERIOL, V184, P1693, DOI 10.1128/JB.184.6.1693-1702.2002; Grove J, 1996, MOL MICROBIOL, V19, P467, DOI 10.1046/j.1365-2958.1996.383914.x; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; Kamps A, 2004, MOL MICROBIOL, V52, P713, DOI 10.1111/j.1365-2958.2004.04024.x; KERBER NL, 1982, J BACTERIOL, V150, P1091, DOI 10.1128/JB.150.3.1091-1097.1982; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCEWAN AG, 1984, ARCH MICROBIOL, V137, P344, DOI 10.1007/BF00410732; Moreno-Vivian C, 1999, J BACTERIOL, V181, P6573; MORENOVIVIAN C, 1986, FEMS MICROBIOL LETT, V34, P105, DOI 10.1111/j.1574-6968.1986.tb01358.x; Nilsson UA, 2002, FREE RADICAL RES, V36, P677, DOI 10.1080/10715760290029128; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Potter LC, 1999, BIOCHEM J, V344, P69, DOI 10.1042/0264-6021:3440069; Potter LC, 1999, BIOCHEM J, V344, P77, DOI 10.1042/0264-6021:3440077; Reyes F, 1996, MOL MICROBIOL, V19, P1307, DOI 10.1111/j.1365-2958.1996.tb02475.x; Reyes F, 1998, BIOCHEM J, V331, P897, DOI 10.1042/bj3310897; ROLDAN MD, 1994, CURR MICROBIOL, V29, P241, DOI 10.1007/BF01570161; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sears HJ, 2000, MICROBIOL-UK, V146, P2977, DOI 10.1099/00221287-146-11-2977; SMITH AF, 1983, METHOD ENZYMAT AN, V3, P166; Stoll R, 1996, MICROBIOL-UK, V142, P2577, DOI 10.1099/00221287-142-9-2577; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	44	34	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49727	49735		10.1074/jbc.M406502200	http://dx.doi.org/10.1074/jbc.M406502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371424	hybrid			2022-12-25	WOS:000225229500023
J	Riquelme, G; Llanos, P; Tischner, E; Neil, J; Campos, BA				Riquelme, G; Llanos, P; Tischner, E; Neil, J; Campos, BA			Annexin 6 modulates the maxi-chloride channel of the apical membrane of syncytiotrophoblast isolated from human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNEL; PROTEIN-KINASE-C; LARGE-CONDUCTANCE; MICROVILLOUS MEMBRANE; PLASMA-MEMBRANE; GIANT LIPOSOMES; SPINAL-CORD; CELLS; VI; LOCALIZATION	The syncytiotrophoblast separates the maternal and fetal blood and constitutes the primary barrier for maternal-fetal transport. The Maxi-chloride channel from the apical membrane of the syncytiotrophoblast plays a role in the chloride conductance. Annexins can play an important role in the regulation of membrane events. In this study we evaluate the role of annexin 6 in the Maxichloride channel properties. The results showed that annexin 6 is bound in the apical placenta membranes in a calcium-dependent phospholipid-binding manner but also in a calcium-independent fashion. The neutralization of annexin 6 decreased the total current by 39 +/- 1.9% in the range of +/- 80 mV, and the currents decrease with the time. The single-channel slope conductance was decreased from 253 +/- 7.4 pS ( control) to 105 +/- 13 pS, and the amplitude decreased by 50%. The open probability was also affected when higher voltage steps were used, changes in either the positive or negative direction induced the channel to close, and the open probability (P-o) did not decrease. In channels with neutralized annexin 6, it was maintained at 1 at +/- 40 mV and at +/- 80 mV. These results suggest that endogenous annexin 6 could regulate the Maxi-chloride channel. The results obtained with normal placentae, in which annexin 6 was neutralized, are similar to those described for the Maxichloride channel isolated from pre-eclamptic placenta. Together these data suggest that annexin 6 could play an important role in ion transport of the placenta.	Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, Cincinnati, OH 45267 USA; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Fisiol & Biofis, Santiago 7, Chile	University System of Ohio; University of Cincinnati; Universidad de Chile	Campos, BA (corresponding author), Univ Cincinnati, Coll Med, Dept Obstet & Gynecol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Begona.Campos@uc.edu		Neil, Jessica/0000-0003-0770-5321; Llanos, Paola/0000-0003-1383-7961				Babiychuk EB, 1999, J BIOL CHEM, V274, P35191, DOI 10.1074/jbc.274.49.35191; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Babiychuk EB, 2004, J MEMBRANE BIOL, V198, P95, DOI 10.1007/s00232-004-0663-1; Babiychuk EB, 2002, BBA-PROTEINS PROTEOM, V1600, P154, DOI 10.1016/S1570-9639(02)00456-9; Bahamonde MI, 2003, J BIOL CHEM, V278, P33284, DOI 10.1074/jbc.M302814200; Bathori G, 1999, J BIOL CHEM, V274, P29607, DOI 10.1074/jbc.274.42.29607; Bernucci L, 2003, PLACENTA, V24, P895, DOI 10.1016/S0143-4004(03)00144-9; Birdsey TJ, 1999, AM J PHYSIOL-REG I, V276, pR1479, DOI 10.1152/ajpregu.1999.276.5.R1479; BISSONNETTE JM, 1994, PLACENTA, V15, P445, DOI 10.1016/0143-4004(94)90011-6; BLATZ AL, 1983, BIOPHYS J, V43, P237, DOI 10.1016/S0006-3495(83)84344-6; BROWN PD, 1993, PLACENTA, V14, P103, DOI 10.1016/S0143-4004(05)80253-X; BUDAVARI S, 1996, MERCK INDEX, P1438; Buettner R, 2000, P NATL ACAD SCI USA, V97, P3201, DOI 10.1073/pnas.060242297; CHAN HC, 1994, J BIOL CHEM, V269, P32464; Clarson LH, 2001, PLACENTA, V22, P328, DOI 10.1053/plac.2000.0622; Colombini M, 1996, Ion Channels, V4, P169; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; de Diego I, 2002, J BIOL CHEM, V277, P32187, DOI 10.1074/jbc.M205499200; DIAZMUNOZ M, 1990, J BIOL CHEM, V265, P15894; DUBOIS T, 1995, BIOCHEM BIOPH RES CO, V212, P270, DOI 10.1006/bbrc.1995.1966; Dubois T, 1998, BIOCHEM J, V330, P1277, DOI 10.1042/bj3301277; Dubois T, 1996, BBA-MOL CELL RES, V1313, P290, DOI 10.1016/0167-4889(96)00102-4; GASNIER F, 1993, ANAL BIOCHEM, V212, P173, DOI 10.1006/abio.1993.1309; Golczak M, 2001, BIOCHEM BIOPH RES CO, V284, P785, DOI 10.1006/bbrc.2001.5051; Golczak M, 2001, FEBS LETT, V496, P49, DOI 10.1016/S0014-5793(01)02402-4; Golczak Marcin, 2001, FASEB Journal, V15, P1083; Gray H H, 1984, J Hypertens Suppl, V2, pS467; HALM DR, 1992, J GEN PHYSIOL, V99, P339, DOI 10.1085/jgp.99.3.339; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Henriquez M, 2003, J MEMBRANE BIOL, V191, P59, DOI 10.1007/s00232-002-1038-0; ILLSLEY NP, 1990, BIOCHIM BIOPHYS ACTA, V1029, P218, DOI 10.1016/0005-2736(90)90157-J; Jimenez V, 2004, PLACENTA, V25, P422, DOI 10.1016/j.placenta.2003.10.013; KAETZEL MA, 1994, BBA-MOL CELL RES, V1223, P368, DOI 10.1016/0167-4889(94)90097-3; Mira JP, 1997, J BIOL CHEM, V272, P10474; Naciff JM, 1996, AM J PHYSIOL-CELL PH, V271, pC2004; Naciff JM, 1996, J COMP NEUROL, V368, P356; NELSON DJ, 1984, J MEMBRANE BIOL, V80, P81, DOI 10.1007/BF01868692; Nilius B, 1996, J BIOL CHEM, V271, P30631, DOI 10.1074/jbc.271.48.30631; NOBILE M, 1988, BIOCHEM BIOPH RES CO, V154, P719, DOI 10.1016/0006-291X(88)90199-4; RAMBOTTI MG, 1993, CELL MOL BIOL RES, V39, P579; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REYMANN S, 1995, BIOCHEM MOL MED, V54, P75, DOI 10.1006/bmme.1995.1011; Riquelme G, 1999, AM J OBSTET GYNECOL, V180, P469, DOI 10.1016/S0002-9378(99)70234-6; RIQUELME G, 1995, AM J OBSTET GYNECOL, V173, P733, DOI 10.1016/0002-9378(95)90332-1; RIQUELME G, 1990, FEBS LETT, V276, P54, DOI 10.1016/0014-5793(90)80505-D; Russo-Marie F, 1999, CLIN CHEM LAB MED, V37, P287, DOI 10.1515/CCLM.1999.050; Sabirov RZ, 2001, J GEN PHYSIOL, V118, P251, DOI 10.1085/jgp.118.3.251; Seaton BA, 1998, BIOMETALS, V11, P399, DOI 10.1023/A:1009205925714; Sun JX, 2002, P NATL ACAD SCI USA, V99, P13108, DOI 10.1073/pnas.202260999; Suzuki M, 2004, J BIOL CHEM, V279, P22461, DOI 10.1074/jbc.M313813200; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; THINNES FP, 1992, J BIOENERG BIOMEMBR, V24, P71, DOI 10.1007/BF00769533; Uittenbogaard A, 2002, J BIOL CHEM, V277, P4925, DOI 10.1074/jbc.M109278200; Yu WH, 1996, J BIOENERG BIOMEMBR, V28, P93, DOI 10.1007/BF02110638	54	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50601	50608		10.1074/jbc.M407859200	http://dx.doi.org/10.1074/jbc.M407859200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355961	hybrid			2022-12-25	WOS:000225229500124
J	Thai, R; Moine, G; Desmadril, M; Servent, D; Tarride, JL; Menez, A; Leonetti, M				Thai, R; Moine, G; Desmadril, M; Servent, D; Tarride, JL; Menez, A; Leonetti, M			Antigen stability controls antigen presentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II MOLECULES; T-CELL DETERMINANT; NAJA-NIGRICOLLIS; INTACT PROTEINS; DISULFIDE BONDS; EPITOPE IMMUNODOMINANCE; ACETYLCHOLINE-RECEPTOR; QUATERNARY STRUCTURE; CURAREMIMETIC TOXIN; MONOCLONAL-ANTIBODY	We investigated whether protein stability controls antigen presentation using a four disulfide-containing snake toxin and three derivatives carrying one or two mutations (L1A, L1A/H4Y, and H4Y). These mutations were anticipated to increase (H4Y) or decrease (L1A) the antigen non-covalent stabilizing interactions, H4Y being naturally and frequently observed in neurotoxins. The chemically synthesized derivatives shared similar three-dimensional structure, biological activity, and T epitope pattern. However, they displayed differential thermal unfolding capacities, ranging from 65 to 98degreesC. Using these differentially stable derivatives, we demonstrated that antigen stability controls antigen proteolysis, antigen processing in antigen-presenting cells, T cell stimulation, and kinetics of expression of T cell determinants. Therefore, non-covalent interactions that control the unfolding capacity of an antigen are key parameters in the efficacy of antigen presentation. By affecting the stabilizing interaction network of proteins, some natural mutations may modulate the subsequent T-cell stimulation and might help microorganisms to escape the immune response.	Ctr Etud Saclay, Commissariat Energie Atom, DIEP, F-91191 Gif Sur Yvette, France; EP1088 Univ Paris Sud, Lab Modelisat & Ingn Prot, F-91405 Orsay, France	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Universite Paris Saclay	Leonetti, M (corresponding author), Ctr Etud Saclay, Commissariat Energie Atom, DIEP, Batiment 152, F-91191 Gif Sur Yvette, France.	michel.leonetti@cea.fr	Desmadril, Michel/AAC-8174-2020	Thai, Robert/0000-0001-9438-4225; Servent, Denis/0000-0002-0774-1691				Akasako A, 1997, J BIOL CHEM, V272, P18686, DOI 10.1074/jbc.272.30.18686; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ALLEN PM, 1984, AM J ANAT, V170, P483, DOI 10.1002/aja.1001700319; Ametani A, 2003, BIOSCI BIOTECH BIOCH, V67, P1507, DOI 10.1271/bbb.67.1507; Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; BONIFACINO JS, 2001, CURRENT PROTOCOLS IM, V2; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Buckle AM, 1996, BIOCHEMISTRY-US, V35, P4298, DOI 10.1021/bi9524676; Carmicle S, 2002, J BIOL CHEM, V277, P155, DOI 10.1074/jbc.M107624200; Castellino F, 1998, J IMMUNOL, V161, P4048; CHESNUT RW, 1982, J IMMUNOL, V128, P1764; Chianese-Bullock KA, 1998, J IMMUNOL, V161, P1599; COLLINS DS, 1991, J IMMUNOL, V147, P4054; Dai GX, 2002, J BIOL CHEM, V277, P161, DOI 10.1074/jbc.M102259200; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DONERMEYER DL, 1989, J IMMUNOL, V142, P1063; EISENLOHR LC, 1988, J IMMUNOL, V141, P1870; Endo T., 1991, P165; FAGAIN C, 1995, BBA-PROTEIN STRUCT M, V1252, P1, DOI 10.1016/0167-4838(95)00133-F; GLIMCHER LH, 1983, J IMMUNOL, V131, P2868; Hsieh CS, 2002, J IMMUNOL, V168, P2618, DOI 10.4049/jimmunol.168.6.2618; ISHIKAWA Y, 1977, TOXICON, V15, P477, DOI 10.1016/0041-0101(77)90098-8; Janssen R, 1996, INT IMMUNOL, V8, P829, DOI 10.1093/intimm/8.6.829; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; JENSEN PE, 1993, J IMMUNOL, V150, P3347; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; Larsen SL, 1996, J EXP MED, V184, P183, DOI 10.1084/jem.184.1.183; LEE P, 1988, J IMMUNOL, V140, P1063; LEONETTI M, 1990, J IMMUNOL, V145, P4214; MAILLERE B, 1993, J IMMUNOL, V150, P5270; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; Maric M, 2001, SCIENCE, V294, P1361, DOI 10.1126/science.1065500; MATSUMURA M, 1986, NATURE, V323, P356, DOI 10.1038/323356a0; MCCOY KL, 1989, J IMMUNOL, V143, P29; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MENEZ A, 1971, FEBS LETT, V17, P333, DOI 10.1016/0014-5793(71)80180-1; Moudgil KD, 1998, IMMUNOL TODAY, V19, P217, DOI 10.1016/S0167-5699(97)01233-4; Mourier G, 2000, PROTEIN ENG, V13, P217, DOI 10.1093/protein/13.3.217; Nelson CA, 1997, P NATL ACAD SCI USA, V94, P628, DOI 10.1073/pnas.94.2.628; PERKINS DL, 1991, J IMMUNOL, V146, P2137; Pluger EBE, 2002, EUR J IMMUNOL, V32, P467, DOI 10.1002/1521-4141(200202)32:2<467::AID-IMMU467>3.0.CO;2-Y; ROUAS N, 1993, J IMMUNOL, V150, P782; Ruegg U T, 1977, Methods Enzymol, V47, P111; Runnels HA, 1997, MOL IMMUNOL, V34, P471, DOI 10.1016/S0161-5890(97)00043-6; Schneider SC, 2000, J IMMUNOL, V165, P20, DOI 10.4049/jimmunol.165.1.20; SETTE A, 1989, J IMMUNOL, V143, P1265; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; So T, 2001, IMMUNOLOGY, V104, P259, DOI 10.1046/j.1365-2567.2001.01314.x; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STREICHER HZ, 1984, P NATL ACAD SCI-BIOL, V81, P6831, DOI 10.1073/pnas.81.21.6831; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; Villadangos JA, 2000, IMMUNITY, V12, P233, DOI 10.1016/S1074-7613(00)80176-4; WANG Y, 1992, J IMMUNOL, V148, P3034; Watts C, 2001, CURR OPIN IMMUNOL, V13, P26, DOI 10.1016/S0952-7915(00)00177-1; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175; ZINNJUSTIN S, 1993, BIOCHEMISTRY-US, V32, P6884, DOI 10.1021/bi00078a011; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	61	61	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50257	50266		10.1074/jbc.M405738200	http://dx.doi.org/10.1074/jbc.M405738200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364925	hybrid			2022-12-25	WOS:000225229500087
J	Wicher, D; Messutat, S; Lavialle, C; Lapied, B				Wicher, D; Messutat, S; Lavialle, C; Lapied, B			A new regulation of non-capacitative calcium entry in insect pacemaker neurosecretory neurons - Involvement of arachidonic acid, NO-guanylyl cyclase/cGMP, and cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-A; CA2+ ENTRY; NITRIC-OXIDE; CYCLIC-GMP; PEPTIDERGIC MODULATION; MEDIAN NEURONS; CURRENTS; PATHWAYS; VASOPRESSIN	Efferent dorsal unpaired median neurons are pacemaker neurosecretory cells. A Ca2+ background current contributing to the pacemaker activity of cockroach dorsal unpaired median neurons is up-regulated by neurohormone D (NHD), an octapeptide belonging to the adipokinetic hormone family. This modulation accelerates spiking and increases [Ca2+](i). Using patch clamp, calcium imaging, and immunocytochemistry, we investigated the signaling pathway of NHD-induced current modulation. The membrane depolarization produced by NHD was related to the increase in membrane conductance for Ca-+(2), Ba2+, or Sr2+. This increase was abolished by LOE 908, an inhibitor of noncapacitive Ca2+ entry (NCCE), and it was strongly attenuated by the phospholipase C inhibitor U37122 and the diacylglycerol lipase inhibitor RHC80267. Arachidonic acid and ETYA mimicked the NHD effect on background current. This was abolished by L-NAME and ODQ, inhibitors of NO synthase and NO-sensitive guanylyl cyclase, respectively, but mimicked by the NO donor sodium nitroprusside and 8-bromo-cGMP. Immunocytochemistry using cGMP antibodies indicated that NHD and ETYA increase cGMP. Inhibition of protein kinase G with KT5823 and R-p-8-pCPT-cGMPS had no effect, whereas zaprinast, a cGMP-specific phosphodiesterase 5,6,9 inhibitor, mimicked the NHD effect. Furthermore, inhibition of the cGMP-activated phosphodiesterase 2 by EHNA and trequinsin abolished the effect of NHD. We conclude that the final step of the NHD signal transduction is the phosphodiesterase 2-induced down-regulation of the cAMP level. This removes a depression of NCCE directly attributed to cAMP because inhibition of protein kinase A with KT5720, R-p-cAMPS, and PKI14-22 amide did not mimic the NHD effect. We also demonstrate that any mechanism increasing the cGMP level can induce NCCE.	Saxon Acad Sci, Dept Neurohormones, D-07743 Jena, Germany; Univ Angers, Lab Recepteurs & Canaus Ioniques Membranaires, RCIM, UPRES EA 2647, F-49045 Angers, France	Universite d'Angers	Wicher, D (corresponding author), Saxon Acad Sci, Dept Neurohormones, Erbertstr 1, D-07743 Jena, Germany.	b6widi@pan.zoo.uni-jena.de	; Defaix, Celine/G-9339-2018	Lapied, Bruno/0000-0002-0354-4375; Defaix, Celine/0000-0002-2354-855X				Achenbach H, 1997, NEUROREPORT, V8, P3737, DOI 10.1097/00001756-199712010-00016; Amat C, 1998, J NEUROPHYSIOL, V80, P2718, DOI 10.1152/jn.1998.80.5.2718; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; Burrows M., 1996, NEUROBIOLOGY INSECT; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; De Vente J, 1998, NEUROSCIENCE, V87, P207, DOI 10.1016/S0306-4522(98)00171-7; FRENCH AS, 1993, J NEUROBIOL, V24, P939, DOI 10.1002/neu.480240707; Grolleau F, 1996, J NEUROPHYSIOL, V76, P963, DOI 10.1152/jn.1996.76.2.963; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Heine M, 1998, NEUROREPORT, V9, P3309, DOI 10.1097/00001756-199810050-00029; IGNARRO LJ, 1987, BIOCHIM BIOPHYS ACTA, V928, P160, DOI 10.1016/0167-4889(87)90117-0; LAPIED B, 1989, J EXP BIOL, V144, P535; Lucas KA, 2000, PHARMACOL REV, V52, P375; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Messutat S, 2001, CELL CALCIUM, V30, P199, DOI 10.1054/ceca.2001.0227; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Moneer Z, 2003, BIOCHEM J, V370, P439, DOI 10.1042/BJ20021104; Moneer Z, 2002, BIOCHEM J, V362, P13, DOI 10.1042/0264-6021:3620013; MORTON DB, 1992, J NEUROCHEM, V59, P1522, DOI 10.1111/j.1471-4159.1992.tb08469.x; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patton C, 2004, CELL CALCIUM, V35, P427, DOI 10.1016/j.ceca.2003.10.006; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Shuttleworth TJ, 1996, BIOCHEM J, V316, P819, DOI 10.1042/bj3160819; Taylor CW, 2002, CELL, V111, P767, DOI 10.1016/S0092-8674(02)01197-2; WICHER D, 1994, J COMP PHYSIOL A, V174, P507; Wicher D, 1997, J NEUROPHYSIOL, V77, P186, DOI 10.1152/jn.1997.77.1.186; Wicher D, 2001, PROG NEUROBIOL, V64, P431, DOI 10.1016/S0301-0082(00)00066-6; Wicher D, 2001, J NEUROPHYSIOL, V85, P374, DOI 10.1152/jn.2001.85.1.374; Wicher D, 2001, J NEUROPHYSIOL, V86, P2353, DOI 10.1152/jn.2001.86.5.2353	29	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50410	50419		10.1074/jbc.M405800200	http://dx.doi.org/10.1074/jbc.M405800200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364947	hybrid			2022-12-25	WOS:000225229500106
J	Kibler, KV; Miyazato, A; Yedavalli, VSRK; Dayton, AI; Jacobs, BL; Dapolito, G; Kim, SJ; Jeang, KT				Kibler, KV; Miyazato, A; Yedavalli, VSRK; Dayton, AI; Jacobs, BL; Dapolito, G; Kim, SJ; Jeang, KT			Polyarginine inhibits gp160 processing by furin and suppresses productive human immunodeficiency virus type 1 infection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENVELOPE GLYCOPROTEIN; HIV-1; ACTIVATION; PRECURSOR; CLEAVAGE; PROTEIN; MATURATION; PEPTIDES; CONVERTASES; PROTEASES	Correct endoproteolytic maturation of gp160 is essential for the infectivity of human immunodeficiency virus type 1. This processing of human immunodeficiency virus-1 envelope protein, gp160, into gp120 and gp41 has been attributed to the activity of the cellular subtilisin-like proprotein convertase furin. The prototypic furin recognition cleavage site is Arg-X-Arg/Lys-Arg. Arg-Arg-Arg-Arg- Arg-Arg or longer iterations of polyarginine have been shown to be competitive inhibitors of substrate cleavage by furin. Here, we tested polyarginine for inhibition of productive human immunodeficiency virus-1-infection in T-cell lines, primary peripheral blood mononuclear cells, and macrophages. We found that polyarginine inhibited significantly human immunodeficiency virus-1 replication at concentrations that were benign to cell cultures ex vivo and mice in vivo. Using a fluorogenic assay, we demonstrated that polyarginine potently inhibited substrate-specific proteolytic cleavage by furin. Moreover, we verified that authentic processing of human immunodeficiency virus-1 gp160 synthesized in human cells from an infectious human immunodeficiency virus-1 (HIV-1) molecular clone was effectively blocked by polyarginine. Taken together, our data support that inhibitors of proteolytic processing of gp160 may be useful for combating human immunodeficiency virus-1 and that polyarginine represents a lead example of such inhibitors.	NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Arizona State Univ, Biodesign Inst, Ctr Infect Dis & Vaccinol, Tempe, AZ 85287 USA; NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); US Food & Drug Administration (FDA); Arizona State University; Arizona State University-Tempe; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Jeang, KT (corresponding author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Rm 306,9000 Rockville Pike, Bethesda, MD 20892 USA.	kj7e@nih.gov	Jeang, Kuan-Teh/A-2424-2008		NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; Bahbouhi B, 2002, BIOCHEM J, V366, P863, DOI 10.1042/BJ20020052; Bahbouhi B, 2001, BIOCHEM J, V360, P127, DOI 10.1042/0264-6021:3600127; Bultmann A, 2001, J VIROL, V75, P5263, DOI 10.1128/JVI.75.11.5263-5276.2001; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Cushman DW, 1999, NAT MED, V5, P1110, DOI 10.1038/13423; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200; GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H; Hallenberger S, 1997, J VIROL, V71, P1036, DOI 10.1128/JVI.71.2.1036-1045.1997; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Hook VYH, 2003, J NEUROSCI RES, V74, P393, DOI 10.1002/jnr.10784; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kimura T, 1996, FEBS LETT, V390, P15, DOI 10.1016/0014-5793(96)00614-X; Komiyama T, 2000, BIOCHEMISTRY-US, V39, P15156, DOI 10.1021/bi001907c; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; Menard J, 2001, ADV PROTEIN CHEM, V56, P13; Miller WR, 2003, J STEROID BIOCHEM, V86, P413, DOI 10.1016/S0960-0760(03)00352-2; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; Natsume H, 1999, INT J PHARM, V185, P1, DOI 10.1016/S0378-5173(99)00100-3; Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173; Rich EA, 2002, J BIOMED SCI, V9, P721, DOI 10.1159/000067293; RYSER HJP, 1965, SCIENCE, V150, P501, DOI 10.1126/science.150.3695.501; Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; SEIDAH NG, 1998, MOL B INT U, V2, P49; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STIENEKEGROBER A, 1992, EMBO J, V11, P2407, DOI 10.1002/j.1460-2075.1992.tb05305.x; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Theodore TS, 1996, AIDS RES HUM RETROV, V12, P191, DOI 10.1089/aid.1996.12.191; VANTWOUT AB, 1994, J CLIN INVEST, V94, P2060, DOI 10.1172/JCI117560; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453	47	34	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49055	49063		10.1074/jbc.M403394200	http://dx.doi.org/10.1074/jbc.M403394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371436	hybrid			2022-12-25	WOS:000225098100069
J	Lee, JH; Lau, KF; Perkinton, MS; Standen, CL; Rogelj, B; Falinska, A; McLoughlin, DM; Miller, CCJ				Lee, JH; Lau, KF; Perkinton, MS; Standen, CL; Rogelj, B; Falinska, A; McLoughlin, DM; Miller, CCJ			The neuronal adaptor protein X11 beta reduces amyloid beta-protein levels and amyloid plaque formation in the brains of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR-PROTEIN; ALZHEIMERS-DISEASE; MUTANT PRESENILIN-1; CYTOPLASMIC DOMAIN; DISTINCT SITES; X11; PHOSPHORYLATION; METABOLISM; DEPOSITION; EXPRESSION	Accumulation of cerebral amyloid beta-protein (Abeta) is believed to be part of the pathogenic process in Alzheimer's disease. Abeta is derived by proteolytic cleavage from a precursor protein, the amyloid precursor protein (APP). APP is a type-1 membrane-spanning protein, and its carboxyl-terminal intracellular domain binds to X11beta, a neuronal adaptor protein. X11beta has been shown to inhibit the production of Abeta in transfected non-neuronal cells in culture. However, whether this is also the case in vivo in the brain and whether X11beta can also inhibit the deposition of Abeta as amyloid plaques is not known. Here we show that transgenic overexpression of X11beta in neurons leads to a decrease in cerebral Abeta levels in transgenic APPswe Tg2576 mice that are a model of the amyloid pathology of Alzheimer's disease. Moreover, overexpression of X11beta retards amyloid plaque formation in these APPswe mice. Our findings suggest that modulation of X11beta function may represent a novel therapeutic approach for preventing the amyloid pathology of Alzheimer's disease.	Kings Coll London, Inst Psychiat, Dept Neurosci, London SE5 8AF, England; Kings Coll London, Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England	University of London; King's College London; University of London; King's College London	Miller, CCJ (corresponding author), Kings Coll London, Inst Psychiat, Dept Neurosci, POB P037,De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@iop.kcl.ac.uk	Rogelj, Boris/G-9252-2011; Miller, Christopher/H-5733-2012	Rogelj, Boris/0000-0003-3898-1943; McLoughlin, Declan/0000-0003-4574-2799; Miller, Christopher/0000-0002-5130-1845; Lau, Kwok-Fai/0000-0002-0193-1152	Medical Research Council [G0000749] Funding Source: Medline; MRC [G0000749] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Araki Y, 2003, J BIOL CHEM, V278, P49448, DOI 10.1074/jbc.M306024200; Biederer T, 2000, J BIOL CHEM, V275, P39803, DOI 10.1074/jbc.C000656200; Biederer T, 2002, J NEUROSCI, V22, P7340; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Borchelt DR, 1996, GENET ANAL-BIOMOL E, V13, P159, DOI 10.1016/S1050-3862(96)00167-2; Borchelt DR, 1997, NEURON, V19, P939, DOI 10.1016/S0896-6273(00)80974-5; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dineley KT, 2002, J BIOL CHEM, V277, P22768, DOI 10.1074/jbc.M200164200; Duff K, 2001, CURR OPIN NEUROL, V14, P441, DOI 10.1097/00019052-200108000-00003; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; King GD, 2004, J NEUROCHEM, V88, P971, DOI 10.1046/j.1471-4159.2003.02234.x; Kurt MA, 2001, EXP NEUROL, V171, P59, DOI 10.1006/exnr.2001.7717; Lau KF, 2002, MOL CELL NEUROSCI, V20, P13, DOI 10.1006/mcne.2002.1108; Lau KF, 2000, MOL CELL NEUROSCI, V16, P557, DOI 10.1006/mcne.2000.0898; Lee DS, 2000, J BIOL CHEM, V275, P23134, DOI 10.1074/jbc.C000302200; Lee JH, 2003, J BIOL CHEM, V278, P47025, DOI 10.1074/jbc.M300503200; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Lesuisse C, 2001, HUM MOL GENET, V10, P2525, DOI 10.1093/hmg/10.22.2525; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Nakajima Y, 2001, MOL BRAIN RES, V92, P27, DOI 10.1016/S0169-328X(01)00126-7; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Okamoto M, 1998, EUR J CELL BIOL, V77, P161, DOI 10.1016/S0171-9335(98)80103-9; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; Sumioka A, 2003, BIOCHEM J, V374, P261, DOI 10.1042/BJ20030489; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Taru H, 2004, J BIOL CHEM, V279, P21628, DOI 10.1074/jbc.M312007200; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Turner RS, 1996, J BIOL CHEM, V271, P8966, DOI 10.1074/jbc.271.15.8966; Wong PC, 2002, NAT NEUROSCI, V5, P633, DOI 10.1038/nn0702-633; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	54	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49099	49104		10.1074/jbc.M405602200	http://dx.doi.org/10.1074/jbc.M405602200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347685	hybrid, Green Published			2022-12-25	WOS:000225098100074
J	Liao, BS; Patel, M; Hu, Y; Charles, S; Herrick, DJ; Brewer, G				Liao, BS; Patel, M; Hu, Y; Charles, S; Herrick, DJ; Brewer, G			Targeted knockdown of the RNA-binding protein CRD-BP promotes cell proliferation via an insulin-like growth factor II-dependent pathway in human K562 leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; BECKWITH-WIEDEMANN-SYNDROME; CULTURED-MAMMALIAN-CELLS; C-MYC EXPRESSION; IN-VITRO; INTERFERING RNA; IGF-II; ANTISENSE OLIGONUCLEOTIDES; CAENORHABDITIS-ELEGANS; BIOLOGICAL ACTIONS	The c-myc mRNA coding region determinant-binding protein (CRD-BP) was first identified as a masking protein that stabilizes c-myc mRNA in a cell-free mRNA degradation system. Thus, CRD-BP is thought to promote cell proliferation by maintaining c-Myc at critical levels. CRD-BP also appears to be an oncofetal protein, based upon its expression during mammalian development and in some tumors. By using K562 leukemia cells as a model, we show that CRD-BP gene silencing by RNA interference significantly promoted proliferation, indicating an inhibitory effect of CRD-BP on proliferation. Unexpectedly, CRD-BP knockdown had no discernible effect on c-myc mRNA levels. CRD-BP is also known as insulin-like growth factor II (IGF-II) mRNA-binding protein-1. It has been reported to repress translation of a luciferase reporter mRNA containing an IGF-II 5'-untranslated region known as leader 3 but not one containing IGF-II leader 4. CRD-BP knockdown markedly increased IGF-II mRNA and protein levels but did not alter translation of luciferase reporter mRNAs containing 5'-untranslated regions consisting of either IGF-II leader 3 or leader 4. Addition of antibody against IGF-II to cell cultures inhibited the proliferative effect of CRD-BP knockdown, suggesting that regulation of IGF-II gene expression, rather than c-myc mRNA levels, mediates the proliferative effect of CRD-BP knockdown. Thus, we have identified a dominant function for CRD-BP in cell proliferation of human K562 cells, involving a possible IGF-II-dependent mechanism that appears independent of its ability to serve as a c-myc mRNA masking protein.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Jefferson University	Brewer, G (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.	brewerga@umdnj.edu			NCI NIH HHS [CA094243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Brewer G, 2000, J BIOL CHEM, V275, P33336, DOI 10.1074/jbc.M006145200; BREWER G, 1989, MOL CELL BIOL, V9, P1996, DOI 10.1128/MCB.9.5.1996; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; Coulis CM, 2000, MOL PHARMACOL, V57, P485, DOI 10.1124/mol.57.3.485; Doyle GA, 2000, CANCER RES, V60, P2756; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; HAMMARBERG B, 1991, J BIOL CHEM, V266, P11058; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; Hansen TVO, 2004, MOL CELL BIOL, V24, P4448, DOI 10.1128/MCB.24.10.4448-4464.2004; Harborth J, 2001, J CELL SCI, V114, P4557; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; Ioannidis P, 2001, INT J CANCER, V94, P480, DOI 10.1002/ijc.1512; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Khandwala HM, 2000, ENDOCR REV, V21, P215, DOI 10.1210/er.21.3.215; Langenau DM, 2003, SCIENCE, V299, P887, DOI 10.1126/science.1080280; Lee CH, 1998, J BIOL CHEM, V273, P25261, DOI 10.1074/jbc.273.39.25261; Leeds P, 1997, ONCOGENE, V14, P1279, DOI 10.1038/sj.onc.1201093; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Li YM, 1998, J BIOL CHEM, V273, P28247, DOI 10.1074/jbc.273.43.28247; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; Ross J, 2001, ONCOGENE, V20, P6544, DOI 10.1038/sj.onc.1204838; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; SANDBERG AC, 1988, NEUROSCI LETT, V93, P114, DOI 10.1016/0304-3940(88)90022-5; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; Sharp PA, 2000, SCIENCE, V287, P2431, DOI 10.1126/science.287.5462.2431; SINGH P, 1994, AM J PHYSIOL, V267, P608; Stewart DA, 2002, NUCLEIC ACIDS RES, V30, P2565, DOI 10.1093/nar/30.11.2565; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; TALLY M, 1987, BIOCHEM BIOPH RES CO, V148, P811, DOI 10.1016/0006-291X(87)90948-X; Tessier CR, 2004, CANCER RES, V64, P209, DOI 10.1158/0008-5472.CAN-03-2927; Thorgeirsson SS, 1996, BRIT J CLIN PHARMACO, V42, P43, DOI 10.1046/j.1365-2125.1996.03748.x; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; van Dijk EL, 2001, NUCLEIC ACIDS RES, V29, P3477, DOI 10.1093/nar/29.17.3477; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; WORBY CA, 2001, SCI STKE; Yi HK, 2001, EUR J CANCER, V37, P2257, DOI 10.1016/S0959-8049(01)00269-6; ZAPF J, 1986, HORM RES, V24, P121, DOI 10.1159/000180551; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; Zhang QM, 1997, J BIOL CHEM, V272, P23703, DOI 10.1074/jbc.272.38.23703; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	61	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48716	48724		10.1074/jbc.M405853200	http://dx.doi.org/10.1074/jbc.M405853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355996	hybrid			2022-12-25	WOS:000225098100029
J	Moussatche, P; Klee, HJ				Moussatche, P; Klee, HJ			Autophosphorylation activity of the Arabidopsis ethylene receptor multigene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE KINASE; RAF-LIKE KINASE; HISTIDINE KINASE; PROTEIN-KINASE; GENE FAMILY; ETR1; PHYTOCHROME; DOMAIN; BINDING; CTR1	Receptors for the gaseous phytohormone ethylene show sequence similarity to bacterial two-component histidine kinases. These receptors are encoded by a multigene family that can be divided into subfamilies 1 and 2. It has been previously shown that a subfamily 1 Arabidopsis thaliana ethylene receptor, ETR1, autophosphorylates in vitro on a conserved histidine residue (1). However, sequence comparisons between the five ethylene receptor family members suggest that subfamily 2 members do not have all the motifs necessary for histidine kinase activity. Further, a tobacco subfamily 2 receptor, NTHK1, autophosphorylates on serines and threonines in vitro (2). Here we show that all five Arabidopsis ethylene receptor proteins autophosphorylate in vitro. We analyzed the nature of the phosphorylated amino acids by acid/base stability and bi-dimensional thin layer electrophoresis and demonstrated that unlike ETR1 all other ethylene receptors autophosphorylate predominantly on serine residues. ERS1, the only other subfamily 1 receptor, is able to phosphorylate on both histidine and serine residues in the presence of Mn2+. However, histidine autophosphorylation is lost when ERS1 is assayed in the presence of both Mg2+ and Mn2+, suggesting that this activity may not occur in vivo. Furthermore, mutation of the histidine residue conserved in two-component systems does not abolish serine autophosphorylation, eliminating the possibility of a histidine to serine phosphotransfer. Our biochemical observations complement the recently published genetic data that histidine kinase activity is not necessary for ethylene receptor function in plants and suggest that ethylene signal transduction does not occur through a phosphorelay mechanism.	Univ Florida, Plant Mol & Cellular Biol Program, Gainesville, FL 32611 USA	State University System of Florida; University of Florida	Klee, HJ (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	hjklee@ifas.ufl.edu	Klee, Harry/A-7912-2008	Moussatche, Patricia/0000-0003-4540-0609				Abeles F, 1992, ETHYLENE PLANT BIOL; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHANG C, 1995, P NATL ACAD SCI USA, V92, P4129, DOI 10.1073/pnas.92.10.4129; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Fankhauser C, 1999, SCIENCE, V284, P1539, DOI 10.1126/science.284.5419.1539; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Gamble RL, 2002, PLANT PHYSIOL, V128, P1428, DOI 10.1104/pp.010777; Gao ZY, 2003, J BIOL CHEM, V278, P34725, DOI 10.1074/jbc.M305548200; Hall AE, 1999, PLANT PHYSIOL, V121, P291, DOI 10.1104/pp.121.1.291; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Huang YF, 2003, PLANT J, V33, P221, DOI 10.1046/j.1365-313X.2003.01620.x; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; Inoue T, 2001, NATURE, V409, P1060, DOI 10.1038/35059117; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; Lapko VN, 1999, PROTEIN SCI, V8, P1032, DOI 10.1110/ps.8.5.1032; Liu GZ, 2002, J BIOL CHEM, V277, P20264, DOI 10.1074/jbc.M110999200; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MUKHOPADHYAY MJ, 1991, BOT REV, V57, P117, DOI 10.1007/BF02858767; Nollen EAA, 2002, J CELL SCI, V115, P2809; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POPOV KM, 1992, J BIOL CHEM, V267, P13127; POPOV KM, 1993, J BIOL CHEM, V268, P26602; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; PUTNAMEVANS CL, 1990, BIOCHEMISTRY-US, V29, P2488, DOI 10.1021/bi00462a008; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SCHNEIDERPOETSCH HAW, 1991, FEBS LETT, V281, P245, DOI 10.1016/0014-5793(91)80403-P; SHERMAN MY, 1991, J BACTERIOL, V173, P7249, DOI 10.1128/jb.173.22.7249-7256.1991; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Thelen JJ, 2000, BIOCHEM J, V349, P195, DOI 10.1042/0264-6021:3490195; Tuazon PT, 1998, BIOCHEMISTRY-US, V37, P17024, DOI 10.1021/bi982103o; Tuganova A, 2001, J BIOL CHEM, V276, P17994, DOI 10.1074/jbc.M009327200; Wang WY, 2003, P NATL ACAD SCI USA, V100, P352, DOI 10.1073/pnas.0237085100; Xie C, 2003, PLANT J, V33, P385, DOI 10.1046/j.1365-313X.2003.01631.x; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976	48	146	159	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48734	48741		10.1074/jbc.M403100200	http://dx.doi.org/10.1074/jbc.M403100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358768	hybrid			2022-12-25	WOS:000225098100031
J	Namkung, Y; Sibley, DR				Namkung, Y; Sibley, DR			Protein kinase C mediates phosphorylation, desensitization, and trafficking of the D-2 dopamine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; HAMSTER OVARY CELLS; COUPLED RECEPTORS; BETA(2)-ADRENERGIC RECEPTOR; D2 RECEPTORS; HETEROLOGOUS-DESENSITIZATION; DEPENDENT PHOSPHORYLATION; DIFFERENTIAL REGULATION; CROSS-TALK; BETA	Previously, D-2 dopamine receptors (D-2 DARs) have been shown to undergo G-protein-coupled receptor kinase phosphorylation in an agonist-specific fashion. We have now investigated the ability of the second messenger-activated protein kinases, protein kinase A (PKA) and protein kinase C (PKC), to mediate phosphorylation and desensitization of the D-2 DAR. HEK293T cells were transiently transfected with the D-2 DAR and then treated with intracellular activators and inhibitors of PKA or PKC. Treatment with agents that increase cAMP, and activate PKA, had no effect on the phosphorylation state of the D-2 DAR, suggesting that PKA does not phosphorylate the D-2 DAR in HEK293T cells. In contrast, cellular treatment with phorbol 12-myristate 13-acetate (PMA), a PKC activator, resulted in an similar to3-fold increase in D-2 DAR phosphorylation. The phosphorylation was specific for PKC as the PMA effect was mimicked by phorbol 12,13-dibutyrate, but not by 4alpha-phorbol 12,13-didecanoate, active and inactive, phorbol diesters, respectively. The PMA-mediated D-2 DAR phosphorylation was completely blocked by co-treatment with the PKC inhibitor, bisindolylmaleimide II, and augmented by co-transfection with PKCbetaI. In contrast, PKC inhibition had no effect on agonist-promoted phosphorylation, suggesting that PKC is not involved in this response. PKC phosphorylation of the D-2 DAR was found to promote receptor desensitization as reflected by a decrease in agonist potency for inhibiting cAMP accumulation. Most interestingly, PKC phosphorylation also promoted internalization of the D-2 DAR through a beta-arrestin- and dynamin-dependent pathway, a response not usually associated with PKC phosphorylation of G-protein-coupled receptors. Site-directed mutagenesis experiments resulted in the identification of two domains of PKC phosphorylation sites within the third intracellular loop of the receptor. Both of these domains are involved in regulating sequestration of the D-2 DAR, whereas only one domain is involved in receptor desensitization. These results indicate that PKC can mediate phosphorylation of the D-2 DAR, resulting in both functional desensitization and receptor internalization.	NINDS, NIH, Mol Neuropharmacol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Sibley, DR (corresponding author), NINDS, NIH, Mol Neuropharmacol Sect, Bldg 10,Rm 5C108,10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.	sibley@helix.nih.gov	Sibley, David/AAC-3591-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002263, Z01NS002263] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akam E, 2004, BIOCHEM PHARMACOL, V67, P2039, DOI 10.1016/j.bcp.2004.02.017; CUBEDDU LX, 1989, J PHARMACOL EXP THER, V251, P687; DIMARZO V, 1993, J NEUROSCI, V13, P4846; ELAZAR Z, 1991, J NEUROCHEM, V56, P75, DOI 10.1111/j.1471-4159.1991.tb02564.x; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gainetdinov RR, 2003, NEURON, V38, P291, DOI 10.1016/S0896-6273(03)00192-2; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Gardner B, 2001, MOL PHARMACOL, V59, P310, DOI 10.1124/mol.59.2.310; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUAN XM, 1992, J BIOL CHEM, V267, P21995; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; Hosey MM, 1999, AM J PHYSIOL-CELL PH, V277, pC856, DOI 10.1152/ajpcell.1999.277.5.C856; Ito K, 1999, EUR J BIOCHEM, V260, P112, DOI 10.1046/j.1432-1327.1999.00125.x; Itokawa M, 1996, MOL PHARMACOL, V49, P560; Iwata K, 1999, EUR J BIOCHEM, V263, P596, DOI 10.1046/j.1432-1327.1999.00549.x; Jackson A, 2002, J NEUROCHEM, V82, P683, DOI 10.1046/j.1471-4159.2002.01001.x; Jirousek MR, 1996, J MED CHEM, V39, P2664, DOI 10.1021/jm950588y; Kabbani N, 2004, CELL SIGNAL, V16, P497, DOI 10.1016/j.cellsig.2003.09.011; Kalatskaya I, 2004, J BIOL CHEM, V279, P31268, DOI 10.1074/jbc.M401796200; Kapur S, 2003, PROG NEURO-PSYCHOPH, V27, P1081, DOI 10.1016/j.pnpbp.2003.09.004; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200; Kim OJ, 2004, J BIOL CHEM, V279, P7999, DOI 10.1074/jbc.M308281200; Koks S, 2003, NEUROPEPTIDES, V37, P25, DOI 10.1016/S0143-4179(02)00137-3; Krasel C, 2001, J BIOL CHEM, V276, P1911, DOI 10.1074/jbc.M008773200; Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lachowicz JE, 1997, BIOCHEM BIOPH RES CO, V237, P394, DOI 10.1006/bbrc.1997.7146; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; Legault M, 2002, NEUROSCIENCE, V111, P177, DOI 10.1016/S0306-4522(01)00614-5; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; LIU YF, 1992, J NEUROCHEM, V59, P2311; Mason JN, 2002, MOL PHARMACOL, V61, P806, DOI 10.1124/mol.61.4.806; Milligan G, 2003, MOL PHARMACOL, V64, P1271, DOI 10.1124/mol.64.6.1271; Murthy KS, 2000, AM J PHYSIOL-CELL PH, V279, pC925, DOI 10.1152/ajpcell.2000.279.4.C925; Naik MU, 2000, J COMP NEUROL, V426, P243, DOI 10.1002/1096-9861(20001016)426:2<243::AID-CNE6>3.0.CO;2-8; Neve K. A., 1997, DOPAMINE RECEPTORS, P27; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; ROGUE P, 1990, BIOCHEM INT, V22, P575; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SIBLEY DR, 1997, DOPAMINE RECEPTORS, P383; Tiberi M, 1996, J BIOL CHEM, V271, P3771; Tran TM, 2004, MOL PHARMACOL, V65, P196, DOI 10.1124/mol.65.1.196; VALLAR L, 1990, J BIOL CHEM, V265, P10320; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vazquez-Prado J, 2003, CELL SIGNAL, V15, P549, DOI 10.1016/S0898-6568(02)00151-1; Vickery RG, 1999, J CELL BIOL, V144, P31, DOI 10.1083/jcb.144.1.31; Wagey R, 2001, J NEUROCHEM, V78, P715, DOI 10.1046/j.1471-4159.2001.00459.x; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wise A, 2004, ANNU REV PHARMACOL, V44, P43, DOI 10.1146/annurev.pharmtox.44.101802.121419; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; Yu SG, 2003, J NEUROCHEM, V86, P1006, DOI 10.1046/j.1471-4159.2003.01912.x; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878	58	115	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49533	49541		10.1074/jbc.M408319200	http://dx.doi.org/10.1074/jbc.M408319200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347675	hybrid			2022-12-25	WOS:000225098100124
J	Rosner, M; Hengstschlager, M				Rosner, M; Hengstschlager, M			Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; SCLEROSIS COMPLEX; TSC2 GENE; INHIBITOR P27; DEGRADATION; PRODUCT; HAMARTIN; PATHWAY	TSC1 ((t) under bar uberous (s) under bar clerosis (c) under bar omplex (1) under bar) encoding hamartin and TSC2 encoding tuberin are tumor suppressor genes responsible for the autosomal dominantly inherited disease tuberous sclerosis. These genes have been demonstrated to negatively regulate cell cycle progression, the activity of cdk2, and the degradation of the cyclin-dependent kinase inhibitor p27. To date, the underlying molecular mechanism remains elusive. Here, we show that tuberin binds to p27. Whereas tuberin also binds p27 in TSC1-negative cells, hamartin does not bind p27 without tuberin. p27 protein levels are regulated through ubiquitin-dependent degradation. Skp2 is the F-box protein, which, together with other proteins, forms an SCF ((S) under bar kp1/(c) under bar ullin/(F) under bar -box protein)-type E3 ubiquitin ligase complex whose task is to target p27 for degradation by the proteasome. We found that neither tuberin nor hamartin are in a complex with Skp2. Tuberin does not affect Skp2 protein levels, and the SCFSkp2 ubiquitin ligase does not regulate tuberin stability. But binding of tuberin to p27 sequesters p27 from Skp2 accompanied by an up-regulation of the p27 interaction with cdk2. Skp2-induced p27 degradation and cell cycle progression is abolished by tuberin's protective binding to p27. This work, the first description of the direct interaction of a tumor suppressor protein with p27, provides a molecular explanation for the effects of tuberous sclerosis complex genes on the cell cycle and demonstrates a new aspect of the SCFSkp2-mediated regulation of p27 stability.	Med Univ Vienna, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@akh-wien.ac.at						Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Honda S, 2003, MOL CARCINOGEN, V37, P122, DOI 10.1002/mc.10123; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Miloloza A, 2002, J NEUROPATH EXP NEUR, V61, P154, DOI 10.1093/jnen/61.2.154; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; NELLIST M, 1993, CELL, V75, P1305; Nho Richard Seonghun, 2003, Prog Cell Cycle Res, V5, P249; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Plank TL, 1998, CANCER RES, V58, P4766; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Uhlmann EJ, 2002, ANN NEUROL, V52, P285, DOI 10.1002/ana.10283; Uhlmann EJ, 2002, ONCOGENE, V21, P4050, DOI 10.1038/sj.onc.1205435; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381	34	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48707	48715		10.1074/jbc.M405528200	http://dx.doi.org/10.1074/jbc.M405528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355997	hybrid			2022-12-25	WOS:000225098100028
J	Weiser, DC; Sikes, S; Li, S; Shenolikar, S				Weiser, DC; Sikes, S; Li, S; Shenolikar, S			The inhibitor-1 C terminus facilitates hormonal regulation of cellular protein phosphatase-1 - Functional implications for inhibitor-1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED RAT HEMICORPUS; SKELETAL-MUSCLE; TYPE-1 PHOSPHATASE; CATALYTIC SUBUNIT; GROWTH ARREST; PHOSPHORYLATION; DARPP-32; EXPRESSION; KINASE; PHOSPHOPROTEIN	Inhibitor-1 (I-1) is a selective inhibitor of protein phosphatase-1 (PP1) and regulates several PP1-dependent signaling pathways, including cardiac contractility and regulation of learning and memory. The human I-1 gene has been spliced to generate two alternative mRNAs, termed I-1alpha and I-1beta, encoding polypeptides that differ from I-1 in their C-terminal sequences. Reverse transcription-PCR established that I-1alpha and I-1beta mRNAs are expressed in a developmental and tissue-specific manner. Functional analysis of I-1 in a Saccharomyces cerevisiae strain dependent on human I-1 for viability established that a novel domain encompassing amino acids 77-110 is necessary for PP1 inhibition in yeast. Expression of human I-1 in S. cerevisiae with a partial loss-of-function eukaryotic initiation factor-2alpha (eIF2alpha) kinase (Gcn2p) mutation permitted growth during amino acid starvation, consistent with the inhibition of Glc7p/PP1, the yeast eIF2alpha phosphatase. In contrast, human I-1alpha, which lacks amino acids 83-134, and I-1 with C-terminal deletions were significantly less effective in promoting yeast growth under starvation conditions. These data suggest that C-terminal sequences of I-1 enhance regulation of the eukaryotic eIF2alpha phosphatase. In vitro studies established that C-terminal sequences, deleted in both I-1alpha and I-1beta, enhance PP1 binding and inhibition. Expression of full-length and C-terminally truncated I-1 in HEK293T cells established the importance of the I-1 C terminus in transducing cAMP signals that promote eIF2alpha phosphorylation. This study demonstrates that multiple domains in I-1 target cellular PP1 complexes and establishes I-1 as a cellular regulator of eIF2alpha phosphorylation.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Shenolikar, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.	sheno001@mc.duke.edu			NIDDK NIH HHS [R01-DK52054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052054] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; Aleem EA, 2001, MOL CELL BIOCHEM, V217, P1, DOI 10.1023/A:1007141514750; Allen PB, 2000, J NEUROSCI, V20, P3537, DOI 10.1523/JNEUROSCI.20-10-03537.2000; Bibb JA, 1999, NATURE, V402, P669, DOI 10.1038/45251; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003; Carr AN, 2002, MOL CELL BIOL, V22, P4124, DOI 10.1128/MCB.22.12.4124-4135.2002; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chyan CL, 2001, J BIOMOL NMR, V21, P287, DOI 10.1023/A:1012968805525; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 1998, METH MOL B, V93, P41; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; DESDOUITS F, 1995, BIOCHEM BIOPH RES CO, V206, P652, DOI 10.1006/bbrc.1995.1092; Desdouits F, 1998, BIOCHEM J, V330, P211, DOI 10.1042/bj3300211; Dever TE, 1998, METH MOL B, V77, P167; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 2002, J BIOL CHEM, V277, P44013, DOI 10.1074/jbc.M208035200; FOULKES JG, 1982, J BIOL CHEM, V257, P2493; GIRAULT JA, 1989, J BIOL CHEM, V264, P21748; HEMMINGS HC, 1992, J NEUROCHEM, V59, P1053, DOI 10.1111/j.1471-4159.1992.tb08347.x; Jousse C, 2003, J CELL BIOL, V163, P767, DOI 10.1083/jcb.200308075; KIMBALL SR, 1994, BIOCHIMIE, V76, P729, DOI 10.1016/0300-9084(94)90077-9; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; LEVIN D, 1979, J BIOL CHEM, V254, P7935; Liu HT, 2002, BIOCHEM BIOPH RES CO, V291, P1293, DOI 10.1006/bbrc.2002.6602; MACDOUGALL LK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P218, DOI 10.1016/0167-4889(89)90164-X; McLaren L, 2000, MECH DEVELOP, V96, P237, DOI 10.1016/S0925-4773(00)00388-9; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; PREEDY VR, 1988, BIOCHEM J, V251, P727, DOI 10.1042/bj2510727; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; Scrimgeour AG, 1999, J BIOL CHEM, V274, P20949, DOI 10.1074/jbc.274.30.20949; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P46535, DOI 10.1074/jbc.M206960200; TOWLE CA, 1984, BIOCHEM BIOPH RES CO, V121, P134, DOI 10.1016/0006-291X(84)90697-1; WEK RC, 1992, MOL CELL BIOL, V12, P5700, DOI 10.1128/MCB.12.12.5700; Zheng JH, 2000, J BIOL CHEM, V275, P18070, DOI 10.1074/jbc.M000918200	41	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48904	48914		10.1074/jbc.M404416200	http://dx.doi.org/10.1074/jbc.M404416200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15345721	hybrid			2022-12-25	WOS:000225098100052
J	Barriault, D; Lepine, F; Mohammadi, M; Milot, S; Leberre, N; Sylvestre, M				Barriault, D; Lepine, F; Mohammadi, M; Milot, S; Leberre, N; Sylvestre, M			Revisiting the regiospecificity of Burkholderia xenovorans LB400 biphenyl dioxygenase toward 2,2 '-dichlorobiphenyl and 2,3,2 ',3 '-tetrachlorobiphenyl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMAMONAS-TESTOSTERONI B-356; SP STRAIN LB400; OXYGENASE COMPONENT; PURIFICATION; GENES; 2,3-DIOXYGENASE; DEGRADATION; DECHLORINATION; DEHYDROGENASE; METABOLISM	2,2'-Dichlorobiphenyl (CB) is transformed by the biphenyl dioxygenase of Burkholderia xenovorans LB400 (LB400 BPDO) into two metabolites (1 and 2). The most abundant metabolite, 1, was previously identified as 2,3-dihydroxy-2'-chlorobiphenyl and was presumed to originate from the initial attack by the oxygenase on the chlorine-bearing ortho carbon and on its adjacent meta carbon of one phenyl ring. 2,3,2', 3'-Tetrachlorobiphenyl is transformed by LB400 BPDO into two metabolites that had never been fully characterized structurally. We determined the precise identity of the metabolites produced by LB400 BPDO from 2,2'-CB and 2,3,2', 3'-CB, thus providing new insights on the mechanism by which 2,2'-CB is dehalogenated to generate 2,3-dihydroxy-2'-chlorobiphenyl. We reacted 2,2'-CB with the BPDO variant p4, which produces a larger proportion of metabolite 2. The structure of this compound was determined as cis-3,4-dihydro-3,4-dihydroxy-2,2'-dichlorobiphenyl by NMR. Metabolite 1 obtained from 2,2'-CB-d(8) was determined to be a dihydroxychlorobiphenyl-d(7) by gas chromatographic-mass spectrometric analysis, and the observed loss of only one deuterium clearly shows that the oxygenase attack occurs on carbons 2 and 3. An alternative attack at the 5 and 6 carbons followed by a rearrangement leading to the loss of the ortho chlorine would have caused the loss of more than one deuterium. The major metabolite produced from catalytic oxygenation of 2,3,2', 3'-CB by LB400 BPDO was identified by NMR as cis-4,5-dihydro-4,5-dihydroxy-2,3,2', 3'-tetrachlorobiphenyl. These findings show that LB400 BPDO oxygenates 2,2'-CB principally on carbons 2 and 3 and that BPDO regiospecificity toward 2,2'-CB and 2,3,2,',3'-CB disfavors the dioxygenation of the chlorine-free orthometa carbons 5 and 6 for both congeners.	Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada	University of Quebec; Institut national de la recherche scientifique (INRS)	Sylvestre, M (corresponding author), INRS, IAF, 245 Boul Hymus, Pointe Claire, PQ H9R 1G6, Canada.	michel.sylvestre@inrs-iaf.uquebec.ca		Sylvestre, Michel/0000-0002-6942-3373				ABRAMOWICZ DA, 1994, RES MICROBIOL, V145, P42, DOI 10.1016/0923-2508(94)90067-1; Arnett CM, 2000, APPL ENVIRON MICROB, V66, P2928, DOI 10.1128/AEM.66.7.2928-2933.2000; Barriault D, 2004, J BIOL CHEM, V279, P47480, DOI 10.1074/jbc.M406805200; Barriault D, 1999, BIOCHEM BIOPH RES CO, V260, P181, DOI 10.1006/bbrc.1999.0706; Barriault D, 1998, APPL ENVIRON MICROB, V64, P4637; Barriault D, 2002, J BACTERIOL, V184, P3794, DOI 10.1128/JB.184.14.3794-3800.2002; Denef VJ, 2004, APPL ENVIRON MICROB, V70, P4961, DOI 10.1128/AEM.70.8.4961-4970.2004; ERICKSON BD, 1992, J BACTERIOL, V174, P2903, DOI 10.1128/JB.174.9.2903-2912.1992; FETZNER S, 1992, J BACTERIOL, V174, P279, DOI 10.1128/jb.174.1.279-290.1992; Francova K, 2004, ENVIRON POLLUT, V127, P41, DOI 10.1016/S0269-7491(03)00257-4; Haddock JD, 1997, J IND MICROBIOL BIOT, V19, P355, DOI 10.1038/sj.jim.2900429; HADDOCK JD, 1995, J BACTERIOL, V177, P5834, DOI 10.1128/jb.177.20.5834-5839.1995; HADDOCK JD, 1995, J BACTERIOL, V177, P20, DOI 10.1128/jb.177.1.20-26.1995; Hein P, 1998, CAN J MICROBIOL, V44, P42, DOI 10.1139/cjm-44-1-42; Hurtubise Y, 1996, J BIOL CHEM, V271, P8152, DOI 10.1074/jbc.271.14.8152; HURTUBISE Y, 1995, J BACTERIOL, V177, P6610, DOI 10.1128/jb.177.22.6610-6618.1995; Hurtubise Y, 1998, J BACTERIOL, V180, P5828, DOI 10.1128/JB.180.22.5828-5835.1998; LIN JJ, 1992, BIOTECHNIQUES, V12, P718; MASSE R, 1989, BIOMED ENVIRON MASS, V18, P27, DOI 10.1002/bms.1200180106; Mondello FJ, 1997, APPL ENVIRON MICROB, V63, P3096, DOI 10.1128/AEM.63.8.3096-3103.1997; NAKATSU CH, 1993, APPL ENVIRON MICROB, V59, P3625, DOI 10.1128/AEM.59.11.3625-3633.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Seeger M, 2001, J BACTERIOL, V183, P3548, DOI 10.1128/JB.183.12.3548-3555.2001; SIMON MJ, 1993, GENE, V127, P31, DOI 10.1016/0378-1119(93)90613-8; Sondossi M, 2004, APPL ENVIRON MICROB, V70, P174, DOI 10.1128/AEM.70.1.174-181.2004; Suenaga H, 2002, J BACTERIOL, V184, P3682, DOI 10.1128/JB.184.13.3682-3688.2002; Sylvestre M, 1996, APPL ENVIRON MICROB, V62, P2710, DOI 10.1128/AEM.62.8.2710-2715.1996; Sylvestre M, 1996, GENE, V174, P195, DOI 10.1016/0378-1119(96)00039-X; Zielinski M, 2003, J BACTERIOL, V185, P6976, DOI 10.1128/JB.185.23.6976-6980.2003; Zielinski M, 2002, MICROBIOL-SGM, V148, P2439, DOI 10.1099/00221287-148-8-2439	30	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47489	47496		10.1074/jbc.M406808200	http://dx.doi.org/10.1074/jbc.M406808200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342625	hybrid			2022-12-25	WOS:000224957000011
J	Beer, SM; Taylor, ER; Brown, SE; Dahm, CC; Costa, NJ; Runswick, MJ; Murphy, MP				Beer, SM; Taylor, ER; Brown, SE; Dahm, CC; Costa, NJ; Runswick, MJ; Murphy, MP			Glutaredoxin 2 catalyzes the reversible oxidation and glutathionylation of mitochondrial membrane thiol proteins - Implications for mitochondrial redox regulation and antioxidant defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; ELECTRON-TRANSPORT CHAIN; CARBONIC-ANHYDRASE III; COMPLEX-I; DISULFIDE-ISOMERASE; MIXED DISULFIDE; THIOREDOXIN; SUPEROXIDE; APOPTOSIS; STRESS	The redox poise of the mitochondrial glutathione pool is central in the response of mitochondria to oxidative damage and redox signaling, but the mechanisms are uncertain. One possibility is that the oxidation of glutathione (GSH) to glutathione disulfide (GSSG) and the consequent change in the GSH/GSSG ratio causes protein thiols to change their redox state, enabling protein function to respond reversibly to redox signals and oxidative damage. However, little is known about the interplay between the mitochondrial glutathione pool and protein thiols. Therefore we investigated how physiological GSH/GSSG ratios affected the redox state of mitochondrial membrane protein thiols. Exposure to oxidized GSH/GSSG ratios led to the reversible oxidation of reactive protein thiols by thiol-disulfide exchange, the extent of which was dependent on the GSH/GSSG ratio. There was an initial rapid phase of protein thiol oxidation, followed by gradual oxidation over 30 min. A large number of mitochondrial proteins contain reactive thiols and most of these formed intraprotein disulfides upon oxidation by GSSG; however, a small number formed persistent mixed disulfides with glutathione. Both protein disulfide formation and glutathionylation were catalyzed by the mitochondrial thiol transferase glutaredoxin 2 (Grx2), as were protein deglutathionylation and the reduction of protein disulfides by GSH. Complex I was the most prominent protein that was persistently glutathionylated by GSSG in the presence of Grx2. Maintenance of complex I with an oxidized GSH/GSSG ratio led to a dramatic loss of activity, suggesting that oxidation of the mitochondrial glutathione pool may contribute to the selective complex I inactivation seen in Parkinson's disease. Most significantly, Grx2 catalyzed reversible protein glutathionylation/deglutathionylation over a wide range of GSH/GSSG ratios, from the reduced levels accessible under redox signaling to oxidized ratios only found under severe oxidative stress. Our findings indicate that Grx2 plays a central role in the response of mitochondria to both redox signals and oxidative stress by facilitating the interplay between the mitochondrial glutathione pool and protein thiols.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Dahm, Christina C/G-9787-2014; Murphy, Michael P/C-2120-2009	Dahm, Christina C/0000-0003-0481-2893; Murphy, Michael P/0000-0003-1115-9618				Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Bustamante J, 1997, ARCH BIOCHEM BIOPHYS, V337, P121, DOI 10.1006/abbi.1996.9754; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; Costa NJ, 2003, ANTIOXID REDOX SIGN, V5, P291, DOI 10.1089/152308603322110878; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Di Simplicio P, 1998, ARCH BIOCHEM BIOPHYS, V355, P145, DOI 10.1006/abbi.1998.0694; DIMONTE DA, 1992, ANN NEUROL, V32, pS111, DOI 10.1002/ana.410320719; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Ghibelli L, 1999, FASEB J, V13, P2031, DOI 10.1096/fasebj.13.14.2031; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; GILBERT HF, 1984, METHOD ENZYMOL, V107, P330; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gladyshev VN, 2001, J BIOL CHEM, V276, P30374, DOI 10.1074/jbc.M100020200; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Jacob C, 2003, ANGEW CHEM INT EDIT, V42, P4742, DOI 10.1002/anie.200300573; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Lundberg M, 2001, J BIOL CHEM, V276, P26269, DOI 10.1074/jbc.M011605200; Mallis RJ, 2000, FEBS LETT, V482, P237, DOI 10.1016/S0014-5793(00)02022-6; MEREDITH MJ, 1982, J BIOL CHEM, V257, P3747; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spyrou G, 1997, J BIOL CHEM, V272, P2936, DOI 10.1074/jbc.272.5.2936; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Taylor ER, 2003, J BIOL CHEM, V278, P19603, DOI 10.1074/jbc.M209359200; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VANDENDOBBELSTE.AF, 1996, BIOCHIM BIOPHYS ACTA, V271, P15420; Venkatraman A, 2004, AM J PHYSIOL-GASTR L, V286, pG521, DOI 10.1152/ajpgi.00399.2003; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	50	321	325	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47939	47951		10.1074/jbc.M408011200	http://dx.doi.org/10.1074/jbc.M408011200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347644	hybrid			2022-12-25	WOS:000224957000064
J	Bikker, FJ; Lightenberg, AJM; End, C; Renner, M; Blaich, S; Lyer, S; Wittig, R; van't Hof, W; Veerman, ECI; Nazmi, K; de Blieck-Hogervorst, JMA; Kioschis, P; Amerongen, AVN; Poustka, A; Mollenhauer, J				Bikker, FJ; Lightenberg, AJM; End, C; Renner, M; Blaich, S; Lyer, S; Wittig, R; van't Hof, W; Veerman, ECI; Nazmi, K; de Blieck-Hogervorst, JMA; Kioschis, P; Amerongen, AVN; Poustka, A; Mollenhauer, J			Bacteria binding by DMBT1/SAG/gp-340 is confined to the VEVLXXXXW motif in its scavenger receptor cysteine-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONGE GEODIA-CYDONIUM; SURFACTANT PROTEIN-D; SALIVARY AGGLUTININ; SRCR DOMAIN; MOLECULAR-CLONING; MEMBER; FAMILY; DMBT1; SUPERFAMILY; GENE	The scavenger receptor cysteine-rich (SRCR) proteins form an archaic group of metazoan proteins characterized by the presence of SRCR domains. These proteins are classified in group A and B based on the number of conserved cysteine residues in their SRCR domains, i.e. six for group A and eight for group B. The protein DMBT1 (deleted in malignant brain tumors 1), which is identical to salivary agglutinin and lung gp-340, belongs to the group B SRCR proteins and is considered to be involved in tumor suppression and host defense by pathogen binding. In a previous study we used non-overlapping synthetic peptides covering the SRCR consensus sequence to identify a 16-amino acid bacteria-binding protein loop (peptide SRCRP2; QGRVEVLYRGSWGTVC) within the SRCR domains. In this study, using overlapping peptides, we pinpointed the minimal bacteria-binding site on SRCRP2, and thus DMBT1, to an 11-amino acid motif (DMBT1 pathogen-binding site 1 or DMBT1pbs1; GRVEVLYRGSW). An alanine substitution scan revealed that VEVL and Trp are critical residues in this motif. Bacteria binding by DMBT1pbs1 was different from the bacteria binding by the macrophage receptor MARCO in which an RXR motif was critical. In addition, the homologous consensus sequences of a number of SRCR proteins were synthesized and tested for bacteria binding. Only consensus sequences of DMBT1 orthologues bound bacteria by this motif.	Free Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Biochem, NL-1081 BT Amsterdam, Netherlands; Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands; German Canc Res Ctr, Dept Mol Genome Anal, D-69120 Heidelberg, Germany; Univ Appl Sci Mannheim, Inst Mol Biol & Cell Culture Technol, D-68163 Mannheim, Germany	Academic Center for Dentistry Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ); University of Mannheim	Lightenberg, AJM (corresponding author), Free Univ Amsterdam, Acad Ctr Dent Amsterdam, Dept Oral Biochem, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	ajm.ligtenberg@vumc.nl	Mollenhauer, Jan/G-4452-2012; Abrams, William R/A-5782-2008; Bikker, Floris/R-1941-2019; Bikker, Floris/B-1187-2012; Wittig, Rainer/AAT-5361-2021	Bikker, Floris/0000-0002-9453-4630; Wittig, Rainer/0000-0002-3735-9370				ARUFFO A, 1991, J EXP MED, V174, P949, DOI 10.1084/jem.174.4.949; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Bikker FJ, 2002, J BIOL CHEM, V277, P32109, DOI 10.1074/jbc.M203788200; Bikker FJ, 2002, J DENT RES, V81, P134, DOI 10.1177/154405910208100210; Bosch JA, 2003, J MICROBIOL METH, V53, P51, DOI 10.1016/S0167-7012(02)00220-8; Brannstrom A, 2002, BIOCHEM BIOPH RES CO, V290, P1462, DOI 10.1006/bbrc.2002.6378; Carlen A, 1998, J DENT RES, V77, P81, DOI 10.1177/00220345980770011301; Cheng H, 1996, ANAT REC, V244, P327; DOI T, 1993, J BIOL CHEM, V268, P2126; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; Elomaa O, 1998, J BIOL CHEM, V273, P4530, DOI 10.1074/jbc.273.8.4530; ERICSON T, 1983, EUR J BIOCHEM, V133, P255, DOI 10.1111/j.1432-1033.1983.tb07456.x; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; Gebe JA, 1997, J BIOL CHEM, V272, P6151, DOI 10.1074/jbc.272.10.6151; Gronlund J, 2000, J IMMUNOL, V165, P6406, DOI 10.4049/jimmunol.165.11.6406; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; JONES NH, 1986, NATURE, V323, P346, DOI 10.1038/323346a0; Kang WQ, 2003, FEBS LETT, V540, P21, DOI 10.1016/S0014-5793(03)00217-5; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; LAW SKA, 1993, EUR J IMMUNOL, V23, P2320, DOI 10.1002/eji.1830230940; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; Ligtenberg TJM, 2001, BIOCHEM J, V359, P243, DOI 10.1042/0264-6021:3590243; MAYER WE, 1995, GENE, V164, P267, DOI 10.1016/0378-1119(95)94092-Z; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mollenhauer J, 1999, ONCOGENE, V18, P6233, DOI 10.1038/sj.onc.1203071; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; Nagle GT, 2001, EUR J BIOCHEM, V268, P1213, DOI 10.1046/j.1432-1327.2001.01972.x; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; Pahler S, 1998, J EXP ZOOL, V282, P332, DOI 10.1002/(SICI)1097-010X(19981015)282:3<332::AID-JEZ6>3.3.CO;2-6; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schuster-Bockler B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-7; Takito J, 1999, AM J PHYSIOL-RENAL, V277, pF277, DOI 10.1152/ajprenal.1999.277.2.F277; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759, DOI 10.1165/ajrcmb.20.4.3439	37	99	102	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47699	47703		10.1074/jbc.M406095200	http://dx.doi.org/10.1074/jbc.M406095200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355985	hybrid			2022-12-25	WOS:000224957000035
J	Ize, B; Porcelli, I; Lucchini, S; Hinton, JC; Berks, BC; Palmer, T				Ize, B; Porcelli, I; Lucchini, S; Hinton, JC; Berks, BC; Palmer, T			Novel phenotypes of Escherichia coli tat mutants revealed by global gene expression and phenotypic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TWIN-ARGININE TRANSLOCASE; SEC-INDEPENDENT PROTEIN; PHAGE SHOCK PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; TRANSPORT-SYSTEM; OUTER-MEMBRANE; EXPORT PATHWAY; CYTOPLASMIC MEMBRANE; BIOFILM FORMATION; ANAEROBIC GROWTH	The Tat protein export system serves to export folded proteins harboring an N-terminal twin arginine signal peptide across the cytoplasmic membrane. In this study, we have used gene expression profiling of Escherichia coli supported by phenotypic analysis to investigate how cells respond to a defect in the Tat pathway. Previous work has demonstrated that strains mutated in genes encoding essential Tat pathway components are defective in the integrity of their cell envelope because of the mislocalization of two amidases involved in cell wall metabolism (Ize, B., Stanley, N.R., Buchanan, G., and Palmer, T. (2003) Mol. Microbiol. 48, 1183-1193). To distinguish between genes that are differentially expressed specifically because of the cell envelope defect and those that result from other effects of the tatC deletion, we also analyzed two different transposon mutants of the DeltatatC strain that have their outer membrane integrity restored. Approximately 50% of the genes that were differentially expressed in the tatC mutant are linked to the envelope defect, with the products of many of these genes involved in self-defense or protection mechanisms, including the production of exopolysaccharide. Among the changes that were not explicitly linked to envelope integrity, we characterized a role for the Tat system in iron acquisition and copper homeostasis. Finally, we have demonstrated that overproduction of the Tat substrate SufI saturates the Tat translocon and produces effects on global gene expression that are similar to those resulting from the DeltatatC mutation.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Inst Food Res, Inst Food Res, Mol Microbiol Grp, Norwich NR4 7UA, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia; University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of East Anglia	Palmer, T (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Colney Lane, Norwich NR4 7UH, Norfolk, England.	tracy.palmer@bbsrc.ac.uk	IZE, Bérengère/GLQ-7207-2022; Hinton, Jay C. D./B-2142-2008	IZE, Bérengère/0000-0001-9106-9254; Hinton, Jay C. D./0000-0003-2671-6026; Berks, Ben/0000-0001-9685-4067; Palmer, Tracy/0000-0001-9043-2592				Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Anjum MF, 2003, INFECT IMMUN, V71, P4674, DOI 10.1128/IAI.71.8.4674-4683.2003; Beloin C, 2004, MOL MICROBIOL, V51, P659, DOI 10.1046/j.1365-2958.2003.03865.x; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 2003, ADV MICROB PHYSIOL, V47, P187, DOI 10.1016/S0065-2911(03)47004-5; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bernhardt TG, 2003, MOL MICROBIOL, V48, P1171, DOI 10.1046/j.1365-2958.2003.03511.x; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; BRISSETTE JL, 1990, P NATL ACAD SCI USA, V87, P862, DOI 10.1073/pnas.87.3.862; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; COHEN N, 1956, ANN I PASTEUR PARIS, V91, P693; CROOKE H, 2001, ABSTR MICR PATH HOST; Danese PN, 2000, J BACTERIOL, V182, P3593, DOI 10.1128/JB.182.12.3593-3596.2000; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; de Leeuw E, 2002, J MOL BIOL, V322, P1135, DOI 10.1016/S0022-2836(02)00820-3; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; DeLisa MP, 2004, J BACTERIOL, V186, P366, DOI 10.1128/JB.186.2.366-373.2004; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ding ZY, 2003, J BACTERIOL, V185, P760, DOI 10.1128/JB.185.3.760-771.2003; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; EVANS DG, 1977, INFECT IMMUN, V18, P330, DOI 10.1128/IAI.18.2.330-337.1977; Ferrieres L, 2003, MOL MICROBIOL, V50, P1665, DOI 10.1046/j.1365-2958.2003.03815.x; GOTTESMAN S, 1991, MOL MICROBIOL, V5, P1599, DOI 10.1111/j.1365-2958.1991.tb01906.x; GUTIERREZ C, 1987, J MOL BIOL, V195, P289, DOI 10.1016/0022-2836(87)90650-4; Hagenmaier S, 1997, J BACTERIOL, V179, P2073, DOI 10.1128/jb.179.6.2073-2076.1997; Hagiwara D, 2003, J BACTERIOL, V185, P5735, DOI 10.1128/JB.185.19.5735-5746.2003; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hatzixanthis K, 2003, MOL MICROBIOL, V49, P1377, DOI 10.1046/j.1365-2958.2003.03642.x; Heidrich C, 2001, MOL MICROBIOL, V41, P167, DOI 10.1046/j.1365-2958.2001.02499.x; Hoshino N, 1999, FREE RADICAL BIO MED, V27, P1245, DOI 10.1016/S0891-5849(99)00157-4; Ize B, 2003, MOL MICROBIOL, V48, P1183, DOI 10.1046/j.1365-2958.2003.03504.x; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Kaldalu M, 2004, ANTIMICROB AGENTS CH, V48, P890, DOI 10.1128/AAC.48.3.890-896.2004; KATO JI, 1988, J BACTERIOL, V170, P3967, DOI 10.1128/jb.170.9.3967-3977.1988; Kleerebezem M, 1996, EMBO J, V15, P162, DOI 10.1002/j.1460-2075.1996.tb00344.x; KOSTER W, 1991, BIOL MET, V4, P23, DOI 10.1007/BF01135553; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; MECSAS J, 1993, GENE DEV, V7, P2618, DOI 10.1101/gad.7.12b.2618; Munson GP, 2000, J BACTERIOL, V182, P5864, DOI 10.1128/JB.182.20.5864-5871.2000; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nienaber A, 2001, MOL MICROBIOL, V41, P787, DOI 10.1046/j.1365-2958.2001.02555.x; NIKAIDO H, 1996, ESCHERICHIA COLI SAL, P29; Ochsner UA, 2002, P NATL ACAD SCI USA, V99, P8312, DOI 10.1073/pnas.082238299; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Outten FW, 2000, J BIOL CHEM, V275, P31024, DOI 10.1074/jbc.M006508200; Porcelli I, 2002, BIOCHEMISTRY-US, V41, P13690, DOI 10.1021/bi026142i; Pradel N, 2003, INFECT IMMUN, V71, P4908, DOI 10.1128/IAI.71.9.4908-4916.2003; Pratt LA, 1998, MOL MICROBIOL, V30, P285, DOI 10.1046/j.1365-2958.1998.01061.x; Prigent-Combaret C, 2000, ENVIRON MICROBIOL, V2, P450, DOI 10.1046/j.1462-2920.2000.00128.x; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Raffa RG, 2002, MOL MICROBIOL, V45, P1599, DOI 10.1046/j.1365-2958.2002.03112.x; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; Rensing C, 2003, FEMS MICROBIOL REV, V27, P197, DOI 10.1016/S0168-6445(03)00049-4; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Salmon K, 2003, J BIOL CHEM, V278, P29837, DOI 10.1074/jbc.M213060200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; Schembri MA, 2001, J INFECT DIS, V183, pS28, DOI 10.1086/318847; SILVESTRO A, 1988, BIOCHIM BIOPHYS ACTA, V954, P1, DOI 10.1016/0167-4838(88)90049-0; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Stanley NR, 2001, J BACTERIOL, V183, P139, DOI 10.1128/JB.183.1.139-144.2001; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STYRVOLD OB, 1991, J BACTERIOL, V173, P1187, DOI 10.1128/jb.173.3.1187-1192.1991; TSUI HCT, 1994, MOL MICROBIOL, V11, P189, DOI 10.1111/j.1365-2958.1994.tb00300.x; Voulhoux R, 2001, EMBO J, V20, P6735, DOI 10.1093/emboj/20.23.6735; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; WEINER L, 1994, P NATL ACAD SCI USA, V91, P2191, DOI 10.1073/pnas.91.6.2191; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472	78	54	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47543	47554		10.1074/jbc.M406910200	http://dx.doi.org/10.1074/jbc.M406910200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347649	hybrid			2022-12-25	WOS:000224957000018
J	Karamysheva, ZN; Surovtseva, YV; Vespa, L; Shakirov, EV; Shippen, DE				Karamysheva, ZN; Surovtseva, YV; Vespa, L; Shakirov, EV; Shippen, DE			A C-terminal Myb extension domain defines a novel family of double-strand telomeric DNA-binding proteins in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPEATS IN-VITRO; GENE-EXPRESSION; THALIANA; LENGTH; TRF1; SEQUENCE; CELLS; YEAST; COMPLEX; MAINTENANCE	Little is known about the protein composition of plant telomeres. We queried the Arabidopsis thaliana genome data base in search of genes with similarity to the human telomere proteins hTRF1 and hTRF2. hTRF1/hTRF2 are distinguished by the presence of a single Myb-like domain in their C terminus that is required for telomeric DNA binding in vitro. Twelve Arabidopsis genes fitting this criterion, dubbed TRF-like (TRFL), fell into two distinct gene families. Notably, TRFL family 1 possessed a highly conserved region C-terminal to the Myb domain called Myb-extension (Myb-ext) that is absent in TRFL family 2 and hTRF1/hTRF2. Immunoprecipitation experiments revealed that recombinant proteins from TRFL family 1, but not those from family 2, formed homodimers and heterodimers in vitro. DNA binding studies with isolated C-terminal fragments from TRFL family 1 proteins, but not family 2, showed specific binding to double-stranded plant telomeric DNA in vitro. Removal of the Myb-ext domain from TRFL1, a family 1 member, abolished DNA binding. However, when the Myb-ext domain was introduced into the corresponding region in TRFL3, a family 2 member, telomeric DNA binding was observed. Thus, Myb-ext is required for binding plant telomeric DNA and defines a novel class of proteins in Arabidopsis.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Shippen, DE (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, TAMU 2128, College Stn, TX 77643 USA.	dshippen@tamu.edu	Shakirov, Eugene V/A-1363-2012	Shakirov, Eugene V/0000-0003-2689-7410	NIGMS NIH HHS [GM65383] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065383] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Chen CM, 2001, J BIOL CHEM, V276, P16511, DOI 10.1074/jbc.M009659200; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; De Rycker M, 2003, BIOCHEM J, V372, P87, DOI 10.1042/BJ20021450; Fairall L, 2001, MOL CELL, V8, P351, DOI 10.1016/S1097-2765(01)00321-5; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gallego ME, 2003, PLANT CELL, V15, P782, DOI 10.1105/tpc.008623; Hall AR, 1997, ONCOGENE, V14, P1371, DOI 10.1038/sj.onc.1200962; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; ISHIKAWA T, 2001, NUCL ACIDS RES S, V1, P273; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim SH, 1999, NAT GENET, V23, P405, DOI 10.1038/70508; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; Krutilina RI, 2001, BIOCHEM BIOPH RES CO, V280, P471, DOI 10.1006/bbrc.2000.4143; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; LUGERT T, 1994, PLANT MOL BIOL, V25, P493, DOI 10.1007/BF00043877; Marian CO, 2003, PLANT PHYSIOL, V133, P1336, DOI 10.1104/pp.103.026856; McKnight TD, 2004, PLANT CELL, V16, P794, DOI 10.1105/tpc.160470; McKnight TD, 2002, PLANT MOL BIOL, V48, P331, DOI 10.1023/A:1014091032750; Nishikawa T, 1998, STRUCT FOLD DES, V6, P1057, DOI 10.1016/S0969-2126(98)00106-3; Pina B, 2003, MOL GENET GENOMICS, V268, P791, DOI 10.1007/s00438-002-0801-3; REGAD F, 1994, J MOL BIOL, V239, P163, DOI 10.1006/jmbi.1994.1360; Rhodes D, 2002, EMBO REP, V3, P1139, DOI 10.1093/embo-reports/kvf246; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; Riha K, 2003, P NATL ACAD SCI USA, V100, P611, DOI 10.1073/pnas.0236128100; Riha K, 2002, EMBO J, V21, P2819, DOI 10.1093/emboj/21.11.2819; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schrumpfova P, 2004, GENOME, V47, P316, DOI [10.1139/G03-136, 10.1139/g03-136]; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SILVA ODE, 1993, PLANT J, V4, P125, DOI 10.1046/j.1365-313X.1993.04010125.x; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Tremousaygue D, 2003, PLANT J, V33, P957, DOI 10.1046/j.1365-313X.2003.01682.x; Tremousaygue D, 1999, PLANT J, V20, P553, DOI 10.1046/j.1365-313X.1999.00627.x; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Yang SW, 2003, J BIOL CHEM, V278, P21395, DOI 10.1074/jbc.M209973200; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	53	66	79	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47799	47807		10.1074/jbc.M407938200	http://dx.doi.org/10.1074/jbc.M407938200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364931	hybrid			2022-12-25	WOS:000224957000048
J	Krause, F; Reifschneider, NH; Vocke, D; Seelert, H; Rexroth, S; Dencher, NA				Krause, F; Reifschneider, NH; Vocke, D; Seelert, H; Rexroth, S; Dencher, NA			"Respirasome"-like supercomplexes in green leaf mitochondria of spinach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN COMPLEXES; RESPIRATORY-CHAIN; ALTERNATIVE OXIDASE; PLANT-MITOCHONDRIA; PHOTOCHEMICAL SYSTEMS; THYLAKOID MEMBRANES; ELECTRON-TRANSPORT; GENE-EXPRESSION; ATP-SYNTHASE; IDENTIFICATION	Higher plant mitochondria have many unique features compared with their animal and fungal counterparts. This is to a large extent related to the close functional interdependence of mitochondria and chloroplasts, in which the two ATP-generating processes of oxidative phosphorylation and photosynthesis, respectively, take place. We show that digitonin treatment of mitochondria contaminated with chloroplasts from spinach (Spinacia oleracea) green leaves at two different buffer conditions, performed to solubilize oxidative phosphorylation supercomplexes, selectively extracts the mitochondrial membrane protein complexes and only low amounts of stroma thylakoid membrane proteins. By analysis of digitonin extracts from partially purified mitochondria of green leaves from spinach using blue and colorless native electrophoresis, we demonstrate for the first time that in green plant tissue a substantial proportion of the respiratory complex IV is assembled with complexes I and III into "respirasome"-like supercomplexes, previously observed in mammalian, fungal, and non-green plant mitochondria only. Thus, fundamental features of the supramolecular organization of the standard respiratory complexes I, III, and IV as a respirasome are conserved in all higher eukaryotes. Because the plant respiratory chain is highly branched possessing additional alternative enzymes, the functional implications of the occurrence of respiratory supercomplexes in plant mitochondria are discussed.	Tech Univ Darmstadt, Dept Chem, D-64287 Darmstadt, Germany	Technical University of Darmstadt	Krause, F (corresponding author), Tech Univ Darmstadt, Dept Chem, Petersenstr 22, D-64287 Darmstadt, Germany.	f_krause@pop.tu-darmstadt.de	Dencher, Norbert/G-6640-2014; Rexroth, Sascha/H-3702-2011	Rexroth, Sascha/0000-0003-3819-2127				Acin-Perez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8; ANDERSON JM, 1966, BIOCHIM BIOPHYS ACTA, V112, P403, DOI 10.1016/0926-6585(66)90244-5; Anderson JM, 1999, AUST J PLANT PHYSIOL, V26, P625, DOI 10.1071/PP99070; ANDERSSON B, 1980, BIOCHIM BIOPHYS ACTA, V593, P427, DOI 10.1016/0005-2728(80)90078-X; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Bianchi C, 2003, BIOFACTORS, V18, P3, DOI 10.1002/biof.5520180202; Bianchi C, 2004, J BIOL CHEM, V279, P36562, DOI 10.1074/jbc.M405135200; Borghouts C, 2001, MOL CELL BIOL, V21, P390, DOI 10.1128/MCB.21.2.390-399.2001; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Douce R, 2001, TRENDS PLANT SCI, V6, P167, DOI 10.1016/S1360-1385(01)01892-1; Eubel H, 2004, PLANT PHYSIOL, V134, P1450, DOI 10.1104/pp.103.038018; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; Finnegan PM, 1997, PLANT PHYSIOL, V114, P455, DOI 10.1104/pp.114.2.455; FROMME P, 1987, Z NATURFORSCH C, V42, P1239; Glaser E, 1995, METHOD CELL BIOL, V50, P269, DOI 10.1016/S0091-679X(08)61036-5; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Joseph-Horne T, 2000, PEST MANAG SCI, V56, P24, DOI 10.1002/(SICI)1526-4998(200001)56:1<24::AID-PS71>3.0.CO;2-Y; Joseph-Horne T, 2001, BBA-BIOENERGETICS, V1504, P179, DOI 10.1016/S0005-2728(00)00251-6; Joseph-Horne T, 1998, J BIOL CHEM, V273, P11127, DOI 10.1074/jbc.273.18.11127; Krause F, 2004, J BIOL CHEM, V279, P26453, DOI 10.1074/jbc.M402756200; KROMER S, 1995, ANNU REV PLANT PHYS, V46, P45, DOI 10.1146/annurev.pp.46.060195.000401; Mackenzie S, 1999, PLANT CELL, V11, P571, DOI 10.1105/tpc.11.4.571; Michalecka AM, 2003, PLANT PHYSIOL, V133, P642, DOI 10.1104/pp.103.024208; Moller IM, 2002, TRENDS PLANT SCI, V7, P235, DOI 10.1016/S1360-1385(02)02281-1; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; Moore AL, 2002, TRENDS PLANT SCI, V7, P478, DOI 10.1016/S1360-1385(02)02366-X; MOORE AL, 1982, PLANT PHYSIOL, V70, P1271, DOI 10.1104/pp.70.5.1271; Neff D, 1999, BIOCHEM BIOPH RES CO, V259, P569, DOI 10.1006/bbrc.1999.0820; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; PICK U, 1979, J BIOL CHEM, V254, P2793; Raghavendra AS, 2003, TRENDS PLANT SCI, V8, P546, DOI 10.1016/j.tplants.2003.09.015; Rexroth S, 2004, BBA-BIOENERGETICS, V1658, P202, DOI 10.1016/j.bbabio.2004.05.014; Rexroth S, 2003, ELECTROPHORESIS, V24, P2814, DOI 10.1002/elps.200305543; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; Schagger H, 2001, J BIOL CHEM, V276, P37861; Schuenemann D, 1999, J BIOL CHEM, V274, P12177, DOI 10.1074/jbc.274.17.12177; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; Svensson AS, 2001, PLANT J, V28, P73, DOI 10.1046/j.1365-313X.2001.01128.x; Tanton LL, 2003, FUNGAL GENET BIOL, V39, P176, DOI 10.1016/S1087-1845(03)00002-1; Tielens AGM, 2002, TRENDS BIOCHEM SCI, V27, P564, DOI 10.1016/S0968-0004(02)02193-X; Timperio AM, 2004, J CHROMATOGR A, V1040, P73, DOI 10.1016/j.chroma.2004.03.068; van Lis R, 2003, PLANT PHYSIOL, V132, P318, DOI 10.1104/pp.102.018325; Veiga A, 2003, FEMS YEAST RES, V3, P141, DOI 10.1016/S1567-1356(02)00189-7; WESSELS JSC, 1962, BIOCHIM BIOPHYS ACTA, V65, P561, DOI 10.1016/0006-3002(62)90476-6; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang SP, 2004, J BIOL CHEM, V279, P3180, DOI 10.1074/jbc.M311640200	52	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48369	48375		10.1074/jbc.M406085200	http://dx.doi.org/10.1074/jbc.M406085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342644	hybrid			2022-12-25	WOS:000224957000112
J	Leal, NA; Olteanu, H; Banerjee, R; Bobik, TA				Leal, NA; Olteanu, H; Banerjee, R; Bobik, TA			Human ATP : Cob(I)alamin adenosyltransferase and its interaction with methionine synthase reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLMALONYL-COA MUTASE; ATP-CORRINOID ADENOSYLTRANSFERASE; SEROVAR TYPHIMURIUM LT2; COMPLEMENTATION GROUP; SALMONELLA-TYPHIMURIUM; ENZYMATIC CONVERSION; COBALAMIN METABOLISM; FLAVOPROTEIN SYSTEM; INBORN ERROR; VITAMIN B12S	The final step in the conversion of vitamin B-12 into coenzyme B-12 (adenosylcobalamin, AdoCbl) is catalyzed by ATP: cob(I) alamin adenosyltransferase (ATR). Prior studies identified the human ATR and showed that defects in its encoding gene underlie cblB methylmalonic aciduria. Here two common polymorphic variants of the ATR that are found in normal individuals are expressed in Escherichia coli, purified, and partially characterized. The specific activities of ATR variants 239K and 239M were 220 and 190 nmol min(-1) mg(-1), and their K-m values were 6.3 and 6.9 muM for ATP and 1.2 and 1.6 muM for cob(I) alamin, respectively. These values are similar to those obtained for previously studied bacterial ATRs indicating that both human variants have sufficient activity to mediate AdoCbl synthesis in vivo. Investigations also showed that purified recombinant human methionine synthase reductase (MSR) in combination with purified ATR can convert cob(II) alamin to AdoCbl in vitro. In this system, MSR reduced cob( II) alamin to co-b(I) alamin that was adenosylated to AdoCbl by ATR. The optimal stoichiometry for this reaction was similar to4 MSR/ATR and results indicated that MSR and ATR physically interacted in such a way that the highly reactive reaction intermediate [cob(I) alamin] was sequestered. The finding that MSR reduced cob(II) alamin to cob(I) alamin for AdoCbl synthesis (in conjunction with the prior finding that MSR reduced cob(II) alamin for the activation of methionine synthase) indicates a dual physiological role for MSR.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA; Univ Florida, Dept Microbiol & Cell Sci, Gainesville, FL 32611 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	Iowa State University; State University System of Florida; University of Florida; University of Nebraska System; University of Nebraska Lincoln	Bobik, TA (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	bobik@iastate.edu	Olteanu, Horatiu/AAH-1051-2021	Olteanu, Horatiu/0000-0001-5783-4485; Leal, Nicole/0000-0001-6953-4519	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045776, R01DK064959, R01DK045776, R01DK064771] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064771, DK45776, DK64959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee R., 1999, Chemistry and biochemistry of B12., P707; Banerjee R., 1999, CHEM BIOCH B 12; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; Bauer CB, 2001, BIOCHEMISTRY-US, V40, P361, DOI 10.1021/bi002145o; BOBIK TA, 1989, J BACTERIOL, V171, P1423, DOI 10.1128/jb.171.3.1423-1427.1989; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; DEBUSSCHE L, 1991, J BACTERIOL, V173, P6300, DOI 10.1128/jb.173.19.6300-6302.1991; Dobson CM, 2002, HUM MOL GENET, V11, P3361, DOI 10.1093/hmg/11.26.3361; Dobson CM, 2002, P NATL ACAD SCI USA, V99, P15554, DOI 10.1073/pnas.242614799; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; Fonseca MV, 2002, J BIOL CHEM, V277, P33127, DOI 10.1074/jbc.M203893200; FRIEDMANN HC, 1975, COBALAMIN BIOCH PATH, P75; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; HUENNEKENS FM, 1982, B12, V1, P145; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Korotkova N, 2004, J BIOL CHEM, V279, P13652, DOI 10.1074/jbc.M312852200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Leal NA, 2003, J BIOL CHEM, V278, P9227, DOI 10.1074/jbc.M212739200; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; Leclerc D, 1999, GENE, V240, P75, DOI 10.1016/S0378-1119(99)00431-X; Maniatis T., 1982, MOL CLONING LAB MANU; MATTHEWS RG, 1999, CHEM BIOCH B12, P707; MELLMAN I, 1979, J BIOL CHEM, V254, P1847; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; NHAM SU, 1990, GENOMICS, V8, P710, DOI 10.1016/0888-7543(90)90259-W; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; PEZACKA E, 1990, BIOCHEM BIOPH RES CO, V169, P443, DOI 10.1016/0006-291X(90)90351-M; PEZACKA EH, 1993, BIOCHIM BIOPHYS ACTA, V1157, P167, DOI 10.1016/0304-4165(93)90061-C; Rosenblatt D. S., 1999, Chemistry and biochemistry of B12., P367; Saridakis V, 2004, J BIOL CHEM, V279, P23646, DOI 10.1074/jbc.M401395200; Schneider Z., 1987, COMPREHENSIVE B12, P157, DOI [10.1515/9783110844795.157, DOI 10.1515/9783110844795.157]; Schneider Z., 1987, COMPREHENSIVE B12; SCHRAUZER GN, 1968, J AM CHEM SOC, V90, P2441, DOI 10.1021/ja01011a054; Segel I.H., 1976, BIOCH CALCULATIONS S; SUH SJ, 1995, J BACTERIOL, V177, P921, DOI 10.1128/jb.177.4.921-925.1995; VASSILIADIS A, 1991, EXP CELL RES, V195, P295, DOI 10.1016/0014-4827(91)90376-6; VITOLS E, 1966, J BIOL CHEM, V241, P1455; Watkins D, 2001, ENDOCRINOLOGIST, V11, P98, DOI 10.1097/00019616-200103000-00005; Watkins D, 2000, J MED GENET, V37, P510, DOI 10.1136/jmg.37.7.510; WEISSBACH H, 1963, J BIOL CHEM, V238, P3318; WEISSBACH H, 1961, J BIOL CHEM, V236, pPC40; Wilson A, 1999, HUM MOL GENET, V8, P2009, DOI 10.1093/hmg/8.11.2009	47	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47536	47542		10.1074/jbc.M405449200	http://dx.doi.org/10.1074/jbc.M405449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347655	hybrid			2022-12-25	WOS:000224957000017
J	Pappan, K; Zheng, L; Krishnamoorthi, R; Wang, XM				Pappan, K; Zheng, L; Krishnamoorthi, R; Wang, XM			Evidence for and characterization of Ca2+ binding to the catalytic region of Arabidopsis thaliana phospholipase D beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; D-ALPHA; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PLASMA-MEMBRANE; D-DELTA; CALCIUM; ACTIVATION; DOMAINS; MECHANISM; ACID	Most types of plant phospholipase D (PLD) require Ca2+ for activity, but how Ca2+ affects PLD activity is not well understood. We reported previously that Ca2+ binds to the regulatory C2 domain that occurs in the N terminus of the Ca2+-requiring PLDs. Using Arabidopsis thaliana PLDbeta and C2-deleted PLDbeta (PLDbetacat), we now show that Ca2+ also interacts with the catalytic regions of PLD. PLDbetacat exhibited Ca2+-dependent activity, was much less active, and required a higher level of Ca2+ than the full-length PLDbeta. Ca2+ binding of the proteins was stimulated by phospholipids; phosphatidylserine was the most effective among those tested. Scatchard plot analysis of Ca2+ binding data yielded an estimate of 3.6 high affinity (K-d = 29 muM) binding sites on PLDbeta. The Ca2+-PLDbetacat interaction increased the affinity of the protein for the activator, phosphatidylinositol 4,5-bisphosphate, but not for the substrate, phosphatidylcholine. This is in contrast to the effect of Ca2+ binding to the C2 domain, which stimulates phosphatidylcholine binding but inhibits phosphatidylinositol 4,5-bisphosphate binding of the domain. These results demonstrate the contrasting and complementary effects of the Ca2+- and lipid-binding properties of the C2 and catalytic domains of plant PLD and provide insight into the mechanism by which Ca2+ regulates PLD activity.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA	Kansas State University	Wang, XM (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	wangxue@umsl.edu	Wang, Xuemin/M-2853-2013; Pappan, Kirk/AAV-5946-2021	Pappan, Kirk/0000-0002-2341-8798; wang, xuemin/0000-0002-6251-6745				BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; deVrije T, 1997, J EXP BOT, V48, P1631, DOI 10.1093/jexbot/48.314.1631; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; EVANS TC, 1994, BIOCHEMISTRY-US, V33, P13231, DOI 10.1021/bi00249a009; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; Heller M, 1978, Adv Lipid Res, V16, P267; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; Li WQ, 2004, NAT BIOTECHNOL, V22, P427, DOI 10.1038/nbt949; LUO JH, 1993, J BIOL CHEM, V268, P3715; LUO JH, 1993, J BIOL CHEM, V268, P23580; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NORBY JG, 1980, ANAL BIOCHEM, V102, P318, DOI 10.1016/0003-2697(80)90160-8; Nozawa Y, 2002, BBA-MOL CELL BIOL L, V1585, P77, DOI 10.1016/S1388-1981(02)00327-X; Pappan K, 1999, ARCH BIOCHEM BIOPHYS, V368, P347, DOI 10.1006/abbi.1999.1325; Pappan K, 1997, J BIOL CHEM, V272, P7055, DOI 10.1074/jbc.272.11.7055; Pappan K, 1998, ARCH BIOCHEM BIOPHYS, V353, P131, DOI 10.1006/abbi.1998.0640; Pappan K, 1997, J BIOL CHEM, V272, P7048, DOI 10.1074/jbc.272.11.7048; POINTING CP, 1996, PROTEIN SCI, V5, P914; Ponting CP, 1996, PROTEIN SCI, V5, P162; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Qin CB, 2002, PLANT PHYSIOL, V128, P1057, DOI 10.1104/pp.010928; Qin WS, 1997, J BIOL CHEM, V272, P28267, DOI 10.1074/jbc.272.45.28267; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Ryu SB, 1996, BBA-LIPID LIPID MET, V1303, P243, DOI 10.1016/0005-2760(96)00096-3; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Shank KJ, 2001, PLANT PHYSIOL, V126, P267, DOI 10.1104/pp.126.1.267; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang XM, 2002, CURR OPIN PLANT BIOL, V5, P408, DOI 10.1016/S1369-5266(02)00283-2; Wang XM, 2001, ANNU REV PLANT PHYS, V52, P211, DOI 10.1146/annurev.arplant.52.1.211; White PJ, 2003, ANN BOT-LONDON, V92, P487, DOI 10.1093/aob/mcg164; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zhang WH, 2003, PLANT CELL, V15, P2285, DOI 10.1105/tpc.013961; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200; Zheng L, 2002, BIOCHEMISTRY-US, V41, P4546, DOI 10.1021/bi0158775	40	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47833	47839		10.1074/jbc.M402789200	http://dx.doi.org/10.1074/jbc.M402789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15356005	hybrid, Green Published			2022-12-25	WOS:000224957000052
J	Riganti, C; Gazzano, E; Polimeni, M; Costamagna, C; Bosia, A; Ghigo, D				Riganti, C; Gazzano, E; Polimeni, M; Costamagna, C; Bosia, A; Ghigo, D			Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-GENERATING-SYSTEM; NEUTROPHIL NADPH OXIDASE; PENTOSE CYCLE ACTIVITY; GLUCOSE-6-PHOSPHATE DEHYDROGENASE; DIAPHORASE ACTIVITY; IODONIUM COMPOUNDS; DIPHENYLIODONIUM; GLUTATHIONE; MECHANISM; REDUCTASE	Diphenyleneiodonium (DPI) and the structurally related compound diphenyliodonium ( DIP) are widely used as inhibitors of flavoenzymes, particularly NADPH oxidase. Here we report further evidence that DPI and DIP are not specific flavin binders. A 3-h incubation of N11 glial cells with DPI significantly inhibited in a dose-dependent way both the pentose phosphate pathway and the tricarboxylic acid cycle. In parallel, we observed a dose-dependent increase of reactive oxygen species generation and lipoperoxidation and increased leakage of lactate dehydrogenase activity in the extracellular medium. The glutathione/glutathione disulfide ratio decreased, whereas the efflux of glutathione out of the cells increased. This suggests that DPI causes an augmented oxidative stress and exerts a cytotoxic effect in N11 cells. Indeed, the cells were protected from these events when loaded with glutathione. Similar results were observed using DIP instead of DPI and also in other cell types. We suggest that the DPI-elicited inhibition of the pentose phosphate pathway and tricarboxylic acid cycle may be mediated by the blockade of several NAD(P)-dependent enzymes, such as glucose 6-phosphate dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase, and lactate dehydrogenase. In light of these results, we think that some effects of DPI or DIP in in vitro and in vivo experimental models should be interpreted with caution.	Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	University of Turin	Ghigo, D (corresponding author), Univ Turin, Dept Genet Biol & Biochem, Via Santena 5 Bis, I-10126 Turin, Italy.	dario.ghigo@unito.it		Ghigo, Dario/0000-0001-6050-1577; Riganti, Chiara/0000-0001-9787-4836				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beutler E, 1982, GLUTATHIONE RED CELL, V3 rd; Brandes RP, 1997, J PHYSIOL-LONDON, V500, P331, DOI 10.1113/jphysiol.1997.sp022024; Colavitti R, 2002, J BIOL CHEM, V277, P3101, DOI 10.1074/jbc.M107711200; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; CROSS AR, 1987, BIOCHEM PHARMACOL, V36, P489, DOI 10.1016/0006-2952(87)90356-X; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; Doussiere J, 1999, BIOCHEMISTRY-US, V38, P3694, DOI 10.1021/bi9823481; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GATLEY SJ, 1976, BIOCHEM J, V158, P307, DOI 10.1042/bj1580307; Gerard-Monnier D, 1998, CHEM RES TOXICOL, V11, P1176, DOI 10.1021/tx9701790; GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199; HOLLAND PC, 1973, J BIOL CHEM, V248, P6050; Li NY, 2003, FREE RADICAL BIO MED, V34, P465, DOI 10.1016/S0891-5849(02)01325-4; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; LUZZATTO L, 1967, BIOCHIM BIOPHYS ACTA, V146, P18, DOI 10.1016/0005-2744(67)90069-1; MARKS PA, 1960, P NATL ACAD SCI USA, V46, P447, DOI 10.1073/pnas.46.4.447; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; NAFTALIN RJ, 1993, BIOCHIM BIOPHYS ACTA, V1148, P39, DOI 10.1016/0005-2736(93)90158-V; Nakamura Y, 1997, NEUROSCIENCE, V76, P459, DOI 10.1016/S0306-4522(96)00375-2; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; PESCARMONA GP, 1982, INT J BIOCHEM, V14, P243, DOI 10.1016/0020-711X(82)90146-X; Pullar JM, 2002, J BIOL CHEM, V277, P19402, DOI 10.1074/jbc.M111053200; RAGAN CI, 1977, BIOCHEM J, V163, P605, DOI 10.1042/bj1630605; RIEGER D, 1992, REPROD FERT DEVELOP, V4, P547, DOI 10.1071/RD9920547; Riganti C, 2002, FREE RADICAL BIO MED, V32, P938, DOI 10.1016/S0891-5849(02)00800-6; Ryter SW, 2002, ANTIOXID REDOX SIGN, V4, P587, DOI 10.1089/15230860260220085; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; Shuto M, 1997, NEUROCHEM INT, V31, P73, DOI 10.1016/S0197-0186(96)00140-4; SPOLARICS Z, 1993, HEPATOLOGY, V17, P615, DOI 10.1002/hep.1840170415; SPOLARICS Z, 1993, BIOCHIM BIOPHYS ACTA, V1179, P134, DOI 10.1016/0167-4889(93)90134-B; Spolarics Z, 1998, J LEUKOCYTE BIOL, V63, P534, DOI 10.1002/jlb.63.5.534; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; WEFERS H, 1983, ARCH BIOCHEM BIOPHYS, V224, P568, DOI 10.1016/0003-9861(83)90244-8; WEIR EK, 1994, J APPL PHYSIOL, V76, P2611, DOI 10.1152/jappl.1994.76.6.2611; WYATT CN, 1994, NEUROSCI LETT, V172, P63, DOI 10.1016/0304-3940(94)90663-7	39	156	161	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47726	47731		10.1074/jbc.M406314200	http://dx.doi.org/10.1074/jbc.M406314200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358777	hybrid			2022-12-25	WOS:000224957000039
J	Tsukamoto, H; Irie, A; Nishimura, Y				Tsukamoto, H; Irie, A; Nishimura, Y			B-Raf contributes to sustained extracellular signal-regulated kinase activation associated with interleukin-2 production stimulated through the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE THYMOCYTE SELECTION; IL-2 GENE-TRANSCRIPTION; PROTEIN-KINASE; MAP-KINASE; CD69 EXPRESSION; NUCLEAR FACTOR; PC12 CELLS; NF-AT; PATHWAY; ERK	A T cell receptor (TCR) recognizes and responds to an antigenic peptide in the context of major histocompatibility complex-encoded molecules. This provokes T cells to produce interleukin-2 (IL-2) through extracellular signal-regulated kinase (ERK) activation. We investigated the roles of B-Raf in TCR-mediated IL-2 production coupled with ERK activation in the Jurkat human T cell line. We found that TCR cross-linking could induce up-regulation of both B-Raf and Raf-1 activities, but Raf-1 activity was decreased rapidly. On the other hand, TCR-stimulated kinase activity of B-Raf was sustained. Expression of a dominant-negative mutant of B-Raf abrogated sustained but not transient TCR-mediated MEK/ERK activation. The inhibition of sustained ERK activation by either expression of a dominant-negative B-Raf or treatment with a MEK inhibitor resulted in a decrease of the TCR-stimulated nuclear factor of activated T cells (NFAT) activity and IL-2 production. Collectively, our data provide the first direct evidence that B-Raf is a positive regulator of TCR-mediated sustained ERK activation, which is required for NFAT activation and the full production of IL-2.	Kumamoto Univ, Dept Immunogenet, Grad Sch Med Sci, Kumamoto 8608556, Japan	Kumamoto University	Nishimura, Y (corresponding author), Kumamoto Univ, Dept Immunogenet, Grad Sch Med Sci, Honjo 1-1-1, Kumamoto 8608556, Japan.	mxnishim@gpo.kumamoto-u.ac.jp	Tsukamoto, Hirotake/S-2448-2019; Tsukamoto, Hirotake/GRJ-7436-2022	Tsukamoto, Hirotake/0000-0003-3214-1652				BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bommhardt U, 2000, J IMMUNOL, V164, P2326, DOI 10.4049/jimmunol.164.5.2326; Borovsky Z, 2002, J BIOL CHEM, V277, P21529, DOI 10.1074/jbc.M201613200; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Chen YZ, 1996, J IMMUNOL, V157, P3783; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; EYCHENE A, 1995, ONCOGENE, V10, P1159; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Huang Y, 2003, J CELL PHYSIOL, V194, P162, DOI 10.1002/jcp.10199; Irie A, 2003, EUR J IMMUNOL, V33, P1497, DOI 10.1002/eji.200323618; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; Li YQ, 1999, IMMUNOLOGY, V96, P524; MAGNUSON NS, 1994, SEMIN CANCER BIOL, V5, P247; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mariathasan S, 2001, J IMMUNOL, V167, P4966, DOI 10.4049/jimmunol.167.9.4966; Mariathasan S, 2000, EUR J IMMUNOL, V30, P1060, DOI 10.1002/(SICI)1521-4141(200004)30:4<1060::AID-IMMU1060>3.0.CO;2-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Ohtsuka M, 2004, P NATL ACAD SCI USA, V101, P8126, DOI 10.1073/pnas.0401119101; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PARK JH, 1993, BLOOD, V82, P2470; Pathan NI, 1996, J BIOL CHEM, V271, P30315, DOI 10.1074/jbc.271.48.30315; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Reynolds LF, 2004, J BIOL CHEM, V279, P18239, DOI 10.1074/jbc.M400257200; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; TaylorFishwick DA, 1995, EUR J IMMUNOL, V25, P3215, DOI 10.1002/eji.1830251203; Uemura Y, 2003, J IMMUNOL, V170, P947, DOI 10.4049/jimmunol.170.2.947; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; WOTTON D, 1993, J BIOL CHEM, V268, P17975; Xiang XQ, 2002, J BIOL CHEM, V277, P44996, DOI 10.1074/jbc.M203953200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	53	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48457	48465		10.1074/jbc.M403087200	http://dx.doi.org/10.1074/jbc.M403087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339934	hybrid			2022-12-25	WOS:000224957000123
J	Yue, LL; Rasouli, N; Ranganathan, G; Kern, PA; Mazzone, T				Yue, LL; Rasouli, N; Ranganathan, G; Kern, PA; Mazzone, T			Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENE; HUMAN ADIPOSE-TISSUE; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; PLASMA-MEMBRANE; MACROPHAGES; OBESITY; DIFFERENTIATION; ATHEROSCLEROSIS; IDENTIFICATION	ApoE is expressed in multiple mammalian cell types in which it supports cellular differentiated function. In this report we demonstrate that apoE expression in adipocytes is regulated by factors involved in modulating systemic insulin sensitivity. Systemic treatment with pioglitazone increased systemic insulin sensitivity and increased apoE mRNA levels in adipose tissue by 2-3fold. Treatment of cultured 3T3-L1 adipocytes with ciglitazone increased apoE mRNA levels by 2-4-fold in a dose-dependent manner and increased apoE secretion from cells. Conversely, treatment of adipocytes with tumor necrosis factor (TNF) alpha reduced apoE mRNA levels and apoE secretion by 60%. Neither insulin nor a peroxisome proliferator-activated receptor (PPAR) alpha agonist regulated adipocyte apoE gene expression. In addition, treatment of human monocyte-derived macrophages with ciglitazone did not regulate expression of apoE. Additional analyses using reporter genes indicated that the effect of TNFalpha and PPARgamma agonists on the apoE gene was mediated via distinct gene control elements. The TNFalpha effect was mediated by elements within the proximal promoter, whereas the PPARgamma effect was mediated by elements within a downstream enhancer. However, the addition of TNFalpha substantially reduced the absolute levels of apoE reporter gene response even in the presence of ciglitazone. These results indicate for the first time that adipose tissue expression of apoE is modulated by physiologic regulators of insulin sensitivity.	Univ Illinois, Dept Med, Chicago, IL 60612 USA; Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences	Mazzone, T (corresponding author), Univ Illinois, Dept Med, 1819 W Polk St,M-C 797, Chicago, IL 60612 USA.	tmazzone@uic.edu		Rasouli, Neda/0000-0003-1269-3580	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR014288] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK039176, R01DK039176, R29DK039176] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR14288] Funding Source: Medline; NHLBI NIH HHS [HL 39653] Funding Source: Medline; NIDDK NIH HHS [DK 39176] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; BERG DT, 1995, J BIOL CHEM, V270, P15447, DOI 10.1074/jbc.270.26.15447; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BERGMAN RN, 1987, J CLIN INVEST, V79, P790, DOI 10.1172/JCI112886; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Chen GP, 2001, J BIOL CHEM, V276, P49142, DOI 10.1074/jbc.M104879200; Chiba T, 2003, ARTERIOSCL THROM VAS, V23, P1423, DOI 10.1161/01.ATV.0000085040.58340.36; Curtiss LK, 2000, CURR OPIN LIPIDOL, V11, P243, DOI 10.1097/00041433-200006000-00004; Dalen KT, 2003, J BIOL CHEM, V278, P48283, DOI 10.1074/jbc.M302287200; Do Carmo S, 2002, J BIOL CHEM, V277, P5514, DOI 10.1074/jbc.M105057200; DRISCOLL DM, 1984, J LIPID RES, V25, P1368; DUAN HW, 1995, J CLIN INVEST, V96, P915, DOI 10.1172/JCI118139; DYER CA, 1988, J BIOL CHEM, V263, P10965; Galetto R, 2001, BIOCHEM J, V357, P521, DOI 10.1042/0264-6021:3570521; Green A, 2004, DIABETES, V53, P74, DOI 10.2337/diabetes.53.1.74; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Harris FM, 2004, J BIOL CHEM, V279, P3862, DOI 10.1074/jbc.M309475200; Hasty AH, 1999, J LIPID RES, V40, P1529; Huang ZH, 2003, BIOCHEMISTRY-US, V42, P3949, DOI 10.1021/bi0269207; Huang ZH, 2002, J LIPID RES, V43, P375; Juvet LK, 2003, MOL ENDOCRINOL, V17, P172, DOI 10.1210/me.2001-0210; Kern PA, 2003, DIABETES, V52, P1779, DOI 10.2337/diabetes.52.7.1779; Laffitte BA, 2001, MOL CELL BIOL, V21, P7558, DOI 10.1128/MCB.21.22.7558-7568.2001; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lay S. L., 2002, J BIOL CHEM, V277, P35625, DOI DOI 10.1074/JBC.M203913200; Le Lay S, 2001, J BIOL CHEM, V276, P16904, DOI 10.1074/jbc.M010955200; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Mayeux R, 1998, NEW ENGL J MED, V338, P506, DOI 10.1056/NEJM199802193380804; MAZZONE T, 1987, J BIOL CHEM, V262, P11657; Mazzone T, 1996, CURR OPIN LIPIDOL, V7, P303, DOI 10.1097/00041433-199610000-00008; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; PAIK YK, 1985, P NATL ACAD SCI USA, V82, P3445, DOI 10.1073/pnas.82.10.3445; Ricote M, 2004, ARTERIOSCL THROM VAS, V24, P230, DOI 10.1161/01.ATV.0000103951.67680.B1; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Ruan H, 2002, DIABETES, V51, P3176, DOI 10.2337/diabetes.51.11.3176; Salero E, 2001, J BIOL CHEM, V276, P1881, DOI 10.1074/jbc.M007008200; Shigematsu S, 2003, J BIOL CHEM, V278, P10683, DOI 10.1074/jbc.M208563200; Shih SJ, 2000, J BIOL CHEM, V275, P31567, DOI 10.1074/jbc.M005468200; SMITH JD, 1988, J BIOL CHEM, V263, P8300; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Tangirala RK, 2001, J BIOL CHEM, V276, P261, DOI 10.1074/jbc.M003324200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; van Wijk JPH, 2004, ARTERIOSCL THROM VAS, V24, P798, DOI 10.1161/01.ATV.0000127311.38703.1f; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI20514; ZECHNER R, 1991, J BIOL CHEM, V266, P10583; Zhao YW, 2000, J BIOL CHEM, V275, P4759, DOI 10.1074/jbc.275.7.4759; Zhao YW, 2002, J BIOL CHEM, V277, P29477, DOI 10.1074/jbc.M200219200; ZUU Y, 1998, P NATL ACAD SCI USA, V93, P7585	53	55	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47626	47632		10.1074/jbc.M408461200	http://dx.doi.org/10.1074/jbc.M408461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339912	hybrid			2022-12-25	WOS:000224957000027
J	Rui, LY; Cao, L; Chen, W; Reardon, KF; Wood, TK				Rui, LY; Cao, L; Chen, W; Reardon, KF; Wood, TK			Active site engineering of the epoxide hydrolase from Agrobacterium radiobacter AD1 to enhance aerobic mineralization of cis-1,2-dichloroethylene in cells expressing an evolved toluene ortho-monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; BURKHOLDERIA-CEPACIA G4; CHLORINATED ETHENES; CATALYTIC MECHANISM; TRICHLOROETHYLENE OXIDATION; HALOALKANE DEHALOGENASE; 1-NAPHTHOL SYNTHESIS; CORYNEBACTERIUM SP; O-MONOOXYGENASE; ENCODING GENE	Chlorinated ethenes are the most prevalent groundwater pollutants, and the toxic epoxides generated during their aerobic biodegradation limit the extent of transformation. Hydrolysis of the toxic epoxide by epoxide hydrolases represents the major biological detoxification strategy; however, chlorinated epoxyethanes are not accepted by known bacterial epoxide hydrolases. Here, the epoxide hydrolase from Agrobacterium radiobacter AD1 (EchA), which enables growth on epichlorohydrin, was tuned to accept cis-1,2-dichloroepoxyethane as a substrate by accumulating beneficial mutations from three rounds of saturation mutagenesis at three selected active site residues, Phe-108, Ile-219, and Cys-248 (no beneficial mutations were found at position Ile-111). The EchA F108L/I219L/C248I variant coexpressed with a DNA-shuffled toluene ortho-monooxygenase, which initiates attack on the chlorinated ethene, enhanced the degradation of cis-dichloroethylene (cis-DCE) an infinite extent compared with wildtype EchA at low concentrations (6.8 muM) and up to 10-fold at high concentrations (540 muM). EchA variants with single mutations (F108L, I219F, or C248I) enhanced cis-DCE mineralization 2.5-fold (540 muM), and EchA variants with double mutations, I219L/C248I and F108L/C248I, increased cis-DCE mineralization 4- and 7-fold, respectively (540 muM). For complete degradation of cis-DCE to chloride ions, the apparent V-max/K-m for the recombinant Escherichia coli strain expressing the EchA F108L/I219L/C248I variant was increased over 5-fold as a result of the evolution of EchA. The EchA F108L/I219L/C248I variant also had enhanced activity for 1,2-epoxyhexane (2-fold) and the natural substrate epichlorohydrin (6-fold).	Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA; Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA; Univ Calif Riverside, Dept Environm Chem & Engn, Riverside, CA 92521 USA; Colorado State Univ, Dept Chem Engn, Ft Collins, CO 80523 USA	University of Connecticut; University of Connecticut; University of California System; University of California Riverside; Colorado State University	Wood, TK (corresponding author), Univ Connecticut, Dept Chem Engn, Storrs, CT 06269 USA.	twood@engr.uconn.edu	Wood, Thomas/GWZ-2481-2022; Reardon, Kenneth/A-1952-2016; Chen, Wilfred/H-4335-2013; Reardon, Kenneth/X-8472-2019	Wood, Thomas/0000-0001-8962-8571; Reardon, Kenneth/0000-0002-7753-4049; Reardon, Kenneth/0000-0002-7753-4049; Wood, Thomas/0000-0002-6258-529X				Archelas A, 1998, TRENDS BIOTECHNOL, V16, P108, DOI 10.1016/S0167-7799(97)01161-X; Argiriadi MA, 1999, P NATL ACAD SCI USA, V96, P10637, DOI 10.1073/pnas.96.19.10637; Baskaran N, 1996, GENOME RES, V6, P633, DOI 10.1101/gr.6.7.633; BOLT HM, 1982, BIOCHEM PHARMACOL, V31, P1, DOI 10.1016/0006-2952(82)90227-1; Bradley PM, 1998, ENVIRON SCI TECHNOL, V32, P553, DOI 10.1021/es970498d; Brannigan JA, 2002, NAT REV MOL CELL BIO, V3, P964, DOI 10.1038/nrm975; Canada KA, 2002, J BACTERIOL, V184, P344, DOI 10.1128/JB.184.2.344-349.2002; CARTER SR, 1993, WATER RES, V27, P607, DOI 10.1016/0043-1354(93)90170-M; Dolfing Jan, 1993, Biodegradation, V4, P261, DOI 10.1007/BF00695974; Faber K, 1996, ACTA CHEM SCAND, V50, P249, DOI 10.3891/acta.chem.scand.50-0249; FRANKEN SM, 1991, EMBO J, V10, P1297, DOI 10.1002/j.1460-2075.1991.tb07647.x; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; Gibson T. J., 1984, THESIS CAMBRIDGE U C; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENSCHLER D, 1994, ANGEW CHEM INT EDIT, V33, P1920, DOI 10.1002/anie.199419201; HERNANDEZ O, 1982, METABOLIC BASIS DETO, P207; JACOBS MHJ, 1991, EUR J BIOCHEM, V202, P1217, DOI 10.1111/j.1432-1033.1991.tb16493.x; Luu PP, 1995, APPL MICROBIOL BIOT, V44, P259, DOI 10.1007/BF00164512; Magnuson JK, 1998, APPL ENVIRON MICROB, V64, P1270; McCarty PL, 1997, SCIENCE, V276, P1521, DOI 10.1126/science.276.5318.1521; Misawa E, 1998, EUR J BIOCHEM, V253, P173, DOI 10.1046/j.1432-1327.1998.2530173.x; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; NAKAMURA T, 1994, APPL ENVIRON MICROB, V60, P4630, DOI 10.1128/AEM.60.12.4630-4633.1994; Nardini M, 1999, J BIOL CHEM, V274, P14579, DOI 10.1074/jbc.274.21.14579; Nardini M, 2001, J MOL CATAL B-ENZYM, V11, P1035, DOI 10.1016/S1381-1177(00)00049-7; NELSON MJK, 1986, APPL ENVIRON MICROB, V52, P383, DOI 10.1128/AEM.52.2.383-384.1986; Newman LM, 1997, J BACTERIOL, V179, P90, DOI 10.1128/jb.179.1.90-96.1997; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Perry R. H, 1973, CHEM ENG HDB; Rink R, 1997, J BIOL CHEM, V272, P14650, DOI 10.1074/jbc.272.23.14650; Rink R, 2000, BIOCHEMISTRY-US, V39, P5600, DOI 10.1021/bi9922392; Rui LY, 2004, APPL ENVIRON MICROB, V70, P3246, DOI 10.1128/AEM.70.6.3246-3252.2004; Rui LY, 2004, ENVIRON MICROBIOL, V6, P491, DOI 10.1111/j.1462-2920.2004.00586.x; Sakamoto T, 2001, APPL ENVIRON MICROB, V67, P3882, DOI 10.1128/AEM.67.9.3882-3887.2001; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; SHIELDS MS, 1994, BIOREMEDIATION OF CHLORINATED AND POLYCYCLIC AROMATIC HYDROCARBON COMPOUNDS, P50; SHIELDS MS, 1989, APPL ENVIRON MICROB, V55, P1624, DOI 10.1128/AEM.55.6.1624-1629.1989; SHIELDS MS, 1996, Patent No. 5543317; Shim HJ, 2000, BIOTECHNOL BIOENG, V70, P693, DOI 10.1002/1097-0290(20001220)70:6<693::AID-BIT12>3.0.CO;2-W; Spelberg JHL, 1998, TETRAHEDRON-ASYMMETR, V9, P459, DOI 10.1016/S0957-4166(98)00003-2; Steinreiber A, 2001, CURR OPIN BIOTECH, V12, P552, DOI 10.1016/S0958-1669(01)00262-2; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0; Visser H, 2000, APPL MICROBIOL BIOT, V53, P415, DOI 10.1007/s002530051635; Visser H, 1999, APPL ENVIRON MICROB, V65, P5459; Vlieg JETV, 1997, APPL ENVIRON MICROB, V63, P4961, DOI 10.1128/AEM.63.12.4961-4964.1997; Vlieg JETV, 1996, APPL ENVIRON MICROB, V62, P3304, DOI 10.1128/AEM.62.9.3304-3312.1996; Vlieg JETV, 2001, J BIOTECHNOL, V85, P81, DOI 10.1016/S0168-1656(00)00364-3; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; Weijers CAGM, 1999, J MOL CATAL B-ENZYM, V6, P199, DOI 10.1016/S1381-1177(98)00123-4; Yeager CM, 2001, APPL ENVIRON MICROB, V67, P2107, DOI 10.1128/AEM.67.5.2107-2115.2001; Zou JY, 2000, STRUCTURE, V8, P111, DOI 10.1016/S0969-2126(00)00087-3	54	44	51	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46810	46817		10.1074/jbc.M407466200	http://dx.doi.org/10.1074/jbc.M407466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347647	hybrid			2022-12-25	WOS:000224832400061
J	Sarmiento, JM; Anazco, CC; Campos, DM; Prado, GN; Navarro, J; Gonzalez, CB				Sarmiento, JM; Anazco, CC; Campos, DM; Prado, GN; Navarro, J; Gonzalez, CB			Novel down-regulatory mechanism of the surface expression of the vasopressin V-2 receptor by an alternative splice receptor variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NEURODEGENERATIVE DISEASE; PROTEIN; RESCUE; CELL; OLIGOMERIZATION; CHAPERONES; OXYTOCIN; PATHWAYS; KIDNEY	In rat kidney, two alternatively spliced transcripts are generated from the V-2 vasopressin receptor gene. The large transcript (1.2 kb) encodes the canonical V-2 receptor, whereas the small transcript encodes a splice variant displaying a distinct sequence corresponding to the putative seventh transmembrane domain and the intracellular C terminus of the V-2 receptor. This work showed that the small spliced transcript is translated in the rat kidney collecting tubules. However, the protein encoded by the small transcript (here called the V-2b splice variant) is retained inside the cell, in contrast to the preferential surface distribution of the V-2 receptor (here called the V-2a receptor). Cells expressing the V-2b splice variant do not exhibit binding to H-3-labeled vasopressin. Interestingly, we found that expression of the splice variant V-2b down-regulates the surface expression of the V(2)a receptor, most likely via the formation of V-2a.V-2b heterodimers as demonstrated by co-immunoprecipitation and fluorescence resonance energy transfer experiments between the V-2a receptor and the V-2b splice variant. The V-2b splice variant would then be acting as a dominant negative. The effect of the V-2b splice variant is specific, as it does not affect the surface expression of the G protein-coupled interleukin-8 receptor (CXCR1). Furthermore, the sequence encompassing residues 242-339, corresponding to the C-terminal domain of the V-2b splice variant, also down-regulates the surface expression of the V-2a receptor. We suggest that some forms of nephrogenic diabetes insipidus are due to overexpression of the splice variant V-2b, which could retain the wild-type V-2a receptor inside the cell via the formation of V-2a.V-2b heterodimers.	Univ Austral Chile, Dept Physiol, Valdivia 2 5119300, Chile; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	Universidad Austral de Chile; University of Texas System; University of Texas Medical Branch Galveston	Gonzalez, CB (corresponding author), Univ Austral Chile, Dept Physiol, Valdivia 2 5119300, Chile.	cbgonzal@uach.cl		Navarro, Javier/0000-0001-7098-4373; Anazco, Carolina/0000-0003-1311-9492	NATIONAL EYE INSTITUTE [R01EY014218] Funding Source: NIH RePORTER; NEI NIH HHS [EY014218] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; BIRBAUMER M, 1999, ARCH MED RES, V30, P465; Birnbaumer M, 2000, TRENDS ENDOCRIN MET, V11, P406, DOI 10.1016/S1043-2760(00)00304-0; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Bouley R, 2003, AM J PHYSIOL-CELL PH, V285, pC750, DOI 10.1152/ajpcell.00477.2002; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Buxbaum JN, 2003, TRENDS BIOCHEM SCI, V28, P585, DOI 10.1016/j.tibs.2003.09.009; Chelli M, 2001, J BIOL CHEM, V276, P46975, DOI 10.1074/jbc.M106432200; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; FIRSOV D, 1994, PFLUG ARCH EUR J PHY, V429, P79, DOI 10.1007/BF02584033; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Gonzalez CB, 1999, BIOL RES, V32, P63; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; PIND S, 1994, J BIOL CHEM, V269, P12784; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schulz A, 2000, J BIOL CHEM, V275, P2381, DOI 10.1074/jbc.275.4.2381; Seck T, 2003, J BIOL CHEM, V278, P23085, DOI 10.1074/jbc.M211280200; SEIBOLD A, 1992, AM J HUM GENET, V51, P1078; SzczepanskaSadowska E, 1996, REGUL PEPTIDES, V66, P65, DOI 10.1016/0167-0115(96)00053-5; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Zhang XM, 2003, J BIOL CHEM, V278, P51232, DOI 10.1074/jbc.M309076200; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	29	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47017	47023		10.1074/jbc.M410011200	http://dx.doi.org/10.1074/jbc.M410011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15355989	hybrid			2022-12-25	WOS:000224832400086
J	Wang, F; Zhang, RX; Beischlag, TV; Muchardt, C; Yaniv, M; Hankinson, O				Wang, F; Zhang, RX; Beischlag, TV; Muchardt, C; Yaniv, M; Hankinson, O			Roles of Brahma and Brahma/SWI2-related gene 1 in hypoxic induction of the erythropoietin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; REMODELING COMPLEX; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; ENHANCER ELEMENT; BINDING-PROTEIN; HIF-ALPHA; EXPRESSION; RECEPTOR	Upon hypoxia, the human erythropoietin (EPO) gene is transactivated by the heterodimeric hypoxia-inducible factor 1 (HIF-1). Mammalian SWI/SNF is a chromatin-remodeling complex involved in the modulation of gene expression. We demonstrate that Brahma (Brm) and Brahma/SWI2-related gene 1 (Brg-1), alternative ATPase subunits of SWI/SNF, potentiate reporter gene activation mediated by HIF-1 in an ATPase-dependent manner. Brm was more potent than Brg-1 in the reporter gene assays. Simultaneous depletion of both Brm and Brg-1 by small interfering RNAs significantly compromised the transcription of the endogenous EPO gene triggered by hypoxia. Whereas knocking down Brm alone resulted in a moderate reduction in transcription of the EPO gene, depletion of Brg-1 resulted in an augmentation of transcription of both the EPO gene and the Brm gene, indicating that Brm can compensate for loss of Brg-1. Chromatin immunoprecipitation (ChIP) and sequential ChIP (re-ChIP) analysis showed that both Brm and Brg-1 associate with the enhancer region of the EPO gene in vivo in a hypoxia-dependent fashion and that each is present in a complex with HIF-1. Brm and Brg-1 were also recruited to the promoter of the vascular endothelial growth factor (VEGF) gene in a hypoxia-dependent fashion, although hypoxic induction of VEGF transcription was not affected by depletions of either or both Brm and Brg-1. Together these studies reveal a novel role for SWI/SNF in the activation of transcription of the EPO gene, indicate an important communication and compensation between Brm and Brg-1, and suggest that the requirement for SWI/SNF during hypoxic induction is gene-specific.	Univ Calif Los Angeles, Inst Mol Biol, Jonsson Comprehens Canc Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Penn State Univ, Dept Vet Sci, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA; Inst Pasteur, Dept Dev Biol, CNRS, URA 1644,Unite Express Genet & Malad, F-75724 Paris, France	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hankinson, O (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Pathol & Lab Med, Ctr Hlth Sci, Box 951732, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA28868, R01 CA028868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; BECK I, 1991, J BIOL CHEM, V266, P15563; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Goldmark JP, 2000, CELL, V103, P423, DOI 10.1016/S0092-8674(00)00134-3; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; MAHER PA, 1993, J BIOL CHEM, V268, P4244; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Sanchez-Elsner T, 2004, J MOL BIOL, V336, P9, DOI 10.1016/j.jmb.2003.12.023; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P8725, DOI 10.1073/pnas.88.19.8725; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang S, 2002, J BIOL CHEM, V277, P11821, DOI 10.1074/jbc.M110122200	40	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46733	46741		10.1074/jbc.M409002200	http://dx.doi.org/10.1074/jbc.M409002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347669	hybrid			2022-12-25	WOS:000224832400051
J	Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH				Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH			Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis	ONCOGENE			English	Article						PDCD4; apoptosis; retinoic acid receptor; breast cancer; cell cycle	RETINOIC ACID RECEPTORS; MAMMARY EPITHELIAL-CELLS; TRANSFORMATION SUPPRESSOR; GROWTH-INHIBITION; CYCLIN D1; PROTEIN; ARREST; ALPHA; CARCINOMA; DEATH	The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better de. ne the genes involved in RAR-mediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RARalpha-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2/neu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER+, RAR(+)) and MDA-MB-231 (ER-, RAR(-)) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2/neu antagonist in breast cancer cells and its potential role in apoptosis in these cells.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Saga Med Sch, Dept Internal Med, Saga 8498501, Japan	New York University; New York University; Saga University	Afonja, O (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave, New York, NY 10016 USA.	afonjo01@popmail.med.nyu.edu			NCI NIH HHS [K12CA01713] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMOS B, 1990, METHOD ENZYMOL, V190, P217; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grunt TW, 2003, CANCER LETT, V189, P147, DOI 10.1016/S0304-3835(02)00512-8; Gumireddy K, 2003, CLIN CANCER RES, V9, P4052; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; Jansen Aaron P., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P938; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MATSUHASHI S, 1987, EXP CELL RES, V170, P351, DOI 10.1016/0014-4827(87)90312-0; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Offterdinger M, 2003, J CELL PHYSIOL, V195, P260, DOI 10.1002/jcp.10237; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Orlandi M, 2003, MED PRIN PRACT, V12, P164, DOI 10.1159/000070753; Pratt MAC, 2003, J CELL BIOCHEM, V90, P692, DOI 10.1002/jcb.10682; Raffo P, 2000, ANTICANCER RES, V20, P1535; ROMAN SD, 1993, CANCER RES, V53, P5940; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Suzuki T, 2001, BREAST CANCER RES TR, V65, P31, DOI 10.1023/A:1006433929792; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Veselska R, 2003, ONCOL REP, V10, P1049; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Wilcken NRC, 1997, INT J CANCER, V70, P291, DOI 10.1002/(SICI)1097-0215(19970127)70:3<291::AID-IJC8>3.3.CO;2-B; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Ye XF, 2004, INT J BIOCHEM CELL B, V36, P98, DOI 10.1016/S1357-2725(03)00143-2; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	58	135	145	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8135	8145		10.1038/sj.onc.1207983	http://dx.doi.org/10.1038/sj.onc.1207983			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361828				2022-12-25	WOS:000224692500011
J	Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O				Damiola, F; Keime, C; Gonin-Giraud, S; Dazy, B; Gandrillon, O			Global transcription analysis of immature avian erythrocytic progenitors: from self-renewal to differentiation	ONCOGENE			English	Article						self-renewal; differentiation; SAGE; erythroid progenitors	STEM-CELLS; GENE-EXPRESSION; SERIAL ANALYSIS; GLUCOCORTICOID-RECEPTOR; CANCER; ADULT; SAGE; PHOSPHORYLATION; CANDIDATE; INDUCE	The molecular mechanisms regulating the cell fate decision between self-renewal and differentiation/apoptosis in stem and progenitor cells are poorly understood. Here, we report the first comprehensive identification of genes potentially involved in the switch from self-renewal toward differentiation of primary, non-immortalized erythroid avian progenitor cells (T2EC cells). We used the Serial Analysis of Gene Expression ( SAGE) technique in order to identify and quantify the genome fraction functionally active in a self-renewing versus a differentiating cell population. We generated two SAGE libraries and sequenced a total of 37 589 tags, thereby obtaining the first transcriptional pro. le characterization of a chicken cell. Tag identification was performed using a new relational database (Identitag) developed in the laboratory, which allowed a highly satisfactory level of identification. Among 123 differentially expressed genes, 11 were investigated further and for nine of them the differential expression was subsequently confirmed by real-time PCR. The comparison of tag abundance between the two libraries revealed that only a small fraction of transcripts was differentially expressed. The analysis of their functions argue against a prominent role for a master switch in T2EC cells decision-making, but are in favor of a critical role for coordinated small variations in a relatively small number of genes that can lead to essential cellular identity changes.	Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Damiola, F (corresponding author), Univ Lyon 1, CNRS,UMR 5534, Ctr Genet Mol & Cellulaire, Equipe Signalisat & Ident Cellulaires, Bat Gregore Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Damiola@cgmc.univ-lyon1.fr; Keime@cgmc.univ-lyon1.fr; Gonin@cgmc.univ-lyon1.fr; Dazy@cgmc.univ-lyon1.fr; Gandrillon@cgmc.univ-lyon1.fr		Damiola, Francesca/0000-0002-0238-1252; KEIME, Celine/0000-0001-7604-3814				ABE I, 1995, P NATL ACAD SCI USA, V92, P9274, DOI 10.1073/pnas.92.20.9274; Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; Antica M, 1997, IMMUNOL LETT, V55, P47, DOI 10.1016/S0165-2478(96)02682-X; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Becquet C, 2002, GENOME BIOL, V3; Boheler KR, 2003, TRENDS BIOTECHNOL, V21, P55, DOI 10.1016/S0167-7799(02)00031-8; Cao A, 2002, PEDIATR RES, V51, P415, DOI 10.1203/00006450-200204000-00003; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Dazy S, 2003, ONCOGENE, V22, P9205, DOI 10.1038/sj.onc.1207049; Detmer K, 2000, BLOOD CELL MOL DIS, V26, P360, DOI 10.1006/bcmd.2000.0318; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; Fortunel NO, 2003, SCIENCE, V302, P393; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; Heller S, 1998, P NATL ACAD SCI USA, V95, P11400, DOI 10.1073/pnas.95.19.11400; HINSSEN H, 1987, J CELL BIOL, V105, P1425, DOI 10.1083/jcb.105.3.1425; Ito CY, 2003, BLOOD, V101, P517, DOI 10.1182/blood-2002-06-1918; Ivanova NB, 2003, SCIENCE, V302; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; KEIME C, 2004, UNPUB; Keith WN, 2004, ONCOGENE, V23, P5092, DOI 10.1038/sj.onc.1207762; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Man MZ, 2000, BIOINFORMATICS, V16, P953, DOI 10.1093/bioinformatics/16.11.953; Margulies EH, 2000, BIOINFORMATICS, V16, P650, DOI 10.1093/bioinformatics/16.7.650; Marone M, 2002, LEUKEMIA, V16, P94, DOI 10.1038/sj.leu.2402334; Matsumura F, 2001, CELL STRUCT FUNCT, V26, P639, DOI 10.1247/csf.26.639; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piquemal D, 2002, GENOMICS, V80, P361, DOI 10.1006/geno.2002.6836; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roessler E, 1999, HUM GENET, V105, P489, DOI 10.1007/s004390051135; Terskikh AV, 2003, BLOOD, V102, P94, DOI 10.1182/blood-2002-08-2509; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vinogradov AE, 1998, CYTOMETRY, V31, P100, DOI 10.1002/(SICI)1097-0320(19980201)31:2<100::AID-CYTO5>3.0.CO;2-Q; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhou GL, 2001, P NATL ACAD SCI USA, V98, P13966, DOI 10.1073/pnas.241526198	44	13	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7628	7643		10.1038/sj.onc.1208061	http://dx.doi.org/10.1038/sj.onc.1208061			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15378009				2022-12-25	WOS:000224306700004
J	Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M				Yao, RS; Wang, Y; Lemon, WJ; Lubet, RA; You, M			Budesonide exerts its chemopreventive efficacy during mouse lung tumorigenesis by modulating gene expressions	ONCOGENE			English	Article						budesonide; lung cancer; chemoprevention; A/J mice; expression profile	FEMALE A/J MICE; PULMONARY CARCINOGENESIS; APOPTOSIS; MYOINOSITOL; PROGRESSION; CARCINOMAS; RESISTANCE; MECHANISMS; HORMONES; PATHWAYS	Budesonide, a glucocorticoid, was proven to be a highly effective agent in preventing the development of lung tumors in A/J mice. In a lung tumor bioassay, budesonide produced 70% inhibition of tumor multiplicity and 94% reduction of total tumor load compared to benzopyrene ( B[ a] P) treated mice. Gene expression array analysis was performed on mouse lung tumors from this bioassay using Affymetrix U74Av2 GeneChips to determine gene expression changes associated with budesonide treatment. We found 363 genes that were changed between lung tumors induced by treatment with B[ a] P and similar tumors treated with budesonide. Among them, 243 genes were overexpressed and 120 genes were underexpressed after budesonide treatment. In addition, 108 genes differentially expressed during mouse lung tumorigenesis (50 genes overexpressed and 58 genes underexpressed) were modulated back to normal levels after budesonide treatment when compared with the controls group. These genes are involved in a broad range of different pathways including control of cell cycle, signal transduction, and apoptosis and may play a role in the observed preventive effect. Our results suggest that budesonide exerts its effects of chemoprevention through growth arrest via Mad2/3 and through apoptosis via Bim/Blk and, by inference, caspase-8/9. Using the pathway visualization tool GenMapp, G protein pathway and MAPK cascade were also regulated by budesonide. Thus, we have determined, for the first time, the expression profiles of genes modulated by budesonide during murine lung tumorigenesis. Our results indicate that the chemopreventive effects of budesonide in the mouse lung tumorigenesis assay involved increase and decrease expression of a wide variety of genes in multiple signaling pathways.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NCI, Chemoprevent Branch, Bethesda, MD 20892 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, Campus Box 8109,660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu						*AM CANC SOC, 2003, CANC FACTS FIG 2003, P4; BELMAN S, 1972, CANCER RES, V32, P450; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939, DOI 10.1164/ajrccm.164.10.2103013; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Herr I, 2003, CANCER RES, V63, P3112; Herzog CR, 1997, J CELL BIOCHEM, P49; HUANG J, 2003, J BIOL CHEM, V16, P16; KITAZONO AA, 2003, MOL GENET GENOMICS, V24, P24; Li Xia, 2003, Journal of Shanghai Fisheries University, V12, P12; MALKINSON AM, 1992, CANCER RES, V52, pS2670; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Schmidt S, 2004, CELL DEATH DIFFER, V11, pS45, DOI 10.1038/sj.cdd.4401456; Wang Y, 2003, CANCER RES, V63, P4389; Wattenberg LW, 2000, CARCINOGENESIS, V21, P179, DOI 10.1093/carcin/21.2.179; Wattenberg LW, 1996, CANCER RES, V56, P5132; Wattenberg LW, 1997, CARCINOGENESIS, V18, P2015, DOI 10.1093/carcin/18.10.2015; Yao RS, 2003, NEOPLASIA, V5, P41, DOI 10.1016/S1476-5586(03)80016-7; Yao RS, 2002, ONCOGENE, V21, P5814, DOI 10.1038/sj.onc.1205422; Yin XY, 2001, ONCOGENE, V20, P2908, DOI 10.1038/sj.onc.1204417; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	25	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7746	7752		10.1038/sj.onc.1207985	http://dx.doi.org/10.1038/sj.onc.1207985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361829				2022-12-25	WOS:000224306700016
J	Balschun, D; Wetzel, W; del Rey, A; Pitossi, F; Schneider, H; Zuschratter, W; Besedovsky, HO				Balschun, D; Wetzel, W; del Rey, A; Pitossi, F; Schneider, H; Zuschratter, W; Besedovsky, HO			Interleukin-6: a cytokine to forget	FASEB JOURNAL			English	Article						IL-6; LTP; spatial learning; hippocampus; rat	LONG-TERM POTENTIATION; FREELY MOVING RATS; DENTATE GYRUS; TRANSGENIC MICE; WORKING-MEMORY; CEREBRAL OVEREXPRESSION; HIPPOCAMPAL-LESIONS; PROTEIN-SYNTHESIS; LATE-PHASE; IN-VITRO	It is known that proinflammatory cytokines such as interleukin-6 (IL-6) are expressed in the central nervous system (CNS) during disease conditions and affect several brain functions including memory and learning. In contrast to these effects observed during pathological conditions, here we describe a physiological function of IL-6 in the "healthy" brain in synaptic plasticity and memory consolidation. During long-term potentiation (LTP) in vitro and in freely moving rats, IL-6 gene expression in the hippocampus was substantially increased. This increase was long lasting, specific to potentiation, and was prevented by inhibition of N-methyl-D-spartate receptors with (+/-)-2-amino-5-phosphonopentanoic acid (AP-5). Blockade of endogenous IL-6 by application of a neutralizing anti-IL6 antibody 90 min after tetanus caused a remarkable prolongation of LTP. Consistently, blockade of endogenous IL-6, 90 min after hippocampus-dependent spatial alternation learning resulted in a significant improvement of long-term memory. In view of the suggested role of LTP in memory formation, these data implicate IL-6 in the mechanisms controlling the kinetics and amount of information storage.	Univ Marburg, Inst Physiol, Div Immunophysiol, D-35037 Marburg, Germany; Leibniz Inst Neurobiol, D-39008 Magdeburg, Germany; Fdn Campomar, Inst Biomed Res, RA-1405 Buenos Aires, DF, Argentina	Philipps University Marburg; Leibniz Institut fur Neurobiologie (LIN); Leloir Institute	Besedovsky, HO (corresponding author), Univ Marburg, Inst Physiol, Div Immunophysiol, Deutschhausstr 2, D-35037 Marburg, Germany.	besedovs@mailer.uni-marburg.de		Pitossi, Fernando/0000-0001-5104-9726				Abraham WC, 1996, BRAIN RES, V722, P217, DOI 10.1016/0006-8993(96)00130-8; AGGLETON JP, 1986, BEHAV BRAIN RES, V19, P133, DOI 10.1016/0166-4328(86)90011-2; AGRANOFF BERNARD W., 1966, BRAIN RES, V1, P303, DOI 10.1016/0006-8993(66)90095-3; AUBERT A, 1995, BRAIN BEHAV IMMUN, V9, P129, DOI 10.1006/brbi.1995.1013; Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; Balschun D, 1999, LEARN MEMORY, V6, P138; Barrientos RM, 2002, BEHAV BRAIN RES, V134, P291, DOI 10.1016/S0166-4328(02)00043-8; BELLINGER FP, 1995, NEUROSCI LETT, V198, P95, DOI 10.1016/0304-3940(95)11976-4; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; BESEDOVSKY HO, 1991, J STEROID BIOCHEM, V40, P613, DOI 10.1016/0960-0760(91)90284-C; Cahill L, 2000, PROG BRAIN RES, V126, P29; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; Coogan AN, 1999, NEUROSCIENCE, V93, P57, DOI 10.1016/S0306-4522(99)00100-1; D'Arcangelo G, 2000, EUR J NEUROSCI, V12, P1241, DOI 10.1046/j.1460-9568.2000.00011.x; Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GADIENT RA, 1994, BRAIN RES, V637, P10, DOI 10.1016/0006-8993(94)91211-4; Gibertini M, 1998, NEUROIMMUNOMODULAT, V5, P160, DOI 10.1159/000026332; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Jankowsky JL, 2000, LEARN MEMORY, V7, P400, DOI 10.1101/lm.32600; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; KRUG M, 1984, BRAIN RES BULL, V13, P39, DOI 10.1016/0361-9230(84)90005-4; Kulla A, 1999, EUR J NEUROSCI, V11, P3864, DOI 10.1046/j.1460-9568.1999.00807.x; Li AJ, 1997, BRAIN RES, V748, P30, DOI 10.1016/S0006-8993(96)01283-8; MAIER SF, 1995, BRAIN RES, V695, P279, DOI 10.1016/0006-8993(95)00930-O; Matsumoto Y, 2001, EUR J PHARMACOL, V430, P283, DOI 10.1016/S0014-2999(01)01374-7; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; MIZUMORI SJY, 1985, BEHAV NEUROSCI, V99, P220, DOI 10.1037/0735-7044.99.2.220; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; Pitossi F, 1997, J NEUROSCI RES, V48, P287, DOI 10.1002/(SICI)1097-4547(19970515)48:4<287::AID-JNR1>3.0.CO;2-7; Pugh CR, 1999, BEHAV BRAIN RES, V106, P109, DOI 10.1016/S0166-4328(99)00098-4; Reyes TM, 1998, AM J PHYSIOL-REG I, V274, pR139, DOI 10.1152/ajpregu.1998.274.1.R139; Scharf MT, 2002, J NEUROPHYSIOL, V87, P2770, DOI 10.1152/jn.2002.87.6.2770; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; Seidenbecher T, 1997, P NATL ACAD SCI USA, V94, P1494, DOI 10.1073/pnas.94.4.1494; Song C, 2002, BRAIN BEHAV IMMUN, V16, P557, DOI 10.1016/S0889-1591(02)00012-0; STANTON PK, 1984, J NEUROSCI, V4, P3080; STEVENS R, 1973, BRAIN RES, V52, P203, DOI 10.1016/0006-8993(73)90659-8; Vitkovic L, 2000, J NEUROCHEM, V74, P457, DOI 10.1046/j.1471-4159.2000.740457.x; Wang XiaoLan, 1999, Journal of Herbs, Spices & Medicinal Plants, V6, P1, DOI 10.1300/J044v06n03_01; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072	46	215	226	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1788	+		10.1096/fj.04-1625fje	http://dx.doi.org/10.1096/fj.04-1625fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345694	Green Published, Green Accepted			2022-12-25	WOS:000224243200047
J	Stuermer, CAO; Langhorst, MF; Wiechers, MF; Legler, DF; von Hanwehr, SH; Guse, AH; Plattner, H				Stuermer, CAO; Langhorst, MF; Wiechers, MF; Legler, DF; von Hanwehr, SH; Guse, AH; Plattner, H			PrPc capping in T cells promotes its association with the lipid raft proteins reggie-1 and reggie-2 and leads to signal transduction	FASEB JOURNAL			English	Article						noncaveolar microdomains; reggie/flotillin; PrPc cross-linking	CELLULAR PRION PROTEIN; ANCHORED PROTEINS; MEMBRANE; IDENTIFICATION; MICRODOMAINS; ACTIVATION; EXPRESSION; DOMAINS; RECRUITMENT; COMPONENTS	The cellular prion protein (PrPc) resides in lipid rafts, yet the type of raft and the physiological function of PrPc are unclear. We show here that cross-linking of PrPc with specific antibodies leads to 1) PrPc capping in Jurkat and human peripheral blood T cells; 2) to cocapping with the intracellular lipid raft proteins reggie-1 and reggie-2; 3) to signal transduction as seen by MAP kinase phosphorylation and an elevation of the intracellular Ca2+ concentration; 4) to the recruitment of Thy-1, TCR/CD3, fyn, lck and LAT into the cap along with local tyrosine phosphorylation and F-actin polymerization, and later, internalization of PrPc together with the reggies into limp-2 positive lysosomes. Thus, PrPc association with reggie rafts triggers distinct transmembrane signal transduction events in T cells that promote the focal concentration of PrPc itself by guiding activated PrPc into preformed reggie caps and then to the recruitment of important interacting signaling molecules.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany; Univ Hosp Hamburg Eppendorf, Inst Biochem & Mol Biol Cellular Signal Transduct, Ctr Med Expt, Hamburg, Germany	University of Konstanz; University of Hamburg; University Medical Center Hamburg-Eppendorf	Stuermer, CAO (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	Claudia.Stuermer@uni-konstanz.de		Legler, Daniel F./0000-0001-8610-4764				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Chiarini LB, 2002, EMBO J, V21, P3317, DOI 10.1093/emboj/cdf324; Deininger SO, 2003, MOL CELL NEUROSCI, V22, P544, DOI 10.1016/S1044-7431(03)00028-9; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Durig J, 2000, BRIT J HAEMATOL, V108, P488, DOI 10.1046/j.1365-2141.2000.01881.x; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Felberbaum-Corti M, 2003, NAT CELL BIOL, V5, P382, DOI 10.1038/ncb0503-382; Fivaz M, 2002, EMBO J, V21, P3989, DOI 10.1093/emboj/cdf398; Foger N, 2001, J CELL SCI, V114, P1169; FRA AM, 1994, J BIOL CHEM, V269, P30745; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li RL, 2001, CELL IMMUNOL, V207, P49, DOI 10.1006/cimm.2000.1751; Mabbott NA, 1997, IMMUNOLOGY, V92, P161, DOI 10.1046/j.1365-2567.1997.00331.x; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Morrow IC, 2002, J BIOL CHEM, V277, P48834, DOI 10.1074/jbc.M209082200; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; Neumann-Giesen C, 2004, BIOCHEM J, V378, P509, DOI 10.1042/BJ20031100; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; PETERS PJ, 2003, P NATL ACAD SCI USA, V162, P703; PRESKY DH, 1990, J IMMUNOL, V144, P860; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rajendran L, 2003, P NATL ACAD SCI USA, V100, P8241, DOI 10.1073/pnas.1331629100; Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100; SCHROEDER WT, 1994, J BIOL CHEM, V269, P19983; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Schulte T, 1997, DEVELOPMENT, V124, P577; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Solforosi L, 2004, SCIENCE, V303, P1514, DOI 10.1126/science.1094273; Spielhaupter C, 2001, J BIOL CHEM, V276, P44604, DOI 10.1074/jbc.M103289200; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Sunyach C, 2003, EMBO J, V22, P3591, DOI 10.1093/emboj/cdg344; THOMAS LJ, 1991, J BIOL CHEM, V266, P23175; VEGA MA, 1991, J BIOL CHEM, V266, P16818; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 1999, J BIOL CHEM, V274, P3, DOI 10.1074/jbc.274.1.3	63	120	130	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1731	+		10.1096/fj.04-2150fje	http://dx.doi.org/10.1096/fj.04-2150fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345693				2022-12-25	WOS:000224243200046
J	Yang, GD; Sun, XF; Wang, R				Yang, GD; Sun, XF; Wang, R			Hydrogen sulfide-induced apoptosis of human aorta smooth muscle cells via the activation of mitogen-activated protein kinases and caspase-3	FASEB JOURNAL			English	Article						blood vessel; ERK; gasotransmitter; p38; remodeling	N-TERMINAL KINASE; CARBON-MONOXIDE; NITRIC-OXIDE; CYTOCHROME-C; P38 KINASE; PATHWAY; ERK; SURVIVAL; STRESS; H2S	The endogenous production of hydrogen sulfide (H2S) and its physiological functions, including membrane hyperpolarization and smooth muscle cell relaxation, position this gas well in the family of gasotransmitters together with nitric oxide ( NO) and carbon monoxide (CO). In this study, we demonstrate that H2S at physiologically relevant concentrations induced apoptosis of human aorta smooth muscle cells (HASMCs). Exposure of HASMCs to H2S did not induce necrosis as verified with Trypan blue exclusion and LDH release analysis. After inhibiting endogenous H2S production, exogenous H2S induced much more significant apoptosis, which was not altered by the presence of albumin or glutathione. H2S treatment increased the activities of ERK and p38 mitogen-activated protein kinase (MAPK), but not c-Jun N-terminal kinase activity. Suppression of extracellular signal-regulated kinase (ERK) activity, but not of p38 activity, inhibited the H2S-induced apoptosis of HASMCs. The activation of ERK by H2S in HASMCs was accompanied by increased caspase-3 activity. Inhibition of caspase-3 by AC-DEVD-CHO attenuated the H2S-induced cell apoptosis. Inhibition of ERK by U0126 decreased caspase-3 activity, whereas AC-DEVD-CHO did not alter ERK activity. In conclusion, exogenous H2S induces apoptosis of HASMCs, which is significantly affected by the endogenous H2S level. Of the three investigated MAPKs, only ERK played an active role in mediating H2S-induced apoptosis of HASMCs by activating caspase-3. These findings may help reveal novel mechanisms for many diseases linked to H2S-related abnormal cellular proliferation and apoptosis.	Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan	Wang, R (corresponding author), Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wangrui@duke.usask.ca	Yang, Guangdong/G-4129-2011; Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620				Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOCHATONPIALLAT ML, 1995, AM J PATHOL, V146, P1059; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chen YR, 2000, INT J ONCOL, V16, P651; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Choi YJ, 2003, BIOCHEM BIOPH RES CO, V305, P176, DOI 10.1016/S0006-291X(03)00719-8; Cunningham KA, 2003, VIRUS RES, V92, P179, DOI 10.1016/S0168-1702(03)00044-3; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Deplancke B, 2003, FASEB J, V17, P1310, DOI 10.1096/fj.02-0883fje; Enomoto A, 2003, BIOCHEM BIOPH RES CO, V306, P837, DOI 10.1016/S0006-291X(03)01050-7; Frese S, 2003, ONCOGENE, V22, P5427, DOI 10.1038/sj.onc.1206842; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hershenson MB, 1997, CAN J PHYSIOL PHARM, V75, P898, DOI 10.1139/cjpp-75-7-898; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; Levonen AL, 2000, BIOCHEM J, V347, P291, DOI 10.1042/0264-6021:3470291; Najib S, 2002, CELL IMMUNOL, V220, P143, DOI 10.1016/S0008-8749(03)00027-3; Negre-Aminou P, 2002, BIOCHEM PHARMACOL, V64, P1483, DOI 10.1016/S0006-2952(02)01388-6; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ozaki I, 1999, J BIOL CHEM, V274, P5310, DOI 10.1074/jbc.274.9.5310; Peyot ML, 2000, CIRC RES, V86, P76, DOI 10.1161/01.RES.86.1.76; Peyton KJ, 2002, BLOOD, V99, P4443, DOI 10.1182/blood.V99.12.4443; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schmid FX, 2003, EUR J CARDIO-THORAC, V23, P537, DOI 10.1016/S1010-7940(02)00833-3; Shiota M, 2003, ZOOL SCI, V20, P193, DOI 10.2108/zsj.20.193; Tamagno E, 2000, NEUROREPORT, V11, P1865, DOI 10.1097/00001756-200006260-00013; VALITUTTI S, 1990, ANN ALLERGY, V65, P463; Varghese J, 2003, APOPTOSIS, V8, P363, DOI 10.1023/A:1024121017841; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhang CY, 2003, BIOCHEM BIOPH RES CO, V302, P810, DOI 10.1016/S0006-291X(03)00256-0; Zhang QY, 2004, BIOCHEM BIOPH RES CO, V317, P30, DOI 10.1016/j.bbrc.2004.02.176; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2002, AM J PHYSIOL-HEART C, V283, pH474, DOI 10.1152/ajpheart.00013.2002; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	45	250	284	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1782	+		10.1096/fj.04-2279fje	http://dx.doi.org/10.1096/fj.04-2279fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371330				2022-12-25	WOS:000224243200026
J	Jiang, TY; Guo, ZY; Dai, BJ; Kang, MY; Ann, DK; Kung, HJ; Qiu, Y				Jiang, TY; Guo, ZY; Dai, BJ; Kang, MY; Ann, DK; Kung, HJ; Qiu, Y			Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; PROSTATE-CANCER CELLS; WILD-TYPE P53; C-ABL; APOPTOTIC RESPONSE; FAMILY KINASES; BREAST-CANCER; PH-DOMAIN; BAX GENE; ACTIVATION	Etk/Bmx, a member of the Tec family of nonreceptor tyrosine kinases, has been implicated in the regulation of various cellular processes including proliferation, differentiation, motility, and apoptosis. Here, we report the identification of Tec family kinases as the potential interacting proteins of the tumor suppressor p53 by an Src homology 3 domain array screening. Etk is physically associated with p53 through its Src homology 3 domain and the proline-rich domain of p53. Induction of p53 expression by DNA damage inhibits Etk activity in several cell types. Down-regulation of Etk expression by a specific small interfering RNA sensitizes prostate cancer cells to doxorubicin-induced apoptosis, suggesting that inhibition of Etk activity is required for apoptosis in response to DNA damage. We also show that Etk primarily interacts with p53 in the cytoplasm and that such interaction leads to bidirectional inhibition of the activities of both proteins. Overexpression of Etk in prostate cancer cells results in inhibition of p53 transcriptional activity and its interaction with the mitochondrial protein BAK and confers the resistance to doxorubicin. Therefore, we propose that the stoichiometry between p53 and the Tec family kinases in a given cell type may determine its sensitivity to chemotherapeutic drugs.	Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, Baltimore, MD 21201 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University System of Maryland; University of Maryland Baltimore; University of Southern California; University of California System; University of California Davis	Qiu, Y (corresponding author), Univ Maryland, Sch Med, Dept Pharmacol & Expt Therapeut, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu	Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Barton GM, 2002, P NATL ACAD SCI USA, V99, P14943, DOI 10.1073/pnas.242594499; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Drabek D, 1997, P NATL ACAD SCI USA, V94, P610, DOI 10.1073/pnas.94.2.610; Gong JG, 1999, NATURE, V399, P806; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paavonen K, 2004, MOL BIOL CELL, V15, P4226, DOI 10.1091/mbc.E04-03-0241; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; TSUKADA S, 1994, ADV EXP MED BIOL, V365, P233; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yang HB, 2002, J BIOL CHEM, V277, P30219, DOI 10.1074/jbc.M111933200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533	43	30	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50181	50189		10.1074/jbc.M409108200	http://dx.doi.org/10.1074/jbc.M409108200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355990	hybrid			2022-12-25	WOS:000225229500078
J	Pitts, KR; McNiven, MA; Yoon, Y				Pitts, KR; McNiven, MA; Yoon, Y			Mitochondria-specific function of the dynamin family protein DLP1 is mediated by its C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; GTPASE EFFECTOR DOMAIN; TRANS-GOLGI NETWORK; MAMMALIAN-CELLS; SH3 DOMAINS; ENDOPLASMIC-RETICULUM; NEUROENDOCRINE CELLS; BINDING PROTEIN; PH DOMAIN; ENDOCYTOSIS	The dynamin superfamily of large GTPases has been implicated in a variety of distinct intracellular membrane remodeling events. One of these family members, DLP1/Drp1, is similar to conventional dynamins as it contains an N-terminal GTPase domain followed by a middle region (MID), an unconserved region (UC), and a coiled-coil (CC) domain. DLP1 has been shown to function in membrane-based processes distinct from conventional dynamin, most notably mitochondrial fission. In this study, we tested whether the functional specificities of DLP1 and dynamin stems from differences in the individual domains of these proteins by generating dynamin/DLP1 chimeras in which correlate domains had been interchanged. Here we report that three consecutive C-terminal domains of DLP1 (MID-UC-CC) contain information necessary for DLP1-specific function and removing any one of these domains results in a loss of DLP1 function. Importantly, the coiled-coil (CC) domain of DLP1 alone targets specifically and exclusively to mitochondria, implicating its involvement in localizing DLP1 to this organelle in vivo. The mitochondrial targeting information within the DLP1 CC domain is not sufficient to retarget dynamin to mitochondria but is still able to adequately function as an assembly domain in a dynamin background. These data suggest that whereas the GTPase domain of DLP1 provides an enzymatic function, other domains contain information for intermolecular assembly and mitochondrial targeting.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Sch Med & Dent, Dept Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Sch Med & Dent, Dept Physiol, Rochester, NY 14642 USA; Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA	University of Rochester; University of Rochester; University of Rochester; Mayo Clinic	Yoon, Y (corresponding author), 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA.	yisang_yoon@urmc.rochester.edu	Yoon, Yisang/AAJ-7910-2020	Yoon, Yisang/0000-0002-1618-5439	NIDDK NIH HHS [DK44650, R01 DK061991, DK61991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061991, R01DK044650, R29DK044650, R37DK044650] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artalejo CR, 1997, EMBO J, V16, P1565, DOI 10.1093/emboj/16.7.1565; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Fukushima NH, 2001, MOL BIOL CELL, V12, P2756, DOI 10.1091/mbc.12.9.2756; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Kamimoto T, 1998, J BIOL CHEM, V273, P1044, DOI 10.1074/jbc.273.2.1044; Koch A, 2003, J BIOL CHEM, V278, P8597, DOI 10.1074/jbc.M211761200; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; Li XL, 2003, J BIOL CHEM, V278, P17012, DOI 10.1074/jbc.M212031200; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; Liu X, 2000, P NATL ACAD SCI USA, V97, P12553, DOI 10.1073/pnas.230441497; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; McNiven MA, 1998, CELL, V94, P151, DOI 10.1016/S0092-8674(00)81414-2; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Okamoto PM, 1999, J BIOL CHEM, V274, P10277, DOI 10.1074/jbc.274.15.10277; Pitts KR, 1999, MOL BIOL CELL, V10, P4403, DOI 10.1091/mbc.10.12.4403; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; SCHWEMMLE M, 1995, J BIOL CHEM, V270, P13518, DOI 10.1074/jbc.270.22.13518; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shin HW, 1999, J BIOL CHEM, V274, P2780, DOI 10.1074/jbc.274.5.2780; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shu S, 2002, J CELL SCI, V115, P4237, DOI 10.1242/jcs.00112; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 1999, J BIOL CHEM, V274, P14942, DOI 10.1074/jbc.274.21.14942; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Takei K, 1999, NAT CELL BIOL, V1, P33, DOI 10.1038/9004; Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7; TUMA PL, 1994, J BIOL CHEM, V269, P30842; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Yang ZY, 2001, J BIOL CHEM, V276, P4251, DOI 10.1074/jbc.M006371200; Yoon Y, 1998, J CELL BIOL, V140, P779, DOI 10.1083/jcb.140.4.779; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zhang ZM, 2000, J BIOL CHEM, V275, P8779, DOI 10.1074/jbc.275.12.8779; Zheng J, 1996, J MOL BIOL, V255, P14, DOI 10.1006/jmbi.1996.0002; Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200	53	47	49	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50286	50294		10.1074/jbc.M405531200	http://dx.doi.org/10.1074/jbc.M405531200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364948	hybrid			2022-12-25	WOS:000225229500091
J	Faria, TQ; Lima, JC; Bastos, M; Macanita, AL; Santos, H				Faria, TQ; Lima, JC; Bastos, M; Macanita, AL; Santos, H			Protein stabilization by osmolytes from hyperthermophiles - Effect of mannosylglycerate on the thermal unfolding of recombinant nuclease a from Staphylococcus aureus studied by picosecond time-resolved fluorescence and calorimetry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPATIBLE SOLUTES; DIGLYCEROL PHOSPHATE; ESCHERICHIA-COLI; RIBONUCLEASE-A; SALT-SOLUTIONS; ANION-BINDING; STABILITY; TRYPTOPHAN; DECAY; WATER	2-O-alpha-Mannosylglycerate, a negatively charged osmolyte widely distributed among (hyper) thermophilic microorganisms, is known to provide notable protection to proteins against thermal denaturation. To study the mechanism responsible for protein stabilization, picosecond time-resolved fluorescence spectroscopy was used to characterize the thermal unfolding of a model protein, Staphylococcus aureus recombinant nuclease A ( SNase), in the presence or absence of mannosylglycerate. The fluorescence decay times are signatures of the protein state, and the pre-exponential coefficients are used to evaluate the molar fractions of the folded and unfolded states. Hence, direct determination of equilibrium constants of unfolding from molar fractions was carried out. Van't Hoff plots of the equilibrium constants provided reliable thermodynamic data for SNase unfolding. Differential scanning calorimetry was used to validate this thermodynamic analysis. The presence of 0.5 M potassium mannosylglycerate caused an increase of 7 degreesC in the SNase melting temperature and a 2-fold increase in the unfolding heat capacity. Despite the considerable degree of stabilization rendered by this solute, the nature and population of protein states along unfolding were not altered in the presence of mannosylglycerate, denoting that the unfolding pathway of SNase was unaffected. The stabilization of SNase by mannosylglycerate arises from decreased unfolding entropy up to 65 degreesC and from an enthalpy increase above this temperature. In molecular terms, stabilization is interpreted as resulting from destabilization of the denatured state caused by preferential exclusion of the solute from the protein hydration shell upon unfolding, and stabilization of the native state by specific interactions. The physiological significance of charged solutes in hyperthermophiles is discussed.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal; Univ Porto, Fac Ciencias, Ctr Invest Quim, P-4169007 Oporto, Portugal; Univ Tecn Lisboa, Inst Super Tecn, P-1049001 Lisbon, Portugal	Universidade Nova de Lisboa; Universidade do Porto; Universidade de Lisboa; Instituto Superior Tecnico	Santos, H (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Rua Quinta Grande 6,Apartado 127, P-2780156 Oeiras, Portugal.	santos@itqb.unl.pt	Santos, Helena/B-9141-2011; Bastos, Margarida/A-4791-2009; Faria, Tiago/A-4223-2015; Lima, João/F-3658-2010; Macanita, Antonio L./H-9284-2012	Santos, Helena/0000-0002-8050-9485; Bastos, Margarida/0000-0001-7464-3568; Faria, Tiago/0000-0003-0564-8415; Lima, João/0000-0003-0528-1967; Macanita, Antonio L./0000-0003-0976-6654				Ababou A, 2001, PROTEIN SCI, V10, P2102, DOI 10.1110/ps.05501; Anjum F, 2000, BBA-PROTEIN STRUCT M, V1476, P75, DOI 10.1016/S0167-4838(99)00215-0; BAILEY JE, 1968, EUR J BIOCHEM, V7, P5, DOI 10.1111/j.1432-1033.1968.tb19566.x; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Borges ML, 1998, PHOTOCHEM PHOTOBIOL, V67, P184, DOI 10.1562/0031-8655(1998)067<0184:PPAPAO>2.3.CO;2; Borges N, 2002, EXTREMOPHILES, V6, P209, DOI 10.1007/s007920100236; Bostrom M, 2003, BIOPHYS J, V85, P686, DOI 10.1016/S0006-3495(03)74512-3; BROCHON JC, 1974, EUR J BIOCHEM, V41, P577, DOI 10.1111/j.1432-1033.1974.tb03299.x; BUSBY TF, 1984, BIOCHIM BIOPHYS ACTA, V799, P80, DOI 10.1016/0304-4165(84)90329-5; Chen HM, 1999, EUR J BIOCHEM, V261, P599, DOI 10.1046/j.1432-1327.1999.00317.x; CHEN RF, 1991, BIOCHEMISTRY-US, V30, P5184, DOI 10.1021/bi00235a011; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; COWGILL RW, 1976, BIOCH FLUORESCENCE C, V2, P411; da Costa M. S., 1998, V61, P117; Davis-Searles PR, 2001, ANNU REV BIOPH BIOM, V30, P271, DOI 10.1146/annurev.biophys.30.1.271; DELPINO IMP, 1995, BIOCHEMISTRY-US, V34, P8621, DOI 10.1021/bi00027a011; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; EFTINK MR, 1991, BIOCHEMISTRY-US, V30, P8945, DOI 10.1021/bi00101a005; Faria TQ, 2003, CHEMBIOCHEM, V4, P734, DOI 10.1002/cbic.200300574; Giestas L, 2003, J PHYS CHEM A, V107, P3263, DOI 10.1021/jp0265900; GRIKO YV, 1988, P NATL ACAD SCI USA, V85, P3343, DOI 10.1073/pnas.85.10.3343; GRINVALD A, 1976, BIOCHIM BIOPHYS ACTA, V427, P663, DOI 10.1016/0005-2795(76)90210-5; Guzman-Casado M, 2003, J MOL BIOL, V329, P731, DOI 10.1016/S0022-2836(03)00513-8; Hinz HJ, 2001, PURE APPL CHEM, V73, P745, DOI 10.1351/pac200173040745; Kaushik JK, 1999, PROTEIN SCI, V8, P222; Kaushik JK, 2003, J BIOL CHEM, V278, P26458, DOI 10.1074/jbc.M300815200; KIRCHHOFF WH, 1993, 1401 NIST; Lakowicz JR, 2000, PHOTOCHEM PHOTOBIOL, V72, P421, DOI 10.1562/0031-8655(2000)072<0421:OSRIP>2.0.CO;2; Lamosa P, 2003, EUR J BIOCHEM, V270, P4606, DOI 10.1046/j.1432-1033.2003.03861.x; Lamosa P, 2000, APPL ENVIRON MICROB, V66, P1974, DOI 10.1128/AEM.66.5.1974-1979.2000; LEE JC, 1981, J BIOL CHEM, V256, P7193; MACANITA AL, 1989, J PHYS CHEM-US, V93, P336, DOI 10.1021/j100338a066; Makhatadze GI, 1998, PROTEIN SCI, V7, P689, DOI 10.1002/pro.5560070318; MARTINS LO, 1995, APPL ENVIRON MICROB, V61, P3299, DOI 10.1128/AEM.61.9.3299-3303.1995; MELO ECC, 1991, J COLLOID INTERF SCI, V141, P439, DOI 10.1016/0021-9797(91)90341-5; MELO TSE, 1988, PHOTOCHEM PHOTOBIOL, V48, P429, DOI 10.1111/j.1751-1097.1988.tb02841.x; Murov S.L., 1993, HDB PHOTOCHEMISTRY, P1; NEU HC, 1965, J BIOL CHEM, V240, P3685; Nishimura C, 2001, BIOCHEMISTRY-US, V40, P2113, DOI 10.1021/bi000861k; PETRICH JW, 1983, J AM CHEM SOC, V105, P3824, DOI 10.1021/ja00350a014; Ramos A, 1997, APPL ENVIRON MICROB, V63, P4020, DOI 10.1128/AEM.63.10.4020-4025.1997; Ramos CHI, 2002, PROTEIN SCI, V11, P1771, DOI 10.1110/ps.0205902; Robertson AD, 1997, CHEM REV, V97, P1251, DOI 10.1021/cr960383c; Robic S, 2003, P NATL ACAD SCI USA, V100, P11345, DOI 10.1073/pnas.1635051100; Russo AT, 2003, J MOL BIOL, V330, P851, DOI 10.1016/S0022-2836(03)00626-0; SANTORO MM, 1992, BIOCHEMISTRY-US, V31, P5278, DOI 10.1021/bi00138a006; Santos H, 2002, ENVIRON MICROBIOL, V4, P501, DOI 10.1046/j.1462-2920.2002.00335.x; Schellman JA, 2003, BIOPHYS J, V85, P108, DOI 10.1016/S0006-3495(03)74459-2; SHORTLE D, 1988, BIOCHEMISTRY-US, V27, P4761, DOI 10.1021/bi00413a027; Striker G, 1999, J PHYS CHEM B, V103, P8612, DOI 10.1021/jp991425e; SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/ja00522a020; TAKAHARA M, 1985, J BIOL CHEM, V260, P2670; Timasheff S. N., 1992, WATER LIFE, P70; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Uversky VN, 1998, J MOL BIOL, V278, P879, DOI 10.1006/jmbi.1998.1741; VARELA AP, 1995, J PHYS CHEM-US, V99, P16093, DOI 10.1021/j100043a059; Zhou HX, 2002, BIOPHYS J, V83, P3126, DOI 10.1016/S0006-3495(02)75316-2	57	54	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48680	48691		10.1074/jbc.M408806200	http://dx.doi.org/10.1074/jbc.M408806200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347691	hybrid			2022-12-25	WOS:000225098100025
J	Koren, R; Rainis, L; Kleinberger, T				Koren, R; Rainis, L; Kleinberger, T			The scaffolding A/Tpd3 subunit and high phosphatase activity are dispensable for Cdc55 function in the Saccharomyces cerevisiae spindle checkpoint and in cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS E4ORF4 PROTEIN; TERMINAL LEUCINE RESIDUE; PP2A CATALYTIC SUBUNIT; B-ALPHA SUBUNIT; EARLY REGION 4; REGULATORY SUBUNIT; BUDDING YEAST; CELL-CYCLE; P53-INDEPENDENT APOPTOSIS; CARBOXYL METHYLATION	Protein serine/threonine phosphatase 2A (PP2A) is a multifunctional enzyme whose trimeric form consists of a scaffolding A subunit, a catalytic C subunit, and one of several regulatory B subunits (B, B', and B"). The adenovirus E4orf4 protein associates with PP2A by directly binding the B or B' subunits. An interaction with an active PP2A containing the B subunit, or its homologue in yeast, Cdc55, is required for E4orf4-induced apoptosis in mammalian cells and for induction of growth arrest in Saccharomyces cerevisiae. In this work, Cdc55 was randomly mutagenized by low-fidelity PCR amplification, and Cdc55 mutants that lost the ability to transduce the E4orf4 toxic signal in yeast were selected. The mutations obtained by this protocol inhibited the association of Cdc55 with E4orf4, or with the PP2A-AC subunits, or both. Functional analysis revealed that a mutant that does not bind Tpd3, the yeast A subunit, as well as wild type Cdc55 in a tpd3Delta background, can form a heterodimer with the catalytic subunit. This association requires C subunit carboxyl methylation. The residual phosphatase activity associated with Cdc55 in the absence of Tpd3 is sufficient to maintain a partially active spindle checkpoint and to prevent cytokinesis defects.	Technion Israel Inst Technol, Fac Med, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Kleinberger, T (corresponding author), Technion Israel Inst Technol, Fac Med, Gonda Ctr Mol Microbiol, IL-31096 Haifa, Israel.	tamark@tx.technion.ac.il						Afifi R, 2001, J VIROL, V75, P4444, DOI 10.1128/JVI.75.9.4444-4447.2001; Aronheim A, 2001, METHOD ENZYMOL, V332, P260; Bondesson M, 1996, J VIROL, V70, P3844, DOI 10.1128/JVI.70.6.3844-3851.1996; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; DEANA AD, 1988, BIOCHIM BIOPHYS ACTA, V968, P179, DOI 10.1016/0167-4889(88)90006-7; Evans DRH, 2000, MOL GEN GENET, V264, P425; Evans DRH, 1999, J BIOL CHEM, V274, P24038, DOI 10.1074/jbc.274.34.24038; Gentry MS, 2002, MOL BIOL CELL, V13, P3477, DOI 10.1091/mbc.02-05-0065; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; KLEINBERGER T, 1993, J VIROL, V67, P7556, DOI 10.1128/JVI.67.12.7556-7560.1993; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Lavoie JN, 1998, J CELL BIOL, V140, P637, DOI 10.1083/jcb.140.3.637; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Marcellus RC, 1998, J VIROL, V72, P7144, DOI 10.1128/JVI.72.9.7144-7153.1998; Marcellus RC, 2000, J VIROL, V74, P7869, DOI 10.1128/JVI.74.17.7869-7877.2000; Minshull J, 1996, CURR BIOL, V6, P1609, DOI 10.1016/S0960-9822(02)70784-7; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; MULLER U, 1992, J VIROL, V66, P5867; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nickels JT, 1996, GENE DEV, V10, P382, DOI 10.1101/gad.10.4.382; Roopchand DE, 2001, ONCOGENE, V20, P5279, DOI 10.1038/sj.onc.1204693; Sherman F., 1982, METHODS YEAST GENETI; Shtrichman R, 2000, ONCOGENE, V19, P3757, DOI 10.1038/sj.onc.1203705; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Shtrichman R, 1998, J VIROL, V72, P2975, DOI 10.1128/JVI.72.4.2975-2982.1998; Shu YM, 1997, MOL CELL BIOL, V17, P3242, DOI 10.1128/MCB.17.6.3242; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Tolstykh T, 2000, EMBO J, V19, P5682, DOI 10.1093/emboj/19.21.5682; Toyn JH, 2000, YEAST, V16, P553, DOI 10.1002/(SICI)1097-0061(200004)16:6<553::AID-YEA554>3.0.CO;2-7; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANZYL W, 1992, MOL CELL BIOL, V12, P4946, DOI 10.1128/MCB.12.11.4946; Voth WP, 2003, YEAST, V20, P985, DOI 10.1002/yea.1018; Wang YC, 1997, MOL CELL BIOL, V17, P620, DOI 10.1128/MCB.17.2.620; Wei HJ, 2001, J BIOL CHEM, V276, P1570, DOI 10.1074/jbc.M008694200; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672; Yu XX, 2001, MOL BIOL CELL, V12, P185, DOI 10.1091/mbc.12.1.185; Zhu T, 1997, ARCH BIOCHEM BIOPHYS, V339, P210, DOI 10.1006/abbi.1996.9835	49	26	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48598	48606		10.1074/jbc.M409359200	http://dx.doi.org/10.1074/jbc.M409359200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347656	hybrid			2022-12-25	WOS:000225098100015
J	Tsujita, T; Tsukada, H; Nakao, M; Oshiumi, H; Matsumoto, M; Seya, T				Tsujita, T; Tsukada, H; Nakao, M; Oshiumi, H; Matsumoto, M; Seya, T			Sensing bacterial flagellin by membrane and soluble orthologs of toll-like receptor 5 in rainbow trout (Onchorhynchus mikiss)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE FLAGELLIN; INNATE IMMUNE-RESPONSE; NF-KAPPA-B; SIGNALING PATHWAY; ADAPTER MOLECULE; CELL ACTIVATION; INTERFERON-BETA; MESSENGER-RNA; GENE FAMILY; EXPRESSION	Rainbow trout (Onchorhynchus mikiss) possess two genes encoding putative leucine-rich repeat (LRR)-containing proteins similar to human TLR5. Molecular cloning of these two LRR proteins suggested the presence of a TLR5-like membrane form (rtTLR5M) and a soluble form (rtTLR5S). Here we elucidated the primary structures and the unique combinational functions of these fish versions of TLR5. The LRR regions of rtTLR5S and rtTLR5M exhibited 81% homology and relatively high (35.6 and 33.7%) homology to the extracellular domains of human TLR5 (huTLR5). Thus, two distinct genes encode the TLR5 orthologs in fish, one of which has a consensus intracellular domain (TIR). In order to test their functions, we constructed fusion proteins with the LRR region of rtTLR5S (S-chimera) or that of rtTLR5M and the TIR of huTLR5 (M-chimera). The S- and M-chimeras expressed in HeLa or CHO cells signaled the presence of Vibrio anguillarum flagellin, resulting in NF-kappaB activation. rtTLR5M was ubiquitously expressed, whereas rtTLR5S was predominantly expressed in the liver. In the hepatoma cell lines of the rainbow trout RTH-149, stimulation of rtTLR5M with V. anguillarum or its flagellin allowed the up-regulation of rtTLR5S. Flagellin-mediated NF-kappaB activation was more significant in the presence of or simultaneous expression of rtTLR5S. Therefore, a two-step flagellin response occurred for host defense against bacterial infection in fish: ( a) flagellin first induced basal activation of NF-kappaB via membrane TLR5, facilitating the production of soluble TLR5 and minimal acute phase proteins, and (b) the inducible soluble TLR5 amplifies membrane TLR5-mediated cellular responses in a positive feedback fashion.	Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Kita Ku, Sapporo, Hokkaido 0608637, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Immunol, Higashinari Ku, Osaka 5378511, Japan; Nara Inst Sci & Technol, Dept Mol Immunol, Nara 6310101, Japan; Kyushu Univ, Grad Sch Bioresource & Bioenvironm Sci, Marine Biochem Lab, Fukuoka 8128582, Japan	Hokkaido University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Nara Institute of Science & Technology; Kyushu University	Seya, T (corresponding author), Hokkaido Univ, Grad Sch Med, Dept Microbiol & Immunol, Kita Ku, Sapporo, Hokkaido 0608637, Japan.	seya-tu@med.hokudai.ac.jp	Oshiumi, Hiroyuki/G-1645-2012; Tsujita, Tadayuki/AAH-2347-2019; Seya, Tsukasa/A-4336-2012; 美佐子, 松本/A-4497-2012	Tsujita, Tadayuki/0000-0002-7189-0376; Oshiumi, Hiroyuki/0000-0003-1567-8722				Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Akira S, 2003, J BIOL CHEM, V278, P38105, DOI 10.1074/jbc.R300028200; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Azumi K, 2003, IMMUNOGENETICS, V55, P570, DOI 10.1007/s00251-003-0606-5; Bayne CJ, 2001, DEV COMP IMMUNOL, V25, P205, DOI 10.1016/S0145-305X(00)00057-4; Che FS, 2000, J BIOL CHEM, V275, P32347, DOI 10.1074/jbc.M004796200; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hughes AL, 2004, MOL PHYLOGENET EVOL, V32, P337, DOI 10.1016/j.ympev.2003.12.007; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Jault C, 2004, MOL IMMUNOL, V40, P759, DOI 10.1016/j.molimm.2003.10.001; Kimura Y, 2004, J IMMUNOL, V173, P1118, DOI 10.4049/jimmunol.173.2.1118; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litman GW, 1996, SCI AM, V275, P67, DOI 10.1038/scientificamerican1196-67; MacKenzie S, 2003, DEV COMP IMMUNOL, V27, P393, DOI 10.1016/S0145-305X(02)00135-0; McDermott PF, 2000, INFECT IMMUN, V68, P5525, DOI 10.1128/IAI.68.10.5525-5529.2000; Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Meijer AH, 2004, MOL IMMUNOL, V40, P773, DOI 10.1016/j.molimm.2003.10.003; Milston RH, 2003, FISH SHELLFISH IMMUN, V15, P145, DOI 10.1016/S1050-4648(02)00151-1; Milton DL, 1996, J BACTERIOL, V178, P1310, DOI 10.1128/jb.178.5.1310-1319.1996; Mizel SB, 2003, J IMMUNOL, V170, P6217, DOI 10.4049/jimmunol.170.12.6217; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moors MA, 2001, INFECT IMMUN, V69, P4424, DOI 10.1128/IAI.69.7.4424-4429.2001; Nishiguchi M, 2001, J IMMUNOL, V166, P2610, DOI 10.4049/jimmunol.166.4.2610; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, IMMUNOGENETICS, V54, P791, DOI 10.1007/s00251-002-0519-8; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sambrook HC., 2001, MOL CLONING LAB MANU; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Sebastiani G, 2000, GENOMICS, V64, P230, DOI 10.1006/geno.2000.6115; SEYA T, 2004, IN PRESS REV MED VIR; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Smith KD, 2002, CURR TOP MICROBIOL, V270, P93; Trede NS, 2004, IMMUNITY, V20, P367, DOI 10.1016/S1074-7613(04)00084-6; Tsukada H, 2001, JPN SOC MOL BIOL, V16, P102; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003; Ulevitch RJ, 2004, NAT REV IMMUNOL, V4, P512, DOI 10.1038/nri1396; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830	47	174	188	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48588	48597		10.1074/jbc.M407634200	http://dx.doi.org/10.1074/jbc.M407634200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339910	hybrid, Green Published			2022-12-25	WOS:000225098100014
J	Xu, YH; Lou, ZY; Liu, YW; Pang, H; Tien, P; Gao, GF; Rao, ZH				Xu, YH; Lou, ZY; Liu, YW; Pang, H; Tien, P; Gao, GF; Rao, ZH			Crystal structure of severe acute respiratory syndrome coronavirus spike protein fusion core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARS-ASSOCIATED CORONAVIRUS; EBOLA-VIRUS GLYCOPROTEIN; MEDIATED MEMBRANE-FUSION; COILED-COIL; HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN; PEPTIDE INHIBITORS; POTENT INHIBITORS; RECEPTOR-BINDING; ATOMIC-STRUCTURE	Severe acute respiratory syndrome coronavirus is a newly emergent virus responsible for a recent outbreak of an atypical pneumonia. The coronavirus spike protein, an enveloped glycoprotein essential for viral entry, belongs to the class I fusion proteins and is characterized by the presence of two heptad repeat (HR) regions, HR1 and HR2. These two regions are understood to form a fusion-active conformation similar to those of other typical viral fusion proteins. This hairpin structure likely juxtaposes the viral and cellular membranes, thus facilitating membrane fusion and subsequent viral entry. The fusion core protein of severe acute respiratory syndrome coronavirus spike protein was crystallized, and the structure was determined at 2.8 of resolution. The fusion core is a six-helix bundle with three HR2 helices packed against the hydrophobic grooves on the surface of central coiled coil formed by three parallel HR1 helices in an oblique antiparallel manner. This structure shares significant similarity with the fusion core structure of mouse hepatitis virus spike protein and other viral fusion proteins, suggesting a conserved mechanism of membrane fusion. Drug discovery strategies aimed at inhibiting viral entry by blocking hairpin formation, which have been successfully used in human immunodeficiency virus 1 inhibitor development, may be applicable to the inhibition of severe acute respiratory syndrome coronavirus on the basis of structural information provided here. The relatively deep grooves on the surface of the central coiled coil will be a good target site for the design of viral fusion inhibitors.	Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China; Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Chinese Acad Sci, Inst Microbiol, Beijing 100080, Peoples R China	Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS; University of Oxford; Chinese Academy of Sciences; Institute of Microbiology, CAS	Rao, ZH (corresponding author), Tsing Hua Univ, Struct Biol Lab, Beijing 100084, Peoples R China.	raozh@xtal.tsinghua.edu.cn	Gao, George Fu/ABD-5229-2021; Rao, Zihe/HCH-6944-2022; Xu, Yanhui/D-5119-2019					Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Bonavia A, 2003, J VIROL, V77, P2530, DOI 10.1128/JVI.77.4.2530-2538.2003; Bosch BJ, 2004, P NATL ACAD SCI USA, V101, P8455, DOI 10.1073/pnas.0400576101; Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CAVANAGH D, 1983, J GEN VIROL, V64, P2577, DOI 10.1099/0022-1317-64-12-2577; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; DELMAS B, 1990, J VIROL, V64, P5367, DOI 10.1128/JVI.64.11.5367-5375.1990; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Eickmann M, 2003, SCIENCE, V302, P1504; Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627; Imai M, 2000, MICROBIOL IMMUNOL, V44, P205, DOI 10.1111/j.1348-0421.2000.tb02485.x; Ingallinella P, 2004, P NATL ACAD SCI USA, V101, P8709, DOI 10.1073/pnas.0402753101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; SIDDELL S, 1983, J GEN VIROL, V64, P761, DOI 10.1099/0022-1317-64-4-761; Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796; Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775; TAGUCHI F, 1995, J VIROL, V69, P7260, DOI 10.1128/JVI.69.11.7260-7263.1995; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Tripet B, 2004, J BIOL CHEM, V279, P20836, DOI 10.1074/jbc.M400759200; Tsang KW, 2003, RESPIROLOGY, V8, P259, DOI 10.1046/j.1440-1843.2003.00486.x; Watanabe S, 2000, J VIROL, V74, P10194, DOI 10.1128/JVI.74.21.10194-10201.2000; Weissenhorn W, 1998, P NATL ACAD SCI USA, V95, P6032, DOI 10.1073/pnas.95.11.6032; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Xu YH, 2004, J BIOL CHEM, V279, P30514, DOI 10.1074/jbc.M403760200; Yuan KH, 2004, BIOCHEM BIOPH RES CO, V319, P746, DOI 10.1016/j.bbrc.2004.05.046; Zhu JQ, 2004, BIOCHEM BIOPH RES CO, V319, P283, DOI 10.1016/j.bbrc.2004.04.141	51	166	186	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49414	49419		10.1074/jbc.M408782200	http://dx.doi.org/10.1074/jbc.M408782200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15345712	Green Published, hybrid			2022-12-25	WOS:000225098100110
J	Yang, GD; Cao, K; Wu, LY; Wang, R				Yang, GD; Cao, K; Wu, LY; Wang, R			Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21(Cip/WAK-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE TRANSCRIPTION-PCR; PROTEIN-KINASE PATHWAY; HYDROGEN-SULFIDE; BETA-SYNTHASE; CYCLE ARREST; MYELOID-LEUKEMIA; GROWTH-FACTOR; RAT; EXPRESSION; ACTIVATION	Cystathionine gamma-lyase (CSE) is a key enzyme in the trans-sulfuration pathway. CSE uses L-cysteine as a substrate to produce hydrogen sulfide (H2S). The CSE/H2S system has been shown to play an important role in regulating cellular functions in different systems. In the present study, we used CSE stably overexpressed HEK293 cells to explore the effect of the CSE/H2S system on cell growth and proliferation. The overexpression of CSE resulted in increases in CSE mRNA levels, CSE proteins, and intracellular H2S production rates, as well as the inhibition of cell proliferation and DNA synthesis. These effects were accompanied by a sustained ERK activation and up-regulation of the cyclin-dependent kinase inhibitor p21(Cip/WAK-1). Blocking the action of ERK with U0126 inhibited the induction of p21(Cip/WAK-1), suggesting that ERK activation functions upstream of p21(Cip/WAK-1) activation to initiate the CSE overexpression-induced cell growth inhibition. The antiproliferative effect of CSE is likely mediated by endogenously produced H2S because the H2S scavenger methemoglobin (10 muM) significantly decreased the H2S production rate and reversed the antiproliferative effect afforded by CSE. Exogenous H2S (100 muM) also inhibited cell proliferation. However, the other CSE-catalyzed products, ammonium and pyruvate, failed to inhibit cell proliferation. Methemoglobin also abolished the inhibitory effect of exogenous H2S on cell proliferation. Moreover, exogenous H2S induced a sustained ERK and p21(Cip/WAK-1) activation. These findings support the hypothesis that endogenously produced H2S may play a fundamental role in cell proliferation and survival.	Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Dept Pharmacol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan	Wang, R (corresponding author), Univ Saskatchewan, Coll Med, Dept Physiol, Cardiovasc Res Grp, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	wangrui@duke.usask.ca	Yang, Guangdong/G-4129-2011; Wang, Rui/C-7824-2012	Wang, Rui/0000-0003-3825-3620				Barber T, 1999, J NUTR, V129, P928, DOI 10.1093/jn/129.5.928; Baumbach GL, 2002, CIRC RES, V91, P931, DOI 10.1161/01.RES.0000041408.64867.1D; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Brenneman KA, 2002, TOXICOL PATHOL, V30, P200, DOI 10.1080/019262302753559533; Cao K, 2002, BIOCHEM BIOPH RES CO, V296, P463, DOI 10.1016/S0006-291X(02)00892-6; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dombkowski RA, 2004, AM J PHYSIOL-REG I, V286, pR678, DOI 10.1152/ajpregu.00419.2003; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; EPLANCKE B, 2003, FASEB J, V17, P1310; ERICKSON PF, 1990, BIOCHEM J, V269, P335, DOI 10.1042/bj2690335; Eto K, 2002, J NEUROCHEM, V83, P80, DOI 10.1046/j.1471-4159.2002.01097.x; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HRISTL SU, 1996, DIGEST DIS SCI, V41, P2477; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; KERY V, 1994, J BIOL CHEM, V269, P25283; Kobayashi T, 2004, BIOL PHARM BULL, V27, P587, DOI 10.1248/bpb.27.587; Leung DW, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-15; Mariggio MA, 1998, IMMUNOPHARM IMMUNOT, V20, P399, DOI 10.3109/08923979809034822; Martin S, 2003, BIOCHEM PHARMACOL, V65, P669, DOI 10.1016/S0006-2952(02)01568-X; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Saussoy P, 2004, CLIN CHEM, V50, P1165, DOI 10.1373/clinchem.2003.030114; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shu PY, 2003, J CLIN MICROBIOL, V41, P2408, DOI 10.1128/JCM.41.6.2408-2416.2003; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Sun XF, 2004, BIOCHEM PHARMACOL, V67, P147, DOI 10.1016/j.bcp.2003.08.041; Taniguchi F, 2003, J CLIN ENDOCR METAB, V88, P773, DOI 10.1210/jc.2002-021062; Ullmannova V, 2003, LEUKEMIA RES, V27, P1115, DOI 10.1016/S0145-2126(03)00103-6; VALITUTTI S, 1990, ANN ALLERGY, V65, P463; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Wang R, 2003, ANTIOXID REDOX SIGN, V5, P493, DOI 10.1089/152308603768295249; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhao WM, 2003, CAN J PHYSIOL PHARM, V81, P848, DOI 10.1139/Y03-077; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008; Zhu HB, 2004, ONCOGENE, V23, P4984, DOI 10.1038/sj.onc.1207645	38	138	152	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49199	49205		10.1074/jbc.M408997200	http://dx.doi.org/10.1074/jbc.M408997200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347670	hybrid			2022-12-25	WOS:000225098100085
J	Bertos, NR; Gilquin, B; Chan, GKT; Yen, TJ; Khochbin, S; Yang, XJ				Bertos, NR; Gilquin, B; Chan, GKT; Yen, TJ; Khochbin, S; Yang, XJ			Role of the tetradecapeptide repeat domain of human histone deacetylase 6 in cytoplasmic retention	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; IMPORTIN-BETA; TUBULIN; RAN; IDENTIFICATION; MICROTUBULES; LEUKEMIA; PROTEIN; HDAC6; RNA	Histone deacetylase 6 (HDAC6) contains tandem catalytic domains and a ubiquitin-binding zinc finger and displays deacetylase activity toward acetylated microtubules. Here we show that unlike its orthologs from Caenorhabditis elegans, Drosophila, and mouse, human HDAC6 possesses a tetradecapeptide repeat domain located between the second deacetylase domain and the C-terminal ubiquitin-binding motif. Related to this structural difference, the cytoplasmic localization of human, but not murine, HDAC6 is resistant to treatment with leptomycin B (LMB). Although it is dispensable for the deacetylase and ubiquitin binding activities of human HDAC6, the tetradecapeptide repeat domain displays acetyl-microtubule targeting ability. Moreover, it forms a unique structure and is required for the LMB-resistant cytoplasmic localization of human HDAC6. Besides the tetradecapeptide repeat domain, human HDAC6 possesses two LMB-sensitive nuclear export signals and a nuclear localization signal. These results thus indicate that the cytoplasmic localization for murine and human HDAC6 proteins is differentially regulated and suggest that the tetradecapeptide repeat domain serves as an important sequence element to stably retain human HDAC6 in the cytoplasm.	McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Fac Med, Inst Albert Bonniot, INSERM U309, Equipe Chromat & Express Genes, F-38706 La Tronche, France; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Fox Chase Cancer Center	Yang, XJ (corresponding author), McGill Univ, Ctr Hlth, Royal Victoria Hosp, Mol Oncol Grp, Rm H5-41,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	xiang-jiao.yang@mcgill.ca	Khochbin, Saadi/M-8090-2013; GILQUIN, Benoit/A-6234-2014; Chan, Gordon/AAN-7784-2020	Khochbin, Saadi/0000-0002-0455-0857; Chan, Gordon/0000-0003-0497-9407; GILQUIN, benoit/0000-0001-8138-7021; Yen, Tim/0000-0003-2159-0997				Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Champagne N, 1999, J BIOL CHEM, V274, P28528, DOI 10.1074/jbc.274.40.28528; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Khochbin S, 2001, CURR OPIN GENET DEV, V11, P162, DOI 10.1016/S0959-437X(00)00174-X; Kovacs Jeffery J, 2004, Novartis Found Symp, V259, P170; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Matsuyama A, 2002, EMBO J, V21, P6820, DOI 10.1093/emboj/cdf682; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Palazzo A, 2003, NATURE, V421, P230, DOI 10.1038/421230a; PERKINS A, 1989, J ACQ IMMUN DEF SYND, V2, P256; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Schatz CA, 2003, EMBO J, V22, P2060, DOI 10.1093/emboj/cdg195; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; Verdel A, 2000, CURR BIOL, V10, P747, DOI 10.1016/S0960-9822(00)00542-X; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; Wang AH, 2000, MOL CELL BIOL, V20, P6904, DOI 10.1128/MCB.20.18.6904-6912.2000; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Yamaguchi R, 2003, CELL, V113, P115, DOI 10.1016/S0092-8674(03)00200-9; Yang XJ, 2004, BIOESSAYS, V26, P1076, DOI 10.1002/bies.20104; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115	48	114	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48246	48254		10.1074/jbc.M408583200	http://dx.doi.org/10.1074/jbc.M408583200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347674	hybrid			2022-12-25	WOS:000224957000100
J	Chow, MKM; Ellisdon, AM; Cabrita, LD; Bottomley, SP				Chow, MKM; Ellisdon, AM; Cabrita, LD; Bottomley, SP			Polyglutamine expansion in ataxin-3 does not affect protein stability - Implications for misfolding and disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM SPECTRA; NEURONAL INTRANUCLEAR INCLUSIONS; MACHADO-JOSEPH-DISEASE; HUNTINGTONS-DISEASE; SECONDARY STRUCTURE; THERMODYNAMIC STABILITY; CASPASE CLEAVAGE; PRION PROTEIN; NET CHARGE; IN-VITRO	Polyglutamine proteins that cause neurodegenerative disease are known to form proteinaceous aggregates, such as nuclear inclusions, in the neurons of affected patients. Although polyglutamine proteins have been shown to form fibrillar aggregates in a variety of contexts, the mechanisms underlying the aberrant conformational changes and aggregation are still not well understood. In this study, we have investigated the hypothesis that polyglutamine expansion in the protein ataxin-3 destabilizes the native protein, leading to the accumulation of a partially unfolded, aggregation-prone intermediate. To examine the relationship between polyglutamine length and native state stability, we produced and analyzed three ataxin-3 variants containing 15, 28, and 50 residues in their respective glutamine tracts. At pH 7.4 and 37degreesC, Atax3(Q50), which lies within the pathological range, formed fibrils significantly faster than the other proteins. Somewhat surprisingly, we observed no difference in the acid-induced equilibrium and kinetic un/folding transitions of all three proteins, which indicates that the stability of the native conformation was not affected by polyglutamine tract extension. This has led us to reconsider the mechanisms and factors involved in ataxin-3 misfolding, and we have developed a new model for the aggregation process in which the pathways of un/folding and misfolding are distinct and separate. Furthermore, given that native state stability is unaffected by polyglutamine length, we consider the possible role and influence of other factors in the fibrillization of ataxin-3.	Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia	Monash University	Bottomley, SP (corresponding author), Monash Univ, Dept Biochem & Mol Biol, POB 13D, Clayton, Vic 3800, Australia.	steve.bottomley@med.monash.edu.au		Chow, Michelle/0000-0001-6389-0942; Cabrita, Lisa/0000-0003-2963-8078; Ellisdon, Andrew/0000-0002-2248-9914				Bennett MJ, 2002, P NATL ACAD SCI USA, V99, P11634, DOI 10.1073/pnas.182393899; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Chai YH, 2004, J BIOL CHEM, V279, P3605, DOI 10.1074/jbc.M310939200; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chow MKM, 2004, CURR MED CHEM, V11, P491, DOI 10.2174/0929867043455936; Chow MKM, 2004, BIOCHEM BIOPH RES CO, V322, P387, DOI 10.1016/j.bbrc.2004.07.131; Chow MKM, 2004, J MOL BIOL, V335, P333, DOI 10.1016/j.jmb.2003.08.064; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Ding QX, 2002, J BIOL CHEM, V277, P13935, DOI 10.1074/jbc.M107706200; Dobson CM, 2004, SEMIN CELL DEV BIOL, V15, P3, DOI 10.1016/j.semcdb.2003.12.008; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Doss-Pepe EW, 2003, MOL CELL BIOL, V23, P6469, DOI 10.1128/MCB.23.18.6469-6483.2003; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellisdon AM, 2004, IUBMB LIFE, V56, P119, DOI 10.1080/15216540410001674003; Goto J, 1997, NEUROSCI RES, V28, P373, DOI 10.1016/S0168-0102(97)00056-4; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Horwich A, 2002, J CLIN INVEST, V110, P1221, DOI 10.1172/JCI200216781; IOEROVNIK E, 2002, EUR J BIOCHEM, V269, P3362; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kim YJ, 2001, P NATL ACAD SCI USA, V98, P12784, DOI 10.1073/pnas.221451398; Ladurner AG, 1997, J MOL BIOL, V273, P330, DOI 10.1006/jmbi.1997.1304; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lobley A, 2001, BIOPHYS J, V80, p373A; Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211; Marchal S, 2003, J BIOL CHEM, V278, P31554, DOI 10.1074/jbc.M304205200; Margolis RL, 2001, TRENDS MOL MED, V7, P479, DOI 10.1016/S1471-4914(01)02179-7; Masino L, 2003, FEBS LETT, V549, P21, DOI 10.1016/S0014-5793(03)00748-8; McGowan DP, 2000, NEUROSCIENCE, V100, P677, DOI 10.1016/S0306-4522(00)00391-2; Monti M, 2004, J MOL BIOL, V336, P253, DOI 10.1016/j.jmb.2003.10.082; Nozaki K, 2001, NEUROREPORT, V12, P3357, DOI 10.1097/00001756-200110290-00042; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; Plakoutsi G, 2004, J BIOL CHEM, V279, P14111, DOI 10.1074/jbc.M312961200; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Schilling G, 1999, NEURON, V24, P275, DOI 10.1016/S0896-6273(00)80839-9; Schmittschmitt JP, 2003, PROTEIN SCI, V12, P2374, DOI 10.1110/ps.03152903; Shaw KL, 2001, PROTEIN SCI, V10, P1206, DOI 10.1110/ps.440101; Shehi E, 2003, BIOCHEMISTRY-US, V42, P14626, DOI 10.1021/bi0352825; Stefani M, 2003, J MOL MED, V81, P678, DOI 10.1007/s00109-003-0464-5; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Tanaka M, 2001, J BIOL CHEM, V276, P45470, DOI 10.1074/jbc.M107502200; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VANSTOKKUM IHM, 1990, ANAL BIOCHEM, V191, P110, DOI 10.1016/0003-2697(90)90396-Q; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Wellington CL, 2000, J BIOL CHEM, V275, P19831, DOI 10.1074/jbc.M001475200; Zander C, 2001, HUM MOL GENET, V10, P2569, DOI 10.1093/hmg/10.22.2569; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	56	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47643	47651		10.1074/jbc.M405799200	http://dx.doi.org/10.1074/jbc.M405799200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15345714	hybrid			2022-12-25	WOS:000224957000029
J	Crespo, PM; Iglesias-Bartolome, R; Daniotti, JL				Crespo, PM; Iglesias-Bartolome, R; Daniotti, JL			Ganglioside GD3 traffics from the trans-Golgi network to plasma membrane by a Rab11-independent and brefeldin A-insensitive exocytic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CELL-SURFACE; ADP-RIBOSYLATION; PDMP BLOCKS; BULK FLOW; GLYCOSPHINGOLIPIDS; RAFTS; GLYCOPROTEIN; RAB11; DISSOCIATION	Gangliosides, complex glycosphingolipids containing sialic acids, have been found to reside in glycosphingolipid-enriched microdomains ( GEM) at the plasma membrane. They are synthesized in the lumen of the Golgi complex and appear unable to translocate from the lumenal toward the cytosolic surface of Golgi membrane to access the monomeric lipid transport. As a consequence, they can only leave the Golgi complex via the lumenal surface of transport vesicles. In this work we analyzed the exocytic transport of the disialo ganglioside GD3 from trans-Golgi network (TGN) to plasma membrane in CHO-K1 cells by immunodetection of endogenously synthesized GD3. We found that ganglioside GD3, unlike another luminal membrane-bounded lipid (glycosylphosphatidylinositol-anchored protein), did not partition into GEM domains in the Golgi complex and trafficked from TGN to plasma membrane by a brefeldin A-insensitive exocytic pathway. Moreover, a dominant negative form of Rab11, which prevents exit of vesicular stomatitis virus glycoprotein from the Golgi complex, did not influence the capacity of GD3 to reach the cell surface. Our results strongly support the notion that most ganglioside GD3 traffics from the TGN to the plasma membrane by a nonconventional vesicular pathway where lateral membrane segregation of vesicular stomatitis virus glycoprotein (non-GEM resident) and glycosylphosphatidylinositol-anchored proteins ( GEM resident) from GD3 is required before exiting TGN.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, RA-5000 Cordoba, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba	Daniotti, JL (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CONICET,CIQUIBIC, Ciudad Univ, RA-5000 Cordoba, Argentina.	daniotti@dqb.fcq.unc.edu.ar	Iglesias-Bartolome, Ramiro/H-4460-2014	Iglesias-Bartolome, Ramiro/0000-0002-0792-1254				Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; Chatterjee S, 2001, CELL MOL LIFE SCI, V58, P1969, DOI 10.1007/PL00000831; Chen W, 1998, MOL BIOL CELL, V9, P3241, DOI 10.1091/mbc.9.11.3241; Chen W, 2001, METHOD ENZYMOL, V329, P165; Crespo PM, 2004, BIOCHEM J, V377, P561, DOI 10.1042/BJ20031016; Crespo PM, 2002, J BIOL CHEM, V277, P44731, DOI 10.1074/jbc.M204604200; Daniotti JL, 2000, J NEUROCHEM, V74, P1711, DOI 10.1046/j.1471-4159.2000.0741711.x; De Matteis MA, 1999, FEBS LETT, V459, P310, DOI 10.1016/S0014-5793(99)01269-7; FOLCH J, 1951, J BIOL CHEM, V191, P819; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; FRITZ VMR, 1995, J NEUROCHEM, V65, P1859; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Giraudo CG, 1999, BIOCHEM J, V342, P633, DOI 10.1042/0264-6021:3420633; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kok JW, 1998, J CELL BIOL, V142, P25, DOI 10.1083/jcb.142.1.25; Li RX, 2000, J BIOL CHEM, V275, P34213, DOI 10.1074/jbc.M906368199; Maier O, 2003, J BIOL CHEM, V278, P164, DOI 10.1074/jbc.M208259200; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; Nakamura M, 2001, BIOSCI BIOTECH BIOCH, V65, P1812, DOI 10.1271/bbb.65.1812; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; Pagano RE, 2003, PHILOS T R SOC B, V358, P885, DOI 10.1098/rstb.2003.1275; Polishchuk EV, 2003, MOL BIOL CELL, V14, P4470, DOI 10.1091/mbc.E03-01-0033; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodman JS, 2000, J CELL SCI, V113, P183; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; ROSENWALD AG, 1993, J BIOL CHEM, V268, P4577; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; Slimane TA, 2002, FEBS LETT, V529, P54, DOI 10.1016/S0014-5793(02)03183-6; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; van Meer G, 2002, J BIOL CHEM, V277, P25855, DOI 10.1074/jbc.R200010200; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WATTENBERG BW, 1990, J CELL BIOL, V111, P421, DOI 10.1083/jcb.111.2.421; YOUNG WW, 1992, J BIOL CHEM, V267, P12011; Zhao XH, 2002, MOL BIOL CELL, V13, P119, DOI 10.1091/mbc.01-08-0420; Ziulkoski AL, 2001, BIOCHEM BIOPH RES CO, V281, P971, DOI 10.1006/bbrc.2001.4440; Zurita AR, 2001, BIOCHEM J, V355, P465, DOI 10.1042/0264-6021:3550465; Zurita AR, 2004, EUR J BIOCHEM, V271, P2428, DOI 10.1111/j.1432-1033.2004.04165.x	51	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47610	47618		10.1074/jbc.M407181200	http://dx.doi.org/10.1074/jbc.M407181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339909	hybrid			2022-12-25	WOS:000224957000025
J	Miki, T; Yoneda, Y				Miki, T; Yoneda, Y			Alternative splicing of Staufen2 creates the nuclear export signal for CRM1 (exportin 1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LOCALIZATION; PROTEIN; IDENTIFICATION; TRANSPORT; DOMAIN; MECHANISMS; PARTICLES; GRANULES; HOMOLOG	Mammalian Staufen2 (Stau2), a brain-specific double-stranded RNA-binding protein, is involved in the localization of mRNA in neurons. To gain insights into the function of Stau2, the subcellular localization of Stau2 isoforms fused to the green fluorescence protein was examined. Fluorescence microscopic analysis showed that Stau2 functions as a nucleocytoplasmic shuttle protein. The nuclear export of the 62-kDa isoform of Stau2 (Stau2(62)) is mediated by the double-stranded RNA-binding domain 3 (RBD3) because a mutation to RBD3 led to nuclear accumulation. On the other hand, the shorter isoform of Stau2, Stau2(59), is exported from the nucleus by two distinct pathways, one of which is RBD3-mediated and the other of which is CRM1 (exportin1)-dependent. The nuclear export signal recognized by CRM1 was found to be located in the N-terminal region of Stau2(59). These results suggest that Stau2 may carry a variety of RNAs out of the nucleus, using the two export pathways. The present study addresses the issue of why plural Stau2 isoforms are expressed in neurons.	Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Yoneda, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Cell Biol & Neurosci, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yyoneda@anat3.med.osaka-u.ac.jp	Miki, Takashi/S-7569-2018; Miki, Takashi/AGV-9237-2022	Miki, Takashi/0000-0003-3715-7039; Miki, Takashi/0000-0003-3715-7039				Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Buchner G, 1999, GENOMICS, V62, P113, DOI 10.1006/geno.1999.6015; Duchaine TF, 2002, J CELL SCI, V115, P3285; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Gwizdek C, 2004, J BIOL CHEM, V279, P884, DOI 10.1074/jbc.M306808200; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Knowles RB, 1996, J NEUROSCI, V16, P7812; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Kress TL, 2004, J CELL BIOL, V165, P203, DOI 10.1083/jcb.200309145; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Macchi P, 2004, J BIOL CHEM, V279, P31440, DOI 10.1074/jbc.C400226200; Mallardo M, 2003, P NATL ACAD SCI USA, V100, P2100, DOI 10.1073/pnas.0334355100; Ohashi S, 2002, J BIOL CHEM, V277, P37804, DOI 10.1074/jbc.M203608200; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Saxton WM, 2001, CELL, V107, P707, DOI 10.1016/S0092-8674(01)00602-X; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2	24	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47473	47479		10.1074/jbc.M407883200	http://dx.doi.org/10.1074/jbc.M407883200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364930	hybrid			2022-12-25	WOS:000224957000009
J	Paillart, JC; Dettenhofer, M; Yu, XF; Ehresmann, C; Ehresmann, B; Marquet, R				Paillart, JC; Dettenhofer, M; Yu, XF; Ehresmann, C; Ehresmann, B; Marquet, R			First snapshots of the HIV-1 RNA structure in infected cells and in virions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PRIMER ACTIVATION SIGNAL; DIMERIZATION INITIATION SITE; MAJOR SPLICE DONOR; IN-VITRO EVIDENCE; REVERSE TRANSCRIPTION; GENOMIC-RNA; PACKAGING SIGNAL; NUCLEOCAPSID PROTEIN; SECONDARY STRUCTURE	With the increasing interest of RNAs in regulating a range of cell biological processes, very little is known about the structure of RNAs in tissue culture cells. We focused on the 5'-untranslated region of the human immunodeficiency virus type 1 RNA genome, a highly conserved RNA region, which contains structural domains that regulate key steps in the viral replication cycle. Up until now, structural information only came from in vitro studies. Here, we developed chemical modification assays to test nucleotide accessibility directly in infected cells and viral particles, thus circumventing possible biases and artifacts linked to in vitro assays. The secondary structure of the 5'-untranslated region in infected cells points to the existence of the various stem-loop motifs associated to distinct functions, proposed from in vitro probing, mutagenesis, and phylogeny. However, compared with in vitro data, subtle differences were observed in the dimerization initiation site hairpin, and none of the proposed long range interactions were observed between the functional domains. Moreover, no global RNA rearrangement was observed; structural differences between infected cells and viral particles were limited to the primer binding site, which became protected against chemical modification upon tRNA(3)(Lys) annealing in virions and to the main packaging signal. In addition, our data suggested that the genomic RNA could already dimerize in the cytoplasm of infected cells. Taken together, our results provided the first analysis of the dynamic of RNA structure of the human immunodeficiency virus type 1 RNA genome during virus assembly ex vivo.	Univ Strasbourg 1, Inst Biol Mol & Cellulaire, CNRS, UPR 9002, F-67084 Strasbourg, France; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Johns Hopkins University	Paillart, JC (corresponding author), Univ Strasbourg 1, Inst Biol Mol & Cellulaire, CNRS, UPR 9002, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	jc.paillart@ibmc.u-strasbg.fr	Dettenhofer, Markus/ABB-9840-2021; Paillart, Jean-Christophe/A-4171-2010	Dettenhofer, Markus/0000-0003-1972-7026; Paillart, Jean-Christophe/0000-0003-1647-8917; Marquet, Roland/0000-0002-4209-3976				Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ALFORD RL, 1991, VIROLOGY, V183, P611, DOI 10.1016/0042-6822(91)90990-S; Andersen ES, 2004, J BIOL CHEM, V279, P22243, DOI 10.1074/jbc.M314326200; Ashe MP, 2000, RNA, V6, P170, DOI 10.1017/S1355838200991957; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Berkowitz R, 1996, CURR TOP MICROBIOL, V214, P177; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Clever JL, 1999, J VIROL, V73, P101, DOI 10.1128/JVI.73.1.101-109.1999; Clever JL, 2002, J VIROL, V76, P12381, DOI 10.1128/JVI.76.23.12381-12387.2002; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; Damgaard CK, 2004, J MOL BIOL, V336, P369, DOI 10.1016/j.jmb.2003.12.010; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Fabris D, 1996, J AM CHEM SOC, V118, P12242, DOI 10.1021/ja962863r; Fabris D, 1999, INORG CHEM, V38, P1322, DOI 10.1021/ic9809963; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; Goldschmidt V, 2004, J BIOL CHEM, V279, P35923, DOI 10.1074/jbc.M404473200; Goldschmidt V, 2003, NUCLEIC ACIDS RES, V31, P850, DOI 10.1093/nar/gkg187; Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; Harrison GP, 1998, J VIROL, V72, P5886, DOI 10.1128/JVI.72.7.5886-5896.1998; Helga-Maria C, 1999, J VIROL, V73, P4127, DOI 10.1128/JVI.73.5.4127-4135.1999; Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585; Huang Y, 1997, J VIROL, V71, P726, DOI 10.1128/JVI.71.1.726-728.1997; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2002, BIOCHEMISTRY-US, V41, P10439, DOI 10.1021/bi025993n; Huthoff H, 2004, RNA, V10, P412, DOI 10.1261/rna.5161304; Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038; ISEL C, 1995, J MOL BIOL, V247, P236, DOI 10.1006/jmbi.1994.0136; Iwatani Y, 2003, J BIOL CHEM, V278, P14185, DOI 10.1074/jbc.M211618200; Kao S, 2003, J VIROL, V77, P1131, DOI 10.1128/JVI.77.2.1131-1140.2003; Khan MA, 2001, J VIROL, V75, P7252, DOI 10.1128/JVI.75.16.7252-7265.2001; Kleiman L, 2004, CURR HIV RES, V2, P163, DOI 10.2174/1570162043484988; KUIKEN CI, 2002, 033564 LAUR LOS AL N; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Le Grice SFJ, 2003, BIOCHEMISTRY-US, V42, P14349, DOI 10.1021/bi030201q; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; MOOG C, 1994, ANTIVIR RES, V24, P275, DOI 10.1016/0166-3542(94)90075-2; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903; Paillart JC, 2002, J BIOL CHEM, V277, P5995, DOI 10.1074/jbc.M108972200; Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; Poon DTK, 2002, VIROLOGY, V293, P368, DOI 10.1006/viro.2001.1283; Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0; Richter S, 2002, P NATL ACAD SCI USA, V99, P7928, DOI 10.1073/pnas.122119999; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; Shehu-Xhilaga M, 2001, J VIROL, V75, P9156, DOI 10.1128/JVI.75.19.9156-9164.2001; Shen N, 2000, J VIROL, V74, P5729, DOI 10.1128/JVI.74.12.5729-5735.2000; Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Yu E, 2003, J MOL BIOL, V330, P211, DOI 10.1016/S0022-2836(03)00589-8; Zeffman A, 2000, J MOL BIOL, V297, P877, DOI 10.1006/jmbi.2000.3611; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	67	116	119	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48397	48403		10.1074/jbc.M408294200	http://dx.doi.org/10.1074/jbc.M408294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355993	hybrid			2022-12-25	WOS:000224957000115
J	Chan, MHS; McGee, SL; Watt, MJ; Hargreaves, M; Febbraio, MA				Chan, MHS; McGee, SL; Watt, MJ; Hargreaves, M; Febbraio, MA			Altering dietary nutrient intake that reduces glycogen content leads to phosphorylation of nuclear p38 MAP kinase in human skeletal muscle: association with IL-6 gene transcription during contraction	FASEB JOURNAL			English	Article						cytokines; JNK; nuclear transcription factors; myocellular	NF-KAPPA-B; JUN NH2-TERMINAL KINASE; C-JUN; SIGNALING PATHWAYS; INTERLEUKIN-6; EXPRESSION; EXERCISE; ACTIVATION; INCREASES; LIPOPOLYSACCHARIDE	To determine the effect of glycogen availability and contraction on intracellular signaling and IL-6 gene transcription, eight males performed 60 min of exercise on two occasions: either with prior ingestion of a normal (Con) or low carbohydrate (LCHO) diet that reduced pre-exercise muscle glycogen content. Muscle biopsies were obtained and analyzed for IL-6 mRNA. In addition, nuclear proteins were isolated from the samples and analyzed for the mitogen-activated protein kinases ( MAPK) c-jun amino-terminal kinase (JNK) 1 and 2 and p38 MAPK. Nuclear fractions were also analyzed for the phosphorylated forms of JNK (p-JNK) and p38 MAPK (p-p38 MAPK) and the abundance of the nuclear transcription factors nuclear factor of activated T cells (NFAT) and nuclear factor kappa-beta (NF-kappabeta). No differences were observed in the protein abundance of total JNK 1/2, p38 MAPK, NFAT, or NF-kappabeta before exercise, but the nuclear abundance of p-p38 MAPK was higher (P<0.05) in LCHO. Contraction resulted in an increase (P<0.05) in nuclear p-JNK 1/2, but there were no differences when comparing CON with LCHO. The fold increase in IL-6 mRNA with contraction was potentiated (P<0.05) in LCHO. A correlation between pre-exercise nuclear phosphorylated p38 MAPK and contraction-induced fold increase in IL-6 mRNA was performed, revealing a highly significant correlation (r=0.96; P<0.01). We next incubated L6 myotubes in ionomycin ( a compound known to induce IL-6 mRNA) with or without the pyridinylimidazole p38 MAPK inhibitor SB203580. Treatments did not affect total nuclear p38 MAPK, but ionomycin increased (P<0.05) both nuclear p-p38 MAPK and IL-6 mRNA. The addition of SB203580 to ionomycin decreased (P<0.05) nuclear p-p38 MAPK and totally abolished (P<0.05) the ionomycin-induced increase in IL-6 mRNA. These data suggest that reduced carbohydrate intake that results in low intramuscular glycogen leads to phosphorylation of p38 MAPK at the nucleus. Furthermore, phosphorylation of p38 MAPK in the nucleus appears to be an upstream target for IL-6, providing new insights into the regulation of IL-6 gene transcription.	Royal Melbourne Inst Technol, Sch Med Sci, Skeletal Muscle Res Lab, Bundoora, Vic 3083, Australia; Deakin Univ, Sch Exercise & Nutr Sci, Ctr Phys Act & Nutr, Burwood 3125, Australia	Royal Melbourne Institute of Technology (RMIT); Deakin University	Febbraio, MA (corresponding author), RMIT Univ, Sch Med Sci, Skeletal Muscle Res Lab, POB 71, Bundoora, Vic 3083, Australia.	mark.febbraio@rmit.edu.au	Febbraio, Mark/AAE-9632-2019; Watt, Matthew J/B-2089-2014	McGee, Sean/0000-0001-6953-106X; Chan, Stanley/0000-0002-4103-9441; Febbraio, Mark/0000-0002-9296-4418; Hargreaves, Mark/0000-0002-3694-5335				Aronson D, 1998, BIOCHEM BIOPH RES CO, V251, P106, DOI 10.1006/bbrc.1998.9435; Baldwin J, 2003, J APPL PHYSIOL, V94, P2181, DOI 10.1152/japplphysiol.00866.2002; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; Carey AL, 2003, BIOCHEM BIOPH RES CO, V302, P837, DOI 10.1016/S0006-291X(03)00267-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1055, DOI 10.1152/jappl.2000.89.3.1055; Frost RA, 2003, AM J PHYSIOL-REG I, V285, pR1153, DOI 10.1152/ajpregu.00164.2003; Frost RA, 2002, AM J PHYSIOL-REG I, V283, pR698, DOI 10.1152/ajpregu.00039.2002; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Hiscock N, 2004, FASEB J, V18, P992, DOI 10.1096/fj.03-1259fje; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KELLER C, 2002, J PHYSL, pP539; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Lemieux K, 2003, FASEB J, V17, P1658, DOI 10.1096/fj.02-1125com; Li NX, 2000, METHOD ENZYMOL, V319, P273; Luo GJ, 2003, AM J PHYSIOL-REG I, V284, pR1249, DOI 10.1152/ajpregu.00490.2002; McGee SL, 2003, DIABETES, V52, P926, DOI 10.2337/diabetes.52.4.926; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Shi Y, 2002, BIOL CHEM, V383, P1519, DOI 10.1515/BC.2002.173; Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; STRAUSS CC, 1992, J ANXIETY DISORD, V6, P89, DOI 10.1016/0887-6185(92)90029-7; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Ullum H, 1996, J ACQ IMMUN DEF SYND, V13, P93, DOI 10.1097/00042560-199609000-00013; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673	33	91	94	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1785	+		10.1096/fj.03-1039fje	http://dx.doi.org/10.1096/fj.03-1039fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345683				2022-12-25	WOS:000224243200036
J	Maga, G; Blanca, G; Shevelev, I; Frouin, I; Ramadan, K; Spadari, S; Villani, G; Hubscher, U				Maga, G; Blanca, G; Shevelev, I; Frouin, I; Ramadan, K; Spadari, S; Villani, G; Hubscher, U			The human DNA polymerase lambda interacts with PCNA through a domain important for DNA primer binding and the interaction is inhibited by p21(/WAF1/CIP1)	FASEB JOURNAL			English	Article						DNA replication; cell cycle; abasic sites; protein-protein interactions	CELL NUCLEAR ANTIGEN; REPLICATION; REPAIR; PROTEINS; KINASE; ROLES; BETA; ETA; CDK	In this paper we show that DNA polymerase lambda (pol lambda) interacts with proliferating cell nuclear antigen ( PCNA) in vivo in human cells. Moreover, by using recombinant mutated PCNA, we could demonstrate that pol lambda interacts with both the interdomain-connecting loop and the nearby hydrophobic pocket on the anterior of PCNA and that critical residues within a helix-hairpin-helix domain of pol lambda, important for proper DNA primer binding, are also involved in the enzyme's interaction with PCNA. Finally, we show that the tumor suppressor protein p21(WAF1/CIP1) can efficiently compete in vitro with pol lambda for binding to PCNA. Given the high rate of frameshift mutations induced by pol lambda and its ability to bypass abasic sites, accurate regulation of pol lambda activity by PCNA and p21 concerted action might be important for preventing genetic instability.	CNR, IGM, I-27100 Pavia, Italy; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Consiglio Nazionale delle Ricerche (CNR); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Zurich	Maga, G (corresponding author), CNR, IGM, Via Abbiategrasso 207, I-27100 Pavia, Italy.	maga@igm.cnr.it	Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Blanca G, 2003, BIOCHEMISTRY-US, V42, P7467, DOI 10.1021/bi034198m; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Delarue M, 2002, EMBO J, V21, P427, DOI 10.1093/emboj/21.3.427; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Garcia-Diaz M, 2004, MOL CELL, V13, P561, DOI 10.1016/S1097-2765(04)00061-9; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maga G, 2002, J BIOL CHEM, V277, P48434, DOI 10.1074/jbc.M206889200; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Ramadan K, 2003, J MOL BIOL, V328, P63, DOI 10.1016/S0022-2836(03)00265-1; Ramadan K, 2002, J BIOL CHEM, V277, P18454, DOI 10.1074/jbc.M200421200; Shevelev I, 2003, NUCLEIC ACIDS RES, V31, P6916, DOI 10.1093/nar/gkg896; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R	32	24	26	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1743	+		10.1096/fj.04-2268fje	http://dx.doi.org/10.1096/fj.04-2268fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358682	Green Accepted			2022-12-25	WOS:000224243200034
J	Russo, S; Baumann, U				Russo, S; Baumann, U			Crystal structure of a dodecameric tetrahedral-shaped aminopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROMONAS-PROTEOLYTICA AMINOPEPTIDASE; TRICORN PROTEASE; DIFFRACTION DATA; 20S PROTEASOME; RESOLUTION; ZINC; REFINEMENT; MECHANISM; DATABASE; REVEALS	Protein turnover is an essential process in living cells. The degradation of cytosolic polypeptides is mainly carried out by the proteasome, resulting in 7 - 9-amino acid long peptides. Further degradation is usually carried out by energy-independent proteases like the tricorn protease from Thermoplasma acidophilum. Recently, a novel tetrahedral-shaped dodecameric 480-kDa aminopeptidase complex (TET) has been described in Haloarcula marismortui that differs from the known ring- or barrel-shaped self-compartmentalizing proteases. This complex is capable of degrading most peptides down to amino acids. We present here the crystal structure of the tetrahedral aminopeptidase homolog FrvX from Pyrococcus horikoshii. The monomer has a typical clan MH fold, as found for example in Aeromonas proteolytica aminopeptidase, containing a dinuclear zinc active center. The quaternary structure is built by dimers with a length of 100 Angstrom that form the edges of the tetrahedron. All 12 active sites are located on the inside of the tetrahedron. Substrate access is granted by pores with a maximal diameter of 10 Angstrom, allowing only small peptides and unfolded proteins access to the active site.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland	University of Bern	Baumann, U (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	ulrich.baumann@ibc.unibe.ch	Baumann, Ulrich/B-1220-2013					Bennett B, 1997, BIOCHEMISTRY-US, V36, P9837, DOI 10.1021/bi970735p; Bennett B, 1997, J AM CHEM SOC, V119, P1923, DOI 10.1021/ja963021v; Brandstetter H, 2001, NATURE, V414, P466, DOI 10.1038/35106609; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURLEY SK, 1990, P NATL ACAD SCI USA, V87, P6878, DOI 10.1073/pnas.87.17.6878; CHEVRIER B, 1994, STRUCTURE, V2, P283, DOI 10.1016/S0969-2126(00)00030-7; Chevrier B, 1996, EUR J BIOCHEM, V237, P393, DOI 10.1111/j.1432-1033.1996.0393k.x; De Paola CC, 1999, BIOCHEMISTRY-US, V38, P9048, DOI 10.1021/bi9900572; Franzetti B, 2002, EMBO J, V21, P2132, DOI 10.1093/emboj/21.9.2132; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gonzales T, 1996, FEMS MICROBIOL REV, V18, P319, DOI 10.1111/j.1574-6976.1996.tb00247.x; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lowther WT, 2002, CHEM REV, V102, P4581, DOI 10.1021/cr0101757; Maher MJ, 2004, BIOCHEMISTRY-US, V43, P2771, DOI 10.1021/bi0356451; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PRESCOTT JM, 1983, BIOCHEM BIOPH RES CO, V114, P646, DOI 10.1016/0006-291X(83)90829-X; Rawlings ND, 1999, NUCLEIC ACIDS RES, V27, P325, DOI 10.1093/nar/27.1.325; Remaut H, 2001, NAT STRUCT BIOL, V8, P674, DOI 10.1038/90380; RODERICK SL, 1993, BIOCHEMISTRY-US, V32, P3907, DOI 10.1021/bi00066a009; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Stamper C, 2001, BIOCHEMISTRY-US, V40, P7035, DOI 10.1021/bi0100891; Tamura T, 1996, SCIENCE, V274, P1385, DOI 10.1126/science.274.5291.1385; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Walz J, 1997, MOL CELL, V1, P59, DOI 10.1016/S1097-2765(00)80007-6; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2	38	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51275	51281		10.1074/jbc.M409455200	http://dx.doi.org/10.1074/jbc.M409455200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15375159	hybrid, Green Published			2022-12-25	WOS:000225355800076
J	Tsukatani, Y; Miyamoto, R; Itoh, S; Oh-oka, H				Tsukatani, Y; Miyamoto, R; Itoh, S; Oh-oka, H			Function of a PscD subunit in a homodimeric reaction center complex of the photosynthetic green sulfur bacterium Chlorobium tepidum studied by Insertional gene inactivation - Regulation of energy transfer and ferredoxin-mediated NADP(+) reduction on the cytoplasmic side	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-I; CYTOCHROME-C; PROSTHECOCHLORIS-AESTUARII; BACTERIOCHLOROPHYLL-C; ANGSTROM RESOLUTION; ELECTRON-ACCEPTORS; CRYSTAL-STRUCTURE; P840; PROTEIN; VIBRIOFORME	The PscD subunit in the homodimeric "type I" photosynthetic reaction center (RC) complex of the green sulfur bacterium Chlorobium tepidum was disrupted by insertional mutagenesis of its relevant pscD gene. This is the first report on the use of the direct mutagenic approach into the RC-related genes in green sulfur bacteria. The RC complex of C. tepidum is supposed to form a homodimer of two identical PscA subunits together with three other subunits: PscB (F-A/F-B-containing protein), PscC ( cytochrome c(z)), and PscD. PscD shows a relatively low but significant similarity in its amino acid sequence to PsaD in the photosystem I of plants and cyanobacteria. We studied the biochemical and spectroscopic properties of a mutant lacking PscD in order to elucidate its unknown function. 1) The RC complex isolated from the mutant cells showed no band corresponding to PscD on SDS-PAGE analysis. 2) The growth rate of the PscD-less mutant was slower than that of the wildtype cells at low light intensities. 3) Time-resolved fluorescence spectra at 77 K revealed prolonged decay times of the fluorescence from bacteriochlorophyll c on the antenna chlorosome and from bacteriochlorophyll a on the Fenna-Matthews-Olson antenna protein in the mutant cells. The loss of PscD led to a much slower energy transfer from the antenna pigments to the special pair bacteriochlorophyll a (P840). 4) The mutant strain exhibited slightly less activity of ferredoxin-mediated NADP(+) photoreduction compared with that in the wild-type strain. The extent of suppression, however, was less significant than that reported in the PsaD-less mutants of cyanobacterial photosystem I. The evolutionary relationship between PscD and PsaD was also discussed based on a structural homology modeling of the former.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Nagoya Univ, Grad Sch Sci, Sch Mat Sci Phys, Nagoya, Aichi 4648602, Japan	Osaka University; Nagoya University	Tsukatani, Y (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Machikaneyama 1-1, Osaka 5600043, Japan.	tsuka@bio.sci.osaka-u.ac.jp	Tsukatani, Yusuke/A-6448-2014	Tsukatani, Yusuke/0000-0003-2831-8996				Blankenship RE, 1995, ANOXYGENIC PHOTOSYNT, V2, P399, DOI DOI 10.1007/0-306-47954-0; BUTTNER M, 1992, P NATL ACAD SCI USA, V89, P8135, DOI 10.1073/pnas.89.17.8135; CUI JY, 1989, J BIOCHEM-TOKYO, V105, P390, DOI 10.1093/oxfordjournals.jbchem.a122674; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; Eisen JA, 2002, P NATL ACAD SCI USA, V99, P9509, DOI 10.1073/pnas.132181499; Frigaard NU, 2002, J BACTERIOL, V184, P3368, DOI 10.1128/JB.184.12.3368-3376.2002; Frigaard NU, 2001, APPL ENVIRON MICROB, V67, P2538, DOI 10.1128/AEM.67.6.2538-2544.2001; Griesbeck C, 1998, BBA-BIOENERGETICS, V1365, P285, DOI 10.1016/S0005-2728(98)00081-4; HAGERBRAUN C, 1995, BIOCHEMISTRY-US, V34, P9617, DOI 10.1021/bi00029a039; HagerBraun C, 1997, PHOTOSYNTH RES, V51, P127, DOI 10.1023/A:1005787209977; Hauska G, 2001, BBA-BIOENERGETICS, V1507, P260, DOI 10.1016/S0005-2728(01)00200-6; Heathcote P, 2003, PHILOS T ROY SOC B, V358, P231, DOI 10.1098/rstb.2002.1178; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; KJAER B, 1994, PHOTOSYNTH RES, V41, P105, DOI 10.1007/BF02184150; KJAER B, 1996, PHOTOSYNTH RES, V17, P33; KUSUMOTO N, 1994, PLANT CELL PHYSIOL, V35, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; Li YF, 1997, J MOL BIOL, V271, P456, DOI 10.1006/jmbi.1997.1189; Maresca JA, 2004, J BACTERIOL, V186, P2558, DOI 10.1128/JB.186.9.2558-2566.2004; MATTHEWS BW, 1979, J MOL BIOL, V131, P259, DOI 10.1016/0022-2836(79)90076-7; NITSCHKE W, 1990, BIOCHEMISTRY-US, V29, P3834, DOI 10.1021/bi00468a005; Oh-Oka H, 1998, BIOCHEMISTRY-US, V37, P12293, DOI 10.1021/bi9800799; OhOka H, 1997, BIOCHEMISTRY-US, V36, P9267, DOI 10.1021/bi9701787; OHOKA H, 1995, FEBS LETT, V365, P30, DOI 10.1016/0014-5793(95)00433-A; OKKELS JS, 1992, J BIOL CHEM, V267, P21139; Olson JM, 1998, PHOTOCHEM PHOTOBIOL, V67, P61, DOI 10.1111/j.1751-1097.1998.tb05166.x; Permentier HP, 2000, PHOTOSYNTH RES, V64, P27, DOI 10.1023/A:1026515027824; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; Remigy HW, 2002, PHOTOSYNTH RES, V71, P91, DOI 10.1023/A:1014963816574; Remigy HW, 1999, J MOL BIOL, V290, P851, DOI 10.1006/jmbi.1999.2925; Sakurai H, 1996, PHOTOCHEM PHOTOBIOL, V64, P5, DOI 10.1111/j.1751-1097.1996.tb02414.x; Sambrook J., 2002, MOL CLONING LAB MANU; Seo D, 2001, BBA-BIOENERGETICS, V1503, P377, DOI 10.1016/S0005-2728(00)00245-0; Tsukatani Y, 2004, PHOTOSYNTH RES, V79, P83, DOI 10.1023/B:PRES.0000011922.56394.92; Vassiliev IR, 2000, BIOPHYS J, V78, P3160, DOI 10.1016/S0006-3495(00)76852-4; Vassiliev IR, 2001, BBA-BIOENERGETICS, V1507, P139, DOI 10.1016/S0005-2728(01)00197-9; WAHLUND TM, 1995, J BACTERIOL, V177, P2583, DOI 10.1128/jb.177.9.2583-2588.1995; WANG J, 1990, BIOCHIM BIOPHYS ACTA, V1015, P457, DOI 10.1016/0005-2728(90)90079-J; XU Q, 1994, J BIOL CHEM, V269, P21512; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	41	30	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51122	51130		10.1074/jbc.M410432200	http://dx.doi.org/10.1074/jbc.M410432200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371432	hybrid			2022-12-25	WOS:000225355800058
J	Wilkinson, JC; Wilkinson, AS; Scott, FL; Csomos, RA; Salvesen, GS; Duckett, CS				Wilkinson, JC; Wilkinson, AS; Scott, FL; Csomos, RA; Salvesen, GS; Duckett, CS			Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs) - A caspase-independent mechanism for apoptotic inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BACULOVIRUS INHIBITOR; OP-IAP; MAMMALIAN-CELLS; PROTEINS; XIAP; ACTIVATION; BINDING; GENES; P35	Numerous members of the IAP family can suppress apoptotic cell death in physiological settings. Whereas certain IAPs directly inhibit caspases, the chief proteolytic effectors of apoptosis, the protective effects of other IAPs do not correlate well with their caspase inhibitory activities, suggesting the involvement of alternative cytoprotective abilities. To examine this issue, we have characterized the protective effects of an ancestral, baculoviral IAP (Op-IAP) in mammalian cells. We show that although Op-IAP potently inhibited Bax-mediated apoptosis in human cells, Op-IAP failed to directly inhibit mammalian caspases. However, Op-IAP efficiently bound the IAP antagonist Smac/Diablo, thereby preventing Smac/Diablo-mediated inhibition of cellular IAPs. Whereas reduction of Smac/Diablo protein levels in the absence of Op-IAP prevented Bax-mediated apoptosis, overexpression of Smac/Diablo neutralized Op-IAP-mediated protection, and an Op-IAP variant unable to bind Smac/Diablo failed to prevent apoptosis. Finally, Op-IAP catalyzed the ubiquitination of Smac/Diablo, an activity that contributed to Op-IAP-mediated inhibition of apoptosis. These data show that cytoprotective IAPs can inhibit apoptosis through the neutralization of IAP antagonists, rather than by directly inhibiting caspases.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Sanford Burnham Prebys Medical Discovery Institute	Duckett, CS (corresponding author), Med Sci 1,Rm 5315,1301 Catherine, Ann Arbor, MI 48109 USA.	colind@umich.edu			NCI NIH HHS [T32 CA09676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Bratton SB, 2002, CELL DEATH DIFFER, V9, P881, DOI 10.1038/sj.cdd.4401069; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Hawkins CJ, 1998, CELL DEATH DIFFER, V5, P569, DOI 10.1038/sj.cdd.4400389; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Huang QH, 2000, P NATL ACAD SCI USA, V97, P1427, DOI 10.1073/pnas.97.4.1427; Hunter AM, 2003, J BIOL CHEM, V278, P7494, DOI 10.1074/jbc.C200695200; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; Lewis J, 2004, J BIOL CHEM, V279, P9023, DOI 10.1074/jbc.M312891200; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Manji GA, 2001, J BIOL CHEM, V276, P16704, DOI 10.1074/jbc.M010179200; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Vucic D, 1998, J BIOL CHEM, V273, P33915, DOI 10.1074/jbc.273.51.33915; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wright CW, 2002, J BIOL CHEM, V277, P2454, DOI 10.1074/jbc.M110500200; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874	43	88	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51082	51090		10.1074/jbc.M408655200	http://dx.doi.org/10.1074/jbc.M408655200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371416	hybrid			2022-12-25	WOS:000225355800054
J	Yasuoka, C; Ihara, Y; Ikeda, S; Miyahara, Y; Kondo, T; Kohno, S				Yasuoka, C; Ihara, Y; Ikeda, S; Miyahara, Y; Kondo, T; Kohno, S			Antiapoptotic activity of Akt is down-regulated by Ca2+ in myocardiac H9c2 cells - Evidence of Ca2+-dependent regulation of protein phosphatase 2Ac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; KINASE-B; ENDOPLASMIC-RETICULUM; CATALYTIC SUBUNIT; GRANULOCYTIC DIFFERENTIATION; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; TUMOR PROMOTER; RETINOIC ACID; OKADAIC ACID	Cell survival signaling of the Akt/protein kinase B pathway was influenced by a change in the cytoplasmic free calcium concentration ([Ca2+](i)) for over 2 h via the regulation of a Ser/Thr phosphatase, protein phosphatase 2Ac (PP2Ac), in rat myocardiac H9c2 cells. Akt was down-regulated when [Ca2+](i) was elevated by thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase, but was up-regulated when it was suppressed by 1,2-bis(o-aminophenoxy) ethane-N,N,N', N'-tetraacetic acid tetra( acetoxymethyl) ester (BAPTA-AM), a cell permeable Ca2+ chelator. The inactivation of Akt was well correlated with the susceptibility to oxidant-induced apoptosis in H9c2 cells. To investigate the mechanism of the Ca2+-dependent regulation of Akt via the regulation of PP2A, we examined the transcriptional regulation of PP2Acalpha in H9c2 cells with Ca2+ modulators. Transcription of the PP2Acalpha gene was increased by thapsigargin but decreased by BAPTA-AM. The promoter activity was examined and the cAMP response element (CRE) was found responsible for the Ca2+-dependent regulation of PP2Acalpha. Furthermore, phosphorylation of CRE-binding protein increased with thapsigargin but decreased with BAPTA-AM. A long term change of [Ca2+](i) regulates PP2Acalpha gene transcription via CRE, resulting in a change in the activation status of Akt leading to an altered susceptibility to apoptosis.	Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, Nagasaki 8528523, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Internal Med 2, Nagasaki 8528523, Japan	Nagasaki University; Nagasaki University	Ihara, Y (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Biochem & Mol Biol Dis, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	y-ihara@net.nagasaki-u.ac.jp						Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Altiok S, 1997, GENE DEV, V11, P1987, DOI 10.1101/gad.11.15.1987; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Campos SV, 2000, J CELL PHYSIOL, V182, P88; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gehringer MM, 2004, FEBS LETT, V557, P1, DOI 10.1016/S0014-5793(03)01447-9; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1991, CIRC RES, V69, P1476, DOI 10.1161/01.RES.69.6.1476; Huber M, 2000, J IMMUNOL, V165, P124, DOI 10.4049/jimmunol.165.1.124; Ihara Y, 1997, J BIOL CHEM, V272, P9629; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kane CD, 2000, EMBO J, V19, P691, DOI 10.1093/emboj/19.4.691; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KHEWGOODALL Y, 1991, BIOCHEMISTRY-US, V30, P89, DOI 10.1021/bi00215a014; KITAGAWA Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P339, DOI 10.1016/0167-4781(91)90174-K; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KITAMURA K, 1991, J BIOCHEM-TOKYO, V109, P307; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; Luo HR, 2003, P NATL ACAD SCI USA, V100, P11712, DOI 10.1073/pnas.1634990100; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Mora A, 2002, CELL SIGNAL, V14, P557, DOI 10.1016/S0898-6568(01)00282-0; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; Muroya T, 2003, BIOCHEM BIOPH RES CO, V309, P900, DOI 10.1016/j.bbrc.2003.08.090; Murriel CL, 2003, ARCH BIOCHEM BIOPHYS, V420, P246, DOI 10.1016/j.abb.2003.08.038; NISHIKAWA M, 1994, CANCER RES, V54, P4879; ORRENIUS S, 2003, NAT REV, V5, P552; Ozes ON, 1999, NATURE, V401, P82; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Rizzuto R, 2003, ONCOGENE, V22, P8619, DOI 10.1038/sj.onc.1207105; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; TAWARA I, 1993, FEBS LETT, V321, P224, DOI 10.1016/0014-5793(93)80113-9; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu XL, 2001, J BIOL CHEM, V276, P1735, DOI 10.1074/jbc.M006727200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	69	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51182	51192		10.1074/jbc.M407225200	http://dx.doi.org/10.1074/jbc.M407225200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15375154	hybrid			2022-12-25	WOS:000225355800065
J	Xu, L; Li, CL; Olson, AJ; Wilson, IA				Xu, L; Li, CL; Olson, AJ; Wilson, IA			Crystal structure of avian aminoimidazole-4-carboxamide ribonucleotide transformylase in complex with a novel non-folate inhibitor identified by virtual ligand screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTISUBSTRATE ADDUCT INHIBITOR; HUMAN GAR TFASE; FUNCTIONALIZED ANALOGS; AICAR TRANSFORMYLASE; POTENT INHIBITOR; ACTIVE-SITE; HIGH PH; DESIGN; CYCLOHYDROLASE; INSIGHTS	Aminoimidazole-4-carboxamide ribonucleotide transformylase (AICAR Tfase), one of the two folate-dependent enzymes in the de novo purine biosynthesis pathway, is a promising target for anti-neoplastic chemotherapy. Although classic antifolates, such as methotrexate, have been developed as anticancer agents, their general toxicity and drug resistance are major issues associated with their clinical use and future development. Identification of inhibitors with novel scaffolds could be an attractive alternative. We present here the crystal structure of avian AICAR Tfase complexed with the first non-folate based inhibitor identified through virtual ligand screening of the National Cancer Institute Diversity Set. The inhibitor 326203-A (2-[5-hydroxy-3-methyl-1-(2-methyl-4-sulfophenyl)-1H- pyrazol-4-ylazo]-4-sulfo-benzoic acid) displayed competitive inhibition against the natural cofactor, 10-formyl-tetrahydrofolate, with a K-i of 7.1 muM. The crystal structure of AICAR Tfase with 326203-A at 1.8 Angstrom resolution revealed a unique binding mode compared with antifolate inhibitors. The inhibitor also accessed an additional binding pocket that is not occupied by antifolates. The sulfonate group of 326203-A appears to form the dominant interaction of the inhibitor with the proposed oxyanion hole through interaction with a helix dipole and Lys(267). An aromatic interaction with Phe(316) also likely contributes to favorable binding. Based on these structural insights, several inhibitors with improved potency were subsequently identified in the National Cancer Institute Compound Library and the Available Chemical Directory by similarity search and molecular modeling methods. These results provide further support for our combined virtual ligand screening rational design approach for the discovery of novel, non-folate-based inhibitors of AICAR Tfase.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Li, Chenglong/E-7182-2010	Li, Chenglong/0000-0003-3174-8719	NCI NIH HHS [R24 CA95830, P01 CA63536] Funding Source: Medline; NCRR NIH HHS [P41 RR08606] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095830, P01CA063536] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beardsley GP, 1998, ADV EXP MED BIOL, V431, P221; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BLACK SL, 1978, ANAL BIOCHEM, V90, P397, DOI 10.1016/0003-2697(78)90042-8; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1839, DOI 10.1016/S0968-0896(97)00122-3; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1817, DOI 10.1016/S0968-0896(97)00120-X; Boger DL, 1997, BIOORGAN MED CHEM, V5, P1831, DOI 10.1016/S0968-0896(97)00121-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calvert H, 1999, SEMIN ONCOL, V26, P3; Chen JM, 1998, BIOCHEMISTRY-US, V37, P17735, DOI 10.1021/bi981848r; Cheong CG, 2004, J BIOL CHEM, V279, P18034, DOI 10.1074/jbc.M313691200; Christopherson RI, 2002, ACCOUNTS CHEM RES, V35, P961, DOI 10.1021/ar0000509; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO;2-R; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2; Greasley SE, 1999, BIOCHEMISTRY-US, V38, P16783, DOI 10.1021/bi991888a; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Greasley SE, 2001, BIOCHEMISTRY-US, V40, P13538, DOI 10.1021/bi011482+; Hanauske AR, 2001, ONCOLOGIST, V6, P363, DOI 10.1634/theoncologist.6-4-363; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamen B, 1997, SEMIN ONCOL, V24, P30; KLEIN C, 1995, J MOL BIOL, V249, P153, DOI 10.1006/jmbi.1995.0286; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI C, 2004, IN PRESS J MED CHEM; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Roberts JD, 2000, CANCER CHEMOTH PHARM, V45, P103, DOI 10.1007/s002800050017; Rowe P.B, 1971, METHODS ENZYMOL B, V18, P733; Segel I. H., 1993, ENZYME KINETICS BEHA, P100; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; Stout TJ, 1996, STRUCTURE, V4, P67, DOI 10.1016/S0969-2126(96)00010-X; Su Y, 1998, J MOL BIOL, V281, P485, DOI 10.1006/jmbi.1998.1931; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wolan DW, 2004, BIOCHEMISTRY-US, V43, P1171, DOI 10.1021/bi030162i; Wolan DW, 2003, BIOCHEMISTRY-US, V42, P10904, DOI 10.1021/bi030106h; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Zhang Y, 2002, BIOCHEMISTRY-US, V41, P14206, DOI 10.1021/bi020522m; Zhang Y, 2003, BIOCHEMISTRY-US, V42, P6043, DOI 10.1021/bi034219c	46	18	18	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50555	50565		10.1074/jbc.M406801200	http://dx.doi.org/10.1074/jbc.M406801200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355974	hybrid			2022-12-25	WOS:000225229500120
J	Chen, JH; Stoeber, K; Kingsbury, S; Ozanne, SE; Williams, GH; Hales, CN				Chen, JH; Stoeber, K; Kingsbury, S; Ozanne, SE; Williams, GH; Hales, CN			Loss of proliferative capacity and induction of senescence in oxidatively stressed human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFE-SPAN; DNA-REPLICATION; PREMATURE SENESCENCE; CELLULAR SENESCENCE; HYDROGEN-PEROXIDE; GROWTH ARREST; ONCOGENIC RAS; S-PHASE; P53; PROTEIN	Cellular senescence can result from short, dysfunctional telomeres, oxidative stress, or oncogene expression, and may contribute to aging. To investigate the role of cellular senescence in aging it is necessary to define the time-dependent molecular events by which it is characterized. Here we investigated changes in levels of key proteins involved in cell cycle regulation, DNA replication, and stress resistance in senescing human fibroblasts following oxidative stress. An immediate response in stressed cells was dephosphorylation of retinoblastoma (Rb) and cessation of DNA synthesis. This was followed by sequential induction of p53, p21, and p16. Increase in hypophosphorylated Rb and induction of p53 and p21 by a single stress treatment was transient, whereas sustained induction or dephosphorylation were achieved by a second stress. Down-regulation of the critical DNA replication initiation factor Cdc6 occurred early after stress concurring with p53 induction, and was followed by a decrease in Mcm2 levels. A late event in the stress-induced molecular sequence was the induction of SOD1, catalase, and HSP27 coinciding with development of the fully senescent phenotype. Our data suggest that loss of proliferative capacity in oxidatively stressed cells is a multistep process regulated by time-dependent molecular events that may play differential roles in induction and maintenance of cellular senescence.	Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2QR, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; UCL, Dept Histopathol, London WC1E 6JJ, England	University of Cambridge; University of London; University College London; University of London; University College London	Chen, JH (corresponding author), Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2QR, England.	jhc36@cam.ac.uk		Ozanne, Susan/0000-0001-8753-5144				Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2000, BIOGERONTOLOGY, V1, P335, DOI 10.1023/A:1026590501344; Cherif H, 2003, NUCLEIC ACIDS RES, V31, P1576, DOI 10.1093/nar/gkg208; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ferbeyre G, 2000, GENE DEV, V14, P2015; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Genova ML, 2004, ANN NY ACAD SCI, V1011, P86, DOI 10.1196/annals.1293.010; Hales CN, 2003, J PHYSIOL-LONDON, V547, P5, DOI 10.1113/jphysiol.2002.024406; Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7; Harman D, 2001, ANN NY ACAD SCI, V928, P1, DOI 10.1111/j.1749-6632.2001.tb05631.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Honda Y, 2002, ANN NY ACAD SCI, V959, P466, DOI 10.1111/j.1749-6632.2002.tb02117.x; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Martin-Ruiz C, 2004, J BIOL CHEM, V279, P17826, DOI 10.1074/jbc.M311980200; Melk A, 2003, KIDNEY INT, V63, P2134, DOI 10.1046/j.1523-1755.2003.00032.x; Melk A, 2004, KIDNEY INT, V65, P510, DOI 10.1111/j.1523-1755.2004.00438.x; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sasaki M, 2001, MECH AGEING DEV, V122, P1695, DOI 10.1016/S0047-6374(01)00281-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stoeber K, 1999, LANCET, V354, P1524, DOI 10.1016/S0140-6736(99)04265-8; Stoeber K, 2001, J CELL SCI, V114, P2027; Takayama S, 2003, ONCOGENE, V22, P9041, DOI 10.1038/sj.onc.1207114; Toussaint Olivier, 2002, TheScientificWorldJOURNAL, V2, P230; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	49	118	122	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49439	49446		10.1074/jbc.M409153200	http://dx.doi.org/10.1074/jbc.M409153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15377661	hybrid			2022-12-25	WOS:000225098100113
J	Pucci, B; De Felice, M; Rossi, M; Onesti, S; Pisani, FM				Pucci, B; De Felice, M; Rossi, M; Onesti, S; Pisani, FM			Amino acids of the Sulfolobus solfataricus mini-chromosome maintenance-like DNA helicase involved in DNA binding/remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MCM PROTEINS; REPLICATION INITIATION; BIOCHEMICAL-ANALYSIS; COMPLEX; THERMOAUTOTROPHICUM; BINDING; DUPLEX; FORK; MECHANISM; SUBSTRATE	Herein we report the identification of amino acids of the Sulfolobus solfataricus mini-chromosome maintenance (MCM)-like DNA helicase (SsoMCM), which are critical for DNA binding/remodeling. The crystallographic structure of the N-terminal portion (residues 2-286) of the Methanothermobacter thermoautotrophicum MCM protein revealed a dodecameric assembly with two hexameric rings in a head-to-head configuration and a positively charged central channel proposed to encircle DNA molecules. A structure-guided alignment of the M. thermoautotrophicum and S. solfataricus MCM sequences identified positively charged amino acids in SsoMCM that could point to the center of the channel. These residues (Lys-129, Lys-134, His-146, and Lys-194) were changed to alanine. The purified mutant proteins were all found to form homo-hexamers in solution and to retain full ATPase activity. K129A, H146A, and K194A SsoMCMs are unable to bind DNA either in single- or double-stranded form in band shift assays and do not display helicase activity. In contrast, the substitution of lysine 134 to alanine affects only binding to duplex DNA molecules, whereas it has no effect on binding to single- stranded DNA and on the DNA unwinding activity. These results have important implications for the understanding of the molecular mechanism of the MCM DNA helicase action.	CNR, Ist Biochim Prot, I-80131 Naples, Italy; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR); Imperial College London	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.	fm.pisani@ibp.cnr.it	Pucci, Biagio/AAS-7502-2021; Pisani, Francesca M./AAX-4025-2020; pucci, biagio/AAA-9268-2020	pucci, biagio/0000-0003-4502-1748; Onesti, Silvia/0000-0002-0612-7948				Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Carpentieri F, 2002, J BIOL CHEM, V277, P12118, DOI 10.1074/jbc.M200091200; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; De Felice M, 2004, J BIOL CHEM, V279, P43008, DOI 10.1074/jbc.M406693200; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Forsburg SL, 2004, MICROBIOL MOL BIOL R, V68, P109, DOI 10.1128/MMBR.68.1.109-131.2004; Grabowski B, 2003, ANNU REV MICROBIOL, V57, P487, DOI 10.1146/annurev.micro.57.030502.090709; Grainge I, 2003, NUCLEIC ACIDS RES, V31, P4888, DOI 10.1093/nar/gkg662; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishimi Y, 1998, J BIOL CHEM, V273, P8369, DOI 10.1074/jbc.273.14.8369; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Kaplan DL, 2003, J BIOL CHEM, V278, P49171, DOI 10.1074/jbc.M308074200; Kasiviswanathan R, 2004, J BIOL CHEM, V279, P28358, DOI 10.1074/jbc.M403202200; Kelman LM, 2003, MOL MICROBIOL, V48, P605, DOI 10.1046/j.1365-2958.2003.03369.x; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Laskey RA, 2003, EMBO REP, V4, P26, DOI 10.1038/sj.embor.embor706; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; Neuwald AF, 1999, GENOME RES, V9, P27; Pape T, 2003, EMBO REP, V4, P1079, DOI 10.1038/sj.embor.7400010; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; Putnam CD, 2001, J MOL BIOL, V311, P297, DOI 10.1006/jmbi.2001.4852; Sato M, 2000, J MOL BIOL, V300, P421, DOI 10.1006/jmbi.2000.3865; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Shin JH, 2003, J BIOL CHEM, V278, P49053, DOI 10.1074/jbc.M308599200; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; THOMPSON JD, 1997, NUCLEIC ACIDS RES, V25, P4867; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Yabuta N, 2003, GENES CELLS, V8, P413, DOI 10.1046/j.1365-2443.2003.00645.x; You ZY, 2003, EMBO J, V22, P6148, DOI 10.1093/emboj/cdg576; You ZY, 1999, MOL CELL BIOL, V19, P8003; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	39	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49222	49228		10.1074/jbc.M408967200	http://dx.doi.org/10.1074/jbc.M408967200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371413	hybrid			2022-12-25	WOS:000225098100088
J	Alric, J; Cuni, A; Maki, H; Nagashima, KVP; Vermeglio, A; Rappaport, F				Alric, J; Cuni, A; Maki, H; Nagashima, KVP; Vermeglio, A; Rappaport, F			Electrostatic interaction between redox cofactors in photosynthetic reaction centers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRIDIS REACTION-CENTER; REACTION-CENTER COMPLEX; CYTOCHROME-C SUBUNIT; RHODOPSEUDOMONAS-VIRIDIS; TETRAHEME CYTOCHROME; RUBRIVIVAX-GELATINOSUS; OXIDATION-REDUCTION; FUMARATE REDUCTASE; PURPLE BACTERIUM; DONOR SIDE	Intramolecular electron transfer within proteins is an essential process in bioenergetics. Redox cofactors are embedded in proteins, and this matrix strongly influences their redox potential. Several cofactors are usually found in these complexes, and they are structurally organized in a chain with distances between the electron donor and acceptor short enough to allow rapid electron tunneling. Among the different interactions that contribute to the determination of the redox potential of these cofactors, electrostatic interactions are important but restive to direct experimental characterization. The influence of interaction between cofactors is evidenced here experimentally by means of redox titrations and time-resolved spectroscopy in a chimeric bacterial reaction center (Maki, H., Matsuura, K., Shimada, K., and Nagashima, K. V. P. (2003) J. Biol. Chem. 278, 3921-3928) composed of the core subunits of Rubrivivax gelatinosus and the tetraheme cytochrome of Blastochloris viridis. The absorption spectra and orientations of the various cofactors of this chimeric reaction center are similar to those found in their respective native protein, indicating that their local environment is conserved. However, the redox potentials of both the primary electron donor and its closest heme are changed. The redox potential of the primary electron donor is downshifted in the chimeric reaction center when compared with the wild type, whereas, conversely, that of its closet heme is upshifted. We propose a model in which these reciprocal shifts in the midpoint potentials of two electron transfer partners are explained by an electrostatic interaction between them.	CNRS, UPR 1261, Inst Biol Physicochim, F-75005 Paris, France; CEA Aix Marseille II, CNRS, UMR 6191, Lab Genet & Biophys Plantes, F-13288 Marseille, France; Tokyo Metropolitan Univ, Dept Biol, Tokyo 1920397, Japan; CEA Aix Marseille II, CNRS,UMR 6191, CEA Cadarache, DSV DEVM Lab Bioenerget Cellulaire, F-13108 St Paul Les Durance, France	Centre National de la Recherche Scientifique (CNRS); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Tokyo Metropolitan University; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Rappaport, F (corresponding author), CNRS, UPR 1261, Inst Biol Physicochim, 13 Rue P&M Curie, F-75005 Paris, France.	Fabrice.Rappaport@ibpc.fr	Nagashima, Kenji V. P./M-2208-2017; Alric, Jean/E-3538-2013	Nagashima, Kenji V. P./0000-0002-4526-6625; Alric, Jean/0000-0003-3574-2234; Rappaport, Fabrice/0000-0001-9377-4934				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P258, DOI 10.1016/S0005-2728(05)80108-2; Armstrong FA, 2000, FARADAY DISCUSS, V116, P191, DOI 10.1039/b002290j; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; Baymann F, 1998, BIOCHEMISTRY-US, V37, P15320, DOI 10.1021/bi980963z; Beal D, 1999, REV SCI INSTRUM, V70, P202, DOI 10.1063/1.1149566; BEAL D, 1995, REV SCI INSTRUM, V1232, P180; Chen IP, 2000, BIOCHEMISTRY-US, V39, P3592, DOI 10.1021/bi992443p; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DRACHEVA SM, 1986, FEBS LETT, V205, P41, DOI 10.1016/0014-5793(86)80862-6; DUTTON PL, 1971, BIOCHIM BIOPHYS ACTA, V226, P63, DOI 10.1016/0005-2728(71)90178-2; GAO JL, 1990, BIOCHIM BIOPHYS ACTA, V1015, P96, DOI 10.1016/0005-2728(90)90220-X; Gunner MR, 1997, J BIOL INORG CHEM, V2, P126, DOI 10.1007/s007750050116; GUNNER MR, 1991, P NATL ACAD SCI USA, V88, P9151, DOI 10.1073/pnas.88.20.9151; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Johnson ET, 2002, BIOCHEMISTRY-US, V41, P6483, DOI 10.1021/bi012131y; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; Maki H, 2003, J BIOL CHEM, V278, P3921, DOI 10.1074/jbc.M209069200; Nagashima KVP, 1996, FEBS LETT, V385, P209, DOI 10.1016/0014-5793(96)00382-1; Nagashima KVP, 2002, BIOCHEMISTRY-US, V41, P14028, DOI 10.1021/bi026511a; NAGASHIMA KVP, 2004, 13 INT C PHOT; NITSCHKE W, 1994, BIOCHEM SOC T, V22, P694, DOI 10.1042/bst0220694; NITSCHKE W, 1989, BIOCHEMISTRY-US, V28, P3161, DOI 10.1021/bi00434a008; Nitschke W., 1995, ANOXYGENIC PHOTOSYNT, P775; ORTEGA JM, 1992, PHOTOSYNTH RES, V34, P127; ORTEGA JM, 1993, BIOCHEMISTRY-US, V32, P1141, DOI 10.1021/bi00055a020; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PARSON WW, 1990, BIOCHIM BIOPHYS ACTA, V1017, P251, DOI 10.1016/0005-2728(90)90192-7; Rappaport F, 1998, PHOTOSYNTH RES, V55, P317, DOI 10.1023/A:1005930018775; RUTHERFORD AW, 1990, BIOCHIM BIOPHYS ACTA, V1019, P128, DOI 10.1016/0005-2728(90)90133-O; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; Schutz CN, 2001, PROTEINS, V44, P400, DOI 10.1002/prot.1106; SEBBAN P, 1989, BIOCHIM BIOPHYS ACTA, V974, P54, DOI 10.1016/S0005-2728(89)80165-3; Ullmann GM, 1999, EUR BIOPHYS J BIOPHY, V28, P533, DOI 10.1007/s002490050236; UNDEN G, 1980, BIOCHIM BIOPHYS ACTA, V591, P275, DOI 10.1016/0005-2728(80)90159-0; VERMEGLIO A, 1989, FEBS LETT, V243, P259, DOI 10.1016/0014-5793(89)80140-1; Warshel A, 1998, CURR OPIN STRUC BIOL, V8, P211, DOI 10.1016/S0959-440X(98)80041-9; WARSHEL A, 1991, ANNU REV BIOPHYS BIO, V20, P267, DOI 10.1146/annurev.biophys.20.1.267; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4	38	14	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47849	47855		10.1074/jbc.M408888200	http://dx.doi.org/10.1074/jbc.M408888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347641	hybrid			2022-12-25	WOS:000224957000054
J	Aouacheria, A; Cluzel, C; Lethias, C; Gouy, M; Garrone, R; Exposito, JY				Aouacheria, A; Cluzel, C; Lethias, C; Gouy, M; Garrone, R; Exposito, JY			Invertebrate data predict an early emergence of vertebrate fibrillar collagen clades and an anti-incest model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V COLLAGEN; SEQUENCE ALIGNMENT; EXON STRUCTURE; GENE; EVOLUTION; PROCOLLAGEN; EXPRESSION; FIBRILLOGENESIS; IDENTIFICATION; HETEROTRIMERS	Fibrillar collagens are involved in the formation of striated fibrils and are present from the first multicellular animals, sponges, to humans. Recently, a new evolutionary model for fibrillar collagens has been suggested (Boot-Handford, R. P., Tuckwell, D. S., Plumb, D. A., Farrington Rock, C., and Poulsom, R. (2003) J. Biol. Chem. 278, 31067-31077). In this model, a rare genomic event leads to the formation of the founder vertebrate fibrillar collagen gene prior to the early vertebrate genome duplications and the radiation of the vertebrate fibrillar collagen clades (A, B, and C). Here, we present the modular structure of the fibrillar collagen chains present in different invertebrates from the protostome Anopheles gambiae to the chordate Ciona intestinalis. From their modular structure and the use of a triple helix instead of C-propeptide sequences in phylogenetic analyses, we were able to show that the divergence of A and B clades arose early during evolution because alpha chains related to these clades are present in protostomes. Moreover, the event leading to the divergence of B and C clades from a founder gene arose before the appearance of vertebrates; altogether these data contradict the Boot-Handford model. Moreover, they indicate that all the key steps required for the formation of fibrils of variable structure and functionality arose step by step during invertebrate evolution.	Univ Lyon 1, Inst Federat Rech Biosci Lyon Gerland 128, Inst Biol & Chim Prot, CNRS,UMR 5086, F-69367 Lyon 07, France; Univ Lyon 1, Lab Biometrie & Biol Evolut, CNRS, UMR 5558, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup	Exposito, JY (corresponding author), Univ Lyon 1, Inst Federat Rech Biosci Lyon Gerland 128, Inst Biol & Chim Prot, CNRS,UMR 5086, 7 Passage Vercors, F-69367 Lyon 07, France.	jy.exposito@ibcp.fr		Cluzel, Caroline/0000-0001-8946-3439; Exposito, Jean-Yves/0000-0002-4926-4942				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bailey WJ, 1997, MOL BIOL EVOL, V14, P843, DOI 10.1093/oxfordjournals.molbev.a025825; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; BLUMBERG B, 1988, J BIOL CHEM, V263, P18328; Boot-Handford RP, 2003, BIOESSAYS, V25, P142, DOI 10.1002/bies.10230; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; Cluzel C, 2004, J BIOL CHEM, V279, P9811, DOI 10.1074/jbc.M311803200; Cluzel C, 2001, J BIOL CHEM, V276, P18108, DOI 10.1074/jbc.M009597200; Exposito JY, 2000, MATRIX BIOL, V19, P275, DOI 10.1016/S0945-053X(00)00067-6; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; EXPOSITO JY, 1993, J MOL EVOL, V37, P254, DOI 10.1007/BF00175502; EXPOSITO JY, 1992, J BIOL CHEM, V267, P17404; EXPOSITO JY, 1992, J BIOL CHEM, V267, P15559; Exposito JY, 2002, ANAT RECORD, V268, P302, DOI 10.1002/ar.10162; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Garrone R, 1985, BIOL INVERTEBRATE LO, P157; HOLLAND PWH, 1994, DEVELOPMENT, P125; Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MIURA S, 1985, J BIOL CHEM, V260, P5352; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Ohno S., 1970, EVOLUTION GENE DUPLI; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; PERALA M, 1994, J BIOL CHEM, V269, P5064; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Saito M, 2001, EUR J BIOCHEM, V268, P2817, DOI 10.1046/j.1432-1327.2001.02160.x; Sicot FX, 1997, EUR J BIOCHEM, V246, P50, DOI 10.1111/j.1432-1033.1997.00050.x; Smith NGC, 1999, BIOESSAYS, V21, P697, DOI 10.1002/(SICI)1521-1878(199908)21:8<697::AID-BIES9>3.0.CO;2-X; TAKAHARA K, 1995, GENOMICS, V29, P588, DOI 10.1006/geno.1995.9961; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tillet E, 1996, COMP BIOCHEM PHYS B, V113, P239, DOI 10.1016/0305-0491(95)02014-4	33	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47711	47719		10.1074/jbc.M408950200	http://dx.doi.org/10.1074/jbc.M408950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358765	Green Published, hybrid			2022-12-25	WOS:000224957000037
J	Chaban, YL; Coskun, U; Keegstra, W; Oostergetel, GT; Boekema, EJ; Gruber, G				Chaban, YL; Coskun, U; Keegstra, W; Oostergetel, GT; Boekema, EJ; Gruber, G			Structural characterization of an ATPase active F-1-/V-1-ATPase (alpha(3)beta(3)EG) hybrid complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; THERMOPHILIC BACTERIUM PS3; ELECTRON-MICROSCOPY; SUBUNIT-G; V-ATPASE; BIOLOGICAL MACROMOLECULES; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; NEUROSPORA-CRASSA; MANDUCA-SEXTA	Co-reconstitution of subunits E and G of the yeast V-ATPase and the alpha and beta subunits of the F-1-ATPase from the thermophilic Bacillus PS3 (TF1) resulted in an alpha(3)beta(3)EG hybrid complex showing 53% of the ATPase activity of TF1. The alpha(3)beta(3)EG oligomer was characterized by electron microscopy. By processing 40,000 single particle projections, averaged two-dimensional projections at 1.2-2.4-nm resolution were obtained showing the hybrid complex in various positions. Difference mapping of top and side views of this complex with projections of the atomic model of the alpha(3)beta(3) subcomplex from TF1 (Shirakihara, Y., Leslie, A.G., Abrahams, J.P., Walker, J.E., Ueda, T., Sekimoto, Y., Kambara, M., Saika, K., Kagawa, Y., and Yoshida, M. (1997) Structure 5, 825-836) demonstrates that a seventh mass is located inside the shaft of the alpha(3)beta(3) barrel and extends out from the hexamer. Furthermore, difference mapping of the alpha(3)beta(3)EG oligomer with projections of the A(3)B(3)E and A(3)B(3)EC subcomplexes of the V-1 from Caloramator fervidus (Chaban, Y., Ubbink-Kok, T., Keegstra, W., Lolkema, J.S., and Boekema, E. J. (2002) EMBO Rep. 3, 982-987) shows that the mass inside the shaft is made up of subunit E, whereby subunit G was assigned to belong at least in part to the density of the protruding stalk. The formation of an active alpha(3)beta(3)EG hybrid complex indicates that the coupling subunit gamma inside the alpha(3)beta(3) oligomer of F-1 can be effectively replaced by subunit E of the V-ATPase. Our results have also demonstrated that the E and gamma subunits are structurally similar, despite the fact that their genes do not show significant homology.	Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Saarland, Fachrichtung Biophys 2 5, D-66421 Homburg, Germany	University of Groningen; Saarland University	Boekema, EJ (corresponding author), Univ Groningen, Dept Biophys Chem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	boekema@chem.rug.nl; ggrueber@uniklinik-saarland.de	Coskun, Ünal/F-4683-2011	Coskun, Ünal/0000-0003-4375-3144				Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Armbruster A, 2003, FEBS LETT, V546, P395, DOI 10.1016/S0014-5793(03)00643-4; ARNOLD A, 1976, ANAL BIOCHEM, V71, P209, DOI 10.1016/0003-2697(76)90029-4; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; Chaban Y, 2002, EMBO REP, V3, P982, DOI 10.1093/embo-reports/kvf196; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Crider BP, 1997, J BIOL CHEM, V272, P10721; Domgall I, 2002, J BIOL CHEM, V277, P13115, DOI 10.1074/jbc.M112011200; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; Dube P, 1998, J MOL BIOL, V279, P403, DOI 10.1006/jmbi.1998.1804; FRANK J, 1995, OPTIK, V98, P125; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; GOGARTEN JP, 1992, PHOTOSYNTH RES, V33, P137, DOI 10.1007/BF00039176; Gruber G, 2002, BIOCHEM BIOPH RES CO, V298, P383, DOI 10.1016/S0006-291X(02)02468-3; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; Hilario E, 1998, J MOL EVOL, V46, P703, DOI 10.1007/PL00006351; Inoue T, 2003, J BIOENERG BIOMEMBR, V35, P291, DOI 10.1023/A:1025720713747; ISHII N, 1993, J BIOCHEM-TOKYO, V113, P245, DOI 10.1093/oxfordjournals.jbchem.a124034; Jones RPO, 2001, MOL MEMBR BIOL, V18, P283; Kagawa Y, 1979, Methods Enzymol, V55, P781; Kaibara C, 1996, J BIOL CHEM, V271, P2433, DOI 10.1074/jbc.271.5.2433; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Z, 2004, IN PRESS PLANTA; Lolkema JS, 2003, J BIOENERG BIOMEMBR, V35, P323, DOI 10.1023/A:1025776831494; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Muller V, 2003, CELL MOL LIFE SCI, V60, P474, DOI 10.1007/s000180300040; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; Oostergetel GT, 1998, ULTRAMICROSCOPY, V74, P47, DOI 10.1016/S0304-3991(98)00022-9; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; Rizzo VF, 2003, J BIOL CHEM, V278, P270, DOI 10.1074/jbc.M208623200; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; Sun-Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; VANHEEL M, 1981, ULTRAMICROSCOPY, V6, P187, DOI 10.1016/0304-3991(81)90059-0; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6	51	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47866	47870		10.1074/jbc.M408460200	http://dx.doi.org/10.1074/jbc.M408460200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355991	Green Published, hybrid			2022-12-25	WOS:000224957000056
J	Lesnefsky, EJ; Chen, Q; Moghaddas, S; Hassan, MO; Tandler, B; Hoppel, CL				Lesnefsky, EJ; Chen, Q; Moghaddas, S; Hassan, MO; Tandler, B; Hoppel, CL			Blockade of electron transport during ischemia protects cardiac mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; MYOCARDIAL-ISCHEMIA; COMPLEX-III; OXIDATIVE-PHOSPHORYLATION; SUPEROXIDE-PRODUCTION; HEART-MITOCHONDRIA; ADENINE-NUCLEOTIDE; CARDIOLIPIN; PHOSPHOLIPIDS; RADICALS	Subsarcolemmal mitochondria sustain progressive damage during myocardial ischemia. Ischemia decreases the content of the mitochondrial phospholipid cardiolipin accompanied by a decrease in cytochrome c content and a diminished rate of oxidation through cytochrome oxidase. We propose that during ischemia mitochondria produce reactive oxygen species at sites in the electron transport chain proximal to cytochrome oxidase that contribute to the ischemic damage. Isolated, perfused rabbit hearts were treated with rotenone, an irreversible inhibitor of complex I in the proximal electron transport chain, immediately before ischemia. Rotenone pretreatment preserved the contents of cardiolipin and cytochrome c measured after 45 min of ischemia. The rate of oxidation through cytochrome oxidase also was improved in rotenone-treated hearts. Inhibition of the electron transport chain during ischemia lessens damage to mitochondria. Rotenone treatment of isolated subsarcolemmal mitochondria decreased the production of reactive oxygen species during the oxidation of complex I substrates. Thus, the limitation of electron flow during ischemia preserves cardiolipin content, cytochrome c content, and the rate of oxidation through cytochrome oxidase. The mitochondrial electron transport chain contributes to ischemic mitochondrial damage that in turn augments myocyte injury during subsequent reperfusion.	Louis Stokes Vet Adm Med Ctr, Med Serv, Cleveland, OH 44106 USA; Louis Stokes Vet Adm Med Ctr, Pathol Serv, Cleveland, OH 44106 USA; Louis Stokes Vet Adm Med Ctr, Lab Med Serv, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Dent, Dept Med, Div Cardiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Dent, Dept Med, Div Clin Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Dent, Dept Med, Div Pharmacol, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Lesnefsky, EJ (corresponding author), Louis Stokes VA Med Ctr, Cardiol Sect, Med Serv 111W, 10701 E Blvd, Cleveland, OH 44106 USA.	EXL9@po.cwru.edu			NIA NIH HHS [1K04AG00676] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K04AG000676] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; ASIMAKIS GK, 1984, J MOL CELL CARDIOL, V16, P439, DOI 10.1016/S0022-2828(84)80615-X; BABCOCK GT, 1993, J BIOENERG BIOMEMBR, V25, P71, DOI 10.1007/BF00762849; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Borutaite V, 2003, FEBS LETT, V541, P1, DOI 10.1016/S0014-5793(03)00278-3; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; COOPER CE, 1990, BIOCHEMISTRY-US, V29, P3865, DOI 10.1021/bi00468a010; DAS DK, 1989, BIOCHEM BIOPH RES CO, V165, P1004, DOI 10.1016/0006-291X(89)92702-2; DUAN JM, 1989, CAN J PHYSIOL PHARM, V67, P704, DOI 10.1139/y89-114; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; FLAMENG W, 1991, J MOL CELL CARDIOL, V23, P1, DOI 10.1016/0022-2828(91)90034-J; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; Gille L, 2001, ARCH BIOCHEM BIOPHYS, V388, P34, DOI 10.1006/abbi.2000.2257; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Herrero A, 1997, MECH AGEING DEV, V98, P95, DOI 10.1016/S0047-6374(97)00076-6; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; INGALLS ST, 1993, J CHROMATOGR-BIOMED, V619, P9, DOI 10.1016/0378-4347(93)80441-6; KAJIYAMA K, 1987, CIRC RES, V61, P301, DOI 10.1161/01.RES.61.2.301; Kevin LG, 2003, AM J PHYSIOL-HEART C, V284, pH566, DOI 10.1152/ajpheart.00711.2002; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lesnefsky EJ, 2000, ANAL BIOCHEM, V285, P246, DOI 10.1006/abio.2000.4783; Lesnefsky EJ, 1997, AM J PHYSIOL-HEART C, V273, pH1544, DOI 10.1152/ajpheart.1997.273.3.H1544; Lesnefsky EJ, 2001, AM J PHYSIOL-HEART C, V280, pH2770; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P37, DOI 10.1006/jmcc.2000.1273; Lesnefsky EJ, 2001, J MOL CELL CARDIOL, V33, P1065, DOI 10.1006/jmcc.2001.1378; Lesnefsky EJ, 2001, ARCH BIOCHEM BIOPHYS, V385, P117, DOI 10.1006/abbi.2000.2066; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Paradies G, 1998, FEBS LETT, V424, P155, DOI 10.1016/S0014-5793(98)00161-6; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PARADIES G, 1993, ARCH BIOCHEM BIOPHYS, V307, P91, DOI 10.1006/abbi.1993.1565; PARINANDI NL, 1991, ARCH BIOCHEM BIOPHYS, V289, P118, DOI 10.1016/0003-9861(91)90450-W; PIPER HM, 1985, J MOL CELL CARDIOL, V17, P885, DOI 10.1016/S0022-2828(85)80102-4; POWELL GL, 1985, BIOCHIM BIOPHYS ACTA, V816, P191, DOI 10.1016/0005-2736(85)90409-2; Raha S, 2000, FREE RADICAL BIO MED, V29, P170, DOI 10.1016/S0891-5849(00)00338-5; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; ROUSLIN W, 1983, AM J PHYSIOL, V244, pH743, DOI 10.1152/ajpheart.1983.244.6.H743; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Salamon Z, 1997, J BIOENERG BIOMEMBR, V29, P211, DOI 10.1023/A:1022401825287; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; SHLAFER M, 1990, BASIC RES CARDIOL, V85, P318, DOI 10.1007/BF01907125; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Steel R.G., 1980, PRINCIPLES PROCEDURE, P481; UETA H, 1990, J MOL CELL CARDIOL, V22, P893, DOI 10.1016/0022-2828(90)90120-Q; VandenHoek TL, 1997, J MOL CELL CARDIOL, V29, P2571, DOI 10.1006/jmcc.1997.0497; VEITCH K, 1992, BIOCHEM J, V281, P709, DOI 10.1042/bj2810709; VIK SB, 1977, BIOCHEMISTRY-US, V16, P5755, DOI 10.1021/bi00645a016	55	179	181	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47961	47967		10.1074/jbc.M409720200	http://dx.doi.org/10.1074/jbc.M409720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347666	hybrid			2022-12-25	WOS:000224957000066
J	Osterloh, A; Meier-Stiegen, F; Veit, A; Fleischer, B; von Bonin, A; Breloer, M				Osterloh, A; Meier-Stiegen, F; Veit, A; Fleischer, B; von Bonin, A; Breloer, M			Lipopolysaccharide-free heat shock protein 60 activates T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; INNATE IMMUNE-SYSTEM; MURINE MACROPHAGES; EXPRESSION VECTOR; DENDRITIC CELLS; DANGER SIGNALS; RECEPTOR; INDUCTION; ENDOTOXIN	A possible function of eukaryotic heat shock protein 60 (Hsp60) as endogenous danger signal has been controversially discussed in the past. Hsp60 was shown to induce the secretion of proinflammatory cytokines in professional antigen-presenting cells and to enhance the activation of T cells in primary stimulation. However, in vitro activation of macrophages by Hsp60 was attributed to contaminating endotoxin in the recombinant Hsp60 protein preparations. Here, we employ low endotoxin recombinant human Hsp60 and murine Hsp60 expressed by eukaryotic cell lines to dissect the Hsp60 protein-mediated effects from biologic effects that are mediated by prokaryotic contaminants in the Hsp60 protein preparation. The induction of tumor necrosis factor-alpha secretion in mouse macrophages is lost after endotoxin removal and is not mediated by Hsp60 expressed in eukaryotic systems. In contrast, the Hsp60-mediated enhancement of antigen-specific T cell activation does not correlate with endotoxin contamination. Moreover, Hsp60 that is expressed on the surface of different eukaryotic cell lines increases the activation of T cells in primary stimulation. Taken together, we provide evidence that endogenous Hsp60, which is thought to be released from dying infected cells in vivo, has a biological function that is not due to contaminating pathogen-associated molecules.	Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Bernhard Nocht Institut fur Tropenmedizin	Breloer, M (corresponding author), Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.	MBreloer@aol.com	Breloer, Minka/F-3999-2018; Osterloh, Anke/ABA-8626-2021	Breloer, Minka/0000-0001-6199-4908; 				Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Bethke K, 2002, J IMMUNOL, V169, P6141, DOI 10.4049/jimmunol.169.11.6141; Birk OS, 1999, P NATL ACAD SCI USA, V96, P5159, DOI 10.1073/pnas.96.9.5159; Breloer M, 2001, EUR J IMMUNOL, V31, P2051, DOI 10.1002/1521-4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H; Chen W, 1999, J IMMUNOL, V162, P3212; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gao BC, 2004, BIOCHEM BIOPH RES CO, V317, P1149, DOI 10.1016/j.bbrc.2004.03.160; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Heyrovska N, 1998, BIOL CHEM, V379, P301, DOI 10.1515/bchm.1998.379.3.301; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Lee HK, 2002, J IMMUNOL, V168, P4012, DOI 10.4049/jimmunol.168.8.4012; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu B, 2003, P NATL ACAD SCI USA, V100, P15824, DOI 10.1073/pnas.2635458100; Matzinger P, 2002, ANN NY ACAD SCI, V961, P341, DOI 10.1111/j.1749-6632.2002.tb03118.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; More SH, 2001, INT IMMUNOL, V13, P1121, DOI 10.1093/intimm/13.9.1121; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Singh-Jasuja H, 2001, BIOL CHEM, V382, P629, DOI 10.1515/BC.2001.074; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Wang MH, 2004, BRIT J CANCER, V90, P926, DOI 10.1038/sj.bjc.6601583; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zanin-Zhorov A, 2003, FASEB J, V17, P1567, DOI 10.1096/fj.02-1139fje	33	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47906	47911		10.1074/jbc.M408440200	http://dx.doi.org/10.1074/jbc.M408440200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15371451	hybrid			2022-12-25	WOS:000224957000061
J	Woo, JR; Kim, SJ; Jeong, WJ; Cho, YH; Lee, SC; Chung, YJ; Rhee, SG; Ryu, SE				Woo, JR; Kim, SJ; Jeong, WJ; Cho, YH; Lee, SC; Chung, YJ; Rhee, SG; Ryu, SE			Structural basis of cellular redox regulation by human TRP14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-RELATED PROTEIN; DNA-BINDING ACTIVITY; CRYSTAL-STRUCTURES; IDENTIFICATION; ASSOCIATION; REDUCTION; OXIDATION; INSIGHTS; PEPTIDE; TARGET	Thioredoxin-related protein 14 (TRP14) is involved in regulating tumor necrosis factor-alpha-induced signaling pathways in a different manner from human thioredoxin 1 (Trx1). Here, we report the crystal structure of human TRP14 determined at 1.8-Angstrom resolutions. The structure reveals a typical thioredoxin fold with characteristic structural features that account for the substrate specificity of the protein. The surface of TRP14 in the vicinity of the active site includes an extended loop and an additional alpha-helix, and the distribution of charged residues in the surface is different from Trx1. The distinctive dipeptide between the redox-active cysteines contributes to stabilizing the thiolate anion of the active site cysteine 43, increasing reactivity of the cysteine toward substrates. These structural differences in the active site suggest that TRP14 has evolved to regulate cellular redox signaling by recognizing a distinctive group of substrates that would complement the group of proteins regulated by Trx1.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Taejon 305806, South Korea; Korea Res Inst Biosci & Biotechnol, Systemic Proteom Res Ctr, Taejon 305806, South Korea; Chungbuk Natl Univ, Dept Biochem, Chonju 360763, South Korea; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungbuk National University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Ewha Womans University	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, 52 Euh Eun Dong, Taejon 305806, South Korea.	ryuse@kribb.re.kr						Akamatsu Y, 1997, J BIOL CHEM, V272, P14497, DOI 10.1074/jbc.272.23.14497; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Guddat LW, 1997, PROTEIN SCI, V6, P1893, DOI 10.1002/pro.5560060910; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; HALLIWELL B, 1999, FREE RADICAL BIO MED, P430; Hirota K, 2002, ANN NY ACAD SCI, V957, P189, DOI 10.1111/j.1749-6632.2002.tb02916.x; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; Jeong W, 2004, J BIOL CHEM, V279, P3151, DOI 10.1074/jbc.M307959200; Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim SJ, 2003, J BIOL CHEM, V278, P10790, DOI 10.1074/jbc.M209553200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laughner BJ, 1998, PLANT PHYSIOL, V118, P987, DOI 10.1104/pp.118.3.987; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Matsuo Y, 2002, DRUG NEWS PERSPECT, V15, P575, DOI 10.1358/dnp.2002.15.9.840062; Matsuo Y, 2001, J BIOL CHEM, V276, P10032, DOI 10.1074/jbc.M011037200; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Stadtman ER, 2002, MOL CELL BIOCHEM, V234, P3, DOI 10.1023/A:1015916831583; Stehr M, 2001, J BIOL CHEM, V276, P35836, DOI 10.1074/jbc.M105094200; Stubbe J, 1998, TRENDS BIOCHEM SCI, V23, P438, DOI 10.1016/S0968-0004(98)01296-1; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2	35	32	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48120	48125		10.1074/jbc.M407079200	http://dx.doi.org/10.1074/jbc.M407079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355959	hybrid			2022-12-25	WOS:000224957000085
J	Boyd, JM; Ellsworth, H; Ensign, SA				Boyd, JM; Ellsworth, H; Ensign, SA			Bacterial acetone carboxylase is a manganese-dependent metalloenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XANTHOBACTER STRAIN PY2; ELECTRON-PARAMAGNETIC-RESONANCE; SULFATE-REDUCING BACTERIUM; DESULFOCOCCUS-BIACUTUS; RHODOBACTER-CAPSULATUS; ANAEROBIC DEGRADATION; DENITRIFYING BACTERIA; MICROBIAL-METABOLISM; CYTOCHROME-P450 2E1; PROTEIN PHOSPHATASE	Bacterial acetone carboxylase catalyzes the ATP-dependent carboxylation of acetone to acetoacetate with the concomitant production of AMP and two inorganic phosphates. The importance of manganese in Rhodobacter capsulatus acetone carboxylase has been established through a combination of physiological, biochemical, and spectroscopic studies. Depletion of manganese from the R. capsulatus growth medium resulted in inhibition of acetone-dependent but not malate-dependent cell growth. Under normal growth conditions (0.5 muM Mn2+ in medium), growth with acetone as the carbon source resulted in a 4-fold increase in intracellular protein-bound manganese over malate-grown cells and the appearance of a Mn2+ EPR signal centered at g = 2 that was absent in malate-grown cells. Acetone carboxylase purified from cells grown with 50 muM Mn2+ had a 1.6-fold higher specific activity and 1.9-fold higher manganese content than cells grown with 0.5 muM Mn2+, consistently yielding a stoichiometry of 1.9 manganese/alpha(2)beta(2)gamma(2) multimer, or 0.95 manganese/alphabetagamma protomer. Manganese in acetone carboxylase was tightly bound and not removed upon dialysis against various metal ion chelators. The addition of acetone to malate-grown cells grown in medium depleted of manganese resulted in the high level synthesis of acetone carboxylase (15-20% soluble protein), which, upon purification, exhibited 7% of the activity and 6% of the manganese content of the enzyme purified from acetone-grown cells. EPR analysis of purified acetone carboxylase indicates the presence of a mononuclear Mn2+ center, with possible spin coupling of two mononuclear sites. The addition of Mg.ATP or Mg.AMP resulted in EPR spectral changes, whereas the addition of acetone, CO2, inorganic phosphate, and acetoacetate did not perturb the EPR. These studies demonstrate that manganese is essential for acetone carboxylation and suggest a role for manganese in nucleotide binding and activation.	Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Utah System of Higher Education; Utah State University	Ensign, SA (corresponding author), Utah State Univ, Dept Chem & Biochem, 0300 Old Main Hill, Logan, UT 84322 USA.	ensigns@cc.usu.edu		Boyd, Jeffrey/0000-0001-7721-3926	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051805, R01GM051805] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51805] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen JR, 1996, J BACTERIOL, V178, P1469, DOI 10.1128/jb.178.5.1469-1472.1996; ARGILES JM, 1986, TRENDS BIOCHEM SCI, V11, P61, DOI 10.1016/0968-0004(86)90256-2; Ash DE, 2000, MET IONS BIOL SYST, V37, P407; Birks SJ, 1997, MICROBIOL-UK, V143, P755, DOI 10.1099/00221287-143-3-755; Bondoc FY, 1999, BIOCHEM PHARMACOL, V58, P461, DOI 10.1016/S0006-2952(99)00111-2; BONNETSMITS EM, 1988, J GEN MICROBIOL, V134, P2281; CHEN LS, 1994, BIOCHEM PHARMACOL, V48, P2199, DOI 10.1016/0006-2952(94)00435-8; CHROMY V, 1974, CLIN CHEM, V20, P1362; Clark DD, 1999, J BACTERIOL, V181, P2752, DOI 10.1128/JB.181.9.2752-2758.1999; Crowley JD, 2000, MET IONS BIOL SYST, V37, P209; Davies R, 1941, BIOCHEM J, V35, P1320, DOI 10.1042/bj0351320; Ensign SA, 1998, ARCH MICROBIOL, V169, P179, DOI 10.1007/s002030050558; GRISCOM DL, 1967, J CHEM PHYS, V47, P2711, DOI 10.1063/1.1712288; JANSSEN PH, 1995, J BACTERIOL, V177, P277, DOI 10.1128/jb.177.2.277-282.1995; JANSSEN PH, 1995, ARCH MICROBIOL, V163, P188, DOI 10.1007/BF00305352; Kalapos MP, 1999, MED HYPOTHESES, V53, P236, DOI 10.1054/mehy.1998.0752; Kelly BS, 2002, J BIOL CHEM, V277, P50, DOI 10.1074/jbc.M107961200; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; KOOP DR, 1985, J BIOL CHEM, V260, P3607; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKINS HB, 1963, J BACTERIOL, V85, P1074, DOI 10.1128/JB.85.5.1074-1087.1963; MADIGAN MT, 1990, FEMS MICROBIOL LETT, V71, P281, DOI 10.1016/0378-1097(90)90234-H; Nocek B, 2004, ACTA CRYSTALLOGR D, V60, P385, DOI 10.1107/S0907444903028373; Pierce BS, 2003, J AM CHEM SOC, V125, P8748, DOI 10.1021/ja021290h; PLATEN H, 1989, J GEN MICROBIOL, V135, P883; PLATEN H, 1987, ARCH MICROBIOL, V149, P136, DOI 10.1007/BF00425079; PLATEN H, 1990, ARCH MICROBIOL, V154, P355, DOI 10.1007/BF00276531; PLATEN H, 1994, FEMS MICROBIOL LETT, V122, P27, DOI 10.1111/j.1574-6968.1994.tb07138.x; Platen H, 1990, BIODEGRADATION, V1, P243, DOI 10.1007/BF00119761; Poyner RR, 2001, BIOCHEMISTRY-US, V40, P8009, DOI 10.1021/bi0103922; Rabus R, 2002, ARCH MICROBIOL, V178, P506, DOI 10.1007/s00203-002-0487-2; RECZKOWSKI RS, 1992, J AM CHEM SOC, V114, P10992, DOI 10.1021/ja00053a064; Reed G., 1984, BIOL MAGN RESON, V6, P73; REED GH, 1974, BIOCHEMISTRY-US, V13, P3537, DOI 10.1021/bi00714a020; Reed GH, 2000, MET IONS BIOL SYST, V37, P183; Requena L, 1999, BIOCHEM J, V343, P185, DOI 10.1042/0264-6021:3430185; Rusnak F, 1999, BIOCHEMISTRY-US, V38, P6943, DOI 10.1021/bi982606u; SCHREURS JWH, 1978, J CHEM PHYS, V69, P2151, DOI 10.1063/1.436815; Shi L, 2001, J BACTERIOL, V183, P7053, DOI 10.1128/JB.183.24.7053-7057.2001; SIEGEL JM, 1950, J BACTERIOL, V60, P595, DOI 10.1128/JB.60.5.595-606.1950; Sluis MK, 1997, P NATL ACAD SCI USA, V94, P8456, DOI 10.1073/pnas.94.16.8456; Sluis MK, 2002, J BACTERIOL, V184, P2969, DOI 10.1128/JB.184.11.2969-2977.2002; Sluis MK, 1996, J BACTERIOL, V178, P4020, DOI 10.1128/jb.178.14.4020-4026.1996; Tanner A, 2001, J BIOL CHEM, V276, P43627, DOI 10.1074/jbc.M107202200; TAYLOR DG, 1980, J GEN MICROBIOL, V118, P159; VESTAL JR, 1969, J BACTERIOL, V99, P216, DOI 10.1128/JB.99.1.216-221.1969; VILLAFRANCA JJ, 1976, BIOCHEMISTRY-US, V15, P544, DOI 10.1021/bi00648a014; WESTHEIMER FH, 1969, METHOD ENZYMOL, V14, P231; White DJ, 2001, BIOCHEMISTRY-US, V40, P8918, DOI 10.1021/bi010637a; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; Whittaker MM, 2002, J BIOL INORG CHEM, V7, P136, DOI 10.1007/s007750100281; ZHUO S, 1993, J BIOL CHEM, V268, P17754	53	31	32	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46644	46651		10.1074/jbc.M407177200	http://dx.doi.org/10.1074/jbc.M407177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337755	hybrid			2022-12-25	WOS:000224832400039
J	Das, A; Rajagopalan, L; Mathura, VS; Rigby, SJ; Mitra, S; Hazra, TK				Das, A; Rajagopalan, L; Mathura, VS; Rigby, SJ; Mitra, S; Hazra, TK			Identification of a zinc finger domain in the human NEIL2 (Nei-like-2) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ENDONUCLEASE-VIII; HUMAN DNA GLYCOSYLASE; BASE EXCISION-REPAIR; OXIDATIVELY DAMAGED DNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; FPG PROTEIN; BINDING DOMAIN; ENZYME; POLY(ADP-RIBOSE)POLYMERASE	The recently identified human NEIL2 (Nei-like-2) protein, a DNA glycosylase/AP lyase specific for oxidatively damaged bases, shares structural features and reaction mechanism with the Escherichia coli DNA glycosylases, Nei and Fpg. Amino acid sequence analysis of NEIL2 suggested it to have a zinc finger-like Nei/Fpg. However, the Cys-X-2-His-X-16-Cys-X-2-Cys (CHCC) motif present near the C terminus of NEIL2 is distinct from the zinc finger motifs of Nei/Fpg, which are of the C4 type. Here we show the presence of an equimolar amount of zinc in NEIL2 by inductively coupled plasma mass spectrometry. Individual mutations of Cys-291, His-295, Cys-315, and Cys-318, candidate residues for coordinating zinc, inactivated the enzyme by abolishing its DNA binding activity. H295A and C318S mutants were also shown to lack bound zinc, and a significant change in their secondary structure was revealed by CD spectra analysis. Molecular modeling revealed Arg-310 of NEIL2 to be a critical residue in its zinc binding pocket, which is highly conserved throughout the Fpg/Nei family. A R310Q mutation significantly reduced the activity of NEIL2. We thereby conclude that the zinc finger motif in NEIL2 is essential for its structural integrity and enzyme activity.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Roskamp Inst, Sarasota, FL 34243 USA; Univ Calif San Diego, Scripps Inst Oceanog, Dept Geol, La Jolla, CA 92093 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Diego; Scripps Institution of Oceanography	Hazra, TK (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-136 Med Res Bldg,Rte 1079, Galveston, TX 77555 USA.	tkhazra@utmb.edu	Classen, Scott/AAY-8176-2020		NCI NIH HHS [P01 CA 92584, R01 CA81063] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081063, P01CA092584] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Baldwin MA, 2002, METHOD ENZYMOL, V353, P54; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; Bates PA, 2001, PROTEINS, P39; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; BOITEUX S, 1993, J PHOTOCH PHOTOBIO B, V19, P87, DOI 10.1016/1011-1344(93)87101-R; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; BROWN RS, 1985, FEBS LETT, V186, P271, DOI 10.1016/0014-5793(85)80723-7; DOOLITTLE RF, 1986, NATURE, V323, P451, DOI 10.1038/323451a0; Dou H, 2003, J BIOL CHEM, V278, P49679, DOI 10.1074/jbc.M308658200; Doublie S, 2004, P NATL ACAD SCI USA, V101, P10284, DOI 10.1073/pnas.0402051101; Falchuk K H, 1993, Prog Clin Biol Res, V380, P91; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Hasan RJ, 2002, INFECT IMMUN, V70, P4485, DOI 10.1128/IAI.70.8.4485-4493.2002; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Ho E, 2003, J NUTR, V133, P2543, DOI 10.1093/jn/133.8.2543; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Ivanciuc O, 2004, CURR MED CHEM, V11, P583, DOI 10.2174/0929867043455819; Jiang DY, 1997, J BACTERIOL, V179, P3773, DOI 10.1128/jb.179.11.3773-3782.1997; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; Krokan HE, 1997, BIOCHEM J, V325, P1; Labesse G, 1998, BIOINFORMATICS, V14, P206, DOI 10.1093/bioinformatics/14.2.206; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Mathura VS, 2003, J MOL MODEL, V9, P298, DOI 10.1007/s00894-003-0152-y; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; McCullough AK, 1999, ANNU REV BIOCHEM, V68, P255, DOI 10.1146/annurev.biochem.68.1.255; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; Rosenquist TA, 2003, DNA REPAIR, V2, P581, DOI 10.1016/S1568-7864(03)00025-9; SCHAUMANN T, 1990, BIOPOLYMERS, V29, P679, DOI 10.1002/bip.360290403; Sugahara M, 2000, EMBO J, V19, P3857, DOI 10.1093/emboj/19.15.3857; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Zharkov DO, 2003, DNA REPAIR, V2, P839, DOI 10.1016/S1568-7864(03)00084-3; Zharkov DO, 1997, J BIOL CHEM, V272, P5335, DOI 10.1074/jbc.272.8.5335; Zharkov DO, 2002, EMBO J, V21, P789, DOI 10.1093/emboj/21.4.789	49	30	32	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47132	47138		10.1074/jbc.M406224200	http://dx.doi.org/10.1074/jbc.M406224200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339932	hybrid			2022-12-25	WOS:000224832400100
J	Lou, ZK; Chen, BPC; Asaithamby, A; Minter-Dykhouse, K; Chen, DJ; Chen, JJ				Lou, ZK; Chen, BPC; Asaithamby, A; Minter-Dykhouse, K; Chen, DJ; Chen, JJ			MDC1 regulates DNA-PK autophosphorylation in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; ATM ACTIVATION; PHOSPHORYLATION; REPAIR; REQUIREMENT; MEDIATOR; COMPLEX; 53BP1; CHK2	DNA damage initiates signaling events through kinase cascades that result in cell cycle checkpoint control and DNA repair. However, it is not yet clear how the signaling pathways relay to DNA damage repair. Using the repeat region of checkpoint protein MDC1 (mediator of DNA damage checkpoint protein 1), we identified DNA-PKcs/Ku as MDC1-associated proteins. Here, we show that MDC1 directly interacts with the Ku/DNA-PKcs complex. Down-regulation of MDC1 resulted in defective phospho-DNA-PKcs foci formation and DNA-PKcs autophosphorylation, suggesting that MDC1 regulates autophosphorylation of DNA-PKcs following DNA damage. Furthermore, DNA-PK-dependent DNA damage repair is defective in cells depleted of MDC1. Taken together, these results suggest that the MDC1 repeat region is involved in protein-protein interaction with DNA-PKcs/Ku, and MDC1 regulates DNA damage repair by influencing DNA-PK autophosphorylation. Therefore, MDC1 acts not only as a mediator of DNA damage checkpoint but also as a mediator of DNA damage repair.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Mayo Clinic; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, 200 1st St SW, Rochester, MN 55905 USA.	Chen.Junjie@mayo.edu	Minter Dykhouse, Katherine/L-4573-2013	Minter Dykhouse, Katherine/0000-0003-4363-5826	NATIONAL CANCER INSTITUTE [R37CA050519, R01CA050519, R01CA092312, R01CA089239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018949] Funding Source: NIH RePORTER; NCI NIH HHS [CA92312, CA50519, R01 CA89239] Funding Source: Medline; NIA NIH HHS [AG18949] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Mochan TA, 2003, CANCER RES, V63, P8586; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; SMITHRAVIN J, 1989, INT J RADIAT BIOL, V56, P951, DOI 10.1080/09553008914552411; Soubeyrand S, 2003, CANCER RES, V63, P1198; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200	22	64	70	6	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46359	46362		10.1074/jbc.C400375200	http://dx.doi.org/10.1074/jbc.C400375200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15377652	hybrid			2022-12-25	WOS:000224832400003
J	Yang, XL; Karsenty, G				Yang, XL; Karsenty, G			ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; CLEIDOCRANIAL DYSPLASIA; OSTEOGENESIS IMPERFECTA; SELECTIVE INHIBITORS; DEGRADATION; ELEMENT; DIFFERENTIATION; OSF2/CBFA1	Based on the analysis of a loss-of-function model, we recently showed that ATF4 regulates osteoblast terminal differentiation and function and is implicated in the pathophysiology of Coffin-Lowry syndrome. That study, however, did not address whether forced expression of Atf4 in non-osteoblastic cells would lead to osteoblast-specific gene expression, one of the most important features of a cell differentiation factor. To address this question we searched for cell lines that would not express Atf4. Contrasting with the restricted pattern of its protein accumulation, Atf4 mRNA was found in all cell lines and mouse tissues tested. Treatment of non-osteoblastic cells with MG115, a proteasome inhibitor, induced ATF4 accumulation and resulted in activation of an Osteocalcin promoter luciferase construct as well as expression of endogenous Osteocalcin, a molecular marker of differentiated osteoblasts and a target gene of ATF4. Eliminating the expression of beta-TrCP1, an ubiquitin-protein isopeptide ligase interacting with ATF4 by RNA interference, led to ATF4 accumulation and to endogenous Osteocalcin expression in fibroblasts. These results indicate that the absence of ATF4 in most cell types is determined, at least in part, by an ubiquitination-dependent process. To our knowledge ATF4 is the first cell-specific transcription factor in which cell-specific distribution is achieved post-translationally. This study also establishes that ATF4, like other osteoblast differentiation factors, such as Runx2 and Osterix, has the ability to induce osteoblast-specific gene expression in non-osteoblastic cells.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Bone Dis Program Texas, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Karsenty, G (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.	karsenty@bcm.tmc.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01 DE 11290] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BYERS PH, 1984, AM J MED GENET, V17, P429, DOI 10.1002/ajmg.1320170206; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fischer C, 2004, BIOL REPROD, V70, P371, DOI 10.1095/biolreprod.103.021600; Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; KLEEREKOPER M, 1998, METABOLIC BONE DIS, P387; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; MIELNICKI LM, 1991, NUCLEIC ACIDS RES, V19, P6332, DOI 10.1093/nar/19.22.6332; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PROCKOP DJ, 1984, AM J HUM GENET, V36, P499; Raisz L.G., 2002, PRINCIPLES BONE BIOL, P59; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rowe NM, 1998, PLAST RECONSTR SURG, V102, P2022, DOI 10.1097/00006534-199811000-00033; Schinke T, 1999, J BIOL CHEM, V274, P30182, DOI 10.1074/jbc.274.42.30182; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tanaka T, 1998, GENES CELLS, V3, P801, DOI 10.1046/j.1365-2443.1998.00230.x; TSUJIMOTO A, 1991, J VIROL, V65, P1420, DOI 10.1128/JVI.65.3.1420-1426.1991; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7	28	140	148	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47109	47114		10.1074/jbc.M410010200	http://dx.doi.org/10.1074/jbc.M410010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15377660	hybrid			2022-12-25	WOS:000224832400097
J	Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA				Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA			Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells	ONCOGENE			English	Article						BMP; BMP receptors; prostate cancer	OSTEOGENIC PROTEIN-1; GROWTH-FACTOR; IB RECEPTOR; PROLIFERATION; DIFFERENTIATION; INSENSITIVITY; PROGRESSION; TISSUES; MOUSE	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily and signal through a number of membrane receptors. We have previously demonstrated that the loss of expression of BMP receptors (BMPRs) type IA, - IB, and - II (BMP-RIA, - RIB, and - RII) correlates with Gleason score in prostate cancer patients. To evaluate the prognostic value of this observation, we used immunohistochemistry to investigate the expression of BMPRs in association with disease progression in 60 patients. The results demonstrated a significant association between the loss of expression of the three BMPRs and Gleason score and clinical stage. However, only the loss of expression of BMP-RII showed a statistically significant association with 5-year survival rate ( P<0.05) and biochemical recurrence-free rate following radical prostatectomy ( P<0.005). To elucidate the effect of an abnormal BMP signaling in prostate cancer cells, we transfected dominant-negative BMP-RII (BMP-RIIDN) into the human prostate cancer cell line, PC3M. When a stable clone overexpressing BMP-RIIDN was inoculated subcutaneously into nude mice, the tumor growth rate was approximately 10 times that of control and parental cell line. These observations, taken together, indicate that the loss of BMP-RII expression as measured by immunohistochemistry may be a prognostic marker in prostate cancer patients, and that the loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells.	Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Ewha Womans Univ, Dept Urol, Seoul, South Korea; Asan Med Ctr, Dept Urol, Seoul, South Korea; Univ Calif Irvine, Dept Urol, Orange, CA 92868 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ewha Womans University; University of Ulsan; Asan Medical Center; University of California System; University of California Irvine	Morton, RA (corresponding author), Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA.	mortonra@umdnj.edu			NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Hamdy FC, 1997, CANCER RES, V57, P4427; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; HOGAN BL, 1996, GENE DEV, V10, P1540; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Ide H, 1997, CANCER RES, V57, P5022; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 2003, CLIN CANCER RES, V9, P6046; Kim IY, 1996, CANCER RES, V56, P44; Lamm MLG, 2001, DEV BIOL, V232, P301, DOI 10.1006/dbio.2001.0187; LIU F, 1995, MOL CELL BIOL, V15, P3479; Masuda H, 2004, PROSTATE, V59, P101, DOI 10.1002/pros.20030; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Pouliot F, 2003, CANCER RES, V63, P277; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Sintich SM, 1999, ENDOCRINOLOGY, V140, P3411, DOI 10.1210/en.140.8.3411; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yonemori K, 1997, AM J PATHOL, V150, P1335; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	33	64	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7651	7659		10.1038/sj.onc.1207924	http://dx.doi.org/10.1038/sj.onc.1207924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15354178				2022-12-25	WOS:000224306700006
J	Foltz, M; Boll, M; Raschka, L; Kottra, G; Daniel, H				Foltz, M; Boll, M; Raschka, L; Kottra, G; Daniel, H			A novel bifunctionality: PAT1 and PAT2 mediate electrogenic proton/amino acid and electroneutral proton/fatty acid symport	FASEB JOURNAL			English	Article						Xenopus laevis oocytes; SCFA; proton symporter; ph-recording	CHAIN FATTY-ACIDS; GRADIENT-DEPENDENT TRANSPORT; LUMINAL MEMBRANE-VESICLES; CACO-2 CELLS; MOLECULAR-BIOLOGY; PLASMA-MEMBRANE; BUTYRATE UPTAKE; AMINO-ACIDS; ABSORPTION; FAMILY	Recently, the PAT family of proton-dependent amino acid transporters has been identified as a novel class of mammalian amino acid symporters. PAT1 and PAT2 members mediate electrogenic uptake of small, neutral amino acids and derivatives by cotransport of protons. Analysis of the structural requirements for substrate recognition by PAT1 identified that a free amino group in a substrate is not essential for recognition. We therefore hypothesized that PAT1 and its ortholog PAT2 may also be able to recognize and transport the homologous short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. We examined in Xenopus laevis oocytes whether the SCFAs interact with the transporter by employing flux studies, electrophysiology and intracellular pH recordings. SCFAs did not induce positive inward currents but inhibited glycine-induced transport currents. PAT-mediated uptake of radiolabeled proline was also dose-dependently reduced by SCFA and could be described by first order competition kinetics with apparent K-i-values for butyrate of 6.0 +/- 0.7 and 7.6 +/- 1.3 mM for PAT1 and PAT2, respectively. Acetate as well as propionate uptake was significantly enhanced in oocytes expressing PAT1 or PAT2. An electroneutral H+/SCFA symport mode was demonstrated by recording intracellular pH changes under voltage clamp conditions with rate constants for the initial intracellular acidification in the presence of SCFAs significantly increased in PAT-expressing oocytes. In conclusion, our data demonstrate that the PAT1 and PAT2 proteins are capable to transport selected SCFAs in an electroneutral and the homologous amino acids in an electrogenic mode and are therefore a paradigm for bifunctional solute carriers.	Tech Univ Munich, Ctr Life & Food Sci, Inst Nutr Sci, Mol Nutr Unit, D-85350 Freising Weihenstephan, Germany	Technical University of Munich	Daniel, H (corresponding author), Tech Univ Munich, Ctr Life & Food Sci, Inst Nutr Sci, Mol Nutr Unit, Hochfeldweg 2, D-85350 Freising Weihenstephan, Germany.	daniel@wzw.tum.de	Daniel, Hannelore/B-8982-2009					Agulhon C, 2003, J COMP NEUROL, V462, P71, DOI 10.1002/cne.10712; BERGMAN EN, 1990, PHYSIOL REV, V70, P567, DOI 10.1152/physrev.1990.70.2.567; Boll M, 2004, PFLUG ARCH EUR J PHY, V447, P776, DOI 10.1007/s00424-003-1073-4; Boll M, 2003, MOL MEMBR BIOL, V20, P261, DOI 10.1080/0968768031000100759; Boll M, 2003, GENOMICS, V82, P47, DOI 10.1016/S0888-7543(03)00099-5; Boll M, 2002, J BIOL CHEM, V277, P22966, DOI 10.1074/jbc.M200374200; Cavaglieri CR, 2003, LIFE SCI, V73, P1683, DOI 10.1016/S0024-3205(03)00490-9; Charney AN, 1998, AM J PHYSIOL, V274, P518; Chen Z, 2003, J PHYSIOL-LONDON, V546, P349, DOI 10.1113/jphysiol.2002.026500; Chen Z, 2003, BIOCHEM BIOPH RES CO, V304, P747, DOI 10.1016/S0006-291X(03)00648-X; CLAUSEN MR, 1994, GASTROENTEROLOGY, V106, P423, DOI 10.1016/0016-5085(94)90601-7; Cook SI, 1998, ALIMENT PHARM THER, V12, P499, DOI 10.1046/j.1365-2036.1998.00337.x; DESOIGNIE R, 1994, GASTROENTEROLOGY, V107, P347, DOI 10.1016/0016-5085(94)90158-9; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; Gasnier B, 2004, PFLUG ARCH EUR J PHY, V447, P756, DOI 10.1007/s00424-003-1091-2; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2; HEDIGER MA, 1995, J PHYSIOL-LONDON, V482P, pS7; JESSEN H, 1988, BIOCHIM BIOPHYS ACTA, V942, P262; JESSEN H, 1991, J PHYSIOL-LONDON, V436, P149, DOI 10.1113/jphysiol.1991.sp018544; Kottra G, 2002, J BIOL CHEM, V277, P32683, DOI 10.1074/jbc.M204192200; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MASCOLO N, 1991, GASTROENTEROLOGY, V101, P331, DOI 10.1016/0016-5085(91)90008-9; Massillon D, 2003, J BIOL CHEM, V278, P40694, DOI 10.1074/jbc.M303182200; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; MORTENSEN FV, 1991, BRIT J SURG, V78, P1208, DOI 10.1002/bjs.1800781019; Ogawa H, 2003, BIOCHEM BIOPH RES CO, V309, P512, DOI 10.1016/j.bbrc.2003.08.026; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; POMARE EW, 1985, J CLIN INVEST, V75, P1448, DOI 10.1172/JCI111847; RAJENDRAN VM, 1987, J BIOL CHEM, V262, P14974; REMESY C, 1980, REPROD NUTR DEV, V20, P1339, DOI 10.1051/rnd:19800725; REYNOLDS DA, 1993, GASTROENTEROLOGY, V105, P725, DOI 10.1016/0016-5085(93)90889-K; Ritzhaupt A, 1998, J PHYSIOL-LONDON, V507, P819, DOI 10.1111/j.1469-7793.1998.819bs.x; ROIGAARDPETERSEN H, 1987, AM J PHYSIOL, V253, pF15, DOI 10.1152/ajprenal.1987.253.1.F15; Rubio-Aliaga I, 2004, J BIOL CHEM, V279, P2754, DOI 10.1074/jbc.M305556200; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; Sagne C, 2001, P NATL ACAD SCI USA, V98, P7206, DOI 10.1073/pnas.121183498; Stein J, 2000, EUR J NUTR, V39, P121, DOI 10.1007/s003940070028; THWAITES DT, 1994, J MEMBRANE BIOL, V140, P143; THWAITES DT, 1993, FEBS LETT, V333, P78, DOI 10.1016/0014-5793(93)80378-8; THWAITES DT, 1995, BRIT J PHARMACOL, V115, P761, DOI 10.1111/j.1476-5381.1995.tb14998.x; Thwaites DT, 2000, BRIT J PHARMACOL, V129, P457, DOI 10.1038/sj.bjp.0703069; THWAITES DT, 1995, J MEMBRANE BIOL, V145, P245; Tyagi S, 2002, AM J PHYSIOL-GASTR L, V282, pG676, DOI 10.1152/ajpgi.00173.2000; VONENGELHARDT W, 1994, J PHYSIOL-LONDON, V477, P365, DOI 10.1113/jphysiol.1994.sp020198; Wreden CC, 2003, J NEUROSCI, V23, P1265, DOI 10.1523/JNEUROSCI.23-04-01265.2003; WUNZ TM, 1993, AM J PHYSIOL, V264, pF948, DOI 10.1152/ajprenal.1993.264.6.F948	47	41	41	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1758	+		10.1096/fj.03-1387fje	http://dx.doi.org/10.1096/fj.03-1387fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345686				2022-12-25	WOS:000224243200039
J	McNamara, N; Gallup, M; Khong, A; Sucher, A; Maltseva, I; Fahy, JV; Basbaum, C				McNamara, N; Gallup, M; Khong, A; Sucher, A; Maltseva, I; Fahy, JV; Basbaum, C			Adenosine up-regulation of the mucin gene, MU2, in asthma	FASEB JOURNAL			English	Article						CLCA1; EGFR	PROTEIN-COUPLED RECEPTORS; BRONCHOALVEOLAR LAVAGE FLUID; ACTIVATED CHLORIDE CHANNEL; BETA-GAMMA-SUBUNITS; EPITHELIAL-CELLS; EGF RECEPTOR; AIRWAY HYPERREACTIVITY; MUCUS OVERPRODUCTION; 5'-FLANKING REGION; BRONCHIAL-ASTHMA	Mucus hypersecretion is a hallmark of asthma that contributes to airway obstruction. While the etiology is not well understood, hypersecretion has been linked to the presence of cytokines such as IL-4, IL-5, IL-9, and IL-13 in the inflamed airway. The presence of adenosine has also been noted in asthmatic airways, and adenosine-mediated signaling in mast cells has been implicated in the severe bronchoconstriction and inflammation prevalent in these patients ( 1, 2). Here we examine the possibility that adenosine also contributes to mucus hypersecretion by airway epithelial cells. Results in cultured airway epithelial cells showed that MUC2 mucin expression increased in response to adenosine. This appeared to be mediated by a pathway initiated at the adenosine A1 receptor that transduced signals through a Ca2+-activated Cl- channel and EGFR. That this signaling cascade is relevant to asthmatic hypersecretion was indicated by results showing that mucin induction by asthmatic tracheal aspirates was reduced by A1, CLCA1, and EGFR inhibitors. These results suggest that adenosine cooperates with inflammatory cytokines to stimulate mucin production in the asthmatic airway and supports the use of A1, CLCA1, and EGFR inhibitors in the treatment of asthma.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pulm, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Dept Anat, Box 0452,513 Parnassus,HSW 1330, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu			NEI NIH HHS [K23 EY00371] Funding Source: Medline; NHLBI NIH HHS [HLP0124136, HLR0143762] Funding Source: Medline; NATIONAL EYE INSTITUTE [K23EY000371] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL024136, R01HL043762] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Blackburn MR, 2000, J EXP MED, V192, P159, DOI 10.1084/jem.192.2.159; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Carlstedt I, 1995, BIOCHEM SOC T, V23, P845, DOI 10.1042/bst0230845; Chen Y, 2001, AM J RESP CELL MOL, V25, P409, DOI 10.1165/ajrcmb.25.4.4413; Chunn JL, 2001, J IMMUNOL, V167, P4676, DOI 10.4049/jimmunol.167.8.4676; Cohn L, 1999, J IMMUNOL, V162, P6178; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161, DOI 10.1111/j.1365-2125.1983.tb01481.x; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dickenson JM, 1998, EUR J PHARMACOL, V355, P85, DOI 10.1016/S0014-2999(98)00468-3; DRIVER AG, 1993, AM REV RESPIR DIS, V148, P91, DOI 10.1164/ajrccm/148.1.91; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Fozard JR, 2000, CLIN EXP ALLERGY, V30, P1213; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gum JR, 1997, BIOCHEM J, V325, P259, DOI 10.1042/bj3250259; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115, DOI 10.1164/ajrccm.158.supplement_2.13tac700; HALEEN SJ, 1987, LIFE SCI, V40, P555, DOI 10.1016/0024-3205(87)90369-9; Huber HL, 1922, ARCH INTERN MED, V30, P689, DOI 10.1001/archinte.1922.00110120002001; Jacobson KA, 1997, NEUROPHARMACOLOGY, V36, P1157, DOI 10.1016/S0028-3908(97)00104-4; JACOBSON KA, 1987, BIOCHEM PHARMACOL, V36, P1697, DOI 10.1016/0006-2952(87)90056-6; JARVIS MF, 1989, J PHARMACOL EXP THER, V251, P888; Jiang JL, 1996, J MED CHEM, V39, P4667, DOI 10.1021/jm960457c; KIM KC, 1991, BRIT J PHARMACOL, V103, P1053, DOI 10.1111/j.1476-5381.1991.tb12299.x; KUAN SF, 1987, CANCER RES, V47, P5715; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee FS, 2002, CYTOKINE GROWTH F R, V13, P11, DOI 10.1016/S1359-6101(01)00024-7; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; LEE KS, 1986, BRAIN RES, V368, P394, DOI 10.1016/0006-8993(86)90589-5; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; MURTHY KS, 1995, MOL PHARMACOL, V47, P1172; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ralevic V, 1998, PHARMACOL REV, V50, P413; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEALE TW, 1988, LIFE SCI, V43, P1671, DOI 10.1016/0024-3205(88)90478-X; SHEEHAN JK, 1995, AM J RESP CELL MOL, V13, P748, DOI 10.1165/ajrcmb.13.6.7576713; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134, DOI 10.1152/ajplung.2001.280.1.L134; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; TANIZAKI Y, 1993, J ASTHMA, V30, P257, DOI 10.3109/02770909309054525; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; UKENA D, 1986, LIFE SCI, V39, P743, DOI 10.1016/0024-3205(86)90023-8; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546, DOI 10.1164/ajrccm.163.7.2010145; VANBELLE H, 1987, AM J PHYSIOL, V252, pH886, DOI 10.1152/ajpheart.1987.252.5.H886; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhou YH, 2001, AM J RESP CELL MOL, V25, P486, DOI 10.1165/ajrcmb.25.4.4578; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	61	51	51	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1770	+		10.1096/fj.04-1964fje	http://dx.doi.org/10.1096/fj.04-1964fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345696				2022-12-25	WOS:000224243200049
J	Kitazume, S; Nakagawa, K; Oka, R; Tachida, Y; Ogawa, K; Luo, Y; Citron, M; Shitara, H; Taya, C; Yonekawa, H; Paulson, JC; Miyoshi, E; Taniguchi, N; Hashimoto, Y				Kitazume, S; Nakagawa, K; Oka, R; Tachida, Y; Ogawa, K; Luo, Y; Citron, M; Shitara, H; Taya, C; Yonekawa, H; Paulson, JC; Miyoshi, E; Taniguchi, N; Hashimoto, Y			In vivo cleavage of alpha 2,6-sialyltransferase by Alzheimer beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GALACTOSIDE ALPHA-2,6 SIALYLTRANSFERASE; HEREDITARY HEPATITIS; DIFFERENTIAL EXPRESSION; SERUM SIALYLTRANSFERASE; ASPARTYL PROTEASE; CLEAVING ENZYME; GOLGI-APPARATUS; SIGNAL ANCHOR; LEC RATS	beta-Site amyloid precursor protein-cleaving enzyme 1 (BACE1) is a membrane-bound aspartic protease that cleaves amyloid precursor protein to produce a neurotoxic peptide, Abeta, and is implicated in triggering the pathogenesis of Alzheimer disease. We previously reported that BACE1 cleaved rat beta-galactoside alpha2,6-sialyl-transferase (ST6Gal I) that was overexpressed in COS cells and that the NH2 terminus of ST6Gal I secreted from the cells (E41 form) was Glu(41). Here we report that BACE1 gene knock-out mice have one third as much plasma ST6Gal I as control mice, indicating that BACE1 is a major protease which is responsible for cleaving ST6Gal I in vivo. We also found that BACE1-transgenic mice have increased level of ST6Gal I in plasma. Secretion of ST6Gal I from the liver into the plasma is known to be up-regulated during the acute-phase response. To investigate the role of BACE1 in ST6Gal I secretion in vivo, we analyzed the levels of BACE1 mRNA in the liver, as well as the plasma levels of ST6Gal I, in a hepatopathological model, i.e. Long-Evans Cinnamon (LEC) rats. This rat is a mutant that spontaneously accumulates copper in the liver and incurs hepatic damage. LEC rats exhibited simultaneous increases in BACE1 mRNA in the liver and in the E41 form of the ST6Gal I protein, the BACE1 product, in plasma as early as 6 weeks of age, again suggesting that BACE1 cleaves ST6Gal I in vivo and controls the secretion of the E41 form.	RIKEN, Glyco Chain Funct Lab, Supra Biomol Syst Grp, Frontier Res Syst, Wako, Saitama 3510198, Japan; CREST, Sci & Technol Agcy, Kawaguchi, Saitama 5600082, Japan; Amgen Inc, Dept Biol Sci, Thousand Oaks, CA 91320 USA; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Tokyo 1138613, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Osaka Univ, Grad Sch Med, Dept Mol Biochem & Clin Invest, Suita, Osaka 565871, Japan	RIKEN; Japan Science & Technology Agency (JST); Amgen; Tokyo Metropolitan Institute of Medical Science; Scripps Research Institute; Osaka University	Hashimoto, Y (corresponding author), RIKEN, Glyco Chain Funct Lab, Supra Biomol Syst Grp, Frontier Res Syst, 2-1 Hirosaw, Wako, Saitama 3510198, Japan.	yasua@postman.riken.go.jp	Taniguchi, Naoyuki/I-4182-2014; Paulson, James/AAG-3565-2019; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; BERNACKI RJ, 1977, SCIENCE, V195, P577, DOI 10.1126/science.835014; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Cao Y, 2002, LAB INVEST, V82, P1515, DOI 10.1097/01.LAB.0000038503.34655.98; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Dalziel M, 1999, GLYCOBIOLOGY, V9, P1003, DOI 10.1093/glycob/9.10.1003; DE SB, 1999, NATURE, V398, P518; Harrison SM, 2003, MOL CELL NEUROSCI, V24, P646, DOI 10.1016/S1044-7431(03)00227-6; Hong L, 2000, SCIENCE, V290, P150, DOI 10.1126/science.290.5489.150; Hussain I, 2000, MOL CELL NEUROSCI, V16, P609, DOI 10.1006/mcne.2000.0884; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; IP C, 1977, CANCER RES, V37, P3442; KAPLAN HA, 1983, J BIOL CHEM, V258, P1505; KESSEL D, 1975, CANCER RES, V35, P670; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kitazume-Kawaguchi S, 1999, GLYCOBIOLOGY, V9, P1397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LI Y, 1991, J CLIN INVEST, V87, P1858, DOI 10.1172/JCI115208; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MIYOSHI E, 1993, CANCER RES, V53, P3899; Mori M., 1991, LEC RAT NEW MODEL HE; Motonaga K, 2002, NEUROSCI LETT, V326, P64, DOI 10.1016/S0304-3940(02)00287-2; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shitara H, 2001, FEBS LETT, V500, P7, DOI 10.1016/S0014-5793(01)02574-1; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; SUGIYAMA T, 1989, CARCINOGENESIS, V10, P2155, DOI 10.1093/carcin/10.11.2155; SUGIYAMA T, 1988, CARCINOGENESIS, V9, P1569, DOI 10.1093/carcin/9.9.1569; SUZUKI K, 1993, CARCINOGENESIS, V14, P1881, DOI 10.1093/carcin/14.9.1881; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13845; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; YOSHIDA MC, 1987, J HERED, V78, P361, DOI 10.1093/oxfordjournals.jhered.a110416	48	75	86	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 4	2005	280	9					8589	8595		10.1074/jbc.M409417200	http://dx.doi.org/10.1074/jbc.M409417200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	902ZR	15364953	hybrid			2022-12-25	WOS:000227395700135
J	Wilkinson, JC; Richter, BWM; Wilkinson, AS; Burstein, E; Rumble, JM; Balliu, B; Duckett, CS				Wilkinson, JC; Richter, BWM; Wilkinson, AS; Burstein, E; Rumble, JM; Balliu, B; Duckett, CS			VIAF, a conserved inhibitor of apoptosis (IAP)-interacting factor that modulates caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; X-LINKED INHIBITOR; CELL-DEATH; STRUCTURAL BASIS; BACULOVIRUS INHIBITOR; MEDIATED APOPTOSIS; ENDOTHELIAL-CELLS; BINDING-PROTEINS; MAMMALIAN-CELLS	Inhibitor of apoptosis (IAP) proteins are involved in the suppression of apoptosis, signal transduction, cell cycle control and gene regulation. Here we describe the cloning and characterization of viral IAP-associated factor (VIAF), a highly conserved, ubiquitously expressed phosphoprotein with limited homology to members of the phosducin family that associates with baculovirus Op-IAP. VIAF bound Op-IAP both in vitro and in intact cells, with each protein displaying a predominantly cytoplasmic localization. VIAF lacks a consensus IAP binding motif, and overexpression of VIAF failed to prevent Op-IAP from protecting human cells from a variety of apoptotic stimuli, suggesting that VIAF does not function as an IAP antagonist. VIAF was unable to directly inhibit caspase activation in vitro and a reduction of VIAF protein levels by RNA interference led to a decrease in Bax-mediated caspase activation, suggesting that VIAF functions to co-regulate the apoptotic cascade. Finally, VIAF is a substrate for ubiquitination mediated by Op-IAP. Thus, VIAF is a novel IAP-interacting factor that functions in caspase activation during apoptosis.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; NCI, Metab Branch, Div Clin Sci, NIH, Bethesda, MD 20892 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Duckett, CS (corresponding author), Med Sci 1,Room 5315,1301 Catherine St, Ann Arbor, MI 48109 USA.	colind@umich.edu	Burstein, Ezra/B-7247-2016	Burstein, Ezra/0000-0003-4341-6367; Duckett, Colin/0000-0001-9413-2263; Rumble, Julie/0000-0001-7220-7631	NCI NIH HHS [T32 CA09676] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Beltrami E, 2004, J BIOL CHEM, V279, P2077, DOI 10.1074/jbc.M309479200; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clem RJ, 1996, CELL DEATH DIFFER, V3, P9; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Flanary PL, 2000, J BIOL CHEM, V275, P18462, DOI 10.1074/jbc.M002163200; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Hawkins CJ, 1998, CELL DEATH DIFFER, V5, P569, DOI 10.1038/sj.cdd.4400389; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hegde R, 2003, J BIOL CHEM, V278, P38699, DOI 10.1074/jbc.M303179200; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang QH, 2000, P NATL ACAD SCI USA, V97, P1427, DOI 10.1073/pnas.97.4.1427; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Jacob J, 2004, J BIOMOL NMR, V28, P197, DOI 10.1023/B:JNMR.0000013820.43366.99; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson BW, 2000, J BIOL CHEM, V275, P31546, DOI 10.1074/jbc.M001363200; Jordan BWM, 2001, J BIOL CHEM, V276, P39985, DOI 10.1074/jbc.C100171200; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; LEE RH, 1988, EXP EYE RES, V46, P829, DOI 10.1016/S0014-4835(88)80035-6; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Lewis J, 2004, J BIOL CHEM, V279, P9023, DOI 10.1074/jbc.M312891200; Li FZ, 2000, J BIOL CHEM, V275, P6707, DOI 10.1074/jbc.275.10.6707; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lohse MJ, 1996, BIOCHEM SOC T, V24, P975, DOI 10.1042/bst0240975; Lopez P, 2003, J BIOL CHEM, V278, P1751, DOI 10.1074/jbc.M207434200; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Sanna MG, 1998, P NATL ACAD SCI USA, V95, P6015, DOI 10.1073/pnas.95.11.6015; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silke J, 2001, J CELL SCI, V114, P1821; Silke J, 2000, CELL DEATH DIFFER, V7, P1275, DOI 10.1038/sj.cdd.4400790; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wilkinson JC, 2004, J BIOL CHEM, V279, P51082, DOI 10.1074/jbc.M408655200; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Wright CW, 2002, J BIOL CHEM, V277, P2454, DOI 10.1074/jbc.M110500200; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	77	22	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51091	51099		10.1074/jbc.M409623200	http://dx.doi.org/10.1074/jbc.M409623200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371430	hybrid			2022-12-25	WOS:000225355800055
J	Argraves, KM; Wilkerson, BA; Argraves, WS; Fleming, PA; Obeid, LM; Drake, CJ				Argraves, KM; Wilkerson, BA; Argraves, WS; Fleming, PA; Obeid, LM; Drake, CJ			Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SPHINGOSINE 1-PHOSPHATE RECEPTOR; VEIN ENDOTHELIAL-CELLS; EMBRYONIC BLOOD-VESSELS; LYSOPHOSPHATIDIC ACID; MURINE ALLANTOIS; EDG-1; LIGAND; MOTILITY; ANGIOGENESIS	Here we have investigated the role of sphingosine-1-phosphate (S1P) signaling in the process of vasculogenesis in the mouse embryo. At stages preceding the formation of blood vessels (7.5 - 8 dpc) in the embryo proper, yolk sac, and allantois, the S1P receptor S1P(2) is expressed in conjunction with S1P(1) and/or S1P(3). Additionally, sphingosine kinase-2 (SK2), an enzyme that catalyzes the formation of S1P, is expressed in these tissues throughout periods of vasculogenesis. Using the cultured mouse allantois explant model of blood vessel formation, we found that vasculogenesis was dependent on S1P signaling. We showed that S1P could replace the ability of serum to promote vasculogenesis in cultured allantois explants. Instead of small poorly reticulated clusters of rounded endothelial cells that formed under serum-free conditions, S1P promoted the formation of elongated endothelial cells that arranged into expansive branched networks of capillary-like vessels. These effects could not be reproduced by vascular endothelial growth factor or basic fibroblast growth factor administration. The ability of S1P to promote blood vessel formation was not due to effects on cell survival or on changes in numbers of endothelial cells (Flk1(+)/PECAM(+)), angioblasts (Flk1(+)/PECAM(+)), or undifferentiated mesodermal cells (Flk1(+)/PECAM(-)). The S1P effect on blood vessel formation was attributed to it promoting migratory activities of angioblasts and early endothelial cells required for the expansion of vascular networks. Together, our findings suggest that migratory events critical to the de novo formation of blood vessels are under the influence of S1P, possibly synthesized via the action of SK2, with signaling mediated by S1P receptors that include S1P(1), S1P(2), and S1P(3).	Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Dept Vet Affairs, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Argraves, KM (corresponding author), Med Univ S Carolina, Dept Anat & Cell Biol, Charleston, SC 29425 USA.	argravek@musc.edu		Wilkerson, Brent/0000-0002-3532-3075; obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA097132] Funding Source: Medline; NCRR NIH HHS [RR17677] Funding Source: Medline; NHLBI NIH HHS [HL52813, HL57375, HL61873] Funding Source: Medline; NIDCR NIH HHS [DE014347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061873, P01HL052813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014347] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		An SZ, 1997, FEBS LETT, V417, P279, DOI 10.1016/S0014-5793(97)01301-X; Argraves WS, 2002, DEV DYNAM, V225, P298, DOI 10.1002/dvdy.10162; Bayless KJ, 2003, BIOCHEM BIOPH RES CO, V312, P903, DOI 10.1016/j.bbrc.2003.11.017; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Downs KM, 1998, DEVELOPMENT, V125, P4507; Downs KM, 2001, DEV BIOL, V233, P347, DOI 10.1006/dbio.2001.0227; Drake CJ, 1997, DEV BIOL, V192, P17, DOI 10.1006/dbio.1997.8751; Drake CJ, 2000, BLOOD, V95, P1671, DOI 10.1182/blood.V95.5.1671.005k39_1671_1679; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; HLA T, 1990, J BIOL CHEM, V265, P9308; Igarashi Y, 1998, AM J HEMATOL, V57, P261; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; LaRue AC, 2003, DEV DYNAM, V228, P21, DOI 10.1002/dvdy.10339; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Niedernberg A, 2003, CELL SIGNAL, V15, P435, DOI 10.1016/S0898-6568(02)00119-5; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Okamoto H, 2000, MOL CELL BIOL, V20, P9247, DOI 10.1128/MCB.20.24.9247-9261.2000; Rosen H, 2003, CURR OPIN CHEM BIOL, V7, P461, DOI 10.1016/S1367-5931(03)00085-1; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; Uhlenbrock K, 2003, CELL PHYSIOL BIOCHEM, V13, P75, DOI 10.1159/000070251; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Van Brocklyn JR, 2003, CANCER LETT, V199, P53, DOI 10.1016/S0304-3835(03)00334-3; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu CB, 2002, ATHEROSCLEROSIS, V164, P237, DOI 10.1016/S0021-9150(02)00100-4; Yamashita J, 2000, NATURE, V408, P92, DOI 10.1038/35040568; Zeng X, 1998, DEV DYNAM, V211, P215, DOI 10.1002/(SICI)1097-0177(199803)211:3<215::AID-AJA3>3.0.CO;2-K; Zhang GF, 1999, GENE, V227, P89, DOI 10.1016/S0378-1119(98)00589-7	46	50	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50580	50590		10.1074/jbc.M404432200	http://dx.doi.org/10.1074/jbc.M404432200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377653	hybrid			2022-12-25	WOS:000225229500122
J	Fukatsu, K; Bannai, H; Zhang, SB; Nakamura, H; Inoue, T; Mikoshiba, K				Fukatsu, K; Bannai, H; Zhang, SB; Nakamura, H; Inoue, T; Mikoshiba, K			Lateral diffusion of inositol 1,4,5-trisphosphate receptor type 1 is regulated by actin filaments and 4.1N in neuronal Dendrites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; FLUORESCENT PROTEIN; HIPPOCAMPAL-NEURONS; SYNAPTIC PLASTICITY; PLASMA-MEMBRANE; GROWTH CONES; CELLS; EXPRESSION; DEPRESSION	Inositol 1,4,5-trisphosphate receptor type1 (IP(3)R1) plays an important role in neuronal functions; however, the lateral diffusion of IP(3)R1 on the endoplasmic reticulum membrane and its regulation in the living neurons remain unknown. We expressed green fluorescent protein-tagged IP(3)R1 in cultured rat hippocampal neurons and observed the lateral diffusion by the fluorescence recovery after photobleaching technique. IP(3)R1 showed lateral diffusion with an effective diffusion constant of similar to 0.3 mum(2)/s. Depletion of actin filaments increased the diffusion constant of IP(3)R1, suggesting that the diffusion of IP(3)R1 is regulated negatively through actin filaments. We also found that protein 4.1N, which binds to IP(3)R1 and contains an actin-spectrin-binding region, was responsible for this actin regulation of the IP(3)R1 diffusion constant. Overexpression of dominant-negative 4.1N and blockade of 4.1N binding to IP3R1 increased the IP(3)R1 diffusion constant. The diffusion of IP3R type 3 (IP(3)R3), one of the isoforms of IP(3)Rs lacking the binding ability to 4.1N, was not dependent on actin filaments but became dependent on actin filaments after the addition of a 4.1N-binding sequence. These data suggest that 4.1N serves as a linker protein between IP(3)R1 and actin filaments. This actin filament-dependent regulation of IP(3)R1 diffusion may be important for the spatiotemporal regulation of intracellular Ca2+ signaling.	Univ Tokyo, Inst Med Sci, Nippon Telegraph & Tel Co, Div Mol Neurobiol,Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Nippon Telegraph & Tel Co, Div Neural Signal Informat,Minato Ku, Tokyo 1088639, Japan; RIKEN, Brain Sci Inst, Dev Neurobiol Lab, Wako, Saitama 3510198, Japan; Japan Sci & Technol Corp, ICORP, Calcium Oscillat Project, Minato Ku, Tokyo 1080071, Japan; Univ Tokyo, Grad Sch Sci, Dept Phys, Bunkyo Ku, Tokyo 1130033, Japan	Nippon Telegraph & Telephone Corporation; University of Tokyo; Nippon Telegraph & Telephone Corporation; University of Tokyo; RIKEN; Japan Science & Technology Agency (JST); University of Tokyo	Inoue, T (corresponding author), Univ Tokyo, Inst Med Sci, Nippon Telegraph & Tel Co, Div Mol Neurobiol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tinoue@ims.u-tokyo.ac.jp	Mikoshiba, Katsuhiko/N-7943-2015; Bannai, Hiroko/I-7130-2014; Inoue, Takafumi/AAM-9533-2020	Bannai, Hiroko/0000-0002-0951-488X; Inoue, Takafumi/0000-0002-2728-0060; Zhang, Songbai/0000-0002-2033-8389; Nakamura, Hideki/0000-0003-2749-8323				Aihara Y, 2001, J NEUROSCI RES, V65, P236, DOI 10.1002/jnr.1147; Bannai H, 2004, J CELL SCI, V117, P163, DOI 10.1242/jcs.00854; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Binda AV, 2002, MOL PHARMACOL, V62, P507, DOI 10.1124/mol.62.3.507; Borgdorff AJ, 2002, NATURE, V417, P649, DOI 10.1038/nature00780; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Choquet D, 2003, NAT REV NEUROSCI, V4, P251, DOI 10.1038/nrn1077; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; Fujii S, 2000, LEARN MEMORY, V7, P312, DOI 10.1101/lm.34100; Fujiwara T, 2002, J CELL BIOL, V157, P1071, DOI 10.1083/jcb.200202050; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Haggie PM, 2004, J BIOL CHEM, V279, P5494, DOI 10.1074/jbc.M312445200; Inoue T, 1998, J NEUROSCI, V18, P5366, DOI 10.1523/JNEUROSCI.18-14-05366.1998; Kaech S, 2001, P NATL ACAD SCI USA, V98, P7086, DOI 10.1073/pnas.111146798; Kohrmann M, 1999, J NEUROSCI RES, V58, P831; LEE C, 1988, CELL, V54, P37, DOI 10.1016/0092-8674(88)90177-8; Lencesova L, 2004, J BIOL CHEM, V279, P2885, DOI 10.1074/jbc.M310365200; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; MARSH L, 1984, J CELL BIOL, V99, P2041, DOI 10.1083/jcb.99.6.2041; Matsumoto M, 1996, NATURE, V379, P168, DOI 10.1038/379168a0; Miyata M, 2000, NEURON, V28, P233, DOI 10.1016/S0896-6273(00)00099-4; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; Nishiyama M, 2000, NATURE, V408, P584, DOI 10.1038/35046067; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; SAFFMAN PG, 1975, P NATL ACAD SCI USA, V72, P3111, DOI 10.1073/pnas.72.8.3111; Shen L, 2000, J NEUROSCI, V20, P7932; Siggia ED, 2000, BIOPHYS J, V79, P1761, DOI 10.1016/S0006-3495(00)76428-9; Street VA, 1997, J NEUROSCI, V17, P635; Takechi H, 1998, NATURE, V396, P757, DOI 10.1038/25547; Takei K, 1998, SCIENCE, V282, P1705, DOI 10.1126/science.282.5394.1705; Tardin C, 2003, EMBO J, V22, P4656, DOI 10.1093/emboj/cdg463; Vermassen E, 2004, BIOL CELL, V96, P3, DOI 10.1016/j.biolcel.2003.11.004; Walensky LD, 1999, J NEUROSCI, V19, P6457; Wang Y, 2002, J NEUROCHEM, V82, P945, DOI 10.1046/j.1471-4159.2002.01059.x; YAMADA KM, 1971, J CELL BIOL, V49, P614, DOI 10.1083/jcb.49.3.614; Zhang SB, 2003, J BIOL CHEM, V278, P4048, DOI 10.1074/jbc.M209960200	39	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48976	48982		10.1074/jbc.M408364200	http://dx.doi.org/10.1074/jbc.M408364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364918	hybrid			2022-12-25	WOS:000225098100060
J	Wang, XZ; Grammatikakis, N; Siganou, A; Stevenson, MA; Calderwood, SK				Wang, XZ; Grammatikakis, N; Siganou, A; Stevenson, MA; Calderwood, SK			Interactions between extracellular signal-regulated protein kinase 1, 14-3-3 epsilon, and heat shock factor 1 during stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DNA-BINDING ABILITY; TRANSCRIPTIONAL ACTIVATION; FACTOR-I; GENE-TRANSCRIPTION; C-FOS; PHOSPHORYLATION; CELLS; HSF1; THERMOTOLERANCE	Cytoprotection during the heat shock response is a complex phenomenon involving multiple inducible mechanisms. We have examined the interaction of two key molecular components in the response, heat shock transcription factor 1 (HSF1) and extracellular signal regulated protein kinase (ERK). Whereas both HSF1 and ERK are required to protect cells against apoptosis, ERK activation is paradoxically antagonistic to transactivation of hsp promoters by HSF1 and HSP accumulation during heat shock. We have found that the two pathways interact directly and that heat shock causes the physical association of ERK1 with HSF1, an interaction that promotes the kinase activity of ERK in heat-shocked cells. ERK activation results in the recruitment of the phosphoserine binding protein 14-3-3epsilon in a manner dependent on previous HSF1 phosphorylation by ERK. The effects of 14-3-3epsilon binding on HSF1 were complex, however, depending on extracellular conditions, in that HSF1-14-3-3 binding at 37degreesC led to the cytoplasmic sequestration and repression of HSF1, whereas heat shock overrode these effects and caused quantitative nuclear localization of HSF1. Although the effects of 14-3-3epsilon binding to HSF1 were overridden acutely by stress, during recovery from heat shock, 14-3-3epsilon association again led to enhanced cytoplasmic localization of HSF1, implicating a role for ERK/14-3-3epsilon in HSF1 deactivation in recovering cells. Association of HSF1 with ERK and 14-3-3epsilon during heat shock may thus modulate the amplitude of the response and lead to efficient termination of HSP expression on resumption of growth conditions.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Mol & Cellular Radiat Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Boston University	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Mol & Cellular Radiat Oncol, 21-27 Burlington Ave,Room 553B, Boston, MA 02215 USA.	scalderw@bidmc.harvard.edu			NCI NIH HHS [CA31303, CA47407, CA50642] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047407, P01CA031303, R01CA050642] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Boellmann F, 2004, P NATL ACAD SCI USA, V101, P4100, DOI 10.1073/pnas.0304768101; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Chu BY, 1998, J BIOL CHEM, V273, P18640, DOI 10.1074/jbc.273.29.18640; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; FEDER JH, 1992, GENE DEV, V6, P1402, DOI 10.1101/gad.6.8.1402; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; GREEN M, 1995, MOL CELL BIOL, V15, P3354; He B, 1998, MOL CELL BIOL, V18, P6624, DOI 10.1128/MCB.18.11.6624; He HY, 2003, J BIOL CHEM, V278, P35465, DOI 10.1074/jbc.M304663200; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kline MP, 1997, MOL CELL BIOL, V17, P2107, DOI 10.1128/MCB.17.4.2107; Knauf U, 1996, GENE DEV, V10, P2782, DOI 10.1101/gad.10.21.2782; Krebs RA, 1997, CELL STRESS CHAPERON, V2, P60, DOI 10.1379/1466-1268(1997)002<0060:DCOHOI>2.3.CO;2; Kyriakis JM, 1999, BIOCHEM SOC SYMP, P29; KYRIAKIS JM, 1994, PROTEIN KINASES, P81; LANDRY J, 1982, CANCER RES, V42, P2457; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mercier PA, 1999, J CELL SCI, V112, P2765; MIVECHI NF, 1995, CANCER RES, V55, P5512; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; Newton EM, 1996, MOL CELL BIOL, V16, P839; PRICE BD, 1991, MOL CELL BIOL, V11, P3365, DOI 10.1128/MCB.11.6.3365; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Raman M, 2003, CURR BIOL, V13, pR886, DOI 10.1016/j.cub.2003.10.053; Rosenquist M, 2003, BRAZ J MED BIOL RES, V36, P403, DOI 10.1590/S0100-879X2003000400001; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHELDON LA, 1993, GENE DEV, V7, P1549, DOI 10.1101/gad.7.8.1549; Song JW, 2001, NAT CELL BIOL, V3, P276, DOI 10.1038/35060068; SUBJECK JR, 1982, BRIT J RADIOL, V55, P579, DOI 10.1259/0007-1285-55-656-579; Tsuchiya S, 1999, J BIOCHEM-TOKYO, V125, P1151, DOI 10.1093/oxfordjournals.jbchem.a022398; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; Wang XZ, 2003, MOL CELL BIOL, V23, P6013, DOI 10.1128/MCB.23.17.6013-6026.2003; Wang XZ, 2000, CELL STRESS CHAPERON, V5, P432, DOI 10.1379/1466-1268(2000)005<0432:RRHADH>2.0.CO;2; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; Woessmann W, 1999, J CELL BIOCHEM, V74, P648, DOI 10.1002/(SICI)1097-4644(19990915)74:4<648::AID-JCB14>3.0.CO;2-6; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xie Y, 2003, J BIOL CHEM, V278, P4687, DOI 10.1074/jbc.M210189200; Xie Y, 2002, BIOCHEM BIOPH RES CO, V291, P1071, DOI 10.1006/bbrc.2002.6562; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Yaglom J, 2003, MOL CELL BIOL, V23, P3813, DOI 10.1128/MCB.23.11.3813-3824.2003; Zhang JL, 2003, J BIOL CHEM, V278, P29901, DOI 10.1074/jbc.M303909200; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319	62	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49460	49469		10.1074/jbc.M406059200	http://dx.doi.org/10.1074/jbc.M406059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364926	hybrid			2022-12-25	WOS:000225098100116
J	Zhao, M; Wimmer, A; Trieu, K; DiScipio, RG; Schraufstatter, IU				Zhao, M; Wimmer, A; Trieu, K; DiScipio, RG; Schraufstatter, IU			Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PROTEIN-KINASE; INTERLEUKIN-8 RECEPTORS; MEDIATED ENDOCYTOSIS; BINDING; RAC; PATHWAY; STRESS; ERK; RHO	Activation of CXCR2 IL-8 receptor leads to activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and rapid receptor endocytosis. Co-immunoprecipitation and co-localization experiments showed that arrestin and CXCR2 form complexes with components of the ERK1/2 cascade following ligand stimulation. However, in contrast to the activation of the beta(2)-adrenergic receptor, arrestin was not necessary for ERK1/2 phosphorylation or receptor endocytosis. In contrast, beta-arrestin 1/2 double knockout cells showed greatly enhanced phosphorylation of ERK1/2, as well as phosphorylation of the stress kinases p38 and c-Jun N-terminal protein kinase. The stimulation of stress kinases in arrestin double knockout cells could be attenuated in the presence of diphenylene iodonium (DPI), an inhibitor of the NADPH oxidase, suggesting that reactive oxidant species (ROS) participated in mitogen-activated protein kinase (MAPK) activation. ROS could indeed be detected in IL-8-stimulated beta-arrestin 1/2 knockout cells, and cytoplasmic Rac was translocated to the membrane fraction, which is a prerequisite for oxidant formation. The oxidative burst induced cell death within 6 h of IL-8 stimulation of these cells, which could be prevented in the presence of DPI. These results indicate a novel function for arrestin, which is protection from an excessive oxidative burst, resulting from the sustained stimulation of G-protein-coupled receptors that cause Rac translocation.	La Jolla Inst Mol Med, Div Canc Biol, San Diego, CA 92121 USA		Zhao, M (corresponding author), La Jolla Inst Mol Med, Div Canc Biol, 4570 Execut Dr,100, San Diego, CA 92121 USA.	mzhao@ljimm.org	Sawant, Kirti V/H-3778-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bokoch GM, 2002, BLOOD, V100, P2692, DOI 10.1182/blood-2002-04-1149; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; Dalle S, 2002, MOL CELL BIOL, V22, P6272, DOI 10.1128/MCB.22.17.6272-6285.2002; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Fan GH, 2002, J BIOL CHEM, V277, P6590, DOI 10.1074/jbc.M110588200; Fan GH, 2001, BIOCHEMISTRY-US, V40, P791, DOI 10.1021/bi001661b; Fan GH, 2001, J BIOL CHEM, V276, P16960, DOI 10.1074/jbc.M009292200; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GE L, 2003, J BIOL CHEM, P73200; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LEE J, 1995, J IMMUNOL, V155, P2158; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; Nabi IR, 2003, J CELL BIOL, V161, P673, DOI 10.1083/jcb.200302028; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; PAYNE DM, 1909, EMBRO J, V10, P885; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200; Pullar CE, 2003, J BIOL CHEM, V278, P22555, DOI 10.1074/jbc.M300205200; REVANKAR CM, 2004, J BIOL CHEM, P21200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schlunck G, 2004, MOL BIOL CELL, V15, P256, DOI 10.1091/mbc.E03-01-0019; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; Schraufstatter IU, 1998, BIOCHEM BIOPH RES CO, V244, P243, DOI 10.1006/bbrc.1998.8246; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542; Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Vines CM, 2003, J BIOL CHEM, V278, P41581, DOI 10.1074/jbc.C300291200; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WOODMAN RC, 1995, BLOOD, V85, P231, DOI 10.1182/blood.V85.1.231.bloodjournal851231; Yang W, 1999, J BIOL CHEM, V274, P11328, DOI 10.1074/jbc.274.16.11328	63	61	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49259	49267		10.1074/jbc.M405118200	http://dx.doi.org/10.1074/jbc.M405118200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364949	hybrid			2022-12-25	WOS:000225098100093
J	Konishi, K; Ishida, K; Oinuma, KI; Ohta, T; Hashimoto, Y; Higashibata, H; Kitagawa, T; Kobayashi, M				Konishi, K; Ishida, K; Oinuma, KI; Ohta, T; Hashimoto, Y; Higashibata, H; Kitagawa, T; Kobayashi, M			Identification of crucial histidines involved in carbon-nitrogen triple bond synthesis by aldoxime dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOCOCCUS-RHODOCHROUS J1; MASS NITRILE HYDRATASE; PSEUDOMONAS-CHLORORAPHIS B23; SITE-DIRECTED MUTAGENESIS; HORSERADISH-PEROXIDASE; ESCHERICHIA-COLI; GENE-CLUSTER; PHENYLACETALDOXIME DEHYDRATASE; MOLECULAR CHARACTERIZATION; ISONITRILE HYDRATASE	Aldoxime dehydratase (OxdA), which is a novel heme protein, catalyzes the dehydration of an aldoxime to a nitrile even in the presence of water in the reaction mixture. The combination of site-directed mutagenesis of OxdA (mutation of all conserved histidines in the aldoxime dehydratase superfamily), estimation of the heme contents and specific activities of the mutants, and CD and resonance Raman spectroscopic analyses led to the identification of the proximal and distal histidines in this unique enzyme. The heme contents and CD spectra in the far-UV region of all mutants except for the H299A one were almost identical to those of the wild-type OxdA, whereas the H299A mutant lost the ability of binding heme, demonstrating that His(299) is the proximal histidine. On the other hand, substitution of alanine for His(320) did not affect the overall structure of OxdA but caused loss of its ability of carbon-nitrogen triple bond synthesis and a lower shift of the Fe-C stretching band in the resonance Raman spectrum for the CO-bound form. Furthermore, the pH dependence of the wild-type OxdA closely followed the His protonation curves observed for other proteins. These findings suggest that His(320) is located in the distal heme pocket of OxdA and would donate a proton to the substrate in the aldoxime dehydration mechanism.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan; Natl Inst Nat Sci, Okazaki Inst Integrat Biosci, Aichi 4448787, Japan	University of Tsukuba; University of Tsukuba; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB)	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.			HIGASHIBATA, Hiroki/0000-0001-7416-5316				ASANO Y, 1980, AGR BIOL CHEM TOKYO, V44, P2251, DOI 10.1080/00021369.1980.10864311; BARTLING D, 1994, P NATL ACAD SCI USA, V91, P6021, DOI 10.1073/pnas.91.13.6021; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P831, DOI 10.1006/jmbi.1994.1192; BOUCHER JL, 1994, BIOCHEMISTRY-US, V33, P7811, DOI 10.1021/bi00191a008; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cortajarena AL, 2002, J BIOL CHEM, V277, P23223, DOI 10.1074/jbc.M202028200; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Endo I, 1999, TRENDS BIOTECHNOL, V17, P244, DOI 10.1016/S0167-7799(99)01303-7; Feng ML, 2003, J BIOL INORG CHEM, V8, P699, DOI 10.1007/s00775-003-0460-9; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Goda M, 2002, J BIOL CHEM, V277, P45860, DOI 10.1074/jbc.M208571200; Goda M, 2001, J BIOL CHEM, V276, P23480, DOI 10.1074/jbc.M007856200; Hann EC, 1999, BIOORGAN MED CHEM, V7, P2239, DOI 10.1016/S0968-0896(99)00157-1; Hart-Davis J, 1998, J AM CHEM SOC, V120, P12524, DOI 10.1021/ja981805y; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Inuzuka T, 2004, J BIOL CHEM, V279, P6778, DOI 10.1074/jbc.C300464200; Kato Y, 2000, BIOCHEMISTRY-US, V39, P800, DOI 10.1021/bi991598u; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; Kobayashi M, 2000, CURR OPIN CHEM BIOL, V4, P95, DOI 10.1016/S1367-5931(99)00058-7; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, BIOCHEMISTRY-US, V31, P9000, DOI 10.1021/bi00152a042; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; Nagano S, 2003, BIOCHEMISTRY-US, V42, P14507, DOI 10.1021/bi035410p; NAGASAWA T, 1989, EXPERIENTIA, V45, P1066, DOI 10.1007/BF01950160; Normanly J, 1997, PLANT CELL, V9, P1781, DOI 10.1105/tpc.9.10.1781; Oinuma KI, 2003, J BIOL CHEM, V278, P29600, DOI 10.1074/jbc.M211832200; Oinuma KI, 2004, FEBS LETT, V568, P44, DOI 10.1016/j.febslet.2004.05.008; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; Phillips GN, 1999, J PHYS CHEM B, V103, P8817, DOI 10.1021/jp9918205; Pogulis R J, 1996, Methods Mol Biol, V57, P167; Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f; Sasakura Y, 2002, J BIOL CHEM, V277, P23821, DOI 10.1074/jbc.M202738200; Sato Y, 2001, J INORG BIOCHEM, V87, P261, DOI 10.1016/S0162-0134(01)00334-8; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STRICKLAND EH, 1968, BIOCHIM BIOPHYS ACTA, V151, P70; Taguchi S, 2004, J BIOL CHEM, V279, P3340, DOI 10.1074/jbc.M301013200; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; TERAOKA J, 1981, J BIOL CHEM, V256, P3969; Tosha T, 2002, BIOCHEMISTRY-US, V41, P13883, DOI 10.1021/bi0261037; Uchida T, 1997, J BIOL CHEM, V272, P30108, DOI 10.1074/jbc.272.48.30108; Uzawa T, 2004, P NATL ACAD SCI USA, V101, P1171, DOI 10.1073/pnas.0305376101; WEDEL B, 1994, P NATL ACAD SCI USA, V91, P2592, DOI 10.1073/pnas.91.7.2592; Xie SX, 2003, BIOCHEMISTRY-US, V42, P12056, DOI 10.1021/bi035092u; Xie SX, 2001, BIOSCI BIOTECH BIOCH, V65, P2666, DOI 10.1271/bbb.65.2666; Yamada H, 2001, CHEM REC, V1, P152; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391	60	28	28	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47619	47625		10.1074/jbc.M407223200	http://dx.doi.org/10.1074/jbc.M407223200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339918	hybrid			2022-12-25	WOS:000224957000026
J	Fulda, S; Jeremias, I; Debatin, KM				Fulda, S; Jeremias, I; Debatin, KM			Cooperation of betulinic acid and TRAIL to induce apoptosis in tumor cells	ONCOGENE			English	Article						apoptosis; TRAIL; betulinic acid; cancer resistance	IN-VIVO; DECOY RECEPTORS; HUMAN-MELANOMA; LIGAND TRAIL; CANCER; DEATH; SENSITIZATION; CYTOTOXICITY; CHEMOTHERAPY; IRRADIATION	We previously reported that the TRAIL ( tumor necrosis factor (TNF)-related apoptosis-inducinglig and)-induced death signal requires amplification by mitochondria in certain cell types, for example, in type II cells. Here, we provide for the first time evidence that the natural compound betulinic acid (BetA) cooperated with TRAIL to induce apoptosis in tumor cells. Through functional complementation, simultaneous stimulation of the death receptor pathway by TRAIL and the mitochondrial pathway by BetA resulted in complete activation of effector caspases, apoptosis and inhibition of clonogenic survival. BetA and TRAIL cooperated to trigger loss of mitochondrial membrane potential and release of cytochrome c and Smac from mitochondria. Also, combination treatment with BetA and TRAIL resulted in increased cleavage of caspase-8 and Bid indicating that activation of effector caspases may feed back in a positive amplification loop. Importantly, the combination treatment with BetA and TRAIL cooperated to induce apoptosis in different tumor cell lines and also in primary tumor cells, but not in normal human fibroblasts indicating some tumor specificity. Since most human cancers represent type II cells, triggering the mitochondrial pathway by BetA may be a novel approach to enhance the efficacy of TRAIL-based therapies, which warrants further investigation.	Univ Childrens Hosp, D-89075 Ulm, Germany; Dr von Haunersches Kinderspital, Dept Hematol Oncol, D-80337 Munich, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich	Fulda, S (corresponding author), Univ Childrens Hosp, Prittwitzstr 43, D-89075 Ulm, Germany.	simone.fulda@medizin.uni-ulm.de	Jeremias, Irmela/Q-5934-2019; Jeremias, Irmela/C-6090-2015; Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Jeremias, Irmela/0000-0003-1773-7677; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fulda S, 1997, CANCER RES, V57, P4956; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 1998, KLIN PADIATR, V210, P148, DOI 10.1055/s-2008-1043870; Gliniak B, 1999, CANCER RES, V59, P6153; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Nagane M, 2000, CANCER RES, V60, P847; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Selzer E, 2000, J INVEST DERMATOL, V114, P935, DOI 10.1046/j.1523-1747.2000.00972.x; Stahnke K, 2003, LEUKEMIA, V17, P2130, DOI 10.1038/sj.leu.2403144; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373; Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2	31	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7611	7620		10.1038/sj.onc.1207970	http://dx.doi.org/10.1038/sj.onc.1207970			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361826				2022-12-25	WOS:000224306700002
J	Iacobini, C; Menini, S; Oddi, G; Ricci, C; Amadio, L; Pricci, F; Olivieri, A; Sorcini, M; Di Mario, U; Pesce, C; Pugliese, G				Iacobini, C; Menini, S; Oddi, G; Ricci, C; Amadio, L; Pricci, F; Olivieri, A; Sorcini, M; Di Mario, U; Pesce, C; Pugliese, G			Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor	FASEB JOURNAL			English	Article						RAGE; extracellular matrix; kidney disease	GLYCATION END-PRODUCTS; GENE-EXPRESSION; DIABETIC-NEPHROPATHY; MATRIX METALLOPROTEINASES; MESANGIAL EXPANSION; OXIDATIVE STRESS; BINDING-PROTEIN; RAGE; ACTIVATION; INHIBITOR	We previously showed that mice lacking galectin-3/AGE-receptor 3 develop accelerated diabetic glomerulopathy. To further investigate the role of galectin-3/AGE-receptor function in the pathogenesis of diabetic renal disease, galectin-3 knockout ( KO) and coeval wild-type (WT) mice were injected for 3 months with 30 mug/day of N-epsilon-carboxymethyllysine (CML)-modified or unmodified mouse serum albumin (MSA). Despite receiving equal doses of CML, KO had higher circulating and renal AGE levels and showed more marked renal functional and structural changes than WT mice, with significantly higher proteinuria, albuminuria, glomerular, and mesangial area and glomerular sclerosis index. Renal 4-hydroxy-2-nonenal content and NFkappaB activation were also more pronounced in KO-CML vs. WT-CML. Kidney mRNA levels of fibronectin, laminin, collagen IV, and TGF-beta were up-regulated, whereas those of matrix metalloproteinase-2 and -14 were down-regulated, again more markedly in KO-CML than WT-CML mice. Basal and CML-induced RAGE and 80K-H mRNA levels were higher in KO vs. WT mice. MSA injection did not produce any significant effect in both genotypes. The association of galectin-3 ablation with enhanced susceptibility to AGE-induced renal disease, increased AGE levels and signaling, and altered AGE-receptor pattern indicates that galectin-3 is operating in vivo as an AGE receptor to afford protection toward AGE-dependent tissue injury.	Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy; Univ Genoa, Sch Med, DISTBIMO, I-16132 Genoa, Italy; Univ Roma La Sapienza, Dept Clin Sci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); University of Genoa; Sapienza University Rome	Pugliese, G (corresponding author), Dipartimento Sci Clin Endocrinol, Viale Policlin 155, I-00161 Rome, Italy.	giuseppe.pugliese@uniroma1.it	Menini, Stefano/G-1130-2010; Pricci, Flavia/K-7739-2016; Pugliese, Giuseppe/G-8776-2012; Olivieri, Antonella/AAC-1644-2019	Menini, Stefano/0000-0001-7328-2385; Pricci, Flavia/0000-0002-1877-4376; Olivieri, Antonella/0000-0002-7565-4370; Pugliese, Giuseppe/0000-0003-1574-0397				ABEL M, 1995, NEPHROL DIAL TRANSPL, V10, P1662; Arar C, 1998, FEBS LETT, V430, P307, DOI 10.1016/S0014-5793(98)00683-8; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Benotmane AM, 1997, ANAL BIOCHEM, V250, P181, DOI 10.1006/abio.1997.2231; Bierhaus A, 1997, DIABETES, V46, P1481, DOI 10.2337/diabetes.46.9.1481; Bucciarelli LG, 2002, CIRCULATION, V106, P2827, DOI 10.1161/01.CIR.0000039325.03698.36; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Degenhardt TP, 2002, KIDNEY INT, V61, P939, DOI 10.1046/j.1523-1755.2002.00207.x; DelPrete D, 1997, DIABETOLOGIA, V40, P1449, DOI 10.1007/s001250050848; Di Mario U, 2001, DIABETOLOGIA, V44, P674, DOI 10.1007/s001250051676; EDELSTEIN D, 1992, DIABETES, V41, P26, DOI 10.2337/diabetes.41.1.26; Figarola JL, 2003, DIABETOLOGIA, V46, P1140, DOI 10.1007/s00125-003-1162-0; Forbes JM, 2003, FASEB J, V17, P1762, DOI 10.1096/fj.02-1102fje; FUKUI M, 1992, DIABETES, V41, P1520, DOI 10.2337/diabetes.41.12.1520; Gaedeke J, 2001, CONTRIB NEPHROL, V135, P153; He CJ, 2000, KIDNEY INT, V58, P1931, DOI 10.1046/j.1523-1755.2000.00365.x; Hofmann SM, 2002, DIABETES, V51, P2082, DOI 10.2337/diabetes.51.7.2082; Horiuchi S, 1996, DIABETES, V45, pS73, DOI 10.2337/diab.45.3.S73; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; Iacobini C, 2003, J AM SOC NEPHROL, V14, pS264, DOI 10.1097/01.ASN.0000077402.95720.B4; Iwashima Y, 2000, BIOCHEM BIOPH RES CO, V277, P368, DOI 10.1006/bbrc.2000.3685; Karachalias N, 2003, BIOCHEM SOC T, V31, P1423; Kislinger T, 1999, J BIOL CHEM, V274, P31740, DOI 10.1074/jbc.274.44.31740; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lenz O, 2000, J AM SOC NEPHROL, V11, P574, DOI 10.1681/ASN.V113574; Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; McLennan SV, 2000, DIABETOLOGIA, V43, P642, DOI 10.1007/s001250051353; Mitsuhashi T, 1997, J IMMUNOL METHODS, V207, P79, DOI 10.1016/S0022-1759(97)00110-5; Nachtigal M, 1998, AM J PATHOL, V152, P1199; Nakamura S, 1997, DIABETES, V46, P895, DOI 10.2337/diabetes.46.5.895; Nakamura S, 2003, AM J KIDNEY DIS, V41, pS68, DOI 10.1053/ajkd.2003.50088; NAKAMURA T, 1994, RENAL PHYSIOL BIOCH, V17, P316; Ochieng J, 1998, BIOCHEM BIOPH RES CO, V246, P788, DOI 10.1006/bbrc.1998.8708; Ohgami N, 2001, J BIOL CHEM, V276, P3195, DOI 10.1074/jbc.M006545200; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pesce C, 1998, ANAT REC, V251, P66, DOI 10.1002/(SICI)1097-0185(199805)251:1<66::AID-AR11>3.0.CO;2-9; Pesce C, 2002, NEPHRON, V90, P484, DOI 10.1159/000054738; Pricci F, 2000, KIDNEY INT, V58, pS31, DOI 10.1046/j.1523-1755.2000.07706.x; Pugliese G, 2001, FASEB J, V15, P2471, DOI 10.1096/fj.01-0006com; Pugliese G, 1997, DIABETES, V46, P1198, DOI 10.2337/diabetes.46.7.1198; Pugliese G, 2000, DIABETES, V49, P1249, DOI 10.2337/diabetes.49.7.1249; RAIJ L, 1984, KIDNEY INT, V26, P137, DOI 10.1038/ki.1984.147; RECKELHOFF JF, 1993, DIABETES, V42, P1425, DOI 10.2337/diabetes.42.10.1425; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1; Schleicher ED, 1997, J CLIN INVEST, V99, P457, DOI 10.1172/JCI119180; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEFFES MW, 1989, DIABETES, V38, P1077, DOI 10.2337/diabetes.38.9.1077; Stern DM, 2002, AGEING RES REV, V1, P1, DOI 10.1016/S0047-6374(01)00366-9; Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291; Suzuki D, 1999, J AM SOC NEPHROL, V10, P822; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; Thornalley PJ, 1998, CELL MOL BIOL, V44, P1013; Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1; VLASSARA H, 1994, P NATL ACAD SCI USA, V91, P11704, DOI 10.1073/pnas.91.24.11704; VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604; Wautier MP, 2003, DIABETES METAB, V29, P44, DOI 10.1016/S1262-3636(07)70006-X; Wendt TM, 2003, AM J PATHOL, V162, P1123, DOI 10.1016/S0002-9440(10)63909-0; Wilkinson-Berka JL, 2002, DIABETES, V51, P3283, DOI 10.2337/diabetes.51.11.3283; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YANG CW, 1994, P NATL ACAD SCI USA, V91, P9436, DOI 10.1073/pnas.91.20.9436; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Zhu WQ, 2001, BIOCHEM BIOPH RES CO, V280, P1183, DOI 10.1006/bbrc.2001.4256	65	87	88	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1773	+		10.1096/fj.04-2031fje	http://dx.doi.org/10.1096/fj.04-2031fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15361471	Green Submitted			2022-12-25	WOS:000224243200032
J	Bakin, RE; Jung, MO				Bakin, RE; Jung, MO			Cytoplasmic sequestration of HDAC7 from mitochondrial and nuclear compartments upon initiation of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; PROCESSING PEPTIDASE; MEMBRANE; PROTEINS; INTERACTS; FRATAXIN; TUBULIN; CELLS; FORM	Control of global histone acetylation status is largely governed by the opposing enzymatic activities of histone acetyltransferases and deacetylases (HDACs). HDACs were originally identified as modulators of nuclear histone acetylation status and have been linked to chromosomal condensation and subsequent gene repression. Accumulating evidence highlights HDAC modification of non-histone targets. Mitochondria were first characterized as intracellular organelles responsible for energy production through the coupling of oxidative phosphorylation to respiration. More recently, mitochondria have been implicated in programmed cell death whereby release of pro-apoptotic inner membrane space factors facilitates apoptotic progression. Here we describe the novel discovery that the nuclear encoded Class II human histone deacetylase HDAC7 localizes to the mitochondrial inner membrane space of prostate epithelial cells and exhibits cytoplasmic relocalization in response to initiation of the apoptotic cascade. These results highlight a previously unrecognized link between HDACs, mitochondria, and programmed cell death.	Georgetown Univ, Sch Med, Lombardi Comprehens Canc Ctr, Dept Radiat Med,Div Radiat Res, Washington, DC 20007 USA	Georgetown University	Jung, MO (corresponding author), Georgetown Univ, Sch Med, Dept Radiat Med, Res Bldg,Rm E-211,Box 571482,3970 Reservoir Rd NW, Washington, DC 20057 USA.	jungm@georgetown.edu			NCI NIH HHS [2P30-CA-51008] Funding Source: Medline; PHS HHS [1S10R15768-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Gakh E, 2002, BBA-MOL CELL RES, V1592, P63, DOI 10.1016/S0167-4889(02)00265-3; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; Jordan J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Liu F, 2004, J BIOL CHEM, V279, P34537, DOI 10.1074/jbc.M402475200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Paroni G, 2004, MOL BIOL CELL, V15, P2804, DOI 10.1091/mbc.E03-08-0624; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Rapaport D, 2003, EMBO REP, V4, P948, DOI 10.1038/sj.embor.embor937; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Verdin E, 2004, NOVART FDN SYMP, V259, P163; Verdin Eric, 2004, Novartis Found Symp, V259, P115; Zhang Y, 2003, EMBO J, V22, P1168, DOI 10.1093/emboj/cdg115; Zhang Y, 2004, RADIAT RES, V161, P667, DOI 10.1667/RR3192	29	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51218	51225		10.1074/jbc.M409271200	http://dx.doi.org/10.1074/jbc.M409271200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15364908	hybrid			2022-12-25	WOS:000225355800069
J	Hull, JJ; Ohnishi, A; Moto, K; Kawasaki, Y; Kurata, R; Suzuki, MG; Matsumoto, S				Hull, JJ; Ohnishi, A; Moto, K; Kawasaki, Y; Kurata, R; Suzuki, MG; Matsumoto, S			Cloning and characterization of the pheromone biosynthesis activating neuropeptide receptor from the silkmoth, Bombyx mori - Significance of the carboxyl terminus in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FORMYL PEPTIDE RECEPTOR; SIGNAL-TRANSDUCTION; BETA(2)-ADRENERGIC RECEPTOR; GENOME SEQUENCE; HELICOVERPA-ZEA; HORMONE; IDENTIFICATION; TAIL; ENDOCYTOSIS	In most Lepidoptera, pheromone biosynthesis is regulated by a neuropeptide termed pheromone biosynthesis activating neuropeptide ( PBAN). Although much is known about the cellular targets of PBAN, identification and functional characterization of the PBAN receptor (PBANR) has proven to be elusive. Given the sequence similarity between the active C-terminal regions of PBAN and neuromedin U, it was hypothesized that their respective receptors might also be similar in structure ( Park, Y., Kim, Y. J., and Adams, M. E. ( 2002) Proc. Natl. Acad. Sci. U. S. A. 99, 11423 - 11428). Consequently, utilizing primers constructed from the conserved regions of insect neuromedin U receptor homologues, a full-length 2780-nucleotide clone encoding a 46-kDa G protein-coupled receptor was amplified from a Bombyx mori pheromone gland cDNA library. Tissue distribution analyses revealed that the receptor transcript is specific to the pheromone gland where it undergoes significant up-regulation in the day preceding eclosion. When transiently expressed in Sf9 cells, the B. mori PBANR responds to PBAN by mobilizing extracellular calcium in a dose-dependent manner. Confocal microscopic studies demonstrated the specificity of enhanced green fluorescent protein-tagged B. mori PBANR for PBAN and showed that PBAN induces internalization of the PBANR . PBAN complex. The rapid onset of internalization is mediated by a 67-amino acid C-terminal extension absent in the cloned Helicoverpa zea PBANR, which suggests that receptor internalization in that species likely utilizes a different mechanism. From these results, we have concluded that the cloned receptor gene encodes the B. mori PBANR and that it is both structurally and functionally distinct from the H. zea PBANR.	RIKEN, Inst Phys & Chem Res, Mol Entomol Lab, Wako, Saitama 3510198, Japan; Saitama Univ, Grad Sch Sci & Engn, Saitama 3388570, Japan	RIKEN; Saitama University	Matsumoto, S (corresponding author), RIKEN, Inst Phys & Chem Res, Mol Entomol Lab, Hirosawa 2-1, Wako, Saitama 3510198, Japan.	smatsu@riken.jp		Ohnishi, Atsushi/0000-0003-1213-4439				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; Becamel Carine, 2002, Biological Procedures Online, V4, P94, DOI 10.1251/bpo39; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Bockaert J, 2003, FEBS LETT, V546, P65, DOI 10.1016/S0014-5793(03)00453-8; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Choi MY, 2003, P NATL ACAD SCI USA, V100, P9721, DOI 10.1073/pnas.1632485100; Cornea A, 1999, ENDOCRINOLOGY, V140, P4272, DOI 10.1210/en.140.9.4272; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FONAGY A, 1992, J PESTIC SCI, V17, P47; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gripentrog JM, 2000, BIOCHEM J, V352, P399, DOI 10.1042/0264-6021:3520399; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; JURENKA RA, 1991, ARCH INSECT BIOCHEM, V17, P81, DOI 10.1002/arch.940170203; JURENKA RA, 1991, P NATL ACAD SCI USA, V88, P8621, DOI 10.1073/pnas.88.19.8621; KITAMURA A, 1989, BIOCHEM BIOPH RES CO, V163, P520, DOI 10.1016/0006-291X(89)92168-2; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Lyu RM, 2000, J BIOL CHEM, V275, P36134, DOI 10.1074/jbc.M004612200; Matsumoto S., 1997, Recent Research Developments in Agricultural & Biological Chemistry, V1, P33; Matsumoto S, 2001, INSECT BIOCHEM MOLEC, V31, P603, DOI 10.1016/S0965-1748(00)00165-X; Moto K, 2004, P NATL ACAD SCI USA, V101, P8631, DOI 10.1073/pnas.0402056101; Moto K, 2003, P NATL ACAD SCI USA, V100, P9156, DOI 10.1073/pnas.1531993100; Oh DY, 2003, MOL CELL ENDOCRINOL, V205, P89, DOI 10.1016/S0303-7207(03)00204-1; OZAWA RA, 1993, BIOSCI BIOTECH BIOCH, V57, P2144, DOI 10.1271/bbb.57.2144; Paing MM, 2004, J BIOL CHEM, V279, P21938, DOI 10.1074/jbc.M401672200; Pankevych H, 2003, J BIOL CHEM, V278, P30283, DOI 10.1074/jbc.M212918200; Park Y, 2002, P NATL ACAD SCI USA, V99, P11423, DOI 10.1073/pnas.162276199; Pawson AJ, 1998, J ENDOCRINOL, V156, pR9, DOI 10.1677/joe.0.156R009; Rafaeli A, 2002, INT REV CYTOL, V213, P49; RAINA AK, 1990, INSECT BIOCHEM, V20, P849, DOI 10.1016/0020-1790(90)90103-2; RAINA AK, 1993, ARCH INSECT BIOCHEM, V22, P141, DOI 10.1002/arch.940220112; RAINA AK, 1989, SCIENCE, V244, P796, DOI 10.1126/science.244.4906.796; ROELOFS W, 1984, BIOORG CHEM, V12, P279, DOI 10.1016/0045-2068(84)90011-7; Roelofs WL, 2003, P NATL ACAD SCI USA, V100, P9179, DOI 10.1073/pnas.1233767100a; Rosenkilde C, 2003, BIOCHEM BIOPH RES CO, V309, P485, DOI 10.1016/j.bbrc.2003.08.022; Seifert R, 2003, LIFE SCI, V73, P2263, DOI 10.1016/S0024-3205(03)00654-4; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Tetsuka M, 2004, ENDOCRINOLOGY, V145, P3712, DOI 10.1210/en.2003-1638; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Tillman JA, 1999, INSECT BIOCHEM MOLEC, V29, P481, DOI 10.1016/S0965-1748(99)00016-8; VanLeeuwen D, 2003, J BIOL CHEM, V278, P15935, DOI 10.1074/jbc.M211546200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Yoshiga T, 2000, GENE, V246, P339, DOI 10.1016/S0378-1119(00)00047-0	48	84	93	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51500	51507		10.1074/jbc.M408142200	http://dx.doi.org/10.1074/jbc.M408142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358772	hybrid			2022-12-25	WOS:000225355800103
J	Shats, I; Milyavsky, M; Tang, XH; Stambolsky, P; Erez, N; Brosh, R; Kogan, I; Braunstein, I; Tzukerman, M; Ginsberg, D; Rotter, V				Shats, I; Milyavsky, M; Tang, XH; Stambolsky, P; Erez, N; Brosh, R; Kogan, I; Braunstein, I; Tzukerman, M; Ginsberg, D; Rotter, V			p53-dependent down-regulation of telomerase is mediated by p21(waf1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; Y TRANSCRIPTION FACTOR; NORMAL HUMAN-CELLS; GENE-EXPRESSION; CANCER-CELLS; HISTONE ACETYLATION; NEGATIVE REGULATION; EPITHELIAL-CELLS; CYCLE ARREST	Inactivation of p53 and activation of telomerase occur in the majority of human cancers, raising the possibility of a link between these two pathways. Overexpression of wild-type p53 down-regulates the enzymatic activity of telomerase in various cancer cell lines through transcriptional repression of its catalytic subunit, human telomerase reverse transcriptase ( hTERT). In this study, we re-evaluated the role of p53 in telomerase regulation using isogenic cell lines expressing physiological levels of p53. We demonstrate that endogenous wild-type p53 was able to down-regulate telomerase activity, hTERT mRNA levels, and promoter activity; however, the ability to repress hTERT expression was found to be cell type-specific. The integrity of the DNA-binding core domain, the N-terminal transactivation domain, and the C-terminal oligomerization domains of p53 was essential for hTERT promoter repression, whereas the proline-rich domain and the extreme C terminus were not required. Southwestern and chromatin immunoprecipitation experiments demonstrated lack of p53 binding to the hTERT promoter, raising the possibility of an indirect repressive mechanism. The down-regulation of hTERT promoter activity was abolished by a dominant-negative E2F1 mutant. Mutational analysis identified a specific E2F site responsible for p53-mediated repression. Knockdown of the key p53 transcriptional target, p21, was sufficient to eliminate the p53-dependent repression of hTERT. Inactivation of the Rb family using either viral oncoproteins or RNA interference attenuated the repression. Inhibition of histone deacetylases also interfered with the repression of hTERT by p53. Therefore, our results suggest that repression of hTERT by endogenous p53 is mediated by p21 and E2F.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Rappaport Fac Med, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Res Inst, IL-31096 Haifa, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Herzl 1, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Milyavsky, Michael/E-8306-2011; Brosh, Ran/H-7309-2019; Tang, Xiaohu/AAX-4577-2021; Shats, Igor/AAD-8775-2019; Brosh, Ran/HDL-9562-2022	Brosh, Ran/0000-0001-9714-8623; Shats, Igor/0000-0001-6449-5979; ginsberg, doron/0000-0002-1257-4920; Erez, Neta/0000-0001-6506-9074				Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Braunstein I, 2001, CANCER RES, V61, P5529; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drissi R, 2001, J BIOL CHEM, V276, P29994, DOI 10.1074/jbc.M101899200; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Gollahon LS, 1996, ONCOGENE, V12, P715; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kiyooka K, 1999, Ann Thorac Cardiovasc Surg, V5, P293; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Li BQ, 2001, J BIOL CHEM, V276, P29729, DOI 10.1074/jbc.M101167200; Lin SY, 2003, CELL, V113, P881, DOI 10.1016/S0092-8674(03)00430-6; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mittelman JM, 1999, SOMAT CELL MOLEC GEN, V25, P115, DOI 10.1023/A:1018822121890; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nair P, 2000, ACTA ONCOL, V39, P65, DOI 10.1080/028418600430996; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Park M, 2000, CANCER RES, V60, P542; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Seger YR, 2002, CANCER CELL, V2, P401, DOI 10.1016/S1535-6108(02)00183-6; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Siddiqui H, 2003, MOL CELL BIOL, V23, P7719, DOI 10.1128/MCB.23.21.7719-7731.2003; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takakura M, 1999, CANCER RES, V59, P551; Tang XH, 2004, ONCOGENE, V23, P5759, DOI 10.1038/sj.onc.1207706; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Ulaner GA, 1998, CANCER RES, V58, P4168; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Wege H, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng003; Wisman GBA, 2003, INT J ONCOL, V23, P1451; Won J, 2004, P NATL ACAD SCI USA, V101, P11328, DOI 10.1073/pnas.0401801101; Won JJ, 2002, FASEB J, V16, P1943, DOI 10.1096/fj.02-0311fje; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhao RB, 2000, GENE DEV, V14, P981; Zhou XL, 1999, CANCER RES, V59, P843; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	65	118	128	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50976	50985		10.1074/jbc.M402502200	http://dx.doi.org/10.1074/jbc.M402502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371422	hybrid			2022-12-25	WOS:000225355800042
J	Bruderer, RM; Brasseur, C; Meyer, HH				Bruderer, RM; Brasseur, C; Meyer, HH			The AAA ATPase p97/VCP interacts with its alternative co-factors, Ufd1-Npl4 and p47, through a common bipartite binding mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; UBIQUITIN INTERACTIONS; TRANSCRIPTION FACTOR; UBX DOMAIN; P97; PROTEIN; ER; COMPLEX; ADAPTER; CDC48	The AAA ATPase p97/VCP forms complexes with different adapters to fulfill distinct cellular functions. We analyzed the structural organization of the Ufd1-Npl4 adapter complex and its interaction with p97 and compared it with another adapter, p47. We found that the binary Ufd1-Npl4 complex forms a heterodimer that cooperatively interacts with p97 via a bipartite binding mechanism. Binding site 1 (BS1) is a short hydrophobic stretch in the C-terminal domain of Ufd1. The second binding site is located at the N terminus of Npl4 and is activated upon binding of Ufd1 to Npl4. It consists of about 80 amino acids that are predicted to form a ubiquitin fold domain (UBD). Despite the lack of overall homology between Ufd1-Npl4 and p47, both adapters use identical binding mechanisms. Like the ubiquitin fold ubiquitin regulatory X (UBX) domain in p47, the Npl4-UBD interacts with p97 via the loop between its strands 3 and 4 and a conserved arginine in strand 1. Furthermore, we identified a region in p47 homologous to Ufd1-BS1. The UBD/UBX and the BS1 of both adapters interact with p97 independently, whereas homologous binding sites in both adapters compete for binding to p97. In contrast to p47, however, Ufd1-Npl4 does not regulate the ATPase activity of p97; nor does a variant of p47 that contains both binding sites but lacks the N-terminal domains. Therefore, the binding sites alone do not regulate p97 directly but rather serve as anchor points to position adapter-specific domains at critical locations to modulate p97-mediated reactions.	ETH Honggerberg HPM, Inst Biochem, Swiss Fed Sch Technol ETH, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Meyer, HH (corresponding author), ETH Honggerberg HPM, Inst Biochem, Swiss Fed Sch Technol ETH, CH-8093 Zurich, Switzerland.	hemmo.meyer@bc.biol.ethz.ch	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796; Bruderer, Roland/0000-0002-1049-5524; Stober Brasseur, Catherine/0000-0002-9481-013X				Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Beuron F, 2003, J MOL BIOL, V327, P619, DOI 10.1016/S0022-2836(03)00178-5; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; Coles M, 1999, CURR BIOL, V9, P1158, DOI 10.1016/S0960-9822(00)80017-2; Decottignies A, 2004, YEAST, V21, P127, DOI 10.1002/yea.1071; DeLaBarre B, 2003, NAT STRUCT BIOL, V10, P856, DOI 10.1038/nsb972; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; Hartmann-Petersen R, 2004, SEMIN CELL DEV BIOL, V15, P247, DOI 10.1016/j.semcdb.2003.12.006; Hartmann-Petersen R, 2004, CURR BIOL, V14, P824, DOI 10.1016/j.cub.2004.04.029; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Huyton T, 2003, J STRUCT BIOL, V144, P337, DOI 10.1016/j.jsb.2003.10.007; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Meyer HH, 1998, FEBS LETT, V437, P255, DOI 10.1016/S0014-5793(98)01232-0; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Schuberth C, 2004, EMBO REP, V5, P818, DOI 10.1038/sj.embor.7400203; Song CC, 2003, J BIOL CHEM, V278, P3648, DOI 10.1074/jbc.M208422200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchiyama K, 2002, J CELL BIOL, V159, P855, DOI 10.1083/jcb.200208112; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wang YZ, 2004, J CELL BIOL, V164, P973, DOI 10.1083/jcb.200401010; Woodman PG, 2003, J CELL SCI, V116, P4283, DOI 10.1242/jcs.00817; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yuan XM, 2004, EMBO J, V23, P1463, DOI 10.1038/sj.emboj.7600152; Yuan XM, 2001, J MOL BIOL, V311, P255, DOI 10.1006/jmbi.2001.4864; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	38	114	119	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49609	49616		10.1074/jbc.M408695200	http://dx.doi.org/10.1074/jbc.M408695200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371428	hybrid			2022-12-25	WOS:000225229500010
J	Chandrashekaran, S; Saravanan, M; Radha, DR; Nagaraja, V				Chandrashekaran, S; Saravanan, M; Radha, DR; Nagaraja, V			Ca2+-mediated site-specific DNA cleavage and suppression of promiscuous activity of KpnI restriction endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECORI ENDONUCLEASE; CALCIUM-IONS; RECOGNITION SEQUENCE; BINDING SPECIFICITY; CRYSTAL-STRUCTURE; BAMHI; ISOSCHIZOMER; SUBSTRATE; ENZYMES; RSRI	The characteristic feature of type II restriction endonucleases (REases) is their exquisite sequence specificity and obligate Mg2+ requirement for catalysis. Efficient cleavage of DNA only in the presence of Ca2+ ions, comparable with that of Mg2+, is previously not described. Most intriguingly, KpnI REase exhibits Ca2+-dependent specific DNA cleavage. Moreover, the enzyme is highly promiscuous in its cleavage pattern on plasmid DNAs in the presence of Mn2+ or Mg2+, with the complete suppression of promiscuous activity in the presence of Ca2+. KpnI methyltransferase does not exhibit promiscuous activity unlike its cognate REase. The REase binds to oligonucleotides containing canonical and mapped noncanonical sites with comparable affinities. However, the extent of cleavage is varied depending on the metal ion and the sequence. The ability of the enzyme to be promiscuous or specific may reflect an evolutionary design. Based on the results, we suggest that the enzyme KpnI represents an REase evolving to attain higher sequence specificity from an ancient nonspecific nuclease.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Nagaraja, V (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	vraj@mcbl.iisc.ernet.in	Matheshwaran, Saravanan/CAG-9469-2022; Matheshwaran, Saravanan/E-9461-2010	MATHESHWARAN, SARAVANAN/0000-0001-6762-9928				AIKEN C, 1988, NUCLEIC ACIDS RES, V16, P7901, DOI 10.1093/nar/16.16.7901; AIKEN CR, 1991, J BIOL CHEM, V266, P19063; BALKE V, 1992, NUCLEIC ACIDS RES, V20, P2777, DOI 10.1093/nar/20.11.2777; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujnicki JM, 2001, VIRUS GENES, V22, P219, DOI 10.1023/A:1008131810233; Chandrashekaran S, 1999, J BIOSCIENCE, V24, P269, DOI 10.1007/BF02941240; Cheng XD, 2001, NUCLEIC ACIDS RES, V29, P3784, DOI 10.1093/nar/29.18.3784; Cowan JA, 1998, CHEM REV, V98, P1067, DOI 10.1021/cr960436q; Dorner LF, 1999, J MOL BIOL, V285, P1515, DOI 10.1006/jmbi.1998.2408; Gormley NA, 2000, J BIOL CHEM, V275, P6928, DOI 10.1074/jbc.275.10.6928; HALFORD SE, 1986, GENE, V41, P173, DOI 10.1016/0378-1119(86)90096-X; Horton JR, 2000, J MOL BIOL, V300, P1049, DOI 10.1006/jmbi.2000.3938; Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11093, DOI 10.1021/bi963126a; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; Lukacs CM, 2000, NAT STRUCT BIOL, V7, P134; MAKULA RA, 1980, NUCLEIC ACIDS RES, V8, P3125, DOI 10.1093/nar/8.14.3125; Martin AM, 1999, NAT STRUCT BIOL, V6, P269; Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359; NASRI M, 1987, NUCLEIC ACIDS RES, V15, P7677, DOI 10.1093/nar/15.19.7677; Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466; Perona JJ, 1997, J MOL BIOL, V273, P207, DOI 10.1006/jmbi.1997.1315; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; Roberts R, 1993, NUCLEASES, P35; ROBINSON CR, 1995, P NATL ACAD SCI USA, V92, P3444, DOI 10.1073/pnas.92.8.3444; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P2186, DOI 10.1073/pnas.95.5.2186; SAMBROOK J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Skirgaila R, 1998, BIOL CHEM, V379, P595; TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005; TOMASSINI J, 1978, NUCLEIC ACIDS RES, V5, P4055, DOI 10.1093/nar/5.11.4055; Viadiu H, 1998, NAT STRUCT BIOL, V5, P910, DOI 10.1038/2352; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; XU SY, 1991, J BIOL CHEM, V266, P4425; ZEBALA JA, 1992, J BIOL CHEM, V267, P8097	34	18	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49736	49740		10.1074/jbc.M409483200	http://dx.doi.org/10.1074/jbc.M409483200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375161	hybrid			2022-12-25	WOS:000225229500024
J	Rozanov, DV; Sikora, S; Godzik, A; Postnova, TI; Golubkov, V; Savinov, A; Tomlinson, S; Strongin, AY				Rozanov, DV; Sikora, S; Godzik, A; Postnova, TI; Golubkov, V; Savinov, A; Tomlinson, S; Strongin, AY			Non-proteolytic, receptor/ligand interactions associate cellular membrane type-1 matrix metalloproteinase with the complement component C1q	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CARCINOMA CELLS; INTEGRIN ALPHA(V) SUBUNIT; CRYSTAL-STRUCTURE; ALPHA-1-PROTEINASE INHIBITOR; PEPTIDE SEQUENCE; MALIGNANT-CELLS; IV COLLAGENASE; GLOBULAR HEAD; MT1-MMP; PROTEIN	Membrane type-1 matrix metalloproteinase (MT1-MMP), a prototypic member of the membrane-tethered MMP family, is an essential component of a cellular proteolysis apparatus. Recognition of protein cleavage targets followed by proteolysis is a main function of MT1-MMP. For the first time, however, we present evidence that MT1-MMP and other structurally related membrane MMPs bind C1q, the recognition unit of the first component of complement C1 that initiates activation of the classical pathway of complement. These interactions involve the catalytic domain of MT1-MMP and the C1q globular domain. In silico modeling followed by mutagenesis and the in vitro and cell-based binding studies showed that the His(171)-Glu-Lys-Gln-Ala-Asp(176) and Val(223)-Arg-Asn(224) peptide sequences of MT1-MMP are directly involved in the binding with C1q. These sequence regions are spatially distant from the active site of the protease. As a result, the catalytically active and the catalytically latent forms of cellular MT1-MMP are both efficient in binding with C1q. In agreement, despite the MT1-MMP/C1q interactions, C1q is totally resistant to MT1-MMP proteolysis. The discovery of the unconventional, receptor/ligand-like interactions of MT1-MMP with C1q, an essential component of immunity, is a significant step toward a more complete understanding of the role of this membrane-tethered protease in cancer.	Burnham Inst, La Jolla, CA 92037 USA; Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Sanford Burnham Prebys Medical Discovery Institute; Medical University of South Carolina	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	strongin@burnham.org	Strongin, Alex/R-6609-2019; Golubkov, Vladislav/L-6828-2017; Godzik, Adam/AAW-1467-2020; Godzik, Adam/A-7279-2009	Strongin, Alex/0000-0003-3765-3016; Godzik, Adam/0000-0002-2425-852X; Godzik, Adam/0000-0002-2425-852X	NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER; NCI NIH HHS [CA83017, CA77470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alonso-Escolano D, 2004, BRIT J PHARMACOL, V141, P241, DOI 10.1038/sj.bjp.0705606; Arlaud GJ, 2002, MOL IMMUNOL, V39, P383, DOI 10.1016/S0161-5890(02)00143-8; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Deryugina EI, 2004, TRAFFIC, V5, P627, DOI 10.1111/j.1600-0854.2004.00206.x; Deryugina EI, 2003, INT J CANCER, V104, P533, DOI 10.1002/ijc.10977; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Gaboriaud C, 2003, J BIOL CHEM, V278, P46974, DOI 10.1074/jbc.M307764200; Ghebrehiwet B, 2004, MOL IMMUNOL, V41, P173, DOI 10.1016/j.molimm.2004.03.014; Gregory LA, 2003, J BIOL CHEM, V278, P32157, DOI 10.1074/jbc.M305175200; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2004, TRENDS BIOCHEM SCI, V29, P285, DOI 10.1016/j.tibs.2004.04.001; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kishore U, 2002, IMMUNOBIOLOGY, V205, P355, DOI 10.1078/0171-2985-00138; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; MAST AE, 1991, J BIOL CHEM, V266, P15810; Matsuda A, 2003, J BIOL CHEM, V278, P36350, DOI 10.1074/jbc.M301509200; McGreal E, 2002, BIOCHEM SOC T, V30, P1010, DOI 10.1042/BST0301010; Morgan B P, 2000, Methods Mol Biol, V150, P1; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nakamura H, 2004, CANCER RES, V64, P876, DOI 10.1158/0008-5472.CAN-03-3502; Ratnikov B, 2000, ANAL BIOCHEM, V286, P149, DOI 10.1006/abio.2000.4798; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rozanov DV, 2004, J BIOL CHEM, V279, P46551, DOI 10.1074/jbc.M405284200; Rozanov DV, 2004, EXP CELL RES, V293, P81, DOI 10.1016/j.yexcr.2003.10.006; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Rozanov DV, 2003, J BIOL CHEM, V278, P8257, DOI 10.1074/jbc.M213246200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2002, FEBS LETT, V527, P51, DOI 10.1016/S0014-5793(02)03153-8; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Sikora S, 2004, PROTEIN SCI, V13, P786, DOI 10.1110/ps.03454904; Sim RB, 2004, BIOCHEM SOC T, V32, P21, DOI 10.1042/BST0320021; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Vakser IA, 1997, PROTEINS, P226; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50321	50328		10.1074/jbc.M409174200	http://dx.doi.org/10.1074/jbc.M409174200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375167	hybrid			2022-12-25	WOS:000225229500095
J	Suzuki, H; Kadowaki, T; Maeda, M; Sasaki, H; Nabekura, J; Sakaguchi, M; Mihara, K				Suzuki, H; Kadowaki, T; Maeda, M; Sasaki, H; Nabekura, J; Sakaguchi, M; Mihara, K			Membrane-embedded C-terminal segment of rat mitochondrial TOM40 constitutes protein-conducting pore with enriched beta-structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; IMPORT RECEPTORS; PREPROTEIN TRANSLOCASE; CORE COMPLEX; CHANNEL; PRESEQUENCE; COMPONENT; DOMAINS; BINDING; PLAYS	TOM40 is the central component of the preprotein translocase of the mitochondrial outer membrane ( TOM complex). We purified recombinant rat TOM40 (rTOM40), which was refolded in Brij35 after solubilization from inclusion bodies by guanidine HCl. rTOM40 ( i) consisted of a 63% beta-sheet structure and (ii) bound a matrix-targeted preprotein with high affinity and partially translocated it into the rTOM40 pore. This partial translocation was inhibited by stabilization of the mature domain of the precursor. (iii) rTOM40 bound preprotein initially through ionic interactions, followed by salt-resistant non-ionic interactions, and (iv) exhibited presequence-sensitive, cation-specific channel activity in reconstituted liposomes. Based on the domain structure of rTOM40 deduced by protease treatment, we purified the elastase-resistant and membrane-embedded C-terminal segment ( rTOM40(DeltaN165)) as a recombinant protein with 62% beta-structure that exhibited properties comparable with those of full-size rTOM40. We concluded that the membrane-embedded C-terminal half of rTOM40 constitutes the preprotein recognition domain with an enriched beta-structure, which forms the preprotein conducting pore containing a salt-sensitive cis-binding site and a salt-resistant trans-binding site.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Dent Sci, Dept Pharmacol, Tokyo 1058451, Japan; Jikei Univ, Sch Med, Dept Mol Cell Biol, Tokyo 1058451, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cellular & Syst Physiol, Fukuoka 8128582, Japan; Univ Hyogo, Grad Sch Life Sci, Ako, Hyogo 6781297, Japan	Kyushu University; Kyushu University; Jikei University; Kyushu University; University of Hyogo	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan.	mihara@cell.med.kyushu-u.ac.jp		Sasaki, Hiroyuki/0000-0002-5358-5853				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Ahting U, 2001, J CELL BIOL, V153, P1151, DOI 10.1083/jcb.153.6.1151; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; COURT DA, 1995, CAN J BOT, V73, P193; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Diekert K, 2001, EMBO J, V20, P5626, DOI 10.1093/emboj/20.20.5626; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Gabriel K, 2003, EMBO J, V22, P2380, DOI 10.1093/emboj/cdg229; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; IWAHASHI J, 1992, J BIOCHEM-TOKYO, V111, P451, DOI 10.1093/oxfordjournals.jbchem.a123778; Iwata K, 1998, BIOCHEM BIOPH RES CO, V253, P648, DOI 10.1006/bbrc.1998.9769; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; Kanamori T, 1999, P NATL ACAD SCI USA, V96, P3634, DOI 10.1073/pnas.96.7.3634; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; Model K, 2002, J MOL BIOL, V316, P657, DOI 10.1006/jmbi.2001.5365; Nabekura J, 1996, J NEUROPHYSIOL, V76, P2447, DOI 10.1152/jn.1996.76.4.2447; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rapaport D, 1998, J BIOL CHEM, V273, P8806, DOI 10.1074/jbc.273.15.8806; Rapaport D, 2001, MOL BIOL CELL, V12, P1189, DOI 10.1091/mbc.12.5.1189; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Reed J, 1997, ANAL BIOCHEM, V254, P36, DOI 10.1006/abio.1997.2355; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Stan T, 2000, EMBO J, V19, P4895, DOI 10.1093/emboj/19.18.4895; Suzuki H, 2000, J BIOL CHEM, V275, P37930, DOI 10.1074/jbc.M006558200; Taylor RD, 2003, J BIOL CHEM, V278, P765, DOI 10.1074/jbc.M208083200; Vasiljev A, 2004, MOL BIOL CELL, V15, P1445, DOI 10.1091/mbc.E03-05-0272; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771	36	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50619	50629		10.1074/jbc.M408604200	http://dx.doi.org/10.1074/jbc.M408604200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15347672	hybrid			2022-12-25	WOS:000225229500126
J	Tamamori-Adachi, M; Hayashida, K; Nobori, K; Omizu, C; Yamada, K; Sakamoto, N; Kamura, T; Fukuda, K; Ogawa, S; Nakayama, KI; Kitajima, S				Tamamori-Adachi, M; Hayashida, K; Nobori, K; Omizu, C; Yamada, K; Sakamoto, N; Kamura, T; Fukuda, K; Ogawa, S; Nakayama, KI; Kitajima, S			Down-regulation of p27(Kip1) promotes cell proliferation of rat neonatal cardiomyocytes induced by nuclear expression of cyclin d1 and CDK4-Evidence for impaired Skp2-dependent degradation of p27 in terminal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK INHIBITORS P27(KIP1); MYOCARDIAL REGENERATION; UBIQUITIN LIGASE; STEM-CELLS; S-PHASE; P57(KIP2); GROWTH; SKP2; SCFSKP2; COMPLEX	Mammalian cardiomyocytes lose their capacity to proliferate during terminal differentiation. We have previously reported that the expression of nuclear localization signal-tagged cyclin D1 (D1NLS) and its partner cyclin-dependent kinase 4 (CDK4) induces proliferation of rat neonatal cardiomyocytes. Here we show that the D1NLS/CDK4 cells, after their entry into the cell cycle, accumulated cyclin-dependent kinase inhibitor p27 in the nuclei and decreased the cyclin-dependent kinase 2 (CDK2) activity, leading to early cell cycle arrest. Biochemical analysis demonstrated that Skp2-dependent p27 ubiquitylation was remarkably suppressed in cardiomyocytes, whereas Skp2, a component of Skp1-CullinF- box protein ubiquitin ligase, was more actively ubiquitylated compared with proliferating rat fibroblasts. Specific degradation of p27 by co-expressing Skp2 or p27 small interfering RNA caused an increase of CDK2 activity and overrode the limited cell cycle. These data altogether indicate that the impaired Skp2-dependent p27 degradation is causally related to the loss of proliferation in cardiomyocytes. This provides a novel insight in understanding the molecular mechanism by which mammalian cardiomyocytes cease to proliferate during terminal differentiation.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Lab Genome Struct & Regulat, Sch Biomed Sci, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Gastroenterol & Hepatol, Bunkyo Ku, Tokyo 1138510, Japan; Keio Univ, Sch Med, Cardiopulm Div, Dept Internal Med, Tokyo 1608582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Keio University; Kyushu University	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp	Fukuda, Keiichi/L-3777-2013; Sakamoto, Naoya/G-2734-2012; Hayashida, Kentaro/J-5071-2014	Sakamoto, Naoya/0000-0003-0061-059X; Hayashida, Kentaro/0000-0002-1750-1982				Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Dyer MA, 2001, J NEUROSCI, V21, P4259, DOI 10.1523/JNEUROSCI.21-12-04259.2001; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Kirshenbaum LA, 1996, DEV BIOL, V179, P402, DOI 10.1006/dbio.1996.0270; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nagahama H, 2001, ANAT EMBRYOL, V203, P77, DOI 10.1007/s004290000146; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Olson EN, 2003, GENE DEV, V17, P1937, DOI 10.1101/gad.1110103; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pasumarthi KBS, 2002, CIRC RES, V90, P1044, DOI 10.1161/01.RES.0000020201.44772.67; Poolman RA, 1999, CIRC RES, V85, P117, DOI 10.1161/01.RES.85.2.117; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori-Adachi M, 2002, BIOCHEM BIOPH RES CO, V296, P274, DOI 10.1016/S0006-291X(02)00854-9; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; von Harsdorf R, 1999, CIRC RES, V85, P128, DOI 10.1161/01.RES.85.2.128; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162	32	32	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50429	50436		10.1074/jbc.M403084200	http://dx.doi.org/10.1074/jbc.M403084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371458	hybrid			2022-12-25	WOS:000225229500108
J	Ye, X; Nalepa, G; Welcker, M; Kessler, BM; Spooner, E; Qin, J; Ellege, SJ; Clurman, BE; Harper, JW				Ye, X; Nalepa, G; Welcker, M; Kessler, BM; Spooner, E; Qin, J; Ellege, SJ; Clurman, BE; Harper, JW			Recognition of phosphodegron motifs in human cyclin E by the SCFFbw7 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; MULTISITE PHOSPHORYLATION; DEPENDENT DEGRADATION; C-MYC; PROTEIN; SCF; COMPLEX; BETA; CDK; PROTEOLYSIS	Turnover of cyclin E is controlled by SCFFbw7. Three isoforms of Fbw7 are produced by alternative splicing. Whereas Fbw7alpha and -gamma are nuclear and the beta-isoform is cytoplasmic in 293T cells, all three isoforms induce cyclin E destruction in an in vivo degradation assay. Cyclin E is phosphorylated on Thr(62), Ser(88), Ser(372), Thr(380), and Ser(384) in vivo. To examine the roles of phosphorylation in cyclin E turnover, a series of alanine point mutations in each of these sites were analyzed for Fbw7-driven degradation. As expected, mutation of the previously characterized residue Thr(380) to alanine led to profound defects of cyclin E turnover, and largely abolished association with Fbw7. Mutation of Thr(62) to alanine led to a dramatic reduction in the extent of Thr(380) phosphorylation, suggesting an indirect effect of this mutation on cyclin E turnover. Nevertheless, phosphopeptides centered at Thr(62) associated with Fbw7, and residual binding of cyclin E-T380A to Fbw7 was abolished upon mutation of Thr(62), suggesting a minor role for this residue in direct association with Fbw7. Mutation of Ser(384) to alanine also rendered cyclin E resistant to degradation by Fbw7, with the largest effects being observed with Fbw7beta. Cyclin E-S384A associated more weakly with Fbw7alpha and -beta isoforms but was not defective in Thr(380) phosphorylation. Analysis of the localization of cyclin E mutant proteins indicated selective accumulation of cyclin ES384A in the nucleus, which may contribute to the inability of cytoplasmic Fbw7beta to promote turnover of this cyclin E mutant protein.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Genet & Genom, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs McLean Dept Biochem, Houston, TX 77030 USA; Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Fred Hutchinson Cancer Center	Harper, JW (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	wade_harper@hms.harvard.edu	Clurman, Bruce/AAV-3854-2021; Kessler, Benedikt/AAY-8614-2021	Kessler, Benedikt/0000-0002-8160-2446; Nalepa, Grzegorz/0000-0002-5779-9103; Lab, Nalepa/0000-0002-7560-1906; Harper, Jeffrey/0000-0002-6944-7236; Welcker, Markus/0000-0001-6723-4790	NCI NIH HHS [CA102742] Funding Source: Medline; NIA NIH HHS [R01 AG011085, AG11095] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Deshaies RJ, 2001, CELL, V107, P819, DOI 10.1016/S0092-8674(01)00620-1; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Harper JW, 2002, TRENDS CELL BIOL, V12, P104, DOI 10.1016/S0962-8924(01)02238-3; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spruck CH, 2002, CANCER RES, V62, P4535; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tetzlaff MT, 2004, P NATL ACAD SCI USA, V101, P3338, DOI 10.1073/pnas.0307875101; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	114	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50110	50119		10.1074/jbc.M409226200	http://dx.doi.org/10.1074/jbc.M409226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364936	hybrid, Green Published			2022-12-25	WOS:000225229500070
J	Yu, JQ; Bian, DF; Mahanivong, C; Cheng, RK; Zhou, WY; Huang, S				Yu, JQ; Bian, DF; Mahanivong, C; Cheng, RK; Zhou, WY; Huang, S			p38 mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; SIGNAL-TRANSDUCTION PATHWAY; MESSENGER-RNA STABILITY; MURINE MESANGIAL CELLS; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; MAP KINASE; SPHINGOSINE 1-PHOSPHATE; EPITHELIAL-CELLS	The migration of endothelial cells in response to various stimulating factors plays an essential role in angiogenesis. The p38 MAPK pathway has been implicated to play an important role in endothelial cell migration because inhibiting p38 MAPK activity down-regulates vascular endothelial growth factor ( VEGF)-stimulated migration. Currently, the signaling components in the p38 MAPK activation pathway and especially the mechanisms responsible for p38 MAPK-regulated endothelial cell migration are not well understood. In the present study, we found that p38 MAPK activity is required for endothelial cell migration stimulated by both VEGF and nongrowth factor stimulants, sphingosine 1-phosphate and soluble vascular cell adhesion molecule. By using dominant negative forms of signaling components in the p38 MAPK pathway, we identified that a regulatory pathway consisting of MKK3-p38alpha/gamma-MAPK-activated protein kinase 2 participated in VEGF-stimulated migration. In further studies, we showed that a minimum of a 10-h treatment with SB203580 ( specific p38 MAPK inhibitor) was needed to block VEGF-stimulated migration, suggesting an indirect role of p38 MAPK in this cellular event. Most interestingly, the occurrence of SB203580-induced migratory inhibition coincided with a reduction of urokinase plasminogen activator (uPA) expression. Furthermore, agents disrupting uPA and uPA receptor interaction abrogated VEGF-stimulated cell migration. These results suggest a possible association between cell migration and uPA expression. Indeed, VEGF-stimulated migration was not compromised by SB203580 in endothelial cells expressing the uPA transgene; however, VEGF-stimulated migration was inhibited by agents disrupting uPA-uPA receptor interaction. These results thus suggest that the p38 MAPK pathway participates in endothelial cell migration by regulating uPA expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Huang, S (corresponding author), Scripps Res Inst, Dept Immunol, IMM-19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	shuang@scripps.edu			NCI NIH HHS [R01 CA93926] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blagosklonny MV, 2004, CANCER CELL, V5, P13, DOI 10.1016/S1535-6108(03)00336-2; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Collen D, 1999, THROMB HAEMOSTASIS, V82, P259; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Denes L, 2002, BRIT J PHARMACOL, V136, P597, DOI 10.1038/sj.bjp.0704738; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hannigan MO, 2001, J IMMUNOL, V167, P3953, DOI 10.4049/jimmunol.167.7.3953; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Huang XJ, 2002, CANCER RES, V62, P5727; Kaneko T, 2003, CANCER SCI, V94, P43, DOI 10.1111/j.1349-7006.2003.tb01350.x; Kavurma MM, 2003, J CELL BIOCHEM, V89, P289, DOI 10.1002/jcb.10497; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Kim MS, 2003, CANCER RES, V63, P5454; Koolwijk P, 2001, J CLIN ENDOCR METAB, V86, P3359, DOI 10.1210/jc.86.7.3359; Kotlyarov A, 2002, MOL CELL BIOL, V22, P4827, DOI 10.1128/MCB.22.13.4827-4835.2002; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; Li W, 2001, J INVEST DERMATOL, V117, P1601, DOI 10.1046/j.0022-202x.2001.01608.x; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Montero L, 1999, CANCER RES, V59, P5286; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakao S, 2003, J IMMUNOL, V170, P5704, DOI 10.4049/jimmunol.170.11.5704; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Pichon S, 2004, J CELL SCI, V117, P2569, DOI 10.1242/jcs.01110; Prager GW, 2004, BLOOD, V103, P955, DOI 10.1182/blood-2003-07-2214; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Ray AK, 2003, J PERIODONTOL, V74, P1320, DOI 10.1902/jop.2003.74.9.1320; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sandberg T, 2001, J CLIN ENDOCR METAB, V86, P1724, DOI 10.1210/jc.86.4.1724; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Sliva D, 2002, BIOCHEM BIOPH RES CO, V290, P552, DOI 10.1006/bbrc.2001.6225; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Verma A, 2002, J BIOL CHEM, V277, P44988, DOI 10.1074/jbc.M207176200; Wang L, 2004, J BIOL CHEM, V279, P33213, DOI 10.1074/jbc.M403758200; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Wang Q, 2001, J IMMUNOL, V166, P6877, DOI 10.4049/jimmunol.166.11.6877; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Wilson AJ, 2000, GUT, V47, P105, DOI 10.1136/gut.47.1.105; Xiong SB, 2001, CANCER RES, V61, P1727; Zachary I, 2003, BIOCHEM SOC T, V31, P1171	61	48	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50446	50454		10.1074/jbc.M409221200	http://dx.doi.org/10.1074/jbc.M409221200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371454	hybrid			2022-12-25	WOS:000225229500110
J	Kumamoto, Y; Higashi, N; Denda-Nagai, K; Tsuiji, M; Sato, K; Crocker, PR; Irimura, T				Kumamoto, Y; Higashi, N; Denda-Nagai, K; Tsuiji, M; Sato, K; Crocker, PR; Irimura, T			Identification of sialoadhesin as a dominant lymph node counter-receptor for mouse macrophage galactose-type C-type lectin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-RECEPTOR; CYSTEINE-RICH DOMAIN; SENSITIZATION PHASE; MOLECULAR-CLONING; CELLS; PURIFICATION; TRAFFICKING; SPECIFICITY; SIGLECS	In the sensitization phase of contact hypersensitivity in mice, dermal macrophages (MOs) expressing MO galactose-type C-type lectin1 (MGL1) are known to migrate from the dermis to lymph nodes (LNs) where they accumulate in the subcapsular sinus, interfollicular regions, and areas surrounding high endothelial venules. We hypothesize that the interactions between MGL1 and its ligands determine the localizations of MGL1-positive cells within the LNs. In the present study, our major aim was to isolate MGL1 counter-receptor(s) from lysates of LNs using affinity chromatography with immobilized recombinant MGL1. Fractions bound and eluted with EDTA were analyzed by SDS-PAGE and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. One of the predominant components was sialoadhesin (Sn, Siglec-1). Sn from lysates of LNs was immobilized on microtiter plates precoated with anti-Sn monoclonal antibody, and binding of recombinant MGL1 and adhesion of cells expressing MGL1 were tested. The binding of recombinant MGL1 to Sn was shown to be dependent on Ca2+ and N-glycans on Sn. MGL1-transfected Chinese hamster ovary cells adhered to the Sn-coated plates, whereas mock transfectants did not. Immunohistochemical localization of anti-Sn monoclonal antibody in LN coincided with the subcapsular sinus area to which recombinant MGL1 was bound. Furthermore, the distribution of MGL1+ cells after sensitization with FITC was demonstrated to overlap with that of Sn within the subcapsular sinus of draining LNs. These results suggest that Sn acts as an endogenous counter-receptor for MGL1.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of Tokyo; University of Dundee	Irimura, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.	irimura@mol.f.u-tokyo.ac.jp	Tsuiji, Makoto/G-1411-2010	Tsuiji, Makoto/0000-0002-5607-4880; Denda-Nagai, Kaori/0000-0001-8325-3289; Kumamoto, Yosuke/0000-0001-9369-4934; Crocker, Paul/0000-0001-6230-0293				Angata T, 2002, BBA-GEN SUBJECTS, V1572, P294, DOI 10.1016/S0304-4165(02)00316-1; Chun KH, 2000, INT IMMUNOL, V12, P1695, DOI 10.1093/intimm/12.12.1695; Chun KH, 2000, J LEUKOCYTE BIOL, V68, P471; CROCKER PR, 1989, J EXP MED, V169, P1333, DOI 10.1084/jem.169.4.1333; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; Crocker PR, 2001, IMMUNOLOGY, V103, P137, DOI 10.1046/j.0019-2805.2001.01241.x; Denda-Nagai K, 2002, GLYCOBIOLOGY, V12, P443, DOI 10.1093/glycob/cwf061; Feizi T, 2000, IMMUNOL REV, V173, P79, DOI 10.1034/j.1600-065X.2000.917310.x; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; Geijtenbeek TBH, 2000, NAT IMMUNOL, V1, P353, DOI 10.1038/79815; Higashi N, 2002, J BIOL CHEM, V277, P20686, DOI 10.1074/jbc.M202104200; Kimura T, 2000, MOL IMMUNOL, V37, P151, DOI 10.1016/S0161-5890(00)00027-4; KIMURA T, 1995, J BIOL CHEM, V270, P16056, DOI 10.1074/jbc.270.27.16056; Martinez-Pomares L, 1999, J BIOL CHEM, V274, P35211, DOI 10.1074/jbc.274.49.35211; Mizuochi S, 1997, GLYCOBIOLOGY, V7, P137, DOI 10.1093/glycob/7.1.137; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; ODA S, 1988, J BIOCHEM-TOKYO, V104, P600, DOI 10.1093/oxfordjournals.jbchem.a122518; Sato K, 1998, J IMMUNOL, V161, P6835; Schadee-Eestermans IL, 2000, IMMUNOBIOLOGY, V202, P309, DOI 10.1016/S0171-2985(00)80036-4; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Suzuki N, 1996, J IMMUNOL, V156, P128; Tsuiji M, 2002, J BIOL CHEM, V277, P28892, DOI 10.1074/jbc.M203774200; YAMAMOTO K, 1994, BIOCHEMISTRY-US, V33, P8159, DOI 10.1021/bi00192a021	24	42	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49274	49280		10.1074/jbc.M409300200	http://dx.doi.org/10.1074/jbc.M409300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364954	hybrid			2022-12-25	WOS:000225098100095
J	Li, AL; Li, HY; Jin, BF; Ye, QN; Zhou, T; Yu, XD; Pan, X; Man, JH; He, K; Yu, M; Hu, MR; Wang, J; Yang, SC; Shen, BF; Zhang, XM				Li, AL; Li, HY; Jin, BF; Ye, QN; Zhou, T; Yu, XD; Pan, X; Man, JH; He, K; Yu, M; Hu, MR; Wang, J; Yang, SC; Shen, BF; Zhang, XM			A novel eIF5A complex functions as a regulator of p53 and p53-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 5A; HYPUSINE FORMATION; PROTEOMIC ANALYSIS; PROTEIN-SYNTHESIS; NITRIC-OXIDE; EIF-5A; PHOSPHORYLATION; RAS; UBIQUITINATION; ACTIVATION	Although eukaryotic translation initiation factor 5A (eIF5A) was originally designated as an "initiation factor," recent data have shown it to be also involved in apoptosis. However, the actual function of eIF5A in apoptosis is still unknown. In this study, we performed yeast two-hybrid screens to identify eIF5A-interacting proteins to help us understand the mechanisms of eIF5A. Our results demonstrated that eIF5A and syntenin could engage in a specific interaction both in vitro and in vivo and functioned collaboratively to regulate p53 activity. Our findings, for the first time, revealed a new biological activity for eIF5A as the regulator of p53. Overexpression of eIF5A or its EFP domain resulted in up-regulation of p53, and silencing eIF5A by small interfering RNA reduced the p53 protein level. Further analysis by reverse transcription PCR showed eIF5A-activated p53 transcription. The effect of eIF5A on p53 transcriptional activity was further demonstrated by the increasing expressions of p21 and Bax, well known target genes of p53. In contrast, a point mutant of eIF5A, hypusination being abolished, was revealed to be functionally defective in p53 up-regulation. Overexpression of eIF5A led to a p53-dependent apoptosis or sensitized cells to induction of apoptosis by chemotherapeutic agents. However, when eIF5A interacted with its novel partner, syntenin, the eIF5A-induced increase in p53 protein level was significantly inhibited. Therefore, eIF5A seems to be a previously unrecognized regulator of p53 that may define a new pathway for p53-dependent apoptosis, and syntenin might regulate p53 by balancing the regulation of eIF5A signaling to p53 for apoptosis.	Natl Ctr Biomed Anal, Inst Basic Med Sci, Beijing 100850, Peoples R China; Beijing Inst Biotechnol, Beijing 100850, Peoples R China		Zhang, XM (corresponding author), Natl Ctr Biomed Anal, Inst Basic Med Sci, 27 Tai Ping Rd, Beijing 100850, Peoples R China.	xmzhang@nic.bmi.ac.cn		Pan, Xin/0000-0002-1982-2261				Appella E, 2000, PATHOL BIOL, V48, P227; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BENNE R, 1978, J BIOL CHEM, V253, P3078; BEVEC D, 1994, P NATL ACAD SCI USA, V91, P10829, DOI 10.1073/pnas.91.23.10829; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Chen G, 2003, PROTEOMICS, V3, P496, DOI 10.1002/pmic.200390063; Chen KY, 1999, J CHIN CHEM SOC-TAIP, V46, P727, DOI 10.1002/jccs.199900100; Chen KY, 1997, BIOL SIGNAL, V6, P105; Chen ZP, 1997, CANCER LETT, V115, P235, DOI 10.1016/S0304-3835(97)04741-1; Chung HJ, 2000, J NEUROSCI, V20, P7258; Dev KK, 2000, J NEUROSCI, V20, P7252; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Jin BF, 2003, ONCOGENE, V22, P4819, DOI 10.1038/sj.onc.1206738; KANG HA, 1994, J BIOL CHEM, V269, P3934; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kruse M, 2000, J EXP MED, V191, P1581, DOI 10.1084/jem.191.9.1581; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rohan TE, 1998, JNCI-J NATL CANCER I, V90, P1262, DOI 10.1093/jnci/90.17.1262; Rosorius O, 1999, J CELL SCI, V112, P2369; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Tome ME, 1997, BIOCHEM J, V328, P847; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9	35	101	119	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49251	49258		10.1074/jbc.M407165200	http://dx.doi.org/10.1074/jbc.M407165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371445	hybrid			2022-12-25	WOS:000225098100092
J	van der Goot, FG; van Nhieu, GT; Allaoui, A; Sansonetti, P; Lafont, F				van der Goot, FG; van Nhieu, GT; Allaoui, A; Sansonetti, P; Lafont, F			Rafts can trigger contact-mediated secretion of bacterial effectors via a lipid-based mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLEXNERI IPA INVASINS; III PROTEIN SECRETION; SHIGELLA-FLEXNERI; EPITHELIAL-CELLS; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; SERINE PALMITOYLTRANSFERASE; YERSINIA-ENTEROCOLITICA; TRANSLOCATION PORE; PLASMA-MEMBRANE	Infection by the Gram-negative bacterial pathogen Shigella flexneri depends on its ability to invade host cells. Bacterial engulfment requires a functional type III secretion system (TTSS) allowing the translocation into host cells of bacterial effectors that activate cell-signaling cascades. We demonstrated previously that specialized lipid membrane domains enriched in cholesterol and sphingolipids (rafts) are involved during early steps of invasion, namely in binding and host cell entry. In this study, we addressed the issue of contact-mediated secretion by the TTSS. We show that contact-mediated and TTSS-induced hemolysis depend on the presence of cholesterol on the host cell surface. We found that purified detergent resistant membranes were able to activate TTSS. Finally, we found that artificial liposomes, devoid of proteins, were able to activate the TTSS but only when their composition mimicked that of lipid rafts. Altogether, these data indicate that specific lipid packing can trigger contact-mediated secretion by S. flexneri.	Univ Geneva, Fac Med, Dept Microbiol & Mol Med, CH-1211 Geneva 4, Switzerland; Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France; Free Univ Brussels, Fac Med, Lab Bacteriol Mol, B-1070 Brussels, Belgium	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Lafont, F (corresponding author), Univ Geneva, Fac Med, Dept Microbiol & Mol Med, 1 Rue Michel Servet, CH-1211 Geneva 4, Switzerland.	Frank.Lafont@medecine.unige.ch	van der Goot, Gisou G/B-2279-2012; Van Nhieu, Guy Tran/Y-6359-2018	van der Goot, Gisou G/0000-0002-8522-274X; Van Nhieu, Guy Tran/0000-0002-3901-2186; Lafont, frank/0000-0001-8668-2580				Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; ADAM T, 1995, J CELL BIOL, V129, P367, DOI 10.1083/jcb.129.2.367; Aizawa S, 2001, FEMS MICROBIOL LETT, V202, P157, DOI 10.1111/j.1574-6968.2001.tb10797.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ALLAOUI A, 1993, INFECT IMMUN, V61, P1707, DOI 10.1128/IAI.61.5.1707-1714.1993; Bahrani FK, 1997, INFECT IMMUN, V65, P4005, DOI 10.1128/IAI.65.10.4005-4010.1997; Barzu S, 1997, INFECT IMMUN, V65, P1599; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Blocker A, 2003, P NATL ACAD SCI USA, V100, P3027, DOI 10.1073/pnas.0535335100; Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Burton EA, 2003, EMBO J, V22, P5471, DOI 10.1093/emboj/cdg512; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Dacheux D, 2001, MOL MICROBIOL, V40, P76, DOI 10.1046/j.1365-2958.2001.02368.x; Daefler S, 1999, MOL MICROBIOL, V31, P45, DOI 10.1046/j.1365-2958.1999.01141.x; De Geyter C, 2000, EUR J BIOCHEM, V267, P5769, DOI 10.1046/j.1432-1327.2000.01649.x; DeGeyter C, 1997, FEBS LETT, V400, P149, DOI 10.1016/S0014-5793(96)01379-8; Frithz-Lindsten E, 1998, MOL MICROBIOL, V29, P1155, DOI 10.1046/j.1365-2958.1998.00994.x; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Giocondi MC, 2004, BIOPHYS J, V86, P861, DOI 10.1016/S0006-3495(04)74161-2; Goure J, 2004, INFECT IMMUN, V72, P4741, DOI 10.1128/IAI.72.8.4741-4750.2004; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Greenberg JT, 2003, CURR OPIN MICROBIOL, V6, P20, DOI 10.1016/S1369-5274(02)00004-8; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; HANADA K, 1990, J BIOL CHEM, V265, P22137; HIRANO T, 1994, J BACTERIOL, V176, P5439, DOI 10.1128/JB.176.17.5439-5449.1994; Ide T, 2001, CELL MICROBIOL, V3, P669, DOI 10.1046/j.1462-5822.2001.00146.x; Jin QL, 2003, MICROBES INFECT, V5, P301, DOI 10.1016/S1286-4579(03)00032-7; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kenny B, 2002, INT J MED MICROBIOL, V291, P469; Knodler LA, 2003, MOL MICROBIOL, V49, P685, DOI 10.1046/j.1365-2958.2003.03598.x; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; Lafont F, 2002, EMBO J, V21, P4449, DOI 10.1093/emboj/cdf457; Lafont F, 2004, CURR OPIN MICROBIOL, V7, P4, DOI 10.1016/j.mib.2003.12.007; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Magdalena J, 2002, J BACTERIOL, V184, P3433, DOI 10.1128/JB.184.13.3433-3441.2002; Makishima S, 2001, SCIENCE, V291, P2411, DOI 10.1126/science.1058366; MENARD R, 1993, J BACTERIOL, V175, P5899; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; Mounier J, 1997, INFECT IMMUN, V65, P774, DOI 10.1128/IAI.65.2.774-782.1997; Neyt C, 1999, MOL MICROBIOL, V33, P971, DOI 10.1046/j.1365-2958.1999.01537.x; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; Rathman M, 2000, MOL MICROBIOL, V35, P974, DOI 10.1046/j.1365-2958.2000.01770.x; Sansonetti PJ, 2001, FEMS MICROBIOL REV, V25, P3, DOI 10.1111/j.1574-6976.2001.tb00569.x; Schoehn G, 2003, EMBO J, V22, P4957, DOI 10.1093/emboj/cdg499; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Skoudy A, 2000, CELL MICROBIOL, V2, P19, DOI 10.1046/j.1462-5822.2000.00028.x; Tamano K, 2002, J BACTERIOL, V184, P1244, DOI 10.1128/JB.184.5.1244-1252.2002; Tamano K, 2000, EMBO J, V19, P3876, DOI 10.1093/emboj/19.15.3876; Tardy F, 1999, EMBO J, V18, P6793, DOI 10.1093/emboj/18.23.6793; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Vallis AJ, 1999, INFECT IMMUN, V67, P914, DOI 10.1128/IAI.67.2.914-920.1999; Wachter C, 1999, MOL MICROBIOL, V31, P1695, DOI 10.1046/j.1365-2958.1999.01303.x; Warawa J, 1999, INFECT IMMUN, V67, P5538, DOI 10.1128/IAI.67.10.5538-5540.1999; WATARAI M, 1995, EMBO J, V14, P2461, DOI 10.1002/j.1460-2075.1995.tb07243.x; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Wolff C, 1998, MOL MICROBIOL, V28, P143, DOI 10.1046/j.1365-2958.1998.00782.x; Zaharik ML, 2002, INT J MED MICROBIOL, V291, P593, DOI 10.1078/1438-4221-00179; ZIERLER MK, 1995, INFECT IMMUN, V63, P4024, DOI 10.1128/IAI.63.10.4024-4028.1995; Zobiack N, 2002, J CELL SCI, V115, P91	65	67	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47792	47798		10.1074/jbc.M406824200	http://dx.doi.org/10.1074/jbc.M406824200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364928	hybrid			2022-12-25	WOS:000224957000047
J	Zoldak, G; Zubrik, A; Musatov, A; Stupak, M; Sedlak, E				Zoldak, G; Zubrik, A; Musatov, A; Stupak, M; Sedlak, E			Irreversible thermal denaturation of glucose oxidase from Aspergillus niger is the transition to the denatured state with residual structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; GUANIDINE HYDROCHLORIDE; SUBUNIT STRUCTURE; SURFACE-AREAS; PROTEIN; STABILITY; ENZYME; STABILIZATION; INACTIVATION; DISSOCIATION	Glucose oxidase (GOX; beta-D-glucose: oxygen oxidoreductase) from Aspergillus niger is a dimeric flavoprotein with a molecular mass of 80 kDa/monomer. Thermal denaturation of glucose oxidase has been studied by absorbance, circular dichroism spectroscopy, viscosimetry, and differential scanning calorimetry. Thermal transition of this homodimeric enzyme is irreversible and, surprisingly, independent of GOX concentration (0.2-5.1 mg/ml). It has an apparent transition temperature of 55.8 +/- 1.2 degreesC and an activation energy of similar to280 kJ/mol, calculated from the Lumry-Eyring model. The thermally denatured state of GOX after recooling has the following characteristics. (i) It retains similar to70% of the native secondary structure ellipticity; (ii) it has a relatively low intrinsic viscosity, 7.5 ml/g; (iii) it binds ANS; (iv) it has a low Stern-Volmer constant of tryptophan quenching; and ( v) it forms defined oligomeric ( dimers, trimers, tetramers) structures. It is significantly different from chemically denatured (6.67 M GdmHCl) GOX. Both the thermal and the chemical denaturation of GOX cause dissociation of the flavin cofactor; however, only the chemical denaturation is accompanied by dissociation of the homodimeric GOX into monomers. The transition temperature is independent of the protein concentration, and the properties of the thermally denatured protein indicate that thermally denatured GOX is a compact structure, a form of molten globule-like apoenzyme. GOX is thus an exceptional example of a relatively unstable mesophilic dimeric enzyme with residual structure in its thermally denatured state.	Safarik Univ, Fac Sci, Dept Biochem, Kosice 04154, Slovakia; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Pavol Jozef Safarik Kosice; University of Texas System; University of Texas Health San Antonio	Sedlak, E (corresponding author), Safarik Univ, Fac Sci, Dept Biochem, 11 Moyzesova, Kosice 04154, Slovakia.	sedlak_er@saske.sk	Sedlak, Erik/A-9989-2013; Musatov, Andrej/K-8963-2012; Zoldak, Gabriel/Q-7412-2017; Zoldak, Gabriel/AAI-3266-2020	Zoldak, Gabriel/0000-0002-5271-8837; Musatov, Andrey/0000-0001-8991-2468; Stupak, Marek/0000-0002-3371-9623; Sedlak, Erik/0000-0003-1290-5774				Ahmad A, 2001, BIOCHEMISTRY-US, V40, P1945, DOI 10.1021/bi001933a; Akhtar MS, 2002, BIOCHEMISTRY-US, V41, P7142, DOI 10.1021/bi020080e; Bano M, 2003, REV SCI INSTRUM, V74, P4788, DOI 10.1063/1.1614881; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; CIOCI F, 1994, BIOCHEM MOL BIOL INT, V34, P705; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FREW JE, 1987, PHILOS T ROY SOC B, V316, P95, DOI 10.1098/rstb.1987.0020; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; Gouda MD, 2003, J BIOL CHEM, V278, P24324, DOI 10.1074/jbc.M208711200; Gouda MD, 2002, BIOSENS BIOELECTRON, V17, P503, DOI 10.1016/S0956-5663(02)00021-0; Haouz A, 1998, EUR BIOPHYS J BIOPHY, V27, P19, DOI 10.1007/s002490050106; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; KALISZ HM, 1991, BIOCHIM BIOPHYS ACTA, V1080, P138, DOI 10.1016/0167-4838(91)90140-U; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; Komineck J., 1983, BIOTECHNOLOGY, V3, P455; LUMRY R, 1954, J PHYS CHEM-US, V58, P110, DOI 10.1021/j150512a005; MARKY LA, 1987, BIOPOLYMERS, V26, P1601, DOI 10.1002/bip.360260911; MASUDA T, 1955, PHARM SOC JAPAN, V75, P802; Motono C, 2001, PROTEIN ENG, V14, P961, DOI 10.1093/protein/14.12.961; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Musatov A, 1999, FEBS LETT, V457, P153, DOI 10.1016/S0014-5793(99)01020-0; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAKAMURA S, 1974, FEBS LETT, V41, P327, DOI 10.1016/0014-5793(74)81240-8; NAKAMURA S, 1968, J BIOCHEM-TOKYO, V63, P51, DOI 10.1093/oxfordjournals.jbchem.a128747; NAKAMURA S, 1977, BIOCHEM BIOPH RES CO, V78, P806, DOI 10.1016/0006-291X(77)90251-0; OMALLEY JJ, 1972, BIOCHEMISTRY-US, V11, P3527, DOI 10.1021/bi00769a006; OMALLEY JJ, 1973, BIOTECHNOL BIOENG, V15, P917, DOI 10.1002/bit.260150509; Pace C N, 1986, Methods Enzymol, V131, P266; Perl D, 2002, BIOPHYS CHEM, V96, P173, DOI 10.1016/S0301-4622(02)00024-8; RAO VB, 1981, BIOCHEM J, V193, P389, DOI 10.1042/bj1930389; Robic S, 2003, P NATL ACAD SCI USA, V100, P11345, DOI 10.1073/pnas.1635051100; Sanchez-Ruiz J M, 1995, Subcell Biochem, V24, P133; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; Sedlak E, 2001, BIOCHEMISTRY-US, V40, P9579, DOI 10.1021/bi010274e; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Seymour SL, 2002, BIOCHEMISTRY-US, V41, P8747, DOI 10.1021/bi020054g; Shi ZS, 2002, ADV PROTEIN CHEM, V62, P163; SHORTLE D, 1993, STRUCTURE, V1, P121, DOI 10.1016/0969-2126(93)90027-E; SOLOMON B, 1977, BIOPOLYMERS, V16, P1837, DOI 10.1002/bip.1977.360160902; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; SWOBODA BEP, 1969, BIOCHIM BIOPHYS ACTA, V175, P365, DOI 10.1016/0005-2795(69)90014-2; SWOBODA BEP, 1965, J BIOL CHEM, V240, P2209; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P6185, DOI 10.1021/bi00524a042; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TANFORD C, 1966, J BIOL CHEM, V241, P1921; Thorolfsson M, 2002, BIOCHEMISTRY-US, V41, P7573, DOI 10.1021/bi0160720; Tsodikov OV, 2002, J COMPUT CHEM, V23, P600, DOI 10.1002/jcc.10061; TSUGE H, 1975, J BIOCHEM, V78, P835, DOI 10.1093/oxfordjournals.jbchem.a130974; Turner A. P. F., 1987, BIOSENSORS FUNDAMENT, P770; Tzanov T, 2002, J BIOTECHNOL, V93, P87, DOI 10.1016/S0168-1656(01)00386-8; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Wang SQ, 2003, BIOTECHNOL BIOENG, V83, P444, DOI 10.1002/bit.10684; Wong KB, 2000, J MOL BIOL, V296, P1257, DOI 10.1006/jmbi.2000.3523; YE WN, 1989, BIOCHIM BIOPHYS ACTA, V999, P86, DOI 10.1016/0167-4838(89)90034-4; Zoldak G, 2003, EUR J BIOCHEM, V270, P4887, DOI 10.1046/j.1432-1033.2003.03889.x	58	102	106	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47601	47609		10.1074/jbc.M406883200	http://dx.doi.org/10.1074/jbc.M406883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342626	hybrid			2022-12-25	WOS:000224957000024
J	Takahashi, YH; Inaba, K; Ito, K				Takahashi, YH; Inaba, K; Ito, K			Characterization of the menaquinone-dependent disulfide bond formation pathway of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN DSBB; ELECTRON-TRANSPORT; RESPIRATORY-CHAIN; REDOX PROPERTIES; CYSTEINES; IDENTIFICATION; CATALYST; ROLES; DEMETHYLMENAQUINONE; UBIQUINONE	In the protein disulfide-introducing system of Escherichia coli, plasma membrane-integrated DsbB oxidizes periplasmic DsbA, the primary disulfide donor. Whereas the DsbA-DsbB system utilizes the oxidizing power of ubiquinone (UQ) under aerobic conditions, menaquinone (MK) is believed to function as an immediate electron acceptor under anaerobic conditions. Here, we characterized MK reactivities with DsbB. In the absence of UQ, DsbB was complexed with MK8 in the cell. In vitro studies showed that, by binding to DsbB in a manner competitive with UQ, MK specifically oxidized Cys(41) and Cys(44) of DsbB and activated its catalytic function to oxidize reduced DsbA. In contrast, menadione used in earlier studies proved to be a more nonspecific oxidant of DsbB. During catalysis, MK8 underwent a spectroscopic transition to develop a visible violet color (lambda(max) = 550 nm), which required a reduced state of Cys(44) as shown previously for UQ color development (lambda(max) = 500 nm) on DsbB. In an in vitro reaction system of MK8-dependent oxidation of DsbA at 30 degreesC, two reaction components were observed, one completing within minutes and the other taking > 1 h. Both of these reaction modes were accompanied by the transition state of MK, for which the slower reaction proceeded through the disulfide-linked DsbA-DsbB( MK) intermediate. The MK-dependent pathway provides opportunities to further dissect the quinone-dependent DsbA-DsbB redox reactions.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Japan Sci & Technol Corp, Precursory Res Embry Sci & Technol, Kyoto 6068507, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kyoto 6068507, Japan	Kyoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	kito@virus.kyoto-u.ac.jp		Inaba, Kenji/0000-0001-8229-0467				AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; COLLET JF, 2002, MOL MICROBIOL, V179, P2465; Dunphy P.J., 1971, METHODS ENZYMOLOGY, VVolume 18, P407, DOI [10.1016/S0076-6879(71)18035-4, DOI 10.1016/S0076-6879(71)18035-4]; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Kadokura H, 2000, P NATL ACAD SCI USA, V97, P10884, DOI 10.1073/pnas.97.20.10884; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 2001, MOL MICROBIOL, V39, P158, DOI 10.1046/j.1365-2958.2001.02229.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Regeimbal J, 2003, P NATL ACAD SCI USA, V100, P13779, DOI 10.1073/pnas.1935988100; Regeimbal J, 2002, J BIOL CHEM, V277, P32706, DOI 10.1074/jbc.M205433200; UNDEN G, 1988, ARCH MICROBIOL, V150, P499, DOI 10.1007/BF00422294; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WISSENBACH U, 1990, ARCH MICROBIOL, V154, P60; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	31	29	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47057	47065		10.1074/jbc.M407153200	http://dx.doi.org/10.1074/jbc.M407153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347648	hybrid			2022-12-25	WOS:000224832400091
J	Poole, AJ; Heap, D; Carroll, RE; Tyner, AL				Poole, AJ; Heap, D; Carroll, RE; Tyner, AL			Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon	ONCOGENE			English	Article						p21; Waf1; azoxymethane; aberrant crypt foci; colon	ABERRANT CRYPT FOCI; CELL-CYCLE; COLORECTAL-CANCER; INDUCED APOPTOSIS; GENE-TRANSFER; LARGE-BOWEL; DNA-DAMAGE; P21(WAF1/CIP1); CARCINOMA; MICE	The Cdk inhibitor p21 regulates p53-mediated growth arrest following DNA damage. It is expressed during epithelial differentiation in a variety of organs including colon. We investigated susceptibility of p21-deficient mice to the colon carcinogen azoxymethane (AOM). After AOM injections, rodents develop putative premalignant lesions called aberrant crypt foci (ACF) that are localized to the distal three centimeters of the colon. p21-deficient mice developed significantly higher numbers of ACF than wild-type mice in response to AOM, and these were not restricted to distal colon. After AOM treatment, increased numbers of lymphoid aggregates were detected in p21-deficient colon. Proliferation was similar in wild type and p21-deficient colon before and after AOM injection, but AOM-induced apoptosis was detected only in wild-type crypt epithelial cells, and not in the p21-deficient colon. The proapoptotic function uncovered for p21 was unexpected, because p21 acts as an inhibitor of apoptosis in many systems, and is not required for p53-dependent apoptosis. Enhanced formation of ACF in p21-deficient mice supports a tumor suppressor function for p21 in the colon. Reduced apoptosis of colon epithelial cells with deleterious mutations may be an initiating event in the formation of ACF, with inflammatory cell cytokine expression contributing to their further expansion.	Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Med, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tyner, AL (corresponding author), Univ Illinois, Coll Med, Dept Biochem & Mol Genet, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.	atyner@uic.edu		Tyner, Angela/0000-0001-7448-8625	NATIONAL CANCER INSTITUTE [K08CA080360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056283] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80360] Funding Source: Medline; NIDDK NIH HHS [R01 DK056283, DK56283, R01 DK056283-05, DK07788] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; BIRD RP, 1989, CANCER SURV, V8, P189; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CARTER JW, 1994, CANCER RES, V54, P4304; Cheng JD, 1999, CLIN CANCER RES, V5, P1057; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; FEINBERG A, 1980, CANCER RES, V40, P4446; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Hingorani R, 2000, J IMMUNOL, V164, P4032, DOI 10.4049/jimmunol.164.8.4032; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; Jackson RJ, 2003, CANCER RES, V63, P3021; Kadowaki Y, 1999, CLIN CANCER RES, V5, P4233; Kang KH, 1999, EXP CELL RES, V253, P403, DOI 10.1006/excr.1999.4644; Kwon YH, 2003, J BIOL CHEM, V278, P30348, DOI 10.1074/jbc.M300996200; Kwon YH, 2002, J BIOL CHEM, V277, P41417, DOI 10.1074/jbc.M203388200; Lincet H, 2000, CANCER LETT, V161, P17, DOI 10.1016/S0304-3835(00)00586-3; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Paulsen JE, 2001, CANCER RES, V61, P5010; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; POTTEN CS, 1992, CARCINOGENESIS, V13, P2305, DOI 10.1093/carcin/13.12.2305; Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; SHEIKH MS, 1995, ONCOGENE, V11, P1899; Takayama T, 1998, NEW ENGL J MED, V339, P1277, DOI 10.1056/NEJM199810293391803; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wataru AA, 2003, TOXICOL LETT, V144, P213, DOI 10.1016/S0378-4274(03)00221-2; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200	39	70	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8128	8134		10.1038/sj.onc.1207994	http://dx.doi.org/10.1038/sj.onc.1207994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377995				2022-12-25	WOS:000224692500010
J	Wu, JH; Lingrel, JB				Wu, JH; Lingrel, JB			KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21(WAF1/CIP1)	ONCOGENE			English	Article						Kruppel-like factor; KLF2; Jurkat leukemia cells; cell proliferation; p21(WAF1/CIP1)	KRUPPEL-LIKE FACTOR; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; GENE PROMOTER; SP1 SITES; IN-VIVO; CANCER; LKLF; P53; SUPPRESSION	Kruppel-like factor 2 (KLF2) is a member of the KLF family of zinc-finger transcription factors and is involved in maintaining T-cell quiescence, regulating preadipocyte differentiation, endothelial cell function and lung development. We used a tetracycline-inducible system in Jurkat T leukemia cells to study the biological role of KLF2 in cellular growth and differentiation. Our results show that expression of KLF2 inhibits cell growth in autonomously proliferating Jurkat cells. Further, 3H-thymidine uptake assays indicate that KLF2 inhibits DNA synthesis in these cells. Moreover, both activation and inhibitory domains are required for KLF2 to suppress Jurkat cell proliferation. In addition, KLF2 upregulates p21(WAF1/CIP1) expression. Additionally, we found that KLF2 upregulates p21(WAF1/CIP1) promoter activity in Jurkat, HepG2 and SW480 cells. Our analysis shows that the potential KLF2 responsive elements are located between -124 and -60 of the p21(WAF1/CIP1) promoter. The sole CACCC site, a sequence recognized by KLF2, in this region is not the element responsive to KLF2. Finally, we determined that the Sp1-3-binding site is the functional responsive element of KLF2 in the p21(WAF1/CIP1) promoter, and we conclude that KLF2 directly regulates p21(WAF1/CIP1) expression.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Lingrel, JB (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jerry.lingrel@uc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057281] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 57281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Banerjee SS, 2003, J BIOL CHEM, V278, P2581, DOI 10.1074/jbc.M210859200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Buckley AF, 2001, NAT IMMUNOL, V2, P698, DOI 10.1038/90633; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Denkinger DJ, 2001, GENE, V281, P133, DOI 10.1016/S0378-1119(01)00792-2; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Kuo CT, 1997, SCIENCE, V278, P788; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Omotehara F, 2002, BRIT J CANCER, V87, P1042, DOI 10.1038/sj.bjc.6600592; Ratziu V, 1998, P NATL ACAD SCI USA, V95, P9500, DOI 10.1073/pnas.95.16.9500; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wani MA, 1998, TRANSGENIC RES, V7, P229, DOI 10.1023/A:1008809809843; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Wani MA, 1999, GENOMICS, V60, P78, DOI 10.1006/geno.1999.5888; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	39	102	104	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8088	8096		10.1038/sj.onc.1207996	http://dx.doi.org/10.1038/sj.onc.1207996			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361832				2022-12-25	WOS:000224692500006
J	Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP				Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP			RAR beta 2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia	ONCOGENE			English	Article						myelofibrosis; CD34+; RAR beta	ACID RECEPTOR-BETA; RETINOIC ACID; LUNG-CANCER; BREAST-CANCER; EPIGENETIC INACTIVATION; BRONCHIAL EPITHELIUM; COLORECTAL-CARCINOMA; PROMOTER METHYLATION; TRANSCRIPTION FACTOR; HOMOZYGOUS DELETION	Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem-cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular mechanisms underlying the development of this myeloproliferative syndrome are currently unknown. In order to identify tumor suppressor genes that may be involved in the disease process, we performed an analysis for loss of heterozygosity (LOH) in CD34 + cells from 29 patients with MMM. We observed a frequency of allelic loss on chromosomal arm 3p in 24% of cases. Detailed mapping of 3p revealed a distinct region of deletion at 3p24. Among the genes known to map within this region is the retinoic acid receptor-beta (RARbeta2) gene. To determine whether RARbeta2 gene activity is diminished in this disease, we analysed its expression in CD34 + cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARbeta2 is significantly decreased in 100% of patient samples compared to that in CD34+ cells from 10 normal individuals. Since allelic loss at 3p24 occurs in <25% of patients, we investigated the contribution of epigenetic modifications to RAR&beta;2 inactivity. Using methylation-specific PCR, we found hypermethylation of RAR&beta;2 in 16 of 18 patients (89%), while the methylated form of the gene was absent in CD34 + cells from nine normal individuals. Our results suggest that RAR&beta;2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RAR&beta;2 gene activity in these patients.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA; Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Jones, LC (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.	letetiajones@yahoo.com			NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA-75956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Batova A, 1997, CANCER RES, V57, P832; Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153; Breems-de Ridder MC, 2000, MOL CELL ENDOCRINOL, V165, P1, DOI 10.1016/S0303-7207(00)00255-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kuroki T, 2003, CANCER RES, V63, P3724; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lin F, 2000, CANCER RES, V60, P3271; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MARTYRE MC, 1994, BRIT J HAEMATOL, V88, P9, DOI 10.1111/j.1365-2141.1994.tb04970.x; Mesa RA, 2000, BLOOD, V96, P3374; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Prowse AH, 1997, AM J HUM GENET, V60, P765; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shimizu T, 2000, CANCER RES, V60, P4544; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2001, BRIT J HAEMATOL, V113, P763, DOI 10.1046/j.1365-2141.2001.02796.x; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 1997, CANCER RES, V57, P4158; Wistuba II, 2000, CANCER RES, V60, P1949; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xie D, 2000, LEUKEMIA, V14, P805, DOI 10.1038/sj.leu.2401717; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	54	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7846	7853		10.1038/sj.onc.1207510	http://dx.doi.org/10.1038/sj.onc.1207510			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361842				2022-12-25	WOS:000224331600010
J	He, QJ; Peng, H; Collins, SJ; Triche, TJ; Wu, LT				He, QJ; Peng, H; Collins, SJ; Triche, TJ; Wu, LT			Retinoid-modulated MAT1 ubiquitination and CAK activity	FASEB JOURNAL			English	Article						MAT1-dependent CAK activity; decreased CAK phosphorylation of RAR alpha; proliferation/differentiation transition	CDK-ACTIVATING KINASE; ACID RECEPTOR-ALPHA; TRANSCRIPTION FACTOR TFIIH; RING FINGER PROTEIN; CELL-CYCLE CONTROL; PROTEASOME PATHWAY; RETINOBLASTOMA PROTEIN; ASSEMBLY FACTOR; RAR-ALPHA; S-PHASE	Human cyclin-dependent kinase (CDK)-activating kinase (CAK) has a dual function in cross-regulation of cell cycle and differentiation, whereas menage a trois 1 (MAT1) assembles CAK and determines CAK's substrate specificity. Although the dynamic state of MAT1 protein levels is found to modulate CAK activity, how intracellular regulation of MAT1 controls CAK activity is unknown. Recent studies demonstrate that retinoic acid (RA)-induced human HL60 cell proliferation/differentiation (P/D) transition is accompanied by MAT1 degradation and decreased CAK phosphorylation of retinoic acid receptor alpha (RARa). Thus, we investigated the biochemical pathway of MAT1 degradation and its relationship with CAK phosphorylation of RARa. We find that RA induces ubiquitination-proteolysis of MAT1 and that ubiquitin-proteasome targets CAK-free MAT1 only. RA-induced MAT1 ubiquitination reduces CAK abundance and decreases CAK phosphorylation of RARa, whereas inhibition of MAT1 ubiquitination resists this RA-effect. These findings reveal that RA induces MAT1 ubiquitination to decrease CAK phosphorylation of RARa, suggesting a novel mechanism of RA-mediated P/D transition in which MAT1 ubiquitination may act as an integral part of RA-effect to decrease CAK activity in the switch from proliferation to differentiation.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; Childrens Hosp Los Angeles, Saban Res Inst, Los Angeles, CA 90027 USA; Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98104 USA	University of Southern California; Children's Hospital Los Angeles; Fred Hutchinson Cancer Center	Wu, LT (corresponding author), Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pathol, MS 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	lingtaow@usc.edu	he, qiaojun/F-3198-2010					Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Larochelle S, 2001, EMBO J, V20, P3749, DOI 10.1093/emboj/20.14.3749; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POON RYC, 1994, J CELL SCI, V107, P2789; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Rossi DJ, 2001, EMBO J, V20, P2844, DOI 10.1093/emboj/20.11.2844; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Sanchez I, 1996, CURR OPIN CELL BIOL, V8, P318, DOI 10.1016/S0955-0674(96)80004-4; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Shah SA, 2001, SURG ONCOL, V10, P43, DOI 10.1016/S0960-7404(01)00018-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; Svejstrup JQ, 1996, J BIOL CHEM, V271, P643, DOI 10.1074/jbc.271.2.643; Tanaka T, 2001, BIOCHEM PHARMACOL, V61, P1347, DOI 10.1016/S0006-2952(01)00600-1; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TASSAN JP, 1995, EMBO J, V14, P5608, DOI 10.1002/j.1460-2075.1995.tb00248.x; Wang JW, 2002, J BIOL CHEM, V277, P43369, DOI 10.1074/jbc.M206792200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LT, 2001, MOL CELL BIOL, V21, P260, DOI 10.1128/MCB.21.1.260-270.2001; WU LT, 1994, ONCOGENE, V9, P2089; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; YEE A, 1995, CANCER RES, V55, P6058; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu L, 2001, CURR OPIN GENET DEV, V11, P91, DOI 10.1016/S0959-437X(00)00162-3	53	14	16	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1734	+		10.1096/fj.04-2182fje	http://dx.doi.org/10.1096/fj.04-2182fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345685				2022-12-25	WOS:000224243200038
J	Mallat, Z; Heymes, C; Corbaz, A; Logeart, D; Alouani, S; Cohen-Solal, A; Seidler, T; Hasenfuss, G; Chvatchko, Y; Shah, AM; Tedgui, A				Mallat, Z; Heymes, C; Corbaz, A; Logeart, D; Alouani, S; Cohen-Solal, A; Seidler, T; Hasenfuss, G; Chvatchko, Y; Shah, AM; Tedgui, A			Evidence for altered interleukin (IL)-18 pathway in human heart failure	FASEB JOURNAL			English	Article						congestive heart failure; inflammation; cytokines; ischemia	TUMOR-NECROSIS-FACTOR; GAMMA-INDUCING FACTOR; OXIDE SYNTHASE INHIBITION; BLOOD MONONUCLEAR-CELLS; CIRCULATING LEVELS; INTERFERON-GAMMA; IFN-GAMMA; CARDIAC MYOCYTES; TNF-ALPHA; IL-18	Interleukin (IL)-18 is the interferon-gamma- inducing factor and has potent proinflammatory activities. IL-18 has been recently implicated in atherosclerotic plaque instability and myocardial ischemia-reperfusion injury. However, it is unknown whether IL-18 expression is increased in human myocardium or if it has any role in heart failure. We analyzed the expression of IL-18, its receptor IL-18Ralpha, and its endogenous inhibitor, IL-18 binding protein (IL-18BP) in myocardial tissue from patients with end-stage heart failure ( ischemic or dilated cardiomyopathy) and controls by use of quantitative real-time reverse transcriptase polymerase chain reaction, Western blot or immunohistochemical techniques. Plasma levels of IL-18 were also determined in 48 patients with heart failure. IL-18 mRNA and protein levels were up-regulated in the myocardium of patients with ischemic cardiomyopathy. Both ischemic and dilated myocardium showed increased IL-18Ralpha levels, suggesting potential biological effects. In addition, mRNA levels of IL-18 BP were down-regulated in the failing myocardium. Finally, plasma IL-18 levels were significantly elevated in patients with heart failure and were higher in those who died at follow-up than in survivors. The results suggest a potential role for the immunoinflammatory IL-18 signaling pathway in the pathophysiology of heart failure and identify novel therapeutic targets for future testing.	Hop Lariboisiere, INSERM, U541, Inst Federat Rech Paris 7, F-75475 Paris 10, France; Kings Coll London, GKT Sch Med, Dept Cardiol, London, England; Univ Gottingen, Dept Cardiol, D-3400 Gottingen, Germany; Serono Pharmaceut Res Inst, Geneva, Switzerland; Hop Beaujon, Serv Cardiol, Clichy, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of London; King's College London; University of Gottingen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite	Mallat, Z (corresponding author), Hop Lariboisiere, INSERM, U541, Inst Federat Rech Paris 7, 41 Bd Chapelle, F-75475 Paris 10, France.	ziad.mallat@larib.inserm.fr	Seidler, Tim/ABH-8333-2020; Heymes, Christophe/Y-9368-2019; Mallat, Ziad/D-4041-2012; Seidler, Tim/B-3929-2014	Seidler, Tim/0000-0002-6158-5087; Heymes, Christophe/0000-0002-6666-6193; Mallat, Ziad/0000-0003-0443-7878; Shah, Ajay/0000-0002-6547-0631				Aukrust P, 2001, CIRCULATION, V104, P1494, DOI 10.1161/hc3801.096353; Baumgarten G, 2000, TRENDS CARDIOVAS MED, V10, P216, DOI 10.1016/S1050-1738(00)00063-3; Blankenberg S, 2002, CIRCULATION, V106, P24, DOI 10.1161/01.CIR.0000020546.30940.92; Bozkurt B, 2001, CIRCULATION, V103, P1044, DOI 10.1161/01.CIR.103.8.1044; Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cotton JM, 2001, CIRCULATION, V104, P2318, DOI 10.1161/hc4401.098515; Deswal A, 1999, CIRCULATION, V99, P3224, DOI 10.1161/01.CIR.99.25.3224; Dinarello CA, 2000, EUR CYTOKINE NETW, V11, P483; Fantuzzi G, 1999, J CLIN INVEST, V104, P761, DOI 10.1172/JCI7501; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Francis GS, 1999, CIRCULATION, V99, P3213, DOI 10.1161/01.CIR.99.25.3213; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Guttenplan N, 2001, Heart Dis, V3, P313; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Hashimoto W, 1999, J IMMUNOL, V163, P583; Hjalmarson A, 1999, LANCET, V353, P2001; Jeremias I, 2000, CIRCULATION, V102, P915; Kelly RA, 1997, CIRCULATION, V95, P778; Koglin J, 1999, CIRCULATION, V99, P836, DOI 10.1161/01.CIR.99.6.836; Krown KA, 1996, J CLIN INVEST, V98, P2854, DOI 10.1172/JCI119114; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Mallat Z, 2001, CIRC RES, V89, pE41, DOI 10.1161/hh1901.098735; Mallat Z, 2001, CIRCULATION, V104, P1598, DOI 10.1161/hc3901.096721; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; Naito Y, 2002, HEART, V88, P296, DOI 10.1136/heart.88.3.296; Narula Jagat, 2001, Cardiology Clinics, V19, P113, DOI 10.1016/S0733-8651(05)70198-3; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pomerantz BJ, 2001, P NATL ACAD SCI USA, V98, P2871, DOI 10.1073/pnas.041611398; Puren AJ, 1998, J CLIN INVEST, V101, P711, DOI 10.1172/JCI1379; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; Raeburn CD, 2002, AM J PHYSIOL-HEART C, V283, pH650, DOI 10.1152/ajpheart.00043.2002; Testa M, 1996, J AM COLL CARDIOL, V28, P964, DOI 10.1016/S0735-1097(96)00268-9; Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074-7613(00)80111-9; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Whitman SC, 2002, CIRC RES, V90, pE34, DOI 10.1161/hh0202.105292; Woldbaek PR, 2003, CARDIOVASC RES, V59, P122, DOI 10.1016/S0008-6363(03)00339-0; Yamaoka-Tojo M, 2002, J CARD FAIL, V8, P21, DOI 10.1054/jcaf.2002.31628; Yndestad A, 2003, CARDIOVASC RES, V60, P141, DOI 10.1016/S0008-6363(03)00362-6; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	45	117	126	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1752	+		10.1096/fj.04-2426fje	http://dx.doi.org/10.1096/fj.04-2426fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371332				2022-12-25	WOS:000224243200024
J	Kato, S; Ueno, T; Fukuzumi, S; Watanabe, Y				Kato, S; Ueno, T; Fukuzumi, S; Watanabe, Y			Catalase reaction by myoglobin mutants and native catalase - Mechanistic investigation by kinetic isotope effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SPERM-WHALE MYOGLOBIN; COMPOUND-I FORMATION; HYDROGEN-PEROXIDE; HORSERADISH-PEROXIDASE; ELECTRON-TRANSFER; DISTAL HISTIDINE; BOND-CLEAVAGE; HEME ENZYMES; CHLOROPEROXIDASE	The catalase reaction has been studied in detail by using myoglobin (Mb) mutants. Compound I of Mb mutants (Mb-I), a ferryl species ( Fe(IV) = O) paired with a porphyrin radical cation, is readily prepared by the reaction with a nearly stoichiometric amount of m-chloroperbenzoic acid. Upon the addition of H2O2 to an Mb-I solution, Mb-I is reduced back to the ferric state without forming any intermediates. This indicates that Mb-I is capable of performing two-electron oxidation of H2O2 ( catalatic reaction). Gas chromatography-mass spectroscopy analysis of the evolved O-2 from a 50: 50 mixture of (H2O2)-O-18/(H2O2)-O-16 solution containing H64D or F43H/H64L Mb showed the formation of O-18(2) (m/e = 36) and O-16(2) (m/e = 32) but not (OO)-O-16-O-18 (m/e = 34). This implies that O-2 is formed by two-electron oxidation of H2O2 without breaking the O T O bond. Deuterium isotope effects on the catalatic reactions of Mb mutants and catalase suggest that the catalatic reactions of Micrococcus lysodeikticus catalase and F43H/H64L Mb proceed via an ionic mechanism with a small isotope effect of less than 4.0, since the distal histidine residue is located at a proper position to act as a general acid-base catalyst for the ionic reaction. In contrast, other Mb mutants such as H64X (X is Ala, Ser, and Asp) and L29H/H64L Mb oxidize H2O2 via a radical mechanism in which a hydrogen atom is abstracted by Mb-I with a large isotope effect in a range of 10 - 29, due to a lack of the general acid-base catalyst.	Nagoya Univ, Dept Chem, Grad Sch Sci, Nagoya, Aichi 4648602, Japan; Grad Univ Adv Studies, Dept Struct Mol Sci, Okazaki, Aichi 4448585, Japan; Nagoya Univ, Res Ctr Mat Sci, Nagoya, Aichi 4648602, Japan; Osaka Univ, JST, CREST, Grad Sch Engn,Dept Mat & Life Sci, Suita, Osaka 5650871, Japan	Nagoya University; Graduate University for Advanced Studies - Japan; Nagoya University; Japan Science & Technology Agency (JST); Osaka University	Watanabe, Y (corresponding author), Nagoya Univ, Dept Chem, Grad Sch Sci, Nagoya, Aichi 4648602, Japan.	yoshi@nucc.cc.nagoya-u.ac.jp	Fukuzumi, Shunichi/E-4728-2010					ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ARAISO T, 1981, CAN J BIOCHEM CELL B, V59, P233, DOI 10.1139/o81-031; BISHOP GR, 1995, BIOCHEMISTRY-US, V34, P12082, DOI 10.1021/bi00037a052; BONNICHSEN RK, 1947, ACTA CHEM SCAND, V1, P685, DOI 10.3891/acta.chem.scand.01-0685; BRILL AS, 1961, BIOCHEM J, V78, P253, DOI 10.1042/bj0780253; CHANCE B, 1950, BIOCHEM J, V46, P387, DOI 10.1042/bj0460387; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V37, P301, DOI 10.1016/0003-9861(52)90194-X; CHANCE B, 1950, BIOCHEM J, V46, P402, DOI 10.1042/bj0460402; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DUNFORD HB, 1978, CAN J CHEM, V56, P2844, DOI 10.1139/v78-468; DUNFORD HB, 1999, HEME PEROXIDASES, P435; EGEBERG KD, 1990, BIOCHEMISTRY-US, V29, P9783, DOI 10.1021/bi00494a004; FITA I, 1985, J MOL BIOL, V185, P21, DOI 10.1016/0022-2836(85)90180-9; GEORGE P, 1949, BIOCHEM J, V44, P197, DOI 10.1042/bj0440197; Goto Y, 1999, J AM CHEM SOC, V121, P9497, DOI 10.1021/ja9901359; GROVES JT, 1986, J AM CHEM SOC, V108, P7834, DOI 10.1021/ja00284a058; HAGER LP, 1972, J AM CHEM SOC, V94, P4364, DOI 10.1021/ja00767a068; Hara I, 2001, J BIOL CHEM, V276, P36067, DOI 10.1074/jbc.C100371200; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; JARNAGIN RC, 1958, J AM CHEM SOC, V80, P786, DOI 10.1021/ja01537a008; KREMER ML, 1970, BIOCHIM BIOPHYS ACTA, V198, P199, DOI 10.1016/0005-2744(70)90052-5; KWART H, 1982, ACCOUNTS CHEM RES, V15, P401, DOI 10.1021/ar00084a004; Lardinois OM, 1996, BBA-PROTEIN STRUCT M, V1295, P222, DOI 10.1016/0167-4838(96)00043-X; Matsui T, 1999, J BIOL CHEM, V274, P2838, DOI 10.1074/jbc.274.5.2838; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; Matsui T, 1997, J BIOL CHEM, V272, P32735, DOI 10.1074/jbc.272.52.32735; Nagy JM, 1997, J BIOL CHEM, V272, P31265, DOI 10.1074/jbc.272.50.31265; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Ozaki SI, 2001, ACCOUNTS CHEM RES, V34, P818, DOI 10.1021/ar9502590; POULOS TL, 1980, J BIOL CHEM, V255, P575; RAO SI, 1993, J BIOL CHEM, V268, P803; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; SAWAKI Y, 1979, J AM CHEM SOC, V101, P6292, DOI 10.1021/ja00515a023; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SOROKIN A, 1993, J AM CHEM SOC, V115, P7293, DOI 10.1021/ja00069a031; SPRINGER BA, 1989, J BIOL CHEM, V264, P3057; THOMAS JA, 1970, J BIOL CHEM, V245, P3129; TschirretGuth RA, 1996, ARCH BIOCHEM BIOPHYS, V335, P93, DOI 10.1006/abbi.1996.0485; Yang HJ, 2003, BIOCHEMISTRY-US, V42, P10174, DOI 10.1021/bi034605u	41	44	45	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52376	52381		10.1074/jbc.M403532200	http://dx.doi.org/10.1074/jbc.M403532200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15347658	hybrid			2022-12-25	WOS:000225493400081
J	Prevo, R; Banerji, S; Ni, J; Jackson, DG				Prevo, R; Banerji, S; Ni, J; Jackson, DG			Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor stabilin-1 (Feel-1/CLEVER-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN-BINDING DOMAIN; MOLECULAR-WEIGHT PROTEIN; LOX-1 SUPPORTS ADHESION; GLYCATION END-PRODUCTS; LINK MODULE; EXTRACELLULAR-MATRIX; IN-VITRO; CELLS; CD44; IDENTIFICATION	The sinusoidal endothelia of liver, spleen, and lymph node are major sites for uptake and recycling of waste macromolecules through promiscuous binding to a disparate family of scavenger receptors. Among the most complex is stabilin-1, a large multidomain protein containing tandem fasciclin domains, epidermal growth factor-like repeats, and a C-type lectin-like hyaluronan-binding Link module, which functions as an endocytic receptor for acetylated low density lipoprotein and advanced glycation end products. Intriguingly, stabilin-1 has also been reported to mediate both homing of leukocytes across lymph node high endothelial venules and adhesion of metastatic tumor cells to peritumoral lymphatic vessels. Currently, however, it is not clear how stabilin-1 mediates these distinct functions. To address the issue, we have investigated the tissue and subcellular localization of stabilin-1 in detail and assessed the functional status of its Link module. We show that stabilin-1 is almost entirely intracellular in lymph node high endothelial venules, lymphatic sinus endothelium, and cultured endothelial cells but that a finite population, detectable only by fluorescent antibody or fluorescein-labeled (Fl)-acetylated low density lipoprotein uptake, cycles rapidly between the plasma membrane and EEA-1(+ve) (early endosome antigen 1) early endosomes. In addition, we show using full-length stabilin-1 cDNA and a stabilin-1/CD44 chimera in HeLa cells that intracellular targeting is influenced by the transmembrane domain/cytoplasmic tail, which contains a putative dileucine (DXXLL) Golgi to endosomal sorting signal. Finally, we provide evidence that the stabilin-1 Link domain binds neither hyaluronan nor other glycosaminoglycans. These properties support a role for stabilin-1 as a rapidly recycling scavenger receptor and argue against a role in cell adhesion or lymphocyte homing.	John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England; Human Genome Sci Inc, Rockville, MD 20850 USA	University of Oxford; GlaxoSmithKline; Human Genome Sciences Inc	Jackson, DG (corresponding author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.	djackson@hammer.imm.ox.ac.uk		, david/0000-0002-4133-9364				Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; GOERDT S, 1993, AM J PATHOL, V142, P1409; GOERDT S, 1991, J CELL BIOL, V113, P1425, DOI 10.1083/jcb.113.6.1425; Hayashida K, 2002, FEBS LETT, V511, P133, DOI 10.1016/S0014-5793(01)03297-5; Heilker R, 1999, BIOESSAYS, V21, P558, DOI 10.1002/(SICI)1521-1878(199907)21:7<558::AID-BIES4>3.0.CO;2-R; Hess KL, 1997, EXP CELL RES, V236, P404, DOI 10.1006/excr.1997.3745; Irjala H, 2003, CANCER RES, V63, P4671; Irjala H, 2003, EUR J IMMUNOL, V33, P815, DOI 10.1002/eji.200323859; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JACKSON DG, 2002, HYALURONAN, V1, P355; Kashiwazaki M, 2003, INT IMMUNOL, V15, P1219, DOI 10.1093/intimm/dxg121; Katoh S, 2003, J CLIN INVEST, V111, P1563, DOI 10.1172/JCI200316583; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kokkonen TS, 2004, J HISTOCHEM CYTOCHEM, V52, P693, DOI 10.1177/002215540405200513; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; McCourt PAG, 1999, HEPATOLOGY, V30, P1276, DOI 10.1002/hep.510300521; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; Miyazaki A, 2002, TRENDS CARDIOVAS MED, V12, P258, DOI 10.1016/S1050-1738(02)00171-8; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nisato RE, 2004, AM J PATHOL, V165, P11, DOI 10.1016/S0002-9440(10)63271-3; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Shimaoka T, 2001, J IMMUNOL, V166, P5108, DOI 10.4049/jimmunol.166.8.5108; SMEDSROD B, 1984, BIOCHEM J, V223, P617, DOI 10.1042/bj2230617; Stoop R, 2002, EUR J IMMUNOL, V32, P2532, DOI 10.1002/1521-4141(200209)32:9<2532::AID-IMMU2532>3.0.CO;2-A; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Teriete P, 2004, MOL CELL, V13, P483, DOI 10.1016/S1097-2765(04)00080-2; Terpstra V, 2000, ARTERIOSCL THROM VAS, V20, P1860, DOI 10.1161/01.ATV.20.8.1860; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Yokota T, 1998, EXP CELL RES, V239, P16, DOI 10.1006/excr.1997.3876; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	51	71	73	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52580	52592		10.1074/jbc.M406897200	http://dx.doi.org/10.1074/jbc.M406897200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15345716	hybrid			2022-12-25	WOS:000225493400105
J	Yokokura, T; Dresnek, D; Huseinovic, N; Lisi, S; Abdelwahid, E; Bangs, P; White, K				Yokokura, T; Dresnek, D; Huseinovic, N; Lisi, S; Abdelwahid, E; Bangs, P; White, K			Dissection of DIAP1 functional domains via a mutant replacement strategy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE OMI/HTRA2; DROSOPHILA CASPASE DRONC; PROGRAMMED CELL-DEATH; APOPTOSIS PROTEINS; IAP PROTEINS; GRIM-REAPER; REGULATING APOPTOSIS; STRUCTURAL BASIS; LIGASE ACTIVITY; HID	Inhibitor of apoptosis proteins (IAPs) act as endogenous inhibitors of active caspases. Drosophila IAP1 (DIAP1) activity is required to keep cells from undergoing apoptosis. The central cell death regulators Reaper and Hid induce apoptosis very rapidly by inhibiting DIAP1 function. We have developed a system for replacing endogenous DIAP1 with mutant forms of the protein, allowing us to examine the roles of various domains of the protein in living and dying cells. We found that DIAP1 is cleaved by a caspase early after the initiation of apoptosis. This cleavage is required for DIAP1 degradation, but Rpr and Hid can still initiate apoptosis in the absence of cleavage. The cleavage of DIAP1 promotes DIAP1 degradation in a manner dependent on the function of the ubiquitin ligase function of the DIAP1 ring domain. This ring domain function is required for Hid-induced apoptosis. We propose a model that synthesizes our data with those of other laboratories and provide a consistent model for DIAP1 function in living and dying cells.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	White, K (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	kristin.white@CBRC2.MGH.Harvard.edu	White, Kristin/D-7936-2013		NIGMS NIH HHS [R01 GM055568, GM55568] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergmann A, 2003, CURR OPIN CELL BIOL, V15, P717, DOI 10.1016/j.ceb.2003.10.002; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chai JJ, 2003, NAT STRUCT BIOL, V10, P892, DOI 10.1038/nsb989; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 2000, J BIOL CHEM, V275, P27084; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Lisi S, 2000, GENETICS, V154, P669; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Olson MR, 2003, J BIOL CHEM, V278, P4028, DOI 10.1074/jbc.M209734200; Palaga T, 2002, NAT CELL BIOL, V4, pE149, DOI 10.1038/ncb0602-e149; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yan N, 2004, NAT STRUCT MOL BIOL, V11, P420, DOI 10.1038/nsmb764; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zachariou A, 2003, EMBO J, V22, P6642, DOI 10.1093/emboj/cdg617; Zimmermann KC, 2002, J CELL BIOL, V156, P1077, DOI 10.1083/jcb.20112068	52	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52603	52612		10.1074/jbc.M409691200	http://dx.doi.org/10.1074/jbc.M409691200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15371434	hybrid			2022-12-25	WOS:000225493400107
J	Bransteitter, R; Pham, P; Calabrese, P; Goodman, MF				Bransteitter, R; Pham, P; Calabrese, P; Goodman, MF			Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; POLYMERASE-ETA; B-CELLS; AID; MUTATION; REGION; MECHANISM	The synthesis of high affinity antibodies requires activation-induced cytidine deaminase ( AID) to initiate somatic hypermutation and class-switch recombination. Here we investigate AID-catalyzed deamination of C --> U on single-stranded DNA and on actively transcribed closed circular double-stranded DNA. Mutations are initially favored at canonical WRC ( W = A or T, R = A or G) somatic hypermutation hot spot motifs, but over time mutations at neighboring non-hot spot sites increase creating random clusters of mutated regions in a seemingly processive manner. N-terminal AID mutants R35E and R35E/R36D appear less processive and have altered mutational specificity compared with wild type AID. In contrast, a C-terminal deletion mutant defective in CSR in vivo closely resembles wild type AID. A mutational spectrum generated during transcription of closed circular double-stranded DNA indicates that wild type AID retains its specificity for WRC hot spot motifs within the confines of a moving transcription bubble while introducing clusters of multiple deaminations predominantly on the nontranscribed strand.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA; Univ So Calif, Dept Chem, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, SHS Rm 172,Univ Pk, Los Angeles, CA 90089 USA.	mgoodman@usc.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM021422] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES012259] Funding Source: Medline; NIGMS NIH HHS [GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barreto V, 2003, MOL CELL, V12, P501, DOI 10.1016/S1097-2765(03)00309-5; Beale RCL, 2004, J MOL BIOL, V337, P585, DOI 10.1016/j.jmb.2004.01.046; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bhagwat AS, 2004, DNA REPAIR, V3, P85, DOI 10.1016/j.dnarep.2003.09.008; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Honjo T, 2004, IMMUNITY, V20, P659, DOI 10.1016/j.immuni.2004.05.011; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; Lee CG, 2001, J EXP MED, V194, P365, DOI 10.1084/jem.194.3.365; Li ZQ, 2004, J EXP MED, V200, P47, DOI 10.1084/jem.20040355; Liu YJ, 1996, IMMUNITY, V4, P603, DOI 10.1016/S1074-7613(00)80486-0; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; Martomo SA, 2004, J EXP MED, V200, P61, DOI 10.1084/jem.20040691; Milstein C, 1998, P NATL ACAD SCI USA, V95, P8791, DOI 10.1073/pnas.95.15.8791; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Poltoratsky VP, 2004, J IMMUNOL, V172, P4308, DOI 10.4049/jimmunol.172.7.4308; RADA C, 1994, EUR J IMMUNOL, V24, P1453, DOI 10.1002/eji.1830240632; Rada C, 2001, EMBO J, V20, P4570, DOI 10.1093/emboj/20.16.4570; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302; Shen HM, 2004, P NATL ACAD SCI USA, V101, P12997, DOI 10.1073/pnas.0404974101; Shinkura R, 2004, NAT IMMUNOL, V5, P707, DOI 10.1038/ni1086; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Ta VT, 2003, NAT IMMUNOL, V4, P843, DOI 10.1038/ni964; Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Yu KF, 2004, J BIOL CHEM, V279, P6496, DOI 10.1074/jbc.M311616200; Zeng XM, 2001, NAT IMMUNOL, V2, P537, DOI 10.1038/88740	41	120	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51612	51621		10.1074/jbc.M408135200	http://dx.doi.org/10.1074/jbc.M408135200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371439	hybrid			2022-12-25	WOS:000225355800117
J	Corre, S; Primot, A; Sviderskaya, E; Bennett, DC; Vaulont, S; Goding, CR; Galibert, MD				Corre, S; Primot, A; Sviderskaya, E; Bennett, DC; Vaulont, S; Goding, CR; Galibert, MD			UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; LOOP-HELIX PROTEINS; PROOPIOMELANOCORTIN GENE; HUMAN MELANOCYTES; TYROSINASE GENE; RECEPTOR MC1R; DNA-BINDING; CYCLIC-AMP; P38 KINASE; ALPHA-MSH	Protection against UV-mediated DNA damage and the onset of oncogenesis is afforded by the tanning response in which UV irradiation triggers melanocytes to increase production of melanin that is then transferred to keratinocytes. A key component of the tanning process is the UV-mediated induction of the pro-opiomelanocortin (POMC) and MC1R genes encoding the alpha-melanocyte-stimulating hormone and its receptor, respectively, which play a crucial role in pigmentation by regulating the intracellular levels of cAMP. How these genes are regulated in response to UV irradiation is not known. Here we have shown that UV-induced activation of the POMC and MC1R promoters is mediated by p38 stress-activated kinase signaling to the transcription factor, upstream stimulating factor-1 (USF-1). Importantly, melanocytes derived from USF-1 -/- mice exhibit a defective UV response and fail to activate POMC and MC1R expression in response to UV irradiation. The results define USF-1 as a critical UV-responsive activator of genes implicated in protection from solar radiation.	Univ Rennes 1, Fac Med, CNRS,UMR 6061, Lab Genet & Dev, F-35043 Rennes, France; Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England; Fac Med Cochin, Inst Cochin, Dept Genet Dev & Pathol Mol, F-75014 Paris, France; Marie Curie Res Inst, Eukaryot Transcript Lab, Surrey RH8 OTL, England	Centre National de la Recherche Scientifique (CNRS); Universite de Rennes; St Georges University London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Galibert, MD (corresponding author), Univ Rennes 1, Fac Med, CNRS,UMR 6061, Lab Genet & Dev, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.	mgaliber@univ-rennes1.fr	Sviderskaya, Elena V/D-2419-2009; Vaulont, Sophie/O-6732-2017; Bennett, Dorothy C/C-2418-2008; CORRE, Sebastien/B-7069-2018	Bennett, Dorothy C/0000-0002-3639-7527; CORRE, Sebastien/0000-0003-1532-5660; Goding, Colin/0000-0002-1614-3909				ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ABDELMALEK Z, 2004, PIGM CELL RES, V17, P436; Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Alpert D, 1999, J BIOL CHEM, V274, P22176, DOI 10.1074/jbc.274.32.22176; Aoki H, 2002, LIFE SCI, V71, P2171, DOI 10.1016/S0024-3205(02)01996-3; ARLETT CF, 1993, CANCER RES, V53, P609; Bastiaens M, 2001, HUM MOL GENET, V10, P1701, DOI 10.1093/hmg/10.16.1701; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bertolotto C, 1998, MOL CELL BIOL, V18, P694, DOI 10.1128/MCB.18.2.694; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Costin GE, 2003, J CELL SCI, V116, P3203, DOI 10.1242/jcs.00598; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; Flanagan N, 2000, HUM MOL GENET, V9, P2531, DOI 10.1093/hmg/9.17.2531; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; GALIBERT MD, 1993, J IMMUNOL, V151, P6099; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Hadley ME, 1999, ANN NY ACAD SCI, V885, P1; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; Healy E, 2001, HUM MOL GENET, V10, P2397, DOI 10.1093/hmg/10.21.2397; Imokawa G, 1997, PIGM CELL RES, V10, P218, DOI 10.1111/j.1600-0749.1997.tb00488.x; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; Kadekaro AL, 2003, PIGM CELL RES, V16, P434, DOI 10.1034/j.1600-0749.2003.00088.x; Kozawa O, 1999, J CELL BIOCHEM, V74, P479, DOI 10.1002/(SICI)1097-4644(19990901)74:3<479::AID-JCB15>3.3.CO;2-0; Kvam E, 1997, CARCINOGENESIS, V18, P2379, DOI 10.1093/carcin/18.12.2379; Luger TA, 2003, ANN NY ACAD SCI, V994, P133, DOI 10.1111/j.1749-6632.2003.tb03172.x; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Moro O, 1999, BIOCHEM BIOPH RES CO, V262, P452, DOI 10.1006/bbrc.1999.1228; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; North S, 1999, ONCOGENE, V18, P1945, DOI 10.1038/sj.onc.1202506; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Palmer JS, 2000, AM J HUM GENET, V66, P176, DOI 10.1086/302711; Rana BK, 1999, GENETICS, V151, P1547; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Scott MC, 2002, PIGM CELL RES, V15, P433, DOI 10.1034/j.1600-0749.2002.02051.x; Seo M, 2002, J BIOL CHEM, V277, P24197, DOI 10.1074/jbc.M201717200; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Sturm RA, 2003, PIGM CELL RES, V16, P266, DOI 10.1034/j.1600-0749.2003.00041.x; THERRIEN M, 1991, MOL CELL BIOL, V11, P3492, DOI 10.1128/MCB.11.7.3492; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; Thody AJ, 1999, ANN NY ACAD SCI, V885, P217, DOI 10.1111/j.1749-6632.1999.tb08679.x; Tsatmalia M, 1999, ANN NY ACAD SCI, V885, P466; Vallet VS, 1998, J BIOL CHEM, V273, P20175, DOI 10.1074/jbc.273.32.20175; VALVERDE P, 1995, NAT GENET, V11, P328, DOI 10.1038/ng1195-328; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	53	99	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51226	51233		10.1074/jbc.M409768200	http://dx.doi.org/10.1074/jbc.M409768200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358786	hybrid			2022-12-25	WOS:000225355800070
J	Deroo, T; Denayer, T; Van Roy, F; Vleminckx, K				Deroo, T; Denayer, T; Van Roy, F; Vleminckx, K			Global inhibition of Lef1/Tcf-dependent Wnt signaling at its nuclear end point abrogates development in transgenic Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; MEDIATED TRANSCRIPTION; GENE-EXPRESSION; MAMMARY-GLAND; STEM-CELLS; PATHWAY; PROTEIN; COMPLEX; APOPTOSIS; LAEVIS	Analysis of canonical Wnt signaling during vertebrate development by means of knock-out or transgenic approaches is often hampered by functional redundancy as well as pathway bifurcations downstream of the manipulated components. We report the design of an optimized chimera capable of blocking transcriptional activation of Lef1/Tcf-beta-catenin target genes, thus enabling intervention with the canonical Wnt pathway at its nuclear end point. This construct was made hormone-inducible, both functionally and transcriptionally, and was transgenically integrated in Xenopus embryos. Down-regulation of target genes was clearly observed upon treatment of these embryos with dexamethasone. In addition, exposure of variously aged transgenic embryos to dexamethasone caused complex phenotypes with many new but also several recognizable features stemming from inhibition of canonical Wnt signaling. At least in some tissues, a significant reduction in cell proliferation and an increase in programmed cell death appeared to underlie these phenotypes. Our inducible transgenic system can serve a broad range of experimental settings designed to unveil new functional aspects of Lef1/ Tcf-beta-catenin signaling during vertebrate embryogenesis.	Univ Ghent, Flainders Interuniv Biotechnol, Dev Biol Unit, B-9052 Ghent, Belgium; Univ Ghent, Flainders Interuniv Biotechnol, Dept Mol Biomed Res, Mol Cell Biol Unit, B-9052 Ghent, Belgium	Ghent University; Ghent University	Vleminckx, K (corresponding author), Univ Ghent, Flainders Interuniv Biotechnol, Dev Biol Unit, B-9052 Ghent, Belgium.	Kris.Vleminckx@dmbr.ugent.be	van Roy, Frans M/C-6123-2009; Vleminckx, Kris/J-5699-2013	van Roy, Frans M/0000-0003-4358-1039; 				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Baker RK, 2001, MECH DEVELOP, V104, P129, DOI 10.1016/S0925-4773(01)00363-X; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beck CW, 1999, DEVELOPMENT, V126, P1611; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Das B, 2004, P NATL ACAD SCI USA, V101, P4839, DOI 10.1073/pnas.0401011101; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Gloy J, 2002, NAT CELL BIOL, V4, P351, DOI 10.1038/ncb784; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hensey C, 1998, DEV BIOL, V203, P36, DOI 10.1006/dbio.1998.9028; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeya M, 1997, NATURE, V389, P966, DOI 10.1038/40146; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishizuya-Oka A, 1997, DEV BIOL, V192, P149, DOI 10.1006/dbio.1997.8749; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Koster RW, 2001, DEV BIOL, V233, P329, DOI 10.1006/dbio.2001.0242; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; ONATE SA, 1995, SCIENCE, V270, P1354; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Schwartz DR, 2003, CANCER RES, V63, P2913; Sive Hazel L., 2000, EARLY DEV XENOPUS LA; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wong MH, 2002, J BIOL CHEM, V277, P15843, DOI 10.1074/jbc.M200184200; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	50	18	18	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50670	50675		10.1074/jbc.M408969200	http://dx.doi.org/10.1074/jbc.M408969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371453	hybrid			2022-12-25	WOS:000225355800007
J	Giessl, A; Pulvermuller, A; Trojan, P; Park, JH; Choe, HW; Ernst, OP; Hofmann, KP; Wolfrum, U				Giessl, A; Pulvermuller, A; Trojan, P; Park, JH; Choe, HW; Ernst, OP; Hofmann, KP; Wolfrum, U			Differential expression and interaction with the visual G-protein transducin of centrin isoforms in mammalian photoreceptor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC SPINDLE POLES; ROD OUTER SEGMENTS; LIGHT-SCATTERING; CA2+-BINDING PROTEINS; RAT RETINA; RHODOPSIN; TRANSLOCATION; ACTIVATION; MECHANISM; BINDING	Photoisomerization of rhodopsin activates a heterotrimeric G-protein cascade leading to closure of cGMP-gated channels and hyperpolarization of photoreceptor cells. Massive translocation of the visual G-protein transducin, G(t), between subcellular compartments contributes to long term adaptation of photoreceptor cells. Ca2+-triggered assembly of a centrin-transducin complex in the connecting cilium of photoreceptor cells may regulate these transducin translocations. Here we demonstrate expression of all four known, closely related centrin isoforms in the mammalian retina. Interaction assays revealed binding potential of the four centrin isoforms to G(t)betagamma heterodimers. High affinity binding to G(t)betagamma and subcellular localization of the centrin isoforms Cen1 and Cen2 in the connecting cilium indicated that these isoforms contribute to the centrin-transducin complex and potentially participate in the regulation of transducin translocation through the photoreceptor cilium. Binding of Cen2 and Cen4 to Gbetagamma of non-visual G-proteins may additionally regulate G-proteins involved in centrosome and basal body functions.	Univ Mainz, Inst Zool, Abt 1, D-55099 Mainz, Germany; Charite Univ Med Berlin, Inst Med Phys, D-10098 Berlin, Germany; Chonbuk Natl Univ, Coll Nat Sci, Dept Chem, Chonju 561756, South Korea	Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Jeonbuk National University	Pulvermuller, A (corresponding author), Univ Mainz, Inst Zool, Abt 1, Mullerweg 6, D-55099 Mainz, Germany.	alexander.pulvermueller@charite.de; wolfrum@mail.uni-mainz.de		Giessl, Andreas/0000-0002-9768-2049				BARON AT, 1992, BIOL CELL, V76, P383, DOI 10.1016/0248-4900(92)90442-4; BARON AT, 1991, CELL MOTIL CYTOSKEL, V18, P1, DOI 10.1002/cm.970180102; Besharse JC., 1990, CILIARY FLAGELLAR ME, P389; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANN MR, 1987, SCIENCE, V235, P585, DOI 10.1126/science.3101175; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Ernst OP, 2000, METHOD ENZYMOL, V315, P471; ERRABOLU R, 1994, J CELL SCI, V107, P9; Gavet O, 2003, MOL BIOL CELL, V14, P1818, DOI 10.1091/mbc.E02-11-0709; GIESSL A, 2004, CELL BIOL RELATED DI, P195; Goldstein B, 2003, CURR BIOL, V13, pR879, DOI 10.1016/j.cub.2003.10.050; Hardie R, 2002, NEURON, V34, P3, DOI 10.1016/S0896-6273(02)00650-5; Hart PE, 2001, GENE, V264, P205, DOI 10.1016/S0378-1119(01)00342-0; Heck M, 2000, METHOD ENZYMOL, V315, P329; HECK M, 1993, BIOCHEMISTRY-US, V32, P8220, DOI 10.1021/bi00083a024; Heck M, 2001, J BIOL CHEM, V276, P10000, DOI 10.1074/jbc.M009475200; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Knust E, 2001, CELL, V107, P125, DOI 10.1016/S0092-8674(01)00534-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laoukili J, 2000, J CELL SCI, V113, P1355; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Levy YY, 1996, CELL MOTIL CYTOSKEL, V33, P298; Madeddu L, 1996, EUR J BIOCHEM, V238, P121, DOI 10.1111/j.1432-1033.1996.0121q.x; Matthews HR, 2001, J PHYSIOL-LONDON, V532, P305, DOI 10.1111/j.1469-7793.2001.0305f.x; Meng TC, 1996, MOL BIOCHEM PARASIT, V79, P103, DOI 10.1016/0166-6851(96)02636-9; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; Middendorp S, 2000, J CELL BIOL, V148, P405, DOI 10.1083/jcb.148.3.405; MOLDAY RS, 2000, MOL MECH VISUAL TRAN, V3, P143; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, BIOESSAYS, V22, P337, DOI 10.1002/(SICI)1521-1878(200004)22:4<337::AID-BIES4>3.0.CO;2-Z; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PHILP NJ, 1987, FEBS LETT, V225, P127, DOI 10.1016/0014-5793(87)81144-4; Popescu A, 2003, J BIOL CHEM, V278, P40252, DOI 10.1074/jbc.M302546200; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; PULVERMULLER A, 1993, BIOCHEMISTRY-US, V32, P14082, DOI 10.1021/bi00214a002; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SALISBURY JL, 1989, J PHYCOL, V25, P201; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schroder K, 2002, J BIOL CHEM, V277, P43987, DOI 10.1074/jbc.M206211200; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; Wolfrum U, 2000, CELL MOTIL CYTOSKEL, V46, P95, DOI 10.1002/1097-0169(200006)46:2<95::AID-CM2>3.0.CO;2-Q; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; Wolfrum U, 2002, ADV EXP MED BIOL, V514, P155; WOLFRUM U, 1991, CELL TISSUE RES, V266, P231, DOI 10.1007/BF00318178; WOTTRICH R, 1998, THESIS U KARLSRUHE K	56	66	69	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51472	51481		10.1074/jbc.M406770200	http://dx.doi.org/10.1074/jbc.M406770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15347651	hybrid			2022-12-25	WOS:000225355800100
J	Piotrowski, M; Schemenewitz, A; Lopukhina, A; Muller, A; Janowitz, T; Weiler, EW; Oecking, C				Piotrowski, M; Schemenewitz, A; Lopukhina, A; Muller, A; Janowitz, T; Weiler, EW; Oecking, C			Desulfoglucosinolate sulfotransferases from Arabidopsis thaliana catalyze the final step in the biosynthesis of the glucosinolate core structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE STEROID SULFOTRANSFERASE; MOLECULAR-CLONING; OILSEED RAPE; SUSPENSION-CULTURES; BRASSICA-NAPUS; AUXIN; GENE; INVOLVEMENT; CONVERSION; CYP83B1	The phytotoxin coronatine is a structural analog of octadecanoid signaling molecules, which are well known mediators of plant defense reactions. To isolate novel coronatine-regulated genes from Arabidopsis thaliana, differential mRNA display was performed. Transcript levels of CORI-7 ( coronatine induced-7) were rapidly and transiently increased in coronatine-treated plants, and the corresponding cDNA was found to encode the sulfotransferase AtST5a. Likewise, upon wounding, an immediate and transient increase in AtST5a mRNA levels could be observed in both locally wounded and unwounded ( systemic) leaves. Furthermore, application of octadecanoids and ethylene as compounds involved in plant wound defense reactions resulted in AtST5a gene activation, whereas pathogen defense-related signals ( yeast elicitor and salicylic acid) were inactive. AtST5a and its close homologs AtST5b and AtST5c were purified as His(6)-tagged proteins from Escherichia coli. The three enzymes were shown to catalyze the final step in the biosynthesis of the glucosinolate (GS) core structure, the sulfation of desulfoglucosinolates (dsGSs). They accept a broad range of dsGSs as substrates. However, in a competitive situation, AtST5a clearly prefers tryptophan- and phenylalanine-derived dsGSs, whereas long chain dsGSs derived from methionine are the preferred substrates of AtST5b and AtST5c. Treatment of Arabidopsis plants with low concentrations of coronatine resulted in an increase in the amounts of specific GSs, primarily glucobrassicin and neoglucobrassicin. Hence, it is suggested that AtST5a is the sulfotransferase responsible for the biosynthesis of tryptophan- derived GSs in vivo.	Ruhr Univ Bochum, Dept Plant Physiol, D-44801 Bochum, Germany; Univ Tubingen, Ctr Plant Mol Biol, D-72076 Tubingen, Germany	Ruhr University Bochum; Eberhard Karls University of Tubingen	Weiler, EW (corresponding author), Ruhr Univ Bochum, Dept Plant Physiol, Univ Str 150, D-44801 Bochum, Germany.	Elmar.Weiler@ruhr-uni-bochum.de	Piotrowski, Markus/F-5419-2010	Piotrowski, Markus/0000-0002-6347-3337				ANANVORANICH S, 1994, PLANT PHYSIOL, V106, P485, DOI 10.1104/pp.106.2.485; ANANVORANICH S, 1995, PLANT PHYSIOL, V107, P1019, DOI 10.1104/pp.107.3.1019; [Anonymous], 2004, CURRENT PROTOCOLS MO; Bak S, 2001, PLANT CELL, V13, P101, DOI 10.1105/tpc.13.1.101; Bak S, 2001, PLANT PHYSIOL, V127, P108, DOI 10.1104/pp.127.1.108; BARKAN A, 1989, PLANT CELL, V1, P437, DOI 10.1105/tpc.1.4.437; Barlier I, 2000, P NATL ACAD SCI USA, V97, P14819, DOI 10.1073/pnas.260502697; BARRON D, 1988, PHYTOCHEMISTRY, V27, P2375, DOI 10.1016/0031-9422(88)87003-1; Bennett RN, 1997, PLANT PHYSIOL, V114, P1283, DOI 10.1104/pp.114.4.1283; BODNARYK RP, 1994, PHYTOCHEMISTRY, V35, P301, DOI 10.1016/S0031-9422(00)94752-6; BODNARYK RP, 1992, PHYTOCHEMISTRY, V31, P2671, DOI 10.1016/0031-9422(92)83609-3; Brader G, 2001, PLANT PHYSIOL, V126, P849, DOI 10.1104/pp.126.2.849; Brown PD, 2003, PHYTOCHEMISTRY, V62, P471, DOI 10.1016/S0031-9422(02)00549-6; Chen SX, 2003, PLANT J, V33, P923, DOI 10.1046/j.1365-313X.2003.01679.x; DOUGHTY KJ, 1995, PHYTOCHEMISTRY, V38, P347, DOI 10.1016/0031-9422(94)00653-B; ETTLINGER MG, 1961, P NATL ACAD SCI USA, V47, P1875, DOI 10.1073/pnas.47.12.1875; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gidda SK, 2003, J BIOL CHEM, V278, P17895, DOI 10.1074/jbc.M211943200; GLENDENING TM, 1990, PLANT PHYSIOL, V94, P811, DOI 10.1104/pp.94.2.811; Halkier BA, 1997, TRENDS PLANT SCI, V2, P425, DOI 10.1016/S1360-1385(97)01128-X; Hansen CH, 2001, J BIOL CHEM, V276, P24790, DOI 10.1074/jbc.M102637200; Hansen CH, 2001, J BIOL CHEM, V276, P11078, DOI 10.1074/jbc.M010123200; JAIN JC, 1990, PHYTOCHEMISTRY, V29, P1425, DOI 10.1016/0031-9422(90)80094-W; Jones PR, 2003, J BIOL CHEM, V278, P10291, DOI 10.1074/jbc.M212207200; Klein M, 2004, J EXP BOT, V55, P1809, DOI 10.1093/jxb/erh183; Lacomme C, 1996, PLANT MOL BIOL, V30, P995, DOI 10.1007/BF00020810; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lopukhina A, 2001, PLANT PHYSIOL, V126, P1678, DOI 10.1104/pp.126.4.1678; Marillia EF, 2001, PHYSIOL PLANTARUM, V113, P176, DOI 10.1034/j.1399-3054.2001.1130204.x; Marsolais F, 2004, PLANT SCI, V166, P1359, DOI 10.1016/j.plantsci.2004.01.019; Marsolais F, 2000, RECENT ADV PHYTOCHEM, V34, P433, DOI 10.1016/S0079-9920(00)80015-5; Mikkelsen MD, 2000, J BIOL CHEM, V275, P33712, DOI 10.1074/jbc.M001667200; Mikkelsen MD, 2004, PLANT J, V37, P770, DOI 10.1111/j.1365-313X.2004.02002.x; Mikkelsen MD, 2003, PLANT PHYSIOL, V131, P298, DOI 10.1104/pp.011015; Muller A, 2000, PLANTA, V211, P855, DOI 10.1007/s004250000353; Petersen BL, 2002, PLANTA, V214, P562, DOI 10.1007/s004250100659; Rask L, 2000, PLANT MOL BIOL, V42, P93, DOI 10.1023/A:1006380021658; Reichelt M, 2002, PHYTOCHEMISTRY, V59, P663, DOI 10.1016/S0031-9422(02)00014-6; Reintanz B, 2001, PLANT CELL, V13, P351, DOI 10.1105/tpc.13.2.351; Rouleau M, 1999, J BIOL CHEM, V274, P20925, DOI 10.1074/jbc.274.30.20925; Sakakibara Y, 1998, J BIOL CHEM, V273, P33929, DOI 10.1074/jbc.273.51.33929; Sambrook J, 2001, MOL CLONING LAB MANU; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; VARIN L, 1992, P NATL ACAD SCI USA, V89, P1286, DOI 10.1073/pnas.89.4.1286; WEILER EW, 1994, FEBS LETT, V345, P9, DOI 10.1016/0014-5793(94)00411-0; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; XIA ZQ, 1993, PLANTA MED, V59, P575, DOI 10.1055/s-2006-959770; Zhao YD, 2002, GENE DEV, V16, P3100, DOI 10.1101/gad.1035402	49	149	166	2	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50717	50725		10.1074/jbc.M407681200	http://dx.doi.org/10.1074/jbc.M407681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358770	hybrid			2022-12-25	WOS:000225355800013
J	Barlic, J; McDermott, DH; Merrell, MN; Gonzales, J; Via, LE; Murphy, PM				Barlic, J; McDermott, DH; Merrell, MN; Gonzales, J; Via, LE; Murphy, PM			Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED T-CELLS; PERIPHERAL-BLOOD LYMPHOCYTES; INTERFERON-GAMMA; IMMUNOSUPPRESSIVE AGENTS; TARGETED DELETION; NUCLEAR FACTOR; B-CELLS; FRACTALKINE; GENE	We have recently reported that interleukin (IL)-15 and IL-2, which signal through IL-2Rbetagamma, oppositely regulate expression of the proinflammatory chemokine receptor CX3CR1. Here we delineate molecular mechanisms responsible for this paradox. By using a luciferase reporter plasmid, we identified a 433-bp region spanning the major transcriptional start point of human CX3CR1 that, when expressed in human peripheral blood mononuclear cells (PBMCs), possessed strong constitutive promoter activity. IL-2 and IL-15 treatment increased and abolished this activity, respectively, mimicking their effects on endogenous CX3CR1. IL-2 and IL-15 have been reported to also have opposite effects on the immunoregulatory transcription factor NFAT ( nuclear factor of activated T cells), and the 433-bp region contains a kappaB-like NFAT site. The effects of IL-15 and IL-2 on both CX3CR1 reporter activity and endogenous CX3CR1 transcription in PBMCs were abolished by the NFAT inhibitors cyclosporin A and VIVIT. Moreover, mutation of the kappaB-like NFAT sequence markedly attenuated IL-2 and IL-15 modulation of CX3CR1 promoter-reporter activity in PBMCs. Furthermore, chromatin immunoprecipitation revealed that IL-15 promoted specific recruitment of NFAT1 but not NFAT2 to the CX3CR1 promoter, whereas IL-2 had the converse effect. This appears to be relevant in vivo because mouse CX3CR1 mRNA was expressed in both PBMCs and splenocytes from NFAT1(-/-) mice injected with recombinant IL-15 but was undetectable in cells from IL-15-injected NFAT1(+/+) BALB/c mice; as predicted, IL-2 up-regulated cx3cr1 in both mouse strains to a similar extent. Thus, by pharmacologic, genetic, and biochemical criteria in vitro and in vivo, our results suggest that IL-15 and IL-2 oppositely regulate CX3CR1 gene expression by differentially recruiting NFAT1 and NFAT2 to a kappaB-like NFAT site within the CX3CR1 promoter. We propose that expression of CX3CR1 and possibly other immunoregulatory genes may be determined in part by the balance of NFAT1 and NFAT2 activity in leukocytes.	NIAID, Mol Signaling Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA; NIAID, TB Res Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Murphy, PM (corresponding author), NIAID, Mol Signaling Sect, Host Def Lab, NIH, Bldg 10,Rm 11N113, Bethesda, MD 20892 USA.	pmm@nih.gov	Via, Laura/AAD-3917-2021; McDermott, David/AAP-2459-2021	Via, Laura/0000-0001-6074-9521; McDermott, David/0000-0001-6978-0867	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000615, ZIAAI000615] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SS, 1995, TRANSPLANTATION, V60, P718, DOI 10.1097/00007890-199510150-00018; Ancuta P, 2003, J EXP MED, V197, P1701, DOI 10.1084/jem.20022156; ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; Baksh S, 2002, MOL CELL, V10, P1071, DOI 10.1016/S1097-2765(02)00701-3; Barlic J, 2003, BLOOD, V102, P3494, DOI 10.1182/blood-2003-03-0946; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Bulanova E, 2001, J IMMUNOL, V167, P6292, DOI 10.4049/jimmunol.167.11.6292; Campbell JJ, 2001, J IMMUNOL, V166, P6477, DOI 10.4049/jimmunol.166.11.6477; Cao CM, 2003, J PHARMACOL EXP THER, V306, P572, DOI 10.1124/jpet.102.048264; Chen SZ, 2002, J NEUROIMMUNOL, V133, P46, DOI 10.1016/S0165-5728(02)00354-5; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Combadiere C, 1998, BIOCHEM BIOPH RES CO, V253, P728, DOI 10.1006/bbrc.1998.9849; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cristillo AD, 2003, BLOOD, V101, P216, DOI 10.1182/blood-2002-03-0697; Cristillo AD, 2002, J BIOL CHEM, V277, P4465, DOI 10.1074/jbc.M108598200; DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Eicher DM, 2003, CELL IMMUNOL, V223, P133, DOI 10.1016/S0008-8749(03)00168-0; Fehniger T A, 2001, Int Rev Immunol, V20, P503, DOI 10.3109/08830180109054417; Fehniger TA, 2002, CYTOKINE GROWTH F R, V13, P169, DOI 10.1016/S1359-6101(01)00021-1; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413; Forcina G, 2004, CYTOKINE, V25, P283, DOI 10.1016/j.cyto.2003.12.004; Garin A, 2002, BIOCHEM J, V368, P753, DOI 10.1042/BJ20020951; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GEARING AJH, 1985, IMMUNOL LETT, V10, P297, DOI 10.1016/0165-2478(85)90105-1; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; Hanna J, 2003, BLOOD, V102, P1569, DOI 10.1182/blood-2003-02-0517; Haskell CA, 2001, J CLIN INVEST, V108, P679, DOI 10.1172/JCI12976; Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; Haskell Christopher A, 2002, Curr Opin Investig Drugs, V3, P399; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Imaizumi T, 2000, TOHOKU J EXP MED, V192, P127, DOI 10.1620/tjem.192.127; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kershaw MH, 2002, HUM GENE THER, V13, P1971, DOI 10.1089/10430340260355374; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kraan TCTMV, 1996, J IMMUNOL, V156, P1818; Lavergne E, 2003, CANCER RES, V63, P7468; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Malek TR, 2003, J LEUKOCYTE BIOL, V74, P961, DOI 10.1189/jlb.0603272; Mastroianni CM, 2004, TRENDS IMMUNOL, V25, P121, DOI 10.1016/j.it.2004.01.002; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790; McDermott DH, 2001, CIRC RES, V89, P401, DOI 10.1161/hh1701.095642; Nishimura M, 2002, J IMMUNOL, V168, P6173, DOI 10.4049/jimmunol.168.12.6173; Ohteki Toshiaki, 2002, Current Molecular Medicine (Hilversum), V2, P371, DOI 10.2174/1566524023362519; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RAPORT CJ, 1995, GENE, V163, P295, DOI 10.1016/0378-1119(95)00336-5; Robinson LA, 2003, CELL IMMUNOL, V225, P122, DOI 10.1016/j.cellimm.2003.09.010; Schluns KS, 2003, NAT REV IMMUNOL, V3, P269, DOI 10.1038/nri1052; Seidel MG, 1998, N-S ARCH PHARMACOL, V358, P382, DOI 10.1007/PL00005268; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Tsytsykova AV, 2000, J EXP MED, V192, P581, DOI 10.1084/jem.192.4.581; UTSUNOMIYA N, 1986, BIOCHEMISTRY-US, V25, P2582, DOI 10.1021/bi00357a045; Waldmann TA, 2002, J CLIN IMMUNOL, V22, P51, DOI 10.1023/A:1014416616687; Waldmann T, 2002, ARTHRITIS RES THER, V4, pS161, DOI 10.1186/ar584; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yoshida H, 2001, NEUROSCI LETT, V303, P132, DOI 10.1016/S0304-3940(01)01699-8	70	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48520	48534		10.1074/jbc.M406978200	http://dx.doi.org/10.1074/jbc.M406978200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347678	hybrid			2022-12-25	WOS:000225098100007
J	Hoang, T; Fenne, IS; Cook, C; Borud, B; Bakke, M; Lien, EA; Mellgren, G				Hoang, T; Fenne, IS; Cook, C; Borud, B; Bakke, M; Lien, EA; Mellgren, G			cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; AMP SIGNALING PATHWAY; GLUCOCORTICOID-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; ANDROGEN RECEPTOR; BINDING DOMAINS; GENE-EXPRESSION; 26S PROTEASOME; ACTIVATION	Nuclear receptors and their coactivators are key regulators of numerous physiological functions. GRIP1 ( glucocorticoid receptor-interacting protein) is a member of the steroid receptor coactivator family. Here, we show that GRIP1 is regulated by cAMP-dependent protein kinase (PKA) that induces its degradation through the ubiquitin-proteasome pathway. GRIP1 was downregulated in transiently transfected COS-1 cells after treatment with 8-para-chlorophenylthio-cAMP or forskolin and 3-isobutyl-1-methylxanthine and in adrenocortical Y1 cells after incubation with adrenocorticotropic hormone. Pulse-chase experiments with transiently transfected COS-1 cells demonstrated that the half-life of GRIP1 was markedly reduced in cells overexpressing the PKA catalytic subunit, suggesting that activation of PKA increases the turnover of GRIP1 protein. The proteasome inhibitors MG132 and lactacystin abolished the PKA-mediated degradation of GRIP1. Using ts20 cells, a temperature-sensitive cell line that contains a thermolabile ubiquitin-activating E1 enzyme, it was confirmed that PKA-mediated degradation of GRIP1 is dependent upon the ubiquitin-proteasome pathway. Coimmunoprecipitation studies of COS-1 cells transfected with expression vectors encoding GRIP1 and ubiquitin using anti-GRIP1 and anti-ubiquitin antibodies showed that the ubiquitination of GRIP1 was increased by overexpression of PKA. Finally, we show that PKA regulates the intracellular distribution pattern of green fluorescent protein-GRIP1 and stimulates recruitment of GRIP1 to subnuclear foci that are colocalized with the proteasome. Taken together, these data demonstrate that GRIP1 is ubiquitinated and degraded through activation of the PKA pathway. This may represent a novel regulatory mechanism whereby hormones down-regulate a nuclear receptor coactivator.	Univ Bergen, Haukeland Univ Hosp, Inst Med,Sect Endocrinol, Hormone Lab, N-5021 Bergen, Norway; Univ Bergen, Hormone Lab, Endocrinol Sect, Inst Med, N-5020 Bergen, Norway; Univ Bergen, Dept Biomed, Div Anat & Cell Biol, N-5020 Bergen, Norway	University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen	Mellgren, G (corresponding author), Univ Bergen, Haukeland Univ Hosp, Inst Med,Sect Endocrinol, Hormone Lab, N-5021 Bergen, Norway.	gunnar.mellgren@med.uib.no	Mellgren, Gunnar/AAG-6573-2020	Mellgren, Gunnar/0000-0001-6282-4986; Borud, Bente/0000-0002-5460-1800				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BAKKE M, 1995, MOL ENDOCRINOL, V9, P327, DOI 10.1210/me.9.3.327; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Black BE, 2004, MOL ENDOCRINOL, V18, P834, DOI 10.1210/me.2003-0145; Borud B, 2002, MOL ENDOCRINOL, V16, P757, DOI 10.1210/me.16.4.757; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Deroo BJ, 2002, J BIOL CHEM, V277, P20120, DOI 10.1074/jbc.C200173200; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Glass CK, 2000, GENE DEV, V14, P121; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Karvonen U, 2002, FEBS LETT, V523, P43, DOI 10.1016/S0014-5793(02)02929-0; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Le T, 2001, ENDOCRINOLOGY, V142, P4282, DOI 10.1210/en.142.10.4282; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; LIU JL, 1994, BIOCHEM J, V301, P863, DOI 10.1042/bj3010863; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Maruvada P, 2003, J BIOL CHEM, V278, P12425, DOI 10.1074/jbc.M202752200; MCGUINNESS MP, 1994, BIOL REPROD, V51, P116, DOI 10.1095/biolreprod51.1.116; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McKenna NJ, 2000, J STEROID BIOCHEM, V74, P351, DOI 10.1016/S0960-0760(00)00112-6; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOYER ML, 1993, J BIOL CHEM, V268, P22933; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; Nazareth LV, 1999, MOL ENDOCRINOL, V13, P2065, DOI 10.1210/me.13.12.2065; Ogawa H, 2004, BIOCHEM BIOPH RES CO, V320, P218, DOI 10.1016/j.bbrc.2004.05.161; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Teyssier C, 2002, J BIOL CHEM, V277, P46066, DOI 10.1074/jbc.M207623200; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Westin S, 2000, ADV PHARMACOL, V47, P89; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yan F, 2003, MOL ENDOCRINOL, V17, P1315, DOI 10.1210/me.2002-0209; Zhang ZG, 1998, J BIOL CHEM, V273, P30660, DOI 10.1074/jbc.273.46.30660	66	59	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49120	49130		10.1074/jbc.M409746200	http://dx.doi.org/10.1074/jbc.M409746200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347661	hybrid			2022-12-25	WOS:000225098100077
J	Whitaker, SL; Knox, BE				Whitaker, SL; Knox, BE			Conserved transcriptional activators of the Xenopus rhodopsin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONE-ROD HOMEOBOX; LEUCINE-ZIPPER; EYE SPECIFICATION; BRAIN-DEVELOPMENT; NUCLEAR PROTEINS; TRANSGENIC MICE; FACTOR NRL; CRX GENES; OTX GENES; EXPRESSION	Vertebrate rhodopsin promoters exhibit striking sequence identities proximal to the initiation site, suggesting that conserved transcription factors regulate rhodopsin expression in these animals. We identify and characterize two transcriptional activators of the Xenopus rhodopsin gene: homologs of the mammalian Crx and Nrl transcription factors, XOtx5 and XL-Nrl ( originally named XL-maf), respectively. XOtx5 stimulated transcription similar to 10-fold in human 293 cells co-transfected with a plasmid containing the rhodopsin promoter ( - 508 to + 41) upstream of luciferase, similar to the similar to 6-fold stimulation with human Crx. XL-Nrl stimulated transcription similar to 27-fold in mammalian 293 cells co-transfected with the rhodopsin luciferase reporter, slightly more than the similar to 17-fold stimulation with Nrl. Together, the Xenopus transcription factors synergistically activated the rhodopsin promoter (similar to 140-fold), as well as in combination with mammalian homologs. Deletion of the Nrl-response element, TGCTGA, eliminated the synergistic activation by both mammalian and Xenopus transcription factors. Deletion of the conserved ATTA sequences (Ret-1 or BAT-1), binding sites for Crx, did not significantly decrease activation by Crx/XOtx5. However, there was increased activation by Nrl/XL-Nrl and an increased synergy when the Ret-1 site was disrupted. These results illustrate conservation of mechanisms of retinal gene expression among vertebrates. In transgenic tadpoles, XOtx5 and XL-Nrl directed premature and ectopic expression from the Xenopus rhodopsin promoter-GFP transgene. Furthermore, activation of the endogenous rhodopsin gene was also observed in some animals, showing that XOtx5 and XL-Nrl can activate the promoter in native chromatin environment.	SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Ophthalmol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Knox, BE (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.	knoxb@upstate.edu			NEI NIH HHS [EY-12975, EY-11256] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011256, R01EY012975] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acampora D, 2003, GENE EXPR PATTERNS, V3, P497, DOI 10.1016/S1567-133X(03)00056-5; Acampora D, 1998, DEVELOPMENT, V125, P1691; Baas D, 2000, MOL BRAIN RES, V78, P26, DOI 10.1016/S0169-328X(00)00060-7; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; Batni S, 2000, METHOD ENZYMOL, V316, P50; Bibb LC, 2001, HUM MOL GENET, V10, P1571, DOI 10.1093/hmg/10.15.1571; Blank V, 1997, TRENDS BIOCHEM SCI, V22, P437, DOI 10.1016/S0968-0004(97)01105-5; Boatright JH, 2001, FEBS LETT, V504, P27, DOI 10.1016/S0014-5793(01)02662-X; Chen SM, 1997, NEURON, V19, P1017, DOI 10.1016/S0896-6273(00)80394-3; Cook T, 2003, BIOESSAYS, V25, P921, DOI 10.1002/bies.10356; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; Dowling J. E., 1987, RETINA APPROACHABLE; Fei YJ, 2000, INVEST OPHTH VIS SCI, V41, P2849; Felsenstein J, 1993, PHYLIP PHYLOGENY INT; Freund CL, 1997, CELL, V91, P543, DOI 10.1016/S0092-8674(00)80440-7; Gamse JT, 2002, NAT GENET, V30, P117, DOI 10.1038/ng793; Germot A, 2001, MOL BIOL EVOL, V18, P1668, DOI 10.1093/oxfordjournals.molbev.a003955; GOURAS P, 1994, VISUAL NEUROSCI, V11, P1227, DOI 10.1017/S0952523800007021; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; Hanson IM, 2001, SEMIN CELL DEV BIOL, V12, P475, DOI 10.1006/scdb.2001.0271; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Ishibashi S, 2001, MECH DEVELOP, V101, P155, DOI 10.1016/S0925-4773(00)00585-2; *JOINT GEN I, 2004, XEN TROP DAT ASS VER; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Knox BE, 1998, FEBS LETT, V423, P117, DOI 10.1016/S0014-5793(98)00018-0; Kroll KL, 1996, DEVELOPMENT, V122, P3173; Kumar JP, 2001, SEMIN CELL DEV BIOL, V12, P469, DOI 10.1006/scdb.2001.0270; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; Kuroda H, 2000, DEV GROWTH DIFFER, V42, P87; Kuure S, 2000, MECH DEVELOP, V92, P31, DOI 10.1016/S0925-4773(99)00323-8; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; Leuzinger S, 1998, DEVELOPMENT, V125, P1703; Liu YH, 2001, INVEST OPHTH VIS SCI, V42, P481; Ma GC, 2001, FEBS LETT, V508, P265, DOI 10.1016/S0014-5793(01)03058-7; Mani SS, 2001, J BIOL CHEM, V276, P36557, DOI 10.1074/jbc.M101685200; Martinez JA, 1998, BIOCHEM BIOPH RES CO, V250, P175, DOI 10.1006/bbrc.1998.9261; Mitton KP, 2000, J BIOL CHEM, V275, P29794, DOI 10.1074/jbc.M003658200; Oliver G, 1997, TRENDS NEUROSCI, V20, P415, DOI 10.1016/S0166-2236(97)01082-5; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; Perkins BD, 2002, VISUAL NEUROSCI, V19, P257, DOI 10.1017/S0952523802192030; Pichaud F, 2002, CURR OPIN GENET DEV, V12, P430, DOI 10.1016/S0959-437X(02)00321-0; Plouhinec JL, 2003, MOL BIOL EVOL, V20, P513, DOI 10.1093/molbev/msg085; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sauka-Spengler T, 2001, DEV GENES EVOL, V211, P533, DOI 10.1007/s00427-001-0191-2; Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799; SHIMAMURA K, 1994, DEVELOPMENT, V120, P2225; Simeone A, 2002, CURR OPIN GENET DEV, V12, P409, DOI 10.1016/S0959-437X(02)00318-0; Sohocki MM, 1998, AM J HUM GENET, V63, P1307, DOI 10.1086/302101; Sparrow D B, 2000, Nucleic Acids Res, V28, pE12, DOI 10.1093/nar/28.4.e12; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Swain PK, 2001, J BIOL CHEM, V276, P36824, DOI 10.1074/jbc.M105855200; Swain PK, 1997, NEURON, V19, P1329, DOI 10.1016/S0896-6273(00)80423-7; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; SWOFFORD DL, 1996, PAUP 4B10 PHYLOGENET; Tahayato A, 2003, DEV CELL, V5, P391, DOI 10.1016/S1534-5807(03)00239-9; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Toda K, 1999, VISUAL NEUROSCI, V16, P391, DOI 10.1017/S0952523899162187; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; Tzekov R T, 2000, Ophthalmic Genet, V21, P89; Tzekov RT, 2001, INVEST OPHTH VIS SCI, V42, P1319; Viczian AS, 2003, DEVELOPMENT, V130, P1281, DOI 10.1242/dev.00343; Vignali R, 2000, MECH DEVELOP, V96, P3, DOI 10.1016/S0925-4773(00)00367-1; Wang QL, 2004, HUM MOL GENET, V13, P1025, DOI 10.1093/hmg/ddh117; Wang XJ, 2002, J BIOL CHEM, V277, P43288, DOI 10.1074/jbc.M207952200; Yanagi Y, 2000, BIOCHEM BIOPH RES CO, V269, P410, DOI 10.1006/bbrc.2000.2304; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; Zhang T, 2003, GENE, V313, P189, DOI 10.1016/S0378-1119(03)00680-2	69	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49010	49018		10.1074/jbc.M406080200	http://dx.doi.org/10.1074/jbc.M406080200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347652	hybrid			2022-12-25	WOS:000225098100064
J	Derebail, SS; DeStefano, JJ				Derebail, SS; DeStefano, JJ			Mechanistic analysis of pause site-dependent and -independent recombinogenic strand transfer from structurally diverse regions of the HIV genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA SECONDARY STRUCTURE; NUCLEIC-ACID CHAPERONE; NUCLEOCAPSID PROTEIN; REVERSE-TRANSCRIPTASE; DNA-SYNTHESIS; INTERNAL REGIONS; INTERSUBTYPE RECOMBINANTS; RETROVIRAL RECOMBINATION; AVIAN-MYELOBLASTOSIS	Retroviral recombinants are generated by strand transfers occurring within internal regions of the viral genome and are a major source of genetic variability. Strand transfer has been linked to "pausing" occurring at secondary structures during synthesis by reverse transcriptase. Yet, weakly structured templates lacking strong pause sites also undergo efficient transfer. In this report, transfer crossover sites on high and low structured templates from the gag-pol frameshift region (GagPol) and the env (Env) regions, respectively, were determined by using a reconstituted in vitro strand transfer assay. The assay tested transfers occurring between a donor and acceptor template over a 150-nucleotide homologous region. The majority of crossovers were in a small 23-nucleotide region near a major pause site on GagPol, clearly indicating a pause-driven mechanism. In contrast, on Env, transfers were more dispersed clustering toward the end of the homologous region. Slowing down polymerization on Env by decreasing the dNTP concentration resulted in crossovers shifting toward the beginning of the homologous region. Removal of a small 38-nucleotide region at the 3'-end of the Env acceptor had a large effect on the level of strand transfer despite very few crossovers mapping to this region. This implicated this part of the acceptor in transfers occurring at downstream positions. For Env the results support a mechanism where the acceptor rapidly binds nascent DNA, then "zippers" downstream catching up with the donor-DNA hybrid and displacing the donor. Such a mechanism may be important to recombination in low structure regions of the HIV genome.	Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, JJ (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, Bldg 231, College Pk, MD 20742 USA.	jdestefa@umd.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM051140-10A2, R01 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Azoulay J, 2003, J MOL BIOL, V326, P691, DOI 10.1016/S0022-2836(02)01430-4; Bernacchi S, 2002, J MOL BIOL, V317, P385, DOI 10.1006/jmbi.2002.5429; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; Delviks KA, 1999, J VIROL, V73, P7923, DOI 10.1128/JVI.73.10.7923-7932.1999; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Fang GW, 2004, AIDS, V18, P153, DOI 10.1097/00002030-200401230-00003; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Hargittai MRS, 2004, J MOL BIOL, V337, P951, DOI 10.1016/j.jmb.2004.01.054; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; Heath MJ, 2003, J BIOL CHEM, V278, P30755, DOI 10.1074/jbc.M303819200; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; KATI WM, 1992, J BIOL CHEM, V267, P25988; KATZ RA, 1990, ANNU REV GENET, V24, P409, DOI 10.1146/annurev.ge.24.120190.002205; Kijak GH, 2001, AIDS RES HUM RETROV, V17, P1415, DOI 10.1089/088922201753197088; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; Lanciault C, 2004, J BIOL CHEM, V279, P32252, DOI 10.1074/jbc.M404117200; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Magiorkinis G, 2003, J GEN VIROL, V84, P2715, DOI 10.1099/vir.0.19180-0; Matzura O, 1996, COMPUT APPL BIOSCI, V12, P247; Motomura K, 2000, AIDS RES HUM RETROV, V16, P1831, DOI 10.1089/08892220050195793; Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551; Negroni M, 2001, NAT REV MOL CELL BIO, V2, P151, DOI 10.1038/35052098; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Quinones-Mateu ME, 2002, J VIROL, V76, P9600, DOI 10.1128/JVI.76.19.9600-9613.2002; Rhodes T, 2003, J VIROL, V77, P11193, DOI 10.1128/JVI.77.20.11193-11200.2003; Roda RH, 2003, J BIOL CHEM, V278, P31536, DOI 10.1074/jbc.M304608200; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Sambrook J, 2001, MOL CLONING LAB MANU; SRINIVASAN A, 1989, P NATL ACAD SCI USA, V86, P6388, DOI 10.1073/pnas.86.16.6388; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P18682; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; YOU JC, 1993, J BIOL CHEM, V268, P16519; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; Yu Q, 1998, J VIROL, V72, P7676, DOI 10.1128/JVI.72.9.7676-7680.1998; Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002	56	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47446	47454		10.1074/jbc.M408927200	http://dx.doi.org/10.1074/jbc.M408927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342633	hybrid			2022-12-25	WOS:000224957000006
J	Doronin, SV; Potapova, IA; Lu, ZJ; Cohen, IS				Doronin, SV; Potapova, IA; Lu, ZJ; Cohen, IS			Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN VENTRICULAR MYOCYTES; PROTEIN-KINASE-C; CURRENT I-TO; HEART-FAILURE; K+ CURRENTS; GENE-EXPRESSION; LOSARTAN; CANINE; CAPTOPRIL; TRAFFICKING	We report a novel signal transduction complex of the angiotensin receptor type 1. In this complex the angiotensin receptor type 1 associates with the potassium channel alpha-subunit Kv4.3 and regulates its intracellular distribution and gating properties. Co-localization of Kv4.3 with angiotensin receptor type 1 and fluorescent resonance energy transfer between those two proteins labeled with cyan and yellow-green variants of green fluorescent protein revealed that Kv4.3 and angiotensin receptor type I are located in close proximity to each other in the cell. The angiotensin receptor type 1 also co-immunoprecipitates with Kv4.3 from canine ventricle or when co-expressed with Kv4.3 and its beta-subunit KChIP2 in human embryonic kidney 293 cells. Treatment of the cells with angiotensin II results in the internalization of Kv4.3 in a complex with the angiotensin receptor type 1. When stimulated with angiotensin II, angiotensin receptors type 1 modulate gating properties of the remaining Kv4.3 channels on the cell surface by shifting their activation voltage threshold to more positive values. We hypothesize that the angiotensin receptor type 1 provides its internalization molecular scaffold to Kv4.3 and in this way regulates the cell surface representation of the ion channel.	SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Doronin, SV (corresponding author), SUNY Stony Brook, Dept Physiol & Biophys, Inst Mol Cardiol, BST-6,Room 124, Stony Brook, NY 11794 USA.	sdoronin@notes.cc.sunysb.edu	Lu, zhongjul/AAT-5531-2021		NHLBI NIH HHS [HL67101, HL70161, HL20558, HL28958] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067101, R37HL020558, R01HL070161, P01HL028958, R01HL020558] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akar FG, 2004, AM J PHYSIOL-HEART C, V286, pH602, DOI 10.1152/ajpheart.00673.2003; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Antzelevitch C, 2001, CARDIOVASC RES, V50, P426, DOI 10.1016/S0008-6363(01)00285-1; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Brooksby P, 1999, LANCET, V354, P395, DOI 10.1016/S0140-6736(99)01354-9; Cerbai E, 2000, CARDIOVASC RES, V45, P388, DOI 10.1016/S0008-6363(99)00344-2; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dostal DE, 1999, CIRC RES, V85, P643, DOI 10.1161/01.RES.85.7.643; DOSTAL DE, 1992, AM J PHYSIOL, V263, P851; Gansevoort RT, 2000, LANCET, V356, P851, DOI 10.1016/S0140-6736(05)73426-7; Hagiwara K, 2003, BIOCHEM BIOPH RES CO, V310, P634, DOI 10.1016/j.bbrc.2003.09.062; Hall A, 2000, LANCET, V356, P851, DOI 10.1016/S0140-6736(00)02667-2; Han W, 2002, CIRC RES, V91, P790, DOI 10.1161/01.RES.0000039534.18114.D9; Hatano N, 2002, PFLUG ARCH EUR J PHY, V444, P80, DOI 10.1007/s00424-002-0798-9; KANNEL WB, 1988, AM HEART J, V115, P869, DOI 10.1016/0002-8703(88)90891-5; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Lindholm LH, 2003, LANCET, V362, P619, DOI 10.1016/S0140-6736(03)14183-9; Meyer FP, 2000, LANCET, V356, P851, DOI 10.1016/S0140-6736(05)73425-5; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nabauer M, 1996, CIRCULATION, V93, P168, DOI 10.1161/01.CIR.93.1.168; Nakamura TY, 1997, AM J PHYSIOL-HEART C, V273, pH1775, DOI 10.1152/ajpheart.1997.273.4.H1775; Nerbonne JM, 2000, J PHYSIOL-LONDON, V525, P285, DOI 10.1111/j.1469-7793.2000.t01-1-00285.x; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; Oudit GY, 2001, J MOL CELL CARDIOL, V33, P851, DOI 10.1006/jmcc.2001.1376; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; Po SS, 2001, AM J PHYSIOL-HEART C, V281, pH2518, DOI 10.1152/ajpheart.2001.281.6.H2518; Rosati B, 2001, J PHYSIOL-LONDON, V533, P119, DOI 10.1111/j.1469-7793.2001.0119b.x; SAWA H, 1992, CIRCULATION, V86, P138, DOI 10.1161/01.CIR.86.1.138; SCHOLKENS BA, 1988, J HYPERTENS       S4, V6, P25; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Shimoni Y, 1999, J PHYSIOL-LONDON, V514, P735, DOI 10.1111/j.1469-7793.1999.735ad.x; Shimoni Y, 2004, J PHYSIOL-LONDON, V555, P345, DOI 10.1113/jphysiol.2003.055590; Shimoni Y, 2003, AM J PHYSIOL-HEART C, V284, pH1168, DOI 10.1152/ajpheart.00748.2002; Shimoni Y, 1999, J PHYSIOL-LONDON, V520, P439, DOI 10.1111/j.1469-7793.1999.00439.x; Song M, 2001, J BIOL CHEM, V276, P31883, DOI 10.1074/jbc.M101058200; Swedberg K, 1999, EUR HEART J, V20, P136, DOI 10.1053/euhj.1998.1098; TIO RA, 1990, CARDIOVASC DRUG THER, V4, P695, DOI 10.1007/BF01856557; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473; Xia ZP, 2001, BIOPHYS J, V81, P2395, DOI 10.1016/S0006-3495(01)75886-9; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S; Yu HG, 2000, CIRC RES, V86, P1062, DOI 10.1161/01.RES.86.10.1062; ZHANG X, 1995, AM J PHYSIOL-HEART C, V269, pH1791, DOI 10.1152/ajpheart.1995.269.5.H1791	45	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48231	48237		10.1074/jbc.M405789200	http://dx.doi.org/10.1074/jbc.M405789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342638	hybrid			2022-12-25	WOS:000224957000098
J	Ghosh, AK; Bhattacharyya, S; Varga, J				Ghosh, AK; Bhattacharyya, S; Varga, J			The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; HUMAN SKIN FIBROBLASTS; TGF-BETA; PLASMINOGEN-ACTIVATOR; DNA-BINDING; WILD-TYPE; EXPRESSION; TRANSCRIPTION; IDENTIFICATION; STIMULATION	The pleiotropic cytokine transforming growth factor-beta (TGF-beta) is a potent inducer of collagen synthesis and is implicated in the pathogenesis of fibrosis. Acting in concert with transcriptional coactivators p300/CBP, the Smads mediate TGF-beta stimulation of collagen synthesis in human dermal fibroblasts. Little information exists regarding positive and negative modulation of physiological TGF-beta responses. Because the tumor suppressor p53 is implicated in connective tissue homeostasis, here we examined the regulation of collagen gene expression by p53. Forced expression of ectopic p53 in dermal fibroblasts repressed basal and TGF-beta-stimulated collagen gene expression, whereas the absence of cellular p53 was associated with significantly enhanced transcriptional activity of the Type I collagen gene (COL1A2) and collagen synthesis. Ectopic expression of p53 also repressed TGF-beta stimulation of promoter activity driven by minimal Smad-binding elements, suggesting that p53 modulated Smad-dependent intracellular signaling. Inhibition was not due to altered levels, phosphorylation, or nuclear translocation of cellular Smads. Treatment of fibroblasts with etoposide, a potent inducer of cellular p53, abrogated TGF-beta stimulation of COL1A2 promoter activity and collagen synthesis in a p53-dependent manner. Overexpression of the transcriptional coactivator p300 rescued TGF-beta stimulation of COL1A2 promoter activity in fibroblasts overexpressing p53. Furthermore, the ligand-induced interaction of cellular Smad3 with p300 or with its cognate Smad-binding DNA element and recruitment of p300 to the DNA-protein complex assembled on the Smad-binding element were markedly reduced in p53-overexpressing fibroblasts. Collectively, these results indicate, for the first time, that p53 is a potent and selective endogenous repressor of TGF-beta-regulated collagen gene expression in dermal fibroblasts. The ligand-dependent interaction of Smad3 with p300 may be one of the targets of p53-mediated inhibition of TGF-beta responses. These findings suggest that a novel and important physiologic function for the tumor suppressor p53 is the regulation of fibrotic cellular responses.	Univ Illinois, Coll Med, Rheumatol Sect, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Ghosh, AK (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Rheumatol, McGaw Pavil,240 E Huron St,Suite 2300, Chicago, IL 60611 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046390, R01AR042309] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46390, AR-42309] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Alexandrova A, 2000, ONCOGENE, V19, P5826, DOI 10.1038/sj.onc.1203944; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, J CELL SCI, V114, P2363; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Cordenonsi M, 2003, CELL, V113, P301, DOI 10.1016/S0092-8674(03)00308-8; Deng WG, 2003, ANAL BIOCHEM, V323, P12, DOI 10.1016/j.ab.2003.08.007; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Ding H, 2003, BIOCHEM BIOPH RES CO, V305, P950, DOI 10.1016/S0006-291X(03)00873-8; Dkhissi F, 1999, ONCOGENE, V18, P703, DOI 10.1038/sj.onc.1202341; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ghosh AK, 2004, ARTHRITIS RHEUM-US, V50, P1305, DOI 10.1002/art.20104; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Ghosh AK, 2000, ONCOGENE, V19, P3546, DOI 10.1038/sj.onc.1203693; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gudkov AV, 2002, NAT MED, V8, P1196, DOI 10.1038/nm1102-1196; Han ZN, 1999, ARTHRITIS RHEUM, V42, P1088, DOI 10.1002/1529-0131(199906)42:6<1088::AID-ANR4>3.0.CO;2-E; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kaku S, 2001, BIOCHEM BIOPH RES CO, V280, P204, DOI 10.1006/bbrc.2000.4060; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LEVINE A, 1992, J CELL SCI, V113, P1661; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Loging WT, 1999, ONCOGENE, V18, P7608, DOI 10.1038/sj.onc.1203135; Miyazaki M, 1998, BIOCHEM BIOPH RES CO, V246, P873, DOI 10.1006/bbrc.1998.8712; PANNU J, 2004, IN PRESS CURR OPIN R; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; TISHLER RB, 1993, CANCER RES, V53, P2212; Varga J, 2002, ARTHRITIS RHEUM-US, V46, P1703, DOI 10.1002/art.10413; VARGA J, 2001, SEMIN CLIN IMMUNOL, V2, P15; Vulin AI, 2002, J BIOL CHEM, V277, P20169, DOI 10.1074/jbc.M112073200; WHITACRE CM, 1995, CANCER RES, V55, P3697; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	54	51	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47455	47463		10.1074/jbc.M403477200	http://dx.doi.org/10.1074/jbc.M403477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15345715	hybrid			2022-12-25	WOS:000224957000007
J	Hodara, R; Norris, EH; Giasson, BI; Mishizen-Eberz, AJ; Lynch, DR; Lee, VMY; Ischiropoulos, H				Hodara, R; Norris, EH; Giasson, BI; Mishizen-Eberz, AJ; Lynch, DR; Lee, VMY; Ischiropoulos, H			Functional consequences of alpha-synuclein tyrosine nitration - Diminished binding to lipid vesicles and increased fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; PARKINSONS-DISEASE; IN-VITRO; LEWY BODIES; INHIBITS FIBRILLATION; PROTEASOMAL FUNCTION; HUMAN BRAIN; PROTEIN; PATHOGENESIS; AGGREGATION	Previous studies have shown the presence of nitrated alpha-synuclein (alpha-syn) in human Lewy bodies and other alpha-syn inclusions. Herein, the effects of tyrosine nitration on alpha-syn fibril formation, lipid binding, chaperone-like function, and proteolytic degradation were systematically examined by employing chromatographically isolated nitrated monomeric, dimeric, and oligomeric alpha-syn. Nitrated alpha-syn monomers and dimers but not oligomers accelerated the rate of fibril formation of unmodified alpha-syn when present at low concentrations. Immunoelectron microscopy revealed that nitrated monomers and dimers are incorporated into the fibrils. However, the purified nitrated alpha-syn monomer by itself was unable to form fibrils. Nitration of the tyrosine residue at position 39 was largely responsible for decreased binding of nitrated monomeric alpha-syn to synthetic vesicles, which correlated with an impairment of the nitrated protein to adopt alpha-helical conformation in the presence of liposomes. The chaperone-like activity of alpha-syn was not inhibited by nitration or oxidation. Furthermore, the 20 S proteasome and calpain I degraded nitrated monomeric alpha-syn, although at a slower rate compared with control alpha-syn. Collectively, these data suggest that post-translational modification of alpha-syn by nitration can promote the formation of intracytoplasmic inclusions that constitute the hallmark of Parkinson disease and other synucleinopathies.	Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neurol & Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ischiropoulos, H (corresponding author), Childrens Hosp Philadelphia, Stokes Res Inst, Abramson Res Ctr 416D, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ischirop@mail.med.upenn.edu		Norris, Erin/0000-0002-4522-3537				Baba M, 1998, AM J PATHOL, V152, P879; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hokenson MJ, 2004, BIOCHEMISTRY-US, V43, P4621, DOI 10.1021/bi049979h; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Kim SJ, 2003, J BIOL CHEM, V278, P41890, DOI 10.1074/jbc.M306017200; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; Meredith GE, 2002, BRAIN RES, V956, P156, DOI 10.1016/S0006-8993(02)03514-X; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; MORRISON WR, 1964, ANAL BIOCHEM, V7, P218, DOI 10.1016/0003-2697(64)90231-3; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Nuscher B, 2004, J BIOL CHEM, V279, P21966, DOI 10.1074/jbc.M401076200; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi M, 2003, NEUROSCI LETT, V336, P155, DOI 10.1016/S0304-3940(02)01258-2; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Yamin G, 2003, FEBS LETT, V542, P147, DOI 10.1016/S0014-5793(03)00367-3; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	55	202	211	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47746	47753		10.1074/jbc.M408906200	http://dx.doi.org/10.1074/jbc.M408906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364911	hybrid			2022-12-25	WOS:000224957000042
J	Jeon, SH; Kayhan, B; Ben-Yedidia, T; Arnon, R				Jeon, SH; Kayhan, B; Ben-Yedidia, T; Arnon, R			A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; VIRUS HEMAGGLUTININ; MEMBRANE-FUSION; IMMUNIZATION; INHIBITION; ANTIBODIES; LIGANDS; MICE	Influenza A virus infection is a major source of morbidity and mortality worldwide. Current means of control for influenza are based on prophylaxis by vaccines and on treatment by the available specific influenza neuraminidase inhibitor drugs. The approach taken in the present study is to prevent and/or ameliorate influenza infection by site-specific blocking of the viral binding to host cell receptors. We describe a novel oligonucleotide, known also as an aptamer, which has been designed to complement the receptor-binding region of the influenza hemagglutinin molecule. It was constructed by screening a DNA library and processing by the selective evolution of ligands by exponential enrichment (SELEX) procedure. We show that this DNA aptamer is indeed capable of inhibiting the hemagglutinin capacity of the virus, as well as in the prevention of viral infectivity in vitro, in tissue culture. Furthermore, it inhibits viral infection by different influenza strains in an animal model, as manifested by 90-99% reduction of virus burden in the lungs of treated mice. The mode of action of this aptamer is by blocking the binding of influenza virus to target cell receptors and consequently prevention of the virus invasion into the host cells.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Arnon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	ruth.arnon@weizmann.ac.il	KAYHAN, BASAK/ABH-9314-2020					ARNON R, 1992, CURR OPIN IMMUNOL, V4, P449, DOI 10.1016/S0952-7915(06)80037-3; BARRETT T, 1985, GROWTH PURIFICATION, P119; Brody E N, 2000, J Biotechnol, V74, P5, DOI 10.1016/S1389-0352(99)00004-5; BROWN LE, 1990, ARCH VIROL, V114, P1, DOI 10.1007/BF01311008; Bruno JG, 1999, BIOSENS BIOELECTRON, V14, P457, DOI 10.1016/S0956-5663(99)00028-7; Cooper NJ, 2003, BRIT MED J, V326, P1235, DOI 10.1136/bmj.326.7401.1235; Couch RB, 2000, NEW ENGL J MED, V343, P1778, DOI 10.1056/NEJM200012143432407; Demicheli V, 2000, VACCINE, V18, P957, DOI 10.1016/S0264-410X(99)00332-1; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Gerhard W, 2001, CURR TOP MICROBIOL, V260, P171; Gravenstein S, 2002, CLIN INFECT DIS, V35, P729, DOI 10.1086/341246; Guo CT, 2002, GLYCOBIOLOGY, V12, P183, DOI 10.1093/glycob/12.3.183; Hesselberth J, 2000, J Biotechnol, V74, P15, DOI 10.1016/S1389-0352(99)00005-7; Jeon SH, 2002, VIRAL IMMUNOL, V15, P165, DOI 10.1089/088282402317340314; KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358; LEVI R, 1995, J VIROL METHODS, V52, P55, DOI 10.1016/0166-0934(94)00137-6; Lipatov AS, 2004, J VIROL, V78, P8951, DOI 10.1128/JVI.78.17.8951-8959.2004; Matrosovich M, 2003, REV MED VIROL, V13, P85, DOI 10.1002/rmv.372; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Mozdzanowska K, 1997, J VIROL, V71, P4347, DOI 10.1128/JVI.71.6.4347-4355.1997; MULLER GM, 1982, P NATL ACAD SCI-BIOL, V79, P569, DOI 10.1073/pnas.79.2.569; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; Schofield DJ, 1997, J GEN VIROL, V78, P2431, DOI 10.1099/0022-1317-78-10-2431; Sekiya S, 2003, J BIOCHEM, V133, P351, DOI 10.1093/jb/mvg047; Sekkal D, 2002, ANTISENSE NUCLEIC A, V12, P265, DOI 10.1089/108729002320351584; Sidwell RW, 1998, ANTIVIR RES, V37, P107, DOI 10.1016/S0166-3542(97)00065-X; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Skehel JJ, 2001, BIOCHEM SOC T, V29, P623, DOI 10.1042/BST0290623; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Ulrich H, 2002, J BIOL CHEM, V277, P20756, DOI 10.1074/jbc.M111859200; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	32	137	154	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48410	48419		10.1074/jbc.M409059200	http://dx.doi.org/10.1074/jbc.M409059200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358767	hybrid			2022-12-25	WOS:000224957000117
J	Kang, YH; Leung, YM; Manning-Fox, JE; Xia, FZ; Xie, HL; Sheu, L; Tsushima, RG; Light, PE; Gaisano, HY				Kang, YH; Leung, YM; Manning-Fox, JE; Xia, FZ; Xie, HL; Sheu, L; Tsushima, RG; Light, PE; Gaisano, HY			Syntaxin-1A inhibits cardiac KATP channels by its actions on nucleotide binding folds 1 and 2 of sulfonylurea receptor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; SYNAPTOSOME-ASSOCIATED PROTEIN; SMOOTH-MUSCLE; POTASSIUM CHANNELS; BETA-CELLS; SNAP-25; STOICHIOMETRY; ASSOCIATION; EXPRESSION; TERMINUS	ATP-sensitive potassium (K-ATP) channels couple the metabolic status of the cell to its membrane potential to regulate a number of cell actions, including secretion ( neurons and neuroendocrine cells) and muscle contractility ( skeletal, cardiac, and vascular smooth muscle). K-ATP channels consist of regulatory sulfonylurea receptors (SUR) and pore-forming (Kir6.X) subunits. We recently reported (Pasyk, E. A., Kang, Y., Huang, X., Cui, N., Sheu, L., and Gaisano, H. Y. ( 2004) J. Biol. Chem. 279, 4234 - 4240) that syntaxin- 1A (Syn-1A), known to mediate exocytotic fusion, was capable of binding the nucleotide binding folds (NBF1 and C-terminal NBF2) of SUR1 to inhibit the KATP channels in insulin-secreting pancreatic islet beta cells. This prompted us to examine whether Syn-1A might modulate cardiac SUR2A/K-ATP channels. Here, we show that Syn-1A is present in the plasma membrane of rat cardiac myocytes and binds the SUR2A protein ( of rat brain, heart, and human embryonic kidney 293 cells expressing SUR2A/Kir6.2) at its NBF1 and NBF2 domains to decrease K-ATP channel activation. Unlike islet beta cells, in which Syn-1A inhibition of the channel activity was apparently mediated only via NBF1 and not NBF2 of SUR1, both exogenous recombinant NBF1 and NBF2 of SUR2A were found to abolish the inhibitory actions of Syn-1A on K-ATP channels in rat cardiac myocytes and HEK293 cells expressing SUR2A/Kir6.2. Together with our recent report, this study suggests that Syn-1A binds both NBFs of SUR1 and SUR2A but appears to exhibit distinct interactions with NBF2 of these SUR proteins in modulating the K-ATP channels in islet beta cells and cardiac myocytes.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Alberta, Dept Pharmacol, Edmonton, AB T6G 2H7, Canada	University of Toronto; University of Toronto; University of Alberta	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, Rm 7226,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.	Herbert.gaisano@utoronto.ca						AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Babenko AP, 1999, J BIOL CHEM, V274, P11587, DOI 10.1074/jbc.274.17.11587; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Fili O, 2001, J NEUROSCI, V21, P1964, DOI 10.1523/JNEUROSCI.21-06-01964.2001; Fox JEM, 2004, MOL ENDOCRINOL, V18, P679, DOI 10.1210/me.2003-0431; Hambrock A, 1999, MOL PHARMACOL, V55, P832; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Ji JZ, 2002, J BIOL CHEM, V277, P20195, DOI 10.1074/jbc.M201034200; Ji JZ, 2002, GASTROENTEROLOGY, V122, P994, DOI 10.1053/gast.2002.32412; Leung YM, 2003, J BIOL CHEM, V278, P17532, DOI 10.1074/jbc.M213088200; MacDonald PE, 2002, MOL ENDOCRINOL, V16, P2452, DOI 10.1210/me.2002-0058; Matsuo M, 2002, EMBO J, V21, P4250, DOI 10.1093/emboj/cdf419; MAYANIL CSK, 1991, MOL PHARMACOL, V40, P900; Pasyk EA, 2004, J BIOL CHEM, V279, P4234, DOI 10.1074/jbc.M309667200; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Seino S, 2003, J DIABETES COMPLICAT, V17, P2, DOI 10.1016/S1056-8727(02)00274-X; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Sevilla L, 1997, ENDOCRINOLOGY, V138, P3006, DOI 10.1210/en.138.7.3006; Shyng SL, 2000, J GEN PHYSIOL, V116, P599, DOI 10.1085/jgp.116.5.599; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Xia FZ, 2004, J BIOL CHEM, V279, P24685, DOI 10.1074/jbc.M314314200; Yokoshiki H, 1998, AM J PHYSIOL-CELL PH, V274, pC25, DOI 10.1152/ajpcell.1998.274.1.C25; Zingman LV, 2002, P NATL ACAD SCI USA, V99, P13278, DOI 10.1073/pnas.212315199	33	40	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47125	47131		10.1074/jbc.M404954200	http://dx.doi.org/10.1074/jbc.M404954200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339904	hybrid			2022-12-25	WOS:000224832400099
J	Spinella, F; Rosano, L; Di Castro, V; Natali, PG; Bagnato, A				Spinella, F; Rosano, L; Di Castro, V; Natali, PG; Bagnato, A			Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; CANCER CELLS; EMERGING ROLE; EXPRESSION; CYCLOOXYGENASE-2; E-2; ACTIVATION; TRANSACTIVATION; AUTOCRINE; NEOVASCULARIZATION	Cyclooxygenase (COX)-1- and COX-2-derived prostaglandins are implicated in the development and progression of several malignancies. We have recently demonstrated that treatment of ovarian carcinoma cells with endothelin-1 (ET-1) induces expression of both COX-1 and COX-2, which contributes to vascular endothelial growth factor ( VEGF) production. In this study, we show that in HEY and OVCA 433 ovarian carcinoma cells, ET-1, through the binding with ETA receptor (ETAR), induces prostaglandin E2 (PGE(2)) production, as the more represented PG types, and increases the expression of PGE2 receptor type 2 (EP2) and type 4 (EP4). The use of pharmacological EP agonists and antagonists indicates that ET-1 and PGE(2) stimulate VEGF production principally through EP2 and EP4 receptors. At the mechanistic level, we prove that the induction of PGE(2) and VEGF by ET-1 involves Src-mediated epidermal growth factor receptor transactivation. Finally, we demonstrate that ETAR-mediated activation of PGE(2)-dependent signaling participates in the regulation of the invasive behavior of ovarian carcinoma cells by activating tumor-associated matrix metalloproteinase. These results implicate EP2 and EP4 receptors in the induction of VEGF expression and cell invasiveness by ET-1 and provide a mechanism by which ETAR/ET-1 can promote and interact with PGE(2)-dependent machinery to amplify its proangiogenic and invasive phenotype in ovarian carcinoma cells. Pharmacological blockade of ETAR can therefore represent an additional strategy to control PGE(2) signaling, which has been associated with ovarian carcinoma progression.	Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Immunol Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Bagnato, A (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol & Ultrastruct, Via Messi dOro 156, I-00158 Rome, Italy.	bagnato@ifo.it	Rosanò, Laura/B-2863-2018; Di Castro, Valeriana/H-8873-2017; Rosanò, Laura/AAB-7821-2019; Bagnato, Anna/G-9747-2016; ROSANO', Laura/AAK-1424-2020; Rosanò, Laura/I-9266-2012; spinella, francesca/AAZ-8982-2020	Rosanò, Laura/0000-0002-9962-6411; Di Castro, Valeriana/0000-0002-1899-3683; Rosanò, Laura/0000-0002-3981-8593; Bagnato, Anna/0000-0002-7269-9522; ROSANO', Laura/0000-0002-9962-6411; 				ALBINI A, 1987, CANCER RES, V47, P3239; Ashby B, 1998, BIOCHEM PHARMACOL, V55, P239, DOI 10.1016/S0006-2952(97)00241-4; Azuma Y, 2004, J PHARMACOL SCI, V94, P261, DOI 10.1254/jphs.94.261; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1995, CLIN CANCER RES, V1, P1059; Bagnato A, 1997, CANCER RES, V57, P1306; Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Denkert C, 2003, ONCOGENE, V22, P8653, DOI 10.1038/sj.onc.1206920; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Eibl G, 2003, BIOCHEM BIOPH RES CO, V306, P887, DOI 10.1016/S0006-291X(03)01079-9; Erkinheimo TL, 2004, CLIN CANCER RES, V10, P538, DOI 10.1158/1078-0432.CCR-0132-03; Ferrandina G, 2002, GYNECOL ONCOL, V85, P305, DOI 10.1006/gyno.2002.6620; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Fukuda R, 2003, CANCER RES, V63, P2330; Gschwind A, 2002, CANCER RES, V62, P6329; Gupta RA, 2003, CANCER RES, V63, P906; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Narko K, 2001, J CLIN ENDOCR METAB, V86, P1765, DOI 10.1210/jc.86.4.1765; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Rosano L, 2003, CANCER RES, V63, P2447; Rosano L, 2001, CANCER RES, V61, P8340; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Salani D, 2000, AM J PATHOL, V157, P1537, DOI 10.1016/S0002-9440(10)64791-8; Sales KJ, 2002, CANCER RES, V62, P424; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Seno H, 2002, CANCER RES, V62, P506; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Spinella F, 2004, CLIN CANCER RES, V10, P4670, DOI 10.1158/1078-0432.CCR-04-0315; Spinella F, 2003, J BIOL CHEM, V278, P41294, DOI 10.1074/jbc.M304785200; Spinella F, 2002, J BIOL CHEM, V277, P27850, DOI 10.1074/jbc.M202421200; Subbaramaiah K, 2003, TRENDS PHARMACOL SCI, V24, P96, DOI 10.1016/S0165-6147(02)00043-3; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Vacca F, 2000, CANCER RES, V60, P5310; Wang DZ, 2004, P NATL ACAD SCI USA, V101, P415, DOI 10.1073/pnas.0307640100; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286	42	81	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46700	46705		10.1074/jbc.M408584200	http://dx.doi.org/10.1074/jbc.M408584200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347673	hybrid			2022-12-25	WOS:000224832400047
J	Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G				Cavazzoni, A; Petronini, PG; Galetti, M; Roz, L; Andriani, F; Carbognani, P; Rusca, M; Fumarola, C; Alfieri, R; Sozzi, G			Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line	ONCOGENE			English	Article						FHIT; inducible expression system; proliferation; lung cancer; p21	HISTIDINE TRIAD GENE; SUPPRESSES TUMORIGENICITY; GLUTAMINE DEPRIVATION; TUMOR-SUPPRESSOR; APOPTOSIS; SUSCEPTIBILITY; SURVIVAL; PROTEIN	Abnormalities in the expression of the tumour suppressor fragile histidine triad ( FHIT) gene have been reported in a variety of human tumours, including lung cancer and restoration of its expression in cancer cell lines resulted in the inhibition of proliferation and apoptosis induction. Most of the studies that have assigned a proapoptotic role to the FHIT gene were performed in adenoviral-FHIT-transduced cancer cells expressing high levels of the Fhit protein. The present work was the first study designed to investigate the effects of FHIT gene replacement in a human FHIT-negative non-small-cell lung cancer (NSCLC) cell line (Calu-1) by using a hormone-inducible expression system that allows tight modulation of the transgene expression. Through this approach, we demonstrated that a prolonged induction was required to accumulate the Fhit protein at levels adequate to promote a significant decrease of cell proliferation. Analysis of cell-cycle phase distribution showed an accumulation of cells in the G(0)/G(1) phase and a concomitant decrease in the S phase. Moreover, an upregulation of p21(waf1) transcript was found, which could account for the alteration of the cycling properties of the cells. The growth-inhibitory effects observed were not associated with apoptosis appearance, and although in these conditions the Fhit protein content was higher than in normal bronchial human epithelial cells (NHBE), it was still significantly lower than the level capable of inducing apoptosis in Calu-1 cells after adenoviral-mediated FHIT gene transfer. These results indicate that the tumour suppressor properties of Fhit are strictly related to its expression level and show that the Fhit protein has a dose-dependent antiproliferative effect on the Fhit-negative Calu-1 lung cancer cell line.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Parma, Dept Expt Med, I-43100 Parma, Italy; Univ Parma, Dept Surg, Thorac Surg Unit, I-43100 Parma, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Parma; University of Parma	Sozzi, G (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via Venezian 1, I-20133 Milan, Italy.	gabriella.sozzi@istitutotumori.mi.it	sozzi, gabriella/G-8259-2011; Andriani, Francesca/D-4898-2017; Galetti, Maricla/AAJ-8927-2020; Alfieri, Roberta R/G-6350-2012; Cavazzoni, Andrea/J-8079-2019; Carbognani, Paolo/AAC-2610-2019; Roz, Luca/AAB-3889-2019; Galetti, Maricla/CAG-4178-2022	sozzi, gabriella/0000-0001-9360-6914; Andriani, Francesca/0000-0002-6178-7789; Galetti, Maricla/0000-0002-8061-8649; Cavazzoni, Andrea/0000-0002-3752-1868; Roz, Luca/0000-0001-5817-7149; Galetti, Maricla/0000-0002-8061-8649				Alfieri RR, 2002, J PHYSIOL-LONDON, V540, P499, DOI 10.1113/jphysiol.2001.013395; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Dumon KR, 2001, CANCER RES, V61, P4827; FAIRCHILD CR, 2000, P 91 AACR ANN M S FR, V41, P227; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; PETRONINI PG, 1993, BRIT J CANCER, V67, P493, DOI 10.1038/bjc.1993.92; Petronini PG, 1996, J CELL PHYSIOL, V169, P175, DOI 10.1002/(SICI)1097-4652(199610)169:1<175::AID-JCP18>3.0.CO;2-C; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Roz Luca, 2004, Proceedings of the American Association for Cancer Research Annual Meeting, V45, P1129; Roz Luca, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1206; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Werner NS, 2000, CANCER RES, V60, P2780; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	21	32	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8439	8446		10.1038/sj.onc.1207847	http://dx.doi.org/10.1038/sj.onc.1207847			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361849				2022-12-25	WOS:000224870700004
J	Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ				Donninger, H; Bonome, T; Radonovich, M; Pise-Masison, CA; Brady, J; Shih, JH; Barrett, JC; Birrer, MJ			Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways	ONCOGENE			English	Article						ovarian cancer; microarray; signaling pathways	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; TYPE-1 MATRIX-METALLOPROTEINASE; PROTEIN-TYROSINE KINASE; INTEGRIN-ASSOCIATED PROTEIN; SURFACE EPITHELIAL-CELLS; CARCINOMA-CELLS; CYCLIN D1; BREAST-CARCINOMA; CDNA MICROARRAY	Ovarian cancer is the most lethal type of gynecologic cancer in the Western world. The high case fatality rate is due in part because most ovarian cancer patients present with advanced stage disease which is essentially incurable. In order to obtain a whole genome assessment of aberrant gene expression in advanced ovarian cancer, we used oligonucleotide microarrays comprising over 40000 features to profile 37 advanced stage papillary serous primary carcinomas. We identified 1191 genes that were significantly (P<0.001) differentially regulated between the ovarian cancer specimens and normal ovarian surface epithelium. The microarray data were validated using real time RT-PCR on 14 randomly selected differentially regulated genes. The list of differentially expressed genes includes ones that are involved in cell growth, differentiation, adhesion, apoptosis and migration. In addition, numerous genes whose function remains to be elucidated were also identified. The microarray data were imported into PathwayAssist software to identify signaling pathways involved in ovarian cancer tumorigenesis. Based on our expression results, a signaling pathway associated with tumor cell migration, spread and invasion was identified as being activated in advanced ovarian cancer. The data generated in this study represent a comprehensive list of genes aberrantly expressed in serous papillary ovarian adenocarcinoma and may be useful for the identification of potentially new and novel markers and therapeutic targets for ovarian cancer.	NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA; NCI, Cellular Oncol Lab, Virus Tumor Biol Sect, Rockville, MD 20850 USA; NCI, Biometr Res Branch, Rockville, MD 20852 USA; NCI, Lab Biosyst & Canc, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Birrer, MJ (corresponding author), NCI, Dept Cell & Canc Biol, Rockville, MD 20850 USA.	birrerm@bprb.nci.nih.gov	Donninger, Howard/I-9874-2019	Donninger, Howard/0000-0002-8589-1660				Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249; Baciu PC, 2003, EXP CELL RES, V291, P167, DOI 10.1016/S0014-4827(03)00387-2; Bagnato A, 1999, CANCER RES, V59, P720; Bagnato A, 1997, CANCER RES, V57, P1306; Bao JJ, 2002, CANCER RES, V62, P7264; Barbieri F, 1999, CLIN CANCER RES, V5, P1837; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; CAMPBELL IG, 1992, CANCER RES, V52, P5416; Capo-Chichi CD, 2003, CANCER RES, V63, P4967; Cary LA, 1996, J CELL SCI, V109, P1787; Darmoul D, 2003, AM J PATHOL, V162, P1503, DOI 10.1016/S0002-9440(10)64283-6; Davidson B, 1999, CLIN EXP METASTAS, V17, P799, DOI 10.1023/A:1006723011835; Davidson B, 2001, AM J CLIN PATHOL, V115, P517; Dhar KK, 1999, BRIT J CANCER, V81, P1174, DOI 10.1038/sj.bjc.6690826; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Etienne W, 2004, BIOTECHNIQUES, V36, P618, DOI 10.2144/04364ST02; Even-Ram SC, 2001, J BIOL CHEM, V276, P10952, DOI 10.1074/jbc.M007027200; Fashena SJ, 2002, J CELL SCI, V115, P99; Fishman DA, 1996, INVAS METAST, V16, P150; Friedlander ML, 1998, SEMIN ONCOL, V25, P305; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Gibson MA, 1998, J HISTOCHEM CYTOCHEM, V46, P871, DOI 10.1177/002215549804600802; Gibson MA, 1999, J BIOL CHEM, V274, P13060, DOI 10.1074/jbc.274.19.13060; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; Hauptmann S, 2002, HUM PATHOL, V33, P632, DOI 10.1053/hupa.2002.124913; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hough CD, 2000, CANCER RES, V60, P6281; Hu J, 2003, GYNECOL ONCOL, V89, P369, DOI 10.1016/S0090-8258(03)00056-8; Imai K, 1996, CANCER RES, V56, P2707; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Ismail RS, 2000, CANCER RES, V60, P6744; Israeli O, 2003, GYNECOL ONCOL, V90, P629, DOI 10.1016/S0090-8258(03)00375-5; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Judson PL, 1999, CANCER, V86, P1551, DOI 10.1002/(SICI)1097-0142(19991015)86:6<1551::AID-CNCR23>3.0.CO;2-P; Kreuzer KA, 1999, CLIN CHEM, V45, P297; Kurochkin IV, 2001, BIOCHEM BIOPH RES CO, V280, P340, DOI 10.1006/bbrc.2000.4125; Law SF, 1996, MOL CELL BIOL, V16, P3327; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380; MAWBY WJ, 1994, BIOCHEM J, V304, P525, DOI 10.1042/bj3040525; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Molino M, 1997, J BIOL CHEM, V272, P11133; Nap M, 1996, TUMOR BIOL, V17, P325; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ono K, 2000, CANCER RES, V60, P5007; Peng HQ, 2000, INT J CANCER, V86, P690, DOI 10.1002/(SICI)1097-0215(20000601)86:5<690::AID-IJC14>3.0.CO;2-K; Rhee JS, 2002, TRENDS CELL BIOL, V12, P209, DOI 10.1016/S0962-8924(02)02280-8; Rosano L, 2003, AM J PATHOL, V163, P753, DOI 10.1016/S0002-9440(10)63702-9; Rosano L, 2001, CANCER RES, V61, P8340; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sambrano GR, 1999, J BIOL CHEM, V274, P20178, DOI 10.1074/jbc.274.29.20178; Sasaki H, 2000, CANCER RES, V60, P5659; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Scully RE, 1998, TUMORS OVARY MALDEVE, V23; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tapper J, 2001, CANCER GENET CYTOGEN, V128, P1, DOI 10.1016/S0165-4608(01)00386-7; TESTA JR, 1994, CANCER RES, V54, P2778; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; Wang K, 1999, GENE, V229, P101, DOI 10.1016/S0378-1119(99)00035-9; Wang L, 2003, CLIN CANCER RES, V9, P3660; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Wong KK, 2001, BIOTECHNIQUES, V30, P670, DOI 10.2144/01303dd05; Yin YJ, 2003, FASEB J, V17, P163, DOI 10.1096/fj.02-0316com; Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5	92	102	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8065	8077		10.1038/sj.onc.1207959	http://dx.doi.org/10.1038/sj.onc.1207959			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361855				2022-12-25	WOS:000224692500004
J	McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M				McCubrey, JA; Shelton, JG; Steelman, LS; Franklin, RA; Sreevalsan, T; McMahon, M			Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells	ONCOGENE			English	Article						ErbB; EGF-R; Raf/MEK/ERK; PI3K/Akt; signal transduction; apoptosis	CYCLE PROGRESSION; SIGNAL-TRANSDUCTION; PREVENT APOPTOSIS; PROTEIN-KINASE; GM-CSF; RAS/RAF/MEK/ERK PATHWAY; DIFFERENTIAL ABILITIES; PI3K/AKT PATHWAY; PRECURSOR CELLS; BETA-SUBUNIT	Epidermal growth factor (EGF) and its cognate receptor (EGF-R) are often dysregulated in human neoplasia. Moreover, EGF-R-transformed cell lines have constitutive EGF-R activity, which makes elucidation of its effects difficult to determine. In the following studies, the effects of a novel conditionally activated form of EGF-R, v-ErbB:ER, on the morphological transformation of NIH-3T3 cells and the abrogation of hematopoietic cell cytokine dependence were investigated. The v-ErbB ES-4 oncogene was fused to the hormone binding domain of the estrogen receptor (ER). This construct, v-ErbB:ER, requires beta-estradiol or 4-OH tamoxifen for activation. v-ErbB:ER conditionally transformed NIH-3T3 cells and abrogated cytokine dependence of hematopoietic cells. Stimulation of v-ErbB:ER activity resulted in the activation of the phosphatidylinositol 3-kinase (PI3K)/Akt and Raf/MEK/ERK kinase cascades. To determine the importance of these signal transduction pathways, the conditionally transformed hematopoietic cells were treated with EGF-R, PI3K and MEK inhibitors. The EGF-R inhibitor AG1478 effectively inhibited MEK, ERK and Akt activation, and induced apoptosis when the cells were grown in response to v-ErbB:ER. Apoptosis was observed at 100- to 1000-fold lower concentrations of AG1478 when the cells were grown in response to v-ErbB:ER as opposed to IL-3. Furthermore, the parental, BCR-ABL- and Raf-transformed cells were only susceptible to the apoptosis-inducing effects of AG1478 at the highest concentrations demonstrating the specificity of these inhibitors. MEK or PI3K inhibitors suppressed ERK or Akt activation, respectively, and induced apoptosis in the v-ErbB:ER-responsive cells. However, MEK and PI3K inhibitors only induced apoptosis at 1000-fold higher concentrations than the EGFR inhibitor. This novel v-ErbB:ER construct and these conditionally transformed cell lines will be useful to further elucidate ErbB-mediated signal transduction and to determine the effectiveness of various inhibitors in targeting different aspects of EGFR-mediated signal transduction and malignant transformation.	E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Leo Jenkins Canc Ctr, Greenville, NC 27858 USA; Georgetown Univ, Sch Med, Dept Microbiol & Immunol, Washington, DC 20057 USA; UCSF Mt Zion Canc Ctr, San Francisco, CA 94115 USA	University of North Carolina; East Carolina University; University of North Carolina; East Carolina University; Georgetown University; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion	McCubrey, JA (corresponding author), E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Brody Bldg 5N98C, Greenville, NC 27858 USA.	mccubreyj@mail.ecu.edu	McMahon, Martin/L-3303-2013	McMahon, Martin/0000-0003-2812-1042; Franklin, Richard A./0000-0003-0299-9578; McCubrey, James/0000-0001-6027-3156	NCI NIH HHS [R01CA98185, R01CA51025] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098185, R01CA051025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn NG, 2001, METHOD ENZYMOL, V332, P417; Blalock WL, 1999, LEUKEMIA, V13, P1109, DOI 10.1038/sj.leu.2401493; Blalock WL, 2003, LEUKEMIA, V17, P1058, DOI 10.1038/sj.leu.2402925; Blalock WL, 2001, LEUKEMIA, V15, P794, DOI 10.1038/sj.leu.2402109; Blalock WL, 2000, LEUKEMIA, V14, P1080, DOI 10.1038/sj.leu.2401793; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Bosch E, 1997, ONCOGENE, V15, P1021, DOI 10.1038/sj.onc.1201270; BRUSKIN A, 1990, ONCOGENE, V5, P15; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang FM, 2003, INT J ONCOL, V22, P469; Chang FM, 2002, CELL CYCLE, V1, P220, DOI 10.4161/cc.1.3.128; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Fan QW, 2002, CURR BIOL, V12, P1386, DOI 10.1016/S0960-9822(02)01070-9; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KUAN CT, 2001, BRAIN TUMOR PATHOL, V17, P71; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Larson RA, 2003, LEUKEMIA, V17, P2358, DOI 10.1038/sj.leu.2403156; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MCCUBREY JA, 1995, INT J ONCOL, V7, P573; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCMAHON M, 1991, MOL CELL BIOL, V11, P4760, DOI 10.1128/MCB.11.9.4760; McMahon M, 2001, METHOD ENZYMOL, V332, P401; MILLER M, 1990, ONCOGENE, V5, P1125; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Navolanic PM, 2003, INT J ONCOL, V22, P237; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Shelton JG, 2004, CELL CYCLE, V3, P189; Shelton JG, 2004, CELL CYCLE, V3, P372; Shelton JG, 2004, CELL CYCLE, V3, P503; Shelton JG, 2003, ONCOGENE, V22, P2478, DOI 10.1038/sj.onc.1206321; Steelman LS, 1996, LEUKEMIA, V10, P528; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; WEISS R, 1984, RNA TUMOR VIRUSES	50	16	18	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7810	7820		10.1038/sj.onc.1208055	http://dx.doi.org/10.1038/sj.onc.1208055			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361836				2022-12-25	WOS:000224331600007
J	Mitra, R; Dharajiya, N; Kumari, L; Varalakshmi, C; Khar, A				Mitra, R; Dharajiya, N; Kumari, L; Varalakshmi, C; Khar, A			Migration of antigen presenting cells from periphery to the peritoneum during an inflammatory response: role of chemokines and cytokines	FASEB JOURNAL			English	Article						APCs; antigen presentation; cellular influx; antitumor activity	DENDRITIC CELLS; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; FUNCTIONAL LIGAND; ORGAN DEVELOPMENT; RAT HISTIOCYTOMA; LYMPH-NODES; TUMOR SITE; LYMPHOTOXIN; EXPRESSION	We demonstrate the migration of antigen presenting cells (APCs), macrophages, and dendritic cells from the subcutaneous site to the peritoneum after they have picked up the antigen, using cell tracking dye. The migration of the APCs is more universal as it was also observed after injection of MethA tumor, DH-5alpha cells, and leishmania parasites, in addition to AK-5 tumor cells. Cellular migration is mediated by several chemokines and cytokines that also induce heavy influx of immune cells into the peritoneum. MIP-3beta secreted by the mesothelial cells is involved in the cellular influx into the peritoneum, whereas IL-12 and IFN-gamma produced by the APCs induced activation of immune cells in the peritoneum. Our results suggest an antigen presentation function for the APCs in the peritoneum as studied by lymphoproliferation assays. These studies indicate antigen presentation function of the activated migratory APCs from the distant subcutaneous site to the peritoneum, suggesting it acts as an important lymphoid organ involved in the enhancement of effector cell function.	Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Khar, A (corresponding author), Ctr Cellular & Mol Biol, Uppal Rd, Hyderabad 500007, Andhra Pradesh, India.	khar@ccmb.res.in						ABBAS AK, 1998, CELLULAR MOL IMMUNOL, P278; AUSTYN JM, 1988, J EXP MED, V167, P646, DOI 10.1084/jem.167.2.646; BANKS TA, 1995, J IMMUNOL, V155, P1685; Bhaumik S, 2001, EXP CELL RES, V266, P44, DOI 10.1006/excr.2001.5201; Brenan M, 2000, EUR J IMMUNOL, V30, P1527, DOI 10.1002/1521-4141(200006)30:6<1527::AID-IMMU1527>3.0.CO;2-4; CAUX C, 1994, J EXP MED, V180, P1841, DOI 10.1084/jem.180.5.1841; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Gretz JE, 1997, IMMUNOL REV, V156, P11, DOI 10.1111/j.1600-065X.1997.tb00955.x; HENDRIKS HR, 1983, EUR J IMMUNOL, V13, P663, DOI 10.1002/eji.1830130811; Hirao M, 2000, CANCER RES, V60, P2209; IJSSELMUIDEN OE, 1989, J IMMUNOL METHODS, V119, P35, DOI 10.1016/0022-1759(89)90378-5; KAPLAN G, 1987, J EXP MED, V166, P1098, DOI 10.1084/jem.166.4.1098; KAPLAN G, 1992, J EXP MED, V175, P1717, DOI 10.1084/jem.175.6.1717; KHAR A, 1993, INT J ONCOL, V2, P393; KHAR A, 1986, JNCI-J NATL CANCER I, V76, P871; Khar A, 2001, IMMUNOL REV, V184, P244, DOI 10.1034/j.1600-065x.2001.1840122.x; KHAR A, 1990, IN VITRO CELL DEV B, V26, P1024; Kratz A, 1996, J EXP MED, V183, P1461, DOI 10.1084/jem.183.4.1461; KRIST LFG, 1995, ANAT REC, V241, P163, DOI 10.1002/ar.1092410204; Kubicka U, 1996, SCAND J IMMUNOL, V44, P157, DOI 10.1046/j.1365-3083.1996.d01-297.x; MARIATHASAN S, 1995, J INFLAMM, V45, P72; Matsumoto M, 1997, IMMUNOL REV, V156, P137, DOI 10.1111/j.1600-065X.1997.tb00965.x; Muralikrishna T, 1998, DNA CELL BIOL, V17, P603, DOI 10.1089/dna.1998.17.603; NARUMI S, 1990, J BIOL CHEM, V265, P7036; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; OTOVA B, 1987, FOLIA BIOL-PRAGUE, V33, P363; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Sharma S, 2003, HUM GENE THER, V14, P1511, DOI 10.1089/104303403322495025; VALLE MT, 1995, CLIN EXP IMMUNOL, V101, P172; Wu Q, 1999, J EXP MED, V190, P629, DOI 10.1084/jem.190.5.629; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Young AJ, 1999, SEMIN IMMUNOL, V11, P73, DOI 10.1006/smim.1999.0163	35	12	14	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1764	+		10.1096/fj.04-1855fje	http://dx.doi.org/10.1096/fj.04-1855fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358681				2022-12-25	WOS:000224243200035
J	Leithe, E; Rivedal, E				Leithe, E; Rivedal, E			Ubiquitination and down-regulation of gap junction protein connexin-43 in response to 12-O-tetradecanoylphorbol 13-acetate treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER EPITHELIAL-CELLS; BREAST-TUMOR CELLS; INTERCELLULAR COMMUNICATION; PHORBOL-ESTER; PROTEASOME PATHWAY; INTRACELLULAR-TRANSPORT; LIFE-CYCLE; WILD-TYPE; KINASE-C; PHOSPHORYLATION	Gap junctions are specialized plasma membrane domains enriched in connexin proteins that form channels between adjacent cells. Gap junctions are highly dynamic, and modulation of the connexin turnover rate is considered to play an important role in the regulation of gap junctional intercellular communication. In the present study, we show that the tumor-promoting phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) induces ubiquitination of connexin-43 (Cx43) in IAR20 rat liver epithelial cells. The accelerated ubiquitination of Cx43 in response to TPA occurred concomitantly with Cx43 hyperphosphorylation and inhibition of cell-cell communication via gap junctions. The TPA-induced ubiquitination of Cx43 was mediated via protein kinase C and partly involved the mitogen-activated protein kinase pathway. Following ubiquitination, Cx43 was internalized and degraded. The loss of Cx43 protein was counteracted by ammonium chloride, indicating that acidification of internalized Cx43 gap junctions is a prerequisite for its degradation. Furthermore, the Cx43 degradation was partly counteracted by leupeptin, an inhibitor of cathepsin B, H, and L. Cx43 internalization and subsequent degradation were blocked by inhibitors of the proteasome. Evidence is provided that Cx43 is modified by multiple monoubiquitins rather than a polyubiquitin chain in response to TPA. Moreover, the TPA-induced ubiquitination of Cx43 was blocked by proteasomal inhibitors. Taken together, the data indicate that Cx43 ubiquitination is a highly regulated process. Moreover, the results suggest that the proteasome might play an indirect role in Cx43 degradation by affecting the level of monoubiquitin conjugation and trafficking of Cx43 to endosomal compartments.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Oslo	Leithe, E (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.	eleithe@medisin.uio.no						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ASAMOTO M, 1991, MOL CARCINOGEN, V4, P322, DOI 10.1002/mc.2940040411; BERTHOUD VM, 1992, EUR J CELL BIOL, V57, P40; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; FALLON RF, 1981, J CELL BIOL, V90, P521, DOI 10.1083/jcb.90.2.521; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Fujimuro M, 1997, EUR J BIOCHEM, V249, P427, DOI 10.1111/j.1432-1033.1997.00427.x; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Huang RP, 1998, CANCER RES, V58, P5089; Jordan K, 2001, J CELL SCI, V114, P763; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; Laing JG, 1997, EXP CELL RES, V236, P482, DOI 10.1006/excr.1997.3747; Laird DW, 1996, J BIOENERG BIOMEMBR, V28, P311, DOI 10.1007/BF02110107; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; LARSEN WJ, 1978, TISSUE CELL, V10, P585, DOI 10.1016/S0040-8166(16)30351-2; LARSEN WJ, 1979, J CELL BIOL, V83, P576, DOI 10.1083/jcb.83.3.576; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leithe E, 2004, J CELL SCI, V117, P1211, DOI 10.1242/jcs.00951; Leithe E, 2003, CARCINOGENESIS, V24, P1239, DOI 10.1093/carcin/bgg066; LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7; MATESIC DF, 1994, MOL CARCINOGEN, V10, P226, DOI 10.1002/mc.2940100407; Mimnaugh EG, 1997, BIOCHEMISTRY-US, V36, P14418, DOI 10.1021/bi970998j; Mizuno E, 2003, MOL BIOL CELL, V14, P3675, DOI 10.1091/mbc.E02-12-0823; MONTESANO R, 1977, J NATL CANCER I, V59, P1651, DOI 10.1093/jnci/59.6.1651; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAUS CCG, 1993, EXP CELL RES, V206, P72, DOI 10.1006/excr.1993.1122; OH SY, 1991, BIOCHIM BIOPHYS ACTA, V1094, P243, DOI 10.1016/0167-4889(91)90016-Q; Omori Y, 1998, INT J CANCER, V78, P446, DOI 10.1002/(SICI)1097-0215(19981109)78:4<446::AID-IJC10>3.3.CO;2-4; Opsahl H, 2000, CELL ADHES COMMUN, V7, P367, DOI 10.3109/15419060009109019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qin H, 2002, J BIOL CHEM, V277, P29132, DOI 10.1074/jbc.M200797200; Qin H, 2003, J BIOL CHEM, V278, P30005, DOI 10.1074/jbc.M300614200; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Rivedal E, 1996, CARCINOGENESIS, V17, P2321, DOI 10.1093/carcin/17.11.2321; RIVEDAL E, 1994, CARCINOGENESIS, V15, P689, DOI 10.1093/carcin/15.4.689; ROSE B, 1993, CARCINOGENESIS, V14, P1073, DOI 10.1093/carcin/14.5.1073; Ruch RJ, 2001, J CELL BIOCHEM, V83, P163, DOI 10.1002/jcb.1227; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Strous GJ, 1999, J CELL SCI, V112, P1417; Thomas MA, 2003, J CELL SCI, V116, P2213, DOI 10.1242/jcs.00440; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VanSlyke JK, 2002, J CELL BIOL, V157, P381, DOI 10.1083/jcb.200111045; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; YANCEY SB, 1982, EXP CELL RES, V139, P329, DOI 10.1016/0014-4827(82)90257-9	61	139	146	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50089	50096		10.1074/jbc.M402006200	http://dx.doi.org/10.1074/jbc.M402006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371442	hybrid			2022-12-25	WOS:000225229500067
J	Thyagarajan, A; Szaro, BG				Thyagarajan, A; Szaro, BG			Phylogenetically conserved binding of specific K homology domain proteins to the 3 '-untranslated region of the vertebrate middle neurofilament mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; HNRNP-K; POSTTRANSCRIPTIONAL REGULATION; REGULATING NEUROFILAMENT; POLY(C)-BINDING PROTEINS; UNTRANSLATED REGION; NERVOUS-SYSTEM; RADIAL GROWTH; UP-REGULATION; OPTIC-NERVE	As axons mature, neurofilament-M (NF-M) expression rises, contributing to maturation of the axonal cytoskeleton and an expansion in axon caliber. This increase is partly due to a rise in NF-M mRNA stability. Such post-transcriptional regulation is often mediated through the binding of specific proteins to the 3'-untranslated region (3'-UTR) of mRNAs. Vertebrate NF-M 3'-UTRs are remarkably well conserved, prompting us to test whether similar proteins bind the 3'-UTRs of different vertebrate NF-Ms. Identification of such proteins could lead to insights into the regulation of NF-M expression during development and in response to trauma or disease. Ultraviolet cross-linking analysis of proteins isolated from adult frog (Xenopus laevis), mouse, and rat brains revealed three ribonucleoprotein complexes (97, 70, and 47 kDa) that were present in all species and bound specifically to NF-M 3'-UTRs. Affinity purification of NF-M 3'-UTR-binding proteins from rat brain followed by mass spectrometry and immunoprecipitation assays identified heterogeneous nuclear ribonucleoprotein (hnRNP) K and hnRNP E1 as the proteins forming the 70- and 47-kDa complexes, respectively. These RNA-binding proteins of the KH domain family recognize CU-rich motifs identical to ones present in NF-M 3'-UTRs. Ultraviolet cross-linking assays performed on Xenopus embryos at different stages of neural development demonstrated that whereas hnRNP K binding occurred at all stages, hnRNP E binding occurred only at the most mature stages of axon development. Since hnRNP E is known to stabilize mRNAs, these results raise the hypothesis that these proteins may contribute to the increases in cytoplasmic levels of NF-M mRNA that accompany axonal maturation.	SUNY Albany, Dept Biol Sci, Albany, NY 12222 USA; SUNY Albany, Neurosci Res Ctr, Albany, NY 12222 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Szaro, BG (corresponding author), SUNY Albany, Dept Biol Sci, 1400 Washington Ave, Albany, NY 12222 USA.	bgs86@cnsunix.albany.edu						Adams DJ, 2003, J BIOL CHEM, V278, P44894, DOI 10.1074/jbc.M307782200; Antic D, 1999, GENE DEV, V13, P449, DOI 10.1101/gad.13.4.449; Benson DL, 1996, J NEUROCYTOL, V25, P181, DOI 10.1007/BF02284795; Blaxall BC, 2000, J BIOL CHEM, V275, P4290, DOI 10.1074/jbc.275.6.4290; Bomsztyk K, 2004, BIOESSAYS, V26, P629, DOI 10.1002/bies.20048; Brody T, 2002, MECH DEVELOP, V113, P41, DOI 10.1016/S0925-4773(02)00010-2; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Canete-Soler R, 1998, J BIOL CHEM, V273, P12655, DOI 10.1074/jbc.273.20.12655; Canete-Soler R, 1998, J BIOL CHEM, V273, P12650, DOI 10.1074/jbc.273.20.12650; Canete-Soler R, 2001, J BIOL CHEM, V276, P32046, DOI 10.1074/jbc.M104104200; Canete-Soler R, 2000, BRAIN RES, V867, P265, DOI 10.1016/S0006-8993(00)02389-1; Czyzyk-Krzeska MF, 1999, BLOOD, V93, P2111, DOI 10.1182/blood.V93.6.2111.406k24_2111_2120; CzyzykKrzeska MF, 1996, J BIOL CHEM, V271, P3293, DOI 10.1074/jbc.271.6.3293; Davis LG, 1994, BASIC METHODS MOL BI; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gamarnik AV, 1997, RNA, V3, P882; Garcia ML, 2003, J CELL BIOL, V163, P1011, DOI 10.1083/jcb.200308159; Ge WW, 2003, J BIOL CHEM, V278, P26558, DOI 10.1074/jbc.M302886200; Gervasi C, 2003, J COMP NEUROL, V461, P262, DOI 10.1002/cne.10695; Gervasi C, 1997, MOL BRAIN RES, V48, P229, DOI 10.1016/S0169-328X(97)00096-X; GOLDSTEIN ME, 1988, MOL BRAIN RES, V3, P287, DOI 10.1016/0169-328X(88)90051-4; Gravina P, 2002, GENE, V290, P193, DOI 10.1016/S0378-1119(02)00561-9; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hartley R, 2002, BMC MOL BIOL, V3, DOI 10.1186/1471-2199-3-8; Helfand BT, 2003, MOL BIOL CELL, V14, P5069, DOI 10.1091/mbc.E03-06-0376; Holcik M, 1997, P NATL ACAD SCI USA, V94, P2410, DOI 10.1073/pnas.94.6.2410; Julien JP, 1999, CURR OPIN NEUROBIOL, V9, P554, DOI 10.1016/S0959-4388(99)00004-5; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Lee SK, 2003, J CELL SCI, V116, P4467, DOI 10.1242/jcs.00745; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; Lindquist JN, 2004, J BIOL CHEM, V279, P23822, DOI 10.1074/jbc.M314060200; Makeyev AV, 2002, RNA, V8, P265, DOI 10.1017/S1355838202024627; MOSKOWITZ PF, 1995, MOL BRAIN RES, V30, P211, DOI 10.1016/0169-328X(95)00006-E; MUMA NA, 1991, J NEUROCYTOL, V20, P844, DOI 10.1007/BF01191735; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; Nieuwkoop PD, 1956, NORMAL TABLE XENOPUS, P162; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 1998, TRENDS BIOCHEM SCI, V23, P409, DOI 10.1016/S0968-0004(98)01301-2; Paulding WR, 1999, J BIOL CHEM, V274, P2532, DOI 10.1074/jbc.274.4.2532; Paulding WR, 2000, ADV EXP MED BIOL, V475, P111; Peng SSY, 1996, MOL CELL BIOL, V16, P1490; Rao MV, 2003, J CELL BIOL, V163, P1021, DOI 10.1083/jcb.200308076; Ritchie SA, 2003, NUCLEIC ACIDS RES, V31, P1502, DOI 10.1093/nar/gkg246; Roosa JR, 2000, MOL BRAIN RES, V82, P35, DOI 10.1016/S0169-328X(00)00180-7; SAUVE DM, 1995, ANAL BIOCHEM, V226, P382, DOI 10.1006/abio.1995.1242; SCHLAEPFER WW, 1990, J NEUROSCI RES, V25, P39, DOI 10.1002/jnr.490250106; SCHWARTZ ML, 1990, J NEUROSCI RES, V27, P193, DOI 10.1002/jnr.490270209; SCHWARTZ ML, 1994, MOL BRAIN RES, V27, P215, DOI 10.1016/0169-328X(94)90003-5; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; Skalweit A, 2003, CIRC RES, V92, P419, DOI 10.1161/01.RES.0000059300.67152.4E; SMITH C, 1998, RNA PROTEIN INTERACT, P109; Sotelo-Silveira JR, 2000, J NEUROSCI RES, V62, P65, DOI 10.1002/1097-4547(20001001)62:1<65::AID-JNR7>3.0.CO;2-Z; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; SZARO BG, 1989, DEV BRAIN RES, V48, P87, DOI 10.1016/0165-3806(89)90095-3; TESSER P, 1986, J NEUROCHEM, V47, P1235; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; Walker KL, 2001, J NEUROSCI, V21, P9655, DOI 10.1523/JNEUROSCI.21-24-09655.2001; Wang XM, 1996, EMBO J, V15, P5040, DOI 10.1002/j.1460-2075.1996.tb00884.x; Weiner OD, 1996, NEUROSCI LETT, V213, P83, DOI 10.1016/0304-3940(96)12860-3; WEISS IM, 1994, MOL CELL BIOL, V14, P8123, DOI 10.1128/MCB.14.12.8123; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; WICKENS M, 1993, NATURE, V363, P305, DOI 10.1038/363305a0; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WONG J, 1990, J NEUROSCI RES, V27, P332, DOI 10.1002/jnr.490270312; Yeap BB, 2002, J BIOL CHEM, V277, P27183, DOI 10.1074/jbc.M202883200; ZHAO YG, 1995, J NEUROSCI, V15, P4629; ZHAO YG, 1994, J COMP NEUROL, V343, P158, DOI 10.1002/cne.903430112; Zhu Y, 2002, NEUROSCIENCE, V110, P191, DOI 10.1016/S0306-4522(01)00522-X	73	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49680	49688		10.1074/jbc.M408915200	http://dx.doi.org/10.1074/jbc.M408915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364910	hybrid			2022-12-25	WOS:000225229500018
J	Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA				Sevilla, A; Santos, CR; Barcia, R; Vega, FM; Lazo, PA			c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK)	ONCOGENE			English	Article						VRK1; c-Jun; JNK; transcription	CELL LUNG CARCINOMAS; TRANSCRIPTION FACTORS; GENE-EXPRESSION; ACTIVATION; FAMILY; CANCER; ATF2; PROLIFERATION; AP-1	The VRK1 kinase is a novel Ser-Thr kinase in the human kinome that diverged from the casein kinase 1 branch. These kinases phosphorylate transcription factors related to stress responses, such as p53. In this report we have studied the phosphorylation of the transcription factor c-Jun in its N-terminal region. The VRK1 protein phosphorylates c-Jun with a Km of 0.4 muM, and is not inhibited by SP600125. VRK1 phosphorylates c-Jun in Ser63 and Ser73 in vitro, the same residues targeted by the N-terminal kinase of c-Jun (JNK). This phosphorylation induces the stabilization and accumulation of the c-Jun protein. VRK1 phosphorylates the endogenous c-Jun in Ser63. VRK1 activates c-Jun dependent transcription, which is dependent on phosphorylation of Ser63 and Ser73. The c-Jun with Ser63Ala and Ser73Ala substitutions is not transcriptionally active when cotransfected with VRK1. VRK1 interacts with c-Jun but not with JNK. The cotransfection of VRK1 and JNK has an additive effect on the transcriptional activation of c-Jun indicating that they can cooperate when both are at suboptimal dose; otherwise, maximum effect by one of them prevents the effect of the other. The VRK1-c-Jun connection represents a component of a new signaling pathway whose upstream elements remain to be identified.	Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, E-37007 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Lazo, PA (corresponding author), Univ Salamanca, CSIC, Ctr Invest Canc, IBMCC, Campus Miguel Unamuno, E-37007 Salamanca, Spain.	plazozbi@usal.es	Sevilla, Ana/N-8579-2017; Vega, Francisco M./C-4678-2008; Lazo, Pedro A./M-6435-2014	Sevilla, Ana/0000-0002-9251-4759; Vega, Francisco M./0000-0002-9015-864X; Lazo, Pedro A./0000-0001-8997-3025				ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Aoyagi K, 1998, CLIN CANCER RES, V4, P2153; Barcia R, 2002, ARCH BIOCHEM BIOPHYS, V399, P1, DOI 10.1006/abbi.2001.2746; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Clerk A, 1997, BIOCHEM J, V325, P801, DOI 10.1042/bj3250801; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dlakic M, 2001, EMBO J, V20, P828, DOI 10.1093/emboj/20.4.828; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898-6568(01)00275-3; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hall MC, 2003, J BIOL CHEM, V278, P10304, DOI 10.1074/jbc.M212334200; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lopez-Borges S, 2000, ONCOGENE, V19, P3656, DOI 10.1038/sj.onc.1203709; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Meggiato T, 2003, PANCREAS, V26, P65, DOI 10.1097/00006676-200301000-00011; Neyns B, 1996, ONCOGENE, V12, P1247; Nezu J, 1997, GENOMICS, V45, P327, DOI 10.1006/geno.1997.4938; Nichols RJ, 2004, J BIOL CHEM, V279, P7934, DOI 10.1074/jbc.M310813200; Sevilla A, 2004, J BIOL CHEM, V279, P27458, DOI 10.1074/jbc.M401009200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Szabo E, 1996, CANCER RES, V56, P305; TINIAKOS DG, 1994, BRIT J UROL, V74, P757, DOI 10.1111/j.1464-410X.1994.tb07121.x; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vega FM, 2003, FEBS LETT, V544, P176, DOI 10.1016/S0014-5793(03)00501-5; Volm M, 2002, CLIN CANCER RES, V8, P1843; Weiss L, 2000, J EXP MED, V191, P139, DOI 10.1084/jem.191.1.139; WODRICH W, 1993, CARCINOGENESIS, V14, P1121, DOI 10.1093/carcin/14.6.1121; Yunta M, 2002, EUR J BIOCHEM, V269, P1012, DOI 10.1046/j.0014-2956.2001.02741.x	38	84	84	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 25	2004	23	55					8950	8958		10.1038/sj.onc.1208015	http://dx.doi.org/10.1038/sj.onc.1208015			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	874MN	15378002	Bronze, Green Submitted			2022-12-25	WOS:000225354600010
J	Power, MR; Peng, YD; Maydanski, E; Marshall, JS; Lin, TJ				Power, MR; Peng, YD; Maydanski, E; Marshall, JS; Lin, TJ			The development of early host response to Pseudomonas aeruginosa lung infection is critically dependent on myeloid differentiation factor 88 in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MACROPHAGE-INFLAMMATORY PROTEIN-2; RESPIRATORY EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSES; CYSTIC-FIBROSIS; CUTTING EDGE; STAPHYLOCOCCUS-AUREUS; MYD88-DEFICIENT MICE; BACTERIAL-INFECTION; SIGNALING PATHWAYS	Toll-like receptors (TLR) induce distinct patterns of host responses through myeloid differentiation factor 88 (MyD88)-dependent and/or -independent pathways, depending on the nature of the pathogen. Pseudomonas aeruginosa is a cause of serious lung infection in immunocompromised individuals and cystic fibrosis patients. The role of the TLR-MyD88 pathway in P. aeruginosa-induced lung infection in vivo was examined in this study. MyD88(-/-) mice demonstrated an impaired clearance of P. aeruginosa from the lung. Little or no neutrophil recruitment was observed in the airways of MyD88(-/-) mice following P. aeruginosa lung infection. This observation was associated with a reduced production of inflammatory mediators that affect neutrophil recruitment, including macrophage-inflammatory protein-2, tumor necrosis factor, and interleukin-1beta in the airways of MyD88(-/-) mice. Similarly, MyD88(-/-) mice showed inhibited NF-kappaB activation in the lung following P. aeruginosa infection. Interestingly, P. aeruginosa infection induced a 7.5-fold increase of TLR2 mRNA expression in the lungs of MyD88(+/+) mice. Furthermore, host responses to P. aeruginosa lung infection in TLR2(-/-) and TLR4 mutant mice were partially inhibited compared with the responses of respective control mice. Taken together, our results indicate that the MyD88-dependent pathway is essential for the development of early host responses to P. aeruginosa infection, leading to the clearance of this bacterium, and that TLR2 and TLR4 are involved in this process.	Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Pathol, Halifax, NS B3J 3G9, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS B3J 3G9, Canada	Dalhousie University; Dalhousie University; Dalhousie University	Lin, TJ (corresponding author), Isaac Walton Killam Hlth Ctr, Dept Pediat, 5850 Univ Ave, Halifax, NS B3J 3G9, Canada.	tong-jun.lin@dal.ca		Coombs, Melanie/0000-0002-2036-8414; Marshall, Jean S./0000-0002-5642-1379				Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Adamo R, 2004, AM J RESP CELL MOL, V30, P627, DOI 10.1165/rcmb.2003-0260OC; Agramonte-Hevia J, 2002, FEMS IMMUNOL MED MIC, V34, P255, DOI 10.1016/S0928-8244(02)00408-X; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; CRIPPS AW, 1995, IMMUNOL CELL BIOL, V73, P418, DOI 10.1038/icb.1995.65; CROSS A, 1983, REV INFECT DIS, V5, pS837; CROUCH BS, 1996, CHEST, V109, P1019, DOI DOI 10.1378/CHEST.109.4.1019; DeBentzmann S, 1996, INFECT IMMUN, V64, P1582, DOI 10.1128/IAI.64.5.1582-1588.1996; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Faure K, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-1; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; GEORGE SE, 1993, APPL ENVIRON MICROB, V59, P3585, DOI 10.1128/AEM.59.11.3585-3591.1993; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Greenberger PA, 1997, JAMA-J AM MED ASSOC, V278, P1924, DOI 10.1001/jama.278.22.1924; Hashimoto S, 1996, AM J PHYSIOL-LUNG C, V270, pL819, DOI 10.1152/ajplung.1996.270.5.L819; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Kamath S, 1998, MOL MICROBIOL, V30, P933, DOI 10.1046/j.1365-2958.1998.01121.x; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kernacki KA, 1998, INFECT IMMUN, V66, P376, DOI 10.1128/IAI.66.1.376-379.1998; Kernacki KA, 2000, J IMMUNOL, V164, P1037, DOI 10.4049/jimmunol.164.2.1037; KOCH C, 1993, LANCET, V341, P1065, DOI 10.1016/0140-6736(93)92422-P; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; LIEBERMAN MM, 1983, J IMMUNOL, V131, P1; Lin TJ, 2002, J IMMUNOL, V169, P4522, DOI 10.4049/jimmunol.169.8.4522; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Moser C, 2002, CLIN EXP IMMUNOL, V127, P206, DOI 10.1046/j.1365-2249.2002.01731.x; O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Ramesh G, 2003, AM J PHYSIOL-RENAL, V285, pF610, DOI 10.1152/ajprenal.00101.2003; Roger T, 2001, NATURE, V414, P920, DOI 10.1038/414920a; Rudner XL, 2000, J IMMUNOL, V164, P6576, DOI 10.4049/jimmunol.164.12.6576; Sato S, 2000, J IMMUNOL, V165, P7096, DOI 10.4049/jimmunol.165.12.7096; Scanga CA, 2002, J IMMUNOL, V168, P5997, DOI 10.4049/jimmunol.168.12.5997; Schneider T, 1996, J IMMUNOL METHODS, V198, P1, DOI 10.1016/0022-1759(96)00143-3; Schroeder TH, 2002, P NATL ACAD SCI USA, V99, P6907, DOI 10.1073/pnas.092160899; Serbina NV, 2003, IMMUNITY, V19, P891, DOI 10.1016/S1074-7613(03)00330-3; Shi SAP, 2003, J EXP MED, V198, P987, DOI 10.1084/jem.20030603; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; Skerrett SJ, 2004, J IMMUNOL, V172, P3377, DOI 10.4049/jimmunol.172.6.3377; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; Strieter RM, 2003, CURR OPIN INFECT DIS, V16, P193, DOI 10.1097/00001432-200306000-00002; Sugawara I, 2003, MICROBIOL IMMUNOL, V47, P841, DOI 10.1111/j.1348-0421.2003.tb03450.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Vogel Stefanie N, 2003, Mol Interv, V3, P466, DOI 10.1124/mi.3.8.466; Wagner JG, 2000, PHARMACOL REV, V52, P349; Weighardt H, 2002, J IMMUNOL, V169, P2823, DOI 10.4049/jimmunol.169.6.2823; WIDMER U, 1993, J IMMUNOL, V150, P4996; Yamaguchi T, 2000, J MED MICROBIOL, V49, P701, DOI 10.1099/0022-1317-49-8-701; Zhang J, 2003, INVEST OPHTH VIS SCI, V44, P4247, DOI 10.1167/iovs.03-0219; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x	55	84	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49315	49322		10.1074/jbc.M402111200	http://dx.doi.org/10.1074/jbc.M402111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15375173	hybrid			2022-12-25	WOS:000225098100100
J	Taira, K; Umikawa, M; Takei, K; Myagmar, BE; Shinzato, M; Machida, N; Uezato, H; Nonaka, S; Kariya, K				Taira, K; Umikawa, M; Takei, K; Myagmar, BE; Shinzato, M; Machida, N; Uezato, H; Nonaka, S; Kariya, K			The Traf2- and Nck-interacting kinase as a putative effector of Rap2 to regulate actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; N-TERMINAL KINASE; GTP-BINDING PROTEIN; PHOSPHOLIPASE-C; SIGNALING PATHWAY; STE20-RELATED KINASE; M-RAS; ACTIVATION; FAMILY; IDENTIFICATION	Rap2 belongs to the Ras family of small GTP-binding proteins, but its specific roles in cell signaling remain unknown. In the present study, we have affinity-purified from rat brain a Rap2-interacting protein of similar to155 kDa, p155. By liquid chromatography tandem mass spectrometry, we have identified p155 as Traf2- and Nck-interacting kinase (TNIK). TNIK possesses an N-terminal kinase domain homologous to STE20, the Saccharomyces cerevisiae mitogen-activated protein kinase kinase kinase kinase, and a C-terminal regulatory domain termed the citron homology (CNH) domain. TNIK induces disruption of F-actin structure, thereby inhibiting cell spreading. In addition, TNIK specifically activates the c-Jun N-terminal kinase (JNK) pathway. Among our observations, TNIK interacted with Rap2 through its CNH domain but did not interact with Rap1 or Ras. TNIK interaction with Rap2 was dependent on the intact effector region and GTP-bound configuration of Rap2. When co-expressed in cultured cells, TNIK colocalized with Rap2, while a mutant TNIK lacking the CNH domain did not. Rap2 potently enhanced the inhibitory function of TNIK against cell spreading, but this was not observed for the mutant TNIK lacking the CNH domain. Rap2 did not significantly enhance TNIK-induced JNK activation, but promoted autophosphorylation and translocation of TNIK to the detergent-insoluble cytoskeletal fraction. These results suggest that TNIK is a specific effector of Rap2 to regulate actin cytoskeleton.	Univ Ryukyus, Grad Sch Med, Div Cell Biol, Okinawa 9030215, Japan; Univ Ryukyus, Grad Sch Med, Dept Dermatol, Okinawa 9030215, Japan	University of the Ryukyus; University of the Ryukyus	Kariya, K (corresponding author), Univ Ryukyus, Grad Sch Med, Div Cell Biol, 207 Uehara, Okinawa 9030215, Japan.	kariya@med.u-ryukyu.ac.jp						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carlier MF, 2003, BIOESSAYS, V25, P336, DOI 10.1002/bies.10257; Christian SL, 2003, J BIOL CHEM, V278, P41756, DOI 10.1074/jbc.M303180200; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Dan I, 2000, FEBS LETT, V469, P19, DOI 10.1016/S0014-5793(00)01247-3; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Ito M, 1999, MOL CELL BIOL, V19, P7539; Janoueix-Lerosey I, 1998, EUR J BIOCHEM, V252, P290, DOI 10.1046/j.1432-1327.1998.2520290.x; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kanai-Azuma M, 1999, MECH DEVELOP, V89, P155, DOI 10.1016/S0925-4773(99)00193-8; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; Machida N, 2004, J BIOL CHEM, V279, P15711, DOI 10.1074/jbc.C300542200; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; McLeod SJ, 2002, J IMMUNOL, V169, P1365, DOI 10.4049/jimmunol.169.3.1365; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Nancy V, 1999, J BIOL CHEM, V274, P8737, DOI 10.1074/jbc.274.13.8737; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sendoh H, 2000, BIOCHEM BIOPH RES CO, V271, P596, DOI 10.1006/bbrc.2000.2674; Shibatohge M, 1998, J BIOL CHEM, V273, P6218, DOI 10.1074/jbc.273.11.6218; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Su YC, 1998, GENE DEV, V12, P2371, DOI 10.1101/gad.12.15.2371; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Umikawa M, 1999, J BIOL CHEM, V274, P25197, DOI 10.1074/jbc.274.36.25197; Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	48	112	120	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49488	49496		10.1074/jbc.M406370200	http://dx.doi.org/10.1074/jbc.M406370200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15342639	hybrid			2022-12-25	WOS:000225098100119
J	Gostissa, M; Morelli, M; Mantovani, F; Guida, E; Piazza, S; Collavin, L; Brancolini, C; Schneider, C; Del Sal, G				Gostissa, M; Morelli, M; Mantovani, F; Guida, E; Piazza, S; Collavin, L; Brancolini, C; Schneider, C; Del Sal, G			The transcriptional repressor hDaxx potentiates p53-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL KINASE ACTIVATION; INTERACTING PROTEIN KINASE-2; PML ONCOGENIC DOMAINS; NUCLEAR-BODIES; P53 ACTIVITY; MUTANT P53; CELL-DEATH; DAXX; P73; BINDING	p53 and its homologues p73 and p63 are transcription factors that play an essential role in modulating cell cycle arrest and cell death in response to several environmental stresses. The type and intensity of these responses, which can be different depending on the inducing stimulus and on the overall cellular context, are believed to rely on the activation of defined subsets of target genes. The proper activation of p53 family members requires the coordinated action of post-translational modifications and interaction with several cofactors. In this study, we demonstrate that the multifunctional protein hDaxx interacts with p53 and its homologues, both in vitro and in vivo, and modulates their transcriptional activity. Moreover, we show that hDaxx, which has been implicated in several apoptotic pathways, increases the sensitivity to DNA damage-induced cell death and that this effect requires the presence of p53. Although hDaxx represses p53-dependent transcription of the p21 gene, it does not affect the activation of proapoptotic genes, and therefore acts by influencing the balance between cell cycle arrest and proapoptotic p53 targets. Our results therefore underline the central role of hDaxx in modulating the apoptotic threshold upon several stimuli and identify it as a possible integrating factor that coordinates the response of p53 family members.	LNCIB, I-34012 Trieste, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy; Univ Trieste, Ctr Eccellenza Biocristallog, I-34100 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	University of Trieste; University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Del Sal, G (corresponding author), LNCIB, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	delsal@area.trieste.it	Collavin, Licio/A-5312-2010	Collavin, Licio/0000-0001-6815-5381; BRANCOLINI, Claudio/0000-0002-6597-5373; DEL SAL, GIANNINO/0000-0003-2185-6003; Piazza, Silvano/0000-0002-7156-5434	Telethon [GGP02408] Funding Source: Medline	Telethon(Fondazione Telethon)		Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Cermak L, 2002, J BIOL CHEM, V277, P7955, DOI 10.1074/jbc.M108048200; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gostissa M, 2003, CURR OPIN CELL BIOL, V15, P351, DOI 10.1016/S0955-0674(03)00038-3; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jang MS, 2002, BIOCHEM BIOPH RES CO, V295, P495, DOI 10.1016/S0006-291X(02)00699-X; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Komarova EA, 2000, ONCOGENE, V19, P3791, DOI 10.1038/sj.onc.1203717; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Lin DY, 2002, J BIOL CHEM, V277, P25446, DOI 10.1074/jbc.M200633200; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michaelson JS, 2000, APOPTOSIS, V5, P217, DOI 10.1023/A:1009696227420; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Ohiro Y, 2003, MOL CELL BIOL, V23, P322, DOI 10.1128/MCB.23.1.322-334.2003; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SONG JJ, 2003, J BIOL CHEM; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zalcenstein A, 2003, ONCOGENE, V22, P5667, DOI 10.1038/sj.onc.1206724; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	52	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48013	48023		10.1074/jbc.M310801200	http://dx.doi.org/10.1074/jbc.M310801200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339933	hybrid			2022-12-25	WOS:000224957000073
J	Hardie, RC; Gu, YC; Martin, F; Sweeney, ST; Raghu, P				Hardie, RC; Gu, YC; Martin, F; Sweeney, ST; Raghu, P			In vivo light-induced and basal phospholipase C activity in Drosophila photoreceptors measured with genetically targeted phosphatidylinositol 4,5-bisphosphate-sensitive ion channels (Kir2.1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIACYLGLYCEROL KINASE MUTANT; RECTIFYING K+ CHANNELS; SENSITIVE CHANNELS; DIRECT ACTIVATION; TRPL CHANNELS; CA2+ CHANNEL; G-PROTEIN; MEMBRANE; CELLS; PIP2	The phosphatidylinositol 4,5-bisphosphate (PIP2)-sensitive inward rectifier channel Kir2.1 was expressed in Drosophila photoreceptors and used to monitor in vivo PIP2 levels. Since the wild-type (WT) Kir2.1 channel appeared to be saturated by the prevailing PIP2 concentration, we made a single amino acid substitution (R228Q), which reduced the effective affinity for PIP2 and yielded channels generating currents proportional to the PIP2 levels relevant for phototransduction. To isolate Kir2.1 currents, recordings were made from mutants lacking both classes of light-sensitive transient receptor potential channels (TRP and TRPL). Light resulted in the effective depletion of PIP2 by phospholipase C (PLC) in approximately three or four microvilli per absorbed photon at rates exceeding similar to150% of total microvillar phosphoinositides per second. PIP2 was resynthesized with a half-time of similar to50 s. When PIP2 resynthesis was prevented by depriving the cell of ATP, the Kir current spontaneously decayed at maximal rates representing a loss of similar to40% loss of total PIP2 per minute. This loss was attributed primarily to basal PLC activity, because it was greatly decreased in norpA mutants lacking PLC. We tried to confirm this by using the PLC inhibitor U73122; however, this was found to act as a novel inhibitor of the Kir2.1 channel. PIP2 levels were reduced similar to5-fold in the diacylglycerol kinase mutant (rdgA), but basal PLC activity was still pronounced, consistent with the suggestion that raised diacylglycerol levels are responsible for the constitutive TRP channel activity characteristic of this mutant.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of Cambridge; University of California System; University of California San Francisco	Hardie, RC (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.	rch14@hermes.cam.ac.uk	Padinjat, Raghu/Z-5578-2019; Martin, Fernando/AAZ-1300-2020	gu, yuchun/0000-0002-7558-0447; Sweeney, Sean/0000-0003-2673-9578; Martin, Fernando/0000-0003-4380-567X; Hardie, Roger/0000-0001-5531-3264				Agam K, 2000, J NEUROSCI, V20, P5748, DOI 10.1523/JNEUROSCI.20-15-05748.2000; Agam K, 2004, CELL CALCIUM, V35, P87, DOI 10.1016/j.ceca.2003.08.001; Baines RA, 2001, J NEUROSCI, V21, P1523, DOI 10.1523/JNEUROSCI.21-05-01523.2001; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cho H, 2001, BRIT J PHARMACOL, V134, P1066, DOI 10.1038/sj.bjp.0704347; Choe H, 1999, BIOPHYS J, V76, P1988, DOI 10.1016/S0006-3495(99)77357-1; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; DEER JLR, 1995, J BIOL CHEM, V270, P12623, DOI 10.1074/jbc.270.21.12623; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Hardie RC, 2002, NEURON, V36, P689, DOI 10.1016/S0896-6273(02)01048-6; HARDIE RC, 1995, J COMP PHYSIOL A, V177, P707, DOI 10.1007/BF00187630; Hardie RC, 1997, CELL CALCIUM, V21, P431, DOI 10.1016/S0143-4160(97)90054-3; Hardie RC, 2003, J BIOL CHEM, V278, P18851, DOI 10.1074/jbc.M300310200; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; HARDIE RC, 1994, J GEN PHYSIOL, V103, P389, DOI 10.1085/jgp.103.3.389; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Hardie RC, 2001, NEURON, V30, P149, DOI 10.1016/S0896-6273(01)00269-0; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Lopes CMB, 2002, NEURON, V34, P933, DOI 10.1016/S0896-6273(02)00725-0; MASAI I, 1993, P NATL ACAD SCI USA, V90, P11157, DOI 10.1073/pnas.90.23.11157; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Pearn MT, 1996, J BIOL CHEM, V271, P4937; Raghu P, 2000, NEURON, V26, P169, DOI 10.1016/S0896-6273(00)81147-2; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Rohacs T, 2003, P NATL ACAD SCI USA, V100, P745, DOI 10.1073/pnas.0236364100; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P659, DOI 10.1113/jphysiol.1984.sp015089; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	42	39	40	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47773	47782		10.1074/jbc.M407525200	http://dx.doi.org/10.1074/jbc.M407525200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355960	hybrid			2022-12-25	WOS:000224957000045
J	Catalano, A; Rodilossi, S; Rippo, MR; Caprari, P; Procopio, A				Catalano, A; Rodilossi, S; Rippo, MR; Caprari, P; Procopio, A			Induction of stem cell factor/c-Kit/Slug signal transduction in multidrug-resistant malignant mesothelioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; PROTOONCOGENE C-KIT; GROWTH-FACTOR; P-GLYCOPROTEIN; EXPRESSION; CANCER; GENE; ACTIVATION; THERAPY; LINE	Malignant mesothelioma (MM) is strongly resistant to conventional chemotherapy by unclear mechanisms. We and others have previously reported that cytokine- and growth factor-mediated signal transduction is involved in the growth and progression of MM. Here, we identified a pathway that involves stem cell factor (SCF)/c-Kit/Slug in mediating multidrug resistance of MM cells. When we compared gene expression profiles between five MM cells and their multidrug-resistant (MM DX) sublines, we found that MM DX cells expressed both SCF and c-Kit and had higher mRNA levels of Slug. Knockdown of c-Kit or Slug expression with their respective small interfering RNA sensitized MM DX cells to the induction of apoptosis by different chemotherapeutic agents, including doxorubicin, paclitaxel, and vincristine. Transfection of c-Kit in parental MM cells in the presence of SCF up-regulated Slug and increased resistance to the chemotherapeutic agents. Moreover, MM cells expressing Slug showed a similar increased resistance to the chemotherapeutic agents. These results indicate that induction of Slug by autocrine production of SCF and c-Kit activation plays a key role in conferring a broad spectrum chemoresistance on MM cells and reveal a novel signal transduction pathway for pharmacological or genetic intervention of MM patients.	Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, I-60131 Ancona, Italy; Italian Natl Res Ctr Aging, Lab Cytol, I-60124 Ancona, Italy; NCI, Neural Dev Grp, Mouse Canc Genet Program, NIH, Frederick, MD 21701 USA	Marche Polytechnic University; IRCCS INRCA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Catalano, A (corresponding author), Polytech Univ Marche, Dept Mol Pathol & Innovat Therapies, Via Ranieri, I-60131 Ancona, Italy.	catgfp@yahoo.it	Procopio, Antonio Domenico/AAB-2451-2021	Procopio, Antonio Domenico/0000-0001-6897-8724; RIPPO, Maria Rita/0000-0003-3024-3495				Alexander WS, 1998, LEUKEMIA RES, V22, P1097, DOI 10.1016/S0145-2126(98)00110-6; Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Catalano A, 2004, CRIT REV ONCOL HEMAT, V50, P101, DOI 10.1016/j.critrevonc.2003.10.001; Catalano A, 2004, INT J CANCER, V109, P322, DOI 10.1002/ijc.11710; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; Hajra KM, 2002, CANCER RES, V62, P1613; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Horvai AE, 2003, MODERN PATHOL, V16, P818, DOI 10.1097/01.MP.0000083647.69123.5C; INOUE M, 1994, CANCER RES, V54, P3049; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Liang YH, 2004, INT J CANCER, V111, P484, DOI 10.1002/ijc.20230; Liu Z, 2003, THORAX, V58, P198, DOI 10.1136/thorax.58.3.198; Lonardo F, 2003, APPL IMMUNOHISTO M M, V11, P51, DOI 10.1097/00022744-200303000-00009; MATSUDA R, 1993, AM J PATHOL, V142, P339; MONTI F, 1994, J CHEMOTHERAPY, V6, P337; Myers JW, 2003, NAT BIOTECHNOL, V21, P324, DOI 10.1038/nbt792; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Nowak AK, 2002, SEMIN ONCOL, V29, P82, DOI 10.1053/sonc.2002.30234; Ogretmen B, 1998, INT J CANCER, V75, P757, DOI 10.1002/(SICI)1097-0215(19980302)75:5<757::AID-IJC15>3.0.CO;2-3; Orengo AM, 1999, EUR RESPIR J, V13, P527, DOI 10.1183/09031936.99.13352799; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; REALE FR, 1987, CANCER RES, V47, P3199; Ricotti E, 1998, BLOOD, V91, P2397, DOI 10.1182/blood.V91.7.2397.2397_2397_2405; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schuetz EG, 1996, MOL PHARMACOL, V49, P311; Soini Y, 2001, ANN ONCOL, V12, P1239, DOI 10.1023/A:1012292230480; Tomek S, 2003, BRIT J CANCER, V88, P167, DOI 10.1038/sj.bjc.6600673; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; Yamane T, 1999, DEV DYNAM, V216, P450, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<450::AID-DVDY13>3.0.CO;2-0; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Zeuner A, 2003, BLOOD, V102, P87, DOI 10.1182/blood-2002-08-2369	45	77	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46706	46714		10.1074/jbc.M406696200	http://dx.doi.org/10.1074/jbc.M406696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337769	hybrid			2022-12-25	WOS:000224832400048
J	Colombo, S; Ronchetti, D; Thevelein, JM; Winderickx, J; Martegani, E				Colombo, S; Ronchetti, D; Thevelein, JM; Winderickx, J; Martegani, E			Activation state of the Ras2 protein and glucose-induced signaling in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDC25 GENE-PRODUCT; COUPLED RECEPTOR; ADENYLATE-CYCLASE; CYCLIC-AMP; GUANINE-NUCLEOTIDES; EXCHANGE FACTOR; CAMP SIGNAL; YEAST; PATHWAY; KINASE	The activity of adenylate cyclase in the yeast Saccharomyces cerevisiae is controlled by two G-protein systems, the Ras proteins and the Galpha protein Gpa2. Glucose activation of cAMP synthesis is thought to be mediated by Gpa2 and its G-protein-coupled receptor Gpr1. Using a sensitive GTP-loading assay for Ras2 we demonstrate that glucose addition also triggers a fast increase in the GTP loading state of Ras2 concomitant with the glucose-induced increase in cAMP. This increase is severely delayed in a strain lacking Cdc25, the guanine nucleotide exchange factor for Ras proteins. Deletion of the Ras-GAPs IRA2 (alone or with IRA1) or the presence of RAS2(Val19) allele causes constitutively high Ras GTP loading that no longer increases upon glucose addition. The glucose-induced increase in Ras2 GTP-loading is not dependent on Gpr1 or Gpa2. Deletion of these proteins causes higher GTP loading indicating that the two G-protein systems might directly or indirectly interact. Because deletion of GPR1 or GPA2 reduces the glucose-induced cAMP increase the observed enhancement of Ras2 GTP loading is not sufficient for full stimulation of cAMP synthesis. Glucose phosphorylation by glucokinase or the hexokinases is required for glucose-induced Ras2 GTP loading. These results indicate that glucose phosphorylation might sustain activation of cAMP synthesis by enhancing Ras2 GTP loading likely through inhibition of the Ira proteins. Strains with reduced feedback inhibition on cAMP synthesis also display elevated basal and induced Ras2 GTP loading consistent with the Ras2 protein acting as a target of the feedback-inhibition mechanism.	Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, I-20126 Milan, Italy; Katholieke Univ Leuven, Inst Bot & Microbiol, Mol Cell Biol Lab, B-3001 Louvain, Belgium; Flemish Interuniv Inst Biotechnol VIB, Dept Mol Microbiol, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Lab Funct Biol, Inst Plantkunde & Microbiol, B-3001 Louvain, Belgium	University of Milano-Bicocca; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Martegani, E (corresponding author), Univ Milano Bicocca, Dipartimento Biotecnol & Biosci, Piazza Sci 2, I-20126 Milan, Italy.	Enzo.Martegani@unimib.it	Thevelein, Johan M./AAK-4203-2021; Thevelein, Johan M./A-7897-2013	Thevelein, Johan M./0000-0002-2626-0180; Martegani, Enzo/0000-0001-9196-4224; Colombo, Sonia/0000-0001-5104-508X				BEULLENS M, 1988, EUR J BIOCHEM, V172, P227, DOI 10.1111/j.1432-1033.1988.tb13877.x; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; BoyMarcotte E, 1996, MOL BIOL CELL, V7, P529, DOI 10.1091/mbc.7.4.529; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; LOBO Z, 1977, GENETICS, V86, P727; Lorenz MC, 2000, GENETICS, V154, P609; Ma PS, 1999, MOL BIOL CELL, V10, P91, DOI 10.1091/mbc.10.1.91; MAITRA PK, 1983, GENETICS, V105, P501; MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518; MBONYI K, 1988, MOL CELL BIOL, V8, P3051, DOI 10.1128/MCB.8.8.3051; MUNDER T, 1989, FEBS LETT, V242, P341, DOI 10.1016/0014-5793(89)80498-3; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; REIFENBERGER E, 1995, MOL MICROBIOL, V16, P157, DOI 10.1111/j.1365-2958.1995.tb02400.x; RESNICK RJ, 1988, P NATL ACAD SCI USA, V85, P2474, DOI 10.1073/pnas.85.8.2474; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; Rolland F., 2001, FEMS YEAST RES, V1403, P1; Rudoni S, 2001, BBA-MOL CELL RES, V1538, P181, DOI 10.1016/S0167-4889(01)00067-2; SCHOMERUS C, 1990, MOL GEN GENET, V223, P426, DOI 10.1007/BF00264449; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANAELST L, 1990, EUR J BIOCHEM, V193, P675; VANAELST L, 1991, J GEN MICROBIOL, V137, P341, DOI 10.1099/00221287-137-2-341; Versele M, 2001, EMBO REP, V2, P574, DOI 10.1093/embo-reports/kve132; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yun CW, 1997, BIOCHEM BIOPH RES CO, V240, P287, DOI 10.1006/bbrc.1997.7649	38	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46715	46722		10.1074/jbc.M405136200	http://dx.doi.org/10.1074/jbc.M405136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339905	hybrid			2022-12-25	WOS:000224832400049
J	Liu, CJ; Prazak, L; Fajardo, M; Yu, S; Tyagi, N; Di Cesare, PE				Liu, CJ; Prazak, L; Fajardo, M; Yu, S; Tyagi, N; Di Cesare, PE			Leukemia/lymphoma-related factor, a POZ domain-containing transcriptional repressor, interacts with histone deacetylase-1 and inhibits cartilage oligomeric matrix protein gene expression and chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; MESENCHYMAL STEM-CELLS; HOMOLOGOUS FACTOR 1B; COMP GENE; INTERACTION MOTIF; BTB/POZ-DOMAIN; MYOBLAST DIFFERENTIATION; PROMYELOCYTIC LEUKEMIA; SKELETAL DEVELOPMENT; ARTICULAR-CARTILAGE	Mutations in the human cartilage oligomeric matrix protein ( COMP) gene have been linked to the development of pseudoachondroplasia and multiple epiphyseal dysplasia. We previously cloned the promoter region of the COMP gene and delineated a minimal negative regulatory element (NRE) that is both necessary and sufficient to repress its promoter (Issack, P. S., Fang, C. H., Leslie, M. P., and Di Cesare, P. E. (2000) J. Orthop. Res. 18, 345 - 350; Issack, P. S., Liu, C. J., Prazak, L., and Di Cesare, P. E. ( 2004) J. Orthop. Res. 22, 751 - 758). In this study, a yeast one-hybrid screen for proteins that associate with the NRE led to the identification of the leukemia/ lymphoma-related factor (LRF), a transcriptional repressor that contains a POZ ( poxvirus zinc finger) domain, as an NRE-binding protein. LRF bound directly to the NRE both in vitro and in living cells. Nine nucleotides (GAGGGTCCC) in the 30-bp NRE are essential for binding to LRF. LRF showed dose-dependent inhibition of COMP-specific reporter gene activity, and exogenous overexpression of LRF repressed COMP gene expression in both rat chondrosarcoma cells and bone morphogenetic protein-2-treated C3H10T1/2 progenitor cells. In addition, LRF also inhibited bone morphogenetic protein-2-induced chondrogenesis in high density micromass cultures of C3H10T1/2 cells, as evidenced by lack of expression of other chondrocytic markers, such as aggrecan and collagen types II, IX, X, and XI, and by Alcian blue staining. LRF associated with histone deacetylase-1 (HDAC1), and experiments utilizing the HDAC inhibitor trichostatin A revealed that LRF-mediated repression requires deacetylase activity. LRF is the first transcription factor found to bind directly to the COMP gene promoter, to recruit HDAC1, and to regulate both COMP gene expression and chondrogenic differentiation.	NYU, Hosp Joint Dis, Dept Orthoped Surg, Mcclure Musculoskeletal Res Ctr, New York, NY 10003 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Yale University	Di Cesare, PE (corresponding author), NYU, Hosp Joint Dis, Dept Orthoped Surg, Mcclure Musculoskeletal Res Ctr, Rm 1500,301 E 17th St, New York, NY 10003 USA.	PEDiCesare@aol.com	Tyagi, Neetu/AFZ-1370-2022	Tyagi, Neetu/0000-0002-1789-0754; liu, chuanju/0000-0002-7181-8032	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045612] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR45612-01A2] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barry F, 2001, EXP CELL RES, V268, P189, DOI 10.1006/excr.2001.5278; Bianco P, 1998, MATRIX BIOL, V17, P185, DOI 10.1016/S0945-053X(98)90057-9; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DICESARE PE, 1995, J ORTHOPAED RES, V13, P422, DOI 10.1002/jor.1100130316; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Ekman S, 1997, CALCIFIED TISSUE INT, V60, P547, DOI 10.1007/s002239900278; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischer L, 2002, J BIOL CHEM, V277, P30870, DOI 10.1074/jbc.M109330200; Francomano CA, 1996, CURR OPIN GENET DEV, V6, P301, DOI 10.1016/S0959-437X(96)80006-2; FRANZEN A, 1987, DIFFERENTIATION, V36, P199, DOI 10.1111/j.1432-0436.1987.tb00194.x; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; Hashimoto Y, 2003, AM J PATHOL, V163, P101, DOI 10.1016/S0002-9440(10)63634-6; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Horton WA, 1996, ENDOCRIN METAB CLIN, V25, P683, DOI 10.1016/S0889-8529(05)70347-9; Huynh KD, 2000, GENE DEV, V14, P1810; Issack PS, 2000, J ORTHOPAED RES, V18, P345, DOI 10.1002/jor.1100180304; Issack PS, 2004, J ORTHOP RES, V22, P751, DOI 10.1016/j.orthres.2003.12.006; Kajava AV, 1996, PROTEINS, V24, P218, DOI 10.1002/(SICI)1097-0134(199602)24:2<218::AID-PROT8>3.3.CO;2-I; Kawaji H, 2002, SKELETAL RADIOL, V31, P730, DOI 10.1007/s00256-002-0553-5; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kukita A, 1999, BLOOD, V94, P1987, DOI 10.1182/blood.V94.6.1987.418k26_1987_1997; Lee DK, 2002, J BIOL CHEM, V277, P26761, DOI 10.1074/jbc.M202078200; Lee HS, 2003, STEM CELLS, V21, P190, DOI 10.1634/stemcells.21-2-190; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2003, J BIOL CHEM, V278, P1029, DOI 10.1074/jbc.M207074200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P46553, DOI 10.1074/jbc.M108699200; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; Mabuchi A, 2003, HUM GENET, V112, P84, DOI 10.1007/s00439-002-0845-9; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Morrison DJ, 1999, NUCLEIC ACIDS RES, V27, P1251, DOI 10.1093/nar/27.5.1251; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Murakami A, 2001, NUCLEIC ACIDS RES, V29, P3347, DOI 10.1093/nar/29.16.3347; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakayama H, 2003, ONCOL REP, V10, P871; Oda E, 1998, MOL CELL BIOL, V18, P4772, DOI 10.1128/MCB.18.8.4772; Pendergrast PS, 2002, MOL BIOL CELL, V13, P915, DOI 10.1091/mbc.01-08-0383; Pessler F, 1997, MOL CELL BIOL, V17, P3786, DOI 10.1128/MCB.17.7.3786; Pessler F, 2003, J BIOL CHEM, V278, P29327, DOI 10.1074/jbc.M302980200; Recklies AD, 1998, ARTHRITIS RHEUM, V41, P997, DOI 10.1002/1529-0131(199806)41:6<997::AID-ART6>3.0.CO;2-G; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Shen ZX, 1995, MATRIX BIOL, V14, P773, DOI 10.1016/S0945-053X(05)80020-4; Sieweke M, 2000, Methods Mol Biol, V130, P59; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Song HR, 2003, J HUM GENET, V48, P222, DOI 10.1007/s10038-003-0013-7; Susic S, 1997, CLIN GENET, V51, P219; Widom RL, 1997, GENE, V198, P407, DOI 10.1016/S0378-1119(97)00360-0; Widom RL, 2001, MATRIX BIOL, V20, P451, DOI 10.1016/S0945-053X(01)00167-6; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Zaucke F, 2001, BIOCHEM J, V358, P17, DOI 10.1042/0264-6021:3580017; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	76	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47081	47091		10.1074/jbc.M405288200	http://dx.doi.org/10.1074/jbc.M405288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337766	hybrid			2022-12-25	WOS:000224832400094
J	Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD				Semont, A; Nowak, EB; Lages, CS; Mathieu, C; Mouthon, MA; May, E; Allemand, I; Millet, P; Boussin, FD			Involvement of p53 and Fas/CD95 in murine neural progenitor cell response to ionizing irradiation	ONCOGENE			English	Article						p53; Fas/CD95; neural progenitor; apoptosis; radiation	RADIATION-INDUCED APOPTOSIS; CENTRAL-NERVOUS-SYSTEM; CD95 APO-1/FAS; DNA-DAMAGE; WILD-TYPE; IN-VIVO; TUMOR-SUPPRESSOR; DEATH RECEPTOR; DENTATE GYRUS; STEM-CELLS	We investigated the role of tumor suppressor p53 and Fas (CD95/APO-1), a member of the tumor necrosis factor receptor family, in neural progenitors response to gamma-irradiation exposure. Telencephalic cells were obtained from wild-type C57Bl/6, or p53 -/- or fas -/-, 15-day-old mouse embryos. They were cultured in conditions allowing neural progenitors to form proliferating clusters ( neurospheres). A 2 Gy gamma-irradiation induced a G1 cell cycle arrest and triggered apoptosis in wild-type neural progenitor cultures in correlation with an enhanced expression of p53 and of its downstream target p21(WAF1), both of them acquiring a nuclear localization. These effects did not occur in p53 -/- neural progenitors demonstrating the central role played by p53 in their response to ionizing radiation. Furthermore, the monoclonal antibody Jo2 directed against Fas induced apoptosis of wild type but not of fas -/- neural progenitors, indicating the existence of a functional Fas signaling pathway in neural progenitors. Ionizing radiation induced an increase of Fas membrane expression related to a p53-dependent increase of fas mRNA expression in wild-type neural progenitors. Moreover, fas -/- neural progenitors exhibited delayed radiation-induced apoptosis compared to wild-type cells. Therefore, these findings establish a role for Fas/CD95 related to p53 in the response of neural progenitors to gamma-radiation exposure. Similar mechanisms could be triggered in neural progenitors in case of different stresses during brain development or in the course of various diseases affecting the adult brain.	CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France; CEA, CNRS,UMR 217, DRR DSV, Lab Cancerol Mol, Fontenay Aux Roses, France; CEA, IPSC, SEGG DRR DSV, Lab Radiosensibil Cellules Germinales, Fontenay Aux Roses, France	CEA; CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Boussin, FD (corresponding author), CEA, IPSC, DRR DSV, Lab Radiopathol, Fontenay Aux Roses, France.	boussin@cea.fr		Boussin, francois/0000-0003-3778-4403; Mouthon, Marc-Andre/0000-0003-2633-9179; allemand, isabelle/0000-0002-8861-7632; MILLET, Pascal/0000-0001-8877-8455				ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Becher B, 1998, NEUROSCIENCE, V84, P627, DOI 10.1016/S0306-4522(97)00455-7; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Blaschke AJ, 1998, J COMP NEUROL, V396, P39, DOI 10.1002/(SICI)1096-9861(19980622)396:1<39::AID-CNE4>3.0.CO;2-J; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; Chow BM, 2000, CELL DEATH DIFFER, V7, P712, DOI 10.1038/sj.cdd.4400704; Craig CG, 1996, J NEUROSCI, V16, P2649; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DANIEL PT, 1994, J IMMUNOL, V152, P5624; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; DHEIN J, 1992, J IMMUNOL, V149, P3166; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Eizenberg O, 1996, MOL CELL BIOL, V16, P5178; Embree-Ku M, 2002, BIOL REPROD, V66, P1456, DOI 10.1095/biolreprod66.5.1456; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Fuchs EJ, 1997, CANCER RES, V57, P2550; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Haik S, 2000, ONCOGENE, V19, P2957, DOI 10.1038/sj.onc.1203596; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Huang HL, 2003, ONCOGENE, V22, P8168, DOI 10.1038/sj.onc.1206979; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROSCI, V17, P1397; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kovac AD, 2002, EUR J NEUROSCI, V16, P159, DOI 10.1046/j.1460-9568.2002.02060.x; Lee Y, 2001, J NEUROSCI, V21, P6687, DOI 10.1523/JNEUROSCI.21-17-06687.2001; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu X, 1999, NEUROREPORT, V10, P3087, DOI 10.1097/00001756-199909290-00039; Maecker HL, 2000, CANCER RES, V60, P4638; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsui Y, 2001, AM J CLIN ONCOL-CANC, V24, P486, DOI 10.1097/00000421-200110000-00014; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miller FD, 2000, CELL DEATH DIFFER, V7, P880, DOI 10.1038/sj.cdd.4400736; Monje ML, 2003, CURR OPIN NEUROL, V16, P129, DOI 10.1097/00019052-200304000-00002; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nat R, 2001, J CELL MOL MED, V5, P417, DOI 10.1111/j.1582-4934.2001.tb00177.x; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nishimura Y, 1997, INT IMMUNOL, V9, P307, DOI 10.1093/intimm/9.2.307; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; O'Connor L, 2000, CANCER RES, V60, P1217; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; Peissner W, 1999, MOL BRAIN RES, V71, P61, DOI 10.1016/S0169-328X(99)00170-9; Rakic S, 2000, EUR J NEUROSCI, V12, P2721, DOI 10.1046/j.1460-9568.2000.00153.x; Rao MS, 1999, ANAT RECORD, V257, P137; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Reap EA, 1997, P NATL ACAD SCI USA, V94, P5750, DOI 10.1073/pnas.94.11.5750; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Saas P, 1997, J CLIN INVEST, V99, P1173, DOI 10.1172/JCI119273; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sheard MA, 2001, INT J CANCER, V96, P213, DOI 10.1002/ijc.1020; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Strasser-Wozak EMC, 1998, CELL DEATH DIFFER, V5, P687, DOI 10.1038/sj.cdd.4400402; Tada E, 2000, NEUROSCIENCE, V99, P33, DOI 10.1016/S0306-4522(00)00151-2; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; Uberti D, 2001, MOL BRAIN RES, V93, P81, DOI 10.1016/S0169-328X(01)00180-2; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Unger C, 1998, CELL DEATH DIFFER, V5, P87, DOI 10.1038/sj.cdd.4400321; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiang H, 1998, J NEUROSCI, V18, P1363	81	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8497	8508		10.1038/sj.onc.1207821	http://dx.doi.org/10.1038/sj.onc.1207821			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361846				2022-12-25	WOS:000224870700010
J	Cheung, PY; Zhang, Y; Long, JF; Lin, SC; Zhang, MJ; Jiang, Y; Wu, ZG				Cheung, PY; Zhang, Y; Long, JF; Lin, SC; Zhang, MJ; Jiang, Y; Wu, ZG			p150(Glued), dynein, and microtubules are specifically required for activation of MKK3/6 and p38 MAPKs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; LIVING CELLS; DYNACTIN; PROTEIN; PATHWAYS; EXPRESSION; TRANSPORT; SUBUNIT; COMPLEX	To look for regulators of the mitogen-activated protein kinase ( MAPK) kinase 6 (MKK6), a yeast two-hybrid screen was initiated using MKK6 as bait. p150(Glued) dynactin, a key component of the cytoplasmic dynein-dynactin motor complex, was found to specifically interact with MKK6 and its close homologue MKK3. Silencing of p150(Glued) expression by small interference RNA reduced the stimulus-induced phosphorylation of MKK3/6 and p38 MAPKs. The similar adverse effect was also seen when the cytoplasmic dynein motor was disrupted by other means. Like p150(Glued), MKK3/6 directly associate with microtubules. Disruption of microtubules prior to cell stimulation specifically inhibits the stimulus-induced phosphorylation of both MKK3/6 and p38 MAPKs. Our unexpected findings reveal a specific requirement for p150(Glued)/dynein/functional microtubules in activation of MKK3/6 and p38 MAPKs in vivo.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; First Mil Med Univ, Dept Pathophysiol, Guangzhou 510515, Peoples R China	Hong Kong University of Science & Technology; Yale University; Southern Medical University - China	Wu, ZG (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	bczgwu@ust.hk	Lin, SC/G-4666-2010; Long, Jiafu/B-7420-2012	Long, Jiafu/0000-0002-6625-0147; Zhang, Yi/0000-0003-2785-1780; Wu, Zhenguo/0000-0003-3049-8324; Zhang, Mingjie/0000-0001-9404-0190				Allan V, 2000, CURR BIOL, V10, pR432, DOI 10.1016/S0960-9822(00)00550-9; Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dhani SU, 2003, J BIOL CHEM, V278, P16262, DOI 10.1074/jbc.M209828200; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PENNINGROTH SM, 1986, METHOD ENZYMOL, V134, P477; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Verhey KJ, 2001, TRENDS BIOCHEM SCI, V26, P545, DOI 10.1016/S0968-0004(01)01931-4; Xu Q, 2002, MOL BIOL CELL, V13, P1940, DOI 10.1091/mbc.02-02-0016	21	28	29	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45308	45311		10.1074/jbc.C400333200	http://dx.doi.org/10.1074/jbc.C400333200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15375157	hybrid			2022-12-25	WOS:000224694900004
J	Nieman, KM; Rowling, MJ; Garrow, TA; Schalinske, KL				Nieman, KM; Rowling, MJ; Garrow, TA; Schalinske, KL			Modulation of methyl group metabolism by streptozotocin-induced diabetes and all-trans-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE N-METHYLTRANSFERASE; FOLATE-BINDING-PROTEIN; ONE-CARBON METABOLISM; PLASMA HOMOCYSTEINE; RAT-LIVER; DERIVATIVES; METHIONINE; ADENOSYLMETHIONINE; INHIBITION; SYNTHETASE	The hepatic enzyme glycine N-methyltransferase (GNMT) plays a major role in the control of methyl group and homocysteine metabolism. Because disruption of these vital pathways is associated with numerous pathologies, understanding GNMT control is important for evaluating methyl group regulation. Recently, gluconeogenic conditions have been shown to modulate homocysteine metabolism and treatment with glucocorticoids and/or all-trans-retinoic acid (RA)-induced active GNMT protein, thereby leading to methyl group loss. This study was conducted to determine the effect of diabetes, alone and in combination with RA, on GNMT regulation. Diabetes and RA increased GNMT activity 87 and 148%, respectively. Moreover, the induction of GNMT activity by diabetes and RA was reflected in its abundance. Cell culture studies demonstrated that pretreatment with insulin prevented GNMT induction by both RA and dexamethasone. There was a significant decline in homocysteine concentrations in diabetic rats, owing in part to a 38% increase in the abundance of the transsulfuration enzyme cystathionine beta-synthase; treatment of diabetic rats with RA prevented cystathionine beta-synthase induction. A diabetic state also increased the activity of the folate-independent homocysteine remethylation enzyme betaine-homocysteine S-methyltransferase, whereas the activity of the folate-dependent enzyme methionine synthase was diminished 52%. In contrast, RA treatment attenuated the streptozotocin-mediated increase in betaine-homocysteine S-methyltransferase, whereas methionine synthase activity remained diminished. These results indicate that both a diabetic condition and RA treatment have marked effects on the metabolism of methyl groups and homocysteine, a finding that may have significant implications for diabetics and their potential sensitivity to retinoids.	Iowa State Univ Sci & Technol, Dept Food Sci & Human Nutr, Ames, IA 50011 USA; Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA; Univ Illinois, Div Nutr Sci, Urbana, IL 61801 USA	Iowa State University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Schalinske, KL (corresponding author), Iowa State Univ Sci & Technol, Dept Food Sci & Human Nutr, 220 MacKay Hall, Ames, IA 50011 USA.	kschalin@iastate.edu		Nieman, Kristin/0000-0001-7529-0872	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052501, R29DK052501] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALAGHI M, 1993, BIOCHEM J, V291, P145, DOI 10.1042/bj2910145; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cantoni GL., 1980, NATURAL SULFUR COMPO, P67; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; COOK RJ, 1989, J NUTR, V119, P612, DOI 10.1093/jn/119.4.612; FELL D, 1985, J CHROMATOGR, V345, P150, DOI 10.1016/0378-4347(85)80146-8; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; Gil B, 1997, ENDOCRINOLOGY, V138, P1251, DOI 10.1210/en.138.3.1251; Jacobs RL, 1998, DIABETES, V47, P1967, DOI 10.2337/diabetes.47.12.1967; Jacobs RL, 2001, J BIOL CHEM, V276, P43740, DOI 10.1074/jbc.M107553200; JENCKS DA, 1987, J BIOL CHEM, V262, P2485; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KEATING JN, 1985, CLIN SCI, V69, P287, DOI 10.1042/cs0690287; KERR SJ, 1972, J BIOL CHEM, V247, P4248; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; Liu HH, 2003, J BIOMED SCI, V10, P87, DOI 10.1159/000068083; Loktionov A, 2003, J NUTR BIOCHEM, V14, P426, DOI 10.1016/S0955-2863(03)00032-9; McMullen MH, 2002, ARCH BIOCHEM BIOPHYS, V401, P73, DOI 10.1016/S0003-9861(02)00030-9; OGAWA H, 1998, EUR J BIOCHEM, V168, P141; Ozias MK, 2003, J NUTR, V133, P4090, DOI 10.1093/jn/133.12.4090; Ratnam S, 2002, J BIOL CHEM, V277, P42912, DOI 10.1074/jbc.M206588200; Ross SA, 2003, ANN NY ACAD SCI, V983, P197, DOI 10.1111/j.1749-6632.2003.tb05974.x; Rowling MJ, 2003, J NUTR, V133, P3392, DOI 10.1093/jn/133.11.3392; Rowling MJ, 2002, J NUTR, V132, P365, DOI 10.1093/jn/132.3.365; Rowling MJ, 2001, J NUTR, V131, P1914, DOI 10.1093/jn/131.7.1914; Schalinske KL, 1996, CARCINOGENESIS, V17, P1695, DOI 10.1093/carcin/17.8.1695; SCOTT JM, 1990, ANNU REV NUTR, V10, P277, DOI 10.1146/annurev.nu.10.070190.001425; SHANE B, 1985, ANNU REV NUTR, V5, P115, DOI 10.1146/annurev.nu.05.070185.000555; UBBINK JB, 1991, J CHROMATOGR-BIOMED, V565, P441, DOI 10.1016/0378-4347(91)80407-4; WAGNER C, 1989, J BIOL CHEM, V264, P9638; WAGNER C, 1985, BIOCHEM BIOPH RES CO, V127, P746, DOI 10.1016/S0006-291X(85)80006-1; Wagner C, 1995, FOLATE HLTH DIS, P23; Wijekoon EP, 2004, FASEB J, V18, pA546; Wysowski DK, 2002, J AM ACAD DERMATOL, V46, P505, DOI 10.1067/mjd.2002.120529; XUE GP, 1985, BIOCHEM INT, V10, P897; YEO EJ, 1994, P NATL ACAD SCI USA, V91, P210, DOI 10.1073/pnas.91.1.210	37	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45708	45712		10.1074/jbc.M408664200	http://dx.doi.org/10.1074/jbc.M408664200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15347642	Green Published, hybrid			2022-12-25	WOS:000224694900052
J	Skinner, HD; Zheng, JZ; Fang, J; Agani, F; Jiang, BH				Skinner, HD; Zheng, JZ; Fang, J; Agani, F; Jiang, BH			Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1 alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OVARIAN-CANCER; TUMOR-GROWTH; PERMEABILITY FACTOR; FACTOR EXPRESSION; IN-VIVO; ASCITES-FORMATION; GENE-EXPRESSION; O-2 TENSION; INHIBITION; CARCINOMA	Vascular endothelial growth factor (VEGF) expression is elevated in ovarian and other cancer cells. However, the mechanism that causes the increase in VEGF expression still remains to be elucidated. In this study, we demonstrated that activation of PI3K signaling mediated VEGF protein expression at the transcriptional level through hypoxia-inducible factor 1alpha (HIF-1alpha) expression in human ovarian cancer cells. We found that inhibition of PI3K activity by LY294002 decreased VEGF transcriptional activation and that forced expression of AKT completely reversed the inhibitory effect. HDM2 and p70S6K1 are two downstream targets of AKT that mediate growth factor-induced VEGF transcriptional activation and HIF-1alpha expression. The inhibition of PI3K by LY294002 inhibited p70S6K1 and HDM2 activity in the cells. Forced expression of p70S6K1 or HDM2 reversed LY294002-inhibited VEGF transcriptional activation and HIF-1alpha expression. This study identifies a potential novel mechanism responsible for increased VEGF expression in ovarian cancer cells. It also indicates the important role of VEGF and HIF-1 in ovarian tumorigenesis and angiogenesis, which is mediated by the PI3K/AKT/HDM2 and AKT/p70S6K1 pathways in ovarian cancer cells.	W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Case Western Reserve Univ, Dept Anat, Sch Med, Cleveland, OH 44106 USA	West Virginia University; Case Western Reserve University	Jiang, BH (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA.	bhjiang@hsc.wvu.edu	Skinner, Heath/A-1669-2012	Skinner, Heath/0000-0003-1836-151X; Jiang, Bing-Hua/0000-0003-4526-2031	NCRR NIH HHS [RR16440] Funding Source: Medline; NINDS NIH HHS [NS41309] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041309] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbuJawdeh GM, 1996, LAB INVEST, V74, P1105; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Birner P, 2000, CANCER RES, V60, P4693; Birner P, 2001, CANCER, V92, P165, DOI 10.1002/1097-0142(20010701)92:1<165::AID-CNCR1305>3.0.CO;2-F; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Hazelton D A, 1999, Curr Oncol Rep, V1, P59, DOI 10.1007/s11912-999-0011-9; Hu LM, 2002, CANCER RES, V62, P1087; Hu LM, 2000, CLIN CANCER RES, V6, P880; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kraft A, 1999, CANCER-AM CANCER SOC, V85, P178; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Mattern J, 1997, ANTICANCER RES, V17, P621; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; Mu J, 1996, JPN J CANCER RES, V87, P963, DOI 10.1111/j.1349-7006.1996.tb02127.x; NAGY JA, 1995, CANCER RES, V55, P360; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; OLSON TA, 1994, CANCER RES, V54, P276; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; Philp AJ, 2001, CANCER RES, V61, P7426; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tempfer C, 1998, OBSTET GYNECOL, V92, P360, DOI 10.1016/S0029-7844(98)00190-2; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Xu L, 2000, INT J ONCOL, V16, P445; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Yukita A, 2000, ANTICANCER RES, V20, P155; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W	42	177	202	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45643	45651		10.1074/jbc.M404097200	http://dx.doi.org/10.1074/jbc.M404097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15337760	Green Published, hybrid			2022-12-25	WOS:000224694900044
J	Oh, SM; Pyo, CW; Kim, Y; Choi, SY				Oh, SM; Pyo, CW; Kim, Y; Choi, SY			Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappa B activation cascade	ONCOGENE			English	Article						lactoferrin; p53; NF-kappa B	TUMOR-NECROSIS-FACTOR; NUCLEAR-FACTOR; KINASE CASCADES; BINDING; TRANSCRIPTION; EXPRESSION; ALPHA; GRANULOPOIESIS; LOCALIZATION; SEQUENCE	Neutrophil lactoferrin (Lf) was previously shown to act as a transcriptional activator in various mammalian cells. Here, we describe that Lf specifically transactivates the p53 tumor suppressor gene through the activation of nuclear factor-kappaB (NF-kappaB) and consequently regulates p53-responsive oncogenes. In HeLa cervical carcinoma cells stably expressing Lf (HeLa-Lf), expression of mdm2 and p21(waf1/cip1) as well as p53 was greatly enhanced. Transient expression of Lf also markedly transactivates transcription of a p53 promoter-driven reporter and NF-kappaB-driven reporters in various mammalian cells. However, mutation of the NF-kappaB site or treatment with an NF-kappaB inhibitor abrogated the transactivation, suggesting that NF-kappaB should play an essential role in the Lf-induced transactivation. Increased binding activity and nuclear translocation of p65 in response to Lf strongly support these findings. Furthermore, Lf-mediated NF-kappaB activation is diminished in IKKalpha- or IKKbeta-deficient mouse embryonic fibroblast cells. The activation of both IKKs and NF-kappaB by Lf is over-ridden by the expression of dominant-negative mutants of NIK, MEKK 1, IKKalpha and IKKbeta. Collectively, we conclude that overexpressed Lf directly relays signals to upstream components responsible for NF-kappaB activation, thereby leading to the activation of NF-kappaB target genes.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Univ Ulsan, Coll Med, Genome Res Ctr Birth Defects & Genet Disorders, Seoul 138736, South Korea	Korea University; University of Ulsan	Choi, SY (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	sychoi@korea.ac.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAGBY GC, 1989, BLOOD CELLS, V15, P386; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; GALBRAITH PR, 1986, CLIN INVEST MED, V9, P1; GARRE C, 1992, J CELL PHYSIOL, V153, P477, DOI 10.1002/jcp.1041530306; GINSBERG D, 1990, ONCOGENE, V5, P1285; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HE JL, 1995, NATURE, V373, P721, DOI 10.1038/373721a0; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; MIKOGAMI T, 1994, AM J PHYSIOL, V267, pG308, DOI 10.1152/ajpgi.1994.267.2.G308; Oh SM, 2001, J BIOL CHEM, V276, P42575, DOI 10.1074/jbc.M107724200; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schulze-Osthoff K, 1997, IMMUNOBIOLOGY, V198, P35, DOI 10.1016/S0171-2985(97)80025-3; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Suzuki YA, 2002, BIOCHEM CELL BIOL, V80, P75, DOI 10.1139/o01-228; WENG HQ, 1995, J BIOL CHEM, V270, P13637, DOI 10.1074/jbc.270.23.13637; Zhao Q, 1999, J BIOL CHEM, V274, P8355, DOI 10.1074/jbc.274.13.8355	28	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8282	8291		10.1038/sj.onc.1208021	http://dx.doi.org/10.1038/sj.onc.1208021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378004				2022-12-25	WOS:000224749500010
J	Song, H; Jin, XH; Lin, JY				Song, H; Jin, XH; Lin, JY			Stat3 upregulates MEK5 expression in human breast cancer cells	ONCOGENE			English	Article						MEK5; Stat3; breast carcinoma; siRNA	GENE-EXPRESSION; SIGNAL TRANSDUCER; TRANSCRIPTION FACTORS; ACTIVATION; KINASE; OVEREXPRESSION; GROWTH; ADRENOMEDULLIN; RESISTANCE; PATHWAYS	The constitutive activation of signal transducer and activator of transcription 3 (Stat3) is frequently detected in breast cancer cell lines but not in normal breast epithelial cells. Stat3 has been classified as an oncogene, because constitutively active Stat3 can mediate oncogenic transformation in cultured cells and tumor formation in nude mice. Since Stat3 appears to play an important role in breast cancer, it is of interest to investigate Stat3-regulated genes and elucidate Stat3-mediated oncogenesis. In this study, we investigated the Stat3-regulated genes in human breast epithelial cells. Upon overexpression of Stat3-C, a constitutively active Stat3 form, in nonmalignant telomerase immortalized breast (TERT) cells, the total mRNA was extracted and subjected to Affymetrix microarray analysis. Our results showed that mitogen-activated protein kinase kinase 5 (MEK5) was markedly induced (more than 22-fold increase, P < 0.001) by Stat3-C expression. RT-PCR result also demonstrated that MEK5 mRNA was significantly induced by Stat3-C in TERT cells. The upregulation of MEK5 by Stat3-C was further confirmed by Western blot in MCF10A breast epithelial cells. Further more, in MDA-MB-435s breast carcinoma cells, which express high levels of activated Stat3 and MEK5, MEK5 protein was significantly reduced by using Stat3 short interfering RNA. The reduction of MEK5 was consistent with Stat3 knockdown in this breast carcinoma cell line. We also investigated MEK5 expression in different breast carcinoma cell lines and breast cancer tissues using tissue array analysis. Compared with nonmalignant breast epithelial cells or normal tissues without constitutively active Stat3 signaling, MEK5 protein levels are remarkably higher in breast carcinoma cell lines and cancer tissues with constitutively activated Stat3. Taken together, our findings suggest that constitutively active Stat3 upregulates MEK5 in the breast epithelial cells. MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies.	Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Lin, JY (corresponding author), Univ Michigan, Ctr Comprehens Canc, Cellular & Mol Biol Grad Program, Dept Obstet & Gynecol,Div Gynecol Oncol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	linjia@umich.edu	Lin, Jiayuh/E-3515-2011		NCI NIH HHS [R01 CA096714] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096714] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alas S, 2001, CANCER RES, V61, P5137; Atsumi T, 2002, CANCER RES, V62, P5881; Bhat NR, 1999, J NEUROCHEM, V72, P112, DOI 10.1046/j.1471-4159.1999.0720112.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cameron SJ, 2004, J BIOL CHEM, V279, P1506, DOI 10.1074/jbc.M308755200; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Dalton WS, 1999, SEMIN ONCOL, V26, P23; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kauraniemi P, 2004, ONCOGENE, V23, P1010, DOI 10.1038/sj.onc.1207200; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Martinez A, 2002, J NATL CANCER I, V94, P1226; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Mehta PB, 2003, ONCOGENE, V22, P1381, DOI 10.1038/sj.onc.1206154; Mulloy R, 2003, ONCOGENE, V22, P5387, DOI 10.1038/sj.onc.1206839; Nakamura K, 2003, J BIOL CHEM, V278, P36989, DOI 10.1074/jbc.C300313200; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Oehler MK, 2003, BRIT J CANCER, V89, P1927, DOI 10.1038/sj.bjc.6601397; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Okano J, 2001, J BIOL CHEM, V276, P19555, DOI 10.1074/jbc.M011164200; Pollett JB, 2002, BLOOD, V100, P3819, DOI 10.1182/blood-2002-02-0608; Raz R, 1999, P NATL ACAD SCI USA, V96, P2846, DOI 10.1073/pnas.96.6.2846; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shen YH, 2004, MOL CELL BIOL, V24, P407, DOI 10.1128/MCB.24.1.407-419.2004; Song H, 2004, INT J ONCOL, V24, P1017; Song H, 2004, BIOCHEM BIOPH RES CO, V314, P143, DOI 10.1016/j.bbrc.2003.12.048; Stephanou A, 1998, BIOCHEM J, V330, P189, DOI 10.1042/bj3300189; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tan KB, 2004, HISTOPATHOLOGY, V44, P24, DOI 10.1111/j.1365-2559.2004.01774.x; Ueno H, 1997, CANCER RES, V57, P2055; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Yoshizumi M, 2003, J PHARMACOL SCI, V91, P172; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	54	44	50	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8301	8309		10.1038/sj.onc.1208026	http://dx.doi.org/10.1038/sj.onc.1208026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378007				2022-12-25	WOS:000224749500012
J	Albani, D; Peverelli, E; Rametta, R; Batelli, S; Veschini, L; Negro, A; Forloni, G				Albani, D; Peverelli, E; Rametta, R; Batelli, S; Veschini, L; Negro, A; Forloni, G			Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70	FASEB JOURNAL			English	Article						Parkinson's disease; Lewy bodies; neurodegeneration; dopaminergic cells; oxidative stress	FAMILIAL PARKINSONS-DISEASE; CHAPERONE-LIKE ACTIVITY; OXIDATIVE STRESS; NEURONAL CELLS; BINDING DOMAIN; HEAT-SHOCK; IN-VITRO; MUTATION; DEGENERATION; AGGREGATION	alpha-Synuclein (alpha-syn) is a 140-amino acid presinaptic protein whose mutations A30P and A53T have been linked to familiar Parkinson's disease (PD). Many data suggest that alpha-syn aggregation is the key event that triggers alpha-syn-mediated neurotoxicity. Nevertheless, other lines of evidence proposed a protective role of alpha-syn against oxidative stress (a major feature of PD), even if the exact mechanism of this protective action and the role of the pathogenetic mutations to this respect have not been elucidated yet. To address these points, we developed an in vitro model of oxidative stress by exposing PC12 cells to hydrogen peroxide (H2O2) (150 muM) for 72 h, and we evaluated alpha-syn-mediated protection delivering increasing amounts of alpha-syn (wild type [WT] or mutated) inside cells using the fusion proteins TAT-alpha-syn (WT, A30P, and A53T). We found that nanomolar amounts of TAT-alpha-syn-mediated protected against oxidative stress and other cellular injuries (6-hydroxydopamine and serum deprivation), whereas micromolar amounts of the fusion proteins were intrinsically toxic to cells. The protective effect was independent from the presence of the mutations A30P and A53T, but no protection occurred when cells were challenged with the proteasome inhibitors lactacystin and MG132. We verified that the protection mechanism required the presence of the C-terminal domain of alpha-syn, as nanomolar amounts of the C-terminal truncated fusion protein TAT-alpha-syn (WT[1-97]) failed in preventing H2O2 toxicity. To further characterize the molecular mechanisms at the basis of alpha-syn protection, we investigated the possible involvement of the chaperone protein HSP70 that is widely implicated in neuroprotection. We found that, at nanomolar concentrations, TAT-alpha-syn was able to increase HSP70 protein level, whereas at the micromolar scale, TAT-alpha-syn decreased HSP70 at the protein level. These effects on HSP70 were independent from the presence of alpha-syn pathogenetic mutations but required the alpha-syn C-terminal domain. The implications for a-synmediated neurotoxicity and for PD pathogenesis and progression are discussed.	Ist Ric Farmacol Mario Negri, Dept Neurosci, I-20157 Milan, Italy; Univ Padua, Dept Biochem, I-35121 Padua, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Padua	Forloni, G (corresponding author), Ist Ric Farmacol Mario Negri, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.	forloni@marionegri.it	Forloni, Gianluigi/AAB-2115-2020; ALBANI, DIEGO/I-5183-2018	Forloni, Gianluigi/0000-0001-5374-3914; ALBANI, DIEGO/0000-0002-7050-6723; Veschini, Lorenzo/0000-0003-3820-7472; rametta, raffaela/0000-0003-0091-9394; Peverelli, Erika/0000-0002-4424-7895; NEGRO, ALESSANDRO/0000-0003-3142-7632				Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2003, NEUROMOL MED, V3, P1, DOI 10.1385/NMM:3:1:1; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Hashimoto M, 2003, ANN NY ACAD SCI, V991, P171; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Hattori N, 2003, J NEUROL, V250, P2, DOI 10.1007/s00415-003-1302-y; Helfand SL, 2002, SCIENCE, V295, P809, DOI 10.1126/science.1069544; Ischiropoulos H, 2003, J CLIN INVEST, V111, P163, DOI 10.1172/JCI200317638; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x; Kemp TJ, 2003, BIOCHEM BIOPH RES CO, V307, P416, DOI 10.1016/S0006-291X(03)01215-4; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lykkebo S, 2002, NEUROMOL MED, V2, P115, DOI 10.1385/NMM:2:2:115; Ma QL, 2003, J ALZHEIMERS DIS, V5, P139, DOI 10.3233/JAD-2003-5208; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; Norris EH, 2003, J BIOL CHEM, V278, P27230, DOI 10.1074/jbc.M212436200; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Park SM, 2002, BLOOD, V100, P2506, DOI 10.1182/blood.V100.7.2506; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sato K, 1996, BRAIN RES, V740, P117, DOI 10.1016/S0006-8993(96)00846-3; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Volles MJ, 2003, BIOCHEMISTRY-US, V42, P7871, DOI 10.1021/bi030086j; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; Wersinger C, 2003, MOL CELL NEUROSCI, V24, P91, DOI 10.1016/S1044-7431(03)00124-6; Winklhofer KF, 2003, J BIOL CHEM, V278, P47199, DOI 10.1074/jbc.M306769200; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	47	67	71	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1713	+		10.1096/fj.04-1621fje	http://dx.doi.org/10.1096/fj.04-1621fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345691				2022-12-25	WOS:000224243200044
J	Andraos, N; Tabor, S; Richardson, CC				Andraos, N; Tabor, S; Richardson, CC			The highly processive DNA polymerase of bacteriophage T5 - Role of the unique N and C termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID POLYMERASE; ESCHERICHIA-COLI; CONFERS PROCESSIVITY; STRAND DISPLACEMENT; PROTEIN; REPLICATION; BINDING; COMPLEX; MUTANT; DOMAIN	The DNA polymerase encoded by bacteriophage T5 has been reported previously to be processive and to catalyze extensive strand displacement synthesis. The enzyme, purified from phage-infected cells, did not require accessory proteins for these activities. Although T5 DNA polymerase shares extensive sequence homology with Escherichia coli DNA polymerase I and T7 DNA polymerase, it contains unique regions of 130 and 71 residues at its N and C termini, respectively. We cloned the gene encoding wild-type T5 DNA polymerase and characterized the overproduced protein. We also examined the effect of N- and C-terminal deletions on processivity and strand displacement synthesis. T5 DNA polymerase lacking its N- terminal 30 residues resembled the wild-type enzyme albeit with a 2-fold reduction in polymerase activity. Deletion of 24 residues at the C terminus resulted in a 30-fold reduction in polymerase activity on primed circular DNA, had dramatically reduced processivity, and was unable to carry out strand displacement synthesis. Deletion of 63 residues at the C terminus resulted in a 20,000-fold reduction in polymerase activity. The 3' to 5' double-stranded DNA exonuclease activity associated with T5 DNA polymerase was reduced by a factor of 5 in the polymerase truncated at the N terminus but was stimulated by a factor of 7 in the polymerase truncated at the C terminus. We propose a model in which the C terminus increases the affinity of the DNA for the polymerase active site, thus increasing processivity and decreasing the accessibility of the DNA to the exonuclease active site.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Paris 06, CNRS, UMR 7590, Lab Mineral Cristallog Paris, F-75252 Paris, France	Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite	Richardson, CC (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	ccr@hms.harvard.edu			NIGMS NIH HHS [GM-54397] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054397] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; Blanco L, 1996, J BIOL CHEM, V271, P8509, DOI 10.1074/jbc.271.15.8509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; CHATTERJEE DK, 1991, GENE, V97, P13, DOI 10.1016/0378-1119(91)90004-U; DAS SK, 1976, J VIROL, V20, P70, DOI 10.1128/JVI.20.1.70-77.1976; DAS SK, 1980, J BIOL CHEM, V255, P7149; DAS SK, 1979, J BIOL CHEM, V254, P1227; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DEWAARD A, 1965, P NATL ACAD SCI USA, V54, P1241; DOPHEIDE TA, 1967, J BIOL CHEM, V242, P1833; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; ENGLER MJ, 1983, J BIOL CHEM, V258, P1165; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; FUJIMURA RK, 1976, J BIOL CHEM, V251, P2168; FUJIMURA RK, 1976, BIOCHEMISTRY-US, V15, P4403, DOI 10.1021/bi00665a009; He ZG, 2004, J BIOL CHEM, V279, P22190, DOI 10.1074/jbc.M401100200; He ZG, 2003, J BIOL CHEM, V278, P29538, DOI 10.1074/jbc.M304318200; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Kelman Z, 1998, STRUCTURE, V6, P121, DOI 10.1016/S0969-2126(98)00014-8; KORNBERG A, 1992, DNA REPLICATION, P494; Kumar JK, 2001, J BIOL CHEM, V276, P34905, DOI 10.1074/jbc.M104151200; LEAVITT MC, 1989, P NATL ACAD SCI USA, V86, P4465, DOI 10.1073/pnas.86.12.4465; LECHNER RL, 1983, J BIOL CHEM, V258, P1174; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; MASAMUNE Y, 1971, J BIOL CHEM, V246, P2692; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; ORR CWM, 1965, J BIOL CHEM, V240, P4652; Rodriguez I, 2004, J MOL BIOL, V337, P829, DOI 10.1016/j.jmb.2004.02.018; Sambrook J, 2001, MOL CLONING LAB MANU; SCHILDKRAUT CL, 1964, J MOL BIOL, V9, P24, DOI 10.1016/S0022-2836(64)80089-9; STEUART CD, 1968, J BIOL CHEM, V243, P5308; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1989, J BIOL CHEM, V264, P6447; Truniger V, 2004, NUCLEIC ACIDS RES, V32, P361, DOI 10.1093/nar/gkh184; VONHIPPEL PH, 1994, ANN NY ACAD SCI, V726, P118	37	19	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50609	50618		10.1074/jbc.M408428200	http://dx.doi.org/10.1074/jbc.M408428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377656	hybrid			2022-12-25	WOS:000225229500125
J	Bai, M; Zhou, JM; Perrett, S				Bai, M; Zhou, JM; Perrett, S			The yeast prion protein Ure2 shows glutathione peroxidase activity in both native and fibrillar forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; S-TRANSFERASE; HEAVY-METAL; CATALYTIC MECHANISM; AMYLOID FORMATION; CRYSTAL-STRUCTURE; IN-VITRO; DISEASE; DOMAIN; RESISTANCE	Ure2p is the precursor protein of the Saccharomyces cerevisiae prion [URE3]. Ure2p shows homology to glutathione transferases but lacks typical glutathione transferase activity. A recent study found that deletion of the Ure2 gene causes increased sensitivity to heavy metal ions and oxidants, whereas prion strains show normal sensitivity. To demonstrate that protection against oxidant toxicity is an inherent property of native and prion Ure2p requires biochemical characterization of the purified protein. Here we use steady-state kinetic methods to characterize the multisubstrate peroxidase activity of Ure2p using GSH with cumene hydroperoxide, hydrogen peroxide, or tert-butyl hydroperoxide as substrates. Glutathione-dependent peroxidase activity was proportional to the Ure2p concentration and showed optima at pH 8 and 40 degreesC. Michaelis-Menten behavior with convergent straight lines in double reciprocal plots was observed. This excludes a ping-pong mechanism and implies either a rapid-equilibrium random or a steady-state ordered sequential mechanism for Ure2p, consistent with its classification as a glutathione transferase. The mutant 90Ure2, which lacks the unstructured N-terminal prion domain, showed kinetic parameters identical to wild type. Fibrillar aggregates showed the same level of activity as native protein. Demonstration of peroxidase activity for Ure2 represents important progress in elucidation of its role in vivo. Further, establishment of an in vitro activity assay provides a valuable tool for the study of structure-function relationships of the Ure2 protein as both a prion and an enzyme.	Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Zhou, JM (corresponding author), Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	zhoujm@sun5.ibp.ac.cn; sarah.perrett@iname.com	Perrett, Sarah/AAS-9483-2020	Perrett, Sarah/0000-0003-0137-0997				[Anonymous], 1973, CHEM KINETICS ENZYME; Apetri AC, 2004, J BIOL CHEM, V279, P18008, DOI 10.1074/jbc.M313581200; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; Bach S, 2003, NAT BIOTECHNOL, V21, P1075, DOI 10.1038/nbt855; Basu U, 2004, MOL GENET GENOMICS, V271, P627, DOI 10.1007/s00438-004-1015-7; Baxa U, 2002, P NATL ACAD SCI USA, V99, P5253, DOI 10.1073/pnas.082097899; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Collinson EJ, 2003, J BIOL CHEM, V278, P22492, DOI 10.1074/jbc.M301387200; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; Fersht A., 1999, STRUCTURE MECH PROTE; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Fraser JA, 2002, APPL ENVIRON MICROB, V68, P2802, DOI 10.1128/AEM.68.6.2802-2808.2002; Galani D, 2002, J MOL BIOL, V315, P213, DOI 10.1006/jmbi.2001.5234; HOPE J, 1988, NATURE, V336, P390, DOI 10.1038/336390a0; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Labrou NE, 2001, BIOCHEM J, V358, P101, DOI 10.1042/0264-6021:3580101; Laidler K J, 1980, Methods Enzymol, V64, P227; Mannervik B, 1998, CHEM-BIOL INTERACT, V112, P15, DOI 10.1016/S0009-2797(97)00147-6; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Nay B, 1999, INSECT BIOCHEM MOLEC, V29, P71, DOI 10.1016/S0965-1748(98)00106-4; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Rossjohn J, 1996, PROTEIN ENG, V9, P327, DOI 10.1093/protein/9.4.327; Saito Y, 1999, J BIOL CHEM, V274, P2866, DOI 10.1074/jbc.274.5.2866; SEUBERT PA, 1985, ARCH BIOCHEM BIOPHYS, V240, P509, DOI 10.1016/0003-9861(85)90057-8; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Torrent J, 2003, BIOCHEMISTRY-US, V42, P1318, DOI 10.1021/bi0269916; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Vuilleumier S, 1997, J BACTERIOL, V179, P1431, DOI 10.1128/jb.179.5.1431-1441.1997; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhou JM, 2001, BIOCHEM BIOPH RES CO, V287, P147, DOI 10.1006/bbrc.2001.5556; Zhu L, 2003, BIOCHEM BIOPH RES CO, V311, P525, DOI 10.1016/j.bbrc.2003.10.027; Zhu L, 2003, J MOL BIOL, V328, P235, DOI 10.1016/S0022-2836(03)00249-3	52	91	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50025	50030		10.1074/jbc.M406612200	http://dx.doi.org/10.1074/jbc.M406612200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371425	hybrid			2022-12-25	WOS:000225229500060
J	Kumagai, A; Kim, SM; Dunphy, WG				Kumagai, A; Kim, SM; Dunphy, WG			Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; SINGLE-STRANDED-DNA; CHECKPOINT CONTROL; XENOPUS CHK1; BINDING; KINASE; DAMAGE; PHOSPHORYLATION; MRC1; PATHWAY	Claspin is necessary for the ATR-dependent activation of Chk1 in Xenopus egg extracts containing incompletely replicated DNA. ATR possesses a regulatory partner called ATRIP. We have studied the respective roles of ATR-ATRIP and Claspin in the activation of Chk1. ATR-ATRIP bound well to various DNA templates in Xenopus egg extracts. ATR-ATRIP bound to a single-stranded DNA template was weakly active. By contrast, the ATR-ATRIP complex on a DNA template containing both single- and double-stranded regions displayed a large increase in kinase activity. This observation suggests that ATR-ATRIP normally undergoes activation upon association with specific nucleic acid structures at DNA replication forks. Without Claspin, activated ATR-ATRIP phosphorylated Chk1 weakly in a cell-free reaction. The addition of Claspin to this reaction strongly stimulated the phosphorylation of Chk1 by ATR-ATRIP. Claspin also induced significant autophosphorylation of Chk1 in the absence of ATR-ATRIP. Taken together, these results indicate that the checkpoint-dependent phosphorylation of Chk1 is a multistep process involving activation of the ATR-ATRIP complex at replication forks and presentation of Chk1 to this complex by Claspin.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Dunphy, WG (corresponding author), CALTECH, Div Biol, 216-76,1200 E Calif Blvd, Pasadena, CA 91125 USA.	dunphy@cco.caltech.edu			NIGMS NIH HHS [GM043974, GM070891] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043974, R37GM043974, R01GM070891] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bomgarden RD, 2004, J BIOL CHEM, V279, P13346, DOI 10.1074/jbc.M311098200; Caldecott KW, 2003, SCIENCE, V302, P579, DOI 10.1126/science.1091463; Canman CE, 2003, CURR BIOL, V13, pR488, DOI 10.1016/S0960-9822(03)00410-X; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; De Souza CPC, 1999, MOL BIOL CELL, V10, P3661, DOI 10.1091/mbc.10.11.3661; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jeong SY, 2003, J BIOL CHEM, V278, P46782, DOI 10.1074/jbc.M304551200; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Katsuragi Y, 2004, MOL BIOL CELL, V15, P1680, DOI 10.1091/mbc.E03-12-0874; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Kumagai A, 2003, NAT CELL BIOL, V5, P161, DOI 10.1038/ncb921; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Liu QH, 2000, GENE DEV, V14, P1448; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mochida S, 2004, EMBO J, V23, P418, DOI 10.1038/sj.emboj.7600018; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Oe T, 2001, DEV BIOL, V229, P250, DOI 10.1006/dbio.2000.9968; Osborn AJ, 2003, GENE DEV, V17, P1755, DOI 10.1101/gad.1098303; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Paciotti V, 2000, GENE DEV, V14, P2046; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Wakayama T, 2001, MOL CELL BIOL, V21, P755, DOI 10.1128/MCB.21.3.755-764.2001; Wang SX, 2000, FEBS LETT, V487, P277, DOI 10.1016/S0014-5793(00)02370-X; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wolkow TD, 2002, MOL BIOL CELL, V13, P480, DOI 10.1091/mbc.01-03-0104; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	48	112	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49599	49608		10.1074/jbc.M408353200	http://dx.doi.org/10.1074/jbc.M408353200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371427	Green Accepted, hybrid			2022-12-25	WOS:000225229500009
J	Kurata, S; Okuyama, T; Osada, M; Watanabe, T; Tomimori, Y; Sato, S; Iwai, A; Tsuji, T; Ikawa, Y; Katoh, I				Kurata, S; Okuyama, T; Osada, M; Watanabe, T; Tomimori, Y; Sato, S; Iwai, A; Tsuji, T; Ikawa, Y; Katoh, I			p51/p63 controls subunit alpha(3) of the major epidermis integrin anchoring the stem cells to the niche	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53 HOMOLOG P63; SQUAMOUS-CELL; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL TARGET; EXPRESSION PATTERN; BASEMENT-MEMBRANE; GENE; ALPHA-3; GROWTH; MIGRATION	p51/p63, a member of the tumor suppressor p53 gene family, is crucial for skin development. We describe here identification of ITGA3 encoding integrin alpha(3) as a target of its trans-activating function, proposing that p51/p63 allows epidermal stem cells to express laminin receptor alpha(3)beta(1) for anchorage to the basement membrane. When activated by genotoxic stress or overexpressed ectopically in non-adherent cells, p51/p63 transduced a phenotype to attach to extracellular matrices, which was accompanied by expression of ITGA3. Motifs matching the p53-binding consensus sequence were located in a scattered form in intron 1 of human ITGA3, and served as p51/p63-responsive elements in reporter assays. In addition to the trans-activating ability of the TA isoform, we detected a positive effect of the DeltaN isoform on ITGA3. The high level alpha(3) production in human keratinocyte stem cells diminished upon elimination of p51/p63 by small interfering RNA or by Ca2+-induced differentiation. Furthermore, a chromatin immunoprecipitation experiment indicated a physical interaction of p51/p63 with intron 1 of ITGA3. This study provides a molecular basis for the standing hypothesis that p51/p63 is essential for epidermal-mesenchymal interactions.	Inst Phys & Chem Res, Ikawa Lab, Wako, Saitama 3510198, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Human Gene Sci Ctr, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Allied Hlth Sci, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Immune Regulat, Bunkyo Ku, Tokyo 1138510, Japan; Kyoritsu Coll Pharmaceut Sci, Dept Mol Physiol, Minato Ku, Tokyo 1058512, Japan; Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Microbiol, Shinagawa Ku, Tokyo 1428501, Japan	RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Hoshi University	Katoh, I (corresponding author), Inst Phys & Chem Res, Ikawa Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	peace@postman.riken.jp						ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Brunner HG, 2002, J MED GENET, V39, P377, DOI 10.1136/jmg.39.6.377; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; De Arcangelis A, 1999, DEVELOPMENT, V126, P3957; DiPersio CM, 2001, EXP CELL RES, V268, P45, DOI 10.1006/excr.2001.5273; DiPersio CM, 1997, J CELL BIOL, V137, P729, DOI 10.1083/jcb.137.3.729; DiRenzo J, 2002, CANCER RES, V62, P89; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fiucci G, 2004, P NATL ACAD SCI USA, V101, P3510, DOI 10.1073/pnas.0400177101; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Hagiwara K, 1999, CANCER RES, V59, P4165; Hashida H, 2002, INT J CANCER, V97, P518, DOI 10.1002/ijc.1625; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kappert K, 2000, HYPERTENSION, V35, P255, DOI 10.1161/01.HYP.35.1.255; Kato T, 2002, EUR J BIOCHEM, V269, P4524, DOI 10.1046/j.1432-1033.2002.03146.x; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Katoh I, 2004, J BIOL CHEM, V279, P15515, DOI 10.1074/jbc.M311819200; Koga F, 2003, BRIT J CANCER, V88, P740, DOI 10.1038/sj.bjc.6600764; Kojima T, 2001, BIOCHEM BIOPH RES CO, V281, P1170, DOI 10.1006/bbrc.2001.4486; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Lubman RL, 2000, AM J PHYSIOL-LUNG C, V279, pL183, DOI 10.1152/ajplung.2000.279.1.L183; Massion PP, 2003, CANCER RES, V63, P7113; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MICHIELI P, 1994, CANCER RES, V54, P3391; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Osada M, 2001, BIOCHEM BIOPH RES CO, V283, P1135, DOI 10.1006/bbrc.2001.4905; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; Patriarca C, 1998, HUM PATHOL, V29, P1208, DOI 10.1016/S0046-8177(98)90247-7; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Quade BJ, 2001, GYNECOL ONCOL, V80, P24, DOI 10.1006/gyno.2000.5953; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Shimada A, 1999, CANCER RES, V59, P2781; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; STANLEY JR, 1983, J CELL BIOL, V96, P1809, DOI 10.1083/jcb.96.6.1809; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Tomimori Y, 2004, BIOCHEM BIOPH RES CO, V313, P230, DOI 10.1016/j.bbrc.2003.11.113; TSAO MC, 1982, J CELL PHYSIOL, V110, P219, DOI 10.1002/jcp.1041100217; Tsuji T, 2002, CLIN EXP METASTAS, V19, P127, DOI 10.1023/A:1014573204062; Tsuji T, 1999, J BIOCHEM, V125, P1183, DOI 10.1093/oxfordjournals.jbchem.a022402; Tysnes BB, 1996, INT J CANCER, V67, P777, DOI 10.1002/(SICI)1097-0215(19960917)67:6<777::AID-IJC5>3.0.CO;2-O; Wang ZM, 1999, J CELL SCI, V112, P2925; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wiebe JP, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-9; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhang XA, 2001, MOL BIOL CELL, V12, P351, DOI 10.1091/mbc.12.2.351; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	64	57	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50069	50077		10.1074/jbc.M406322200	http://dx.doi.org/10.1074/jbc.M406322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15361520	hybrid			2022-12-25	WOS:000225229500065
J	Moise, AR; Kuksa, V; Imanishi, Y; Palczewski, K				Moise, AR; Kuksa, V; Imanishi, Y; Palczewski, K			Identification of all-trans-retinol: All-trans-13,14-dihydroretinol saturase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENT EPITHELIAL-CELLS; PHYTOENE DESATURASE; ESCHERICHIA-COLI; VITAMIN-A; CAROTENOID BIOSYNTHESIS; ALDEHYDE DEHYDROGENASE; SUBSTRATE-SPECIFICITY; HUMAN CYTOCHROME-P450; 9-CIS-RETINOIC ACID; VERTEBRATE RETINA	Retinoids carry out essential functions in vertebrate development and vision. Many of the retinoid processing enzymes remain to be identified at the molecular level. To expand the knowledge of retinoid biochemistry in vertebrates, we studied the enzymes involved in plant metabolism of carotenoids, a related group of compounds. We identified a family of vertebrate enzymes that share significant similarity and a putative phytoene desaturase domain with a recently described plant carotenoid isomerase (CRTISO), which isomerizes prolycopene to all-trans-lycopene. Comparison of heterologously expressed mouse and plant enzymes indicates that unlike plant CRTISO, the CRTISO-related mouse enzyme is inactive toward prolycopene. Instead, the CRTISO-related mouse enzyme is a retinol saturase carrying out the saturation of the 13-14 double bond of all-trans-retinol to produce all-trans-13,14-dihydroretinol. The product of mouse retinol saturase (RetSat) has a shifted UV absorbance maximum, lambda(max)=290 nm, compared with the parent compound, all-trans-retinol (lambda(max)=325 nm), and its MS analysis (m/z=288) indicates saturation of a double bond. The product was further identified as all-trans-13,14-dihydroretinol, since its characteristics were identical to those of a synthetic standard. Mouse RetSat is membrane-associated and expressed in many tissues, with the highest levels in liver, kidney, and intestine. All-trans-13,14-dihydroretinol was also detected in several tissues of animals maintained on a normal diet. Thus, saturation of all-transretinol to all-trans-13,14-dihydroretinol by RetSat produces a new metabolite of yet unknown biological function.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Moise, AR (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	moise@u.washington.edu; palczews@u.washington.edu	AR, Moise/P-2474-2019; Imanishi, Yoshikazu/E-8178-2010; Moise, Alexander R/C-9498-2009; Moise, Alexander/A-7186-2008	AR, Moise/0000-0003-2307-6035; Imanishi, Yoshikazu/0000-0003-4696-4836; Moise, Alexander R/0000-0003-2307-6035; 	NATIONAL EYE INSTITUTE [R03EY015399] Funding Source: NIH RePORTER; NEI NIH HHS [R03 EY015399-03, R03 EY015399, R03 EY015399-04, R03 EY015399-01, R03 EY015399-02] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1989, IN VITRO CELL DEV B, V25, P1141; AlBabili S, 1996, PLANT J, V9, P601, DOI 10.1046/j.1365-313X.1996.9050601.x; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; Bartley GE, 1999, EUR J BIOCHEM, V259, P396, DOI 10.1046/j.1432-1327.1999.00051.x; Batten ML, 2004, J BIOL CHEM, V279, P10422, DOI 10.1074/jbc.M312410200; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Blobel G, 1979, Symp Soc Exp Biol, V33, P9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breitenbach J, 2001, Z NATURFORSCH C, V56, P915; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; BUEHNER M, 1974, J MOL BIOL, V82, P563, DOI 10.1016/0022-2836(74)90249-6; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; DERGUINI F, 1995, J BIOL CHEM, V270, P18875, DOI 10.1074/jbc.270.32.18875; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Fraser PD, 2004, PROG LIPID RES, V43, P228, DOI 10.1016/j.plipres.2003.10.002; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; Fujiwara S, 2003, ZOOL SCI, V20, P809, DOI 10.2108/zsj.20.809; Garwin GG, 2000, METHOD ENZYMOL, V316, P313; Giuliano G, 2003, TRENDS PLANT SCI, V8, P145, DOI 10.1016/S1360-1385(03)00053-0; Giuliano G, 2002, TRENDS PLANT SCI, V7, P427, DOI 10.1016/S1360-1385(02)02329-4; GIULIANO G, 1986, J BIOL CHEM, V261, P2925; Haeseleer F, 2002, J BIOL CHEM, V277, P45537, DOI 10.1074/jbc.M208882200; HENGARTNER U, 1992, HELV CHIM ACTA, V75, P1848, DOI 10.1002/hlca.19920750611; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079; Isaacson T, 2002, PLANT CELL, V14, P333, DOI 10.1105/tpc.010303; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Kuksa V, 2003, VISION RES, V43, P2959, DOI 10.1016/S0042-6989(03)00482-6; Kushiro T, 2004, EMBO J, V23, P1647, DOI 10.1038/sj.emboj.7600121; LAW WC, 1988, J AM CHEM SOC, V110, P5915, DOI 10.1021/ja00225a062; Lin M, 2003, J BIOL CHEM, V278, P9856, DOI 10.1074/jbc.M211417200; Masamoto K, 2001, PLANT CELL PHYSIOL, V42, P1398, DOI 10.1093/pcp/pce167; Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200; Mic FA, 2000, MECH DEVELOP, V97, P227, DOI 10.1016/S0925-4773(00)00434-2; Park H, 2002, PLANT CELL, V14, P321, DOI 10.1105/tpc.010302; Penzes P, 1997, GENE, V191, P167, DOI 10.1016/S0378-1119(97)00054-1; Raisig A, 1996, J BIOCHEM-TOKYO, V119, P559; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Ruiz A, 1999, J BIOL CHEM, V274, P3834, DOI 10.1074/jbc.274.6.3834; Saito S, 2004, PLANT PHYSIOL, V134, P1439, DOI 10.1104/pp.103.037614; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sandmann G, 2002, PHYSIOL PLANTARUM, V116, P431, DOI 10.1034/j.1399-3054.2002.1160401.x; Schmidt CK, 2002, BBA-MOL CELL BIOL L, V1583, P237, DOI 10.1016/S1388-1981(02)00212-3; Schneider C, 1997, PROTEIN EXPRES PURIF, V10, P175, DOI 10.1006/prep.1997.0730; Shirley MA, 1996, DRUG METAB DISPOS, V24, P293; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Taimi M, 2004, J BIOL CHEM, V279, P77, DOI 10.1074/jbc.M308337200; von Lintig J, 2001, P NATL ACAD SCI USA, V98, P1130, DOI 10.1073/pnas.031576398; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Wang Y, 2001, ONCOGENE, V20, P7710, DOI 10.1038/sj.onc.1204941; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; White JA, 2000, P NATL ACAD SCI USA, V97, P6403, DOI 10.1073/pnas.120161397; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; YAN B, 1995, J BIOL CHEM, V270, P29668; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476; Zechmeister L, 1941, P NATL ACAD SCI USA, V27, P468, DOI 10.1073/pnas.27.10.468; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	65	79	84	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50230	50242		10.1074/jbc.M409130200	http://dx.doi.org/10.1074/jbc.M409130200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358783	Green Accepted, hybrid			2022-12-25	WOS:000225229500084
J	Kunzelmann, K; Konig, J; Sun, J; Markovich, D; King, NJ; Karupiah, G; Young, JA; Cook, DI				Kunzelmann, K; Konig, J; Sun, J; Markovich, D; King, NJ; Karupiah, G; Young, JA; Cook, DI			Acute effects of parainfluenza virus on epithelial electrolyte transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NA+ ABSORPTION; EXTRACELLULAR NUCLEOTIDES; PSEUDOMONAS-AERUGINOSA; MIDDLE-EAR; CLEARANCE; INFECTION; INHIBITION; ATP; HOSPITALIZATIONS; PATHOGENESIS	Parainfluenza viruses are important causes of respiratory disease in both children and adults. In particular, they are the major cause of the serious childhood illness croup (laryngotracheobronchitis). The infections produced by parainfluenza viruses are associated with the accumulation of ions and fluid in the respiratory tract. It is not known, however, whether this accumulation is because of a direct effect of the viruses on ion and fluid transport by the respiratory epithelium. Here we show that a model parainfluenza virus (the Sendai virus), in concentrations observed during respiratory infections, activates Cl- secretion and inhibits Na+ absorption across the tracheal epithelium. It does so by binding to a neuraminidase-insensitive glycolipid, possibly asialo-GM1, triggering the release of ATP, which then acts in an autocrine fashion on apical P2Y receptors to produce the observed changes in ion transport. These findings indicate that fluid accumulation in the respiratory tract associated with parainfluenza virus infection is attributable, at least in part, to direct effects of the virus on ion transport by the respiratory epithelium.	Univ Sydney, Sch Med Sci, Dept Physiol, Sydney, NSW 2006, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia; Australian Natl Univ, John Curtin Sch Med Res, Woden, ACT 2606, Australia	University of Sydney; University of Queensland; University of Sydney; Australian National University; John Curtin School of Medical Research	Cook, DI (corresponding author), Univ Sydney, Sch Med Sci, Dept Physiol, Anderson Stuart Bldg F13, Sydney, NSW 2006, Australia.		Karupiah, Gunasegaran/J-4707-2013; Markovich, Daniel/F-7884-2012	Kunzelmann, Karl/0000-0002-4583-7037; Karupiah, Gunasegaran/0000-0001-6306-4405; King, Nicholas Jonathan Cole/0000-0002-3877-9772				Azzam ZS, 2001, J APPL PHYSIOL, V90, P1088, DOI 10.1152/jappl.2001.90.3.1088; Ball JM, 1996, SCIENCE, V272, P101, DOI 10.1126/science.272.5258.101; BARBOUR S, 1992, J CELL PHYSIOL, V150, P610, DOI 10.1002/jcp.1041500322; Barker PM, 1997, J PEDIATR-US, V130, P373, DOI 10.1016/S0022-3476(97)70198-7; BOUCHER RC, 1982, J APPL PHYSIOL, V52, P893, DOI 10.1152/jappl.1982.52.4.893; CHANOCK RM, 2001, FIELDS VIROLOGY, V1, P1341; Cook DI, 2002, PFLUG ARCH EUR J PHY, V443, P339, DOI 10.1007/s00424-001-0729-1; Counihan ME, 2001, PEDIATR INFECT DIS J, V20, P646, DOI 10.1097/00006454-200107000-00003; Cuffe JE, 2000, J PHYSIOL-LONDON, V524, P77, DOI 10.1111/j.1469-7793.2000.00077.x; Davis IC, 2004, AM J PHYSIOL-LUNG C, V286, pL112, DOI 10.1152/ajplung.00218.2003; DESTGROTH SF, 1966, J EXP MED, V124, P347, DOI 10.1084/jem.124.3.347; Evans DJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1284, DOI 10.1152/ajpcell.1998.275.5.C1284; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8267, DOI 10.1073/pnas.87.21.8267; GRAHAM A, 1993, EXP LUNG RES, V19, P77, DOI 10.3109/01902149309071082; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; HENRICKSON KJ, 1994, CLIN INFECT DIS, V18, P770, DOI 10.1093/clinids/18.5.770; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; HOTEZ PJ, 1990, PEDIATR INFECT DIS J, V9, P751, DOI 10.1097/00006454-199010000-00017; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; JORIS L, 1991, AM J PHYSIOL, V260, pL510, DOI 10.1152/ajplung.1991.260.6.L510; Kerem E, 1999, NEW ENGL J MED, V341, P156, DOI 10.1056/NEJM199907153410304; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; Kunzelmann K, 2002, PFLUG ARCH EUR J PHY, V444, P220, DOI 10.1007/s00424-002-0796-y; LETZ B, 1995, J MEMBRANE BIOL, V148, P127; Mall M, 2004, NAT MED, V10, P487, DOI 10.1038/nm1028; Mall M, 2000, AM J RESP CELL MOL, V23, P755, DOI 10.1165/ajrcmb.23.6.4207; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Marx A, 1997, J INFECT DIS, V176, P1423, DOI 10.1086/514137; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Morris AP, 2001, AM J PHYSIOL-GASTR L, V281, pG303, DOI 10.1152/ajpgi.2001.281.2.G303; OGASAWARA T, 1994, J VIROL, V68, P4022, DOI 10.1128/JVI.68.6.4022-4027.1994; PENACRUZ V, 1992, J INFECT DIS, V165, P846, DOI 10.1093/infdis/165.5.846; Portier F, 1999, AM J PHYSIOL-CELL PH, V276, pC312, DOI 10.1152/ajpcell.1999.276.2.C312; Prince GA, 2001, J VIROL, V75, P12446, DOI 10.1128/JVI.75.24.12446-12451.2001; Ratner AJ, 2001, J BIOL CHEM, V276, P19267, DOI 10.1074/jbc.M007703200; ROBINSON TW, 1968, J MED MICROBIOL, V1, P89, DOI 10.1099/00222615-1-1-89; Scherrer U, 1999, ADV EXP MED BIOL, V474, P93; STUTTS MJ, 1986, AM REV RESPIR DIS, V134, P17; Suzuki T, 2001, J VIROL, V75, P4604, DOI 10.1128/JVI.75.10.4604-4613.2001; TAMAOKI J, 1991, INFECT IMMUN, V59, P716, DOI 10.1128/IAI.59.2.716-717.1991; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200	44	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48760	48766		10.1074/jbc.M409747200	http://dx.doi.org/10.1074/jbc.M409747200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364905	hybrid			2022-12-25	WOS:000225098100034
J	Lee, PHA; Trowbridge, JM; Taylor, KR; Morhenn, VB; Gallo, RL				Lee, PHA; Trowbridge, JM; Taylor, KR; Morhenn, VB; Gallo, RL			Dermatan sulfate proteoglycan and glycosaminoglycan synthesis is induced in fibroblasts by transfer to a three-dimensional extracellular environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; CELL-SURFACE PROTEOGLYCAN; GROWTH-FACTOR; CHONDROITIN SULFATE; EXPRESSION; SYNDECANS; DECORIN; BINDING; FAMILY; INHIBITION	Composition and architecture of the extracellular matrix dictate cell behavior. Proteoglycans bind multiple components of the extracellular matrix by serving as important regulators of cell behavior. Given the influence of culture architecture on cell function, we investigated whether switching NIH3T3 fibroblasts from growth on type 1 collagen in monolayer to a collagen gel might influence dermatan sulfate expression. Immunofluorescent staining, immunoblot, and Western blot demonstrated an induction in decorin expression in cells switched to collagen gels. This induction was associated with a 40-fold increase in decorin transcript expression determined by quantitative real time PCR. Disaccharide analysis of extracted glycosaminoglycans from collagen gels showed an increase in total glycosaminoglycan and in the ratio of chondroitin sulfate to heparan sulfate compared with monolayer culture. The ratio of chondroitin sulfate to heparan sulfate likewise increased on syndecan-1 from gel culture. Digestion with chondroitinase B showed that this induced chondroitin sulfate was dermatan sulfate. Syndecan-1 extracted from wounded mouse skin also displayed an increase in dermatan sulfate synthesis compared with unwounded skin. Furthermore, glycosaminoglycans from collagen gel culture activated keratinocyte growth factor, whereas glycosaminoglycans from monolayer culture lacked this ability. These findings suggest that regulation of dermatan sulfate and dermatan sulfate proteoglycan is dependent on extracellular matrix architecture. The ability of collagen gel culture to mimic better the in vivo dermal environment may be due in part to this influence on dermatan sulfate and dermatan sulfate proteoglycan synthesis.	Univ Calif San Diego, Div Dermatol, San Diego, CA 92161 USA; Vet Affairs San Diego Healthcare Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Gallo, RL (corresponding author), Mail Code 9111B,3350 La Jolla Village Dr, San Diego, CA 92161 USA.	rgallo@vapop.ucsd.edu	Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861	NATIONAL CANCER INSTITUTE [T32CA081211] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052453, R37AI052453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045676] Funding Source: NIH RePORTER; NCI NIH HHS [1T32 CA81211] Funding Source: Medline; NHLBI NIH HHS [HL-57345, HL7261] Funding Source: Medline; NIAID NIH HHS [AI-52453] Funding Source: Medline; NIAMS NIH HHS [AR-45676] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Berman B, 1999, J BIOL CHEM, V274, P36132, DOI 10.1074/jbc.274.51.36132; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CHOI HU, 1989, J BIOL CHEM, V264, P2876; Cukierman E, 2002, CURR OPIN CELL BIOL, V14, P633, DOI 10.1016/S0955-0674(02)00364-2; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Demoor-Fossard M, 1998, BBA-GENE STRUCT EXPR, V1398, P179, DOI 10.1016/S0167-4781(98)00044-X; Di Carlo V, 1999, THROMB HAEMOSTASIS, V82, P30, DOI 10.1055/s-0037-1614625; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; Fernandez JA, 1999, THROMB HAEMOSTASIS, V82, P1462; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Kuwaba K, 2002, J DERMATOL SCI, V29, P185, DOI 10.1016/S0923-1811(02)00023-3; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALI M, 1993, J BIOL CHEM, V268, P24215; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; Masuda T, 2004, MOL CELL NEUROSCI, V25, P217, DOI 10.1016/j.mcn.2003.10.005; Moulin V, 1996, BURNS, V22, P359, DOI 10.1016/0305-4179(95)00167-0; Olsson U, 2001, DIABETES, V50, P2126, DOI 10.2337/diabetes.50.9.2126; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Penc SF, 1999, J CLIN INVEST, V103, P1329, DOI 10.1172/JCI4742; PIERCE GF, 1994, J EXP MED, V179, P831, DOI 10.1084/jem.179.3.831; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; ROMARIS M, 1995, BIOCHEM J, V310, P73, DOI 10.1042/bj3100073; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sakai S, 2002, ANAL BIOCHEM, V302, P169, DOI 10.1006/abio.2001.5545; SCHMIDT G, 1987, J CELL BIOL, V104, P1683, DOI 10.1083/jcb.104.6.1683; Senoo H, 1996, CELL BIOL INT, V20, P501, DOI 10.1006/cbir.1996.0065; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; Trowbridge JM, 2002, GLYCOBIOLOGY, V12, p117R, DOI 10.1093/glycob/cwf066; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Wong WR, 2001, J FORMOS MED ASSOC, V100, P377; Yoneda A, 2003, MATRIX BIOL, V22, P25, DOI 10.1016/S0945-053X(03)00010-6	46	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48640	48646		10.1074/jbc.M407241200	http://dx.doi.org/10.1074/jbc.M407241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347686	hybrid			2022-12-25	WOS:000225098100020
J	Motz, C; Hornung, T; Kersten, M; McLachlin, DT; Dunn, SD; Wise, JG; Vogel, PD				Motz, C; Hornung, T; Kersten, M; McLachlin, DT; Dunn, SD; Wise, JG; Vogel, PD			The subunit b dimer of the FoF1-ATP synthase interaction with F-1-ATPase as deduced by site-specific spin-labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; NUCLEOTIDE-BINDING-SITES; 2ND STALK; DELTA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; CRYSTAL-STRUCTURE; EPSILON-SUBUNIT; CATALYTIC SITES; RESONANCE; DOMAIN	We have used site-specific spin-labeling of single cysteine mutations within a water-soluble mutant of subunit b of the ATP synthase and employed electron spin resonance (ESR) spectroscopy to obtain information about the binding interactions of the b dimer with F-1-ATPase. Interaction of b(2) with a delta-depleted F-1 (F-1-delta) was also studied. The cysteine mutations used for spin-labeling were distributed throughout the cytosolic domain of the b subunit. In addition, each position between residues 101 and 114 of b was individually mutated to cysteine. All mutants were modified with a cysteine-reactive spin label. The room temperature ESR spectra of spin-labeled b(2) in the presence of F-1 or F-1-delta when compared with the spectra of free b(2) indicate a tight binding interaction between b(2) and F-1. The data suggest that b(2) packs tightly to F1 between residues 80 and the C terminus but that there are segments of b2 within that region where packing interactions are quite loose. Two-dimensional gel electrophoresis confirmed binding of the modified b mutants to F-1-ATPase as well as to F-1-delta. Subsequent addition of delta to F-1-delta.b(2) complex resulted in changes in the ESR spectra, indicating different binding interactions of b to F-1 in the presence or absence of delta. The data also suggest that the reconstitution of the ATP synthase is not ordered with respect to these subunits. Additional spectral components observed in b preparations that were spin-labeled between amino acid position 101 and 114 are indicative of either two populations of b subunits with different packing interactions or to helical bending within this region.	So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA; Univ Kaiserslautern, Fachbereich Chem, D-67663 Kaiserslautern, Germany; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Southern Methodist University; University of Kaiserslautern; Western University (University of Western Ontario)	Vogel, PD (corresponding author), So Methodist Univ, Dept Biol Sci, 6501 Airline Dr, Dallas, TX 75275 USA.	pvogel@mail.smu.edu	Dunn, Stanley/D-3418-2013	Wise, John/0000-0001-5398-8794; Vogel, Pia/0000-0002-8135-4649				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; Angevine CM, 2003, J BIOL CHEM, V278, P6066, DOI 10.1074/jbc.M210199200; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgard S, 2003, CELL BIOCHEM BIOPHYS, V39, P175, DOI 10.1385/CBB:39:3:175; BURGARD S, 1994, J BIOL CHEM, V269, P17815; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; COX GB, 1978, J BACTERIOL, V133, P287, DOI 10.1128/JB.133.1.287-292.1978; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Diez M, 2004, BIOCHEMISTRY-US, V43, P1054, DOI 10.1021/bi0357098; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; FEIX JB, 1998, BIO MAGN RE, V14, P251; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Haller M, 1997, J BIOL CHEM, V272, P30103, DOI 10.1074/jbc.272.48.30103; Junge W, 1999, P NATL ACAD SCI USA, V96, P4735, DOI 10.1073/pnas.96.9.4735; Kersten MV, 2000, BIOCHEMISTRY-US, V39, P3856, DOI 10.1021/bi992699v; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Losel RM, 1997, BIOCHEMISTRY-US, V36, P1188, DOI 10.1021/bi9614601; Losel RM, 1996, SPECTROCHIM ACTA A, V52, P73, DOI 10.1016/0584-8539(95)01549-3; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 1997, J BIOL CHEM, V272, P21233, DOI 10.1074/jbc.272.34.21233; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; Neuhofen S, 1996, EUR J BIOCHEM, V240, P78, DOI 10.1111/j.1432-1033.1996.0078h.x; Ogilvie I, 1998, ACTA PHYSIOL SCAND, V163, P169; Panse VG, 2001, J BIOL CHEM, V276, P33681, DOI 10.1074/jbc.M104466200; Panse VG, 2000, J BIOL CHEM, V275, P18698, DOI 10.1074/jbc.275.25.18698; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Revington M, 2002, PROTEIN SCI, V11, P1227, DOI 10.1110/ps.3200102; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Scheibel T, 1997, J BIOL CHEM, V272, P18608, DOI 10.1074/jbc.272.30.18608; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SMITH JB, 1975, J SUPRAMOL STR CELL, V3, P248, DOI 10.1002/jss.400030307; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; Stalz WD, 2003, J BIOL CHEM, V278, P27068, DOI 10.1074/jbc.M302027200; STERNWEIS PC, 1977, BIOCHEMISTRY-US, V16, P4020, DOI 10.1021/bi00637a013; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; TROMMER WE, 1992, BIOACTIVE SPIN LABEL, P405; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; VOGEL PD, 1992, J BIOL CHEM, V267, P11982; Vogel PD, 2000, J BIOENERG BIOMEMBR, V32, P413, DOI 10.1023/A:1005536305526; VOGELCLAUDE P, 1988, FEBS LETT, V227, P107, DOI 10.1016/0014-5793(88)80878-0; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2004, J BIOL CHEM, V279, P11253, DOI 10.1074/jbc.M312576200; Wilkens S, 1997, NAT STRUCT BIOL, V4, P198, DOI 10.1038/nsb0397-198; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WISE JG, 1990, J BIOL CHEM, V265, P10403; WISE JG, 1983, BIOCHEM J, V215, P343, DOI 10.1042/bj2150343; XU YH, 1983, INT J BIOL MACROMOL, V5, P154, DOI 10.1016/0141-8130(83)90030-2; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zhang D, 2003, J BIOL CHEM, V278, P12319, DOI 10.1074/jbc.M212413200; Zhang D, 2003, BIOCHEMISTRY-US, V42, P331, DOI 10.1021/bi026649t	66	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49074	49081		10.1074/jbc.M404543200	http://dx.doi.org/10.1074/jbc.M404543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339903	hybrid			2022-12-25	WOS:000225098100071
J	Shao, E; Forgac, M				Shao, E; Forgac, M			Involvement of the nonhomologous region of subunit A of the yeast V-ATPase in coupling and in vivo dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; 3-DIMENSIONAL STRUCTURE; LUMINAL ACIDIFICATION; CROSS-LINKING; MEMBRANES; GENE; TRIPHOSPHATASE; LOCALIZATION; PURIFICATION	The catalytic nucleotide binding subunit ( subunit A) of the vacuolar proton-translocating ATPase ( or V-ATPase) is homologous to the beta-subunit of the F-ATPase but contains a 90-amino acid insert not present in the beta-subunit, termed the nonhomologous region. We previously demonstrated that mutations in this region lead to changes in coupling of proton transport and ATPase activity and to inhibition of in vivo dissociation of the V-ATPase complex, an important regulatory mechanism ( Shao, E., Nishi T., Kawasaki- Nishi, S., and Forgac, M. (2003) J. Biol. Chem. 278, 12985 - 12991). Measurement of the ATP dependence of coupling for the wild type and mutant proteins demonstrates that the coupling differences are observed at ATP concentrations up to 1 mM. A decrease in coupling efficiency is observed at higher ATP concentrations for the wild type and mutant V-ATPases. Immunoprecipitation of an epitope-tagged nonhomologous region from cell lysates indicates that this region is able to bind to the integral V-0 domain in the absence of the remainder of the A subunit, an interaction confirmed by immunoprecipitation of V-0. Interaction between the nonhomologous region and V-0 is reduced upon incubation of cells in the absence of glucose, suggesting that the nonhomologous region may act as a trigger to activate in vivo dissociation. Immunoprecipitation suggests that the epitope tag on the nonhomologous region becomes less accessible upon glucose withdrawal, possibly due to binding to another cellular target. In vivo dissociation of the V-ATPase in response to glucose removal is also blocked by chloroquine, a weak base that neutralizes the acidic pH of the vacuole. The results suggest that the dependence of in vivo dissociation of the V-ATPase on catalytic activity may be due to neutralization of the yeast vacuole, which in turn blocks glucose-dependent dissociation.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA	Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Physiol, 136 Harrison Ave, Boston, MA 02111 USA.	michael.forgac@tufts.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34928] Funding Source: Medline; NIGMS NIH HHS [GM34478, R37 GM034478, R01 GM034478] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; Bowman EJ, 2000, J EXP BIOL, V203, P97; Brown D, 2000, J EXP BIOL, V203, P137; Canonaco F, 2002, J BIOL CHEM, V277, P31303, DOI 10.1074/jbc.M204052200; Capaldi RA, 2000, J EXP BIOL, V203, P29; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Emerson LR, 2002, ANTIMICROB AGENTS CH, V46, P787, DOI 10.1128/AAC.46.3.787-796.2002; FENG Y, 1992, J BIOL CHEM, V267, P5817; Fillingame RH, 2000, J EXP BIOL, V203, P9; FORGAC M, 1983, P NATL ACAD SCI-BIOL, V80, P1300, DOI 10.1073/pnas.80.5.1300; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Futai M, 2000, BBA-BIOENERGETICS, V1458, P276, DOI 10.1016/S0005-2728(00)00080-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graham LA, 2000, J EXP BIOL, V203, P61; HIRATA R, 1990, J BIOL CHEM, V265, P6726; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ludwig J, 1998, J BIOL CHEM, V273, P10939, DOI 10.1074/jbc.273.18.10939; MacLeod KJ, 1999, J BIOL CHEM, V274, P32869, DOI 10.1074/jbc.274.46.32869; Merzendorfer H, 1999, J BIOL CHEM, V274, P17372, DOI 10.1074/jbc.274.24.17372; Nanda A, 1996, J BIOL CHEM, V271, P15963, DOI 10.1074/jbc.271.27.15963; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; Nelson N, 2000, J EXP BIOL, V203, P89; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sambade M, 2004, J BIOL CHEM, V279, P17361, DOI 10.1074/jbc.M314104200; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Shao E, 2003, J BIOL CHEM, V278, P12985, DOI 10.1074/jbc.M212096200; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; Tomashek JJ, 1997, J BIOL CHEM, V272, P16618, DOI 10.1074/jbc.272.26.16618; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; Vasilyeva E, 2000, J BIOL CHEM, V275, P255, DOI 10.1074/jbc.275.1.255; Weber J, 2000, BBA-BIOENERGETICS, V1458, P300, DOI 10.1016/S0005-2728(00)00082-7; Wieczorek H, 2000, J EXP BIOL, V203, P127; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 2004, J BIOL CHEM, V279, P41942, DOI 10.1074/jbc.M407821200; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; Zhang ZY, 2003, J BIOL CHEM, V278, P47299, DOI 10.1074/jbc.M309445200; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	60	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48663	48670		10.1074/jbc.M408278200	http://dx.doi.org/10.1074/jbc.M408278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355963	hybrid			2022-12-25	WOS:000225098100023
J	Tellinghuisen, TL; Marcotrigiano, J; Gorbalenya, AE; Rice, CM				Tellinghuisen, TL; Marcotrigiano, J; Gorbalenya, AE; Rice, CM			The NS5A protein of hepatitis C virus is a zinc metalloprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL 5A PROTEIN; MAJOR PHOSPHORYLATION SITE; RNA REPLICATION; INTERFERON RESISTANCE; CELL-CULTURE; MOLECULAR-MECHANISMS; MULTIPLE ALIGNMENT; KINASE; PKR; IDENTIFICATION	The NS5A protein of hepatitis C virus is believed to be an integral part of the viral replicase. Despite extensive investigation, the role of this protein remains elusive. Only limited biochemical characterization of NS5A has been performed, with most research to date involving the myriad of host proteins and signaling cascades that interact with NS5A. The need for better characterization of NS5A is paramount for elucidating the role of this protein in the virus life cycle. Examination of NS5A using bioinformatics tools suggested the protein consisted of three domains and contained an unconventional zinc binding motif within the N-terminal domain. We have developed a method to produce NS5A and performed limited proteolysis to confirm the domain organization model. The zinc content of purified NS5A and the N-terminal domain of NS5A was determined, and each of these proteins was found to coordinate one zinc atom per protein. The predicted zinc binding motif consists of four cysteine residues, conserved among the Hepacivirus and Pestivirus genera, fitting the formula of CX17CXCX20C. Mutation of any of the four cysteine components of this motif reduced NS5A zinc coordination and led to a lethal phenotype for HCV RNA replication, whereas mutation of other potential metal coordination residues in the N-terminal domain of NS5A, but outside the zinc binding motif, had little effect on zinc binding and, aside from one exception, were tolerated for replication. Collectively, these results indicate that NS5A is a zinc metalloprotein and that zinc coordination is likely required for NS5A function in the hepatitis C replicase.	Rockefeller Univ, Ctr Study Hepatitis C, Lab Virol & Infect Dis, New York, NY 10021 USA; Leiden Univ, Med Ctr, Ctr Infect Dis, Dept Med Microbiol, NL-2300 RC Leiden, Netherlands	Rockefeller University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Rice, CM (corresponding author), Rockefeller Univ, Ctr Study Hepatitis C, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA.	ricec@rockefeller.edu	Gorbalenya, Alexander E/J-4818-2012; Marcotrigiano, Joseph/K-6697-2016	Gorbalenya, Alexander E/0000-0002-4967-7341; Marcotrigiano, Joseph/0000-0003-0346-3353	NATIONAL CANCER INSTITUTE [R01CA057973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI051820] Funding Source: NIH RePORTER; NCI NIH HHS [5 R01 CA57973-12] Funding Source: Medline; NIAID NIH HHS [5 F32 AI51820-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; BERG JM, 1990, J BIOL CHEM, V265, P6513; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Chung YL, 2003, INT J CANCER, V107, P65, DOI 10.1002/ijc.11303; Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002; Elazar M, 2003, J VIROL, V77, P6055, DOI 10.1128/JVI.77.10.6055-6061.2003; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2003, VIROLOGY, V306, P51, DOI 10.1016/S0042-6822(02)00029-6; Gosert R, 2003, J VIROL, V77, P5487, DOI 10.1128/JVI.77.9.5487-5492.2003; GRAKOUI A, 1993, J VIROL, V67, P2832, DOI 10.1128/JVI.67.5.2832-2843.1993; GRAKOUI A, 1993, P NATL ACAD SCI USA, V90, P10583, DOI 10.1073/pnas.90.22.10583; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; HENIKOFF S, 1994, J MOL BIOL, V243, P574, DOI 10.1016/0022-2836(94)90032-9; Hepatitis C, 1997, WKLY EPIDEMIOL REC, V72, P341; Herold J, 1999, J BIOL CHEM, V274, P14918, DOI 10.1074/jbc.274.21.14918; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Houshmand H, 2003, BIOCHEM BIOPH RES CO, V309, P695, DOI 10.1016/j.bbrc.2003.08.054; Huang LY, 2004, PROTEIN EXPRES PURIF, V37, P144, DOI 10.1016/j.pep.2004.05.005; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; Katze MG, 2000, VIROLOGY, V278, P501, DOI 10.1006/viro.2000.0662; Kim J, 1999, BIOCHEM BIOPH RES CO, V257, P777, DOI 10.1006/bbrc.1999.0460; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 2003, J VIROL, V77, P3007, DOI 10.1128/JVI.77.5.3007-3019.2003; Macdonald A, 2004, J GEN VIROL, V85, P721, DOI 10.1099/vir.0.19691-0; Moradpour D, 2004, J VIROL, V78, P7400, DOI 10.1128/JVI.78.14.7400-7409.2004; Nicholas K.B., 1997, EMBNEW NEWS, V4, P1; Pang PS, 2002, EMBO J, V21, P1168, DOI 10.1093/emboj/21.5.1168; Pawlotsky JM, 1998, J VIROL, V72, P2795, DOI 10.1128/JVI.72.4.2795-2805.1998; Pawlotsky JM, 1999, J VIRAL HEPATITIS, V6, P47, DOI 10.1046/j.1365-2893.1999.00004.x; Penin F, 2004, HEPATOLOGY, V39, P5, DOI 10.1002/hep.20032; Reed KE, 1999, J BIOL CHEM, V274, P28011, DOI 10.1074/jbc.274.39.28011; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; Stempniak M, 1997, J VIROL, V71, P2881, DOI 10.1128/JVI.71.4.2881-2886.1997; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; VARAKLIOTI A, 2002, J BIOL CHEM, V7, P7; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Zech B, 2003, J GEN VIROL, V84, P555, DOI 10.1099/vir.0.18801-0	63	265	280	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48576	48587		10.1074/jbc.M407787200	http://dx.doi.org/10.1074/jbc.M407787200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339921	hybrid			2022-12-25	WOS:000225098100013
J	Bi, XN; Baudry, M; Liu, JH; Yao, YQ; Fu, L; Brucher, F; Lynch, G				Bi, XN; Baudry, M; Liu, JH; Yao, YQ; Fu, L; Brucher, F; Lynch, G			Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; LENS EPITHELIAL-CELLS; ALZHEIMERS-DISEASE; NITRIC-OXIDE; RHO-GTPASE; CYTOSKELETAL REORGANIZATION; KINASE PATHWAYS; STATIN THERAPY; IN-VITRO; CHOLESTEROL	Inflammatory responses involving microglia, the resident macrophages of the brain, are thought to contribute importantly to the progression of Alzheimer's disease ( AD) and possibly other neurodegenerative disorders. The present study tested whether the mevalonate-isoprenoid biosynthesis pathway, which affects inflammation in many types of tissues, tonically regulates microglial activation. This question takes on added significance given the potential use of statins, drugs that block the rate-limiting step (3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase)) in mevalonate and cholesterol synthesis, in AD treatment. Both mevastatin and simvastatin caused a concentration- and time-dependent activation of microglia in cultured rat hippocampal slices. This response consisted of a transformation of the cells from a typical resting configuration to an amoeboid, macrophage-like morphology, increased expression of a macrophage antigen, and up-regulation of the cytokine tumor necrosis factor-alpha. Evidence for proliferation was also obtained. Statin-induced microglial changes were blocked by mevalonate but not by cholesterol, indicating that they were probably due to suppression of isoprenoid synthesis. In accord with this, the statin effects were absent in slices co-incubated with geranylgeranyl pyrophosphate, a mevalonate product that provides for the prenylation of Rho GTPases. Finally, PD98089, a compound that blocks activation of extracellularly regulated kinases1/2, suppressed statin-induced up-regulation of tumor necrosis factor-alpha but had little effect on microglial transformation. These results suggest that 1) the mevalonate-isoprenoid pathway is involved in regulating microglial morphology and in controlling expression of certain cytokines and 2) statins have the potential for enhancing a component of AD with uncertain relationships to other features of the disease.	Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92617 USA; Univ So Calif, Neurobiol Program, Los Angeles, CA 90089 USA	University of California System; University of California Irvine; University of Southern California	Bi, XN (corresponding author), Univ Calif Irvine, Dept Psychiat & Human Behav, 101 Theory Dr,250, Irvine, CA 92617 USA.	xbi@uci.edu			NIA NIH HHS [AG-00538] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG000538] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Aznar S, 2004, CANCER LETT, V206, P181, DOI 10.1016/j.canlet.2003.08.035; Bednarski E, 1997, J NEUROSCI, V17, P4006; Begum N, 2002, DIABETES, V51, P2256, DOI 10.2337/diabetes.51.7.2256; Bi X, 2002, NEUROSCIENCE, V112, P827, DOI 10.1016/S0306-4522(02)00132-X; BI X, 2001, SOC NEUR ABSTR, V27; Bi XN, 2001, P NATL ACAD SCI USA, V98, P8832, DOI 10.1073/pnas.151253098; Bi XN, 2000, METH MOL B, V144, P203; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Bollen ELEM, 2001, ARCH NEUROL-CHICAGO, V58, P1023, DOI 10.1001/archneur.58.6.1023; Brazil MI, 2000, J BIOL CHEM, V275, P16941, DOI 10.1074/jbc.M000937200; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Corsini A, 1999, PHARMACOL THERAPEUT, V84, P413, DOI 10.1016/S0163-7258(99)00045-5; Crisby M, 2002, ALZ DIS ASSOC DIS, V16, P131, DOI 10.1097/00002093-200207000-00001; Eberlein M, 2001, BRIT J PHARMACOL, V133, P1172, DOI 10.1038/sj.bjp.0704173; Finch Caleb E., 2002, P275; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; Hoozemans JJM, 2003, CURR DRUG TARGETS, V4, P461, DOI 10.2174/1389450033490902; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; Huang KC, 2003, J BIOMED SCI, V10, P396, DOI 10.1159/000071159; Huh Y, 2003, NEUROSCI LETT, V349, P63, DOI 10.1016/S0304-3940(03)00743-2; Ikeda U, 2001, J CARDIOVASC PHARM, V38, P69, DOI 10.1097/00005344-200107000-00008; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KATO H, 1995, BRAIN RES, V694, P85, DOI 10.1016/0006-8993(95)00769-M; Kiener PA, 2001, INT IMMUNOPHARMACOL, V1, P105, DOI 10.1016/S0162-3109(00)00272-1; Kusama T, 2003, INT J ONCOL, V23, P1173; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lin YK, 1996, PLANT CELL, V8, P293, DOI 10.1105/tpc.8.2.293; Maddala R, 2003, MOL VIS, V9, P329; Maddala RL, 2001, INVEST OPHTH VIS SCI, V42, P2610; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Meske V, 2003, EUR J NEUROSCI, V17, P93, DOI 10.1046/j.1460-9568.2003.02433.x; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Monick MM, 2003, J IMMUNOL, V171, P2625, DOI 10.4049/jimmunol.171.5.2625; Morgan Dave, 2003, Expert Rev Vaccines, V2, P53, DOI 10.1586/14760584.2.1.53; Nakano K, 2003, GENES CELLS, V8, P357, DOI 10.1046/j.1365-2443.2003.00639.x; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Pasinetti GM, 2002, J ALZHEIMERS DIS, V4, P435, DOI 10.3233/JAD-2002-4510; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; PRINCE M, 1994, NEUROLOGY, V44, P97; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Rockwood K, 2002, ARCH NEUROL-CHICAGO, V59, P223, DOI 10.1001/archneur.59.2.223; Rul W, 2002, ANN NY ACAD SCI, V973, P145, DOI 10.1111/j.1749-6632.2002.tb04624.x; Schenk DB, 2002, NEUROBIOL AGING, V23, P677, DOI 10.1016/S0197-4580(02)00034-9; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Stuve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1; Tafazoli F, 2003, INFECT IMMUN, V71, P872, DOI 10.1128/IAI.71.2.872-881.2003; Thorpe JL, 2004, DEV CELL, V6, P295, DOI 10.1016/S1534-5807(04)00032-2; Urmoneit B, 1998, PROSTAG OTH LIPID M, V55, P331, DOI 10.1016/S0090-6980(98)00032-X; van de Donk NWCJ, 2003, CLIN CANCER RES, V9, P5735; van de Donk NWCJ, 2003, BLOOD, V102, P3354, DOI 10.1182/blood-2003-03-0970; Wagstaff LR, 2003, PHARMACOTHERAPY, V23, P871, DOI 10.1592/phco.23.7.871.32720; Weitz-Schmidt G, 2002, TRENDS PHARMACOL SCI, V23, P482, DOI 10.1016/S0165-6147(02)02077-1; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Woods AG, 1999, NEUROSCIENCE, V91, P1277, DOI 10.1016/S0306-4522(98)00685-X; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zeng PY, 2003, ONCOGENE, V22, P1124, DOI 10.1038/sj.onc.1206181	66	55	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48238	48245		10.1074/jbc.M405442200	http://dx.doi.org/10.1074/jbc.M405442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364922	hybrid			2022-12-25	WOS:000224957000099
J	Jang, GM; Leong, LEC; Hoang, LT; Wang, PH; Gutman, GA; Semler, BL				Jang, GM; Leong, LEC; Hoang, LT; Wang, PH; Gutman, GA; Semler, BL			Structurally distinct elements mediate internal ribosome entry within the 5 '-noncoding region of a voltage-gated potassium channel mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; SARCOMA-ASSOCIATED HERPESVIRUS; 5' NONCODING REGION; OUTWARD K+ CURRENT; HEPATITIS-A VIRUS; C-MYC; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSLATION INITIATION; ALTERNATIVE TRANSLATION; FUNCTIONAL EXPRESSION	The similar to1.2-kb 5'-noncoding region (5'-NCR) of mRNA species encoding mouse Kv1.4, a member of the Shaker-related subfamily of voltage-gated potassium channels, was shown to mediate internal ribosome entry in cells derived from brain, heart, and skeletal muscle, tissues known to express Kv1.4 mRNA species. We also show that the upstream similar to1.0 kb and the downstream similar to0.2 kb of the Kv1.4 5'-NCR independently mediated internal ribosome entry; however, separately, these sequences were less efficient in mediating internal ribosome entry than when together in the complete ( and contiguous) 5'-NCR. Using enzymatic structure probing, the 3'-most similar to0.2 kb was predicted to form three distinct stem-loop structures (stem-loops X, Y, and Z) and two defined single-stranded regions (loops Psi and Omega) in the presence and absence of the upstream similar to1.0 kb. Although the systematic deletion of sequences within the 3'-most similar to0.2 kb resulted in distinct changes in expression, enzymatic structure probing indicated that local RNA folding was not completely altered. Structure probing analysis strongly suggested an interaction between stem-loop X and a downstream polypyrimidine tract; however, opposing changes in activity were observed when sequences within these two regions were independently deleted. Moreover, deletions correlating with positive as well as negative changes in expression altered RNase cleavage within stem-loop X, indicating that this structure may be an integral element. Therefore, these findings indicate that Kv1.4 expression is mediated through a complex interplay between many distinct RNA regions.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Med, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Semler, BL (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	blsemler@uci.edu	Semler, Bert/AAV-8795-2020	Semler, Bert/0000-0002-2424-5155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI026765, R01AI026765] Funding Source: NIH RePORTER; NIAID NIH HHS [AI26765, R01 AI026765] Funding Source: Medline; NIGMS NIH HHS [GM07311] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein J, 1997, J BIOL CHEM, V272, P9356; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; CHAPMAN NM, 1994, ARCH VIROL, V135, P115, DOI 10.1007/BF01309769; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chappell SA, 2001, J BIOL CHEM, V276, P36917, DOI 10.1074/jbc.M106008200; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; COMER MB, 1994, AM J PHYSIOL-HEART C, V267, pH1383, DOI 10.1152/ajpheart.1994.267.4.H1383; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Grentzmann G, 1998, RNA, V4, P479; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; GUTTRIDGE DC, 1993, J BIOL CHEM, V268, P18966; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Huez I, 2001, MOL ENDOCRINOL, V15, P2197, DOI 10.1210/me.15.12.2197; Hunt SL, 1999, RNA, V5, P344, DOI 10.1017/S1355838299981414; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1992, CRIT REV BIOCHEM MOL, V27, P385, DOI 10.3109/10409239209082567; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; Levitan ES, 1998, J NEUROBIOL, V37, P60, DOI 10.1002/(SICI)1097-4695(199810)37:1<60::AID-NEU5>3.0.CO;2-6; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martens JR, 1999, TRENDS CARDIOVAS MED, V9, P253, DOI 10.1016/S1050-1738(00)00037-2; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Nabauer M, 1996, CIRCULATION, V93, P168, DOI 10.1161/01.CIR.93.1.168; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PO S, 1992, CIRC RES, V71, P732, DOI 10.1161/01.RES.71.3.732; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; STERN S, 1988, METHOD ENZYMOL, V164, P481; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Todd S, 1997, VIROLOGY, V229, P90, DOI 10.1006/viro.1996.8416; Todd S, 1996, NUCLEIC ACIDS RES, V24, P2133, DOI 10.1093/nar/24.11.2133; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516; Wang ZG, 1999, CIRC RES, V84, P551, DOI 10.1161/01.RES.84.5.551; WIMMER E, 1993, ANNU REV GENET, V27, P353, DOI 10.1146/annurev.ge.27.120193.002033; Wymore RS, 1996, J BIOL CHEM, V271, P15629, DOI 10.1074/jbc.271.26.15629; Yaman I, 2003, CELL, V113, P519, DOI 10.1016/S0092-8674(03)00345-3; Yang DC, 1997, VIROLOGY, V228, P63, DOI 10.1006/viro.1996.8366; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zuker M, 1999, ALGORITHMS THERMODYN, P11, DOI 10.1007/978-94-011-4485-8_2	67	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47419	47430		10.1074/jbc.M405885200	http://dx.doi.org/10.1074/jbc.M405885200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339906	hybrid			2022-12-25	WOS:000224957000003
J	Naoe, M; Ohwa, Y; Ishikawa, D; Ohshima, C; Nishikawa, S; Yamamoto, H; Endo, T				Naoe, M; Ohwa, Y; Ishikawa, D; Ohshima, C; Nishikawa, S; Yamamoto, H; Endo, T			Identification of Tim40 that mediates protein sorting to the mitochondrial intermembrane space	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; OUTER-MEMBRANE; CYTOCHROME-C; IMPORT; TRANSLOCATION; SUBUNIT; STRAINS; COMPLEX	Most mitochondrial proteins are synthesized in the cytosol, imported into mitochondria, and sorted to one of the four mitochondrial subcompartments. Here we identified a new inner membrane protein, Tim40, that mediates sorting of small Tim proteins to the intermembrane space. Tim40 is essential for yeast cell growth, and its function in vivo requires six conserved Cys residues but not anchoring of the protein to the inner membrane by its N-terminal hydrophobic segment. Depletion of Tim40 impairs the import of small Tim proteins into mitochondria both in vivo and in vitro. In wild-type mitochondria, Tim40 forms a translocation intermediate with small Tim proteins prior to their assembly in the intermembrane space in vitro. These results suggest the essential role of Tim40 in sorting/assembly of small Tim proteins.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	endo@biochem.chem.nagoya-u.ac.jp						Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Esaki M, 1999, P NATL ACAD SCI USA, V96, P11770, DOI 10.1073/pnas.96.21.11770; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Ishikawa D, 2004, J CELL BIOL, V166, P621, DOI 10.1083/jcb.200405138; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; Koehler CM, 2004, TRENDS BIOCHEM SCI, V29, P1, DOI 10.1016/j.tibs.2003.11.003; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Lutz T, 2003, EMBO J, V22, P4400, DOI 10.1093/emboj/cdg421; Marchler-Bauer A, 2003, NUCLEIC ACIDS RES, V31, P383, DOI 10.1093/nar/gkg087; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Rehling P, 2003, J MOL BIOL, V326, P639, DOI 10.1016/S0022-2836(02)01440-7; Rose M. D., 1990, METHODS YEAST GENOMI; SIKORSKI RS, 1989, GENETICS, V122, P19; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	23	173	179	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47815	47821		10.1074/jbc.M410272200	http://dx.doi.org/10.1074/jbc.M410272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364952	hybrid			2022-12-25	WOS:000224957000050
J	Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T				Kato, Y; Sasagawa, I; Kaneko, M; Osawa, M; Fujita, N; Tsuruo, T			Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors	ONCOGENE			English	Article						Aggrus; seminoma; embryonal carcinoma; germ cell tumor	EUROPEAN COUNTRIES; EXPRESSION; T1-ALPHA; CANCER; IDENTIFICATION; ANTIGENS; PROTEIN; BIRTH; RAT	Aggrus ( also known as T1alpha/podoplanin) is a membrane sialoglycoprotein whose function in tumors is unknown. We recently determined that Aggrus possessed the ability of inducing platelet aggregation and that its expression was frequently upregulated in colorectal tumors. Thus, Aggrus expression might be associated with tumor-induced platelet aggregation and tumor metastasis. Here we show, by means of cancer pro. ling array and real-time PCR, that aggrus mRNA expression is frequently upregulated in testicular germ cell tumors when compared with the surrounding normal tissue. Immunohistochemical staining revealed that Aggrus protein expression was detected in 10 of 11 seminomas (90.9%), but its expression was not observed in embryonal carcinomas (0/4; 0%). Specific markers for seminomas have not been reported, and Aggrus is a potential diagnostic marker for seminomas and may be associated with malignancies of the testis.	Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Yamagata Univ, Sch Med, Dept Expt & Forens Pathol, Yamagata 9909585, Japan; Yamagata Univ, Sch Med, Dept Urol, Yamagata 9909585, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Yamagata University; Yamagata University; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Lab Cell Growth & Regulat, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	ttsuruo@iam.u-tokyo.ac.jp	Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; K. Kaneko, Mika/0000-0002-4158-9208; Kato, Yukinari/0000-0001-5385-8201				ADAMI HO, 1994, INT J CANCER, V59, P33, DOI 10.1002/ijc.2910590108; Bergstrom R, 1996, J NATL CANCER I, V88, P727, DOI 10.1093/jnci/88.11.727; Cheville JC, 1999, MODERN PATHOL, V12, P974; DEJONG B, 1990, CANCER GENET CYTOGEN, V48, P143, DOI 10.1016/0165-4608(90)90115-Q; FOGEL M, 1990, DIFFERENTIATION, V45, P242, DOI 10.1111/j.1432-0436.1990.tb00478.x; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.0.CO;2-N; Kato Y, 2003, J BIOL CHEM, V278, P51599, DOI 10.1074/jbc.M309935200; Ma TH, 1998, AM J RESP CELL MOL, V19, P143, DOI 10.1165/ajrcmb.19.1.2953; MOLLER H, 1993, EUR UROL, V23, P8; Ramirez MI, 2003, DEV BIOL, V256, P61, DOI 10.1016/S0012-1606(02)00098-2; RICHIE JP, 2003, UROL ONCOL, V21, P91; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; WATANABE M, 1988, CANCER RES, V48, P6411; Wetterwald A, 1996, BONE, V18, P125, DOI 10.1016/8756-3282(95)00457-2; Williams MC, 1996, AM J RESP CELL MOL, V14, P577, DOI 10.1165/ajrcmb.14.6.8652186	16	100	137	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8552	8556		10.1038/sj.onc.1207869	http://dx.doi.org/10.1038/sj.onc.1207869			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361850				2022-12-25	WOS:000224870700016
J	Huang, SS; Leal, SM; Chen, CL; Liu, IH; Huang, JS				Huang, SS; Leal, SM; Chen, CL; Liu, IH; Huang, JS			Identification of insulin receptor substrate proteins as key molecules for the T beta R-V/LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells	FASEB JOURNAL			English	Article						IGFBP-3; (Q(3)A(4)Y(15)L(16)) IGF-I; serine-specific dephosphorylation; IRS-1; IRS-2	FACTOR-BETA RECEPTOR; FACTOR-BINDING PROTEIN-3; TGF-BETA; TYROSINE PHOSPHORYLATION; IRS PROTEINS; KINASE-ACTIVITY; DNA-SYNTHESIS; V RECEPTOR; FACTOR-I; TRANSDUCTION	The type V TGF-beta receptor (TbetaR-V) mediates IGF-independent growth inhibition by IGFBP-3 and mediates growth inhibition by TGF-beta (1) in concert with the other TGF-beta receptor types. TbetaR-V was recently found to be identical to LRP-1. Here we find that insulin and (Q(3)A(4)Y(15)L(16)) IGF-I (an IGF-I analog that has a low affinity for IGFBP-3) antagonize growth inhibition by IGFBP-3 in mink lung epithelial cells (Mv1Lu cells) stimulated by serum. In these cells, IGFBP-3 induces serine-specific dephosphorylation of IRS-1 and IRS-2. The IGFBP-3-induced dephosphorylation of IRS-2 is prevented by cotreatment of cells with insulin, (Q(3)A(4)Y(15)L(16)) IGF-I, or TbetaR-V/LRP-1 antagonists. The magnitude of the IRS-2 dephosphorylation induced by IGFBP-3 positively correlates with the degree of growth inhibition by IGFBP-3 in Mv1Lu cells and mutant cells derived from Mv1Lu cells. Stable transfection of murine 32D myeloid cells ( which lack endogenous IRS proteins and are insensitive to growth inhibition by IGFBP-3) with IRS-1 or IRS-2 cDNA confers sensitivity to growth inhibition by IGFBP-3; this IRS-mediated growth inhibition can be completely reversed by insulin in 32D cells stably expressing IRS-2 and the insulin receptor. These results suggest that IRS-1 and IRS-2 are key molecules for the TbetaRV/LRP-1-mediated growth inhibitory signaling cascade.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu			NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Bu GJ, 2001, INT REV CYTOL, V209, P79; Buckley J. S., 1995, SPE ADV TECH SER, V3, P53; CASCIERI MA, 1989, J CELL PHYSIOL, V139, P181, DOI 10.1002/jcp.1041390125; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CONOVER A, 1989, HORM METAB RES, V21, P59, DOI 10.1055/s-2007-1009151; Devi GR, 2001, GROWTH HORM IGF RES, V11, P231, DOI 10.1054/ghir.2001.0231; Dong F, 2002, J CELL PHYSIOL, V190, P63, DOI 10.1002/jcp.10034; Duan C, 2002, J ENDOCRINOL, V175, P41, DOI 10.1677/joe.0.1750041; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Gagnon AM, 1998, J CELL PHYSIOL, V175, P370, DOI 10.1002/(SICI)1097-4652(199806)175:3<370::AID-JCP15>3.0.CO;2-9; Gucev ZS, 1996, CANCER RES, V56, P1545; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Huang JS, 2002, FASEB J, V16, P1269, DOI 10.1096/fj.02-0103fje; Huang SS, 2004, FEBS LETT, V565, P117, DOI 10.1016/j.febslet.2004.03.082; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; JOUNG I, 1995, P NATL ACAD SCI USA, V92, P5778, DOI 10.1073/pnas.92.13.5778; Kelley KM, 1996, INT J BIOCHEM CELL B, V28, P619, DOI 10.1016/1357-2725(96)00005-2; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Kroder G, 1996, J CLIN INVEST, V97, P1471, DOI 10.1172/JCI118569; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; LEAL SM, 1999, THESIS ST LOUIS U ST; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Liu QJ, 1999, J BIOL CHEM, V274, P20002, DOI 10.1074/jbc.274.28.20002; LIU QJ, 1994, J BIOL CHEM, V269, P9221; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; McCluskey A, 2002, J MED CHEM, V45, P1151, DOI 10.1021/jm010066k; Monzavi R, 2002, BEST PRACT RES CL EN, V16, P433, DOI 10.1053/beem.2002.0212; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Oh Youngman, 1995, Progress in Growth Factor Research, V6, P503, DOI 10.1016/0955-2235(95)00025-9; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PERALDI P, 1996, J BIOL CHEM, V271, P13081; Qiao LY, 2002, J BIOL CHEM, V277, P26530, DOI 10.1074/jbc.M201494200; Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; Roehrich ME, 2003, J BIOL CHEM, V278, P18368, DOI 10.1074/jbc.M300102200; Sakaguchi N, 2003, NEUROSCI RES, V45, P219, DOI 10.1016/S0168-0102(02)00226-2; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Taipale J, 1996, J BIOL CHEM, V271, P4342; Tseng WF, 2004, FEBS LETT, V562, P71, DOI 10.1016/S0014-5793(04)00185-1; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J	61	26	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1719	+		10.1096/fj.04-1872fje	http://dx.doi.org/10.1096/fj.04-1872fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15371331				2022-12-25	WOS:000224243200025
J	Horke, S; Reumann, K; Schulze, C; Grosse, F; Heise, T				Horke, S; Reumann, K; Schulze, C; Grosse, F; Heise, T			The La motif and the RNA recognition motifs of human la autoantigen contribute individually to RNA recognition and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTS; SITE-MEDIATED TRANSLATION; SURFACE-PLASMON RESONANCE; PROTEIN MESSENGER-RNA; SS-B AUTOANTIGEN; IN-VITRO; NASCENT RNA; NUCLEOLAR LOCALIZATION; SMALL NUCLEAR; VIRUS-RNA	The human La autoantigen (hLa) protein is a predominantly nuclear phosphoprotein that contains three potential RNA binding domains referred to as the La motif and the (R) under bar NA (r) under bar ecognition (m) under bar otifs RRMs 1 and 2. With this report, we differentiated the contribution of its three RNA binding domains to RNA binding by combining in vitro and in vivo assays. Also, surface plasmon resonance technology was used to generate a model for the sequential contribution of the RNA binding domains to RNA binding. The results indicated that the La motif may contribute to specificity rather than affinity, whereas RRM1 is indispensable for association with pre-tRNA and hY1 RNA. Furthermore, RRM2 was not crucial for the interaction with various RNAs in vivo, although needed for full-affinity binding in vitro. Moreover, earlier studies suggest that RNA binding by hLa may direct its subcellular localization. As shown previously for RRM1, deletion of RNP2 sequence in RRM1 alters nucleolar distribution of hLa, not observed after deletion of the La motif. Here we discuss a model for precursor RNA binding based on a sequential association process mediated by RRM1 and the La motif.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Hamburg Hosp, Ctr Mol Neurobiol, D-20251 Hamburg, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany	Heinrich Pette Institute; University of Hamburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Heise, T (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Postfach 201652,Martinistr 52, D-20251 Hamburg, Germany.	heise@hpi.uni-hamburg.de	Schulze, Christian/AGJ-7744-2022	Schulze, Christian/0000-0001-9442-7141; Horke, Sven/0000-0003-1309-3923; Schulze, Christian/0000-0002-1442-1987				ALFANO C, 2004, NAT STRUCT MOL BIOL, V7, P1; Ali N, 1997, P NATL ACAD SCI USA, V94, P2249, DOI 10.1073/pnas.94.6.2249; ALSPAUGH MA, 1976, ARTHRITIS RHEUM-US, V19, P216, DOI 10.1002/art.1780190214; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; BABOONIAN C, 1989, CLIN EXP IMMUNOL, V78, P454; BACHMANN M, 1989, J GEN VIROL, V70, P881, DOI 10.1099/0022-1317-70-4-881; Bertrand E, 1998, GENE DEV, V12, P2463, DOI 10.1101/gad.12.16.2463; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; Chakshusmathi G, 2003, EMBO J, V22, P6562, DOI 10.1093/emboj/cdg625; CHANG YN, 1994, J VIROL, V68, P7008, DOI 10.1128/JVI.68.11.7008-7020.1994; CHANG YN, 1995, J VIROL, V69, P618, DOI 10.1128/JVI.69.1.618-619.1995; Crosio C, 2000, NUCLEIC ACIDS RES, V28, P2927, DOI 10.1093/nar/28.15.2927; Dong G, 2004, EMBO J, V23, P1000, DOI 10.1038/sj.emboj.7600115; Ford LP, 2001, RNA, V7, P1068, DOI 10.1017/S1355838201010159; Goodier JL, 1997, MOL CELL BIOL, V17, P5823, DOI 10.1128/MCB.17.10.5823; Heise T, 1999, J VIROL, V73, P5767, DOI 10.1128/JVI.73.7.5767-5776.1999; Horke S, 2004, J BIOL CHEM, V279, P26563, DOI 10.1074/jbc.M401017200; Horke S, 2002, J BIOL CHEM, V277, P34949, DOI 10.1074/jbc.M201911200; Intine RV, 2003, MOL CELL, V12, P1301, DOI 10.1016/S1097-2765(03)00429-5; Jacks A, 2003, STRUCTURE, V11, P833, DOI 10.1016/S0969-2126(03)00121-7; Jacobson MR, 1997, J CELL SCI, V110, P829; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Katsamba PS, 2002, METHODS, V26, P95, DOI 10.1016/S1046-2023(02)00012-9; Khaleghpour K, 2001, MOL CELL BIOL, V21, P5200, DOI 10.1128/MCB.21.15.5200-5213.2001; Kufel J, 2000, MOL CELL BIOL, V20, P5415, DOI 10.1128/MCB.20.15.5415-5424.2000; Kufel J, 2003, NUCLEIC ACIDS RES, V31, P6788, DOI 10.1093/nar/gkg904; Long KS, 2001, RNA, V7, P1589; MADORE SJ, 1984, J BIOL CHEM, V259, P1929; Maraia RJ, 2002, GENE EXPRESSION, V10, P41; Maraia RJ, 2001, MOL CELL BIOL, V21, P367, DOI 10.1128/MCB.21.2.367-379.2001; Maraia RJ, 2001, J CELL BIOL, V153, pF13, DOI 10.1083/jcb.153.4.F13; MATTIOLI M, 1974, ARTHRITIS RHEUM-US, V17, P421, DOI 10.1002/art.1780170413; McLaren RS, 1997, MOL CELL BIOL, V17, P3028, DOI 10.1128/MCB.17.6.3028; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; Nashimoto M, 2001, J MOL BIOL, V312, P975, DOI 10.1006/jmbi.2001.5026; Ohndorf UM, 2001, J BIOL CHEM, V276, P27188, DOI 10.1074/jbc.M102891200; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Raats JMH, 2003, EUR J CELL BIOL, V82, P131, DOI 10.1078/0171-9335-00304; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Rutjes SA, 1999, CELL DEATH DIFFER, V6, P976, DOI 10.1038/sj.cdd.4400571; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Spangberg K, 2001, J GEN VIROL, V82, P113, DOI 10.1099/0022-1317-82-1-113; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; Wolin SL, 2002, ANNU REV BIOCHEM, V71, P375, DOI 10.1146/annurev.biochem.71.090501.150003; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Xue DH, 2000, EMBO J, V19, P1650, DOI 10.1093/emboj/19.7.1650; Yoo CJ, 1997, CELL, V89, P393, DOI 10.1016/S0092-8674(00)80220-2	51	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50302	50309		10.1074/jbc.M407504200	http://dx.doi.org/10.1074/jbc.M407504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371415	hybrid			2022-12-25	WOS:000225229500093
J	Munoz-Espin, D; Mateu, MG; Villar, L; Marina, A; Salas, M; Meijer, WJJ				Munoz-Espin, D; Mateu, MG; Villar, L; Marina, A; Salas, M; Meijer, WJJ			Phage sigma 29 DNA replication organizer membrane protein p16.7 contains a coiled coil and a dimeric, homeodomain-related, functional domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; TERMINAL PROTEIN; CELL-MEMBRANE; SWISS-MODEL; DIMERIZATION; SPECIFICITY; STABILITY; COMPLEX; GENES; HELIX	The Bacillus subtilis phage phi29-encoded membrane protein p16.7 is one of the few proteins known to be involved in prokaryotic membrane-associated DNA replication. Protein p16.7 contains an N-terminal transmembrane domain responsible for membrane localization. A soluble variant lacking the N-terminal membrane anchor, p16.7A, forms dimers in solution, binds to DNA, and has affinity for the phi29 terminal protein. Here we show that the soluble N-terminal half of p16.7A can form a dimeric coiled coil. However, a second domain, located in the C-terminal half of the protein, has been characterized as being the main domain responsible for p16.7 dimerization. This 70-residue C-terminal domain, named p16.7C, also constitutes the functional part of the protein as it binds to DNA and terminal protein. Sequence alignments, secondary structure predictions, and spectroscopic analyses suggest that p16.7C is evolutionarily related to DNA binding homeodomains, present in many eukaryotic transcriptional regulator proteins. Based on the results, a structural model of p16.7 is presented.	Univ Autonoma Madrid, Inst Biol Mol Eladio Vinuela, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, Inst Biol Mol Eladio Vinuela, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	msalas@cbm.uam.es	Salas, Margarita/J-9873-2014; Mateu, Mauricio/ABF-2146-2021; Ramírez, Anabel Marina/ABG-7125-2021	Salas, Margarita/0000-0001-5939-3441; Mateu, Mauricio/0000-0002-2915-1529; Ramírez, Anabel Marina/0000-0003-2927-6396; Meijer, Wilfried/0000-0003-1842-0049	NIGMS NIH HHS [2R01 GM27242-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAVO A, 1994, GENE, V148, P107, DOI 10.1016/0378-1119(94)90242-9; Burglin Thomas R., 1994, P25; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Darling PJ, 2000, BIOCHEMISTRY-US, V39, P11500, DOI 10.1021/bi000935s; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; de Jong RN, 2002, EMBO J, V21, P725, DOI 10.1093/emboj/21.4.725; ENGEL M, 1991, BIOCHEMISTRY-US, V30, P3161, DOI 10.1021/bi00227a002; FIRSHEIN W, 1989, ANNU REV MICROBIOL, V43, P89, DOI 10.1146/annurev.micro.43.1.89; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; IVARIE RD, 1973, VIROLOGY, V52, P351, DOI 10.1016/0042-6822(73)90330-9; Kaufman T C, 1990, Adv Genet, V27, P309; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LaRonde-LeBlanc NA, 2003, GENE DEV, V17, P2060, DOI 10.1101/gad.1103303; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mateu MG, 2002, J MOL BIOL, V318, P519, DOI 10.1016/S0022-2836(02)00091-8; Meijer WJJ, 2001, MOL MICROBIOL, V39, P731, DOI 10.1046/j.1365-2958.2001.02260.x; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; MORENO F, 1974, VIROLOGY, V62, P1, DOI 10.1016/0042-6822(74)90298-0; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1996, DNA REPLICATION EUKA, P131; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Serna-Rico A, 2002, J BIOL CHEM, V277, P6733, DOI 10.1074/jbc.M109312200; Serna-Rico A, 2003, EMBO J, V22, P2297, DOI 10.1093/emboj/cdg221; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sueoka N, 1998, PROG NUCLEIC ACID RE, V59, P35; Valdes R Jr, 1979, Methods Enzymol, V61, P125; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZABALLOS A, 1989, GENE, V83, P187, DOI 10.1016/0378-1119(89)90104-2	37	9	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50437	50445		10.1074/jbc.M403297200	http://dx.doi.org/10.1074/jbc.M403297200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371435	hybrid			2022-12-25	WOS:000225229500109
J	Xu, ZB; Chaudhary, D; Olland, S; Wolfrom, S; Czerwinski, R; Malakian, K; Lin, L; Stahl, ML; McCarthy, DJ; Benander, C; Fitz, L; Greco, R; Somers, WS; Mosyak, L				Xu, ZB; Chaudhary, D; Olland, S; Wolfrom, S; Czerwinski, R; Malakian, K; Lin, L; Stahl, ML; McCarthy, DJ; Benander, C; Fitz, L; Greco, R; Somers, WS; Mosyak, L			Catalytic domain crystal structure of protein kinase C-theta (PKC theta)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT; PHOSPHORYLATION; ACTIVATION; DYNAMICS; COMPLEX; MOTIF; INHIBITORS; PDK1	A member of the novel protein kinase C (PKC) subfamily, PKCtheta, is an essential component of the T cell synapse and is required for optimal T cell activation and interleukin-2 production. Selective involvement of PKCtheta in TCR signaling makes this enzyme an attractive therapeutic target in T cell-mediated disease processes. In this report we describe the crystal structure of the catalytic domain of PKCtheta at 2.0-resolution. Human recombinant PKCtheta kinase domain was expressed in bacteria as catalytically active phosphorylated enzyme and co-crystallized with its subnanomolar, ATP site inhibitor staurosporine. The structure follows the classic bilobal kinase fold and shows the enzyme in its active conformation and phosphorylated state. Inhibitory interactions between conserved features of staurosporine and the ATP-binding cleft are accompanied by closing of the glycine-rich loop, which also maintains an inhibitory arrangement by blocking the phosphate recognition sub-site. The two major phosphorylation sites, Thr-538 in the activation loop and Ser-695 in the hydrophobic motif, are both occupied in the structure, playing key roles in stabilizing active conformation of the enzyme and indicative of PKCtheta autocatalytic phosphorylation and activation during bacterial expression. The PKCtheta-staurosporine complex represents the first kinase domain crystal structure of any PKC isotypes to be determined and as such should provide valuable insight into PKC specificity and into rational drug design strategies for PKCtheta selective leads.	Wyeth Ayerst Res, Dept Chem & Screening Sci, Cambridge, MA 02140 USA; Wyeth Ayerst Res, Inflammat Dept, Cambridge, MA 02140 USA	Pfizer; Pfizer	Somers, WS (corresponding author), Wyeth Ayerst Res, Dept Chem & Screening Sci, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	wsomers@wyeth.com; lmosyak@wyeth.com						Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altman A, 2003, IMMUNOL REV, V192, P53, DOI 10.1034/j.1600-065X.2003.00027.x; Arendt CW, 2002, CURR OPIN IMMUNOL, V14, P323, DOI 10.1016/S0952-7915(02)00346-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; Bauer B, 2000, EUR J IMMUNOL, V30, P3645, DOI 10.1002/1521-4141(200012)30:12<3645::AID-IMMU3645>3.0.CO;2-#; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Breitenlechner C, 2003, STRUCTURE, V11, P1595, DOI 10.1016/j.str.2003.11.002; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; DELANO WL, 2002, PYMOL MOL GRPAHCIS S; Diaz-Flores E, 2003, J BIOL CHEM, V278, P29208, DOI 10.1074/jbc.M303165200; Gassel M, 2003, J MOL BIOL, V329, P1021, DOI 10.1016/S0022-2836(03)00518-7; Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P, 10.1002/(SICI)1096-987X(199604)17:5/6<616::AID-JCC5>3.0.CO;2-X]; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Johnson DA, 2001, CHEM REV, V101, P2243, DOI 10.1021/cr000226k; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Liu Y, 2002, BIOCHEM J, V361, P255, DOI 10.1042/bj3610255; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Prade L, 1997, STRUCTURE, V5, P1627, DOI 10.1016/S0969-2126(97)00310-9; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; Villalba M, 2002, CURR CANCER DRUG TAR, V2, P125, DOI 10.2174/1568009023333908; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	41	122	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50401	50409		10.1074/jbc.M409216200	http://dx.doi.org/10.1074/jbc.M409216200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364937	hybrid			2022-12-25	WOS:000225229500105
J	Bhosale, P; Larson, AJ; Frederick, JM; Southwick, K; Thulin, CD; Bernstein, PS				Bhosale, P; Larson, AJ; Frederick, JM; Southwick, K; Thulin, CD; Bernstein, PS			Identification and characterization of a Pi isoform of glutathione S-transferase (GSTP1) as a zeaxanthin-binding protein in the macula of the human eye	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINA; CYTOPLASMIC MEMBRANE; IN-VITRO; CAROTENOIDS; ISOMERIZATION; DEGENERATION; XANTHOPHYLLS; PIGMENT; LUTEIN; LIVER	Uptake, metabolism, and stabilization of xanthophyll carotenoids in the retina are thought to be mediated by specific xanthophyll-binding proteins (XBPs). A membrane-associated XBP was purified from human macula using ion-exchange chromatography followed by gel-exclusion chromatography. Two-dimensional gel electrophoresis showed a prominent spot of 23 kDa and an isoelectric point of 5.7. Using mass spectral sequencing methods and the public NCBI database, it was identified as a Pi isoform of human glutathione S-transferase (GSTP1). Dietary (3R,3'R)-zeaxanthin displayed the highest affinity with an apparent K-d of 0.33 muM, followed by (3R,3'S-meso)-zeaxanthin with an apparent K-d of 0.52 muM. (3R,3'R,6'R)-Lutein did not display any high-affinity binding to GSTP1. Other human recombinant glutathione S-transferase (GST) proteins, GSTA1 and GSTM1, exhibited only low affinity binding of xanthophylls. (3R,3'S-meso)-Zeaxanthin, an optically inactive non-dietary xanthophyll carotenoid present in the human macula, exhibited a strong induced CD spectrum in association with human macular XBP that was nearly identical to the CD spectrum induced by GSTP1. Likewise, dietary (3R,3'R)-zeaxanthin displayed alterations in its CD spectrum in association with GSTP1 and XBP. Other mammalian xanthophyll carrier proteins such as tubulin, high-density lipoprotein, low-density lipoprotein, albumin, and beta-lactoglobulin did not bind zeaxanthins with high affinity, and they failed to induce or alter xanthophyll CD spectra to any significant extent. Immunocytochemistry with an antibody to GSTP1 on human macula sections showed highest labeling in the outer and inner plexiform layers. These results indicate that GSTP1 is a specific XBP in human macula that interacts with (3R,3'S-meso)-zeaxanthin and dietary (3R,3'R)-zeaxanthin in contrast to apparently weaker interactions with (3R,3'R,6'R)-lutein.	Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA	Utah System of Higher Education; University of Utah; Brigham Young University	Bernstein, PS (corresponding author), Univ Utah, Sch Med, Moran Eye Ctr, Dept Ophthalmol & Visual Sci, 50 N Med Dr, Salt Lake City, UT 84132 USA.	paul.bernstein@hsc.utah.edu			NATIONAL EYE INSTITUTE [R01EY008123, R01EY011600, R29EY011600] Funding Source: NIH RePORTER; NEI NIH HHS [EY-08123, EY-11600] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler A J, 1973, Methods Enzymol, V27, P675; AliOsman F, 1997, J BIOL CHEM, V272, P10004; Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167; Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9; Bernstein PS, 2001, EXP EYE RES, V72, P215, DOI 10.1006/exer.2000.0954; Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2; BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033; BUCHECKER R, 1995, CAROTENOIDS, P63; BULLERJAHN GS, 1986, J BACTERIOL, V167, P396, DOI 10.1128/jb.167.1.396-399.1986; Chen H, 1997, BIOCHEM J, V327, P721, DOI 10.1042/bj3270721; CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33; Crabtree DV, 2001, BIOORGAN MED CHEM, V9, P1967, DOI 10.1016/S0968-0896(01)00103-1; HABIG WH, 1974, P NATL ACAD SCI USA, V71, P3879, DOI 10.1073/pnas.71.10.3879; HJELMELAND LM, 1984, METHOD ENZYMOL, V104, P305; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; Juronen E, 2000, INVEST OPHTH VIS SCI, V41, P2262; Khachik F, 2002, INVEST OPHTH VIS SCI, V43, P3383; Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3; KROPF A, 1982, VISION RES, V22, P495, DOI 10.1016/0042-6989(82)90199-7; Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171; Lederer B, 2003, BBA-GEN SUBJECTS, V1621, P226, DOI 10.1016/S0304-4165(03)00073-4; Lo HW, 1997, J BIOL CHEM, V272, P32743, DOI 10.1074/jbc.272.52.32743; Lutnaes BF, 2001, CHIRALITY, V13, P224, DOI 10.1002/chir.1023; Marrs KA, 1996, ANNU REV PLANT PHYS, V47, P127, DOI 10.1146/annurev.arplant.47.1.127; Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; PFANDER H, 1992, METHOD ENZYMOL, V213, P3; Rao MN, 1997, J BIOL CHEM, V272, P24455, DOI 10.1074/jbc.272.39.24455; Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200; REDDY KJ, 1989, J BACTERIOL, V171, P3486, DOI 10.1128/jb.171.6.3486-3493.1989; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simonyi M, 2003, CHIRALITY, V15, P680, DOI 10.1002/chir.10282; SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268; SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674; Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276; Tabunoki H, 2002, J BIOL CHEM, V277, P32133, DOI 10.1074/jbc.M204507200; van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x; Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965; ZAGALSKY PF, 1995, ADV SPACE RES, V16, P91, DOI 10.1016/0273-1177(95)00276-K; Zhang HB, 2003, INVEST OPHTH VIS SCI, V44, P2858, DOI 10.1167/iovs.03-0072; Zsila F, 2002, BIOCHEM PHARMACOL, V64, P1651, DOI 10.1016/S0006-2952(02)01350-3; Zsila F, 2001, CHIRALITY, V13, P446, DOI 10.1002/chir.1060	45	203	213	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49447	49454		10.1074/jbc.M405334200	http://dx.doi.org/10.1074/jbc.M405334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355982	hybrid			2022-12-25	WOS:000225098100114
J	Chamberlain, MD; Berry, TR; Pastor, MC; Anderson, DH				Chamberlain, MD; Berry, TR; Pastor, MC; Anderson, DH			The p85 alpha subunit of phosphatidylinositol 3 '-kinase binds to and stimulates the GTPase activity of rab proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; 3-KINASE ACTIVITY; AUTOANTIGEN EEA1; P85 SUBUNIT; RECEPTOR; ACTIVATION; DOMAIN; INTERNALIZATION	Rab5 and Rab4 are small monomeric GTPases localized on early endosomes and function in vesicle fusion events. These Rab proteins regulate the endocytosis and recycling or degradation of activated receptor tyrosine kinases such as the platelet-derived growth factor receptor (PDGFR). The p85alpha subunit of phosphatidylinositol 3'-kinase contains a BH domain with sequence homology to GTPase activating proteins (GAPs), but has not previously been shown to possess GAP activity. In this report, we demonstrate that p85alpha has GAP activity toward Rab5, Rab4, Cdc42, Rac1 and to a lesser extent Rab6, with little GAP activity toward Rab11. Purified recombinant Rab5 and p85alpha can bind directly to each other and not surprisingly, the p85alpha-encoded GAP activity is present in the BH domain. Because p85alpha stays bound to the PDGFR during receptor endocytosis, p85alpha will also be localized to the same early endosomal compartment as Rab5 and Rab4. Taken together, the physical co-localization and the ability of p85alpha to preferentially stimulate the down-regulation of Rab5 and Rab4 GTPases suggests that p85alpha regulates how long Rab5 and Rab4 remain in their GTP-bound active state. Cells expressing BH domain mutants of p85 show a reduced rate of PDGFR degradation as compared with wild type p85 expressing cells. These cells also show sustained activation of the mitogen-activated protein kinase and Akt pathways. Thus, the p85alpha protein may play a role in the down-regulation of activated receptors through its temporal control of the GTPase cycles of Rab5 and Rab4.	Saskatchewan Canc Agcy, Hlth Res Div, Canc Res Unit, Saskatoon, SK S7N 4H4, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Dept Oncol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatchewan Canc Agcy, Hlth Res Div, Canc Res Unit, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	danderson@scf.sk.ca	Chamberlain, Michael/A-9107-2016; Chamberlain, Michael Dean/AAX-1670-2021	Chamberlain, Michael/0000-0003-1813-8545; Chamberlain, Michael Dean/0000-0003-1813-8545				Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Armstrong J, 2000, INT J BIOCHEM CELL B, V32, P303, DOI 10.1016/S1357-2725(99)00112-0; Barbieri MA, 1996, BIOCELL, V20, P331; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chiarugi P, 2002, J CELL SCI, V115, P2219; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Fang Y, 2002, BIOCHEM BIOPH RES CO, V290, P1267, DOI 10.1006/bbrc.2002.6347; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; HART MJ, 1994, J BIOL CHEM, V269, P62; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; King TR, 2000, J BIOL CHEM, V275, P36450, DOI 10.1074/jbc.M004720200; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Li GP, 1996, BIOCELL, V20, P325; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; Low BC, 1999, J BIOL CHEM, V274, P33123, DOI 10.1074/jbc.274.46.33123; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Musacchio A, 1996, P NATL ACAD SCI USA, V93, P14373, DOI 10.1073/pnas.93.25.14373; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; ROSENFELD ME, 1984, J CELL PHYSIOL, V121, P263, DOI 10.1002/jcp.1041210202; Rubino M, 2000, J BIOL CHEM, V275, P3745, DOI 10.1074/jbc.275.6.3745; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014; SELF AJ, 1995, METHOD ENZYMOL, V256, P67; Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Stenmark H, 2001, GENOME BIOL, V2; SUNG CK, 1994, J BIOL CHEM, V269, P12503; Szafer E, 2000, J BIOL CHEM, V275, P23615, DOI 10.1074/jbc.M003171200; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	45	85	88	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48607	48614		10.1074/jbc.M409769200	http://dx.doi.org/10.1074/jbc.M409769200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15377662	hybrid			2022-12-25	WOS:000225098100016
J	Choi, J; Park, SY; Costantini, F; Jho, EH; Joo, CK				Choi, J; Park, SY; Costantini, F; Jho, EH; Joo, CK			Adenomatous polyposis coli is down-regulated by the ubiquitin-proteasome pathway in a process facilitated by axin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; WNT SIGNALING PATHWAY; BETA-CATENIN; NEGATIVE REGULATOR; HEPATOCELLULAR CARCINOMAS; SUBCELLULAR-LOCALIZATION; COLORECTAL-CANCER; NUCLEAR EXPORT; CANONICAL WNT; PROTEIN	Adenomatous polyposis coli (APC) protein and Axin form a complex that mediates the down-regulation of beta-catenin, a key effector of Wnt signaling. Truncation mutations in APC are responsible for familial and sporadic colorectal tumors due to failure in the down-regulation of beta-catenin. While the regulation of beta-catenin by APC has been extensively studied, the regulation of APC itself has received little attention. Here we show that the level of APC is down-regulated by the ubiquitin-proteasome pathway and that Wnt signaling inhibits the process. The domain responsible for the down-regulation and direct ubiquitination was identified. We also show an unexpected role for Axin in facilitating the ubiquitination-proteasome-mediated down-regulation of APC through the oligomerization of Axin. Our results suggest a new mechanism for the regulation of APC by Axin and Wnt signaling.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Catholic Univ Korea, Lab Ophthalmol & Visual Sci, Seoul 137701, South Korea; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	University of Seoul; Catholic University of Korea; Columbia University	Jho, EH (corresponding author), Univ Seoul, Dept Life Sci, 90 Cheonnong Dong, Seoul 130743, South Korea.	ej70@uos.ac.kr; ckjoo@catholic.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044265] Funding Source: NIH RePORTER; NICHD NIH HHS [HD44265] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Baeza N, 2003, ONCOGENE, V22, P632, DOI 10.1038/sj.onc.1206156; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Fagman H, 2003, ONCOGENE, V22, P6013, DOI 10.1038/sj.onc.1206731; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Melman L, 2002, MOL BIOL CELL, V13, P3325, DOI 10.1091/mbc.E02-03-0152; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vleminckx K, 1997, J CELL BIOL, V136, P411, DOI 10.1083/jcb.136.2.411; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	59	34	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49188	49198		10.1074/jbc.M404655200	http://dx.doi.org/10.1074/jbc.M404655200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355978	hybrid			2022-12-25	WOS:000225098100084
J	Sauna, ZE; Nandigama, K; Ambudkar, SV				Sauna, ZE; Nandigama, K; Ambudkar, SV			Multidrug resistance protein 4 (ABCC4)-mediated ATP hydrolysis - Effect of transport substrates and characterization of the post-hydrolysis transition state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; NUCLEOTIDE-BINDING DOMAINS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MYOSIN MOTOR DOMAIN; CATALYTIC CYCLE; ABC TRANSPORTER; PROSTAGLANDIN E-2; CRYSTAL-STRUCTURE; 2ND DOMAIN; CELLS	Multidrug resistance protein 4 (MRP4/ABCC4), transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and prostaglandins. In this study we characterize ATP hydrolysis by human MRP4 expressed in insect cells. MRP4 hydrolyzes ATP (K-m, 0.62 mM), which is inhibited by orthovanadate and beryllium fluoride. However, unlike ATPase activity of P-glycoprotein, which is equally sensitive to both inhibitors, MRP4-ATPase is more sensitive to beryllium fluoride than to orthovanadate. 8-Azido[alpha-P-32] ATP binds to MRP4 (concentration for half-maximal binding similar to3 muM) and is displaced by ATP or by its nonhydrolyzable analog AMPPNP (concentrations for half-maximal inhibition of 13.3 and 308 muM). MRP4 substrates, the prostaglandins E1 and E2, stimulate ATP hydrolysis 2- to 3-fold but do not affect the K-m for ATP. Several other substrates, azidothymidine, 9-(2-phosphonylmethoxyethyl) adenine, and methotrexate do not stimulate ATP hydrolysis but inhibit prostaglandin E2-stimulated ATP hydrolysis. Although both post-hydrolysis transition states MRP4.8-azido[alpha-P-32] ADP.Vi and MRP4.8-azido[alpha-P-32] ADP.beryllium fluoride can be generated, nucleotide trapping is similar to4-fold higher with beryllium fluoride. The divalent cations Mg2+ and Mn2+ support comparable levels of nucleotide binding, hydrolysis, and trapping. However, Co2+ increases 8-azido[alpha-P-32] ATP binding and beryllium fluoride-induced 8-azido[alpha-P-32] ADP trapping but does not support steady-state ATP hydrolysis. ADP inhibits basal and prostaglandin E2-stimulated ATP hydrolysis (concentrations for half-maximal inhibition 0.19 and 0.25 mM, respectively) and beryllium fluoride-induced 8-azido[alpha-P-32] ADP trapping, whereas P-i has no effect up to 20 mM. In aggregate, our results demonstrate that MRP4 exhibits substrate-stimulated ATP hydrolysis, and we propose a kinetic scheme suggesting that ADP release from the post-hydrolysis transition state may be the rate-limiting step during the catalytic cycle.	NCI, Cell Biol Lab, Ctr Canc Res, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH,Dept Hlth & Human Serv, Bldg 37, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016; Sauna, Zuben E./AAA-7149-2019		NATIONAL CANCER INSTITUTE [ZIABC010030, Z01BC010030] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2002, ADV DRUG DELIVER REV, V54, P1333, DOI 10.1016/S0169-409X(02)00166-7; Adam L, 2001, CANCER RES, V61, P81; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; ALSHAWI MK, 1988, J BIOL CHEM, V263, P19633; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ambudkar SV, 1998, METHOD ENZYMOL, V292, P504; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Bera TK, 2002, P NATL ACAD SCI USA, V99, P6997, DOI 10.1073/pnas.102187299; BISHOP JE, 1988, J BIOL CHEM, V263, P1886; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Chen M, 2003, J BIOL CHEM, V278, P29686, DOI 10.1074/jbc.M302757200; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Chick J, 1999, DRUG SAFETY, V20, P427, DOI 10.2165/00002018-199920050-00003; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199; Hooijberg JH, 2000, FEBS LETT, V469, P47, DOI 10.1016/S0014-5793(00)01238-2; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kool M, 1997, CANCER RES, V57, P3537; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Lee K, 1998, CANCER RES, V58, P2741; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Loo TW, 2000, JNCI-J NATL CANCER I, V92, P898, DOI 10.1093/jnci/92.11.898; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Reid G, 2003, P NATL ACAD SCI USA, V100, P9244, DOI 10.1073/pnas.1033060100; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2004, MOL PHARMACOL, V65, P675, DOI 10.1124/mol.65.3.675; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vane JR, 1998, INFLAMM RES, V47, pS78; Warner TD, 2003, P NATL ACAD SCI USA, V100, P9108, DOI 10.1073/pnas.1733826100; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200	68	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48855	48864		10.1074/jbc.M408849200	http://dx.doi.org/10.1074/jbc.M408849200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364914	hybrid			2022-12-25	WOS:000225098100047
J	Jayasinghe, SA; Langen, R				Jayasinghe, SA; Langen, R			Identifying structural features of fibrillar islet amyloid polypeptide using site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLID-STATE NMR; PARALLEL BETA-SHEET; DIABETES-MELLITUS; FULL-LENGTH; MODEL; ANTIPARALLEL; PEPTIDE; IDENTIFICATION; ORGANIZATION; RESIDUES	Pancreatic amyloid deposits, composed primarily of the 37-residue islet amyloid polypeptide (IAPP), are a characteristic feature found in more than 90% of patients with type II diabetes. Although IAPP amyloid deposits are associated with areas of pancreatic islet beta-cell dysfunction and depletion and are thought to play a role in disease, their structure is unknown. We used electron paramagnetic resonance spectroscopy to analyze eight spin-labeled derivatives of IAPP in an effort to determine structural features of the peptide. In solution, all eight derivatives gave rise to electron paramagnetic resonance spectra with sharp lines indicative of rapid motion on the sub-nanosecond time scale. These spectra are consistent with a rapidly tumbling and highly dynamic peptide. In contrast, spectra for the fibrillar form exhibit reduced mobility and the presence of strong intermolecular spin-spin interactions. The latter implies that the peptide subunits are ordered and that the same residues from neighboring peptides are in close proximity to one another. Our data are consistent with a parallel arrangement of IAPP peptides within the amyloid fibril. Analysis of spin label mobility indicates a high degree of order throughout the peptide, although the N-terminal region is slightly less ordered. Possible similarities with respect to the domain organization and parallelism of Alzheimer's amyloid beta peptide fibrils are discussed.	Univ So Calif, Dept Biochem & Mol Biol, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA	University of Southern California	Langen, R (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Zilkha Neurogenet Inst, 1501 San Pablo St, Los Angeles, CA 90033 USA.	langen@usc.edu						Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; ASHBURN TT, 1992, J AM CHEM SOC, V114, P790, DOI 10.1021/ja00028a073; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; Cornish J, 1998, AM J PHYSIOL-ENDOC M, V274, pE827, DOI 10.1152/ajpendo.1998.274.5.E827; DEKONING EJP, 1993, DIABETOLOGIA, V36, P378, DOI 10.1007/BF00402271; DEKONING EJP, 1994, P NATL ACAD SCI USA, V91, P8467, DOI 10.1073/pnas.91.18.8467; Der-Sarkissian A, 2003, J BIOL CHEM, V278, P37530, DOI 10.1074/jbc.M305266200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldsbury C, 2000, J STRUCT BIOL, V130, P352, DOI 10.1006/jsbi.2000.4268; Goldsbury CS, 1997, J STRUCT BIOL, V119, P17, DOI 10.1006/jsbi.1997.3858; Gordon DJ, 2004, BIOPHYS J, V86, P428, DOI 10.1016/S0006-3495(04)74119-3; GRIFFITHS JM, 1995, J AM CHEM SOC, V117, P3539, DOI 10.1021/ja00117a023; Higham CE, 2000, FEBS LETT, V470, P55, DOI 10.1016/S0014-5793(00)01287-4; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Jaikaran ETAS, 2001, J MOL BIOL, V308, P515, DOI 10.1006/jmbi.2001.4593; Janson J, 1996, P NATL ACAD SCI USA, V93, P7283, DOI 10.1073/pnas.93.14.7283; Kahn SE, 1999, DIABETES, V48, P241, DOI 10.2337/diabetes.48.2.241; Kajava AV, 2004, P NATL ACAD SCI USA, V101, P7885, DOI 10.1073/pnas.0402427101; Kayed R, 1999, J MOL BIOL, V287, P781, DOI 10.1006/jmbi.1999.2646; Kudva YC, 1998, BIOCHEM J, V331, P809, DOI 10.1042/bj3310809; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; MacArthur DLA, 1999, DIABETOLOGIA, V42, P1219, DOI 10.1007/s001250051295; Makin OS, 2004, J MOL BIOL, V335, P1279, DOI 10.1016/j.jmb.2003.11.048; Margittai M, 2004, P NATL ACAD SCI USA, V101, P10278, DOI 10.1073/pnas.0401911101; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nilsson MR, 1999, J MOL BIOL, V294, P1375, DOI 10.1006/jmbi.1999.3286; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; OBRIEN T, 1995, AM J PATHOL, V147, P609; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Padrick SB, 2001, J MOL BIOL, V308, P783, DOI 10.1006/jmbi.2001.4608; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Petkova AT, 2004, J MOL BIOL, V335, P247, DOI 10.1016/j.jmb.2003.10.044; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Soto C, 2003, NAT REV NEUROSCI, V4, P49, DOI 10.1038/nrn1007; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Torok M, 2002, J BIOL CHEM, V277, P40810, DOI 10.1074/jbc.M205659200; Tycko R, 2000, CURR OPIN CHEM BIOL, V4, P500, DOI 10.1016/S1367-5931(00)00123-X; Tycko R, 2004, CURR OPIN STRUC BIOL, V14, P96, DOI 10.1016/j.sbi.2003.12.002; WESTERMARK P, 1987, AM J PATHOL, V127, P414; Westermark P, 1996, FEBS LETT, V379, P203, DOI 10.1016/0014-5793(95)01512-4; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008	48	131	131	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48420	48425		10.1074/jbc.M406853200	http://dx.doi.org/10.1074/jbc.M406853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358791	hybrid			2022-12-25	WOS:000224957000118
J	Liu, DY; Li, CS; Chen, YL; Burnett, C; Liu, XY; Doens, S; Collins, RD; Hawiger, J				Liu, DY; Li, CS; Chen, YL; Burnett, C; Liu, XY; Doens, S; Collins, RD; Hawiger, J			Nuclear import of proinflammatory transcription factors is required for massive liver apoptosis induced by bacterial lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; GALACTOSAMINE-INDUCED SENSITIZATION; DEPENDENT FULMINANT-HEPATITIS; STAPHYLOCOCCAL-ENTEROTOXIN-B; NF-KAPPA-B; EMBRYONIC LETHALITY; ENDOTOXIC-SHOCK; TNF-ALPHA; HEPATOCYTE APOPTOSIS; DNA FRAGMENTATION	Stimulation of macrophages with lipopolysaccharide (LPS) leads to the production of cytokines that elicit massive liver apoptosis. We investigated the in vivo role of stress-responsive transcription factors (SRTFs) in this process focusing on the precipitating events that are sensitive to a cell-permeant peptide inhibitor of SRTF nuclear import (cSN50). In the absence of cSN50, mice challenged with LPS displayed very early bursts of inflammatory cytokines/chemokines, tumor necrosis factor alpha (1 h), interleukin 6 (2 h), interleukin 1 beta (2 h), and monocyte chemoattractant protein 1 (2 h). Activation of both initiator caspases 8 and 9 and effector caspase 3 was noted 4 h later when full-blown DNA fragmentation and chromatin condensation were first observed (6 h). At this time an increase of pro-apoptotic Bax gene expression was observed. It was preceded by a decrease of anti-apoptotic Bcl2 and BclX(L) gene transcripts. Massive apoptosis was accompanied by microvascular injury manifested by hemorrhagic necrosis and a precipitous drop in blood platelets observed at 6 h. An increase in fibrinogen/fibrin degradation products and a rise in plasminogen activator inhibitor 1 occurred between 4 and 6 h. Inhibition of SRTFs nuclear import with the cSN50 peptide abrogated all these changes and increased survival from 7 to 71%. Thus, the nuclear import of SRTFs induced by LPS is a prerequisite for activation of the genetic program that governs cytokines/chemokines production, liver apoptosis, microvascular injury, and death. These results should facilitate the rational design of drugs that protect the liver from inflammation-driven apoptosis.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pathol, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Hawiger, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Med Ctr, 1161 21st Ave S,A-5321 MCN, Nashville, TN 37232 USA.	jacek.hawiger@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062356, P01HL068744, R43HL069542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK054072] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA 68485] Funding Source: Medline; NHLBI NIH HHS [HL62356, HL69542, HL68744] Funding Source: Medline; NIDDK NIH HHS [5P30DK058404-03, DK54072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chen R, 1999, CLIN CHEM, V45, P1693; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deaciuc IV, 2000, ALCOHOL CLIN EXP RES, V24, P1557, DOI 10.1111/j.1530-0277.2000.tb04575.x; Doerschug K, 2002, J IMMUNOL, V169, P6539, DOI 10.4049/jimmunol.169.11.6539; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dufour DR, 2000, CLIN CHEM, V46, P2027; Eitzman DT, 2000, BLOOD, V95, P577, DOI 10.1182/blood.V95.2.577; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Feng Jun-Ming, 2003, Hepatobiliary Pancreat Dis Int, V2, P265; FREUDENBERG MA, 1986, INFECT IMMUN, V51, P891, DOI 10.1128/IAI.51.3.891-895.1986; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; HAWIGER J, 1970, J LAB CLIN MED, V75, P93; Hawiger J, 2001, IMMUNOL RES, V23, P99, DOI 10.1385/IR:23:2-3:099; Jaeschke H, 2004, LIVER INT, V24, P85, DOI 10.1111/j.1478-3231.2004.0906.x; Kadenbach B, 2004, BBA-BIOENERGETICS, V1655, P400, DOI 10.1016/j.bbabio.2003.06.005; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LIEBER CS, 1988, NEW ENGL J MED, V319, P1639; Liu DY, 2004, J BIOL CHEM, V279, P19239, DOI 10.1074/jbc.M313442200; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu XY, 2000, J BIOL CHEM, V275, P16774; Matsumoto G, 2002, J IMMUNOL, V169, P7087, DOI 10.4049/jimmunol.169.12.7087; McCarter SD, 2004, SURGERY, V136, P67, DOI 10.1016/j.surg.2003.11.002; McMullen MR, 2003, J BIOL CHEM, V278, P38333, DOI 10.1074/jbc.M304566200; MIETHKE T, 1992, J EXP MED, V175, P91, DOI 10.1084/jem.175.1.91; Mignon A, 1999, AM J RESP CRIT CARE, V159, P1308, DOI 10.1164/ajrccm.159.4.9712012; Morikawa A, 1996, INFECT IMMUN, V64, P734, DOI 10.1128/IAI.64.3.734-738.1996; Oreopoulos GD, 2004, HEPATOLOGY, V40, P211, DOI 10.1002/hep.20281; Osawa Y, 2001, LIVER, V21, P309, DOI 10.1034/j.1600-0676.2001.210503.x; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Qiu FH, 2000, P NATL ACAD SCI USA, V97, P4267, DOI 10.1073/pnas.97.8.4267; Raper SE, 2002, HUM GENE THER, V13, P163, DOI 10.1089/10430340152712719; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004; Song Y, 2003, WORLD J GASTROENTERO, V9, P1799, DOI 10.3748/wjg.v9.i8.1799; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Wada H, 2003, AM J HEMATOL, V74, P17, DOI 10.1002/ajh.10377; Wang XD, 2001, GENE DEV, V15, P2922; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Yajima T, 1998, CLIN CHEM, V44, P2441; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 2003, CURR MOL MED, V3, P491, DOI 10.2174/1566524033479555; Zhou ZX, 2003, AM J PATHOL, V163, P1137, DOI 10.1016/S0002-9440(10)63473-6	49	92	123	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48434	48442		10.1074/jbc.M407190200	http://dx.doi.org/10.1074/jbc.M407190200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15345713	hybrid			2022-12-25	WOS:000224957000120
J	Manaka, J; Kuraishi, T; Shiratsuchi, A; Nakai, Y; Higashida, H; Henson, P; Nakanishi, Y				Manaka, J; Kuraishi, T; Shiratsuchi, A; Nakai, Y; Higashida, H; Henson, P; Nakanishi, Y			Draper-mediated and phosphatidylserine-independent phagocytosis of apoptotic cells by drosophila hemocytes/macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNITY; C-ELEGANS; ENDOPLASMIC-RETICULUM; SURFACE CALRETICULIN; CORPSE ENGULFMENT; DEATH; RECEPTOR; RECOGNITION; CLEARANCE; MECHANISMS	The mechanism of phagocytic elimination of dying cells in Drosophila is poorly understood. This study was undertaken to examine the recognition and engulfment of apoptotic cells by Drosophila hemocytes/macrophages in vitro and in vivo. In the in vitro analysis, l(2)mbn cells (a cell line established from larval hemocytes of a tumorous Drosophila mutant) were used as phagocytes. When l(2) mbn cells were treated with the molting hormone 20-hydroxyecdysone, the cells acquired the ability to phagocytose apoptotic S2 cells, another Drosophila cell line. S2 cells undergoing cycloheximide-induced apoptosis exposed phosphatidylserine on their surface, but their engulfment by l(2) mbn cells did not seem to be mediated by phosphatidylserine. The level of Croquemort, a candidate phagocytosis receptor of Drosophila hemocytes/macrophages, increased in l(2) mbn cells after treatment with 20-hydroxyecdysone, whereas that of Draper, another candidate phagocytosis receptor, remained unchanged. However, apoptotic cell phagocytosis was reduced when the expression of Draper, but not of Croquemort, was inhibited by RNA interference in hormone-treated l(2) mbn cells. We next examined whether Draper is responsible for the phagocytosis of apoptotic cells in vivo using an assay for engulfment based on assessing DNA degradation of apoptotic cells in dICAD mutant embryos (which only occurred after ingestion by the phagocytes). RNA interference-mediated decrease in the level of Draper in embryos of mutant flies was accompanied by a decrease in the number of cells containing fragmented DNA. Furthermore, histochemical analyses of dispersed embryonic cells revealed that the level of phagocytosis of apoptotic cells by hemocytes/macrophages was reduced when Draper expression was inhibited. These results indicate that Drosophila hemocytes/macrophages execute Draper-mediated phagocytosis to eliminate apoptotic cells.	Kanazawa Univ, Grad Sch Med Sci, Ishikari, Hokkaido 9201192, Japan; Kanazawa Univ, Grad Sch Nat Sci & Technol, Ishikari, Hokkaido 9201192, Japan; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Kanazawa University; Kanazawa University; National Jewish Health	Nakanishi, Y (corresponding author), Kanazawa Univ, Grad Sch Med Sci, Ishikari, Hokkaido 9201192, Japan.	nakanaka@kenroku.kanazawa-u.ac.jp	Shiratsuchi, Akiko/D-8391-2015; NAKAI, Yuji/G-3433-2014; Nakanishi, Yoshinobu/D-4602-2014; higashida, haruhiro/L-3773-2015	Shiratsuchi, Akiko/0000-0002-7811-4409; NAKAI, Yuji/0000-0002-2458-3875; Nakanishi, Yoshinobu/0000-0002-8767-3587; higashida, haruhiro/0000-0002-1779-0606				ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Asgari S, 2003, J INSECT PHYSIOL, V49, P545, DOI 10.1016/S0022-1910(03)00025-8; Balasubramanian K, 2003, ANNU REV PHYSIOL, V65, P701, DOI 10.1146/annurev.physiol.65.092101.142459; Chimini G, 2001, CELL DEATH DIFFER, V8, P545, DOI 10.1038/sj.cdd.4400833; Dimarcq JL, 1997, INSECT BIOCHEM MOLEC, V27, P877, DOI 10.1016/S0965-1748(97)00072-6; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Gumienny TL, 2001, CELL DEATH DIFFER, V8, P564, DOI 10.1038/sj.cdd.4400850; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Horvitz HR, 1999, CANCER RES, V59, p1701S; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Koulov AV, 2003, CELL DEATH DIFFER, V10, P1357, DOI 10.1038/sj.cdd.4401315; Kunisaki Y, 2004, BLOOD, V103, P3362, DOI 10.1182/blood-2003-09-3245; Lauber K, 2004, MOL CELL, V14, P277, DOI 10.1016/S1097-2765(04)00237-0; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Mukae N, 2002, GENE DEV, V16, P2662, DOI 10.1101/gad.1022802; Muller-Taubenberger A, 2001, EMBO J, V20, P6772, DOI 10.1093/emboj/20.23.6772; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Okazaki Y, 2000, J BIOL CHEM, V275, P35751, DOI 10.1074/jbc.M007476200; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Roos A, 2004, EUR J IMMUNOL, V34, P921, DOI 10.1002/eji.200424904; Rosen A, 2001, NAT MED, V7, P664, DOI 10.1038/89034; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Savill J, 1997, BRIT MED BULL, V53, P491; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; SONNENFELD MJ, 1995, J COMP NEUROL, V359, P644, DOI 10.1002/cne.903590410; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Walport MJ, 2000, NAT GENET, V25, P135, DOI 10.1038/75963; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yokoyama H, 2000, J BIOL CHEM, V275, P12978, DOI 10.1074/jbc.275.17.12978; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	48	151	156	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48466	48476		10.1074/jbc.M408597200	http://dx.doi.org/10.1074/jbc.M408597200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342648	Green Submitted, hybrid			2022-12-25	WOS:000224957000124
J	Mi, ZY; Guo, HT; Wai, PY; Gao, CJ; Wei, JP; Kuo, PC				Mi, ZY; Guo, HT; Wai, PY; Gao, CJ; Wei, JP; Kuo, PC			Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; NEOPLASTIC TRANSFORMATION; BONE SIALOPROTEIN; GROWTH-FACTOR; PTEN GENE; PROMOTER; PROTEIN; INFLAMMATION; KINASE; OVEREXPRESSION	Cancer progression depends on an accumulation of metastasis-supporting cell signaling molecules, which target signal transduction pathways and, ultimately, gene expression. One such molecule, osteopontin (OPN), represents a key molecular signaling event in tumor progression and metastasis. However, the transcriptional regulatory mechanisms that underlie OPN expression in the setting of breast cancer have not been well studied. In this regard, we have examined the differential transcriptional regulation of OPN in the murine mammary epithelial tumor cell lines, 4T1 and 4T07, which are sublines derived from the parental population of 410.4 cells from Balb/cfC3H mice. These lines are phenotypically heterogeneous in their metastatic behavior. 4T1 hematogenously metastasizes to the lung, liver, bone, and brain, whereas 4T07 is highly tumorigenic but fails to metastasize. The tumor growth and metastatic spread of 4T1 cells closely mimics stage IV breast cancer. We demonstrate that a Ras-independent, phosphoinositide-3 kinase-dependent, c-Jun N-terminal kinase-dependent phosphorylation of c-Jun results in binding of an AP-1 c-Jun homodimer to the OPN promoter in 4T1 cells. This differential up-regulation of OPN gene transcription and protein expression in 4T1 cells conveys in vitro correlates of a metastatic phenotype. These results provide new insight into the transcriptional regulation of OPN as a key mediator of metastatic behavior in malignancy.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Duke University	Kuo, PC (corresponding author), 110 Bell Bldg,DUMC Box 3522, Durham, NC 27710 USA.	kuo00004@mc.duke.edu		Gao, Chengjiang/0000-0002-9365-4497	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI044629, R01AI044629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065113, R01GM065113, T32GM069331] Funding Source: NIH RePORTER; NIAID NIH HHS [AI44629] Funding Source: Medline; NIGMS NIH HHS [GM069331, GM65113] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 2002, J NATL CANCER I, V94, P513; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; BAUTISTA DS, 1994, J BIOL CHEM, V269, P23280; BROWN LF, 1994, AM J PATHOL, V145, P610; Carlinfante G, 2003, CLIN EXP METASTAS, V20, P437, DOI 10.1023/A:1025419708343; Chung MJ, 2004, PATHOL INT, V54, P10, DOI 10.1111/j.1440-1827.2004.01576.x; Coppola D, 2004, CLIN CANCER RES, V10, P184, DOI 10.1158/1078-0432.CCR-1405-2; CRAIG AM, 1991, GENE, V100, P163, DOI 10.1016/0378-1119(91)90362-F; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DENHARDT DT, 1995, ANN NY ACAD SCI, V760, P127, DOI 10.1111/j.1749-6632.1995.tb44625.x; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DENHARDT DT, 1994, J CELL BIOCHEM, V56, P48, DOI 10.1002/jcb.240560109; El-Tanani M, 2001, CANCER RES, V61, P5619; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Gao CJ, 2004, J BIOL CHEM, V279, P11236, DOI 10.1074/jbc.M313385200; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Gotoh M, 2002, PATHOL INT, V52, P19, DOI 10.1046/j.1440-1827.2002.01316.x; Grano M, 2002, J BIOL REG HOMEOS AG, V16, P190; Heppner GH, 2000, BREAST CANCER RES, V2, P331; HIJIYA N, 1994, BIOCHEM J, V303, P255, DOI 10.1042/bj3030255; Korkola JE, 2003, CANCER RES, V63, P7167; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365-2613.2000.00163.x; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; SENGER DR, 1988, CANCER RES, V48, P5770; Tan M, 1999, CANCER RES, V59, P1620; van Golen KL, 2002, CLIN EXP METASTAS, V19, P301, DOI 10.1023/A:1015518114931; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wu Y, 2000, BRIT J CANCER, V83, P156; Zhang GX, 2003, MOL CELL BIOL, V23, P6507, DOI 10.1128/MCB.23.18.6507-6519.2003; Zhang GX, 2004, WORLD J GASTROENTERO, V10, P205	37	42	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46659	46667		10.1074/jbc.M407952200	http://dx.doi.org/10.1074/jbc.M407952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347645	hybrid			2022-12-25	WOS:000224832400041
J	Tokarz, S; Berset, C; La Rue, J; Friedman, K; Nakayama, KI; Nakayama, K; Zhang, DE; Lanker, S				Tokarz, S; Berset, C; La Rue, J; Friedman, K; Nakayama, KI; Nakayama, K; Zhang, DE; Lanker, S			The ISG15 isopeptidase UBP43 is regulated by proteolysis via the SCFSkp2 ubiquitin ligase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX PROTEIN SKP2; DEGRADATION; COMPLEX; PHOSPHORYLATION; EXPRESSION; HOMOLOG; TARGETS; CLONING; CKS1	The Skp2 oncoprotein belongs to the family of F-box proteins that function as substrate recognition factors for SCF (Skp1, cullin, F-box protein) E3 ubiquitin-ligase complexes. Binding of the substrate to the SCFSkp2 complex catalyzes the conjugation of ubiquitin molecules to the bound substrate, resulting in multi-ubiquitination and rapid degradation by the 26 S proteasome. Using Skp2 as bait in a yeast two-hybrid screen, we have identified UBP43 as a novel substrate for Skp2. UBP43 belongs to the family of ubiquitin isopeptidases and specifically cleaves ISG15, a ubiquitin-like molecule that is induced by cellular stresses, such as type 1 interferons (IFN), nephrotoxic damage, and bacterial infection. UBP43 was originally identified as an up-regulated gene in knock-in mice expressing an acute myelogenous leukemia fusion protein, AML1-ETO, as well as in melanoma cell lines treated with IFN-beta. The phenotype of UBP43 knockout mice includes shortened life span, hypersensitivity to IFN, and neuronal damage, suggesting that tight regulation of ISG15 conjugation is critical for normal cellular function. In this study, we demonstrate that UBP43 is ubiquitinated in vivo and accumulates in cells treated with proteasome inhibitors. We also show that Skp2 promotes UBP43 ubiquitination and degradation, resulting in higher levels of ISG15 conjugates. In Skp2-/- mouse cells, levels of UBP43 are consistently up-regulated, whereas levels of ISG15 conjugates are reduced. Our results demonstrate that the SCFSkp2 is involved in controlling UBP43 protein levels and may therefore play an important role in modulating type 1 IFN signaling.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Sch Med, Portland, OR 97239 USA; ESBATech AG, CH-8952 Zurich, Switzerland; Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Oregon Health & Science University; Kyushu University; Scripps Research Institute	Lanker, S (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Sch Med, Portland, OR 97239 USA.	lankers@ohsu.edu			NCI NIH HHS [R01-CA079849] Funding Source: Medline; NIGMS NIH HHS [R01-GM59759] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berset G, 2002, MOL CELL BIOL, V22, P4463, DOI 10.1128/MCB.22.13.4463-4476.2002; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; GRAY DA, 1995, ONCOGENE, V10, P2179; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; Liu LQ, 1999, MOL CELL BIOL, V19, P3029; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200; Malakhov MP, 2003, J BIOL CHEM, V278, P16608, DOI 10.1074/jbc.M208435200; Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ritchie KJ, 2002, GENE DEV, V16, P2207, DOI 10.1101/gad.1010202; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schwer H, 2000, GENOMICS, V65, P44, DOI 10.1006/geno.2000.6148; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Yeh KH, 2001, BIOCHEM BIOPH RES CO, V281, P884, DOI 10.1006/bbrc.2001.4442; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362	35	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46424	46430		10.1074/jbc.M403189200	http://dx.doi.org/10.1074/jbc.M403189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342634	hybrid			2022-12-25	WOS:000224832400012
J	Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A				Gelman, MS; Ye, XK; Stull, R; Suhy, D; Jin, L; Ng, D; Than, B; Ji, M; Pan, A; Perez, P; Sun, Y; Yeung, P; Garcia, LM; Harte, R; Lu, Y; Lamar, E; Tavassoli, R; Kennedy, S; Osborn, S; Chin, DJ; Meshaw, K; Holzmayer, TA; Axenovich, SA; Abo, A			Identification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen	ONCOGENE			English	Article						genetic suppressor element (GSE); cancer therapeutic target; tumor cell; apoptosis; essential gene; xenograft	FACTOR-II RECEPTOR; MONOCLONAL-ANTIBODY; CANCER-CELLS; EXPRESSION SELECTION; RETROVIRAL VECTORS; INDUCED APOPTOSIS; RNA INTERFERENCE; CARCINOMA CELLS; MAMMALIAN-CELLS; CDNA LIBRARIES	Survival factors play critical roles in regulating cell growth in normal and cancer cells. We designed a genetic screen to identify survival factors which protect tumor cells from apoptosis. A retroviral expression library of random cDNA fragments was constructed from cancer cells and used to transduce the colon carcinoma cell line HCT116. Recipient cells were functionally selected for induction of caspase 3-mediated apoptosis. Analyses of over 10000 putative genetic suppression elements (GSEs) sequences revealed cognate gene candidates that are implicated in apoptosis. We further analysed 26 genes encoding cell surface and secreted proteins that can potentially serve as targets for therapeutic antibodies. Tetracycline-inducible GSEs from several gene candidates induced apoptosis in stable HCT 116 cell lines. Similar phenotypes were caused by RNAi derived from the same genes. Our data suggest requirement for the cell surface targets IGF2R, L1CAM and SLC31A1 in tumor cell growth in vitro, and suggests that IGF2R is required for xenograft tumor growth in a mouse model.	PPD Discovery Inc, Menlo Pk, CA 94025 USA; PPD Discovery Inc, Piedmont Res Ctr, Morrisville, NC 27560 USA		Axenovich, SA (corresponding author), 1018 4th Av,Suite 119, Oakland, CA 94606 USA.	sergey.axenovich@gmail.com; arieabo@yahoo.com						Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Chen ZH, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-18; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Dunn SJ, 1999, GENE THER, V6, P130, DOI 10.1038/sj.gt.3300791; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fogel M, 2003, CANCER LETT, V189, P237, DOI 10.1016/S0304-3835(02)00513-X; Gallagher WM, 1997, ONCOGENE, V14, P185; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Gros L, 2003, CANCER RES, V63, P164; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Gudkov A V, 1997, Methods Mol Biol, V69, P221; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Gutheil JC, 2000, CLIN CANCER RES, V6, P3056; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFMANN MA, 1991, BIOTECHNIQUES, V11, P30; HOLZMAYER TA, 1992, NUCLEIC ACIDS RES, V20, P711, DOI 10.1093/nar/20.4.711; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jamieson TA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-4; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; Levenson VV, 2000, CANCER RES, V60, P5027; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; Neznanov N, 2003, J BIOL CHEM, V278, P3809, DOI 10.1074/jbc.M210698200; Ouyang H, 1997, CANCER RES, V57, P1851; Pegues JC, 1997, CANCER LETT, V117, P73, DOI 10.1016/S0304-3835(97)00209-7; Primiano T, 2003, CANCER CELL, V4, P41, DOI 10.1016/S1535-6108(03)00169-7; RONINSON IB, 1995, CANCER RES, V55, P4023; Schaffer BS, 2003, ENDOCRINOLOGY, V144, P955, DOI 10.1210/en.2002-220751; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Torrance CJ, 2001, NAT BIOTECHNOL, V19, P940, DOI 10.1038/nbt1001-940; Tucker Gordon C, 2003, Curr Opin Investig Drugs, V4, P722; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; Yang XD, 1999, CANCER RES, V59, P1236; Zhou GY, 2002, J VIROL, V76, P6197, DOI 10.1128/JVI.76.12.6197-6204.2002	42	14	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8158	8170		10.1038/sj.onc.1208054	http://dx.doi.org/10.1038/sj.onc.1208054			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361835				2022-12-25	WOS:000224692500014
J	Seufferheld, M; Lea, CR; Vieira, M; Oldfield, E; Docampo, R				Seufferheld, M; Lea, CR; Vieira, M; Oldfield, E; Docampo, R			The H+-pyrophosphatase of Rhodospirillum rubrum is predominantly located in polyphosphate-rich acidocalcisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-PUMPING PYROPHOSPHATASE; TRYPANOSOMA-CRUZI; INORGANIC PYROPHOSPHATE; PLASMA-MEMBRANE; TRANSLOCATING PYROPHOSPHATASE; CHLAMYDOMONAS-REINHARDTII; ESCHERICHIA-COLI; PLANT; IDENTIFICATION; LOCALIZATION	Acidocalcisomes are acidic, calcium storage compartments with a H+ pump located in their membrane that have been described in several unicellular eukaryotes, including trypanosomatid and apicomplexan parasites, algae, and slime molds, and have also been found in the bacterium Agrobacterium tumefaciens. In this work, we report that the H+-pyrophosphatase (H+-PPase) of Rhodospirillum rubrum, the first enzyme of this type that was identified and thought to be localized only to chromatophore membranes, is predominantly located in acidocalcisomes. The identification of the acidocalcisomes of R. rubrum was carried out by using transmission electron microscopy, x-ray microanalysis, and immunofluorescence microscopy. Purification of acidocalcisomes using iodixanol gradients indicated co-localization of the H+-PPase with pyrophosphate (PPi) and short and long chain polyphosphates (polyPs) but a lack of markers of the plasma membrane. polyP was also localized to the acidocalcisomes by using 4', 6'-diamino-2- phenylindole staining and identified by using P-31 NMR and biochemical methods. Calcium in the acidocalcisomes increased when the bacteria were incubated at high extracellular calcium concentrations. The number of acidocalcisomes and chromatophore membranes as well as the amounts of PPi and polyP increased when bacteria were grown in the light. Taken together, these results suggest that the H+-PPase of R. rubrum has two distinct roles depending on its location acting as an intracellular proton pump in acidocalcisomes but in PPi synthesis in the chromatophore membranes.	Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, Urbana, IL 61802 USA; Univ Illinois, Ctr Zoonoses Res, Urbana, IL 61802 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Docampo, R (corresponding author), Univ Illinois, Dept Pathobiol, Mol Parasitol Lab, 2001 S Lincoln Ave, Urbana, IL 61802 USA.	rodoc@uiuc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI023259, R01AI023259] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI23259] Funding Source: Medline; NIGMS NIH HHS [GM50694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALTSCHEFFSKY H, 1966, SCIENCE, V153, P1120, DOI 10.1126/science.153.3740.1120; Baltscheffsky M, 1999, FEBS LETT, V457, P525, DOI 10.1016/S0014-5793(99)00914-X; BALTSCHEFFSKY M, 1967, NATURE, V216, P241, DOI 10.1038/216241a0; Baltscheffsky M, 1998, BBA-BIOENERGETICS, V1364, P301, DOI 10.1016/S0005-2728(98)00062-0; Belogurov GA, 2002, J BIOL CHEM, V277, P49651, DOI 10.1074/jbc.M210341200; Belogurov GA, 2002, J BIOL CHEM, V277, P22209, DOI 10.1074/jbc.M202951200; COHENBAZIRE G, 1963, BACTERIAL PHOTOSYNTH, P89; CROOK SM, 1986, J BACTERIOL, V167, P89, DOI 10.1128/jb.167.1.89-95.1986; DASILVA LP, 1993, ARCH BIOCHEM BIOPHYS, V30, P310; Docampo R, 2001, MOL BIOCHEM PARASIT, V114, P151, DOI 10.1016/S0166-6851(01)00246-8; Drebin R. A., 1988, P 15 ANN C COMP GRAP, P65, DOI DOI 10.1145/54852.378484; Drozdowicz YM, 2001, TRENDS PLANT SCI, V6, P206, DOI 10.1016/S1360-1385(01)01923-9; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; Lemercier G, 2004, J BIOL CHEM, V279, P3420, DOI 10.1074/jbc.M309974200; Lin HJ, 2001, ANAL BIOCHEM, V294, P118, DOI 10.1006/abio.2001.5155; LONG AR, 1995, J PLANT PHYSIOL, V146, P629, DOI 10.1016/S0176-1617(11)81925-5; Lopez-Marques RL, 2004, J BACTERIOL, V186, P5418, DOI 10.1128/JB.186.16.5418-5426.2004; LUNDIN M, 1992, BIOCHIM BIOPHYS ACTA, V1098, P217, DOI 10.1016/S0005-2728(05)80339-1; Luo SH, 2001, EMBO J, V20, P55, DOI 10.1093/emboj/20.1.55; Maeshima M, 1999, PLANT CELL PHYSIOL, V40, P439, DOI 10.1093/oxfordjournals.pcp.a029560; Marchesini N, 2002, J BIOL CHEM, V277, P8146, DOI 10.1074/jbc.M111130200; Martinez R, 2002, MOL BIOCHEM PARASIT, V120, P205, DOI 10.1016/S0166-6851(01)00456-X; MEISSNER M, 2000, P 2000 IEEE S VOL VI, P81; Meyer A., 1904, BOT Z, V62, P113; Moreno B, 2000, J BIOL CHEM, V275, P28356, DOI 10.1074/jbc.M003893200; MOYLE J, 1972, FEBS LETT, V23, P233, DOI 10.1016/0014-5793(72)80349-1; OELZE J, 1972, BIOCHIM BIOPHYS ACTA, V265, P209, DOI 10.1016/0304-4157(72)90003-2; PawleyJB, 1994, 3 DIMENSIONAL CONFOC, P47; Perez-Castineira JR, 2002, BIOCHEM BIOPH RES CO, V294, P567, DOI 10.1016/S0006-291X(02)00517-X; Perez-Castineira JR, 2001, FEBS LETT, V496, P6, DOI 10.1016/S0014-5793(01)02390-0; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; Robinson DG, 1996, PLANTA, V198, P95, DOI 10.1007/BF00197591; Robinson DG, 1998, BOT ACTA, V111, P108, DOI 10.1111/j.1438-8677.1998.tb00685.x; Romero I, 2003, ARCH MICROBIOL, V179, P377, DOI 10.1007/s00203-003-0537-4; Ruiz FA, 2001, J BIOL CHEM, V276, P46196, DOI 10.1074/jbc.M105268200; Ruiz FA, 2001, J BIOL CHEM, V276, P26114, DOI 10.1074/jbc.M102402200; RUSS JC, 1995, IMAGE PROCESSING HDB, P151; RUSS JC, 1995, IMAGE PROCESSING HDB, P1; SALIH GF, 1990, CURR RES PHOTOSYNTH, V3, P209; Schultz A, 2003, BBA-BIOENERGETICS, V1607, P141, DOI 10.1016/j.bbabio.2003.09.003; Scott DA, 1998, J BIOL CHEM, V273, P22151, DOI 10.1074/jbc.273.34.22151; Scott DA, 2000, J BIOL CHEM, V275, P24215, DOI 10.1074/jbc.M002454200; Seufferheld M, 2003, J BIOL CHEM, V278, P29971, DOI 10.1074/jbc.M304548200; SISTROM WR, 1960, J GEN MICROBIOL, V22, P778, DOI 10.1099/00221287-22-3-778; Slater, 1970, ELECTRON TRANSPORT E, P221; Van Wazer J. R., 1987, PHOSPHORUS NMR BIOL, P1; VANKEMPEN GMP, 1997, 3 D MICROSCOPY IMAGE, V4, P114; Vianello A, 1997, PLANT CELL PHYSIOL, V38, P87, DOI 10.1093/oxfordjournals.pcp.a029090; VONSTEDINGK LV, 1966, ARCH BIOCHEM BIOPHYS, V40, P400; ZHEN RG, 1994, PLANT PHYSIOL, V104, P153, DOI 10.1104/pp.104.1.153; Zhen RG, 1997, J BIOL CHEM, V272, P22340, DOI 10.1074/jbc.272.35.22340; Zhen RG, 1997, ADV BOT RES, V25, P297, DOI 10.1016/S0065-2296(08)60156-1	52	64	68	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51193	51202		10.1074/jbc.M406099200	http://dx.doi.org/10.1074/jbc.M406099200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371423	hybrid			2022-12-25	WOS:000225355800066
J	Somerville, RPT; Jungers, KA; Apte, SS				Somerville, RPT; Jungers, KA; Apte, SS			Discovery and characterization of a novel, widely expressed metalloprotease, ADAMTS10, and its proteolytic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; THROMBOSPONDIN MOTIFS; CHONDROITIN SULFATE; FAMILY; CLONING; AGGRECANASE-1; DISINTEGRIN; CLEAVAGE; PROTEIN; MEMBER	We describe the discovery and characterization of ADAMTS10, a novel metalloprotease encoded by a locus on human chromosome 19 and mouse chromosome 17. ADAMTS10 has the typical modular organization of the ADAMTS family, with five thrombospondin type 1 repeats and a cysteine-rich PLAC ( protease and lacunin) domain at the carboxyl terminus. Its domain organization and primary structure is similar to a novel long form of ADAMTS6. In contrast to many ADAMTS proteases, ADAMTS10 is widely expressed in adult tissues and throughout mouse embryo development. In situ hybridization analysis showed widespread expression of Adamts10 in the mouse embryo until 12.5 days of gestation, after which it is then expressed in a more restricted fashion, with especially strong expression in developing lung, bone, and craniofacial region. Mesenchymal, not epithelial, expression in the developing lung, kidney, gonad, salivary gland, and gastrointestinal tract is a consistent feature of Adamts10 regulation. N-terminal sequencing and treatment with decanoyl-Arg-Val-Lys- Arg-chloromethylketone indicate that the ADAMTS10 zymogen is processed by a subtilisin-like proprotein convertase at two sites (Arg(64)down arrowGly and Arg(233)down arrowSer). The widespread expression of ADAMTS10 suggests that furin, a ubiquitously expressed proprotein convertase, is the likely processing enzyme. ADAMTS10 expressed in HEK293F and COS-1 cells is N-glycosylated and is secreted into the medium, as well as sequestered at the cell surface and extracellular matrix, as demonstrated by cell surface biotinylation and immunolocalization in nonpermeabilized cells. ADAMTS10 is a functional metalloprotease as demonstrated by cleavage of alpha(2)-macroglobulin, although physiological substrates are presently unknown.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Orthopaed Res Ctr, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	aptes@ccf.org		Apte, Suneel/0000-0001-8441-1226	NIAMS NIH HHS [AR 49930] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049930, R56AR049930] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; Gao G, 2004, J BIOL CHEM, V279, P10042, DOI 10.1074/jbc.M312100200; Gao G, 2002, J BIOL CHEM, V277, P11034, DOI 10.1074/jbc.M107443200; Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hirohata S, 2002, J BIOL CHEM, V277, P12182, DOI 10.1074/jbc.M109665200; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kheradmand F, 2002, BIOESSAYS, V24, P8, DOI 10.1002/bies.10037; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Matthews RT, 2000, J BIOL CHEM, V275, P22695, DOI 10.1074/jbc.M909764199; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; Rao C, 2003, DEVELOPMENT, V130, P4665, DOI 10.1242/dev.00668; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Rodriguez-Manzaneque JC, 2002, BIOCHEM BIOPH RES CO, V293, P501; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Somerville RPT, 2004, J BIOL CHEM, V279, P35159, DOI 10.1074/jbc.M402380200; Somerville RPT, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-6-216; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Wang P, 2004, J BIOL CHEM, V279, P15434, DOI 10.1074/jbc.M312797200; Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	40	66	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51208	51217		10.1074/jbc.M409036200	http://dx.doi.org/10.1074/jbc.M409036200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15355968	hybrid			2022-12-25	WOS:000225355800068
J	Williams, TM; Medina, F; Badano, I; Hazan, RB; Hutchinson, J; Muller, WJ; Chopra, NG; Scherer, PE; Pestell, RG; Lisanti, MP				Williams, TM; Medina, F; Badano, I; Hazan, RB; Hutchinson, J; Muller, WJ; Chopra, NG; Scherer, PE; Pestell, RG; Lisanti, MP			Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo - Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NITRIC-OXIDE SYNTHASE; CYCLIN D1 OVEREXPRESSION; ROUS-SARCOMA VIRUS; MAP KINASE CASCADE; MEMBRANE DOMAINS; PROSTATE-CANCER; MICE SHOW; NULL MICE; RETINOBLASTOMA PROTEIN	Caveolin-1 (Cav-1) is the principal structural component of caveolae membrane domains in non-muscle cells, including mammary epithelia. There is now clear evidence that caveolin-1 influences the development of human cancers. For example, a dominant-negative mutation (P132L) in the Cav-1 gene has been detected in up to 16% of human breast cancer samples. However, the exact functional role of caveolin-1 remains controversial. Mechanistically, in cultured cell models, Cav-1 is known to function as a negative regulator of the Rasp-42/ 44 MAP kinase cascade and as a transcriptional repressor of cyclin D1 gene expression, possibly explaining its in vitro transformation suppressor activity. Genetic validation of this hypothesis at the in vivo and whole organismal level has been prevented by the lack of a Cav-1 (-/-)-null mouse model. Here, we examined the role of caveolin-1 in mammary tumorigenesis and lung metastasis using a molecular genetic approach. We interbred a well characterized transgenic mouse model of breast cancer, MMTV-PyMT ( mouse mammary tumor virus-polyoma middle T antigen), with Cav-1(-/-)-null mice. Then, we followed the onset and progression of mammary tumors and lung metastases in female mice over a 14-week period. Interestingly, PyMT/Cav-1 (-/-) mice showed an accelerated onset of mammary tumors, with increased multiplicity and tumor burden ( similar to 2-fold). No significant differences were detected between PyMT/ Cav-1 (-/-) and PyMT/ Cav-1 (+/-) mice, indicating that complete loss of caveolin-1 is required to accelerate both tumorigenesis and metastasis. Molecularly, mammary tumor samples derived from PyMT/Cav-1 (-/-) mice showed ERK-1/2 hyperactivation, cyclin D1 up-regulation, and Rb hyperphosphorylation, consistent with dysregulated cell proliferation. PyMT/Cav-1 (-/-) mice also developed markedly advanced metastatic lung disease. Conversely, recombinant expression of Cav-1 in a highly metastatic PyMT mammary carcinoma-derived cell line, namely Met-1 cells, suppressed lung metastasis by similar to4.5-fold. In vitro, these Cav-1-expressing Met-1 cells (Met-1/ Cav-1) demonstrated a similar to 4.8-fold reduction in invasion through Matrigel-coated membranes. Interestingly, delivery of a cell permeable peptide encoding the caveolin-1 scaffolding domain ( residues 82 - 101) into Met-1 cells was sufficient to inhibit invasion. Coincident with this decreased invasive index, Met-1/ Cav-1 cells exhibited marked reductions in MMP-9 and MMP-2 secretion and associated gelatinolytic activity, as well as diminished ERK-1/2 signaling in response to growth factor stimulation. These results demonstrate, for the first time, that caveolin-1 is a potent suppressor of mammary tumor growth and metastasis using novel in vivo animal model approaches.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol & Med, Bronx, NY 10461 USA; Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; McGill Univ, Dept Med & Biochem, Montreal, PQ H3G 1Y6, Canada; Jacboi Med Ctr, Dept Pathol, Bronx, NY 10461 USA; Georgetown Univ, Dept Oncol, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Massachusetts Institute of Technology (MIT); Whitehead Institute; McGill University; Georgetown University	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol & Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Williams, Terence M/I-9614-2014; Scherer, Philipp E/K-7819-2012; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; Badano, Ines/0000-0003-3033-3802	NCI NIH HHS [P30 CA51008-13, R01CA86072, R01CA75503, R01CA70896] Funding Source: Medline; NIDDK NIH HHS [R01-DK55758, T32-DK07513] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070896, R01CA075503, P30CA051008, R01CA086072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007513, R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBINI A, 1987, CANCER RES, V47, P3239; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; COFFER P, 1994, ONCOGENE, V9, P911; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; FILMUS J, 1994, ONCOGENE, V9, P3627; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; GALARDY RE, 1994, CANCER RES, V54, P4715; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Galvez BG, 2004, MOL BIOL CELL, V15, P678, DOI 10.1091/mbc.E03-07-0516; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Han SE, 2004, INT J ONCOL, V24, P435; Hayashi K, 2001, CANCER RES, V61, P2361; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; Ichaso N, 2001, ONCOGENE, V20, P7908, DOI 10.1038/sj.onc.1204859; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Itoh T, 1998, CANCER RES, V58, P1048; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; Kruger JS, 2003, MOL CANCER RES, V1, P801; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li LK, 2001, CANCER RES, V61, P4386; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu J, 2002, J BIOL CHEM, V277, P10661, DOI 10.1074/jbc.M110354200; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Maglione JE, 2001, CANCER RES, V61, P8298; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Neumeister P, 2003, MOL BIOL CELL, V14, P2005, DOI 10.1091/mbc.02-07-0102; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Puyraimond A, 2001, EXP CELL RES, V262, P28, DOI 10.1006/excr.2000.5069; Razani B, 2001, J BIOL CHEM, V276, P38121; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schubert W, 2002, J BIOL CHEM, V277, P40091, DOI 10.1074/jbc.M205948200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLOAN EK, 2004, ONCOGENE        0830; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Tahir SA, 2001, CANCER RES, V61, P3882; Tamura Y, 1998, J MED CHEM, V41, P640, DOI 10.1021/jm9707582; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503; Woodman SE, 2003, AM J PATHOL, V162, P2059, DOI 10.1016/S0002-9440(10)64337-4; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199	85	253	262	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51630	51646		10.1074/jbc.M409214200	http://dx.doi.org/10.1074/jbc.M409214200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15355971	hybrid			2022-12-25	WOS:000225355800119
J	Koziczak, M; Hynes, NE				Koziczak, M; Hynes, NE			Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; ACTIVATED PROTEIN-KINASE; MAMMALIAN TARGET; MESSENGER-RNA; SIGNALING PATHWAYS; GENE-EXPRESSION; RAPAMYCIN; PHOSPHORYLATION; PROLIFERATION; INHIBITORS	Alterations in ErbB2 or fibroblast growth factor receptor-4 (FGFR-4) expression and activity occur in a significant fraction of breast cancers. Because signaling molecules and pathways cooperate to drive cancer progression, simultaneous targeting of multiple pathways is an appealing therapeutic strategy. With this in mind, we examined breast tumor cells for their sensitivity to the ErbB2 and FGFR inhibitors, PKI166 and PD173074, respectively. Simultaneous blocking of ErbB2 and FGFR-4 in MDA-MB-453 tumor cells had a stronger antiproliferative effect than treatment with individual inhibitors. Examination of cell cycle regulators revealed a novel translation-mediated mechanism whereby ErbB2 and FGFR-4 cooperate to regulate cyclin D1 levels. Our results showed that FGFR-4 and ErbB2 via the MAPK and the phosphatidylinositol 3-kinase/protein kinase B pathways, respectively, both contribute to the maintenance of constitutive activity of the mammalian target of rapamycin translational pathway. Dual inhibition of these receptors strongly blocked S6 kinase 1 (S6K1) activity and cyclin D1 translation, as attested by a decrease in cyclin D1 mRNA association with polysomes. Ectopic expression of active protein kinase B or active S6K1 abrogated the dual inhibitor-mediated down-regulation of cyclin D1 expression, demonstrating the importance of these FGFR-4/ErbB2 signaling targets in regulating cyclin D1 translation. S6K1 has the central role in this process, since small interfering RNA-targeted S6K1 depletion led to a decrease in cellular S6K1 activity and, as a consequence, repression of cyclin D1 expression. Thus, we propose a novel mechanism for controlling cyclin D1 expression downstream of combined activity of ErbB2 and FGFR-4 that involves S6K1-mediated translation.	Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	nancy.hynes@fmi.ch						Adams J, 2002, CURR OPIN CHEM BIOL, V6, P486, DOI 10.1016/S1367-5931(02)00357-5; Bange J, 2002, CANCER RES, V62, P840; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; BERGER U, 1989, CANCER RES, V49, P5176; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Couch FJ, 1999, CANCER RES, V59, P1408; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P2852; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; HERBER B, 1994, ONCOGENE, V9, P1295; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; Kawamata S, 1998, BLOOD, V91, P561, DOI 10.1182/blood.V91.2.561.561_561_569; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koziczak M, 2004, ONCOGENE, V23, P3501, DOI 10.1038/sj.onc.1207331; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Munster PN, 2002, CANCER RES, V62, P3132; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; Neve RM, 2002, ONCOGENE, V21, P4567, DOI 10.1038/sj.onc.1205555; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; Ross, 1998, Oncologist, V3, P237; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zubilewicz A, 2001, ONCOGENE, V20, P1403, DOI 10.1038/sj.onc.1204231	53	57	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50004	50011		10.1074/jbc.M404252200	http://dx.doi.org/10.1074/jbc.M404252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377668	hybrid			2022-12-25	WOS:000225229500057
J	Hung, GC; Brown, CR; Wolfe, AB; Liu, JJ; Chiang, HL				Hung, GC; Brown, CR; Wolfe, AB; Liu, JJ; Chiang, HL			Degradation of the gluconeogenic enzymes fructose-1,6-bisphosphatase and malate dehydrogenase is mediated by distinct proteolytic pathways and signaling events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; GLUCOSE-INDUCED DEGRADATION; PROTEIN COUPLED RECEPTOR; CATABOLITE INACTIVATION; MDH2 ISOZYME; CYCLIC-AMP; IN-VITRO; VACUOLE; PHOSPHORYLATION; REPRESSOR	The key gluconeogenic enzyme fructose-1,6-bisphosphatase (FBPase) is subjected to catabolite inactivation and degradation when glucose-starved cells are replenished with fresh glucose. In various studies, the proteasome and the vacuole have each been reported to be the major site of FBPase degradation. Because different growth conditions were used in these studies, we examined whether variations in growth conditions could alter the site of FBPase degradation. Here, we demonstrated that FBPase was degraded outside the vacuole ( most likely in the proteasome), when glucose was added to cells that were grown in low glucose media for a short period of time. By contrast, cells that were grown in the same low glucose media for longer periods of time degraded FBPase in the vacuole in response to glucose. Another gluconeogenic enzyme malate dehydrogenase (MDH2) showed the same degradation characteristics as FBPase in that the short term starvation of cells led to a non-vacuolar degradation, whereas long term starvation resulted in the vacuolar degradation of this protein. The N-terminal proline is required for the degradation of FBPase and MDH2 for both the vacuolar and nonvacuolar proteolytic pathways. The cAMP signaling pathway and the phosphorylation of glucose were needed for the vacuolar-dependent degradation of FBPase and MDH2. By contrast, the cAMP-dependent signaling pathway was not involved in the non-vacuolar degradation of these proteins, although the phosphorylation of glucose was required.	Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Brown, CR (corresponding author), Penn State Univ, Coll Med, Dept Cellular & Mol Physiol, 500 Univ Dr, Hershey, PA 17033 USA.	crb13@psu.edu			NIGMS NIH HHS [R01GM59480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2001, MICROBIOL MOL BIOL R, V65, P463, DOI 10.1128/MMBR.65.3.463-479.2001; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Brown CR, 2001, J BIOL CHEM, V276, P48017, DOI 10.1074/jbc.M109222200; Brown CR, 2003, J BIOL CHEM, V278, P25688, DOI 10.1074/jbc.M210549200; Brown CR, 2002, J CELL SCI, V115, P655; Brown CR, 2000, J CELL BIOL, V150, P65, DOI 10.1083/jcb.150.1.65; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; Chiang MC, 1998, J CELL BIOL, V140, P1347, DOI 10.1083/jcb.140.6.1347; CLIFTON D, 1993, J BACTERIOL, V175, P3289, DOI 10.1128/jb.175.11.3289-3294.1993; Cui DY, 2004, J BIOL CHEM, V279, P9713, DOI 10.1074/jbc.M310793200; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Eitzen G, 2000, EMBO J, V19, P6713, DOI 10.1093/emboj/19.24.6713; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; FOY JJ, 1978, J BACTERIOL, V136, P647, DOI 10.1128/JB.136.2.647-656.1978; GAMO FJ, 1994, EUR J BIOCHEM, V222, P879, DOI 10.1111/j.1432-1033.1994.tb18935.x; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gibson N, 2003, J BIOL CHEM, V278, P25628, DOI 10.1074/jbc.M213231200; Hammerle M, 1998, J BIOL CHEM, V273, P25000, DOI 10.1074/jbc.273.39.25000; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffman M, 1996, GENETICS, V143, P1555; HOLZER H, 1989, RBC-CELL BIOL REV, V21, P305; HOLZER H, 1986, BIOMED BIOCHIM ACTA, V45, P1657; Horak J, 2002, J BIOL CHEM, V277, P8248, DOI 10.1074/jbc.M107255200; Huang PH, 1997, J CELL BIOL, V136, P803, DOI 10.1083/jcb.136.4.803; Jiang Y, 1998, EMBO J, V17, P6942, DOI 10.1093/emboj/17.23.6942; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; JONES EW, 1991, J BIOL CHEM, V266, P7963; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Ludin K, 1998, P NATL ACAD SCI USA, V95, P6245, DOI 10.1073/pnas.95.11.6245; MAZON MJ, 1982, J BIOL CHEM, V257, P1128; MINARD KI, 1994, ARCH BIOCHEM BIOPHYS, V315, P302, DOI 10.1006/abbi.1994.1504; MINARD KI, 1992, J BIOL CHEM, V267, P17458; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Ostling J, 1998, EUR J BIOCHEM, V252, P162, DOI 10.1046/j.1432-1327.1998.2520162.x; Papamichos-Chronakis M, 2004, EMBO REP, V5, P368, DOI 10.1038/sj.embor.7400120; Price A, 2000, J CELL BIOL, V148, P1231, DOI 10.1083/jcb.148.6.1231; Regelmann J, 2003, MOL BIOL CELL, V14, P1652, DOI 10.1091/mbc.E02-08-0456; RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; Rolland F, 2002, FEMS YEAST RES, V2, P183, DOI 10.1111/j.1567-1364.2002.tb00084.x; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Rolland F, 2001, FEMS YEAST RES, V1, P33, DOI 10.1111/j.1567-1364.2001.tb00011.x; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Schule T, 2000, EMBO J, V19, P2161, DOI 10.1093/emboj/19.10.2161; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Shieh HL, 1998, J BIOL CHEM, V273, P3381, DOI 10.1074/jbc.273.6.3381; Shieh HL, 2001, J BIOL CHEM, V276, P10398, DOI 10.1074/jbc.M001767200; Smith FC, 1999, FEBS LETT, V453, P219, DOI 10.1016/S0014-5793(99)00725-5; Treitel MA, 1998, MOL CELL BIOL, V18, P6273, DOI 10.1128/MCB.18.11.6273; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; WALSH RB, 1991, GENETICS, V128, P521; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995; Zaragoza O, 1999, J BACTERIOL, V181, P2640, DOI 10.1128/JB.181.8.2640-2642.1999; Zaragoza O, 2001, FEBS LETT, V506, P262, DOI 10.1016/S0014-5793(01)02922-2	66	85	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49138	49150		10.1074/jbc.M404544200	http://dx.doi.org/10.1074/jbc.M404544200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358789	hybrid			2022-12-25	WOS:000225098100079
J	Nash, MS; Willets, JM; Billups, B; Challiss, RAJ; Nahorski, SR				Nash, MS; Willets, JM; Billups, B; Challiss, RAJ; Nahorski, SR			Synaptic activity augments muscarinic acetylcholine receptor-stimulated inositol 1,4,5-trisphosphate production to facilitate Ca2+ release in hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE; SIGNALING MICRODOMAINS; OSCILLATIONS; DYNAMICS; STORES; ACCUMULATION; ACTIVATION; MECHANISMS; FREQUENCY; AGONISTS	Intracellular Ca2+ store release contributes to activity-dependent synaptic plasticity in the central nervous system by modulating the amplitude, propagation, and temporal dynamics of cytoplasmic Ca2+ changes. However, neuronal Ca2+ stores can be relatively insensitive to increases in the store-mobilizing messenger inositol 1,4,5-trisphosphate (IP3). Using a fluorescent biosensor we have visualized M-1 muscarinic acetylcholine (mACh) receptor signaling in individual hippocampal neurons and observed increased IP3 production in the absence of concurrent Ca2+ store release. However, coincident glutamate-mediated synaptic activity elicited enhanced and oscillatory IP3 production that was dependent upon ongoing mACh receptor stimulation and S-alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid receptor activation of Ca2+ entry. Moreover, the enhanced levels of IP3 now mobilized Ca2+ from intracellular stores that were refractory to the activation of mACh receptors alone. We conclude that convergent ionotropic and metabotropic receptor inputs can facilitate Ca2+ signaling by enhancing IP3 production as well as augmenting release by Ca2+-induced Ca2+ release.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Challiss, RAJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	jc36@le.ac.uk	Challiss, R.A. John/A-9412-2008	Billups, Brian/0000-0001-5378-2809; Challiss, John/0000-0001-5506-2848				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; Augustine GJ, 2003, NEURON, V40, P331, DOI 10.1016/S0896-6273(03)00639-1; Bacci A, 1999, EUR J NEUROSCI, V11, P389, DOI 10.1046/j.1460-9568.1999.00440.x; BAIRD JG, 1991, J NEUROCHEM, V57, P629, DOI 10.1111/j.1471-4159.1991.tb03794.x; Barbara JG, 2002, BBA-PROTEINS PROTEOM, V1600, P12, DOI 10.1016/S1570-9639(02)00439-9; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Blackstone C, 2002, FRONT BIOSCI, V7, pD872, DOI 10.2741/blacksto; CHALLISS RAJ, 1991, J NEUROCHEM, V57, P1042, DOI 10.1111/j.1471-4159.1991.tb08255.x; Delmas P, 2004, TRENDS NEUROSCI, V27, P41, DOI 10.1016/j.tins.2003.10.013; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; DELRIO E, 1994, J NEUROCHEM, V63, P535; Eglen RM, 1996, PHARMACOL TOXICOL, V78, P59, DOI 10.1111/j.1600-0773.1996.tb00181.x; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Hardingham GE, 2001, NAT NEUROSCI, V4, P261, DOI 10.1038/85109; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; KHODAKHAH K, 1993, P NATL ACAD SCI USA, V90, P4976, DOI 10.1073/pnas.90.11.4976; Larkum ME, 2003, J PHYSIOL-LONDON, V549, P471, DOI 10.1113/jphysiol.2002.037614; Leinekugel X, 1997, NEURON, V18, P243, DOI 10.1016/S0896-6273(00)80265-2; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; Liu ZJ, 2003, J NEUROSCI, V23, P4156; Nahorski SR, 2003, TRENDS NEUROSCI, V26, P444, DOI 10.1016/S0166-2236(03)00178-4; Nakamura T, 2002, J PHYSIOL-LONDON, V543, P465, DOI 10.1113/jphysiol.2002.020362; Nakamura T, 2000, J NEUROSCI, V20, P8365, DOI 10.1523/JNEUROSCI.20-22-08365.2000; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Nishida M, 2003, EMBO J, V22, P4677, DOI 10.1093/emboj/cdg457; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Power JM, 2002, J NEUROSCI, V22, P3454; Rae MG, 2000, J NEUROSCI, V20, P8628; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rose CR, 2001, NEURON, V31, P519, DOI 10.1016/S0896-6273(01)00402-0; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Stutzmann GE, 2003, J NEUROSCI, V23, P758; Willets JM, 2004, J NEUROSCI, V24, P4157, DOI 10.1523/JNEUROSCI.5506-03.2004; Young KW, 2003, J BIOL CHEM, V278, P20753, DOI 10.1074/jbc.M211555200	40	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49036	49044		10.1074/jbc.M407277200	http://dx.doi.org/10.1074/jbc.M407277200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15342646	hybrid			2022-12-25	WOS:000225098100067
J	Orr, AW; Pallero, MA; Xiong, WC; Murphy-Ullrich, JE				Orr, AW; Pallero, MA; Xiong, WC; Murphy-Ullrich, JE			Thrombospondin induces RhoA inactivation through FAK-dependent signaling to stimulate focal adhesion disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; PAXILLIN TYROSINE PHOSPHORYLATION; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR-RELATED PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TERMINAL DOMAIN; CELL-MIGRATION; EPITHELIAL-CELLS; SWISS 3T3-CELLS; CROSS-TALK	Cells utilize dynamic interactions with the extracellular matrix to adapt to changing environmental conditions. Thrombospondin 1 (TSP1) induces focal adhesion disassembly and cell migration through a sequence (hep I) in its heparin-binding domain signaling through the calreticulin-low density lipoprotein receptor-related protein receptor complex. This involves the Galpha(i)-dependent activation of ERK and phosphoinositide ( PI) 3-kinase, both of which are required for focal adhesion disassembly. Focal adhesion kinase (FAK) regulates adhesion dynamics, acting in part by modulating RhoA activity, and FAK is implicated in ERK and PI 3-kinase activation. In this work, we sought to determine the role of FAK in TSP1-induced focal adhesion disassembly. TSP1/hep I does not stimulate focal adhesion disassembly in FAK knockout fibroblasts, whereas re-expressing FAK rescues responsiveness. Inhibiting FAK signaling through FRNK or FAK Y397F expression in endothelial cells also abrogates this response. TSP1/hep I stimulates a transient increase in FAK phosphorylation that requires calreticulin and Galpha(i), but not ERK or PI 3-kinase. Hep I does not activate ERK or PI 3-kinase in FAK knockout fibroblasts, suggesting activation occurs downstream of FAK. TSP1/hep I stimulates RhoA inactivation with kinetics corresponding to focal adhesion disassembly in a FAK, ERK, and PI 3-kinase-dependent manner. Furthermore, hep I does not stimulate focal adhesion disassembly in cells expressing constitutively active RhoA, suggesting that RhoA inactivation is required for this response. This is the first work to illustrate a connection between FAK phosphorylation in response to a soluble factor and RhoA inactivation, as well as the first report of PI 3-kinase and ERK in FAK regulation of RhoA activity.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, VH 668,1530 3rd Ave S, Birmingham, AL 35294 USA.	murphy@path.uab.edu	Orr, Anthony/P-8927-2015	Orr, Anthony/0000-0002-2377-213X	NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575, T32HL007918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NCRR NIH HHS [C06RR15490] Funding Source: Medline; NHLBI NIH HHS [T32 HL07918, HL44575] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Allen WE, 1997, J CELL SCI, V110, P707; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; Brunton VG, 2001, NEOPLASIA, V3, P215, DOI 10.1038/sj.neo.7900149; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Gahtan V, 1999, J VASC SURG, V29, P1031, DOI 10.1016/S0741-5214(99)70244-2; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Goicoechea S, 2002, J BIOL CHEM, V277, P37219, DOI 10.1074/jbc.M202200200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Greenwood JA, 1998, J BIOL CHEM, V273, P1755, DOI 10.1074/jbc.273.3.1755; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; ILLC D, 1995, NATURE, V377, P539; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099; Lymn JS, 1999, ARTERIOSCL THROM VAS, V19, P2133, DOI 10.1161/01.ATV.19.9.2133; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Orr AW, 2004, FRONT BIOSCI-LANDMRK, V9, P1254, DOI 10.2741/1239; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Orr AW, 2002, J BIOL CHEM, V277, P20453, DOI 10.1074/jbc.M112091200; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Pfaff M, 1999, FEBS LETT, V460, P17, DOI 10.1016/S0014-5793(99)01250-8; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Ren XD, 2000, J CELL SCI, V113, P3673; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Ren XR, 2001, J CELL BIOL, V152, P971, DOI 10.1083/jcb.152.5.971; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rodriguez-Fernandez JL, 1999, BIOESSAYS, V21, P1069, DOI 10.1002/(SICI)1521-1878(199912)22:1<1069::AID-BIES13>3.0.CO;2-C; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sharma SV, 1998, ONCOGENE, V17, P271, DOI 10.1038/sj.onc.1201921; Taylor JM, 1999, J CELL SCI, V112, P231; TRANQUI L, 1995, EXP CELL RES, V217, P149, DOI 10.1006/excr.1995.1074; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; Zamir E, 2001, J CELL SCI, V114, P3583	73	56	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48983	48992		10.1074/jbc.M404881200	http://dx.doi.org/10.1074/jbc.M404881200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371459	hybrid			2022-12-25	WOS:000225098100061
J	Sanjay, KS; Singh, SK; Gurha, P; Tran, EJ; Maxwell, ES; Gupta, R				Sanjay, KS; Singh, SK; Gurha, P; Tran, EJ; Maxwell, ES; Gupta, R			Sequential 2 '-O-methylation of archaeal pre-tRNA(Trp) nucleotides is guided by the intron-encoded but trans-acting box c/D ribonucleoprotein of pre-tRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RNAS; HALOBACTERIUM-VOLCANII; RIBOSE METHYLATION; SNORNP; PROTEIN; IDENTIFICATION; TRANSCRIPTION; PRECURSOR; HOMOLOGS	Haloferax volcanii pre-tRNA(Trp) processing requires box C/D ribonucleoprotein (RNP)-guided 2'-O-methylation of nucleotides C34 and U39 followed by intron excision. Positioning of the box C/D guide RNA within the intron of this pre-tRNA led to the assumption that nucleotide methylation is guided by the cis-positioned box C/D RNPs. We have now investigated the mechanism of 2'-O-methylation for the H. volcanii pre-tRNA(Trp) in vitro by assembling methylation-competent box C/D RNPs on both the pre-tRNA and the excised intron ( both linear and circular forms) using Methanocaldococcus jannaschii box C/D RNP core proteins. With both kinetic studies and single nucleotide substitutions of target and guide nucleotides, we now demonstrate that pre-tRNA methylation is guided in trans by the intron-encoded box C/D RNPs positioned in either another pre-tRNA(Trp) or in the excised intron. Methylation by in vitro assembled RNPs prefers but does not absolutely require Watson-Crick pairing between the guide and target nucleotides. We also demonstrate for the first time that methylation of two nucleotides guided by a single box C/D RNA is sequential, that is, box C'/D' RNP-guided U39 methylation first requires box C/D RNP-guided methylation of C34. Methylation of the two nucleotides of exogenous pre-tRNA(Trp) added to an H. volcanii cell extract also occurs sequentially and is also accomplished in trans using RNPs that pre-exist in the extract. Thus, this trans mechanism is analogous to eukaryal pre-rRNA 2'-O-methylation guided by intron-encoded but trans-acting box C/D small nucleolar RNPs. This trans mechanism could explain the observed accumulation of the excised H. volcanii pre-tRNA(Trp) intron in vivo. A trans mechanism would also eliminate the obligatory refolding of the pre-tRNA that would be required to carry out two cis-methylation reactions before pre-tRNA splicing.	So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA; N Carolina State Univ, Dept Mol & Struct Biochem, Raleigh, NC 27695 USA	Southern Illinois University System; Southern Illinois University; University of North Carolina; North Carolina State University	Gupta, R (corresponding author), So Illinois Univ, Dept Biochem & Mol Biol, Carbondale, IL 62901 USA.	rgupta@siumed.edu	Tran, Elizabeth/G-7818-2018	Tran, Elizabeth/0000-0002-9541-004X; Gurha, Priyatansh/0000-0003-4867-7785	NIGMS NIH HHS [GM55945] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Bortolin ML, 2003, NUCLEIC ACIDS RES, V31, P6524, DOI 10.1093/nar/gkg860; Cahill NM, 2002, EMBO J, V21, P3816, DOI 10.1093/emboj/cdf376; Cavaille J, 1998, NUCLEIC ACIDS RES, V26, P1576, DOI 10.1093/nar/26.7.1576; d'Orval BC, 2001, NUCLEIC ACIDS RES, V29, P4518, DOI 10.1093/nar/29.22.4518; DANIELS CJ, 1985, J BIOL CHEM, V260, P3132; Decatur WA, 2003, J BIOL CHEM, V278, P695, DOI 10.1074/jbc.R200023200; Dennis PP, 2001, MOL MICROBIOL, V40, P509, DOI 10.1046/j.1365-2958.2001.02381.x; Filipowicz W, 2002, CURR OPIN CELL BIOL, V14, P319, DOI 10.1016/S0955-0674(02)00334-4; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; GUPTA R, 1984, J BIOL CHEM, V259, P9461; King TH, 2001, MOL CELL BIOL, V21, P7731, DOI 10.1128/MCB.21.22.7731-7746.2001; Kiss T, 2002, CELL, V109, P145, DOI 10.1016/S0092-8674(02)00718-3; Kuhn JF, 2002, NUCLEIC ACIDS RES, V30, P931, DOI 10.1093/nar/30.4.931; Maden BEH, 2001, METHODS, V25, P374, DOI 10.1006/meth.2001.1250; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; Newman DR, 2000, RNA, V6, P861, DOI 10.1017/S1355838200992446; Omer AD, 2000, SCIENCE, V288, P517, DOI 10.1126/science.288.5465.517; Omer AD, 2003, MOL MICROBIOL, V48, P617, DOI 10.1046/j.1365-2958.2003.03483.x; Omer AD, 2002, P NATL ACAD SCI USA, V99, P5289, DOI 10.1073/pnas.082101999; Rashid R, 2003, J MOL BIOL, V333, P295, DOI 10.1016/j.jmb.2003.08.012; Salgia SR, 2003, RNA, V9, P319, DOI 10.1261/rna.2118203; Szewczak LBW, 2002, CHEM BIOL, V9, P1095, DOI 10.1016/S1074-5521(02)00239-9; Tang TH, 2002, P NATL ACAD SCI USA, V99, P7536, DOI 10.1073/pnas.112047299; Terns MP, 2002, GENE EXPRESSION, V10, P17; Tran EJ, 2003, EMBO J, V22, P3930, DOI 10.1093/emboj/cdg368; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Zofallova L, 2000, RNA, V6, P1019, DOI 10.1017/S1355838200000613	28	51	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47661	47671		10.1074/jbc.M408868200	http://dx.doi.org/10.1074/jbc.M408868200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347671	hybrid			2022-12-25	WOS:000224957000031
J	Zvonic, S; Hogan, JC; Arbour-Reily, P; Mynatt, RL; Stephens, JM				Zvonic, S; Hogan, JC; Arbour-Reily, P; Mynatt, RL; Stephens, JM			Effects of cardiotrophin on adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; ACTIVATED PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ONCOSTATIN-M; IN-VITRO; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; SIGNAL TRANSDUCERS; RECEPTOR COMPONENT; INSULIN-RESISTANCE	Cardiotrophin (CT-1) is a naturally occurring protein member of the interleukin (IL)-6 cytokine family and signals through the gp130/leukemia inhibitory factor receptor (LIFR) heterodimer. The formation of gp130/LIFR complex triggers the auto/trans-phosphorylation of associated Janus kinases, leading to the activation of Janus kinase/STAT and MAPK (ERK1 and -2) signaling pathways. Since adipocytes express both gp130 and LIFR proteins and are responsive to other IL-6 family cytokines, we examined the effects of CT-1 on 3T3-L1 adipocytes. Our studies have shown that CT-1 administration results in a dose- and time-dependent activation and nuclear translocation of STAT1, -3, -5A, and -5B as well as ERK1 and -2. We also confirmed the ability of CT-1 to induce signaling in fat cells in vivo. Our studies revealed that neither CT-1 nor ciliary neurotrophic factor treatment affected adipocyte differentiation. However, acute CT-1 treatment caused an increase in SOCS-3 mRNA in adipocytes and a transient decrease in peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA that was regulated by the binding of STAT1 to the PPARgamma2 promoter. The effects of CT-1 on SOCS-3 and PPARgamma mRNA were independent of MAPK activation. Chronic administration of CT-1 to 3T3-L1 adipocytes resulted in a decrease of both fatty acid synthase and insulin receptor substrate-1 protein expression yet did not effect the expression of a variety of other adipocyte proteins. Moreover, chronic CT-1 treatment resulted in the development of insulin resistance as judged by a decrease in insulin-stimulated glucose uptake. In summary, CT-1 is a potent regulator of signaling in adipocytes in vitro and in vivo, and our current efforts are focused on determining the role of this cardioprotective cytokine on adipocyte physiology.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Stephens, JM (corresponding author), Louisiana State Univ, Dept Biol Sci, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.	jsteph1@lsu.edu	Stephens, Jacqueline M/R-5217-2018; Mynatt, Randall L/N-1980-2017	Mynatt, Randall L/0000-0003-4399-0019	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052968] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK52968-02] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2003, REV CARDIOVASC MED; Aubert J, 1999, CELL MOL LIFE SCI, V56, P538, DOI 10.1007/s000180050450; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Benigni F, 1996, AM J PATHOL, V149, P1847; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Freed DH, 2003, MOL CELL BIOCHEM, V254, P247, DOI 10.1023/A:1027332504861; Henderson JT, 1996, CYTOKINE, V8, P784, DOI 10.1006/cyto.1996.0104; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Hogan JC, 2001, BIOCHEM BIOPH RES CO, V287, P484, DOI 10.1006/bbrc.2001.5606; Jin HK, 1996, CYTOKINE, V8, P920, DOI 10.1006/cyto.1996.0123; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KUMAR G, 1994, J IMMUNOL, V153, P4436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATINI R, 1994, J CARDIOVASC PHARM, V23, P1, DOI 10.1097/00005344-199401000-00026; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Pennica D, 1996, CYTOKINE, V8, P183, DOI 10.1006/cyto.1996.0026; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PETERS M, 1995, FEBS LETT, V372, P177, DOI 10.1016/0014-5793(95)00972-C; Reaven G, 2004, RECENT PROG HORM RES, V59, P207, DOI 10.1210/rp.59.1.207; ROBINSON RC, 1994, CELL, V77, P1101, DOI 10.1016/0092-8674(94)90449-9; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; Sowers JR, 2004, MED CLIN N AM, V88, P63, DOI 10.1016/S0025-7125(03)00128-7; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Tanaka T, 1999, DIABETOLOGIA, V42, P702, DOI 10.1007/s001250051218; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; Zvonic S, 2003, BIOCHEM BIOPH RES CO, V302, P359, DOI 10.1016/S0006-291X(03)00179-7; Zvonic S, 2003, J BIOL CHEM, V278, P2228, DOI 10.1074/jbc.M205871200	35	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47572	47579		10.1074/jbc.M403998200	http://dx.doi.org/10.1074/jbc.M403998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339920	hybrid, Green Published			2022-12-25	WOS:000224957000021
J	Bleijlevens, B; Buhrke, T; van der Linden, E; Friedrich, B; Albracht, SPJ				Bleijlevens, B; Buhrke, T; van der Linden, E; Friedrich, B; Albracht, SPJ			The auxiliary protein HypX provides oxygen tolerance to the soluble [NiFe]-hydrogenase of Ralstonia eutropha H16 by way of a cyanide ligand to nickel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD-REDUCING HYDROGENASE; OXIDOREDUCTASE COMPLEX I; ALCALIGENES-EUTROPHUS; NIFE-HYDROGENASE; ACTIVE-SITE; CARBON-MONOXIDE; CHROMATIUM-VINOSUM; METHANOBACTERIUM-THERMOAUTOTROPHICUM; DEPENDENT HYDROGENASE; DESULFOVIBRIO-GIGAS	The hypX gene of the facultative lithoautotrophic bacterium Ralstonia eutropha is part of a cassette of accessory genes (the hyp cluster) required for the proper assembly of the active site of the [NiFe]-hydrogenases in the bacterium. A deletion of the hypX gene led to a severe growth retardation under lithoautotrophic conditions with 5 or 15% oxygen, when the growth was dependent on the activity of the soluble NAD(+)-reducing hydrogenase. The enzymatic and infrared spectral properties of the soluble hydrogenase purified from a HypX-negative strain were compared with those from an enzyme purified from a HypX-positive strain. In activity assays under anaerobic conditions both enzyme preparations behaved the same. Under aerobic conditions, however, the mutant enzyme became irreversibly inactivated during H-2 oxidation with NAD(+) or benzyl viologen as the electron acceptor. Infrared spectra and chemical determination of cyanide showed that one of the four cyanide groups in the wild-type enzyme was missing in the mutant enzyme. The data are consistent with the proposal that the HypX protein is specifically involved in the biosynthetic pathway that delivers the nickel-bound cyanide. The data support the proposal that this cyanide is crucial for the enzyme to function under aerobic conditions.	Univ Amsterdam, Swammerdam Inst Life Sci, NL-1018 TV Amsterdam, Netherlands; Humboldt Univ, Inst Biol Mikrobiol, D-10115 Berlin, Germany	University of Amsterdam; Humboldt University of Berlin	Albracht, SPJ (corresponding author), Univ Amsterdam, Swammerdam Inst Life Sci, Plantage Muidergracht 12, NL-1018 TV Amsterdam, Netherlands.	asiem@science.uva.nl						ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; Afting C, 1998, ARCH MICROBIOL, V169, P206, DOI 10.1007/s002030050562; ALBRACHT SPJ, 1994, BBA-BIOENERGETICS, V1188, P167, DOI 10.1016/0005-2728(94)90036-1; Albracht SPJ, 2003, BBA-BIOENERGETICS, V1557, P41, DOI 10.1016/S0005-2728(02)00393-6; Albracht SPJ, 2000, FEBS LETT, V485, P1, DOI 10.1016/S0014-5793(00)02172-4; BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGLEY KA, 1994, BIOCHEMISTRY-US, V33, P9229, DOI 10.1021/bi00197a026; Bernhard M, 1996, J BACTERIOL, V178, P4522, DOI 10.1128/jb.178.15.4522-4529.1996; Blokesch M, 2002, J MOL BIOL, V324, P287, DOI 10.1016/S0022-2836(02)01070-7; BRADFORD MM, 1976, ANAL BIOCHEM, V100, P201; Buhrke T, 2001, J BACTERIOL, V183, P7087, DOI 10.1128/JB.183.24.7087-7093.2001; Buhrke T, 1998, ARCH MICROBIOL, V170, P460, DOI 10.1007/s002030050667; Cammack R., 2001, HYDROGEN FUEL LEARNI; COREMANS JMCC, 1989, BIOCHIM BIOPHYS ACTA, V997, P256, DOI 10.1016/0167-4838(89)90196-9; Davidson G, 2000, BIOCHEMISTRY-US, V39, P7468, DOI 10.1021/bi000300t; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; DeLacey AL, 2002, J BIOL INORG CHEM, V7, P318, DOI 10.1007/s00775-001-0301-7; Erkens A, 1996, J BIOL INORG CHEM, V1, P99, DOI 10.1007/s007750050028; FRIEDRICH B, 1981, J BACTERIOL, V145, P1144, DOI 10.1128/JB.145.3.1144-1149.1981; Garcin E, 1999, STRUCT FOLD DES, V7, P557, DOI 10.1016/S0969-2126(99)80072-0; George SJ, 2004, BIOCHEMISTRY-US, V43, P6808, DOI 10.1021/bi049853k; Gu ZJ, 1996, J AM CHEM SOC, V118, P11155, DOI 10.1021/ja962429p; Happe RP, 2000, FEBS LETT, V466, P259, DOI 10.1016/S0014-5793(99)01799-8; Happe RP, 1997, NATURE, V385, P126, DOI 10.1038/385126a0; Higuchi Y, 1999, STRUCT FOLD DES, V7, P549, DOI 10.1016/S0969-2126(99)80071-9; Jones AK, 2002, CHEM COMMUN, P866, DOI 10.1039/b201337a; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; Lyon EJ, 2004, EUR J BIOCHEM, V271, P195, DOI 10.1046/j.1432-1033.2003.03920.x; Massanz C, 1998, J BACTERIOL, V180, P1023, DOI 10.1128/JB.180.5.1023-1029.1998; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; Ogata H, 2002, J AM CHEM SOC, V124, P11628, DOI 10.1021/ja012645k; PETROV RR, 1989, ARCH BIOCHEM BIOPHYS, V268, P287, DOI 10.1016/0003-9861(89)90590-0; Pierik AJ, 1999, J BIOL CHEM, V274, P3331, DOI 10.1074/jbc.274.6.3331; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; Rey L, 1996, MOL GEN GENET, V252, P237; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SCHLESIER M, 1981, ARCH MICROBIOL, V129, P150, DOI 10.1007/BF00455352; SCHNEIDER K, 1981, BIOCHEM J, V193, P99, DOI 10.1042/bj1930099; SCHNEIDER K, 1979, BIOCHIM BIOPHYS ACTA, V578, P445, DOI 10.1016/0005-2795(79)90175-2; SCHNEIDER K, 1976, BIOCHIM BIOPHYS ACTA, V452, P66, DOI 10.1016/0005-2744(76)90058-9; SCHNEIDER K, 1986, BIOCHIMIE, V68, P5, DOI 10.1016/S0300-9084(86)81062-8; Schwartz E, 1998, J BACTERIOL, V180, P3197, DOI 10.1128/JB.180.12.3197-3204.1998; Shima S, 2004, ANGEW CHEM INT EDIT, V43, P2547, DOI 10.1002/anie.200353763; SIMON R, 1983, BIOTECHNOLOGY, V1, P717; TRANBETCKE A, 1990, J BACTERIOL, V172, P2920, DOI 10.1128/jb.172.6.2920-2929.1990; Van der Linden E, 2004, J BIOL INORG CHEM, V9, P616, DOI 10.1007/s00775-004-0555-y; van der Linden E, 2004, EUR J BIOCHEM, V271, P801, DOI 10.1111/j.1432-1033.2004.03984.x; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; Volbeda A, 1996, J AM CHEM SOC, V118, P12989, DOI 10.1021/ja962270g	50	60	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46686	46691		10.1074/jbc.M406942200	http://dx.doi.org/10.1074/jbc.M406942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342627	hybrid			2022-12-25	WOS:000224832400045
J	Nonaka, T; Fujihashi, M; Kita, A; Saeki, K; Ito, S; Horikoshi, K; Miki, K				Nonaka, T; Fujihashi, M; Kita, A; Saeki, K; Ito, S; Horikoshi, K; Miki, K			The crystal structure of an oxidatively stable subtilisin-like alkaline serine protease, KP-43, with a C-terminal beta-barrel domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; 3-DIMENSIONAL STRUCTURE; ALKALIPHILIC BACILLUS; AQUALYSIN-I; PRO-SEQUENCE; COMPLEX; INHIBITOR; TRANSPORTER; SITE	The crystal structure of an oxidatively stable subtilisin-like alkaline serine protease, KP-43 from Bacillus sp. KSM-KP43, with a C-terminal extension domain, was determined by the multiple isomorphous replacements method with anomalous scattering. The native form was refined to a crystallographic R factor of 0.134 (R-free of 0.169) at 1.30-Angstrom resolution. KP-43 consists of two domains, a subtilisin-like alpha/beta domain and a C-terminal jelly roll beta-barrel domain. The topological architecture of the molecule is similar to that of kexin and furin, which belong to the subtilisin-like proprotein convertases, whereas the amino acid sequence and the binding orientation of the C-terminal beta-barrel domain both differ in each case. Since the C-terminal domains of subtilisin-like proprotein convertases are essential for folding themselves, the domain of KP-43 is also thought to play such a role. KP-43 is known to be an oxidation-resistant protease among the general subtilisin-like proteases. To investigate how KP-43 resists oxidizing reagents, the structure of oxidized KP-43 was also determined and refined to a crystallographic R factor of 0.142 (R-free of 0.212) at 1.73-Angstrom resolution. The structure analysis revealed that Met-256, adjacent to catalytic Ser-255, was oxidized similarly to an equivalent residue in subtilisin BPN'. Although KP-43, as well as proteinase K and subtilisin Carlsberg, lose their hydrolyzing activity against synthetic peptides after oxidation treatment, all of them retain 70 - 80% activity against proteinaceous substrates. These results, as well as the beta-casein digestion pattern analysis, have indicated that the oxidation of the methionine adjacent to the catalytic serine is not a dominant modification but might alter the substrate specificities.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Inst Res Reactor, Osaka 5900494, Japan; Kao Corp, Biol Sci Labs, Haga, Tochigi 3213497, Japan; Japan Agcy Marine Earth Sci & Technol, Kanagawa 2370061, Japan; SPring8, RIKEN Harima Inst, Mikazuki, Hyogo 6795148, Japan	Kyoto University; Kyoto University; KAO Corporation; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Japan Synchrotron Radiation Research Institute; RIKEN	Miki, K (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.	miki@kuchem.kyoto-u.ac.jp						Anson ML, 1938, J GEN PHYSIOL, V22, P79, DOI 10.1085/jgp.22.1.79; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOTT R, 1988, J BIOL CHEM, V263, P7895; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DAUTER Z, 1988, FEBS LETT, V236, P171, DOI 10.1016/0014-5793(88)80309-0; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESTELL DA, 1985, J BIOL CHEM, V260, P6518; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Good JR, 2003, DEVELOPMENT, V130, P2953, DOI 10.1242/dev.00523; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Holyoak T, 2003, BIOCHEMISTRY-US, V42, P6709, DOI 10.1021/bi034434t; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim DW, 1997, BIOCHEM BIOPH RES CO, V231, P535, DOI 10.1006/bbrc.1996.5899; Kim DW, 2000, BIOCHEM BIOPH RES CO, V277, P216, DOI 10.1006/bbrc.2000.3657; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE MC, 2000, J APPL CRYSTALLOGR, V33, P990; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MCPHALEN CA, 1985, FEBS LETT, V188, P55, DOI 10.1016/0014-5793(85)80873-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nonaka T, 2001, ACTA CRYSTALLOGR D, V57, P717, DOI 10.1107/S0907444901002566; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAHLER A, 1984, EMBO J, V3, P1311, DOI 10.1002/j.1460-2075.1984.tb01968.x; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Saeki K, 2002, EXTREMOPHILES, V6, P65, DOI 10.1007/s007920100224; Saeki K, 2000, BIOCHEM BIOPH RES CO, V279, P313, DOI 10.1006/bbrc.2000.3931; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHAULSKY G, 1995, GENE DEV, V9, P1111, DOI 10.1101/gad.9.9.1111; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Siezen RJ, 1997, PROTEIN SCI, V6, P501; STAUFFER CE, 1969, J BIOL CHEM, V244, P5333; TAKEUCHI Y, 1991, J MOL BIOL, V221, P309, DOI 10.1016/0022-2836(91)80221-F; TERADA I, 1990, J BIOL CHEM, V265, P6576; Ueda K, 2003, P NATL ACAD SCI USA, V100, P5622, DOI 10.1073/pnas.0631617100; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107	39	31	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47344	47351		10.1074/jbc.M409089200	http://dx.doi.org/10.1074/jbc.M409089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342641	hybrid			2022-12-25	WOS:000224832400123
J	Saoncella, S; Calautti, E; Neveu, W; Goetinck, PF				Saoncella, S; Calautti, E; Neveu, W; Goetinck, PF			Syndecan-4 regulates ATF-2 transcriptional activity in a Rac1-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASES; GENE-EXPRESSION; RHO-GTPASES; RAC; TRANSDUCTION; INTEGRINS; BINDING; JUN; PATHWAYS	Syndecan-4 is a transmembrane heparan sulfate proteoglycan that co-operates with integrins during cell-matrix interactions for the assembly of focal adhesions and actin stress fibers and in the phosphorylation of focal adhesion kinase (FAK) on Tyr(397). These cellular events are regulated by the small GTPase Rho, and in the absence of syndecan-4 ligation, cellular levels of GTP-bound Rho are decreased implicating syndecan-4 in the regulation of the small GTPases. In the present study we report that, compared with wild type cells, fibronectin-adherent syndecan-4-null fibroblasts showed enhanced lamellipodia and increased Rac1 activity that could be down-regulated by re-expression of syndecan-4 in the mutant cells. Consistent with the role for Rac1 in activating p38 and JNK signaling, syndecan-4-null cells display higher levels of active p38 MAPK and JNK that were abolished by the expression of a dominant-negative RacN17 mutant. Since p38 and JNK regulate gene expression by phosphorylating and activating transcription factors, we compared both the phosphorylation state and the transcriptional activity of the ATF-2 transcription factor, as a direct p38 and JNK target in syndecan-4-null and wild type cells. In the absence of syndecan-4, both ATF-2 phosphorylation and transcriptional activity were significantly more elevated compared with wild type cells, and both activities were decreased either by the re-expression of syndecan-4 or by the expression of RacN17. Our results reveal a novel function for syndecan-4 in modulating nuclear transcriptional activity and indicate an underlying mechanism that acts at the level of Rac1-p38/JNK signaling.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Goetinck, PF (corresponding author), MGH E, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	paul.goetinck@cbrc2.mgh.harvard.edu	Calautti, Enzo/M-8283-2018	Calautti, Enzo/0000-0002-4439-9709	NICHD NIH HHS [HD-37490] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037490] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Igishi T, 1999, J BIOL CHEM, V274, P30738, DOI 10.1074/jbc.274.43.30738; Ishiguro K, 2001, J BIOL CHEM, V276, P47483, DOI 10.1074/jbc.M106268200; Ishiguro K, 2001, LAB INVEST, V81, P509, DOI 10.1038/labinvest.3780259; Kim J, 2001, BIOCHEM J, V360, P239, DOI 10.1042/0264-6021:3600239; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Li L, 2002, ARTERIOSCL THROM VAS, V22, P61, DOI 10.1161/hq0102.100314; LI L, 2002, J VASC SURG, V36, P1; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ott VL, 1998, J BIOL CHEM, V273, P35291, DOI 10.1074/jbc.273.52.35291; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Schwartz MA, 2001, J CELL SCI, V114, P2553; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wilcox-Adelman SA, 2002, GLYCOCONJUGATE J, V19, P305, DOI 10.1023/A:1025304602057; Wilcox-Adelman SA, 2002, J BIOL CHEM, V277, P32970, DOI 10.1074/jbc.M201283200; Zhang YF, 1999, J BIOL CHEM, V274, P14786, DOI 10.1074/jbc.274.21.14786	36	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47172	47176		10.1074/jbc.C400299200	http://dx.doi.org/10.1074/jbc.C400299200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15371457	hybrid			2022-12-25	WOS:000224832400104
J	Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE				Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE			Alternative splicing and mutation status of CHEK2 in stage III breast cancer	ONCOGENE			English	Article						breast cancer; CHEK2; mutation; splicing; p53	DNA-DAMAGE CHECKPOINT; MDM2 TRANSCRIPTS; TUMOR-SUPPRESSOR; HEREDITARY BREAST; KINASE CHK2; P53; PHOSPHORYLATION; EXPRESSION; PROTEIN; GENE	The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.	Univ Bergen, Dept Mol Biol, Bergen, Norway; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Haukeland Hosp, Inst Med, Sect Oncol, N-5021 Bergen, Norway; Norwegian Radium Hosp, Dept Genet, Oslo, Norway	University of Bergen; Danish Cancer Society; University of Bergen; Haukeland University Hospital; University of Oslo	Lonning, PE (corresponding author), Univ Bergen, Dept Mol Biol, Bergen, Norway.	per.lonning@helse-bergen.no	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Lonning, Per Eystein/0000-0002-8890-6303				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartel F, 2004, INT J ONCOL, V24, P143; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Evdokiou A, 2001, INT J ONCOL, V19, P625; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Frebourg T, 2001, B CANCER, V88, P581; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Ishimoto O, 2002, CANCER RES, V62, P636; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2000, Science, V289, P359; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zheng YX, 2001, CARCINOGENESIS, V22, P2005, DOI 10.1093/carcin/22.12.2005; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	52	63	64	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8535	8544		10.1038/sj.onc.1207928	http://dx.doi.org/10.1038/sj.onc.1207928			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361853				2022-12-25	WOS:000224870700014
J	Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K				Duensing, S; Duensing, A; Lee, DC; Edwards, KM; Piboonniyom, SO; Manuel, E; Skaltsounis, L; Meijer, L; Munger, K			Cyclin-dependent kinase inhibitor indirubin-3 '-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies	ONCOGENE			English	Article						cancer; cell cycle; centrosome anomalies; chromosomal instability; human papillomavirus	RETINOBLASTOMA TUMOR-SUPPRESSOR; E7 ONCOPROTEIN; CELL-DIVISION; DNA-SYNTHESIS; DUPLICATION; CDK2; DEGRADATION; INDUCTION; PROTEIN; DIFFERENTIATION	Dysregulation of the centrosome duplication cycle has been implicated in tumorigenesis. Our previous work has shown that the human papillomavirus type 16 (HPV-16) E7 oncoprotein rapidly induces aberrant centrosome and centriole duplication in normal human cells. We report here that HPVE7-induced abnormal centriole duplication is specifically abrogated by a small molecule CDK inhibitor, indirubin-3'-oxime (IO), but not a kinase-inactive derivative. Importantly, normal centriole duplication was not markedly affected by IO, and the inhibitory effects were observed at concentrations that did not affect the G1/S transition of the cell division cycle. Depletion of CDK2 by siRNA similarly abrogated HPV E7-induced abnormal centrosome duplication and ectopic expression of CDK2 in combination with cyclin E or cyclin A could rescue the inhibitory effect of IO. IO treatment also reduced the steady-state level of aneuploid cells in HPV-16 E7-expressing cell populations. Our results suggest that cyclin/CDK2 activity is critically involved in abnormal centrosome duplication induced by HPV-16 E7 oncoprotein expression, but may be dispensable for normal centrosome duplication and cell cycle progression.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Athens, Dept Pharm, Div Pharmacognosy & Nat Prod Chem, GR-15771 Athens, Greece; CNRS, Biol Stn, Cell Cycle Grp, F-29682 Roscoff, Bretagne, France	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; National & Kapodistrian University of Athens; Centre National de la Recherche Scientifique (CNRS)	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu; karl_munger@hms.harvard.edu	skaltsounis, alexios leandros/AAE-9617-2019; MEIJER, Laurent/ABE-7465-2021	Manuel, Edwin/0000-0002-4602-7060; , laurent/0000-0003-3511-4916; Duensing, Anette/0000-0002-0168-4067; Munger, Karl/0000-0003-3288-9935				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Boyer SN, 1996, CANCER RES, V56, P4620; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Damiens E, 2001, ONCOGENE, V20, P3786, DOI 10.1038/sj.onc.1204503; Davies TG, 2001, STRUCTURE, V9, P389, DOI 10.1016/S0969-2126(01)00598-6; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Duensing S, 2001, CANCER RES, V61, P2356; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Klausner RD, 2002, CANCER CELL, V1, P3, DOI 10.1016/S1535-6108(02)00020-X; Knockaert M, 2004, ONCOGENE, V23, P4400, DOI 10.1038/sj.onc.1207535; KURIYAMA R, 1986, CELL MOTIL CYTOSKEL, V6, P355, DOI 10.1002/cm.970060402; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Marko D, 2001, BRIT J CANCER, V84, P283, DOI 10.1054/bjoc.2000.1546; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumoto Y, 2002, SCIENCE, V295, P499, DOI 10.1126/science.1065693; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Paoletti A, 1996, J CELL SCI, V109, P3089; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Piboonniyom SO, 2003, CANCER RES, V63, P476; Pihan GA, 1998, CANCER RES, V58, P3974; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Polychronopoulos P, 2004, J MED CHEM, V47, P935, DOI 10.1021/jm031016d; Ruesch MN, 1998, VIROLOGY, V250, P19, DOI 10.1006/viro.1998.9359; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1996, ONCOGENE, V13, P2323; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	60	61	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8206	8215		10.1038/sj.onc.1208012	http://dx.doi.org/10.1038/sj.onc.1208012			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378001				2022-12-25	WOS:000224749500003
J	Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND				Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND			The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression	ONCOGENE			English	Article						forkhead-associated domain; p300; AP-1; Swi/Snf; BRG1	NF-KAPPA-B; DNA-DAMAGE CHECKPOINT; REPLICATION FACTOR-C; SWI/SNF COMPLEX; LARGE SUBUNIT; P53; BINDING; TRANSACTIVATION; TRANSCRIPTION; SPECIFICITY	Smad nuclear interacting protein 1 (SNIP1) is an evolutionarily conserved protein containing a forkhead-associated (FHA) domain that regulates gene expression through interactions with multiple transcriptional regulators. Here, we have used short interfering RNAs (siRNAs) to knockdown SNIP1 expression in human cell lines. Surprisingly, we found that reduction in SNIP1 levels resulted in significantly reduced cell proliferation and accumulation of cells in the G1 phase of the cell cycle. Consistent with this result, we observed that cyclin D1 protein and mRNA levels were reduced. Moreover, SNIP1 depletion results in inhibition of cyclin D1 promoter activity in a manner dependent upon a previously characterized binding site for the AP-1 transcription factor family. SNIP1 itself is induced upon serum stimulation immediately prior to cyclin D1 expression. These effects were independent of the tumour suppressors p53 and retinoblastoma (Rb), but were consistent with an interaction with BRG1, a component of the ATP-dependent chromatin remodelling complex, Swi/Snf. These results define both a new function for SNIP1 and identify a previously unrecognized regulator of the cell cycle and cyclin D1 expression.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Owen-Hughes, Tom/0000-0002-0618-8185				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003; Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Beadling C, 2001, ONCOGENE, V20, P1771, DOI 10.1038/sj.onc.1204212; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chehab NH, 2000, GENE DEV, V14, P278; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; RADNEY C, 2003, J BIOL CHEM, V278, P2370; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2000, CELL GROWTH DIFFER, V11, P491; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhou MM, 2000, NAT STRUCT BIOL, V7, P1085, DOI 10.1038/81919	30	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8185	8195		10.1038/sj.onc.1208025	http://dx.doi.org/10.1038/sj.onc.1208025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378006				2022-12-25	WOS:000224749500001
J	Chu, GX; Kerr, JP; Mitton, B; Egnaczyk, GF; Vazquez, JA; Shen, ML; Kilby, GW; Stevenson, TI; Maggio, JE; Vockley, J; Rapundalo, ST; Kranias, EG				Chu, GX; Kerr, JP; Mitton, B; Egnaczyk, GF; Vazquez, JA; Shen, ML; Kilby, GW; Stevenson, TI; Maggio, JE; Vockley, J; Rapundalo, ST; Kranias, EG			Proteomic analysis of hyperdynamic mouse hearts with enhanced sarcoplasmic reticulum calcium cycling	FASEB JOURNAL			English	Article						phospholamban; phosphorylation; contractility; energetics; heart failure	CARDIAC TROPONIN-T; PHOSPHOLAMBAN ABLATION; HYPERTROPHIC CARDIOMYOPATHY; DILATED CARDIOMYOPATHY; CONTRACTILE PROTEINS; TROPOMYOSIN-1; PHOSPHORYLATION; IDENTIFICATION; GROWTH; MICE	Depressed sarcoplasmic reticulum (SR) Ca-cycling is a hallmark of human and experimental heart failure. Strategies to improve this impairment by either increasing SERCA2a levels or decreasing phospholamban (PLN) activity have been suggested as promising therapeutic targets. Indeed, ablation of PLN gene in mice was associated with greatly enhanced cardiac Ca-cycling and performance. Intriguingly, this hyperdynamic cardiac function was maintained throughout the lifetime of the mouse without observable pathological consequences. To determine the cellular alterations in the expression or modification of myocardial proteins, which are associated with the enhanced cardiac contractility, we performed a proteomics-based analysis of PLN knockout (PLN-KO) hearts in comparison to isogenic wild-types. By use of 2-dimensional gel electrophoresis (2-DE), similar to3300 distinct protein spots were detected in either wild-type or PLN-KO ventricles. Protein spots observed to be altered between PLN-KO and wild-type hearts were subjected to tryptic peptide mass fingerprinting for identification by MALDI-TOF mass spectrometry in combination with LC/MS/MS analysis. In addition, two-dimensional P-32-autoradiography was performed to analyze the phosphorylation profiles of PLN-KO cardiomyocytes. We identified alterations in the expression level of more than 100 ventricular proteins, along with changes in phosphorylation status of important regulatory proteins in the PLN-KO. These protein changes were observed mainly in two subcellular compartments: the cardiac contractile apparatus, and metabolism/energetics. Our findings suggest that numerous alterations in protein expression and phosphorylation state occurred upon ablation of PLN and that a complex functional relationship among proteins involved in calcium handling, myofibrils, and energy production may exist to coordinately maintain the hyperdynamic cardiac contractile performance of the PLN-KO mouse in the long term.	Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA; Pfizer Global Res & Dev, Ann Arbor, MI USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	University System of Ohio; University of Cincinnati; Pfizer; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kranias, EG (corresponding author), Univ Cincinnati, Coll Med, Dept Pharmacol & Cell Biophys, 231 Albert B Sabin Way, Cincinnati, OH 45267 USA.	litsa.kranias@uc.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Kerr, Jaclyn/0000-0002-1416-276X	NHLBI NIH HHS [HL-64018, HL-26057, HL-56370, HL-52318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064018, R37HL026057, P50HL052318, R01HL056370, R01HL026057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; Bharadwaj S, 2002, CANCER LETT, V183, P205, DOI 10.1016/S0304-3835(02)00119-2; BOYD J, 1995, P NATL ACAD SCI USA, V92, P11534, DOI 10.1073/pnas.92.25.11534; Bueno OF, 2002, CIRC RES, V91, P776, DOI 10.1161/01.RES.0000038488.38975.1A; Chien KR, 2000, NAT MED, V6, P942, DOI 10.1038/79595; Chu GX, 2004, CIRC RES, V94, P184, DOI 10.1161/01.RES.0000107198.90218.21; Freeman K, 2001, J CLIN INVEST, V107, P967, DOI 10.1172/JCI12083; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; He HP, 1997, J CLIN INVEST, V100, P380, DOI 10.1172/JCI119544; Houle FO, 2003, MOL BIOL CELL, V14, P1418, DOI 10.1091/mbc.E02-04-0235; Javadpour MM, 2003, J CLIN INVEST, V112, P768, DOI 10.1172/JC1200315967; Kiss E, 1997, AM J PHYSIOL-HEART C, V272, pH785, DOI 10.1152/ajpheart.1997.272.2.H785; Lu QW, 2003, J MOL CELL CARDIOL, V35, P1421, DOI 10.1016/j.yjmcc.2003.09.003; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MacLennan DH, 2003, NAT REV MOL CELL BIO, V4, P566, DOI 10.1038/nrm1151; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; Pan Y, 2004, P NATL ACAD SCI USA, V101, P2241, DOI 10.1073/pnas.0308174101; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; Sakamoto K, 2000, BIOCHEM BIOPH RES CO, V269, P137, DOI 10.1006/bbrc.2000.2233; Sanbe A, 1999, J BIOL CHEM, V274, P21085, DOI 10.1074/jbc.274.30.21085; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Schwinger RHG, 2000, BASIC RES CARDIOL, V95, P12, DOI 10.1007/s003950050003; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Slack JP, 2001, J MOL CELL CARDIOL, V33, P1031, DOI 10.1006/jmcc.2001.1370; Song QJ, 2003, J CLIN INVEST, V111, P859, DOI 10.1172/JCI200316738; Stangl K, 2002, BIOCHEM BIOPH RES CO, V291, P542, DOI 10.1006/bbrc.2002.6476; Torricelli F, 2003, AM J CARDIOL, V92, P1358, DOI 10.1016/j.amjcard.2003.08.031; van der Velden J, 2003, CARDIOVASC RES, V57, P37, DOI 10.1016/S0008-6363(02)00606-5; Wolska BM, 2003, PFLUG ARCH EUR J PHY, V446, P1, DOI 10.1007/s00424-002-0900-3; Zhao W, 2003, CARDIOVASC RES, V57, P71, DOI 10.1016/S0008-6363(02)00609-0; Zheng MZ, 2004, AM J PHYSIOL-HEART C, V286, pH424, DOI 10.1152/ajpheart.00110.2003	34	21	24	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1725	+		10.1096/fj.04-2025fje	http://dx.doi.org/10.1096/fj.04-2025fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15358683				2022-12-25	WOS:000224243200033
J	Larcher, JC; Gasmi, L; Viranaicken, W; Edde, B; Bernard, R; Ginzburg, I; Denoulet, P				Larcher, JC; Gasmi, L; Viranaicken, W; Edde, B; Bernard, R; Ginzburg, I; Denoulet, P			Ilf3 and NF90 associate with the axonal targeting element of Tau mRNA	FASEB JOURNAL			English	Article						microtubule; protein-RNA interactions; Northwestern blotting; mRNA trafficking; 2-D PAGE	INTRACELLULAR-LOCALIZATION; PROTEIN; BINDING; IDENTIFICATION; EXPRESSION; ARGININE; CELLS; PHOSPHOPROTEINS; METHYLATION; TRANSPORT	In neurons, the selective translocation of Tau mRNA toward axons is due to the presence of a nucleotide sequence located in its 3' untranslated region and serving as axonal targeting element. Using this RNA sequence as a probe by a Northwestern approach, we have detected several proteins that interact with the targeting RNA element and could potentially be involved in Tau mRNA translocation, translation halting, and/or stabilization. Among them, two proteins were identified as the interleukin enhancer binding factor 3 (Ilf3) and NF90, two isoforms derived from a single gene product through alternative splicing. Each protein comprises two double-stranded RNA binding motifs that can interact with the predicted stem-loop secondary structure of the axonal targeting element. Specific antibodies raised against common or specific peptide sequences showed that both Ilf3 and NF90 are polymorphic proteins that are detected in neuronal nuclei and cell bodies, as well as in the proximal neuritic segments. This observation favors the idea that Ilf3 and NF90 are part of a protein complex that escorts Tau mRNA toward the axon.	Univ Paris 06, Biochim Cellulaire Lab, CNRS, UMR 7098, F-75252 Paris 05, France; CRBM, CNRS, UPR 1086, F-34293 Montpellier, France; Univ Paris 06, CNRS, UMR 7101, F-75252 Paris 05, France; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Weizmann Institute of Science	Larcher, JC (corresponding author), Univ Paris 06, Biochim Cellulaire Lab, CNRS, UMR 7098, 9 Quai St Bernard,Batiment C,Case 265, F-75252 Paris 05, France.	jclarche@snv.jussieu.fr						Aranda-Abreu GE, 1999, J NEUROSCI, V19, P6907, DOI 10.1523/JNEUROSCI.19-16-06907.1999; Aronov S, 2002, J CELL SCI, V115, P3817, DOI 10.1242/jcs.00058; Aronov S, 2001, J NEUROSCI, V21, P6577, DOI 10.1523/JNEUROSCI.21-17-06577.2001; Aronov S, 1999, J MOL NEUROSCI, V12, P131, DOI 10.1007/BF02736927; BAAS PW, 1991, J CELL BIOL, V115, P1333, DOI 10.1083/jcb.115.5.1333; BEHAR L, 1995, INT J DEV NEUROSCI, V13, P113, DOI 10.1016/0736-5748(95)00001-W; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Goedert M, 1996, J CELL SCI, V109, P2661; Gwizdek C, 2004, J BIOL CHEM, V279, P884, DOI 10.1074/jbc.M306808200; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Kim S, 1998, AMINO ACIDS, V15, P291, DOI 10.1007/BF01320895; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARCHER JC, 1992, DEV BIOL, V154, P195, DOI 10.1016/0012-1606(92)90059-P; LITMAN P, 1993, NEURON, V10, P627, DOI 10.1016/0896-6273(93)90165-N; LITMAN P, 1994, NEURON, V13, P1463, DOI 10.1016/0896-6273(94)90432-4; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; Moldrich RX, 2000, J NEUROSCI RES, V59, P788, DOI 10.1002/(SICI)1097-4547(20000315)59:6<788::AID-JNR11>3.0.CO;2-K; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Palacios IM, 2001, ANNU REV CELL DEV BI, V17, P569, DOI 10.1146/annurev.cellbio.17.1.569; SADOT E, 1994, J MOL BIOL, V241, P325, DOI 10.1006/jmbi.1994.1508; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Wild K, 2002, CURR OPIN STRUC BIOL, V12, P72, DOI 10.1016/S0959-440X(02)00292-0; WOLFF A, 1992, EUR J CELL BIOL, V59, P425; Zuker M., 1999, V70, P11	42	45	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1761	+		10.1096/fj.04-1763fje	http://dx.doi.org/10.1096/fj.04-1763fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364895				2022-12-25	WOS:000224243200028
J	Sundberg, C; Thodeti, CK; Kveiborg, M; Larsson, C; Parker, P; Albrechtsen, R; Wewer, UM				Sundberg, C; Thodeti, CK; Kveiborg, M; Larsson, C; Parker, P; Albrechtsen, R; Wewer, UM			Regulation of ADAM12 cell-surface expression by protein kinase C epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; METALLOPROTEASE DISINTEGRIN ADAM12; AMYLOID PRECURSOR PROTEIN; CYSTEINE-RICH DOMAIN; MELTRIN-ALPHA; PKC-EPSILON; CONVERTING-ENZYME; GROWTH-FACTOR; SECRETASE CLEAVAGE; MYOBLAST FUSION	The ADAM ( a disintegrin and metalloprotease) family consists of multidomain cell-surface proteins that have a major impact on cell behavior. These transmembrane-anchored proteins are synthesized as proforms that have ( from the N terminus): a prodomain; a metalloprotease, disintegrin-like-, cysteine-rich, epidermal growth factor-like, and transmembrane domain; and a cytoplasmic tail. The 90-kDa mature form of human ADAM12 is generated in the trans-Golgi through cleavage of the prodomain by a furin-peptidase and is stored intracellularly until translocation to the cell surface as a constitutively active protein. However, little is known about the regulation of ADAM12 cell-surface translocation. Here, we used human RD rhabdomyosarcoma cells, which express ADAM12 at the cell surface, in a temporal pattern. We report that protein kinase C ( PKC) epsilon induces ADAM12 translocation to the cell surface and that catalytic activity of PKCepsilon is required for this translocation. The following results support this conclusion: 1) treatment of cells with 0.1 muM phorbol 12-myristate 13-acetate (PMA) enhanced ADAM12 cell-surface immunostaining, 2) ADAM12 and PKCepsilon could be co-immunoprecipitated from membrane-enriched fractions of PMA-treated cells, 3) RD cells transfected with EGFP-tagged, myristoylated PKCepsilon expressed more ADAM12 at the cell surface than did non-transfected cells, and 4) RD cells transfected with a kinase-inactive PKCepsilon mutant did not exhibit ADAM12 cell-surface translocation upon PMA treatment. Finally, we demonstrate that the C1 and C2 domains of PKCepsilon both contain a binding site for ADAM12. These studies show that PKCepsilon plays a critical role in the regulation of ADAM12 cell-surface expression.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Lund Univ, Univ Hosp, Dept Lab Med, S-20502 Malmo, Sweden; Canc Res UK London Res Inst, London WC2A 3PX, England	University of Copenhagen; Lund University; Skane University Hospital; Cancer Research UK	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	ullaw@pai.ku.dk	Parker, Peter j/D-5192-2013; Kveiborg, Marie/AAM-3019-2020	Kveiborg, Marie/0000-0002-1293-1019; parker, peter/0000-0002-6218-2933; Albrechtsen, Reidar/0000-0003-4180-1827				Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Astolfi A, 2001, GENE, V274, P139, DOI 10.1016/S0378-1119(01)00619-9; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Bornemann A, 2000, J MUSCLE RES CELL M, V21, P475, DOI 10.1023/A:1005657607591; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao Y, 2003, MOL CELL BIOL, V23, P6725, DOI 10.1128/MCB.23.19.6725-6738.2003; Cao Y, 2002, J BIOL CHEM, V277, P26403, DOI 10.1074/jbc.M110814200; Cao Y, 2001, BIOCHEM J, V357, P353, DOI 10.1042/0264-6021:3570353; Diaz-Rodriguez E, 2002, MOL BIOL CELL, V13, P2031, DOI 10.1091/mbc.01-11-0561; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hougaard S, 2000, BIOCHEM BIOPH RES CO, V275, P261, DOI 10.1006/bbrc.2000.3295; Iba K, 1999, AM J PATHOL, V154, P1489, DOI 10.1016/S0002-9440(10)65403-X; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Ivaska J, 2003, BIOCHEM SOC T, V31, P90, DOI 10.1042/bst0310090; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kang Q, 2001, J BIOL CHEM, V276, P24466, DOI 10.1074/jbc.M101162200; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; Kawaguchi N, 2003, J CELL SCI, V116, P3893, DOI 10.1242/jcs.00699; Kronqvist P, 2002, AM J PATHOL, V161, P1535, DOI 10.1016/S0002-9440(10)64431-8; Kurisaki T, 1998, MECH DEVELOP, V73, P211, DOI 10.1016/S0925-4773(98)00043-4; Kurisaki T, 2003, MOL CELL BIOL, V23, P55, DOI 10.1128/MCB.23.1.55-61.2003; Laigaard J, 2003, PRENATAL DIAG, V23, P1086, DOI 10.1002/pd.762; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Moghadaszadeh B, 2003, HUM MOL GENET, V12, P2467, DOI 10.1093/hmg/ddg264; Mori S, 2003, J BIOL CHEM, V278, P46029, DOI 10.1074/jbc.M306393200; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Shimizu E, 2003, BIOCHEM BIOPH RES CO, V309, P779, DOI 10.1016/j.bbrc.2003.08.070; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; Thodeti CK, 2003, J BIOL CHEM, V278, P9576, DOI 10.1074/jbc.M208937200; Troller U, 2004, CELL SIGNAL, V16, P245, DOI 10.1016/S0898-6568(03)00135-9; Van Eerdewegh P, 2001, GENET EPIDEMIOL, V21, pS67; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; Wu DQ, 2002, CANCER RES, V62, P2423; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210	56	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51601	51611		10.1074/jbc.M403753200	http://dx.doi.org/10.1074/jbc.M403753200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15364951	hybrid			2022-12-25	WOS:000225355800116
J	Zhu, CL; Saberwal, G; Lu, YF; Platanias, LC; Eklund, EA				Zhu, CL; Saberwal, G; Lu, YF; Platanias, LC; Eklund, EA			The interferon consensus sequence-binding protein activates transcription of the gene encoding Neurofibromin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GP91(PHOX) EXPRESSION; HEMATOPOIETIC-CELLS; REGULATORY FACTOR-1; MYELOID CELLS; NF1 GENE; MACROPHAGES; ICSBP; PU.1; GROWTH; DIFFERENTIATION	Deficiency of the interferon consensus sequence-binding protein (ICSBP) is associated with increased myeloid cell proliferation in response to hematopoietic cytokines. However, previously identified ICSBP target genes do not indicate a mechanism for this "cytokine hypersensitivity." In these studies, we identify the gene encoding neurofibromin 1 (Nf1) as an ICSBP target gene, by chromatin immunoprecipitation. Additionally, we find decreased Nf1 expression in bone marrow-derived myeloid cells from ICSBP-/- mice. Since Nf1 deficiency is also associated with cytokine hypersensitivity, our results suggested that NF1 is a functionally significant ICSBP target gene. Consistent with this, we find that the hypersensitivity of ICSBP -/- myeloid cells to granulocyte monocyte colony-stimulating factor (GM-CSF) is reversed by expression of the Nf1 GAP-related domain. We also find that treatment of ICSBP-deficient myeloid cells with monocyte colony-stimulating factor (M-CSF) results in sustained Ras activation, ERK phosphorylation, and proliferation associated with impaired Nf1 expression. These M-CSF effects are reversed by ICSBP expression in ICSBP -/- cells. Consistent with this, we find that ICSBP activates the NF1 promoter in myeloid cell line transfectants and identify an ICSBP-binding NF1 cis element. Therefore, the absence of ICSBP leads to Nf1 deficiency, impairing down-regulation of Ras activation by GM-CSF or M-CSF. These results suggest that one mechanism of increased myeloid proliferation, in ICSBP-deficient cells, is decreased NF1 gene transcription. This novel ICSBP function provides insight into regulation of myelopoiesis under normal conditions and in myeloproliferative disorders.	Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Chicago Lakeside Vet Affairs Hosp, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Eklund, EA (corresponding author), Northwestern Univ, Feinberg Sch Med, 710 N Fairbanks Court,Olson Pavil,Rm 8524, Chicago, IL 60611 USA.	e-eklund@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA095266] Funding Source: NIH RePORTER; NCI NIH HHS [CA095266, CA95266] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585; Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; BOGUSKI M, 1990, NATURE, V366, P643; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Chatterjee D, 1997, CELL GROWTH DIFFER, V8, P1083; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Donovan S, 2002, CANCER CELL, V2, P507, DOI 10.1016/S1535-6108(02)00214-3; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Fehr T, 1997, J EXP MED, V185, P921, DOI 10.1084/jem.185.5.921; GABBIANELLI M, 1995, BLOOD, V86, P1661, DOI 10.1182/blood.V86.5.1661.bloodjournal8651661; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; GROOT RP, 1998, CELL SIGNAL, V10, P619; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ingram DA, 2003, BLOOD, V101, P1984, DOI 10.1182/blood-2002-08-2635; Kallies A, 2002, BLOOD, V99, P3213, DOI 10.1182/blood.V99.9.3213; Kantakamalakul W, 1999, J IMMUNOL, V162, P7417; Kautz B, 2001, J BIOL CHEM, V276, P37868; KERST JM, 1992, EXP HEMATOL, V20, P1188; LARRICK JW, 1980, J IMMUNOL, V125, P6; Osborn M, 2000, CLIN GENET, V57, P221, DOI 10.1034/j.1399-0004.2000.570308.x; POLITIS AD, 1994, J IMMUNOL, V152, P2270; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; SCHWARTZ RM, 1991, BLOOD, V78, P3155; Sharf R, 1997, J BIOL CHEM, V272, P9785; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Zhang YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/jem.187.11.1893	36	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50874	50885		10.1074/jbc.M405736200	http://dx.doi.org/10.1074/jbc.M405736200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371411	hybrid			2022-12-25	WOS:000225355800030
J	Necula, M; Kuret, J				Necula, M; Kuret, J			Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMER-LIKE FILAMENTS; LASER-LIGHT SCATTERING; MICROTUBULE-BINDING; ABNORMAL PHOSPHORYLATION; NEUROFIBRILLARY TANGLES; ACTIN POLYMERIZATION; DISEASE PATHOLOGY; BETA-STRUCTURE; END-PRODUCTS	Alzheimer's disease is defined in part by the intraneuronal aggregation of tau protein into filamentous lesions. The pathway is accompanied by posttranslational modifications including phosphorylation and glycation, each of which has been shown to promote tau fibrillization in vitro when present at high stoichiometry. To clarify the site-specific impact of posttranslational modification on tau fibrillization, the ability of recombinant full-length four repeat tau protein (htau40) and 11 pseudophosphorylation mutants to fibrillize in the presence of anionic inducer was assayed in vitro using transmission electron microscopy and laser light scattering assays. Tau glycated with D-glucose was examined as well. Both glycated tau and pseudophosphorylation mutants S199E, T212E, S214E, double mutant T212E/S214E, and triple mutant S199E/S202E/T205E yielded increased filament mass at equilibrium relative to wild-type tau. Increases in filament mass correlated strongly with decreases in critical concentration, indicating that both pseudophosphorylation and glycation promoted fibrillization by shifting equilibrium toward the fibrillized state. Analysis of reaction time courses further revealed that increases in filament mass were not associated with reduced lag times, indicating that these posttranslational modifications did not promote filament nucleation. The results suggest that site-specific posttranslational modifications can stabilize filaments once they nucleate, and thereby support their accumulation at low intracellular tau concentrations.	Ohio State Univ, Coll Med & Publ Hlth, Biophys Program, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Kuret, J (corresponding author), Ohio State Univ, Ctr Biotechnol, 1060 Carmack Rd, Columbus, OH 43210 USA.	kuret.3@osu.edu			NIA NIH HHS [AG14452] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014452] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraha A, 2000, J CELL SCI, V113, P3737; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Alonso AD, 2004, J BIOL CHEM, V279, P34873, DOI 10.1074/jbc.M405131200; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; BANCHER C, 1989, BRAIN RES, V477, P90, DOI 10.1016/0006-8993(89)91396-6; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Bubb MR, 2000, J BIOL CHEM, V275, P5163, DOI 10.1074/jbc.275.7.5163; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Carmel G, 1996, J BIOL CHEM, V271, P32789, DOI 10.1074/jbc.271.51.32789; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; Chirita CN, 2003, J BIOL CHEM, V278, P25644, DOI 10.1074/jbc.M301663200; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; Edelstein-Keshet L, 1998, B MATH BIOL, V60, P449, DOI 10.1006/bulm.1997.0011; Eidenmuller J, 2000, BIOCHEMISTRY-US, V39, P13166, DOI 10.1021/bi001290z; Eidenmuller J, 2001, BIOCHEM J, V357, P759, DOI 10.1042/0264-6021:3570759; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Fath T, 2002, J NEUROSCI, V22, P9733; FESCE R, 1992, J BIOL CHEM, V267, P11289; Friedhoff P, 1998, P NATL ACAD SCI USA, V95, P15712, DOI 10.1073/pnas.95.26.15712; Friedhoff P, 1998, BIOCHEMISTRY-US, V37, P10223, DOI 10.1021/bi980537d; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P6136, DOI 10.1021/bi000201f; Gamblin TC, 2000, BIOCHEMISTRY-US, V39, P14203, DOI 10.1021/bi001876l; Garcia-Sierra F, 2003, J ALZHEIMERS DIS, V5, P65, DOI 10.3233/JAD-2003-5201; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goedert M, 1996, ANN NY ACAD SCI, V777, P121, DOI 10.1111/j.1749-6632.1996.tb34410.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GRAY EG, 1987, NEUROPATH APPL NEURO, V13, P91, DOI 10.1111/j.1365-2990.1987.tb00174.x; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Haase C, 2004, J NEUROCHEM, V88, P1509, DOI 10.1046/j.1471-4159.2003.02287.x; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; Kashchiev D., 2000, NUCL BASIC THEORY AP; KENESSEY A, 1993, BRAIN RES, V629, P40, DOI 10.1016/0006-8993(93)90478-6; Kimura T, 1996, DEMENTIA, V7, P177, DOI 10.1159/000106875; King ME, 1999, BIOCHEMISTRY-US, V38, P14851, DOI 10.1021/bi9911839; King ME, 2000, J NEUROCHEM, V74, P1749, DOI 10.1046/j.1471-4159.2000.0741749.x; Ko LW, 2002, J MOL NEUROSCI, V19, P311; KOPKE E, 1993, J BIOL CHEM, V268, P24374; KSIEZAKREDING H, 1992, BRAIN RES, V597, P209, DOI 10.1016/0006-8993(92)91476-U; Ledesma MD, 1996, MOL CHEM NEUROPATHOL, V27, P249, DOI 10.1007/BF02815107; LEDESMA MD, 1994, J BIOL CHEM, V269, P21614; LEDESMA MD, 1995, J NEUROCHEM, V65, P1658; Leger J, 1997, J BIOL CHEM, V272, P8441, DOI 10.1074/jbc.272.13.8441; Li GB, 2004, J BIOL CHEM, V279, P15938, DOI 10.1074/jbc.M314116200; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; Mena R, 1996, ACTA NEUROPATHOL, V91, P633, DOI 10.1007/s004010050477; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Nacharaju P, 1997, J NEUROCHEM, V69, P1709; Necula M, 2003, J BIOL CHEM, V278, P46674, DOI 10.1074/jbc.M308231200; Necula M, 2004, ANAL BIOCHEM, V333, P205, DOI 10.1016/j.ab.2004.05.044; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Perez M, 1996, J NEUROCHEM, V67, P1183; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Shahani N, 2002, CELL MOL LIFE SCI, V59, P1668, DOI 10.1007/PL00012495; Smith MA, 1996, NEUROSCI LETT, V217, P210, DOI 10.1016/S0304-3940(96)13100-1; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9; Timasheff S. N., 1981, PROTEIN PROTEIN INTE, P315; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; von Bergen M, 2000, P NATL ACAD SCI USA, V97, P5129, DOI 10.1073/pnas.97.10.5129; Watanabe A, 1999, J BIOL CHEM, V274, P7368, DOI 10.1074/jbc.274.11.7368; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; Wilson DM, 1997, AM J PATHOL, V150, P2181; Winsor CP, 1932, P NATL ACAD SCI USA, V18, P1, DOI 10.1073/pnas.18.1.1; YAN SD, 1994, P NATL ACAD SCI USA, V91, P7787, DOI 10.1073/pnas.91.16.7787	76	112	115	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49694	49703		10.1074/jbc.M405527200	http://dx.doi.org/10.1074/jbc.M405527200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364924	hybrid			2022-12-25	WOS:000225229500020
J	Baglia, FA; Shrimpton, CN; Emsley, J; Kitagawa, K; Ruggeri, ZM; Lopez, JA; Walsh, PN				Baglia, FA; Shrimpton, CN; Emsley, J; Kitagawa, K; Ruggeri, ZM; Lopez, JA; Walsh, PN			Factor XI interacts with the leucine-rich repeats of glycoprotein Ib alpha on the activated platelet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; IX-V COMPLEX; COAGULATION-FACTOR-XI; FACTOR A1 DOMAIN; CRYSTAL-STRUCTURE; VONWILLEBRAND-FACTOR; BINDING-SITE; THROMBIN BINDING; IDENTIFICATION; AGGREGATION	Factor XI (FXI) binds specifically and reversibly to high affinity sites on the surface of stimulated platelets (K-d app of similar to10 nM; B-max of similar to1,500 sites/platelet) utilizing residues exposed on the Apple 3 domain in the presence of high molecular weight kininogen and Zn2+ or prothrombin and Ca2+. Because the FXI receptor in the platelet membrane is contained within the glycoprotein Ibalpha subunit of the glycoprotein Ib-IX-V complex (Baglia, F. A., Badellino, K. O., Li, C. Q., Lopez, J. A., and Walsh, P.N. (2002) J. Biol. Chem. 277, 1662-1668), we utilized mocarhagin, a cobra venom metalloproteinase, to generate a fragment (His(1)-Glu(282)) of glycoprotein Ibalpha that contains the leucine-rich repeats of the NH2-terminal globular domain and excludes the macroglycopeptide portion of glycocalicin, the soluble extracytoplasmic portion of glycoprotein Ibalpha. This fragment was able to compete with FXI for binding to activated platelets (K-i of 3.125+/-0.25 nM) with a potency similar to that of intact glycocalicin (K-i of 3.72+/-0.30 nM). However, a synthetic glycoprotein Ibalpha peptide, Asp(269)-Asp(287), containing a thrombin binding site had no effect on the binding of FXI to activated platelets. Moreover, the binding of I-125-labeled thrombin to glycocalicin was unaffected by the presence of FXI at concentrations up to 10(-5) M. The von Willebrand factor A1 domain, which binds the leucine-rich repeats, inhibited the binding of FXI to activated platelets. Thus, we examined the effect of synthetic peptides of each of the seven leucine-rich repeats on the binding of I-125-FXI to activated platelets. All leucine-rich repeat (LRR) peptides derived from glycoprotein Ibalpha were able to inhibit FXI binding to activated platelets in the following order of decreasing potency: LRR7, LRR1, LRR4, LRR5, LRR6, LRR3, and LRR2. However, the leucine-rich repeat synthetic peptides derived from glycoprotein Ibbeta and Toll protein had no effect. We conclude that FXI binds to glycoprotein Ibalpha at sites comprising the leucine-rich repeat sequences within the NH2-terminal globular domain that are separate and distinct from the thrombin-binding site.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Univ Nottingham, Ctr Biomol Sci, Sch Pharm, Nottingham NG7 2RD, England; Niigata Univ Pharm & Appl Life Sci, Niigata 9502081, Japan; Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nottingham; Niigata University; Scripps Research Institute	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.	pnw@temple.edu	emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070683, P01HL064943, R01HL046213, P01HL048728, P01HL074124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL70683, HL74124, HL48728, HL64943] Funding Source: Medline; PHS HHS [P5065967] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; Baglia FA, 2003, J BIOL CHEM, V278, P21744, DOI 10.1074/jbc.M212991200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 2003, J THROMB HAEMOST S1, V1, pP1097; BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354; BRUNNEE T, 1993, BLOOD, V81, P580; Cauwenberghs N, 2001, BLOOD, V98, P652, DOI 10.1182/blood.V98.3.652; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Celikel R, 2003, SCIENCE, V301, P218, DOI 10.1126/science.1084183; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; De Cristofaro R, 2001, BIOCHEMISTRY-US, V40, P13268, DOI 10.1021/bi010491f; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Dumas JJ, 2004, J BIOL CHEM, V279, P23327, DOI 10.1074/jbc.M401659200; Dumas JJ, 2003, SCIENCE, V301, P222, DOI 10.1126/science.1083917; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GRALNICK HR, 1994, P NATL ACAD SCI USA, V91, P6334, DOI 10.1073/pnas.91.14.6334; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HESS D, 1991, EUR J BIOCHEM, V199, P389, DOI 10.1111/j.1432-1033.1991.tb16135.x; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x; Kitagawa K, 2001, J ORG CHEM, V66, P1, DOI 10.1021/jo000895y; LI CY, 1995, BLOOD, V86, P3805, DOI 10.1182/blood.V86.10.3805.bloodjournal86103805; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; MOHRI H, 1989, J BIOL CHEM, V264, P17361; PETERSON DM, 1987, BLOOD, V69, P625; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200	45	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49323	49329		10.1074/jbc.M407889200	http://dx.doi.org/10.1074/jbc.M407889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15375170	hybrid			2022-12-25	WOS:000225098100101
J	Diks, SH; Kok, K; O'Toole, T; Hommes, DW; van Dijken, P; Joore, J; Peppelenbosch, MP				Diks, SH; Kok, K; O'Toole, T; Hommes, DW; van Dijken, P; Joore, J; Peppelenbosch, MP			Kinome profiling for studying lipopolysaccharide signal transduction in human peripheral blood mononuclear cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHORYLATION SITES; HUMAN NEUTROPHILS; GENE-EXPRESSION; MICROARRAYS; PEPTIDE; ARRAYS; PHOSPHOBASE; DATABASE; COMPLEX	The DNA array technique allows comprehensive analysis of the genome and transcriptome, but the high throughput array-based assessment of intracellular signal transduction remains troublesome. The goal of this study was to test a new peptide array technology for studying the activity of all kinases of whole cell lysates, the kinome. Cell lysates from human peripheral blood mononuclear cells before and after stimulation with lipopolysaccharide were used for in vitro phosphorylation with [gamma-P-33] ATP arrays consisting of 192 peptides ( substrates for kinases) spotted on glass. The usefulness of peptide arrays for studying signal transduction was demonstrated by the generation of the first comprehensive description of the temporal kinetics of phosphorylation events induced by lipopolysaccharide stimulation. Furthermore analysis of the signals obtained suggested activation of p21Ras by lipopolysaccharide, and this was confirmed by direct measurement of p21Ras GTP levels in lipopolysaccharide-stimulated human peripheral blood mononuclear cells, which represents the first direct demonstration of p21Ras activation by stimulation of a Toll receptor family member. Further confidence in the usefulness of peptide array technology for studying signal transduction came from Western blot analysis of lipopolysaccharide-stimulated cells, which corroborated the signals obtained using peptide arrays as well as from the demonstration that kinase inhibitors effected peptide array phosphorylation patterns consistent with the expected action of these inhibitors. We conclude that this first metabolic array is a useful method to determine the enzymatic activities of a large group of kinases, offering high throughput analysis of cellular metabolism and signal transduction.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands; Pepscan Syst, NL-8219 PH Lelystad, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Kok, K (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, Meibergdreef 9,G2-132, NL-1105 AZ Amsterdam, Netherlands.	k.kok@amc.uva.nl		Joore, Jos/0000-0002-2744-4862; Peppelenbosch, Maikel/0000-0001-9112-6028				Arenkov P, 2000, ANAL BIOCHEM, V278, P123, DOI 10.1006/abio.1999.4363; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; Conway T, 2003, MOL MICROBIOL, V47, P879, DOI 10.1046/j.1365-2958.2003.03338.x; Coxon PY, 2003, CELL SIGNAL, V15, P993, DOI 10.1016/S0898-6568(03)00074-3; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141; Diks SH, 2001, J ENDOTOXIN RES, V7, P335, DOI 10.1177/09680519010070050101; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Falsey JR, 2001, BIOCONJUGATE CHEM, V12, P346, DOI 10.1021/bc000141q; Gilmore WJ, 2003, TOXICOLOGY, V184, P211, DOI 10.1016/S0300-483X(02)00581-4; Head MW, 1996, J CELL SCI, V109, P1029; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Houseman BT, 2002, TRENDS BIOTECHNOL, V20, P279, DOI 10.1016/S0167-7799(02)01984-4; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Kristof AS, 2003, J BIOL CHEM, V278, P33637, DOI 10.1074/jbc.M301053200; Lee PS, 2000, CURR OPIN BIOTECH, V11, P171, DOI 10.1016/S0958-1669(00)00077-X; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Morrison D C, 1979, Adv Immunol, V28, P293; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Peppelenbosch MP, 1999, BLOOD, V93, P4011, DOI 10.1182/blood.V93.11.4011.411a29_4011_4018; Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6; Suzuki N, 2003, J IMMUNOL, V171, P6065, DOI 10.4049/jimmunol.171.11.6065; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Wurmbach E, 2002, NEUROCHEM RES, V27, P1027, DOI 10.1023/A:1020900720328; Zhou HP, 2003, AM J PHYSIOL-GASTR L, V284, pG472, DOI 10.1152/ajpgi.00345.2002; Zhu H, 2001, CURR OPIN CHEM BIOL, V5, P40, DOI 10.1016/S1367-5931(00)00170-8	33	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49206	49213		10.1074/jbc.M405028200	http://dx.doi.org/10.1074/jbc.M405028200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355981	hybrid			2022-12-25	WOS:000225098100086
J	Finlan, L; Hupp, TR				Finlan, L; Hupp, TR			The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDM2; TRANSCRIPTION; PROTEINS; CBP	Two high affinity Ser-20-phospho-LXXLL p53-binding domains of p300 map to the C-terminal interferon-binding domain (IBiD) and N-terminal IBiD homology domain (IHD) regions. Purified fractions of a recombinant IHD miniprotein are active in a set of in vitro assays highlighting its affinity to the N-terminal LXXLL domain of p53 including (i) dose-dependent binding to Ser-20-phosphorylated p53 tetramers; (ii) DNA-stimulated binding to p53 tetramers; and (iii) inhibition of MDM2-mediated p53 ubiquitination. The active component of the IHD miniprotein was localized to a 75-amino-acid fragment corresponding to amino acids 401-475 on human p300. This minimal IHD miniprotein can function in vivo as a p53-binding polypeptide in assays including: (i) complex formation with VP16-LXXLL peptide motifs in the two-hybrid assay; (ii) action as a dominant negative inhibitor of p53 from p21 luciferase templates; and (iii) attenuation of endogenous p21 protein levels. Further, we show here that the IRF-1-dependent stabilization and reactivation of p53DeltaPRO protein (LXXLL+/PXXP-) can be neutralized by the minimal IHD miniprotein, suggesting that IHD can bind to the p53 LXXLL domain in vivo. Phage-peptide display to the IHD miniprotein gave rise to an LSQXTFSXLXXLL consensus binding site that displays significant homology to the LXXLL transactivation domain of p53. These data validate the IHD scaffold as an independent LXXLL peptide-binding domain within the p300 protein, complementing the known peptide-binding domains including IBiD, C/H1, and C/H3.	Univ Edinburgh, Div Oncol, CRUK Cell Signalling Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Hupp, TR (corresponding author), Univ Edinburgh, Div Oncol, CRUK Cell Signalling Unit, S Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Ted.Hupp@ed.ac.uk	Finlan, Lee/B-2111-2008					ARANY I, 1994, SURG ONCOL, V3, P153, DOI 10.1016/0960-7404(94)90044-2; Burch L, 2004, J MOL BIOL, V337, P129, DOI 10.1016/j.jmb.2004.01.017; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Chan HM, 2001, J CELL SCI, V114, P2363; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Dornan D, 2003, MOL CELL BIOL, V23, P8846, DOI 10.1128/MCB.23.23.8846-8861.2003; DORNAN D, 2004, IN PRESS MOL CELL BI; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Janknecht R, 2002, HISTOL HISTOPATHOL, V17, P657, DOI 10.14670/HH-17.657; Lane DR, 2003, DRUG DISCOV TODAY, V8, P347, DOI 10.1016/S1359-6446(03)02669-2; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; MACPHERSON D, 2004, IN PRESS EMBO J; Saenz-Robles MT, 2001, ONCOGENE, V20, P7899, DOI 10.1038/sj.onc.1204936; Schon O, 2002, J MOL BIOL, V323, P491, DOI 10.1016/S0022-2836(02)00852-5; Shikama N, 2003, EMBO J, V22, P5175, DOI 10.1093/emboj/cdg502; Shimizu H, 2003, TRENDS BIOCHEM SCI, V28, P346, DOI 10.1016/S0968-0004(03)00140-3; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	25	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49395	49405		10.1074/jbc.M405974200	http://dx.doi.org/10.1074/jbc.M405974200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15337767	hybrid			2022-12-25	WOS:000225098100108
J	Stein, S; Thomas, EK; Herzog, B; Westfall, MD; Rocheleau, JV; Jackson, RS; Wang, M; Liang, P				Stein, S; Thomas, EK; Herzog, B; Westfall, MD; Rocheleau, JV; Jackson, RS; Wang, M; Liang, P			NDRG1 is necessary for p53-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL DISPLAY ANALYSIS; TUMOR-SUPPRESSOR PROTEIN; N-MYC; GENE-EXPRESSION; CANCER-CELLS; DNA-DAMAGE; CAP43 GENE; PROSTATE-CANCER; COLON-CANCER; P53 PROTEIN	Although a number of target genes for the tumor suppressor p53 have been described, the mechanism of p53-dependent apoptosis is incompletely understood. Thus, it is essential to identify and characterize additional target genes that could mediate apoptosis. In the study reported here, we isolated a p53-regulated gene named NDRG1 (N-Myc down-regulated gene 1). Its expression is induced by DNA damage in a p53-dependent fashion. The promoter region of the NDRG1 gene contains a p53 binding site that confers p53-dependent transcriptional activation via a heterologous reporter. RNA interference and inducible gene expression approaches suggest that NDRG1 is necessary but not sufficient for p53-mediated caspase activation and apoptosis. This report further supports the notion that p53 controls a network of genes that are required for its apoptotic function.	Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Liang, P (corresponding author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA.	S.Stein@med.uni-frankfurt.de; peng.liang@vanderbilt.edu		Rocheleau, Jonathan/0000-0002-1760-2564	NATIONAL CANCER INSTITUTE [R01CA076960, R01CA105024] Funding Source: NIH RePORTER; NCI NIH HHS [CA76960, CA105024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwala KL, 2000, BIOCHEM BIOPH RES CO, V272, P641, DOI 10.1006/bbrc.2000.2833; Arizti P, 2000, MOL CELL BIOL, V20, P7450, DOI 10.1128/MCB.20.20.7450-7459.2000; Bandyopadhyay S, 2003, CANCER RES, V63, P1731; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cangul H, 2002, CELL BIOL TOXICOL, V18, P87, DOI 10.1023/A:1015376032736; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cho Y, 2001, BIOTECHNIQUES, V30, P562, DOI 10.2144/01303rr01; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guang RJ, 2000, CANCER RES, V60, P749; Herzog B, 2004, MOL ENDOCRINOL, V18, P807, DOI 10.1210/mg.2003-0384; Hohenstein P, 2003, TRENDS GENET, V19, P489, DOI 10.1016/S0168-9525(03)00193-8; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hunter M, 2003, HUM MUTAT, V22, P129, DOI 10.1002/humu.10240; Kalaydjieva L, 2000, AM J HUM GENET, V67, P47, DOI 10.1086/302978; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Kurdistani SK, 1998, CANCER RES, V58, P4439; Lachat P, 2002, HISTOCHEM CELL BIOL, V118, P399, DOI 10.1007/s00418-002-0460-9; Li J, 2003, MOL CELL BIOCHEM, V250, P91, DOI 10.1023/A:1024918328162; Liang P, 2003, NAT REV CANCER, V3, P869, DOI 10.1038/nrc1214; Liang P, 2002, BIOTECHNIQUES, V33, P338, DOI 10.2144/02332rv01; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; Malette B, 2003, MOL HUM REPROD, V9, P671, DOI 10.1093/molehr/gag084; Masuda K, 2003, INT J CANCER, V105, P803, DOI 10.1002/ijc.11152; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Motwani M, 2002, CANCER RES, V62, P3950; Nimmrich I, 2000, CANCER LETT, V160, P37, DOI 10.1016/S0304-3835(00)00553-X; Nishie A, 2001, CLIN CANCER RES, V7, P2145; Okuda T, 2004, MOL CELL BIOL, V24, P3949, DOI 10.1128/MCB.24.9.3949-3956.2004; Park H, 2000, BIOCHEM BIOPH RES CO, V276, P321, DOI 10.1006/bbrc.2000.3475; Piquemal D, 1999, BBA-MOL CELL RES, V1450, P364, DOI 10.1016/S0167-4889(99)00056-7; Qu XH, 2002, MOL CELL BIOCHEM, V229, P35, DOI 10.1023/A:1017934810825; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Salnikow K, 1999, TOXICOL APPL PHARM, V160, P127, DOI 10.1006/taap.1999.8759; Salnikow K, 2000, CANCER RES, V60, P38; Segawa T, 2002, ONCOGENE, V21, P8749, DOI 10.1038/sj.onc.1205992; Shimono A, 1999, MECH DEVELOP, V83, P39, DOI 10.1016/S0925-4773(99)00025-8; Stein S, 2002, CELL MOL LIFE SCI, V59, P1274, DOI 10.1007/s00018-002-8506-7; Stein Susanne, 2003, Methods Mol Biol, V234, P51; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Taketomi Y, 2003, BIOCHEM BIOPH RES CO, V306, P339, DOI 10.1016/S0006-291X(03)00942-2; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; vanBelzen N, 1997, LAB INVEST, V77, P85; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Xu B, 1999, BIOL REPROD, V61, P681, DOI 10.1095/biolreprod61.3.681; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou DJ, 1998, CANCER RES, V58, P2182; Zoroddu MA, 2001, J INORG BIOCHEM, V84, P47, DOI 10.1016/S0162-0134(00)00204-X	57	166	182	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48930	48940		10.1074/jbc.M400386200	http://dx.doi.org/10.1074/jbc.M400386200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15377670	hybrid			2022-12-25	WOS:000225098100055
J	Coyne, CB; Voelker, T; Pichla, SL; Bergelson, JM				Coyne, CB; Voelker, T; Pichla, SL; Bergelson, JM			The coxsackievirus and adenovirus receptor interacts with the multi-PDZ domain protein-1 (MUPP-1) within the tight junction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; BLADDER-CANCER; LNX; CAR; IDENTIFICATION; PURIFICATION; EXPRESSION; MECHANISM; VIRUSES; LIGAND	The coxsackievirus and adenovirus receptor ( CAR) is a component of the epithelial cell tight junction. In a yeast two-hybrid screen we identified the multi-PDZ domain protein MUPP1 as an interaction partner for the CAR cytoplasmic domain. CAR and MUPP1 were found to colocalize at the tight junction, to coprecipitate from epithelial cells, and to interact in vitro. The interaction was found to specifically involve the PDZ-binding motif within the CAR C terminus and MUPP1 PDZ domain 13. In transfected cells, CAR recruited MUPP1 to cell-cell contacts. The inhibition of CAR expression with small interfering RNA inhibited MUPP1 localization to the tight junction. The results indicated that CAR interacts with MUPP1 and is involved in MUPP1 recruitment to the tight junction.	Childrens Hosp Philadelphia, Div Infect Dis, Abramson Res Ctr 1202, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Bergelson, JM (corresponding author), Childrens Hosp Philadelphia, Div Infect Dis, Abramson Res Ctr 1202, 3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	bergelson@email.chop.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007324] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL54734] Funding Source: Medline; NIAID NIH HHS [R01AI5228-1, T32AI07324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balda MS, 2003, J CELL BIOL, V160, P423, DOI 10.1083/jcb.200210020; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Carson SD, 1997, BIOCHEM BIOPH RES CO, V233, P325, DOI 10.1006/bbrc.1997.6449; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Fuxe J, 2003, INT J CANCER, V103, P723, DOI 10.1002/ijc.10891; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Ivanov AI, 2004, MOL BIOL CELL, V15, P176, DOI 10.1091/mbc.E03-05-0319; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; MAPOLES JE, 1985, J VIROL, V55, P560, DOI 10.1128/JVI.55.3.560-566.1985; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Okegawa T, 2001, CANCER RES, V61, P6592; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Sachs MD, 2002, UROLOGY, V60, P531, DOI 10.1016/S0090-4295(02)01748-X; Shieh JTC, 2002, J VIROL, V76, P9474, DOI 10.1128/JVI.76.18.9474-9480.2002; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Xie Y, 2001, BIOCHEM GENET, V39, P117, DOI 10.1023/A:1010269908398	27	102	106	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48079	48084		10.1074/jbc.M409061200	http://dx.doi.org/10.1074/jbc.M409061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364909	hybrid			2022-12-25	WOS:000224957000080
J	Serres, S; Bezancon, E; Franconi, JM; Merle, M				Serres, S; Bezancon, E; Franconi, JM; Merle, M			Ex vivo analysis of lactate and glucose metabolism in the rat brain under different states of depressed activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-LAEVIS OOCYTES; ADULT-MOUSE BRAIN; MONOCARBOXYLATE TRANSPORTER; NEURONAL-ACTIVITY; PYRUVATE-CARBOXYLASE; CEREBRAL METABOLISM; IN-VIVO; ASTROCYTES; GLUTAMATE; MCT2	Brain metabolism of glucose and lactate was analyzed by ex vivo NMR spectroscopy in rats presenting different cerebral activities induced after the administration of pentobarbital, alpha-chloralose, or morphine. The animals were infused with a solution of either [1-C-13] glucose plus lactate or glucose plus [3-C-13] lactate for 20 min. Brain metabolite contents and enrichments were determined from analyses of brain tissue perchloric acid extracts according to their post-mortem evolution kinetics. When amino acid enrichments were compared, both the brain metabolic activity and the contribution of blood glucose relative to that of blood lactate to brain metabolism were linked with cerebral activity. The data also indicated the production in the brain of lactate from glycolysis in a compartment other than the neurons, presumably the astrocytes, and its subsequent oxidative metabolism in neurons. Therefore, a brain electrical activity-dependent increase in the relative contribution of blood glucose to brain metabolism occurred via the increase in the metabolism of lactate generated from brain glycolysis at the expense of that of blood lactate. This result strengthens the hypothesis that brain lactate is involved in the coupling between neuronal activation and metabolism.	Univ Victor Segalen, CNRS, Unite Mixte Rech 5536, Unite Resonance Magnet Syst Biol, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Merle, M (corresponding author), Univ Victor Segalen, CNRS, Unite Mixte Rech 5536, Unite Resonance Magnet Syst Biol, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	merle@rmsb.u-bordeaux2.fr		serres, sebastien/0000-0002-1573-1581				BENYOSEPH O, 1993, BIOCHEM J, V291, P915, DOI 10.1042/bj2910915; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Bouzier AK, 2000, J NEUROCHEM, V75, P480, DOI 10.1046/j.1471-4159.2000.0750480.x; Broer S, 1997, J BIOL CHEM, V272, P30096, DOI 10.1074/jbc.272.48.30096; Broer S, 1999, BIOCHEM J, V341, P529, DOI 10.1042/0264-6021:3410529; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Choi IY, 2001, J CEREBR BLOOD F MET, V21, P653, DOI 10.1097/00004647-200106000-00003; Cholet N, 2002, CEREB CORTEX, V12, P515, DOI 10.1093/cercor/12.5.515; Cruz F, 2001, J NEUROSCI RES, V66, P771, DOI 10.1002/jnr.10048; Demestre M, 1997, J PHYSIOL-LONDON, V499, P825, DOI 10.1113/jphysiol.1997.sp021971; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; GJEDDE A, 1980, J NEUROCHEM, V35, P1382, DOI 10.1111/j.1471-4159.1980.tb09013.x; Gruetter R, 1998, J NEUROCHEM, V70, P397; Haspel HC, 1999, J MEMBRANE BIOL, V169, P45, DOI 10.1007/PL00005900; Hassel B, 2000, J CEREBR BLOOD F MET, V20, P327, DOI 10.1097/00004647-200002000-00014; Hu YB, 1997, J NEUROCHEM, V69, P1484; Jones P, 1999, NEUROCHEM RES, V24, P1327, DOI 10.1023/A:1022516219647; LAMANNA JC, 1993, BRAIN RES, V614, P164, DOI 10.1016/0006-8993(93)91030-V; Lowry JP, 1997, J PHYSIOL-LONDON, V498, P497, DOI 10.1113/jphysiol.1997.sp021875; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Merle M, 2002, J NEUROCHEM, V82, P47, DOI 10.1046/j.1471-4159.2002.00924.x; NORBERG K, 1975, BRAIN RES, V86, P31, DOI 10.1016/0006-8993(75)90635-6; OTSUKA T, 1991, AM J PHYSIOL, V261, pR265, DOI 10.1152/ajpregu.1991.261.2.R265; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pierre K, 2002, J CEREBR BLOOD F MET, V22, P586, DOI 10.1097/00004647-200205000-00010; POITRYYAMATE CL, 1995, J NEUROSCI, V15, P5179; Qu H, 2000, DEV NEUROSCI-BASEL, V22, P429, DOI 10.1159/000017472; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; Serres S, 2003, NMR BIOMED, V16, P430, DOI 10.1002/nbm.838; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; VEECH RL, 1973, RES METHODS NEUROCHE, V2, P171; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Waagepetersen HS, 2000, J NEUROCHEM, V75, P471, DOI 10.1046/j.1471-4159.2000.0750471.x; Zwingmann C, 2000, GLIA, V32, P286, DOI 10.1002/1098-1136(200012)32:3<286::AID-GLIA80>3.0.CO;2-P	36	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47881	47889		10.1074/jbc.M409429200	http://dx.doi.org/10.1074/jbc.M409429200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15361523	hybrid			2022-12-25	WOS:000224957000058
J	Wang, H; Zhang, Y; Toratani, S; Okamoto, T				Wang, H; Zhang, Y; Toratani, S; Okamoto, T			Transformation of vascular endothelial cells by a point mutation in the Tie2 gene from human intramuscular haemangioma	ONCOGENE			English	Article						Tie2; VEGF; haemangioma; angiosarcoma; endothelial cell	GROWTH-FACTOR; MOUSE; ACTIVATION; INHIBITION; EXPRESSION; ONCOGENE; DELIVERY; PROTEIN; DOMAIN	Tie2, an endothelial-cell-specific receptor tyrosine kinase, collaborates with vascular endothelial growth factor (VEGF) in regulating angiogenesis and vascular maturation. Here, we report a mutation of glycine to aspartic acid at the second glycine of the GXGXXG motif of Tie2 ((G833D)Tie2) in human intramuscular haemangiomas (IMHs) of the capillary type. Murine endothelial cells (ECs) overexpressing this (G833D)Tie2 receptor exhibited an increase in cell proliferation at low serum concentrations and angiosarcomas developed in nude mice, whereas cells overexpressing either wild-type Tie2 or (Q837H)Tie2 failed to elicit these responses. Furthermore, the (G833D)Tie2 receptor increased VEGF expression in ECs. These findings provide molecular mechanisms for pathogenesis of IMH.	Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan; Second Mil Med Univ, Shanghai Changhai Hosp, Dept Oral Med & Maxillofacial Surg, Shanghai 200433, Peoples R China	Hiroshima University; Naval Medical University	Okamoto, T (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Div Frontier Med Sci, Dept Mol Oral Med & Maxillofacial Surg, Hiroshima 7348553, Japan.	tetsuok@hiroshima-u.ac.jp						Akada T, 2002, J CELL PHYSIOL, V193, P253, DOI 10.1002/jcp.10169; Balmain A, 2000, CARCINOGENESIS, V21, P371, DOI 10.1093/carcin/21.3.371; Brown LF, 2000, AM J PATHOL, V156, P2179, DOI 10.1016/S0002-9440(10)65088-2; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1994, GENE DEV, V8, P1879; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P512; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Holliday R, 1996, CANCER SURV, V28, P103; Lee RJ, 2000, CIRCULATION, V102, P898; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Spitaler M, 2000, J BIOL CHEM, V275, P33289, DOI 10.1074/jbc.M002742200; Springer ML, 1998, MOL CELL, V2, P549, DOI 10.1016/S1097-2765(00)80154-9; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; YANAI N, 1991, CELL STRUCT FUNCT, V16, P87, DOI 10.1247/csf.16.87; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P11336, DOI 10.1073/pnas.191377098	19	15	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8700	8704		10.1038/sj.onc.1208006	http://dx.doi.org/10.1038/sj.onc.1208006			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15377998				2022-12-25	WOS:000224988800017
J	Chandrasekharan, UM; Yang, L; Walters, A; Howe, P; DiCorleto, PE				Chandrasekharan, UM; Yang, L; Walters, A; Howe, P; DiCorleto, PE			Role of CL-100, a dual specificity phosphatase, in thrombin-induced endothelial cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PHOSPHATASE-1; E-SELECTIN EXPRESSION; KAPPA-B; RECEPTOR ACTIVATION; ADHESION MOLECULE-1; GENE-EXPRESSION; SHAPE CHANGES; P38 MAPK; MITOGEN; STRESS	Using a cDNA microarray screening approach, we have identified seven novel thrombin-responsive genes in human umbilical vein endothelial cells that were verifiable by Northern blot analysis. Among them CL-100, a dual-specificity phosphatase also known as MAP kinase phosphatase-1 (MKP-1), showed greatest induction by thrombin. Steady-state levels of CL-100 mRNA induction by thrombin peaked at 1 h and declined rapidly (t(1/2) similar to45 min). Induction by thrombin was protease-activated receptor-1-mediated, protein synthesis-independent, and transcriptionally regulated. Metabolic labeling followed by immunoprecipitation verified that the thrombin-induced CL-100 mRNA was translated into protein. We found that both Src-kinase and p42/p44 ERK activity are critical for thrombin-induced CL-100 expression, whereas phosphatidylinositol 3-kinase and protein kinase C activity were not required. Antisense-mediated inhibition of CL-100 was shown to prolong thrombin-induced ERK activity in endothelial cells, concomitant with an inhibition in thrombin-induced PDGF-A (platelet-derived growth factor A) and PDGF-B gene expression and an up-regulation in thrombin-induced VCAM-1 and E-selectin gene expression. Inhibition of ERK activation by PD98059 in endothelial cells was shown to potentiate thrombin-induced expression of PDGF-B (similar to3-fold) while inhibiting thrombin-induced VCAM-1 and E-selectin gene expression by 60 and 70%, respectively. These results suggested that induced expression of the CL-100 phosphatase and its subsequent regulation of ERK activity play a key regulatory role in the thrombin signaling pathway and in the transcriptional regulation of pathologically important "endothelial cell activation genes."	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation	DiCorleto, PE (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	dicorlp@ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Curry FE, 2003, AM J PHYSIOL-HEART C, V285, pH2446, DOI 10.1152/ajpheart.00262.2003; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Eto M, 2001, CIRC RES, V89, P583, DOI 10.1161/hh1901.097084; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; GALDAL KS, 1983, THROMB RES, V32, P57, DOI 10.1016/0049-3848(83)90154-8; Gilchrist A, 2001, J BIOL CHEM, V276, P25672, DOI 10.1074/jbc.M100914200; Grand RJA, 1996, BIOCHEM J, V313, P353, DOI 10.1042/bj3130353; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Jin EJ, 2003, CANCER-AM CANCER SOC, V97, P703, DOI 10.1002/cncr.11087; Kaplanski G, 1998, BLOOD, V92, P1259, DOI 10.1182/blood.V92.4.1259.416k11_1259_1267; Kaur J, 2003, AM J PHYSIOL-HEART C, V284, pH1095, DOI 10.1152/ajpheart.00016.2002; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; Liu CJ, 2003, BIOCHEM BIOPH RES CO, V312, P780, DOI 10.1016/j.bbrc.2003.10.186; Maruyama I, 1998, LUPUS, V7, pS41, DOI 10.1177/096120339800700210; Metzler B, 1999, ARTERIOSCL THROM VAS, V19, P1862, DOI 10.1161/01.ATV.19.8.1862; Minami T, 2004, ARTERIOSCL THROM VAS, V24, P41, DOI 10.1161/01.ATV.0000099880.09014.7D; Minami T, 2003, J BIOL CHEM, V278, P6976, DOI 10.1074/jbc.M208974200; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; O'Brien PJ, 2000, J BIOL CHEM, V275, P13502, DOI 10.1074/jbc.275.18.13502; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pietersma A, 1997, BIOCHEM BIOPH RES CO, V230, P44, DOI 10.1006/bbrc.1996.5886; Potente M, 2002, J BIOL CHEM, V277, P15671, DOI 10.1074/jbc.M110806200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Reddy S, 2001, J BIOL CHEM, V276, P17030, DOI 10.1074/jbc.M011663200; Ryser S, 2001, J BIOL CHEM, V276, P33319, DOI 10.1074/jbc.M102326200; Scarpati EM, 1996, J BIOL CHEM, V271, P3025, DOI 10.1074/jbc.271.6.3025; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SHIMIZU T, 2004, J BIOL CHEM; Siflinger-Birnboim A, 2003, AM J PHYSIOL-LUNG C, V284, pL435, DOI 10.1152/ajplung.00106.2002; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Strukova SM, 2001, BIOCHEMISTRY-MOSCOW+, V66, P8, DOI 10.1023/A:1002869310180; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; Vouret-Craviari V, 2003, J THROMB HAEMOST, V1, P1103, DOI 10.1046/j.1538-7836.2003.00238.x; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WheelerJones CPD, 1996, FEBS LETT, V388, P180, DOI 10.1016/0014-5793(96)00547-9	47	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46678	46685		10.1074/jbc.M406441200	http://dx.doi.org/10.1074/jbc.M406441200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339908	hybrid			2022-12-25	WOS:000224832400044
J	Imamura, R; Konaka, K; Matsumoto, N; Hasegawa, M; Fukui, M; Mukaida, N; Kinoshita, T; Suda, T				Imamura, R; Konaka, K; Matsumoto, N; Hasegawa, M; Fukui, M; Mukaida, N; Kinoshita, T; Suda, T			Fas ligand induces cell-autonomous NF-kappa B activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH DOMAIN PROTEIN; FADD-DEPENDENT APOPTOSIS; CONFER IMMUNE PRIVILEGE; SIGNALING PATHWAYS; FACTOR RECEPTOR; CD95 LIGAND; MUTATIONAL ANALYSIS; GENE-EXPRESSION; ESSENTIAL ROLES; IL-8 SECRETION	Fas ligand (FasL) has been well characterized as a death factor. However, recent studies revealed that FasL possesses inflammatory activity. Here we found that FasL induces production of the inflammatory chemokine IL-8 without inducing apoptosis in HEK293 cells. Reporter gene assays involving wild-type and mutated IL-8 promoters and NF-kappaB- and AP-1 reporter constructs indicated that an FasL-induced NF-kappaB and AP-1 activity are required for maximal promoter activity. FasL induced NF-kappaB activation with slower kinetics than did TNF-alpha, yet this response was cell autonomous and not mediated by secondary paracrine factors. The death domain of Fas, FADD, and caspase-8 were required for NF-kappaB activation by FasL. A dominant-negative mutant of IKKgamma inhibited the FasL-induced NF-kappaB activation. However, TRADD and RIP, which are essential for the TNF-alpha-induced NF-kappaB activation, were not involved in the FasL-induced NF-kappaB activation. Moreover, CLARP/FLIP inhibited the FasL- but not the TNF-alpha-induced NF-kappaB activation. These results show that FasL induces NF-kappaB activation and IL-8 production by a novel mechanism, distinct from that of TNF-alpha. In addition, we found that mouse FADD had a dominant-negative effect on the FasL-induced NF-kappaB activation in HEK293 cells, which may indicate a species difference between human and mouse in the FasL-induced NF-kappaB activation.	Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Div Tissue Mol Struct, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University; Kanazawa University	Suda, T (corresponding author), Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	KINOSHITA, Takeshi/D-8436-2015; IMAMURA, Ryu/D-8433-2015; Mukaida, Naofumi/D-7623-2011	Mukaida, Naofumi/0000-0002-4193-1851				ABREUMARTIN MT, 1995, J IMMUNOL, V155, P4147; Ahn JH, 2001, J BIOL CHEM, V276, P47100, DOI 10.1074/jbc.M107385200; Alappat EC, 2003, J BIOL CHEM, V278, P41585, DOI 10.1074/jbc.C300385200; Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Choi C, 2001, CANCER RES, V61, P3084; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Hagimoto N, 1999, AM J RESP CELL MOL, V21, P436, DOI 10.1165/ajrcmb.21.3.3397; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; ISHIKAWA Y, 1995, J BIOL CHEM, V270, P4158, DOI 10.1074/jbc.270.8.4158; ITOH N, 1993, J BIOL CHEM, V268, P10932; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; MAHE Y, 1991, J BIOL CHEM, V266, P13759; Manos EJ, 2001, CANCER RES, V61, P433; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Miwa K, 1999, INT IMMUNOL, V11, P925, DOI 10.1093/intimm/11.6.925; Miwa K, 1998, NAT MED, V4, P1287, DOI 10.1038/3276; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Sakamaki K, 2002, CELL DEATH DIFFER, V9, P1196, DOI 10.1038/sj.cdd.4401090; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Sekine C, 1996, BIOCHEM BIOPH RES CO, V228, P14, DOI 10.1006/bbrc.1996.1610; Shimada M, 2001, J GASTROEN HEPATOL, V16, P1060, DOI 10.1046/j.1440-1746.2001.02583.x; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; Suda T, 1996, J IMMUNOL, V157, P3918; SUDA T, 1994, J EXP MED, V179, P873, DOI 10.1084/jem.179.3.873; SUDA T, 1997, J ALLERGY CLIN IMMUN, V100, P97; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	57	80	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46415	46423		10.1074/jbc.M403226200	http://dx.doi.org/10.1074/jbc.M403226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337758	hybrid			2022-12-25	WOS:000224832400011
J	Kumar, KGS; Krolewski, JJ; Fuchs, SY				Kumar, KGS; Krolewski, JJ; Fuchs, SY			Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE TYK2; BETA-TRCP; KAPPA-B; ALPHA/BETA RECEPTOR; LIGASE; SCF; COMPLEX; BINDING; DOMAIN; MONOUBIQUITINATION	Ubiquitination, endocytosis, and lysosomal degradation of the IFNAR1 (interferon alpha receptor 1) subunit of the type I interferon (IFN) receptor is mediated by the SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein) E3 ubiquitin ligase in a phosphorylation-dependent manner. In addition, stability of IFNAR1 is regulated by its binding to Tyk2 kinase. Here we characterize the determinants of IFNAR1 ubiquitination and degradation. We found that the integrity of two Ser residues at positions 535 and 539 within the specific destruction motif present in the cytoplasmic tail of IFNAR1 is essential for the ability of IFNAR1 to recruit beta-Trcp as well as to undergo efficient ubiquitination and degradation. Using an antibody that specifically recognizes IFNAR1 phosphorylated on Ser(535) we found that IFNAR1 is phosphorylated on this residue in cells. This phosphorylation is promoted by treatment of cells with IFNalpha. Although the cytoplasmic tail of IFNAR1 contains seven Lys residues that could function as potential ubiquitin acceptor sites, we found that only three (Lys(501), Lys(525), and Lys(526)), all located proximal to the destruction motif, are essential for ubiquitination and degradation of IFNAR1. Expression of Tyk2 stabilized IFNAR1 in a manner that was dependent neither on its binding to beta-Trcp nor IFNAR1 ubiquitination. We discuss the complexities and specifics of the ubiquitination and degradation of IFNAR1, which is a beta-Trcp substrate that undergoes degradation via a lysosomal pathway.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA	University of Pennsylvania; University of California System; University of California Irvine	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu			NCI NIH HHS [CA058682, CA 92900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Coadou G, 2003, BIOCHEMISTRY-US, V42, P14741, DOI 10.1021/bi035207u; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Kumar KGS, 2003, EMBO J, V22, P5480; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Tang WG, 2003, J BIOL CHEM, V278, P48942, DOI 10.1074/jbc.M307962200; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yan H, 1996, MOL CELL BIOL, V16, P2074; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	31	113	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46614	46620		10.1074/jbc.M407082200	http://dx.doi.org/10.1074/jbc.M407082200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337770	hybrid			2022-12-25	WOS:000224832400035
J	Liu, XY; Yu, CA; Yu, L				Liu, XY; Yu, CA; Yu, L			The role of extra fragment at the C-terminal of cytochrome b (residues 421-445) in the cytochrome bc(1) complex from Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; ELECTRON-TRANSFER; PARACOCCUS-DENITRIFICANS; OXIDOREDUCTASE COMPLEX; ENERGY TRANSDUCTION; Q0 SITE; UBIQUINONE; SUBUNIT; CLUSTER; EPR	Sequence alignment of cytochrome b of the cytochrome bc(1) complex from various sources reveals that bacterial cytochrome b contain an extra fragment at the C terminus. To study the role of this fragment in bacterial cytochrome bc(1) complex, Rhodobacter sphaeroides mutants expressing His-tagged cytochrome bc(1) complexes with progressive deletion from this fragment ( residues 421 - 445) were generated and characterized. The cytb Delta-(433 - 445) bc(1) complex, in which 13 residues from the C-terminal end of this fragment are deleted, has electron transfer activity, subunit composition, and physical properties similar to those of the complement complex, indicating that this region of the extra fragment is not essential. In contrast, the electron transfer activity, binding of cytochrome b, ISP, and subunit IV to cytochrome c(1), redox potentials of cytochromes b and c(1) in the cytbDelta-(427 - 445), cytbDelta-( 425 - 445), and cytbDelta-(421-445) mutant complexes, in which 19, 21, or all residues of this fragment are deleted, decrease progressively. EPR spectra of the [2Fe-2S] cluster and the cytochromes b in these three deletion mutant bc(1) complexes are also altered; the extent of spectral alteration increases as this extra fragment is shortened. These results indicate that the first 12 residues ( residues 421 - 432) from the N-terminal end of the C-terminal extra fragment of cytochrome b are essential for maintaining structural integrity of the bc(1) complex.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, L (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.	linda@okstate.edu			NIGMS NIH HHS [GM30721] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; BERDEN JA, 1970, BIOCHIM BIOPHYS ACTA, V216, P237, DOI 10.1016/0005-2728(70)90215-X; DEVRIES S, 1979, BIOCHIM BIOPHYS ACTA, V546, P316, DOI 10.1016/0005-2728(79)90049-5; DING HG, 1992, BIOCHEMISTRY-US, V31, P3144, DOI 10.1021/bi00127a015; Dutton P L, 1978, Methods Enzymol, V54, P411; Ghaim JB, 1997, BBA-BIOMEMBRANES, V1330, P113, DOI 10.1016/S0005-2736(97)00127-2; GUNER S, 1991, BIOCHIM BIOPHYS ACTA, V1058, P269, DOI 10.1016/S0005-2728(05)80247-6; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; MATHER MW, 1995, J BIOL CHEM, V270, P28668, DOI 10.1074/jbc.270.48.28668; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; MCCURLEY JP, 1990, BIOCHIM BIOPHYS ACTA, V1020, P176, DOI 10.1016/0005-2728(90)90049-A; MEINHARDT SW, 1987, J BIOL CHEM, V262, P8702; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; ORMEJOHNSON NR, 1974, BIOCHEM BIOPH RES CO, V45, P871; PHILLIPS JD, 1993, J BIOL CHEM, V268, P11727; ROBERTSON DE, 1990, BIOCHEMISTRY-US, V29, P11249, DOI 10.1021/bi00503a014; SALERNO JC, 1984, J BIOL CHEM, V259, P2331; Tian H, 1998, J BIOL CHEM, V273, P27953, DOI 10.1074/jbc.273.43.27953; Tian H, 1997, J BIOL CHEM, V272, P23722, DOI 10.1074/jbc.272.38.23722; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; Xiao KH, 2004, BIOCHEMISTRY-US, V43, P1488, DOI 10.1021/bi035378z; YANG XH, 1988, J BIOL CHEM, V263, P11962; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; Yu L, 1999, J BIOENERG BIOMEMBR, V31, P251, DOI 10.1023/A:1005423913639; YU L, 1986, BIOCHIM BIOPHYS ACTA, V852, P203, DOI 10.1016/0005-2728(86)90225-2	27	8	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47363	47371		10.1074/jbc.M406497200	http://dx.doi.org/10.1074/jbc.M406497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339929	hybrid			2022-12-25	WOS:000224832400125
J	Gangalum, RK; Schibler, MJ; Bhat, SP				Gangalum, RK; Schibler, MJ; Bhat, SP			Small heat shock protein alpha B-crystallin is part of cell cycle-dependent Golgi reorganization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS; COMPLEX; INHERITANCE; EXPRESSION; CHAPERONE; CATARACT; MUTATION; MITOSIS; MICE	alphaB-Crystallin is a developmentally regulated small heat shock protein known for its binding to a variety of denatured polypeptides and suppression of protein aggregation in vitro. Elevated levels of alphaB-crystallin are known to be associated with a number of neurodegenerative pathologies such as Alzheimer disease and multiple sclerosis. Mutations in alphaB-crystallin gene have been linked to desmin-related cardiomyopathy and cataractogenesis. The physiological function of this protein, however, is unknown. Using discontinuous sucrose density gradient fractionation of post-nuclear supernatants, prepared from rat tissues and human glioblastoma cell line U373MG, we have identified discrete membrane-bound fractions of alphaB-crystallin, which co-sediment with the Golgi matrix protein, GM130. Confocal microscopy reveals co-localization of alphaB-crystallin with BODIPY TR ceramide and the Golgi matrix protein, GM130, in the perinuclear Golgi in human glioblastoma U373MG cells. Examination of synchronized cultures indicated that alphaB-crystallin follows disassembly of the Golgi at prometaphase and its reassembly at the completion of cytokinesis, suggesting that this small heat shock protein, with its chaperone-like activity, may have an important role in the Golgi reorganization during cell division.	Univ Calif Los Angeles, Jules Stein Eye Inst, Vis Mol Biol Lab, Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Bhat, SP (corresponding author), Univ Calif Los Angeles, Jules Stein Eye Inst, Vis Mol Biol Lab, Geffen Sch Med, BH 623, Los Angeles, CA 90095 USA.	bhat@jsei.ucla.edu	Gangalum, Rajendra K/H-1369-2013	Gangalum, Rajendra K/0000-0002-8746-0266; Bhat, Suraj P/0000-0003-4707-5870				Andley UP, 2001, FASEB J, V15, P221, DOI 10.1096/fj.00-0296com; Barr FA, 2004, J CELL BIOL, V164, P955, DOI 10.1083/jcb.200402011; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Bhat SP, 2003, PROG DRUG RES, V60, P205; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; BHAT SP, 1991, EUR J BIOCHEM, V202, P775, DOI 10.1111/j.1432-1033.1991.tb16432.x; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Cobb BA, 2000, J BIOL CHEM, V275, P6664, DOI 10.1074/jbc.275.9.6664; DERETIC D, 1994, J BIOL CHEM, V269, P16853; Derham BK, 1999, PROG RETIN EYE RES, V18, P463, DOI 10.1016/S1350-9462(98)00030-5; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Haynes JI, 1996, DEV DYNAM, V207, P75, DOI 10.1002/(SICI)1097-0177(199609)207:1<75::AID-AJA8>3.3.CO;2-O; Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6; Jamieson JD, 1998, BBA-MOL CELL RES, V1404, P3, DOI 10.1016/S0167-4889(98)00043-3; KATO K, 1993, BIOCHIM BIOPHYS ACTA, V1175, P257, DOI 10.1016/0167-4889(93)90214-A; KIBBELAAR MA, 1979, EUR J BIOCHEM, V95, P543, DOI 10.1111/j.1432-1033.1979.tb12995.x; Puthenveedu MA, 2001, EXP CELL RES, V271, P22, DOI 10.1006/excr.2001.5367; Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Seemann J, 2002, SCIENCE, V295, P848, DOI 10.1126/science.1068064; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, V1, P509; STEIN GS, 1994, CELL BIOL LAB HDB, V1, P282; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Van Noort JM, 1998, PROG BRAIN RES, V117, P435; van Rijk AF, 2003, EUR J CELL BIOL, V82, P361, DOI 10.1078/0171-9335-00321; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726	30	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 15	2004	279	42					43374	43377		10.1074/jbc.C400371200	http://dx.doi.org/10.1074/jbc.C400371200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	860YY	15339919	hybrid			2022-12-25	WOS:000224383100004
J	Inouye, M; Ke, HP; Yashio, A; Yamanaka, K; Nariya, H; Shimamoto, T; Inouye, S				Inouye, M; Ke, HP; Yashio, A; Yamanaka, K; Nariya, H; Shimamoto, T; Inouye, S			Complex formation between a putative 66-residue thumb domain of bacterial reverse transcriptase RT-Ec86 and the primer recognition RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; CDNA PRIMING REACTION; ESCHERICHIA-COLI; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; BIOSYNTHESIS; SEQUENCE; MSDNA	Reverse transcriptases (RT) are found in a minor population of Escherichia coli and are responsible for the synthesis of multicopy single-stranded DNA. These RTs specifically recognize RNA structures in their individual primer-template RNAs to initiate cDNA synthesis from the 2'-OH group of a specific internal G residue ( branching G residue). Here, we purified the 66-residue, C-terminal fragment of RT-Ec86, RT from E. coli, which is responsible for the synthesis of multicopy single-stranded DNA-Ec86. This fragment, RT-Ec86-( 255 - 320), was found to consist mainly of alpha-helical structures on the basis of its CD spectrum, which is consistent with the prediction of this region as the thumb domain from the structural alignment of RT-Ec86 with human immunodeficiency virus-1 RT. RT-Ec86-( 255 - 320) was able to bind to a 28-base synthetic RNA consisting of the 5'-end single-stranded RNA containing the branching G residue and the recognition stem-loop structure in the RT-Ec86 primer-template RNA with a K-d value of 5 x 10(-8) M. By stepwise shortening of the 5'-end single-stranded region of the RNA, RT-Ec86-( 255 - 320) was found still to be able to form a stable complex with only the stem-loop structure consisting of an 8-bp stem and a 3-base loop. In this stem-loop structure, the UUU loop was essential for the complex formation. RT-Ec73-(251 - 316) from another E. coli RT could not bind to the 28-base RNA for RT-Ec86 but could bind to its own stem-loop structure having a 3-base AGU loop. These results support the notion that the highly diverse C-terminal regions of bacterial RTs play an important role in recognizing their own specific primer-template RNA structure for the cDNA priming reaction.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan; Kumamoto Univ, Inst Mol Embryol & Genet, Div Mol Cell Biol, Kumamoto 8620976, Japan	Rutgers State University New Brunswick; Rutgers State University Medical Center; Hiroshima University; Kumamoto University	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	inouye@umdnj.edu	Inouye, Sharon/R-7216-2019; Shimamoto, Tadashi/A-7109-2018	Shimamoto, Tadashi/0000-0002-5538-0595	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063853] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM63853] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		HERZER PJ, 1992, MOL MICROBIOL, V6, P345, DOI 10.1111/j.1365-2958.1992.tb01477.x; HSU MY, 1989, J BIOL CHEM, V264, P6214; Inouye S, 1999, J BIOL CHEM, V274, P31236, DOI 10.1074/jbc.274.44.31236; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAMPSON BC, 1989, SCIENCE, V243, P1033, DOI 10.1126/science.2466332; LIM D, 1989, CELL, V56, P891, DOI 10.1016/0092-8674(89)90693-4; LIM DB, 1992, MOL MICROBIOL, V6, P3531, DOI 10.1111/j.1365-2958.1992.tb01788.x; Lima TMO, 1997, PLASMID, V38, P25, DOI 10.1006/plas.1997.1298; Mao JR, 1997, J BACTERIOL, V179, P7865, DOI 10.1128/jb.179.24.7865-7868.1997; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; SHIMAMOTO T, 1995, J BIOL CHEM, V270, P581, DOI 10.1074/jbc.270.2.581; SHIMAMOTO T, 1993, J BIOL CHEM, V268, P2684; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; SUN J, 1991, J BACTERIOL, V173, P4171, DOI 10.1128/jb.173.13.4171-4181.1991; Yamanaka K, 2002, MOBILE DNA, VII, P784	17	3	3	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50735	50742		10.1074/jbc.M408462200	http://dx.doi.org/10.1074/jbc.M408462200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371452	hybrid			2022-12-25	WOS:000225355800015
J	Ahmed, R; Duncan, RF				Ahmed, R; Duncan, RF			Translational regulation of Hsp90 mRNA - AUG-proximal 5 '-untranslated region elements essential for preferential heat shock translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; GEL-ELECTROPHORESIS; SEQUENCE; CELLS; INACTIVATION; DEGRADATION; INHIBITION; 4E-BP	Heat shock in Drosophila results in repression of most normal (non-heat shock) mRNA translation and the preferential translation of the heat shock mRNAs. The sequence elements that confer preferential translation have been localized to the 5'-untranslated region (5'-UTR) for Hsp22 and Hsp70 mRNAs (in Drosophila). Hsp90 mRNA is unique among the heat shock mRNAs in having extensive secondary structure in its 5'-UTR and being abundantly represented in the non-heat shocked cell. In this study, we show that Hsp90 mRNA translation is inefficient at normal growth temperature, and substantially activated by heat shock. Its preferential translation is not based on an IRES-mediated translation pathway, because overexpression of eIF4E-BP inhibits its translation (and the translation of Hsp70 mRNA). The ability of Hsp90 mRNA to be preferentially translated is conferred by its 5'-UTR, but, in contrast to Hsp22 and -70, is primarily influenced by nucleotides close to the AUG initiation codon. We present a model to account for Hsp90 mRNA translation, incorporating results indicating that heat shock inhibits eIF4F activity, and that Hsp90 mRNA translation is sensitive to eIF4F inactivation.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Duncan, RF (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA.	rduncan@usc.edu						BONNER JJ, 1984, CELL, V37, P979; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DUNCAN R, 1984, ANAL BIOCHEM, V138, P144, DOI 10.1016/0003-2697(84)90783-8; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; Duncan RF, 1999, EUR J BIOCHEM, V265, P728, DOI 10.1046/j.1432-1327.1999.00776.x; Gabai VL, 2002, J APPL PHYSIOL, V92, P1743, DOI 10.1152/japplphysiol.01101.2001; GARBE JC, 1989, GENETICS, V122, P403; Hess MA, 1996, NUCLEIC ACIDS RES, V24, P2441, DOI 10.1093/nar/24.12.2441; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDQUIST S, 1990, ENZYME, V44, P147, DOI 10.1159/000468754; LINDQUIST S, 1980, J MOL BIOL, V137, P151, DOI 10.1016/0022-2836(80)90322-8; LINDQUIST S, 1987, TRANSLATIONAL REGULA, P187; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Morita MT, 1999, GENE DEV, V13, P655, DOI 10.1101/gad.13.6.655; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Pearl LH, 2002, ADV PROTEIN CHEM, V59, P157; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Scheper GC, 1997, J BIOL CHEM, V272, P26850, DOI 10.1074/jbc.272.43.26850; YOST HJ, 1990, TRENDS GENET, V6, P223, DOI 10.1016/0168-9525(90)90183-7; Yueh A, 2000, GENE DEV, V14, P414; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; ZAPATA JM, 1994, J BIOL CHEM, V269, P18047; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	31	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49919	49930		10.1074/jbc.M404681200	http://dx.doi.org/10.1074/jbc.M404681200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15347681	hybrid			2022-12-25	WOS:000225229500047
J	Gutierrez-Juarez, R; Obici, S; Rossetti, L				Gutierrez-Juarez, R; Obici, S; Rossetti, L			Melanocortin-independent effects of leptin on hepatic glucose fluxes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSES INSULIN-RESISTANCE; CENTRAL-NERVOUS-SYSTEM; FOOD-INTAKE; BODY-WEIGHT; VISCERAL ADIPOSITY; INDUCED ANOREXIA; ARCUATE NUCLEUS; SKELETAL-MUSCLE; GENE-EXPRESSION; CONSCIOUS RATS	Leptin and insulin share some hypothalamic signaling molecules, but their central administration induces different effects on hepatic glucose fluxes. Acute insulin infusion in the third cerebral ventricle inhibits endogenous glucose production (GP), whereas acute leptin infusion stimulates gluconeogenesis but does not alter GP because of a compensatory decrease in glycogenolysis. Because melanocortin agonists also stimulate hepatic gluconeogenesis, here we examined whether central melanocortin blockade modifies the acute effects of leptin on GP, on gluconeogenesis, on glycogenolysis, and/or on the hepatic expression of the gluconeogenic enzymes glucose-6-phosphatase (Glc-6-Pase) and phosphoenolpyruvate carboxykinase (PEPCK). Systemic or central administration of leptin alone did not alter GP, despite increasing both the rate of gluconeogenesis and the expression of Glc-6-Pase and PEPCK. When activation of the central melanocortin pathway was prevented, the effects of leptin on gluconeogenesis, Glc-6-Pase, and PEPCK were abolished, and a marked suppression of glycogenolysis resulted in decreased GP. We conclude that leptin regulates hepatic glucose fluxes through a melanocortin-dependent pathway leading to stimulation of gluconeogenesis and a melanocortin-independent pathway causing inhibition of GP and glycogenolysis.	Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Rossetti, L (corresponding author), Albert Einstein Coll Med, Ctr Diabet Res & Training, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	rossetti@aecom.yu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048321, R01DK048321, R29DK045024, R01DK045024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45024, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Air EL, 2002, ENDOCRINOLOGY, V143, P2449, DOI 10.1210/en.143.6.2449; Bai YL, 1996, J BIOL CHEM, V271, P13939, DOI 10.1074/jbc.271.24.13939; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; Barzilai N, 1999, AM J PHYSIOL-ENDOC M, V277, pE291, DOI 10.1152/ajpendo.1999.277.2.E291; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Baskin DG, 1999, BRAIN RES, V848, P114, DOI 10.1016/S0006-8993(99)01974-5; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Bluher S, 2004, DIABETES, V53, P82, DOI 10.2337/diabetes.53.1.82; Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; da Silva AA, 2004, HYPERTENSION, V43, P1312, DOI 10.1161/01.HYP.0000128421.23499.b9; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; GIACCARI A, 1989, J CHROMATOGR-BIOMED, V497, P69, DOI 10.1016/0378-4347(89)80006-4; GIACCARI A, 1992, J CLIN INVEST, V89, P36, DOI 10.1172/JCI115583; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Hidaka S, 2002, FASEB J, V16, P509, DOI 10.1096/fj.01-0164com; HUANG W, 1994, J BIOL CHEM, V279, P21695; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lam NT, 2004, MOL ENDOCRINOL, V18, P1333, DOI 10.1210/me.2002-0193; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Muoio DM, 1997, DIABETES, V46, P1360, DOI 10.2337/diabetes.46.8.1360; Muoio DM, 1999, AM J PHYSIOL-ENDOC M, V276, pE913, DOI 10.1152/ajpendo.1999.276.5.E913; Muzumdar R, 2003, FASEB J, V17, P1130, DOI 10.1096/fj.02-0991fje; Myers MG, 2004, RECENT PROG HORM RES, V59, P287, DOI 10.1210/rp.59.1.287; Niswender KD, 2003, DIABETES, V52, P227, DOI 10.2337/diabetes.52.2.227; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2002, NAT MED, V8, P1376, DOI 10.1038/nm798; Petersen KF, 2002, J CLIN INVEST, V109, P1345, DOI [10.1172/JCI0215001, 10.1172/JCI200215001]; Pierroz DD, 2002, DIABETES, V51, P1337, DOI 10.2337/diabetes.51.5.1337; Rahmouni K, 2003, J NEUROSCI, V23, P5998, DOI 10.1523/JNEUROSCI.23-14-05998.2003; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Rossetti L, 1997, J BIOL CHEM, V272, P27758, DOI 10.1074/jbc.272.44.27758; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Seeley RJ, 1997, NATURE, V390, P349, DOI 10.1038/37016; Shi ZQ, 1998, METABOLISM, V47, P1274, DOI 10.1016/S0026-0495(98)90336-5; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Yaspelkis BB, 2001, AM J PHYSIOL-ENDOC M, V280, pE130, DOI 10.1152/ajpendo.2001.280.1.E130; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao AZ, 2000, J BIOL CHEM, V275, P11348, DOI 10.1074/jbc.275.15.11348	48	84	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49704	49715		10.1074/jbc.M408665200	http://dx.doi.org/10.1074/jbc.M408665200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364916	hybrid			2022-12-25	WOS:000225229500021
J	Kang, RJ; Swayze, R; Lise, MF; Gerrow, K; Mullard, A; Honer, WG; El-Husseini, A				Kang, RJ; Swayze, R; Lise, MF; Gerrow, K; Mullard, A; Honer, WG; El-Husseini, A			Presynaptic trafficking of synaptotagmin I is regulated by protein palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; FATTY ACYLATION; CALCIUM SENSOR; PC12 CELLS; T-SNARE; SNAP-25; BINDING; EXOCYTOSIS; DOMAINS	Protein palmitoylation plays a critical role in sorting and targeting of several proteins to pre- and postsynaptic sites. In this study, we have analyzed the role of palmitoylation in trafficking of synaptotagmin I and its modulation by synaptic activity. We found that palmitoylation of N-terminal cysteines contributed to sorting of synaptotagmin I to an intracellular vesicular compartment at the presynaptic terminal. Presynaptic targeting is a unique feature of N-terminal sequences of synaptotagmin I because the palmitoylated N terminus of synaptotagmin VII failed to localize to presynaptic sites. We also found that palmitate was stably associated with both synaptotagmin I and SNAP-25 and that rapid neuronal depolarization did not affect palmitate turnover on these proteins. However, long-term treatment with drugs that either block synaptic activity or disrupt SNARE complex assembly modulated palmitoylation and accumulation of synaptotagmin I at presynaptic sites. We conclude that palmitoylation is involved in trafficking of specific elements involved in transmitter release and that distinct mechanisms regulate addition and removal of palmitate on select neuronal proteins.	Univ British Columbia, Dept Psychiat, Ctr Complex Disorders, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	El-Husseini, A (corresponding author), Univ British Columbia, Dept Psychiat, Ctr Complex Disorders, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	alaa@interchange.ubc.ca		Swayze, Richard/0000-0003-0692-5648				Bradke F, 1998, BBA-MOL CELL RES, V1404, P245, DOI 10.1016/S0167-4889(98)00060-3; Calakos N, 1996, PHYSIOL REV, V76, P1; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Chapman ER, 2002, NAT REV MOL CELL BIO, V3, P498, DOI 10.1038/nrm855; Christopherson KS, 2003, J CELL SCI, V116, P3213, DOI 10.1242/jcs.00617; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Damer CK, 1996, J NEUROCHEM, V67, P1661; DeSouza S, 2002, J NEUROSCI, V22, P3493; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 2000, J BIOL CHEM, V275, P28180; Fukuda M, 2001, J BIOL CHEM, V276, P27670, DOI 10.1074/jbc.M100851200; Gonzalo S, 1998, MOL BIOL CELL, V9, P585, DOI 10.1091/mbc.9.3.585; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Han WP, 2004, NEURON, V41, P85, DOI 10.1016/S0896-6273(03)00820-1; Heindel U, 2003, FEBS LETT, V544, P57, DOI 10.1016/S0014-5793(03)00449-6; HESS DT, 1992, J NEUROSCI, V12, P4634; Honer WG, 1997, NEUROSCIENCE, V78, P99, DOI 10.1016/S0306-4522(96)00489-7; Kammer B, 2003, MOL CELL NEUROSCI, V23, P333, DOI 10.1016/S1044-7431(03)00064-2; Kanaani J, 2004, J CELL SCI, V117, P2001, DOI 10.1242/jcs.01030; Kanaani J, 2002, J CELL BIOL, V158, P1229, DOI 10.1083/jcb.200205053; Krasnov PA, 2000, J CELL SCI, V113, P1389; Linder ME, 2003, BIOCHEMISTRY-US, V42, P4311, DOI 10.1021/bi034159a; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Patterson SI, 2002, BIOL RES, V35, P139, DOI 10.4067/S0716-97602002000200005; PERIN MS, 1991, J BIOL CHEM, V266, P623; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Sudhof TC, 2002, J BIOL CHEM, V277, P7629, DOI 10.1074/jbc.R100052200; Veit M, 2000, BIOCHEM J, V345, P145, DOI 10.1042/0264-6021:3450145; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; Virmani T, 2003, EMBO J, V22, P5347, DOI 10.1093/emboj/cdg514; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; von Poser C, 2000, J BIOL CHEM, V275, P30916, DOI 10.1074/jbc.M005559200; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	43	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50524	50536		10.1074/jbc.M404981200	http://dx.doi.org/10.1074/jbc.M404981200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355980	hybrid			2022-12-25	WOS:000225229500118
J	Xiao, RY; Wilkinson, B; Solovyov, A; Winther, JR; Holmgren, A; Lundstrom-Ljung, J; Gilbert, HF				Xiao, RY; Wilkinson, B; Solovyov, A; Winther, JR; Holmgren, A; Lundstrom-Ljung, J; Gilbert, HF			The contributions of protein disulfide isomerase and its homologues to oxidative protein folding in the yeast endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BOND FORMATION; ESCHERICHIA-COLI; RIBONUCLEASE-A; IN-VIVO; GENE; CATALYSIS; PATHWAY; THIOREDOXIN; SUPPRESSES	In vitro, protein disulfide isomerase (Pdi1p) introduces disulfides into proteins (oxidase activity) and provides quality control by catalyzing the rearrangement of incorrect disulfides (isomerase activity). Protein disulfide isomerase (PDI) is an essential protein in Saccharomyces cerevisiae, but the contributions of the catalytic activities of PDI to oxidative protein folding in the endoplasmic reticulum (ER) are unclear. Using variants of Pdi1p with impaired oxidase or isomerase activity, we show that isomerase-deficient mutants of PDI support wild-type growth even in a strain in which all of the PDI homologues of the yeast ER have been deleted. Although the oxidase activity of PDI is sufficient for wild-type growth, pulse-chase experiments monitoring the maturation of carboxypeptidase Y reveal that oxidative folding is greatly compromised in mutants that are defective in isomerase activity. Pdi1p and one or more of its ER homologues (Mpd1p, Mpd2p, Eug1p, Eps1p) are required for efficient carboxypeptidase Y maturation. Consistent with its function as a disulfide isomerase in vivo, the active sites of Pdi1p are partially reduced (32+/-8%) in vivo. These results suggest that PDI and its ER homologues contribute both oxidase and isomerase activities to the yeast ER. The isomerase activity of PDI can be compromised without affecting growth and viability, implying that yeast proteins that are essential under laboratory conditions may not require efficient disulfide isomerization.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Carlsberg Lab, DK-2500 Copenhagen, Denmark; Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Baylor College of Medicine; Karolinska Institutet	Gilbert, HF (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, 1 Baylor Plaza, Houston, TX 77030 USA.	hgilbert@bcm.tmc.edu	Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Cabibbo A, 2000, J BIOL CHEM, V275, P4827, DOI 10.1074/jbc.275.7.4827; Cherry JM, 1997, NATURE, V387, P67, DOI 10.1038/387s067; Collet JF, 2002, MOL MICROBIOL, V44, P1, DOI 10.1046/j.1365-2958.2002.02851.x; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; Holst B, 1997, J CELL BIOL, V138, P1229, DOI 10.1083/jcb.138.6.1229; JAMSA E, 1994, YEAST, V10, P355, DOI 10.1002/yea.320100308; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; Norgaard P, 2003, YEAST, V20, P645, DOI 10.1002/yea.978; Norgaard P, 2001, J CELL BIOL, V152, P553, DOI 10.1083/jcb.152.3.553; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; SIKORSKI RS, 1989, GENETICS, V122, P19; Solovyov A, 2004, J BIOL CHEM, V279, P34095, DOI 10.1074/jbc.M405640200; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; Tachikawa H, 1997, BIOCHEM BIOPH RES CO, V239, P710, DOI 10.1006/bbrc.1997.7426; TACHIKAWA H, 1995, FEBS LETT, V369, P212, DOI 10.1016/0014-5793(95)00750-4; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Walker KW, 1997, J BIOL CHEM, V272, P8845; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Westphal V, 1999, J MOL BIOL, V286, P1229, DOI 10.1006/jmbi.1999.2560; Wu HH, 2000, BIOCHEM J, V351, P87, DOI 10.1042/0264-6021:3510087; Xiao R, 2001, J BIOL CHEM, V276, P27975, DOI 10.1074/jbc.M104203200; Zhan XM, 1999, BIOTECHNOL PROGR, V15, P1033, DOI 10.1021/bp990083r	37	49	53	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49780	49786		10.1074/jbc.M409210200	http://dx.doi.org/10.1074/jbc.M409210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377672	hybrid			2022-12-25	WOS:000225229500030
J	Zhao, LY; Liu, JL; Sidhu, GS; Niu, YX; Liu, Y; Wang, RP; Liao, DQ				Zhao, LY; Liu, JL; Sidhu, GS; Niu, YX; Liu, Y; Wang, RP; Liao, DQ			Negative regulation of p53 functions by Daxx and the involvement of MDM2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E1B 55-KILODALTON ONCOPROTEIN; EMBRYONIC LETHALITY; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; MDM2-DEFICIENT MICE; INDUCED APOPTOSIS; SYNDROME PROTEIN; TERMINAL DOMAIN; IN-VITRO; ACETYLATION	In normal cells p53 activity is tightly controlled and MDM2 is a known negative regulator. Here we show that via its acidic domain, Daxx binds to the COOH-terminal domain of p53, whose positive charges are critical for this interaction, as Lys to Arg mutations preserved, but Lys to Ala or Ser to Glu mutations abolished Daxx-p53 interaction. These results thus implicate acetylation and phosphorylation of p53 in regulating its binding to Daxx. Interestingly, whereas Daxx did not bind to p53 in cells as assessed by immunoprecipitation, MDM2 expression restored p53-Daxx interaction, and this correlated with deacetylation of p53. In p53/MDM2-null mouse embryonic fibroblasts (DKO MEF), Daxx repressed p53 target promoters whose p53-binding elements were required for the repression. Coexpression of Daxx and MDM2 led to further repression. p53 expression in DKO MEF induced apoptosis and Daxx expression relieved this effect. Similarly, in HCT116 cells, Daxx conferred striking resistance to 5-fluorouracil-induced apoptosis. As p53 is required for 5-fluorouracil-induced cell death, our data show that Daxx can suppress cell death induced by p53 overexpression and p53-dependent stress response. Collectively, our data reveal Daxx as a novel negative regulator of p53. Importantly, posttranslational modifications of p53 inhibit Daxx-p53 interaction, thereby relieving negative regulation of p53 by Daxx.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ J1H 5N4, Canada	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Sherbrooke	Liao, DQ (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	dliao@ufl.edu			NATIONAL CANCER INSTITUTE [R01CA092236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen LY, 2003, MOL CELL BIOL, V23, P7108, DOI 10.1128/MCB.23.20.7108-7121.2003; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; Emelyanov AV, 2002, J BIOL CHEM, V277, P11156, DOI 10.1074/jbc.M111763200; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hollenbach AD, 2002, J CELL SCI, V115, P3319; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jiang C, 1999, GENOMICS, V62, P508, DOI 10.1006/geno.1999.6052; JIN Y, 2002, J BIOL CHEM; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kim EJ, 2003, NUCLEIC ACIDS RES, V31, P5356, DOI 10.1093/nar/gkg741; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; LUNA RMD, 1995, NATURE, V378, P203; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Michaelson JS, 2003, J CELL SCI, V116, P345, DOI 10.1242/jcs.00234; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohiro Y, 2003, MOL CELL BIOL, V23, P322, DOI 10.1128/MCB.23.1.322-334.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Prives C, 1999, J PATHOL, V187, P112; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhao LY, 2003, J VIROL, V77, P13171, DOI 10.1128/JVI.77.24.13171-13181.2003; Zhao LY, 2003, ONCOGENE, V22, P8316, DOI 10.1038/sj.onc.1206916; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631	51	51	59	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50566	50579		10.1074/jbc.M406743200	http://dx.doi.org/10.1074/jbc.M406743200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364927	hybrid			2022-12-25	WOS:000225229500121
J	Alderson, NL; Rembiesa, BM; Walla, MD; Bielawska, A; Bielawski, J; Hama, H				Alderson, NL; Rembiesa, BM; Walla, MD; Bielawska, A; Bielawski, J; Hama, H			The human FA2H gene encodes a fatty acid 2-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN MICROSOMES; CYTOCHROME B(5)-LIKE DOMAIN; B(5) FUSION PROTEIN; ALPHA-HYDROXYLATION; LIGNOCEROYL-COA; MOLECULAR ARRANGEMENTS; CERAMIDES; SPHINGOLIPIDS; CEREBROSIDES; GALACTOCEREBROSIDE	2-Hydroxysphingolipids are a subset of sphingolipids containing 2-hydroxy fatty acids. The 2-hydroxylation occurs during de novo ceramide synthesis and is catalyzed by fatty acid 2-hydroxylase ( also known as fatty acid alpha-hydroxylase). In mammals, 2-hydroxysphingolipids are present abundantly in brain because the major myelin lipids galactosylceramides and sulfatides contain 2-hydroxy fatty acids. Here we report identification and characterization of a human gene that encodes a fatty acid 2-hydroxylase. Data base searches revealed a human homologue of the yeast ceramide 2-hydroxylase gene (FAH1), which we named FA2H. The FA2H gene encodes a 372-amino acid protein with 36% identity and 46% similarity to yeast Fah1p. The amino acid sequence indicates that FA2H protein contains an N-terminal cytochrome b(5) domain and four potential transmembrane domains. FA2H also contains the iron-binding histidine motif conserved among membrane-bound desaturases/ hydroxylases. COS7 cells expressing human FA2H contained 3 - 20-fold higher levels of 2-hydroxyceramides (C16, C18, C24, and C24: 1) and 2-hydroxy fatty acids compared with control cells. Microsomal fractions prepared from transfected COS7 cells showed tetracosanoic acid 2-hydroxylase activities in an NADPH- and NADPH: cytochrome P-450 reductase-dependent manner. FA2H lacking the N-terminal cytochrome b5 domain had little activity, indicating that this domain is a functional component of this enzyme. Northern blot analysis showed that the FA2H gene is highly expressed in brain and colon tissues. These results demonstrate that the human FA2H gene encodes a fatty acid 2-hydroxylase. FA2H is likely involved in the formation of myelin 2-hydroxy galactosylceramides and - sulfatides.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Univ S Carolina, Dept Chem & Biochem, Columbia, SC 29208 USA	Medical University of South Carolina; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Hama, H (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashely Ave, Charleston, SC 29425 USA.	hama@musc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR 17677-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKANUMA H, 1979, J BIOL CHEM, V254, P1050; BOGGS JM, 1988, BIOCHIM BIOPHYS ACTA, V938, P361, DOI 10.1016/0005-2736(88)90134-4; Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280; Coetzee T, 1998, TRENDS NEUROSCI, V21, P126, DOI 10.1016/S0166-2236(97)01178-8; Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092-8674(00)80093-8; DICKSON RC, 1990, MOL CELL BIOL, V10, P2176, DOI 10.1128/MCB.10.5.2176; DOWNING DT, 1992, J LIPID RES, V33, P301; Dunn TM, 1998, YEAST, V14, P311, DOI 10.1002/(SICI)1097-0061(19980315)14:4<311::AID-YEA220>3.0.CO;2-B; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hama H, 2000, FEBS LETT, V478, P26, DOI 10.1016/S0014-5793(00)01821-4; HOSHI M, 1973, J NEUROCHEM, V21, P709, DOI 10.1111/j.1471-4159.1973.tb06017.x; HOSHI M, 1973, J BIOL CHEM, V248, P4123; KAYA K, 1984, J BIOL CHEM, V259, P3548; LOFGREN H, 1977, CHEM PHYS LIPIDS, V20, P273, DOI 10.1016/0009-3084(77)90068-8; Mao CG, 2003, J BIOL CHEM, V278, P31184, DOI 10.1074/jbc.M303875200; Mitchell AG, 1997, J BIOL CHEM, V272, P28281, DOI 10.1074/jbc.272.45.28281; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MURAD S, 1977, J BIOL CHEM, V252, P5206; Napier JA, 2003, PROSTAG LEUKOTR ESS, V68, P135, DOI 10.1016/S0952-3278(02)00263-6; NONAKA G, 1979, BIOCHIM BIOPHYS ACTA, V572, P432, DOI 10.1016/0005-2760(79)90150-4; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; PASCHER I, 1977, CHEM PHYS LIPIDS, V20, P175, DOI 10.1016/0009-3084(77)90033-0; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; SHIGEMATSU H, 1990, INT J BIOCHEM, V22, P1427; SHIGEMATSU H, 1987, INT J BIOCHEM, V19, P41, DOI 10.1016/0020-711X(87)90121-2; Sperling P, 1998, J BIOL CHEM, V273, P28590, DOI 10.1074/jbc.273.44.28590; Stoffel W, 1997, CURR OPIN NEUROBIOL, V7, P654, DOI 10.1016/S0959-4388(97)80085-2; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2665; VANVELDHOVEN PP, 1988, BIOCHIM BIOPHYS ACTA, V959, P185, DOI 10.1016/0005-2760(88)90030-6; WERTZ PW, 1983, J LIPID RES, V24, P759	31	124	129	3	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48562	48568		10.1074/jbc.M406649200	http://dx.doi.org/10.1074/jbc.M406649200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15337768	hybrid			2022-12-25	WOS:000225098100011
J	Silhan, J; Obsilova, V; Vecer, J; Herman, P; Sulc, M; Teisinger, J; Obsil, T				Silhan, J; Obsilova, V; Vecer, J; Herman, P; Sulc, M; Teisinger, J; Obsil, T			14-3-3 protein C-terminal stretch occupies ligand binding groove and is displaced by phosphopeptide binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 14-3-3 PROTEINS; DNA-BINDING; COMPLEX; PHOSPHORYLATION; IDENTIFICATION; ASSOCIATION; ACTIVATION; DOMAINS; SITE	14-3-3 proteins are important regulators of numerous cellular signaling circuits. They bind to phosphorylated protein ligands and regulate their functions by a number of different mechanisms. The C-terminal part of the 14-3-3 protein is known to be involved in the regulation of 14-3-3 binding properties. The structure of this region is unknown; however, a possible location of the C-terminal stretch within the ligand binding groove of the 14-3-3 protein has been suggested. To fully understand the role of the C-terminal stretch in the regulation of the 14-3-3 protein binding properties, we investigated the physical location of the C-terminal stretch and its changes upon the ligand binding. For this purpose, we have used Forster resonance energy transfer ( FRET) measurements and molecular dynamics simulation. FRET measurements between Trp(242) located at the end of the C-terminal stretch and a dansyl group attached at two different cysteine residues (Cys(25) or Cys(189)) indicated that in the absence of the ligand, the C-terminal stretch occupies the ligand binding groove of 14-3-3 protein. Our data also showed that phosphopeptide binding displaces the C-terminal stretch from the ligand binding groove. Intramolecular distances calculated from FRET measurements fit well with distances obtained from molecular dynamics simulation of full-length 14-3-3 zeta protein.	Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic; Charles Univ Prague, Fac Sci, Dept Biochem, Prague 12843, Czech Republic; Charles Univ Prague, Fac Math & Phys, Inst Phys, CR-12116 Prague, Czech Republic; Acad Sci Czech Republ, Inst Physiol, CR-14220 Prague, Czech Republic; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic	Charles University Prague; Charles University Prague; Charles University Prague; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences	Obsil, T (corresponding author), Charles Univ Prague, Fac Sci, Dept Phys & Macromol Chem, Prague 12843, Czech Republic.	obsil@natur.cuni.cz	Obsilova, Veronika/B-7116-2012; Sulc, Miroslav/K-1029-2014; Herman, Petr/A-2626-2008; Obsil, Tomas/B-7142-2012; Teisinger, Jan/B-7122-2012	Obsilova, Veronika/0000-0003-4887-0323; Sulc, Miroslav/0000-0002-2659-0489; Herman, Petr/0000-0001-6918-2576; Obsil, Tomas/0000-0003-4602-1272; 				BAUDETNESSLER S, 1993, BIOCHEMISTRY-US, V32, P8457, DOI 10.1021/bi00084a010; Bridges D, 2004, SCI STKE, V2004, pre10; BROCHON JC, 1994, METHOD ENZYMOL, V240, P262; BROCHON JC, 1999, FLUORESCENCE ANISOTR, P33; BRYAN RK, 1990, EUR BIOPHYS J, V18, P165, DOI 10.1007/BF02427376; CHEN R F, 1967, Analytical Letters, V1, P35; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Hansson T, 1997, J MOL BIOL, V265, P118, DOI 10.1006/jmbi.1996.0716; Hassinen T, 2001, J COMPUT CHEM, V22, P1229, DOI 10.1002/jcc.1080; ICHIMURA T, 1995, J BIOL CHEM, V270, P28515, DOI 10.1074/jbc.270.48.28515; Kohler JJ, 2001, BIOCHEMISTRY-US, V40, P130, DOI 10.1021/bi001881p; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Obsilova V, 2004, J BIOL CHEM, V279, P4531, DOI 10.1074/jbc.M306939200; Polit A, 2003, EUR J BIOCHEM, V270, P1413, DOI 10.1046/j.1432-1033.2003.03497.x; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rommel C, 1996, ONCOGENE, V12, P609; Shen W, 2003, PLANT J, V34, P473, DOI 10.1046/j.1365-313X.2003.01739.x; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Truong AB, 2002, PROTEINS, V49, P321, DOI 10.1002/prot.10210; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zhang HB, 2004, J BIOL CHEM, V279, P407, DOI 10.1074/jbc.M306559200	32	43	43	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49113	49119		10.1074/jbc.M408671200	http://dx.doi.org/10.1074/jbc.M408671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347690	hybrid			2022-12-25	WOS:000225098100076
J	Yang, F; Peng, Y; Schoenberg, DR				Yang, F; Peng, Y; Schoenberg, DR			Endonuclease-mediated mRNA decay requires tyrosine phosphorylation of polysomal ribonuclease 1 (PMR1) for the targeting and degradation of polyribosome-bound substrate mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-CELLS; XENOPUS-LAEVIS; CLEAVAGE; DESTABILIZATION; PROTEINS; KINASE; TURNOVER; PATHWAY; DOMAINS; REGION	PMR1 is an endonuclease that is activated by estrogen to degrade Xenopus albumin mRNA. A previous report showed that the functional unit of endonuclease-mediated mRNA decay is a similar to680-kDa polysome-bound complex that contains both PMR1 and substrate mRNA. PMR1 contains two domains involved in endonuclease targeting to polysomes, an N-terminal domain that lies between residues 200 and 250, and a C-terminal domain that lies within the last 100 residues. Loss of either domain inactivated PMR1 targeting to polysomes and stabilized albumin mRNA. The current study identified a phosphorylated tyrosine residue within the C-terminal polysome-targeting domain and showed that this modification is required for PMR1-mediated mRNA decay. Changing this tyrosine to phenylalanine inactivated the targeting of PMR1 to polysomes, blocked binding of PMR1 to the functional complex containing its substrate mRNA, prevented the targeting of a green fluorescent protein fusion protein to this complex, and stabilized albumin mRNA to degradation by PMR1 in vivo. A general tyrosine kinase inhibitor inhibited the phosphorylation of PMR1, which in turn inhibited PMR1-catalyzed degradation of albumin mRNA. These results indicate that one or more tyrosine kinases functions as a regulator of endonuclease-mediated mRNA decay.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Ohio State Biochem Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Schoenberg, DR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 333 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	schoenberg.3@osu.edu	Schoenberg, Daniel/J-3423-2019	Schoenberg, Daniel/0000-0003-4570-1946	NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038277] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016058, P30 CA16058] Funding Source: Medline; NIGMS NIH HHS [R01 GM038277, GM38277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINDER R, 1989, J BIOL CHEM, V264, P16910; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; Bremer KA, 2003, RNA, V9, P1157, DOI 10.1261/rna.5720303; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chernokalskaya E, 1998, RNA, V4, P1537, DOI 10.1017/S1355838298980451; Cunningham KS, 2000, P NATL ACAD SCI USA, V97, P12498, DOI 10.1073/pnas.220425497; Cunningham KS, 2001, NUCLEIC ACIDS RES, V29, P1156, DOI 10.1093/nar/29.5.1156; DAS GJ, 1998, RNA, V4, P766; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; Eystathioy T, 2003, RNA, V9, P1171, DOI 10.1261/rna.5810203; He F, 2003, MOL CELL, V12, P1439, DOI 10.1016/S1097-2765(03)00446-5; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; PASTORI RL, 1991, BIOCHEMISTRY-US, V30, P10490, DOI 10.1021/bi00107a018; PASTORI RL, 1991, MOL ENDOCRINOL, V5, P461, DOI 10.1210/mend-5-4-461; Schoenberg DR, 1999, METHODS, V17, P60, DOI 10.1006/meth.1998.0708; SCHOENBERG DR, 1989, MOL ENDOCRINOL, V3, P805, DOI 10.1210/mend-3-5-805; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Stevens A, 2002, P NATL ACAD SCI USA, V99, P12741, DOI 10.1073/pnas.192442399; Tharun S, 2001, MOL CELL, V8, P1075, DOI 10.1016/S1097-2765(01)00395-1; van Dijk EL, 2000, J MOL BIOL, V300, P449, DOI 10.1006/jmbi.2000.3856; van Hoof A, 2000, MOL CELL BIOL, V20, P8230, DOI 10.1128/MCB.20.21.8230-8243.2000; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yang F, 2004, MOL CELL, V14, P435, DOI 10.1016/j.molcel.2004.05.001	25	21	21	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48993	49002		10.1074/jbc.M409776200	http://dx.doi.org/10.1074/jbc.M409776200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15375158	Green Accepted, hybrid			2022-12-25	WOS:000225098100062
J	Deng, WL; Poppleton, H; Yasuda, S; Makarova, N; Shinozuka, Y; Wang, DA; Johnson, LR; Patel, TB; Tigyi, G				Deng, WL; Poppleton, H; Yasuda, S; Makarova, N; Shinozuka, Y; Wang, DA; Johnson, LR; Patel, TB; Tigyi, G			Optimal lysophosphatidic acid-induced DNA synthesis and cell migration but not survival require intact autophosphorylation sites of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RAS-GRF/CDC25(MM) EXCHANGE FACTOR; INTESTINAL EPITHELIAL-CELLS; BETA-GAMMA-SUBUNITS; COUPLED RECEPTOR; EGF-RECEPTOR; TYROSINE KINASE; JUXTAMEMBRANE REGION; MITOGENIC ACTIVITY; RAS ACTIVATION	Lysophosphatidic acid (LPA)-elicited transphosphorylation of receptor tyrosine kinases has been implicated in mediating extracellular signal-regulated kinase (ERK)1/2 activation, which is necessary for LPA-induced cell proliferation, migration, and survival. B82L cells lack epidermal growth factor receptor ( EGFR) but express LPA(1-3), platelet-derived growth factor ( PDGF), ErbB2, and insulin-like growth factor receptor transcripts, yet LPA caused no detectable transphosphorylation of these receptor tyrosine kinases. LPA equally protected B82L cells, or transfectants expressing EGFR, the kinase dead EGFR(K721A), EGFR(Y5F) receptor mutant, which lacks five autophosphorylation sites, or EGFR(Y845F), which lacks the Src phosphorylation site from tumor necrosis factor-alpha-induced apoptosis. In contrast, LPA-elicited DNA synthesis and migration were augmented in cells expressing EGFR, EGFR(K721A), or EGFR(Y845F), but not EGFR(Y5F), although the PDGF responses were indistinguishable. LPA-induced transphosphorylation of the EGFR, ErbB2, or PDGF receptor was not required for its antiapoptotic effect. EGFR with or without intrinsic kinase activity or without the Src-phosphorylation site augmented, but was not required for, LPA-elicited cell proliferation or migration. In B82L cells, augmentation of these two LPA responses required intact autophosphorylation sites because among the four EGFR mutants, only cells expressing the EGFR(Y5F) mutant showed no enhancement. In EGFR(Y5F)-expressing cells, LPA failed to elicit tyrosine phosphorylation of Src homologous and collagen protein (SHC) and caused only a modest increase in ERK1/2 phosphorylation similar to that in wild-type B82L cells. The present data pinpoint the lack of importance of the intrinsic kinase activity in contrast to the importance of autophosphorylation sites of the EGFR for SHC phosphorylation in the enhancement of select ERK1/2-dependent LPA responses.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Ochanomizu Univ, Dept Biol, Bunkyo Ku, Tokyo 1128610, Japan	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Ochanomizu University	Tigyi, G (corresponding author), 894 Union Ave, Memphis, TN 38163 USA.	gtigyi@physio1.utmem.edu		YASUDA, Satoshi/0000-0002-1011-0815	NCI NIH HHS [CA92160] Funding Source: Medline; NHLBI NIH HHS [HL59679, HL61469, HL48308] Funding Source: Medline; NIDDK NIH HHS [DK16505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061469, R01HL059679, R01HL048308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK016505, R01DK016505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DAUB H, 1996, NATURE, V379, P560; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Deng WL, 2003, AM J PHYSIOL-GASTR L, V284, pG821, DOI 10.1152/ajpgi.00406.2002; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; Downward Julian, 2003, Biochem J, V376, pe9, DOI 10.1042/BJ20031745; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Goppelt-Struebe M, 2000, BIOCHEM J, V345, P217, DOI 10.1042/0264-6021:3450217; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Li J, 1999, J BIOL CHEM, V274, P11209, DOI 10.1074/jbc.274.16.11209; LI NX, 1994, ONCOGENE, V9, P3457; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mattingly RR, 1999, CELL SIGNAL, V11, P603, DOI 10.1016/S0898-6568(99)00034-0; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Poppleton H, 1996, J BIOL CHEM, V271, P6947, DOI 10.1074/jbc.271.12.6947; Poppleton HM, 1999, ARCH BIOCHEM BIOPHYS, V363, P227, DOI 10.1006/abbi.1998.1095; Poppleton HM, 2000, ARCH BIOCHEM BIOPHYS, V383, P309, DOI 10.1006/abbi.2000.2095; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Sakai T, 1999, J BIOL CHEM, V274, P15480, DOI 10.1074/jbc.274.22.15480; Sautin YY, 2001, AM J PHYSIOL-CELL PH, V281, pC2010, DOI 10.1152/ajpcell.00077.2001; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; Sun H, 1997, J BIOL CHEM, V272, P5413, DOI 10.1074/jbc.272.9.5413; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tigyi G, 2003, PROG LIPID RES, V42, P498, DOI 10.1016/S0163-7827(03)00035-3; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wang DA, 2002, AM J PHYSIOL-CELL PH, V283, pC1646, DOI 10.1152/ajpcell.00323.2002; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	52	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47871	47880		10.1074/jbc.M405443200	http://dx.doi.org/10.1074/jbc.M405443200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364923	hybrid			2022-12-25	WOS:000224957000057
J	Tanida, I; Ueno, T; Kominami, E				Tanida, I; Ueno, T; Kominami, E			Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met(121) to expose Gly(120) for lipidation and targeting to autophagosomal membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; HOMOLOG; APG12P; MAP-LC3; GATE-16; GABARAP; CONJUGATION; APG7P/CVT2P; CYTOPLASM; APG8P	Human light chain 3/MAP1LC3B, an autophagosomal ortholog of yeast Atg8, is conjugated to phospholipid (PL) via ubiquitylation-like reactions mediated by human Atg7 and Atg3. Since human Atg4B was found to cleave the carboxyl terminus of MAP1LC3B in vitro, we hypothesized that this exposes its carboxyl-terminal Gly(120). It was recently reported, however, that when Myc-MAP1LC3B-His is expressed in HEK293 cells, its carboxyl terminus is not cleaved. (Tanida, I., Sou, Y.-s., Ezaki, J., Minematsu-Ikeguchi, N., Ueno, T., and Kominami, E. (2004) J. Biol. Chem. 279, 36268-36276). To clarify this contradiction, we sought to determine whether the carboxyl terminus of MAP1LC3B is cleaved to expose Gly(120) for further ubiquitylation-like reactions. When MAP1LC3B-3xFLAG and Myc-MAP1LC3B-His were expressed in HEK293 cells, their carboxyl termini were cleaved, whereas there was little cleavage of mutant proteins MAP1LC3B(G120A)-3xFLAG and Myc-MAP1LC3B(G120A)-His, containing Ala in place of Gly(120). An in vitro assay showed that Gly(120) is essential for carboxyl-terminal cleavage by human Atg4B as well as for formation of the intermediates Atg7-MAP1LC3B (ubiquitin-activating enzyme-substrate) and Atg3-MAP1LC3B (ubiquitin carrier protein-substrate). Recombinant MAP1LC3B-PL was fractionated into the 100,000 x g pellet in a manner similar to that shown for endogenous MAP1LC3B-PL. RNA interference of MAP1LC3B mRNA resulted in a decrease in both endogenous MAP1LC3B-PL and MAP1LC3B. These results indicate that the carboxyl terminus of MAP1LC3B is cleaved to expose Gly(120) for further ubiquitylation-like reactions.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kominami@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009	Tanida, Isei/0000-0001-8999-3990				Asanuma K, 2003, FASEB J, V17, P1165, DOI 10.1096/fj.02-0580fje; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2004, AUTOPHAGY; Nemoto T, 2003, J BIOL CHEM, V278, P39517, DOI 10.1074/jbc.M300550200; Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200; Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2002, BIOCHEM BIOPH RES CO, V292, P256, DOI 10.1006/bbrc.2002.6645; Tanida I, 2002, BIOCHEM BIOPH RES CO, V296, P1164, DOI 10.1016/S0006-291X(02)02057-0; Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	18	206	216	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47704	47710		10.1074/jbc.M407016200	http://dx.doi.org/10.1074/jbc.M407016200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355958	hybrid			2022-12-25	WOS:000224957000036
J	Tosti, E; Waldbaum, L; Warshaw, G; Gross, EA; Ruggieri, R				Tosti, E; Waldbaum, L; Warshaw, G; Gross, EA; Ruggieri, R			The stress kinase MRK contributes to regulation of DNA damage checkpoints through a p38 gamma-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHK2 PROTEIN-KINASE; S-PHASE CHECKPOINT; CELL-CYCLE ARREST; I-KAPPA-B; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; G(1)/S TRANSITION; ACTIVATION; PHOSPHORYLATION; ATM	DNA damage induced by ionizing radiation (IR) activates a complex cellular response that includes checkpoints leading to cell cycle arrest. The stress-activated mitogen-activated protein kinase ( MAPK) p38gamma has been implicated in the G(2) phase checkpoint induced by IR. We recently discovered MRK as a member of the MAPK kinase kinase family that activates p38gamma. Here we investigated the role of MRK in the checkpoint response to IR. We identified autophosphorylation sites on MRK that are important for its kinase activity. A phospho-specific antibody that recognizes these sites showed that MRK is activated upon IR in a rapid and sustained manner. MRK depletion by RNA interference resulted in defective S and G(2) checkpoints induced by IR that were accompanied by reduced Chk2 phosphorylation and delayed Cdc25A degradation. We also showed that Chk2 is a substrate for MRK in vitro and is phosphorylated at Thr(68) by active MRK in cells. MRK depletion also increased sensitivity to the killing effects of IR. In addition, MRK depletion reduced IR-induced activation of p38gamma but had no effect on p38gamma activation, indicating that MRK is a specific activator of p38gamma after IR. Inhibition of p38gamma by RNA interference, however, did not impair IR-induced checkpoints. Thus, in response to IR MRK controls two independent pathways: the Chk2-Cdc25A pathway leading to cell cycle arrest and the p38gamma MAPK pathway.	N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, Manhasset, NY 11030 USA	Northwell Health	Ruggieri, R (corresponding author), N Shore Long Isl Jewish Res Inst, Ctr Oncol & Cell Biol, 350 Community Dr, Manhasset, NY 11030 USA.	mruggier@nshs.edu		Tosti, Elena/0000-0001-7953-8329	NCI NIH HHS [CA-86858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA086858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Gross EA, 2002, J BIOL CHEM, V277, P13873, DOI 10.1074/jbc.M111994200; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2001, NATURE, V410, P766, DOI 10.1038/35071218; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Mochan TA, 2003, CANCER RES, V63, P8586; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vacratsis PO, 2000, J BIOL CHEM, V275, P27893; van Drogen F, 2002, CURR BIOL, V12, pR53, DOI 10.1016/S0960-9822(01)00672-8; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamazaki V, 1998, CANCER RES, V58, P2316; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	62	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47652	47660		10.1074/jbc.M409961200	http://dx.doi.org/10.1074/jbc.M409961200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342622	hybrid			2022-12-25	WOS:000224957000030
J	Portis, T; Longnecker, R				Portis, T; Longnecker, R			Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway	ONCOGENE			English	Article						EBV; LMP2A; ras; PI3K; akt; apoptosis	MEMBRANE-PROTEIN 2A; REED-STERNBERG CELLS; GENE-TRANSCRIPTION; DEVELOPMENTAL PROGRESSION; IN-VIVO; KINASE; APOPTOSIS; EXPRESSION; 3-KINASE; SIGNALS	Epstein-Barr virus (EBV) establishes a lifelong latent infection in host B cells and is associated with the development of a variety of malignancies. The viral LMP2A protein mediates viral latency by mimicking a constitutively activated B-cell receptor (BCR). In vivo LMP2A provides developmental and survival signals to BCR-negative B cells, allowing them to survive in peripheral lymphoid organs. In this study, we have demonstrated that Ras is constitutively active in peripheral, BCR-negative B cells from LMP2A transgenic mice. Furthermore, increased expression of activated Ras correlated with elevated levels of Bcl-xL expression and a slower migrating, band-shifted form of Bcl-2. B cells from LMP2A transgenic mice were sensitive to apoptosis induction in the presence of specific inhibitors of Ras, phosphatidylinositol 3-kinase (PI3K), and Akt, indicating that LMP2A activates the Ras/PI3K/Akt pathway to mediate B-cell survival. Increased B-cell apoptosis correlated with reduced expression of Bcl-xL, suggesting that this Bcl-2 family member may be involved in apoptosis inhibition mediated by LMP2A. The ability of LMP2A to activate constitutively the Ras pathway, a common event during tumorigenesis, suggests that this viral protein plays an active role in the development of EBV-associated malignancies.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Longnecker, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol & Immunol, Ward 6-231,303 E Chicago Ave, Chicago, IL 60611 USA.	r-longnecker@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA073507, R01CA093444, R01CA062234] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013127] Funding Source: NIH RePORTER; NCI NIH HHS [CA62234, CA93444, CA73507] Funding Source: Medline; NIDCR NIH HHS [DE13127] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; Bairey O, 1999, CLIN CANCER RES, V5, P2860; Blank N, 2002, CYTOMETRY, V48, P179, DOI 10.1002/cyto.10127; Brinkmann MM, 2003, J VIROL, V77, P9346, DOI 10.1128/JVI.77.17.9346-9358.2003; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BURKHARDT AL, 1992, J VIROL, V66, P5161, DOI 10.1128/JVI.66.8.5161-5167.1992; Caldwell RG, 2000, J VIROL, V74, P1101, DOI 10.1128/JVI.74.3.1101-1113.2000; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; CHEN F, 1995, J VIROL, V69, P3752, DOI 10.1128/JVI.69.6.3752-3758.1995; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Fang W, 1996, IMMUNITY, V4, P291, DOI 10.1016/S1074-7613(00)80437-9; Fruehling S, 1998, J VIROL, V72, P7796, DOI 10.1128/JVI.72.10.7796-7806.1998; Fruehling S, 1997, VIROLOGY, V235, P241, DOI 10.1006/viro.1997.8690; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fuentes-Panana EM, 2004, IMMUNOL REV, V197, P26, DOI 10.1111/j.0105-2896.2004.0105.x; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kuppers R, 2002, ANN ONCOL, V13, P11, DOI 10.1093/annonc/13.S1.11; Longnecker R, 1998, HUMAN TUMOR VIRUSES, P133; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Merchant M, 2001, VIROLOGY, V291, P46, DOI 10.1006/viro.2001.1187; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; Milne CD, 2004, IMMUNOL REV, V197, P75, DOI 10.1111/j.0105-2896.2004.0103.x; Nagaoka H, 2000, J EXP MED, V192, P171, DOI 10.1084/jem.192.2.171; Niedobitek G, 1997, BLOOD, V90, P1664, DOI 10.1182/blood.V90.4.1664.1664_1664_1672; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Portis T, 2003, BLOOD, V102, P4166, DOI 10.1182/blood-2003-04-1018; Portis T, 2003, J VIROL, V77, P105, DOI 10.1128/JVI.77.1.105-114.2003; Portis T, 2002, FRONT BIOSCI-LANDMRK, V7, pD414, DOI 10.2741/portis; QU LR, 1992, J VIROL, V66, P3715, DOI 10.1128/JVI.66.6.3715-3724.1992; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schlaifer D, 1996, AM J PATHOL, V149, P177; SCHLAIFER D, 1995, BLOOD, V85, P2671, DOI 10.1182/blood.V85.10.2671.bloodjournal85102671; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shaw AC, 1999, P NATL ACAD SCI USA, V96, P2239, DOI 10.1073/pnas.96.5.2239; Shaw AC, 1999, J EXP MED, V189, P123, DOI 10.1084/jem.189.1.123; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; TIERNEY RJ, 1994, J VIROL, V68, P7374, DOI 10.1128/JVI.68.11.7374-7385.1994; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556	56	148	155	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8619	8628		10.1038/sj.onc.1207905	http://dx.doi.org/10.1038/sj.onc.1207905			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15361852				2022-12-25	WOS:000224988800008
J	Lytle, BL; Peterson, FC; Qiu, SH; Luo, M; Zhao, Q; Markley, JL; Volkman, BF				Lytle, BL; Peterson, FC; Qiu, SH; Luo, M; Zhao, Q; Markley, JL; Volkman, BF			Solution structure of a ubiquitin-like domain from tubulin-binding cofactor B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; PROTEIN STRUCTURES; PB1 DOMAIN; FOLDING COFACTORS; CRYSTAL-STRUCTURE; GTP HYDROLYSIS; FISSION YEAST; PC MOTIF; NMR; CHAPERONIN	Proper folding and assembly of tubulin alphabeta-heterodimers involves a stepwise progression mediated by a group of protein cofactors A through E. Upon release of the tubulin monomers from the chaperonin CCT, they are acted upon by each cofactor in the folding pathway through a unique combination of protein interaction domains. Three-dimensional structures have previously been reported for cofactor A and the C-terminal CAP-Gly domain of cofactor B (CoB). Here we report the NMR structure of the N-terminal domain of Caenorhabditis elegans CoB and show that it closely resembles ubiquitin as was recently postulated on the basis of bioinformatic analysis (Grynberg, M., Jaroszewski, L., and Godzik, A. (2003) BMC Bioinformatics 4, 46). CoB binds partially folded alpha-tubulin monomers, and a putative tubulin-binding motif within the N-terminal domain is identified from sequence and structure comparisons. Based on modeling of the homologous cofactor E ubiquitin-like domain, we hypothesize that cofactors B and E may associate via their beta-grasp domains in a manner analogous to the PB1 and caspase-activated deoxyribonuclease superfamily of protein interaction domains.	Ctr Eukaryot Struct Genom, Madison, WI 53706 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Alabama, Ctr Biophys Sci & Engn, SE Collaboratory Struct Genom, Birmingham, AL 35294 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Medical College of Wisconsin; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	Volkman, BF (corresponding author), Ctr Eukaryot Struct Genom, Madison, WI 53706 USA.	bvolkman@mcw.edu	Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NIGMS NIH HHS [1 P50 GM64598] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM064598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; Bartels C, 1996, J BIOMOL NMR, V7, P207, DOI 10.1007/BF00202037; Bhamidipati A, 2000, J CELL BIOL, V149, P1087, DOI 10.1083/jcb.149.5.1087; Billeter M, 1995, J BIOMOL NMR, V5, P1; Buchberger A, 2001, J MOL BIOL, V307, P17, DOI 10.1006/jmbi.2000.4462; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dreveny I, 2004, EMBO J, V23, P1030, DOI 10.1038/sj.emboj.7600139; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; FONTALBA A, 1993, J CELL SCI, V106, P627; Fujiwara K, 2004, J BIOL CHEM, V279, P4760, DOI 10.1074/jbc.M309448200; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; Grynberg M, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-46; Guasch A, 2002, J MOL BIOL, V318, P1139, DOI 10.1016/S0022-2836(02)00185-7; Hartmann-Petersen R, 2004, SEMIN CELL DEV BIOL, V15, P247, DOI 10.1016/j.semcdb.2003.12.006; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Li SL, 2002, J BIOL CHEM, V277, P48596, DOI 10.1074/jbc.M208512200; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Lopez-Fanarraga M, 2001, J STRUCT BIOL, V135, P219, DOI 10.1006/jsbi.2001.4386; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Otomo T, 2000, NAT STRUCT BIOL, V7, P658, DOI 10.1038/77957; Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Radcliffe PA, 2000, MOL GEN GENET, V263, P752, DOI 10.1007/s004380000252; Radcliffe PA, 1999, MOL BIOL CELL, V10, P2987, DOI 10.1091/mbc.10.9.2987; Rickard JE, 1996, TRENDS CELL BIOL, V6, P178, DOI 10.1016/0962-8924(96)10017-9; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Steinbacher S, 1999, NAT STRUCT BIOL, V6, P1029, DOI 10.1038/14912; Terasawa H, 2001, EMBO J, V20, P3947, DOI 10.1093/emboj/20.15.3947; Tian GL, 1997, J CELL BIOL, V138, P821, DOI 10.1083/jcb.138.4.821; Tian GL, 1996, CELL, V86, P287, DOI 10.1016/S0092-8674(00)80100-2; Tian GL, 1999, J BIOL CHEM, V274, P24054, DOI 10.1074/jbc.274.34.24054; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Ye YZ, 2003, BIOINFORMATICS, V19, pII246, DOI 10.1093/bioinformatics/btg1086; Yoshinaga S, 2003, EMBO J, V22, P4888, DOI 10.1093/emboj/cdg475	47	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46787	46793		10.1074/jbc.M409422200	http://dx.doi.org/10.1074/jbc.M409422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15364906	hybrid			2022-12-25	WOS:000224832400058
J	Sancar, F; Szajkowski, C				Sancar, F; Szajkowski, C			A GABA(A) receptor mutation linked to human epilepsy (gamma(2)R43Q) impairs cell surface expression of alpha beta gamma receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHILDHOOD ABSENCE EPILEPSY; FEBRILE SEIZURES; SUBUNIT; GAMMA-2-SUBUNIT; BINDING; STOICHIOMETRY; PHARMACOLOGY; SYNAPSES; KINETICS	A mutation in the gamma(2) subunit of the gamma-aminobutyric acid (GABA) type A receptor (GABAR), which changes an arginine to a glutamine at position 43 (R43Q), is linked to familial idiopathic epilepsies. We used radioligand binding, immunoblotting, and immunofluorescence techniques to examine the properties of wild-type alpha(1)beta(2)gamma(2) and mutant alpha(1)beta(2)gamma(2)R43Q GABARs expressed in HEK 293 cells. The gamma(2)R43Q mutation had no affect on the binding affinity of the benzodiazepine flunitrazepam. However, in cells expressing alpha(1)beta(2)gamma(2)R43Q GABARs, the number of binding sites for [H-3]flunitrazepam relative to wild-type receptors was decreased 75%. Using surface protein biotinylation, affinity purification, and immunoblotting, we demonstrated that expression of cell surface alpha(1)beta(2)gamma(2)R43Q GABARs was decreased. Surface immunostaining of HEK 293 cells expressing alpha(1)beta(2)gamma(2)R43Q GABARs confirmed that surface expression of the gamma(2)R43Q subunit was reduced. These data demonstrate that the gamma(2)R43Q mutation impairs expression of cell surface GABARs. A deficit in surface GABAR expression would reduce synaptic inhibition and result in neuronal hyperexcitability, which could explain why families possessing the gamma(2)R43Q subunit have epilepsy.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Szajkowski, C (corresponding author), Univ Wisconsin, Dept Physiol, Rm 197 MSC,1300 Univ Ave, Madison, WI 53706 USA.	czajkowski@physiology.wisc.edu			PHS HHS [34727] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Barnard EA, 1998, PHARMACOL REV, V50, P291; Baulac S, 2001, NAT GENET, V28, P46, DOI 10.1038/88254; Bianchi MT, 2002, J NEUROSCI, V22, P5321; Boileau AJ, 2003, NEUROPHARMACOLOGY, V44, P1003, DOI 10.1016/S0028-3908(03)00114-X; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Bowser DN, 2002, P NATL ACAD SCI USA, V99, P15170, DOI 10.1073/pnas.212320199; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Chang YC, 1996, J NEUROSCI, V16, P5415; Cossette P, 2002, NAT GENET, V31, P184, DOI 10.1038/ng885; Cromer BA, 2002, TRENDS BIOCHEM SCI, V27, P280, DOI 10.1016/S0968-0004(02)02092-3; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; Harkin LA, 2002, AM J HUM GENET, V70, P530, DOI 10.1086/338710; Jin P, 2004, J BIOL CHEM, V279, P14179, DOI 10.1074/jbc.M313411200; Kananura C, 2002, ARCH NEUROL-CHICAGO, V59, P1137, DOI 10.1001/archneur.59.7.1137; Kittler JT, 2003, CURR OPIN NEUROBIOL, V13, P341, DOI 10.1016/S0959-4388(03)00064-3; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Klausberger T, 2001, J NEUROSCI, V21, P9124, DOI 10.1523/JNEUROSCI.21-23-09124.2001; Moss SJ, 2001, NAT REV NEUROSCI, V2, P240, DOI 10.1038/35067500; NAYEEM N, 1994, J NEUROCHEM, V62, P815; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SANCAR F, 2003, SOC NEUR ANN M; Sarto I, 2002, NEUROPHARMACOLOGY, V43, P482, DOI 10.1016/S0028-3908(02)00160-0; Schweizer C, 2003, MOL CELL NEUROSCI, V24, P442, DOI 10.1016/S1044-7431(03)00202-1; Steinlein OK, 2001, AM J MED GENET, V106, P139, DOI 10.1002/ajmg.1571; STEPHENSON FA, 1995, BIOCHEM J, V310, P1; Tretter V, 1997, J NEUROSCI, V17, P2728; Wallace RH, 2001, NAT GENET, V28, P49, DOI 10.1038/ng0501-49	27	52	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47034	47039		10.1074/jbc.M403388200	http://dx.doi.org/10.1074/jbc.M403388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342642	hybrid			2022-12-25	WOS:000224832400088
J	Villena, JA; Roy, S; Sarkadi-Nagy, E; Kim, KH; Sul, HS				Villena, JA; Roy, S; Sarkadi-Nagy, E; Kim, KH; Sul, HS			Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID ACYL HYDROLASE; HORMONE-SENSITIVE LIPASE; ADIPOSE-TISSUE; DIFFERENTIATION; EXPRESSION; ADIPOGENESIS; LIPOLYSIS; OBESITY; POTATO; TRANSCRIPTION	We have used rat cDNA microarrays to identify adipocyte-specific genes that could play an important role in adipocyte differentiation or function. Here, we report the cloning and identification of a 2.0-kb mRNA coding for a putative protein that we have designated as desnutrin. The novel gene is expressed predominantly in adipose tissue, and its expression is induced early during 3T3-L1 adipocyte differentiation. Desnutrin mRNA levels were regulated by the nutritional status of animals, being transiently induced during fasting. In vitro desnutrin gene expression was up-regulated by dexamethasone in a dose-dependent manner but not by cAMP, suggesting that glucocorticoids could mediate the increase in desnutrin mRNA levels observed during fasting. Desnutrin mRNA codes for a 486-amino acid putative protein containing a patatin-like domain, characteristic of many plant acyl hydrolases belonging to the patatin family. Confocal microscopy of enhanced green fluorescent protein-tagged desnutrin protein-transfected cells showed that the fusion protein localized in the cytoplasm. Moreover, cells overexpressing desnutrin by transfection showed an increase in triglyceride hydrolysis. Interestingly, we also found that the desnutrin gene expression level was lower in ob/ob and db/db obese mouse models. Overall, our data suggest that the newly identified desnutrin gene codes for an adipocyte protein that may function as a lipase and play a role in the adaptive response to a low energy state, such as fasting, by providing fatty acids to other tissues for oxidation. In addition, decreased expression of desnutrin in obesity models suggests its possible contribution to the pathophysiology of obesity.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Villena, Josep A/H-1597-2015; Han, Zaiqi/AAI-2233-2019	Villena, Josep A/0000-0002-2200-2985	NIDDK NIH HHS [DK050828, DK068439] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828, R01DK068439] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allewelt M, 2000, INFECT IMMUN, V68, P3998, DOI 10.1128/IAI.68.7.3998-4004.2000; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Banerjee RR, 2004, SCIENCE, V303, P1195, DOI 10.1126/science.1092341; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Burton GR, 2004, GENE, V329, P167, DOI 10.1016/j.gene.2003.12.012; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; GANAL MW, 1991, MOL GEN GENET, V225, P501, DOI 10.1007/BF00261693; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GULICK T, 1996, CURRENT PROTOCOLS MO; Guo XM, 2000, GENE, V251, P45, DOI 10.1016/S0378-1119(00)00192-X; Hirschberg HJHB, 2001, EUR J BIOCHEM, V268, P5037, DOI 10.1046/j.0014-2956.2001.02411.x; Holm C, 2003, BIOCHEM SOC T, V31, P1120, DOI 10.1042/BST0311120; Kim KH, 2004, P NATL ACAD SCI USA, V101, P6780, DOI 10.1073/pnas.0305905101; Kim KH, 2001, J BIOL CHEM, V276, P11252, DOI 10.1074/jbc.C100028200; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MARTIN ML, 1991, J CLIN INVEST, V88, P609, DOI 10.1172/JCI115345; NAKADA MT, 1987, MOL PHARMACOL, V31, P377; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Rydel TJ, 2003, BIOCHEMISTRY-US, V42, P6696, DOI 10.1021/bi027156r; SADOWSKI HB, 1992, J BIOL CHEM, V267, P4722; Sato H, 2003, EMBO J, V22, P2959, DOI 10.1093/emboj/cdg290; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; STRICKLAND JA, 1995, PLANT PHYSIOL, V109, P667, DOI 10.1104/pp.109.2.667; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Villena JA, 2002, HORM METAB RES, V34, P664, DOI 10.1055/s-2002-38244; WAHRENBERG H, 1989, J CLIN INVEST, V84, P458, DOI 10.1172/JCI114187; Zhao L, 2000, J BIOL CHEM, V275, P16845, DOI 10.1074/jbc.275.22.16845	35	490	532	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47066	47075		10.1074/jbc.M403855200	http://dx.doi.org/10.1074/jbc.M403855200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337759	hybrid			2022-12-25	WOS:000224832400092
J	Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY				Ishii, H; Vecchione, A; Furukawa, Y; Croce, CM; Huebner, K; Fong, LYY			Differentially expressed genes execute zinc-induced apoptosis in precancerous esophageal epithelium of zinc-deficient rats	ONCOGENE			English	Article						esophagus; apoptosis; gene expression analysis; zinc replenishment	CELL-PROLIFERATION; N-NITROSOMETHYLBENZYLAMINE; CANCER; INDUCTION; CARCINOGENESIS; PROGRESSION; METABOLISM; ALCOHOL; DEATH; LINE	Zinc deficiency (ZD) in rats increases esophageal cell proliferation and the incidence of N-nitrosomethylbenzylamine-induced esophageal tumors. Conversely, zinc replenishment (ZR) rapidly induces apoptosis in esophageal epithelia and reverses cancer development. We investigated gene expression changes in ZR versus ZD esophageal epithelia to identify differentially expressed genes associated with the antitumor effect of ZR. Weanling rats were fed a ZD diet for 6 weeks to establish esophageal cell proliferation or a zinc-sufficient (ZS) diet. Then, 10 ZD rats were treated with zinc gluconate intragastrically and switched to ZS diet; the remaining 10 ZD and ZS animals were treated with saline. All animals were killed 26-28 h later. Using cDNA microarrays, real-time polymerase chain reaction amplification and RNA hybridization techniques, we identified novel differentially expressed genes, including a RNA-binding protein with two RNA recognition motifs and a zinc knuckle (ZD7), and a DNA/RNA helicase with a DEAD box (ZD10) with two splice variants, ZD10a and ZD10b. In situ hybridization detected increased mRNA expression of ZD7, ZD10a and ZD10b in ZR esophageal epithelia, which displayed markedly increased occurrence of apoptotic cells, relative to ZD epithelia. Overexpression of ZD7 in human esophageal cancer cells resulted in induction of apoptosis and activation of caspase-3 and -7, activities that were inhibited by caspase-specific inhibitors. In addition, ZD7 mRNA levels and zinc-induced apoptosis in rat squamous carcinoma cells were reduced by specific small interfering ribonucleic acids. Thus, ZR rapidly induces ZD7 and ZD10 expression, which in turn stimulates apoptosis. These results provide the beginnings of a molecular pathway for zinc-induced apoptosis under conditions that reverse esophageal tumor initiation.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Jichi Med Sch, Ctr Mol Med, Minami Kawachi, Tochigi 3290498, Japan	Jefferson University; Jichi Medical University	Fong, LYY (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, 1020 Locust St, Philadelphia, PA 19107 USA.	L_Fong@mail.jci.tju.edu	Furukawa, Yusuke/Y-1342-2018; Young, Richard A/F-6495-2012	Furukawa, Yusuke/0000-0002-7249-6418; Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856; Fong, Louise/0000-0001-7654-7035	NCI NIH HHS [CA56036, CA77738] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077738, P30CA056036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARCH DH, 1984, CANCER RES, V44, P5629; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Cintorino M, 2001, ANTICANCER RES, V21, P4195; COIA LR, 1994, CURR PROB CANCER, V18, P189; Cousins RJ, 2003, J NUTR, V133, p1521S, DOI 10.1093/jn/133.5.1521S; Cousins RJ, 2003, P NATL ACAD SCI USA, V100, P6952, DOI 10.1073/pnas.0732111100; Didenko Vladimir V, 2002, Methods Mol Biol, V203, P143; Didenko VV, 1998, AM J PATHOL, V152, P897; Dieck HT, 2003, J NUTR, V133, P1004, DOI 10.1093/jn/133.4.1004; Fong LYY, 1999, CANCER LETT, V143, P63, DOI 10.1016/S0304-3835(99)00191-3; Fong LYY, 2003, CANCER RES, V63, P186; Fong LYY, 2001, JNCI-J NATL CANCER I, V93, P1525, DOI 10.1093/jnci/93.20.1525; Fong LYY, 1996, CARCINOGENESIS, V17, P1841, DOI 10.1093/carcin/17.9.1841; FONG LYY, 1978, J NATL CANCER I, V61, P145, DOI 10.1093/jnci/61.1.145; Fong LYY, 2000, CANCER RES, V60, P4589; Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132; GABRIAL GN, 1982, J NATL CANCER I, V68, P785; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Ishii H, 2001, CANCER RES, V61, P1578; Kadkol Shrihari, 2003, Methods Mol Biol, V223, P51; Kindermann B, 2004, J NUTR, V134, P57, DOI 10.1093/jn/134.1.57; Lu S H, 1991, IARC Sci Publ, P11; LU SH, 1986, J CELL PHYSIOL, P51; MAGEE PN, 1989, CANCER SURV, V8, P207; Moore JB, 2003, P NATL ACAD SCI USA, V100, P3883, DOI 10.1073/pnas.0330670100; Newberne PM, 1997, PATHOBIOLOGY, V65, P39, DOI 10.1159/000164101; Nodera M, 2001, LIFE SCI, V69, P1639, DOI 10.1016/S0024-3205(01)01252-8; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; SUNDERMAN FW, 1995, ANN CLIN LAB SCI, V25, P134; Truong-Tran AQ, 2000, J NUTR, V130, p1459S, DOI 10.1093/jn/130.5.1459S; VANRENSBURG SJ, 1981, J NATL CANCER I, V67, P243; YANG CS, 1980, CANCER RES, V40, P2633	33	6	7	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8040	8048		10.1038/sj.onc.1207974	http://dx.doi.org/10.1038/sj.onc.1207974			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361827				2022-12-25	WOS:000224692500002
J	Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C				Verrier, F; Deniaud, A; LeBras, M; Metivier, D; Kroemer, G; Mignotte, B; Jan, G; Brenner, C			Dynamic evolution of the adenine nucleotide translocase interactome during chemotherapy-induced apoptosis	ONCOGENE			English	Article						ADP/ATP carrier; cell death; glutathion-S-transferase; mitochondrion; permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; BCL-2 FAMILY PROTEINS; BENZODIAZEPINE-RECEPTOR; SIGNALING PATHWAY; BAX TRANSLOCATION; OXIDATIVE STRESS; PORE COMPLEX; BH4 DOMAIN	The mitochondrial permeability transition pore complex (PTPC) is involved in the control of the mitochondrial membrane permeabilization during apoptosis, necrosis and autophagy. Indeed, the adenine nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC), two major components of PTPC, are the targets of a variety of proapoptotic inducers. Using co-immunoprecipitation and proteomic analysis, we identified some of the interacting partners of ANT in several normal tissues and human cancer cell lines. During chemotherapy-induced apoptosis, some of these interactions were constant (e g. ANT-VDAC), whereas others changed strongly concomitantly with the dissipation of the mitochondrial transmembrane potential and until nuclear degradation occurred (e.g. Bax, Bcl-2, subunits of the respiratory chain, a subunit of the phosphatase PP2A, phospholipase PLC beta 4 and IP3 receptor). In addition, a glutathione-S-transferase (GST) interacts with ANT in normal tissue, in colon carcinoma cells and in vitro. This interaction is lost during apoptosis induction, suggesting that GST behaves as an endogenous repressor of PTPC and ANT pore opening. Thus, ANT is connected to mitochondrial proteins as well as to proteins from other organelles such as the endoplasmic reticulum forming a dynamic polyprotein complex. Changes within this ANT interactome coordinate the lethal response of cells to apoptosis induction.	Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France; Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France; INRA, UR 121, Rech Technol Laitiere Lab, F-35042 Rennes, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; INRAE	Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Mignotte, Bernard/A-3499-2009; Jan, Gwenael/K-6767-2014	KROEMER, Guido/0000-0002-9334-4405; Mignotte, Bernard/0000-0002-8512-8518; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ARMSTRONG JS, 2002, FASEB J, V7, P7; Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Bribes E, 2003, IMMUNOL LETT, V85, P13, DOI 10.1016/S0165-2478(02)00177-3; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Dorner A, 1997, MOL CELL BIOCHEM, V174, P261, DOI 10.1023/A:1006825028170; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769; Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Susin SA, 2000, METHOD ENZYMOL, V322, P205; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yin ZM, 2000, CANCER RES, V60, P4053; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	74	78	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8049	8064		10.1038/sj.onc.1208001	http://dx.doi.org/10.1038/sj.onc.1208001			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377997				2022-12-25	WOS:000224692500003
J	Armstrong, JS; Yang, HY; Duan, W; Whiteman, M				Armstrong, JS; Yang, HY; Duan, W; Whiteman, M			Cytochrome bc(1) regulates the mitochondrial permeability transition by two distinct pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; IRON-SULFUR PROTEIN; RESPIRATORY-CHAIN; CELL-DEATH; CYCLOPHILIN-D; ELECTRON-TRANSFER; COMPLEX-III; SUPEROXIDE-PRODUCTION; HYDROGEN-PEROXIDE; BC1 COMPLEX	The mitochondrial permeability transition (MPT) pore is a calcium-sensitive channel in the mitochondrial inner membrane that plays a crucial role in cell death. Here we show that cytochrome bc(1) regulates the MPT in isolated rat liver mitochondria and in CEM and HL60 cells by two independent pathways. Glutathione depletion activated the MPT via increased production of reactive oxygen species (ROS) generated by cytochrome bc1. The ROS producing mechanism in cytochrome bc1 involves movement of the "Rieske" iron-sulfur protein subunit of the enzyme complex, because inhibition of cytochrome bc1 by pharmacologically blocking iron-sulfur protein movement completely abolished ROS production, MPT activation, and cell death. The classical inhibitor of the MPT, cyclosporine A, had no protective effect against MPT activation. In contrast, the calcium-activated, cyclosporine A-regulated MPT in rat liver mitochondria was also blocked with inhibitors of cytochrome bc1. These results indicate that electron flux through cytochrome bc1 regulates two distinct pathways to the MPT, one unregulated and involving mitochondrial ROS and the other regulated and activated by calcium.	Natl Univ Singapore, Dept Biochem, Singapore 117597, Singapore	National University of Singapore	Armstrong, JS (corresponding author), Natl Univ Singapore, Dept Biochem, Kent Rd, Singapore 117597, Singapore.	bchjsa@nus.edu.sg	Yang, Hongyuan/AAR-1326-2020; Whiteman, Matthew/C-6079-2009; Duan, Wei/A-5181-2015	Yang, Hongyuan/0000-0002-8482-6031; Whiteman, Matthew/0000-0002-6583-6779; Duan, Wei/0000-0001-5782-9184				Armstrong JS, 2003, J BIOL CHEM, V278, P49079, DOI 10.1074/jbc.M307841200; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; ARMSTRONG JS, 2004, IN PRESS IOVS; Barrientos A, 1999, J BIOL CHEM, V274, P16188, DOI 10.1074/jbc.274.23.16188; BASS DA, 1983, J IMMUNOL, V130, P1910; Bianchi C, 2003, BIOFACTORS, V18, P3, DOI 10.1002/biof.5520180202; BOVERIS A, 1976, BIOCHEM J, V156, P435, DOI 10.1042/bj1560435; Boveris A, 2000, IUBMB LIFE, V50, P245, DOI 10.1080/15216540051080912; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; ESPOSTI MD, 1993, BIOCHEM BIOPH RES CO, V190, P1090, DOI 10.1006/bbrc.1993.1161; Eubel H, 2003, PLANT PHYSIOL, V133, P274, DOI 10.1104/pp.103.024620; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FERNANDEZCHECA JC, 1990, ANAL BIOCHEM, V190, P212, DOI 10.1016/0003-2697(90)90183-A; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Fontaine E, 1998, J BIOL CHEM, V273, P12662, DOI 10.1074/jbc.273.20.12662; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776; He LH, 2003, J BIOL CHEM, V278, P16755, DOI 10.1074/jbc.M300153200; He LH, 2002, FEBS LETT, V512, P1, DOI 10.1016/S0014-5793(01)03314-2; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2003, BIOCHEM BIOPH RES CO, V304, P433, DOI 10.1016/S0006-291X(03)00614-4; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; Lemasters JJ, 1999, BIOCHEM SOC SYMP, V66, P205, DOI 10.1042/bss0660205; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Lenaz G, 2001, IUBMB LIFE, V52, P159, DOI 10.1080/15216540152845957; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; Moghaddas S, 2003, ARCH BIOCHEM BIOPHYS, V414, P59, DOI 10.1016/S0003-9861(03)00166-8; Muller FL, 2003, BIOCHEMISTRY-US, V42, P6493, DOI 10.1021/bi0342160; RAMSAY RR, 1981, P NATL ACAD SCI-BIOL, V78, P825, DOI 10.1073/pnas.78.2.825; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Starkov AA, 2001, BIOCHEM BIOPH RES CO, V281, P645, DOI 10.1006/bbrc.2001.4409; Sultan A, 2001, ARCH BIOCHEM BIOPHYS, V386, P37, DOI 10.1006/abbi.2000.2194; Sun H, 2003, ARCH BIOCHEM BIOPHYS, V419, P198, DOI 10.1016/j.abb.2003.08.028; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; Tsujimoto Y, 2002, BIOSCIENCE REP, V22, P47, DOI 10.1023/A:1016061006256; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; Yang JH, 2001, J CELL SCI, V114, P1655; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Zhang L, 2000, J BIOL CHEM, V275, P7656, DOI 10.1074/jbc.275.11.7656; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	55	45	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50420	50428		10.1074/jbc.M408882200	http://dx.doi.org/10.1074/jbc.M408882200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364912	Green Submitted, hybrid			2022-12-25	WOS:000225229500107
J	Copeland, JW; Copeland, SJ; Treisman, R				Copeland, JW; Copeland, SJ; Treisman, R			Homo-oligomerization is essential for F-actin assembly by the formin family FH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; SMALL G-PROTEIN; DIAPHANOUS-RELATED FORMINS; CANINE KIDNEY-CELLS; SRF ACTIVITY; CYTOSKELETON; NUCLEATION; PROFILIN; DYNAMICS; MDIA1	Formin proteins regulate the actin and microtubule cytoskeletons and also control the activity of the SRF transcription factor through depletion of the G-actin pool. Although the conserved formin homology 2 (FH2) domains of the mDia1 and Bni1 formins can nucleate actin polymerization in vitro, the activity of other FH2 domains and the relationship between actin polymerization and microtubule reorganization have been controversial. We show that, similar to the mDia1 FH2 domain, the FH2 domains of mDia2 and ld are sufficient for SRF activation in vivo. We demonstrate that an mDia1 mutant defective for microtubule rearrangement in vivo is also defective in SRF activation in vivo as well as actin polymerization in vitro and that the mDia2 FH2 domain promotes actin polymerization in vitro. Using co-immunoprecipitation, we show that mDia1 is oligomeric in its inactive autoinhibited state in vivo, that the active mDia1 and mDia2 FH2 domains form homo- but not hetero-oligomers in vivo, and that oligomerization is abolished by inactivating FH2 deletion and point mutations. Nevertheless, inactive mDia1 FH2 domain mutants retain the ability to interfere with cellular mDia activity. Our results show that self-oligomerization is essential for SRF activation in vivo and F-actin assembly in vitro and provide strong support for recent structural models of the FH2 domain.	London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, Transcript Lab, London C2A 3PX, England; London Res Inst, Canc Res UK, Lincolns Inn Fields Labs, Prot Isolat Lab, London C2A 3PX, England	Cancer Research UK; Cancer Research UK	Copeland, JW (corresponding author), Univ Ottawa, Fac Med, Ottawa, ON K1H 8M5, Canada.	jcopelan@uottawa.ca		Treisman, Richard/0000-0002-9658-0067				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Fujiwara T, 2000, BIOCHEM BIOPH RES CO, V271, P626, DOI 10.1006/bbrc.2000.2671; Grosse R, 2003, EMBO J, V22, P3050, DOI 10.1093/emboj/cdg287; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092-8674(03)00813-4; Kovar DR, 2003, J CELL BIOL, V161, P875, DOI 10.1083/jcb.200211078; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Moseley JB, 2004, MOL BIOL CELL, V15, P896, DOI 10.1091/mbc.E03-08-0621; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Shimada A, 2004, MOL CELL, V13, P511, DOI 10.1016/S1097-2765(04)00059-0; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takaishi K, 2000, GENES CELLS, V5, P929, DOI 10.1046/j.1365-2443.2000.00377.x; Takeya R, 2003, J CELL SCI, V116, P4567, DOI 10.1242/jcs.00769; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Zhuang SH, 2004, J BIOL CHEM, V279, P10397, DOI 10.1074/jbc.M313048200; Zigmond SH, 2003, CURR BIOL, V13, P1820, DOI 10.1016/j.cub.2003.09.057	27	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50250	50256		10.1074/jbc.M404429200	http://dx.doi.org/10.1074/jbc.M404429200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371418	hybrid			2022-12-25	WOS:000225229500086
J	Gan, XQ; Ma, ZH; Deng, N; Wang, JY; Ding, JP; Li, L				Gan, XQ; Ma, ZH; Deng, N; Wang, JY; Ding, JP; Li, L			Involvement of the C-terminal proline-rich motif of G protein-coupled receptor kinases in recognition of activated rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 GRK2; PHOSPHORYLATES TUBULIN; ESCHERICHIA-COLI; BETA-GAMMA; BINDING; DOMAIN; MECHANISM; SUBUNITS; MEMBRANE	G protein-coupled receptor kinases (GRKs) are a family of serine/threonine kinases that phosphorylate many activated G protein-coupled receptors (GPCRs) and play an important role in GPCR desensitization. Our previous work has demonstrated that the C-terminal conserved region (CC) of GRK-2 participates in interaction with rhodopsin and that this interaction is necessary for GRK-2-mediated receptor phosphorylation (Gan, X. Q., Wang, J. Y., Yang, Q. H., Li, Z., Liu, F., Pei, G., and Li, L. (2000) J. Biol. Chem. 275, 8469-8474). In this report, we further investigated whether the CC of other GRKs had the same functions and defined the specific sequences in CC that are required for the functions. The CC regions of GRK-1, GRK-2, and GRK-5, representatives of the three subfamilies of GRKs, could bind rhodopsin in vitro and inhibit GRK-2-mediated phosphorylation of rhodopsin, but not a peptide GRK substrate. Through a series of mutagenesis analyses, a proline-rich motif in the CC was identified as the key element involved in the interaction between the CC region and rhodopsin. Point mutations of this motif not only disrupted the interaction of GRK-2 with rhodopsin but also abolished the ability of GRK-2 to phosphorylate rhodopsin. The findings that the CC region of GRKs interact only with the light-activated but not the non-activated rhodopsin and that the N-terminal domain of GRK-2 interacts with rhodopsin in a light-independent manner suggest that the CC region is responsible for the recognition of activated GPCRs in the canonical model.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Key Lab Proteom, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, L (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.	lli@sibs.ac.cn	Ma, Zhihai/E-7130-2015; Deng, Ning/H-6561-2014	ding, jian ping/0000-0001-7029-7346; DENG, NING/0000-0002-1321-5508				Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Day PW, 2003, BIOCHEMISTRY-US, V42, P9176, DOI 10.1021/bi034442+; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Freeman JLR, 1998, J BIOL CHEM, V273, P20653, DOI 10.1074/jbc.273.32.20653; Freeman JLR, 2002, BIOCHEMISTRY-US, V41, P12850, DOI 10.1021/bi020145d; Gan XQ, 1999, ACTA BIOCH BIOPH SIN, V31, P648; Gan XQ, 2000, J BIOL CHEM, V275, P8469, DOI 10.1074/jbc.275.12.8469; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158; Oneyama C, 2003, CHEM BIOL, V10, P443, DOI 10.1016/S1074-5521(03)00101-7; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Pitcher JA, 1999, J BIOL CHEM, V274, P34531, DOI 10.1074/jbc.274.49.34531; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prasad SVN, 2001, J BIOL CHEM, V276, P18953, DOI 10.1074/jbc.M102376200; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Ruiz-Gomez A, 2000, J BIOL CHEM, V275, P29724, DOI 10.1074/jbc.M001864200; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Shiina T, 2001, J BIOL CHEM, V276, P33019, DOI 10.1074/jbc.M100140200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Yang QH, 1997, PROTEIN EXPRES PURIF, V10, P320, DOI 10.1006/prep.1997.0749	37	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49741	49746		10.1074/jbc.M407570200	http://dx.doi.org/10.1074/jbc.M407570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375171	hybrid			2022-12-25	WOS:000225229500025
J	Garside, H; Stevens, A; Farrow, S; Normand, C; Houle, B; Berry, A; Maschera, B; Ray, D				Garside, H; Stevens, A; Farrow, S; Normand, C; Houle, B; Berry, A; Maschera, B; Ray, D			Glucocorticoid ligands specify different interactions with NF-kappa B by allosteric effects on the glucocorticoid receptor DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; LIVING CELLS; CROSS-TALK; REPRESSION; ANTAGONISM; PROTEIN; COACTIVATOR-1; RECRUITMENT; INHIBITION	Glucocorticoids inhibit inflammation by acting through the glucocorticoid receptor (GR) and powerfully repressing NF-kappaB function. Ligand binding to the C-terminal of GR promotes the nuclear translocation of the receptor and binding to NF-kappaB through the GR DNA binding domain. We sought how ligand recognition influences the interaction between NF-kappaB and GR. Both dexamethasone ( agonist) and RU486 ( antagonist) promote efficient nuclear translocation, and we show occupancy of the same intranuclear compartment as NF-kappaB with both ligands. However, unlike dexamethasone, RU486 had negligible activity to inhibit NF-kappaB transactivation. This failure may stem from altered co-factor recruitment or altered interaction with NF-kappaB. Using both glutathione S-transferase pull-down and bioluminescence resonance energy transfer approaches, we identified a major glucocorticoid ligand effect on interaction between the GR and the p65 component of NF-kappaB, with RU486 inhibiting recruitment compared with dexamethasone. Using the bioluminescence resonance energy transfer assay, we found that RU486 efficiently recruited NCoR to the GR, unlike dexamethasone, which recruited SRC1. Therefore, RU486 promotes differential protein recruitment to both the C-terminal and DNA binding domain of the receptor. Importantly, using chromatin immunoprecipitation, we show that impaired interaction between GR and p65 with RU486 leads to reduced recruitment of the GR to the NF-kappaB-responsive region of the interleukin-8 promoter, again in contrast to dexamethasone that significantly increased GR binding. We demonstrate that ligand-induced conformation of the GR C-terminal has profound effects on the functional surface generated by the DNA binding domain of the GR. This has implications for understanding ligand-dependent interdomain communication.	Univ Manchester, Fac Med, Ctr Mol Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Med, Endocrine Sci Res Grp, Manchester M13 9PT, Lancs, England; GlaxoSmithKline, Dept Asthma Biol, Stevenage SG1 2NY, Herts, England; PerkinElmer Biosignal Inc, PerkinElmer Life & Analyt Sci, Montreal, PQ H3J 1R4, Canada; Montreal Proteom Network, Montreal, PQ, Canada	University of Manchester; University of Manchester; GlaxoSmithKline	Ray, D (corresponding author), Univ Manchester, Fac Med, Ctr Mol Med, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.w.ray@man.ac.uk	Stevens, Adam/D-6476-2012; Stevens, Adam/AAB-6301-2020	Stevens, Adam/0000-0002-1950-7325; Stevens, Adam/0000-0002-1950-7325; Ray, David/0000-0002-4739-6773				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BECK CA, 1993, ENDOCRINOLOGY, V133, P728, DOI 10.1210/en.133.2.728; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Nelson G, 2002, J CELL SCI, V115, P1137; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pandit S, 2002, J BIOL CHEM, V277, P1538, DOI 10.1074/jbc.M105438200; QI M, 1990, MOL ENDOCRINOL, V4, P455, DOI 10.1210/mend-4-3-455; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMIDT TJ, 1986, J STEROID BIOCHEM, V24, P853, DOI 10.1016/0022-4731(86)90446-2; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002-0320; Widen C, 2003, BIOCHEM J, V373, P211, DOI 10.1042/BJ20030175	30	87	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50050	50059		10.1074/jbc.M407309200	http://dx.doi.org/10.1074/jbc.M407309200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15355994	hybrid			2022-12-25	WOS:000225229500063
J	Kim, SJ; Kim, JH; Kim, YG; Lim, HS; Oh, JW				Kim, SJ; Kim, JH; Kim, YG; Lim, HS; Oh, JW			Protein kinase C-related kinase 2 regulates hepatitis C virus RNA polymerase function by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; POTENTIAL EFFECTOR; CATALYTIC DOMAIN; PHAGE DISPLAY; CDNA-CLONE; INITIATION; NS5B; REPLICATION; EXPRESSION	The hepatitis C virus (HCV) NS5B protein is the viral RNA-dependent RNA polymerase required for replication of the HCV RNA genome. We have identified a peptide that most closely resembles a short region of the protein kinase C-related kinase 2 (PRK2) by screening of a random 12-mer peptide library displayed on the surface of the M13 bacteriophage with NS5B proteins immobilized on microwell plates. Competitive phage enzyme-linked immunosorbent assay with a synthetic peptide showed that the phage clone displaying this peptide could bind HCV RNA polymerase with a high affinity. Coimmunoprecipitation and colocalization studies demonstrated in vivo interaction of NS5B with PRK2. In vitro kinase assays demonstrated that PRK2 specifically phosphorylates NS5B by interaction with the N-terminal finger domain of NS5B ( amino acids 1 - 187). Consistent with the in vitro NS5B-phosphorylating activity of PRK2, we detected the phosphorylated form of NS5B by metabolic cell labeling. Furthermore, HCV NS5B immunoprecipitated from HCV subgenomic replicon cells was specifically recognized by an antiphosphoserine antibody. Knock-down of the endogenous PRK2 expression using a PRK2-specific small interfering RNA inhibited HCV RNA replication. In contrast, PRK2 overexpression, which was accompanied by an increase of in the level of its active form, dramatically enhanced HCV RNA replication. Altogether, our results indicate that HCV RNA replication is regulated by NS5B phosphorylation by PRK2.	Yonsei Univ, Dept Biotechnol, Seoul 120749, South Korea	Yonsei University	Oh, JW (corresponding author), Yonsei Univ, Dept Biotechnol, 134 Sinchon Dong, Seoul 120749, South Korea.	jwoh@yonsei.ac.kr						Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Amin A, 2003, VIROLOGY, V313, P158, DOI 10.1016/S0042-6822(03)00313-1; Bahr C, 2000, J BIOL CHEM, V275, P36350, DOI 10.1074/jbc.M004771200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cortese R, 1996, CURR OPIN BIOTECH, V7, P616, DOI 10.1016/S0958-1669(96)80072-3; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Di Bisceglie Adrian M., 1998, Hepatology, V28, P1161, DOI 10.1002/hep.510280436; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Forwood JK, 1999, BIOCHEM BIOPH RES CO, V257, P731, DOI 10.1006/bbrc.1999.0370; Frese M, 2003, J GEN VIROL, V84, P1253, DOI 10.1099/vir.0.18997-0; Gao L, 2003, J VIROL, V77, P4149, DOI 10.1128/JVI.77.7.4149-4159.2003; GONZALEZAMARO R, 1994, J EXP MED, V179, P841, DOI 10.1084/jem.179.3.841; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hericourt F, 2000, BIOCHEM J, V349, P417, DOI 10.1042/0264-6021:3490417; Holliger P, 1997, STRUCTURE, V5, P265, DOI 10.1016/S0969-2126(97)00184-6; Hwang SB, 1997, VIROLOGY, V227, P439, DOI 10.1006/viro.1996.8357; Ishida R, 2001, CELL STRUCT FUNCT, V26, P215, DOI 10.1247/csf.26.215; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; Ivashkina N, 2002, J VIROL, V76, P13088, DOI 10.1128/JVI.76.24.13088-13093.2002; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KAVANAUGH WM, 1994, BIOCHEMISTRY-US, V33, P11046, DOI 10.1021/bi00202a026; Kay BK, 2001, METHODS, V24, P240, DOI 10.1006/meth.2001.1185; Kim SH, 2002, EMBO J, V21, P2292, DOI 10.1093/emboj/21.9.2292; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; KITAGAWA M, 1995, BIOCHEM J, V310, P657, DOI 10.1042/bj3100657; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; Laura RP, 2002, J BIOL CHEM, V277, P12906, DOI 10.1074/jbc.M200818200; Lee KJ, 2004, J VIROL, V78, P3797, DOI 10.1128/JVI.78.7.3797-3802.2004; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LINDENBACH BD, 2001, FIELDS VIROLOGY, P991; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1996, J HEPATOL, V24, P11; LOHR HF, 1994, LIVER, V14, P161; Lubkowski J, 1998, NAT STRUCT BIOL, V5, P140, DOI 10.1038/nsb0298-140; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Mottola G, 2002, VIROLOGY, V293, P31, DOI 10.1006/viro.2001.1229; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Neddermann P, 1999, J VIROL, V73, P9984, DOI 10.1128/JVI.73.12.9984-9991.1999; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; PALMER RH, 1995, EUR J BIOCHEM, V227, P344, DOI 10.1111/j.1432-1033.1995.tb20395.x; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; Piccininni S, 2002, J BIOL CHEM, V277, P45670, DOI 10.1074/jbc.M204124200; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Reed KE, 1998, J VIROL, V72, P6199, DOI 10.1128/JVI.72.7.6199-6206.1998; Schmidt-Mende J, 2001, J BIOL CHEM, V276, P44052, DOI 10.1074/jbc.M103358200; Schub O, 2001, J BIOL CHEM, V276, P38076; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Uchida M, 2002, HEPATOL RES, V22, P297, DOI 10.1016/S1386-6346(02)00005-0; Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247; Wang MT, 2003, J BIOL CHEM, V278, P9489, DOI 10.1074/jbc.M209397200; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Yamamoto S, 2001, MOL CELL BIOL, V21, P1, DOI 10.1128/MCB.21.1.1-15.2001; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yu WP, 1997, J BIOL CHEM, V272, P10030; Zhu Q, 2003, J VIROL, V77, P9204, DOI 10.1128/JVI.77.17.9204-9210.2003	74	58	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50031	50041		10.1074/jbc.M408617200	http://dx.doi.org/10.1074/jbc.M408617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364941	hybrid			2022-12-25	WOS:000225229500061
J	Rossi, F; Han, Q; Li, JS; Li, JY; Rizzi, M				Rossi, F; Han, Q; Li, JS; Li, JY; Rizzi, M			Crystal structure of human kynurenine aminotransferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-PHENYLPYRUVATE AMINOTRANSFERASE; THERMUS-THERMOPHILUS HB8; ASPARTATE-AMINOTRANSFERASE; BLOOD-PRESSURE; RAT-BRAIN; ACID; BIOACTIVATION; TRANSAMINASE; EXPRESSION; RECEPTOR	The kynurenine pathway has long been regarded as a valuable target for the treatment of several neurological disorders accompanied by unbalanced levels of metabolites along the catabolic cascade, kynurenic acid among them. The irreversible transamination of kynurenine is the sole source of kynurenic acid, and it is catalyzed by different isoforms of the 5'-pyridoxal phosphate-dependent kynurenine aminotransferase (KAT). The KAT-I isozyme has also been reported to possess beta-lyase activity toward several sulfur- and selenium-conjugated molecules, leading to the proposal of a role of the enzyme in carcinogenesis associated with environmental pollutants. We solved the structure of human KAT-I in its 5'-pyridoxal phosphate and pyridoxamine phosphate forms and in complex with the competing substrate L-Phe. The enzyme active site revealed a striking crown of aromatic residues decorating the ligand binding pocket, which we propose as a major molecular determinant for substrate recognition. Ligand-induced conformational changes affecting Tyr(101) and the Trp(18)-bearing alpha-helix H1 appear to play a central role in catalysis. Our data reveal a key structural role of Glu(27), providing a molecular basis for the reported loss of enzymatic activity displayed by the equivalent Glu-->Gly mutation in KAT-I of spontaneously hypertensive rats.	Univ Piemonte Orientale Amedeo Avogadro, DiSCAFF, Ist Nazl Fis Mat, I-28100 Novara, Italy; Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Eastern Piedmont Amedeo Avogadro; University of Illinois System; University of Illinois Urbana-Champaign	Rizzi, M (corresponding author), Univ Piemonte Orientale Amedeo Avogadro, DiSCAFF, Ist Nazl Fis Mat, Via Bovio 6, I-28100 Novara, Italy.	rizzi@ipvgen.unipv.it	Han, Qian/AAS-2134-2020; Han, Qian/J-8696-2014	Han, Qian/0000-0001-6245-5252	NIAID NIH HHS [AI 44399] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044399] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERATIGIANI D, 1995, J NEUROCHEM, V64, P1448; Alkondon M, 2004, J NEUROSCI, V24, P4635, DOI 10.1523/JNEUROSCI.5631-03.2004; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baran H, 1996, LIFE SCI, V58, P1891, DOI 10.1016/0024-3205(96)00173-7; BARAN H, 1994, J NEUROCHEM, V62, P730; Baran H, 1999, J NEURAL TRANSM, V106, P165, DOI 10.1007/s007020050149; BIRCH PJ, 1988, EUR J PHARMACOL, V154, P85, DOI 10.1016/0014-2999(88)90367-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BUCHLI R, 1995, J BIOL CHEM, V270, P29330, DOI 10.1074/jbc.270.49.29330; Colombari E, 2001, HYPERTENSION, V38, P549, DOI 10.1161/01.HYP.38.3.549; Commandeur JNM, 2000, J PHARMACOL EXP THER, V294, P753; Cooper AJL, 2004, NEUROCHEM INT, V44, P557, DOI 10.1016/j.neuint.2003.12.002; COOPER AJL, 1974, J BIOL CHEM, V249, P2554; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323, DOI 10.1152/physrev.1994.74.2.323; Denesyuk AI, 2002, J MOL BIOL, V316, P155, DOI 10.1006/jmbi.2001.5310; EASTMAN CL, 1989, BRAIN RES, V495, P225, DOI 10.1016/0006-8993(89)90216-3; Erhardt S, 2003, ADV EXP MED BIOL, V527, P155; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FUKUMOTO Y, 1991, J BIOL CHEM, V266, P4187; Goto M, 2004, J BIOL CHEM, V279, P16518, DOI 10.1074/jbc.M311575200; GRAMSBERGEN JBP, 1992, BRAIN RES, V588, P1, DOI 10.1016/0006-8993(92)91337-E; Guidetti P, 1997, J NEUROSCI RES, V50, P457; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; Hosono A, 2003, J BIOCHEM, V134, P843, DOI 10.1093/jb/mvg210; Ito S, 2000, HYPERTENSION, V35, P413, DOI 10.1161/01.HYP.35.1.413; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPOOR V, 1994, CLIN EXP PHARMACOL P, V21, P891, DOI 10.1111/j.1440-1681.1994.tb02460.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwok JBJ, 2002, J BIOL CHEM, V277, P35779, DOI 10.1074/jbc.C200303200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEESON PD, 1994, J MED CHEM, V37, P4053, DOI 10.1021/jm00050a001; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; OKUNO E, 1991, BRAIN RES, V542, P307, DOI 10.1016/0006-8993(91)91583-M; OKUNO E, 1990, BRAIN RES, V534, P37, DOI 10.1016/0006-8993(90)90109-O; PELLICCIARI R, 1994, J MED CHEM, V37, P647, DOI 10.1021/jm00031a015; Pereira EFR, 2002, J NEUROBIOL, V53, P479, DOI 10.1002/neu.10146; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PERRY S, 1995, FEBS LETT, V360, P277, DOI 10.1016/0014-5793(95)00123-Q; Rooseboom M, 2002, CHEM RES TOXICOL, V15, P1610, DOI 10.1021/tx020034f; Schwarcz R, 2002, J PHARMACOL EXP THER, V303, P1, DOI 10.1124/jpet.102.034439; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Stone TW, 2000, TRENDS PHARMACOL SCI, V21, P149, DOI 10.1016/S0165-6147(00)01451-6; Ura H, 2001, J BIOCHEM, V130, P89, DOI 10.1093/oxfordjournals.jbchem.a002966; YAMAMOTO H, 1994, PEDIATR NEUROL, V10, P9, DOI 10.1016/0887-8994(94)90060-4	51	59	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50214	50220		10.1074/jbc.M409291200	http://dx.doi.org/10.1074/jbc.M409291200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364907	hybrid			2022-12-25	WOS:000225229500082
J	Burgess, SC; Hausler, N; Merritt, M; Jeffrey, FMH; Storey, C; Milde, A; Koshy, S; Lindner, J; Magnuson, MA; Malloy, CR; Sherry, AD				Burgess, SC; Hausler, N; Merritt, M; Jeffrey, FMH; Storey, C; Milde, A; Koshy, S; Lindner, J; Magnuson, MA; Malloy, CR; Sherry, AD			Impaired tricarboxylic acid cycle activity in mouse livers lacking cytosolic phosphoenolpyruvate carboxykinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; NUCLEAR-MAGNETIC-RESONANCE; GLUCOSE-PRODUCTION; ENERGY-METABOLISM; C-13 NMR; INSULIN SENSITIVITY; OXYGEN-CONSUMPTION; DIABETES-MELLITUS; TRANSGENIC MICE; BETA-OXIDATION	Liver-specific phosphoenolpyruvate carboxykinase ( PEPCK) null mice, when fasted, maintain normal whole body glucose kinetics but develop dramatic hepatic steatosis. To identify the abnormalities of hepatic energy generation that lead to steatosis during fasting, we studied metabolic fluxes in livers lacking hepatic cytosolic PEPCK by NMR using H-2 and C-13 tracers. After a 4-h fast, glucose production from glycogenolysis and conversion of glycerol to glucose remains normal, whereas gluconeogenesis from tricarboxylic acid (TCA) cycle intermediates was nearly absent. Upon an extended 24-h fast, livers that lack PEPCK exhibit both 2-fold lower glucose production and oxygen consumption, compared with the controls, with all glucose production being derived only from glycerol. The mitochondrial reduction-oxidation (red-ox) state, as indicated by the NADH/ NAD(+) ratio, is 5-fold higher, and hepatic TCA cycle intermediate concentrations are dramatically increased in the PEPCK null livers. Consistent with this, flux through the TCA cycle and pyruvate cycling pathways is 10- and 40-fold lower, respectively. Disruption of hepatic cataplerosis due to loss of PEPCK leads to the accumulation of TCA cycle intermediates and a nearly complete blockage of gluconeogenesis from amino acids and lactate ( an energy demanding process) but intact gluconeogenesis from glycerol ( which contributes to net NADH production). Inhibition of the TCA cycle and fatty acid oxidation due to increased TCA cycle intermediate concentrations and reduced mitochondrial red-ox state lead to the development of steatosis.	Univ Texas, SW Med Ctr, Mary Nell & Ralph B Rogers Magnet Resonance Ctr, Dept Radiol, Dallas, TX 75235 USA; Univ Texas, Dept Chem, Richardson, TX 75083 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol, Nashville, TN 37232 USA; Univ Texas, SW Med Ctr, Vet Affairs N Texas Hlth Care Syst, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA North Texas Health Care System	Burgess, SC (corresponding author), Univ Texas, SW Med Ctr, Mary Nell & Ralph B Rogers Magnet Resonance Ctr, Dept Radiol, 5801 Forest Pk Rd, Dallas, TX 75235 USA.	shawn.burgess@utsouthwestern.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Lindner, Jill/K-5511-2012; Sherry, Dean/P-2348-2018	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Lindner, Jill/0000-0002-8897-7494; Sherry, Dean/0000-0001-7150-8301; Merritt, Matthew/0000-0003-4617-9651; Malloy, Craig/0000-0001-5077-0642	NCRR NIH HHS [RR02584] Funding Source: Medline; NHLBI NIH HHS [HL-34557] Funding Source: Medline; NIDDK NIH HHS [U24-DK59632] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034557, R01HL034557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U24DK059632] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beale EG, 2004, TRENDS ENDOCRIN MET, V15, P129, DOI 10.1016/j.tem.2004.02.006; Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; Beauvieux MC, 2001, J NUTR, V131, P1986, DOI 10.1093/jn/131.7.1986; BREMER J, 1972, BIOCHIM BIOPHYS ACTA, V280, P515, DOI 10.1016/0005-2760(72)90131-2; Burgess SC, 2003, ANAL BIOCHEM, V318, P321, DOI 10.1016/S0003-2697(03)00158-1; Burgess SC, 2003, ANAL BIOCHEM, V312, P228, DOI 10.1016/S0003-2697(02)00465-7; CHUNG YG, 1992, BIOCHEMISTRY-US, V31, P11159, DOI 10.1021/bi00160a029; COLET JM, 1994, MAGN RESON MATER PHY, V2, P303, DOI 10.1007/BF01705258; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; DITULLIO NW, 1974, BIOCHEM J, V138, P387, DOI 10.1042/bj1380387; Dufour S., 1996, MAGN RESON MATER PHY, V4, P329; Eaton S, 1997, EUR J CLIN INVEST, V27, P719, DOI 10.1046/j.1365-2362.1997.1780727.x; FELLENIU.E, 1973, ACTA CHEM SCAND, V27, P2893, DOI 10.3891/acta.chem.scand.27-2893; Gastaldelli A, 2000, DIABETES, V49, P1367, DOI 10.2337/diabetes.49.8.1367; GENEVE J, 1987, J PHARMACOL EXP THER, V242, P1133; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; HILTUNEN JK, 1977, INT J BIOCHEM, V8, P505, DOI 10.1016/0020-711X(77)90112-4; Jin ES, 2004, ANAL BIOCHEM, V327, P149, DOI 10.1016/j.ab.2003.12.036; Jones JG, 2001, AM J PHYSIOL-ENDOC M, V281, pE848, DOI 10.1152/ajpendo.2001.281.4.E848; Jones JG, 1997, FEBS LETT, V412, P131, DOI 10.1016/S0014-5793(97)00764-3; Kalhan SC, 2001, J BIOL CHEM, V276, P12928, DOI 10.1074/jbc.M006186200; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; KUWAJIMA M, 1986, J BIOL CHEM, V261, P2632; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LEHNINGER A, 2000, PRINCIPLES BIOCH, P586; Magnuson MA, 2003, J BIOL CHEM, V278, P32485, DOI 10.1074/jbc.R300020200; NEELY JR, 1967, AM J PHYSIOL, V212, P804; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; PERONI O, 1995, AM J PHYSIOL-ENDOC M, V269, pE516, DOI 10.1152/ajpendo.1995.269.3.E516; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; SCHOLZ R, 1984, EUR J BIOCHEM, V141, P223, DOI 10.1111/j.1432-1033.1984.tb08179.x; Schumann WC, 2001, ANAL BIOCHEM, V297, P195, DOI 10.1006/abio.2001.5326; She P, 2000, MOL CELL BIOL, V20, P6508, DOI 10.1128/MCB.20.17.6508-6517.2000; She PX, 2003, DIABETES, V52, P1649, DOI 10.2337/diabetes.52.7.1649; SHERRY AD, 1994, BIOCHEMISTRY-US, V33, P6268, DOI 10.1021/bi00186a029; Sherry AD, 1998, AM J PHYSIOL-HEART C, V274, pH591, DOI 10.1152/ajpheart.1998.274.2.H591; Sun Y, 2002, J BIOL CHEM, V277, P23301, DOI 10.1074/jbc.M200964200; Sunehag AL, 2001, PEDIATR RES, V50, P115, DOI 10.1203/00006450-200107000-00021; Sunehag AL, 1999, DIABETES, V48, P791, DOI 10.2337/diabetes.48.4.791; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VENKATESAN S, 1988, BIOCHIM BIOPHYS ACTA, V960, P61, DOI 10.1016/0005-2760(88)90009-4; Wajngot A, 2001, METABOLISM, V50, P47, DOI 10.1053/meta.2001.19422; Weis BC, 2004, MAGN RESON MED, V51, P649, DOI 10.1002/mrm.20057; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; WILLIAMSON JR, 1969, J BIOL CHEM, V244, P4607; YOUNES M, 1988, PHARMACOL TOXICOL, V63, P382, DOI 10.1111/j.1600-0773.1988.tb00972.x	47	124	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48941	48949		10.1074/jbc.M407120200	http://dx.doi.org/10.1074/jbc.M407120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347677	hybrid			2022-12-25	WOS:000225098100056
J	Cherepanov, P; Devroe, E; Silver, PA; Engelman, A				Cherepanov, P; Devroe, E; Silver, PA; Engelman, A			Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEAR-LOCALIZATION; HUMAN-CELLS; PREINTEGRATION COMPLEXES; LTR-RETROTRANSPOSONS; HUMAN GENOME; GENE FAMILY; PWWP DOMAIN; PROTEIN; DNA	Human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) protein was recently identified as a binding partner for HIV-1 integrase (IN) in human cells. In this work, we used biochemical and bioinformatic approaches to define the domain organization of LEDGF/p75. Using limited proteolysis and deletion mutagenesis we show that the protein contains a pair of evolutionarily conserved domains, assuming about 35% of its sequence. Whereas the N-terminal PWWP domain had been recognized previously, the second domain is novel. It is comprised of similar to80 amino acid residues and is both necessary and sufficient for binding to HIV-1 IN. Strikingly, the integrase binding domain (IBD) is not unique to LEDGF/p75, as a second human protein, hepatoma-derived growth factor-related protein 2 (HRP2), contains a homologous sequence. LEDGF/p75 and HRP2 IBDs avidly bound HIV-1 IN in an in vitro GST pull-down assay and each full-length protein potently stimulated HIV-1 IN activity in vitro. LEDGF/p75 and HRP2 are predicted to share a similar domain organization and have an evident evolutionary and likely functional relationship.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Engelman, A (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.	alan_engelman@dfci.harvard.edu	Cherepanov, Peter P/F-6859-2010	Cherepanov, Peter P/0000-0002-0634-538X	NIAID NIH HHS [AI39394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039394, R37AI039394] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6; Booth V, 2000, J BIOL CHEM, V275, P31266, DOI 10.1074/jbc.M002595200; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; Brown P. O., 1997, P161; Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Cherepanov P, 1999, NUCLEIC ACIDS RES, V27, P2202, DOI 10.1093/nar/27.10.2202; Cherepanov P, 2000, FASEB J, V14, P1389, DOI 10.1096/fj.14.10.1389; Cherepanov P, 2003, J BIOL CHEM, V278, P372, DOI 10.1074/jbc.M209278200; COWAN R, 1990, Peptide Research, V3, P75; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Dietz F, 2002, BIOCHEM J, V366, P491, DOI 10.1042/BJ20011811; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; Engelman A, 2003, CURR TOP MICROBIOL, V281, P209; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; Ge H, 1998, EMBO J, V17, P6723, DOI 10.1093/emboj/17.22.6723; Ge YZ, 2004, J BIOL CHEM, V279, P25447, DOI 10.1074/jbc.M312296200; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; Huntley MA, 2002, PROTEINS, V48, P134, DOI 10.1002/prot.10150; Ikegame K, 1999, BIOCHEM BIOPH RES CO, V266, P81, DOI 10.1006/bbrc.1999.1733; Izumoto Y, 1997, BIOCHEM BIOPH RES CO, V238, P26, DOI 10.1006/bbrc.1997.7233; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Kishima Y, 2002, J BIOL CHEM, V277, P10315, DOI 10.1074/jbc.M111122200; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; Letunic I, 2004, NUCLEIC ACIDS RES, V32, pD142, DOI 10.1093/nar/gkh088; Limon A, 2002, J VIROL, V76, P10598, DOI 10.1128/JVI.76.21.10598-10607.2002; Liu JF, 2003, NUCLEIC ACIDS RES, V31, P3833, DOI 10.1093/nar/gkg515; Liu JF, 2002, J MOL BIOL, V322, P53, DOI 10.1016/S0022-2836(02)00736-2; Llano M, 2004, J VIROL, V78, P9524, DOI 10.1128/JVI.78.17.9524-9537.2004; Maertens G, 2004, J BIOL CHEM, V279, P33421, DOI 10.1074/jbc.M404700200; Maertens G, 2003, J BIOL CHEM, V278, P33528, DOI 10.1074/jbc.M303594200; Malik HS, 1999, J VIROL, V73, P5186, DOI 10.1128/JVI.73.6.5186-5190.1999; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mulder LCF, 2002, J BIOL CHEM, V277, P27489, DOI 10.1074/jbc.M203061200; Nakajima N, 2001, J VIROL, V75, P7944, DOI 10.1128/JVI.75.17.7944-7955.2001; Nishizawa Y, 2001, CELL TISSUE RES, V305, P107, DOI 10.1007/s004410100398; Parissi V, 2001, J VIROL, V75, P11344, DOI 10.1128/JVI.75.23.11344-11353.2001; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; Slater LM, 2003, J MOL BIOL, V330, P571, DOI 10.1016/S0022-2836(03)00470-4; Stec I, 2000, FEBS LETT, V473, P1, DOI 10.1016/S0014-5793(00)01449-6; Turlure F, 2004, FRONT BIOSCI-LANDMRK, V9, P3187, DOI 10.2741/1472; Violot S, 2003, J VIROL, V77, P12507, DOI 10.1128/JVI.77.23.12507-12522.2003; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu X, 2002, CELL DEATH DIFFER, V9, P915, DOI 10.1038/sj.cdd.4401063; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Wu XY, 1999, J VIROL, V73, P2126, DOI 10.1128/JVI.73.3.2126-2135.1999; Xie WW, 2001, MOL CELL BIOL, V21, P6606, DOI 10.1128/MCB.21.19.6606-6614.2001; Yieh L, 2002, J BIOL CHEM, V277, P25920, DOI 10.1074/jbc.M202729200; Zdobnov EM, 2001, BIOINFORMATICS, V17, P847, DOI 10.1093/bioinformatics/17.9.847; Zhu YX, 2003, P NATL ACAD SCI USA, V100, P5891, DOI 10.1073/pnas.1036705100	59	225	234	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48883	48892		10.1074/jbc.M406307200	http://dx.doi.org/10.1074/jbc.M406307200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371438	hybrid, Green Published			2022-12-25	WOS:000225098100050
J	Giron-Monzon, L; Manelyte, L; Ahrends, R; Kirsch, D; Spengler, B; Friedhoff, P				Giron-Monzon, L; Manelyte, L; Ahrends, R; Kirsch, D; Spengler, B; Friedhoff, P			Mapping protein-protein interactions between MutL and MutH by cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA MISMATCH REPAIR; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HOT-SPOTS; IN-VIVO; BINDING; SUBSTRATE	Strand discrimination in Escherichia coli DNA mismatch repair requires the activation of the endonuclease MutH by MutL. There is evidence that MutH binds to the N-terminal domain of MutL in an ATP-dependent manner; however, the interaction sites and the molecular mechanism of MutH activation have not yet been determined. We used a combination of site-directed mutagenesis and site-specific cross-linking to identify protein interaction sites between the proteins MutH and MutL. Unique cysteine residues were introduced in cysteine-free variants of MutH and MutL. The introduced cysteines were modified with the cross-linking reagent 4-maleimidobenzophenone. Photoactivation resulted in cross-links verified by mass spectrometry of some of the single cysteine variants to their respective Cys-free partner proteins. Moreover, we mapped the site of interaction by cross-linking different combinations of single cysteine MutH and MutL variants with thiol-specific homobifunctional cross-linkers of varying length. These results were used to model the MutH.MutL complex and to explain the ATP dependence of this interaction.	Univ Giessen, Inst Biochem FB 08, D-35392 Giessen, Germany; Univ Giessen, Inst Anorgan & Analyt Chem FB 08, D-35392 Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Friedhoff, P (corresponding author), Univ Giessen, Inst Biochem FB 08, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	friedhoff@chemie.bio.uni-giessen.de	Spengler, Bernhard/A-9497-2012; Friedhoff, Peter/G-7905-2012	Ahrends, Robert/0000-0003-0232-3375; Spengler, Bernhard/0000-0003-0179-5653; Friedhoff, Peter/0000-0003-1946-1117				Acharya S, 2003, MOL CELL, V12, P233, DOI 10.1016/S1097-2765(03)00219-3; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Ban C, 1998, EMBO J, V17, P1526, DOI 10.1093/emboj/17.5.1526; Bjornson KP, 2003, J BIOL CHEM, V278, P18557, DOI 10.1074/jbc.M301101200; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; CREIGHTON TE, 1993, PROTEINS, P333; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Evans SJ, 2000, NUCLEIC ACIDS RES, V28, P1059, DOI 10.1093/nar/28.5.1059; FENG G, 1995, BIOTECHNIQUES, V19, P956; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Friedhoff P, 2003, J MOL BIOL, V325, P285, DOI 10.1016/S0022-2836(02)01224-X; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; Harris SF, 2004, STRUCTURE, V12, P1087, DOI 10.1016/j.str.2004.03.020; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Junop MS, 2003, DNA REPAIR, V2, P387, DOI 10.1016/S1568-7864(02)00245-8; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kunkel TA, 2004, J BIOL CHEM, V279, P16895, DOI 10.1074/jbc.R400006200; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; Loh T, 2001, J BIOL CHEM, V276, P12113, DOI 10.1074/jbc.M007935200; Martik D, 2004, J BIOL CHEM, V279, P28402, DOI 10.1074/jbc.M312108200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; Selmane T, 2003, J MOL BIOL, V334, P949, DOI 10.1016/j.jmb.2003.10.010; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; Thomas E, 2002, BIOL CHEM, V383, P1459, DOI 10.1515/BC.2002.166; Toedt GH, 2003, NUCLEIC ACIDS RES, V31, P819, DOI 10.1093/nar/gkg191; Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097	36	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49338	49345		10.1074/jbc.M409307200	http://dx.doi.org/10.1074/jbc.M409307200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371440	hybrid			2022-12-25	WOS:000225098100103
J	Muller, L; Schaupp, A; Walerych, D; Wegele, H; Buchner, J				Muller, L; Schaupp, A; Walerych, D; Wegele, H; Buchner, J			Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; DNA-BINDING ACTIVITY; N-TERMINAL DOMAIN; MUTANT P53; MOLECULAR CHAPERONE; CRYSTAL-STRUCTURE; ATP HYDROLYSIS; IN-VITRO; SEQUENCE; CONTAINS	The activity and structural integrity of the tumor suppressor protein p53 is of crucial importance for the prevention of cancer. p53 is a conformational flexible and labile protein, in which structured and unstructured regions function in a synergistic manner. The molecular chaperone Hsp90 is known to bind to mutant and wild type p53 in vivo. Using highly purified proteins we analyzed the interaction and the binding sites between both proteins in detail. Our results demonstrate that Hsp90 binds to a folded, native-like conformation of p53 in vitro with micromolar affinity. Specifically, the DNA-binding domain of p53 and the middle and carboxyterminal domains of Hsp90 are responsible for this interaction, which is essential to stabilize p53 at physiological temperatures and to prevent it from irreversible thermal inactivation. Our results are in agreement with a model in which Hsp90 is required to maintain the folded, active state of p53 by a reversible interaction, thus introducing an additional level of regulation.	Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; Int Inst Mol & Cell Biol Warsaw, Dept Mol Biol, PL-02109 Warsaw, Poland	Technical University of Munich; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Buchner, J (corresponding author), Tech Univ Munich, Dept Chem, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Walerych, Dawid/I-2517-2016; Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737; Walerych, Dawid/0000-0002-8440-1375				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BORKOVICH KA, 1989, MOL CELL BIOL, V9, P3919, DOI 10.1128/MCB.9.9.3919; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Harris SF, 2004, STRUCTURE, V12, P1087, DOI 10.1016/j.str.2004.03.020; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; Johnson BD, 2000, J BIOL CHEM, V275, P32499, DOI 10.1074/jbc.M005195200; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Knarr G, 2002, J MOL BIOL, V318, P611, DOI 10.1016/S0022-2836(02)00166-3; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Louvion JF, 1996, P NATL ACAD SCI USA, V93, P13937, DOI 10.1073/pnas.93.24.13937; Maki CG, 1996, CANCER RES, V56, P2649; Maruya M, 1999, J MOL BIOL, V285, P903, DOI 10.1006/jmbi.1998.2349; Meyer P, 2003, MOL CELL, V11, P647, DOI 10.1016/S1097-2765(03)00065-0; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Minami M, 2001, EUR J BIOCHEM, V268, P2520, DOI 10.1046/j.1432-1327.2001.02145.x; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; OwensGrillo JK, 1996, J BIOL CHEM, V271, P13468, DOI 10.1074/jbc.271.23.13468; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y; Rudiger S, 2002, P NATL ACAD SCI USA, V99, P11085, DOI 10.1073/pnas.132393699; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walerych D, 2004, J BIOL CHEM, V279, P48836, DOI 10.1074/jbc.M407601200; Walter S, 2002, ANGEW CHEM INT EDIT, V41, P1098, DOI 10.1002/1521-3773(20020402)41:7<1098::AID-ANIE1098>3.0.CO;2-9; Wang CG, 2003, J BIOL CHEM, V278, P2066, DOI 10.1074/jbc.M206697200; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	68	111	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48846	48854		10.1074/jbc.M407687200	http://dx.doi.org/10.1074/jbc.M407687200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358771	hybrid			2022-12-25	WOS:000225098100046
J	Tian, R; Li, SJ; Wang, DL; Zhao, Z; Liu, Y; He, RQ				Tian, R; Li, SJ; Wang, DL; Zhao, Z; Liu, Y; He, RQ			The acidic C-terminal domain stabilizes the chaperone function of protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTATE-DEHYDROGENASE; LACTIC-DEHYDROGENASE; RIBONUCLEASE-A; REACTIVATION; DENATURATION; THIOREDOXIN; DEPENDENCE; SUBUNIT; ENZYME	Protein disulfide isomerase (PDI, EC 5.3.4.1) is a chaperone and catalyzes the formation and rearrangement of disulfide bonds in proteins. Domain c-(463-491), containing 18 acidic residues, is an interesting and important C-terminal extension of PDI. In this study, the PDI mutant abb'a', in which domain c is truncated, was used to investigate the relationship between the C-terminal structure and chaperone function. Reactivation and light-scattering experiments show that both wild-type PDI and abb'a' interact with lactate dehydrogenase (LDH, EC 1.1.1.27), which tends to self-aggregate during reactivation. The interaction enhances reactivation of LDH and reduces aggregation. According to these results, it seems as if domain c might be dispensable to the chaperone function of PDI. However, abb'a' is prone to self-aggregation and causes increased aggregation of LDH during thermal denaturation. In contrast, wildtype PDI remains active as a chaperone under these conditions and prevents self-aggregation of LDH. Furthermore, measurements of intrinsic fluorescence and difference absorbance during denaturation show that abb'a' is much more labile to heat or guanidine hydrochloride denaturation than wild-type PDI. This suggests that domain c is required for the stabilization and maintenance of the chaperone function of PDI under extreme conditions.	Chinese Acad Sci, Inst Biophys, Lab Visual Informat Proc, Beijing 100101, Peoples R China; Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	He, RQ (corresponding author), Chinese Acad Sci, Inst Biophys, Lab Visual Informat Proc, 15 Da Tun Rd, Beijing 100101, Peoples R China.	herq@sun5.ibp.ac.cn	Liu, Ying/D-8933-2013; li, shengjian/B-4866-2013	Liu, Ying/0000-0003-0802-3832; 				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAI H, 1994, J BIOL CHEM, V269, P24550; Chen YH, 2000, BIOCHEM J, V351, P233, DOI 10.1042/0264-6021:3510233; Churchich JE, 1999, BIOCHEM BIOPH RES CO, V261, P41, DOI 10.1006/bbrc.1999.0908; Dai Y, 1997, J BIOL CHEM, V272, P27572, DOI 10.1074/jbc.272.44.27572; Dams T, 1996, EUR J BIOCHEM, V240, P274, DOI 10.1111/j.1432-1033.1996.0274h.x; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; HANA TB, 1976, BIOCHIM BIOPHYS ACTA, V445, P261; Hayano T, 1995, FEBS LETT, V377, P505, DOI 10.1016/0014-5793(95)01410-1; JAENICKE R, 1971, EUR J BIOCHEM, V23, P150, DOI 10.1111/j.1432-1033.1971.tb01602.x; JAENICKE R, 1990, PROTEIN STRUCTURE PR, P191; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Koivunen P, 1999, EMBO J, V18, P65, DOI 10.1093/emboj/18.1.65; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MA YZ, 1991, BIOCHEM J, V277, P207, DOI 10.1042/bj2770207; NOIVA R, 1997, PROLYL 4 HYDROXYLASE, P369; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; RUDOLPH R, 1979, BIOCHEMISTRY-US, V18, P5572, DOI 10.1021/bi00592a008; Ruoppolo M, 2003, PROTEIN SCI, V12, P939, DOI 10.1110/ps.0242803; Song JL, 1997, BIOCHEM J, V328, P841, DOI 10.1042/bj3280841; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TSOU CL, 1965, ACTA BIOCH BIOPH SIN, V5, P398; WANG CC, 1993, FASEB J, V7, P1515, DOI 10.1096/fasebj.7.15.7903263; Yao Y, 1997, EMBO J, V16, P651, DOI 10.1093/emboj/16.3.651; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2	29	28	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48830	48835		10.1074/jbc.M407076200	http://dx.doi.org/10.1074/jbc.M407076200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358778	hybrid			2022-12-25	WOS:000225098100044
J	Zhao, Q; Chang, XB				Zhao, Q; Chang, XB			Mutation of the aromatic amino acid interacting with adenine moiety of ATP to a polar residue alters the properties of multidrug resistance protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; CYSTIC-FIBROSIS MUTATIONS; TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN P-GLYCOPROTEIN; BREAST-CANCER CELLS; ABC TRANSPORTER; LEUKOTRIENE C-4; GENE; SITES; OVEREXPRESSION	Structural analyses of several bacterial ATP-binding cassette (ABC) transporters indicate that an aromatic amino acid residue in a nucleotide-binding domain (NBD) interacts with the adenine ring of the bound ATP and contributes to the ATP binding. Substitution of this aromatic residue with a polar serine residue in bacterial histidine transporter completely abolished both ATP binding and ATP-dependent histidine transport. However, substitution of the aromatic amino acid residue in the human cystic fibrosis transmembrane conductance regulator with a polar cysteine residue did not have any effect on the ATP-dependent chloride channel function of the protein. To determine whether the other eucaryotic ABC transporters use the strategy analogous to that in some bacterial ABC transporters, the aromatic Trp(653) residue in NBD1 and the Tyr(1302) residue in NBD2 of human multidrug resistance-associated protein 1 (MRP1) was mutated to either a different aromatic residue or a polar cysteine residue. Substitution of the aromatic residue with a different aromatic amino acid, such as W653Y or Y1302W, did not affect ATP-dependent leukotriene C4 (LTC4) transport. In contrast, substitution of the aromatic residue with a polar cysteine residue, such as W653C or Y1302C, decreased the affinity for ATP, resulting in greatly increased K-d values for ATP binding or K-m values for ATP in ATP-dependent LTC4 transport. Interestingly, although substitution of the aromatic Trp(653) in NBD1 of MRP1 with a polar cysteine residue greatly decreases the affinity for ATP, the ATP-dependent LTC4 transport activities are much higher than that of wild-type MRP1, supporting our hypothesis that the increased release rate of the bound ATP from the mutated NBD1 facilitates the protein to start a new cycle of ATP-dependent solute transport.	Mayo Clin, Coll Med, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Chang, XB (corresponding author), Mayo Clin, Coll Med, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	xbchang@mayo.edu			NCI NIH HHS [CA89078] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089078] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allikmets R, 1998, CANCER RES, V58, P5337; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Berger AL, 2000, J BIOL CHEM, V275, P29407, DOI 10.1074/jbc.M004790200; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Chen J, 2003, MOL CELL, V12, P651, DOI 10.1016/j.molcel.2003.08.004; CHEN YN, 1990, J BIOL CHEM, V265, P10073; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Coutelle Charles, 1992, Human Mutation, V1, P109, DOI 10.1002/humu.1380010205; Cui LY, 2001, ARCH BIOCHEM BIOPHYS, V392, P153, DOI 10.1006/abbi.2001.2441; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Lewis HA, 2004, EMBO J, V23, P282, DOI 10.1038/sj.emboj.7600040; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; MIRSKI SEL, 1987, CANCER RES, V47, P2594; Ramaen O, 2003, BIOCHEM J, V376, P749, DOI 10.1042/BJ20030998; REISS J, 1991, HUM GENET, V87, P457; Ren XQ, 2004, MOL PHARMACOL, V65, P1536, DOI 10.1124/mol.65.6.1536; RONINSON IB, 1992, BIOCHEM PHARMACOL, V43, P95, DOI 10.1016/0006-2952(92)90666-7; SHRIMPTON AE, 1991, J MED GENET, V28, P317, DOI 10.1136/jmg.28.5.317; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Verdon G, 2003, J MOL BIOL, V330, P343, DOI 10.1016/S0022-2836(03)00575-8; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; Yang RY, 2003, J BIOL CHEM, V278, P30764, DOI 10.1074/jbc.M304118200; Zhu QC, 1997, ONCOL RES, V9, P229	34	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48505	48512		10.1074/jbc.M408343200	http://dx.doi.org/10.1074/jbc.M408343200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355964	hybrid			2022-12-25	WOS:000225098100005
J	Chen, CY; Mosbaugh, DW; Bennett, SE				Chen, CY; Mosbaugh, DW; Bennett, SE			Mutational analysis of arginine 276 in the leucine-loop of human uracil-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURES; INHIBITOR PROTEIN; UNG GENE; BINDING; IDENTIFICATION; COMPLEX; MECHANISM; EXCISION	Uracil residues are eliminated from cellular DNA by uracil-DNA glycosylase, which cleaves the N-glycosylic bond between the uracil base and deoxyribose to initiate the uracil-DNA base excision repair pathway. Co-crystal structures of the core catalytic domain of human uracil-DNA glycosylase in complex with uracil-containing DNA suggested that arginine 276 in the highly conserved leucine intercalation loop may be important to enzyme interactions with DNA. To investigate further the role of Arg(276) in enzyme-DNA interactions, PCR-based codon-specific random mutagenesis, and site-specific mutagenesis were performed to construct a library of 18 amino acid changes at Arg(276). All of the R276X mutant proteins formed a stable complex with the uracil-DNA glycosylase inhibitor protein in vitro, indicating that the active site structure of the mutant enzymes was not perturbed. The catalytic activity of the R276X preparations was reduced; the least active mutant, R276E, exhibited 0.6% of wildtype activity, whereas the most active mutant, R276H, exhibited 43%. Equilibrium binding studies utilizing a 2-aminopurine deoxypseudouridine DNA substrate showed that all R276X mutants displayed greatly reduced base flipping/DNA binding. However, the efficiency of UV-catalyzed cross-linking of the R276X mutants to single-stranded DNA was much less compromised. Using a concatemeric [P-32]U.A DNA polynucleotide substrate to assess enzyme processivity, human uracil-DNA glycosylase was shown to use a processive search mechanism to locate successive uracil residues, and Arg(276) mutations did not alter this attribute.	Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA; Oregon State Univ, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA	Oregon State University; Oregon State University; Oregon State University	Bennett, SE (corresponding author), Oregon State Univ, Dept Environm & Mol Toxicol, ALS 1007, Corvallis, OR 97331 USA.	bennetsa@onid.oregonstate.edu	Chen, Cheng-Yao/C-5376-2016		NIEHS NIH HHS [P30 ES00210, P30 ES000210] Funding Source: Medline; NIGMS NIH HHS [R01 GM032823-21S1, R01 GM066245, R01 GM032823, GM32823, GM66245] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066245, R01GM032823] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; BENNETT SE, 1994, J BIOL CHEM, V269, P21870; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BENNETT SE, 1995, THESIS OREGON STATE; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; Bianchet MA, 2003, BIOCHEMISTRY-US, V42, P12455, DOI 10.1021/bi035372+; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dizdaroglu M, 1996, NUCLEIC ACIDS RES, V24, P418, DOI 10.1093/nar/24.3.418; Gerland U, 2002, P NATL ACAD SCI USA, V99, P12015, DOI 10.1073/pnas.192693599; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LINDAHL T, 1977, J BIOL CHEM, V252, P3286; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Putnam CD, 1999, J MOL BIOL, V287, P331, DOI 10.1006/jmbi.1999.2605; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanderson RJ, 1996, J BIOL CHEM, V271, P29170, DOI 10.1074/jbc.271.46.29170; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; Shroyer MJN, 1999, BIOCHEMISTRY-US, V38, P4834, DOI 10.1021/bi982986j; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1993, NUCLEIC ACIDS RES, V21, P2579, DOI 10.1093/nar/21.11.2579; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Wong I, 2002, J BIOL CHEM, V277, P19424, DOI 10.1074/jbc.M201198200	36	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48177	48188		10.1074/jbc.M407836200	http://dx.doi.org/10.1074/jbc.M407836200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339922	Green Accepted, hybrid			2022-12-25	WOS:000224957000092
J	Mille, C; Janbon, G; Delplace, F; Ibata-Ombetta, S; Gaillardin, C; Strecker, G; Jouault, T; Trinel, PA; Poulain, D				Mille, C; Janbon, G; Delplace, F; Ibata-Ombetta, S; Gaillardin, C; Strecker, G; Jouault, T; Trinel, PA; Poulain, D			Inactivation of CaMIT1 inhibits Candida albicans phospholipomannan beta-mannosylation, reduces virulence, and alters cell wall protein beta-mannosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-1,2-LINKED OLIGOMANNOSIDIC EPITOPES; SABOURAUD LIQUID-MEDIUM; NECROSIS-FACTOR-ALPHA; SACCHAROMYCES-CEREVISIAE; SEROTYPE-A; MONOCLONAL-ANTIBODIES; YEAST EXTRACT; IN-VITRO; MACROPHAGE; MANNANS	Studies on Candida albicans phospholipomannan have suggested a novel biosynthetic pathway for yeast glycosphingolipids. This pathway is thought to diverge from the usual pathway at the mannose-inositol-phosphoceramide (MIPC) step. To confirm this hypothesis, a C. albicans gene homologue for the Saccharomyces cerevisiae SUR1 gene was identified and named MIT1 as it coded for GDP-mannose: inositol-phospho-ceramide mannose transferase. Two copies of this gene were disrupted. Western blots of cell extracts revealed that strain mit1Delta contained no PLM. Thin layer chromatography and mass spectrometry confirmed that mit1Delta did not synthesize MIPC, demonstrating a role of MIT1 in the mannosylation of C. albicans IPCs. As MIT1 disruption prevented downstream beta-1,2 mannosylation, mit1Delta represents a new C. albicans mutant affected in the expression of these specific virulence attributes, which act as adhesins/immunomodulators. mit1Delta was less virulent during both the acute and chronic phases of systemic infection in mice (75 and 50% reduction in mortality, respectively). In vitro, mit1Delta was not able to escape macrophage lysis through down-regulation of the ERK1/2 phosphorylation pathway previously shown to be triggered by PLM. Phenotypic analysis also revealed pleiotropic effects of MIT1 disruption. The most striking observation was a reduced beta-mannosylation of phosphopeptidomannan. Increased beta-mannosylation of mannoproteins was observed under growth conditions that prevented the association of beta-oligomannosides with phosphopeptidomannan, but not with PLM. This suggests that C. albicans has strong regulatory mechanisms associating beta-oligomannoses with different cell wall carrier molecules. These mechanisms and the impact of the different presentations of beta-oligomannoses on the host response need to be defined.	Fac Med Lille, Lab Mycol Fondamentale & Appl, Equipe INSERM, E0360, F-59045 Lille, France; Inst Pasteur, Unite Mycol Mol, F-75015 Paris, France; Univ Sci & Technol Lille, CNRS, Unite Mixte Rech 8576, Unite Glycobiol Struct & Fonct, F-59655 Villeneuve Dascq, France; Inst Natl Agron Paris Grignon, Lab Genet Mol & Cellulaire, F-78850 Thiverval Grignon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; AgroParisTech	Poulain, D (corresponding author), Fac Med Lille, Lab Mycol Fondamentale & Appl, Equipe INSERM, E0360, Pole Rech,Pl Verdun, F-59045 Lille, France.	dpoulain@univ-lille2.fr	Jouault, Thierry/J-7437-2012; Jouault, Thierry/I-1071-2018; Janbon, Guilhem/AAL-6607-2021; Janbon, Guilhem/AAW-7398-2021; Poulain, Daniel/I-6095-2018	Jouault, Thierry/0000-0003-1988-8647; Janbon, Guilhem/0000-0002-4788-1154; Poulain, Daniel/0000-0002-0729-5468				Beeler TJ, 1997, MOL GEN GENET, V255, P570, DOI 10.1007/s004380050530; CANNON RD, 1992, MOL GEN GENET, V235, P453, DOI 10.1007/BF00279393; CANTELLI C, 1995, MICROBIOL-SGM, V141, P2693, DOI 10.1099/13500872-141-10-2693; Choi W, 2003, YEAST, V20, P1053, DOI 10.1002/yea.1022; Dalle F, 2003, INFECT IMMUN, V71, P7061, DOI 10.1128/IAI.71.12.7061-7068.2003; Dromer F, 2002, ANTIMICROB AGENTS CH, V46, P3869, DOI 10.1128/AAC.46.12.3869-3876.2002; DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0; FAILLE C, 1991, BIOCHEM BIOPH RES CO, V181, P1251, DOI 10.1016/0006-291X(91)92073-S; FONZI WA, 1993, GENETICS, V134, P717; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Fradin C, 1996, J LEUKOCYTE BIOL, V60, P81, DOI 10.1002/jlb.60.1.81; Han Y, 1997, INFECT IMMUN, V65, P4100, DOI 10.1128/IAI.65.10.4100-4107.1997; Han Y, 2000, INFECT IMMUN, V68, P1649, DOI 10.1128/IAI.68.3.1649-1654.2000; Han YM, 1998, INFECT IMMUN, V66, P5771, DOI 10.1128/IAI.66.12.5771-5776.1998; HANSON BA, 1980, J LIPID RES, V21, P309; Ibata-Ombetta S, 2003, J BIOL CHEM, V278, P13086, DOI 10.1074/jbc.M210680200; Ibata-Ombetta S, 2001, J LEUKOCYTE BIOL, V70, P149; Jouault T, 2003, J INFECT DIS, V188, P165, DOI 10.1086/375784; Jouault T, 1998, J INFECT DIS, V178, P792, DOI 10.1086/515361; JOUAULT T, 1994, IMMUNOLOGY, V83, P268; JOUAULT T, 1995, INFECT IMMUN, V63, P2378, DOI 10.1128/IAI.63.6.2378-2381.1995; Jouault T, 2000, INFECT IMMUN, V68, P965, DOI 10.1128/IAI.68.2.965-968.2000; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kapteyn JC, 2000, MOL MICROBIOL, V35, P601, DOI 10.1046/j.1365-2958.2000.01729.x; KOBAYASHI H, 1994, INFECT IMMUN, V62, P968, DOI 10.1128/IAI.62.3.968-973.1994; KOBAYASHI H, 1992, INFECT IMMUN, V60, P2106, DOI 10.1128/IAI.60.5.2106-2109.1992; KOBAYASHI H, 1991, BIOCHEM BIOPH RES CO, V175, P1003, DOI 10.1016/0006-291X(91)91664-X; KOCOUREK J, 1969, J BACTERIOL, V100, P1175, DOI 10.1128/JB.100.3.1175-1181.1969; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagorce A, 2003, J BIOL CHEM, V278, P20345, DOI 10.1074/jbc.M211604200; Lorenz MC, 2001, NATURE, V412, P83, DOI 10.1038/35083594; Lunghi P, 2003, LEUKEMIA, V17, P1783, DOI 10.1038/sj.leu.2403032; Nitz M, 2002, J BIOL CHEM, V277, P3440, DOI 10.1074/jbc.M109274200; Park MT, 2003, J BIOL CHEM, V278, P50624, DOI 10.1074/jbc.M309011200; Poulain D, 2004, CURR OPIN MICROBIOL, V7, P342, DOI 10.1016/j.mib.2004.06.011; Poulain D, 2002, INFECT IMMUN, V70, P4323, DOI 10.1128/IAI.70.8.4323-4328.2002; RUSTCHENKO EP, 1994, J BACTERIOL, V176, P3231, DOI 10.1128/jb.176.11.3231-3241.1994; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sanglard D, 1996, ANTIMICROB AGENTS CH, V40, P2300, DOI 10.1128/AAC.40.10.2300; Sendid B, 2004, J CLIN MICROBIOL, V42, P164, DOI 10.1128/JCM.42.1.164-171.2004; SUZUKI A, 1995, FEBS LETT, V373, P275, DOI 10.1016/0014-5793(95)01061-I; Trinel PA, 1997, HOST-FUNGUS INTERPLAY, P37; TRINEL PA, 1992, INFECT IMMUN, V60, P3845, DOI 10.1128/IAI.60.9.3845-3851.1992; Trinel PA, 2002, J BIOL CHEM, V277, P37260, DOI 10.1074/jbc.M202295200; TRINEL PA, 1993, INFECT IMMUN, V61, P4398, DOI 10.1128/IAI.61.10.4398-4405.1993; Trinel PA, 1996, MICROBIOL-UK, V142, P2263, DOI 10.1099/13500872-142-8-2263; Trinel PA, 2002, INFECT IMMUN, V70, P5274, DOI 10.1128/IAI.70.9.5274-5278.2002; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Zhong B, 2003, BLOOD, V101, P3240, DOI 10.1182/blood-2001-12-0180	49	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47952	47960		10.1074/jbc.M405534200	http://dx.doi.org/10.1074/jbc.M405534200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347680	hybrid, Green Published			2022-12-25	WOS:000224957000065
J	Qu, QH; Lee, SJ; Boos, W				Qu, QH; Lee, SJ; Boos, W			TreT, a novel trehalose glycosyltransferring synthase of the hyperthermophilic Archaeon Thermococcus litoralis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABC TRANSPORTER; ESCHERICHIA-COLI; BIOCHEMICAL-ANALYSIS; CRYSTAL-STRUCTURE; SUCROSE SYNTHASE; BINDING PROTEIN; GENE; METABOLISM; CLONING; SYSTEM	The gene cluster in Thermococcus litoralis encoding a multicomponent and binding protein-dependent ABC transporter for trehalose and maltose contains an open reading frame of unknown function. We cloned this gene (now called treT), expressed it in Escherichia coli, purified the encoded protein, and identified it as an enzyme forming trehalose and ADP from ADP-glucose and glucose. The enzyme can also use UDP- and GDP-glucose but with less efficiency. The reaction is reversible, and ADP-glucose plus glucose can also be formed from trehalose and ADP. The rate of reaction and the equilibrium favor the formation of trehalose. At 90degreesC, the optimal temperature for the enzymatic reaction, the half-maximal concentration of ADP-glucose at saturating glucose concentrations is 1.14 mM and the V-max is 160 units/mg protein. In the reverse reaction, the half-maximal concentration of trehalose at saturating ADP concentrations is 11.5 mM and the V-max was estimated to be 17 units/mg protein. Under non-denaturating in vitro conditions the enzyme behaves as a dimer of identical subunits of 48 kDa. As the transporter encoded in the same gene cluster, TreT is induced by trehalose and maltose in the growth medium.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Boos, W (corresponding author), Univ Konstanz, Dept Biol, D-78457 Constance, Germany.	winfried.boos@uni-konstanz.de	Lee, Sungjae/AAI-8586-2020	Lee, Sungjae/0000-0002-3997-9020				BOOS W, 1987, J BIOL CHEM, V262, P13212; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Diez J, 2001, J MOL BIOL, V305, P905, DOI 10.1006/jmbi.2000.4203; DiRuggiero J, 2000, MOL MICROBIOL, V38, P684, DOI 10.1046/j.1365-2958.2000.02161.x; Eis C, 2001, BIOCHEM J, V356, P757, DOI 10.1042/0264-6021:3560757; Eis C, 1999, BIOCHEM J, V341, P385, DOI 10.1042/0264-6021:3410385; Greller G, 1999, J BIOL CHEM, V274, P20259, DOI 10.1074/jbc.274.29.20259; Greller G, 2001, EUR J BIOCHEM, V268, P4011, DOI 10.1046/j.1432-1327.2001.02313.x; Higashiyama T, 2002, PURE APPL CHEM, V74, P1263, DOI 10.1351/pac200274071263; HIRIMBUREGAMA K, 1992, J GEN MICROBIOL, V138, P2035, DOI 10.1099/00221287-138-10-2035; Horlacher R, 1996, J BACTERIOL, V178, P6250, DOI 10.1128/jb.178.21.6250-6257.1996; Horlacher R, 1998, J BACTERIOL, V180, P680, DOI 10.1128/JB.180.3.680-689.1998; KLEIN W, 1995, J BACTERIOL, V177, P4043, DOI 10.1128/jb.177.14.4043-4052.1995; Lamosa P, 1998, APPL ENVIRON MICROB, V64, P3591; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; Maruta K, 1996, BBA-GEN SUBJECTS, V1291, P177, DOI 10.1016/S0304-4165(96)00082-7; Porchia AC, 1999, PLANTA, V210, P34, DOI 10.1007/s004250050651; Qu QH, 2004, EXTREMOPHILES, V8, P301, DOI 10.1007/s00792-004-0392-5; RIMMELE M, 1994, J BACTERIOL, V176, P5654, DOI 10.1128/JB.176.18.5654-5664.1994; SEBKOVA V, 1995, PLANT PHYSIOL, V108, P75, DOI 10.1104/pp.108.1.75; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; Shockley KR, 2003, APPL ENVIRON MICROB, V69, P2365, DOI 10.1128/AEM.69.4.2365-2371.2003; STROM AR, 1993, MOL MICROBIOL, V8, P205, DOI 10.1111/j.1365-2958.1993.tb01564.x; Tsusaki K, 1997, BBA-GEN SUBJECTS, V1334, P28, DOI 10.1016/S0304-4165(96)00103-1; Xavier KB, 1999, J BACTERIOL, V181, P3358, DOI 10.1128/JB.181.11.3358-3367.1999; Xavier KB, 1996, J BACTERIOL, V178, P4773, DOI 10.1128/jb.178.16.4773-4777.1996	26	80	85	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47890	47897		10.1074/jbc.M404955200	http://dx.doi.org/10.1074/jbc.M404955200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364950	hybrid			2022-12-25	WOS:000224957000059
J	Nakajima, S; Lan, L; Kanno, S; Takao, M; Yamamoto, K; Eker, APM; Yasui, A				Nakajima, S; Lan, L; Kanno, S; Takao, M; Yamamoto, K; Eker, APM; Yasui, A			Light-induced DNA damage and tolerance for the survival of nucleotide excision repair-deficient human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-4 PHOTOPRODUCTS; ULTRAVIOLET; POLYMERASE; PHOTOLYASE; EXPRESSION; MUTATIONS; CHROMATIN; GENE; PHOTOREPAIR; BYPASS	DNA damage can cause cell death unless it is either repaired or tolerated. The precise contributions of repair and tolerance mechanisms to cell survival have not been previously evaluated. Here we have analyzed the cell killing effect of the two major UV light-induced DNA lesions, cyclobutane pyrimidine dimers (CPDs) and 6-4 pyrimidine-pyrimidone photoproducts (6-4PPs), in nucleotide excision repair-deficient human cells by expressing photolyase(s) for light-dependent photorepair of either or both lesions. Immediate repair of the less abundant 6-4PPs enhances the survival rate to a similar extent as the immediate repair of CPDs, indicating that a single 6-4PP lesion is severalfold more toxic than a CPD in the cells. Because UV light-induced DNA damage is not repaired at all in nucleotide excision repair-deficient cells, proliferation of these cells after UV light irradiation must be achieved by tolerance of the damage at replication. We found that RNA interference designed to suppress polymerase zeta activity made the cells more sensitive to UV light. This increase in sensitivity was prevented by photorepair of 6-4PPs but not by photorepair of CPDs, indicating that polymerase zeta is involved in the tolerance of 6-4PPs in human cells.	Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Grad Sch Life Sci, Dept Biomol Sci, Sendai, Miyagi 9808578, Japan; Erasmus Univ, Med Ctr, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Tohoku University; Tohoku University; Erasmus University Rotterdam; Erasmus MC	Yasui, A (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan.	ayasui@idac.tohoku.ac.jp	Kanno, Shin-ichiro/AAE-4549-2019					Asahina H, 1999, MUTAT RES-DNA REPAIR, V435, P255, DOI 10.1016/S0921-8777(99)00051-8; Chigancas V, 2000, CANCER RES, V60, P2458; Friedberg EC, 1995, DNA REPAIR MUTAGENES, P24; HARM H, 1980, BIOL EFFECTS ULTRAVI, P84; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; Lehmann AR, 2002, MUTAT RES-FUND MOL M, V509, P23, DOI 10.1016/S0027-5107(02)00227-0; Lin WS, 1999, MUTAT RES-DNA REPAIR, V433, P89, DOI 10.1016/S0921-8777(98)00065-2; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1990, J BIOL CHEM, V265, P5353; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; Nakajima S, 1998, NUCLEIC ACIDS RES, V26, P638, DOI 10.1093/nar/26.2.638; NIGGLI HJ, 1982, BIOCHEM BIOPH RES CO, V105, P1215, DOI 10.1016/0006-291X(82)91098-1; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SATOKATA I, 1992, MUTAT RES, V273, P193, DOI 10.1016/0921-8777(92)90080-M; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; YASUI A, 1975, INT J RADIAT BIOL, V28, P511, DOI 10.1080/09553007514551371; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x; Yasui A, 1998, CONT CANC RES, P9	32	71	73	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46674	46677		10.1074/jbc.M406070200	http://dx.doi.org/10.1074/jbc.M406070200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342631	hybrid			2022-12-25	WOS:000224832400043
J	Esufali, S; Bapat, B				Esufali, S; Bapat, B			Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation	ONCOGENE			English	Article						Rac1; beta-catenin; TCF-mediated transcription; Wnt signaling; PBR	ADENOMATOUS POLYPOSIS-COLI; FACTOR-KAPPA-B; RHO-GTPASES; CARCINOMA-CELLS; CYCLIN D1; PROTEIN; CANCER; CDC42; TCF; ADHESION	Aberrant activation of the Wnt pathway is observed in numerous cancers, and is particularly important in colon cancer. We demonstrate that Rac1 GTPase can significantly increase the signaling activity of beta-catenin in cells with inherent dysregulation of the canonical Wnt signaling pathway. Expression of dominant-negative (N17)Rac1 mutant in colon cancer cells caused a marked inhibition of Wnt signaling, as determined by the TCF/LEF-responsive (TOPFLASH) transcription assay. Expression of a constitutively active (V12)Rac1 mutant caused up to 40-fold induction from the TOPFLASH promoter, and this was dependent on the presence of stabilized beta-catenin. This induction was completely blocked by the expression of dominant-negative TCF-4, suggesting that beta-catenin and TCF-4 complex formation is required for Rac1-mediated transcription. Furthermore, we show that Cyclin D1, an important biological Wnt target gene, is regulated by Rac1 in a beta-catenin/TCF-dependent manner. We observed that Rac1 co-immunoprecipitates with beta-catenin and TCF-4 only in its active GTP-bound form. Both cell fractionation studies and fluorescence microscopy indicate that overexpression of V12Rac1 results in increased cytosolic and nuclear expression of beta-catenin. Interestingly, mutation of the polybasic region of Rac1, which prevents its nuclear localization, also caused an appreciable decrease in nuclear localization of beta-catenin, and effectively abolished its beta-catenin-dependent transcription co-activator function. Taken together, our data demonstrate a novel mechanism of Wnt pathway regulation whereby activation of Rac1 amplifies the signaling activity of stabilized/mutated beta-catenin by promoting its accumulation in the nucleus, and synergizing with beta-catenin to augment TCF/LEF-dependent gene transcription.	Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Bapat, B (corresponding author), Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Pathol & Lab Med, 9th Floor,Room 992B,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	bapat@mshri.on.ca	Bapat, Bharati/B-5839-2014					Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Briggs MW, 2002, J BIOL CHEM, V277, P7453, DOI 10.1074/jbc.M104315200; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jordan P, 1999, ONCOGENE, V18, P6835, DOI 10.1038/sj.onc.1203233; Joyce D, 1999, J BIOL CHEM, V274, P25245, DOI 10.1074/jbc.274.36.25245; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Malliri A, 2003, CURR OPIN CELL BIOL, V15, P583, DOI 10.1016/S0955-0674(03)00098-X; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Polakis P, 2000, GENE DEV, V14, P1837; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	39	77	78	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8260	8271		10.1038/sj.onc.1208007	http://dx.doi.org/10.1038/sj.onc.1208007			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15377999				2022-12-25	WOS:000224749500008
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Lacal, JC			Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action	ONCOGENE			English	Article						choline kinase; drug design; MN58b; apoptosis; cell cycle arrest; phospholipid metabolism	HAMSTER OVARY CELLS; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; EPIDERMAL-GROWTH-FACTOR; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; CDP-CHOLINE; GLUTATHIONE-PEROXIDASE; INDUCED APOPTOSIS; IN-VIVO; PHOSPHATIDYLETHANOLAMINE	Choline kinase (ChoK, E. C. 2.7.1.32) is involved in the synthesis of phosphatidylcholine ( PC), and has been found to be increased in human tumors and tumor-derived cell lines. Furthermore, ChoK inhibitors have been reported to show a potent and selective antitumoral activity both in vitro and in vivo. Here, we provide the basis for a rational understanding of the antitumoral activity of ChoK inhibitors. In normal cells, blockage of de novo phosphorylcholine (PCho) synthesis by inhibition of ChoK promotes the dephosphorylation of pRb, resulting in a reversible cell cycle arrest at G0/G1 phase. In contrast, ChoK inhibition in tumor cells renders cells unable to arrest in G0/G1 as manifested by a lack of pRb dephosphorylation. Furthermore, tumor cells specifically suffer a drastic wobble in the metabolism of main membrane lipids PC and sphingomyelin (SM). This lipid disruption results in the enlargement of the intracellular levels of ceramides. As a consequence, normal cells remain unaffected, but tumor cells are promoted to apoptosis. Thus, we provide in this study the rationale for the potential clinical use of ChoK inhibitors.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Translat Oncol Unit, Arturo Duperier 4, E-28029 Madrid, Spain.	jclacal@iib.uam.es	Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				BIELAWSKA A, 1992, FEBS LETT, V307, P211, DOI 10.1016/0014-5793(92)80769-D; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brindley DN, 1996, BIOCHEM CELL BIOL, V74, P469, DOI 10.1139/o96-051; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cui Z, 2002, BBA-MOL CELL BIOL L, V1585, P87, DOI 10.1016/S1388-1981(02)00328-1; Davies SMA, 2001, BIOCHEMISTRY-US, V40, P10522, DOI 10.1021/bi010904c; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DEMOLINA AR, IN PRESS CANC RES; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; Fernandez-Tome MD, 2002, BBA-MOL CELL BIOL L, V1583, P185, DOI 10.1016/S1388-1981(02)00208-1; Finney RE, 2000, CANCER RES, V60, P5204; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1998, J IMMUNOL, V160, P3528; Foster DA, 2003, MOL CANCER RES, V1, P789; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; Hundertmark S, 1999, HORM METAB RES, V31, P8, DOI 10.1055/s-2007-978688; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; KUGE O, 1986, J BIOL CHEM, V261, P5795; Lacal J C, 2001, IDrugs, V4, P419; Lacal JC, 1997, FEBS LETT, V410, P73, DOI 10.1016/S0014-5793(97)00444-4; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MAN AS, 1994, LIPIDS, V29, P15, DOI 10.1007/BF02537085; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; Rodriguez-Gonzalez A, 2003, ONCOGENE, V22, P8803, DOI 10.1038/sj.onc.1207062; RUIZRUIZ CAL, 2002, BIOCHEM J, P825; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sillence DJ, 1998, BIOCHEM J, V331, P251, DOI 10.1042/bj3310251; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; UCHIDA T, 1994, J BIOCHEM-TOKYO, V116, P508, DOI 10.1093/oxfordjournals.jbchem.a124554; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Vance DE, 1997, BBA-LIPID LIPID MET, V1348, P142, DOI 10.1016/S0005-2760(97)00108-2; Wang XD, 2001, GENE DEV, V15, P2922; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINHOLD PA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P299, DOI 10.1016/0005-2760(89)90017-9; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WITTENBERG J, 1953, J BIOL CHEM, V202, P431; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZEISEL SH, 1993, FASEB J, V7, P551, DOI 10.1096/fasebj.7.6.8472893; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061	66	70	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8247	8259		10.1038/sj.onc.1208045	http://dx.doi.org/10.1038/sj.onc.1208045			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378008				2022-12-25	WOS:000224749500007
J	Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL				Slavin, DA; Koritschoner, NP; Prieto, CC; Lopez-Diaz, FJ; Chatton, B; Bocco, JL			A new role for the Kruppel-like transcription factor KLF6 as an inhibitor of c-Jun proto-oncoprotein function	ONCOGENE			English	Article						Kruppel-like; c-Jun; proliferation; TPA/ionomycin	TUMOR-SUPPRESSOR GENE; PROMOTER-BINDING PROTEIN; ZINC-FINGER PROTEIN; CELL-GROWTH; HA-RAS; ACTIVATION; EXPRESSION; KINASE; SP1; PROGRESSION	Kruppel-like transcription factors (KLFs) represent one of the most diverse set of regulators in vertebrate organisms. KLF family members are involved in cell proliferation and differentiation control in normal as well as in pathological situations. Here, we demonstrate that KLF6 behaves as a functional antagonist of the c-Jun proto-oncoprotein. Thus, KLF6 overexpression downregulated c-Jun-dependent transcription and a physical interaction between c-Jun and KLF6 was detected. Moreover, cell proliferation induced by c-Jun was significantly decreased by KLF6. The inhibition of c-Jun functions correlates directly with c-Jun protein degradation induced by KLF6. We also show that all KLF6 effects on c-Jun were largely dependent on phorbol ester (TPA/ionomycin) extracellular stimulation, which enhanced KLF6 nuclear translocation and transcriptional activity and modified its phosphorylation status. Our data are consistent with a novel mechanism of KLF6's role as an inhibitor of cell proliferation by counteracting the function of the c-Jun proto-oncoprotein involving enhanced c-Jun degradation by the proteasome-dependent pathway, and further reinforces KLF6 as a potential tumor suppressor gene product.	Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, RA-5016 Cordoba, Argentina; Univ Strasbourg, Ecole Super Biotechnol Strasbourg, Strasbourg, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Cordoba; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bocco, JL (corresponding author), Natl Univ Cordoba, Fac Ciencias Quim, Dept Bioquim Clin, CONICET,CIBICI, Haya Torre & Medina Allende,Ciudad Univ, RA-5016 Cordoba, Argentina.	jbocco@fcq.unc.edu.ar	CHATTON, Bruno/R-3813-2019	Bocco, Jose Luis/0000-0002-9682-1270; CHATTON, Bruno/0000-0003-4515-7119				ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; BISHOP JM, 1996, MOL ONCOLOGY; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Blanchon L, 2001, MECH DEVELOP, V105, P185, DOI 10.1016/S0925-4773(01)00391-4; Bocco JL, 1996, ONCOGENE, V12, P1971; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Cook T, 2000, AM J PHYSIOL-GASTR L, V278, pG513, DOI 10.1152/ajpgi.2000.278.4.G513; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kojima S, 2000, BLOOD, V95, P1309; Koritschoner NP, 1997, J BIOL CHEM, V272, P9573; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laub F, 2001, MECH DEVELOP, V106, P167, DOI 10.1016/S0925-4773(01)00419-1; Lei L, 2001, DEVELOPMENT, V128, P1147; Matsumoto N, 1998, J BIOL CHEM, V273, P28229, DOI 10.1074/jbc.273.43.28229; Muhlbauer KR, 2003, BRIT J CANCER, V89, P687, DOI 10.1038/sj.bjc.6601164; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Slavin D, 1999, BIOL REPROD, V61, P1586, DOI 10.1095/biolreprod61.6.1586; Tupler R, 2001, NATURE, V409, P832, DOI 10.1038/35057011; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhao JL, 2000, J BIOL CHEM, V275, P8903, DOI 10.1074/jbc.275.12.8903	44	74	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8196	8205		10.1038/sj.onc.1208020	http://dx.doi.org/10.1038/sj.onc.1208020			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378003				2022-12-25	WOS:000224749500002
J	Wodarz, D				Wodarz, D			Checkpoint genes, ageing, and the development of cancer	ONCOGENE			English	Article						mathematical; computational; p53	STROMAL CELLS; TUMOR-GROWTH; P53; APOPTOSIS; PROGRESSION; SENESCENCE; DEATH; LIFE; MICE	Mathematical models are used to examine the relationship between checkpoint competence, ageing, and the development of cancer. The models take into account the dynamics of healthy tissue, the dynamics of initial tumor growth, and the interactions between healthy tissue and tumor cells. Two types of behavior are found. (i) A reduction of checkpoint competence results in reduced ageing of tissue, but in faster development and progression of tumors. (ii) Reduced checkpoint competence results both in reduced ageing of tissue, and in a reduced incidence of tumors. The tumors which do become established, however, are predicted to progress at an accelerated rate. The models define the conditions under which this counter-intuitive finding is observed. One reason could be the relationship between checkpoint activity and the ability of the tissue environment to exert inhibitory effects on tumor cells. Checkpoints induce senescence in tissue cells, and this compromises their ability to suppress tumor growth. Reduced checkpoint competence leads to reduced tissue senescence, and this results in higher amounts of tumor inhibition. The theoretical work is discussed with respect to data from p53 mutant mice, which show both types of relationships suggested by the models. The models help to identify differences in the experimental protocols which could explain the seemingly contradictory observations.	Univ Calif Irvine, Dept Ecol & Evolut, Irvine, CA 92697 USA; Inst Adv Study, Princeton, NJ 08540 USA	University of California System; University of California Irvine; Institute for Advanced Study - USA	Wodarz, D (corresponding author), Univ Calif Irvine, Dept Ecol & Evolut, Steinhaus Hall, Irvine, CA 92697 USA.	dwodarz@uci.edu						Bayko L, 1998, Angiogenesis, V2, P203, DOI 10.1023/A:1009275307663; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi Judith, 2001, ScientificWorldJournal, V1, P65, DOI 10.1100/tsw.2001.106; Camplejohn RS, 2003, BRIT J CANCER, V88, P487, DOI 10.1038/sj.bjc.6600767; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Cunha GR, 2002, DIFFERENTIATION, V70, P469, DOI 10.1046/j.1432-0436.2002.700901.x; Donehower LA, 2002, J CELL PHYSIOL, V192, P23, DOI 10.1002/jcp.10104; Evans SC, 1997, MOL MED TODAY, V3, P390, DOI 10.1016/S1357-4310(97)01105-2; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Gilhar A, 2004, BRIT J DERMATOL, V150, P56, DOI 10.1111/j.1365-2133.2004.05715.x; Guba M, 2001, CANCER RES, V61, P5575; Hahnfeldt P, 1999, CANCER RES, V59, P4770; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jansen-Durr Pidder, 2002, TheScientificWorldJOURNAL, V2, P943; Kahlem P, 2004, J CLIN INVEST, V113, P169, DOI 10.1172/JCI200420784; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kirkwood TBL, 2002, BIOESSAYS, V24, P577, DOI 10.1002/bies.10111; Komarova NL, 2003, CANCER RES, V63, P6635; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mueller MM, 2002, DIFFERENTIATION, V70, P486, DOI 10.1046/j.1432-0436.2002.700903.x; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	34	5	5	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7799	7809		10.1038/sj.onc.1207833	http://dx.doi.org/10.1038/sj.onc.1207833			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361848				2022-12-25	WOS:000224331600006
J	Stoyanova, V; Rossetti, S; van Unen, L; Oostra, BA; Hoogeveen, AT				Stoyanova, V; Rossetti, S; van Unen, L; Oostra, BA; Hoogeveen, AT			Loss of FMR1 hypermethylation in somatic cell heterokaryons	FASEB JOURNAL			English	Article						fragile X syndrome; FMR1 promoter; active demethylation	DNA DEMETHYLATION; METHYLATION ANALYSIS; GENE; 5-METHYLCYTOSINE; TRANSCRIPTION; REACTIVATION; IDENTIFICATION; HETEROGENEITY; EXPRESSION	Fragile X syndrome is associated with a trinucleotide (CGG) repeat expansion in the 5'-untranslated region of the FMR1 gene and hypermethylation of the FMR1 promoter. Rare cases of clinically normal males (HFM) have been identified with an expanded CGG repeat; however, here, the FMR1 promoter is not methylated. Using classical complementation ( cell fusion) studies, we analyzed if possible differences in the genetic background between HFM and cells from individuals with fragile X syndrome (FX cells) could have an influence on the methylation status of the FMR1 promoter. We observed that demethylation of the hypermethylated FMR1 promoter can occur when FX cells are complemented ( by cell fusion) with cells from HFM as well as with cells from control individuals. The observed demethylation is specific and can happen without DNA replication. In contrast, demethylation was not observed when cells from unrelated individuals with fragile X syndrome were fused, indicating that FX cells have lost the necessary factor(s) to demethylate the aberrantly methylated FMR1 promoter.	Erasmus MC, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Hoogeveen, AT (corresponding author), Erasmus MC, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.	a.hoogeveen@erasmusmc.nl						Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887; Cedar H, 1999, NATURE, V397, P568, DOI 10.1038/17492; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Grunau C, 2001, NUCLEIC ACIDS RES, V29, P270, DOI 10.1093/nar/29.1.270; Hagerman RJ, 2002, FRAGILE X SYNDROME D, P3; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HOOGEVEEN AT, 1980, NATURE, V285, P500, DOI 10.1038/285500a0; JONGKIND JF, 1979, EXP CELL RES, V120, P444, DOI 10.1016/0014-4827(79)90410-5; Kress C, 2001, FEBS LETT, V494, P135, DOI 10.1016/S0014-5793(01)02328-6; Kubota T, 1997, NAT GENET, V16, P16, DOI 10.1038/ng0597-16; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Pietrobono R, 2002, NUCLEIC ACIDS RES, V30, P3278, DOI 10.1093/nar/gkf434; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; SMEETS HJM, 1995, HUM MOL GENET, V4, P2103, DOI 10.1093/hmg/4.11.2103; SMITH KT, 2004, HUM MOL GENET; Stoger R, 1997, HUM MOL GENET, V6, P1791, DOI 10.1093/hmg/6.11.1791; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; VERHEIJ C, 1993, NATURE, V363, P722, DOI 10.1038/363722a0; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Weiss A, 1997, GENES CELLS, V2, P481, DOI 10.1046/j.1365-2443.1997.1390337.x; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; Wohrle D, 2001, AM J HUM GENET, V69, P504, DOI 10.1086/322739; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157	35	2	2	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1964	+		10.1096/fj.04-2499fje	http://dx.doi.org/10.1096/fj.04-2499fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15377638				2022-12-25	WOS:000224243200020
J	Takeda, K; Araki, W; Akiyama, H; Tabira, T				Takeda, K; Araki, W; Akiyama, H; Tabira, T			Amino-truncated amyloid beta-peptide (A beta 5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain	FASEB JOURNAL			English	Article						BACE; alpha-secretase; apoptosis	CEREBRAL-CORTEX; NEURONS; SECRETASE; ACTIVATION; A-BETA-42; APOPTOSIS; PATHWAY; CELLS; TAU; PRESENILIN-2	Caspase activation and apoptosis are implicated in Alzheimer's disease ( AD). In view of the finding that the amyloid precursor protein (APP) undergoes caspase-mediated cleavage in the cytoplasmic region, we analyzed amyloid beta-peptide (Abeta) production in human neuronal and nonneuronal cells expressing wild-type APP and the caspase-cleaved form of APP (APPDeltaC). Biochemical analyses, including immunoprecipitation/mass spectrometry, revealed that APPDeltaC-expressing cells secrete increased levels of amino-terminally truncated Abeta5-40/42 and reduced levels of Abeta1-40/42, compared with wild-type APP-expressing cells. We propose that Abeta5-40/42 is derived from alternative beta-cleavage of APP by alpha-secretase-like protease(s), based on data from treatment of cells with inhibitors of BACE and alpha-secretase. Apoptosis induction resulted in this alternative cleavage of APP in wild-type APP-expressing cells. Moreover, immunohistochemical staining of the AD brain with an end-specific antibody to Abeta5-40/42 revealed peptide deposits in vascular lesions with amyloid angiopathy. The data collectively suggest that caspase cleavage of APP leads to increased production and deposition of Abeta5-40/42 in the AD brain, and highlight the significance of amino-truncated Abeta in the pathogenesis of AD.	NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; NCGG, Natl Inst Longev Sci, Dept Vasc Dementia Res, Aichi 4748522, Japan; Tokyo Inst Psychiat, Setagaya Ku, Tokyo 1568585, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo Institute of Psychiatry	Araki, W (corresponding author), NCNP, Natl Inst Neurosci, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan.	araki@ncnp.go.jp; tabira@nils.go.jp	Araki, Wataru/G-7913-2014	Araki, Wataru/0000-0001-8467-6937				Akiyama H, 1999, GLIA, V25, P324, DOI 10.1002/(SICI)1098-1136(19990215)25:4<324::AID-GLIA2>3.0.CO;2-5; Akiyama H, 1997, NEUROCHEM RES, V22, P1499, DOI 10.1023/A:1021910729963; Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Ayala-Grosso C, 2002, BRAIN PATHOL, V12, P430; Chui DH, 2001, J ALZHEIMERS DIS, V3, P231; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; Gamblin TC, 2003, P NATL ACAD SCI USA, V100, P10032, DOI 10.1073/pnas.1630428100; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; PALMERT MR, 1989, BIOCHEM BIOPH RES CO, V165, P182, DOI 10.1016/0006-291X(89)91052-8; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Selkoe DJ, 2002, J CLIN INVEST, V110, P1375, DOI 10.1172/JCI200216783; Sergeant N, 2003, J NEUROCHEM, V85, P1581, DOI 10.1046/j.1471-4159.2003.01818.x; Shinkai Y, 1997, ANN NEUROL, V42, P899, DOI 10.1002/ana.410420612; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Takeda K, 2004, EUR J NEUROSCI, V19, P258, DOI 10.1111/j.0953-816X.2003.03135.x; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Zheng WH, 2002, NEUROSCIENCE, V115, P201, DOI 10.1016/S0306-4522(02)00404-9	42	42	44	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1755	+		10.1096/fj.03-1070fje	http://dx.doi.org/10.1096/fj.03-1070fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15364896				2022-12-25	WOS:000224243200027
J	Canovas, D; Vooijs, R; Schat, H; de Lorenzo, V				Canovas, D; Vooijs, R; Schat, H; de Lorenzo, V			The role of thiol species in the hypertolerance of Aspergillus sp P37 to arsenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-METAL DETOXIFICATION; PHYTOCHELATIN SYNTHASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; TOLERANCE; GLUTATHIONE; GENE; NIDULANS; PLANTS; TRANSFERASE	Aspergillus sp. P37 is an arsenate-hypertolerant fungus isolated from a river in Spain with a long history of contamination with metals. This strain is able to grow in the presence of 0.2 M arsenate, i.e. 20-fold higher than the reference strain, Aspergillus nidulans TS1. Although Aspergillus sp. P37 reduces As( V) to As(III), which is slowly pumped out of the cell, the measured efflux of oxyanions is insufficient to explain the high tolerance levels of this strain. To gain an insight into this paradox, the accumulation of acid-soluble thiol species in Aspergillus sp. P37 when exposed to arsenic was compared with that of the arsenic-sensitive A. nidulans TS1 strain. Increasing levels of arsenic in the medium did not diminish the intracellular pool of reduced glutathione in Aspergillus sp. P37, in sharp contrast with the decline of glutathione in A. nidulans under the same conditions. Furthermore, concentrations of arsenic that were inhibitory for the sensitive A. nidulans strain ( e. g. 50 mM and above) provoked a massive formation of vacuoles filled with thiol species. Because the major fraction of the cellular arsenic was present as the glutathione conjugate As(GS)(3), it is plausible that the arsenic-hypertolerant phenotype of Aspergillus sp. P37 is in part due to an enhanced capacity to maintain a large intracellular glutathione pool under conditions of arsenic exposure and to sequester As( GS) 3 in vacuoles. High pressure liquid chromatography analysis of cell extracts revealed that the contact of Aspergillus sp. P37 ( but not A. nidulans) with high arsenic concentrations (greater than or equal to 150 mM) induced the production of small quantities of a distinct thiol species indistinguishable from plant phytochelatin-2. Yet, we argue that phytochelatins do not explain arsenic resistance in Aspergillus, and we advocate the role of As( GS) 3 complexes in arsenic detoxification.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Ecol & Physiol Plants, NL-1081 HV Amsterdam, Netherlands; CSIC, Ctr Astrobiol, Inst Nacl Tecn Aerospacial, Madrid 28850, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Vrije Universiteit Amsterdam; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Astrobiologia (INTA)	de Lorenzo, V (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Camous Cantablanco, E-28049 Madrid, Spain.	vdlorenzo@cnb.uam.es	Schat, Henk/AAB-8723-2019; Cánovas, David/L-7628-2014	Cánovas, David/0000-0002-7293-7332; de Lorenzo, Victor/0000-0002-6041-2731				Amaral Zettler Linda A., 2002, Nature (London), V417, P137, DOI 10.1038/417137a; Bleeker PM, 2003, NEW PHYTOL, V157, P33, DOI 10.1046/j.1469-8137.2003.00542.x; Canovas D, 2003, ENVIRON MICROBIOL, V5, P1242, DOI 10.1046/j.1462-2920.2003.00463.x; Canovas D, 2003, ENVIRON MICROBIOL, V5, P133, DOI 10.1046/j.1462-2920.2003.00386.x; Canovas D, 2003, ENVIRON MICROBIOL, V5, P1087, DOI 10.1046/j.1462-2920.2003.00508.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M; Cobbett CS, 2000, PLANT PHYSIOL, V123, P825, DOI 10.1104/pp.123.3.825; COLE SPC, 1994, CANCER RES, V54, P5902; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; de Souza CC, 1998, CURR GENET, V33, P60, DOI 10.1007/s002940050309; Dhankher OP, 2002, NAT BIOTECHNOL, V20, P1140, DOI 10.1038/nbt747; Fraser JA, 2002, APPL ENVIRON MICROB, V68, P2802, DOI 10.1128/AEM.68.6.2802-2808.2002; Ghosh M, 1999, P NATL ACAD SCI USA, V96, P5001, DOI 10.1073/pnas.96.9.5001; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; Hartley-Whitaker J, 2001, PLANT PHYSIOL, V126, P299, DOI 10.1104/pp.126.1.299; Kaiser C., 1994, METHODS YEAST GENETI; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Lu YP, 1997, P NATL ACAD SCI USA, V94, P8243, DOI 10.1073/pnas.94.15.8243; MEHRA RK, 1988, P NATL ACAD SCI USA, V85, P8815, DOI 10.1073/pnas.85.23.8815; Miersch J, 2001, MYCOL RES, V105, P883, DOI 10.1017/S095375620100404X; Mingot JM, 1999, J BIOL CHEM, V274, P14545, DOI 10.1074/jbc.274.21.14545; Pickering IJ, 2000, PLANT PHYSIOL, V122, P1171, DOI 10.1104/pp.122.4.1171; Pompella A, 2003, BIOCHEM PHARMACOL, V66, P1499, DOI 10.1016/S0006-2952(03)00504-5; Rosen BP, 1999, TRENDS MICROBIOL, V7, P207, DOI 10.1016/S0966-842X(99)01494-8; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Schat H, 2002, J EXP BOT, V53, P2381, DOI 10.1093/jxb/erf107; Shimizu M, 1998, TOXICOL SCI, V45, P204, DOI 10.1093/toxsci/45.2.204; Sneller FEC, 2000, J AGR FOOD CHEM, V48, P4014, DOI 10.1021/jf9903105; TAMAKI S, 1992, REV ENVIRON CONTAM T, V124, P79; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110	35	65	68	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51234	51240		10.1074/jbc.M408622200	http://dx.doi.org/10.1074/jbc.M408622200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15364940	hybrid, Green Published			2022-12-25	WOS:000225355800071
J	Felczak, MM; Kaguni, JM				Felczak, MM; Kaguni, JM			The Box VII motif of Escherichia coli DnaA protein is required for DnaA oligomerization at the E-coli replication origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL ORIGIN; GEL-ELECTROPHORESIS; BINDING DOMAIN; ATP BINDING; INITIATION; COMPLEX; HELICASE; GENE; SITES; RECOGNITION	Escherichia coli DnaA protein initiates DNA replication from the chromosomal origin, oriC, and regulates the frequency of this process. Structure-function studies indicate that the replication initiator comprises four domains. Based on the structural similarity of Aquifex aeolicus DnaA to other AAA(+) proteins that are oligomeric, it was proposed that Domain III functions in oligomerization at oriC (Erzberger, J. P., Pirruccello, M. M., and Berger, J. M. ( 2002) EMBO J. 21, 4763 - 4773). Because the Box VII motif within Domain III is conserved among DnaA homologues and may function in oligomerization, we substituted conserved Box VII amino acids of E. coli DnaA with alanine by site-directed mutagenesis to examine the role of this motif. All mutant proteins are inactive in initiation from oriC in vivo and in vitro, but they support RK2 plasmid DNA replication in vivo. Thus, RK2 requires only a subset of DnaA functions for plasmid DNA replication. Biochemical studies on a mutant DnaA carrying an alanine substitution at arginine 281 (R281A) in Box VII show that it is inactive in in vitro replication of an oriC plasmid, but this defect is not from the failure to bind to ATP, DnaB in the DnaB-DnaC complex, or oriC. Because the mutant DnaA is also active in the strand opening of oriC, whereas DnaB fails to bind to this unwound region, the open structure is insufficient by itself to load DnaB helicase. Our results show that the mutant fails to form a stable oligomeric DnaA-oriC complex, which is required for the loading of DnaB.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	kaguni@msu.edu		Kaguni, Jon/0000-0002-3096-4447	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033992] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM033992, GM33992] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Bell SP, 2002, GENE DEV, V16, P659, DOI 10.1101/gad.969602; Blaesing F, 2000, MOL MICROBIOL, V36, P557, DOI 10.1046/j.1365-2958.2000.01881.x; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; Carr KM, 1996, MOL MICROBIOL, V20, P1307, DOI 10.1111/j.1365-2958.1996.tb02649.x; Carr KM, 2002, J BIOL CHEM, V277, P39815, DOI 10.1074/jbc.M205031200; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; Erzberger JP, 2002, EMBO J, V21, P4763, DOI 10.1093/emboj/cdf496; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FRIED MG, 1994, NUCLEIC ACIDS RES, V22, P5054, DOI 10.1093/nar/22.23.5054; Fujikawa N, 2003, NUCLEIC ACIDS RES, V31, P2077, DOI 10.1093/nar/gkg309; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; HWANG DS, 1988, J BIOL CHEM, V263, P10633; Jakimowicz D, 1998, MICROBIOL-SGM, V144, P1281, DOI 10.1099/00221287-144-5-1281; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kornberg A., 1992, DNA REPLICATION; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Margulies C, 1996, J BIOL CHEM, V271, P17035, DOI 10.1074/jbc.271.29.17035; MARGULIES CA, 1997, INFLUENCE IHF FIS OR; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MASAI H, 1990, J BIOL CHEM, V265, P15134; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Neuwald AF, 1999, GENOME RES, V9, P27; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; Seitz H, 2000, MOL MICROBIOL, V37, P1270, DOI 10.1046/j.1365-2958.2000.02096.x; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; Simmons LA, 2003, MOL MICROBIOL, V49, P849, DOI 10.1046/j.1365-2958.2003.03603.x; Simmons LA, 2003, MOL MICROBIOL, V47, P755, DOI 10.1046/j.1365-2958.2003.03333.x; Sutton MD, 1997, J MOL BIOL, V271, P693, DOI 10.1006/jmbi.1997.1209; Sutton MD, 1997, J MOL BIOL, V274, P546, DOI 10.1006/jmbi.1997.1425; Sutton MD, 1997, J BIOL CHEM, V272, P23017, DOI 10.1074/jbc.272.37.23017; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Vossen KM, 1997, ANAL BIOCHEM, V245, P85, DOI 10.1006/abio.1996.9944; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025	50	57	57	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51156	51162		10.1074/jbc.M409695200	http://dx.doi.org/10.1074/jbc.M409695200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371441	hybrid			2022-12-25	WOS:000225355800062
J	Suk, JY; Jensen, S; McGettrick, A; Willis, AC; Whiteman, P; Redfield, C; Handford, PA				Suk, JY; Jensen, S; McGettrick, A; Willis, AC; Whiteman, P; Redfield, C; Handford, PA			Structural consequences of cysteine substitutions C1977Y and C1977R in calcium-binding epidermal growth factor-like domain 30 of human fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-S; EGF-LIKE DOMAINS; HUMAN FACTOR-IX; MARFAN-SYNDROME; MOLECULAR-GENETICS; FBN1 MUTATIONS; FACTOR MODULES; IN-VITRO; PAIR; AFFINITY	The largest group of disease-causing mutations affecting calcium-binding epidermal growth factor-like (cbEGF) domain function in a wide variety of extracellular and transmembrane proteins is that which results in cysteine substitutions. Although known to introduce proteolytic susceptibility, the detailed structural consequences of cysteine substitutions in cbEGF domains are unknown. Here, we studied pathogenic mutations C1977Y and C1977R, which affect cbEGF30 of human fibrillin-1, in a recombinant three cbEGF domain fragment (cbEGF29- 31). Limited proteolysis, H-1 NMR, and calcium chelation studies have been used to probe the effect of each substitution on cbEGF30 and its flanking domains. Analysis of the wild-type fragment identified two high affinity and one low affinity calcium-binding sites. Each substitution caused the loss of high affinity calcium binding to cbEGF30, consistent with intradomain misfolding, but the calcium binding properties of cbEGF29 and cbEGF31 were surprisingly unaffected. Further analysis of mutant fragments showed that domain packing of cbEGF29 - 30, but not cbEGF30 - 31, was disrupted. These data demonstrate that C1977Y and C1977R have localized structural effects, confined to the N-terminal end of the mutant domain, which disrupt domain packing. Cysteine substitutions affecting other cbEGF disulfide bonds are likely to have different effects. This proposed structural heterogeneity may underlie the observed differences in stability and cellular trafficking of proteins containing such changes.	Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3TA, England; Univ Oxford, Oxford Ctr Mol Sci, Chem Res Lab, Oxford OX1 3TA, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford	Handford, PA (corresponding author), Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England.	penny@bioch.ox.ac.uk	Jensen, Sacha A./AAB-4034-2019	Jensen, Sacha A./0000-0002-0560-9531; Redfield, Christina/0000-0001-7297-7708				AOYAMA T, 1995, AM J MED GENET, V58, P169, DOI 10.1002/ajmg.1320580216; AOYAMA T, 1993, HUM MOL GENET, V2, P2135, DOI 10.1093/hmg/2.12.2135; AOYAMA T, 1994, J CLIN INVEST, V94, P130, DOI 10.1172/JCI117298; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Booms P, 2000, HUM GENET, V107, P216, DOI 10.1007/s004390000368; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; FENG YQ, 1991, BIOPHYS J, V59, P323, DOI 10.1016/S0006-3495(91)82226-3; Giannelli F, 1997, NUCLEIC ACIDS RES, V25, P133, DOI 10.1093/nar/25.1.133; Halliday D, 1999, HUM GENET, V105, P587, DOI 10.1007/s004390051150; Halliday DJ, 2002, J MED GENET, V39, P589, DOI 10.1136/jmg.39.8.589; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Joutel A, 2000, J CLIN INVEST, V105, P597, DOI 10.1172/JCI8047; Kettle S, 1999, J MOL BIOL, V285, P1277, DOI 10.1006/jmbi.1998.2368; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; Malby S, 2001, BIOCHEMISTRY-US, V40, P2555, DOI 10.1021/bi002322l; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Rand MD, 1997, PROTEIN SCI, V6, P2059; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Robinson PN, 2000, J MED GENET, V37, P9, DOI 10.1136/jmg.37.1.9; Schrijver I, 1999, AM J HUM GENET, V65, P1007, DOI 10.1086/302582; Smallridge RS, 2003, J BIOL CHEM, V278, P12199, DOI 10.1074/jbc.M208266200; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; Stenberg Y, 1999, J MOL BIOL, V293, P653, DOI 10.1006/jmbi.1999.3139; Stenberg Y, 1997, EUR J BIOCHEM, V248, P163, DOI 10.1111/j.1432-1033.1997.t01-1-00163.x; Vollbrandt T, 2004, J BIOL CHEM, V279, P32924, DOI 10.1074/jbc.M405239200; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Whiteman P, 1998, PROTEIN ENG, V11, P957, DOI 10.1093/protein/11.11.957; Whiteman P, 2001, J BIOL CHEM, V276, P17156, DOI 10.1074/jbc.M006547200; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807	39	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51258	51265		10.1074/jbc.M408156200	http://dx.doi.org/10.1074/jbc.M408156200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371449	hybrid			2022-12-25	WOS:000225355800074
J	Mukai, T; Kawai, S; Mori, S; Mikami, B; Murata, K				Mukai, T; Kawai, S; Mori, S; Mikami, B; Murata, K			Crystal structure of bacterial inorganic polyphosphate/ATP-glucomannokinase - Insights into kinase evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BRAIN HEXOKINASE; ADP-DEPENDENT GLUCOKINASE; SP STRAIN KM; YEAST HEXOKINASE; CONFORMATIONAL-CHANGE; ALLOSTERIC REGULATION; MEMBRANE ASSOCIATION; PROTEIN STRUCTURES; DIFFRACTION DATA; SUGAR KINASES	Inorganic polyphosphate ( poly( P)) is a biological high energy compound presumed to be an ancient energy carrier preceding ATP. Several poly(P)-dependent kinases that use poly( P) as a phosphoryl donor are known to function in bacteria, but crystal structures of these kinases have not been solved. Here we present the crystal structure of bacterial poly( P)/ATP-glucomannokinase, belonging to Gram-positive bacterial glucokinase, complexed with 1 glucose molecule and 2 phosphate molecules at 1.8 Angstrom resolution, being the first among poly(P)-dependent kinases and bacterial glucokinases. The poly( P)/ATP-glucomannokinase structure enabled us to understand the structural relationship of bacterial glucokinase to eucaryotic hexokinase and ADP-glucokinase, which has remained a matter of debate. These comparisons also enabled us to propose putative binding sites for phosphoryl groups for ATP and especially for poly( P) and to obtain insights into the evolution of kinase, particularly from primordial poly(P)-specific to ubiquitous ATP-specific proteins.	Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Div Food & Biol Sci, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Div Agron & Hort Sci, Lab Food Qual Design & Dev, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Murata, K (corresponding author), Kyoto Univ, Grad Sch Agr, Dept Basic & Appl Mol Biotechnol, Div Food & Biol Sci, Kyoto 6110011, Japan.	kmurata@kais.kyoto-u.ac.jp						Aleshin AE, 1998, FEBS LETT, V434, P42, DOI 10.1016/S0014-5793(98)00952-1; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ANDERSON CM, 1978, J MOL BIOL, V123, P15, DOI 10.1016/0022-2836(78)90374-1; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BORK P, 1993, PROTEIN SCI, V2, P31; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR VERSION 3 851; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Cesar MD, 1998, ARCH BIOCHEM BIOPHYS, V350, P109; Cheek S, 2002, J MOL BIOL, V320, P855, DOI 10.1016/S0022-2836(02)00538-7; Fang TY, 1998, J BIOL CHEM, V273, P19548, DOI 10.1074/jbc.273.31.19548; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Ito S, 2003, J MOL BIOL, V331, P871, DOI 10.1016/S0022-2836(03)00792-7; Ito S, 2001, STRUCTURE, V9, P205, DOI 10.1016/S0969-2126(01)00577-9; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kawai S, 2000, BIOCHEM BIOPH RES CO, V276, P57, DOI 10.1006/bbrc.2000.3433; Kornberg A, 1999, Prog Mol Subcell Biol, V23, P1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuser PR, 2000, J BIOL CHEM, V275, P20814, DOI 10.1074/jbc.M910412199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mukai T, 2003, ACTA CRYSTALLOGR D, V59, P1662, DOI 10.1107/S0907444903015464; Mukai T, 2003, APPL ENVIRON MICROB, V69, P3849, DOI 10.1128/AEM.69.7.3849-3857.2003; Mulichak AM, 1998, NAT STRUCT BIOL, V5, P555, DOI 10.1038/811; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Phillips N F, 1999, Prog Mol Subcell Biol, V23, P101; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rosano C, 1999, STRUCT FOLD DES, V7, P1427, DOI 10.1016/S0969-2126(00)80032-5; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; STEITZ TA, 1976, J MOL BIOL, V104, P197, DOI 10.1016/0022-2836(76)90009-7; Tanaka S, 2003, J BACTERIOL, V185, P5654, DOI 10.1128/JB.185.18.5654-5656.2003; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuge H, 2002, PROTEIN SCI, V11, P2456, DOI 10.1110/ps.0215602; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Wu G, 2001, GENE, V264, P265, DOI 10.1016/S0378-1119(01)00329-8; Zeng CB, 1998, J BIOL CHEM, V273, P700, DOI 10.1074/jbc.273.2.700	46	36	39	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50591	50600		10.1074/jbc.M408126200	http://dx.doi.org/10.1074/jbc.M408126200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377666	hybrid			2022-12-25	WOS:000225229500123
J	Gee, GV; Tsomaia, N; Mierke, DF; Atwood, WJ				Gee, GV; Tsomaia, N; Mierke, DF; Atwood, WJ			Modeling a sialic acid binding pocket in the external loops of JC virus VP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLOLIGOSACCHARIDE RECEPTORS; SWISS-MODEL; GLIAL-CELLS; POLYOMAVIRUS; INFECTION	JC virus (JCV) is a common human polyomavirus that infects over 70% of the population worldwide. JCV has a restricted cell tropism that is caused partly by the initial interaction between the virus and sialic acid-containing host cell receptors. To identify the molecular interactions between the virus and its cellular receptor, we used a combined approach of site-directed mutagenesis and homology-based molecular modeling. A model of the major viral capsid protein VP1 based on sequence alignment with other closely related polyomaviruses allowed us to target specific amino acids in the extracellular loops of VP1 for mutagenesis. An analysis of the growth rates of 17 point mutants led to the identification of VP1 amino acids that are critical in virus-host cell receptor interactions. Molecular dynamics simulations were then used to build and confirm a model of the interaction between VP1 and the sialic acid component of the JCV receptor.	Brown Univ, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Brown Univ, Grad Program Mol & Cell Biol & Biochem, Providence, RI 02912 USA; Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Brown University; Brown University; Brown University	Atwood, WJ (corresponding author), Brown Univ, Dept Mol Microbiol & Immunol, Box G-B616,171 Meeting St, Providence, RI 02912 USA.	Walter_Atwood@Brown.edu		Gee, Gretchen/0000-0003-0403-3240	NCI NIH HHS [R01 CA71878] Funding Source: Medline; NINDS NIH HHS [R01 NS43097] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043097] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ATWOOD WJ, 1989, J VIROL, V63, P4474, DOI 10.1128/JVI.63.10.4474-4477.1989; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; CAHAN LD, 1983, VIROLOGY, V130, P281, DOI 10.1016/0042-6822(83)90083-1; FREUND R, 1991, J VIROL, V65, P350, DOI 10.1128/JVI.65.1.350-355.1991; FRIED H, 1981, VIROLOGY, V109, P188, DOI 10.1016/0042-6822(81)90485-2; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hou J, 2000, J NEUROVIROL, V6, pS98; Komagome R, 2002, J VIROL, V76, P12992, DOI 10.1128/JVI.76.24.12992-13000.2002; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; Liu CK, 1998, J VIROL, V72, P4643, DOI 10.1128/JVI.72.6.4643-4649.1998; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; Monaco MCG, 1996, J VIROL, V70, P7004, DOI 10.1128/JVI.70.10.7004-7012.1996; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Stehle T, 1997, EMBO J, V16, P5139, DOI 10.1093/emboj/16.16.5139; STEHLE T, 1994, NATURE, V369, P160, DOI 10.1038/369160a0; VACANTE DA, 1989, VIROLOGY, V170, P353, DOI 10.1016/0042-6822(89)90425-X	17	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49172	49176		10.1074/jbc.M409326200	http://dx.doi.org/10.1074/jbc.M409326200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347668	hybrid			2022-12-25	WOS:000225098100082
J	Potthast, R; Abbey-Hosch, SE; Antos, LK; Marchant, JS; Kuhn, M; Potter, LR				Potthast, R; Abbey-Hosch, SE; Antos, LK; Marchant, JS; Kuhn, M; Potter, LR			Calcium-dependent dephosphorylation mediates the hyperosmotic and lysophosphatidic acid-dependent inhibition of natriuretic peptide receptor-B/guanylyl cyclase-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CGMP ACCUMULATION; DESENSITIZATION; ACTIVATION; MECHANISM; CELLS; PATHWAY; FAMILY	C-type natriuretic peptide binding to natriuretic peptide receptor-B (NPR-B) stimulates cGMP synthesis, which regulates vasorelaxation, cell proliferation, and bone growth. Here, we investigated the mechanistic basis for hyperosmotic and lysophosphatidic acid-dependent inhibition of NPR-B. Whole cell cGMP measurements and guanylyl cyclase assays indicated that acute hyperosmolarity decreased NPR-B activity in a reversible, concentration- and time-dependent manner, whereas chronic exposure had no effect. Acute hyperosmolarity elevated intracellular calcium in a concentration-dependent fashion that paralleled NPR-B desensitization. A calcium chelator, but not a protein kinase C inhibitor, blocked both calcium elevations and desensitization. Hyperosmotic medium stimulated NPR-B dephosphorylation, and the receptor was rapidly rephosphorylated and resensitized when the hypertonic media was removed. Lysophosphatidic acid also inhibited NPR-B in a calcium- and phosphorylation-dependent process, consistent with calcium being a universal regulator of NPR-B. The absolute requirement of dephosphorylation in this process was demonstrated by showing that a receptor with glutamates substituted at all known NPR-B phosphorylation sites is unresponsive to hyperosmotic stimuli. This is the first study to measure the phosphorylation state of an endogenous guanylyl cyclase and to link intracellular calcium elevations with its dephosphorylation.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ Klinikum Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Munster	Potter, LR (corresponding author), 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	potter@umn.edu	MARCHANT, Jonathan/B-8051-2009; Marchant, Jonathan/Q-5484-2019	MARCHANT, Jonathan/0000-0001-6592-0877; Marchant, Jonathan/0000-0001-6592-0877	NHLBI NIH HHS [R01 HL066397, R01HL66397] Funding Source: Medline; NIAMS NIH HHS [AR07612] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbey SE, 2003, ENDOCRINOLOGY, V144, P240, DOI 10.1210/en.2002-220702; Abbey SE, 2002, J BIOL CHEM, V277, P42423, DOI 10.1074/jbc.M206686200; Abbey-Hosch SE, 2004, HYPERTENSION, V43, P1103, DOI 10.1161/01.HYP.0000124668.80811.d3; Chrisman TD, 1999, J BIOL CHEM, V274, P4293, DOI 10.1074/jbc.274.7.4293; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; CLAVELL AL, 1993, AM J PHYSIOL, V264, P290; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; IIMURA O, 1995, PFLUG ARCH EUR J PHY, V430, P81, DOI 10.1007/BF00373842; Joubert S, 2001, BIOCHEMISTRY-US, V40, P11096, DOI 10.1021/bi010580s; KATAFUCHI T, 1992, J BIOL CHEM, V267, P7624; Kuhn M, 2003, CIRC RES, V93, P700, DOI 10.1161/01.RES.0000094745.28948.4D; Levin ER, 1998, NEW ENGL J MED, V339, P321; NAMBI P, 1986, P NATL ACAD SCI USA, V83, P8492, DOI 10.1073/pnas.83.22.8492; Potter LR, 2000, J BIOL CHEM, V275, P31099, DOI 10.1074/jbc.M005506200; POTTER LR, 1992, J BIOL CHEM, V267, P14531; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Schulz S, 1999, VITAM HORM, V57, P123; SECHI LA, 1995, J CLIN INVEST, V95, P2451, DOI 10.1172/JCI117945; SMITS P, 1993, DIABETES, V42, P1454, DOI 10.2337/diabetes.42.10.1454; SUDOH T, 1990, BIOCHEM BIOPH RES CO, V168, P863, DOI 10.1016/0006-291X(90)92401-K; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; TSUTAMOTO T, 1993, CIRCULATION, V87, P70, DOI 10.1161/01.CIR.87.1.70; Yamahara K, 2003, P NATL ACAD SCI USA, V100, P3404, DOI 10.1073/pnas.0538059100; Yasoda A, 1998, J BIOL CHEM, V273, P11695, DOI 10.1074/jbc.273.19.11695	27	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48513	48519		10.1074/jbc.M408247200	http://dx.doi.org/10.1074/jbc.M408247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371450	hybrid			2022-12-25	WOS:000225098100006
J	Hines, ER; Kolek, OI; Jones, MD; Serey, SH; Sirjani, NB; Kiela, PR; Jurutka, PW; Haussler, MR; Collins, JF; Ghishan, FK				Hines, ER; Kolek, OI; Jones, MD; Serey, SH; Sirjani, NB; Kiela, PR; Jurutka, PW; Haussler, MR; Collins, JF; Ghishan, FK			1,25-dihydroxyvitamin D-3 down-regulation of PHEX gene expression is mediated by apparent repression of a 110 kDa transfactor that binds to a polyadenine element in the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D-RECEPTOR; D-3-MEDIATED TRANSCRIPTIONAL REPRESSION; MESSENGER-RNA EXPRESSION; D-RESPONSIVE ELEMENT; DNA-BINDING; PARATHYROID-HORMONE; NEGATIVE REGULATION; OSTEOBLASTIC CELLS; ARID PROTEINS; RAT BONE	The PHEX gene encodes an endopeptidase expressed in osteoblasts that inactivates an uncharacterized peptide hormone, phosphatonin, which suppresses bone mineralization as well as renal phosphate reabsorption and vitamin D bioactivation. We demonstrate that 1alpha-25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), the active renal vitamin D metabolite, decreases PHEX mRNA in the rat osteoblastic cell line, UMR-106, as well as in mouse calvaria. Promoter/reporter construct analysis of the murine PHEX gene in transfected UMR-106 cells localized the repressive effect of 1,25(OH)(2)D-3 to the -133 to -74 bp region, and gel mobility shift experiments revealed that 1,25(OH)(2)D-3 treatment of the cells diminished the binding of a nuclear protein(s) to a stretch of 17 adenines from bp -116 to -100 in the proximal PHEX promoter. Either overexpression of a dominant-negative vitamin D receptor (VDR) or deletion of this sequence of 17 A-T base pairs abolished the repressive effect of 1,25(OH)(2)D-3 by attenuating basal promoter activity, indicating that this region mediates the 1,25(OH)(2)D-3 response and is involved in basal transcription. Southwestern blot analysis and DNA affinity purification show that an unidentified 110 kDa nuclear protein binds to the poly(A) element. Because 1,25(OH)(2)D-3-liganded VDR neither binds to the polyadenine region of the PHEX promoter nor directly influences the association of the 110 kDa transfactor, we conclude that 1,25(OH)(2)D-3 indirectly decreases PHEX expression via VDR-mediated repression (or modification) of this novel transactivator. Thus, we have identified a cis-element required for PHEX gene transcription that participates in negative feedback control of PHEX expression and thereby modulates the actions of phosphatonin.	Univ Arizona, Hlth Sci Ctr, Dept Pediat, Steele Mem Childrens Res Ctr,Coll Med, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Dept Orthoped Surg, Steele Mem Childrens Res Ctr,Coll Med, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Dept Biochem & Mol Biophys, Steele Mem Childrens Res Ctr,Coll Med, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Ghishan, FK (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Pediat, Steele Mem Childrens Res Ctr,Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	fghishan@peds.arizona.edu	Kiela, Pawel/AAF-5320-2020	Jurutka, Peter/0000-0002-4950-9161; Haussler, Mark/0000-0002-7097-1801; Kiela, Pawel/0000-0002-0014-3517	NIDDK NIH HHS [R01-DK33209, R01-DK33351] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033351, R01DK033209] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai XY, 2002, MOL ENDOCRINOL, V16, P2913, DOI 10.1210/me.2002-0113; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Brewer AJ, 2004, AM J PHYSIOL-RENAL, V286, pF739, DOI 10.1152/ajprenal.00321.2003; Cippitelli M, 2002, J IMMUNOL, V168, P1154, DOI 10.4049/jimmunol.168.3.1154; Drezner MK, 2000, KIDNEY INT, V57, P9, DOI 10.1046/j.1523-1755.2000.00807.x; Drissi H, 2002, EXP CELL RES, V274, P323, DOI 10.1006/excr.2002.5474; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ecarot B, 1999, ENDOCRINOLOGY, V140, P1192, DOI 10.1210/en.140.3.1192; Ezura Y, 1997, J BIOL CHEM, V272, P29865, DOI 10.1074/jbc.272.47.29865; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Hale LV, 2000, CALCIFIED TISSUE INT, V67, P80, DOI 10.1007/s00223001101; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; Hines ER, 2000, BBA-GENE STRUCT EXPR, V1493, P333, DOI 10.1016/S0167-4781(00)00188-3; Hines ER, 2002, AM J PHYSIOL-RENAL, V283, pF356, DOI 10.1152/ajprenal.00357.2001; HSIEH JC, 1995, J STEROID BIOCHEM, V53, P583, DOI 10.1016/0960-0760(95)00112-D; Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Kinuta K, 2000, J BONE MINER RES, V15, pS180; Kitazawa R, 2002, BIOCHEM BIOPH RES CO, V290, P650, DOI 10.1006/bbrc.2001.6251; Kortschak RD, 2000, TRENDS BIOCHEM SCI, V25, P294, DOI 10.1016/S0968-0004(00)01597-8; LI Q, 1994, J BIOL CHEM, V269, P4934; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Liu SG, 2002, J BIOL CHEM, V277, P3686, DOI 10.1074/jbc.M107707200; Liu SG, 2001, ENDOCRINOLOGY, V142, P3987, DOI 10.1210/en.142.9.3987; Matsue M, 1997, BONE, V20, P329, DOI 10.1016/S8756-3282(97)00005-7; Murayama A, 1999, ENDOCRINOLOGY, V140, P2224, DOI 10.1210/en.140.5.2224; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OKAZAKI T, 1988, J BIOL CHEM, V263, P2203; PAVLIN D, 1994, J CELL BIOCHEM, V56, P490, DOI 10.1002/jcb.240560409; RASMUSSEN H, 1989, METABOLIC BASIS INHE; Siggelkow H, 2002, J CELL BIOCHEM, V85, P279, DOI 10.1002/jcb.10122; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; Tenenhouse HS, 1999, NEPHROL DIAL TRANSPL, V14, P333, DOI 10.1093/ndt/14.2.333; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; Thompson PD, 1999, J CELL BIOCHEM, V75, P462, DOI 10.1002/(SICI)1097-4644(19991201)75:3<462::AID-JCB11>3.0.CO;2-D; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Vargas MA, 2003, ENDOCRINOLOGY, V144, P4876, DOI 10.1210/en.2003-0253; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Xu H, 2002, AM J PHYSIOL-CELL PH, V282, pC487, DOI 10.1152/ajpcell.00412.2001; YAMAMOTO T, 1992, BONE, V13, P209, DOI 10.1016/8756-3282(92)90199-7; Zoidis E, 2000, MOL CELL ENDOCRINOL, V168, P41, DOI 10.1016/S0303-7207(00)00310-5; Zoidis E, 2002, EUR J ENDOCRINOL, V146, P97, DOI 10.1530/eje.0.1460097	46	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46406	46414		10.1074/jbc.M404278200	http://dx.doi.org/10.1074/jbc.M404278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337762	hybrid			2022-12-25	WOS:000224832400010
J	Lim, ACB; Hou, ZB; Goh, CP; Qi, RZ				Lim, ACB; Hou, ZB; Goh, CP; Qi, RZ			Protein kinase CK2 is an inhibitor of the neuronal Cdk5 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; POLYACRYLAMIDE-GELS; P35/CDK5 KINASE; CELL-DIVISION; BOVINE BRAIN; BETA-SUBUNIT; P35; PHOSPHORYLATION; NEUROFILAMENT	The complex of Cdk5 and its neuronal activator p35 is a proline-directed Ser/Thr kinase that plays an important role in various neuronal functions. Deregulation of the Cdk5 enzymatic activity was found to associate with a number of neurodegenerative diseases. To search for regulatory factors of Cdk5-p35 in the brain, we developed biochemical affinity isolation using a recombinant protein comprising the N-terminal 149 amino acids of p35. The catalytic alpha-subunit of protein kinase CK2 ( formerly known as casein kinase 2) was identified by mass spectrometry from the isolation. The association of CK2 with p35 and Cdk5 was demonstrated, and the CK2-binding sites were delineated in p35. Furthermore, CK2 displayed strong inhibition toward the Cdk5 activation by p35. The Cdk5 inhibition is dissociated from the kinase function of CK2 because the kinase-dead mutant of CK2 displayed the similar Cdk5 inhibitory activity as the wild-type enzyme. Further characterization showed that CK2 blocks the complex formation of Cdk5 and p35. Together, these findings suggest that CK2 acts as an inhibitor of Cdk5 in the brain.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Hong Kong University of Science & Technology	Qi, RZ (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	qirz@ust.hk		Qi, Robert Zhong/0000-0001-5596-8172				Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; Ching YP, 2002, J BIOL CHEM, V277, P15237, DOI 10.1074/jbc.C200032200; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Ko J, 2001, J NEUROSCI, V21, P6758; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim ACB, 2004, J BIOL CHEM, V279, P4433, DOI 10.1074/jbc.M310563200; Lim ACB, 2003, NEUROSIGNALS, V12, P230, DOI 10.1159/000074625; Lim ACB, 2003, J ALZHEIMERS DIS, V5, P329, DOI 10.3233/JAD-2003-5409; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Nguyen MD, 2001, NEURON, V30, P135, DOI 10.1016/S0896-6273(01)00268-9; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Patrick GN, 1998, J BIOL CHEM, V273, P24057, DOI 10.1074/jbc.273.37.24057; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pinna LA, 2002, J CELL SCI, V115, P3873, DOI 10.1242/jcs.00074; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Qu DB, 2002, J BIOL CHEM, V277, P7324, DOI 10.1074/jbc.M107270200; Rashid T, 2001, J BIOL CHEM, V276, P49043, DOI 10.1074/jbc.M105599200; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; Saito T, 2003, J NEUROSCI, V23, P1189, DOI 10.1523/JNEUROSCI.23-04-01189.2003; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Xie ZG, 2003, CELL, V114, P469, DOI 10.1016/S0092-8674(03)00605-6; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zukerberg LR, 2000, NEURON, V26, P633, DOI 10.1016/S0896-6273(00)81200-3	55	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46668	46673		10.1074/jbc.M404760200	http://dx.doi.org/10.1074/jbc.M404760200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342635	hybrid			2022-12-25	WOS:000224832400042
J	Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D				Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D			Mutant Ras-induced proliferation of human thyroid epithelial cells requires three effector pathways	ONCOGENE			English	Article						Ras; Ral; thyroid; epithelial; signalling; tumour	ADP-RIBOSYLATION FACTOR; ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-D; EXOCYST COMPLEX; TRANSFORMATION; GTPASE; SUFFICIENT; DIFFERENTIATION; STIMULATION; CONTRIBUTE	Ras mutations occur as an early event in many human tumours of epithelial origin, including thyroid. Using primary human thyroid epithelial cells to model tumour initiation by Ras, we have shown previously that activation of both the MAP kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) effector pathways are necessary, but even when activated together are not sufficient, for Ras-induced proliferation. Here, we show that a third effector, RalGEF, is also activated by Ras in these cells, that this activation is necessary for Ras-induced proliferation, and furthermore that in combination with the MAPK and PI3K effectors, it is able to reproduce the proliferative effect of activated Ras. The requirement for three effector pathways indicates a more robust control of cell proliferation in this normal human epithelial cell type than has been displayed in previous similar studies using rodent and human cell lines. Our findings highlight the importance of the appropriate cellular context in models of Ras-induced tumour development.	Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	52	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7839	7845		10.1038/sj.onc.1208085	http://dx.doi.org/10.1038/sj.onc.1208085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361839				2022-12-25	WOS:000224331600009
J	Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G				Iwakuma, T; Parant, JM; Fasulo, M; Zwart, E; Jacks, T; de Vries, A; Lozano, G			Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice	ONCOGENE			English	Article						p53; phosphorylation; mdm2; mdm4; embryogenesis	DNA-BINDING FUNCTION; PHOSPHORYLATION SITE; MDM2-DEFICIENT MICE; P53-BINDING PROTEIN; CRYSTAL-STRUCTURE; MDM4-NULL MICE; GROWTH ARREST; MURINE P53; CELL-DEATH; ACTIVATION	Mdm2 and its homolog Mdm4 inhibit the function of the tumor suppressor p53. Targeted disruption of either mdm2 or mdm4 genes in mice results in embryonic lethality that is completely rescued by concomitant deletion of p53, suggesting that deletion of negative regulators of p53 results in a constitutively active p53. Thus, these mouse models offer a unique in vivo system to assay the functional significance of different p53 modi. cations. Phosphorylation of serine 389 in murine p53 occurs specifically after ultraviolet-light-induced DNA damage, and phosphorylation of this site enhances p53 activity both in vitro and in vivo. Recently, mice with a serine to alanine substitution at serine 389 (p53(S389A)) in the endogenous p53 locus were generated. To examine the in vivo significance of serine 389 phosphorylation during embryogenesis, we crossed these mutant mice to mice lacking mdm2 or mdm4. The p53S389A allele did not alter the embryonic lethality of mdm2 or mdm4. Additional crosses to assay the effect of one p53S389A allele with a p53 null allele also did not rescue the lethal phenotypes. In conclusion, the phenotypes due to loss of mdm2 or mdm4 were not even partially rescued by p53S389A, suggesting that p53S389A is functionally wild type during embryogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA; Natl Inst Publ Hlth & Environm, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	University of Texas System; UTMD Anderson Cancer Center; Netherlands National Institute for Public Health & the Environment; Massachusetts Institute of Technology (MIT)	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Sect Canc Genet, Houston, TX 77030 USA.	gglozano@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; BRUINS W, 2004, IN PRESS MOL CELL BI; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Finch RA, 2002, CANCER RES, V62, P3221; FISCELLA M, 1994, ONCOGENE, V9, P3249; Furihata M, 2002, J PATHOL, V197, P82, DOI 10.1002/path.1082; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; HARVEY M, 1993, ONCOGENE, V8, P2457; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; Itahana K, 2002, J BIOL CHEM, V277, P18206, DOI 10.1074/jbc.M201028200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; LUNA RMD, 1995, NATURE, V378, P203; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Miller M, 1996, FEBS LETT, V399, P166, DOI 10.1016/S0014-5793(96)01231-8; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; ROLLEY N, 1994, ONCOGENE, V9, P3067; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sluss HK, 2004, MOL CELL BIOL, V24, P976, DOI 10.1128/MCB.24.3.976-984.2004; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	54	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7644	7650		10.1038/sj.onc.1207793	http://dx.doi.org/10.1038/sj.onc.1207793			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361844				2022-12-25	WOS:000224306700005
J	Zhang, YL; Joiner, WJ; Bhattacharjee, A; Rassendren, F; Magoski, NS; Kaczmarek, LK				Zhang, YL; Joiner, WJ; Bhattacharjee, A; Rassendren, F; Magoski, NS; Kaczmarek, LK			The appearance of a protein kinase A-regulated splice isoform of slo is associated with the maturation of neurons that control reproductive behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED POTASSIUM CHANNELS; BAG CELL NEURONS; CA2+-ACTIVATED K+ CHANNEL; RAT CORTICAL-NEURONS; LARGE-CONDUCTANCE; CA CHANNELS; PEPTIDERGIC NEURONS; CATION CHANNEL; BK CHANNEL; CALCIUM	In response to brief synaptic stimulation that activates protein kinase A (PKA), the bag cell neurons of Aplysia trigger the onset of reproductive behaviors by generating a prolonged afterdischarge. In juvenile animals, such afterdischarges are inhibited by a high density of Ca2+-activated K+ (BK) channels, encoded by the slo gene. An increase in this current also follows an afterdischarge in mature animals, contributing to a subsequent refractory state that limits reproductive behaviors. Using a bag cell cDNA library, we have isolated two alternative transcripts of the slo gene, differing in the presence (slo-a) or absence (slo-b) of a consensus phosphorylation site for PKA. Expression of either isoform in Chinese hamster ovary cells produced Ca2+- and voltage-dependent channels with macroscopic and unitary properties matching those in bag cell neurons. The isoforms differed, however, in their response to application of the catalytic subunit of PKA, which reduced the open probability of Slo-a, an effect that was reversed by a PKA inhibitor. In contrast, PKA had no effect on Slo-b. By immunocytochemistry, we determined that the PKA-regulated Slo-a subunit is present in adult, but not juvenile, bag cell neurons. Patch clamp recordings from adult and juvenile bag cell neurons confirmed that PKA decreases BK channel activity only in adults. Our findings suggest that a change in the identity of Slo isoforms expressed during development allows mature neurons to generate afterdischarges that are required for reproduction.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Penn, Dept Neurosci, Philadelphia, PA USA; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier 5, France; Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada	Yale University; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Queens University - Canada	Kaczmarek, LK (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	leonard.kaczmarek@yale.edu	Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461				AZHDERIAN EM, 1994, NEURON, V12, P1223, DOI 10.1016/0896-6273(94)90439-1; BIELEFELDT K, 1994, J PHYSIOL-LONDON, V475, P241, DOI 10.1113/jphysiol.1994.sp020065; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brenner R, 1996, J NEUROSCI, V16, P1827; Brenner R, 1996, DEV BIOL, V177, P536, DOI 10.1006/dbio.1996.0183; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHUNG SK, 1991, SCIENCE, V253, P560, DOI 10.1126/science.1857986; CONN PJ, 1989, MOL NEUROBIOL, V3, P237, DOI 10.1007/BF02740607; EWALD DA, 1985, NATURE, V315, P503, DOI 10.1038/315503a0; GHO M, 1992, J EXP BIOL, V170, P93; GLASS DB, 1989, J BIOL CHEM, V264, P14579; Hall SK, 2000, J BIOL CHEM, V275, P3749, DOI 10.1074/jbc.275.6.3749; JENNINGS KR, 1982, J NEUROSCI, V2, P158; Jiang YX, 2001, NEURON, V29, P593, DOI 10.1016/S0896-6273(01)00236-7; Jones EMC, 1999, J PHYSIOL-LONDON, V518, P653, DOI 10.1111/j.1469-7793.1999.0653p.x; KACZMAREK LK, 1978, P NATL ACAD SCI USA, V75, P5200, DOI 10.1073/pnas.75.10.5200; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KACZMAREK LK, 1984, J NEUROPHYSIOL, V52, P340, DOI 10.1152/jn.1984.52.2.340; KACZMAREK LK, 1982, BRAIN RES, V238, P105, DOI 10.1016/0006-8993(82)90774-0; Kandel E. R., 1979, BEHAV BIOL APLYSIA C; KUPFERMANN I, 1970, J NEUROPHYSIOL, V33, P865, DOI 10.1152/jn.1970.33.6.865; LAGRUTTA A, 1994, J BIOL CHEM, V269, P20347; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LEE K, 1995, J PHYSIOL-LONDON, V488, P319, DOI 10.1113/jphysiol.1995.sp020969; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LOECHNER KJ, 1990, BRAIN RES, V532, P1, DOI 10.1016/0006-8993(90)91733-W; Magoski NS, 2000, J PHYSIOL-LONDON, V522, P271, DOI 10.1111/j.1469-7793.2000.t01-2-00271.x; Nara M, 2000, AM J PHYSIOL-CELL PH, V279, pC1938, DOI 10.1152/ajpcell.2000.279.6.C1938; Nick TA, 1996, J NEUROSCI, V16, P7583; Nick TA, 1996, J NEUROPHYSIOL, V76, P3351, DOI 10.1152/jn.1996.76.5.3351; PEREZ G, 1994, AM J PHYSIOL, V266, pC1459, DOI 10.1152/ajpcell.1994.266.5.C1459; Piskorowski R, 2002, NATURE, V420, P499, DOI 10.1038/nature01199; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; REINHART PH, 1991, J NEUROSCI, V11, P1627; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; Schopperle WM, 1998, NEURON, V20, P565, DOI 10.1016/S0896-6273(00)80995-2; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Shi JY, 2002, NATURE, V418, P876, DOI 10.1038/nature00941; Shipston MJ, 1996, J PHYSIOL-LONDON, V493, P665, DOI 10.1113/jphysiol.1996.sp021413; Shipston MJ, 1996, J BIOL CHEM, V271, P9197, DOI 10.1074/jbc.271.16.9197; Smith MA, 2000, NEUROSCIENCE, V95, P33; Tian LJ, 1998, J BIOL CHEM, V273, P13531, DOI 10.1074/jbc.273.22.13531; Tian LJ, 2001, J BIOL CHEM, V276, P7717, DOI 10.1074/jbc.C000741200; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Wallen K., 2002, HORMONES BRAIN BEHAV, P385, DOI DOI 10.1016/B978-012532104-4/50071-8; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; Xia XM, 1998, J NEUROSCI, V18, P2360; Xia XM, 2002, NATURE, V418, P880, DOI 10.1038/nature00956; Xia XM, 2000, J NEUROSCI, V20, P4890; Xie JY, 1998, SCIENCE, V280, P443, DOI 10.1126/science.280.5362.443; Zhang YL, 2002, J NEUROSCI, V22, P10134; Zhou XB, 2000, J PHYSIOL-LONDON, V524, P339, DOI 10.1111/j.1469-7793.2000.t01-1-00339.x; Zhou Y, 2003, NEUROPHARMACOLOGY, V45, P714, DOI 10.1016/S0028-3908(03)00285-5	55	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52324	52330		10.1074/jbc.M408543200	http://dx.doi.org/10.1074/jbc.M408543200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15375169	hybrid			2022-12-25	WOS:000225493400074
J	Chang, MC; Wu, HL; Lee, JJ; Lee, PH; Chang, HH; Hahn, LJ; Lin, BR; Chen, YJ; Jeng, JH				Chang, MC; Wu, HL; Lee, JJ; Lee, PH; Chang, HH; Hahn, LJ; Lin, BR; Chen, YJ; Jeng, JH			The induction of prostaglandin E-2 production, interleukin-6 production, cell cycle arrest, and cytotoxicity in primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETEL QUID; RISK-FACTORS; CYCLOOXYGENASE-2 EXPRESSION; HEPATOCELLULAR-CARCINOMA; EPITHELIAL-CELLS; C-FOS; INFLAMMATION; ARECOLINE; PATHWAY; KINASE	There are about 200 - 600 million betel quid (BQ) chewers in the world. BQ chewing is one of the major risk factor of hepatocarcinoma, oropharyngeal, and esophagus cancers in Taiwan, India, and Southeast Asian countries. Thus, the precise molecular mechanisms deserve investigation. We used cultured primary keratinocytes and KB cells, RT-PCR, flow cytometry, Western blotting, and ELISA to evaluate whether alterations in early gene expression is crucial in the carcinogenic processes of BQ. We observed the induction of c-Fos mRNA expression in human gingival keratinocyte (GK) and KB carcinoma cells by areca nut ( AN) extract and arecoline. A maximal increment in c-fos gene expression was shown at about 30 min after challenge. AN extract ( 100 - 800 mug/ml) and arecoline (0.1 - 0.8 mM) also stimulated ERK1/ ERK2 phosphorylation with a maximal stimulation at 5 - 10 min of exposure. Pretreatment by U0126 ( 30 muM), a MEK inhibitor, markedly inhibited the c-Fos, cyclooxygenase-2 (COX-2), and IL-6 mRNA expression of the KB epithelial cells. In addition, U0126 and PD98059 ( 50 muM) also decreased AN extract- and arecoline-associated PGE(2) and IL-6 production in GK and KB cells. However, U0126 by itself arrested the cells in G(0)/G(1) phase, but was not able to prevent AN- and arecoline-induced cell death or apoptosis. In contrast, U0126 enhanced the AN- induced apoptosis of KB cells. AN ingredients thus play a significant role in the pathogenesis of oropharyngeal cancer by activation of MEK1/ERK/c-Fos pathway, which promotes keratinocyte inflammation, cell survival, and affects cell cycle progression.	Natl Taiwan Univ Hosp, Coll Med, Sch Dent,Dept Dent, Lab Dent Pharmacol & Toxicol, Taipei, Taiwan; Chang Gung Inst Technol, Team Biomed Sci, Taoyuan, Taiwan; Natl Taiwan Univ Hosp, Hepatitis Res Ctr, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Diagnotherapeut, Taipei, Taiwan	National Taiwan University; National Taiwan University Hospital; Chang Gung University of Science & Technology; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Jeng, JH (corresponding author), Natl Taiwan Univ Hosp, Coll Med, Sch Dent,Dept Dent, Lab Dent Pharmacol & Toxicol, 1 Chang Te St, Taipei, Taiwan.	huei@ha.mc.ntu.edu.tw	Lee, Po-Hsuen/I-7061-2018	Jeng, Jiiang-Huei/0000-0002-2068-5380; CHEN, YI-JANE/0000-0002-9178-8379; LEE, JANG-JAER/0000-0003-0964-0840; LIN, BOR-RU/0000-0001-9545-7393				Brognard J, 2002, CELL DEATH DIFFER, V9, P893, DOI 10.1038/sj.cdd.4401054; Caraglia M, 2003, CELL DEATH DIFFER, V10, P218, DOI 10.1038/sj.cdd.4401131; Dannenberg AJ, 2001, ANN NY ACAD SCI, V952, P109, DOI 10.1111/j.1749-6632.2001.tb02731.x; Dooley S, 1996, ANN RHEUM DIS, V55, P298, DOI 10.1136/ard.55.5.298; FISHER C, 1991, DEVELOPMENT, V111, P253; Formanek M, 1998, J ORAL PATHOL MED, V27, P202; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Glinghammar B, 2001, GASTROENTEROLOGY, V120, P401, DOI 10.1053/gast.2001.21188; Guo YS, 2002, J BIOL CHEM, V277, P48755, DOI 10.1074/jbc.M209016200; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Ho PS, 2002, J ORAL PATHOL MED, V31, P213, DOI 10.1034/j.1600-0714.2002.310404.x; HONN KV, 1981, PROSTAG OTH LIPID M, V21, P833, DOI 10.1016/0090-6980(81)90240-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Huang X, 2003, TOXICOL APPL PHARM, V191, P40, DOI 10.1016/S0041-008X(03)00194-7; IARC, 1985, IARC MON EV CARC RIS, V37; Jeng JH, 1999, J ORAL PATHOL MED, V28, P64; Jeng JH, 2000, CARCINOGENESIS, V21, P1365, DOI 10.1093/carcin/21.7.1365; JENG JH, 1994, J DENT RES, V73, P1043, DOI 10.1177/00220345940730050501; Jeng JH, 2003, CARCINOGENESIS, V24, P1301, DOI 10.1093/carcin/bgg083; Jeng JH, 2004, CELL MOL LIFE SCI, V61, P83, DOI 10.1007/s00018-003-3272-8; Jeng JH, 2002, FREE RADICAL BIO MED, V32, P860, DOI 10.1016/S0891-5849(02)00749-9; Jeng JH, 2001, ORAL ONCOL, V37, P477, DOI 10.1016/S1368-8375(01)00003-3; Kaina B, 1997, CANCER RES, V57, P2721; KO YC, 1992, J ORAL PATHOL MED, V21, P261, DOI 10.1111/j.1600-0714.1992.tb01007.x; Leu CM, 2003, ONCOGENE, V22, P7809, DOI 10.1038/sj.onc.1207084; Lin JK, 2002, ARCH PHARM RES, V25, P561, DOI 10.1007/BF02976924; Mishima K, 2002, ORAL ONCOL, V38, P468, DOI 10.1016/S1368-8375(01)00104-X; Misra SP, 1998, POSTGRAD MED J, V74, P733, DOI 10.1136/pgmj.74.878.733; Ohshima H, 2003, ARCH BIOCHEM BIOPHYS, V417, P3, DOI 10.1016/S0003-9861(03)00283-2; Orlando Roy C, 2002, Rev Gastroenterol Disord, V2 Suppl 2, pS2; Oyama N, 1999, J INVEST DERMATOL, V113, P600, DOI 10.1046/j.1523-1747.1999.00734.x; PANIGRAHI GB, 1982, MUTAT RES, V103, P197, DOI 10.1016/0165-7992(82)90029-X; PARKIN DM, 1991, INT J CANCER, V48, P323, DOI 10.1002/ijc.2910480302; Peng JP, 2002, HUM PATHOL, V33, P100, DOI 10.1053/hupa.2002.30187; Phukan RK, 2001, BRIT J CANCER, V85, P661, DOI 10.1054/bjoc.2001.1920; Roberts RA, 1999, CARCINOGENESIS, V20, P1397, DOI 10.1093/carcin/20.8.1397; SANKARANARAYANAN R, 1991, INT J CANCER, V49, P485, DOI 10.1002/ijc.2910490402; SHIN H, 1995, CLIN IMMUNOL IMMUNOP, V76, P225, DOI 10.1006/clin.1995.1120; SHIRNAME LP, 1984, CARCINOGENESIS, V5, P501, DOI 10.1093/carcin/5.4.501; Souza RF, 2002, GASTROENTEROLOGY, V122, P299, DOI 10.1053/gast.2002.30993; SPITZ MR, 1994, SEMIN ONCOL, V21, P281; STICH HF, 1981, MUTAT RES, V90, P355, DOI 10.1016/0165-1218(81)90058-6; Sun CA, 2003, AM J EPIDEMIOL, V157, P674, DOI 10.1093/aje/kwg041; SUNDQVIST K, 1992, INT J CANCER, V52, P305, DOI 10.1002/ijc.2910520225; SUNDQVIST K, 1989, CANCER RES, V49, P5294; Tominaga S, 1999, CANCER LETT, V143, pS19, DOI 10.1016/S0304-3835(99)90005-8; Tsai JF, 2003, MEDICINE, V82, P365, DOI 10.1097/01.md.0000090401.56130.59; Tsuji S, 2003, ALIMENT PHARM THER, V18, P82, DOI 10.1046/j.1365-2036.18.s1.22.x; Wang LS, 1999, BRIT J CANCER, V80, P1617, DOI 10.1038/sj.bjc.6690571; Wang LY, 2003, CANCER CAUSE CONTROL, V14, P241, DOI 10.1023/A:1023636619477; Wu MT, 2003, BRIT J CANCER, V89, P1202, DOI 10.1038/sj.bjc.6601251; YAAR M, 1993, EXP CELL RES, V206, P235, DOI 10.1006/excr.1993.1143; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zimmermann KC, 1999, CANCER RES, V59, P198	54	112	114	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50676	50683		10.1074/jbc.M404465200	http://dx.doi.org/10.1074/jbc.M404465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15375172	hybrid, Green Published			2022-12-25	WOS:000225355800008
J	Epand, RM; Epand, RF; Sayer, BG; Datta, G; Chaddha, M; Anantharamaiah, GM				Epand, RM; Epand, RF; Sayer, BG; Datta, G; Chaddha, M; Anantharamaiah, GM			Two homologous apolipoprotein AI mimetic peptides - Relationship between membrane interactions and biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL-RICH DOMAINS; MICE; ATHEROSCLEROSIS; PROTEINS; MODEL	Two related 18-amino acid, class A, amphipathic helical peptides termed 3F-2 and 3F(14) were chosen for this study. Although they have identical amino acid compositions and many similar biophysical properties, 3F-2 is more potent than 3F(14) as an apolipoprotein AI mimetic peptide. The two peptides exhibit similar gross conformational properties, forming structures of high helical content on a membrane surface. However, the thermal denaturation transition of 3F-2 is more cooperative, suggesting a higher degree of oligomerization on the membrane. Both 3F-2 and 3F(14) promote the segregation of cholesterol in membranes containing phosphatidylcholine and cholesterol, but 3F-2 exhibits a greater selectivity for partitioning into cholesterol-depleted regions of the membrane. Magic angle spinning/NMR studies indicate that the aromatic residues of 3F-2 are stacked in the presence of lipid. The aromatic side chains of this peptide also penetrate more deeply into membranes of phosphatidylcholine with cholesterol compared with 3F(14). Using the fluorescent probe, 1,3-dipyrenylpropane, we monitored the properties of the lipid hydrocarbon environment. 3F-2 had a greater effect in altering the properties of the hydrocarbon region of the membrane. The results are consistent with our proposed model of the effect of peptide shape on the nature of the difference in peptide insertion into the bilayer.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Biomed Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Chem, Hamilton, ON L8N 3Z5, Canada; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL 35294 USA	McMaster University; McMaster University; McMaster University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Epand, RM (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.	epand@mcmaster.ca	, Richard/R-2316-2019	, Richard/0000-0002-9602-9558	NHLBI NIH HHS [HL 34343, R01 HL 65663] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, R01HL065663] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANANTHARAMAIAH GM, 1993, AMPHIPATHIC HELIX, P109; Arnold MR, 2002, BIOPHYS CHEM, V96, P129, DOI 10.1016/S0301-4622(02)00018-2; Datta G, 2004, J BIOL CHEM, V279, P26509, DOI 10.1074/jbc.M314276200; Datta G, 2001, J LIPID RES, V42, P1096; Epand RM, 2004, BBA-BIOMEMBRANES, V1666, P227, DOI 10.1016/j.bbamem.2004.07.004; Epand RM, 2004, BIOCHEMISTRY-US, V43, P5073, DOI 10.1021/bi049786u; Epand RM, 2003, BIOCHEMISTRY-US, V42, P14677, DOI 10.1021/bi035587j; FORBES J, 1988, J CHEM SOC FARAD T 1, V84, P3821, DOI 10.1039/f19888403821; Garber DW, 2001, J LIPID RES, V42, P545; Guo W, 1996, BIOPHYS J, V71, P2857, DOI 10.1016/S0006-3495(96)79482-1; Hartel S, 1998, ANAL BIOCHEM, V258, P277, DOI 10.1006/abio.1998.2594; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELNICK RL, 1981, BIOPHYS J, V34, P499, DOI 10.1016/S0006-3495(81)84864-3; Navab M, 2004, CIRCULATION, V109, P3215, DOI 10.1161/01.CIR.0000134275.90823.87; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; Navab Mohamad, 2003, Curr Opin Investig Drugs, V4, P1100; Ou ZJ, 2003, CIRCULATION, V107, P1520, DOI 10.1161/01.CIR.0000061949.17174.B6; Tabas I, 2002, J CLIN INVEST, V110, P905, DOI 10.1172/JCI200216452; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486	20	20	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51404	51414		10.1074/jbc.M408581200	http://dx.doi.org/10.1074/jbc.M408581200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358763				2022-12-25	WOS:000225355800092
J	Kisselev, OG; Downs, MA; McDowell, JH; Hargrave, PA				Kisselev, OG; Downs, MA; McDowell, JH; Hargrave, PA			Conformational changes in the phosphorylated C-terminal domain of rhodopsin during rhodopsin arrestin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTORECEPTOR DARK-ADAPTATION; PROTEIN-COUPLED RECEPTOR; POTASSIUM CHANNELS; IN-VIVO; SYNTHETIC PHOSPHOPEPTIDE; MULTIPLE PHOSPHORYLATION; LIGHT ACTIVATION; BOVINE RHODOPSIN; BETA-ARRESTINS; NMR STRUCTURE	Phosphorylation of activated G-protein-coupled receptors and the subsequent binding of arrestin mark major molecular events of homologous desensitization. In the visual system, interactions between arrestin and the phosphorylated rhodopsin are pivotal for proper termination of visual signals. By using high resolution proton nuclear magnetic resonance spectroscopy of the phosphorylated C terminus of rhodopsin, represented by a synthetic 7-phosphopolypeptide, we show that the arrestin-bound conformation is a well ordered helix-loop structure connected to rhodopsin via a flexible linker. In a model of the rhodopsin-arrestin complex, the phosphates point in the direction of arrestin and form a continuous negatively charged surface, which is stabilized by a number of positively charged lysine and arginine residues of arrestin. Opposite to the mostly extended structure of the unphosphorylated C-terminal domain of rhodopsin, the arrestin-bound C-terminal helix is a compact domain that occupies a central position between the cytoplasmic loops and occludes the key binding sites of transducin. In conjunction with other binding sites, the helix-loop structure provides a mechanism of shielding phosphates in the center of the rhodopsin-arrestin complex and appears critical in guiding arrestin for high affinity binding with rhodopsin.	St Louis Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	Saint Louis University; Saint Louis University; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kisselev, OG (corresponding author), St Louis Univ, Sch Med, Dept Ophthalmol, 1755 S Grand Blvd, St Louis, MO 63104 USA.	kisselev@slu.edu			NEI NIH HHS [EY06225] Funding Source: Medline; NIGMS NIH HHS [GM63203] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM063203, R01GM063203] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antz C, 1999, NAT STRUCT BIOL, V6, P146; Antz C, 1997, NATURE, V385, P272, DOI 10.1038/385272a0; Arendt A, 1996, PROTEIN PEPTIDE LETT, V3, P361; Arshavsky VY, 2002, TRENDS NEUROSCI, V25, P124, DOI 10.1016/S0166-2236(00)02094-4; Bentrop D, 2001, J BIOL CHEM, V276, P42116, DOI 10.1074/jbc.M107118200; Brannock MT, 1999, BIOCHEMISTRY-US, V38, P3770, DOI 10.1021/bi982419w; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; Dorey M, 1999, BBA-BIOMEMBRANES, V1416, P217, DOI 10.1016/S0005-2736(98)00224-7; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Getmanova E, 2004, BIOCHEMISTRY-US, V43, P1126, DOI 10.1021/bi030120u; Gurevich VV, 2004, TRENDS PHARMACOL SCI, V25, P105, DOI 10.1016/j.tips.2003.12.008; Hodsdon ME, 1996, J MOL BIOL, V264, P585, DOI 10.1006/jmbi.1996.0663; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; Kisselev OG, 2004, FEBS LETT, V564, P307, DOI 10.1016/S0014-5793(04)00226-1; Kisselev OG, 1998, P NATL ACAD SCI USA, V95, P4270, DOI 10.1073/pnas.95.8.4270; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Luttrell LM, 2002, J CELL SCI, V115, P455; Maeda T, 2003, PROG RETIN EYE RES, V22, P417, DOI 10.1016/S1350-9462(03)00017-X; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Raman D, 2003, J NEUROCHEM, V84, P1040, DOI 10.1046/j.1471-4159.2003.01598.x; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shenoy SK, 2003, BIOCHEM J, V375, P503, DOI 10.1042/BJ20031076; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; SOLARO CR, 1992, SCIENCE, V257, P1694, DOI 10.1126/science.1529355; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	41	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51203	51207		10.1074/jbc.M407341200	http://dx.doi.org/10.1074/jbc.M407341200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15351781	hybrid			2022-12-25	WOS:000225355800067
J	Qanungo, S; Wang, M; Nieminen, AL				Qanungo, S; Wang, M; Nieminen, AL			N-acetyl-L-cysteine enhances apoptosis through inhibition of nuclear factor-kappa B in hypoxic murine embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; NECROTIC CELL-DEATH; CANCER CELLS; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; REDOX REGULATION; SOLID TUMORS; OXYGEN; ACETYLCYSTEINE; GLUTATHIONE	In this study, we investigated the role of reduced glutathione (GSH) and nuclear factor-kappaB (NFkappaB) in hypoxia-induced apoptosis. Hypoxia caused p53-dependent apoptosis in murine embryonic fibroblasts transfected with Ras and E1A. N-Acetyl-L- cysteine (NAC) but not other antioxidants, such as the vitamin E analog trolox and epigallocatechin-3-gallate, enhanced hypoxia-induced caspase-3 activation and apoptosis. NAC also enhanced hypoxia-induced apoptosis in two human cancer cell lines, MIA PaCa-2 pancreatic cancer cells and A549 lung carcinoma cells. In murine embryonic fibroblasts, all three antioxidants blocked hypoxia-induced reactive oxygen species formation. NAC did not enhance hypoxia-induced cytochrome c release but did enhance poly( ADP ribose) polymerase cleavage, indicating that NAC acted at a post-mitochondrial level. NAC-mediated enhancement of apoptosis was mimicked by incubating cells with GSH monoester, which increased intracellular GSH similarly to NAC. Hypoxia promoted degradation of an inhibitor of kappaB (IkappaBalpha), NFkappaB-p65 translocation into the nucleus, NFkappaB binding to DNA, and subsequent transactivation of NFkappaB, which increased X chromosome-linked inhibitor of apoptosis protein levels. NAC failed to block degradation by IkappaBalpha and sequestration of the p65 subunit of NFkappaB to the nucleus. However, NAC did abrogate hypoxia-induced NFkappaB binding to DNA, NFkappaB-dependent gene expression, and induction of X chromosome-linked inhibitor of apoptosis protein. In conclusion, NAC enhanced hypoxic apoptosis by a mechanism apparently involving GSH-dependent suppression of NFkappaB transactivation.	Case Western Reserve Univ, Case Comprehens Canc Ctr Labs, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Anat, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Nieminen, AL (corresponding author), Case Western Reserve Univ, Case Comprehens Canc Ctr Labs, Sch Med, 3-134 Wolstein Res Bldg,10900 Euclid Ave, Cleveland, OH 44106 USA.	axn25@case.edu			NCI NIH HHS [P30 CA43703] Funding Source: Medline; NINDS NIH HHS [R01 NS39469] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039469] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bogatcheva NV, 2003, J INVEST MED, V51, P341, DOI 10.1136/jim-51-06-30; Bose S, 2003, P NATL ACAD SCI USA, V100, P10890, DOI 10.1073/pnas.1832775100; Brar SS, 2001, AM J PHYSIOL-CELL PH, V280, pC659, DOI 10.1152/ajpcell.2001.280.3.C659; Brunelle JK, 2004, J BIOL CHEM, V279, P4305, DOI 10.1074/jbc.M312241200; Cazals V, 1999, BBA-MOL CELL RES, V1448, P349, DOI 10.1016/S0167-4889(98)00095-0; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DAWSON TL, 1993, AM J PHYSIOL, V264, P961; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Jiang BB, 2000, HYPERTENSION, V35, P914, DOI 10.1161/01.HYP.35.4.914; JONES DP, 1995, IMMUNOL LETT, V45, P205, DOI 10.1016/0165-2478(95)00004-O; Kabore AF, 2001, J CELL SCI, V114, P293; Kamata H, 2002, ANN NY ACAD SCI, V973, P419, DOI 10.1111/j.1749-6632.2002.tb04675.x; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kunz Manfred, 2003, Mol Cancer, V2, P23, DOI 10.1186/1476-4598-2-23; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Mansfield KD, 2004, J APPL PHYSIOL, V97, P1358, DOI 10.1152/japplphysiol.00449.2004; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Montiel-Duarte C, 2004, BIOCHEM PHARMACOL, V67, P1025, DOI 10.1016/j.bcp.2003.10.020; NIEMINEN AL, 1988, CELL CALCIUM, V9, P237, DOI 10.1016/0143-4160(88)90004-8; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Park SA, 2000, J NEUROCHEM, V75, P946, DOI 10.1046/j.1471-4159.2000.0750946.x; Porwol T, 1998, EUR J BIOCHEM, V256, P16, DOI 10.1046/j.1432-1327.1998.2560016.x; Qanungo S, 2003, NEOPLASIA, V5, P367, DOI 10.1016/S1476-5586(03)80030-1; Qanungo S, 2002, ONCOGENE, V21, P4149, DOI 10.1038/sj.onc.1205508; Renard P, 1997, BIOCHEM PHARMACOL, V53, P149, DOI 10.1016/S0006-2952(96)00645-4; Rieber M, 2003, BIOCHEM PHARMACOL, V65, P1593, DOI 10.1016/S0006-2952(03)00147-3; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Seres T, 1996, J IMMUNOL, V156, P1973; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Steinbach JP, 2003, CELL DEATH DIFFER, V10, P823, DOI 10.1038/sj.cdd.4401252; VANZANDWIJK N, 1995, CHEST, V107, P1437, DOI 10.1378/chest.107.5.1437; Wang CY, 1999, MOL CELL BIOL, V19, P5923; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001	52	85	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50455	50464		10.1074/jbc.M406749200	http://dx.doi.org/10.1074/jbc.M406749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375156	hybrid			2022-12-25	WOS:000225229500111
J	Herrmann, F; Bossert, M; Schwander, A; Akgun, E; Fackelmayer, FO				Herrmann, F; Bossert, M; Schwander, A; Akgun, E; Fackelmayer, FO			Arginine methylation of scaffold attachment factor A by heterogeneous nuclear ribonucleoprotein particle-associated PRMT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; HNRNP-U/SAF-A; IN-VIVO; N-METHYLTRANSFERASE; SAF-A; SUBSTRATE-SPECIFICITY; SUBCELLULAR-LOCALIZATION; MATRIX PROTEIN; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR	Components of the heterogeneous nuclear ribonucleoprotein (hnRNP) complex and other nucleic acid-binding proteins are subject to methylation on specific arginine residues by the catalytic activity of arginine methyltransferases. The methylation has been implicated in transcriptional regulation and RNA and protein trafficking and signal transduction, but the mechanism by which these functions are achieved has remained undetermined. We show here that the predominant arginine methyltransferase in human cells, protein arginine methyltransferase 1 (PRMT1), is associated with hnRNP complexes, dependent on the methylation status of the cell, and that it methylates its preferred substrates in situ. Binding of PRMT1 occurs through physical interaction with scaffold attachment factor A (SAF-A), also known as hnRNP-U, which is quantitatively methylated by PRMT1 in all investigated cell lines as determined by a novel, highly specific, methylation-sensitive antibody.	Heinrich Pette Inst, Dept Mol Cell Biol, D-20251 Hamburg, Germany	Heinrich Pette Institute	Fackelmayer, FO (corresponding author), Heinrich Pette Inst, Dept Mol Cell Biol, Martinistr 52, D-20251 Hamburg, Germany.	frank@Fackelmayer.de						Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Altschuler L, 1999, J INTERF CYTOK RES, V19, P189, DOI 10.1089/107999099314333; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Eggert H, 2001, J STEROID BIOCHEM, V78, P59, DOI 10.1016/S0960-0760(01)00074-7; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Frankel A, 2002, J BIOL CHEM, V277, P3537, DOI 10.1074/jbc.M108786200; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Helbig R, 2003, CHROMOSOMA, V112, P173, DOI 10.1007/s00412-003-0258-0; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Jenke BHC, 2002, EMBO REP, V3, P349, DOI 10.1093/embo-reports/kvf070; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Lee J, 2002, EMBO REP, V3, P268, DOI 10.1093/embo-reports/kvf052; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Martens JHA, 2002, MOL CELL BIOL, V22, P2598, DOI 10.1128/MCB.22.8.2598-2606.2002; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Miranda TB, 2004, J BIOL CHEM, V279, P22902, DOI 10.1074/jbc.M312904200; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pawlak MR, 2002, J CELL BIOCHEM, V87, P394, DOI 10.1002/jcb.10307; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781	44	55	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48774	48779		10.1074/jbc.M407332200	http://dx.doi.org/10.1074/jbc.M407332200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364944	hybrid			2022-12-25	WOS:000225098100036
J	Vazquez-Ibar, JL; Guan, L; Weinglass, AB; Verner, G; Gordillo, R; Kaback, HR				Vazquez-Ibar, JL; Guan, L; Weinglass, AB; Verner, G; Gordillo, R; Kaback, HR			Sugar recognition by the lactose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TRANSPORT PROTEIN; SUBSTRATE-BINDING SITE; HELIX-VIII; TRYPTOPHAN FLUORESCENCE; SCANNING MUTAGENESIS; MASS-SPECTROMETRY; LAC PERMEASE; RESIDUES; MECHANISM; GLU126	Biochemical, luminescence and mass spectroscopy approaches indicate that Trp- 151 (helix V) plays an important role in hydrophobic stacking with the galactopyranosyl ring of substrate and that Glu-269 (helix VIII) is essential for substrate affinity and specificity. The x-ray structure of the lactose permease (LacY) with bound substrate is consistent with these conclusions and suggests that a possible H-bond between Glu-269 and Trp-151 may play a critical role in the architecture of the binding site. We have now probed this relationship by exploiting the intrinsic luminescence of a single Trp- 151 LacY with various replacements for Glu-269. Mutations at position 269 dramatically alter the environment of Trp- 151 in a manner that correlates with binding affinity of LacY substrates. Furthermore, chemical modification of Trp- 151 with N-bromosuccinimide indicates that Glu-269 forms an H-bond with the indole N. It is concluded that 1) an H-bond between the indole N and Glu-269 optimizes the formation of the substrate binding site in the inward facing conformation of LacY, and 2) the disposition of the residues implicated in sugar binding in different conformers suggests that sugar binding by LacY involves induced fit.	Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Physiol,MacDonald Res Labs 5 748, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gordillo, R (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Inst Mol Biol, Dept Physiol,MacDonald Res Labs 5 748, Box 951662, Los Angeles, CA 90095 USA.	RonaldK@HHMI.UCLA.edu	Guan, Lan/B-5288-2010; Vazquez-Ibar, Jose-Luis/AAD-8827-2021	Vazquez-Ibar, Jose-Luis/0000-0002-8314-3378; Gordillo, Ruth/0000-0001-6533-2493	NIDDK NIH HHS [DK51131:09] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051131] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; COSTELLO MJ, 1987, J BIOL CHEM, V262, P17072; COUTINHO A, 1993, J CHEM EDUC, V70, P425, DOI 10.1021/ed070p425; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1976, J PHYS CHEM-US, V80, P486, DOI 10.1021/j100546a014; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; Frillingos S, 1997, PROTEIN SCI, V6, P431; Frillingos S, 1997, PROTEIN SCI, V6, P438; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; Guan L, 2003, BIOCHEMISTRY-US, V42, P1377, DOI 10.1021/bi027152m; He MM, 1997, BIOCHEMISTRY-US, V36, P13688, DOI 10.1021/bi9715324; Hirai T, 2003, J BACTERIOL, V185, P1712, DOI 10.1128/JB.185.5.1712-1718.2003; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Kaback H R, 1974, Methods Enzymol, V31, P698; Kaback HR, 2001, NAT REV MOL CELL BIO, V2, P610, DOI 10.1038/35085077; Kaback HR, 1997, Q REV BIOPHYS, V30, P333, DOI 10.1017/S0033583597003387; KONINGS WN, 1996, HDB BIOL PHYS TRANSP; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lundblad RL, 1995, TECHNIQUES PROTEIN M, V1, P187; Maki AH, 2001, BIOCHEMISTRY-US, V40, P1403, DOI 10.1021/bi002010i; Misra A, 2000, BIOCHEMISTRY-US, V39, P13772, DOI 10.1021/bi0015663; OLSEN SG, 1989, J BIOL CHEM, V264, P15982; PHILLIPS RS, 1986, J AM CHEM SOC, V108, P2023, DOI 10.1021/ja00268a049; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; Sahin-Toth M, 2002, BIOCHEMISTRY-US, V41, P13039, DOI 10.1021/bi0203076; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; Sahin-Toth M, 2001, BIOCHEMISTRY-US, V40, P13015, DOI 10.1021/bi011233l; Sahin-Toth M, 1999, BIOCHEMISTRY-US, V38, P813, DOI 10.1021/bi982200h; SAHINTOTH M, 1994, P NATL ACAD SCI USA, V91, P5421, DOI 10.1073/pnas.91.12.5421; Saier M H Jr, 1999, J Mol Microbiol Biotechnol, V1, P257; Saier MH, 2000, MOL MICROBIOL, V35, P699, DOI 10.1046/j.1365-2958.2000.01759.x; SANDERMANN H, 1977, EUR J BIOCHEM, V80, P507, DOI 10.1111/j.1432-1033.1977.tb11906.x; Smirnova IN, 2003, BIOCHEMISTRY-US, V42, P3025, DOI 10.1021/bi027329c; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; UJWAL ML, 1994, MOL MEMBR BIOL, V11, P9, DOI 10.3109/09687689409161024; Vazquez-Ibar JL, 2003, P NATL ACAD SCI USA, V100, P12706, DOI 10.1073/pnas.1835645100; Venkatesan P, 1998, P NATL ACAD SCI USA, V95, P9802, DOI 10.1073/pnas.95.17.9802; Weinglass A, 2004, J BIOL CHEM, V279, P41858, DOI 10.1074/jbc.M407555200; Weinglass AB, 2003, EMBO J, V22, P1467, DOI 10.1093/emboj/cdg145; Weinglass AB, 2002, J MOL BIOL, V315, P561, DOI 10.1006/jmbi.2001.5289; Wolin CD, 2000, BIOCHEMISTRY-US, V39, P6130, DOI 10.1021/bi0001269; WU JH, 1994, BIOCHEMISTRY-US, V33, P12166, DOI 10.1021/bi00206a020; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	48	28	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49214	49221		10.1074/jbc.M407408200	http://dx.doi.org/10.1074/jbc.M407408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364943	hybrid			2022-12-25	WOS:000225098100087
J	Fitzgerald, ML; Okuhira, K; Short, GF; Manning, JJ; Bell, SA; Freeman, MW				Fitzgerald, ML; Okuhira, K; Short, GF; Manning, JJ; Bell, SA; Freeman, MW			ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TANGIER-DISEASE; ABCA1 TRANSPORTER; GUANYLATE KINASES; PDZ DOMAINS; PROTEIN; MECHANISM; MUTATIONS; COMPLEX; EVOLUTION	The stimulation of cellular cholesterol and phospholipid efflux by apolipoprotein A-I is mediated by the activity of the ATP-binding cassette transporter A1 (ABCA1). Individuals with Tangier disease harbor loss-of-function mutations in this transporter that have proven useful in illuminating its activity. Here, we analyze a mutation that deletes the last 46 residues of the 2261 amino acid transporter (Delta46) and eliminates its lipid efflux. As the final four amino acids of the C terminus represent a putative PDZ-binding motif, we initially characterized deletion mutants lacking only these residues. Although a moderate decline in lipid efflux was detected, this decline was not as profound as that seen in the Delta46 mutant. Subsequent systematic analysis of the ABCA1 C terminus revealed a novel, highly conserved motif (VFVNFA) that was required for lipid efflux. Alteration of this motif, which is present in some but not all members of the ABCA family, did not prevent trafficking of the transporter to the plasma membrane but did eliminate its binding of apoA-I. Chimeric transporters, generated by substituting the C termini of either ABCA4 or ABCA7 for the endogenous terminus, demonstrated that ABCA1 could stimulate cholesterol efflux without its PDZ-binding motif but not without the VFVNFA motif. When a peptide containing the VFVNFA sequence was introduced into ABCA1-expressing cells, ABCA1-mediated lipid efflux was also markedly inhibited. These results indicate that the C-terminal VFVNFA motif of ABCA1 is essential for its lipid efflux activity. The data also suggest that this motif participates in novel protein-protein interactions that may be shared among members of the ABCA family.	Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Fitzgerald, ML (corresponding author), Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA.	mfitzger@molbio.mgh.harvard.edu; freeman@molbio.mg.harvard.edu			NHLBI NIH HHS [HL68988, HL72358, HL45098] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072358, R01HL068988, R01HL045098, K08HL145098] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Basso F, 2003, J LIPID RES, V44, P296, DOI 10.1194/jlr.M200414-JLR200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P433; Buechler C, 2002, J BIOL CHEM, V277, P41307, DOI 10.1074/jbc.C200436200; Buechler C, 2002, BIOCHEM BIOPH RES CO, V293, P759, DOI 10.1016/S0006-291X(02)00303-0; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Chroni A, 2004, BIOCHEMISTRY-US, V43, P2126, DOI 10.1021/bi035813p; Clee SM, 2001, CIRCULATION, V103, P1198; Davidson B, 2003, P NATL ACAD SCI USA, V100, P11469, DOI 10.1073/pnas.1634991100; Dean M, 2001, J LIPID RES, V42, P1007; Denis M, 2004, J BIOL CHEM, V279, P7384, DOI 10.1074/jbc.M306963200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Fitzgerald ML, 2004, J LIPID RES, V45, P287, DOI 10.1194/jlr.M300355-JLR200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Fitzgerald ML, 1999, BIOCHEM J, V342, P353, DOI 10.1042/0264-6021:3420353; Fitzgerald ML, 2001, J BIOL CHEM, V276, P15137, DOI 10.1074/jbc.M100474200; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jiang Y, 2003, P NATL ACAD SCI USA, V100, P7527, DOI 10.1073/pnas.0932632100; Joly N, 2004, J BIOL CHEM, V279, P33123, DOI 10.1074/jbc.M403615200; Jones PM, 2004, CELL MOL LIFE SCI, V61, P682, DOI 10.1007/s00018-003-3336-9; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Munehira Y, 2004, J BIOL CHEM, V279, P15091, DOI 10.1074/jbc.M313436200; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Niethammer M, 1996, J NEUROSCI, V16, P2157; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Panagotopulos SE, 2002, J BIOL CHEM, V277, P39477, DOI 10.1074/jbc.M207005200; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	42	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48477	48485		10.1074/jbc.M409848200	http://dx.doi.org/10.1074/jbc.M409848200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347662	hybrid			2022-12-25	WOS:000224957000125
J	Gerber, D; Pritsker, M; Gunther-Ausborn, S; Johnson, B; Blumenthal, R; Shai, Y				Gerber, D; Pritsker, M; Gunther-Ausborn, S; Johnson, B; Blumenthal, R; Shai, Y			Inhibition of HIV-1 envelope glycoprotein-mediated cell fusion by a DL-amino acid-containing fusion peptide - Possible recognition of the fusion complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FLUORESCENCE ENERGY-TRANSFER; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; PHOSPHOLIPID-MEMBRANES; INFRARED-SPECTROSCOPY; TRANSMEMBRANE PROTEIN; CHEMOKINE RECEPTORS; TERMINAL PEPTIDE; DEPENDENT FUSION	The N-terminal fusion peptide ( FP) of human immunodeficiency virus-1 (HIV-1) is a potent inhibitor of cell-cell fusion, possibly because of its ability to recognize the corresponding segments inside the fusion complex within the membrane. Here we show that a fusion peptide in which the highly conserved Ile(4), Phe(8), Phe(11), and Ala(14) were replaced by their D-enantiomers (IFFA) is a potent inhibitor of cell-cell fusion. Fourier transform infrared spectroscopy confirmed that despite these drastic modifications, the peptide preserved most of its structure within the membrane. Fluorescence energy transfer studies demonstrated that the diastereomeric peptide interacted with the wild type FP, suggesting this segment as the target site for inhibition of membrane fusion. This is further supported by the similar localization of the wild type and IFFA FPs to microdomains in T cells and the preferred partitioning into ordered regions within sphingomyelin/phosphatidyl-choline/cholesterol giant vesicles. These studies provide insight into the mechanism of molecular recognition within the membrane milieu and may serve in designing novel HIV entry inhibitors.	Weizmann Inst Sci, IL-76100 Rehovot, Israel; NCI, Sect Membrane Struct & Funct, Lab Expt & Computat Biol, Ctr Canc Res,NIH, Frederick, MD 21701 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il			NATIONAL CANCER INSTITUTE [ZIABC008303, Z01BC008303] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avrahami D, 2001, BIOCHEMISTRY-US, V40, P12591, DOI 10.1021/bi0105330; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; BOSCH ML, 1989, SCIENCE, V244, P694, DOI 10.1126/science.2541505; BRASSEUR R, 1988, AIDS RES HUM RETROV, V4, P83, DOI 10.1089/aid.1988.4.83; BURGER KNJ, 1991, BIOCHEMISTRY-US, V30, P11173, DOI 10.1021/bi00110a022; BURNY A, 1988, J ACQ IMMUN DEF SYND, V1, P579; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; CLAGUE MJ, 1991, BIOCHEMISTRY-US, V30, P5491, DOI 10.1021/bi00236a023; de Almeida RFM, 2003, BIOPHYS J, V85, P2406, DOI 10.1016/S0006-3495(03)74664-5; Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DURELL SR, 1997, MOL MEMBR BIOL, V14, P97; EPAND RM, 1994, BIOCHEM BIOPH RES CO, V202, P1420, DOI 10.1006/bbrc.1994.2089; FREED EO, 1990, P NATL ACAD SCI USA, V87, P4650, DOI 10.1073/pnas.87.12.4650; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; GAZIT E, 1993, BIOCHEMISTRY-US, V32, P12363, DOI 10.1021/bi00097a013; Gerber D, 2002, J MOL BIOL, V322, P491, DOI 10.1016/S0022-2836(02)00807-0; Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6; Gray C, 1996, BIOPHYS J, V70, P2275, DOI 10.1016/S0006-3495(96)79793-X; Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434; Hetru C, 2000, BIOCHEM J, V345, P653, DOI 10.1042/0264-6021:3450653; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JIANG SB, 1993, BIOCHEM BIOPH RES CO, V195, P533, DOI 10.1006/bbrc.1993.2078; JONAK ZL, 1993, AIDS RES HUM RETROV, V9, P23, DOI 10.1089/aid.1993.9.23; Karle IL, 2003, P NATL ACAD SCI USA, V100, P13946, DOI 10.1073/pnas.2336106100; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; Kliger Y, 1997, J BIOL CHEM, V272, P13496, DOI 10.1074/jbc.272.21.13496; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1; LEAR JD, 1987, J BIOL CHEM, V262, P6500; MARTIN I, 1993, BIOCHIM BIOPHYS ACTA, V1145, P124, DOI 10.1016/0005-2736(93)90389-H; Martin I, 1996, J VIROL, V70, P298, DOI 10.1128/JVI.70.1.298-304.1996; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; MORRIS SJ, 1989, J BIOL CHEM, V264, P3972; Moscho A, 1996, P NATL ACAD SCI USA, V93, P11443, DOI 10.1073/pnas.93.21.11443; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Oren Z, 2002, EUR J BIOCHEM, V269, P3869, DOI 10.1046/j.1432-1033.2002.03080.x; OWENS RJ, 1990, AIDS RES HUM RETROV, V6, P1289, DOI 10.1089/aid.1990.6.1289; Pereira FB, 1997, BIOPHYS J, V73, P1977, DOI 10.1016/S0006-3495(97)78228-6; Pritsker M, 1999, BIOCHEMISTRY-US, V38, P11359, DOI 10.1021/bi990232e; Pritsker M, 1998, P NATL ACAD SCI USA, V95, P7287, DOI 10.1073/pnas.95.13.7287; RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020; RAPAPORT D, 1993, BIOCHEMISTRY-US, V32, P3291, DOI 10.1021/bi00064a011; RAPAPORT D, 1992, J BIOL CHEM, V267, P6502; RAPAPORT D, 1994, J BIOL CHEM, V269, P15124; Rucker J, 1997, J VIROL, V71, P8999, DOI 10.1128/JVI.71.12.8999-9007.1997; Ruiz-Arguello MB, 1998, J VIROL, V72, P1775; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; Sackett K, 2003, J MOL BIOL, V333, P47, DOI 10.1016/j.jmb.2003.07.008; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; SLEPUSHKIN VA, 1990, BIOCHEM BIOPH RES CO, V172, P952, DOI 10.1016/0006-291X(90)90768-I; TAKEDA M, 2003, P NATL ACAD SCI US; Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; Yang J, 2003, BIOCHEMISTRY-US, V42, P11879, DOI 10.1021/bi0348157	63	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48224	48230		10.1074/jbc.M403436200	http://dx.doi.org/10.1074/jbc.M403436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339935	hybrid			2022-12-25	WOS:000224957000097
J	Rezaie, AR; Kittur, FS				Rezaie, AR; Kittur, FS			The critical role of the 185-189-loop in the factor Xa interaction with Na plus and factor Va in the prothrombinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TICK ANTICOAGULANT PEPTIDE; BLOOD-COAGULATION FACTOR; SODIUM-BINDING-SITE; BOVINE FACTOR XA; CATALYTIC-ACTIVITY; BASIC RESIDUES; PROTEIN-C; FACTOR-IX; S1 SITE; INHIBITION	The S1 site (Asp(189)) of factor Xa (fXa) is located on a loop (residues 185-189) that contains three solvent-exposed charged residues (Asp(185), Lys(186), and Glu(188)) below the active-site pocket of the protease. To investigate the role of these residues in the catalytic function of fXa, we expressed three mutants of the protease in which the charges of these residues were neutralized by their substitutions with Ala (D185A, K186A, and E188A). Kinetic studies revealed that E188A has a normal catalytic activity toward small synthetic and natural substrates and inhibitors of fXa; however, the same activities were slightly (similar to2-fold) and dramatically (similar to20-50-fold) impaired for the D185A and K186A mutants, respectively. Further studies revealed that the affinity of D185A and K186A for interaction with Na+ has also been altered, with a modest impairment (similar to2-fold) for the former and a dramatic impairment for the latter mutant. Both prothrombinase and direct binding studies indicated that K186A also has an similar to6-fold impaired affinity for factor Va. Interestingly, a saturating concentration of factor Va restored the catalytic defect of K186A in reactions with prothrombin and the recombinant tick anticoagulant peptide that is known to interact with the Na+ loop of fXa, but not with other substrates. These results suggest that factor Va interacts with 185-189-loop for fXa, which is energetically linked to the Na+-binding site of the protease.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA	Saint Louis University	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu	Kittur, Farooqahmed S/G-3832-2012	Kittur, Farooqahmed/0000-0002-2272-3387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R01HL068571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL 68571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Beck DO, 2004, J BIOL CHEM, V279, P3084, DOI 10.1074/jbc.M306850200; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Camire RM, 2002, J BIOL CHEM, V277, P37863, DOI 10.1074/jbc.M203692200; Chen L, 2004, PROTEIN SCI, V13, P431, DOI 10.1110/ps.03406904; Chen L, 2003, J BIOL CHEM, V278, P27564, DOI 10.1074/jbc.M302707200; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; JACKSON CM, 1980, ANNU REV BIOCHEM, V49, P765, DOI 10.1146/annurev.bi.49.070180.004001; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; Manithody C, 2002, BIOCHEMISTRY-US, V41, P6780, DOI 10.1021/bi0255367; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; OLSON ST, 1991, ARCH BIOCHEM BIOPHYS, V286, P533, DOI 10.1016/0003-9861(91)90076-U; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Prasad S, 2003, P NATL ACAD SCI USA, V100, P13785, DOI 10.1073/pnas.2333109100; Rezaie AR, 2000, J BIOL CHEM, V275, P3320, DOI 10.1074/jbc.275.5.3320; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P3368, DOI 10.1021/bi036177y; Rezaie AR, 2004, BIOCHEMISTRY-US, V43, P2898, DOI 10.1021/bi036145a; Rezaie AR, 2003, THROMB HAEMOSTASIS, V89, P112; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2001, J BIOL CHEM, V276, P5123, DOI 10.1074/jbc.M006961200; SMIRNOV MD, 1994, J BIOL CHEM, V269, P816; Toso R, 2004, J BIOL CHEM, V279, P21643, DOI 10.1074/jbc.M402107200; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; VLASUK GP, 1993, THROMB HAEMOSTASIS, V70, P212; Wei AZ, 1998, J MOL BIOL, V283, P147, DOI 10.1006/jmbi.1998.2069; Yegneswaran S, 2003, J BIOL CHEM, V278, P33312, DOI 10.1074/jbc.M305906200	34	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48262	48269		10.1074/jbc.M409964200	http://dx.doi.org/10.1074/jbc.M409964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347660	hybrid			2022-12-25	WOS:000224957000102
J	Pavithra, SR; Banumathy, G; Joy, O; Singh, V; Tatu, U				Pavithra, SR; Banumathy, G; Joy, O; Singh, V; Tatu, U			Recurrent fever promotes Plasmodium falciparum development in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID-RECEPTOR; FEBRILE TEMPERATURES; IN-VITRO; HSP90; CHAPERONE; GROWTH; KINASE; GELDANAMYCIN; MALARIA; COMPLEX	The human malarial parasite Plasmodium falciparum (Pf) is exposed to wide temperature fluctuations during its life cycle, ranging from 25degreesC in the mosquito vector and 37degreesC in humans to 41degreesC during febrile episodes in the patient. The repeated occurrence of fever at regular intervals is a characteristic of human malaria. We have examined the influence of repeated exposure to elevated temperatures encountered during fever on the intra-erythrocytic development of the parasite. Using flow cytometry, we show that repeated exposure to temperatures mimicking febrile episodes promotes parasite development in human erythrocytes. Heat shock-mediated cytoprotection and growth promotion is dependent on the heat shock protein 90 (PfHsp90) multi-chaperone complex. Inhibition of PfHsp90 function using geldanamycin attenuates temperature-dependent progression from the ring to the trophozoite stage. Geldanamycin inhibits parasite development by disrupting the PfHsp90 complex consisting of PfHsp70, PfPP5, and tubulin, among other proteins. While explaining the contribution of febrile episodes to the pathogenesis of malaria, our results implicate temperature as an important environmental cue used by the parasite to coordinate its development in humans.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Tatu, U (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	tatu@biochem.iisc.ernet.in	Viswanath, Pavithra/I-4318-2015	Viswanath, Pavithra/0000-0003-2980-3109; Tatu, Utpal/0000-0003-0404-8872				Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Banumathy G, 2003, J BIOL CHEM, V278, P18336, DOI 10.1074/jbc.M211309200; Brandts CH, 1997, LANCET, V350, P704, DOI 10.1016/S0140-6736(97)02255-1; BRUCECHWATT LJ, 1986, CHEMOTHERAPY MALARIA, P120; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Dobson S, 2001, BMC Microbiol, V1, P31, DOI 10.1186/1471-2180-1-31; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Garnier C, 1998, BIOCHEM BIOPH RES CO, V250, P414, DOI 10.1006/bbrc.1998.9319; Hu YZ, 2003, J BIOL CHEM, V278, P17299, DOI 10.1074/jbc.M300788200; Kaiser K, 2003, J EXP MED, V197, P1045, DOI 10.1084/jem.20022100; KARNUMAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200; KWIATKOWSKI D, 1989, J EXP MED, V169, P357, DOI 10.1084/jem.169.1.357; Ochel HJ, 1999, MOL GENET METAB, V66, P24, DOI 10.1006/mgme.1998.2774; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Saito-Ito A, 2001, PARASITOL INT, V50, P249, DOI 10.1016/S1383-5769(01)00091-5; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Shao J, 2002, BIOCHEMISTRY-US, V41, P6770, DOI 10.1021/bi025737a; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SOETE M, 1994, EXP PARASITOL, V78, P361, DOI 10.1006/expr.1994.1039; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Udomsangpetch R, 2002, P NATL ACAD SCI USA, V99, P11825, DOI 10.1073/pnas.172398999; Webb CP, 2000, CANCER RES, V60, P342; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wiesgigl M, 2001, MOL BIOL CELL, V12, P3307, DOI 10.1091/mbc.12.11.3307; Xu Y, 1999, P NATL ACAD SCI USA, V96, P109, DOI 10.1073/pnas.96.1.109	29	64	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46692	46699		10.1074/jbc.M409165200	http://dx.doi.org/10.1074/jbc.M409165200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339915	hybrid			2022-12-25	WOS:000224832400046
J	Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P				Herrant, M; Jacquel, A; Marchetti, S; Belhacene, N; Colosetti, P; Luciano, F; Auberger, P			Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis	ONCOGENE			English	Article						Mcl-1; Bim; caspases; cleavage; mitochondria	HUMAN MYELOMA CELLS; FAS-MEDIATED APOPTOSIS; PROTEIN-KINASE-C; BCL-2 FAMILY; INTERFERON-ALPHA; T-LYMPHOCYTES; GENE-PRODUCT; EXPRESSION; SURVIVAL; DEATH	Mcl-1 is an antiapoptotic member of the Bcl-2 family that can promote cell viability. We report here that Mcl-1 is a new substrate for caspases during induction of apoptosis. Mcl-1 cleavage occurs after Asp127 and Asp157 and generates four fragments of 24, 19, 17 and 12 kDa in both intact cells and in vitro, an effect prevented by selective caspase inhibitors. As a consequence, the resulting protein that lacks the first 127 or 157 amino acids contains only the BH1-BH3 domains of Bcl-2 family members. Mutation of Asp127 and Asp157 abolishes the generation of the 24 and 12 kDa fragments and that of the 19 and 17 kDa fragments, respectively. Interestingly, when expressed in HeLa cells Mcl-1 wt and Mcl-1 Delta127 showed a markedly different intracellular distribution. Mcl-1 wt colocalized with a-Tubulin near the internal face of the plasma membrane, while Mcl-1 Delta127 coassociated with Bim-EL at the mitochondrial level. Coinamunoprecipitation experiments also demonstrated that Mcl1 Delta127 exhibited increased binding to Bim when compared to Mcl-1 wt. Finally, Mcl-1 wt unlike Mcl-1 Delta127 inhibited Bim-EL-induced caspase activation. Altogether, our findings demonstrate that cleavage of Mcl-1 by caspases modifies its subcellular localization, increases its association with Bim and inhibits its antiapoptotic function.	Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, F-06107 Nice 2, France; Burnham Inst, La Jolla, CA 92037 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Sanford Burnham Prebys Medical Discovery Institute	Auberger, P (corresponding author), Fac Med Nice, INSERM, U526, Equipe Labellisee Ligue Natl Canc,IFR50, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Jacquel, Arnaud/O-1928-2017; Colosetti, Pascal/ABH-4585-2020; Jacquel, Arnaud/AAJ-4760-2021; AUBERGER, Patrick/G-1491-2013; Marchetti, Sandrine/P-6479-2016; luciano, frederic/P-6264-2016	Jacquel, Arnaud/0000-0001-5062-8048; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; Marchetti, Sandrine/0000-0001-8326-5730; luciano, frederic/0000-0001-9253-4998				Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199; Bae JY, 2003, J BIOL CHEM, V278, P5195, DOI 10.1074/jbc.M201988200; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fujita N, 1998, ONCOGENE, V17, P1295, DOI 10.1038/sj.onc.1202065; HAN J, 2004, J BIOL CHEM, V10, P10; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; JACQUEL A, 2003, FASEB J, V4, P4; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Luciano F, 2003, FASEB J, V17, P711, DOI 10.1096/fj.02-0716fje; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; Mouhamad S, 2004, J IMMUNOL, V172, P2084, DOI 10.4049/jimmunol.172.4.2084; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Puthier D, 2001, BRIT J HAEMATOL, V112, P358, DOI 10.1046/j.1365-2141.2001.02575.x; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; Rinkenberger JL, 2000, GENE DEV, V14, P23; Snowden RT, 2003, LEUKEMIA, V17, P1981, DOI 10.1038/sj.leu.2403088; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHU Y, 2004, P NATL ACAD SCI USA, V10, P10; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	43	150	151	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7863	7873		10.1038/sj.onc.1208069	http://dx.doi.org/10.1038/sj.onc.1208069			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378010				2022-12-25	WOS:000224331600012
J	Jozsef, L; Khreiss, T; Filep, JG				Jozsef, L; Khreiss, T; Filep, JG			CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes	FASEB JOURNAL			English	Article						neutrophil survival; toll-like receptor-9; mitochondrial dysfunction; caspase-3; inflammation	PROGRAMMED CELL-DEATH; TOLL-LIKE RECEPTORS; ACTIVATED PROTEIN-KINASE; C-REACTIVE PROTEIN; NITRIC-OXIDE; ENDOTHELIAL-CELLS; AGING NEUTROPHILS; ACIDIFICATION; OLIGODEOXYNUCLEOTIDES; INFLAMMATION	Human neutrophil granulocytes die rapidly, and their survival is contingent upon rescue from programmed cell death by signals from the environment. We now show that a novel signal for delaying neutrophil apoptosis is unmethylated CpG motifs prevalent in bacterial DNA ( CpG-DNA). Human neutrophils express toll-like receptor 9 that recognizes these motifs. CpG-DNA, but not mammalian DNA or methylated bacterial DNA, markedly enhanced neutrophil viability by delaying spontaneous apoptosis. Endosomal maturation of CpG-DNA is prerequisite for these actions and was coupled to concurrent activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase/Akt signaling pathways, leading to phosphorylation of BAD at Ser(112) and Ser(136), respectively, and to prevention of decreases in mitochondrial transmembrane potential, cytochrome c release and caspase-3 activation. Consistently, pharmacological inhibition of either ERK or phosphatidylinositol 3-kinase partially reversed these actions of CpG-DNA; however, they did not produce additive inhibition. Furthermore, intravenous injection of CpG-DNA (200 mug/kg) into rats evoked slight decreases in blood pressure and induced a modest leukocytosis, whereas it effectively suppressed neutrophil apoptosis as assayed ex vivo. Our results indicate that unmethylated CpG motifs in bacterial DNA promote neutrophil survival by suppressing the apoptotic machinery and may therefore contribute to prolongation and amplification of inflammation.	Maisonneuve Rosemont Hosp, Res Ctr, Montreal, PQ H1T 2M4, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Filep, JG (corresponding author), Maisonneuve Rosemont Hosp, Res Ctr, 5415 Blvd Assompt, Montreal, PQ H1T 2M4, Canada.	janos.g.filep@umontreal.ca						Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akhtar M, 2003, FASEB J, V17, P1319, DOI 10.1096/fj.02-0950fje; Alvarado-Kristensson M, 2001, FASEB J, V15, P129, DOI 10.1096/fj.01-0817fje; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; COLOTTA F, 1992, BLOOD, V80, P2012; Cowdery J, 1996, J IMMUNOL, V156, P4570; COX G, 1995, AM J RESP CELL MOL, V12, P232, DOI 10.1165/ajrcmb.12.2.7865221; Filep JG, 1997, CIRC RES, V81, P840; Filep JG, 1996, BLOOD, V87, P5136, DOI 10.1182/blood.V87.12.5136.bloodjournal87125136; Frasch SC, 1998, J BIOL CHEM, V273, P8389, DOI 10.1074/jbc.273.14.8389; Gao JJ, 1999, J IMMUNOL, V163, P4095; GOTTLIEB RA, 1995, P NATL ACAD SCI USA, V92, P5965, DOI 10.1073/pnas.92.13.5965; Hacker G, 2002, IMMUNOLOGY, V105, P245; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Keel M, 1997, BLOOD, V90, P3356, DOI 10.1182/blood.V90.9.3356; Khreiss T, 2002, J BIOL CHEM, V277, P40775, DOI 10.1074/jbc.M205378200; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LEE A, 1993, J LEUKOCYTE BIOL, V54, P283, DOI 10.1002/jlb.54.4.283; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LILES WC, 1995, BLOOD, V86, P3181; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; MatuteBello G, 1997, AM J RESP CRIT CARE, V156, P1969, DOI 10.1164/ajrccm.156.6.96-12081; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pillinger MH, 1996, J BIOL CHEM, V271, P12049, DOI 10.1074/jbc.271.20.12049; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sanghavi DM, 1998, FEBS LETT, V422, P179, DOI 10.1016/S0014-5793(98)00004-0; SAVILL J, 1994, EUR J CLIN INVEST, V24, P715, DOI 10.1111/j.1365-2362.1994.tb01067.x; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Stacey KJ, 2003, J IMMUNOL, V170, P3614, DOI 10.4049/jimmunol.170.7.3614; TONKINSON JL, 1994, NUCLEIC ACIDS RES, V22, P4268, DOI 10.1093/nar/22.20.4268; Trevani AS, 2003, EUR J IMMUNOL, V33, P3164, DOI 10.1002/eji.200324334; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Weighardt H, 2000, J IMMUNOL, V165, P4537, DOI 10.4049/jimmunol.165.8.4537; WHYTE MKB, 1993, J IMMUNOL, V150, P5124; Yamada H, 2002, J IMMUNOL, V169, P5590, DOI 10.4049/jimmunol.169.10.5590; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yi AK, 1998, J IMMUNOL, V160, P4755; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561; Zouki C, 2001, FASEB J, V15, P25	57	78	79	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1776	+		10.1096/fj.04-2048fje	http://dx.doi.org/10.1096/fj.04-2048fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345690				2022-12-25	WOS:000224243200043
J	He, JQ; Bellini, M; Xu, JG; Castleberry, AM; Hall, RA				He, JQ; Bellini, M; Xu, JG; Castleberry, AM; Hall, RA			Interaction with cystic fibrosis transmembrane conductance regulator-associated ligand (CAL) inhibits beta 1-adrenergic receptor surface expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTORS; D-ASPARTATE RECEPTORS; BETA(1)-ADRENERGIC RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; FREQUENCY STIMULATION; SYNAPTIC PLASTICITY; GOLGI PROTEIN; HEART-FAILURE; PDZ PROTEINS; MODULATION	G protein-coupled receptors such as the beta1-adrenergic receptor (beta1AR) must be trafficked to the plasma membrane in order to bind with their extracellular ligands and regulate cellular physiology. By using glutathione S-transferase pull-down techniques, we found that the beta1AR carboxyl terminus directly interacts with the cystic fibrosis transmembrane conductance regulator-associated ligand (CAL; also known as PIST, GOPC, and FIG), a protein known to be primarily localized to the Golgi apparatus. CAL contains two predicted coiled-coil domains and one PSD-95/Discs-large/ZO-1 homology (PDZ) domain. The beta1AR carboxyl terminus (CT) binds to the PDZ domain of CAL, with the last few amino acids (ESKV) of the beta1AR-CT being the key determinants for the interaction. Mutation of the terminal valine residue resulted in markedly reduced association of the beta1AR-CT with CAL. Numerous other mutations to the ESKV motif also impaired the beta1AR-CT/CAL interaction, suggesting that this motif is close to optimal for association with the CAL PDZ domain. In cells, full-length beta1AR robustly associates with CAL, and this interaction is abolished by mutation of the terminal valine to alanine of the receptor (V477A), as determined by co-immunoprecipitation experiments and immunofluorescence co-localization studies. Consistent with observations that CAL is a Golgi-associated protein, overexpression of CAL reduces surface expression of beta1AR. Interaction with CAL promotes retention of beta1AR within the cell, whereas PSD-95, another beta1AR-associated PDZ domain-containing protein, competitively blocks beta1AR association with CAL and promotes receptor trafficking to the cell surface. These data reveal that CAL, a novel beta1AR-binding partner, modulates beta1AR intracellular trafficking, thereby revealing a new mechanism of regulation for beta1AR anterograde trafficking through the endoplasmic reticulum-Golgi complex to the plasma membrane.	Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr, Atlanta, GA 30322 USA; Capital Univ Med Sci, Dept Biochem, Beijing 100054, Peoples R China; Peking Univ, Basic Med Coll, Inst Vasc Med, Stem Cell Ctr, Beijing 100083, Peoples R China	Emory University; Capital Medical University; Peking University	He, JQ (corresponding author), Emory Univ, Sch Med, Dept Pharmacol, Rollins Res Ctr 5113, 1510 Clifton Rd, Atlanta, GA 30322 USA.	jqhe53@hotmail.com; rhall@pharm.emory.edu		Hall, Randy/0000-0002-8318-8728	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060982] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM60982] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; Dorn GW, 2004, CIRCULATION, V109, P150, DOI 10.1161/01.CIR.0000111581.15521.F5; Farquhar MG, 1998, TRENDS CELL BIOL, V8, P2, DOI 10.1016/S0962-8924(97)01187-2; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; He JQ, 2003, ONCOGENE, V22, P4524, DOI 10.1038/sj.onc.1206767; He JQ, 2002, BIOCHEM BIOPH RES CO, V297, P565, DOI 10.1016/S0006-291X(02)02259-3; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Huang YY, 1996, NEURON, V16, P611, DOI 10.1016/S0896-6273(00)80080-X; Huet G, 2003, BIOCHIMIE, V85, P323, DOI 10.1016/S0300-9084(03)00056-7; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Hunt CA, 1996, J NEUROSCI, V16, P1380; Lohse MJ, 2003, CIRC RES, V93, P896, DOI 10.1161/01.RES.0000102042.83024.CA; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Pak Y, 2002, MOL CELL BIOL, V22, P7942, DOI 10.1128/MCB.22.22.7942-7952.2002; Pham N, 2000, CURR BIOL, V10, P555, DOI 10.1016/S0960-9822(00)00473-5; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Wang SJ, 1999, J NEUROSCI, V19, P570; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Watanabe Y, 1996, NEUROSCIENCE, V71, P1031, DOI 10.1016/0306-4522(95)00498-X; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; Xiang Y, 2003, SCIENCE, V300, P1530, DOI 10.1126/science.1079206; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	42	48	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50190	50196		10.1074/jbc.M404876200	http://dx.doi.org/10.1074/jbc.M404876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358775	hybrid			2022-12-25	WOS:000225229500079
J	Hemmi, H; Shibuya, K; Takahashi, Y; Nakayama, T; Nishino, T				Hemmi, H; Shibuya, K; Takahashi, Y; Nakayama, T; Nishino, T			(S)-2,3-Di-O-geranylgeranylglyceryl phosphate synthase from the thermoacidophilic Archaeon Sulfolobus solfataricus - Molecular cloning and characterization of a membrane-intrinsic prenyltransferase involved in the biosynthesis of archaeal ether-linked membrane lipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENANTIOMERIC GLYCEROPHOSPHATE BACKBONE; FARNESYLGERANYL DIPHOSPHATE SYNTHASE; METHANOBACTERIUM-THERMOAUTOTROPHICUM; SN-GLYCEROL-1-PHOSPHATE DEHYDROGENASE; THERMOPLASMA-ACIDOPHILUM; METHANOGENIC ARCHAEA; ESCHERICHIA-COLI; PURIFICATION; ENZYME; GENE	The core structure of membrane lipids of archaea have some unique properties that permit archaea to be distinguished from the others, i.e. bacteria and eukaryotes. (S)-2,3-Di-O-geranylgeranylglyceryl phosphate synthase, which catalyzes the transfer of a geranylgeranyl group from geranylgeranyl diphosphate to (S)-3-O-geranylgeranylglyceryl phosphate, is involved in the biosynthesis of archaeal membrane lipids. Enzymes of the UbiA prenyltransferase family are known to catalyze the transfer of a prenyl group to various acceptors with hydrophobic ring structures in the biosynthesis of respiratory quinones, hemes, chlorophylls, vitamin E, and shikonin. The thermoacidophilic archaeon Sulfolobus solfataricus was found to encode three homologues of UbiA prenyltransferase in its genome. One of the homologues encoded by SSO0583 was expressed in Escherichia coli, purified, and characterized. Radio-assay and mass spectrometry analysis data indicated that the enzyme specifically catalyzes the biosynthesis of ( S)-2,3-di-O- geranylgeranylglyceryl phosphate. The fact that the orthologues of the enzyme are encoded in almost all archaeal genomes clearly indicates the importance of their functions. A phylogenetic tree constructed using the amino acid sequences of some typical members of the UbiA prenyltransferase family and their homologues from S. solfataricus suggests that the two other S. solfataricus homologues, excluding the ( S)-2,3-di-O-geranylgeranylglyceryl phosphate synthase, are involved in the production of respiratory quinone and heme, respectively. We propose here that archaeal prenyltransferases involved in membrane lipid biosynthesis might be prototypes of the protein family and that archaea might have played an important role in the molecular evolution of prenyltransferases.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan	Tohoku University	Hemmi, H (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	hhemmi@seika.che.tohoku.ac.jp	Hemmi, Hisashi/I-6868-2014	Hemmi, Hisashi/0000-0002-9538-809X				Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998; Beifuss U, 2000, ANGEW CHEM INT EDIT, V39, P2470, DOI 10.1002/1521-3773(20000717)39:14<2470::AID-ANIE2470>3.0.CO;2-R; CHEN AJ, 1993, J BIOL CHEM, V268, P21701; CHEN AJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P399, DOI 10.1006/abbi.1994.1459; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; DEROSA M, 1977, J CHEM SOC PERK T 1, P653, DOI 10.1039/p19770000653; Eguchi T, 2003, TETRAHEDRON LETT, V44, P3275, DOI 10.1016/S0040-4039(03)00627-0; FUJII H, 1982, BIOCHIM BIOPHYS ACTA, V712, P716; GAMBACORTA A, 1994, SYST APPL MICROBIOL, V16, P518; Kon T, 2002, J BACTERIOL, V184, P1395, DOI 10.1128/JB.184.5.1395-1401.2002; LUBBEN M, 1994, J BIOL CHEM, V269, P21473; MELZER M, 1994, BBA-LIPID LIPID MET, V1212, P93, DOI 10.1016/0005-2760(94)90193-7; Morii H, 2000, J BIOL CHEM, V275, P36568, DOI 10.1074/jbc.M005925200; Morii H, 2003, J BACTERIOL, V185, P1181, DOI 10.1128/JB.185.4.1181-1189.2003; Muhlenweg A, 1998, PLANTA, V205, P407, DOI 10.1007/s004250050337; Nemoto N, 2003, J BIOCHEM, V133, P651, DOI 10.1093/jb/mvg083; NISHIHARA M, 1995, J BIOCHEM-TOKYO, V117, P933, DOI 10.1093/oxfordjournals.jbchem.a124822; Nishihara M, 1997, J BIOCHEM-TOKYO, V122, P572; OHNUMA S, 1994, J BIOL CHEM, V269, P14792; Soderberg T, 2001, BIOCHEMISTRY-US, V40, P14847, DOI 10.1021/bi0111799; TACHIBANA A, 1994, FEBS LETT, V341, P291, DOI 10.1016/0014-5793(94)80475-3; Tachibana A, 2000, EUR J BIOCHEM, V267, P321, DOI 10.1046/j.1432-1327.2000.00967.x; Wang CW, 1999, BIOTECHNOL BIOENG, V62, P235, DOI 10.1002/(SICI)1097-0290(19990120)62:2<235::AID-BIT14>3.0.CO;2-U; Waters E, 2003, P NATL ACAD SCI USA, V100, P12984, DOI 10.1073/pnas.1735403100; ZHANG DL, 1990, J AM CHEM SOC, V112, P1264, DOI 10.1021/ja00159a067; ZHANG DL, 1993, J ORG CHEM, V58, P3919, DOI 10.1021/jo00067a025; ZHANG DL, 1993, J AM CHEM SOC, V115, P1270, DOI 10.1021/ja00057a008; ZHANG DL, 1993, ANAL BIOCHEM, V213, P356, DOI 10.1006/abio.1993.1432	28	50	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50197	50203		10.1074/jbc.M409207200	http://dx.doi.org/10.1074/jbc.M409207200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15356000	hybrid			2022-12-25	WOS:000225229500080
J	Nakatsukasa, K; Okada, S; Umebayashi, K; Fukuda, R; Nishikawa, S; Endo, T				Nakatsukasa, K; Okada, S; Umebayashi, K; Fukuda, R; Nishikawa, S; Endo, T			Roles of O-mannosylation of aberrant proteins in reduction of the load for endoplasmic reticulum chaperones in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSIDASE-LIKE PROTEIN; MISFOLDED SECRETORY PROTEIN; NIVEUS ASPARTIC PROTEINASE; ALPHA-FACTOR PRECURSOR; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; RETRO-TRANSLOCATION; MOLECULAR CHAPERONES; DEGRADATION; ER	The protein quality control system in the endoplasmic reticulum (ER) ensures that only properly folded proteins are deployed throughout the cells. When nonnative proteins accumulate in the ER, the unfolded protein response is triggered to limit further accumulation of nonnative proteins and the ER is cleared of accumulated nonnative proteins by the ER-associated degradation (ERAD). In the yeast ER, aberrant nonnative proteins are mainly directed for the ERAD, but a distinct fraction of them instead receive O-mannosylation. In order to test whether O-mannosylation might also be a mechanism to process aberrant proteins in the ER, here we analyzed the effect of O-mannosylation on two kinds of model aberrant proteins, a series of N-glycosylation site mutants of prepro-alpha-factor and a pro-region-deleted derivative of Rhizopus niveus aspartic proteinase-I (Deltapro) both in vitro and in vivo. O-Mannosylation increases solubilities of the aberrant proteins and renders them less dependent on the ER chaperone, BiP, for being soluble. The release from ER chaperones allows the aberrant proteins to exit out of the ER for the normal secretory pathway transport. When the gene for Pmt2p, responsible for the O-mannosylation of these aberrant proteins, and that for the ERAD were simultaneously deleted, the cell exhibited enhanced unfolded protein response. O-Mannosylation may therefore function as a fail-safe mechanism for the ERAD by solubilizing the aberrant proteins that overflowed from the ERAD pathway and reducing the load for ER chaperones.	Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Genet, Dept Cell Genet, Shizuoka 4118540, Japan; Univ Tokyo, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Nagoya Univ, Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; University of Tokyo; Japan Science & Technology Agency (JST); Nagoya University; Nagoya University	Endo, T (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Chem, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	endo@biochem.chem.nagoya-u.ac.jp						Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Brachmann CB, 1998, YEAST, V14, P115; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; Coughlan CM, 2004, J BIOL CHEM, V279, P15289, DOI 10.1074/jbc.M309673200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Fukuda R, 1996, J BIOL CHEM, V271, P14252, DOI 10.1074/jbc.271.24.14252; Gentzsch M, 1996, EMBO J, V15, P5752, DOI 10.1002/j.1460-2075.1996.tb00961.x; Gillece P, 1999, J CELL BIOL, V147, P1443, DOI 10.1083/jcb.147.7.1443; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; Hosokawa N, 2001, EMBO REP, V2, P415, DOI 10.1093/embo-reports/kve084; Imperiali B, 1999, CURR OPIN CHEM BIOL, V3, P643, DOI 10.1016/S1367-5931(99)00021-6; Ioannou YA, 1998, BIOCHEM J, V332, P789, DOI 10.1042/bj3320789; Jakob CA, 2001, EMBO REP, V2, P423; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kaiser C., 1994, METHODS YEAST GENETI; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Kostova Z, 2003, EMBO J, V22, P2309, DOI 10.1093/emboj/cdg227; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; Lee RJ, 2004, EMBO J, V23, P2206, DOI 10.1038/sj.emboj.7600232; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; Lommel M, 2004, MOL CELL BIOL, V24, P46, DOI 10.1128/MCB.24.1.46-57.2004; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; NISHIKAWA S, 1993, P NATL ACAD SCI USA, V90, P8179, DOI 10.1073/pnas.90.17.8179; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Proszynski TJ, 2004, MOL BIOL CELL, V15, P1533, DOI 10.1091/mbc.E03-07-0511; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; Sanders SL, 1999, J CELL BIOL, V145, P1177, DOI 10.1083/jcb.145.6.1177; SCHULKE N, 1988, J BIOL CHEM, V263, P8832; SIKORSKI RS, 1989, GENETICS, V122, P19; Silberstein S, 1998, J CELL BIOL, V143, P921, DOI 10.1083/jcb.143.4.921; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Strahl-Bolsinger S, 1999, BBA-GEN SUBJECTS, V1426, P297, DOI 10.1016/S0304-4165(98)00131-7; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Umebayashi K, 2001, J BIOL CHEM, V276, P41444, DOI 10.1074/jbc.M105829200; Umebayashi K, 1997, YEAST, V13, P1009; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Wojczyk BS, 1998, GLYCOBIOLOGY, V8, P121, DOI 10.1093/glycob/8.2.121; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Ye YH, 2004, NATURE, V429, P841, DOI 10.1038/nature02656	57	60	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49762	49772		10.1074/jbc.M403234200	http://dx.doi.org/10.1074/jbc.M403234200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377669	hybrid			2022-12-25	WOS:000225229500028
J	Singh, CR; Yamamoto, Y; Asano, K				Singh, CR; Yamamoto, Y; Asano, K			Physical association of eukaryotic initiation factor (eIF) 5 carboxyl-terminal domain with the lysine-rich eIF2 beta segment strongly enhances its binding to eIF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; MULTIFACTOR COMPLEX; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; BETA-SUBUNIT; YEAST; GCN4; EVOLUTION; SELECTION; CAP	The carboxyl-terminal domain (CTD) of eukaryotic initiation factor (eIF) 5 interacts with eIF1, eIF2beta, and eIF3c, thereby mediating formation of the multifactor complex (MFC), an important intermediate for the 43 S preinitiation complex assembly. Here we demonstrate in vitro formation of a nearly stoichiometric quaternary complex containing eIF1 and the minimal segments of eIF2beta, eIF3c, and eIF5. In vivo, overexpression of eIF2 and tRNA(i)(Met) suppresses the temperature-sensitive phenotype of tif5-7A altering eIF5-CTD by increasing interaction of the mutant eIF5 with eIF2 by mass action and restoring its defective interaction with eIF3. By contrast, overexpression of eIF1 exacerbated the tif5-7A phenotype because eIF1 forms unusual inhibitory complexes with a hyperstoichiometric amount of eIF1. Formation of such complexes leads to increased GCN4 translation, independent of eIF2 phosphorylation (general control derepressed or Gcd(-) phenotype). We also provide biochemical evidence indicating that the association of eIF5-CTD with eIF2beta strongly enhances its binding to eIF3c. Our results suggest strongly that MFC formation is an ordered event involving specific enhancement of eIF5-CTD binding to eIF3 on its binding to eIF2beta. We propose that the primary function of eIF5-CTD is to serve as an assembly guide by rapidly promoting stoichiometric MFC assembly with the aid of eIF2 while excluding formation of nonfunctional complexes.	Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Manhattan, KS 66506 USA	Kansas State University	Asano, K (corresponding author), Kansas State Univ, Div Biol, Mol Cellular & Dev Biol Program, Ackert Hall, Manhattan, KS 66506 USA.	kasano@ksu.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064781] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR15563] Funding Source: Medline; NIGMS NIH HHS [R01 GM64781] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 2000, GENOME RES, V10, P1172, DOI 10.1101/gr.10.8.1172; Asano K, 2000, GENE DEV, V14, P2534, DOI 10.1101/gad.831800; Asano K, 1998, J BIOL CHEM, V273, P18573, DOI 10.1074/jbc.273.29.18573; Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Asano K, 2001, EMBO J, V20, P2326, DOI 10.1093/emboj/20.9.2326; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boesen T, 2004, J BIOL CHEM, V279, P10584, DOI 10.1074/jbc.M311055200; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; Das S, 2001, J BIOL CHEM, V276, P6720, DOI 10.1074/jbc.M008863200; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; Donahue TF, 2000, COLD SPRING HARBOR M, V39, P487; Endy D, 2003, NATURE, V426, P614, DOI 10.1038/426614a; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gross JD, 2003, CELL, V115, P739, DOI 10.1016/S0092-8674(03)00975-9; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; He H, 2003, MOL CELL BIOL, V23, P5431, DOI 10.1128/MCB.23.15.5431-5445.2003; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; KOONIN EV, 1995, PROTEIN SCI, V4, P1608, DOI 10.1002/pro.5560040819; Maag D, 2003, J MOL BIOL, V330, P917, DOI 10.1016/S0022-2836(03)00665-X; Nielsen KH, 2004, EMBO J, V23, P1166, DOI 10.1038/sj.emboj.7600116; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Phan L, 2001, EMBO J, V20, P2954, DOI 10.1093/emboj/20.11.2954; Singh CR, 2004, J BIOL CHEM, V279, P31910, DOI 10.1074/jbc.M313940200; Valasek L, 1998, J BIOL CHEM, V273, P21253, DOI 10.1074/jbc.273.33.21253; Valasek L, 2003, GENE DEV, V17, P786, DOI 10.1101/gad.1065403; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; von der Haar T, 2002, MOL MICROBIOL, V46, P531, DOI 10.1046/j.1365-2958.2002.03172.x; Zarrinpar A, 2003, NATURE, V426, P676, DOI 10.1038/nature02178; Zhou P, 2001, P NATL ACAD SCI USA, V98, P6051, DOI 10.1073/pnas.111145098	34	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49644	49655		10.1074/jbc.M409609200	http://dx.doi.org/10.1074/jbc.M409609200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377664	hybrid			2022-12-25	WOS:000225229500014
J	Tang, HL; Yeh, LS; Chen, NK; Ripmaster, T; Schimmel, P; Wang, CC				Tang, HL; Yeh, LS; Chen, NK; Ripmaster, T; Schimmel, P; Wang, CC			Translation of a yeast mitochondrial tRNA synthetase initiated at redundant non-AUG codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE ENCODES; MESSENGER-RNAS; PROTEIN; SELECTION; REGION; AMINOACYLATION; RECOGNITION; FEATURES; THALIANA	Although initiation of translation at non-AUG codons occurs occasionally in prokaryotes and higher eukaryotes, it has not been reported in yeast until very recently. Evidence presented here shows that redundant ACG codons are recognized as alternative translation start sites for ALA1, the only gene in Saccharomyces cerevisiae coding for alanyl-tRNA synthetase. ALA1 is shown to be a bifunctional gene that provides both cytoplasmic and mitochondrial activities. Unlike most bifunctional genes that contain alternative in-frame AUG initiators, there is only one AUG codon, designated AUG(1), close to the 5'-end of the ALA1 open reading frame. Transcriptional mapping identified three overlapping transcripts, with 5'-ends at positions 54, 105, and 117 nucleotides upstream of AUG(1), respectively. Site-specific mutagenesis demonstrated that the cytoplasmic and mitochondrial functions of ALA1 are provided by two protein isoforms with distinct amino termini; that is, a short cytoplasmic form initiated at AUG(1) and a longer mitochondrial isoform initiated at two upstream in-frame ACG codons, i.e. ACG(-25) and ACG(-24). These two ACG codons function redundantly in initiation of translation. Either codon can function in the absence of the other. The short transcript appears to serve as the template for the cytoplasmic form, whereas the longer transcripts are likely to code for both isoforms via alternative initiation. Because yeast ribosomes in general cannot efficiently recognize a non-AUG initiator, this unique feature of redundancy of non-AUG initiators in a single mRNA may in itself represent a novel paradigm for translation initiation from poor initiators.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Natl Cent Univ, Dept Life Sci, Chungli 32054, Taiwan; Tzu Chi Univ, Dept Life Sci, Hualien 97041, Taiwan; MIT, Dept Biol, Cambridge, MA 02139 USA	Scripps Research Institute; National Central University; Tzu Chi University; Massachusetts Institute of Technology (MIT)	Schimmel, P (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd,BCC-379, La Jolla, CA 92037 USA.	schimmel@scripps.edu; dukewang@cc.ncu.edu.tw			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23562] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramczyk D, 2003, YEAST, V20, P1045, DOI 10.1002/yea.1020; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; Chang KJ, 2004, J BIOL CHEM, V279, P13778, DOI 10.1074/jbc.M311269200; CHATTON B, 1988, J BIOL CHEM, V263, P52; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; CLEMENTS JM, 1988, MOL CELL BIOL, V8, P4533, DOI 10.1128/MCB.8.10.4533; DONAHUE TF, 1988, MOL CELL BIOL, V8, P2955, DOI 10.1128/MCB.8.7.2955; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MARECHALDROUARD L, 1993, ANN REV CELL BIOL, V8, P115; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; MARTINIS SA, 1996, ESCHERICHIA COLI SAL, P887; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Pelchat M, 1999, BIOCHEM CELL BIOL, V77, P343, DOI 10.1139/bcb-77-4-343; Riechmann JL, 1999, MOL CELL BIOL, V19, P8505; RIPMASTER TL, 1995, P NATL ACAD SCI USA, V92, P4932, DOI 10.1073/pnas.92.11.4932; Sachs MS, 2002, METHODS, V26, P105, DOI 10.1016/S1046-2023(02)00013-0; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; SHERMAN F, 1980, CELL, V20, P215, DOI 10.1016/0092-8674(80)90249-4; SIKORSKI RS, 1989, GENETICS, V122, P19; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; Souciet G, 1999, EUR J BIOCHEM, V266, P848, DOI 10.1046/j.1432-1327.1999.00922.x; Turner RJ, 2000, J BIOL CHEM, V275, P27681; WOLFE CL, 1994, J BIOL CHEM, V269, P13361; YOON H, 1992, MOL MICROBIOL, V6, P1413, DOI 10.1111/j.1365-2958.1992.tb00861.x	40	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49656	49663		10.1074/jbc.M408081200	http://dx.doi.org/10.1074/jbc.M408081200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358761	hybrid			2022-12-25	WOS:000225229500015
J	Yamaguchi, K; Lee, SH; Eling, TE; Baek, SJ				Yamaguchi, K; Lee, SH; Eling, TE; Baek, SJ			Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA SUPERFAMILY MEMBER; COLON-CANCER CELLS; GROWTH-FACTOR-BETA; 3-KINASE INHIBITOR; MOLECULAR-CLONING; SIGNALING PATHWAY; CARCINOMA CELLS; KINASE 3-BETA; TUMOR-CELLS	The signaling pathway of phosphatidylinositol 3-kinase (PI3K)/AKT, which is involved in cell survival, proliferation, and growth, has become a major focus in targeting cancer therapeutics. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) was previously identified as a gene induced by several anti-tumorigenic compounds including nonsteroidal anti-inflammatory drugs, peroxisome proliferator-activated receptor gamma ligands, and dietary compounds. NAG-1 has been shown to exhibit anti-tumorigenic and/or pro-apoptotic activities in vivo and in vitro. In this report, we showed a PI3K/AKT/glycogen synthase kinase-3beta (GSK-3beta) pathway regulates NAG-1 expression in human colorectal cancer cells as assessed by the inhibition of PI3K, AKT, and GSK-3beta. PI3K inhibition by LY294002 showed an increase in NAG-1 protein and mRNA expression, and 1L-6-hydroxymethyl-chiroinositol 2(R)-2-O-methyl-3-O-octadecylcarbonate (AKT inhibitor) also induced NAG-1 expression. LY294002 caused increased apoptosis, cell cycle, and cell growth arrest in HCT-116 cells. Inhibition of GSK-3beta, which is negatively regulated by AKT, using AR-A014418 and lithium chloride completely abolished LY294002-induced NAG-1 expression as well as the NAG-1 promoter activity. Furthermore, the down-regulation of GSK-3 gene using small interference RNA resulted in a decline of the NAG-1 expression in the presence of LY294002. These data suggest that expression of NAG-1 is regulated by PI3K/AKT/GSK-3beta pathway in HCT-116 cells and may provide a further understanding of the important role of PI3K/AKT/GSK-3beta pathway in tumorigenesis.	Univ Tennessee, Coll Vet Med, Dept Pathobiol, Lab Environm Carcinogensis, Knoxville, TN 37996 USA; NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Baek, SJ (corresponding author), Univ Tennessee, Coll Vet Med, Dept Pathobiol, Lab Environm Carcinogensis, 2407 River Dr, Knoxville, TN 37996 USA.	sbaek2@utk.edu		Baek, Seung/0000-0001-7866-7778	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES011657] Funding Source: NIH RePORTER; NIEHS NIH HHS [K22ES011657] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; Baek SJ, 2004, J BIOL CHEM, V279, P6883, DOI 10.1074/jbc.M305295200; Baek SJ, 2002, J PHARMACOL EXP THER, V301, P1126, DOI 10.1124/jpet.301.3.1126; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, J BIOL CHEM, V276, P33384, DOI 10.1074/jbc.M101814200; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Bottone FG, 2002, J NUTR, V132, P773, DOI 10.1093/jn/132.4.773; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Izuishi K, 2000, CANCER RES, V60, P6201; Khaleghpour K, 2004, CARCINOGENESIS, V25, P241, DOI 10.1093/carcin/bgg195; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kulik G, 2001, CANCER RES, V61, P2713; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Monks A, 2003, MOL PHARMACOL, V63, P766, DOI 10.1124/mol.63.3.766; Newman D, 2003, MOL PHARMACOL, V63, P557, DOI 10.1124/mol.63.3.557; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003; Semba S, 2002, CLIN CANCER RES, V8, P1957; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shingu T, 2003, CANCER RES, V63, P4044; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang QD, 2002, J BIOL CHEM, V277, P36602, DOI 10.1074/jbc.M206306200; Wilson LC, 2003, INT J CANCER, V105, P747, DOI 10.1002/ijc.11173; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Xavier IJ, 2000, J BIOL CHEM, V275, P29147, DOI 10.1074/jbc.M002169200; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	42	89	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49617	49623		10.1074/jbc.M408796200	http://dx.doi.org/10.1074/jbc.M408796200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377673	hybrid			2022-12-25	WOS:000225229500011
J	Antoniacci, LM; Kenna, MA; Uetz, P; Fields, S; Skibbens, RV				Antoniacci, LM; Kenna, MA; Uetz, P; Fields, S; Skibbens, RV			The spindle pole body assembly component Mps3p/Nep98p functions in sister chromatid cohesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR DIVISION; DNA-REPLICATION; YEAST; PROTEIN; CHROMOSOME; COMPLEX; GENOME; IDENTIFICATION; ESTABLISHMENT	For successful chromosome segregation during mitosis, several processes must occur early in the cell cycle, including spindle pole duplication, DNA replication, and the establishment of cohesion between nascent sister chromatids. Spindle pole body duplication begins in G(1) and continues during early S-phase as spindle pole bodies mature and start to separate. Key steps in spindle pole body duplication are the sequential recruitment of Cdc31p and Spc42p by the nuclear envelope transmembrane protein Msp3p/Nep98p (herein termed Mps3p). Concurrent with DNA replication, Ctf7p/Eco1p (herein termed Ctf7p) ensures that nascent sister chromatids are paired together, identifying the products of replication as sister chromatids. Here, we provide the first evidence that the nuclear envelope spindle pole body assembly component Mps3p performs a function critical to sister chromatid cohesion. Mps3p was identified as interacting with Ctf7p from a genome-wide two-hybrid screen, and the physical interaction was confirmed by both in vivo (co-immunoprecipitation) and in vitro (GST pull-down) assays. An in vivo cohesion assay on new mps3/nep98 alleles revealed that loss of Mps3p results in precocious sister chromatid separation and that Mps3p functions after G(1), coincident with Ctf7p. Mps3p is not required for cohesion during mitosis, revealing that Mps3p functions in cohesion establishment and not maintenance. Mutated Mps3p that results in cohesion defects no longer binds to Ctf7p in vitro, demonstrating that the interaction between Mps3p and Ctf7p is physiologically relevant. In support of this model, mps3 ctf7 double mutant cells exhibit conditional synthetic lethality. These findings document a new role for Mps3p in sister chromatid cohesion and provide novel insights into the mechanism by which a spindle pole body component, when mutated, contributes to aneuploidy.	Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	Lehigh University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Skibbens, RV (corresponding author), Lehigh Univ, Dept Biol Sci, Bethlehem, PA 18015 USA.	rvs3@Lehigh.edu	Uetz, Peter/A-7119-2012	Uetz, Peter/0000-0001-6194-4927	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR11823] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; Belgareh N, 2001, J CELL BIOL, V154, P1147, DOI 10.1083/jcb.200101081; Bellows AM, 2003, NUCLEIC ACIDS RES, V31, P6334, DOI 10.1093/nar/gkg811; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Cassimeris Lynne, 2003, Current Issues in Molecular Biology, V5, P99; Castillo AR, 2002, J CELL BIOL, V156, P453, DOI 10.1083/jcb.200111025; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Cohen-Fix O, 2001, CELL, V106, P137, DOI 10.1016/S0092-8674(01)00439-1; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Edwards S, 2003, MOL CELL BIOL, V23, P2733, DOI 10.1128/MCB.23.8.2733-2748.2003; Francis SE, 2000, CURR TOP DEV BIOL, V49, P105; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hanna JS, 2001, MOL CELL BIOL, V21, P3144, DOI 10.1128/MCB.21.9.3144-3158.2001; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; James P, 1996, GENETICS, V144, P1425; Jasperson SL, 2002, J CELL BIOL, V159, P945, DOI 10.1083/jcb.200208169; KASSENBROCK CK, 1993, EMBO J, V12, P3023, DOI 10.1002/j.1460-2075.1993.tb05971.x; Kenna MA, 2003, MOL CELL BIOL, V23, P2999, DOI 10.1128/MCB.23.8.2999-3007.2003; Koshland DE, 2000, CURR OPIN CELL BIOL, V12, P297, DOI 10.1016/S0955-0674(00)00092-2; Krause SA, 2001, MOL CELL BIOL, V21, P5156, DOI 10.1128/MCB.21.15.5156-5168.2001; KURLANDZKA A, 1995, YEAST, V11, P885, DOI 10.1002/yea.320110910; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Mayer ML, 2004, MOL BIOL CELL, V15, P1736, DOI 10.1091/mbc.E03-08-0619; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nishikawa S, 2003, J BIOL CHEM, V278, P9938, DOI 10.1074/jbc.M210934200; Panizza S, 2000, CURR BIOL, V10, P1557, DOI 10.1016/S0960-9822(00)00854-X; Salina D, 2003, J CELL BIOL, V162, P991, DOI 10.1083/jcb.200304080; Skibbens RV, 2000, GENOME RES, V10, P1664, DOI 10.1101/gr.153600; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Skibbens RV, 2004, GENETICS, V166, P33, DOI 10.1534/genetics.166.1.33; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Taddei A, 2004, EMBO J, V23, P1301, DOI 10.1038/sj.emboj.7600144; Teixeira MT, 2002, J MOL BIOL, V321, P551, DOI 10.1016/S0022-2836(02)00652-6; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774; Warren CD, 2004, MOL BIOL CELL, V15, P1724, DOI 10.1091/mbc.E03-09-0637; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Winey M, 2001, NAT CELL BIOL, V3, pE23, DOI 10.1038/35050663; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	51	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49542	49550		10.1074/jbc.M404324200	http://dx.doi.org/10.1074/jbc.M404324200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355977	hybrid			2022-12-25	WOS:000225098100125
J	Lee, M; Kim, JY; Anderson, WB				Lee, M; Kim, JY; Anderson, WB			Src tyrosine kinase inhibitor PP2 markedly enhances Ras-independent activation of Raf-1 protein kinase by phorbol myristate acetate and H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; HYDROGEN-PEROXIDE; PHOSPHORYLATION SITES; C-EPSILON; B-RAF; TRANSDUCTION; SERINE; REQUIREMENT; MEMBRANE; RECEPTOR	Recently we reported that simultaneous treatment of NIH 3T3 cells with the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H2O2) resulted in synergistic activation of Raf-1 kinase ( Lee, M., Petrovics, G., and Anderson, W. B. ( 2003) Biochem. Biophys. Res. Commun. 311, 1026 - 1033). In this study we have demonstrated that PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, greatly potentiated the ability of PMA and/or H2O2 to activate Raf-1 kinase, whereas it blocked the tyrosine phosphorylation of Raf-1. Unlike PMA/H2O2 treatment, which showed transient activation, PP2-mediated Raf-1 activation was sustained and continued to increase through 4 h of treatment. Transient transfection studies with a dominant-negative mutant of Ras (N19Ras) indicated that this PP2-induced activation of Raf-1 was Ras-independent. Moreover, PP2 showed no effect on platelet-derived growth factor-induced Raf-1 activation. Interestingly, mutation of the reported Raf-1 Src family tyrosine kinase phosphorylation site by conversion of tyrosines 340 and 341 to phenylalanine (YY340/341FF Raf) had limited effect on the ability of PP2 to induce significant stimulation of Raf-1 kinase activity. Taken together, our results suggest that a tyrosine phosphorylation event is involved in the negative feedback regulation of Raf-1. Inhibition of a Src family tyrosine kinase by PP2 appears to alleviate this tyrosine kinase-mediated inhibition of Raf-1 and allow activating modification( s) of Raf-1 to proceed. This PP2 effect resulted in significant and sustained Ras-independent activation of Raf-1 by PMA and H2O2.	Korea Res Inst Chem Technol, Korea Inst Toxicol, Lab Genet Toxicol, Taejon 305600, South Korea; NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	Korea Institute of Toxicology; Korea Research Institute of Chemical Technology (KRICT); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Anderson, WB (corresponding author), Korea Res Inst Chem Technol, Korea Inst Toxicol, Lab Genet Toxicol, POB 123, Taejon 305600, South Korea.	mikelee@kitox.re.kr						Abe MK, 1998, AM J RESP CELL MOL, V18, P562, DOI 10.1165/ajrcmb.18.4.2958; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; ANDERSON WB, 1995, ADV CYCLIC NUCLEOTID, V19, P287; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; GERHARD C, 2003, NAT CELL BIOL, V5, P377; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hekman M, 2002, J BIOL CHEM, V277, P24090, DOI 10.1074/jbc.M200576200; Hindley A, 2002, J CELL SCI, V115, P1575; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; Laird AD, 1999, J BIOL CHEM, V274, P4430, DOI 10.1074/jbc.274.7.4430; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee M, 2003, BIOCHEM BIOPH RES CO, V311, P1026, DOI 10.1016/j.bbrc.2003.10.107; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Morrison DK, 2001, J CELL SCI, V114, P1609; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; MURAKAMI MS, 2001, SCI STKE; Natarajan V, 1998, ENVIRON HEALTH PERSP, V106, P1205, DOI 10.2307/3433987; OLAH Z, 1995, BIOCHEM BIOPH RES CO, V214, P340, DOI 10.1006/bbrc.1995.2293; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Perletti GP, 1998, ONCOGENE, V16, P3345, DOI 10.1038/sj.onc.1201871; PREISS J, 1986, J BIOL CHEM, V261, P8597; Raabe T, 2003, CURR BIOL, V13, pR635, DOI 10.1016/S0960-9822(03)00568-2; Rao GN, 1996, ONCOGENE, V13, P713; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Ueffing M, 1997, ONCOGENE, V15, P2921, DOI 10.1038/sj.onc.1201477; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	76	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48692	48701		10.1074/jbc.M403132200	http://dx.doi.org/10.1074/jbc.M403132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15356004	hybrid			2022-12-25	WOS:000225098100026
J	Macauley, MS; Errington, WJ; Okon, M; Scharpf, M; Mackereth, CD; Schulman, BA; McIntosh, LP				Macauley, MS; Errington, WJ; Okon, M; Scharpf, M; Mackereth, CD; Schulman, BA; McIntosh, LP			Structural and dynamic independence of isopeptide-linked RanGAP1 and SUMO-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; MOLYBDOPTERIN SYNTHASE; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; UBIQUITIN; BINDING; UBC9; NMR; IDENTIFICATION; COMPLEX	Although sumoylation regulates a diverse and growing number of recognized biological processes, the molecular mechanisms by which the covalent attachment of the ubiquitin-like protein SUMO can alter the properties of a target protein remain to be established. To address this question, we have used NMR spectroscopy to characterize the complex of mature SUMO-1 with the C-terminal domain of human RanGAP1. Based on amide chemical shift and N-15 relaxation measurements, we show that the C terminus of SUMO-1 and the loop containing the consensus sumoylation site in RanGAP1 are both conformationally flexible. Furthermore, the overall structure and backbone dynamics of each protein remain unchanged upon the covalent linkage of Lys(524) in RanGAP1 to the C-terminal Gly(97) of SUMO-1. Therefore, SUMO-1 and RanGAP1 behave as "beads-on-a-string," connected by a flexible isopeptide tether. Accordingly, the sumoylation-dependent interaction of RanGAP1 with the nucleoporin RanBP2 may arise through the bipartite recognition of both RanGAP1 and SUMO-1 rather than through a new binding surface induced in either individual protein upon their covalent linkage. We hypothesize that this conformational flexibility may be a general feature contributing to the recognition of ubiquitin-like modified proteins by their downstream effector machineries.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet Tumor Cell Biol, Memphis, TN 38105 USA	University of British Columbia; University of British Columbia; University of British Columbia; St Jude Children's Research Hospital; St Jude Children's Research Hospital	McIntosh, LP (corresponding author), Univ British Columbia, Dept Biochem, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	mcintosh@otter.biochem.ubc.ca	Mackereth, Cameron D./F-7946-2013	Mackereth, Cameron D./0000-0002-0776-7947; Macauley, Matthew/0000-0003-4579-1048	NIGMS NIH HHS [R01GM69530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bencsath KP, 2002, J BIOL CHEM, V277, P47938, DOI 10.1074/jbc.M207442200; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; COOK WJ, 1992, J BIOL CHEM, V267, P16467; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fuchs Serge Y, 2002, Cell, V110, P531, DOI 10.1016/S0092-8674(02)00902-9; Goddard T. D., 1999, SPARKY; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Joseph J, 2004, CURR BIOL, V14, P611, DOI 10.1016/j.cub.2004.03.031; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Lin DH, 2002, J BIOL CHEM, V277, P21740, DOI 10.1074/jbc.M108418200; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MCINTOSH LP, 1990, Q REV BIOPHYS, V23, P1, DOI 10.1017/S0033583500005400; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Quimby BB, 2003, CURR OPIN CELL BIOL, V15, P338, DOI 10.1016/S0955-0674(03)00046-2; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rudolph MJ, 2003, J BIOL CHEM, V278, P14514, DOI 10.1074/jbc.M300449200; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Tatham MH, 2003, BIOCHEMISTRY-US, V42, P9959, DOI 10.1021/bi0345283; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Uchimura Y, 2004, FEBS LETT, V564, P85, DOI 10.1016/S0014-5793(04)00321-7; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Varadan R, 2004, J BIOL CHEM, V279, P7055, DOI 10.1074/jbc.M309184200; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Wagner G, 1997, NAT STRUCT BIOL, V4, P841; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7	46	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49131	49137		10.1074/jbc.M408705200	http://dx.doi.org/10.1074/jbc.M408705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355965	hybrid			2022-12-25	WOS:000225098100078
J	Okamoto, H; Watanabe, K; Ikeuchi, Y; Suzuki, T; Endo, Y; Hori, H				Okamoto, H; Watanabe, K; Ikeuchi, Y; Suzuki, T; Endo, Y; Hori, H			Substrate tRNA recognition mechanism of tRNA (m(7)G46) methyltransferase from Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSFER-RNA; ANTICODON WOBBLE POSITION; ESCHERICHIA-COLI; PSEUDOURIDINE-SYNTHASE; GUANINE TRANSGLYCOSYLASE; SACCHAROMYCES-CEREVISIAE; GM18 METHYLTRANSFERASE; MODIFICATION DATABASE; NUCLEOTIDE-SEQUENCE; MODIFICATION ENZYME	Transfer RNA (m(7)G46) methyltransferase catalyzes the methyl transfer from S-adenosylmethionine to N-7 atom of the guanine 46 residue in tRNA. Analysis of the Aquifex aeolicus genome revealed one candidate open reading frame, aq065, encoding this gene. The aq065 protein was expressed in Escherichia coli and purified to homogeneity on 15% SDS-polyacrylamide gel electrophoresis. Although the overall amino acid sequence of the aq065 protein differs considerably from that of E. coli YggH, the purified aq065 protein possessed a tRNA (m(7)G46) methyltransferase activity. The modified nucleoside and its location were determined by liquid chromatography-mass spectroscopy. To clarify the RNA recognition mechanism of the enzyme, we investigated the methyl transfer activity to 28 variants of yeast tRNA(Phe) and E. coli tRNA(Thr). It was confirmed that 5'-leader and 3'-trailer RNAs of tRNA precursor are not required for the methyl transfer. We found that the enzyme specificity was critically dependent on the size of the variable loop. Experiments using truncated variants showed that the variable loop sequence inserted between two stems is recognized as a substrate, and the most important recognition site is contained within the T stem. These results indicate that the L-shaped tRNA structure is not required for methyl acceptance activity. It was also found that nucleotide substitutions around G46 in three-dimensional core decrease the activity.	Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 7908577, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Kashiwa, Chiba 2778562, Japan; Ehime Univ, Venture Business Lab, Matsuyama, Ehime 7908577, Japan; Ehime Univ, Cell Free Sci & Technol Res Ctr, Matsuyama, Ehime 7908577, Japan	Ehime University; University of Tokyo; Ehime University; Ehime University	Hori, H (corresponding author), Ehime Univ, Fac Engn, Dept Appl Chem, Bunkyo 3, Matsuyama, Ehime 7908577, Japan.	hori@eng.ehime-u.ac.jp	Suzuki, Tsutomu/J-1776-2015; ikeuchi, yoshiho/C-1713-2014; Ikeuchi, Yoshiho/N-1057-2019; Hori, Hiroyuki/AAB-3911-2021	Suzuki, Tsutomu/0000-0002-9731-1731; ikeuchi, yoshiho/0000-0002-2829-3840; 				Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; Ansmant I, 2001, J BIOL CHEM, V276, P34934, DOI 10.1074/jbc.M103131200; ASCHHOFF HJ, 1976, NUCLEIC ACIDS RES, V3, P3109, DOI 10.1093/nar/3.11.3109; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; Behm-Ansmant I, 2003, RNA, V9, P1371, DOI 10.1261/rna.5520403; Benne R., 1998, MODIFICATION EDITING, P543; Bjork Glenn R., 1995, P165; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BURGGRAF S, 1992, SYST APPL MICROBIOL, V15, P353; CARBON P, 1983, EMBO J, V2, P1093, DOI 10.1002/j.1460-2075.1983.tb01551.x; CHANG S, 1975, J BIOL CHEM, V250, P5542; CIMINO F, 1981, MOL CELL BIOCHEM, V36, P95, DOI 10.1007/BF02354908; Constantinesco F, 1999, J MOL BIOL, V291, P375, DOI 10.1006/jmbi.1999.2976; De Bie LGS, 2003, J BACTERIOL, V185, P3238, DOI 10.1128/JB.185.10.3238-3243.2003; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DRABKIN HJ, 1985, J BIOL CHEM, V260, P5580; Droogmans L, 2003, NUCLEIC ACIDS RES, V31, P2148, DOI 10.1093/nar/gkg314; DROOGMANS L, 1986, EMBO J, V5, P1105, DOI 10.1002/j.1460-2075.1986.tb04329.x; EDQVIST J, 1993, NUCLEIC ACIDS RES, V21, P413, DOI 10.1093/nar/21.3.413; EDQVIST J, 1992, NUCLEIC ACIDS RES, V20, P6575, DOI 10.1093/nar/20.24.6575; GARCIA GR, 1998, MODIFICATION EDITING, P555; Gerber A, 1998, EMBO J, V17, P4780, DOI 10.1093/emboj/17.16.4780; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GU XG, 1994, BIOCHEMISTRY-US, V33, P2255, DOI 10.1021/bi00174a036; Hoang C, 2001, CELL, V107, P929, DOI 10.1016/S0092-8674(01)00618-3; Hori H, 2003, J BIOL CHEM, V278, P25081, DOI 10.1074/jbc.M212577200; Hori H, 2002, GENES CELLS, V7, P259, DOI 10.1046/j.1365-2443.2002.00520.x; Hori H, 1998, J BIOL CHEM, V273, P25721, DOI 10.1074/jbc.273.40.25721; HUBER R, 1992, SYST APPL MICROBIOL, V15, P340, DOI 10.1016/S0723-2020(11)80206-7; HURWITZ J, 1964, J BIOL CHEM, V239, P3474; Ishitani R, 2003, CELL, V113, P383, DOI 10.1016/S0092-8674(03)00280-0; JAKAB G, 1990, NUCLEIC ACIDS RES, V18, P7444, DOI 10.1093/nar/18.24.7444; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KOSKI RA, 1982, J BIOL CHEM, V257, P4514; Kung FL, 2000, RNA, V6, P233, DOI 10.1017/S135583820099191X; Lecointe F, 1998, J BIOL CHEM, V273, P1316, DOI 10.1074/jbc.273.3.1316; Li JN, 1999, RNA, V5, P395, DOI 10.1017/S1355838299980834; Matsuyama S, 1998, J BIOL CHEM, V273, P3363, DOI 10.1074/jbc.273.6.3363; McCloskey JA, 1998, NUCLEIC ACIDS RES, V26, P196, DOI 10.1093/nar/26.1.196; MELTON DA, 1980, NATURE, V284, P143, DOI 10.1038/284143a0; MOROZOV IA, 1982, EUR J BIOCHEM, V129, P429, DOI 10.1111/j.1432-1033.1982.tb07068.x; Motorin Y, 1998, RNA, V4, P856, DOI 10.1017/S1355838298980396; Motorin Y, 1999, RNA, V5, P1105, DOI 10.1017/S1355838299982201; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; Ohtsuki T, 1998, J BIOCHEM-TOKYO, V124, P28, DOI 10.1093/oxfordjournals.jbchem.a022092; Pan H, 2003, P NATL ACAD SCI USA, V100, P12648, DOI 10.1073/pnas.2135585100; Phannachet K, 2004, NUCLEIC ACIDS RES, V32, P1422, DOI 10.1093/nar/gkh287; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; Redlak M, 1997, BIOCHEMISTRY-US, V36, P8699, DOI 10.1021/bi9701538; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Roovers M, 2004, NUCLEIC ACIDS RES, V32, P465, DOI 10.1093/nar/gkh191; Rozenski J, 1999, NUCLEIC ACIDS RES, V27, P196, DOI 10.1093/nar/27.1.196; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; Soma A, 2003, MOL CELL, V12, P689, DOI 10.1016/S1097-2765(03)00346-0; STANGE N, 1987, EMBO J, V6, P2811, DOI 10.1002/j.1460-2075.1987.tb02577.x; Tomita K, 1998, BBA-GENE STRUCT EXPR, V1399, P78, DOI 10.1016/S0167-4781(98)00099-2; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; WATANABE YI, 1994, J BIOL CHEM, V269, P22902; Xie W, 2003, NAT STRUCT BIOL, V10, P781, DOI 10.1038/nsb976	59	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49151	49159		10.1074/jbc.M408209200	http://dx.doi.org/10.1074/jbc.M408209200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358762	hybrid			2022-12-25	WOS:000225098100080
J	Seaver, LC; Imlay, JA				Seaver, LC; Imlay, JA			Are respiratory enzymes the primary sources of intracellular hydrogen peroxide?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ESCHERICHIA-COLI K-12; MANGANESE-SUPEROXIDE-DISMUTASE; CATALYZED CHAIN OXIDATION; FUMARATE REDUCTASE; POSITIVE REGULATOR; REDUCED FLAVINS; DNA-DAMAGE; OXYGEN; RADICALS	Endogenous H2O2 is believed to be a source of chronic damage in aerobic organisms. To quantify H2O2 formation, we have generated strains of Escherichia coli that lack intracellular scavenging enzymes. The H2O2 that is formed within these mutants diffuses out into the medium, where it can be measured. We sought to test the prevailing hypothesis that this H2O2 is primarily generated by the autoxidation of redox enzymes within the respiratory chain. The rate of H2O2 production increased when oxygen levels were raised, confirming that H2O2 is formed by an adventitious chemical process. However, mutants that lacked NADH dehydrogenase II and fumarate reductase, the most oxidizable components of the respiratory chain in vitro, continued to form H2O2 at normal rates. NADH dehydrogenase II did generate substantial H2O2 when it was overproduced or when quinones were absent, forcing electrons to accumulate on the enzyme. Mutants that lacked both NADH dehydrogenases respired very slowly, as expected; however, these mutants showed no diminution of H2O2 excretion, suggesting that H2O2 is primarily formed by a source outside the respiratory chain. That source has not yet been identified. In respiring cells the rate of H2O2 production was similar to0.5% the rate of total oxygen consumption, with only modest changes when cells used different carbon sources.	Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Imlay, JA (corresponding author), Univ Illinois, Dept Microbiol, 131 Burrill Hall, Urbana, IL 61801 USA.	jimlay@uiuc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049640, R01GM049640] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49640, GM07283] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; BIELSKI BHJ, 1976, J BIOL CHEM, V251, P3841; BLAUT M, 1989, J BIOL CHEM, V264, P13599; BOLING M, 1984, J BACTERIOL, V160, P706, DOI 10.1128/JB.160.2.706-710.1984; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1982, SUPEROXIDE DISMUTASE, V2, P15; CALHOUN MW, 1993, J BACTERIOL, V175, P3013, DOI 10.1128/JB.175.10.3013-3019.1993; CARLIOZ A, 1986, EMBO J, V5, P623, DOI 10.1002/j.1460-2075.1986.tb04256.x; CHAN PC, 1980, J BIOL CHEM, V255, P874; CHAN PC, 1974, J BIOL CHEM, V249, P1317; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANG EC, 1991, J BIOL CHEM, V266, P4417; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CHUNG CT, 1988, NUCLEIC ACIDS RES, V16, P3580, DOI 10.1093/nar/16.8.3580; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Fridovich I, 2004, AGING CELL, V3, P13, DOI 10.1046/j.1474-9728.2003.00075.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P92; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GAUDU P, 1994, J BIOL CHEM, V269, P8182; Gort AS, 1998, J BACTERIOL, V180, P1402, DOI 10.1128/JB.180.6.1402-1410.1998; Han D, 2001, BIOCHEM J, V353, P411, DOI 10.1042/0264-6021:3530411; Huycke MM, 2001, MOL MICROBIOL, V42, P729, DOI 10.1046/j.1365-2958.2001.02638.x; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; IMLAY JA, 1995, J BIOL CHEM, V270, P19767; IMLAY JA, 1986, J BACTERIOL, V166, P519, DOI 10.1128/jb.166.2.519-527.1986; KUO CF, 1987, J BIOL CHEM, V262, P4724; Lambert AJ, 2004, J BIOL CHEM, V279, P39414, DOI 10.1074/jbc.M406576200; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; MARKLUND S, 1974, European Journal of Biochemistry, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MATSUSHITA K, 1987, BIOCHEMISTRY-US, V26, P7732, DOI 10.1021/bi00398a029; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Messner KR, 1999, J BIOL CHEM, V274, P10119, DOI 10.1074/jbc.274.15.10119; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Miller JH, 1972, EXPT MOL GENETICS, P201; MORIMYO M, 1982, J BACTERIOL, V152, P208; NAQUI A, 1986, ANNU REV BIOCHEM, V55, P137, DOI 10.1146/annurev.biochem.55.1.137; SAKAMOTO H, 1984, J BACTERIOL, V159, P418, DOI 10.1128/JB.159.1.418-420.1984; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Seaver LC, 2001, J BACTERIOL, V183, P7182, DOI 10.1128/JB.183.24.7182-7189.2001; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; Staniek K, 1999, BBA-BIOENERGETICS, V1413, P70, DOI 10.1016/S0005-2728(99)00083-3; Staniek K, 2000, BBA-BIOENERGETICS, V1460, P268, DOI 10.1016/S0005-2728(00)00152-3; THORNALLEY P, 1984, BIOCHIM BIOPHYS ACTA, V797, P276, DOI 10.1016/0304-4165(84)90131-4; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; VANLOON APGM, 1986, P NATL ACAD SCI USA, V83, P3820; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; Wallace MA, 2004, J BIOL CHEM, V279, P32055, DOI 10.1074/jbc.M403590200; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; Yamashita M, 1996, J BACTERIOL, V178, P2941, DOI 10.1128/jb.178.10.2941-2947.1996	56	157	165	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48742	48750		10.1074/jbc.M408754200	http://dx.doi.org/10.1074/jbc.M408754200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15361522	hybrid			2022-12-25	WOS:000225098100032
J	Leng, FF; Amado, L; McMacken, R				Leng, FF; Amado, L; McMacken, R			Coupling DNA supercoiling to transcription in defined protein systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							R-LOOP FORMATION; ESCHERICHIA-COLI; IN-VITRO; RNA-POLYMERASE; PLASMID DNA; TOPOISOMERASES; INVITRO; REPLICATION; TERMINATION; TEMPLATE	Transcription of closed circular DNA templates in the presence of DNA gyrase is known to stimulate negative DNA supercoiling both in vivo and in vitro. It has proven elusive, however, to establish a general system in vitro that supports transcription-coupled DNA supercoiling (TCDS) by the "twin-domain" mechanism (Liu, L. F. and Wang, J. C. (1987) Proc. Natl. Acad. Sci. USA 84, 7024-7027) that operates in bacteria. In this report, we examine the properties of TCDS in defined protein systems that minimally contained T7 RNA polymerase and DNA gyrase. Specifically designed plasmid DNA templates permitted us to control the location and length of RNA transcripts. We demonstrate that TCDS takes place by two separate, and apparently independent, mechanistic pathways in vitro. The first supercoiling pathway, which is not likely to be significant in vivo, was found to be dependent on R-loop formation and could be suppressed by the presence of RNase H or bacterial HU protein. The second pathway for TCDS was much more potent, but became predominant in vitro only when sequence-specific DNA-bending proteins were present during transcription, and RNA transcript lengths exceeded 3 kb. This major supercoiling route was shown to be resistant to RNase H and had functional properties consistent with those predicted for the twin-domain mechanism. For example, DNA supercoiling activity was proportional to RNA transcript length and was greatly stimulated by macromolecular crowding agents. Under optimal conditions, the twin domain pathway of TCDS rapidly and efficiently generated superhelicity levels more than twice that typically found in vivo.	Florida Int Univ, Dept Chem & Biochem, Miami, FL 33199 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	State University System of Florida; Florida International University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Leng, FF (corresponding author), Florida Int Univ, Dept Chem & Biochem, 11200 SW 8th St, Miami, FL 33199 USA.	lengf@fiu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM061347, S06GM008205, R01GM032253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32253, R25 GM61347, S06 GM008205] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; CHAMPOUX JJ, 1975, BIOCHEMISTRY-US, V14, P307, DOI 10.1021/bi00673a017; Chen DR, 1999, J MOL BIOL, V285, P443, DOI 10.1006/jmbi.1998.2358; DROGE P, 1994, BIOESSAYS, V16, P91, DOI 10.1002/bies.950160205; DROGE P, 1991, NUCLEIC ACIDS RES, V19, P2941, DOI 10.1093/nar/19.11.2941; DROLET M, 1994, J BIOL CHEM, V269, P2068; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; JENG ST, 1990, J BIOL CHEM, V265, P3823; KORNBERG A, 1992, DNA REPLICATION, P521; Leng FF, 2002, P NATL ACAD SCI USA, V99, P9139, DOI 10.1073/pnas.142002099; Lilley DMJ, 1996, Q REV BIOPHYS, V29, P203, DOI 10.1017/S0033583500005825; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LIU LF, 1978, CELL, V15, P979, DOI 10.1016/0092-8674(78)90281-7; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; Masse E, 1999, J MOL BIOL, V294, P321, DOI 10.1006/jmbi.1999.3264; Masse E, 1999, J BIOL CHEM, V274, P16659, DOI 10.1074/jbc.274.23.16659; Masse E, 1997, J BIOL CHEM, V272, P12816, DOI 10.1074/jbc.272.19.12816; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; NORGARD MV, 1981, ANAL BIOCHEM, V113, P34, DOI 10.1016/0003-2697(81)90040-3; Phoenix P, 1997, J BIOL CHEM, V272, P1473, DOI 10.1074/jbc.272.3.1473; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; Sambrook J., 2002, MOL CLONING LAB MANU; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang ZY, 1997, J MOL BIOL, V271, P499, DOI 10.1006/jmbi.1997.1197; Wang ZY, 1996, EMBO J, V15, P581, DOI 10.1002/j.1460-2075.1996.tb00390.x; WOLD MS, 1982, P NATL ACAD SCI-BIOL, V79, P6176, DOI 10.1073/pnas.79.20.6176; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	32	24	26	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47564	47571		10.1074/jbc.M403798200	http://dx.doi.org/10.1074/jbc.M403798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342629	hybrid			2022-12-25	WOS:000224957000020
J	Toda, M; Dawson, M; Nakamura, T; Munro, PMG; Richardson, RM; Bailly, M; Ono, SJ				Toda, M; Dawson, M; Nakamura, T; Munro, PMG; Richardson, RM; Bailly, M; Ono, SJ			Impact of engagement of Fc delta RI and CC chemokine receptor 1 on mast cell activation and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; RHO GTPASES; RAC; CDC42; MIGRATION; ROLES; MORPHOLOGY; BASOPHILS; KINASE; FAMILY	CC chemokines participate in the recruitment and activation of immune cells through CC chemokine receptors (CCRs). Here, we report that cross-talk between CCR1-mediated signaling pathway and FcepsilonRI-mediated signaling pathway affects degranulation positively but affects chemotaxis of mast cells adversely. Costimulation via FcepsilonRI engagement with IgE/antigen and CCR1 engagement with recombinant human CCL3 synergistically enhanced degranulation in rat basophilic leukemia-2H3 cells expressing human CCR1 (RBL-CCR1). Interestingly, FcepsilonRI engagement inhibited CCL3-mediated chemotaxis and membrane ruffling of RBL-CCR1 cells. Small GTP-binding proteins of the Rho family, Rac, Cdc42, and Rho control chemotaxis by mediating the reorganization of the actin cytoskeleton. Both a Rho inhibitor C3 exoenzyme and a Rho kinase (ROCK) inhibitor Y-27632 inhibited chemotaxis of RBL-CCR1 cells toward CCL3, indicating that activation of the Rho/ROCK signaling pathway is required for the CCL3-mediated chemotaxis of the cells. Costimulation with IgE/antigen and CCL3 enhanced Rac and Cdc42 activation but decreased ROCK activation in RBL-CCR1 cells compared with that in the cells stimulated with CCL3 alone. These results suggest that costimulation via FcepsilonRI and CCR1 engagements induced 1) inhibition of membrane ruffling, 2) decreased ROCK activation, and 3) reciprocal imbalance between Small GTP-binding proteins of the Rho family, which result in the inhibition of chemotaxis of RBL-CCR1 cells. The cross-talk between FcepsilonRI-mediated signaling pathway and CCR-mediated signaling pathway would induce optimal activation and arrested chemotaxis of mast cells, thus contributing to allergic inflammation.	UCL, Inst Ophthalmol, Div Ocular Immunol, London EC1V 9EL, England; UCL, Inst Ophthalmol, Div Clin Ophthalmol, London EC1V 9EL, England; UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England; Meharry Med Coll, Dept Biochem, Nashville, TN 37208 USA	University of London; University College London; University of London; University College London; University of London; University College London; Meharry Medical College	Ono, SJ (corresponding author), UCL, Inst Ophthalmol, Div Ocular Immunol, 11-43 Bath St, London EC1V 9EL, England.	santa.ono@ucl.ac.uk	Toda, Masako/S-9810-2019; Bailly, Maryse/C-1663-2008	Bailly, Maryse/0000-0002-0593-6356	NATIONAL EYE INSTITUTE [T32EY007156, R01EY012523, R01EY011901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049661] Funding Source: NIH RePORTER; NEI NIH HHS [1R01EY011901, 5R01EY012523, T32EY007156] Funding Source: Medline; NIGMS NIH HHS [7R01GM049661] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALAM R, 1995, CHEM IMMUNOL, V61, P148; ALAM R, 1994, J IMMUNOL, V152, P1298; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Benard V, 2002, METHOD ENZYMOL, V345, P349; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; CONTI P, 1995, IMMUNOLOGY, V86, P434; Doughman RL, 2003, J BIOL CHEM, V278, P23036, DOI 10.1074/jbc.M211397200; Guillemot JC, 1997, J CELL SCI, V110, P2215; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ishizuka T, 2001, J IMMUNOL, V167, P2298, DOI 10.4049/jimmunol.167.4.2298; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Smith LG, 2004, CURR BIOL, V14, pR109, DOI 10.1016/j.cub.2004.01.016; Srinivasan S, 2003, J CELL BIOL, V160, P375, DOI 10.1083/jcb.200208179; Takenawa T, 2001, J CELL SCI, V114, P1801; Tashiro A, 2000, CEREB CORTEX, V10, P927, DOI 10.1093/cercor/10.10.927; Tkaczyk C, 2001, CLIN IMMUNOL, V99, P198, DOI 10.1006/clim.2001.4992; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Wang HW, 1998, J CLIN INVEST, V102, P1617, DOI 10.1172/JCI3704; Woo CH, 2002, BIOCHEM BIOPH RES CO, V298, P392, DOI 10.1016/S0006-291X(02)02432-4; Zhao ZZ, 2001, ORAL DIS, V7, P246, DOI 10.1034/j.1601-0825.2001.70408.x	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48443	48448		10.1074/jbc.M408725200	http://dx.doi.org/10.1074/jbc.M408725200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337751	hybrid			2022-12-25	WOS:000224957000121
J	Elimova, E; Kisilevsky, R; Szarek, WA; Ancsin, JB				Elimova, E; Kisilevsky, R; Szarek, WA; Ancsin, JB			Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy	FASEB JOURNAL			English	Article						anti-amyloid; AA-amyloid; J774A.1 cells; thioflavin T; amyloid enhancing factor	SERUM AMYLOID-A; CREUTZFELDT-JAKOB-DISEASE; GERSTMANN-STRAUSSLER SYNDROME; FIBROBLAST-GROWTH-FACTOR; HUMAN APOLIPOPROTEIN-E; ALZHEIMERS-DISEASE; PRION PROTEIN; FIBRIL FORMATION; BINDING-SITES; BETA-PEPTIDE	To date 22 different polypeptides, including Abeta in Alzheimer's disease and PrPSc in prion disorders, are known to re-fold and assemble into highly organized fibrils, which associate with heparan sulfate (HS) proteoglycans to form tissue deposits called amyloid. Mononuclear phagocytes have long been thought to be involved in this process, and we describe a monocytic cell culture system that can transform the acute-phase protein serum amyloid A (SAA1.1) into AA-amyloid and appears to recapitulate all the main features of amyloidogenesis observed in vivo. These features in common include nucleation-dependent kinetics, identical proteolytic processing of SAA1.1, and co-deposition of HS with the fibrils. Heparin and polyvinylsulfonate previously reported to block AA-amyloidogenesis in mice are also effective inhibitors in this cell culture model. Furthermore, a synthetic peptide (27-mer) corresponding to a HS binding site of SAA, blocks amyloid deposition at a concentration that is several-orders-of-magnitude lower than any other peptide-based inhibitor previously reported. The 27-mer's inhibitory activity may target the amyloidogenic pathway specifically as it does not interfere with the binding of SAA to monocytes. These data provide direct evidence that SAA1.1: HS interactions are a critical step in AA-amyloidogenesis and suggest a novel treatment strategy for other amyloidoses.	Queens Univ, Kingston Gen Hosp, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Kingston Gen Hosp, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Kingston Gen Hosp, Syl & Molly Apps Res Ctr, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Chem, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada	Ancsin, JB (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	3jba1@post.queensu.ca						Ahmad A, 2003, BIOCHEMISTRY-US, V42, P11404, DOI 10.1021/bi034868o; Ancsin JB, 1999, J BIOL CHEM, V274, P7172, DOI 10.1074/jbc.274.11.7172; Ancsin JB, 2003, AMYLOID, V10, P67, DOI 10.3109/13506120309041728; ARAI K, 1994, J PATHOL, V173, P127, DOI 10.1002/path.1711730209; ARGILES A, 1994, NEPHROL DIAL TRANSPL, V9, P662, DOI 10.1093/ndt/9.6.662; AXELRAD MA, 1982, LAB INVEST, V47, P139; BENDITT EP, 1971, FEBS LETT, V19, P169, DOI 10.1016/0014-5793(71)80506-9; BRUNDEN KR, 1993, J NEUROCHEM, V61, P2147, DOI 10.1111/j.1471-4159.1993.tb07453.x; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; Castillo GM, 1998, DIABETES, V47, P612, DOI 10.2337/diabetes.47.4.612; Castillo GM, 1997, J NEUROCHEM, V69, P2452; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CHRONOPOULOS S, 1994, J PATHOL, V173, P361, DOI 10.1002/path.1711730412; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; ERICSSON LH, 1987, FEBS LETT, V218, P11, DOI 10.1016/0014-5793(87)81008-6; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; GUIROY DC, 1994, ACTA NEUROPATHOL, V87, P526; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heegaard NHH, 2002, J BIOL CHEM, V277, P11184, DOI 10.1074/jbc.M108837200; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Jemth P, 2002, J BIOL CHEM, V277, P30567, DOI 10.1074/jbc.M203404200; Jiang XL, 1997, BIOCHEMISTRY-US, V36, P13187, DOI 10.1021/bi970408h; Kazlauskaite J, 2003, BIOCHEMISTRY-US, V42, P3295, DOI 10.1021/bi026872q; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KISILEVSKY R, 1992, LAB INVEST, V66, P778; KISILEVSKY R, 1994, INT J EXP CLIN INVES, V1, P174; Kluve-Beckerman B, 1999, AM J PATHOL, V155, P123, DOI 10.1016/S0002-9440(10)65107-3; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; LeVine H, 1999, METHOD ENZYMOL, V309, P274; Libeu CP, 2001, J BIOL CHEM, V276, P39138, DOI 10.1074/jbc.M104746200; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAGNUS JH, 1991, SCAND J IMMUNOL, V34, P63, DOI 10.1111/j.1365-3083.1991.tb01521.x; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; McLaurin J, 2002, ANN NY ACAD SCI, V977, P376, DOI 10.1111/j.1749-6632.2002.tb04840.x; MEEK RL, 1986, J EXP MED, V163, P499, DOI 10.1084/jem.163.3.499; MIURA K, 1990, J IMMUNOL, V144, P610; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Muhleisen H, 1995, NEUROPATH APPL NEURO, V21, P505, DOI 10.1111/j.1365-2990.1995.tb01097.x; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Ohashi K, 2002, NEPHRON, V90, P158, DOI 10.1159/000049037; Park K, 2001, J BIOL CHEM, V276, P16611, DOI 10.1074/jbc.M008423200; PERLMUTTER LS, 1990, BRAIN RES, V508, P13, DOI 10.1016/0006-8993(90)91111-S; Rocken C, 1998, VIRCHOWS ARCH, V432, P547, DOI 10.1007/s004280050204; Rymer DL, 2000, J NEUROCHEM, V75, P2536, DOI 10.1046/j.1471-4159.2000.0752536.x; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Scrocchi LA, 2003, J STRUCT BIOL, V141, P218, DOI 10.1016/S1047-8477(02)00630-5; Scrocchi LA, 2002, J MOL BIOL, V318, P697, DOI 10.1016/S0022-2836(02)00164-X; Sengupta P, 2003, BIOCHEMISTRY-US, V42, P10506, DOI 10.1021/bi0341410; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIROO M, 1987, SCAND J IMMUNOL, V26, P709, DOI 10.1111/j.1365-3083.1987.tb02307.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SNOW AD, 1987, LAB INVEST, V56, P665; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SNOW AD, 1990, LAB INVEST, V63, P601; SNOW AD, 1985, LAB INVEST, V53, P37; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; TAKAHASHI M, 1989, VIRCHOWS ARCH A, V415, P411, DOI 10.1007/BF00747742; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; VANDUINEN SG, 1995, LAB INVEST, V73, P183; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; Yazawa H, 2001, FASEB J, V15, P2454, DOI 10.1096/fj.01-0251com; YOUNG ID, 1992, ARCH PATHOL LAB MED, V116, P951; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210; Zhu H, 2001, MOL MED, V7, P517, DOI 10.1007/BF03401857	85	56	58	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1749	+		10.1096/fj.03-1436fje	http://dx.doi.org/10.1096/fj.03-1436fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345688				2022-12-25	WOS:000224243200041
J	Gassanov, N; Er, F; Zagidullin, N; Hoppe, UC				Gassanov, N; Er, F; Zagidullin, N; Hoppe, UC			Endothelin induces differentiation of ANP-EGFP expressing embryonic stem cells towards a pacemaker phenotype	FASEB JOURNAL			English	Article						conduction system; cardiogenesis; electrophysiology	PURKINJE-FIBER DIFFERENTIATION; ACTIVATED INWARD CURRENT; CARDIAC PRECURSOR CELLS; IN-VITRO; FUNCTIONAL-PROPERTIES; GENE-EXPRESSION; RETINOIC ACID; MUSCLE CELLS; MOUSE HEART; CARDIOMYOCYTES	Currently, only limited insight into mechanisms promoting the differentiation and specification of the mammalian cardiac conduction system is available. Therefore, we established a murine embryonic stem (ES) cell line stably expressing the enhanced green fluorescent protein (EGFP) under the transcriptional control of the human atrial natriuretic peptide (ANP) promoter to further characterize the development of very early stages of the mammalian cardiac conduction tissue. The cardiac nature of ANP-EGFP positive cells was confirmed by immunostaining. In ANP-EGFP expressing ES cell-derived cardiomyocytes, a distinct sublineage of pacemaker cells could be identified. Pacemaker cells displayed a spindle shape and exhibited a higher spontaneous beating rate, faster I-f current activation and larger I-f current densities compared with triangular atrial-like cardiocytes. Exposure to endothelin-1 significantly increased the percentage of pacemaker-like cells without affecting their electrophysiological properties. These findings were corroborated by immunostaining with antibodies against connexin 40 and connexin 45, known markers for cardiac conduction tissue. Conversely, treatment of ANP-EGFP expressing ES cells with neuregulin-1 exhibited no effect on differentiation. These results indicate that ANP-EGFP expression enables the identification of ES cell-derived pacemaker cells by their fluorescence and morphology and that endothelin-1 promotes the development of ANP-EGFP positive cardiomyocytes to a pacemaker-like phenotype.	Univ Cologne, Dept Internal Med 3, D-50924 Cologne, Germany; Univ Cologne, Ctr Mol Med, D-50924 Cologne, Germany	University of Cologne; University of Cologne	Hoppe, UC (corresponding author), Univ Cologne, Dept Internal Med 3, Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	uta.hoppe@uni-koeln.de	Zagidullin, Naufal/O-8304-2016	Zagidullin, Naufal/0000-0003-2386-6707				Abi-Gerges N, 2000, J PHYSIOL-LONDON, V523, P377, DOI 10.1111/j.1469-7793.2000.t01-2-00377.x; Alcolea S, 2004, CIRC RES, V94, P100, DOI 10.1161/01.RES.0000108261.67979.2A; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Coppen SR, 1999, DEV GENET, V24, P82, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<82::AID-DVG9>3.0.CO;2-1; Coppen SR, 2003, MOL CELL BIOCHEM, V242, P121, DOI 10.1023/A:1021150014764; DELORME B, 1995, DEV DYNAM, V204, P358, DOI 10.1002/aja.1002040403; Delorme B, 1997, CIRC RES, V81, P423, DOI 10.1161/01.RES.81.3.423; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; Er F, 2003, CIRCULATION, V107, P485, DOI 10.1161/01.CIR.0000045672.32920.CB; Gepstein L, 2002, CIRC RES, V91, P866, DOI 10.1161/01.RES.0000041435.95082.84; Gourdie RG, 1998, P NATL ACAD SCI USA, V95, P6815, DOI 10.1073/pnas.95.12.6815; GOURDIE RG, 1995, DEVELOPMENT, V121, P1423; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hidaka K, 2003, FASEB J, V17, P740, DOI 10.1096/fj.02-0104fje; Hoppe UC, 1998, CIRCULATION, V97, P55, DOI 10.1161/01.CIR.97.1.55; Hoppe UC, 1998, CARDIOVASC RES, V38, P788, DOI 10.1016/S0008-6363(98)00047-9; Hoppe UC, 2001, P NATL ACAD SCI USA, V98, P5335, DOI 10.1073/pnas.091239098; Kanzawa N, 2002, DEVELOPMENT, V129, P3185; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Kupershmidt S, 1999, CIRC RES, V84, P146, DOI 10.1161/01.RES.84.2.146; LAPOINTE MC, 1988, J BIOL CHEM, V263, P9075; MALTSEV VA, 1994, CIRC RES, V75, P233, DOI 10.1161/01.RES.75.2.233; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Pourrier M, 2003, J MEMBRANE BIOL, V194, P141, DOI 10.1007/s00232-003-2034-8; Rentschler S, 2002, P NATL ACAD SCI USA, V99, P10464, DOI 10.1073/pnas.162301699; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Schiaffino S, 1997, CIRC RES, V80, P749, DOI 10.1161/01.RES.80.5.749; Takebayashi-Suzuki K, 2000, DEVELOPMENT, V127, P3523; Wobus AM, 1997, J MOL CELL CARDIOL, V29, P1525, DOI 10.1006/jmcc.1997.0433; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Yu H, 2001, CIRC RES, V88, pE84, DOI 10.1161/hh1201.093511; Zhang YM, 2002, CIRCULATION, V106, P1294, DOI 10.1161/01.CIR.0000027585.05868.67	42	66	69	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1710	+		10.1096/fj.04-1619fje	http://dx.doi.org/10.1096/fj.04-1619fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345687				2022-12-25	WOS:000224243200040
J	Saaristo, A; Tammela, T; Timonen, J; Yla-Herttuala, S; Tukiainen, E; Asko-Seljavaara, S; Alitalo, K				Saaristo, A; Tammela, T; Timonen, J; Yla-Herttuala, S; Tukiainen, E; Asko-Seljavaara, S; Alitalo, K			Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds	FASEB JOURNAL			English	Article						skin flaps; edema; perfusion; lymphangiogenesis	LYMPHANGIOGENESIS; MUSCLE	Edema and insufficient blood perfusion are common problems in reconstructive surgery. The blood vasculature is reconstructed in microvascular flaps, whereas lymphatic vessel function is lost after surgical incision. Here, we demonstrate that vascular endothelial growth factor C (VEGF-C) gene transfer can be used to reconstruct a lymphatic vessel network severed by incision of skin flaps. We used adenoviral VEGF-C gene transfer at the edges of epigastric skin flaps in mice. Our results show that VEGF-C gene expression results in the formation of anastomoses between the lymphatic vessels of the skin flap and the surrounding lymphatic vasculature. Some spontaneous lymphangiogenesis also took place in the control mice, but the lymphatic vessels generated remained nonfunctional even 2 months postoperatively. In contrast, the VEGF-C treated mice demonstrated persistent lymphatic vessel function during the 2 month follow-up despite the transient nature of the adenoviral VEGF-C gene expression. The restoration of lymphatic function by VEGF-C in skin flaps provides new tools to promote vascular perfusion and to reduce tissue edema in skin and muscle flaps. These results have important implications for the prevention and treatment of surgically induced secondary lymphedema.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Plast Surg, FIN-00014 Helsinki, Finland; Paijat Hame Cent Hosp, Dept Surg, Lahti, Finland; Univ Kuopio, AI Virtanen Inst, Dept Med, FIN-70211 Kuopio, Finland; Univ Kuopio, Gene Therapy Unit, FIN-70211 Kuopio, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Paijat Hame Central Hospital; University of Eastern Finland; University of Eastern Finland	Saaristo, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; /0000-0003-3675-6961; Yla-Herttuala, Seppo/0000-0001-7593-2708				BELLMAN S, 1959, Acta Chir Scand, V116, P99; Diaz-Sandoval LJ, 2003, EXPERT OPIN BIOL TH, V3, P599, DOI 10.1517/14712598.3.4.599; Gurunluoglu R, 2002, ANN PLAS SURG, V49, P161, DOI 10.1097/00000637-200208000-00009; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Jung H, 2003, MICROSURG, V23, P374, DOI 10.1002/micr.10140; Karkkainen MJ, 2001, P NATL ACAD SCI USA, V98, P12677, DOI 10.1073/pnas.221449198; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; KERRIGAN CL, 1983, PLAST RECONSTR SURG, V72, P766, DOI 10.1097/00006534-198312000-00003; Lohela M, 2003, THROMB HAEMOSTASIS, V90, P167, DOI 10.1160/TH03-04-0200; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; Rissanen TT, 2003, CIRC RES, V92, P1098, DOI 10.1161/01.RES.0000073584.46059.E3; Rockson SG, 2002, ANN NY ACAD SCI, V979, P64, DOI 10.1111/j.1749-6632.2002.tb04868.x; ROCKSON SG, 2002, ANN NY ACAD SCI, V979, P76; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Salmi A, 1996, PLAST RECONSTR SURG, V97, P1443, DOI 10.1097/00006534-199606000-00021; Shimoda H, 2004, CELL TISSUE RES, V316, P325, DOI 10.1007/s00441-004-0889-3; Szuba A, 2002, FASEB J, V16, P1985, DOI 10.1096/fj.02-0401fje; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4; Yang Y, 1996, GENE THER, V3, P137; Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694; Yla-Herttuala S, 2001, J INTERN MED, V250, P367; Yoon Y, 2003, J CLIN INVEST, V111, P717, DOI 10.1172/JCI200315830	24	73	80	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1707	+		10.1096/fj.04-1592fje	http://dx.doi.org/10.1096/fj.04-1592fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15361472				2022-12-25	WOS:000224243200031
J	O'Keeffe, D; Olson, ST; Gasiunas, N; Gallagher, J; Baglin, TP; Huntington, JA				O'Keeffe, D; Olson, ST; Gasiunas, N; Gallagher, J; Baglin, TP; Huntington, JA			The heparin binding properties of heparin cofactor II suggest an antithrombin-like activation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; HIGH-AFFINITY; CONFORMATIONAL-CHANGE; PROTEINASE REACTIONS; THROMBIN INHIBITION; ANTICOAGULANT; ACCELERATION; INACTIVATION; CHAIN; SITE	The serpin heparin cofactor II (HCII) is a glycosaminoglycan-activated inhibitor of thrombin that circulates at a high concentration in the blood. The antithrombotic effect of heparin, however, is due primarily to the specific interaction of a fraction of heparin chains with the related serpin antithrombin (AT). What currently prevents selective therapeutic activation of HCII is the lack of knowledge of the determinants of glycosaminoglycan binding specificity. In this report we investigate the heparin binding properties of HCII and conclude that binding is nonspecific with a minimal heparin length of 13 monosaccharide units required and affinity critically dependent on ionic strength. Rapid kinetics of heparin binding indicate an induced fit mechanism that involves a conformational change in HCII. Thus, HCII binds to heparin in a manner analogous to the interaction of AT with low affinity heparin. A fully allosteric 2000-fold heparin activation of thrombin inhibition by HCII is demonstrated for heparin chains up to 26 monosaccharide units in length. We conclude that the heparin-binding mechanism of HCII is closely analogous to that of AT and that the induced fit mechanism suggests the potential design or discovery of specific HCII agonists.	Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Div Struct Med,Thrombosis Res Unit, Cambridge CB2 2XY, England; Univ Manchester, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Cambridge; University of Manchester; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Huntington, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Haematol, Div Struct Med,Thrombosis Res Unit, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	jah52@cam.ac.uk			MRC [G117/444] Funding Source: UKRI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068629, R29HL039888, P01HL064013, R37HL039888, R01HL039888] Funding Source: NIH RePORTER; Medical Research Council [G117/444] Funding Source: Medline; NHLBI NIH HHS [HL39888, HL68629, HL64013] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aihara K, 2004, CIRCULATION, V109, P2761, DOI 10.1161/01.CIR.0000129968.46095.F3; Atchley WR, 2001, MOL BIOL EVOL, V18, P1502, DOI 10.1093/oxfordjournals.molbev.a003936; Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Belzar KJ, 2000, J BIOL CHEM, V275, P8733, DOI 10.1074/jbc.275.12.8733; BRAY B, 1989, BIOCHEM J, V262, P225, DOI 10.1042/bj2620225; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; Gandossi E, 1998, THROMB HAEMOSTASIS, V80, P840; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; He L, 2002, J CLIN INVEST, V109, P213, DOI 10.1172/JCI200213432; Huntington JA, 2003, TRENDS PHARMACOL SCI, V24, P589, DOI 10.1016/j.tips.2003.09.002; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; Mascellani G, 1996, THROMB RES, V84, P21, DOI 10.1016/0049-3848(96)00158-2; Meagher JL, 2000, J BIOL CHEM, V275, P2698, DOI 10.1074/jbc.275.4.2698; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PETITOU M, 1988, J BIOL CHEM, V263, P8685; Ragg H, 2001, MOL BIOL EVOL, V18, P577, DOI 10.1093/oxfordjournals.molbev.a003838; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCULLY MF, 1987, THROMB RES, V46, P491, DOI 10.1016/0049-3848(87)90136-8; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SIE P, 1986, BRIT J HAEMATOL, V64, P707, DOI 10.1111/j.1365-2141.1986.tb02232.x; SIE P, 1993, BLOOD, V81, P1771; SIE P, 1988, BIOCHIM BIOPHYS ACTA, V966, P188, DOI 10.1016/0304-4165(88)90111-0; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; Takamori N, 2004, CIRCULATION, V109, P481, DOI 10.1161/01.CIR.0000109695.39671.37; Tollefsen DM, 2002, ARCH PATHOL LAB MED, V126, P1394; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; Verhamme IM, 2004, J BIOL CHEM, V279, P9785, DOI 10.1074/jbc.M313962200; Weitz JI, 1999, CIRCULATION, V99, P682, DOI 10.1161/01.CIR.99.5.682; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723	38	45	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50267	50273		10.1074/jbc.M408774200	http://dx.doi.org/10.1074/jbc.M408774200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371417	hybrid			2022-12-25	WOS:000225229500088
J	Ujvari, A; Luse, DS				Ujvari, A; Luse, DS			Newly initiated RNA encounters a factor involved in splicing immediately upon emerging from within RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; NASCENT RNA; TRANSCRIPTION ELONGATION; MESSENGER-RNA; COMPLEX; U2AF; RESOLUTION; SUBUNITS; SITE; DNA	We employed RNA-protein cross-linking to map the path of the nascent RNA as it emerges from within RNA polymerase II. A UV-cross-linkable uridine analog was incorporated at two positions within the first five nucleotides of the transcript. Only the two largest subunits of RNA polymerase II cross-linked to the transcript in complexes containing 17-24-nucleotide (nt) RNAs. Extension of the RNA to 26 or 28 nt revealed an additional strong cross-link to the splicing factor U2AF65. In U17 complexes, in which the RNA is still contained within the polymerase, U2AF65 is tightly bound. In contrast, U2AF65 is more loosely bound in C28 transcription complexes, in which about 10 nt of transcript have emerged from the RNA polymerase. Cross-linking of U2AF65 to RNA in a C28 complex was eliminated by the addition of an excess of an RNA oligonucleotide containing the consensus U2AF65 binding site, but U2AF65 was not displaced by a nonconsensus RNA. These findings indicate that U2AF65 shifts from protein-protein to protein-RNA interactions as the RNA emerges from the polymerase. During transcription of one particular template at low UTP concentration, RNA polymerase II pauses just after synthesizing a transcript segment that is a U2AF65 binding site. Dwell time of the polymerase at this pause site was significantly and specifically reduced by the addition of recombinant U2AF65 to the transcription reaction. Therefore, the association of U2AF65 with RNA polymerase II may function not only to deliver U2AF65 to the nascent transcript but also to modulate efficient transcript elongation.	Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Luse, DS (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Lerner Res Inst, NC20,9500 Euclid Ave, Cleveland, OH 44195 USA.	lused@ccf.org			NIGMS NIH HHS [GM 29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Arndt KM, 2003, TRENDS GENET, V19, P543, DOI 10.1016/j.tig.2003.08.008; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; Belotserkovskaya R, 2004, CURR OPIN GENET DEV, V14, P139, DOI 10.1016/j.gde.2004.02.004; Blanchette M, 2004, MOL CELL, V14, P775, DOI 10.1016/j.molcel.2004.06.012; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Cramer P, 2004, CURR OPIN GENET DEV, V14, P218, DOI 10.1016/j.gde.2004.01.003; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; GamaCarvalho M, 1997, J CELL BIOL, V137, P975, DOI 10.1083/jcb.137.5.975; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Gu HD, 2003, NUCLEIC ACIDS RES, V31, P6264, DOI 10.1093/nar/gkg823; Gu WG, 1996, P NATL ACAD SCI USA, V93, P6935, DOI 10.1073/pnas.93.14.6935; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; Hartzog GA, 2003, CURR OPIN GENET DEV, V13, P119, DOI 10.1016/S0959-437X(03)00024-8; Hawryluk PJ, 2004, NUCLEIC ACIDS RES, V32, P1904, DOI 10.1093/nar/gkh505; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Kent OA, 2003, J BIOL CHEM, V278, P50572, DOI 10.1074/jbc.M307976200; Kielkopf CL, 2004, GENE DEV, V18, P1513, DOI 10.1101/gad.1206204; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Manley JL, 2002, NAT STRUCT BIOL, V9, P790, DOI 10.1038/nsb1102-790; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; Meisenheimer KM, 2000, METHOD ENZYMOL, V318, P88; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Pal M, 2003, P NATL ACAD SCI USA, V100, P5700, DOI 10.1073/pnas.1037057100; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; RICE GA, 1991, P NATL ACAD SCI USA, V88, P4245, DOI 10.1073/pnas.88.10.4245; Robert F, 2002, J BIOL CHEM, V277, P9302, DOI 10.1074/jbc.M110516200; Samkurashvili I, 1998, MOL CELL BIOL, V18, P5343, DOI 10.1128/MCB.18.9.5343; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Shilatifard A, 2004, BBA-GENE STRUCT EXPR, V1677, P79, DOI 10.1016/j.bbaexp.2003.11.013; SINGH R, 1995, SCIENCE, V268, P1173, DOI 10.1126/science.7761834; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Ujvari A, 2002, J BIOL CHEM, V277, P32527, DOI 10.1074/jbc.M201145200; VALCARCEL J, 1997, MRNA FORMATION FUNCT, P31; Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; Zhang CF, 2003, J BIOL CHEM, V278, P50101, DOI 10.1074/jbc.M307590200; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	48	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49773	49779		10.1074/jbc.M409087200	http://dx.doi.org/10.1074/jbc.M409087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377657	hybrid			2022-12-25	WOS:000225229500029
J	Gloster, TM; Macdonald, JM; Tarling, CA; Stick, RV; Withers, SG; Davies, GJ				Gloster, TM; Macdonald, JM; Tarling, CA; Stick, RV; Withers, SG; Davies, GJ			Structural, thermodynamic, and kinetic analyses of tetrahydrooxazine-derived inhibitors bound to beta-glucosidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-RESOLUTION ANALYSES; REACTION COORDINATE; GLYCOSIDASE; ISOFAGOMINE; ENZYMES; BINDING; ENDOGLUCANASE; REFINEMENT; MOLSCRIPT; POTENT	The understanding of transition state mimicry in glycoside hydrolysis is increasingly important both in the quest for novel specific therapeutic agents and for the deduction of enzyme function and mechanism. To aid comprehension, inhibitors can be characterized through kinetic, thermodynamic, and structural dissection to build an "inhibition profile." Here we dissect the binding of a tetrahydrooxazine inhibitor and its derivatives, which display K-i values around 500 nM. X-ray structures with both a beta-glucosidase, at 2 Angstrom resolution, and an endoglucanase at atomic (similar to1Angstrom) resolution reveal similar interactions between the tetrahydrooxazine inhibitor and both enzymes. Kinetic analyses reveal the pH dependence of k(cat)/K-m and 1/K-i with both enzyme systems, and isothermal titration calorimetry unveils the enthalpic and entropic contributions to beta-glucosidase inhibition. The pH dependence of enzyme activity mirrored that of 1/K-i in both enzymes, unlike the cases of isofagomine and 1-deoxynojirimycin that have been characterized previously. Calorimetric dissection reveals a large favorable enthalpy that is partially offset by an unfavorable entropy upon binding. In terms of the similar profile for the pH dependence of 1/K-i and the pH dependence of k(cat)/K-m, the significant enthalpy of binding when compared with other glycosidase inhibitors, and the tight binding at the optimal pH of the enzymes tested, tetrahydrooxazine and its derivatives are a significantly better class of glycosidase inhibitor than previously assumed.	Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Univ Western Australia, Sch Biomed & Chem Sci M313, Crawley, WA 6009, Australia; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	University of York - UK; University of Western Australia; University of British Columbia	Davies, GJ (corresponding author), Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England.	davies@ysbl.york.ac.uk	Davies, Gideon J/A-9042-2011; Macdonald, James M/H-4209-2013	Davies, Gideon J/0000-0002-7343-776X; 				Bach P, 1999, TETRAHEDRON LETT, V40, P3461, DOI 10.1016/S0040-4039(99)00423-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Best WM, 2002, CAN J CHEM, V80, P857, DOI 10.1139/V02-060; Bulow A, 2000, J AM CHEM SOC, V122, P8567, DOI 10.1021/ja001762x; Coutinho PM, 1999, ROY SOC CH, P3; DAVIES G, 1997, COMPREHENSIVE BIOL C, V1, P119; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P11707, DOI 10.1021/bi981315i; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Ganem B, 1996, ACCOUNTS CHEM RES, V29, P340, DOI 10.1021/ar9502184; Gloster TM, 2004, CHEM COMMUN, P1794, DOI 10.1039/b405152a; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Ichikawa Y, 1998, J AM CHEM SOC, V120, P3007, DOI 10.1021/ja973443k; JESPERSEN TM, 1994, ANGEW CHEM INT EDIT, V33, P1778, DOI 10.1002/anie.199417781; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R.J., 2001, GRAFIT VERSION 5; Macdonald JM, 2002, AUST J CHEM, V55, P747, DOI 10.1071/CH02165; Mader MM, 1997, CHEM REV, V97, P1281, DOI 10.1021/cr960435y; McIntosh LP, 1996, BIOCHEMISTRY-US, V35, P9958, DOI 10.1021/bi9613234; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sidhu G, 1999, BIOCHEMISTRY-US, V38, P5346, DOI 10.1021/bi982946f; Snider MJ, 2001, BIOCHEMISTRY-US, V40, P11364, DOI 10.1021/bi011189+; Varrot A, 2003, J AM CHEM SOC, V125, P7496, DOI 10.1021/ja034917k; Varrot A, 2003, ACTA CRYSTALLOGR D, V59, P447, DOI 10.1107/S0907444902023405; Vasella A, 2002, CURR OPIN CHEM BIOL, V6, P619, DOI 10.1016/S1367-5931(02)00380-0; Withers S. G., 1999, IMINOSUGARS GLYCOSID, P188; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Wolfenden R, 1998, J AM CHEM SOC, V120, P6814, DOI 10.1021/ja9813055; Zechel DL, 2003, J AM CHEM SOC, V125, P14313, DOI 10.1021/ja036833h	33	38	40	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49236	49242		10.1074/jbc.M407195200	http://dx.doi.org/10.1074/jbc.M407195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15356002	hybrid			2022-12-25	WOS:000225098100090
J	Komenda, J; Reisinger, V; Muller, BC; Dobakova, M; Granvogl, B; Eichacker, LA				Komenda, J; Reisinger, V; Muller, BC; Dobakova, M; Granvogl, B; Eichacker, LA			Accumulation of the D2 protein is a key regulatory step for assembly of the photosystem II reaction center complex in Synechocystis PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; ENCODED D1 PROTEIN; MEMBRANE-PROTEIN; CHLAMYDOMONAS-REINHARDTII; ARABIDOPSIS-THALIANA; DIRECTED MUTAGENESIS; DELETION MUTAGENESIS; THYLAKOID MEMBRANES; ELECTRON-TRANSPORT; GENE-PRODUCT	Accumulation of monomer and dimer photosystem (PS) II reaction center core complexes has been analyzed by two-dimensional Blue-native/ SDS-PAGE in Synechocystis PCC 6803 wild type and in mutant strains lacking genes psbA, psbB, psbC, psbDIC/DII, or the psbEFLJ operon. In vivo pulse-chase radiolabeling experiments revealed that mutant cells assembled PSII precomplexes only. In DeltapsbC and DeltapsbB, assembly of reaction center cores lacking CP43 and reaction center complexes was detected, respectively. In DeltapsbA, protein subunits CP43, CP47, D2, and cytochrome b(559) were synthesized, but proteins did not assemble. Similarly, in DeltapsbD/C lacking D2, and CP43, the de novo synthesized proteins D1, CP47, and cytochrome b559 did not form any mutual complexes, indicating that assembly of the reaction center complex is a prerequisite for assembly with core subunits CP47 and CP43. Finally, although CP43 and CP47 accumulated in DeltapsbEFLJ, D2 was neither expressed nor accumulated. We, furthermore, show that the amount of D2 is high in the strain lacking D1, whereas the amount of D1 is low in the strain lacking D2. We conclude that expression of the psbEFLJ operon is a prerequisite for D2 accumulation that is the key regulatory step for D1 accumulation and consecutive assembly of the PSII reaction center complex.	Univ Munich, Inst Bot, D-80368 Munich, Germany; Opatovicky Mlyn, Inst Microbiol, Trebon 37981, Czech Republic; Univ S Bohemia, Inst Phys Biol, Nove Hrady 37005, Czech Republic; Hoffmann La Roche AG, RCMG, CH-4070 Basel, Switzerland	University of Munich; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Roche Holding	Eichacker, LA (corresponding author), Univ Munich, Inst Bot, Menzinger Str 67, D-80368 Munich, Germany.	eichacker@lmu.de	Komenda, Josef/H-4083-2014	Komenda, Josef/0000-0003-4588-0382				ANBUDURAI PR, 1993, Z NATURFORSCH C, V48, P267; Andersson B, 2001, ADV PHOTOSYNTH, V11, P377; Barber J, 2002, CURR OPIN STRUC BIOL, V12, P523, DOI 10.1016/S0959-440X(02)00357-3; Barber J, 2003, Q REV BIOPHYS, V36, P71, DOI 10.1017/S0033583502003839; Bergantino E, 2003, J BIOL CHEM, V278, P41820, DOI 10.1074/jbc.M303096200; Choquet Y, 2001, BIOCHEM SOC T, V29, P421, DOI 10.1042/BST0290421; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; EGGERS B, 1993, BIOCHEMISTRY-US, V32, P11419, DOI 10.1021/bi00093a020; EICHACKER LA, 2001, Patent No. 101195974; ErmakovaGerdes S, 1996, PLANT MOL BIOL, V30, P243, DOI 10.1007/BF00020111; HAAG E, 1993, BIOCHEMISTRY-US, V32, P4444, DOI 10.1021/bi00067a037; Hager M, 2002, J BIOL CHEM, V277, P14031, DOI 10.1074/jbc.M112053200; IKEUCHI M, 1991, J BIOL CHEM, V266, P11111; Ikeuchi M, 1995, MOL GEN GENET, V249, P622, DOI 10.1007/BF00418031; Inagaki N, 2001, FEBS LETT, V509, P197, DOI 10.1016/S0014-5793(01)03180-5; Kaneko T, 1997, PLANT CELL PHYSIOL, V38, P1171, DOI 10.1093/oxfordjournals.pcp.a029103; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KOMENDA J, 1995, EUR J BIOCHEM, V233, P677, DOI 10.1111/j.1432-1033.1995.677_2.x; Komenda J, 2002, EUR J BIOCHEM, V269, P610, DOI 10.1046/j.0014-2956.2001.02693.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIND LK, 1993, J BIOL CHEM, V268, P1575; MAYES SR, 1993, BIOCHEMISTRY-US, V32, P1454, DOI 10.1021/bi00057a008; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; Muller B, 1999, PLANT CELL, V11, P2365, DOI 10.1105/tpc.11.12.2365; NILSSON FJ, 1992, PLANT MOL BIOL, V14, P1051; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; Ohnishi N, 2001, J BIOL CHEM, V276, P33798, DOI 10.1074/jbc.M104454200; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; Ozawa S, 1997, PLANT MOL BIOL, V34, P151, DOI 10.1023/A:1005800909495; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PAKRASI HB, 1989, PLANT CELL, V1, P591, DOI 10.2307/3868946; PAKRASI HB, 1990, Z NATURFORSCH C, V45, P423; Plucken H, 2002, FEBS LETT, V532, P85, DOI 10.1016/S0014-5793(02)03634-7; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P295; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; ROGNER M, 1991, BIOCHEMISTRY-US, V30, P5387; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Shi LX, 2000, J BIOL CHEM, V275, P37945, DOI 10.1074/jbc.M006300200; SHUKLA VK, 1992, MOL MICROBIOL, V6, P947, DOI 10.1111/j.1365-2958.1992.tb01544.x; Silva P, 2003, PLANT CELL, V15, P2152, DOI 10.1105/tpc.012609; Sugimoto I, 2003, J BIOL CHEM, V278, P45004, DOI 10.1074/jbc.M307537200; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347; Szabo I, 2001, EUR J BIOCHEM, V268, P5129, DOI 10.1046/j.0014-2956.2001.02441.x; TAKAHASHI Y, 1994, PLANT MOL BIOL, V24, P779, DOI 10.1007/BF00029859; Thidholm E, 2002, FEBS LETT, V513, P217, DOI 10.1016/S0014-5793(02)02314-1; Tichy M, 2003, BBA-BIOENERGETICS, V1605, P55, DOI 10.1016/S0005-2728(03)00064-1; vanWijk KJ, 1996, J BIOL CHEM, V271, P9627, DOI 10.1074/jbc.271.16.9627; vanWijk KJ, 1997, BIOCHEMISTRY-US, V36, P6178, DOI 10.1021/bi962921l; VERMAAS WFJ, 1988, PHOTOSYNTH RES, V17, P97, DOI 10.1007/BF00047683; WELLBURN AR, 1984, ADV PHOTOSYNTHESIS R, V2, P10; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; YU JJ, 1990, PLANT CELL, V2, P315; Zhang LX, 1999, J BIOL CHEM, V274, P16062, DOI 10.1074/jbc.274.23.16062; Zhang LX, 2002, FEBS LETT, V512, P13, DOI 10.1016/S0014-5793(02)02218-4; Zhang LX, 2001, J BIOL CHEM, V276, P37809; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	60	132	139	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48620	48629		10.1074/jbc.M405725200	http://dx.doi.org/10.1074/jbc.M405725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347679	hybrid			2022-12-25	WOS:000225098100018
J	Rotem, D; Schuldiner, S				Rotem, D; Schuldiner, S			EmrE, a multidrug transporter from Escherichia coli, transports monovalent and divalent substrates with the same stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BINDING-SITE; NA+/H+ ANTIPORTER; ACTIVE-TRANSPORT; EFFLUX; MEMBRANE; PH; PROTEIN; MODEL; GENES; MDFA	Multidrug transporters recognize and transport substrates with apparently little common structural features. At times these substrates are neutral, negatively, or positively charged, and only limited information is available as to how these proteins deal with the energetic consequences of transport of substrates with different charges. Multidrug transporters and drug-specific efflux systems are responsible for clinically significant resistance to chemotherapeutic agents in pathogenic bacteria, fungi, parasites, and human cancer cells. Understanding how these efflux systems handle different substrates may also have practical implications in the development of strategies to overcome the resistance mechanisms mediated by these proteins. Here, we compare transport of monovalent and divalent substrates by EmrE, a multidrug transporter from Escherichia coli, in intact cells and in proteoliposomes reconstituted with the purified protein. The results demonstrated that whereas the transport of monovalent substrates involves charge movement (i.e. electrogenic), the transport of divalent substrate does not (i.e. electroneutral). Together with previous results, these findings suggest that an EmrE dimer exchanges two protons per substrate molecule during each transport cycle. In intact cells, under conditions where the only driving force is the electrical potential, EmrE confers resistance to monovalent substrates but not to divalent ones. In the presence of proton gradients, resistance to both types of substrates is detected. The finding that under some conditions EmrE does not remove certain types of drugs points out the importance of an in-depth understanding of mechanisms of action of multidrug transporters to devise strategies for coping with the problem of multidrug resistance.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Schuldiner, S (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	Shimon.Schuldiner@huji.ac.il	Schuldiner, Shimon/F-7628-2012; Rotem, Dvir/G-1396-2013	Schuldiner, Shimon/0000-0002-4874-6237; Rotem, Dvir/0000-0002-1840-6530	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016708, R56NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bibi E, 2001, J MOL MICROB BIOTECH, V3, P171; Brown MH, 2001, J MOL MICROB BIOTECH, V3, P163; Chung Y J, 2001, Curr Opin Drug Discov Devel, V4, P237; EISENBERG ES, 1984, J BACTERIOL, V157, P863, DOI 10.1128/JB.157.3.863-867.1984; Elbaz Y, 2004, P NATL ACAD SCI USA, V101, P1519, DOI 10.1073/pnas.0306533101; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Lewinson O, 2003, P NATL ACAD SCI USA, V100, P1667, DOI 10.1073/pnas.0435544100; Ma C, 2004, P NATL ACAD SCI USA, V101, P2852, DOI 10.1073/pnas.0400137101; MINAKAMI H, 1990, J BACTERIOL, V172, P691, DOI 10.1128/jb.172.2.691-695.1990; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ninio S, 2003, J BIOL CHEM, V278, P12000, DOI 10.1074/jbc.M213119200; Ninio S, 2001, J BIOL CHEM, V276, P48250, DOI 10.1074/jbc.M108231200; Nishino K, 2001, J BACTERIOL, V183, P5803, DOI 10.1128/JB.183.20.5803-5812.2001; PADAN E, 1987, J MEMBRANE BIOL, V95, P189, DOI 10.1007/BF01869481; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Paulsen IT, 1996, MOL MICROBIOL, V19, P1167, DOI 10.1111/j.1365-2958.1996.tb02462.x; Rotem D, 2001, J BIOL CHEM, V276, P48243, DOI 10.1074/jbc.M108229200; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Schuldiner S, 2001, J MOL MICROB BIOTECH, V3, P155; Schuldiner S, 2001, NEWS PHYSIOL SCI, V16, P130; SCHULDINER S, 1975, BIOCHEMISTRY-US, V14, P5451, DOI 10.1021/bi00696a011; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Schumacher MA, 2002, MOL MICROBIOL, V45, P885, DOI 10.1046/j.1365-2958.2002.03039.x; Soskine M, 2004, J BIOL CHEM, V279, P9951, DOI 10.1074/jbc.M312853200; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Tate CG, 2001, EMBO J, V20, P77, DOI 10.1093/emboj/20.1.77; Ubarretxena-Belandia I, 2003, EMBO J, V22, P6175, DOI 10.1093/emboj/cdg611; Ueda K, 1997, SEMIN CANCER BIOL, V8, P151, DOI 10.1006/scbi.1997.0066; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yerushalmi H, 2000, BIOCHEMISTRY-US, V39, P14711, DOI 10.1021/bi001892i; Yerushalmi H, 2000, FEBS LETT, V476, P93, DOI 10.1016/S0014-5793(00)01677-X; Yerushalmi H, 2000, J BIOL CHEM, V275, P5264, DOI 10.1074/jbc.275.8.5264; YERUSHALMI H, 1995, J BIOL CHEM, V270, P6856, DOI 10.1074/jbc.270.12.6856; Yerushalmi H, 2001, J BIOL CHEM, V276, P12744, DOI 10.1074/jbc.M010979200; Yerushalmi H, 1996, J BIOL CHEM, V271, P31044, DOI 10.1074/jbc.271.49.31044; ZILBERSTEIN D, 1979, BIOCHEMISTRY-US, V18, P669, DOI 10.1021/bi00571a018	39	63	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48787	48793		10.1074/jbc.M408187200	http://dx.doi.org/10.1074/jbc.M408187200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371426	hybrid			2022-12-25	WOS:000225098100038
J	Harry, JB; Kobrinsky, E; Abernethy, DR; Soldatov, NM				Harry, JB; Kobrinsky, E; Abernethy, DR; Soldatov, NM			New short splice variants of the human cardiac Ca-v beta(2) subunit - Redefining the major functional motifs implemented in modulation of the Ca(v)1.2 channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CA2+ CHANNELS; CALCIUM-CHANNEL; BETA-SUBUNIT; SKELETAL-MUSCLE; HUMAN HEART; EXPRESSION; DOMAIN; CELLS; BRAIN; HETEROGENEITY	Two new short splice variants of the Ca2+ channel beta(2) subunit were cloned from human heart poly(A)(+) mRNA. The 410-amino acid beta(2f) subunit is encoded by exons 1A, 2A, 3, 4, 12, 13, and 14 of the human Ca(v)beta(2) gene and lacks the protein kinase A phosphorylation site, the beta-interaction domain (De Waard, M., Pragnell, M., and Campbell, K. P. (1994) Neuron 13, 495-503), 40% of the beta-SH3 domain, and 73% of the guanylate kinase domain of the putative membrane-associated guanylate kinases module (McGee, A. W., Nunziato, D. A., Maltez, J. M., Prehoda, K. E., Pitt, G. S., and Bredt, D. S. (2004) Neuron 42, 89-99), and helix alpha3 of the alpha(1)-subunit binding pocket (Van Petegem F., Clark, K. A., Chatelain, F. C., and Minor, D. L., Jr. (2004) Nature 429, 671-675). The beta(2g) transcript has two potential initiation codons. With the second ATG codon, it generates the 164-amino acid beta(2Deltag) subunit encoded essentially by the distal part of exon 14, and thus beta(2Deltag) completely lacks any of the above motifs. Immunoprecipitation analysis confirmed stable association of beta(2f) and beta(2Deltag) with the alpha(1C) subunit. The plasma membrane localization of beta(2f) and beta(2Deltag) was substantially increased by co-expression of the alpha(1C,77) and alpha(2)delta subunits. In COS1 cells, beta(2f) and beta(2Deltag) increased plasma membrane targeting of the pore-forming alpha(1C) subunit and differentially facilitated (beta(2f) > beta(2Deltag)) the voltage gating of otherwise silent Ca(v)1.2 channels. We conclude that it is unlikely that the beta-interaction domain, membrane-associated guanylate kinases module, and the alpha(1)-subunit binding pocket helix alpha3 are essential for the interaction of the alpha(1C) and beta(2) subunits and suggest that in addition to the alpha(1)-subunit binding pocket helices alpha5 and alpha8, a yet unresolved C-terminal beta(2) region plays a crucial role.	NIA, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), NIA, NIH, Baltimore, MD 21224 USA.	soldatovN@grc.nia.nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000294, ZIAAG000294] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Kobrinsky E, 2003, J BIOL CHEM, V278, P5021, DOI 10.1074/jbc.M211254200; LORY P, 1993, FEBS LETT, V315, P167, DOI 10.1016/0014-5793(93)81156-T; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; McGee AW, 2004, NEURON, V42, P89, DOI 10.1016/S0896-6273(04)00149-7; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; POWERS PA, 1992, J BIOL CHEM, V267, P22967; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Takahashi SX, 2004, P NATL ACAD SCI USA, V101, P7193, DOI 10.1073/pnas.0306665101; Taviaux S, 1997, HUM GENET, V100, P151, DOI 10.1007/PL00008704; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588	27	28	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46367	46372		10.1074/jbc.M409523200	http://dx.doi.org/10.1074/jbc.M409523200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15339916	hybrid			2022-12-25	WOS:000224832400005
J	Schwartz, SH; Qin, XQ; Loewen, MC				Schwartz, SH; Qin, XQ; Loewen, MC			The biochemical characterization of two carotenoid cleavage enzymes from Arabidopsis indicates that a carotenoid-derived compound inhibits lateral branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID BIOSYNTHESIS; BETA-CAROTENE; 9-CIS-EPOXYCAROTENOID DIOXYGENASE; OXIDATIVE CLEAVAGE; IDENTIFICATION; EXPRESSION; MUTANT; MAIZE; GENE; 15,15'-DIOXYGENASE	Enzymes that are able to oxidatively cleave carotenoids at specific positions have been identified in animals and plants. The first such enzyme to be identified was a nine-cis-epoxy carotenoid dioxygenase from maize, which catalyzes the rate-limiting step of abscisic acid biosynthesis. Similar enzymes are necessary for the synthesis of vitamin A in animals and other carotenoid-derived molecules in plants. In the model plant, Arabidopsis, there are nine hypothetical proteins that share some degree of sequence similarity to the nine-cis-epoxy carotenoid dioxygenases. Five of these proteins appear to be involved in abscisic acid biosynthesis. The remaining four proteins are expected to catalyze other carotenoid cleavage reactions and have been named carotenoid cleavage dioxygenases (CCDs). The hypothetical proteins, AtCCD7 and AtCCD8, are the most disparate members of this protein family in Arabidopsis. The max3 and max4 mutants in Arabidopsis result from lesions in AtCCD7 and AtCCD8. Both mutants display a dramatic increase in lateral branching and are believed to be impaired in the synthesis of an unidentified compound that inhibits axillary meristem development. To determine the biochemical function of AtCCD7, the protein was expressed in carotenoid-accumulating strains of Escherichia coli. The activity of AtCCD7 was also tested in vitro with several of the most common plant carotenoids. It was shown that the recombinant AtCCD7 protein catalyzes a specific 9-10 cleavage of beta-carotene to produce the 10'-apo-beta-carotenal (C-27) and beta-ionone (C-13). When AtCCD7 and AtCCD8 were co-expressed in a beta-carotene-producing strain of E. coli, the 13-apo-beta-carotenone (C-18) was produced. The C-18 product appears to result from a secondary cleavage of the AtCCD7-derived C-27 product. The sequential cleavages of beta-carotene by AtCCD7 and AtCCD8 are likely the initial steps in the synthesis of a carotenoid-derived signaling molecule that is necessary for the regulation lateral branching.	Michigan State Univ, Dept Energy Plant Res Lab, E Lansing, MI 48824 USA; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada	Michigan State University; National Research Council Canada	Schwartz, SH (corresponding author), Michigan State Univ, Dept Energy Plant Res Lab, E Lansing, MI 48824 USA.	schwart1@msu.edu		Schwartz, Steve/0000-0002-5982-8553				Barua AB, 2000, J NUTR, V130, P1996, DOI 10.1093/jn/130.8.1996; Booker J, 2004, CURR BIOL, V14, P1232, DOI 10.1016/j.cub.2004.06.061; Bouvier F, 2003, SCIENCE, V300, P2089, DOI 10.1126/science.1085162; Bouvier F, 2003, PLANT CELL, V15, P47, DOI 10.1105/tpc.006536; Burbidge A, 1999, PLANT J, V17, P427, DOI 10.1046/j.1365-313X.1999.00386.x; Chernys JT, 2000, PLANT PHYSIOL, V124, P343, DOI 10.1104/pp.124.1.343; DAS PK, 1978, J PHYS CHEM-US, V82, P2081, DOI 10.1021/j100508a009; Iuchi S, 2000, PLANT PHYSIOL, V123, P553, DOI 10.1104/pp.123.2.553; Iuchi S, 2001, PLANT J, V27, P325, DOI 10.1046/j.1365-313x.2001.01096.x; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; Kiefer C, 2001, J BIOL CHEM, V276, P14110, DOI 10.1074/jbc.M011510200; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; Lindqvist A, 2002, J BIOL CHEM, V277, P23942, DOI 10.1074/jbc.M202756200; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Makoto N, 2001, J MICROBIOL BIOTECHN, V11, P884; Morris SE, 2001, PLANT PHYSIOL, V126, P1205, DOI 10.1104/pp.126.3.1205; Napoli C, 1996, PLANT PHYSIOL, V111, P27, DOI 10.1104/pp.111.1.27; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627; Qin XQ, 1999, P NATL ACAD SCI USA, V96, P15354, DOI 10.1073/pnas.96.26.15354; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; ROCK CD, 1991, P NATL ACAD SCI USA, V88, P7496, DOI 10.1073/pnas.88.17.7496; Schwartz SH, 2001, J BIOL CHEM, V276, P25208, DOI 10.1074/jbc.M102146200; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; Sorefan K, 2003, GENE DEV, V17, P1469, DOI 10.1101/gad.256603; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; Tanumihardjo SA, 2001, J LABELLED COMPD RAD, V44, P365, DOI 10.1002/jlcr.464; Turnbull CGN, 2002, PLANT J, V32, P255, DOI 10.1046/j.1365-313X.2002.01419.x; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305	32	229	264	4	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46940	46945		10.1074/jbc.M409004200	http://dx.doi.org/10.1074/jbc.M409004200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15342640	hybrid			2022-12-25	WOS:000224832400077
J	Mahapatra, NR; Mahata, M; Hazra, PP; McDonough, PM; O'Connor, DT; Mahata, SK				Mahapatra, NR; Mahata, M; Hazra, PP; McDonough, PM; O'Connor, DT; Mahata, SK			A dynamic pool of calcium in catecholamine storage vesicles - Exploration in living cells by a novel vesicle-targeted chromogranin A-aequorin chimeric photoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; ENDOPLASMIC-RETICULUM; RECOMBINANT AEQUORIN; CA2+ CONCENTRATION; RECEPTOR/CA2+ CHANNEL; SECRETORY VESICLES; REGULATED PATHWAY; GENE-EXPRESSION; PROTEIN; GRANULES	Chromaffin vesicles contain very high concentration of Ca2+ ( similar to 20 - 40 mM total), compared with similar to 100 nM in the cytosol. Aequorin, a jellyfish photoprotein with Ca2+-dependent luminescence, measures [Ca2+] in specific subcellular compartments wherein proteins with organelle-specific trafficking domains are fused in-frame to aequorin. Because of the presence of vesicular trafficking domain within CgA we engineered sorting of an expressed human CgA-Aequorin fusion protein (hCgA-Aeq) into the vesicle compartment as confirmed by sucrose density gradients and confocal immunofluorescent co-localization studies. hCgA-Aeq and cytoplasmic aequorin (Cyto-Aeq) luminescence displayed linear functions of [Ca2+] in vitro, over > 5 log(10) orders of magnitude ( r > 0.99), and down to at least 10(-7) M sensitivity. Calibrating the pH dependence of hCgA-Aeq luminescence allowed estimation of [Ca2+](ves) at granule interior pH ( similar to 5.5). In the cytoplasm, Cyto-Aeq accurately determined [Ca2+](cyto) under both basal ([Ca2+](cyto) = 130 +/- 35 nM) and exocytosis-stimulated conditions, confirmed by an independent reference technique (Indo-1 fluorescence). The hCgA-Aeq chimera determined vesicular free [Ca2+](ves) = 1.4 +/- 0.3 muM under basal conditions indicating that > 99% of granule total Ca2+ is in a "bound" state. The basal free [Ca2+](ves)/[Ca2+](cyto) ratio was thus similar to 10.8-fold, indicating active, dynamic Ca2+ uptake from cytosol into the granules. Stimulation of exocytotic secretion revealed prompt, dynamic increases in both [Ca2+](ves) and [Ca2+](cyto), and an exponential relation between the two ( y = 0.99 x e((1.53x)), r = 0.99), reflecting a persistent [Ca2+](ves)/[Ca2+](cyto) gradient, even during sharp increments of both values. Studies with inhibitors of Ca2+ translocation (Ca2+-ATPase), Na+/ Ca+-exchange, Na+/ H+-exchange, and vesicle acidification ( H+-translocating ATPase), documented a role for these four ion transporter classes in accumulation of Ca2+ inside the vesicles.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	O'Connor, DT (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	doconnor@ucsd.edu; smahata@ucsd.edu	Mahapatra, Nitish R/D-4123-2014; Mahata, Sushil/AAF-8781-2021	Mahapatra, Nitish R/0000-0002-0695-3510; 				ABERER W, 1979, J NEUROCHEM, V33, P797, DOI 10.1111/j.1471-4159.1979.tb05227.x; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; DAWSON RMC, 1986, DATA BIOCH RES, P6; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; DOUGLAS WW, 1968, BRIT J PHARMACOL, V34, P453, DOI DOI 10.1111/J.1476-5381.1968.TB08474.X; Filippin L, 2003, J BIOL CHEM, V278, P39224, DOI 10.1074/jbc.M302301200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAIGH JR, 1993, NEUROREPORT, V4, P571, DOI 10.1097/00001756-199305000-00028; HAIGH JR, 1989, BIOCHEM J, V259, P485, DOI 10.1042/bj2590485; HELMAN LJ, 1988, J BIOL CHEM, V263, P11559; Herrero CJ, 2002, J NEUROSCI, V22, P377, DOI 10.1523/JNEUROSCI.22-02-00377.2002; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hilfiker S, 2003, BIOCHEM SOC T, V31, P828, DOI 10.1042/BST0310828; JAN CR, 1992, J BIOL CHEM, V267, P9695; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; KAGAYA Y, 1995, J CLIN INVEST, V95, P2766, DOI 10.1172/JCI117980; LATTANZIO FA, 1990, BIOCHEM BIOPH RES CO, V171, P102, DOI 10.1016/0006-291X(90)91362-V; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Machado JD, 2000, J BIOL CHEM, V275, P20274, DOI 10.1074/jbc.M000930200; Machado JD, 2002, CIRC RES, V91, P830, DOI 10.1161/01.RES.0000039530.30495.6F; Mahapatra NR, 2000, ENDOCRINOLOGY, V141, P3668, DOI 10.1210/en.141.10.3668; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; Mitchell KJ, 2004, DIABETES, V53, P393, DOI 10.2337/diabetes.53.2.393; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Pan CY, 1998, BIOCHEM J, V336, P305, DOI 10.1042/bj3360305; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PHILLIPS JH, 1981, BIOCHEM J, V200, P99, DOI 10.1042/bj2000099; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rigual R, 2002, EUR J NEUROSCI, V16, P1690, DOI 10.1046/j.1460-9568.11-2.02244.x; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 2000, METHOD ENZYMOL, V327, P440, DOI 10.1016/S0076-6879(00)27295-9; RUTTER GA, 1993, J BIOL CHEM, V268, P22385; Schneider AS, 2002, ANN NY ACAD SCI, V971, P142, DOI 10.1111/j.1749-6632.2002.tb04449.x; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630; Tang YM, 2000, J NEUROCHEM, V74, P702, DOI 10.1046/j.1471-4159.2000.740702.x; Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405; Taupenot L, 2002, J CELL SCI, V115, P4827, DOI 10.1242/jcs.00140; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; Villalobos C, 2002, FASEB J, V16, DOI 10.1096/fj.01-0630com; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; Yoo SH, 1996, J BIOL CHEM, V271, P17041, DOI 10.1074/jbc.271.29.17041; Yoo SH, 2002, ANN NY ACAD SCI, V971, P300, DOI 10.1111/j.1749-6632.2002.tb04484.x; Yoo SH, 2000, TRENDS NEUROSCI, V23, P424, DOI 10.1016/S0166-2236(00)01621-0	55	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51107	51121		10.1074/jbc.M408742200	http://dx.doi.org/10.1074/jbc.M408742200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15358782	hybrid			2022-12-25	WOS:000225355800057
J	Choi, JH; Hur, J; Yoon, CH; Kim, JH; Lee, CS; Youn, SW; Oh, IY; Skurk, C; Murohara, T; Park, YB; Walsh, K; Kim, HS				Choi, JH; Hur, J; Yoon, CH; Kim, JH; Lee, CS; Youn, SW; Oh, IY; Skurk, C; Murohara, T; Park, YB; Walsh, K; Kim, HS			Augmentation of therapeutic angiogenesis using genetically modified human endothelial progenitor cells with altered glycogen synthase kinase-3 beta activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BETA-CATENIN; BONE-MARROW; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; DEPENDENT REGULATION; GROWTH-FACTORS; GENE-TRANSFER; PHOSPHORYLATION; BLOOD	Previously we reported that inhibition of glycogen synthase kinase-3beta (GSK3beta), a key regulator in many intracellular signaling pathways, enhances the survival and migration of vascular endothelial cells. Here we investigated the effect of inhibition of GSK3beta activity on the angiogenic function of endothelial progenitor cell (EPC) and demonstrated a new therapeutic angiogenesis strategy using genetically modified EPC. As we previously reported, two biologically distinct types of EPC, spindle-shaped "early EPC" and cobblestone-shaped "late EPC" could be cultivated from human peripheral blood. Catalytically inactive GSK3beta gene was transduced into both EPC. Inhibition of GSK3beta signaling pathway led to increased nuclear translocation of beta-catenin and increased secretion of angiogenic cytokines (vascular endothelial growth factor and interleukin-8). It enhanced the survival and proliferation of early EPC, whereas it promoted the survival and differentiation of late EPC. Transplantation of either of these genetically modified EPC into the ischemic hind limb model of athymic nude mouse significantly improved blood flow, limb salvage, and tissue capillary density compared with nontransduced EPC. Inhibition of GSK3beta signaling of either of these genetically modified EPC augmented the in vitro and in vivo angiogenic potency of these cell populations. These data provide evidence that GSK3beta has a key role in the angiogenic properties of EPC. Furthermore, the genetic modification of EPC to alter this signaling step can improve the efficacy of cell-based therapeutic vasculogenesis.	Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Cardiovasc Lab, Seoul 110744, South Korea	Seoul National University (SNU); Nagoya University; Boston University; Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul National University Hospital	Kim, HS (corresponding author), Seoul Natl Univ, Coll Med, Dept Internal Med, 28 Yongon Dong Chong Gu, Seoul 110744, South Korea.	hyosoo@snu.ac.kr	Kim, Hyo Soo/J-2753-2012; Park, Young-Bae/J-5490-2012; Murohara, Toyoaki/M-4958-2014	Youn, Seock-Won/0000-0003-3275-2170; Yoon, Chang-Hwan/0000-0001-6305-4442	NIAMS NIH HHS [AR40197] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chu BY, 1996, J BIOL CHEM, V271, P30847, DOI 10.1074/jbc.271.48.30847; Couffinhal T, 1998, AM J PATHOL, V152, P1667; Crosby JR, 2000, CIRC RES, V87, P728, DOI 10.1161/01.RES.87.9.728; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Eberhart CG, 2001, PEDIATR DEVEL PATHOL, V4, P351, DOI 10.1007/s10024001-0037-y; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Hagen T, 2002, J BIOL CHEM, V277, P23330, DOI 10.1074/jbc.M201364200; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Ikpeazu C, 2000, BIOL BLOOD MARROW TR, V6, P301, DOI 10.1016/S1083-8791(00)70055-3; INGRAM DA, 2004, IN PRESS BLOOD; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2001, CIRCULATION, V103, P634; Kim HS, 2002, J BIOL CHEM, V277, P41888, DOI 10.1074/jbc.M206657200; Levy L, 2002, J BIOL CHEM, V277, P42386, DOI 10.1074/jbc.M207418200; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mogi M, 2003, J BIOL CHEM, V278, P39068, DOI 10.1074/jbc.M306362200; Murasawa S, 2002, CIRCULATION, V106, P1133, DOI 10.1161/01.CIR.0000027584.85865.B4; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Park KW, 2003, ARTERIOSCL THROM VAS, V23, P1364, DOI 10.1161/01.ATV.0000081633.53390.B4; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; SAKSELA K, 1992, ONCOGENE, V7, P347; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Tepper OM, 2002, CIRCULATION, V106, P2781, DOI 10.1161/01.CIR.0000039526.42991.93; Wang XH, 2002, CIRC RES, V90, P340, DOI 10.1161/hh0302.104466; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611	44	79	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49430	49438		10.1074/jbc.M402088200	http://dx.doi.org/10.1074/jbc.M402088200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339925	hybrid			2022-12-25	WOS:000225098100112
J	Ghersi, E; Noviello, C; D'Adamio, L				Ghersi, E; Noviello, C; D'Adamio, L			Amyloid-beta protein precursor (A beta PP) intracellular domain-associated protein-1 proteins bind to A beta PP and modulate its processing in an isoform-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; RECEPTOR-RELATED PROTEIN; GAMMA-SECRETASE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; MISSENSE MUTATIONS; PRESENILIN; CLEAVAGE; GENE; FE65	The amyloid-beta protein precursor (AbetaPP) is a type I transmembrane molecule that undergoes several finely regulated cleavage events. The physiopathological relevance of AbetaPP derives from the fact that its aberrant processing strongly correlates with the onset of Alzheimer's disease (AD). AD is a neurodegenerative disorder characterized by neuronal cell death, loss of synapses, and deposition of misfolded protein plaques in the brain; the main constituent of these plaques is the amyloid-beta peptide, a 40 - 42 amino-acid-long protein fragment derived by AbetaPP upon two sequential processing events. Mutations in the genes encoding for AbetaPP and some of the enzymes responsible for its processing are strongly associated with familial forms of early onset AD. Therefore, the elucidation of the mechanisms underlying AbetaPP metabolism appears crucial to understanding the basis for the onset of AD. Apart from Abeta, upon processing of AbetaPP other fragments are generated. The long extracellular domain is released in the extracellular space, whereas the short cytoplasmic tail, named AbetaPP intracellular domain (AID) is released intracellularly. AID appears be involved in several cellular processes, apoptosis, calcium homeostasis, and transcriptional regulation. We have recently reported the cloning and characterization of different isoforms of AID associated protein-1 (AIDA-1), a novel AID-binding protein. Here we further analyzed the interaction between several AIDA-1 isoforms and the cytoplasmic tail of AbetaPP. Our data demonstrated that the interaction between the two molecules is regulated by alternative splicing of the AIDA-1 proteins. Furthermore, we provide data supporting a possible function for AIDA-1a as a modulator of AbetaPP processing.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	ldadamio@aecom.yu.edu		D'Adamio, Luciano/0000-0002-2204-9441; D'Adamio, Luciano/0000-0002-9820-4882	NATIONAL INSTITUTE ON AGING [R01AG022024, R01AG021588] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG22024, R01 AG21588] Funding Source: Medline; Telethon [GFP02006] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cao XW, 2004, J BIOL CHEM, V279, P24601, DOI 10.1074/jbc.M402248200; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Ghersi E, 2004, J ALZHEIMERS DIS, V6, P67; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Ho A, 2004, P NATL ACAD SCI USA, V101, P2548, DOI 10.1073/pnas.0308655100; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; King GD, 2004, EXP NEUROL, V185, P208, DOI 10.1016/j.expneurol.2003.10.011; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Leissring MA, 2002, P NATL ACAD SCI USA, V99, P4697, DOI 10.1073/pnas.072033799; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Matsuda S, 2003, J BIOL CHEM, V278, P38601, DOI 10.1074/jbc.M304379200; Matsuda S, 2001, J NEUROSCI, V21, P6597; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mueller HT, 2000, J BIOL CHEM, V275, P39302, DOI 10.1074/jbc.M008453200; Noviello C, 2003, J BIOL CHEM, V278, P31843, DOI 10.1074/jbc.M304133200; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Scheinfeld MH, 2003, J BIOL CHEM, V278, P42058, DOI 10.1074/jbc.M304853200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Scheinfeld MH, 2003, P NATL ACAD SCI USA, V100, P1729, DOI 10.1073/pnas.0437908100; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Steiner H, 2000, NAT REV MOL CELL BIO, V1, P217, DOI 10.1038/35043065; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhou DW, 2004, J BIOL CHEM, V279, P25374, DOI 10.1074/jbc.M400488200	55	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49105	49112		10.1074/jbc.M405329200	http://dx.doi.org/10.1074/jbc.M405329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347684	hybrid			2022-12-25	WOS:000225098100075
J	Radhika, V; Onesime, D; Ha, JH; Dhanasekaran, N				Radhika, V; Onesime, D; Ha, JH; Dhanasekaran, N			G alpha(13) stimulates cell migration through cortactin-interacting protein Hax-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION; ALPHA-SUBUNIT; RHO GTPASES; ACTIVATION; MOTILITY; EXCHANGE; KINASE; G(13)	Galpha(13), the alpha-subunit of the heterotrimeric G protein G13, has been shown to stimulate cell migration in addition to inducing oncogenic transformation. Cta, a Drosophila ortholog of G13, has been shown to be critical for cell migration leading to the ventral furrow formation in Drosophila embryos. Loss of Galpha(13) has been shown to disrupt cell migration associated with angiogenesis in developing mouse embryos. Whereas these observations point to the vital role of G13-orthologs in regulating cell migration, widely across the species barrier, the mechanism by which Galpha(13) couples to cytoskeleton and cell migration is largely unknown. Here we show that Galpha(13) physically interacts with Hax-1, a cytoskeleton-associated, cortactin-interacting intracellular protein, and this interaction is required for Galpha(13)-stimulated cell migration. Hax-1 interaction is specific to Galpha(13), and this interaction is more pronounced with the mutationally or functionally activated form of Galpha(13) as compared with the wild-type Galpha(13). Expression of Hax-1 reduces the formation of actin stress fibers and focal adhesion complexes in Galpha(13)-expressing NIH3T3 cells. Coexpression of Hax-1 also attenuates Galpha(13)-stimulated activity of Rho while potentiating Galpha(13)-stimulated activity of Rac. The presence of a quadnary complex consisting of Galpha(13), Hax-1, Rac, and cortactin indicates the role of Hax-1 in tethering Galpha(13) to the cytoskeletal component(s) involved in cell movement. Whereas the expression of Hax-1 potentiates Galpha(13)-mediated cell movement, silencing of endogenous Hax-1 with Hax-1-specific small interfering RNAs drastically reduces Galpha(13)-mediated cell migration. These findings, along with the observation that Hax-1 is overexpressed in metastatic tumors and tumor cell lines, suggest a novel role for the association of oncogenic Galpha(13) and Hax-1 in tumor metastasis.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu		HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Dermott JM, 2004, ONCOGENE, V23, P226, DOI 10.1038/sj.onc.1207009; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Franz CM, 2002, DEV CELL, V2, P153, DOI 10.1016/S1534-5807(02)00120-X; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gu JL, 2002, P NATL ACAD SCI USA, V99, P9352, DOI 10.1073/pnas.102291599; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mirmohammadsadegh A, 2003, J INVEST DERMATOL, V120, P1045, DOI 10.1046/j.1523-1747.2003.12247.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Radhika V, 2000, CYTOMETRY, V42, P379, DOI 10.1002/1097-0320(20001215)42:6<379::AID-CYTO1005>3.0.CO;2-Q; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Suzuki Y, 1997, J IMMUNOL, V158, P2736; URNO T, 2003, BIOCHEM J, V371, P485; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; VIAL E, 2003, CANCER CELL, V4, P6779; Vicente-Manzanares M, 2002, INT REV CYTOL, V216, P233; Weed SA, 1998, J CELL SCI, V111, P2433; Yuan JZ, 2001, J BIOL CHEM, V276, P38619, DOI 10.1074/jbc.M105530200	33	110	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49406	49413		10.1074/jbc.M408836200	http://dx.doi.org/10.1074/jbc.M408836200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339924	Green Published, hybrid			2022-12-25	WOS:000225098100109
J	Squires, EJ; Sueyoshi, T; Negishi, M				Squires, EJ; Sueyoshi, T; Negishi, M			Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; ENHANCER MODULE; CYP2B GENE; CAR; PROTEIN; TRANSCRIPTION; IDENTIFICATION	The pregnane X receptor (PXR) plays an important role in the response to xenobiotics and endogenous toxins. We have used a specific anti-PXR antibody in the Western blotting of mouse liver nuclear extracts to show that PXR is accumulated in the nucleus after treatment with 5-pregnen-3beta-ol-20-one-16alpha-carbonitrile (PCN), followed by an increase in Cyp3a11 mRNA. Expression of wild type PXR and various mutants as green fluorescent fusion proteins in mouse livers showed that PXR was retained in the cytoplasm from where PCN treatment translocated PXR into the nucleus. Furthermore, the xenochemical response signal, the nuclear translocation signal, and the activation function 2 domain were all required for the nuclear translocation to occur. Immunoprecipitation experiments using the hsp90 antibody demonstrated the presence of PXR in a complex with the endogenous cytoplasmic constitutive active/androstane receptor retention protein (CCRP) in HepG2 cells. Fluorescence resonance energy transfer analysis of mouse liver sections after co-expression of cyan fluorescent protein-CCRP and yellow fluorescent protein-PXR also indicated that CCRP and PXR were closely associated in vivo. Overexpression of exogenous CCRP increased the cytoplasmic level of the PXR.CCRP.hsp90 complex, whereas a decrease in endogenous CCRP by treatment with small interfering RNA for CCRP repressed the PXR-mediated reporter activity in HepG2 cells. We conclude that the CCRP mediates the retention of PXR in the cytosol and modulates the activation of PXR in response to PCN treatment.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, ZIAES080040] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; Brychzy A, 2003, EMBO J, V22, P3613, DOI 10.1093/emboj/cdg362; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARPUR AG, 2001, MOL CLONING LAB MANU; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kawana K, 2003, MOL PHARMACOL, V63, P524, DOI 10.1124/mol.63.3.524; KOBAYASHI K, 2003, MOL PHARMACOL, V64, P1; Murthy AE, 1996, DNA CELL BIOL, V15, P727, DOI 10.1089/dna.1996.15.727; Pratt WB, 2004, CELL SIGNAL, V16, P857, DOI 10.1016/j.cellsig.2004.02.004; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Sueyoshi T, 2002, METHOD ENZYMOL, V357, P205; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; Swales K, 2004, MOL ENDOCRINOL, V18, P1589, DOI 10.1210/me.2003-0397; Yoshinari K, 2003, FEBS LETT, V548, P17, DOI 10.1016/S0014-5793(03)00720-8; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001	27	144	154	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49307	49314		10.1074/jbc.M407281200	http://dx.doi.org/10.1074/jbc.M407281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347657	hybrid			2022-12-25	WOS:000225098100099
J	Lei, JX; Mariash, CN; Ingbar, DH				Lei, JX; Mariash, CN; Ingbar, DH			3,3 ',5-triiodo-L-thyronine up-regulation of Na,K-ATPase activity and cell surface expression in alveolar epithelial cells is Src kinase- and phosphoinositide 3-kinase-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; NA+,K+-ATPASE ALPHA-SUBUNIT; NA-K-ATPASE; PHOSPHATIDYLINOSITOL 3-KINASE; THYROID-HORMONE; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; SKELETAL-MUSCLE; FACTOR RECEPTOR	We previously reported that thyroid hormone, 3,3', 5-triiodo-L-thyronine (T3), increased Na, K-ATPase activity of adult rat alveolar epithelial cells in a transcription-independent manner via increased cell surface expression of the alpha(1) and beta(1) subunits of Na, K-ATPase. Now we sought to identify signaling molecules necessary for T3 stimulation of Na, K-ATPase activity in alveolar epithelial cells. Whereas protein kinase A inhibitor H-8 and protein kinase C inhibitor bisindolymaleimide did not block the T3-induced increase in Na, K-ATPase activity, two inhibitors of phosphoinositide 3-kinase (PI3K), wortmannin and Ly294002, and two Src kinase inhibitors, PP1 and PP2, blocked the T3-induced Na, K-ATPase activity. T3 stimulated the activity of PI3K as measured by phosphatidylinositol 3-phosphate. T3 also stimulated the serine 473 phosphorylation of the PI3K downstream molecule PKB/Akt in a dose-dependent manner. Transient expression of a constitutively active mutant of the PI3K catalytic subunit p110 augmented Na, K-ATPase activity and increased the amount of cell surface Na, K-ATPase alpha(1) subunit protein. T3 also stimulated Src family kinase activity. Transient expression of a constitutively active Src kinase increased Na, K-ATPase activity, PI3K activity, and phosphorylation of PKB/Akt at serine 473. PP1 or PP2 blocked T3-stimulated PKB/Akt phosphorylation at serine 473 and PI3K activity that was activated by an active mutant of Src; however, wortmannin did not inhibit the T3-stimulated Src kinase activity. Although PP1 and wortmannin abolished the increase in Na, K-ATPase activity induced by the active mutant of Src, PP1 did not inhibit the active mutant of PI3K-up-regulated Na, K-ATPase activity. In summary, T3 stimulates the PI3K/PKB pathway via the Src family of tyrosine kinases, and activation of both the Src family kinases and PI3K is required for the T3-induced stimulation of Na, K-ATPase activity and its cell surface expression in adult rat alveolar epithelial cells.	Univ Minnesota, Dept Med, Pulm Allergy & Crit Care Div, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Ingbar, DH (corresponding author), Univ Minnesota, Dept Med, Pulm Allergy & Crit Care Div, MMC276,420 Delaware St SE, Minneapolis, MN 55455 USA.	ingba001@umn.edu		Ingbar, David H./0000-0003-1695-4493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050152] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL50152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad S, 2003, AM J RESP CELL MOL, V28, P179, DOI 10.1165/rcmb.2002-0004OC; Al-Khalili L, 2003, FEBS LETT, V536, P198, DOI 10.1016/S0014-5793(03)00047-4; Blanco G, 1998, AM J PHYSIOL-RENAL, V275, pF633, DOI 10.1152/ajprenal.1998.275.5.F633; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Corvera S, 2001, TRAFFIC, V2, P859, DOI 10.1034/j.1600-0854.2001.21201.x; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; DRISCOLL KE, 1995, IN VITRO CELL DEV-AN, V31, P516; Esposito DL, 2001, ENDOCRINOLOGY, V142, P2833, DOI 10.1210/en.142.7.2833; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gonin S, 2001, MOL BIOL CELL, V12, P255, DOI 10.1091/mbc.12.2.255; HARLOW E, 1988, ANTIBODIES, P425; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hunter S, 1999, J BIOL CHEM, V274, P2097, DOI 10.1074/jbc.274.4.2097; Incerpi S, 2002, ENDOCRINOLOGY, V143, P1660, DOI 10.1210/en.143.5.1660; Ingbar DH, 1996, AM J PHYSIOL-LUNG C, V270, pL619, DOI 10.1152/ajplung.1996.270.4.L619; Jiang X, 2001, J MEMBRANE BIOL, V181, P195, DOI 10.1007/s00232-001-0022-4; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Lasnier JM, 1998, J APPL PHYSIOL, V84, P740, DOI 10.1152/jappl.1998.84.2.740; Lee-Kwon W, 2001, J BIOL CHEM, V276, P31296, DOI 10.1074/jbc.M103900200; Lei JX, 2003, AM J PHYSIOL-LUNG C, V285, pL762, DOI 10.1152/ajplung.00376.2002; Li DL, 1999, AM J PHYSIOL-HEART C, V276, pH2109, DOI 10.1152/ajpheart.1999.276.6.H2109; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014, DOI 10.1152/ajpcell.1999.276.5.C1014; Niisato N, 1999, AM J PHYSIOL-LUNG C, V277, pL727, DOI 10.1152/ajplung.1999.277.4.L727; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; Pesce L, 2000, FEBS LETT, V486, P310, DOI 10.1016/S0014-5793(00)02298-5; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pore N, 2003, CANCER RES, V63, P236; Ragolia L, 1997, J BIOL CHEM, V272, P23653, DOI 10.1074/jbc.272.38.23653; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ridge KM, 2002, MOL BIOL CELL, V13, P1381, DOI 10.1091/mbc.01-07-0323; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Sznajder JI, 2002, J APPL PHYSIOL, V93, P1860, DOI 10.1152/japplphysiol.00022.2002; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	47	65	74	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47589	47600		10.1074/jbc.M405497200	http://dx.doi.org/10.1074/jbc.M405497200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342623	hybrid			2022-12-25	WOS:000224957000023
J	Razidlo, GL; Kortum, RL; Haferbier, JL; Lewis, RE				Razidlo, GL; Kortum, RL; Haferbier, JL; Lewis, RE			Phosphorylation regulates KSR1 stability, ERK activation, and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PROTEIN MAP KINASE; SIGNAL-TRANSDUCTION; SCAFFOLD PROTEINS; 14-3-3 BINDING; RAS EFFECTORS; GENE ENCODES; C-ELEGANS; SUPPRESSOR; MEK	Kinase suppressor of Ras (KSR) is a molecular scaffold that interacts with the components of the Raf/MEK/ERK kinase cascade and positively regulates ERK signaling. Phosphorylation of KSR1, particularly at Ser(392), is a critical regulator of KSR1 subcellular localization and ERK activation. We examined the role of phosphorylation of both Ser(392) and Thr(274) in regulating ERK activation and cell proliferation. We hypothesized that KSR1 phosphorylation is involved in generating signaling specificity through the Raf/MEK/ERK kinase cascade in response to stimulation by different growth factors. In fibroblasts, platelet-derived growth factor stimulation induces sustained ERK activation and promotes S-phase entry. Treatment with epidermal growth factor induces transient ERK activation but fails to drive cells into S phase. Mutation of Ser(392) and Thr(274) ( KSR1.TVSA) promotes sustained ERK activation and cell cycle progression with either platelet-derived growth factor or epidermal growth factor treatment. KSR1(-/-) mouse embryo fibroblasts expressing KSR1. TVSA proliferate two times faster and grow to a higher density than cells expressing the same level of wild-type KSR1. In addition, KSR1. TVSA is more stable than wild-type KSR1. These data demonstrate that phosphorylation and stability of the molecular scaffold KSR1 are critical regulators of growth factor-specific responses that promote cell proliferation.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lewis, RE (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	rlewis@unmc.edu	Lewis, Robert E./H-3404-2019	Razidlo, Gina/0000-0002-9042-2738	NATIONAL CANCER INSTITUTE [R01CA090400, P30CA036727] Funding Source: NIH RePORTER; NCI NIH HHS [CA90400, CA36727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; FERRELL JE, 2000, SCI STKE; Giblett SM, 2002, CELL GROWTH DIFFER, V13, P307; Hartsough MT, 2002, J BIOL CHEM, V277, P32389, DOI 10.1074/jbc.M203115200; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; Lozano J, 2003, CANCER RES, V63, P4232; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Muller J, 2000, MOL CELL BIOL, V20, P5529, DOI 10.1128/MCB.20.15.5529-5539.2000; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Stewart S, 1999, MOL CELL BIOL, V19, P5523; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Volle DJ, 1999, BIOCHEMISTRY-US, V38, P5130, DOI 10.1021/bi983050d; Wang XN, 2004, J CELL PHYSIOL, V198, P333, DOI 10.1002/jcp.10443; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Xing HR, 2000, J BIOL CHEM, V275, P17276, DOI 10.1074/jbc.C900989199; Xing HR, 2004, J BIOL CHEM, V279, P26210, DOI 10.1074/jbc.M401323200; Xing HR, 2001, J BIOL CHEM, V276, P9733, DOI 10.1074/jbc.M008096200; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	48	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47808	47814		10.1074/jbc.M406395200	http://dx.doi.org/10.1074/jbc.M406395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15371409	hybrid			2022-12-25	WOS:000224957000049
J	Legembre, P; Schickel, R; Barnhart, BC; Peter, ME				Legembre, P; Schickel, R; Barnhart, BC; Peter, ME			Identification of SNF1/AMP kinase-related kinase as an NF-kappa B-regulated anti-apoptotic kinase involved in CD95-induced motility and invasiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELLS; CANCER; FAMILY; MEMBER; SNARK	The death receptor CD95 (APO-1/Fas) induces apoptosis in many tissues. However, in apoptosis-resistant tumor cells, stimulation of CD95 induces up-regulation of a defined number of mostly anti-apoptotic genes, resulting in increased motility and invasiveness of tumor cells. The majority of these genes are known NF-kappaB target genes. We have identified one of the CD95-regulated genes as the serine/threonine kinase (SNF1/AMP kinase-related kinase (SNARK)), which is induced in response to various forms of metabolic stress. We demonstrate that up-regulation of SNARK in response to CD95 ligand and tumor necrosis factor alpha depends on activation of NF-kappaB. Overexpression of SNARK rendered tumor cells more resistant, whereas a kinase-inactive mutant of SNARK sensitized cells to CD95-mediated apoptosis. Furthermore, small interfering RNA-mediated knockdown of SNARK increased the sensitivity of tumor cells to CD95 ligand- and TRAIL-induced apoptosis. Importantly, cells with reduced expression of SNARK also showed reduced motility and invasiveness in response to CD95 engagement. SNARK therefore represents an NF-kappaB-regulated anti-apoptotic gene that contributes to the tumor-promoting activity of CD95 in apoptosis-resistant tumor cells.	Univ Chicago, Comm Immunol, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Comm Canc Biol, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Peter, ME (corresponding author), Univ Chicago, Comm Immunol, Ben May Inst Canc Res, Chicago, IL 60637 USA.	mpeter@uchicago.edu	legembre, patrick/L-3475-2016; Legembre, Patrick/U-1882-2019	legembre, patrick/0000-0001-6649-8049; Legembre, Patrick/0000-0001-6649-8049; Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL CANCER INSTITUTE [R01CA095319] Funding Source: NIH RePORTER; NCI NIH HHS [CA95319] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Algeciras-Schimnich A, 2003, P NATL ACAD SCI USA, V100, P11445, DOI 10.1073/pnas.2034995100; Barnhart BC, 2004, EMBO J, V23, P3175, DOI 10.1038/sj.emboj.7600325; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lee JK, 2003, APOPTOSIS, V8, P151, DOI 10.1023/A:1022918625509; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; Nagata D, 2003, J BIOL CHEM, V278, P31000, DOI 10.1074/jbc.M300643200; Peter M E, 1999, Results Probl Cell Differ, V23, P25; Peter M.E., 2003, CYTOKINE HAND BOOK, VVolume 2, P885; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; SULLIVAN JE, 1994, BIOCHEM BIOPH RES CO, V200, P1551, DOI 10.1006/bbrc.1994.1627; Suzuki A, 2003, BIOCHEM BIOPH RES CO, V311, P156, DOI 10.1016/j.bbrc.2003.09.184; Suzuki A, 2003, J BIOL CHEM, V278, P48, DOI 10.1074/jbc.M206025200; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Wajant H, 2003, CYTOKINE GROWTH F R, V14, P53, DOI 10.1016/S1359-6101(02)00072-2	18	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46742	46747		10.1074/jbc.M404334200	http://dx.doi.org/10.1074/jbc.M404334200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15345718	hybrid			2022-12-25	WOS:000224832400052
J	Hirokane, H; Nakahara, M; Tachibana, S; Shimizu, M; Sato, R				Hirokane, H; Nakahara, M; Tachibana, S; Shimizu, M; Sato, R			Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL HETERODIMER PARTNER; ELEMENT-BINDING PROTEINS; NEGATIVE FEEDBACK-REGULATION; TRANSCRIPTIONAL REGULATION; PROTEASOME PATHWAY; APOLIPOPROTEIN-B; FACTOR 4-ALPHA; RECEPTOR; ALPHA; SHP	Microsomal triglyceride transfer protein (MTP) is involved in the transfer of triglycerides, cholesterol esters, and phospholipids to newly synthesized apolipoprotein (apo) B. It is therefore essential for lipoprotein synthesis and secretion in the liver and the small intestine. Although several recent experiments have revealed the transcriptional regulation of the MTP gene, little has been revealed to date about hepatocyte nuclear factor-4 (HNF-4)-dependent regulation. We here report that the human MTP gene promoter contains a pair of functional responsive elements for HNF-4 and HNF-1, the latter of which is another target gene of HNF-4. Chromatin immunoprecipitation assays provide evidence that endogenous HNF-4 and HNF-1 can bind these elements in chromatin. In Hep G2 cells overexpression of either a dominant negative form of HNF-4 or small interfering RNAs (siRNAs) against HNF-4 dramatically reduces the activities of both the wild type and the HNF-4 site mutant MTP promoter. This suggests that HNF-4 regulates MTP gene expression either directly or indirectly through elevated HNF-1 levels. When Hep G2 cells were cultured with chenodeoxycholic acid (CDCA), a ligand for the farnesoid X receptor (FXR), mRNA levels for MTP and apo B were reduced because of increased expression of the factor small heterodimer partner (SHP), which factor suppresses HNF-4 activities. Chenodeoxycholic acid, but not a synthetic FXR ligand, attenuated expression of HNF-4, bringing about a further suppression of MTP gene expression. Over time the intracellular MTP protein levels and apo B secretion in the culture medium significantly declined. These results indicate that two nuclear receptors, HNF-4 and FXR, are closely involved in MTP gene expression, and the results provide evidence for a novel interaction between bile acids and lipoprotein metabolism.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Basic Res Activ Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp						Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Bartoov-Shifman R, 2002, J BIOL CHEM, V277, P25914, DOI 10.1074/jbc.M201582200; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HAGAN DL, 1994, J BIOL CHEM, V269, P28737; HALTZIS P, 2001, MOL CELL BIOL, V21, P7320; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kang S, 2003, J BIOL CHEM, V278, P30478, DOI 10.1074/jbc.M304201200; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Petrescu AD, 2002, J BIOL CHEM, V277, P23988, DOI 10.1074/jbc.M201241200; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Reddy S, 1999, J BIOL CHEM, V274, P33050, DOI 10.1074/jbc.274.46.33050; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SATO R, 1990, J BIOL CHEM, V265, P11880; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shimamoto Y, 2004, J BIOL CHEM, V279, P7770, DOI 10.1074/jbc.M310577200; Ueda A, 1996, J BIOL CHEM, V271, P20265, DOI 10.1074/jbc.271.34.20265; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; WETTERAU JR, 1992, SCIENCE, V258, P999; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Yamagata K, 2004, J BIOL CHEM, V279, P23158, DOI 10.1074/jbc.M314322200; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	43	125	133	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45685	45692		10.1074/jbc.M404255200	http://dx.doi.org/10.1074/jbc.M404255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15337761	hybrid			2022-12-25	WOS:000224694900049
J	Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P				Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P			Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding	ONCOGENE			English	Article						CD44; angiogenesis; hyaluronic acid	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; TUMOR-GROWTH; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; CARCINOMA-CELLS; SOLUBLE CD44; E-SELECTIN; IN-VIVO; MIGRATION; RECEPTOR	CD44 is the main cellular receptor for hyaluronic acid (HA). We previously found that overexpression of CD44 inhibited tumor growth of mouse fibrosarcoma cells in mice. Here, we show that soluble recombinant CD44 HA-binding domain (CD44-HABD) acts directly onto endothelial cells by inhibiting endothelial cell proliferation in a cell-specific manner. Consequently, soluble recombinant CD44-HABD also blocked angiogenesis in vivo in chick and mouse, and thereby inhibited tumor growth of various origins at very low doses (0.25 mg/kg x day). The antiangiogenic effect of CD44 is independent of its HA-binding capacity, since mutants deficient in HA binding still maintain their antiangiogenic and antiproliferative properties. Recombinant CD44-HABD represents a novel class of angiogenesis inhibitors based on a cell-surface receptor.	NICPB, Mol Genet Lab, EE-12618 Tallinn, Estonia; Huddinge Univ Hosp F 46, Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia	National Institute of Chemical Physics & Biophysics (NICPB); Karolinska Institutet; Tallinn University of Technology	Kogerman, P (corresponding author), NICPB, Mol Genet Lab, Akadeemia 23, EE-12618 Tallinn, Estonia.	priit@kbfi.ee	Kogerman, Priit/B-6333-2008; Gad, Annica/X-8294-2018; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brooks PC, 1999, METH MOL B, V129, P257; Cichy J, 2002, J BIOL CHEM, V277, P44440, DOI 10.1074/jbc.M207437200; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo NH, 1997, CANCER RES, V57, P1735; GUO YJ, 1994, CANCER RES, V54, P1561; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KATOH S, 1994, J IMMUNOL, V153, P3440; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kogerman P, 1997, ONCOGENE, V15, P1407, DOI 10.1038/sj.onc.1201306; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	51	10	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7874	7881		10.1038/sj.onc.1208083	http://dx.doi.org/10.1038/sj.onc.1208083			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361838				2022-12-25	WOS:000224331600013
J	Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM				Usary, J; Llaca, V; Karaca, G; Presswala, S; Karaca, M; He, XP; Langerod, A; Karesen, R; Oh, DS; Dressler, LG; Lonning, PE; Strausberg, RL; Chanock, S; Borresen-Dale, AL; Perou, CM			Mutation of GATA3 in human breast tumors	ONCOGENE			English	Article						breast cancer; microarrays; estrogen receptor; transcription factor; GATA3	GENE-EXPRESSION PATTERNS; CELL RECEPTOR-ALPHA; TRANSCRIPTION FACTOR; ACQUIRED MUTATIONS; ESTROGEN-RECEPTOR; NERVOUS-SYSTEM; HDR SYNDROME; CANCER; BINDING; BENIGN	GATA3 is an essential transcription factor that was first identified as a regulator of immune cell function. In recent microarray analyses of human breast tumors, both normal breast luminal epithelium and estrogen receptor (ESR1)positive tumors showed high expression of GATA3. We sequenced genomic DNA from 111 breast tumors and three breast-tumor-derived cell lines and identified somatic mutations of GATA3 in five tumors and the MCF-7 cell line. These mutations cluster in the vicinity of the highly conserved second zinc-finger that is required for DNA binding. In addition to these five, we identified using cDNA sequencing a unique mis-splicing variant that caused a frameshift mutation. One of the somatic mutations we identified was identical to a germline GATA3 mutation reported in two kindreds with HDR syndrome/OMIM # 146255, which is an autosomal dominant syndrome caused by the haplo-insufficiency of GATA3. The ectopic expression of GATA3 in human 293T cells caused the induction of 73 genes including six cytokeratins, and inhibited cell line doubling times. These data suggest that GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells, and that GATA3 variants may contribute to tumorigenesis in ESR1-positive breast tumors.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; NCI, Sect Genom Variat, Pediat Oncol Branch, Ctr Adv Technol, Bethesda, MD 20892 USA; Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway; Ullevaal Univ Hosp, Dept Surg, Oslo, Norway; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Haukeland Hosp, Dept Med, Sect Oncol, N-5021 Bergen, Norway; Inst Genom Res, Rockville, MD 20850 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Oslo; University of North Carolina; University of North Carolina Chapel Hill; University of Bergen; Haukeland University Hospital; J. Craig Venter Institute; University of North Carolina; University of North Carolina Chapel Hill	Perou, CM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	cperou@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247; Lonning, Per Eystein/0000-0002-8890-6303	NATIONAL CANCER INSTITUTE [P50CA058223, Z01SC010083] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA58223-09A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOCKER W, 1992, VIRCHOWS ARCH A, V421, P315, DOI 10.1007/BF01660978; Boecker W, 2003, CELL PROLIFERAT, V36, P73, DOI 10.1046/j.1365-2184.36.s.1.7.x; DAIRKEE SH, 1988, J NATL CANCER I, V80, P691, DOI 10.1093/jnci/80.9.691; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; FINLIN BS, 2001, J BIOL CHEM, V31, P31; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Groet J, 2003, LANCET, V361, P1617, DOI 10.1016/S0140-6736(03)13266-7; Gruvberger S, 2001, CANCER RES, V61, P5979; GUELSTEIN VI, 1988, INT J CANCER, V42, P147, DOI 10.1002/ijc.2910420202; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Hoch RV, 1999, INT J CANCER, V84, P122; Kaufman CK, 2003, GENE DEV, V17, P2108, DOI 10.1101/gad.1115203; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Loots GG, 2002, GENOME RES, V12, P832, DOI 10.1101/gr.225502; Ma GT, 1997, DEVELOPMENT, V124, P907; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muroya K, 2001, J MED GENET, V38, P374, DOI 10.1136/jmg.38.6.374; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; ORKIN SH, 1992, BLOOD, V80, P575; Packer BR, 2004, NUCLEIC ACIDS RES, V32, pD528, DOI 10.1093/nar/gkh005; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531; Sena-Esteves M, 1999, J VIROL, V73, P10426, DOI 10.1128/JVI.73.12.10426-10439.1999; SMITH VM, 1995, J BIOL CHEM, V270, P1515, DOI 10.1074/jbc.270.4.1515; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tavassoli FA, 1992, PATHOLOGY BREAST, P193; Troester MA, 2002, TOXICOL SCI, V68, P314, DOI 10.1093/toxsci/68.2.314; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; Van Esch H, 2000, NATURE, V406, P419, DOI 10.1038/35019088; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	41	198	205	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7669	7678		10.1038/sj.onc.1207966	http://dx.doi.org/10.1038/sj.onc.1207966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361840				2022-12-25	WOS:000224306700008
J	de Fourmestraux, V; Neubauer, H; Poussin, C; Farmer, P; Falquet, L; Burcelin, R; Delorenzi, M; Thorens, B				de Fourmestraux, V; Neubauer, H; Poussin, C; Farmer, P; Falquet, L; Burcelin, R; Delorenzi, M; Thorens, B			Transcript profiling suggests that differential metabolic adaptation of mice to a high fat diet is associated with changes in liver to muscle lipid fluxes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE-1; NITRIC-OXIDE SYNTHASE; INDUCED INSULIN-RESISTANCE; GENE-EXPRESSION; CANCER EPIGENETICS; DNA METHYLATION; ACID OXIDATION; OBESITY; LEPTIN; OVEREXPRESSION	Genetically homogenous C57Bl/6 mice display differential metabolic adaptation when fed a high fat diet for 9 months. Most become obese and diabetic, but a significant fraction remains lean and diabetic or lean and non-diabetic. Here, we performed microarray analysis of "metabolic" transcripts expressed in liver and hindlimb muscles to evaluate: (i) whether expressed transcript patterns could indicate changes in metabolic pathways associated with the different phenotypes, (ii) how these changes differed from the early metabolic adaptation to short term high fat feeding, and (iii) whether gene classifiers could be established that were characteristic of each metabolic phenotype. Our data indicate that obesity/diabetes was associated with preserved hepatic lipogenic gene expression and increased plasma levels of very low density lipoprotein and, in muscle, with an increase in lipoprotein lipase gene expression. This suggests increased muscle fatty acid uptake, which may favor insulin resistance. In contrast, the lean mice showed a strong reduction in the expression of hepatic lipogenic genes, in particular of Scd-1, a gene linked to sensitivity to diet-induced obesity; the lean and non-diabetic mice presented an additional increased expression of eNos in liver. After 1 week of high fat feeding the liver gene expression pattern was distinct from that seen at 9 months in any of the three mouse groups, thus indicating progressive establishment of the different phenotypes. Strikingly, development of the obese phenotype involved re-expression of Scd-1 and other lipogenic genes. Finally, gene classifiers could be established that were characteristic of each metabolic phenotype. Together, these data suggest that epigenetic mechanisms influence gene expression patterns and metabolic fates.	Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland; Inst Suisse Rech Expt Canc, Natl Ctr Competence Res Mol Oncol, CH-1066 Epalinges, Switzerland; Swiss Inst Bioinformat, CH-1066 Epalinges, Switzerland; Univ Toulouse 3, CHU Rangueil, CNRS, UMR 5018,IFR31, F-31403 Toulouse, France	University of Lausanne; Swiss Institute of Bioinformatics; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Thorens, B (corresponding author), Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland.	Bernard.Thorens@iphysiol.unil.ch	burcelin, remy/M-6013-2014; Neubauer, Hans/C-4467-2016; Falquet, Laurent/C-2541-2013	Neubauer, Hans/0000-0002-3467-4105; 				Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; BUCHANAN TA, 1992, AM J PHYSIOL, V263, pR785, DOI 10.1152/ajpregu.1992.263.4.R785; Burcelin M, 2002, AM J PHYSIOL-ENDOC M, V282, pE834, DOI 10.1152/ajpendo.00332.2001; Butler A A, 2001, Trends Genet, V17, pS50, DOI 10.1016/S0168-9525(01)02481-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cohen P, 2002, SCIENCE, V297, P240, DOI 10.1126/science.1071527; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; Cook S, 2004, DIABETES, V53, P2067, DOI 10.2337/diabetes.53.8.2067; Duplain H, 2001, CIRCULATION, V104, P342, DOI 10.1161/01.CIR.104.3.342; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Friso S, 2002, J NUTR, V132, p2382S, DOI 10.1093/jn/132.8.2382S; Hajri T, 2002, J CLIN INVEST, V109, P1381, DOI [10.1172/JCI200214596, 10.1172/JCI0214596]; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Kim JK, 2004, J CLIN INVEST, V113, P756, DOI 10.1172/JCI200418917; Kim JK, 2001, P NATL ACAD SCI USA, V98, P7522, DOI 10.1073/pnas.121164498; Kulkarni RN, 2003, DIABETES, V52, P1528, DOI 10.2337/diabetes.52.6.1528; Maier S, 2002, J NUTR, V132, p2440S, DOI 10.1093/jn/132.8.2440S; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Nagase H, 1996, AM J PHYSIOL-REG I, V270, pR489, DOI 10.1152/ajpregu.1996.270.3.R489; Ntambi JM, 2003, CURR OPIN LIPIDOL, V14, P255, DOI 10.1097/00041433-200306000-00005; Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shankar RR, 2000, DIABETES, V49, P684, DOI 10.2337/diabetes.49.5.684; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	39	69	76	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50743	50753		10.1074/jbc.M408014200	http://dx.doi.org/10.1074/jbc.M408014200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15377667	hybrid			2022-12-25	WOS:000225355800016
J	Paschinger, K; Rendic, D; Lochnit, GN; Jantsch, V; Wilson, IBH				Paschinger, K; Rendic, D; Lochnit, GN; Jantsch, V; Wilson, IBH			Molecular basis of anti-horseradish peroxidase staining in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; FUCOSYL-TRANSFERASE; DROSOPHILA-MELANOGASTER; INSECT GLYCOPROTEIN; MASS-SPECTROMETRY; IMPORTANT EPITOPE; CDNA CLONING; LEWIS-X; GLYCANS; EXPRESSION	Cross-reactivity with anti-horseradish peroxidase antiserum is a feature of many glycoproteins from plants and invertebrates; indeed staining with this reagent has been used to track neurons in Drosophila melanogaster and Caenorhabditis elegans. Although in insects the evidence indicates that the cross-reaction results from the presence of core alpha1,3-fucosylated N-glycans, the molecular basis for anti-horseradish peroxidase staining in nematodes has been unresolved to date. By using Western blots of wild-type and mutant C. elegans extracts in conjunction with specific inhibitors, we show that the cross-reaction is due to core alpha1,3-fucosylation. Of the various mutants examined, one with a deletion of the fut-1 (K08F8.3) gene showed no reaction to anti-horseradish peroxidase; the molecular phenotype was rescued by injection of either the K08F8 cosmid or the fut-1 open reading frame under control of the let-858 promoter. Furthermore, expression of fut-1 cDNA in Pichia and insect cells in conjunction with antibody staining, high pressure liquid chromatography, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry analyses showed that FUT-1 is a core alpha1,3-fucosyltransferase with an unusual substrate specificity. It is the only core fucosyltransferase in plants and animals described to date that does not require the prior action of N-acetylglucosaminyltransferase I.	Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria; Univ Giessen, Inst Biochem, D-35292 Giessen, Germany; Univ Vienna, Inst Bot, A-1030 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Justus Liebig University Giessen; University of Vienna	Wilson, IBH (corresponding author), Univ Bodenkultur Wien, Dept Chem, A-1190 Vienna, Austria.	iwilson@edv2.boku.ac.at	Jantsch, Verena/A-3910-2017; Rendic, Dubravko/A-9368-2010; Wilson, Iain/B-3326-2009	Jantsch, Verena/0000-0002-1978-682X; Wilson, Iain/0000-0001-8996-1518; Paschinger, Katharina/0000-0002-3594-7136				ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Altmann F, 2001, BIOCHIMIE, V83, P703, DOI 10.1016/S0300-9084(01)01297-4; Bencurova M, 2004, GLYCOBIOLOGY, V14, P457, DOI 10.1093/glycob/cwh058; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; Cipollo JF, 2002, J BIOL CHEM, V277, P49143, DOI 10.1074/jbc.M208020200; CUMMINGS RD, 2000, Patent No. 0014199; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; DeBose-Boyd RA, 1998, GLYCOCONJUGATE J, V15, P789, DOI 10.1023/A:1006912032273; Dell A, 1999, BBA-MOL BASIS DIS, V1455, P353, DOI 10.1016/S0925-4439(99)00064-2; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; Friedl CH, 2003, BIOCHEM J, V369, P89, DOI 10.1042/BJ20021074; Gerdt S, 1999, EUR J BIOCHEM, V266, P952, DOI 10.1046/j.1432-1327.1999.00937.x; GEYER R, 1994, METHOD ENZYMOL, V230, P86; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Haase A, 2001, DEV GENES EVOL, V211, P428, DOI 10.1007/s004270100173; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hanneman A, 2003, GLYCOBIOLOGY, V13, P899; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 2000, GLYCOBIOLOGY, V10, P223, DOI 10.1093/glycob/10.2.223; Haslam SM, 2003, BIOCHIMIE, V85, P25, DOI 10.1016/S0300-9084(03)00041-5; Haslam SM, 2002, BIOCHEM SOC SYMP, V69, P117; Haslam SM, 1998, MOL BIOCHEM PARASIT, V93, P143, DOI 10.1016/S0166-6851(98)00020-6; Hirabayashi J, 2002, J BIOCHEM, V132, P103, DOI 10.1093/oxfordjournals.jbchem.a003186; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; JASMER DP, 1993, J IMMUNOL, V151, P5450; Kaji H, 2003, NAT BIOTECHNOL, V21, P667, DOI 10.1038/nbt829; Kawar ZS, 2002, J BIOL CHEM, V277, P34924, DOI 10.1074/jbc.M206112200; Khoo KH, 2001, GLYCOBIOLOGY, V11, P149, DOI 10.1093/glycob/11.2.149; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Leiter H, 1999, J BIOL CHEM, V274, P21830, DOI 10.1074/jbc.274.31.21830; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Mello C, 1995, METHOD CELL BIOL, V48, P451; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Mucha J, 2004, BIOCHEM J, V382, P67, DOI 10.1042/BJ20040535; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; Nguyen K, 2001, GLYCOBIOLOGY, V11, P885; Nyame AK, 1998, GLYCOBIOLOGY, V8, P615, DOI 10.1093/glycob/8.6.615; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PAZPARENTE J, 1985, CARBOHYD RES, V141, P41; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Roitinger A, 1998, GLYCOCONJUGATE J, V15, P89, DOI 10.1023/A:1006951802623; Schachter H, 2002, BIOCHEM SOC SYMP, V69, P1; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; STAUDACHER E, 1992, EUR J BIOCHEM, V207, P987, DOI 10.1111/j.1432-1033.1992.tb17134.x; Takahashi N, 2003, EUR J BIOCHEM, V270, P2627, DOI 10.1046/j.1432-1033.2003.03636.x; Tawill S, 2004, INFECT IMMUN, V72, P398, DOI 10.1128/IAI.72.1.398-407.2004; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; Vervelde L, 2003, GLYCOBIOLOGY, V13, P795, DOI 10.1093/glycob/cwg107; Warren CE, 2002, GLYCOBIOLOGY, V12, p8G; Warren CE, 2002, J BIOL CHEM, V277, P22829, DOI 10.1074/jbc.M201390200; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 2001, GLYCOCONJUGATE J, V18, P439, DOI 10.1023/A:1016030000527; Wilson IBH, 2001, BBA-GEN SUBJECTS, V1527, P88, DOI 10.1016/S0304-4165(01)00151-9; WILSON JR, 1976, BIOCHEM BIOPH RES CO, V72, P909, DOI 10.1016/S0006-291X(76)80218-5; Zhang WL, 2003, BIOCHEM J, V372, P53, DOI 10.1042/BJ20021931; Zheng QL, 2002, J BIOL CHEM, V277, P39823, DOI 10.1074/jbc.M207487200; Zhu SX, 2004, BIOCHEM J, V382, P995, DOI 10.1042/BJ20040793	60	63	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49588	49598		10.1074/jbc.M408978200	http://dx.doi.org/10.1074/jbc.M408978200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364955	hybrid			2022-12-25	WOS:000225229500008
J	Westergaard, UB; Sorensen, ES; Hermey, G; Nielsen, MS; Nykjaer, A; Kirkegaard, K; Jacobsen, C; Gliemann, J; Madsen, P; Petersen, CM				Westergaard, UB; Sorensen, ES; Hermey, G; Nielsen, MS; Nykjaer, A; Kirkegaard, K; Jacobsen, C; Gliemann, J; Madsen, P; Petersen, CM			Functional organization of the sortilin Vps10p domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED PROTEIN; MOSAIC RECEPTOR; FAMILY-MEMBER; SORTILIN/NEUROTENSIN RECEPTOR-3; IN-VITRO; BINDS; IDENTIFICATION; CHAPERONE; INTERNALIZATION; TRAFFICKING	A Vps10p domain makes up the entire luminal part of Sortilin, and this type of domain is the hallmark of a new family of neuronal receptors that target a variety of ligands, including neurotrophins and neuropeptides. We have shown that two structural features of the Vps10p domain, the N-terminal propeptide and the C-terminal segment of ten conserved cysteines (10CC), are key elements in the function of Sortilin. The propeptide has two functions. (i) It binds the mature part of Sortilin and prevents ligands in the biosynthetic pathway from binding to the uncleaved proreceptor, and (ii) it facilitates receptor transport in early Golgi compartments by a mechanism that does not depend on its ability to prevent ligand binding. In contrast, other Vps10p domain receptors, such as SorLA and SorCS3, do not need their propeptide for normal and swift processing. The 10CC segment constitutes an exchangeable module containing five conserved disulfide bridges, and using module-shuffling and truncations, we have shown that the 10CC segment is a major ligand-binding region in Sortilin.	Aarhus Univ, Inst Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol Biol, Prot Chem Lab, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Petersen, CM (corresponding author), Aarhus Univ, Inst Med Biochem, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.	cmp@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016; Hermey, Guido/AAC-5565-2020; Matrone, Carmela/AAR-5405-2020	Nielsen, Morten Schallburg/0000-0001-9863-9694; Hermey, Guido/0000-0003-4762-5262; Sorensen, Esben Skipper/0000-0002-7050-3354; Kirkegaard, Kirstine/0000-0001-8267-9042; Madsen, Peder Sondergaard/0000-0002-8845-4802; Nykjaer, Anders/0000-0001-6422-6736				Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; Bu GJ, 1998, TRENDS CELL BIOL, V8, P272, DOI 10.1016/S0962-8924(98)01283-5; Conticello SG, 2003, J BIOL CHEM, V278, P26311, DOI 10.1074/jbc.C300141200; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Gliemann J, 2004, BIOCHEM J, V381, P203, DOI 10.1042/BJ20040149; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hermey G, 2004, J NEUROCHEM, V88, P1470, DOI 10.1046/j.1471-4159.2004.02286.x; Hermey G, 1999, BIOCHEM BIOPH RES CO, V266, P347, DOI 10.1006/bbrc.1999.1822; Hermey G, 2003, J BIOL CHEM, V278, P7390, DOI 10.1074/jbc.M210851200; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Jacobsen L, 2001, J BIOL CHEM, V276, P22788, DOI 10.1074/jbc.M100857200; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Lefrancois S, 2003, EMBO J, V22, P6430, DOI 10.1093/emboj/cdg629; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Navarro V, 2001, FEBS LETT, V495, P100, DOI 10.1016/S0014-5793(01)02367-5; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Sarret P, 2003, J COMP NEUROL, V461, P483, DOI 10.1002/cne.10708; SCHERZER CR, 2004, ARCH NEUROL-CHICAGO, V61, P1178; SORENSEN ES, 1995, PROTEIN SCI, V4, P2040, DOI 10.1002/pro.5560041009; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Willnow TE, 1998, BIOL CHEM, V379, P1025; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; Zhu YJ, 2004, CIRC RES, V94, P752, DOI 10.1161/01.RES.0000120862.79154.0F; Zhu YJ, 2002, CIRCULATION, V105, P1830, DOI 10.1161/01.CIR.0000014413.91312.EF	31	68	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50221	50229		10.1074/jbc.M408873200	http://dx.doi.org/10.1074/jbc.M408873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364913	hybrid			2022-12-25	WOS:000225229500083
J	Blanchette, JM; Abazeed, ME; Fuller, RS				Blanchette, JM; Abazeed, ME; Fuller, RS			Cell-free reconstitution of transport from the trans-Golgi network to the late endosome/prevacuolar compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN RETENTION; CLATHRIN-COATED VESICLES; SACCHAROMYCES-CEREVISIAE; KEX2 PROTEASE; PREVACUOLAR COMPARTMENT; LOCALIZATION SIGNAL; ENDOSOME TRANSPORT; SORTING RECEPTOR; CYTOSOLIC TAIL; YEAST	Vesicle-mediated transport between the trans-Golgi network (TGN) and the late endosome/prevacuolar compartment (PVC) is an essential step in lysosomal/vacuolar biogenesis. In addition, localization of integral membrane proteins to the TGN requires continual cycles of vesicular transport between the TGN and endosomal compartments. Genetic and biochemical analyses in yeast have identified a variety of proteins required for TGN-to-PVC transport. However, the precise mechanisms of vesicle formation, transport, and fusion have not been fully elucidated. To study the steps of TGN-to-PVC transport in mechanistic detail, we have developed a cell-free assay to monitor delivery of the processing protease Kex2p from the TGN to PVC compartments containing a Kex2p substrate. Transport is time-, temperature, and ATP-dependent and requires the t-SNARE Pep12p. Moreover, cell-free delivery of Kex2p to the PVC results in the co-integration of Kex2p into PVC membranes containing the Kex2p substrate as determined by co-immunoisolation of Kex2p and the substrate using antibody against the Kex2p cytosolic tail. This work represents the first cell-free reconstitution and biochemical analysis of the essential vacuolar/lysosomal sorting step TGN to late endosome transport.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Fuller, RS (corresponding author), Univ Michigan, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	bfuller@umich.edu	Abazeed, Mohamed/AAN-2376-2020	Abazeed, Mohamed/0000-0002-6614-4440	NCI NIH HHS [P30 CA46592] Funding Source: Medline; NIGMS NIH HHS [GM50915, GM39697, GM07544, R01 GM050915, T32 GM007544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050915, T32GM007544, R55GM039697, R01GM039697] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1989, METHOD CELL BIOL, V31, P127; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; Balch W E, 1988, Prog Clin Biol Res, V270, P333; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1989, J BIOL CHEM, V264, P16965; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; Brickner JH, 2001, J CELL BIOL, V155, P969, DOI 10.1083/jcb.200104093; Bryant NJ, 1997, J CELL BIOL, V136, P287, DOI 10.1083/jcb.136.2.287; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Deloche O, 2001, MOL BIOL CELL, V12, P475, DOI 10.1091/mbc.12.2.475; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Gerrard SR, 2000, TRAFFIC, V1, P259, DOI 10.1034/j.1600-0854.2000.010308.x; GODA Y, 1992, METHOD ENZYMOL, V219, P153; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; Gueldener U, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.6.e23; Gurunathan S, 2002, EMBO J, V21, P602, DOI 10.1093/emboj/21.4.602; Ha SA, 2003, MOL BIOL CELL, V14, P1319, DOI 10.1091/mbc.E02-10-0686; Harlow E., 1988, ANTIBODIES LABORATOR, P628; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Newmyer SL, 2001, J CELL BIOL, V152, P607, DOI 10.1083/jcb.152.3.607; Nothwehr SF, 2000, J CELL BIOL, V151, P297, DOI 10.1083/jcb.151.2.297; NOTHWEHR SF, 1993, J CELL BIOL, V121, P1197, DOI 10.1083/jcb.121.6.1197; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Redding K, 1996, MOL BIOL CELL, V7, P1667, DOI 10.1091/mbc.7.11.1667; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; Sipos G, 2004, MOL BIOL CELL, V15, P3196, DOI 10.1091/mbc.E03-10-0755; Sipos G, 2002, METHOD ENZYMOL, V351, P351; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; Vida T, 1999, J CELL BIOL, V146, P85; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILCOX CA, 1992, MOL BIOL CELL, V3, P1353, DOI 10.1091/mbc.3.12.1353	45	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48767	48773		10.1074/jbc.M406368200	http://dx.doi.org/10.1074/jbc.M406368200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364946	hybrid			2022-12-25	WOS:000225098100035
J	Furumoto, Y; Nunomura, S; Terada, T; Rivera, J; Ra, C				Furumoto, Y; Nunomura, S; Terada, T; Rivera, J; Ra, C			The Fc epsilon RI beta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and I kappa B kinase phosphorylation and mast cell cytokine production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; IMMUNOGLOBULIN-E RECEPTOR; LYN KINASE; INOSITOL 5'-PHOSPHATASE; NEGATIVE REGULATION; ALLERGIC RESPONSE; SUBUNIT; DOMAIN; SHIP; DEGRANULATION	The high affinity IgE Fc receptor (FcepsilonRI) beta chain functions as a signal amplifier and has been linked to atopy, asthma, and allergy. Herein, we report on a previously unrecognized negative regulatory role for the nonconventional beta chain immunoreceptor tyrosine-based activation motif that contains three tyrosine residues (YX5YX3Y). Degranulation and leukotriene production was found to be impaired in cells expressing the mutated FcepsilonRIbeta immunoreceptor tyrosine-based activation motifs FYY, YYF, FYF, and FFF. In contrast, cytokine synthesis and secretion were enhanced in the YFY and FFF mutants. FcepsilonRI phosphorylation and Lyn kinase co-immunoprecipitation was intact in the YFY mutant but was lost in the FYF and FFF mutants. The phosphorylation of Syk, LAT, phospholipase gamma1/2, and Src-homology 2 domain-containing protein phosphatase 2 was intact, whereas the phosphorylation of SHIP-1 was significantly reduced in the YFY mutant cells. The FYF and FFF mutants were defective in phosphorylating all of these molecules. In contrast, the phosphorylation of ERK, p38 MAPK, IkappaB kinase beta(IKKbeta), and nuclear NFkappaB activity was enhanced in the YFY and FFF mutants. These findings show that the FcepsilonRIbeta functions to both selectively amplify (degranulation and leukotriene secretion) and dampen (lymphokine) mast cell effector responses.	NIAMSD, Mol Inflammat Sect, Mol Immunol & Inflammat Branch, NIH, Bethesda, MD 20892 USA; Nihon Univ, Grad Sch Med Sci, Adv Med Res Ctr, Div Mol Cell Immunobiol & Allergol,Itabashi Ku, Tokyo 1378610, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Nihon University	Rivera, J (corresponding author), NIAMS, NIH, Bldg 10,Rm 9N228, Bethesda, MD 20892 USA.	juan_rivera@nih.gov	Nunomura, Satoshi/Q-4249-2017	Nunomura, Satoshi/0000-0002-9315-4185	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041101, ZIAAR041101] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baran CP, 2003, J BIOL CHEM, V278, P38628, DOI 10.1074/jbc.M305021200; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; Donnadieu E, 2000, J IMMUNOL, V165, P3917, DOI 10.4049/jimmunol.165.7.3917; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; EISEMAN E, 1992, NATURE, V355, P78; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Furumoto Y, 2000, BIOCHEM BIOPH RES CO, V273, P765, DOI 10.1006/bbrc.2000.2989; GORDON JR, 1997, IGE RECEPTOR FCERI F, P209; Gu HH, 2001, NATURE, V412, P186, DOI 10.1038/35084076; Gupta N, 1999, J BIOL CHEM, V274, P7489, DOI 10.1074/jbc.274.11.7489; Harder KW, 2001, IMMUNITY, V15, P603, DOI 10.1016/S1074-7613(01)00208-4; Hernandez-Hansen V, 2004, J IMMUNOL, V173, P100, DOI 10.4049/jimmunol.173.1.100; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hiraoka S, 1999, INT IMMUNOL, V11, P199, DOI 10.1093/intimm/11.2.199; Huber M, 1999, CURR TOP MICROBIOL, V244, P29; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Kalesnikoff J, 2002, J IMMUNOL, V168, P4737, DOI 10.4049/jimmunol.168.9.4737; Kawakami Y, 2000, J IMMUNOL, V165, P1210, DOI 10.4049/jimmunol.165.3.1210; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kim YK, 2002, CLIN EXP ALLERGY, V32, P751, DOI 10.1046/j.1365-2222.2002.01295.x; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kovarova M, 2001, MOL CELL BIOL, V21, P8318, DOI 10.1128/MCB.21.24.8318-8328.2001; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIU FT, 1980, J IMMUNOL, V124, P2728; Lu-Kuo JM, 1999, J BIOL CHEM, V274, P5791, DOI 10.1074/jbc.274.9.5791; Malbec O, 1998, J IMMUNOL, V160, P1647; Marquardt DL, 2000, J ALLERGY CLIN IMMUN, V105, P500, DOI 10.1067/mai.2000.104942; Nadler M J, 2000, Adv Immunol, V76, P325; Nishizumi H, 1997, J IMMUNOL, V158, P2350; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Pelletier C, 1998, J IMMUNOL, V161, P4768; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Saitoh S, 2003, J EXP MED, V198, P831, DOI 10.1084/jem.20030574; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; SWIETER M, 1995, J IMMUNOL, V155, P5330; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Wilson BS, 2001, J CELL BIOL, V154, P645, DOI 10.1083/jcb.200104049; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	52	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49177	49187		10.1074/jbc.M404730200	http://dx.doi.org/10.1074/jbc.M404730200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355979	hybrid			2022-12-25	WOS:000225098100083
J	Murata, Y; Hamada, S; Morishita, H; Mutoh, T; Yagi, T				Murata, Y; Hamada, S; Morishita, H; Mutoh, T; Yagi, T			Interaction with protocadherin-gamma regulates the cell surface expression of protocadherin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC ORGANIZATION; ADHESION RECEPTOR; LARGE FAMILY; N-CADHERIN; SPECIFICITY; MOLECULES; TRANSPORT; SYNAPSES; PROMOTER; SURVIVAL	The protocadherin-alpha (CNR/Pcdhalpha) and protocadherin-gamma (Pcdhgamma) proteins, members of the cadherin superfamily, are putative cell recognition/adhesion molecules in the brain. Overexpressed cadherins are generally expressed on the cell surface and elicit cell adhesion activity in several cell lines, although hardly any overexpressed CNR/Pcdhalpha proteins are expressed on the cell surface, except on HEK293T cells, which show low expression. We analyzed the expression of CNR/Pcdhalpha and Pcdhgamma in HEK293T cells and found that they formed a protein complex and that Pcdhgamma enhanced the surface expression of CNR/Pcdhalpha. This enhanced surface expression was confirmed by flow cytometry analysis and by marking cell surface proteins with biotin. The enhancement was observed using different combinations of CNR/Pcdhalpha and Pcdhgamma proteins. The surface expression activity was enhanced by the extracellular domains of the proteins, which could bind each other. Their cytoplasmic domains also had binding activity and influenced their localization. Their protein-protein interaction was also detected in extracts of mouse brain and two neuroblastoma cell lines. Thus, interactions between CNR/Pcdhalpha and Pcdhgamma regulate their surface expression and contribute to the combinatorial diversity of cell recognition proteins in the brain.	Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, Suita, Osaka 5650871, Japan; Natl Inst Physiol Sci, Lab Neurobiol & Behav Genet, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tokyo, Japan	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Japan Science & Technology Agency (JST)	Yagi, T (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, Labs Integrated Biol, KOKORO Biol Grp, 1-3 Yamadaoka, Suita, Osaka 5650871, Japan.	yagi@fbs.osaka-u.ac.jp	Morishita, Hirofumi/J-9619-2015	Morishita, Hirofumi/0000-0002-1045-1337; Murata, Yoji/0000-0002-9576-7030				Bozdagi O, 2000, NEURON, V28, P245, DOI 10.1016/S0896-6273(00)00100-8; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Faivre-Sarrailh C, 2000, J CELL BIOL, V149, P491, DOI 10.1083/jcb.149.2.491; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; Lee CH, 2001, NEURON, V30, P437, DOI 10.1016/S0896-6273(01)00291-4; Manabe T, 2000, MOL CELL NEUROSCI, V15, P534, DOI 10.1006/mcne.2000.0849; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mutoh T, 2004, EXP CELL RES, V294, P494, DOI 10.1016/j.yexcr.2003.11.019; OBATA S, 1995, J CELL SCI, V108, P3765; Obata S, 1998, CELL ADHES COMMUN, V6, P323, DOI 10.3109/15419069809010791; Phillips GR, 2003, J NEUROSCI, V23, P5096; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; Sugino H, 2000, GENOMICS, V63, P75, DOI 10.1006/geno.1999.6066; Takei Y, 2001, GENOMICS, V72, P321, DOI 10.1006/geno.2000.6468; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Tasic B, 2002, MOL CELL, V10, P21, DOI 10.1016/S1097-2765(02)00578-6; Togashi H, 2002, NEURON, V35, P77, DOI 10.1016/S0896-6273(02)00748-1; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; Wang XZ, 2002, GENE DEV, V16, P1890, DOI 10.1101/gad.1004802; Wang XZ, 2002, NEURON, V36, P843, DOI 10.1016/S0896-6273(02)01090-5; Wu Q, 1999, CELL, V97, P779, DOI 10.1016/S0092-8674(00)80789-8; Yagi T, 2000, GENE DEV, V14, P1169	27	77	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49508	49516		10.1074/jbc.M408771200	http://dx.doi.org/10.1074/jbc.M408771200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347688	hybrid			2022-12-25	WOS:000225098100121
J	Tsuneshige, A; Kanaori, K; Samuni, U; Danstker, D; Friedman, JM; Neya, S; Giangiacomo, L; Yonetani, T				Tsuneshige, A; Kanaori, K; Samuni, U; Danstker, D; Friedman, JM; Neya, S; Giangiacomo, L; Yonetani, T			Semihemoglobins, high oxygen affinity dimeric forms of human hemoglobin respond efficiently to allosteric effectors without forming tetramers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; FUNCTIONAL PROPERTIES; HYBRID HEMOGLOBIN; CRYSTAL-STRUCTURE; ADULT HEMOGLOBIN; R-STATE; T-STATE; BINDING; ALPHA; BETA	Significant reduction in oxygen affinity resulting from interactions between heterotropic allosteric effectors and hemoglobin in not only the unligated derivative but also the fully ligated form has been reported (Tsuneshige, A., Park, S. I., and Yonetani, T. ( 2002) Biophys. Chem. 98, 49 - 63; Yonetani, T., Park, S. I., Tsuneshige, A., Imai, K., and Kanaori, K. ( 2002) J. Biol. Chem. 277, 34508 - 34520). To further investigate this effect in more detail, alpha- and beta-semihemoglobins, namely, alpha(heme)beta(apo) and alpha(apo) beta(heme), respectively, were prepared and characterized with respect to the impact of allosteric effectors on both conformation and ligand binding properties. Semihemoglobins are dimers characterized by a high affinity for oxygen and lack of cooperativity. We found that, compared with stripped conditions, semihemoglobins responded to effectors ( inositol hexaphosphate and L35) by decreasing the affinity for oxygen by 60- and 130-fold for alpha- and beta-semihemoglobins, respectively. H-1 NMR and sedimentation velocity experiments carried out with their ligated and unligated forms in the absence and presence of effectors revealed that semihemoglobins always remain as single-heme-carrying dimers. Recombination kinetics of their photolyzed CO derivatives showed that effectors did indeed interact with their ligated forms. Measurements of the Fe-His stretching mode show that the semihemoglobins undergo a large ligand binding-induced conformational shift and that both ligand-free and ligand derivatives respond to the presence of effectors. Contradictions to the Monod-Wyman-Changeaux/Perutz allosteric model arise since 1) the modulation of ligand affinity is not achieved in semihemoglobins by the formation of a low affinity T conformation ( quaternary effect) but by direct interaction with effectors, 2) effectors do interact significantly with ligated forms of high affinity semihemoglobins, and 3) modulation of the ligand affinity and the cooperativity are not necessarily linked but instead can be separated into two distinct phenomena that can be isolated.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Johnson Res Fdn, Philadelphia, PA 19104 USA; Kyoto Inst Technol, Dept Appl Biol, Kyoto 6068585, Japan; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Chiba Univ, Grad Sch Pharmaceut Sci, Chiba 2638522, Japan; Univ Roma La Sapienza, Dept Biomed Sci, Inst Mol Biol & Pathol, CNR, I-00185 Rome, Italy	University of Pennsylvania; Kyoto Institute of Technology; Yeshiva University; Albert Einstein College of Medicine; Chiba University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Tsuneshige, A (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.	ants@mail.med.upenn.edu			NHLBI NIH HHS [HL-14508] Funding Source: Medline; NIGMS NIH HHS [P01-GM58890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014508, R37HL014508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM058890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers GK, 2000, PROTEINS, P23; Ackers GK, 2002, P NATL ACAD SCI USA, V99, P9777, DOI 10.1073/pnas.152225999; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BARNEJEE R, 1967, BIOCHIM BIOPHYS ACTA, V133, P545; BENESCH RE, 1986, J MOL BIOL, V190, P481, DOI 10.1016/0022-2836(86)90016-1; BUCCI E, 1965, J BIOL CHEM, V240, pP551; Cassoly R, 1981, Methods Enzymol, V76, P121; CASSOLY R, 1967, BIOCHIM BIOPHYS ACTA, V133, P557, DOI 10.1016/0005-2795(67)90560-0; CASSOLY R, 1971, EUR J BIOCHEM, V19, P514, DOI 10.1111/j.1432-1033.1971.tb01343.x; CHIANCONE E, 1972, J MOL BIOL, V70, P675, DOI 10.1016/0022-2836(72)90566-9; DALVIT C, 1985, BIOCHEMISTRY-US, V24, P3398, DOI 10.1021/bi00335a003; Dantsker D, 2002, J MOL BIOL, V315, P239, DOI 10.1006/jmbi.2001.5218; DAUGHERTY MA, 1991, P NATL ACAD SCI USA, V88, P1110, DOI 10.1073/pnas.88.4.1110; Fronticelli C, 2002, BIOPHYS CHEM, V98, P115, DOI 10.1016/S0301-4622(02)00089-3; FUNG LWM, 1975, BIOCHEMISTRY-US, V14, P2526, DOI 10.1021/bi00682a036; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; Imai K, 1981, Methods Enzymol, V76, P438; KAWAMURAKONISHI Y, 1988, BIOCHEM BIOPH RES CO, V156, P348, DOI 10.1016/S0006-291X(88)80847-7; KAWAMURAKONISHI Y, 1992, EUR BIOPHYS J BIOPHY, V21, P85; Khan I, 2001, BIOCHEMISTRY-US, V40, P7581, DOI 10.1021/bi010051o; Kidd RD, 2001, BIOCHEMISTRY-US, V40, P15669, DOI 10.1021/bi011329f; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; LALEZARI I, 1988, P NATL ACAD SCI USA, V85, P6117, DOI 10.1073/pnas.85.16.6117; LALEZARI I, 1990, P NATL ACAD SCI USA, V85, P1515; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOULTON DP, 1994, BIOCHEM BIOPH RES CO, V199, P1278, DOI 10.1006/bbrc.1994.1369; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PERUTZ MF, 1968, NATURE, V256, P759; Peterson ES, 2004, BIOCHEMISTRY-US, V43, P4832, DOI 10.1021/bi035481o; Peterson ES, 1998, BIOCHEMISTRY-US, V37, P4346, DOI 10.1021/bi9708693; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; Ramadas N, 1999, BIOPHYS J, V76, P1796, DOI 10.1016/S0006-3495(99)77340-6; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P397; ROSSIFANELLI A, 1958, ARCH BIOCHEM BIOPHYS, V77, P478, DOI 10.1016/0003-9861(58)90094-8; ROSSIFANELLI A, 1961, J BIOL CHEM, V236, P391; Rujan IN, 2002, PROTEINS, V49, P413, DOI 10.1002/prot.10240; RUSSU IM, 1987, BIOCHIM BIOPHYS ACTA, V914, P40, DOI 10.1016/0167-4838(87)90159-2; Safo MK, 2001, PROTEIN SCI, V10, P951, DOI 10.1110/ps.50601; Samuni U, 2003, BIOCHEMISTRY-US, V42, P8272, DOI 10.1021/bi020648j; Samuni U, 2002, J BIOL CHEM, V277, P25783, DOI 10.1074/jbc.M200301200; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Shibayama N, 1998, BIOCHEMISTRY-US, V37, P6221, DOI 10.1021/bi980134d; Shibayama N, 2002, J BIOL CHEM, V277, P38791, DOI 10.1074/jbc.M205461200; Tsai CH, 2002, BIOPHYS CHEM, V98, P15, DOI 10.1016/S0301-4622(02)00081-9; TSUNESHIGE A, 1993, J BIOL CHEM, V268, P23031; Tsuneshige A, 2002, BIOPHYS CHEM, V98, P49, DOI 10.1016/S0301-4622(02)00084-4; WATERMAN MR, 1971, ARCH BIOCHEM BIOPHYS, V145, P448, DOI 10.1016/S0003-9861(71)80004-8; WINTERHALTER KH, 1968, BIOCHEMISTRY-US, V7, P2228, DOI 10.1021/bi00846a027; Yasuda JP, 2002, EUR J BIOCHEM, V269, P202, DOI 10.1046/j.0014-2956.2002.02635.x; Yonetani T, 2003, CR BIOL, V326, P523, DOI 10.1016/S1631-0691(03)00150-1; Yonetani T, 2002, J BIOL CHEM, V277, P34508, DOI 10.1074/jbc.M203135200	52	29	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48959	48967		10.1074/jbc.M405909200	http://dx.doi.org/10.1074/jbc.M405909200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15361521	hybrid			2022-12-25	WOS:000225098100058
J	Grabiec, A; Meng, GX; Fichte, S; Bessler, W; Wagner, H; Kirschning, CJ				Grabiec, A; Meng, GX; Fichte, S; Bessler, W; Wagner, H; Kirschning, CJ			Human but not murine Toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATTERN-RECOGNITION RECEPTOR; BACTERIAL-INFECTIONS; CUTTING EDGE; CPG-DNA; LIPOPOLYSACCHARIDE; BINDING; SITES; CELLS; CD14; MD-2	Toll-like receptors (TLRs) mediate activation of the immune system upon challenge with microbial agonists, components of disintegrating cells of the body, or metabolic intermediates of lipidic nature. Comparison of murine (m) and human (h) TLR2 primary sequences revealed 65% of identical residues within the extracellular domains in contrast to 84% in the intracellular domains. Comparative analysis of TLR2-driven cell activation by various TLR2 agonists showed that the tri-lauroylated lipopeptide analog (Lau(3)CSK(4)) is recognized efficiently through mTLR2 but not hTLR2. Genetically complemented human embryonic kidney 293 cells and murine TLR2(-/-) embryonic fibroblasts, as well as human and murine macrophage cells, were used for this analysis. In contrast to cellular activation, which depended on blockable access of the TLR2-ligand to TLR2, cellular uptake of Lau(3)CSK(4) and tri-palmitoylated peptide (P3CSK4) was independent of TLR2. A low-conserved region spanning from leucine-rich repeat (LRR) motif 7 to 10 was found to control TLR2 species-specific cell activation. Exchange of mLRR8 for hLRR8 in mTLR2 abrogated mTLR2-typical cell activation upon cellular challenge with Lau(3)CSK(4) but not P3CSK4, implicating mLRR8 as a central element of Lau(3)CSK(4) recognition. The point mutation L112P within LRR3 abrogated hTLR2-dependent recognition of lipopeptides but merely attenuated mTLR2 function, whereas deletion of the N-terminal third of each LRR-rich domain (LRRs 1 to 7) had the opposite effect on P3CSK4 recognition. Despite similar domain structure of both TLR2 molecules, species-specific properties thus exist. Our results imply distinct susceptibilities of humans and mice to challenge with specific TLR2 ligands.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany	Technical University of Munich; University of Freiburg	Kirschning, CJ (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 4A, D-81675 Munich, Germany.	carsten.kirschning@lrz.tum.de		孟, 广勋/0000-0002-4253-9675				Akashi S, 2001, INT IMMUNOL, V13, P1595, DOI 10.1093/intimm/13.12.1595; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Garduno RA, 1998, INFECT IMMUN, V66, P4602; Haase R, 2003, J IMMUNOL, V171, P4294, DOI 10.4049/jimmunol.171.8.4294; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Heine H, 1999, J IMMUNOL, V162, P6971; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; Meng GX, 2004, J CLIN INVEST, V113, P1473, DOI 10.1172/JCI200420762; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Reschner A, 2003, EUR J IMMUNOL, V33, P2044, DOI 10.1002/eji.200323776; Sanaa N, 2004, J BIOL CHEM, V279, P25189, DOI 10.1074/jbc.M312431200; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schjetne KW, 2003, J IMMUNOL, V171, P32, DOI 10.4049/jimmunol.171.1.32; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 2003, EUR J IMMUNOL, V33, P1767, DOI 10.1002/eji.200324037; Wagner H, 2001, IMMUNITY, V14, P499, DOI 10.1016/S1074-7613(01)00144-3; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Wright SD, 2000, J EXP MED, V191, P1437, DOI 10.1084/jem.191.8.1437; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	41	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48004	48012		10.1074/jbc.M405311200	http://dx.doi.org/10.1074/jbc.M405311200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342637	hybrid			2022-12-25	WOS:000224957000072
J	Strack, S; Cribbs, JT; Gomez, L				Strack, S; Cribbs, JT; Gomez, L			Critical role for protein phosphatase 2A heterotrimers in mammalian cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; REGULATORY B-SUBUNITS; A-SUBUNIT; CATALYTIC SUBUNIT; DNA-REPLICATION; ALPHA-SUBUNIT; OKADAIC ACID; CORE ENZYME; BETA; BINDING	The predominant forms of protein phosphatase 2A (PP2A), one of the major Ser/Thr phosphatases, are dimers of catalytic (C) and scaffolding (A) subunits and trimers with an additional variable regulatory subunit. In mammals, catalytic and scaffolding subunits are encoded by two genes each (alpha/beta), whereas three gene families (B, B', and B") with a total of 12 genes contribute PP2A regulatory subunits. We generated stable PC12 cell lines in which the major scaffolding Aalpha subunit can be knocked down by inducible RNA interference (RNAi) to study its role in cell viability. Aalpha RNAi decreased total PP2A activity as well as protein levels of C, B, and B' but not B" subunits. Inhibitor experiments indicate that monomeric C and B subunits are degraded by the proteosome. Knock-down of Aalpha triggered cell death by redundant apoptotic and non-apoptotic mechanisms because the inhibition of RNAi-associated caspase activation failed to stall cell death. PP2A holoenzymes positively regulate survival kinase signaling, because RNAi reduced basal and epidermal growth factor-stimulated Akt phosphorylation. RNAi-resistant Aalpha cDNAs rescued RNAi-induced loss of the C subunit, and Aalpha point mutants prevented regulatory subunit degradation as predicted from each mutant's binding specificity. In transient, stable, and stable-inducible rescue experiments, both wild-type Abeta and Aalpha mutants capable of binding to at least one family of regulatory subunits were able to delay Aalpha RNAi-induced death of PC12 cells. However, only the expression of wild-type Aalpha restored viability completely. Thus, heterotrimeric PP2A holoenzymes containing the Aalpha subunit and members of all three regulatory subunit families are necessary for mammalian cell viability.	Univ Iowa, Carver Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Strack, S (corresponding author), Univ Iowa, Carver Coll Med, Dept Pharmacol, 2-432 BSB,51 Newton Rd, Iowa City, IA 52242 USA.	stefan-strack@uiowa.edu		Strack, Stefan/0000-0002-6175-7280; Lavadie-Gomez, Eleanor/0000-0002-0602-5618	NINDS NIH HHS [NS43254] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043254] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chou DM, 2002, J BIOL CHEM, V277, P40520, DOI 10.1074/jbc.M207226200; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Colella S, 2001, INT J CANCER, V93, P798, DOI 10.1002/ijc.1423; Dagda RK, 2003, J BIOL CHEM, V278, P24976, DOI 10.1074/jbc.M302832200; Fellner T, 2003, GENE DEV, V17, P2138, DOI 10.1101/gad.259903; Freedman NJ, 2002, J BIOL CHEM, V277, P48261, DOI 10.1074/jbc.M204431200; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; Gehringer MM, 2004, FEBS LETT, V557, P1, DOI 10.1016/S0014-5793(03)01447-9; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Gual P, 2001, ONCOGENE, V20, P156, DOI 10.1038/sj.onc.1204047; Hannon Gregory J, 2004, Methods Mol Biol, V257, P255, DOI 10.1385/1-59259-750-5:255; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; Klumpp S, 2002, CURR OPIN PHARMACOL, V2, P458, DOI 10.1016/S1471-4892(02)00176-5; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Moreno CS, 2000, J BIOL CHEM, V275, P5257, DOI 10.1074/jbc.275.8.5257; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Myslinski E, 2001, NUCLEIC ACIDS RES, V29, P2502, DOI 10.1093/nar/29.12.2502; NESTEROV A, 1994, ARCH BIOCHEM BIOPHYS, V313, P351, DOI 10.1006/abbi.1994.1398; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Schweiger S, 2003, BIOESSAYS, V25, P356, DOI 10.1002/bies.10256; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Turowski P, 1999, MOL BIOL CELL, V10, P1997, DOI 10.1091/mbc.10.6.1997; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Zhou J, 2003, BIOCHEM J, V369, P387, DOI 10.1042/BJ20021244	56	111	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47732	47739		10.1074/jbc.M408015200	http://dx.doi.org/10.1074/jbc.M408015200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364932	hybrid			2022-12-25	WOS:000224957000040
J	van der Spuy, J; Cheetham, ME				van der Spuy, J; Cheetham, ME			The Leber congenital amaurosis protein AIPL1 modulates the nuclear translocation of NUB1 and suppresses inclusion formation by NUB1 fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; X-ASSOCIATED PROTEIN-2; AH RECEPTOR; SUBCELLULAR-LOCALIZATION; DIOXIN RECEPTOR; CORE COMPLEX; NEDD8; UBIQUITINATION; XAP2; INTERACTS	Mutations in the aryl hydrocarbon receptor-interacting protein-like 1 (AIPL1) cause the blinding disease Leber congenital amaurosis (LCA). The similarity of AIPL1 to AIP has led to suggestions that AIPL1 could function in a similar manner to AIP in facilitating protein translocation and as a component of chaperone complexes. AIPL1 interacts with the cell cycle regulator NEDD8 ultimate buster protein 1 (NUB1). As AIPL1 is predominantly cytoplasmic and NUB1 is predominantly nuclear, we tested the hypothesis that AIPL1 could modulate the nuclear translocation of NUB1. Co-transfection of AIPL1 with GFP-NUB1 resulted in a shift of GFP-NUB1 subcellular distribution toward the cytoplasm. Interestingly, AIPL1 was able to act in a chaperone-like fashion to efficiently suppress inclusion formation by NUB1 fragments. Co-transfection of AIPL1 with GFP-NUB1-N and GFP-NUB1-C resulted in an AIPL1-dependent suppression of GFP-NUB1-N perinuclear inclusions and GFP-NUB1-C intranuclear inclusions leading to the redistribution of these fragments in the cytoplasm. This chaperone-like function of AIPL1 was specific for NUB1, since AIPL1 was unable to suppress the inclusion formation by unrelated aggregation-prone proteins and AIP had no effect on NUB1 localization or inclusion formation. We examined the effect of a range of pathogenic and engineered mutations on the ability of AIPL1 to modulate NUB1 localization or inclusion formation. With the exception of W278X, which formed non-functional SDS-insoluble inclusions, all of the pathogenic mutations studied were soluble and could modulate NUB1 with varying efficiency compared with the wildtype protein. The effect of AIPL1 on NUB1 required the C-terminal region of AIPL1, as engineered C-terminal truncation mutations had no effect on NUB1. These data show that AIPL1 can modulate protein translocation and act in a chaperone-like manner and suggest that AIPL1 is an important modulator of NUB1 cellular function.	UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England	University of London; University College London	Cheetham, ME (corresponding author), UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England.	michael.cheetham@ucl.ac.uk	Cheetham, Michael/B-4672-2011	van der Spuy, Jacqueline/0000-0001-5906-2116; Cheetham, Michael/0000-0001-6429-654X				Akey DT, 2002, HUM MOL GENET, V11, P2723, DOI 10.1093/hmg/11.22.2723; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Berg P, 2002, J BIOL CHEM, V277, P32310, DOI 10.1074/jbc.M203351200; Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chapple JP, 2002, INVEST OPHTH VIS SCI, V43, P2015; Chapple JP, 2001, TRENDS MOL MED, V7, P414, DOI 10.1016/S1471-4914(01)02103-7; Cheung-Flynn J, 2003, J BIOL CHEM, V278, P17388, DOI 10.1074/jbc.M300955200; Hipp MS, 2004, J BIOL CHEM, V279, P16503, DOI 10.1074/jbc.M310114200; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kanaya K, 2004, BIOCHEM BIOPH RES CO, V317, P768, DOI 10.1016/j.bbrc.2004.03.108; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kito K, 2001, J BIOL CHEM, V276, P20603, DOI 10.1074/jbc.M100920200; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Lees MJ, 2003, J BIOL CHEM, V278, P35878, DOI 10.1074/jbc.M302430200; Ma Q, 1997, J BIOL CHEM, V272, P8878; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Petrulis JR, 2000, J BIOL CHEM, V275, P37448, DOI 10.1074/jbc.M006873200; Petrulis JR, 2003, J BIOL CHEM, V278, P2677, DOI 10.1074/jbc.M209331200; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Ramamurthy V, 2003, P NATL ACAD SCI USA, V100, P12630, DOI 10.1073/pnas.2134194100; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Saliba RS, 2002, J CELL SCI, V115, P2907; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732; Sohocki MM, 2000, MOL GENET METAB, V70, P142, DOI 10.1006/mgme.2000.3001; Tanaka T, 2004, EUR J BIOCHEM, V271, P972, DOI 10.1111/j.1432-1033.2004.03999.x; Tanaka T, 2003, J BIOL CHEM, V278, P32905, DOI 10.1074/jbc.M212057200; van der Spuy J, 2003, INVEST OPHTH VIS SCI, V44, P5396, DOI 10.1167/iovs.03-0686; van der Spuy J, 2002, HUM MOL GENET, V11, P823, DOI 10.1093/hmg/11.7.823; Yano M, 2003, J CELL BIOL, V163, P45, DOI 10.1083/jcb.200305051; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	40	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48038	48047		10.1074/jbc.M407871200	http://dx.doi.org/10.1074/jbc.M407871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347646	hybrid			2022-12-25	WOS:000224957000075
J	Okahara, F; Ikawa, H; Kanaho, Y; Maehama, T				Okahara, F; Ikawa, H; Kanaho, Y; Maehama, T			Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE PHOSPHATASES; PDZ DOMAIN; BINDING; MYOTUBULARIN; PTEN/MMAC1; KINASE; MAGI-2; REGION; SITES; CELLS	The tumor suppressor PTEN plays an essential role in regulating signaling pathways involved in cell growth and apoptosis and is inactivated in a wide variety of tumors. In this study, we have identified a protein, referred to as PICT-1 ( protein interacting with carboxyl terminus 1), that binds to the C terminus of PTEN and regulates its phosphorylation and turnover. Down-regulation of PICT-1 in MCF7 cells by RNA interference enhances the degradation of PTEN with a concomitant decrease in its phosphorylation. PTEN C-terminal tumor-associated mutants, which are highly susceptible to protein degradation, have lost the ability to bind to PICT-1 along with their reduced phosphorylation, suggesting that their rapid turnover results from impaired binding to PICT-1. Our results identify PICT-1 as a PTEN-interacting protein that promotes the phosphorylation and stability of PTEN. These findings suggest a novel molecular mechanism underlying the turnover of PTEN, which also provides an explanation for the loss of PTEN function due to C-terminal mutations.	Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Metropolitan Univ, Grad Sch Sci, Dept Biol Sci, Tokyo 1920397, Japan	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan University	Maehama, T (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	tmaehama@rinshoken.or.jp	Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317				Adey NB, 2000, CANCER RES, V60, P35; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Birle D, 2002, J IMMUNOL, V169, P286, DOI 10.4049/jimmunol.169.1.286; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Smith JS, 2000, GENOMICS, V64, P44, DOI 10.1006/geno.1999.6101; Sumitomo M, 2004, CANCER CELL, V5, P67, DOI 10.1016/S1535-6108(03)00331-3; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200	24	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45300	45303		10.1074/jbc.C400377200	http://dx.doi.org/10.1074/jbc.C400377200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15355975	hybrid			2022-12-25	WOS:000224694900002
J	On, M; Billingsley, JM; Jouvin, MH; Kinet, JP				On, M; Billingsley, JM; Jouvin, MH; Kinet, JP			Molecular dissection of the FcR beta signaling amplifier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; 5-PHOSPHATASE SHIP BINDS; EPSILON-RI; T-CELL; PHOSPHOTYROSYL PEPTIDE; KINASE ACTIVATION; TYROSINE KINASES; CYTOPLASMIC TAIL; SH2 DOMAIN; SYK	Human high affinity IgE receptors are expressed as two different isoforms: the tetrameric isoform, alphabetagamma(2), or the trimeric isoform, alphagamma(2). The alpha chain is the IgE binding subunit, whereas the FcRbeta and FcRgamma chains are the signaling modules. Both FcRbeta and FcRgamma contain immunoreceptor tyrosine-based activation motifs (ITAM), but the beta ITAM differs from canonical ITAMs in two ways; the spacing between the two canonical tyrosines harbors a third tyrosine, and it is one amino acid shorter than in canonical ITAMs, making it unfit to bind the tandem SH2 of Syk. We have shown that FcRbeta functions as an amplifier of the FcRgamma signaling function. However, the molecular mechanism of this amplification remains unclear. Here we show that mutation of the three tyrosines (Tyr-219, Tyr-225, and Tyr-229) in the beta ITAM essentially converts alphabetagamma(2) into an alphagamma(2) complex in terms of Lyn recruitment, FcRgamma phosphorylation, Syk activation, and calcium mobilization. Tyr-219 is the most critical residue in this regard. In addition, a detailed analysis of the dynamics of calcium mobilization suggests a possible inhibitory role for Tyr-225, which becomes apparent when Tyr-219 is mutated. Thus, the signaling amplification function of FcRbeta is mainly encoded in Tyr-219 and in its capacity to recruit Lyn. In turn, this Tyr-219-mediated Lyn recruitment enhances gamma chain phosphorylation, Syk activation, and calcium mobilization. The two other tyrosines appear to have a modulating function that remains to be fully assessed.	Beth Israel Deaconess Med Ctr, Dept Pathol, RN 227, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kinet, JP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, RN 227, 330 Brookline Ave, Boston, MA 02215 USA.	jkinet@bidmc.harvard.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM053950, R01GM053950] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53950] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; Donnadieu E, 2000, J IMMUNOL, V165, P3917, DOI 10.4049/jimmunol.165.7.3917; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EISEMAN E, 1992, NATURE, V355, P78; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; HARLOW E, 1988, ANTIBODIES LABORATOR, P524; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1997, J IMMUNOL, V159, P4426; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1998, J IMMUNOL, V161, P2731; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Pribluda VS, 1997, J BIOL CHEM, V272, P11185; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Scharenberg AM, 1999, CURR OPIN IMMUNOL, V11, P621, DOI 10.1016/S0952-7915(99)00027-8; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Songyang Zhou, 2004, Cell, V116, pS41, DOI 10.1016/S0092-8674(04)00041-8; Turner H, 1999, NATURE, V402, pB24, DOI 10.1038/35037021; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Waksman Gabriel, 2004, Cell, VS116, pS45, DOI 10.1016/S0092-8674(04)00043-1; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45782	45790		10.1074/jbc.M404890200	http://dx.doi.org/10.1074/jbc.M404890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15339926	hybrid			2022-12-25	WOS:000224694900062
J	Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB				Umetani, N; Fujimoto, A; Takeuchi, H; Shinozaki, M; Bilchik, AJ; Hoon, DSB			Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma	ONCOGENE			English	Article						allelic imbalance; APAF-1; colorectal carcinoma; apoptosis; chromosome 12q23	DNA METHYLATION; MICROSATELLITE INSTABILITY; PROMOTER HYPERMETHYLATION; TRANSCRIPTIONAL TARGET; CUTANEOUS MELANOMA; CANCER; GENE; P53; DISEASE; TUMORS	APAF-1 gene, located at chromosome locus 12q23, is a key factor in the mitochondrial apoptotic pathway downstream of p53, and is a potential tumor suppressor gene. We hypothesized that APAF-1 gene dysfunction due to allelic imbalance ( AI) contributes to the development and progression of colorectal carcinoma (CRC). AI at APAF-1 locus and microsatellite instability (MIN) in CRCs and adenomas were assessed by multiple microsatellite markers. The frequency of AI significantly increased with tumor progression; 0 of 33 (0%) adenomas, 14 of 49 (29%) primary CRCs, and 18 of 34 (53%) liver metastases had AI. A total of 12 metastases were matched with corresponding primary CRCs; in 11 of 12 (92%) pairs, the metastasis had same AI status as the corresponding primary tumor. APAF-1 mRNA transcription level was significantly decreased with AI in liver metastases (P = 0.009). Promoter hypermethylation was found in three of 35 (9%) primary CRCs and one of 15 (7%) liver metastases by methylation-specific PCR but was not correlated with AI. MIN was observed in 11 of 49 (23%) primary CRCs and was a favorable prognostic factor. Our results suggest that APAF-1 gene haploinsufficiency caused by AI increases with tumor progression, and relates to hepatic metastasis.	St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA; St Johns Hlth Sci Ctr, John Wayne Canc Inst, Div Gastrointestinal Oncol, Santa Monica, CA 90404 USA	John Wayne Cancer Institute; John Wayne Cancer Institute	Hoon, DSB (corresponding author), St Johns Hlth Sci Ctr, John Wayne Canc Inst, Dept Mol Oncol, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	hoon@jwci.org	Hoon, Dave SB/C-7146-2018	Hoon, Dave SB/0000-0003-1915-3683	NATIONAL CANCER INSTITUTE [P01CA029605] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA29605] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Baylin SB, 1998, ADV CANCER RES, V72, P141; Boland CR, 1998, CANCER RES, V58, P5248; Deng GR, 1999, CANCER RES, V59, P2029; Esteller M, 2000, CANCER RES, V60, P4366; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fujimoto A, 2004, CANCER RES, V64, P2245, DOI 10.1158/0008-5472.CAN-03-2932; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hao XP, 2002, GUT, V50, P834, DOI 10.1136/gut.50.6.834; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hemminki A, 2000, GASTROENTEROLOGY, V119, P921, DOI 10.1053/gast.2000.18161; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 2002, GASTROENTEROL CLIN N, V31, P945, DOI 10.1016/S0889-8553(02)00058-4; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoon DSB, 2002, METHOD ENZYMOL, V356, P302; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kim H, 1999, CYTOGENET CELL GENET, V87, P252, DOI 10.1159/000015436; Kimura M, 1998, CANCER RES, V58, P2456; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Murty VVVS, 1996, GENOMICS, V35, P562, DOI 10.1006/geno.1996.0398; Nakayama T, 2001, AM J PATHOL, V158, P1371, DOI 10.1016/S0002-9440(10)64088-6; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robles AI, 2001, CANCER RES, V61, P6660; Schneider BG, 2003, J CLIN PATHOL-MOL PA, V56, P141, DOI 10.1136/mp.56.3.141; Shinozaki M, 2004, CLIN CANCER RES, V10, P1753, DOI 10.1158/1078-0432.CCR-1169-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spugnardi M, 2003, CANCER RES, V63, P1639; Takeuchi H, 2004, J CLIN ONCOL, V22, P2671, DOI 10.1200/JCO.2004.12.009; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Xiong ZG, 2001, CANCER EPIDEM BIOMAR, V10, P799; Yatsuoka T, 2000, AM J GASTROENTEROL, V95, P2080	41	27	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8292	8300		10.1038/sj.onc.1208022	http://dx.doi.org/10.1038/sj.onc.1208022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378005				2022-12-25	WOS:000224749500011
J	De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C				De Cecco, L; Marchionni, L; Gariboldi, M; Reid, JF; Lagonigro, MS; Caramuta, S; Ferrario, C; Bussani, E; Mezzanzanica, D; Turatti, F; Delia, D; Daidone, MG; Oggionni, M; Bertuletti, N; Ditto, A; Raspagliesi, F; Pilotti, S; Pierotti, MA; Canevari, S; Schneider, C			Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2	ONCOGENE			English	Article						ovarian cancer; gene expression profiling; automated class discovery; epithelial-mesenchymal transition; epithelial-stromal interaction	FIBROBLAST-GROWTH-FACTOR; SURFACE EPITHELIAL-CELLS; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCAN; ADHESION MOLECULES; SIGNALING PATHWAYS; MESSENGER-RNA; RECEPTOR; CARCINOMAS	Epithelial ovarian cancer (EOC) is the gynecological disease with the highest death rate. We applied an automatic class discovery procedure based on gene expression pro. ling to stages III-IV tumors to search for molecular signatures associated with the biological properties and progression of EOC. Using a complementary DNA microarray containing 4451 cancer-related, sequence-verified features, we identified a subset of EOC characterized by the expression of numerous genes related to the extracellular matrix (ECM) and its remodeling, along with elements of the fibroblast growth factor 2 (FGF2) signaling pathway. A total of 10 genes were validated by quantitative real-time polymerase chain reaction, and coexpression of FGF2 and fibroblast growth factor receptor 4 in tumor cells was revealed by immunohistochemistry, confirming the reliability of gene expression by cDNA microarray. Since the functional relationships among these genes clearly suggested involvement of the identified molecular signature in processes related to epithelial-stromal interactions and/or epithelial-mesenchymal cellular plasticity, we applied supervised learning analysis on ovarian-derived cell lines showing distinct cellular phenotypes in culture. This procedure enabled construction of a gene classifier able to discriminate mesenchymal-like from epithelial-like cells. Genes overexpressed in mesenchymal-like cells proved to match the FGF2 signaling and ECM molecular signature, as identified by unsupervised class discovery on advanced tumor samples. In vitro functional analysis of the cell plasticity classifier was carried out using two isogenic and immortalized cell lines derived from ovarian surface epithelium and displaying mesenchymal and epithelial morphology, respectively. The results indicated the autocrine, but not intracrine stimulation of mesenchymal conversion and cohort/scatter migration of cells by FGF2, suggesting a central role for FGF2 signaling in the maintenance of cellular plasticity of ovary-derived cells throughout the carcinogenesis process. These findings raise mechanistic hypotheses on EOC pathogenesis and progression that might provide a rational underpinning for new therapeutic modalities.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Lab Nazl CIB, I-34012 Trieste, Italy; IFOM FIRC Inst Mol Oncol, I-20139 Milan, Italy; Ist Nazl Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Nazl Tumori, Dept Surg Oncol, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Pierotti, MA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	marco.pierotti@istitutotumori.mi.it; schneide@sci.area.trieste.it	De Cecco, Loris/K-7036-2016; Raspagliesi, Francesco/K-5473-2018; Marchionni, Luigi/S-6774-2017; Pierotti, Marco Alessandro/AAC-4728-2022; Daidone, Maria Grazia/E-9232-2017; Reid, James/G-2496-2010; Ditto, Antonino/H-2219-2017; Mezzanzanica, Delia/C-2607-2017; Gariboldi, Manuela/K-4744-2016	De Cecco, Loris/0000-0002-7066-473X; Raspagliesi, Francesco/0000-0001-8953-1657; Marchionni, Luigi/0000-0002-7336-8071; Pierotti, Marco Alessandro/0000-0002-7431-8332; Daidone, Maria Grazia/0000-0002-4786-1321; Ditto, Antonino/0000-0002-5684-8225; Mezzanzanica, Delia/0000-0002-9664-6871; Reid, James/0000-0001-6997-2850; Gariboldi, Manuela/0000-0001-8406-165X				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Aunoble B, 2000, INT J ONCOL, V16, P567; Balli S, 2000, EUR J CANCER, V36, P2061, DOI 10.1016/S0959-8049(00)00193-3; Bertrand V, 2003, CELL, V115, P615, DOI 10.1016/S0092-8674(03)00928-0; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Davies BR, 1998, HISTOPATHOLOGY, V32, P69; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fujimoto J, 1997, EUR J GYNAECOL ONCOL, V18, P349; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S; HORI A, 1991, CANCER RES, V51, P6180; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Hough CD, 2001, CANCER RES, V61, P3869; Hough CD, 2000, CANCER RES, V60, P6281; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kodama J, 2001, ANTICANCER RES, V21, P2983; KRUK PA, 1990, LAB INVEST, V63, P132; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; Liotta LA, 2002, JNCI-J NATL CANCER I, V94, P1113; Long CJ, 2000, J BIOL CHEM, V275, P13918, DOI 10.1074/jbc.275.18.13918; MainesBandiera SL, 1997, INT J GYNECOL PATHOL, V16, P250, DOI 10.1097/00004347-199707000-00010; Matei D, 2002, ONCOGENE, V21, P6289, DOI 10.1038/sj.onc.1205785; Matias-Guiu X, 1998, VIRCHOWS ARCH, V433, P103, DOI 10.1007/s004280050224; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Obermair A, 1998, CANCER LETT, V130, P69, DOI 10.1016/S0304-3835(98)00119-0; Ornitz DM, 2002, GENE DEV, V16, P1446, DOI 10.1101/gad.990702; Parrott JA, 2001, MOL CELL ENDOCRINOL, V175, P29, DOI 10.1016/S0303-7207(01)00436-1; PERANTONI AO, 1995, P NATL ACAD SCI USA, V92, P4696, DOI 10.1073/pnas.92.10.4696; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Radmacher MD, 2002, J COMPUT BIOL, V9, P505, DOI 10.1089/106652702760138592; Righetti SC, 1999, CELL GROWTH DIFFER, V10, P473; Santala M, 1999, CLIN CANCER RES, V5, P4091; Schafer T, 2004, J BIOL CHEM, V279, P6244, DOI 10.1074/jbc.M310500200; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schwartz DR, 2003, CANCER RES, V63, P2913; Schwartz DR, 2002, CANCER RES, V62, P4722; Sheng GJ, 2003, CELL, V115, P603, DOI 10.1016/S0092-8674(03)00927-9; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shridhar V, 2001, CANCER RES, V61, P5895; Simojoki M, 2001, GYNECOL ONCOL, V82, P110, DOI 10.1006/gyno.2001.6212; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sundfeldt K, 1997, INT J CANCER, V74, P275, DOI 10.1002/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.3.CO;2-V; Taverna S, 2003, J BIOL CHEM, V278, P51911, DOI 10.1074/jbc.M304192200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tonin PN, 2001, ONCOGENE, V20, P6617, DOI 10.1038/sj.onc.1204804; TSAO SW, 1993, GYNECOL ONCOL, V48, P5, DOI 10.1006/gyno.1993.1002; Valve E, 2000, INT J CANCER, V88, P718, DOI 10.1002/1097-0215(20001201)88:5<718::AID-IJC6>3.0.CO;2-F; VANNIEKERK CC, 1993, AM J PATHOL, V142, P157; von Heydebreck A, 2001, Bioinformatics, V17 Suppl 1, pS107; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176	64	71	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8171	8183		10.1038/sj.onc.1207979	http://dx.doi.org/10.1038/sj.onc.1207979			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15377994				2022-12-25	WOS:000224692500015
J	Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y				Anazawa, Y; Arakawa, H; Nakagawa, H; Nakamura, Y			Identification of STAG1 as a key mediator of a p53-dependent apoptotic pathway	ONCOGENE			English	Article						p53; p53-121F; p53 target gene; apoptosis; cDNA microarray; gene therapy	CELL-CYCLE CHECKPOINT; P53 GENE-TRANSFER; POTENTIAL MEDIATOR; DIRECT TARGET; LUNG-CANCER; PROTEIN; MUTATIONS; EXPRESSION; INHIBITOR; KINASES	A mutant version of p53 (p53-121F), in which phenylalanine replaces the 121st serine residue, can induce apoptosis more effectively than wild-type p53 (wt-p53). In view of this observation, we considered that one or more apoptosis-related p53-target genes might be preferentially induced by p53-121F. We carried out cDNA microarray analysis to identify such genes, using mRNAs isolated from LS174T colon-cancer cells infected by adenovirus vectors containing either p53-121F(Ad-p53-121F) or wt-p53 (Ad-p53). The STAG1 gene was one of the transcripts showing higher expression levels in cells infected with Ad-p53-121F as opposed to Ad-wtp53. The encoded product appears to contain a transmembrane domain, and binding motifs for SH3 and WW. In two other cancer cell lines, the expression of STAG1 mRNA was induced in response to various genotoxic stresses in a p53-dependent manner; moreover, enforced expression of STAG1 led to apoptosis in several additional cancer cell lines. Suppression of endogenous STAG1 using the RNA-interference method reduced the apoptotic response, whether induced by Ad-p53-121F or Ad- p53. These results suggest that STAG1, a novel transcriptional target for p53, mediates p53-dependent apoptosis, and might be a good candidate for next-generation gene therapy.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Arakawa, Hirofumi/L-3459-2013	Arakawa, Hirofumi/0000-0001-6077-0638				BAKER SJ, 1990, CANCER RES, V50, P7717; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Furuhata T, 1996, ONCOGENE, V13, P1965; Habib NA, 1999, HUM GENE THER, V10, P2019, DOI 10.1089/10430349950017383; Han HJ, 1998, HUM MOL GENET, V7, P1039, DOI 10.1093/hmg/7.6.1039; HARPER JW, 1993, CELL, V75, P805; Harvey KF, 1998, J BIOL CHEM, V273, P13524, DOI 10.1074/jbc.273.22.13524; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Iiizumi M, 2002, CANCER RES, V62, P1246; Matsuda K, 2002, CANCER RES, V62, P2883; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mori T, 2002, NEOPLASIA, V4, P268, DOI 10.1038/sj.neo.7900235; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Ng CC, 1999, GENE CHROMOSOME CANC, V26, P329, DOI 10.1002/(SICI)1098-2264(199912)26:4<329::AID-GCC7>3.0.CO;2-C; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ono K, 2000, CANCER RES, V60, P5007; Rae FK, 2001, MOL CARCINOGEN, V32, P44, DOI 10.1002/mc.1063; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; Takei Y, 1998, GENE CHROMOSOME CANC, V23, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Urano T, 1997, CANCER RES, V57, P3281; Weill D, 2000, CHEST, V118, P966, DOI 10.1378/chest.118.4.966; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamaguchi T, 2001, CANCER RES, V61, P8256	29	32	33	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7621	7627		10.1038/sj.onc.1207270	http://dx.doi.org/10.1038/sj.onc.1207270			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361841				2022-12-25	WOS:000224306700003
J	Core, N; Joly, F; Boned, A; Djabali, M				Core, N; Joly, F; Boned, A; Djabali, M			Disruption of E2F signaling suppresses the INK4a-induced proliferative defect in M33-deficient mice	ONCOGENE			English	Article						Pc-G; M33; proliferation; Ink4a	HEMATOPOIETIC STEM-CELLS; RESCUES T-LYMPHOPOIESIS; RECEPTOR-DEFICIENT MICE; POLYCOMB-GROUP GENES; B-CELL; FAMILY-MEMBERS; INK4A LOCUS; EXPRESSION; P16(INK4A); BCL-2	Polycomb group (Pc-G) proteins associate to form large complexes that repress Hox genes, thereby imposing Hox gene expression pattern required for development. However, Pc-G proteins have a Hox-independent function in controlling cell proliferation. Here we show that embryonic fibroblasts derived from M33-deficient mice are impaired in the progression into the S phase of the cell cycle, as shown by a reduced rate of incorporation of bromodeoxyuridine. These cells have a senescent phenotype, associated to an abnormal accumulation of the cyclin-dependent kinase inhibitor p16INK4a protein. We demonstrate that this defect is bypassed in mutant embryonic fibroblasts expressing a transdominant negative form of the cell cycle controlling transcription factor E2F (E2F-DB). In addition, we show that the polycomb protein M33 controls critical expansion of B- and T-lymphocyte precursors. Together, our results emphasize M33-Polycomb protein function in cell cycle control.	CNRS, INSERM, Ctr Immunol, F-13288 Marseille 9, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Djabali, M (corresponding author), CNRS, INSERM, Ctr Immunol, Case 906, F-13288 Marseille 9, France.	djabali@cim1.univ-mrs.fr						Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bel S, 1998, DEVELOPMENT, V125, P3543; Core N, 1997, DEVELOPMENT, V124, P721; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HELIN K, 1994, J VIROL, V68, P5027, DOI 10.1128/JVI.68.8.5027-5035.1994; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kondo M, 1997, IMMUNITY, V7, P155, DOI 10.1016/S1074-7613(00)80518-X; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Ohta H, 2002, J EXP MED, V195, P759, DOI 10.1084/jem.20011911; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; PENIT C, 1995, J IMMUNOL, V154, P5103; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCOLLAY R, 1991, CURR OPIN IMMUNOL, V3, P204, DOI 10.1016/0952-7915(91)90051-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; VEIS DJ, 1993, J IMMUNOL, V151, P2546; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	35	24	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7660	7668		10.1038/sj.onc.1207998	http://dx.doi.org/10.1038/sj.onc.1207998			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15377996				2022-12-25	WOS:000224306700007
J	Cerpa, WF; Barria, MI; Chacon, MA; Suazo, M; Gonzalez, M; Opazo, C; Bush, AI; Inestrosa, NC				Cerpa, WF; Barria, MI; Chacon, MA; Suazo, M; Gonzalez, M; Opazo, C; Bush, AI; Inestrosa, NC			The N-terminal copper-binding domain of the amyloid precursor protein protects against Cu2+ neurotoxicity in vivo	FASEB JOURNAL			English	Article						water maze; intracerebral injection	ALZHEIMERS-DISEASE; SUPEROXIDE-DISMUTASE; TYROSINE NITRATION; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; NEURITE OUTGROWTH; OXIDATIVE STRESS; SCIATIC-NERVE; APP; PEROXYNITRITE; REDUCTION	The amyloid precursor protein (APP) contains a Cu binding domain (CuBD) localized between amino acids 135 and 156 (APP(135-156)), which can reduce Cu2+ to Cu1+ in vitro. The physiological function of this APP domain has not yet being established; nevertheless several studies support the notion that the CuBD of APP is involved in Cu homeostasis. We used APP synthetic peptides to evaluate their protective properties against Cu2+ neurotoxicity in a bilateral intra-hippocampal injection model. We found that human APP135-156 protects against Cu2+-induced neurotoxic effects, such as, impairment of spatial memory, neuronal cell loss, and astrogliosis. APP135-156 lacking two histidine residues showed protection against Cu2+; however, APP135-156 mutated in cysteine 144, a key residue in the reduction of Cu2+ to Cu1+, did not protect against Cu2+ neurotoxicity. In accordance with recent reports, the CuBD of the Caenorhabditis elegans, APL-1 protected against Cu2+ neurotoxicity in vivo. We also found that Cu2+ neurotoxicity is associated with an increase in nitrotyrosine immunofluorescence as well as with a decrease in Cu2+ uptake. The CuBD of APP therefore may play a role in the detoxification of brain Cu.	Pontificia Univ Catolica Chile, FONDAP, Biomed Ctr,Gac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Santiago, Chile; Univ Chile, Inst Nutr & Tecnol Alimentos, Santiago 11, Chile; Mental Hlth Res Inst Victoria, Parkville, Vic 3010, Australia; Harvard Univ, Genet & Aging Res Unit, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA	Pontificia Universidad Catolica de Chile; Universidad de Chile; Harvard University; Massachusetts General Hospital	Inestrosa, NC (corresponding author), Pontificia Univ Catolica Chile, FONDAP, Biomed Ctr,Gac Ciencias Biol, Ctr Regulac Celular & Patol Joaquin V Luco, Alameda 340, Santiago, Chile.	ninestr@genes.bio.puc.cl	Bush, Ashley/Y-2457-2019; Cerpa, Waldo/GSI-5204-2022; Gonzalez, Mauricio/I-2772-2013; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Cerpa, Waldo/0000-0001-7344-0144; Bush, Ashley I/0000-0001-8259-9069; Opazo, Carlos/0000-0003-3473-7548; Barria, Maria/0000-0001-6225-5971; Gonzalez Canales, Mauricio Alejandro/0000-0002-1592-9758				ALVAREZ J, 1992, NEUROSCI LETT, V144, P130, DOI 10.1016/0304-3940(92)90733-N; ALVAREZ J, 1995, EUR J NEUROSCI, V7, P152, DOI 10.1111/j.1460-9568.1995.tb01029.x; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Atwood CS, 2000, J NEUROCHEM, V75, P1219, DOI 10.1046/j.1471-4159.2000.0751219.x; Barnham KJ, 2003, J BIOL CHEM, V278, P17401, DOI 10.1074/jbc.M300629200; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bush AI, 2003, TRENDS NEUROSCI, V26, P207, DOI 10.1016/S0166-2236(03)00067-5; Chacon MA, 2003, MOL PSYCHIATR, V8, P853, DOI [10.1038/sj.mp.4001400, 10.1038/sj.mp.4001414]; Chacon MA, 2003, J NEUROCHEM, V87, P195, DOI 10.1046/j.1471-4159.2003.01985.x; Cote S.L., 1993, IMMUNOCYTOCHEMISTRY; DAIGLE I, 1993, P NATL ACAD SCI USA, V90, P12045, DOI 10.1073/pnas.90.24.12045; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harris ED, 2000, ANNU REV NUTR, V20, P291, DOI 10.1146/annurev.nutr.20.1.291; HESSE L, 1994, FEBS LETT, V349, P109, DOI 10.1016/0014-5793(94)00658-X; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; MANDEL RJ, 1989, EXP NEUROL, V104, P208, DOI 10.1016/0014-4886(89)90031-9; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Maynard CJ, 2002, J BIOL CHEM, V277, P44670, DOI 10.1074/jbc.M204379200; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; Moreno RD, 1996, BRAIN RES, V718, P13, DOI 10.1016/0006-8993(95)01555-8; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Multhaup G, 1996, SCIENCE, V271, P1406, DOI 10.1126/science.271.5254.1406; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; Opazo C, 2002, J BIOL CHEM, V277, P40302, DOI 10.1074/jbc.M206428200; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Ruiz FH, 1999, J NEUROCHEM, V73, P1288, DOI 10.1046/j.1471-4159.1999.0731288.x; Simons A, 2002, BIOCHEMISTRY-US, V41, P9310, DOI 10.1021/bi0258647; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMALL DH, 1994, J NEUROSCI, V14, P2117; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tohgi H, 1999, NEUROSCI LETT, V269, P52, DOI 10.1016/S0304-3940(99)00406-1; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1999, BRAIN RES, V842, P439, DOI 10.1016/S0006-8993(99)01861-2; White AR, 2002, J NEUROSCI, V22, P365, DOI 10.1523/JNEUROSCI.22-02-00365.2002; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481	42	31	33	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1701	+		10.1096/fj.03-1349fje	http://dx.doi.org/10.1096/fj.03-1349fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345692				2022-12-25	WOS:000224243200045
J	Jadlowiec, J; Koch, H; Zhang, XY; Campbell, PG; Seyedain, M; Sfeir, C				Jadlowiec, J; Koch, H; Zhang, XY; Campbell, PG; Seyedain, M; Sfeir, C			Phosphophoryn regulates the gene expression and differentiation of NIH3T3, MC3T3-E1, and human mesenchymal stem cells via the integrin/MAPK signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTIN MATRIX PROTEIN-1; EXTRACELLULAR-MATRIX; OSTEOBLASTIC DIFFERENTIATION; HYDROXYAPATITE FORMATION; TRANSCRIPTION FACTOR; OSTEOGENIC DIFFERENTIATION; BONE-FORMATION; I COLLAGEN; PHOSPHOPROTEIN; INDUCTION	Extracellular matrix proteins (ECMs) serve as both a structural support for cells and a dynamic biochemical network that directs cellular activities. ECM proteins such as those of the SIBLING family ( small integrin-binding ligand glycoprotein) could possess inherent growth factor activity. In this study, we demonstrate that exon 5 of dentin matrix protein 3 ( phosphophoryn ( PP)), a non-collagenous dentin ECM protein and SIBLING protein family member, up-regulates osteoblast marker genes in primary human adult mesenchymal stem cells (hMSCs), a mouse osteoblastic cell line (MC3T3-E1), and a mouse fibroblastic cell line (NIH3T3). Quantitative real-time PCR technology was used to quantify gene expression levels of bone markers such as Runx2, Osx (Osterix), bone/liver/kidney Alp ( alkaline phosphatase), Ocn ( osteocalcin), and Bsp ( bone sialoprotein) in response to recombinant PP and stably transfected PP. PP up-regulated Runx2, Osx, and Ocn gene expression. PP increased OCN protein production in hMSCs and MC3T3-E1. ALP activity and calcium deposition was increased by PP in hMSC. Furthermore, an alpha(v)beta(3) integrin-blocking antibody significantly inhibited recombinant PP-induced expression of Runx2 in hMSCs, suggesting that signaling by PP is mediated through the integrin pathway. PP was also shown to activate p38, ERK1/2, and JNK, three components of the MAPK pathway. These data demonstrate a novel signaling function for PP in cell differentiation beyond the hypothesized role of PP in biomineralization.	Univ Pittsburgh, Dept Oral Med & Pathol, Sch Dent Med, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Bone Tissue Engn Ctr, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Inst Complex Engineered Syst, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University; Carnegie Mellon University	Sfeir, C (corresponding author), Univ Pittsburgh, Dept Oral Med & Pathol, Sch Dent Med, 693A Salk Hall, Pittsburgh, PA 15261 USA.	csfeir@pitt.edu						ADAMS JC, 1993, DEVELOPMENT, V117, P1183; Anselme K, 2000, BIOMATERIALS, V21, P667, DOI 10.1016/S0142-9612(99)00242-2; Applied Biosystems, 2001, APPL BIOS US B; BISSELL MJ, 1987, J CELL SCI, P327; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; BOSKEY AL, 1990, BONE MINER, V11, P55, DOI 10.1016/0169-6009(90)90015-8; Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931; Chaplet M, 2003, J BONE MINER RES, V18, P1506, DOI 10.1359/jbmr.2003.18.8.1506; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; Damsky CH, 1999, BONE, V25, P95, DOI 10.1016/S8756-3282(99)00106-4; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DEVRIES IG, 1989, HISTOCHEMISTRY, V91, P69, DOI 10.1007/BF00501914; DSouza RN, 1997, J BONE MINER RES, V12, P2040, DOI 10.1359/jbmr.1997.12.12.2040; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Feng JQ, 1998, J BIOL CHEM, V273, P9457, DOI 10.1074/jbc.273.16.9457; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; Frank O, 2002, J CELL BIOCHEM, V85, P737, DOI 10.1002/jcb.10174; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hayashibara T, 2004, J BONE MINER RES, V19, P455, DOI 10.1359/JBMR.0301263; He G, 2003, CONNECT TISSUE RES, V44, P240, DOI 10.1080/03008200390181726; Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Jain A, 2002, J BIOL CHEM, V277, P13700, DOI 10.1074/jbc.M110757200; Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097-4644(199702)64:2<295::AID-JCB12>3.0.CO;2-I; Jikko A, 1999, J BONE MINER RES, V14, P1075, DOI 10.1359/jbmr.1999.14.7.1075; KUBOKI Y, 1979, J DENT RES, V58, P1926, DOI 10.1177/00220345790580092001; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937; Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; Liapis H, 1996, DIAGN MOL PATHOL, V5, P127, DOI 10.1097/00019606-199606000-00008; LINDE A, 1980, J BIOL CHEM, V255, P5931; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097-4652(200008)184:2<207::AID-JCP8>3.0.CO;2-U; Narayanan K, 2001, P NATL ACAD SCI USA, V98, P4516, DOI 10.1073/pnas.081075198; Puleo DA, 1997, J CELL PHYSIOL, V173, P93, DOI 10.1002/(SICI)1097-4652(199710)173:1<93::AID-JCP11>3.0.CO;2-O; Qin C, 2002, J DENT RES, V81, P392, DOI 10.1177/154405910208100607; RICHARDSON WS, 1978, J BIOL CHEM, V253, P8042; RICKARD DJ, 1994, DEV BIOL, V161, P218, DOI 10.1006/dbio.1994.1022; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; Sfeir C, 1996, CONNECT TISSUE RES, V35, P215, DOI 10.3109/03008209609029194; SFEIR C, 1995, J BONE MINER RES, V10, P607; Sfeir C., 2000, CHEM BIOL MINERALIZE, P181; Shi ST, 1996, J BONE MINER RES, V11, P1139, DOI 10.1002/jbmr.5650110813; Shui CX, 2003, J BONE MINER RES, V18, P213, DOI 10.1359/jbmr.2003.18.2.213; Veis A, 2002, MICROSC RES TECHNIQ, V59, P342, DOI 10.1002/jemt.10216; Veis A, 1998, EUR J ORAL SCI, V106, P234, DOI 10.1111/j.1600-0722.1998.tb02181.x; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; VEIS A, 1993, J BONE MINER RES, V8, pS493; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275; ZANETTI M, 1981, EUR J BIOCHEM, V113, P541, DOI 10.1111/j.1432-1033.1981.tb05096.x	60	127	139	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 17	2004	279	51					53323	53330		10.1074/jbc.M404934200	http://dx.doi.org/10.1074/jbc.M404934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	878XL	15371433	hybrid			2022-12-25	WOS:000225680600064
J	Sen, N; Das, BB; Ganguly, A; Mukherjee, T; Bandyopadhyay, S; Majumder, HK				Sen, N; Das, BB; Ganguly, A; Mukherjee, T; Bandyopadhyay, S; Majumder, HK			Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED THYMOCYTE APOPTOSIS; PLASMA-MEMBRANE; CYTOCHROME-C; DNA TOPOISOMERASES; EARLY EVENTS; ACTIVATION; PROMASTIGOTES; CLEAVAGE; CA2+; DEPOLARIZATION	Leishmania, a unicellular trypanosomatid protozoan parasite, causes a wide range of human diseases ranging from the localized self-healing cutaneous lesions to fatal visceral leishmaniasis. However, it undergoes a process of programmed cell death during treatment with the topoisomerase I poison camptothecin (CPT). The present study shows that CPT-induced formation of reactive oxygen species increases the level of cytosolic calcium through the release of calcium ions from intracellular stores as well as by influx of extracellular calcium. Elevation of cytosolic calcium is responsible for depolarization of mitochondrial membrane potential (DeltaPsi(m)), which is followed by a significant decrease in intracellular pH levels. CPT-induced oxidative stress also causes impairment of the Na+-K+-ATPase pump and subsequently decreases the intracellular K+ level in leishmanial cells. A decrease in both intracellular pH and K+ levels propagates the apoptotic process through activation of caspase 3-like proteases by rapid formation of cytochrome c-mediated apoptotic complex. In addition to caspase-like protease activation, a lower level of intracellular K+ also enhances the activation of apoptotic nucleases at the late stage of apoptosis. This suggests that the physiological level of pH and K+ are inhibitory for apoptotic DNA fragmentation and caspase-like protease activation in leishmanial cells. Moreover, unlike mammalian cells, the intracellular ATP level gradually decreases with an increase in the number of apoptotic cells after the loss of DeltaPsi(m). Taken together, the elucidation of biochemical events, which tightly regulate the process of growth arrest and death of Leishmania donovani promastigotes, allows us to define a more comprehensive view of cell death during treatment with CPT.	Indian Inst Chem Biol, Div Mol Parasitol, Kolkata 700032, W Bengal, India; Indian Inst Chem Biol, Div Infect Dis, Kolkata 700032, W Bengal, India; Indian Inst Chem Biol, Div Immunol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Majumder, HK (corresponding author), Indian Inst Chem Biol, Div Mol Parasitol, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	hkmajumder@iicb.res.in	DAS, BENU BRATA BRATA/AAX-4347-2021; Sen, Nilkantha/AAW-9788-2020; Das, Benu Brata/AAC-3452-2022	DAS, BENU BRATA BRATA/0000-0003-2519-7105; 				Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; CHAKRABORTY AK, 1993, INDIAN J BIOCHEM BIO, V30, P257; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Cunningham D, 1999, SEMIN ONCOL, V26, P6; Das M, 2001, J CELL SCI, V114, P2461; Facompre M, 2001, BIOCHEM PHARMACOL, V61, P299, DOI 10.1016/S0006-2952(00)00553-0; Felibertt P, 1995, MOL BIOCHEM PARASIT, V74, P179, DOI 10.1016/0166-6851(95)02497-2; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P217, DOI 10.1113/jphysiol.1967.sp008297; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hughes FM, 1998, CELL DEATH DIFFER, V5, P1017; JEZEK P, 1990, J BIOL CHEM, V265, P10522; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; KRICKA LJ, 1988, ANAL BIOCHEM, V175, P14, DOI 10.1016/0003-2697(88)90354-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandal D, 1997, BIOCHEM J, V322, P251, DOI 10.1042/bj3220251; Mann CL, 2001, ENDOCRINOLOGY, V142, P5059, DOI 10.1210/en.142.12.5059; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; Mukherjee T, 2001, J BIOL CHEM, V276, P5563, DOI 10.1074/jbc.M008469200; NOSSERI C, 1994, EXP CELL RES, V212, P367, DOI 10.1006/excr.1994.1156; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; SARKAR D, 1995, FEBS LETT, V375, P83, DOI 10.1016/0014-5793(95)01161-7; SCHWARTZMAN RA, 1991, ENDOCRINOLOGY, V128, P1190, DOI 10.1210/endo-128-2-1190; SCHWARTZMAN RA, 1993, ENDOCRINOLOGY, V133, P91; Sen N, 2004, CELL DEATH DIFFER, V11, P924, DOI 10.1038/sj.cdd.4401435; Sledge GW, 1999, SEMIN ONCOL, V26, P1; Stefanelli C, 1997, BIOCHEM J, V322, P909, DOI 10.1042/bj3220909; SUTCLIFFE JA, 1989, ANTIMICROB AGENTS CH, V33, P2027, DOI 10.1128/AAC.33.12.2027; Tagliarino C, 2001, J BIOL CHEM, V276, P19150, DOI 10.1074/jbc.M100730200; TSAO YP, 1993, CANCER RES, V53, P5908; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WANG JC, 1991, J BIOL CHEM, V266, P6659; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yu A, 2000, BBA-MOL CELL BIOL L, V1487, P296, DOI 10.1016/S1388-1981(00)00100-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	106	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52366	52375		10.1074/jbc.M406705200	http://dx.doi.org/10.1074/jbc.M406705200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15355995	hybrid			2022-12-25	WOS:000225493400080
J	Solis-Garrido, LM; Pintado, AJ; Andres-Mateos, E; Figueroa, MA; Matute, C; Montiel, C				Solis-Garrido, LM; Pintado, AJ; Andres-Mateos, E; Figueroa, MA; Matute, C; Montiel, C			Cross-talk between native plasmalemmal Na+/Ca2+ exchanger and inositol 1,4,5-trisphosphate-sensitive Ca2+ internal store in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; INTRACELLULAR CALCIUM; LYSOPHOSPHATIDIC ACID; NA+-CA2+ EXCHANGER; MOLECULAR-CLONING; FERTILIZATION; RELEASE; RECEPTORS; EGGS; TRISPHOSPHATE	Because the presence of a native plasmalemmal Na+/ Ca2+ exchange (NCX) activity in Xenopus laevis oocytes remains controversial, its possible functional role in these cells is poorly understood. Here, in experiments on control oocytes and oocytes overexpressing a cloned NCX1 cardiac protein, confocal microscopy combined with electrophysiological techniques reveal that these cells express an endogenous NCX protein forming a functional microdomain with inositol 1,4,5-trisphosphate receptors (InsP(3)R) that controls intracellular Ca2+ in a restricted subplasmalemmal space. The following data obtained in control denuded oocytes are consistent with this view: (i) reverse transcription-PCR revealed that the oocyte expresses two transcripts for the NCX1 and NCX3 isoforms; (ii) immunofluorescence experiments showed that native NCX1 and InsP(3)Rs are largely codistributed in discrete areas of the plasma membrane in close apposition to the cortical endoplasmic reticulum shell; (iii) when stimulated by rabbit serum, which elevates intracellular Ca2+ mediated by InsP(3), voltage-clamped oocytes display a large and transient inward Ca2+-activated chloride current, I-Cl(Ca), as a result of the Ca2+ rise at the inner surface membrane; (iv) this current is significantly enhanced by KB-R7943 and by an extracellular sodium-depleted medium, two maneuvers that prevent "Ca2+ extrusion" via NCX; and ( v) blocking NCX enhanced the ICl(Ca) elicited by InsP(3) but not by Ca2+ photolysis in oocytes injected with the respective caged compounds. Moreover, overexpression of cardiac NCX1, confirmed by confocal microscopy, has functional consequences for the "Ca2+ influx" but not for the serum-elicited "Ca2+ efflux" mode of basal exchange activity and does not alter the number of endogenous NCX/InsP(3)Rs colocalization sites. Our results suggest that native NCX, because of its strategic position, may regulate InsP(3)-mediated Ca2+ signaling during the early phases of oocyte maturation and/or fertilization, and furthermore foreign cardiac protein is excluded from the Ca2+ microdomains surrounding the native NCX/InsP(3)Rs complex in the oocyte.	Univ Autonoma Madrid, Dept Farmacol, Fac Med, Madrid 28029, Spain; Univ Basque Country, Fac Med, Dept Neurociencias, Leioa 48940, Spain	Autonomous University of Madrid; University of Basque Country	Montiel, C (corresponding author), Univ Autonoma Madrid, Dept Farmacol, Fac Med, C Arzobispo Morcillo 4, Madrid 28029, Spain.	carmen.montiel@uam.es	Montiel, Carmen/L-1407-2017; Matute, Carlos/N-5559-2014; Andres-Mateos, Eva/B-4691-2008	Montiel, Carmen/0000-0003-4845-0484; Matute, Carlos/0000-0001-8672-711X; 				Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; BUSA WB, 1985, J CELL BIOL, V100, P1325, DOI 10.1083/jcb.100.4.1325; BUSA WB, 1985, J CELL BIOL, V101, P677, DOI 10.1083/jcb.101.2.677; Callamaras N, 1998, J PHYSIOL-LONDON, V511, P395, DOI 10.1111/j.1469-7793.1998.395bh.x; Callamaras N, 1999, J GEN PHYSIOL, V113, P199, DOI 10.1085/jgp.113.2.199; Demandolx D, 1997, J MICROSC-OXFORD, V185, P21, DOI 10.1046/j.1365-2818.1997.1470704.x; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FRANK JS, 1992, J CELL BIOL, V117, P337, DOI 10.1083/jcb.117.2.337; GOLDMAN WF, 1994, J NEUROSCI, V14, P5834; Golovina VA, 1996, GLIA, V16, P296; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; HAN JK, 1990, J CELL BIOL, V110, P1103, DOI 10.1083/jcb.110.4.1103; He CL, 1997, BIOL REPROD, V57, P1245, DOI 10.1095/biolreprod57.5.1245; He CL, 1999, BIOL REPROD, V61, P935, DOI 10.1095/biolreprod61.4.935; Herrero CJ, 1999, BRIT J PHARMACOL, V127, P1375, DOI 10.1038/sj.bjp.0702692; Herrero CJ, 2002, J NEUROSCI, V22, P377, DOI 10.1523/JNEUROSCI.22-02-00377.2002; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; IGUSA Y, 1983, J PHYSIOL-LONDON, V340, P611, DOI 10.1113/jphysiol.1983.sp014783; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; IWATA T, 1996, ANN NY ACAD SCI, V15, P37; JUHASZOVA M, 1994, AM J PHYSIOL, V266, pC234, DOI 10.1152/ajpcell.1994.266.1.C234; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; Kimura Y, 2001, J BIOL CHEM, V276, P15208, DOI 10.1074/jbc.M011588200; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; Machaty Z, 2002, BIOL REPROD, V67, P1133, DOI 10.1095/biolreprod67.4.1133; Marchant JS, 2002, AM J PHYSIOL-CELL PH, V282, pC1374, DOI 10.1152/ajpcell.00446.2001; Marchant JS, 2001, BRIT J PHARMACOL, V132, P1396, DOI 10.1038/sj.bjp.0703922; MILEDI R, 1984, J PHYSIOL-LONDON, V357, P173, DOI 10.1113/jphysiol.1984.sp015495; MILEDI R, 1989, J PHYSIOL-LONDON, V416, P601, DOI 10.1113/jphysiol.1989.sp017780; MILEDI R, 1982, EMBO J, V1, P1307, DOI 10.1002/j.1460-2075.1982.tb01315.x; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; Montiel C, 1997, EUR J PHARMACOL, V332, P183, DOI 10.1016/S0014-2999(97)01073-X; MOORE EDW, 1993, NATURE, V365, P657, DOI 10.1038/365657a0; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NUCCITELLI R, 1993, DEV BIOL, V158, P200, DOI 10.1006/dbio.1993.1179; Ottolia M, 2001, J BIOL CHEM, V276, P19603, DOI 10.1074/jbc.M101489200; PARKER I, 1987, PROC R SOC SER B-BIO, V232, P59, DOI 10.1098/rspb.1987.0061; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARYS JB, 1992, J BIOL CHEM, V267, P18776; Pepperell JR, 1999, BIOL REPROD, V60, P1137, DOI 10.1095/biolreprod60.5.1137; Pintado AJ, 2000, BRIT J PHARMACOL, V130, P1893, DOI 10.1038/sj.bjp.0703519; Runft LL, 1999, DEV BIOL, V214, P399, DOI 10.1006/dbio.1999.9415; SCHLIEF T, 1995, J PHYSIOL-LONDON, V486, P123, DOI 10.1113/jphysiol.1995.sp020796; Snow P, 1996, DEV BIOL, V180, P108, DOI 10.1006/dbio.1996.0288; Sobolevsky AI, 1999, NEUROPHARMACOLOGY, V38, P1235, DOI 10.1016/S0028-3908(99)00040-4; STITH BJ, 1993, MOL BIOL CELL, V4, P435, DOI 10.1091/mbc.4.4.435; SUPPLISSON S, 1991, DEV BIOL, V145, P231, DOI 10.1016/0012-1606(91)90122-J; SWANN K, 1994, CELL CALCIUM, V15, P331, DOI 10.1016/0143-4160(94)90072-8; TIGYI G, 1990, P NATL ACAD SCI USA, V87, P1521, DOI 10.1073/pnas.87.4.1521; Watano T, 1996, BRIT J PHARMACOL, V119, P555, DOI 10.1111/j.1476-5381.1996.tb15708.x; ZERNICKAGOETZ M, 1995, J CELL SCI, V108, P469	59	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52414	52424		10.1074/jbc.M408872200	http://dx.doi.org/10.1074/jbc.M408872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15375168	hybrid			2022-12-25	WOS:000225493400086
J	Hearn, AR; de Haan, L; Pemberton, AJ; Hirst, TR; Rivett, AJ				Hearn, AR; de Haan, L; Pemberton, AJ; Hirst, TR; Rivett, AJ			Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HEAT-LABILE ENTEROTOXIN; DENDRITIC CELLS; CHOLERA-TOXIN; CROSS-PRESENTATION; ANTIGENIC PEPTIDE; LEUCINE AMINOPEPTIDASE; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; PROCESSING PATHWAY	The B-subunit component of Escherichia coli heat-labile enterotoxin ( EtxB), which binds to cell surface GM1 ganglioside receptors, was recently shown to be a highly effective vehicle for delivery of conjugated peptides into the major histocompatibility complex (MHC) class I pathway. In this study we have investigated the pathway of epitope delivery. The peptides used contained the epitope either located at the C terminus or with a C-terminal extension. Pretreatment of cells with cholesterol-disrupting agents blocked transport of EtxB conjugates to the Golgi/endoplasmic reticulum, but did not affect EtxB-mediated MHC class I presentation. Under these conditions, EtxB conjugates entered EEA1-positive early endosomes where peptides were cleaved and translocated into the cytosol. Endosome acidification was required for epitope presentation. Purified 20 S immunoproteasomes were able to generate the epitope from peptides in vitro, but 26 S proteasomes were not. Only presentation from the C-terminal extended peptide was proteasome-dependent in cells, and this was found to be significantly slower than presentation from peptides with the epitope at the C terminus. These results implicate the proteasome in the generation of the correct C terminus of the epitope and are consistent with proteasome-independent N-terminal trimming. Epitope presentation was blocked in a TAP-deficient cell line, providing further evidence that conjugated peptides enter the cytosol as well as demonstrating a requirement for the peptide transporter. Our findings demonstrate the utility of EtxB-mediated peptide delivery for rapid and efficient loading of MHC class I epitopes in several different cell types. Conjugated peptides are released from early endosomes into the cytosol where they gain access to proteasomes and TAP in the "classical" pathway of class I presentation.	Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Pathol & Microbiol, Bristol BS8 1TD, Avon, England	University of Bristol; University of Bristol	Rivett, AJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	j.rivett@bris.ac.uk						Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; Ballard JD, 1996, P NATL ACAD SCI USA, V93, P12531, DOI 10.1073/pnas.93.22.12531; Beninga J, 1998, J BIOL CHEM, V273, P18734, DOI 10.1074/jbc.273.30.18734; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Brooks P, 2000, BIOCHEM J, V352, P611, DOI 10.1042/0264-6021:3520611; Butz EA, 1998, J IMMUNOL, V160, P2139; Carbonetti NH, 1999, INFECT IMMUN, V67, P602, DOI 10.1128/IAI.67.2.602-607.1999; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; CHEN JW, 1986, BIOCHEM SOC SYMP, P97; Craiu A, 1997, P NATL ACAD SCI USA, V94, P10850, DOI 10.1073/pnas.94.20.10850; de Haan L, 2002, CURR OPIN DRUG DISC, V5, P269; de Haan L, 2002, INFECT IMMUN, V70, P3249, DOI 10.1128/IAI.70.6.3249-3258.2002; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Goldberg AL, 2002, MOL IMMUNOL, V39, P147, DOI 10.1016/S0161-5890(02)00098-6; Goletz TJ, 1997, P NATL ACAD SCI USA, V94, P12059, DOI 10.1073/pnas.94.22.12059; Gromme M, 2002, MOL IMMUNOL, V39, P181, DOI 10.1016/S0161-5890(02)00101-3; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Haicheur N, 2003, INT IMMUNOL, V15, P1161, DOI 10.1093/intimm/dxg118; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Loregian A, 1999, P NATL ACAD SCI USA, V96, P5221, DOI 10.1073/pnas.96.9.5221; Macagno A, 1999, EUR J IMMUNOL, V29, P4037, DOI 10.1002/(SICI)1521-4141(199912)29:12<4037::AID-IMMU4037>3.0.CO;2-T; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Millar DG, 2001, CELL MICROBIOL, V3, P311, DOI 10.1046/j.1462-5822.2001.00119.x; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nishioku T, 2002, J BIOL CHEM, V277, P4816, DOI 10.1074/jbc.M108382200; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Orlowski M, 2003, ARCH BIOCHEM BIOPHYS, V415, P1, DOI 10.1016/S0003-9861(03)00197-8; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Reidlinger J, 1997, J BIOL CHEM, V272, P24899, DOI 10.1074/jbc.272.40.24899; RICH DH, 1985, BIOCHEMISTRY-US, V24, P3165, DOI 10.1021/bi00334a014; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; ROCK KL, 1990, J IMMUNOL, V145, P804; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAINO T, 1988, J ANTIBIOT, V41, P220, DOI 10.7164/antibiotics.41.220; Saric T, 2002, NAT IMMUNOL, V3, P1169, DOI 10.1038/ni859; Saron MF, 1997, P NATL ACAD SCI USA, V94, P3314, DOI 10.1073/pnas.94.7.3314; Seifert U, 2003, NAT IMMUNOL, V4, P375, DOI 10.1038/ni905; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Shogomori H, 2001, J NEUROCHEM, V78, P991, DOI 10.1046/j.1471-4159.2001.00489.x; Smith DC, 2002, TRAFFIC, V3, P697, DOI 10.1034/j.1600-0854.2002.31001.x; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; TAYLOR A, 1993, BIOCHEMISTRY-US, V32, P784, DOI 10.1021/bi00054a007; Wang EW, 2000, P NATL ACAD SCI USA, V97, P9990, DOI 10.1073/pnas.180328897; Wolf AA, 2002, J BIOL CHEM, V277, P16249, DOI 10.1074/jbc.M109834200; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; YANG Y, 1992, J BIOL CHEM, V267, P11669; York IA, 2003, IMMUNITY, V18, P429, DOI 10.1016/S1074-7613(03)00058-X	55	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51315	51322		10.1074/jbc.M408279200	http://dx.doi.org/10.1074/jbc.M408279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15342647	hybrid			2022-12-25	WOS:000225355800081
J	Olson, GE; Winfrey, VP; NagDas, SK; Melner, MH				Olson, GE; Winfrey, VP; NagDas, SK; Melner, MH			Region-specific expression and secretion of the fibrinogen-related protein, fgl2, by epithelial cells of the hamster epididymis and its role in disposal of defective spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM QUALITY-CONTROL; PROTHROMBINASE ACTIVITY; SPONTANEOUS-ABORTION; VIRAL-HEPATITIS; GENE-EXPRESSION; O-GLYCOSYLATION; T-LYMPHOCYTES; IFN-GAMMA; UBIQUITIN; IDENTIFICATION	The cauda epididymidis functions in the storage and protection of mature, fertile spermatozoa. We previously identified a region-specific secretory glycoprotein ( termed HEP64) of the hamster proximal cauda epididymidis that specifically bound and coated the nonviable, but not the viable, spermatozoa within the epididymal lumen. In this study we employed expression screening of a hamster epididymal cDNA library to obtain the full-length sequence of HEP64 and to identify it as the fibrinogen-like protein fgl2. Northern blot analysis demonstrated that fgl2 mRNA is highly expressed by the proximal cauda epididymidis in comparison to other hamster tissues examined, and, in situ hybridization analysis of the epididymis revealed that fgl2 mRNA exhibited a region- and principal cell-specific expression pattern. Immunohistochemistry confirmed the association of fgl2 with abnormal spermatozoa in the cauda epididymidis and revealed smaller fgl2-containing particles. Immunoelectron microscopy revealed that fgl2 was distributed throughout an amorphous, "death cocoon," complex assembled onto abnormal spermatozoa and that the smaller fgl2 aggregates consisted of the amorphous material with embedded sperm fragments, organelles, and membrane vesicles. A protocol was developed to isolate an enriched death cocoon fraction. SDS-PAGE and microsequence analyses revealed that the M-r 64,000 fgl2 monomer was assembled into two disulfide-linked oligomers of M-r 260,000 and 280,000. These data demonstrate that the epididymis possesses a specific mechanism to identify and envelop defective spermatozoa with a protein complex containing the fibrinogen-like protein fgl2. We propose that this represents an important protective mechanism not only to shield the viable sperm population from potentially deleterious enzymes released by dying spermatozoa but also to prevent the release of sperm proteins that could initiate an immune response if they escaped the epididymal environment.	Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Obstet & Gynecol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Olson, GE (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	gary.olson@vanderbilt.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020419] Funding Source: NIH RePORTER; NICHD NIH HHS [HD20419] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Bailey R, 1999, MOL CELL ENDOCRINOL, V151, P17, DOI 10.1016/S0303-7207(99)00016-7; Barroso G, 2000, HUM REPROD, V15, P1338, DOI 10.1093/humrep/15.6.1338; BEDFORD JM, 1975, HDB PHYSL, P303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan CWY, 2003, J IMMUNOL, V170, P4036, DOI 10.4049/jimmunol.170.8.4036; Chan CWY, 2002, J IMMUNOL, V168, P5170, DOI 10.4049/jimmunol.168.10.5170; Clark DA, 2001, MOL HUM REPROD, V7, P185, DOI 10.1093/molehr/7.2.185; Clark DA, 1999, AM J REPROD IMMUNOL, V42, P37; COOPER TG, 1977, AM J ANAT, V149, P93, DOI 10.1002/aja.1001490107; Cooper TG, 2002, J CELL SCI, V115, P5; CORNWALL GA, 1992, MOL ENDOCRINOL, V6, P1653, DOI 10.1210/me.6.10.1653; Dahl MR, 2001, IMMUNITY, V15, P127, DOI 10.1016/S1074-7613(01)00161-3; Ding JW, 1997, J VIROL, V71, P9223, DOI 10.1128/JVI.71.12.9223-9230.1997; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P1563, DOI 10.1002/pro.5560011204; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; GLOVER TD, 1961, NATURE, V190, P185, DOI 10.1038/190185b0; Hancock WW, 2004, P NATL ACAD SCI USA, V101, P3005, DOI 10.1073/pnas.0308369101; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Hinton BT, 1996, CURR TOP DEV BIOL, V33, P61, DOI 10.1016/S0070-2153(08)60337-3; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; Jervis KM, 2001, BIOL REPROD, V65, P696, DOI 10.1095/biolreprod65.3.696; Jones R, 1998, J REPROD FERTIL, P73; Jones RC, 1999, INT J ANDROL, V22, P57; Kirchhoff C, 1998, ANDROLOGIA, V30, P225; Kirchhoff C, 1999, INT REV CYTOL, V188, P133; Knackstedt M, 2001, AM J REPROD IMMUNOL, V46, P196, DOI 10.1034/j.1600-0897.2001.d01-3.x; KOYAMA T, 1987, P NATL ACAD SCI USA, V84, P1609, DOI 10.1073/pnas.84.6.1609; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFUSE WP, 1995, CELL IMMUNOL, V163, P187, DOI 10.1006/cimm.1995.1115; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Levy GA, 2000, AM J PATHOL, V156, P1217, DOI 10.1016/S0002-9440(10)64992-9; Marazzi S, 1998, J IMMUNOL, V161, P138; Marsden PA, 2003, J CLIN INVEST, V112, P58, DOI 10.1172/JCI200318114; Martan J., 1969, Biology of Reproduction Suppl, VNo. 1, P134, DOI 10.1095/biolreprod1.Supplement_1.134; NagDas SK, 2000, BIOL REPROD, V63, P1428, DOI 10.1095/biolreprod63.5.1428; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLSON GE, 1988, BIOL REPROD, V39, P1145, DOI 10.1095/biolreprod39.5.1145; Olson GE, 1998, CELL TISSUE RES, V293, P489, DOI 10.1007/s004410051141; Olson GE, 2003, MICROSC RES TECHNIQ, V61, P46, DOI 10.1002/jemt.10316; ORGEBINCRIST MC, 1975, HDB PHYSL 7, P319; PANOSKALTSISMORTARI A, 1995, BIOTECHNIQUES, V18, P300; PARR RL, 1995, J VIROL, V69, P5033, DOI 10.1128/JVI.69.8.5033-5038.1995; RUEGG C, 1995, GENE, V160, P257, DOI 10.1016/0378-1119(95)00240-7; Rychlik DF, 2003, J SOC GYNECOL INVEST, V10, P67, DOI 10.1016/S1071-5576(02)00252-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwartz DC, 2003, TRENDS BIOCHEM SCI, V28, P321, DOI 10.1016/S0968-0004(03)00113-0; Simeone FA, 1931, J EXP BIOL, V8, P163; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P88, DOI 10.1002/jemt.10319; Sutovsky P, 2001, J CELL SCI, V114, P1665; Sutovsky P, 2002, MOL REPROD DEV, V61, P406, DOI 10.1002/mrd.10101; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISSENBERG R, 1994, INT J ANDROL, V17, P256, DOI 10.1111/j.1365-2605.1994.tb01251.x; Yuwaraj S, 2001, GENOMICS, V71, P330, DOI 10.1006/geno.2000.6444	61	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51266	51274		10.1074/jbc.M410485200	http://dx.doi.org/10.1074/jbc.M410485200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15377663	hybrid			2022-12-25	WOS:000225355800075
J	Keil, U; Bonert, A; Marques, CA; Scherping, I; Weyermann, JR; Strosznajder, JB; Muller-Spahn, F; Haass, C; Czech, C; Pradier, L; Muller, WE; Eckert, A				Keil, U; Bonert, A; Marques, CA; Scherping, I; Weyermann, JR; Strosznajder, JB; Muller-Spahn, F; Haass, C; Czech, C; Pradier, L; Muller, WE; Eckert, A			Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; GAMMA-SECRETASE INHIBITOR; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; OXIDATIVE STRESS; A-BETA; PLAQUE-FORMATION; CELL-DEATH; IN-VITRO; PEPTIDE	Increasing evidence suggests an important role of mitochondrial dysfunction in the pathogenesis of Alzheimer's disease. Thus, we investigated the effects of acute and chronic exposure to increasing concentrations of amyloid beta(Abeta) on mitochondrial function and nitric oxide (NO) production in vitro and in vivo. Our data demonstrate that PC12 cells and human embryonic kidney cells bearing the Swedish double mutation in the amyloid precursor protein gene (APPsw), exhibiting substantial Abeta levels, have increased NO levels and reduced ATP levels. The inhibition of intracellular Abeta production by a functional gamma-secretase inhibitor normalizes NO and ATP levels, indicating a direct involvement of Abeta in these processes. Extracellular treatment of PC12 cells with comparable Abeta concentrations only leads to weak changes, demonstrating the important role of intracellular Abeta. In 3-month-old APP transgenic (tg) mice, which exhibit no plaques but already detectable Abeta levels in the brain, reduced ATP levels can also be observed showing the in vivo relevance of our findings. Moreover, we could demonstrate that APP is present in the mitochondria of APPsw PC12 cells. This presence might be directly involved in the impairment of cytochrome c oxidase activity and depletion of ATP levels in APPsw PC12 cells. In addition, APPsw human embryonic kidney cells, which produce 20-fold increased Abeta levels compared with APPsw PC12 cells, and APP tg mice already show a significantly decreased mitochondrial membrane potential under basal conditions. We suggest a hypothetical sequence of pathogenic steps linking mutant APP expression and amyloid production with enhanced NO production and mitochondrial dysfunction finally leading to cell death.	Goethe Univ Frankfurt, Bioctr, Dept Pharmacol, D-60439 Frankfurt, Germany; Goethe Univ Frankfurt, Bioctr, Dept Pharmaceut Technol, D-60439 Frankfurt, Germany; Polish Acad Sci, Med Res Ctr, Dept Cellular Signaling, PL-02106 Warsaw, Poland; Psychiatr Univ Clin, Neurobiol Res Lab, CH-4025 Basel, Switzerland; Adolf Butenandt Inst, Dept Biochem, D-80336 Munich, Germany; Aventis Pharma Res & Dev, F-94403 Vitry Sur Seine, France	Goethe University Frankfurt; Goethe University Frankfurt; Polish Academy of Sciences; University of Munich; Sanofi-Aventis; Sanofi France	Eckert, A (corresponding author), Goethe Univ Frankfurt, Bioctr, Dept Pharmacol, Bldg N260,Marie Curie Str 9, D-60439 Frankfurt, Germany.	A.Eckert@em.uni-frankfurt.de		Czech, Christian/0000-0001-7746-0134; Marques, Celio/0000-0002-8438-2354; Eckert, Anne/0000-0002-9341-3669; Muller, Werner E.G./0000-0002-8223-3689; Strosznajder, Joanna/0000-0002-6213-1212				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Anandatheerthavarada HK, 2003, J CELL BIOL, V161, P41, DOI 10.1083/jcb.200207030; Babu BR, 1998, J BIOL CHEM, V273, P8882, DOI 10.1074/jbc.273.15.8882; Baracca A, 2003, BBA-BIOENERGETICS, V1606, P137, DOI 10.1016/S0005-2728(03)00110-5; Bayer TA, 2001, BRAIN PATHOL, V11, P1; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; Blass JP, 2002, J ALZHEIMERS DIS, V4, P225, DOI 10.3233/JAD-2002-4312; Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Canevari L, 1999, FEBS LETT, V457, P131, DOI 10.1016/S0014-5793(99)01028-5; Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2; Casley CS, 2002, NEUROBIOL DIS, V10, P258, DOI 10.1006/nbdi.2002.0516; Casley CS, 2002, J NEUROCHEM, V80, P91, DOI 10.1046/j.0022-3042.2001.00681.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Christen Y, 2000, AM J CLIN NUTR, V71, p621S, DOI 10.1093/ajcn/71.2.621s; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; de la Monte SM, 2003, LAB INVEST, V83, P287, DOI 10.1097/01.LAB.0000056995.07053.C0; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eckert A, 2001, J NEUROSCI RES, V64, P183, DOI 10.1002/jnr.1064; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gibson GE, 1998, J NEURAL TRANSM, V105, P855, DOI 10.1007/s007020050099; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Gottlieb RA, 2002, METHODS, V26, P341, DOI 10.1016/S1046-2023(02)00040-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hartmann T, 1999, EUR ARCH PSY CLIN N, V249, P291, DOI 10.1007/s004060050102; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; Kienlen-Campard P, 2002, J BIOL CHEM, V277, P15666, DOI 10.1074/jbc.M200887200; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lanz TA, 2003, J PHARMACOL EXP THER, V305, P864, DOI 10.1124/jpet.102.048280; Law A, 2001, BRAIN RES REV, V35, P73, DOI 10.1016/S0165-0173(00)00051-5; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; Marques CA, 2003, J BIOL CHEM, V278, P28294, DOI 10.1074/jbc.M212265200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Maurer I, 2000, NEUROBIOL AGING, V21, P455, DOI 10.1016/S0197-4580(00)00112-3; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; PARKER WD, 1994, NEUROLOGY, V44, P1086, DOI 10.1212/WNL.44.6.1086; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Rasmussen UF, 2000, MOL CELL BIOCHEM, V208, P37, DOI 10.1023/A:1007046028132; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Sarti Paolo, 2003, Ital J Biochem, V52, P37; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Smith MA, 1997, J NEUROSCI, V17, P2653; STOLL L, 1992, NEUROBIOL AGING, V13, P39, DOI 10.1016/0197-4580(92)90006-J; Swerdlow RH, 1997, NEUROLOGY, V49, P918, DOI 10.1212/WNL.49.4.918; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; van Gurp M, 2003, BIOCHEM BIOPH RES CO, V304, P487, DOI 10.1016/S0006-291X(03)00621-1; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Wirths O, 2002, BRAIN PATHOL, V12, P275, DOI 10.1111/j.1750-3639.2002.tb00442.x; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	78	247	260	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50310	50320		10.1074/jbc.M405600200	http://dx.doi.org/10.1074/jbc.M405600200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371443	hybrid			2022-12-25	WOS:000225229500094
J	Benjannet, S; Rhainds, D; Essalmani, R; Mayne, J; Wickham, L; Jin, WJ; Asselin, MC; Hamelin, J; Varret, M; Allard, D; Trillard, M; Abifadel, M; Tebon, A; Attie, AD; Rader, DJ; Boileau, C; Brissette, L; Chretien, M; Prat, A; Seidah, NG				Benjannet, S; Rhainds, D; Essalmani, R; Mayne, J; Wickham, L; Jin, WJ; Asselin, MC; Hamelin, J; Varret, M; Allard, D; Trillard, M; Abifadel, M; Tebon, A; Attie, AD; Rader, DJ; Boileau, C; Brissette, L; Chretien, M; Prat, A; Seidah, NG			NARC-1/PCSK9 and its natural mutants - Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE; FAMILIAL HYPERCHOLESTEROLEMIA; MEDIATED ENDOCYTOSIS; PROHORMONE CONVERTASES; PROTEIN; PCSK9; MUTATIONS; BINDING; MICE	The discovery of autosomal dominant hypercholesterolemic patients with mutations in the PCSK9 gene, encoding the proprotein convertase NARC-1, resulting in the missense mutations suggested a role in low density lipoprotein (LDL) metabolism. We show that the endoplasmic reticulum-localized proNARC-1 to NARC-1 zymogen conversion is Ca2+-independent and that within the zymogen autocatalytic processing site SS (V) under bar FA (Q) under bar down arrowSI (P) under bar Val at P4 and Pro at P3' are critical. The S127R and D374Y mutations result in similar to50-60% and greater than or equal to98% decrease in zymogen processing, respectively. In contrast, the double [D374Y+N157K], F216L, and R218S natural mutants resulted in normal zymogen processing. The cell surface LDL receptor (LDLR) levels are reduced by 35% in lymphoblasts of S127R patients. The LDLR levels are also reduced in stable HepG2 cells overexpressing NARC-1 or its natural mutant S127R, and this reduction is abrogated in the presence of 5 mM ammonium chloride, suggesting that overexpression of NARC-1 increases the turnover rate of the LDLR. Adenoviral expression of wild type human NARC-1 in mice resulted in a maximal similar to9-fold increase in circulating LDL cholesterol, while in LDLR(-/-) mice a delayed similar to2-fold increase in LDL cholesterol was observed. In conclusion, NARC-1 seems to affect both the level of LDLR and that of circulating apoB-containing lipoproteins in an LDLR-dependent and -independent fashion.	Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ H2W 1R7, Canada; Ottawa Hlth Res Inst, Dis Ageing Unit, Reg Prot Chem Ctr, Ottawa, ON K1Y 4E9, Canada; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Paris 05, APHP, Hop Necker Enfants Malad, INSERM,U383, F-75743 Paris 15, France; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Quebec, Dept Sci Biol, Montreal, PQ H3C 3P8, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Ottawa; Ottawa Hospital Research Institute; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Wisconsin System; University of Wisconsin Madison; University of Quebec; University of Quebec Montreal	Seidah, NG (corresponding author), Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	seidahn@ircm.qc.ca	Seidah, Nabil/I-3596-2013; Abifadel, Marianne/ABH-5370-2020; boileau, catherine/M-4482-2017; Prat, Annik/S-6757-2018; VARRET, Mathilde/C-2279-2016	Seidah, Nabil/0000-0001-6503-9342; boileau, catherine/0000-0002-0371-7539; Prat, Annik/0000-0002-8007-5277; VARRET, Mathilde/0000-0001-9261-1551; ABIFADEL, Marianne/0000-0001-7645-8323; ALLARD, Delphine/0000-0001-7534-8982; CHRETIEN, Michel/0000-0002-8588-4460	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056593] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56593] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Beisswanger R, 1998, P NATL ACAD SCI USA, V95, P11134, DOI 10.1073/pnas.95.19.11134; BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; BRAYDEN DJ, 1989, BRIT J PHARMACOL, V98, P809, DOI 10.1111/j.1476-5381.1989.tb14609.x; Brissette L, 1996, BIOCHEM J, V318, P841, DOI 10.1042/bj3180841; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Conesa M, 2003, BIOCHEM J, V370, P703, DOI 10.1042/BJ20021301; DeBie I, 1996, J CELL BIOL, V135, P1261, DOI 10.1083/jcb.135.5.1261; Dubuc G, 2004, ARTERIOSCL THROM VAS, V24, P1454, DOI 10.1161/01.ATV.0000134621.14315.43; Elagoz A, 2002, J BIOL CHEM, V277, P11265, DOI 10.1074/jbc.M109011200; GEKLE M, 1995, AM J PHYSIOL-RENAL, V268, pF899, DOI 10.1152/ajprenal.1995.268.5.F899; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gregersen N, 2001, J INHERIT METAB DIS, V24, P189, DOI 10.1023/A:1010319001722; Hatch F T, 1968, Adv Lipid Res, V6, P1; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Jackson RS, 2003, J CLIN INVEST, V112, P1550, DOI 10.1172/JCI18784; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jin WJ, 2003, J CLIN INVEST, V111, P357, DOI [10.1172/JCI16146, 10.1172/JCI200316146]; KINGUNDERWOOD L, 1991, CLIN GENET, V40, P17; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Kunst CB, 1997, NAT GENET, V15, P91, DOI 10.1038/ng0197-91; LANGER T, 1972, J CLIN INVEST, V51, P1528, DOI 10.1172/JCI106949; Leren TP, 2004, CLIN GENET, V65, P419, DOI 10.1111/j.0009-9163.2004.0238.x; LOUIE LG, 1991, AM J HUM GENET, V48, P637; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Maxwell KN, 2003, J LIPID RES, V44, P2109, DOI 10.1194/jlr.M300203-JLR200; Michaely P, 2004, J BIOL CHEM, V279, P34023, DOI 10.1074/jbc.M405242200; Naureckiene S, 2003, ARCH BIOCHEM BIOPHYS, V420, P55, DOI 10.1016/j.abb.2003.09.011; Ouguerram K, 2004, ARTERIOSCL THROM VAS, V24, P1448, DOI 10.1161/01.ATV.0000133684.77013.88; Rader DJ, 2003, J CLIN INVEST, V111, P1795, DOI 10.1172/JCI200318925; REED PW, 1972, J BIOL CHEM, V247, P6970; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Seidah NG, 2002, ESSAYS BIOCHEM, V38, P79, DOI 10.1042/bse0380079; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1999, P NATL ACAD SCI USA, V96, P1321, DOI 10.1073/pnas.96.4.1321; SEIDAH NG, 2001, ENZYMES CO POSTTRANS, P237; SELDAH NG, 2003, P NATL ACAD SCI USA, V100, P928; Shioji K, 2004, J HUM GENET, V49, P109, DOI 10.1007/s10038-003-0114-3; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SOUTAR AK, 1992, J INTERN MED, V231, P633, DOI 10.1111/j.1365-2796.1992.tb01252.x; Taylor NA, 2003, FASEB J, V17, P1215, DOI 10.1096/fj.02-0831rev; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; Timms KM, 2004, HUM GENET, V114, P349, DOI 10.1007/s00439-003-1071-9; Tremblay AJ, 2004, J LIPID RES, V45, P866, DOI 10.1194/jlr.M300448-JLR200; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; Varret M, 1999, AM J HUM GENET, V64, P1378, DOI 10.1086/302370; Wang L, 1997, J BIOL CHEM, V272, P27644, DOI 10.1074/jbc.272.44.27644; Yang J, 2001, P NATL ACAD SCI USA, V98, P13607, DOI 10.1073/pnas.201524598; YOSHIMURA A, 1987, J BIOL CHEM, V262, P13299; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107	62	488	546	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48865	48875		10.1074/jbc.M409699200	http://dx.doi.org/10.1074/jbc.M409699200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358785	hybrid			2022-12-25	WOS:000225098100048
J	Hu, P; Han, Z; Couvillon, AD; Exton, JH				Hu, P; Han, Z; Couvillon, AD; Exton, JH			Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSLATIONAL CONTROL; CASPASE ACTIVATION; INDUCED APOPTOSIS; SURVIVAL; XIAP; AKT; PHOSPHORYLATION	Endoplasmic reticulum (ER) stress has been implicated in the pathogenesis of many diseases and in cancer therapy. Although the unfolded protein response is known to alleviate ER stress by reducing the accumulation of mis-folded proteins, the exact survival elements and their downstream signaling pathways that directly counteract ER stress-stimulated apoptotic signaling remain elusive. Here, we have shown that endogenous Akt and ERK are rapidly activated and act as downstream effectors of phosphatidylinositol 3-kinase in thapsigargin- or tunica-mycin-induced ER stress. Introduction of either dominant-negative Akt or MEK1 or the inhibitors LY294002 and U0126 sensitized cells to ER stress-induced cell death in different cell types. Reverse transcription-PCR analysis of gene expression during ER stress revealed that cIAP-2 and XIAP, members of the IAP family of potent caspase suppressors, were strongly induced. Transcription of cIAP-2 and XIAP was up-regulated by the phosphatidylinositol 3-kinase/ Akt pathway as shown by its reversal by dominant-negative Akt or LY294002. Ablation of these IAPs by RNA interference sensitized cells to ER stress-induced death, which was reversed by the caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone. The protective role of IAPs in ER stress coincided with Smac release from mitochondria to the cytosol. Furthermore, it was shown that mTOR was not required for Akt-mediated survival. These results represent the first demonstration that activation of endogenous Akt/IAPs and MEK/ERK plays a critical role in controlling cell survival by resisting ER stress-induced cell death signaling.	Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Howard Hughes Med Inst, 702 Light Hall, Nashville, TN 37232 USA.	john.exton@vanderbilt.edu						Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; Breckenridge DG, 2003, ONCOGENE, V22, P8608, DOI 10.1038/sj.onc.1207108; Buckley BJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1298, DOI 10.1152/ajpcell.1997.273.4.C1298; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chung J, 2002, J CELL BIOL, V158, P165, DOI 10.1083/jcb.200112015; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Liu CY, 2003, J CELL SCI, V116, P1861, DOI 10.1242/jcs.00408; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Perez-Garcia MJ, 2004, J BIOL CHEM, V279, P6132, DOI 10.1074/jbc.M308367200; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Potts PR, 2003, J CELL BIOL, V163, P789, DOI 10.1083/jcb.200307130; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Song L, 2002, J BIOL CHEM, V277, P44701, DOI 10.1074/jbc.M206047200; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tardif KD, 2004, J BIOL CHEM, V279, P17158, DOI 10.1074/jbc.M312144200; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Whitlock BB, 2000, J CELL BIOL, V151, P1305, DOI 10.1083/jcb.151.6.1305; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	62	285	300	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49420	49429		10.1074/jbc.M407700200	http://dx.doi.org/10.1074/jbc.M407700200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339911	hybrid			2022-12-25	WOS:000225098100111
J	Jeffery, L; Nakielny, S				Jeffery, L; Nakielny, S			Components of the DNA methylation system of chromatin control are RNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; RETT-SYNDROME; TRANSCRIPTIONAL REPRESSION; MAMMALIAN DEVELOPMENT; CHROMOSOMAL PROTEIN; PATERNAL GENOME; GENE-EXPRESSION; MECP2; DOMAIN; RECOGNITION	The view that autosomal gene expression is controlled exclusively by protein trans-acting factors has been challenged recently by the identification of RNA molecules that regulate chromatin. In the majority of cases where RNA molecules are implicated in DNA control, the molecular mechanisms are unknown, in large part because the RNA.protein complexes are uncharacterized. Here, we identify a novel set of RNA-binding proteins that are well known for their function in chromatin regulation. The RNA-interacting proteins are components of the mammalian DNA methylation system. Genomic methylation controls chromatin in the context of transposon silencing, imprinting, and X chromosome dosage compensation. DNA methyltransferases (DNMTs) catalyze methylation of cytosines in CGs. The methyl-CGs are recognized by methyl-DNA-binding domain (MBD) proteins, which recruit histone deacetylases and chromatin remodeling proteins to effect silencing. We show that a subset of the DNMTs and MBD proteins can form RNA.protein complexes. We characterize the MBD protein RNA-binding activity and show that it is distinct from the methyl-CG-binding domain and mediates a high affinity interaction with RNA. The RNA and methyl-CG binding properties of the MBD proteins are mutually exclusive. We speculate that DNMTs and MBD proteins allow RNA molecules to participate in DNA methylation-mediated chromatin control.	Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, London WC2A 3PX, England	Cancer Research UK	Nakielny, S (corresponding author), Canc Res UK, London Res Inst, Lincolns Inn Fields Labs, 44 Lincolns Inn Fields, London WC2A 3PX, England.	Sara.Nakielny@cancer.org.uk						Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Ballestar E, 2000, BIOCHEMISTRY-US, V39, P7100, DOI 10.1021/bi0001271; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cassiday LA, 2002, NUCLEIC ACIDS RES, V30, P4118, DOI 10.1093/nar/gkf512; Chen RZ, 2001, NAT GENET, V27, P327, DOI 10.1038/85906; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Feng Q, 2001, GENE DEV, V15, P827; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Free A, 2001, J BIOL CHEM, V276, P3353, DOI 10.1074/jbc.M007224200; Fribourg S, 2003, NAT STRUCT BIOL, V10, P433, DOI 10.1038/nsb926; Fujita N, 2003, J BIOL CHEM, V278, P24132, DOI 10.1074/jbc.M302283200; Fujita N, 2003, MOL CELL BIOL, V23, P2834, DOI 10.1128/MCB.23.8.2834-2843.2003; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Guy J, 2001, NAT GENET, V27, P322, DOI 10.1038/85899; Hall KB, 2002, CURR OPIN STRUC BIOL, V12, P283, DOI 10.1016/S0959-440X(02)00323-8; Hata K, 2002, DEVELOPMENT, V129, P1983; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; Howell CY, 2001, CELL, V104, P829, DOI 10.1016/S0092-8674(01)00280-X; Hutchins AS, 2002, MOL CELL, V10, P81, DOI 10.1016/S1097-2765(02)00564-6; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jorgensen HF, 2004, MOL CELL BIOL, V24, P3387, DOI 10.1128/MCB.24.8.3387-3395.2004; Kaneda M, 2004, NATURE, V429, P900, DOI 10.1038/nature02633; Kielkopf CL, 2001, CELL, V106, P595, DOI 10.1016/S0092-8674(01)00480-9; Klose R, 2003, SCIENCE, V302, P793, DOI 10.1126/science.1091762; Kriaucionis S, 2003, HUM MOL GENET, V12, pR221, DOI 10.1093/hmg/ddg286; Lau CK, 2003, CURR BIOL, V13, P933, DOI 10.1016/S0960-9822(03)00328-2; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Lu D, 2003, NATURE, V426, P96, DOI 10.1038/nature02088; Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; Meehan RR, 2003, SEMIN CELL DEV BIOL, V14, P53, DOI 10.1016/S1084-9521(02)00137-4; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nan XS, 1996, MOL CELL BIOL, V16, P414; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Niessing D, 2000, MOL CELL, V5, P395, DOI 10.1016/S1097-2765(00)80434-7; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Siomi H, 1997, CURR OPIN GENET DEV, V7, P345, DOI 10.1016/S0959-437X(97)80148-7; Stancheva I, 2003, MOL CELL, V12, P425, DOI 10.1016/S1097-2765(03)00276-4; Tudor M, 2002, P NATL ACAD SCI USA, V99, P15536, DOI 10.1073/pnas.242566899; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	71	129	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49479	49487		10.1074/jbc.M409070200	http://dx.doi.org/10.1074/jbc.M409070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15342650	hybrid			2022-12-25	WOS:000225098100118
J	Korencic, D; Polycarpo, C; Weygand-Durasevic, I; Soll, D				Korencic, D; Polycarpo, C; Weygand-Durasevic, I; Soll, D			Differential modes of transfer RNA(Ser) recognition in Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SACCHAROMYCES-CEREVISIAE TRNA(LEU); ACCEPTOR IN-VITRO; ESCHERICHIA-COLI; IDENTITY DETERMINANTS; TRANSFER RNA(TYR); CRYSTAL-STRUCTURE; HUMAN TRNA(SER); ELEMENTS; NUCLEOTIDES	Two dissimilar seryl-transfer RNA (tRNA) synthetases (SerRSs) exist in Methanosarcina barkeri, one of bacterial type and the other resembling SerRSs present only in some methanogenic archaea. To investigate the requirements of these enzymes for tRNA(Ser) recognition, serylation of variant transcripts of M. barkeri tRNA(Ser) was kinetically analyzed in vitro with pure enzyme preparations. Characteristically for the serine system, the length of the variable arm was shown to be crucial for both enzymes, as was the identity of the discriminator base (G73). Moreover, a novel determinant for the specific tRNA(Ser) recognition was identified as the anticodon stem base pair G30:C40; its contribution to the efficiency of serylation was remarkable for both SerRSs. However, despite these similarities, the two SerRSs do not possess a uniform mode of tRNA(Ser) recognition, and additional determinants are necessary for serylation specificity by the methanogenic enzyme. In particular, the methanogenic SerRS relies on G1:C72 identity and on the number of unpaired nucleotides at the base of the variable stem for tRNA(Ser) recognition, unlike its bacterial type counterpart. We propose that such a distinction between the two enzymes in tRNA(Ser) identity determinants reflects their evolutionary pathways, hence attesting to their diversity.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Zagreb, Fac Sci, Dept Chem, Zagreb 10000, Croatia; Rudjer Boskovic Inst, Zagreb 10000, Croatia	Yale University; Yale University; University of Zagreb; Rudjer Boskovic Institute	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu	Polycarpo, Carla R/G-2832-2011	Polycarpo, Carla/0000-0001-9663-3563				ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Ahel I, 2002, J BIOL CHEM, V277, P34743, DOI 10.1074/jbc.M206928200; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOCK A, 2004, AMINOACYL TRNA SYNTH, P320; BREITSCHOPF K, 1995, NUCLEIC ACIDS RES, V23, P3633, DOI 10.1093/nar/23.18.3633; Breitschopf K, 1996, NUCLEIC ACIDS RES, V24, P405, DOI 10.1093/nar/24.3.405; BREITSCHOPF K, 1994, EMBO J, V13, P3166, DOI 10.1002/j.1460-2075.1994.tb06615.x; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; Fechter P, 2001, EUR J BIOCHEM, V268, P761, DOI 10.1046/j.1432-1327.2001.01931.x; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; Himeno H, 1997, J MOL BIOL, V268, P704, DOI 10.1006/jmbi.1997.0991; Kim HS, 1998, J BACTERIOL, V180, P6446, DOI 10.1128/JB.180.24.6446-6449.1998; Korencic D, 2002, FOOD TECHNOL BIOTECH, V40, P255; Lenhard B, 1999, NUCLEIC ACIDS RES, V27, P721, DOI 10.1093/nar/27.3.721; MCCLAIN WH, 1993, FASEB J, V7, P72, DOI 10.1096/fasebj.7.1.8422977; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; Pallanck Leo, 1995, P371; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; Ruan BF, 2004, J BACTERIOL, V186, P8, DOI 10.1128/JB.186.1.8-14.2004; Saks ME, 1996, EMBO J, V15, P2843, DOI 10.1002/j.1460-2075.1996.tb00645.x; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Salazar JC, 2001, FEBS LETT, V491, P257, DOI 10.1016/S0014-5793(01)02214-1; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHATZ D, 1991, P NATL ACAD SCI USA, V88, P6132, DOI 10.1073/pnas.88.14.6132; Shimada N, 2001, J BIOL CHEM, V276, P46770, DOI 10.1074/jbc.M105150200; Soma A, 1996, J MOL BIOL, V263, P707, DOI 10.1006/jmbi.1996.0610; Soma A, 1999, J MOL BIOL, V293, P1029, DOI 10.1006/jmbi.1999.3219; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; UEDA T, 1992, NUCLEIC ACIDS RES, V20, P2217, DOI 10.1093/nar/20.9.2217; WEYGANDDURASEVIC I, 1994, J BACTERIOL, V176, P232; WEYGANDDURASEVIC I, 1993, EUR J BIOCHEM, V214, P869, DOI 10.1111/j.1432-1033.1993.tb17990.x; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589; Yaremchuk A, 2002, EMBO J, V21, P3829, DOI 10.1093/emboj/cdf373; YOKOGAWA T, 1991, NUCLEIC ACIDS RES, V19, P6101, DOI 10.1093/nar/19.22.6101; Yokogawa T, 2000, J BIOL CHEM, V275, P19913, DOI 10.1074/jbc.M908473199	47	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48780	48786		10.1074/jbc.M408753200	http://dx.doi.org/10.1074/jbc.M408753200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364939	hybrid			2022-12-25	WOS:000225098100037
J	Ost, TWB; Clark, JP; Anderson, JLR; Yellowlees, LJ; Daff, S; Chapman, SK				Ost, TWB; Clark, JP; Anderson, JLR; Yellowlees, LJ; Daff, S; Chapman, SK			4-Cyanopyridine, a versatile spectroscopic probe for cytochrome P450BM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA CYTOCHROME-P-450; FLAVOCYTOCHROME P-450 BM3; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; LIVER MICROSOMES; HEME; SPIN; BINDING; SUBSTRATE; COMPLEXES	The nitrogenous pi-acceptor ligand 4-cyanopyridine (4CNPy) exhibits reversible ligation to ferrous heme in the flavocytochrome P450 BM3 (K-d=1.8 muM for wild type P450 BM3) via its pyridine ring nitrogen. The reduced P450-4CNPy adduct displays unusual spectral properties that provide a useful spectroscopic handle to probe particular aspects of this P450. 4CNPy is competitively displaced upon substrate binding, allowing a convenient route to the determination of substrate dissociation constants for ferrous P450 highlighting an increase in P450 substrate affinity on heme reduction. For wild type P450 BM3, K-d(red)(laurate)=82.4 muM (cf. K-d(ox)=364 muM). In addition, an unusual spectral feature in the red region of the absorption spectrum of the reduced P450-4CNPy adduct is observed that can be assigned as a metal-to-ligand charge transfer (MLCT). It was discovered that the energy of this MLCT varies linearly with respect to the P450 heme reduction potential. By studying the energy of this MLCT for a series of BM3 active site mutants with differing reduction potential (E-m), the relationship E-MLCT=(3.53 x E-m)+17,005 cm(-1) was derived. The use of this ligand thus provides a quick and accurate method for predicting the heme reduction potentials of a series of P450 BM3 mutations using visible spectroscopy, without the requirement for redox potentiometry.	Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh	Chapman, SK (corresponding author), Univ Edinburgh, Dept Chem, W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	s.k.chapman@ed.ac.uk		Anderson, Ross/0000-0002-6796-0482				CHAMPION PM, 1975, BIOCHEMISTRY-US, V14, P4151, DOI 10.1021/bi00690a001; Cowart LA, 2001, ARCH BIOCHEM BIOPHYS, V387, P117, DOI 10.1006/abbi.2000.2246; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DEMONTELLANO PRO, 1995, CYTOCHROME P450 STRU, P473; DODSWORTH ES, 1986, CHEM PHYS LETT, V124, P152, DOI 10.1016/0009-2614(86)85135-1; FORD P, 1968, J AM CHEM SOC, V90, P1187, DOI 10.1021/ja01007a015; GRIFFIN BW, 1972, BIOCHEMISTRY-US, V11, P4740, DOI 10.1021/bi00775a017; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; LEVER ABP, 1990, INORG CHEM, V29, P1271, DOI 10.1021/ic00331a030; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; LOIDA PJ, 1993, BIOCHEMISTRY-US, V32, P11530, DOI 10.1021/bi00094a009; Miles CS, 2000, BBA-PROTEIN STRUCT M, V1543, P383, DOI 10.1016/S0167-4838(00)00236-3; Modi S, 1996, NAT STRUCT BIOL, V3, P414, DOI 10.1038/nsb0596-414; Munro AW, 1999, BIOCHEM SOC T, V27, P190, DOI 10.1042/bst0270190; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1962, J BIOL CHEM, V237, P1375; Ost TWB, 2003, J AM CHEM SOC, V125, P15010, DOI 10.1021/ja035731o; Ost TWB, 2001, BIOCHEMISTRY-US, V40, P13421, DOI 10.1021/bi010716m; POULOS TL, 1985, J BIOL CHEM, V260, P6122; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; SAFO MK, 1992, J AM CHEM SOC, V114, P7066, DOI 10.1021/ja00044a017; SAFO MK, 1994, J AM CHEM SOC, V116, P7760, DOI 10.1021/ja00096a037; SHARROCK M, 1976, BIOCHIM BIOPHYS ACTA, V420, P8, DOI 10.1016/0005-2795(76)90340-8; SLIGAR SG, 1979, BIOCHEM BIOPH RES CO, V90, P925, DOI 10.1016/0006-291X(79)91916-8; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; SONO M, 1982, J BIOL CHEM, V257, P8308; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; Tosha T, 2003, J BIOL CHEM, V278, P39809, DOI 10.1074/jbc.M304265200; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157	30	14	14	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48876	48882		10.1074/jbc.M408601200	http://dx.doi.org/10.1074/jbc.M408601200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364917	hybrid			2022-12-25	WOS:000225098100049
J	Pedley, KF; Martin, GB				Pedley, KF; Martin, GB			Identification of MAPKs and their possible MAPK kinase activators involved in the Pto-mediated defense response of tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-DISEASE RESISTANCE; INDUCED PROTEIN-KINASE; BACTERIAL SPECK DISEASE; SALICYLIC-ACID; CELL-DEATH; PATHOGEN INTERACTIONS; TRANSCRIPTION FACTORS; TRANSGENIC PLANTS; MOLECULAR-BASIS; TOBACCO	The Pto kinase mediates resistance to bacterial speck disease in tomato by activating host defenses upon recognition of Pseudomonas syringae pv. tomato strains expressing the AvrPto or AvrPtoB proteins. Previous gene-silencing experiments have indicated that mitogen activated protein kinase (MAPK) cascades play a key role downstream of the Pto kinase to activate host defense responses. Here we use biochemical methods to demonstrate that two tomato MAPKs, LeMPK2 and LeMPK3, are activated in leaves in a Pto-specific manner upon expression of AvrPto and AvrPtoB. We show that these same MAPKs are activated upon overexpression of LeMAPKKKalpha, a protein previously demonstrated to be involved in Pto-mediated immunity. We identified two phylogenetically unrelated MAPK kinases (LeMKK2 and LeMKK4) that when overexpressed in leaves elicit cell death and activate LeMPK2 and LeMPK3. In vitro analysis demonstrated that LeMKK2 and LeMKK4 each phosphorylate the same subset of three MAPKs. Together these data provide biochemical evidence for the involvement of MAPK cascades in Pto-mediated resistance.	Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA	Cornell University; Boyce Thompson Institute for Plant Research; Cornell University	Martin, GB (corresponding author), Cornell Univ, Boyce Thompson Inst Plant Res, Tower Rd, Ithaca, NY 14853 USA.	gbm7@cornell.edu	Martin, Gregory B/F-6262-2011	Martin, Gregory B/0000-0003-0044-6830				Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Asai T, 2002, NATURE, V415, P977, DOI 10.1038/415977a; Chang JH, 2000, MOL PLANT MICROBE IN, V13, P568, DOI 10.1094/MPMI.2000.13.5.568; del Pozo O, 2004, EMBO J, V23, P3072, DOI 10.1038/sj.emboj.7600283; Ekengren SK, 2003, PLANT J, V36, P905, DOI 10.1046/j.1365-313X.2003.01944.x; Grant M, 1999, CURR OPIN PLANT BIOL, V2, P312, DOI 10.1016/S1369-5266(99)80055-7; Greenberg JT, 2004, CELL MICROBIOL, V6, P201, DOI 10.1111/j.1462-5822.2004.00361.x; Gu YQ, 2000, PLANT CELL, V12, P771, DOI 10.1105/tpc.12.5.771; He XH, 2004, PLANT J, V38, P563, DOI 10.1111/j.1365-313X.2004.02073.x; Holley SR, 2003, PLANT PHYSIOL, V132, P1728, DOI 10.1104/pp.103.024414; Hoyos ME, 2000, PLANT PHYSIOL, V122, P1355, DOI 10.1104/pp.122.4.1355; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Jin HL, 2003, PLANT J, V33, P719, DOI 10.1046/j.1365-313X.2003.01664.x; Kim CY, 2004, PLANT J, V38, P142, DOI 10.1111/j.1365-313X.2004.02033.x; Kim YJ, 2002, CELL, V109, P589, DOI 10.1016/S0092-8674(02)00743-2; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; Lee J, 2001, PLANT CELL, V13, P1079, DOI 10.1105/tpc.13.5.1079; Liu YD, 2003, PLANT J, V34, P149, DOI 10.1046/j.1365-313X.2003.01709.x; Martin GB, 2003, ANNU REV PLANT BIOL, V54, P23, DOI 10.1146/annurev.arplant.54.031902.135035; Mayrose M, 2004, J BIOL CHEM, V279, P14819, DOI 10.1074/jbc.M313388200; Mikolajczyk M, 2000, PLANT CELL, V12, P165, DOI 10.1105/tpc.12.1.165; Pedley KF, 2003, ANNU REV PHYTOPATHOL, V41, P215, DOI 10.1146/annurev.phyto.41.121602.143032; Ren DT, 2002, J BIOL CHEM, V277, P559, DOI 10.1074/jbc.M109495200; Romeis T, 1999, PLANT CELL, V11, P273, DOI 10.1105/tpc.11.2.273; Rushton PJ, 1998, CURR OPIN PLANT BIOL, V1, P311, DOI 10.1016/1369-5266(88)80052-9; Salmeron JM, 1996, CELL, V86, P123, DOI 10.1016/S0092-8674(00)80083-5; Scofield SR, 1996, SCIENCE, V274, P2063, DOI 10.1126/science.274.5295.2063; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Tang XY, 1996, SCIENCE, V274, P2060, DOI 10.1126/science.274.5295.2060; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Voronin V, 2004, FEBS LETT, V560, P86, DOI 10.1016/S0014-5793(04)00076-6; Voronin V, 2001, PLANT MOL BIOL, V45, P679, DOI 10.1023/A:1010645431133; Wendehenne D, 2004, CURR OPIN PLANT BIOL, V7, P449, DOI 10.1016/j.pbi.2004.04.002; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yang KY, 2001, P NATL ACAD SCI USA, V98, P741, DOI 10.1073/pnas.98.2.741; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7433, DOI 10.1073/pnas.95.13.7433; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zhang SQ, 2001, PLANT CELL, V13, P1877, DOI 10.1105/tpc.13.8.1877; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809; Zhang SQ, 2000, PLANT J, V23, P339, DOI 10.1046/j.1365-313x.2000.00780.x; ZHOU JM, 1995, CELL, V83, P925, DOI 10.1016/0092-8674(95)90208-2; Zuo JR, 2000, PLANT J, V24, P265, DOI 10.1046/j.1365-313x.2000.00868.x	42	97	104	5	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49229	49235		10.1074/jbc.M410323200	http://dx.doi.org/10.1074/jbc.M410323200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371431	hybrid			2022-12-25	WOS:000225098100089
J	Zeng, LF; Liao, HL; Liu, Y; Lee, TS; Zhu, MJ; Wang, X; Stemerman, MB; Zhu, Y; Shyy, JYJ				Zeng, LF; Liao, HL; Liu, Y; Lee, TS; Zhu, MJ; Wang, X; Stemerman, MB; Zhu, Y; Shyy, JYJ			Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells - A novel role of SREBP in regulating cholesterol metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN DEFICIENCY; SHEAR-STRESS ACTIVATION; TANGIER-DISEASE; GENE-EXPRESSION; TRANSCRIPTION FACTOR; UP-REGULATION; ABCA1 GENE; PROMOTER; EFFLUX; LIVER	ATP-binding cassette transporter A1 (ABCA1) is a pivotal regulator of cholesterol efflux from cells to apolipoproteins, whereas sterol-responsive element-binding protein 2 (SREBP2) is the key protein regulating cholesterol synthesis and uptake. We investigated the regulation of ABCA1 by SREBP2 in vascular endothelial cells (ECs). Our results showed that sterol depletion activated SREBP2 and increased its target, low density lipoprotein receptor mRNA, with a concurrent decrease in the ABCA1 mRNA. Transient transfection analysis revealed that sterol depletion decreased the ABCA1 promoter activity by 50%, but low density lipoprotein receptor promoter- and the sterol-responsive element-driven luciferase activities were increased. Overexpression of the N terminus of SREBP2 (SREBP2(N)), an active form of SREBP2, also inhibited the ABCA1 promoter activity. Functionally adenovirus-mediated SREBP2(N) expression increased cholesterol accumulation and decreased apoA-I-mediated cholesterol efflux. The conserved E-box motif was responsible for the SREBP2(N)-mediated inhibition since mutation of the E-box increased the basal activity of the ABCA1 promoter and abolished the inhibitory effect of SREBP2(N). Furthermore sterol depletion and SREBP2(N) overexpression induced the binding of SREBP2(N) to both consensus and ABCA1-specific E-box. Chromatin immunoprecipitation assay demonstrated that serum starvation enhanced the association of SREBP2 and the ABCA1 promoter in ECs. To correlate this mechanism pathophysiologically, we found that oscillatory flow caused the activation of SREBP2 and therefore attenuated ABCA1 promoter activity in ECs. Thus, this SREBP-regulated mechanism may control the efflux of cholesterol, which is a newly defined function of SREBP2 in ECs in addition to its role in cholesterol uptake and biosynthesis.	Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; Peking Univ, Ctr Hlth Sci, Key Lab Mol Cardiovasc Sci Educ Minist, Dept Physiol, Beijing 100083, Peoples R China	University of California System; University of California Riverside; Peking University	Zhu, Y (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	yi.zhu@ucr.edu	Lee, Tzong-Shyuan/AAE-5803-2020	Lee, Tzong-Shyuan/0000-0002-9593-4062	NHLBI NIH HHS [HL33742, HL77448, HL56707] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077448, R29HL056707, R01HL056707, R01HL033742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amemiya-Kudo M, 2002, J LIPID RES, V43, P1220, DOI 10.1194/jlr.M100417-JLR200; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Fielding CJ, 1997, J LIPID RES, V38, P1503; Hayden MR, 2000, CURR OPIN LIPIDOL, V11, P117, DOI 10.1097/00041433-200004000-00003; Hoekstra M, 2003, J BIOL CHEM, V278, P25448, DOI 10.1074/jbc.M301189200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; Langmann T, 2002, J BIOL CHEM, V277, P14443, DOI 10.1074/jbc.M110270200; Liao HL, 2002, ARTERIOSCL THROM VAS, V22, P127, DOI 10.1161/hq1201.101772; Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Panzenboeck U, 2002, J BIOL CHEM, V277, P42781, DOI 10.1074/jbc.M207601200; Porsch-Ozcurumez M, 2001, J BIOL CHEM, V276, P12427, DOI 10.1074/jbc.M100218200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rodriguez C, 2003, CARDIOVASC RES, V58, P178, DOI 10.1016/S0008-6363(02)00856-8; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; Yang XP, 2002, J LIPID RES, V43, P297; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106; Zhu Y, 2000, ARTERIOSCL THROM VAS, V20, P2465, DOI 10.1161/01.ATV.20.11.2465; Zhu Y, 1998, ARTERIOSCL THROM VAS, V18, P473, DOI 10.1161/01.ATV.18.3.473	36	86	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48801	48807		10.1074/jbc.M407817200	http://dx.doi.org/10.1074/jbc.M407817200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358760	hybrid			2022-12-25	WOS:000225098100040
J	Kumagai, T; Matsukawa, N; Kaneko, Y; Kusumi, Y; Mitsumata, M; Uchida, K				Kumagai, T; Matsukawa, N; Kaneko, Y; Kusumi, Y; Mitsumata, M; Uchida, K			A lipid peroxidation-derived inflammatory mediator - Identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA STABILITY; GROWTH-FACTOR-RECEPTOR; SMOOTH-MUSCLE CELLS; TRANSCRIPTIONAL REGULATION; NUCLEAR-FACTOR	Cyclooxygenases (COXs) catalyze the conversion of arachidonic acid to eicosanoids, which mediate a variety of biological actions involved in vascular pathophysiology. In the present study, we investigated the role of lipid peroxidation products in the up-regulation of COX-2, an inducible isoform responsible for high levels of prostaglandin production during inflammation and immune responses. COX-2 was found to colocalize with 4-hydroxy-2-nonenal (HNE), a major lipid peroxidation-derived aldehyde, in foamy macrophages within human atheromatous lesions, suggesting that COX-2 expression may be associated with the accumulation of lipid peroxidation products within macrophages. To test the hypothesis that lipid peroxidation products might be involved in the regulation of prostanoid biosynthesis, we conducted a screen of oxidized fatty acid metabolites and found that, among the compounds tested, only HNE showed inducibility of the COX-2 protein in RAW264.7 macrophages. In addition, intraperitoneal administration of HNE resulted in an increase in cell numbers in the peritoneal cavity that was associated with significant increases in the peritoneal and tissue levels of COX-2 in mice. To understand the possible signaling mechanism underlying the inducing effect of HNE on COX-2 up-regulation, we examined the phosphorylation events that may lead to COX-2 induction and found that HNE did not stimulate the induction of nitric oxide synthase and activation of NF-kappaB but significantly activated p38 mitogen-activated protein kinase and its upstream kinase in RAW264.7 macrophages. Tyrosine kinases, such as the epidermal growth factor-like and Src family tyrosine kinases, appeared to mediate the stabilization of COX-2 mRNA via the p38 mitogen-activated protein kinase pathway. These findings suggest that HNE accumulated in macrophages/foam cells may represent an inflammatory mediator that plays a role in stimulation of the inflammatory response and contributes to the progression of atherogenesis.	Nagoya Univ, Lab Food & Biodynam, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Inst Adv Res, Nagoya, Aichi 4648601, Japan; Nihon Univ, Sch Med, Dept Pathol, Tokyo 1738610, Japan	Nagoya University; Nagoya University; Nihon University	Uchida, K (corresponding author), Nagoya Univ, Lab Food & Biodynam, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.	uchidak@agr.nagoya-u.ac.jp		Uchida, Koji/0000-0003-3894-5299				Baughman RP, 1999, SARCOIDOSIS VASC DIF, V16, P57; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; Chung FL, 2000, CANCER RES, V60, P1507; DAVIDGE ST, 1995, CIRC RES, V77, P274, DOI 10.1161/01.RES.77.2.274; De Montarby L., 1988, TETRAHEDRON LETT, V29, P3895; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dianzani Mario Umberto, 2003, Molecular Aspects of Medicine, V24, P263; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Escargueil-Blanc I, 2001, CIRCULATION, V104, P1814, DOI 10.1161/hc4001.097179; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FitzGerald GA, 2000, ANN MED, V32, P21; FRANCHI AM, 1994, P NATL ACAD SCI USA, V91, P539, DOI 10.1073/pnas.91.2.539; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kumagai T, 2002, ARCH BIOCHEM BIOPHYS, V397, P240, DOI 10.1006/abbi.2001.2601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Liu W, 2003, CELL DEATH DIFFER, V10, P772, DOI 10.1038/sj.cdd.4401238; Liu W, 1999, J CELL SCI, V112, P2409; Mark RJ, 1997, J NEUROCHEM, V68, P255; MILANO S, 1995, PROSTAG OTH LIPID M, V49, P105, DOI 10.1016/0090-6980(94)00004-G; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MORI M, 1994, AM J PATHOL, V144, P200; Oe T, 2003, J BIOL CHEM, V278, P42098, DOI 10.1074/jbc.M308167200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; SALVEMINI D, 1994, J CLIN INVEST, V93, P1940, DOI 10.1172/JCI117185; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR-100102336; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Wacker M, 2001, CHEM-BIOL INTERACT, V137, P269, DOI 10.1016/S0009-2797(01)00259-9; Yadav PN, 2003, J PHARMACOL EXP THER, V305, P925, DOI 10.1124/jpet.103.049171; YAMADA T, 1992, RES COMMUN CHEM PATH, V77, P121	57	121	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48389	48396		10.1074/jbc.M409935200	http://dx.doi.org/10.1074/jbc.M409935200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355999	hybrid			2022-12-25	WOS:000224957000114
J	Lima, LMTR; Silva, JL				Lima, LMTR; Silva, JL			Positive contribution of hydration on DNA binding by E2c protein from papillomavirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREFERENTIAL HYDRATION; OSMOTIC-STRESS; CRYSTAL-STRUCTURE; WATER RELEASE; MACROMOLECULAR HYDRATION; FLUORESCENCE ANISOTROPY; BOVINE PAPILLOMAVIRUS; ALLOSTERIC REGULATION; LINKED FUNCTIONS; RECEPTOR-ALPHA	Protein-nucleic acid interactions are responsible for the regulation of key biological events such as genomic transcription and recombination and viral replication. However, the recognition mechanisms involved in these processes are not completely understood. Here, we investigate the dominant forces involved in protein-protein and protein-DNA interactions for the 80-amino-acid C-terminal domain of the E2 protein (E2c) from human papillomavirus (HPV-16). The E2c protein is a homodimer that specifically binds to double-stranded DNA containing the consensus sequence ACCG-N4-CGGT, where N is any nucleotide. DNA binding affinity is reduced by lowering water chemical potential, accompanied by an increase in cooperativity. Wyman linkage relations between affinity and water chemical potential indicate that 11 additional water molecules are bound in the formation of the complex between E2c and DNA. Salt dissociation isotherms showed that 10 counterions are released upon association, even at low water activity, indicating that this latter variable does not change the electrostatic component of the interaction. Further analysis demonstrates a strong dependence of cooperativity of binding on the protein concentration. Altogether, these results reveal a novel binding pathway in which the consolidated complex may achieve its final form via a monomer-DNA intermediate, which favors the binding of a second monomer. This molecular mechanism reveals the contributions of multiple conformers in a tight virus genome modulation that seems to be important in the cell infection scenario.	Univ Fed Rio de Janeiro, CCS, Fac Farm, BR-21941 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Ctr Nacl Ressonancia Magnet Nucl Macromol, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Lima, LMTR (corresponding author), Univ Fed Rio de Janeiro, CCS, Fac Farm, Bss34,Ilha Fundao, BR-21941 Rio De Janeiro, Brazil.	mauricio@pharma.ufrj.br; Jerson@bioqmed.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; Lima, Luis Mauricio/AAL-2098-2021; Silva, Jerson/J-8984-2014	SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; TR Lima, Luis Mauricio/0000-0001-6020-0504				ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; Alexander KA, 1996, BIOCHEMISTRY-US, V35, P9864, DOI 10.1021/bi960447d; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; Antson AA, 2000, NATURE, V403, P805, DOI 10.1038/35001638; BERRY RS, 2000, PHYS CHEM, P694; Boyer M, 2000, NUCLEIC ACIDS RES, V28, P2494, DOI 10.1093/nar/28.13.2494; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P863; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; Colombo MF, 1999, BIOCHEMISTRY-US, V38, P11741, DOI 10.1021/bi9905361; COLOMBO MF, 1994, P NATL ACAD SCI USA, V91, P10517, DOI 10.1073/pnas.91.22.10517; Darling PJ, 2000, J MOL BIOL, V302, P625, DOI 10.1006/jmbi.2000.4050; Dell C, 2001, CELL MOL LIFE SCI, V58, P1923, DOI 10.1007/PL00000827; Dell G, 2003, J MOL BIOL, V334, P979, DOI 10.1016/j.jmb.2003.10.009; Di Pietro SM, 2003, BIOCHEMISTRY-US, V42, P6218, DOI 10.1021/bi026866u; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; Foguel D, 1998, J BIOL CHEM, V273, P9050, DOI 10.1074/jbc.273.15.9050; Foguel D, 1996, P NATL ACAD SCI USA, V93, P10642, DOI 10.1073/pnas.93.20.10642; GARNER MM, 1995, EMBO J, V14, P1257, DOI 10.1002/j.1460-2075.1995.tb07109.x; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4677, DOI 10.1021/bi00519a024; Harris SF, 1999, SCIENCE, V284, P1673, DOI 10.1126/science.284.5420.1673; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; Hegde RS, 1998, J MOL BIOL, V284, P1479, DOI 10.1006/jmbi.1998.2260; Hegde RS, 2002, ANNU REV BIOPH BIOM, V31, P343, DOI 10.1146/annurev.biophys.31.100901.142129; Hines CS, 1998, J MOL BIOL, V276, P809, DOI 10.1006/jmbi.1997.1578; JELESAROV I, 1994, BIOCHEMISTRY-US, V33, P13321, DOI 10.1021/bi00249a019; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kim SS, 2000, J BIOL CHEM, V275, P31245, DOI 10.1074/jbc.M004541200; KORNBLATT MJ, 1993, ARCH BIOCHEM BIOPHYS, V306, P495, DOI 10.1006/abbi.1993.1542; Lewis H, 1999, J MOL BIOL, V294, P885, DOI 10.1006/jmbi.1999.3314; Liang H, 1996, BIOCHEMISTRY-US, V35, P2095, DOI 10.1021/bi951932w; Lima LMTR, 2000, P NATL ACAD SCI USA, V97, P14289, DOI 10.1073/pnas.250352197; Lynch TW, 2000, J BIOL CHEM, V275, P30561, DOI 10.1074/jbc.M000266200; MCBRIDE AA, 1988, EMBO J, V7, P533, DOI 10.1002/j.1460-2075.1988.tb02842.x; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; Mok YK, 2000, PROTEIN SCI, V9, P799; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Mok YK, 1996, PROTEIN SCI, V5, P310; MONINI P, 1991, J VIROL, V65, P2124, DOI 10.1128/JVI.65.4.2124-2130.1991; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Parsegian VA, 2000, P NATL ACAD SCI USA, V97, P3987, DOI 10.1073/pnas.97.8.3987; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROBINSON CR, 1994, BIOCHEMISTRY-US, V33, P3787, DOI 10.1021/bi00179a001; Robinson CR, 1996, PROTEIN SCI, V5, P2119, DOI 10.1002/pro.5560051019; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P2186, DOI 10.1073/pnas.95.5.2186; Ruggiero Neto Joao, 2001, Cellular and Molecular Biology (Noisy-Le-Grand), V47, P801; Salvay AG, 2003, BIOPHYS J, V84, P564, DOI 10.1016/S0006-3495(03)74876-0; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; Senear DF, 1998, METHODS, V16, P3, DOI 10.1006/meth.1998.0641; Shimizu S, 2004, P NATL ACAD SCI USA, V101, P1195, DOI 10.1073/pnas.0305836101; SHORE JD, 1976, BIOCHEMISTRY-US, V15, P875, DOI 10.1021/bi00649a023; Sidorova NY, 1996, P NATL ACAD SCI USA, V93, P12272, DOI 10.1073/pnas.93.22.12272; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SILVA JL, 1993, PROTEIN SCI, V2, P945, DOI 10.1002/pro.5560020608; Suarez MC, 2003, BIOCHEMISTRY-US, V42, P5522, DOI 10.1021/bi027102h; Swaminathan CP, 1999, J BIOL CHEM, V274, P31272, DOI 10.1074/jbc.274.44.31272; TANFORD C, 1969, J MOL BIOL, V39, P539, DOI 10.1016/0022-2836(69)90143-0; Thain A, 1997, J BIOL CHEM, V272, P8236, DOI 10.1074/jbc.272.13.8236; Timasheff SN, 1998, P NATL ACAD SCI USA, V95, P7363, DOI 10.1073/pnas.95.13.7363; Timasheff SN, 2002, P NATL ACAD SCI USA, V99, P9721, DOI 10.1073/pnas.122225399; Timasheff SN, 2002, BIOCHEMISTRY-US, V41, P13473, DOI 10.1021/bi020316e; Vossen KM, 1997, BIOCHEMISTRY-US, V36, P11640, DOI 10.1021/bi971193e; Weber G., 1992, PROTEIN INTERACTIONS; WOLF AV, 1986, CRC HDB CHEM PHYSICS, pD266; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; Wyman J, 1990, BINDING LINKAGE FUNC	68	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47968	47974		10.1074/jbc.M407696200	http://dx.doi.org/10.1074/jbc.M407696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15361525	hybrid			2022-12-25	WOS:000224957000067
J	Tseng, HM; Tomkinson, AE				Tseng, HM; Tomkinson, AE			Processing and joining of DNA ends coordinated by interactions among Dnl4/Lif1, Pol4, and FEN-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE; NONHOMOLOGOUS RECOMBINATION; LIGASE IV; REPAIR; YEAST; PROTEIN; KU; REPLICATION; PATHWAY	The repair of DNA double-strand breaks is critical for maintaining genetic stability. In the non-homologous end-joining pathway, DNA ends are brought together by end-bridging factors. However, most in vivo DNA double-strand breaks have terminal structures that cannot be directly ligated. Thus, the DNA ends are aligned using short regions of sequence microhomology followed by processing of the aligned DNA ends by DNA polymerases and nucleases to generate ligatable termini. Genetic studies in Saccharomyces cerevisiae have implicated the DNA polymerase Pol4 and the DNA structure-specific endonuclease FEN-1(Rad27) in the processing of DNA ends to be joined by Dnl4/Lif1. In this study, we demonstrated that FEN-1(Rad27) physically and functionally interacted with both Pol4 and Dnl4/Lif1 and that together these proteins coordinately processed and joined DNA molecules with incompatible 5' ends. Because Pol4 also interacts with Dnl4/Lif1, our results have revealed a series of pair-wise interactions among the factors that complete the repair of DNA double-strand breaks by non-homologous end-joining and provide a conceptual framework for delineating the end-processing reactions in higher eukaryotes.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Mol Med Grad Program, San Antonio, TX 78245 USA; Univ Maryland, Sch Med, Dept Radiat Oncol, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University of Texas System; University of Texas Health San Antonio; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Tomkinson, AE (corresponding author), 655 W Baltimore St, Baltimore, MD 21201 USA.	atomkinson@som.umaryland.edu			NIGMS NIH HHS [GM47251] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047251, R01GM047251] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Brosh RM, 2001, EMBO J, V20, P5791; Chapados BR, 2004, CELL, V116, P39, DOI 10.1016/S0092-8674(03)01036-5; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chen L, 2001, MOL CELL, V8, P1105, DOI 10.1016/S1097-2765(01)00388-4; Cooper MP, 2000, GENE DEV, V14, P907; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kao HI, 2003, CRIT REV BIOCHEM MOL, V38, P433, DOI 10.1080/10409230390259382; KLUNGLAND A, 1997, EMBO J; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; KREJCI L, 2003, NUCL ACID RES MOL BI, V75, P159; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Liu YL, 2002, BREAST CANCER RES, V4, P9, DOI 10.1186/bcr417; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Milne GT, 1996, MOL CELL BIOL, V16, P4189; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Moreau S, 1999, MOL CELL BIOL, V19, P556; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Ramos W, 1998, NUCLEIC ACIDS RES, V26, P5676, DOI 10.1093/nar/26.24.5676; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Tseng HM, 2002, J BIOL CHEM, V277, P45630, DOI 10.1074/jbc.M206861200; WAGA S, 1994, J BIOL CHEM, V269, P10923; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679	46	41	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47580	47588		10.1074/jbc.M404492200	http://dx.doi.org/10.1074/jbc.M404492200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342630	hybrid			2022-12-25	WOS:000224957000022
J	Wang, WG; Yang, XL; Kawai, T; de Silanes, IL; Mazan-Mamczarz, K; Chen, PL; Chook, YM; Quensel, C; Kohler, M; Gorospe, M				Wang, WG; Yang, XL; Kawai, T; de Silanes, IL; Mazan-Mamczarz, K; Chen, PL; Chook, YM; Quensel, C; Kohler, M; Gorospe, M			AMP-activated protein kinase-regulated phosphorylation and acetylation of importin alpha 1 - Involvement in the nuclear import of RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; MESSENGER-RNA; LOCALIZATION SIGNAL; GENE-EXPRESSION; NUCLEOCYTOPLASMIC TRANSPORT; STRUCTURAL BASIS; MAMMALIAN-CELLS; PHOSPHATASE 2A; UP-REGULATION; ELAV PROTEIN	Nuclear import of HuR, a shuttling RNA-binding protein, is associated with reduced stability of its target mRNAs. Increased function of the AMP-activated protein kinase (AMPK), an enzyme involved in responding to metabolic stress, was recently shown to reduce the cytoplasmic levels of HuR. Here, we provide evidence that importin alpha1, an adaptor protein involved in nuclear import, contributes to the nuclear import of HuR through two AMPK-modulated mechanisms. First, AMPK triggered the acetylation of importin alpha1 on Lys(22), a process dependent on the acetylase activity of p300. Second, AMPK phosphorylated importin alpha1 on Ser(105). Accordingly, expression of importin alpha1 proteins bearing K22R or S105A mutations failed to mediate the nuclear import of HuR in intact cells. Our results point to importin alpha1 as a critical downstream target of AMPK and key mediator of AMPK-triggered HuR nuclear import.	NIA, LCMB, IRP, NIH, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Sydney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Max Delbruck Ctr Mol Med, HELIOS Clin Franz Volhard Clin, D-13125 Berlin, Germany	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Wang, WG (corresponding author), NIA, LCMB, IRP, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	wewang@uchc.edu; myriam-gorospe@nih.gov	Chook, Yuh Min/AAA-9549-2019; Lopez de Silanes, Isabel/K-4962-2015	Kawai, Tomoko/0000-0001-8137-0334; Lopez de Silanes, Isabel/0000-0001-6762-9792	NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		An WJ, 2002, MOL CELL, V9, P811, DOI 10.1016/S1097-2765(02)00497-5; Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; AZUMA Y, 1995, P NATL ACAD SCI USA, V92, P5159, DOI 10.1073/pnas.92.11.5159; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chook YM, 2002, BIOCHEMISTRY-US, V41, P6955, DOI 10.1021/bi012122p; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fanara P, 2000, J BIOL CHEM, V275, P21218, DOI 10.1074/jbc.M002217200; Figueroa A, 2003, MOL CELL BIOL, V23, P4991, DOI 10.1128/MCB.23.14.4991-5004.2003; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Franke J, 2001, J CELL SCI, V114, P2641; Galban S, 2003, MOL CELL BIOL, V23, P7083, DOI 10.1128/MCB.23.20.7083-7095.2003; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 2000, METH MOL B, V99, P63; Izaurralde E, 1998, RNA, V4, P351; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kohler M, 1999, MOL CELL BIOL, V19, P7782; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Leff T, 2003, BIOCHEM SOC T, V31, P224; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; MALTER JS, 1991, J BIOL CHEM, V266, P3167; Mason DA, 2002, GENETICS, V161, P157; Matsuura Y, 2003, EMBO J, V22, P5358, DOI 10.1093/emboj/cdg538; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Melen K, 2003, J BIOL CHEM, V278, P28193, DOI 10.1074/jbc.M303571200; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; Miyamoto Y, 2002, EMBO J, V21, P5833, DOI 10.1093/emboj/cdf569; Muhlhausser P, 2001, EMBO REP, V2, P690, DOI 10.1093/embo-reports/kve168; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rout MP, 2003, TRENDS CELL BIOL, V13, P622, DOI 10.1016/j.tcb.2003.10.007; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Saito S, 1999, BIOCHEM BIOPH RES CO, V259, P471, DOI 10.1006/bbrc.1999.0790; Sarkar B, 2003, J BIOL CHEM, V278, P20700, DOI 10.1074/jbc.M301176200; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Stutz F, 2003, TRENDS CELL BIOL, V13, P319, DOI 10.1016/S0962-8924(03)00106-5; Talcott B, 2000, J BIOL CHEM, V275, P10099, DOI 10.1074/jbc.275.14.10099; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	77	103	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48376	48388		10.1074/jbc.M409014200	http://dx.doi.org/10.1074/jbc.M409014200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342649	hybrid			2022-12-25	WOS:000224957000113
J	Wang, ZL; Cuddy, M; Samuel, T; Welsh, K; Schimmer, A; Hanaii, F; Houghten, R; Pinilla, C; Reed, JC				Wang, ZL; Cuddy, M; Samuel, T; Welsh, K; Schimmer, A; Hanaii, F; Houghten, R; Pinilla, C; Reed, JC			Cellular, biochemical, and genetic analysis of mechanism of small molecule IAP inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS PROTEIN XIAP; X-LINKED INHIBITOR; STRUCTURAL BASIS; CYTOCHROME-C; BIR DOMAIN; IN-VIVO; PROTEOLYTIC ACTIVATION; ENDOPLASMIC-RETICULUM; MEDIATED APOPTOSIS; CASPASE INHIBITION	XIAP is member of the IAP family of anti-apoptotic proteins and is known for its ability to bind and suppress caspase family cell death proteases. A phenylurea series of chemical inhibitors of XIAP was recently generated by our laboratories (Schimmer, A. D., Welsh, K., Pinilla, C., Bonneau, M., Wang, Z., Pedersen, I. M., Scott, F. L., Glinsky, G. V., Scudiero, D. A., Sausville, E., Salvesen, G., Nefzi, A., Ostresh, J.M., Houghten, R. A., and Reed, J.C. (2004) Cancer Cell 5, 25-35). We examined the mechanisms of action of these chemical compounds using biochemical, molecular biological, and genetic methods. Active phenylurea-based compounds dissociated effector protease caspase-3 but not initiator protease caspase-9 from XIAP in vitro and restored caspase-3 but not caspase-9 enzymatic activity. When applied to tumor cell lines in culture, active phenylurea-based compounds induced apoptosis in a rapid, concentration-dependent manner, associated with activation of cellular caspases. Apoptosis induced by active phenylurea-based compounds was blocked by chemical inhibitors of caspases, with inhibitors of downstream effector caspases displaying more effective suppression than inhibitors of upstream initiator caspases. Phenylurea-based XIAP antagonists induced apoptosis ( defined by annexin V staining) prior to mitochondrial membrane depolarization, in contrast to cytotoxic anticancer drugs. Consistent with these findings, apoptosis induced by phenylurea-based compounds was not altered by genetic alterations in the expression of Bcl-2 family proteins that control mitochondria-dependent cell death pathways, including over-expression of anti-apoptotic proteins Bcl-2 or Bcl-X-L and genetic ablation of pro-apoptotic proteins Bax and Bak. Conversely, conditional over-expression of an active fragment of XIAP or genetic ablation of XIAP expression altered the apoptosis dose-response of the compounds. Altogether, these findings indicate that phenylurea-based XIAP antagonists block interaction of downstream effector caspases with XIAP, thus inducing apoptosis of tumor cell lines through a caspase-dependent, Bcl-2/Bax-independent mechanism.	Burnham Inst, La Jolla, CA 92037 USA; Torrey Pines Inst Mol Studies, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; Torrey Pines Institute for Molecular Studies, California	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org		Schimmer, Aaron/0000-0003-4023-3899	NCI NIH HHS [CA-78040] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078040] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gordon GJ, 2002, CARCINOGENESIS, V23, P1017, DOI 10.1093/carcin/23.6.1017; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Krajewska M, 1997, CANCER RES, V57, P1605; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Krajewski S, 1996, ANAL BIOCHEM, V236, P221, DOI 10.1006/abio.1996.0160; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762; Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263; MIYASHITA T, 1993, BLOOD, V81, P151; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; Reed JC, 1999, NAT CELL BIOL, V1, pE199, DOI 10.1038/70227; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sasaki H, 2000, CANCER RES, V60, P5659; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Talanian RV, 1997, J EXP MED, V186, P1323, DOI 10.1084/jem.186.8.1323; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	71	83	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48168	48176		10.1074/jbc.M405022200	http://dx.doi.org/10.1074/jbc.M405022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337764	hybrid			2022-12-25	WOS:000224957000091
J	Brasaemle, DL; Dolios, G; Shapiro, L; Wang, R				Brasaemle, DL; Dolios, G; Shapiro, L; Wang, R			Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; YEAST SACCHAROMYCES-CEREVISIAE; CHANARIN-DORFMAN-SYNDROME; DOMINANT-NEGATIVE MUTANT; A-MEDIATED LIPOLYSIS; PERILIPIN-A; ENDOPLASMIC-RETICULUM; STORAGE DROPLETS; ADIPOSE CONVERSION; CELLS	Adipocytes hold the body's major energy reserve as triacylglycerols packaged in large lipid droplets. Perilipins, the most abundant proteins on these lipid droplets, play a critical role in facilitating both triacylglycerol storage and hydrolysis. The stimulation of lipolysis by beta-adrenergic agonists triggers rapid phosphorylation of perilipin and translocation of hormone-sensitive lipase to the surfaces of lipid droplets and more gradual fragmentation and dispersion of micro-lipid droplets. Because few lipid droplet-associated proteins have been identified in adipocytes, we isolated lipid droplets from basal and lipolytically stimulated 3T3-L1 adipocytes and identified the component proteins by mass spectrometry. Structural proteins identified in both preparations include perilipin, S3-12, vimentin, and TIP47; in contrast, adipophilin, caveolin-1, and tubulin selectively localized to droplets in lipolytically stimulated cells. Lipid metabolic enzymes identified in both preparations include hormone-sensitive lipase, lanosterol synthase, NAD(P)-dependent steroid dehydrogenase-like protein, acyl-CoA synthetase, long chain family member (ACSL) 1, and CGI-58. 17-beta-Hydroxysteroid dehydrogenase, type 7, was identified only in basal preparations, whereas ACSL3 and 4 and two short-chain reductase/dehydrogenases were identified on droplets from lipolytically stimulated cells. Additionally, both preparations contained FSP27, ribophorin I, EHD2, diaphorase I, and ancient ubiquitous protein. Basal preparations contained CGI-49, whereas lipid droplets from lipolytically stimulated cells contained several Rab GTPases and tumor protein D54. A close association of mitochondria with lipid droplets was suggested by the identification of pyruvate carboxylase, prohibitin, and a subunit of ATP synthase in the preparations. Thus, adipocyte lipid droplets contain specific structural proteins as well as lipid metabolic enzymes; the structural reorganization of lipid droplets in response to the hormonal stimulation of lipolysis is accompanied by increases in the relative mass of several proteins and the recruitment of additional proteins.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Columbia University	Brasaemle, DL (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave, New York, NY 10029 USA.	Brasaemle@AESOP.Rutgers.edu; Rong.Wang@mssm.edu	Wang, Rong/A-8721-2009	Brasaemle, Dawn/0000-0002-8553-8285	NCI NIH HHS [CA88325] Funding Source: Medline; NIDDK NIH HHS [DK54797] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA088325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054797] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Athenstaedt K, 1999, J BACTERIOL, V181, P6441, DOI 10.1128/JB.181.20.6441-6448.1999; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 2000, BBA-MOL CELL BIOL L, V1483, P251, DOI 10.1016/S1388-1981(99)00179-1; Caldas H, 2003, HUM MOL GENET, V12, P2981, DOI 10.1093/hmg/ddg321; Clifford GM, 2000, J BIOL CHEM, V275, P5011, DOI 10.1074/jbc.275.7.5011; Cohen AW, 2004, DIABETES, V53, P1261, DOI 10.2337/diabetes.53.5.1261; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Fujimoto Y, 2004, BBA-MOL CELL RES, V1644, P47, DOI 10.1016/j.bbamcr.2003.10.018; Garcia A, 2004, J BIOL CHEM, V279, P8409, DOI 10.1074/jbc.M311198200; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; Granneman JG, 2004, AM J PHYSIOL-ENDOC M, V287, pE574, DOI 10.1152/ajpendo.00567.2003; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Guilherme A, 2004, J BIOL CHEM, V279, P10593, DOI 10.1074/jbc.M307702200; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefevre C, 2001, AM J HUM GENET, V69, P1002, DOI 10.1086/324121; Lieber JG, 1996, J CELL SCI, V109, P3047; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Miura S, 2002, J BIOL CHEM, V277, P32253, DOI 10.1074/jbc.M204410200; Mullner H, 2004, BBA-BIOMEMBRANES, V1663, P9, DOI 10.1016/S0005-2736(04)00079-3; Ohashi M, 2003, J BIOL CHEM, V278, P36819, DOI 10.1074/jbc.M301408200; Ostermeyer AG, 2004, J CELL BIOL, V164, P69, DOI 10.1083/jcb.200303037; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Subramanian V, 2004, J BIOL CHEM, V279, P42062, DOI 10.1074/jbc.M407462200; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tansey JT, 2001, P NATL ACAD SCI USA, V98, P6494, DOI 10.1073/pnas.101042998; Tansey JT, 2003, J BIOL CHEM, V278, P8401, DOI 10.1074/jbc.M211005200; Than NG, 2003, EUR J BIOCHEM, V270, P1176, DOI 10.1046/j.1432-1033.2003.03475.x; Umlauf E, 2004, J BIOL CHEM, V279, P23699, DOI 10.1074/jbc.M310546200; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Wilson-Fritch L, 2003, MOL CELL BIOL, V23, P1085, DOI 10.1128/MCB.23.3.1085-1094.2003; Wolins NE, 2001, J BIOL CHEM, V276, P5101, DOI 10.1074/jbc.M006775200; Wolins NE, 2003, J BIOL CHEM, V278, P37713, DOI 10.1074/jbc.M304025200; Wu CC, 2000, ELECTROPHORESIS, V21, P3470, DOI 10.1002/1522-2683(20001001)21:16<3470::AID-ELPS3470>3.3.CO;2-7; Yamaguchi T, 2004, J BIOL CHEM, V279, P30490, DOI 10.1074/jbc.M403920200; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zweytick D, 2000, BBA-REV BIOMEMBRANES, V1469, P101, DOI 10.1016/S0005-2736(00)00294-7	50	617	642	4	78	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46835	46842		10.1074/jbc.M409340200	http://dx.doi.org/10.1074/jbc.M409340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15337753	hybrid			2022-12-25	WOS:000224832400064
J	Esaki, M; Shimizu, H; Ono, T; Yamamoto, H; Kanamori, T; Nishikawa, S; Endo, T				Esaki, M; Shimizu, H; Ono, T; Yamamoto, H; Kanamori, T; Nishikawa, S; Endo, T			Mitochondrial protein import - Requirement of presequence elements and TOM components for precursor binding to the TOM complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE-SPACE DOMAIN; ACIDIC RECEPTOR DOMAINS; TRANSLOCATION; MEMBRANE; OUTER; PREPROTEINS; RECOGNITION; SITES; GENE	Protein translocation across the outer mitochondrial membrane is mediated by the translocator called the TOM (translocase of the outer mitochondrial membrane) complex. The TOM complex possesses two presequence binding sites on the cytosolic side (the cis site) and on the intermembrane space side (the trans site). Here we analyzed the requirement of presequence elements and subunits of the TOM complex for presequence binding to the cis and trans sites of the TOM complex. The N-terminal 14 residues of the presequence of subunit 9 of F-0-ATPase are required for binding to the trans site. The interaction between the presequence and the cis site is not sufficient to anchor the precursor protein to the TOM complex. Tom7 constitutes or is close to the trans site and has overlapping functions with the C-terminal intermembrane space domain of Tom22 in the mitochondrial protein import.	Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Japan Sci & Technol Corp, Inst Adv Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST); Nagoya University; Japan Science & Technology Agency (JST); Nagoya University	Endo, T (corresponding author), Nagoya Univ, Dept Chem, Grad Sch Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.	endo@biochem.chem.nagoya-u.ac.jp	Esaki, Masatoshi/ABS-6645-2022; Esaki, Masatoshi/L-6591-2017					Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Asai T, 2004, J BIOL CHEM, V279, P19464, DOI 10.1074/jbc.M401291200; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Court DA, 1996, MOL CELL BIOL, V16, P4035; DAUM G, 1982, J BIOL CHEM, V257, P3028; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dekker PJT, 1998, MOL CELL BIOL, V18, P6515, DOI 10.1128/MCB.18.11.6515; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Endo T, 2003, J CELL SCI, V116, P3259, DOI 10.1242/jcs.00667; Endo T, 2002, BBA-MOL CELL RES, V1592, P3, DOI 10.1016/S0167-4889(02)00259-8; Esaki M, 2003, NAT STRUCT BIOL, V10, P988, DOI 10.1038/nsb1008; Frazier AE, 2003, MOL CELL BIOL, V23, P7818, DOI 10.1128/MCB.23.21.7818-7828.2003; Gaume B, 1998, EMBO J, V17, P6497, DOI 10.1093/emboj/17.22.6497; Herrmann JM, 2000, BBA-BIOENERGETICS, V1459, P331, DOI 10.1016/S0005-2728(00)00169-9; Horie C, 2003, J BIOL CHEM, V278, P41462, DOI 10.1074/jbc.M307047200; Iwata K, 1998, BIOCHEM BIOPH RES CO, V253, P648, DOI 10.1006/bbrc.1998.9769; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kanamori T, 1999, P NATL ACAD SCI USA, V96, P3634, DOI 10.1073/pnas.96.7.3634; KITADA K, 1995, GENE, V165, P203, DOI 10.1016/0378-1119(95)00552-H; Komiya T, 1998, EMBO J, V17, P3886, DOI 10.1093/emboj/17.14.3886; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; Moczko M, 1997, MOL CELL BIOL, V17, P6574, DOI 10.1128/MCB.17.11.6574; Nakai M, 1995, J BIOL CHEM, V270, P30571, DOI 10.1074/jbc.270.51.30571; NAKAI M, 1993, J BIOL CHEM, V268, P24262; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; Rapaport D, 1998, J BIOL CHEM, V273, P8806, DOI 10.1074/jbc.273.15.8806; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Schleiff E, 1997, J BIOL CHEM, V272, P17784, DOI 10.1074/jbc.272.28.17784; van Wilpe S, 1999, NATURE, V401, P485, DOI 10.1038/46802; Yamamoto H, 2002, CELL, V111, P519, DOI 10.1016/S0092-8674(02)01053-X	33	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45701	45707		10.1074/jbc.M404591200	http://dx.doi.org/10.1074/jbc.M404591200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15337763	hybrid			2022-12-25	WOS:000224694900051
J	Muslimov, IA; Nimmrich, V; Hernandez, AI; Tcherepanov, A; Sacktor, TC; Tiedge, H				Muslimov, IA; Nimmrich, V; Hernandez, AI; Tcherepanov, A; Sacktor, TC; Tiedge, H			Dendritic transport and localization of protein kinase M zeta mRNA - Implications for molecular memory consolidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL-NEURONS; BC1 RNA; SUBCELLULAR-LOCALIZATION; TARGETING ELEMENT; TRANSLATION; NEUROSCIENCE; TRAFFICKING; MAINTENANCE; MECHANISM	Protein kinase Mzeta (PKMzeta) is an atypical protein kinase C isoform that has been implicated in the protein synthesis-dependent maintenance of long term potentiation and memory storage in the brain. Synapse-associated kinases are uniquely positioned to promote enduring consolidation of structural and functional modifications at the synapse, provided that kinase mRNA is available on site for local input-specific translation. We now report that the mRNA encoding PKMzeta is rapidly transported and specifically localized to synaptodendritic neuronal domains. Transport of PKMzeta mRNA is specified by two cis-acting dendritic targeting elements (Mzeta DTEs). Mzeta DTE1, located at the interface of the 5'-untranslated region and the open reading frame, directs somato-dendritic export of the mRNA. Mzeta DTE2, in contrast, is located in the 3'-untranslated region and is required for delivery of the mRNA to distal dendritic segments. Colocalization with translational repressor BC1 RNA in hippocampal dendrites suggests that PKMzeta mRNA may be subject to translational control in local domains. Dendritic localization of PKMzeta mRNA provides a molecular basis for the functional integration of synaptic signal transduction and translational control pathways.	SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Program Neural & Behav Sci, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Neurol, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Tiedge, H (corresponding author), SUNY Hlth Sci Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA.	htiedge@downstate.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057068, R37MH057068, R29MH053576, R01MH053576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034158, R01NS046769] Funding Source: NIH RePORTER; NIMH NIH HHS [R37 MH057068, MH53576, R01 MH057068, R01 MH053576, R29 MH053576, MH57068] Funding Source: Medline; NINDS NIH HHS [NS46769, NS34158, R01 NS046769] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; Blichenberg A, 2001, EUR J NEUROSCI, V13, P1881, DOI 10.1046/j.0953-816x.2001.01565.x; Brosius J, 2001, Results Probl Cell Differ, V34, P129; BRUCKENSTEIN DA, 1990, NEURON, V5, P809, DOI 10.1016/0896-6273(90)90340-L; BURGIN KE, 1990, J NEUROSCI, V10, P1788; Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820; FORSSPETTER S, 1986, J NEUROSCI RES, V16, P141, DOI 10.1002/jnr.490160114; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; Goslin K., 1998, CULTURING NERVE CELL, P339; Hernandez AI, 2003, J BIOL CHEM, V278, P40305, DOI 10.1074/jbc.M307065200; Higgins D., 1991, CULTURING NERVE CELL, P177; Hobert O, 2002, NAT REV NEUROSCI, V3, P629, DOI 10.1038/nrn897; Jain C, 1996, CELL, V87, P115, DOI 10.1016/S0092-8674(00)81328-8; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; Kakegawa W, 2004, EUR J NEUROSCI, V20, P101, DOI 10.1111/j.1460-9568.2004.03461.x; KELLY PT, 1982, BRAIN RES, V233, P265, DOI 10.1016/0006-8993(82)91202-1; Kindler S, 1997, MOL CELL ENDOCRINOL, V128, P7, DOI 10.1016/S0303-7207(97)04015-X; KLEIMAN R, 1990, NEURON, V5, P821, DOI 10.1016/0896-6273(90)90341-C; LANDRY CF, 1994, MOL BRAIN RES, V27, P1, DOI 10.1016/0169-328X(94)90178-3; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Marshall BS, 2000, DNA CELL BIOL, V19, P707, DOI 10.1089/104454900750058071; Miller S, 2002, NEURON, V36, P507, DOI 10.1016/S0896-6273(02)00978-9; MONAGHAN DT, 1983, NATURE, V306, P176, DOI 10.1038/306176a0; Mori Y, 2000, NAT NEUROSCI, V3, P1079, DOI 10.1038/80591; Muslimov IA, 1998, J CELL BIOL, V141, P1601, DOI 10.1083/jcb.141.7.1601; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Muslimov IA, 2002, J NEUROSCI, V22, P4293, DOI 10.1523/JNEUROSCI.22-11-04293.2002; Naik MU, 2000, J COMP NEUROL, V426, P243, DOI 10.1002/1096-9861(20001016)426:2<243::AID-CNE6>3.0.CO;2-8; Osten P, 1996, J NEUROSCI, V16, P2444; Paulsen O, 2002, NAT NEUROSCI, V5, P289, DOI 10.1038/nn0402-289; POWELL CM, 1994, J BIOL CHEM, V269, P27958; Prakash N, 1997, EUR J NEUROSCI, V9, P523, DOI 10.1111/j.1460-9568.1997.tb01629.x; RICHTER D, 2001, CELL POLARITY SUBCEL; Rozhdestvensky TS, 2001, RNA, V7, P722, DOI 10.1017/S1355838201002485; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; Shan JG, 2003, J NEUROSCI, V23, P8859; Steward O, 2003, NEURON, V40, P347, DOI 10.1016/S0896-6273(03)00635-4; Thio GL, 2000, DEV BIOL, V221, P435, DOI 10.1006/dbio.2000.9690; TIEDGE H, 1991, P NATL ACAD SCI USA, V88, P2093, DOI 10.1073/pnas.88.6.2093; Tiedge H, 1999, SCIENCE, V283, P186, DOI 10.1126/science.283.5399.186; TIEDGE H, 1991, DNA CELL BIOL, V10, P143, DOI 10.1089/dna.1991.10.143; Tiedge H, 1996, J NEUROSCI, V16, P7171; Toga AW, 2003, NAT REV NEUROSCI, V4, P37, DOI 10.1038/nrn1009; TUCKER RP, 1989, NEURON, V2, P1245, DOI 10.1016/0896-6273(89)90309-7; Wang HD, 2002, J NEUROSCI, V22, P10232; Wells DG, 2000, CURR OPIN NEUROBIOL, V10, P132, DOI 10.1016/S0959-4388(99)00050-1; Wells DG, 2000, NAT NEUROSCI, V3, P1062, DOI 10.1038/80560; Wheeler DL, 2001, NUCLEIC ACIDS RES, V29, P11, DOI 10.1093/nar/29.1.11; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	51	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52613	52622		10.1074/jbc.M409240200	http://dx.doi.org/10.1074/jbc.M409240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15371429	Green Accepted, hybrid			2022-12-25	WOS:000225493400108
J	Khurts, S; Masutomi, K; Delgermaa, L; Arai, K; Oishi, N; Mizuno, H; Hayashi, N; Hahn, WC; Murakami, S				Khurts, S; Masutomi, K; Delgermaa, L; Arai, K; Oishi, N; Mizuno, H; Hayashi, N; Hahn, WC; Murakami, S			Nucleolin interacts with telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C VIRUS NS5B; CATALYTIC SUBUNIT; RNA COMPONENT; HUMAN-CELLS; IN-VITRO; REVERSE-TRANSCRIPTASE; ENZYME-ACTIVITY; PROTEIN; LOCALIZATION; DOMAIN	Telomerase is a specialized reverse transcriptase composed of core RNA and protein subunits which plays essential roles in maintaining telomeres in actively dividing cells. Recent work indicates that telomerase shuttles between subcellular compartments during assembly and in response to specific stimuli. In particular, telomerase colocalizes with nucleoli in normal human fibroblasts. Here, we show that nucleolin, a major nucleolar phosphoprotein, interacts with telomerase and alters its subcellular localization. Nucleolin binds the human telomerase reverse transcriptase subunit ( hTERT) through interactions with its RNA binding domain 4 and carboxyl-terminal RGG domain, and this binding also involves the telomerase RNA subunit hTERC. The protein-protein interaction between nucleolin and hTERT is critical for the nucleolar localization of hTERT. These findings indicate that interaction of hTERT and nucleolin participates in the dynamic intracellular localization of telomerase complex.	Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Kanazawa, Ishikawa 9200934, Japan; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Kanazawa University; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Takara Machi 13-1, Kanazawa, Ishikawa 9200934, Japan.	semuraka@kenroku.kanazawa-u.ac.jp	Mizuno, Hideki/E-9133-2011	Hayashi, Naoyuki/0000-0001-9626-3689	NATIONAL CANCER INSTITUTE [K01CA094223] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA94223] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai K, 2002, J BIOL CHEM, V277, P8538, DOI 10.1074/jbc.M111068200; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; Banik SSR, 2002, MOL CELL BIOL, V22, P6234, DOI 10.1128/MCB.22.17.6234-6246.2002; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Chen JL, 2004, TRENDS BIOCHEM SCI, V29, P183, DOI 10.1016/j.tibs.2004.02.003; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Etheridge KT, 2002, J BIOL CHEM, V277, P24764, DOI 10.1074/jbc.M201227200; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Ginisty H, 1999, J CELL SCI, V112, P761; Guiducci C, 2001, ONCOGENE, V20, P714, DOI 10.1038/sj.onc.1204145; Hirano M, 2003, J BIOL CHEM, V278, P5109, DOI 10.1074/jbc.M207629200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Jady BE, 2004, J CELL BIOL, V164, P647, DOI 10.1083/jcb.200310138; Lin J, 2004, GENE DEV, V18, P387, DOI 10.1101/gad.1171804; Lukowiak AA, 2001, RNA, V7, P1833; Masutomi K, 2000, J BIOL CHEM, V275, P22568, DOI 10.1074/jbc.M000622200; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; Narayanan A, 1999, EMBO J, V18, P5120, DOI 10.1093/emboj/18.18.5120; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wong JMY, 2002, NAT CELL BIOL, V4, P731, DOI 10.1038/ncb846; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yang YH, 2002, EXP CELL RES, V277, P201, DOI 10.1006/excr.2002.5541; Zhu YS, 2004, MOL BIOL CELL, V15, P81, DOI 10.1091/mbc.E03-07-0525	33	95	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51508	51515		10.1074/jbc.M407643200	http://dx.doi.org/10.1074/jbc.M407643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371412	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000225355800104
J	Lausen, J; Cho, SG; Liu, SH; Werner, MH				Lausen, J; Cho, SG; Liu, SH; Werner, MH			The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HISTONE ACETYLATION; FUSION PROTEIN; TRANSCRIPTIONAL REPRESSION; T(8-21); GENE; COREPRESSOR; COMPLEX; T(8/21); OLIGOMERIZATION	The acute human leukemias are associated with the presence of chimeric gene products that arise from spontaneous chromosomal translocations. The t(8;21) translocation gene product led to the discovery of the (E) under bar ight (T) under bar wenty-(O) under bar ne (ETO) gene. When fused to RUNX1, ETO is thought to mediate the formation of a repressive complex at RUNX1-dependent genes. ETO has also been found to act as a co-repressor of the promyelocytic zinc finger and Bcl-6 oncoproteins, suggesting that it may play a common role as a transcriptional co-repressor leading to human disease. An analysis of ETO-mediated repression revealed that one of the key binding partners of ETO is the nuclear receptor co-repressor (N-CoR). It is shown that two highly conserved domains of ETO interact with repression domains I and III of N-CoR. One of the ETO domains displays significant homology to Drosophila TAF(II)110, whereas the other is a predicted zinc binding motif that engages a conserved PPLXP motif in repression domain III of N-CoR. Together, these domains of ETO cooperate in repression with N-CoR and the binding sites in N-CoR overlap with those for other repressive factors. Thus, ETO has the potential to participate in a number of repressive complexes, which can be distinguished by their binding partners and target genes.	Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA	Rockefeller University	Werner, MH (corresponding author), Rockefeller Univ, Lab Mol Biophys, 1230 York Ave,Box 42, New York, NY 10021 USA.	mwerner@portugal.rockefeller.edu						Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Cao Y, 2002, MECH DEVELOP, V119, P35, DOI 10.1016/S0925-4773(02)00285-X; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Cosma MP, 2002, MOL CELL, V10, P227, DOI 10.1016/S1097-2765(02)00604-4; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674; Jepsen K, 2002, J CELL SCI, V115, P689; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; McGhee L, 2003, J CELL BIOCHEM, V89, P1005, DOI 10.1002/jcb.10548; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; Sims RJ, 2002, J BIOL CHEM, V277, P26524, DOI 10.1074/jbc.M204121200; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	50	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49281	49288		10.1074/jbc.M407239200	http://dx.doi.org/10.1074/jbc.M407239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15377655	hybrid			2022-12-25	WOS:000225098100096
J	Senin II; Hoppner-Heitmann, D; Polkovnikova, OO; Churumova, VA; Tikhomirova, NK; Philippov, PP; Koch, KW				Senin, II; Hoppner-Heitmann, D; Polkovnikova, OO; Churumova, VA; Tikhomirova, NK; Philippov, PP; Koch, KW			Recoverin and rhodopsin kinase activity in detergent-resistant membrane rafts from rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PROTEIN; PHOTORECEPTOR GUANYLYL CYCLASE; LIGHT-DRIVEN TRANSLOCATION; DISK MEMBRANES; CA2+-MYRISTOYL SWITCH; CELLS; TRANSDUCIN; VERTEBRATE; PHOTOTRANSDUCTION; PHOSPHORYLATION	Cholesterol-rich membranes or detergent-resistant membranes (DRMs) have recently been isolated from bovine rod outer segments and were shown to contain several signaling proteins such as, for example, transducin and its effector, cGMP-phosphodiesterase PDE6. Here we report the presence of rhodopsin kinase and recoverin in DRMs that were isolated in either light or dark conditions at high and low Ca(2+) concentrations. Inhibition of rhodopsin kinase activity by recoverin was more effective in DRMs than in the initial rod outer segment membranes. Furthermore, the Ca(2+) sensitivity of rhodopsin kinase inhibition in DRMs was shifted to lower free Ca(2+) concentration in comparison with the initial rod outer segment membranes (IC(50) = 0.76 muM in DRMs and 1.91 muM in rod outer segments). We relate this effect to the high cholesterol content of DRMs because manipulating the cholesterol content of rod outer segment membranes by methyl-beta-cyclodextrin yielded a similar shift of the Ca(2+)-dependent dose-response curve of rhodopsin kinase inhibition. Furthermore, a high cholesterol content in the membranes also increased the ratio of the membrane-bound form of recoverin to its cytoplasmic free form. These data suggest that the Ca(2+)-dependent feedback loop that involves recoverin is spatially heterogeneous in the rod cell.	Forschungszentrum Julich, Inst Biol Informat Verarbeitung 1, D-52425 Julich, Germany; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119992, Russia	Helmholtz Association; Research Center Julich; Lomonosov Moscow State University	Koch, KW (corresponding author), Forschungszentrum Julich, Inst Biol Informat Verarbeitung 1, Postbox 1913, D-52425 Julich, Germany.	k.w.koch@fz-juelich.de	Philippov, Pavel P/A-8939-2012; Koch, Karl-Wilhelm/C-9551-2015; Senin, Ivan I/D-9163-2012	Koch, Karl-Wilhelm/0000-0003-1501-0044; 				Boesze-Battaglia K, 2002, J BIOL CHEM, V277, P41843, DOI 10.1074/jbc.M207111200; BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867; Brouwers JFHM, 1998, J LIPID RES, V39, P344; Brown BM, 2002, BIOCHEMISTRY-US, V41, P13526, DOI 10.1021/bi0204490; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; Calvert PD, 2001, NATURE, V411, P90, DOI 10.1038/35075083; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; Elliott MH, 2003, BIOCHEMISTRY-US, V42, P7892, DOI 10.1021/bi027162n; Erickson MA, 1998, P NATL ACAD SCI USA, V95, P6474, DOI 10.1073/pnas.95.11.6474; Fischer T, 2002, SPECTROSC-INT J, V16, P271, DOI 10.1155/2002/630549; Frins S, 1996, J BIOL CHEM, V271, P8022, DOI 10.1074/jbc.271.14.8022; GORCZYCA WA, 1995, J BIOL CHEM, V270, P22029, DOI 10.1074/jbc.270.37.22029; GORODOVIKOVA EN, 1994, FEBS LETT, V349, P187, DOI 10.1016/0014-5793(94)00661-X; Haeseleer F, 1999, J BIOL CHEM, V274, P6526, DOI 10.1074/jbc.274.10.6526; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HURST WJ, 1984, J AM OIL CHEM SOC, V61, P1462, DOI 10.1007/BF02636365; Hwang JY, 2003, EUR J BIOCHEM, V270, P3814, DOI 10.1046/j.1432-1033.2003.03770.x; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLENCHIN VA, 1995, J BIOL CHEM, V270, P16147, DOI 10.1074/jbc.270.27.16147; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; Krizaj D, 1998, NEURON, V21, P249, DOI 10.1016/S0896-6273(00)80531-0; LAMBRECHT HG, 1992, BIOCHIM BIOPHYS ACTA, V1160, P63, DOI 10.1016/0167-4838(92)90038-F; LETTER WS, 1992, J LIQ CHROMATOGR, V15, P253, DOI 10.1080/10826079208017168; Liu H, 2003, BIOCHEM BIOPH RES CO, V303, P19, DOI 10.1016/S0006-291X(03)00284-5; Makino CL, 2004, J GEN PHYSIOL, V123, P729, DOI 10.1085/jgp.200308994; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Niu SL, 2002, J BIOL CHEM, V277, P20139, DOI 10.1074/jbc.M200594200; Otto-Bruce AE, 1998, P NATL ACAD SCI USA, V95, P15014, DOI 10.1073/pnas.95.25.15014; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; Pugh E.N., 2000, HDB BIOL PHYS, V3, P183, DOI DOI 10.1016/S1383-8121(00)80008-1; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Pulvermuller A, 2002, MOL CELL BIOL, V22, P2194, DOI 10.1128/MCB.22.7.2194-2203.2002; SCHNAPF JL, 1983, J PHYSIOL-LONDON, V343, P147, DOI 10.1113/jphysiol.1983.sp014886; Senin II, 2003, J MOL BIOL, V330, P409, DOI 10.1016/S0022-2836(03)00581-3; Senin II, 2002, ADV EXP MED BIOL, V514, P69; Senin II, 2002, J BIOL CHEM, V277, P50365, DOI 10.1074/jbc.M204338200; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; WUTHIER RE, 1996, J LIPID RES, V7, P558; Zhang HB, 2003, MOL VIS, V9, P231; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	46	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48647	48653		10.1074/jbc.M402516200	http://dx.doi.org/10.1074/jbc.M402516200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355976	Green Published, hybrid			2022-12-25	WOS:000225098100021
J	Zhang, J; Huang, WD; Qatanani, M; Evans, RM; Moore, DD				Zhang, J; Huang, WD; Qatanani, M; Evans, RM; Moore, DD			The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; XENOBIOTIC RESPONSE; LITHOCHOLIC ACID; ACTIVATED RECEPTOR; CAR; INDUCTION; METABOLISM; PXR; SULFOTRANSFERASE; IDENTIFICATION	A double null mouse line (2XENKO) lacking the xenobiotic receptors CAR (constitutive androstane receptor) (NR1I3) and PXR (pregnane X receptor) (NR1I2) was generated to study their functions in response to potentially toxic xenobiotic and endobiotic stimuli. Like the single knockouts, the 2XENKO mice are viable and fertile and show no overt phenotypes under normal conditions. As expected, they are completely insensitive to broad range xenobiotic inducers able to activate both receptors, such as clotrimazole and dieldrin. Comparisons of the single and double knockouts reveal specific roles for the two receptors. Thus, PXR does not contribute to the process of acetaminophen hepatotoxicity mediated by CAR, but both receptors contribute to the protective response to the hydrophobic bile acid lithocholic acid (LCA). As previously observed with PXR (Xie, W., Radominska-Pandya, A., Shi, Y., Simon, C. M., Nelson, M. C., Ong, E. S., Waxman, D. J., and Evans, R. M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3375-3380), pharmacologic activation of CAR induces multiple LCA detoxifying enzymes and provides strong protection against LCA toxicity. Comparison of their responses to LCA treatment demonstrates that CAR predominantly mediates induction of the cytochrome p450 CYP3A11 and the multidrug resistance-associated protein 3 transporter, whereas PXR is the major regulator of the Na+-dependent organic anion transporter 2. These differential responses may account for the significant sensitivity of the CAR knockouts, but not the PXR knockouts, to an acute LCA dose. Because this sensitivity is not further increased in the 2XENKO mice, CAR may play a primary role in acute responses to this toxic endobiotic. These results define a central role for CAR in LCA detoxification and show that CAR and PXR function coordinately to regulate both xenobiotic and bile acid metabolism.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Salk Institute	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	moore@bcm.tmc.edu	Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NIDDK NIH HHS [F32 DK63780, U19 DK062434, R01 DK46546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046546, U19DK062434, F32DK063780] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; CHEN LJ, 1985, ARCH BIOCHEM BIOPHYS, V241, P371, DOI 10.1016/0003-9861(85)90559-4; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; del Castillo-Olivares A, 2001, NUCLEIC ACIDS RES, V29, P4035, DOI 10.1093/nar/29.19.4035; Guo GL, 2003, J BIOL CHEM, V278, P45062, DOI 10.1074/jbc.M307145200; Gupta S, 2004, J BIOL CHEM, V279, P5821, DOI 10.1074/jbc.M310979200; HOFMANN AF, 1990, HEPATOLOGY, V12, P17; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Huang WD, 2003, P NATL ACAD SCI USA, V100, P4156, DOI 10.1073/pnas.0630614100; Jenkins JK, 2002, ANN PHARMACOTHER, V36, P1462; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kitada H, 2003, J BIOL CHEM, V278, P17838, DOI 10.1074/jbc.M210634200; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; RADOMINSKA A, 1993, SEMIN LIVER DIS, V13, P219, DOI 10.1055/s-2007-1007351; Saini SPS, 2004, MOL PHARMACOL, V65, P292, DOI 10.1124/mol.65.2.292; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Xiong H, 2002, DRUG METAB DISPOS, V30, P918, DOI 10.1124/dmd.30.8.918; Zelko I, 2001, MOL CELL BIOL, V21, P2838, DOI 10.1128/MCB.21.8.2838-2846.2001; Zhang J, 2002, SCIENCE, V298, P422, DOI 10.1126/science.1073502	42	184	187	3	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49517	49522		10.1074/jbc.M409041200	http://dx.doi.org/10.1074/jbc.M409041200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358766	hybrid			2022-12-25	WOS:000225098100122
J	Zhou, GS; Boomer, JS; Tan, TH				Zhou, GS; Boomer, JS; Tan, TH			Protein phosphatase 4 is a positive regulator of hematopoietic progenitor kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; CASPASE-MEDIATED CLEAVAGE; BETA SIGNAL-TRANSDUCTION; GERMINAL CENTER KINASE; ADAPTER PROTEINS; KAPPA-B; HEMATOPOIETIC-PROGENITOR-KINASE-1 HPK1; P21-ACTIVATED KINASE; PROTEASOME PATHWAY; TYROSINE KINASE	Hematopoietic progenitor kinase 1 (HPK1) is a hematopoietic specific mammalian Ste20-like protein kinase and has been implicated in many cellular signaling pathways including T cell receptor (TCR) signaling. However, little is known about the in vivo regulation of HPK1. We present evidence that HPK1 is positively regulated by protein phosphatase 4 (PP4; also called PPX and PPP4), a serine/threonine phosphatase. We found that PP4 interacted with HPK1 and that the proline-rich region of HPK1 was necessary and sufficient for this interaction. We also found that PP4 had phosphatase activity toward HPK1 in vivo and that co-transfection of PP4 with HPK1 resulted in specific kinase activation of HPK1. Moreover, we found that the PP4-induced HPK1 kinase activation was accompanied by an increase in protein expression of HPK1. Pulse-chase analysis showed that PP4 increased the half-life of HPK1. Further studies showed that HPK1 was subject to regulation by ubiquitination and ubiquitin-targeted degradation and that PP4 inhibited HPK1 ubiquitination. In addition, we found that TCR stimulation enhanced the PP4-HPK1 interaction and that wild-type PP4 enhanced, whereas a phosphatase-dead PP4 mutant inhibited, TCR-induced activation of HPK1 in Jurkat T cells. Combined with the observation that PP4 enhanced HPK1-induced JNK activation, our studies identify PP4 as a positive regulator for HPK1 and the HPK1-JNK signaling pathway.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA	Baylor College of Medicine	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, 1 Baylor Plaza,M929, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010	Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL CANCER INSTITUTE [R01CA087076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA87076] Funding Source: Medline; NIAID NIH HHS [R01-AI42532] Funding Source: Medline; PHS HHS [5-T32-A107495] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Arnold R, 2001, J BIOL CHEM, V276, P14675, DOI 10.1074/jbc.M008343200; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; Carnegie GK, 2003, J CELL SCI, V116, P1905, DOI 10.1242/jcs.00409; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Dounay AB, 2002, CURR MED CHEM, V9, P1939, DOI 10.2174/0929867023368791; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Ensenat D, 1999, J BIOL CHEM, V274, P33945, DOI 10.1074/jbc.274.48.33945; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Geisberger Roland, 2002, Dev Immunol, V9, P127, DOI 10.1080/1044667031000137584; Han J, 2003, J BIOL CHEM, V278, P52195, DOI 10.1074/jbc.M305026200; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hastie CJ, 2000, BIOCHEM J, V347, P845, DOI 10.1042/0264-6021:3470845; Helps NR, 1998, J CELL SCI, V111, P1331; Hu MCT, 1999, ONCOGENE, V18, P5514, DOI 10.1038/sj.onc.1202740; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Hu MCT, 2001, GENE, V278, P89, DOI 10.1016/S0378-1119(01)00734-X; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Ito Y, 2001, J BIOL CHEM, V276, P18130, DOI 10.1074/jbc.M007294200; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; JaramilloBabb VL, 1996, J BIOL CHEM, V271, P5988, DOI 10.1074/jbc.271.11.5988; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; Koh CG, 2002, CURR BIOL, V12, P317, DOI 10.1016/S0960-9822(02)00652-8; Le Bras S, 2004, J BIOL CHEM, V279, P15550, DOI 10.1074/jbc.M312659200; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lewitzky M, 2004, J BIOL CHEM, V279, P28724, DOI 10.1074/jbc.M402745200; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Ling P, 1999, MOL CELL BIOL, V19, P1359; Ling P, 2001, J BIOL CHEM, V276, P18908, DOI 10.1074/jbc.M101485200; LING P, 2002, RECENT RES DEV MOL C, V3, P297; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Mihindukulasuriya KA, 2004, J BIOL CHEM, V279, P46588, DOI 10.1074/jbc.M408067200; MORI S, 1992, J BIOL CHEM, V267, P6429; Mourtada-Maarabouni M, 2003, CELL DEATH DIFFER, V10, P1016, DOI 10.1038/sj.cdd.4401274; Nagata Y, 1999, BLOOD, V93, P3347, DOI 10.1182/blood.V93.10.3347.410k06_3347_3354; Nanahoshi M, 1999, FEBS LETT, V446, P108, DOI 10.1016/S0014-5793(99)00189-1; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Pillet NA, 2003, J BIOL CHEM, V278, P48720, DOI 10.1074/jbc.M306745200; Roig J, 2000, P NATL ACAD SCI USA, V97, P14346, DOI 10.1073/pnas.97.26.14346; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sauer K, 2001, J BIOL CHEM, V276, P45207, DOI 10.1074/jbc.M106811200; Sawasdikosol S, 2003, BLOOD, V101, P3687, DOI 10.1182/blood-2002-07-2316; Schulze-Luehrmann J, 2002, BLOOD, V100, P954, DOI 10.1182/blood-2002-01-0089; Sumiyoshi E, 2002, J CELL SCI, V115, P1403; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; Tsuji S, 2001, J EXP MED, V194, P529, DOI 10.1084/jem.194.4.529; Tu H, 1999, MOL CELL BIOL, V19, P602; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yeh PY, 2004, J BIOL CHEM, V279, P26143, DOI 10.1074/jbc.M402362200; Yu J, 2001, MOL CELL BIOL, V21, P6102, DOI 10.1128/MCB.21.18.6102-6112.2001; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhou GS, 2002, J BIOL CHEM, V277, P6391, DOI 10.1074/jbc.M107014200; Zhou GS, 1999, J BIOL CHEM, V274, P13133, DOI 10.1074/jbc.274.19.13133	80	31	38	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49551	49561		10.1074/jbc.M410317200	http://dx.doi.org/10.1074/jbc.M410317200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364934	hybrid			2022-12-25	WOS:000225098100126
J	Lee, CG; Reichman, TW; Baik, T; Mathews, MB				Lee, CG; Reichman, TW; Baik, T; Mathews, MB			MLE functions as a transcriptional regulator of the roX2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOSAGE COMPENSATION COMPLEX; X-CHROMOSOME INACTIVATION; MSL COMPLEX; DROSOPHILA-MELANOGASTER; ACETYL TRANSFERASE; SEX DETERMINATION; MALELESS PROTEIN; RNA HELICASE; XIST GENE; CHROMATIN	Dosage compensation is a process that equalizes transcription activity between the sexes. In Drosophila, two non-coding RNA, roX1 and roX2, and at least six protein regulators, MSL-1, MSL-2, MSL-3, MLE, MOF, and JIL-1, have been identified as essential for dosage compensation. Although there is accumulating evidence of the intricate functional and physical interactions between protein and RNA regulators, little is known about how roX RNA expression and function are modulated in coordination with protein regulators. In this report, we have found that a relatively short (about 350 bp) upstream genomic region of the roX2 gene, Prox2, harbors an activity that drives transcription of the downstream gene. Our study has shown that MLE can stimulate the transcription activity of Prox2 and that MLE associates with Prox2 through direct interaction with a newly identified 54-bp repeat, Prox. Our observations suggest a novel mechanism by which roX2 RNA is regulated at the transcriptional level.	Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Lee, CG (corresponding author), Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07103 USA.	leecg@umdnj.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amrein H, 1997, CELL, V88, P459, DOI 10.1016/S0092-8674(00)81886-3; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; Brockdorff N, 2002, TRENDS GENET, V18, P352, DOI 10.1016/S0168-9525(02)02717-8; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Chang KA, 1998, GENETICS, V150, P699; Chiang PW, 2003, GENETICS, V165, P1167; Cohen DE, 2002, CURR OPIN GENET DEV, V12, P219, DOI 10.1016/S0959-437X(02)00289-7; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; Franke A, 1999, MOL CELL, V4, P117, DOI 10.1016/S1097-2765(00)80193-8; GORMAN M, 1995, DEVELOPMENT, V121, P463; Gu WG, 2000, EMBO J, V19, P5202, DOI 10.1093/emboj/19.19.5202; Hilfiker A, 1997, EMBO J, V16, P2054, DOI 10.1093/emboj/16.8.2054; HODGKIN J, 1990, NATURE, V344, P721, DOI 10.1038/344721a0; Jin Y, 2000, J CELL BIOL, V149, P1005, DOI 10.1083/jcb.149.5.1005; Kageyama Y, 2001, EMBO J, V20, P2236, DOI 10.1093/emboj/20.9.2236; Kelley RL, 1999, CELL, V98, P513, DOI 10.1016/S0092-8674(00)81979-0; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KELLEY RL, 1995, SCIENCE, V270, P1607, DOI 10.1126/science.270.5242.1607; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Meller VH, 2003, MECH DEVELOP, V120, P759, DOI 10.1016/S0925-4773(03)00157-6; Meller VH, 1997, CELL, V88, P445, DOI 10.1016/S0092-8674(00)81885-1; Meller VH, 2000, CURR BIOL, V10, P136, DOI 10.1016/S0960-9822(00)00311-0; Meller VH, 2002, EMBO J, V21, P1084, DOI 10.1093/emboj/21.5.1084; MUKHERJEE AS, 1965, NATURE, V207, P785, DOI 10.1038/207785a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; PALMER MJ, 1993, GENETICS, V134, P545; Pannuti A, 2000, CURR OPIN GENET DEV, V10, P644, DOI 10.1016/S0959-437X(00)00136-2; Park Y, 2003, MOL CELL, V11, P977, DOI 10.1016/S1097-2765(03)00147-3; Park Y, 2001, SCIENCE, V293, P1083, DOI 10.1126/science.1063073; PARKHURST SM, 1994, SCIENCE, V264, P924, DOI 10.1126/science.8178152; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; Scott MJ, 2000, EMBO J, V19, P144, DOI 10.1093/emboj/19.1.144; Zhou K, 2003, NUCLEIC ACIDS RES, V31, P2253, DOI 10.1093/nar/gkg328	37	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47740	47745		10.1074/jbc.M408207200	http://dx.doi.org/10.1074/jbc.M408207200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15358781	hybrid			2022-12-25	WOS:000224957000041
J	Lemaire, C; Guibet-Grandmougin, F; Angles, D; Dujardin, G; Bonnefoy, N				Lemaire, C; Guibet-Grandmougin, F; Angles, D; Dujardin, G; Bonnefoy, N			A yeast mitochondrial membrane methyltransferase-like protein can compensate for oxa1 mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI YIDC; CYTOCHROME-C-OXIDASE; COX2 MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INNER-MEMBRANE; ATP SYNTHASE; NUCLEAR GENE; FUNCTIONAL COMPLEMENTATION; NEUROSPORA-CRASSA; EXPORT MACHINERY	Members of the Oxa1p/Alb3/YidC family mediate the insertion of various organelle or bacterial hydrophobic proteins into membranes. They present at least five transmembrane segments (TM) linked by hydrophilic domains located on both sides of the membrane. To examine how Oxa1p structure relates to its function, we have introduced point mutations and large deletions into various domains of the yeast mitochondrial protein. These mutants allowed us to show the importance of the first TM domain as well as a synergistic interaction between the first loop and the C-terminal tail, which both protrude into the matrix. These mutants also led to the isolation of a high copy suppressor, OMS1, which encodes a member of the methyltransferase family. Overexpression of OMS1 seems to increase the steady-state level of both the mutant and wild-type Oxa1p. We show that Oms1p is a mitochondrial inner membrane protein inserted independently of Oxa1p. Oms1p presents one TM and a N-in C-out topology with the C-terminal domain carrying the methyltransferase-like domain. A conserved motif within this domain is essential for the suppression of oxa1 mutations. We discuss the possible role of Oms1p on Oxa1p intermembrane space domain.	CNRS, Ctr Genet Mol, UPR 2167, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Bonnefoy, N (corresponding author), CNRS, Ctr Genet Mol, UPR 2167, Ave Terrasse, F-91198 Gif Sur Yvette, France.	bonnefoy@cgm.cnrs-gif.fr	Bonnefoy, Nathalie/GYD-2949-2022	Bonnefoy, Nathalie/0000-0002-5068-8849				Altamura N, 1996, FEBS LETT, V382, P111, DOI 10.1016/0014-5793(96)00165-2; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; BRASSEUR G, 1995, J BIOL CHEM, V270, P29356, DOI 10.1074/jbc.270.49.29356; Funes S, 2004, MOL BIOL CELL, V15, P1853, DOI 10.1091/mbc.e03-11-0789; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; Hamel P, 1998, GENETICS, V150, P601; Hamel P, 1997, PLANT J, V12, P1319, DOI 10.1046/j.1365-313x.1997.12061319.x; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Herrmann JM, 2003, IUBMB LIFE, V55, P219, DOI 10.1080/1521654031000123349; Herrmann JM, 2004, J BIOL CHEM, V279, P2507, DOI 10.1074/jbc.M310468200; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jia LX, 2003, EMBO J, V22, P6438, DOI 10.1093/emboj/cdg624; Jiang FL, 2003, J BIOL CHEM, V278, P48965, DOI 10.1074/jbc.M307362200; Kaser M, 2003, J BIOL CHEM, V278, P46414, DOI 10.1074/jbc.M305584200; Kermorgant M, 1997, CURR GENET, V31, P302, DOI 10.1007/s002940050209; Kuhn A, 2003, TRENDS CELL BIOL, V13, P510, DOI 10.1016/j.tcb.2003.08.005; Lemaire C, 2000, J BIOL CHEM, V275, P23471, DOI 10.1074/jbc.M002045200; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Moore M, 2003, J CELL BIOL, V162, P1245, DOI 10.1083/jcb.200307067; MULERO JJ, 1994, MOL GEN GENET, V242, P383, DOI 10.1007/BF00281787; Nargang FE, 2002, J BIOL CHEM, V277, P12846, DOI 10.1074/jbc.M112099200; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; PAJOT P, 1976, EUR J BIOCHEM, V63, P263, DOI 10.1111/j.1432-1033.1976.tb10228.x; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; Saint-Georges Y, 2001, P NATL ACAD SCI USA, V98, P13814, DOI 10.1073/pnas.251503098; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Serek J, 2004, EMBO J, V23, P294, DOI 10.1038/sj.emboj.7600063; SIKORSKI RS, 1989, GENETICS, V122, P19; Spannagel C, 1998, BIOCHEMISTRY-US, V37, P615, DOI 10.1021/bi9714971; Szyrach G, 2003, EMBO J, V22, P6448, DOI 10.1093/emboj/cdg623; TAKATA Y, 1994, J BIOL CHEM, V269, P5537; van der Laan M, 2004, J CELL BIOL, V165, P213, DOI 10.1083/jcb.200402100; van der Laan M, 2003, P NATL ACAD SCI USA, V100, P5801, DOI 10.1073/pnas.0636761100; van Dyck L, 1998, GENE DEV, V12, P1515, DOI 10.1101/gad.12.10.1515; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; Wiedemann N, 2004, J BIOL CHEM, V279, P14473, DOI 10.1074/jbc.R400003200; Yen MR, 2001, FEMS MICROBIOL LETT, V204, P223, DOI 10.1111/j.1574-6968.2001.tb10889.x; Yi L, 2003, BIOCHEMISTRY-US, V42, P10537, DOI 10.1021/bi034309h	52	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47464	47472		10.1074/jbc.M404861200	http://dx.doi.org/10.1074/jbc.M404861200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355998	Green Published, hybrid			2022-12-25	WOS:000224957000008
J	Tourbez, M; Firanescu, C; Yang, A; Unipan, L; Duchambon, P; Blouquit, Y; Craescu, CT				Tourbez, M; Firanescu, C; Yang, A; Unipan, L; Duchambon, P; Blouquit, Y; Craescu, CT			Calcium-dependent self-assembly of human centrin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN; BINDING; TEMPERATURE; CELLS; YEAST; POLYMERIZATION; CALMODULIN	Human centrin 2 (HsCen2) is a member of the EF-hand superfamily of calcium-binding proteins, often associated with the centrosomes and basal bodies. These organelles exhibit different morphological aspects, including a variety of centrin-containing fibers that connect the two centrioles or other structural elements of the pericentriolar space. The molecular basis of the Ca2+-sensitive fibers and their precise role in centrosome duplication are not known. To explore the possible structural role of HsCen2, we initiated a physicochemical study of the self-assembly properties of the purified protein in vitro. Using light scattering experiments, we investigated the temporal evolution of the assembly process and characterized the dependence on various chemical and physical factors, including temperature, di-cation concentration, ionic strength, protein concentration, and pH. The reversible self-assembly revealed many features of a large-size protein polymerization, with nucleation and elongation steps. Kinetic and equilibrium experiments show that a hydrophobic fluorescent probe (ANS) inhibits the polymerization by interfering with the nucleation step, probably through interactions with the apolar exposed sites on the protein surface. A truncated form of HsCen2, lacking the first 25 residues (Delta25HsCen2), shows no detectable self-assembly, pointing to the critical role played by the N-terminal fragment in the supermolecular organization of HsCen2. As revealed by isothermal titration experiments, the isolated N-terminal domains bind with a significant affinity (2 x 10(5) M-1) to preformed oligomers of Delta25HsCen2 through an entropy-driven mechanism.	Ctr Univ Paris Sud, INSERM, F-91405 Orsay, France; Ctr Univ Paris Sud, Inst Curie Rech, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Craescu, CT (corresponding author), Ctr Univ Paris Sud, INSERM, Batiment 112, F-91405 Orsay, France.	Gil.Craescu@curie.u-psud.fr	Chilom, Claudia Gabriela/S-2425-2018	Chilom, Claudia Gabriela/0000-0003-3662-9268				BARON AT, 1994, J CELL SCI, V107, P2993; Beisson J, 2001, PROTIST, V152, P339, DOI 10.1078/1434-4610-00072; Belmont LD, 1999, P NATL ACAD SCI USA, V96, P29, DOI 10.1073/pnas.96.1.29; Black DJ, 2004, CELL CALCIUM, V35, P415, DOI 10.1016/j.ceca.2003.10.005; Buzan JM, 1996, P NATL ACAD SCI USA, V93, P91, DOI 10.1073/pnas.93.1.91; Campbell I.D, 1984, BIOL SPECTROSCOPY; CARLIER MF, 1978, BIOCHEMISTRY-US, V17, P1908, DOI 10.1021/bi00603a017; CARLIER MF, 1991, J BIOL CHEM, V266, P1; CHEN X, 1995, J BIOL CHEM, V270, P11406, DOI 10.1074/jbc.270.19.11406; COOPER JA, 1982, METHOD ENZYMOL, V85, P182; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; Durussel I, 2000, FEBS LETT, V472, P208, DOI 10.1016/S0014-5793(00)01452-6; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Gavet O, 2003, MOL BIOL CELL, V14, P1818, DOI 10.1091/mbc.E02-11-0709; Greer SC, 2002, ANNU REV PHYS CHEM, V53, P173, DOI 10.1146/annurev.physchem.53.082301.111949; Kilmartin JV, 2003, J CELL BIOL, V162, P1211, DOI 10.1083/jcb.200307064; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Laoukili J, 2000, J CELL SCI, V113, P1355; Liliom K, 1999, BIOCHEM BIOPH RES CO, V264, P605, DOI 10.1006/bbrc.1999.1547; LINSE S, 1991, J BIOL CHEM, V266, P8050; Lutz W, 2001, J BIOL CHEM, V276, P20774, DOI 10.1074/jbc.M101324200; Matei E, 2003, BIOCHEMISTRY-US, V42, P1439, DOI 10.1021/bi0269714; MCFADDEN GI, 1987, J CELL BIOL, V105, P903, DOI 10.1083/jcb.105.2.903; McPhail D, 1997, J CHEM SOC FARADAY T, V93, P2283, DOI 10.1039/a701327b; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; Mispelter J, 2000, J MAGN RESON, V143, P229, DOI 10.1006/jmre.1999.2006; NA GC, 1982, METHOD ENZYMOL, V85, P393; Paoletti A, 1996, J CELL SCI, V109, P3089; Popescu A, 2003, J BIOL CHEM, V278, P40252, DOI 10.1074/jbc.M302546200; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1978, SCIENCE, V202, P975, DOI 10.1126/science.202.4371.975; Salisbury JL, 1998, J EUKARYOT MICROBIOL, V45, P28, DOI 10.1111/j.1550-7408.1998.tb05064.x; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; Steinmetz MO, 1997, J CELL BIOL, V138, P559, DOI 10.1083/jcb.138.3.559; Tang DX, 1998, EXP EYE RES, V67, P113, DOI 10.1006/exer.1998.0497; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; Wigge PA, 1998, J CELL BIOL, V141, P967, DOI 10.1083/jcb.141.4.967; Wolfrum U, 2002, ADV EXP MED BIOL, V514, P155	42	62	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47672	47680		10.1074/jbc.M404996200	http://dx.doi.org/10.1074/jbc.M404996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15356003	hybrid			2022-12-25	WOS:000224957000032
J	Hanafy, KA; Martin, E; Murad, F				Hanafy, KA; Martin, E; Murad, F			CCT eta, a novel soluble guanylyl cyclase-interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; MOLECULAR CHAPERONES; CYCLIC-GMP; EXPRESSION; TCP-1; CELLS	Nitric oxide (NO) transduces most of its biological effects through activation of the heterodimeric enzyme, soluble guanylyl cyclase (sGC). Activation of sGC results in the production of cGMP from GTP. In this paper, we demonstrate a novel protein interaction between CCT ( chaperonin containing t-complex polypeptide) subunit eta and the alpha(1)beta(1) isoform of sGC. CCTeta was found to interact with the beta(1) subunit of sGC via a yeast-two-hybrid screen. This interaction was then confirmed in vitro with a co-immunoprecipitation from mouse brain. The interaction between these two proteins was further supported by a co-localization of the proteins within rat brain. Using the yeast two-hybrid system, CCTeta was found to bind to the N-terminal portion of sGC. In vitro assays with purified CCTeta and Sf9 lysate expressing sGC resulted in a 30-50% inhibition of diethylamine diazeniumdiolate-NO-stimulated sGC activity. The same assays were then performed using BAY41-2272, an NO-independent allosteric sGC activator, and CCTeta had no effect on this activity. Furthermore, CCTeta had no effect on basal or sodium nitroprusside-stimulated alphabeta(Cys-105) sGC, a constitutively active mutant that only lacks the heme group. The N-terminal 94 amino acids of CCTeta seem to be critical for the mediation of this inhibition. Lastly, a 45% inhibition of sGC activity by CCTeta was seen in vivo in BE2 cells stably transfected with CCTeta and treated with sodium nitroprusside. These data suggest that CCTeta binds to sGC and, in cooperation with some other factor, inhibits its activity by modifying the binding of NO to the heme group or the subsequent conformational changes.	Univ Texas, Houston Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Houston Sch Med, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas System	Murad, F (corresponding author), Univ Texas, Houston Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.	ferid.murad@uth.tmc.edu		Martin, Emil/0000-0002-9094-4165	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061731] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64221] Funding Source: Medline; NIGMS NIH HHS [GM61731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bellamy TC, 2002, BRIT J PHARMACOL, V136, P95, DOI 10.1038/sj.bjp.0704687; BRANDWEIN H, 1981, P NATL ACAD SCI-BIOL, V78, P4241, DOI 10.1073/pnas.78.7.4241; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; Casalou C, 2001, BBA-GENE STRUCT EXPR, V1522, P9, DOI 10.1016/S0167-4781(01)00294-9; Dunn AY, 2001, J STRUCT BIOL, V135, P176, DOI 10.1006/jsbi.2001.4380; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Lucas KA, 2000, PHARMACOL REV, V52, P375; Martin E, 2003, P NATL ACAD SCI USA, V100, P9208, DOI 10.1073/pnas.1633590100; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; MURAD F, 1993, ADV SEC MESS PHOSPH, V28, P101; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Rademacher F, 1998, MICROBIOL-SGM, V144, P2951, DOI 10.1099/00221287-144-11-2951; Russwurm M, 2001, J BIOL CHEM, V276, P44647, DOI 10.1074/jbc.M105587200; Valpuesta JM, 2002, FEBS LETT, V529, P11, DOI 10.1016/S0014-5793(02)03180-0; Venema RC, 2003, AM J PHYSIOL-HEART C, V285, pH669, DOI 10.1152/ajpheart.01025.2002; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775	18	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					46946	46953		10.1074/jbc.M404134200	http://dx.doi.org/10.1074/jbc.M404134200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347653	hybrid			2022-12-25	WOS:000224832400078
J	Sugimoto, I; Murakami, H; Tonami, Y; Moriyama, A; Nakanishi, M				Sugimoto, I; Murakami, H; Tonami, Y; Moriyama, A; Nakanishi, M			DNA replication checkpoint control mediated by the spindle checkpoint protein Mad2p in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; SCHIZOSACCHAROMYCES-POMBE; DAMAGE CHECKPOINTS; S-PHASE; SACCHAROMYCES-CEREVISIAE; GENETICALLY INTERACTS; KINETOCHORES; MITOSIS; HOMOLOG; CDS1	The relationship between the DNA replication and spindle checkpoints of the cell cycle is unclear, given that in most eukaryotes, spindle formation occurs only after DNA replication is complete. Fission yeast rad3 mutant cells, which are deficient in DNA replication checkpoint function, enter, progress through, and exit mitosis even when DNA replication is blocked. In contrast, the entry of cds1 mutant cells into mitosis is delayed by several hours when DNA replication is inhibited. We show here that this delay in mitotic entry in cds1 cells is due in part to activation of the spindle checkpoint protein Mad2p. In the presence of the DNA replication inhibitor hydroxyurea (HU), cds1 mad2 cells entered and progressed through mitosis earlier than did cds1 cells. Overexpression of Mad2p or inactivation of Slp1p, a regulator of the anaphase-promoting complex, also rescued the checkpoint defect of HU-treated rad3 cells. Rad3p was shown to be involved in the physical interaction between Mad2p and Slp1p in the presence of HU. These results suggested that Mad2p and Slp1p act downstream of Rad3p in the DNA replication checkpoint and that Mad2p is required for the DNA replication checkpoint when Cds1p is compromised.	Nagoya City Univ, Grad Sch Med, Dept Biochem & Cell Biol, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Grad Sch Nat Sci, Div Biomol Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan; London Res Inst, Lincolns Inn Fields Labs, Canc Res UK, Cell Cycle Lab, London WC2A 3PX, England	Nagoya City University; Nagoya City University; Cancer Research UK	Murakami, H (corresponding author), Nagoya City Univ, Grad Sch Med, Dept Biochem & Cell Biol, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.	hmura@med.nagoya-cu.ac.jp		Murakami-Tonami, Yuko/0000-0002-6347-1630				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Garber PM, 2002, GENETICS, V161, P521; Garcia MA, 2002, EMBO J, V21, P6015, DOI 10.1093/emboj/cdf611; Garcia MA, 2001, EMBO J, V20, P3389, DOI 10.1093/emboj/20.13.3389; Hagan IM, 1998, J CELL SCI, V111, P1603; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; Ikui AE, 2002, J CELL SCI, V115, P1603; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; Millband DN, 2002, MOL CELL BIOL, V22, P2728, DOI 10.1128/MCB.22.8.2728-2742.2002; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murakami H, 1999, GENE DEV, V13, P2581, DOI 10.1101/gad.13.19.2581; Murakami H, 2000, BIOCHEM J, V349, P1, DOI 10.1042/0264-6021:3490001; Murakami H, 2002, NAT CELL BIOL, V4, P384, DOI 10.1038/ncb789; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Murakumo Y, 2000, J BIOL CHEM, V275, P4391, DOI 10.1074/jbc.275.6.4391; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yanagida M, 2000, GENES CELLS, V5, P1, DOI 10.1046/j.1365-2443.2000.00306.x; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766	34	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47372	47378		10.1074/jbc.M403231200	http://dx.doi.org/10.1074/jbc.M403231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15347659	hybrid			2022-12-25	WOS:000224832400126
J	Vaghefi, H; Neet, KE				Vaghefi, H; Neet, KE			Deacetylation of p53 after nerve growth factor treatment in PC12 cells as a post-translational modification mechanism of neurotrophin-induced tumor suppressor activation	ONCOGENE			English	Article						acetylation; signal transduction; apoptosis; differentiation	PROTEIN-KINASE ACTIVITY; DNA-DAMAGE; PHEOCHROMOCYTOMA CELLS; HISTONE DEACETYLASE; MEDIATED APOPTOSIS; NEURITE OUTGROWTH; CARCINOMA-CELLS; TRICHOSTATIN-A; PHOSPHORYLATION; INHIBITOR	The tumor suppressor protein p53 is a transcription factor that regulates the response to cellular insults such as DNA damage and growth factor withdrawal. Transcriptional activity of p53 requires post-translational modification by phosphorylation and acetylation. This study used site-specific antibodies to demonstrate that nerve growth factor (NGF) treatment of PC12 cells results in p53 deacetylation at lysine (Lys) 382. Histone deacetylase (HDAC) activity, measured by a direct fluorescent assay, was increased after NGF treatment and peaked before p53 deacetylation. Inhibition of HDAC by trichostatin blocked the deacetylation of p53 and its transcriptional activity toward a reporter gene construct. Comparison of PC12 with PC12 cells containing a temperature-sensitive, dominant-negative construct showed that p53 deacetylation required functional p53. Inhibitors of MAP kinase that block p53 transactivation and inhibitors of TrkA receptor also abolished HDAC activation, indicating that deacetylation of p53 is an NGF-dependent post-translational mechanism of p53 activation. Finally, NGF or serum withdrawal did not lead to p53 deacetylation. A model is proposed in which the acetylation status of Lys 382 of p53 discriminates between cell cycle arrest and apoptosis.	Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Chicago Medical School; Rosalind Franklin University Medical & Science	Neet, KE (corresponding author), Rosalind Franklin Univ Med & Sci, Chicago Med Sch, Dept Biochem & Mol Biol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	kenneth.neet@rosalindfranklin.edu			NINDS NIH HHS [NS24380] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024380] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3; Bayle JH, 1997, CHEM BIOL, V4, P885, DOI 10.1016/S1074-5521(97)90296-9; BENDORI R, 1983, FEBS LETT, V162, P384; Billon N, 1996, ONCOGENE, V13, P2047; Blaydes JP, 2001, J BIOL CHEM, V276, P4699, DOI 10.1074/jbc.M003485200; BOONSTRA J, 1985, BIOCHIMIE, V67, P1177, DOI 10.1016/S0300-9084(85)80117-6; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHANDRASEKARAN K, 1982, J CELL PHYSIOL, V113, P134, DOI 10.1002/jcp.1041130122; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Choi HS, 2002, BIOCHEM BIOPH RES CO, V296, P1005, DOI 10.1016/S0006-291X(02)02001-6; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cregan SP, 1999, J NEUROSCI, V19, P7860; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dornan D, 2003, J BIOL CHEM, V278, P13431, DOI 10.1074/jbc.M211460200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heneka MT, 1998, J NEUROCHEM, V71, P88; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hughes AL, 2000, J BIOL CHEM, V275, P37829, DOI 10.1074/jbc.M003146200; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Iwasaki S, 1999, J BIOL CHEM, V274, P26503, DOI 10.1074/jbc.274.37.26503; Jabbur JR, 2001, INT J MOL MED, V7, P163; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Lad SP, 2003, CNS NEUROL DISORD-DR, V2, P315, DOI 10.2174/1568007033482724; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; LEE V, 1977, P NATL ACAD SCI USA, V74, P5021, DOI 10.1073/pnas.74.11.5021; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; LIU M, 1995, ONCOGENE, V10, P1955; LUCKENBILLEDDS L, 1979, J NEUROCYTOL, V8, P493, DOI 10.1007/BF01214805; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; LUO Y, 1992, J BIOL CHEM, V267, P12275; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Mauser A, 2002, J VIROL, V76, P12503, DOI 10.1128/JVI.76.24.12503-12512.2002; Maxwell SA, 1996, ELECTROPHORESIS, V17, P1772, DOI 10.1002/elps.1150171115; MCGUIRE JC, 1979, J BIOL CHEM, V254, P3362; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Merrick BA, 2001, BIOCHEMISTRY-US, V40, P4053, DOI 10.1021/bi002045i; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; OHMICHI M, 1992, BIOCHEMISTRY-US, V31, P4034, DOI 10.1021/bi00131a019; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Roeder RG, 1998, COLD SPRING HARB SYM, V63, P201, DOI 10.1101/sqb.1998.63.201; Scotto C, 1999, MOL CELL BIOL, V19, P7168; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; Shiseki M, 2003, CANCER RES, V63, P2373; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; SLADEK TL, 1992, ONCOGENE, V7, P1305; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; TAPLEY P, 1992, ONCOGENE, V7, P371; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Vaghefi H, 2004, J BIOL CHEM, V279, P15604, DOI 10.1074/jbc.M311500200; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WOO SB, 1995, J BIOL CHEM, V270, P6278, DOI 10.1074/jbc.270.11.6278; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zeng LF, 2003, J BIOL CHEM, V278, P24594, DOI 10.1074/jbc.M301955200; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	86	21	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8078	8087		10.1038/sj.onc.1207953	http://dx.doi.org/10.1038/sj.onc.1207953			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361854				2022-12-25	WOS:000224692500005
J	Golpon, HA; Fadok, VA; Taraseviciene-Stewart, L; Scerbavicius, R; Sauer, C; Welte, T; Henson, PM; Voelkel, NF				Golpon, HA; Fadok, VA; Taraseviciene-Stewart, L; Scerbavicius, R; Sauer, C; Welte, T; Henson, PM; Voelkel, NF			Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth	FASEB JOURNAL			English	Article						apoptosis; endothelial cells; epithelial cells	IN-VITRO; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MACROPHAGES; PHOSPHATIDYLSERINE; LUNG; INHIBITION; CLEARANCE; PROLIFERATION; RECOGNITION	Removal of apoptotic cells by neighboring viable cells or professional phagocytes is essential for the maintenance of tissue homeostastis. Here we show that the phagocytosis of apoptotic Jurkat T cells by mouse epithelial cells (HC-11) and peritoneal macrophages leads to the secretion of growth and survival factors. We characterized VEGF as one of these factors which subsequently promote the proliferation of endothelial cells. Further we demonstrate that the phagocytosis of apoptotic bodies inhibits both spontanous and UV-irradiation-induced apoptosis in endothelial and epithelial cells. These effects were not observed when phagocytes had been exposed to viable or necrotic Jurkat T cells. We conclude that phagocytosis of apoptotic cells leads to secretion of growth and survival factors by phagocytes that represents a new form of life-promoting cell-cell interaction.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Pulm Hypertens Ctr, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA; Univ Magdeburg, Immunol Res Ctr, D-39120 Magdeburg, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health; Otto von Guericke University	Voelkel, NF (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Pulm Hypertens Ctr, 4200 E 9th Ave, Denver, CO 80262 USA.	norbert.voelkel@uchsc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060195, R01HL066554] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60195, HL 66554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aarbiou J, 2004, AM J RESP CELL MOL, V30, P193, DOI 10.1165/rcmb.2002-0267OC; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Geraci MW, 2001, CIRC RES, V88, P555, DOI 10.1161/01.RES.88.6.555; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hu B, 2000, J IMMUNOL, V165, P2124, DOI 10.4049/jimmunol.165.4.2124; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI200211638; Kaplan F, 2000, MOL GENET METAB, V71, P321, DOI 10.1006/mgme.2000.3040; KUNISAKI Y, 2004, IN PRESS BLOOD; Li MO, 2003, SCIENCE, V302, P1560, DOI 10.1126/science.1087621; Licht R, 1999, J IMMUNOL METHODS, V223, P237, DOI 10.1016/S0022-1759(98)00212-9; McDonald PP, 1999, J IMMUNOL, V163, P6164; Morimoto K, 2001, AM J RESP CELL MOL, V24, P608, DOI 10.1165/ajrcmb.24.5.4292; Ramanathan MD, 2003, EXP BIOL MED, V228, P697, DOI 10.1177/153537020322800608; Reddy SM, 2002, J IMMUNOL, V169, P702, DOI 10.4049/jimmunol.169.2.702; Reiter I, 1999, J IMMUNOL, V163, P1730; Salani D, 2000, AM J PATHOL, V157, P1703, DOI 10.1016/S0002-9440(10)64807-9; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Segura I, 2002, FASEB J, V16, DOI 10.1096/fj.01-0819com; Simamura E, 2001, TISSUE CELL, V33, P161; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Taraseviciene-Stewart L, 2001, FASEB J, V15, P427, DOI 10.1096/fj.00-0343com; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang Q, 2002, AM J RESP CRIT CARE, V166, P872, DOI 10.1164/rccm.2201007; Ware LB, 2002, AM J PHYSIOL-LUNG C, V282, pL924, DOI 10.1152/ajplung.00439.2001; Wright L, 1998, AM J RESP CRIT CARE, V157, P219, DOI 10.1164/ajrccm.157.1.9704003; [No title captured]	39	162	170	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1716	+		10.1096/fj.04-1853fje	http://dx.doi.org/10.1096/fj.04-1853fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345697				2022-12-25	WOS:000224243200050
J	Tam, J; Rosenberg, L; Maysinger, D				Tam, J; Rosenberg, L; Maysinger, D			INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice	FASEB JOURNAL			English	Article						dorsal root ganglia; diabetic neuropathy; STAT	GLUCAGON-LIKE PEPTIDE-1; NEOGENESIS-ASSOCIATED PROTEIN; GROWTH-FACTOR; PERIPHERAL-NERVE; NEURITE OUTGROWTH; ISLET-NEOGENESIS; NEUROTROPHIC FACTOR; CELL REGENERATION; AXONAL-TRANSPORT; GENE-EXPRESSION	INGAP peptide comprises the core active sequence of Islet Neogenesis Associated Protein ( INGAP), a pancreatic cytokine that can induce new islet formation and restore euglycemia in diabetic rodents. The ability of INGAP peptide in vitro to enhance nerve growth from sensory ganglia suggests its potential utility in peripheral nerve disorders. In this study, INGAP peptide was administered alone or in combination with insulin to streptozotocin-induced diabetic mice exhibiting signs of peripheral neuropathy. Following a 2-wk treatment period, thermal hypoalgesia in diabetic mice was significantly improved in groups that received INGAP peptide, without development of hyperalgesia. Explanted dorsal root ganglia (DRG) from these groups showed enhanced nerve outgrowth and evidence of increased mitochondrial activity. Western blotting experiments revealed attenuation of neurofilament hyperphosphorylation, up-regulation of alpha-tubulin and actin, and increased phosphorylation of the transcription factor STAT3 in DRG. These findings suggest that INGAP peptide can activate some of the signaling pathways implicated in nerve regeneration in sensory ganglia, thereby providing a means of improvement of nociceptive dysfunction in the peripheral nervous system.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Maysinger, D (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	dusica.maysinger@mcgill.ca	Maysinger, Dusica/GYU-6332-2022	Tam, Joseph/0000-0002-3864-7008				Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Agresti C, 1996, EUR J NEUROSCI, V8, P1106, DOI 10.1111/j.1460-9568.1996.tb01278.x; Akahori Y, 1997, NEUROREPORT, V8, P2265, DOI 10.1097/00001756-199707070-00034; Akkina SK, 2001, EXP NEUROL, V167, P173, DOI 10.1006/exnr.2000.7547; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Apfel SC, 1999, DIABETES OBES METAB, V1, P3, DOI 10.1046/j.1463-1326.1999.00006.x; Apfel SC, 2000, JAMA-J AM MED ASSOC, V284, P2215, DOI 10.1001/jama.284.17.2215; Apfel SC, 1998, NEUROLOGY, V51, P695, DOI 10.1212/WNL.51.3.695; Averill S, 2002, J NEUROSCI, V22, P7493; BERTELLI JA, 1995, J NEUROSCI METH, V58, P151, DOI 10.1016/0165-0270(94)00169-H; Bilsland J, 1999, J NEUROSCI METH, V92, P75, DOI 10.1016/S0165-0270(99)00099-0; BISBY MA, 1980, EXP NEUROL, V69, P74, DOI 10.1016/0014-4886(80)90144-2; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Calcutt NA, 2003, J CLIN INVEST, V111, P507, DOI 10.1172/JCI200315792; Christianson JA, 2003, J PAIN, V4, P493, DOI 10.1016/j.jpain.2003.07.002; DIAMOND J, 1987, P NATL ACAD SCI USA, V84, P6596, DOI 10.1073/pnas.84.18.6596; DIAMOND J, 1992, J NEUROSCI, V12, P1467; DIAMOND J, 1992, J NEUROSCI, V12, P1454; Dodge ME, 2002, BRAIN RES, V953, P144, DOI 10.1016/S0006-8993(02)03279-1; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Dyck P.J., 1999, DIABETIC NEUROPATHY, V2nd ed.; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FERNYHOUGH P, 1993, BRAIN RES, V607, P117, DOI 10.1016/0006-8993(93)91496-F; Fernyhough P, 1999, DIABETES, V48, P881, DOI 10.2337/diabetes.48.4.881; Flores LE, 2003, J ENDOCRINOL, V177, P243, DOI 10.1677/joe.0.1770243; Fox A, 1999, PAIN, V81, P307, DOI 10.1016/S0304-3959(99)00024-X; Gabra BH, 2002, EUR J PHARMACOL, V457, P115, DOI 10.1016/S0014-2999(02)02658-4; Giasson BI, 1997, J NEUROSCI, V17, P9466; Giasson BI, 1996, J BIOL CHEM, V271, P30404, DOI 10.1074/jbc.271.48.30404; Gold G, 1998, DIABETES, V47, pA253; Grandis M, 2001, MUSCLE NERVE, V24, P622, DOI 10.1002/mus.1047; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Havel PJ, 1998, AM J PHYSIOL-REG I, V274, pR1482, DOI 10.1152/ajpregu.1998.274.5.R1482; HOFFMAN PN, 1987, P NATL ACAD SCI USA, V84, P3472, DOI 10.1073/pnas.84.10.3472; ISHII DN, 1985, INT J NEUROSCI, V26, P109, DOI 10.3109/00207458508985610; Kerekes N, 1997, BRAIN RES, V754, P131, DOI 10.1016/S0006-8993(97)00056-5; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723; KOLB H, 1987, DIABETES METAB REV, V3, P751, DOI 10.1002/dmr.5610030308; Kolta MG, 1996, NEUROPEPTIDES, V30, P335, DOI 10.1016/S0143-4179(96)90022-0; Kunioku H, 2001, NEUROSCI LETT, V309, P13, DOI 10.1016/S0304-3940(01)02012-2; LIEBERMAN AR, 1976, PERIPHERAL NERVE, P188; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Liu RY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-17-j0003.2001; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; LONGO FM, 1986, MUSCLE NERVE, V9, P385, DOI 10.1002/mus.880090502; Middlemas A, 2003, BRAIN, V126, P1671, DOI 10.1093/brain/awg150; Mizisin AP, 1999, J PERIPHER NERV SYST, V4, P211; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Peterziel H, 2002, J CELL BIOL, V159, P157, DOI 10.1083/jcb.200203115; Pierson CR, 2003, J NEUROPATH EXP NEUR, V62, P260, DOI 10.1093/jnen/62.3.260; Pierson CR, 2002, J NEUROPATH EXP NEUR, V61, P857, DOI 10.1093/jnen/61.10.857; PITTENGER GL, 1992, ADV EXP MED BIOL, V321, P123; Rafaeloff R, 1997, J CLIN INVEST, V99, P2100, DOI 10.1172/JCI119383; Rosenberg L, 1996, DIABETOLOGIA, V39, P256; Rosenberg L, 2000, DIABETES, V49, pA256; Rosenberg L, 1998, MICROSC RES TECHNIQ, V43, P337, DOI 10.1002/(SICI)1097-0029(19981115)43:4<337::AID-JEMT8>3.0.CO;2-U; ROSENBERG L, 2004, IN PRESS ANN SURG; Schifitto G, 2001, NEUROLOGY, V57, P1313, DOI 10.1212/WNL.57.7.1313; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Sima AAF, 1999, DIABETOLOGIA, V42, P773, DOI 10.1007/s001250051227; Smith DS, 1997, J NEUROSCI, V17, P646; Snider WD, 1998, NEURON, V20, P629, DOI 10.1016/S0896-6273(00)81003-X; Srinivasan S, 2000, DIABETES, V49, P1932, DOI 10.2337/diabetes.49.11.1932; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stromberg H, 2000, BRAIN RES, V853, P105, DOI 10.1016/S0006-8993(99)02260-X; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; Sun Y, 2002, BIOCHEM BIOPH RES CO, V295, P532, DOI 10.1016/S0006-291X(02)00706-4; Tam J, 2002, BIOCHEM BIOPH RES CO, V291, P649, DOI 10.1006/bbrc.2002.6497; Taylor-Fishwick DA, 2003, BBA-MOL BASIS DIS, V1638, P83, DOI 10.1016/S0925-4439(03)00042-5; Tomlinson DR, 1999, DIABETOLOGIA, V42, P1271, DOI 10.1007/s001250051439; Unno M, 2002, DIABETES, V51, pS478, DOI 10.2337/diabetes.51.2007.S478; Varejao ASP, 2001, J NEUROSCI METH, V108, P1, DOI 10.1016/S0165-0270(01)00378-8; Veeranna, 1998, J NEUROSCI, V18, P4008; Wellmer A, 2001, J PERIPHER NERV SYST, V6, P204, DOI 10.1046/j.1529-8027.2001.01019.x; Woolfe G, 1944, J PHARMACOL EXP THER, V80, P300; Yasuda H, 2003, PROG NEUROBIOL, V69, P229, DOI 10.1016/S0301-0082(03)00034-0; Zhuang HX, 1997, J PHARMACOL EXP THER, V283, P366	83	28	30	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1767	+		10.1096/fj.04-1894fje	http://dx.doi.org/10.1096/fj.04-1894fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345684				2022-12-25	WOS:000224243200037
J	Zhu, YM; Stolz, DB; Guo, FL; Ross, MA; Watkins, SC; Tan, BJ; Qi, RZ; Manser, E; Li, QT; Bay, BH; Teo, TS; Duan, W				Zhu, YM; Stolz, DB; Guo, FL; Ross, MA; Watkins, SC; Tan, BJ; Qi, RZ; Manser, E; Li, QT; Bay, BH; Teo, TS; Duan, W			Signaling via a novel integral plasma membrane pool of a serine/threonine protein kinase PRK1 in mammalian cells	FASEB JOURNAL			English	Article						PKN; RhoA; protein kinase C; androgen receptor; prostate cancer; neurite retraction	RHO-GTPASES; LYSOPHOSPHATIDIC ACID; ANDROGEN RECEPTOR; DIFFERENTIAL LOCALIZATION; PROSTATE-CANCER; PHOSPHORYLATION; ACTIVATION; DOMAIN; PKN; MECHANISMS	Mammalian serine/threonine protein kinases, except for TGF-beta receptor kinase family, are intracellular proteins. PRK1/PKN is a member of the protein kinase C superfamily of serine/threonine kinases and is one of the first identified effectors for RhoA GTPase. However, the role of PRK1 in mediating signaling downstream of activated RhoA is largely unknown. Here, we present evidence that identifies a novel plasma membrane pool of PRK1. This integral membrane form of PRK1 is catalytically active. The phosphorylation of serine(377) of PRK1 is required for its integration into membranes. This integration is essential for PRK1 to function as a Rho effector as only the integral plasma membrane PRK1 is able to initiate RhoA-mediated and ligand-dependent transcriptional activation of the androgen receptor in human epithelial cells and to mediate RhoA-induced neurite retraction in mouse neuronal cells. These results indicate that RhoA signals via the integral membrane pool of its effectors in its immediate vicinity at the plasma membrane, thus establishing a new paradigm in mammalian cell signaling.	Natl Univ Singapore, Fac Med, Dept Biochem, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Anat, Singapore 117597, Singapore; Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA 15261 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore	National University of Singapore; National University of Singapore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Duan, W (corresponding author), Natl Univ Singapore, Fac Med, Dept Biochem, MD4 Annex,Room 02-05,8 Med Dr, Singapore 117597, Singapore.	bchduanw@nus.edu.sg	Watkins, Simon/ABG-2590-2021; Manser, Edward/ABD-2301-2020; Duan, Wei/A-5181-2015	Watkins, Simon/0000-0003-4092-1552; Duan, Wei/0000-0001-5782-9184; Qi, Robert Zhong/0000-0001-5596-8172				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Benard V, 2002, METHOD ENZYMOL, V345, P349; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Bowie JU, 2001, CURR OPIN STRUC BIOL, V11, P397, DOI 10.1016/S0959-440X(00)00223-2; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Cronauer MV, 2003, INT J ONCOL, V23, P1095; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fleming IN, 1996, J BIOL CHEM, V271, P33067, DOI 10.1074/jbc.271.51.33067; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; GARAVITO RM, 2003, BIOPHYS J, V32, P183; Kitagawa M, 1996, BIOCHEM BIOPH RES CO, V220, P963, DOI 10.1006/bbrc.1996.0515; Kranenburg O, 1997, J CELL SCI, V110, P2417; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Liang XQ, 2002, J BIOL CHEM, V277, P33032, DOI 10.1074/jbc.M204607200; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Manser E, 2002, DEV CELL, V3, P323, DOI 10.1016/S1534-5807(02)00268-X; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mukai H, 2003, J BIOCHEM, V133, P17, DOI 10.1093/jb/mvg019; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; OKAMOTO T, 1999, CURRENT PROTOCOLS S, V3; Peng B, 1996, J BIOL CHEM, V271, P32233, DOI 10.1074/jbc.271.50.32233; Pryde JG, 1998, METH MOL B, V88, P23; Pyne S, 2000, PHARMACOL THERAPEUT, V88, P115, DOI 10.1016/S0163-7258(00)00084-X; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sayas CL, 2002, BBA-MOL CELL BIOL L, V1582, P144, DOI 10.1016/S1388-1981(02)00149-X; Shotton DM, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P26; SILVIUS JR, 1992, ANNU REV BIOPH BIOM, V21, P323, DOI 10.1146/annurev.bb.21.060192.001543; Silvius JR, 2002, J MEMBRANE BIOL, V190, P83, DOI 10.1007/s00232-002-1026-4; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	43	19	21	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1722	+		10.1096/fj.04-1876fje	http://dx.doi.org/10.1096/fj.04-1876fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375078				2022-12-25	WOS:000224243200023
J	Dgany, O; Gonzalez, A; Sofer, O; Wang, WX; Zolotnitsky, G; Wolf, A; Shoham, Y; Altman, A; Wolf, SG; Shoseyov, O; Almog, O				Dgany, O; Gonzalez, A; Sofer, O; Wang, WX; Zolotnitsky, G; Wolf, A; Shoham, Y; Altman, A; Wolf, SG; Shoseyov, O; Almog, O			The structural basis of the thermostability of SP1, a novel plant (Populus tremula) boiling stable protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; DIFFERENTIAL ACCUMULATION; SUCROSE SYNTHASE; STRESS; REFINEMENT; TOLERANCE; LESSONS; ENZYMES; GENES	We previously reported on a new boiling stable protein isolated from aspen plants ( Populus tremula), which we named SP1. SP1 is a stress-related protein with no significant sequence homology to other stress-related proteins. It is a 108-amino-acid hydrophilic polypeptide with a molecular mass of 12.4 kDa (Wang, W. X., Pelah, D., Alergand, T., Shoseyov, O., and Altman, A. ( 2002) Plant Physiol. 130, 865 - 875) and is found in an oligomeric form. Preliminary electron microscopy studies and matrix-assisted laser desorption ionization time-of-flight mass spectrometry experiments showed that SP1 is a dodecamer composed of two stacking hexamers. We performed a SDS-PAGE analysis, a differential scanning calorimetric study, and crystal structure determination to further characterize SP1. SDS-PAGE indicated a spontaneous assembly of SP1 to one stable oligomeric form, a dodecamer. Differential scanning calorimetric showed that SP1 has high thermostability i.e. T-m of 107 degreesC (at pH 7.8). The crystal structure of SP1 was initially determined to 2.4 Angstrom resolution by multi-wavelength anomalous dispersion method from a crystal belonging to the space group I422. The phases were extended to 1.8 Angstrom resolution using data from a different crystal form (P21). The final refined molecule includes 106 of the 108 residues and 132 water molecules ( on average for each chain). The R-free is 20.1%. The crystal structure indicated that the SP1 molecule has a ferredoxin-like fold. Strong interactions between each two molecules create a stable dimer. Six dimers associate to form a ring-like-shaped dodecamer strongly resembling the particle visualized in the electron microscopy studies. No structural similarity was found between the crystal structure of SP1 and the crystal structure of other stress-related proteins such as small heat shock proteins, whose structure has been already determined. This structural study further supports our previous report that SP1 may represent a new family of stress-related proteins with high thermostability and oligomerization.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Robert H Smith Inst Plant Sci & Genet Agr, IL-76100 Rehovot, Israel; Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Fulcrum SP Ltd, IL-46104 Herzliyya, Israel; Weizmann Inst Sci, Elect Microscopy Unit, IL-76100 Rehovot, Israel	Ben Gurion University; Hebrew University of Jerusalem; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Technion Israel Institute of Technology; Weizmann Institute of Science	Almog, O (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel.	almogo@bgu.ac.il	Shoham, Yuval/M-4409-2013; WOLF, SHARON G/K-1768-2012; Li, Laigeng/AAA-2067-2020	WOLF, SHARON G/0000-0002-5337-5063; Li, Laigeng/0000-0001-6924-4431; Wang, Wang-Xia/0000-0002-8104-3779				Almog O, 2003, J MOL BIOL, V332, P1071, DOI 10.1016/j.jmb.2003.07.011; Almog O, 2002, J BIOL CHEM, V277, P27553, DOI 10.1074/jbc.M111777200; Arnold FH, 2001, TRENDS BIOCHEM SCI, V26, P100, DOI 10.1016/S0968-0004(00)01755-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; CHEN Q, 1994, J BIOL CHEM, V269, P13216; Clantin B, 2001, EUR J BIOCHEM, V268, P3937, DOI 10.1046/j.1432-1327.2001.02302.x; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DURE L, 1993, PLANT J, V3, P363, DOI 10.1046/j.1365-313X.1993.t01-18-00999.x; Evans PR, 1999, ACTA CRYSTALLOGR D, V55, P1771, DOI 10.1107/S0907444999011117; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LUZZATI V, 1953, ACTA CRYSTALLOGR, V6, P142, DOI 10.1107/S0365110X53000508; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PELAH D, 1995, TREE PHYSIOL, V15, P673, DOI 10.1093/treephys/15.10.673; Pelah D, 1997, PHYSIOL PLANTARUM, V99, P153, DOI 10.1034/j.1399-3054.1997.990121.x; Pelah D, 1997, J PLANT PHYSIOL, V151, P96, DOI 10.1016/S0176-1617(97)80043-0; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; Thomashow MF, 1998, PLANT PHYSIOL, V118, P1, DOI 10.1104/pp.118.1.1; Thomashow MF, 1999, ANNU REV PLANT PHYS, V50, P571, DOI 10.1146/annurev.arplant.50.1.571; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Wang WX, 2004, TRENDS PLANT SCI, V9, P244, DOI 10.1016/j.tplants.2004.03.006; Wang WX, 2003, ACTA CRYSTALLOGR D, V59, P512, DOI 10.1107/S0907444902022618; Wang WX, 2002, PLANT PHYSIOL, V130, P865, DOI 10.1104/pp.002436; Wang WX, 2003, PLANTA, V218, P1, DOI 10.1007/s00425-003-1105-5; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4	33	70	78	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51516	51523		10.1074/jbc.M409952200	http://dx.doi.org/10.1074/jbc.M409952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371455	hybrid			2022-12-25	WOS:000225355800105
J	Ding, WG; Toyoda, F; Matsuura, H				Ding, WG; Toyoda, F; Matsuura, H			Regulation of cardiac I-Ks potassium current by membrane phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CURRENT; INWARD RECTIFIER; PHOSPHOLIPASE-C; 2 COMPONENTS; G-PROTEINS; CHANNELS; ACTIVATION; MODULATION; INHIBITION; RECEPTOR	Regulation of the slowly activating component of delayed rectifier K+ current (I-Ks) by membrane phospholipid phosphatidylinositol 4,5-bisphosphate ( PtdIns( 4,5) P-2) was examined in guinea pig atrial myocytes using the whole-cell patch clamp method. I-Ks was elicited by depolarizing voltage steps given from a holding potential of - 50 mV, and the effect of various test reagents on IKs was assessed by measuring the amplitude of tail current elicited upon return to the holding potential following a 2-s depolarization to + 30 mV. Intracellular application of 50 muM wortmannin through a recording pipette evoked a progressive increase in I-Ks over a 10-15- min period to 208.5 +/- 14.6% (n = 9) of initial magnitude obtained shortly after rupture of the patch membrane. Intracellular application of anti-PtdIns(4,5) P-2 monoclonal antibody also increased the amplitude of IKs to 198.4 +/- 19.9% (n = 5). In contrast, intracellular loading with exogenous PtdIns(4,5) P-2 at 10 and 100 muM produced a marked decrease in the amplitude of I-Ks to 54.3 +/- 3.8% ( n = 5) and 44.8 +/- 8.2% ( n = 5), respectively. Intracellular application of neomycin ( 50 muM) or aluminum ( 50 muM) evoked an increase in the amplitude of I-Ks to 161.0 +/- 13.5% ( n = 4) and 150.0 +/- 8.2% ( n = 4), respectively. These results strongly suggest that I-Ks channel is inhibited by endogenous membrane PtdIns( 4,5) P-2 through the electrostatic interaction with the negatively charged head group on PtdIns(4,5) P-2. Potentiation of I-Ks by P2Y receptor stimulation with 50 muM ATP was almost totally abolished when PtdIns( 4,5) P-2 was included in the pipette solution, suggesting that depletion of membrane PtdIns(4,5) P-2 is involved in the potentiation of I-Ks by P2Y receptor stimulation. Thus, membrane PtdIns( 4,5) P-2 may act as an important physiological regulator of I-Ks in guinea pig atrial myocytes.	Shiga Univ Med Sci, Dept Physiol, Shiga 5202192, Japan	Shiga University of Medical Science	Ding, WG (corresponding author), Shiga Univ Med Sci, Dept Physiol, Shiga 5202192, Japan.	ding@belle.shiga-med.ac.jp						Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bian JS, 2001, CIRC RES, V89, P1168, DOI 10.1161/hh2401.101375; Bosch RF, 1998, CARDIOVASC RES, V38, P441, DOI 10.1016/S0008-6363(98)00021-2; Botelho RJ, 2000, J CELL BIOL, V151, P1353, DOI 10.1083/jcb.151.7.1353; Busch AE, 1996, PFLUG ARCH EUR J PHY, V432, P1094, DOI 10.1007/s004240050240; Cho H, 2002, J BIOL CHEM, V277, P27742, DOI 10.1074/jbc.M203660200; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Ford CP, 2003, J NEUROSCI, V23, P4931, DOI 10.1523/jneurosci.23-12-04931.2003; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; HABUCHI Y, 1992, AM J PHYSIOL, V262, pH345, DOI 10.1152/ajpheart.1992.262.2.H345; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hara Y, 1997, EUR J PHARMACOL, V324, P295, DOI 10.1016/S0014-2999(97)00088-5; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; ISENBERG G, 1982, PFLUG ARCH EUR J PHY, V395, P6, DOI 10.1007/BF00584963; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Li GR, 1996, CIRC RES, V78, P689, DOI 10.1161/01.RES.78.4.689; LIU DW, 1995, CIRC RES, V76, P351, DOI 10.1161/01.RES.76.3.351; Loussouarn G, 2003, EMBO J, V22, P5412, DOI 10.1093/emboj/cdg526; Matsuura H, 1996, J PHYSIOL-LONDON, V490, P647, DOI 10.1113/jphysiol.1996.sp021174; Matsuura H, 1996, J PHYSIOL-LONDON, V490, P659, DOI 10.1113/jphysiol.1996.sp021175; Matsuura H, 1997, J PHYSIOL-LONDON, V503, P45, DOI 10.1111/j.1469-7793.1997.045bi.x; Matsuura H, 1996, J PHYSIOL-LONDON, V497, P379, DOI 10.1113/jphysiol.1996.sp021775; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; Nasuhoglu C, 2002, AM J PHYSIOL-CELL PH, V283, pC223, DOI 10.1152/ajpcell.00486.2001; Oketani N, 2002, AM J PHYSIOL-HEART C, V282, pH757, DOI 10.1152/ajpheart.00246.2001; POWELL T, 1980, J PHYSIOL-LONDON, V302, P131; RAGAZZI E, 1991, CIRC RES, V68, P1035, DOI 10.1161/01.RES.68.4.1035; Ralevic V, 1998, PHARMACOL REV, V50, P413; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; Selyanko AA, 2000, J PHYSIOL-LONDON, V522, P349, DOI 10.1111/j.1469-7793.2000.t01-2-00349.x; Suh BC, 2002, NEURON, V35, P507, DOI 10.1016/S0896-6273(02)00790-0; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; TOHSE N, 1987, AM J PHYSIOL, V253, pH1321, DOI 10.1152/ajpheart.1987.253.5.H1321; TOHSE N, 1992, CIRC RES, V71, P1441, DOI 10.1161/01.RES.71.6.1441; TOHSE N, 1200, AM J PHYSL, V258; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TSIEN RY, 1980, BIOCHIM BIOPHYS ACTA, V599, P623, DOI 10.1016/0005-2736(80)90205-9; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALSH KB, 1988, SCIENCE, V242, P67, DOI 10.1126/science.2845575; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Wu L, 2002, NATURE, V419, P947, DOI 10.1038/nature01118; Xie LH, 1999, J PHYSIOL-LONDON, V514, P655, DOI 10.1111/j.1469-7793.1999.655ad.x; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					50726	50734		10.1074/jbc.M409374200	http://dx.doi.org/10.1074/jbc.M409374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15364935	hybrid			2022-12-25	WOS:000225355800014
J	Steel, R; Doherty, JP; Buzzard, K; Clemons, N; Hawkins, CJ; Anderson, RL				Steel, R; Doherty, JP; Buzzard, K; Clemons, N; Hawkins, CJ; Anderson, RL			Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; STRESS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; N-TERMINAL KINASE; DEPENDENT FORMATION; ENERGY DEPRIVATION; CELL-DEATH; ACTIVATION; HEAT-SHOCK-PROTEIN-70; CASPASE-2	Hsp72 protects cells against apoptosis in response to various stresses. By simultaneously measuring cytochrome c localization and nuclear morphology in mouse embryo fibroblasts, we have shown that Hsp72 blocks cytochrome c release from mitochondria in response to cytotoxic stress and that permeabilization of the outer mitochondrial membrane is the critical point in deciding the fate of the cell. Hsp72 did not inhibit apoptosis in mouse embryo fibroblasts once cytochrome c had been released from the mitochondria. Recent reports have claimed that Hsp72 can prevent caspase activation by inhibiting the oligomerization of Apaf-1 in the presence of cytochrome c and dATP. We now show that this apparent function of recombinant Hsp72 is due to the presence of salt in the Hsp72 preparation and that the same response can be achieved by the addition of heat-denatured Hsp72 in the same high salt buffer or by the high salt buffer alone. Hsp72 expressed in a range of different cell lines had no inhibitory effect on cytochrome c-stimulated caspase activity of cytosolic extracts. We conclude that the protective effect of Hsp72 occurs upstream of the mitochondria and not through the inhibition of the apoptosome.	Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia; Murdock Childrens Res Inst, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Murdoch Children's Research Institute	Anderson, RL (corresponding author), Peter MacCallum Canc Ctr, ABeckett St,Locked Bag 1, Melbourne, Vic 8006, Australia.	robin.anderson@petermac.org	Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Clemons, Nicholas/AAN-6516-2020; Hawkins, Christine/B-8769-2011; Anderson, Robin/S-1005-2017	Clemons, Nicholas/0000-0001-9283-9978; Hawkins, Christine/0000-0001-8120-1071; /0000-0002-0423-6120; Anderson, Robin/0000-0002-6841-7422	NATIONAL CANCER INSTITUTE [R01CA081421] Funding Source: NIH RePORTER; NCI NIH HHS [CA81421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cain K, 2001, J BIOL CHEM, V276, P41985, DOI 10.1074/jbc.M107419200; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Ekert PG, 2004, J CELL BIOL, V165, P835, DOI 10.1083/jcb.200312031; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; GABAI VL, 1993, FEBS LETT, V327, P247, DOI 10.1016/0014-5793(93)80997-9; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gotoh T, 2004, CELL DEATH DIFFER, V11, P390, DOI 10.1038/sj.cdd.4401369; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; KABAKOV AE, 1995, EXP CELL RES, V217, P15, DOI 10.1006/excr.1995.1058; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lawen A, 2003, BIOESSAYS, V25, P888, DOI 10.1002/bies.10329; Lemaire C, 1998, FEBS LETT, V425, P266, DOI 10.1016/S0014-5793(98)00252-X; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; LI LG, 1995, EXP CELL RES, V217, P460, DOI 10.1006/excr.1995.1110; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; Marsden VS, 2004, J CELL BIOL, V165, P775, DOI 10.1083/jcb.200312030; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 2001, CELL STRESS CHAPERON, V6, P49, DOI 10.1379/1466-1268(2001)006<0049:HPMOTC>2.0.CO;2; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Segal MS, 2001, AM J PHYSIOL-CELL PH, V281, pC1196, DOI 10.1152/ajpcell.2001.281.4.C1196; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; Volbracht C, 2001, MOL MED, V7, P36, DOI 10.1007/BF03401837; Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WU BJ, 1986, MOL CELL BIOL, V6, P2994, DOI 10.1128/MCB.6.8.2994; Yaglom JA, 2003, J BIOL CHEM, V278, P50483, DOI 10.1074/jbc.M306903200; Zhuang JG, 1998, TOXICOL LETT, V103, P121, DOI 10.1016/S0378-4274(98)00296-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	54	107	114	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51490	51499		10.1074/jbc.M401314200	http://dx.doi.org/10.1074/jbc.M401314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371421	hybrid			2022-12-25	WOS:000225355800102
J	Al-Rasheed, NM; Chana, RS; Baines, RJ; Willars, GB; Brunskill, NJ				Al-Rasheed, NM; Chana, RS; Baines, RJ; Willars, GB; Brunskill, NJ			Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells - Dependent on phosphatidylinositol 3-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; GENE-EXPRESSION; SIGNALING PATHWAYS; GLUCOSE-TOLERANCE; RESISTANCE; BINDING; CD36; PHOSPHORYLATION; TRANSPORT; PREVENTS	Peroxisome proliferator-activated receptor gamma (PPARgamma) has key roles in the regulation of adipogenesis, inflammation, and lipid and glucose metabolism. C-peptide is believed to be inert and without appreciable biological functions. Recent studies suggest that C-peptide possesses multiple functions. The present study investigated the effects of insulin and C-peptide on PPARgamma transcriptional activity in opossum kidney proximal tubular cells. Both insulin and C-peptide induced a concentration-dependent stimulation of PPARgamma transcriptional activity. Both agents substantially augmented thiazolidinedione-stimulated PPARgamma transcriptional activity. Neither insulin nor C-peptide had any effect on the expression levels of PPARgamma. GW9662, a PPARgamma antagonist, blocked PPARgamma activation by thiazolidinediones but had no effect on either insulin- or C-peptide-stimulated PPARgamma transcriptional activity. Co-transfection of opossum kidney cells with dominant negative mitogen-activated protein kinase kinase significantly depressed basal PPARgamma transcriptional activity but had no effect on that induced by either insulin or C-peptide. Both insulin- and C-peptide-stimulated PPARgamma transcriptional activity were attenuated by wortmannin and by expression of a dominant negative phosphatidylinositol (PI) 3-kinase p85 regulatory subunit. In addition PI 3-kinase-dependent phosphorylation of PPARgamma was observed after stimulation by C-peptide or insulin. C-peptide effects but not insulin on PPARgamma transcriptional activity were abolished by pertussis toxin pretreatment. Finally both C-peptide and insulin positively control the expression of the PPARgamma-regulated CD36 scavenger receptor in human THP-1 monocytes. We concluded that insulin and C-peptide can stimulate PPARgamma activity in a ligand-independent fashion and that this effect is mediated by PI 3-kinase. These results support a new and potentially important physiological role for C-peptide in regulation of PPARgamma-related cell functions.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England; King Saud Univ, Dept Pharmacol, Riyadh, Saudi Arabia	University of Leicester; University of Leicester; King Saud University	Brunskill, NJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	njb18@le.ac.uk		Nigel, Brunskill/0000-0002-7109-7108				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Al-Rasheed NM, 2004, DIABETOLOGIA, V47, P987, DOI 10.1007/s00125-004-1404-9; Arici M, 2003, J AM SOC NEPHROL, V14, P17, DOI 10.1097/01.ASN.0000042167.66685.EA; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Brunskill NJ, 1998, J CLIN INVEST, V101, P2140, DOI 10.1172/JCI1923; Camp HS, 1997, J BIOL CHEM, V272, P10811; Chana RS, 2004, KIDNEY INT, V65, P2081, DOI 10.1111/j.1523-1755.2004.00624.x; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Grunberger G, 2001, DIABETOLOGIA, V44, P1247, DOI 10.1007/s001250100632; Hevener AL, 2001, DIABETES, V50, P2316, DOI 10.2337/diabetes.50.10.2316; Huh HY, 1996, BLOOD, V87, P2020; Ido Y, 1997, SCIENCE, V277, P563, DOI 10.1126/science.277.5325.563; Iwata M, 2001, DIABETES, V50, P1083, DOI 10.2337/diabetes.50.5.1083; Johansson J, 2002, BIOCHEM BIOPH RES CO, V295, P1035, DOI 10.1016/S0006-291X(02)00721-0; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kitamura T, 2003, DIABETOLOGIA, V46, P1698, DOI 10.1007/s00125-003-1232-3; Kitamura T, 2002, BIOCHEM J, V366, P737, DOI 10.1042/BJ20020344; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; MAX N, 2004, ARTERIOSCLER THROMB, V24, P540; Nicholson AC, 2004, TRENDS CARDIOVAS MED, V14, P8, DOI 10.1016/j.tcm.2003.09.004; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Qi NN, 2002, J BIOL CHEM, V277, P48501, DOI 10.1074/jbc.M206655200; Rangwala SM, 2004, TRENDS PHARMACOL SCI, V25, P331, DOI 10.1016/j.tips.2004.03.012; Rieusset J, 1999, DIABETES, V48, P699, DOI 10.2337/diabetes.48.4.699; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; Seda O, 2003, PHYSIOL GENOMICS, V12, P73, DOI 10.1152/physiolgenomics.00113.2002; Sima AAF, 2001, DIABETOLOGIA, V44, P889, DOI 10.1007/s001250100570; VidalPuig AJ, 1997, J CLIN INVEST, V99, P2416, DOI 10.1172/JCI119424; Wahren J, 2004, CLIN PHYSIOL FUNCT I, V24, P180, DOI 10.1111/j.1475-097X.2004.00558.x; Wahren J, 2000, AM J PHYSIOL-ENDOC M, V278, pE759, DOI 10.1152/ajpendo.2000.278.5.E759; Walcher D, 2004, DIABETES, V53, P1664, DOI 10.2337/diabetes.53.7.1664; Werman A, 1997, J BIOL CHEM, V272, P20230, DOI 10.1074/jbc.272.32.20230; Wu W, 1996, ACTA PHYSIOL SCAND, V157, P253, DOI 10.1046/j.1365-201X.1996.489236000.x; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZIERATH JR, 1991, DIABETOLOGIA, V34, P899, DOI 10.1007/BF00400197; Zierath JR, 1996, DIABETOLOGIA, V39, P306	43	58	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49747	49754		10.1074/jbc.M408268200	http://dx.doi.org/10.1074/jbc.M408268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375153	hybrid			2022-12-25	WOS:000225229500026
J	Benzaghou, I; Bougie, I; Bisaillon, M				Benzaghou, I; Bougie, I; Bisaillon, M			Effect of metal ion binding on the structural stability of the hepatitis C virus RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN 5B; DE-NOVO INITIATION; 3'-5' EXONUCLEASE ACTIVITY; VIRAL REPLICATION; CRYSTAL-STRUCTURE; NS5B PROTEIN; MECHANISM; IDENTIFICATION; SITE; REQUIREMENTS	The RNA polymerase activity of the hepatitis C virus, a major human pathogen, has previously been shown to be supported by metal ions. In the present study, we report a systematic analysis of the effect of metal ion binding on the structural stability of the hepatitis C virus RNA polymerase. Chemical and thermal denaturation assays revealed that the stability of the protein is increased significantly in the presence of metal ions. Structural analyses clearly established that metal ion binding increases hydrophobic exposure on the RNA polymerase surface. Furthermore, our denaturation studies, coupled with polymerization assays, demonstrate that the active site region of the polymerase is more sensitive to chemical denaturant than other structural scaffolds. We also report the first detailed study of the thermodynamic parameters involved in the interaction between the hepatitis C virus RNA polymerase and metal ions. Finally, a mutational analysis was also performed to investigate the importance of Asp(220), Asp(318), and Asp(319) for metal ion binding. This mutational study underscores a strict requirement for each of the residues for metal binding, indicating that the active center of the HCV RNA polymerase is intolerant to virtually any perturbations of the metal coordination sphere, thereby highlighting the critical role of the enzyme-bound metal ions. Overall, our results indicate that metal ions play a dual modulatory role in the RNA polymerase reaction by promoting both a favorable geometry of the active site for catalysis and by increasing the structural stability of the enzyme.	Univ Sherbrooke, Fac Med, Dept Biochim, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Bisaillon, M (corresponding author), Univ Sherbrooke, Fac Med, Dept Biochim, 3001 12E Ave, Sherbrooke, PQ J1H 5N4, Canada.	Martin.Bisaillon@USherbrooke.ca						Al RH, 1998, VIRUS RES, V53, P141, DOI 10.1016/S0168-1702(97)00147-0; ALTER HJ, 1995, BLOOD, V85, P1681, DOI 10.1182/blood.V85.7.1681.bloodjournal8571681; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Bougie I, 2003, J BIOL CHEM, V278, P3868, DOI 10.1074/jbc.M209785200; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; CALHOUN DB, 1983, BIOCHEMISTRY-US, V22, P1533, DOI 10.1021/bi00276a003; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Cheney IW, 2002, VIROLOGY, V297, P298, DOI 10.1006/viro.2002.1461; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; DeFrancesco R, 1996, METHOD ENZYMOL, V275, P58; Dimitrova M, 2003, J VIROL, V77, P5401, DOI 10.1128/JVI.77.9.5401-5414.2003; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; HOUGHTON M, 1996, VIROLOGY, P1035; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Hung HC, 2001, PROTEIN SCI, V10, P34, DOI 10.1110/ps.35201; JANEWAY CML, 1993, BIOCHEMISTRY-US, V32, P1601, DOI 10.1021/bi00057a026; Johnson RB, 2000, ARCH BIOCHEM BIOPHYS, V377, P129, DOI 10.1006/abbi.2000.1749; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; LABOWICZ JR, 1999, PRINCIPLES FLUORESCE, P237; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Matulis D, 1998, BIOPHYS J, V74, P422, DOI 10.1016/S0006-3495(98)77799-9; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Moradpour D, 2003, ANTIVIR RES, V60, P103, DOI 10.1016/j.antiviral.2003.08.017; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Scolnick LR, 1997, BIOCHEMISTRY-US, V36, P10558, DOI 10.1021/bi970800v; Shirota Y, 2002, J BIOL CHEM, V277, P11149, DOI 10.1074/jbc.M111392200; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Uchiyama Y, 2002, HEPATOL RES, V23, P90, DOI 10.1016/S1386-6346(01)00167-X; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	49	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49755	49761		10.1074/jbc.M409657200	http://dx.doi.org/10.1074/jbc.M409657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375162	hybrid			2022-12-25	WOS:000225229500027
J	Chou, CL; Christensen, BM; Frische, S; Vorum, H; Desai, RA; Hoffert, JD; de Lanerolle, P; Nielsen, S; Knepper, MA				Chou, CL; Christensen, BM; Frische, S; Vorum, H; Desai, RA; Hoffert, JD; de Lanerolle, P; Nielsen, S; Knepper, MA			Non-muscle myosin II and myosin light chain kinase are downstream targets for vasopressin signaling in the renal collecting duct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI-DERIVED VESICLES; BLADDER GRANULAR-CELL; TOAD URINARY-BLADDER; RAT-KIDNEY; F-ACTIN; WATER PERMEABILITY; EPITHELIAL-CELLS; AQUAPORIN-2 TRAFFICKING; ORGANELLE TRANSPORT; INTRACELLULAR CA2+	We have previously demonstrated that vasopressin increases the water permeability of the inner medullary collecting duct (IMCD) by inducing trafficking of aquaporin-2 to the apical plasma membrane and that this response is dependent on intracellular calcium mobilization and calmodulin activation. Here, we address the hypothesis that this water permeability response is mediated in part through activation of the calcium/calmodulin-dependent myosin light chain kinase (MLCK) and regulation of non-muscle myosin II. Immunoblotting and immunocytochemistry demonstrated the presence of MLCK, the myosin regulatory light chain (MLC), and the IIA and IIB isoforms of the non-muscle myosin heavy chain in rat IMCD cells. Two-dimensional electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry identified two isoforms of MLC, both of which also exist in phosphorylated and non-phosphorylated forms. P-32 incubation of the inner medulla followed by autoradiography of two-dimensional gels demonstrated increased P-32 labeling of both isoforms in response to the V-2 receptor agonist [deamino-Cys(1), D-Arg(8)] vasopressin (DDAVP). Time course studies of MLC phosphorylation in IMCD suspensions ( using immunoblotting with anti-phospho-MLC antibodies) showed that the increase in phosphorylation could be detected as early as 30 s after exposure to vasopressin. The MLCK inhibitor ML-7 blocked the DDAVP-induced MLC phosphorylation and substantially reduced [Arg(8)] vasopressin (AVP)stimulated water permeability. AVP-induced MLC phosphorylation was associated with a rearrangement of actin filaments ( Alexa Fluor 568-phalloidin) in primary cultures of IMCD cells. These results demonstrate that MLC phosphorylation by MLCK represents a downstream effect of AVP-activated calcium/calmodulin signaling in IMCD cells and point to a role for non-muscle myosin II in regulation of water permeability by vasopressin.	NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bethesda, MD 20892 USA; Univ Aarhus, Inst Anat, Water & Salt Res Ctr, DK-8000 Aarhus, Denmark; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Aarhus University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Knepper, MA (corresponding author), NHLBI, Kidney & Electrolyte Metab Lab, NIH, Bldg 10,Rm 6N260,10 Ctr Dr,MSC-1603, Bethesda, MD 20892 USA.	knep@helix.nih.gov	Frische, Sebastian/B-2332-2009; Knepper, Mark/AAF-8412-2020	Frische, Sebastian/0000-0002-0270-3602; Christensen, Birgitte Monster/0000-0002-6140-4629; Desai, Ravi/0000-0002-4217-3351	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL001285] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 HL999999, Z01 HL001285-21] Funding Source: Medline; NHLBI NIH HHS [Z01-HL-02182-KE] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALZAHID G, 1977, J MEMBRANE BIOL, V31, P103, DOI 10.1007/BF01869401; Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; Brown D, 2003, AM J PHYSIOL-RENAL, V284, pF893, DOI 10.1152/ajprenal.00387.2002; BUBB MR, 1994, J BIOL CHEM, V269, P14869; BURG M, 1966, AM J PHYSIOL, V210, P1293, DOI 10.1152/ajplegacy.1966.210.6.1293; Cai S, 1998, AM J PHYSIOL-CELL PH, V275, pC1349, DOI 10.1152/ajpcell.1998.275.5.C1349; Chabardes D, 1996, J BIOL CHEM, V271, P19264, DOI 10.1074/jbc.271.32.19264; CHAMPIGNEULLE A, 1993, AM J PHYSIOL, V265, pF35, DOI 10.1152/ajprenal.1993.265.1.F35; Chen Y, 2003, J BIOL CHEM, V278, P46094, DOI 10.1074/jbc.M305311200; Chou CL, 1998, AM J PHYSIOL-RENAL, V274, pF564, DOI 10.1152/ajprenal.1998.274.3.F564; Chou CL, 2000, J BIOL CHEM, V275, P36839, DOI 10.1074/jbc.M005552200; Christensen BM, 2003, AM J PHYSIOL-RENAL, V284, pF701, DOI 10.1152/ajprenal.00234.2002; DELANEROLLE P, 1981, P NATL ACAD SCI-BIOL, V78, P4738; DePina AS, 1999, MICROSC RES TECHNIQ, V47, P93, DOI 10.1002/(SICI)1097-0029(19991015)47:2<93::AID-JEMT2>3.0.CO;2-P; DING G, 1991, AM J PHYSIOL, V260, pC9, DOI 10.1152/ajpcell.1991.260.1.C9; Ecelbarger CA, 1996, AM J PHYSIOL-RENAL, V270, pF623, DOI 10.1152/ajprenal.1996.270.4.F623; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FRANKI N, 1992, AM J PHYSIOL, V263, pC995, DOI 10.1152/ajpcell.1992.263.5.C995; GANOTE CE, 1968, J CELL BIOL, V36, P355, DOI 10.1083/jcb.36.2.355; GAO Y, 1992, AM J PHYSIOL, V263, pC908, DOI 10.1152/ajpcell.1992.263.4.C908; Goldberg PL, 2002, AM J PHYSIOL-LUNG C, V282, pL146, DOI 10.1152/ajplung.2002.282.1.L146; GRANTHAM JJ, 1969, J CELL BIOL, V41, P562, DOI 10.1083/jcb.41.2.562; Gustafson CE, 2000, AM J PHYSIOL-RENAL, V278, pF317, DOI 10.1152/ajprenal.2000.278.2.F317; Hecht G, 1996, AM J PHYSIOL-CELL PH, V271, pC1678, DOI 10.1152/ajpcell.1996.271.5.C1678; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; Ikonen E, 1997, J CELL SCI, V110, P2155; Jeon US, 2003, NEPHRON EXP NEPHROL, V93, pE36, DOI 10.1159/000066651; KACHADORIAN WA, 1979, AM J PHYSIOL, V236, pF14, DOI 10.1152/ajprenal.1979.236.1.F14; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Lazar V, 1999, GENOMICS, V57, P256, DOI 10.1006/geno.1999.5774; LEVINE SD, 1981, J CLIN INVEST, V67, P662, DOI 10.1172/JCI110081; Lorenz D, 2003, EMBO REP, V4, P88, DOI 10.1038/sj.embor.embor711; Lueck A, 1998, J CELL SCI, V111, P3633; MAEDA Y, 1993, AM J PHYSIOL, V265, pF15, DOI 10.1152/ajprenal.1993.265.1.F15; Marples D, 1998, AM J PHYSIOL-RENAL, V274, pF384, DOI 10.1152/ajprenal.1998.274.2.F384; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Matsumura F, 1998, J CELL BIOL, V140, P119, DOI 10.1083/jcb.140.1.119; MILLERHANCE WC, 1988, J BIOL CHEM, V263, P13979; MOCHIDA S, 1994, NEURON, V13, P1131, DOI 10.1016/0896-6273(94)90051-5; Mortz E, 2001, PROTEOMICS, V1, P1359, DOI 10.1002/1615-9861(200111)1:11<1359::AID-PROT1359>3.0.CO;2-Q; Musch A, 1997, J CELL BIOL, V138, P291, DOI 10.1083/jcb.138.2.291; Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200; Nelson WJ, 2001, TRENDS CELL BIOL, V11, P483, DOI 10.1016/S0962-8924(01)02145-6; NIELSEN S, 1993, AM J PHYSIOL, V265, pF225, DOI 10.1152/ajprenal.1993.265.2.F225; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Rogers SL, 2000, CURR OPIN CELL BIOL, V12, P57, DOI 10.1016/S0955-0674(99)00057-5; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; SABOLIC I, 1995, J MEMBRANE BIOL, V143, P165, DOI 10.1007/BF00233445; Sellers JR, 2000, BBA-MOL CELL RES, V1496, P3, DOI 10.1016/S0167-4889(00)00005-7; SIMON H, 1993, AM J PHYSIOL, V265, pC757, DOI 10.1152/ajpcell.1993.265.3.C757; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Tamma G, 2001, AM J PHYSIOL-RENAL, V281, pF1092, DOI 10.1152/ajprenal.0091.2001; TAYLOR A, 1973, SCIENCE, V181, P347, DOI 10.1126/science.181.4097.347; WADE JB, 1988, AM J PHYSIOL, V255, pC526, DOI 10.1152/ajpcell.1988.255.4.C526; WALL SM, 1992, AM J PHYSIOL, V262, pF989, DOI 10.1152/ajprenal.1992.262.6.F989; Yip KP, 2002, J PHYSIOL-LONDON, V538, P891, DOI 10.1113/jphysiol.2001.012606	65	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49026	49035		10.1074/jbc.M408565200	http://dx.doi.org/10.1074/jbc.M408565200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347643	hybrid			2022-12-25	WOS:000225098100066
J	Gambarotta, G; Garzotto, D; Destro, E; Mautino, B; Giampietro, C; Cutrupi, S; Dati, C; Cattaneo, E; Fasolo, A; Perroteau, I				Gambarotta, G; Garzotto, D; Destro, E; Mautino, B; Giampietro, C; Cutrupi, S; Dati, C; Cattaneo, E; Fasolo, A; Perroteau, I			ErbB4 expression in neural progenitor cells (ST14A) is necessary to mediate neuregulin-1 beta 1-induced migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; NEUREGULIN RECEPTOR ERBB4; ACTIVATED PROTEIN-KINASE; MOUSE OLFACTORY-BULB; RAT PC12 CELLS; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; ADULT-RAT; TYROSINE KINASE; GAMMA-SECRETASE	Activation of the receptor tyrosine kinase ErbB4 leads to various cellular responses such as proliferation, survival, differentiation, and chemotaxis. Two pairs of naturally occurring ErbB4 isoforms differing in their juxtamembrane (JMa/JMb) and C termini (cyt1/cyt2) have been described. To examine the role of ErbB4 in neuron migration, we cloned and stably transfected each of the four ErbB4 isoforms in ST14A cells (a neural progenitor cell line derived from the striatum of embryonic day 14 rats) endogenously expressing the other members of the ErbB family: ErbB1, ErbB2, and ErbB3. Using immunoprecipitation assays, we showed that the neuregulin-1beta1 (NRG1beta1) stimulus induced ErbB4 tyrosine phosphorylation and phosphatidylinositol 3-kinase (PI3K) recruitment and activation (as demonstrated by Akt phosphorylation) either directly (ErbB4 cyt1 isoform) or indirectly (ErbB4 cyt2 isoform). We examined the ability of the four ErbB4 isoforms to induce chemotaxis and cell proliferation in response to NRG1beta1 stimulation. Using migration assays, we observed that only ErbB4-expressing cells stimulated with NRG1beta1 showed a significant increase in migration, whereas the growth rate remained unchanged. Additional assays showed that inhibition of PI3K (but not of phospholipase Cgamma) dramatically reduced migratory activity. Our data show that ErbB4 signaling via PI3K activation plays a fundamental role in controlling NRG1beta1-induced migration.	Univ Turin, Dept Human & Anim Biol, I-10123 Turin, Italy; Univ Piemonto Orientale, Dept Med Sci, I-28100 Novara, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	University of Turin; University of Eastern Piedmont Amedeo Avogadro; University of Milan	Gambarotta, G (corresponding author), Univ Turin, Dept Human & Anim Biol, Via Accademia Albertina 13, I-10123 Turin, Italy.	giovanna.gambarotta@unito.it	Gambarotta, Giovanna/I-8473-2012; cutrupi, santina/AAC-4479-2022; Giampietro, Costanza/D-4643-2016	Gambarotta, Giovanna/0000-0002-8380-5925; Giampietro, Costanza/0000-0001-5229-3835; Perroteau, Isabelle/0000-0001-9797-2276; CATTANEO, ELENA/0000-0002-0755-4917; CUTRUPI, SANTINA/0000-0002-2358-5852				Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; Bonfanti L, 1997, NEUROSCIENCE, V81, P489, DOI 10.1016/S0306-4522(97)00090-0; Carpenter CL, 1997, ADV ENZYME REGUL, V37, P377, DOI 10.1016/S0065-2571(96)00005-2; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Cattaneo E, 1998, J NEUROSCI RES, V53, P223, DOI 10.1002/(SICI)1097-4547(19980715)53:2<223::AID-JNR11>3.0.CO;2-7; Chausovsky A, 1998, MOL BIOL CELL, V9, P3195, DOI 10.1091/mbc.9.11.3195; Chausovsky A, 2000, ONCOGENE, V19, P878, DOI 10.1038/sj.onc.1203410; Cheng QC, 2003, J BIOL CHEM, V278, P38421, DOI 10.1074/jbc.M302111200; Cohen BM, 1996, J BIOL CHEM, V271, P4813; Coskun V, 2002, J NEUROSCI RES, V69, P795, DOI 10.1002/jnr.10336; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Ehrlich ME, 2001, EXP NEUROL, V167, P215, DOI 10.1006/exnr.2000.7551; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fasolo A, 2002, CHEM SENSES, V27, P581, DOI 10.1093/chemse/27.6.581; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gerecke KM, 2001, J COMP NEUROL, V433, P86, DOI 10.1002/cne.1127; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; HELLYER NJ, 1995, GENE, V165, P279, DOI 10.1016/0378-1119(95)00436-A; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Juang SH, 1996, ONCOGENE, V12, P1033; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kita Y, 1998, J CELL SCI, V111, P907; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lai C, 2004, BIOCHEM BIOPH RES CO, V319, P603, DOI 10.1016/j.bbrc.2004.05.027; Lai C, 2004, BIOCHEM BIOPH RES CO, V314, P535, DOI 10.1016/j.bbrc.2003.12.131; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lindholm T, 2002, EXP BRAIN RES, V142, P81, DOI 10.1007/s0021-001-0922-7; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Mautino B, 2004, PROTEIN EXPRES PURIF, V35, P25, DOI 10.1016/j.pep.2003.12.012; Meyer D, 1997, DEVELOPMENT, V124, P3575; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oberto M, 2001, EUR J NEUROSCI, V14, P513, DOI 10.1046/j.0953-816x.2001.01667.x; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Perroteau I, 1998, ANN NY ACAD SCI, V855, P255, DOI 10.1111/j.1749-6632.1998.tb10578.x; Perroteau I, 1999, CELL MOL BIOL, V45, P293; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pollock GS, 1999, EUR J NEUROSCI, V11, P769, DOI 10.1046/j.1460-9568.1999.00484.x; Raabe TD, 1997, J NEUROCHEM, V69, P1859; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Steiner H, 1999, EXP NEUROL, V159, P494, DOI 10.1006/exnr.1999.7163; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; WAINWRIGHT MS, 1995, J NEUROSCI, V15, P676; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Yau HJ, 2003, CEREB CORTEX, V13, P252, DOI 10.1093/cercor/13.3.252; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zuccato C, 2003, NAT GENET, V35, P76, DOI 10.1038/ng1219; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	77	59	61	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48808	48816		10.1074/jbc.M408374200	http://dx.doi.org/10.1074/jbc.M408374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355992	Green Published, hybrid			2022-12-25	WOS:000225098100041
J	Smyth, LM; Bobalova, J; Mendoza, MG; Lew, C; Mutafova-Yambolieva, VN				Smyth, LM; Bobalova, J; Mendoza, MG; Lew, C; Mutafova-Yambolieva, VN			Release of beta-nicotinamide adenine dinucleotide upon stimulation of postganglionic nerve terminals in blood vessels and urinary bladder	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; CANINE MESENTERIC-ARTERY; PIG VAS-DEFERENS; PRESYNAPTIC RECEPTORS; FLUORESCENT ANALOG; SYMPATHETIC-NERVES; ADENOSINE; NORADRENALINE; COTRANSMISSION; NAADP	Chemical signaling in autonomic neuromuscular transmission involves agents that function as neurotransmitters and/or neuromodulators. Using high performance liquid chromatography techniques with fluorescence and electrochemical detection we observed that, in addition to ATP and norepinephrine (NE), electrical field stimulation (EFS, 4-16 Hz, 0.1-0.3 ms, 15 V, 60-120 s) of isolated vascular and non-vascular preparations co-releases a previously unidentified compound with apparent nucleotide or nucleoside structure. Extensive screening of more than 25 nucleotides and nucleosides followed by detailed peak identification revealed that beta-nicotinamide adenine dinucleotide (beta-NAD) is released in tissue superfusates upon EFS of canine mesenteric artery (CMA), canine urinary bladder, and murine urinary bladder in the amounts of 7.1+/-0.7, 26.5+/-4.5, and 15.1+/-3.2 fmol/mg of tissue, respectively. Smaller amounts of the beta-NAD metabolites cyclic adenosine 5'-diphosphoribose (cADPR) and ADPR were also present in the superfusates collected during EFS of CMA (2.5+/-0.9 and 5.8+/-0.8 fmol/mg of tissue, respectively), canine urinary bladder (1.8+/-0.5 and 9.0+/-6.0 fmol/mg of tissue, respectively), and murine urinary bladder (1.4+/-0.1 and 6.2+/-2.4 fmol/mg of tissue, respectively). The three nucleotides were also detected in the samples collected before EFS (0.2-1.6 fmol/mg of tissue). Exogenous beta-NAD, cADPR, and ADPR (all 100 nM) reduced the release of NE in CMA at 16 Hz from 27.8+/-6.0 fmol/mg of tissue to 15.5+/-5.0, 12+/-3.0, and 10.0+/-4.0 fmol/mg of tissue, respectively. In conclusion, we detected constitutive and nerve-evoked overflow of beta-NAD, cADPR, and ADPR in vascular and non-vascular smooth muscles, beta-NAD being the prevailing compound. These substances modulate the release of NE, implicating novel nucleotide mechanisms of autonomic nervous system control of smooth muscle.	Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno	Mutafova-Yambolieva, VN (corresponding author), Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Anderson Me Bldg,MS 352, Reno, NV 89557 USA.	vnm@med.unr.edu	Bobalova, Janette/H-6244-2014	Bobalova, Janette/0000-0003-2395-0845	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060031] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL060031, HL-60031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APRIGLIANO O, 1976, J PHARMACOL EXP THER, V198, P568; BARRIO JR, 1972, P NATL ACAD SCI USA, V69, P2039, DOI 10.1073/pnas.69.8.2039; Bobalova J, 2003, CLIN EXP PHARMACOL P, V30, P194, DOI 10.1046/j.1440-1681.2003.03808.x; Bobalova J, 2002, ANAL BIOCHEM, V305, P269, DOI 10.1006/abio.2002.5667; Bobalova J, 2001, J AUTON PHARMACOL, V21, P47, DOI 10.1046/j.1365-2680.2001.00207.x; Bobalova J, 2001, CLIN EXP PHARMACOL P, V28, P397; Boehm S, 2002, PHARMACOL REV, V54, P43, DOI 10.1124/pr.54.1.43; Burnstock G, 1999, BRAIN RES BULL, V50, P355, DOI 10.1016/S0361-9230(99)00103-3; BURNSTOCK G, 1990, ARCH INT PHARMACOD T, V304, P7; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; da Silva CP, 1998, J CHROMATOGR B, V707, P43, DOI 10.1016/S0378-4347(97)00622-1; Duarte-Araujo M, 2004, BRIT J PHARMACOL, V141, P925, DOI 10.1038/sj.bjp.0705697; Ernsberger U, 2001, AUTON NEUROSCI-BASIC, V94, P1, DOI 10.1016/S1566-0702(01)00336-8; FURNESS JB, 1989, ANNU REV PHARMACOL, V29, P289, DOI 10.1146/annurev.pa.29.040189.001445; GORDON EL, 1986, J BIOL CHEM, V261, P5496; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; Langer SZ, 1997, TRENDS PHARMACOL SCI, V18, P95, DOI 10.1016/S0165-6147(96)01034-6; Leckie C, 2003, J BIOL CHEM, V278, P12247, DOI 10.1074/jbc.M210770200; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEVITT B, 1984, ANAL BIOCHEM, V137, P93, DOI 10.1016/0003-2697(84)90352-X; Lundberg JM, 1996, PHARMACOL REV, V48, P113; Mutafova-Yambolieva VN, 2000, GEN PHARMACOL-VASC S, V34, P127, DOI 10.1016/S0306-3623(00)00054-9; Mutafova-Yambolieva VN, 2003, CARDIOVASC RES, V57, P217, DOI 10.1016/S0008-6363(02)00648-X; Mutafova-Yambolieva VN, 1998, BRIT J PHARMACOL, V123, P136, DOI 10.1038/sj.bjp.0701579; PLESNER L, 1995, INT REV CYTOL, V158, P141; Queiroz G, 2003, J NEUROCHEM, V85, P740, DOI 10.1046/j.1471-4159.2003.01715.x; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; Sher E, 1998, J BIOENERG BIOMEMBR, V30, P399, DOI 10.1023/A:1021945907635; STJARNE L, 1994, ADV SEC MESS PHOSPH, V29, P461; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; WESTFALL DP, 1990, ANN NY ACAD SCI, V603, P300; Zhang FJ, 1999, BIOORGAN MED CHEM, V7, P653, DOI 10.1016/S0968-0896(98)00256-9; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	37	65	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48893	48903		10.1074/jbc.M407266200	http://dx.doi.org/10.1074/jbc.M407266200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364945	hybrid			2022-12-25	WOS:000225098100051
J	Wang, XY; Karbarz, MJ; McGrath, SC; Cotter, RJ; Raetz, CRH				Wang, XY; Karbarz, MJ; McGrath, SC; Cotter, RJ; Raetz, CRH			MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane - Topography of Francisella novicida LpxE expressed in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT SALMONELLA-TYPHIMURIUM; RE-TYPE LIPOPOLYSACCHARIDE; RHIZOBIUM-LEGUMINOSARUM; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; OUTER-MEMBRANE; STRUCTURAL DETERMINATION; MULTICOPY SUPPRESSOR; MASS-SPECTROMETRY; IMMUNE-RESPONSES; BOUND ENZYME	The lipid A anchor of Francisella tularensis lipopolysaccharide (LPS) lacks both phosphate groups present in Escherichia coli lipid A. Membranes of Francisella novicida (an environmental strain related to F. tularensis) contain enzymes that dephosphorylate lipid A and its precursors at the 1- and 4'-positions. We now report the cloning and characterization of a membrane-bound phosphatase of F. novicida that selectively dephosphorylates the 1-position. By transferring an F. novicida genomic DNA library into E. coli and selecting for low level polymyxin resistance, we isolated FnlpxE as the structural gene for the 1-phosphatase, an inner membrane enzyme of 239 amino acid residues. Expression of FnlpxE in a heptose-deficient mutant of E. coli caused massive accumulation of a previously uncharacterized LPS molecule, identified by mass spectrometry as 1-dephospho-Kdo(2)-lipid A. The predicted periplasmic orientation of the FnLpxE active site suggested that LPS export might be required for 1-dephosphorylation of lipid A. LPS and phospholipid export depend on the activity of MsbA, an essential inner membrane ABC transporter. Expression of FnlpxE in the msbA temperature-sensitive E. coli mutant WD2 resulted in 90% 1-dephosphorylation of lipid A at the permissive temperature (30degreesC). However, the 1-phosphate group of newly synthesized lipid A was not cleaved at the nonpermissive temperature (44degreesC). Our findings provide the first direct evidence that lipid A 1-dephosphorylation catalyzed by LpxE occurs on the periplasmic surface of the inner membrane.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008558, R37GM051796, R01GM054882] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM051796, GM-08558, R37-GM-51796, GM-54882, R37 GM051796-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baldridge JR, 1999, METHODS, V19, P103, DOI 10.1006/meth.1999.0834; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; Doerrler WT, 2002, J BIOL CHEM, V277, P36697, DOI 10.1074/jbc.M205857200; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DOERRLER WT, 2004, J BIOL CHEM     0810; Gangloff M, 2004, TRENDS BIOCHEM SCI, V29, P294, DOI 10.1016/j.tibs.2004.04.008; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Kang HY, 2002, INFECT IMMUN, V70, P1739, DOI 10.1128/IAI.70.4.1739-1749.2002; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; Karbarz MJ, 2003, J BIOL CHEM, V278, P39269, DOI 10.1074/jbc.M305830200; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; Kieffer TL, 2003, MICROBES INFECT, V5, P397, DOI 10.1016/S1286-4579(03)00052-2; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; MULFORD CA, 1983, P NATL ACAD SCI-BIOL, V80, P1159, DOI 10.1073/pnas.80.5.1159; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; QURESHI N, 1985, J BIOL CHEM, V260, P5271; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; Ribeiro AA, 1999, MAGN RESON CHEM, V37, P620, DOI 10.1002/(SICI)1097-458X(199909)37:9<620::AID-MRC517>3.0.CO;2-Q; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Saitoh S, 2004, INT IMMUNOL, V16, P961, DOI 10.1093/intimm/dxh097; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sasaki S, 1997, INFECT IMMUN, V65, P3520, DOI 10.1128/IAI.65.9.3520-3528.1997; Sjostedt A, 2003, CURR OPIN MICROBIOL, V6, P66, DOI 10.1016/S1369-5274(03)00002-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Trent M. Stephen, 2002, Journal of Endotoxin Research, V8, P158; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Yoshizaki H, 2001, ANGEW CHEM INT EDIT, V40, P1475, DOI 10.1002/1521-3773(20010417)40:8<1475::AID-ANIE1475>3.0.CO;2-V; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	65	95	106	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49470	49478		10.1074/jbc.M409078200	http://dx.doi.org/10.1074/jbc.M409078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339914	Green Accepted, hybrid			2022-12-25	WOS:000225098100117
J	Kawakami, Y; Nishimoto, H; Kitaura, J; Maeda-Yamamoto, M; Kato, RM; Littman, DR; Rawlings, DJ; Kawakami, T				Kawakami, Y; Nishimoto, H; Kitaura, J; Maeda-Yamamoto, M; Kato, RM; Littman, DR; Rawlings, DJ; Kawakami, T			Protein kinase C beta II regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; INTEGRIN-LINKED KINASE; SER473 KINASE; PDK2 ACTIVITY; MAST-CELLS; ACTIVATION; INSULIN; MICE; INHIBITION; DEFICIENT	Akt (= protein kinase B), a subfamily of the AGC serine/threonine kinases, plays critical roles in survival, proliferation, glucose metabolism, and other cellular functions. Akt activation requires the recruitment of the enzyme to the plasma membrane by interacting with membrane-bound lipid products of phosphatidylinositol 3-kinase. Membrane-bound Akt is then phosphorylated at two sites for its full activation; Thr-308 in the activation loop of the kinase domain is phosphorylated by 3-phosphoinositide-dependent kinase-1 (PDK1) and Ser-473 in the C-terminal hydrophobic motif by a putative kinase PDK2. The identity of PDK2 has been elusive. Here we present evidence that conventional isoforms of protein kinase C (PKC), particularly PKCbetaII, can regulate Akt activity by directly phosphorylating Ser-473 in vitro and in IgE/antigen-stimulated mast cells. By contrast, PKCbeta is not required for Ser-473 phosphorylation in mast cells stimulated with stem cell factor or interleukin-3, in serum-stimulated fibroblasts, or in antigen receptor-stimulated T or B lymphocytes. Therefore, PKCbetaII appears to work as a cell type- and stimulus-specific PDK2.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA; NARO, Natl Inst Vegetables & Tea Sci, Shizuoka 4288501, Japan; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; NYU, Sch Med, Howard Hughes Med Inst, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Howard Hughes Med Inst, Dept Microbiol, New York, NY 10016 USA	La Jolla Institute for Immunology; National Agriculture & Food Research Organization - Japan; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; New York University; Howard Hughes Medical Institute; New York University	Kawakami, T (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	toshi@liai.org	Kawakami, Toshiaki/O-1616-2015	Maeda-Yamamoto, Mari/0000-0002-4494-7509	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033617, R01AI038348] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38348, AI33617] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; CHAN TO, 2001, SCI STKE; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Kawakami Y, 2000, P NATL ACAD SCI USA, V97, P7423, DOI 10.1073/pnas.120175097; Kawakami Y, 2003, P NATL ACAD SCI USA, V100, P9470, DOI 10.1073/pnas.1633695100; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Nechushtan H, 2000, BLOOD, V95, P1752, DOI 10.1182/blood.V95.5.1752.005k18_1752_1757; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3	34	148	154	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47720	47725		10.1074/jbc.M408797200	http://dx.doi.org/10.1074/jbc.M408797200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15364915	hybrid			2022-12-25	WOS:000224957000038
J	Schafer, B; Marg, B; Gschwind, A; Ullrich, A				Schafer, B; Marg, B; Gschwind, A; Ullrich, A			Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TUMOR-NECROSIS-FACTOR; GONADOTROPIN-RELEASING-HORMONE; ALPHA-CONVERTING-ENZYME; NF-KAPPA-B; EGF RECEPTOR; LYSOPHOSPHATIDIC ACID; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; CANCER-CELLS	Cross-talk between G protein-coupled receptor (GPCR) and epidermal growth factor receptor (EGFR) signaling systems is widely established in a variety of normal and transformed cell types. Here, we demonstrate that the EGFR transactivation signal requires metalloproteinase cleavage of epidermal growth factor-like growth factor precursors in fibroblasts, ACHN kidney, and TccSup bladder carcinoma cells. Furthermore, we present evidence that blockade of the metalloproteinase-disintegrin tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17) by a dominant negative ADAM17 mutant prevents angiotensin II-stimulated pro-HB-EGF cleavage, EGFR activation, and cell proliferation in ACHN tumor cells. Moreover, we found that in TccSup cancer cells, the lysophosphatidic acid-induced transactivation signal is mediated by ADAM15, demonstrating that distinct combinations of growth factor precursors and ADAMs ((a) under bar (d) under bar isintegrin (a) under bar nd (m) under bar etalloproteinases) regulate GPCR-EGFR cross-talk pathways in cell lines derived from urogenital cancer. Our data show further that activation of ADAMs results in discrete cellular responses; whereas GPCR agonists promote activation of the Ras/MAPK pathway and cell proliferation via the EGFR in fibroblasts and ACHN cells, EGFR transactivation pathways regulate activation of the survival mediator Akt/protein kinase B and the susceptibility of fibroblasts and TccSup bladder carcinoma cells to proapoptotic signals such as serum deprivation, death receptor stimulation, and the chemotherapeutic drug doxorubicin. Thus, ADAM15 and -17 function as effectors of GPCR-mediated signaling and define critical characteristics of cancer cells.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de						Ahmed I, 2003, MOL ENDOCRINOL, V17, P1607, DOI 10.1210/me.2002-0040; Alaoui-Jamali MA, 1997, BIOCHEM CELL BIOL, V75, P315, DOI 10.1139/bcb-75-4-315; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DICKSTEIN B, 1993, J CELL PHYSIOL, V157, P110, DOI 10.1002/jcp.1041570115; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GLEAVE ME, 1993, CANCER RES, V53, P5300; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Gschwind A, 2002, CANCER RES, V62, P6329; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kruger S, 2002, INT J CANCER, V102, P514, DOI 10.1002/ijc.10731; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Mateo C, 1997, IMMUNOTECHNOLOGY, V3, P71, DOI 10.1016/S1380-2933(97)00065-1; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Mirza AM, 2000, CELL GROWTH DIFFER, V11, P279; Miyamoto H, 2000, UROLOGY, V55, P679, DOI 10.1016/S0090-4295(99)00604-4; Navolanic PM, 2003, INT J ONCOL, V22, P237; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Roelle S, 2003, J BIOL CHEM, V278, P47307, DOI 10.1074/jbc.M304377200; Samanta AK, 2004, J BIOL CHEM, V279, P7576, DOI 10.1074/jbc.M311659200; Santiskulvong C, 2001, AM J PHYSIOL-CELL PH, V281, pC886, DOI 10.1152/ajpcell.2001.281.3.C886; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Tanyi JL, 2003, CANCER RES, V63, P1073; Weiss FU, 1997, CURR OPIN GENET DEV, V7, P80, DOI 10.1016/S0959-437X(97)80113-X; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yu DS, 2003, UROL INT, V70, P161, DOI 10.1159/000068772	45	137	140	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47929	47938		10.1074/jbc.M400129200	http://dx.doi.org/10.1074/jbc.M400129200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15337756	hybrid			2022-12-25	WOS:000224957000063
J	Scott, C; Higgins, ME; Davies, JP; Ioannou, YA				Scott, C; Higgins, ME; Davies, JP; Ioannou, YA			Targeting of NPC1 to late endosomes involves multiple signals, including one residing within the putative sterol-sensing domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIEMANN-PICK C1; MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; CYTOPLASMIC TAIL; MEMBRANE-PROTEINS; ENDOPLASMIC-RETICULUM; SORTING MOTIF; STRUCTURAL REQUIREMENTS; TRANSMEMBRANE DOMAINS; RETRIEVAL RECEPTOR	The NPC1 protein is a multipass transmembrane protein whose deficiency causes the autosomal recessive lipid storage disorder Niemann-Pick type C1. NPC1 localizes predominantly to late endosomes and has a dileucine motif located within a small cytoplasmic tail thought to target the protein to this location. Our data have suggested previously that the protein can reach its correct location in the absence of its cytoplasmic tail, suggesting that other signals contribute to NPC1 targeting. By using various FLAG-tagged and CD32-NPC1 chimeric fusion constructs, we show that multiple signals are responsible for the trafficking of NPC1 to the endosomal compartment, including the dileucine motif and a previously unidentified signal residing within the putative sterol-sensing domain transmembrane domain 3. Neither region alone was capable of directing heterologous CD32 fusions to late endosomes exclusively via the trans-Golgi network to the late endosome route taken by wild-type NPC1; transmembrane domain 3 was unable to maintain CD32 in late endosomes, indicating that two or more signals work in concert to target and retain NPC1 in this compartment. In addition we confirm that the tail dileucine motif is not essential for NPC1 targeting to late endosomes, and we discuss the implications of this finding along with the previously unappreciated role for transmembrane domain 3 in NPC1 localization and function.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Ioannou, YA (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100th St, New York, NY 10029 USA.	yiannis.ioannou@mssm.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054736] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54736, R01 DK065792] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alpy F, 2001, J BIOL CHEM, V276, P4261, DOI 10.1074/jbc.M006279200; Blagoveshchenskaya AD, 1998, J BIOL CHEM, V273, P2729, DOI 10.1074/jbc.273.5.2729; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BREMNES B, 1994, J CELL SCI, V107, P2021; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; Cherqui S, 2001, J BIOL CHEM, V276, P13314, DOI 10.1074/jbc.M010562200; Davies JP, 2000, J BIOL CHEM, V275, P24367, DOI 10.1074/jbc.M002184200; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Dietrich J, 1996, J BIOL CHEM, V271, P11441, DOI 10.1074/jbc.271.19.11441; Epping EA, 2002, J BIOL CHEM, V277, P34860, DOI 10.1074/jbc.M202987200; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; Higgins ME, 1999, MOL GENET METAB, V68, P1, DOI 10.1006/mgme.1999.2882; Higgins ME, 2001, J LIPID RES, V42, P1939; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; John BJ, 2003, J IMMUNOL, V170, P3534, DOI 10.4049/jimmunol.170.7.3534; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; Ko DC, 2001, MOL BIOL CELL, V12, P601, DOI 10.1091/mbc.12.3.601; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Lewis MJ, 2000, MOL BIOL CELL, V11, P23, DOI 10.1091/mbc.11.1.23; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Obermuller S, 2002, J CELL SCI, V115, P185; OGATA S, 1994, J BIOL CHEM, V269, P5210; PENTCHEV PG, 1994, BBA-MOL BASIS DIS, V1225, P235, DOI 10.1016/0925-4439(94)90001-9; Potter PK, 1999, EUR J IMMUNOL, V29, P3936, DOI 10.1002/(SICI)1521-4141(199912)29:12<3936::AID-IMMU3936>3.3.CO;2-B; Reggiori F, 2000, MOL BIOL CELL, V11, P3737, DOI 10.1091/mbc.11.11.3737; Reggiori F, 2002, NAT CELL BIOL, V4, P117, DOI 10.1038/ncb743; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; Royle SJ, 2002, J BIOL CHEM, V277, P35378, DOI 10.1074/jbc.M204844200; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Sato K, 2003, MOL BIOL CELL, V14, P3605, DOI 10.1091/mbc.E02-12-0777; Sato K, 2001, J CELL BIOL, V152, P935, DOI 10.1083/jcb.152.5.935; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Stephens DJ, 1998, BIOCHEM J, V335, P567, DOI 10.1042/bj3350567; Stockklausner C, 2001, FEBS LETT, V493, P129, DOI 10.1016/S0014-5793(01)02286-4; Teuchert M, 1999, J BIOL CHEM, V274, P36781, DOI 10.1074/jbc.274.51.36781; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Votsmeier C, 2001, EMBO J, V20, P6742, DOI 10.1093/emboj/20.23.6742; Watari H, 1999, P NATL ACAD SCI USA, V96, P805, DOI 10.1073/pnas.96.3.805; White S, 1998, J BIOL CHEM, V273, P14355, DOI 10.1074/jbc.273.23.14355; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	55	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48214	48223		10.1074/jbc.M406090200	http://dx.doi.org/10.1074/jbc.M406090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15347664	hybrid			2022-12-25	WOS:000224957000096
J	Vidal, AE; Kannouche, P; Podust, VN; Yang, W; Lehmann, AR; Woodgate, R				Vidal, AE; Kannouche, P; Podust, VN; Yang, W; Lehmann, AR; Woodgate, R			Proliferating cell nuclear antigen-dependent coordination of the biological functions of human DNA polymerase iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; REPLICATION MACHINERY; TRANSLESION SYNTHESIS; CRYSTAL-STRUCTURE; PCNA-BINDING; ERROR-PRONE; Y-FAMILY; ETA; DELTA; MECHANISM	Y-family DNA polymerases are believed to facilitate the replicative bypass of damaged DNA in a process commonly referred to as translesion synthesis. With the exception of DNA polymerase eta (poleta), which is defective in humans with the Xeroderma pigmentosum variant (XP-V) phenotype, little is known about the cellular function(s) of the remaining human Y-family DNA polymerases. We report here that an interaction between human DNA polymerase iota (poliota) and the proliferating cell nuclear antigen (PCNA) stimulates the processivity of poliota in a template-dependent manner in vitro. Mutations in one of the putative PCNA-binding motifs (PIP box) of poliota or the interdomain connector loop of PCNA diminish the binding between poliota and PCNA and concomitantly reduce PCNA-dependent stimulation of poliota activity. Furthermore, although retaining its capacity to interact with poleta in vivo, the poliota-PIP box mutant fails to accumulate in replication foci. Thus, PCNA, acting as both a scaffold and a modulator of the different activities involved in replication, appears to recruit and coordinate replicative and translesion DNA synthesis polymerases to ensure genome integrity.	NICHD, Lab Genome Integr, NIH, Bethesda, MD 20892 USA; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England; Vanderbilt Univ, Dept Biol Sci, Nashville, TN 37232 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Sussex; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Woodgate, R (corresponding author), NICHD, Lab Genome Integr, NIH, Bethesda, MD 20892 USA.	woodgate@nih.gov	Yang, Wei/ABB-4785-2020; Yang, Wei/D-4926-2011; Vidal, Antonio/ABE-5693-2020	Yang, Wei/0000-0002-3591-2195; Yang, Wei/0000-0002-3591-2195; Vidal, Antonio/0000-0001-9491-8901; Woodgate, Roger/0000-0001-5581-4616	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001500] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001500] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bunting KA, 2003, EMBO J, V22, P5883, DOI 10.1093/emboj/cdg568; Burnouf DY, 2004, J MOL BIOL, V335, P1187, DOI 10.1016/j.jmb.2003.11.049; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kannouche PL, 2004, MOL CELL, V14, P491, DOI 10.1016/S1097-2765(04)00259-X; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lenne-Samuel N, 2002, EMBO REP, V3, P45, DOI 10.1093/embo-reports/kvf007; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Pages V, 2002, ONCOGENE, V21, P8957, DOI 10.1038/sj.onc.1206006; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Ulrich HD, 2004, CELL CYCLE, V3, P15; Vaisman A, 2003, DNA REPAIR, V2, P991, DOI 10.1016/S1568-7864(03)00094-6; Vaisman A, 2001, J BIOL CHEM, V276, P30615, DOI 10.1074/jbc.M102694200; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	44	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48360	48368		10.1074/jbc.M406511200	http://dx.doi.org/10.1074/jbc.M406511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15342632	hybrid			2022-12-25	WOS:000224957000111
J	Li, Y; Soos, TJ; Li, XH; Wu, J; DeGennaro, M; Sun, XJ; Littman, DR; Birnbaum, MJ; Polakiewicz, RD				Li, Y; Soos, TJ; Li, XH; Wu, J; DeGennaro, M; Sun, XJ; Littman, DR; Birnbaum, MJ; Polakiewicz, RD			Protein kinase C theta inhibits insulin signaling by phosphorylating IRS1 at Ser(1101)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; SUBSTRATE-1 TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; SKELETAL-MUSCLE; PKC-THETA; T-LYMPHOCYTES; FATTY-ACIDS; RESISTANCE; ACTIVATION; OBESITY	Obesity and stress inhibit insulin action by activating protein kinases that enhance serine phosphorylation of IRS1 and have been thus associated to insulin resistance and the development of type II diabetes. The protein kinase C theta(PKCtheta) is activated by free-fatty acids, and its activity is higher in muscle from obese diabetic patients. However, a molecular link between PKCtheta and insulin resistance has not been defined yet. Here we show that PKCtheta phosphorylates IRS1 at serine 1101 blocking IRS1 tyrosine phosphorylation and downstream activation of the Akt pathway. Mutation of Ser(1101) to alanine makes IRS1 insensitive to the effect of PKCtheta and restores insulin signaling in culture cells. These results provide a novel mechanism linking the activation of PKCtheta to the inhibition of insulin signaling.	Cell Signaling Technol Inc, Beverly, MA 01915 USA; NYU, Sch Med, Howard Hughes Med Inst, Skirball Inst Biomol Med,Mol Pathogenesis Program, New York, NY 10016 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Chicago, Endocrinol Sect, Chicago, IL 60637 USA	Howard Hughes Medical Institute; New York University; Howard Hughes Medical Institute; University of Pennsylvania; University of Chicago	Polakiewicz, RD (corresponding author), Cell Signaling Technol Inc, 166B Cummings Ctr, Beverly, MA 01915 USA.	rpolakiewicz@cellsignal.com	; DeGennaro, Matthew/H-4975-2015	Birnbaum, Morris/0000-0001-9972-8680; DeGennaro, Matthew/0000-0003-3837-4430				Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; BAIER G, 1994, EUR J BIOCHEM, V225, P195, DOI 10.1111/j.1432-1033.1994.00195.x; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Boden G, 2002, AM J PHYSIOL-ENDOC M, V283, pE12, DOI 10.1152/ajpendo.00429.2001; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Giraud J, 2004, J BIOL CHEM, V279, P3447, DOI 10.1074/jbc.M308631200; Greene MW, 2004, BIOCHEM J, V378, P105, DOI 10.1042/BJ20031493; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Itani SI, 2001, METABOLISM, V50, P553, DOI 10.1053/meta.2001.22512; Itani SI, 2000, DIABETES, V49, P1353, DOI 10.2337/diabetes.49.8.1353; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kim JK, 2004, J CLIN INVEST, V114, P823, DOI 10.1172/JCI200422230; Lee YH, 2003, J BIOL CHEM, V278, P2896, DOI 10.1074/jbc.M208359200; Li Y, 2003, MOL CELL BIOL, V23, P6255, DOI 10.1128/MCB.23.17.6255-6266.2003; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534; Qu X, 1999, J ENDOCRINOL, V162, P207, DOI 10.1677/joe.0.1620207; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Serra C, 2003, J CELL PHYSIOL, V196, P89, DOI 10.1002/jcp.10278; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; White MF, 2003, SCIENCE, V302, P1710, DOI 10.1126/science.1092952; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zick Y, 2001, TRENDS CELL BIOL, V11, P437, DOI 10.1016/S0962-8924(01)02129-8	36	242	255	2	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45304	45307		10.1074/jbc.C400186200	http://dx.doi.org/10.1074/jbc.C400186200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15364919	hybrid			2022-12-25	WOS:000224694900003
J	Taguchi, H; Tsukuda, K; Motojima, F; Koike-Takeshita, A; Yoshida, M				Taguchi, H; Tsukuda, K; Motojima, F; Koike-Takeshita, A; Yoshida, M			BeFx stops the chaperonin cycle of GroEL-GroES and generates a complex with double folding chambers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ALPHA-LACTALBUMIN; CENTRAL CAVITY; PROTEIN; BINDING; ATP; POLYPEPTIDE; SUBSTRATE; 2.8-ANGSTROM; MECHANISM	Coupling with ATP hydrolysis and cooperating with GroES, the double ring chaperonin GroEL assists the folding of other proteins. Here we report novel GroEL-GroES complexes formed in fluoroberyllate (BeFx) that can mimic the phosphate part of the enzyme-bound nucleotides. In ATP, BeFx stops the functional turnover of GroEL by preventing GroES release and produces a symmetric 1: 2 GroEL-GroES complex in which both GroEL rings contain ADP.BeFx and an encapsulated substrate protein. In ADP, the substrate protein-loaded GroEL cannot bind GroES. In ADP plus BeFx, however, it can bind GroES to form a stable 1: 1 GroEL-GroES complex in which one of GroEL rings contains ADP.BeFx and an encapsulated substrate protein. This 1: 1 GroEL-GroES complex is converted into the symmetric 1: 2 GroEL-GroES complex when GroES is supplied in ATP plus BeFx. Thus, BeFx stabilizes two GroEL-GroES complexes; one with a single folding chamber and the other with double folding chambers. These results shed light on the intermediate ADP.P-i nucleotide states in the functional cycle of GroEL.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Agcy, PRESTO, Saitama 3320012, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, R1-7,4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp	Motojima, Fumihiro/J-2389-2014; taguchi, hideki/AAM-2663-2021; Taguchi, Hideki/B-6946-2009	Motojima, Fumihiro/0000-0003-4461-8673; taguchi, hideki/0000-0002-6612-9339; Taguchi, Hideki/0000-0002-6612-9339				Aoki K, 1997, J BIOL CHEM, V272, P32158, DOI 10.1074/jbc.272.51.32158; Aoki K, 2000, J BIOL CHEM, V275, P13755, DOI 10.1074/jbc.275.18.13755; AZEM A, 1994, SCIENCE, V265, P653, DOI 10.1126/science.7913553; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Brinker A, 2001, CELL, V107, P223, DOI 10.1016/S0092-8674(01)00517-7; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Chaudhry C, 2003, EMBO J, V22, P4877, DOI 10.1093/emboj/cdg477; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Inobe T, 2003, J MOL BIOL, V329, P121, DOI 10.1016/S0022-2836(03)00409-1; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; Motojima F, 2003, J BIOL CHEM, V278, P26648, DOI 10.1074/jbc.M300806200; Motojima F, 2000, BIOCHEM BIOPH RES CO, V267, P842, DOI 10.1006/bbrc.1999.2020; OKAZAKI A, 1994, NAT STRUCT BIOL, V1, P439, DOI 10.1038/nsb0794-439; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; Saibil HR, 2002, TRENDS BIOCHEM SCI, V27, P627, DOI 10.1016/S0968-0004(02)02211-9; Sakikawa C, 1999, J BIOL CHEM, V274, P21251, DOI 10.1074/jbc.274.30.21251; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; Sparrer H, 1997, P NATL ACAD SCI USA, V94, P1096, DOI 10.1073/pnas.94.4.1096; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; Taguchi H, 2001, NAT BIOTECHNOL, V19, P861, DOI 10.1038/nbt0901-861; Thirumalai D, 2001, ANNU REV BIOPH BIOM, V30, P245, DOI 10.1146/annurev.biophys.30.1.245; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Ueno T, 2004, MOL CELL, V14, P423, DOI 10.1016/S1097-2765(04)00261-8; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944	38	40	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45737	45743		10.1074/jbc.M406795200	http://dx.doi.org/10.1074/jbc.M406795200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15347650	hybrid			2022-12-25	WOS:000224694900056
J	Borkow, G; Gabbay, J				Borkow, G; Gabbay, J			Putting copper into action: copper-impregnated products with potent biocidal activities	FASEB JOURNAL			English	Article						HIV-1; filters; fabrics; dust mites; athlete's foot	PLASMA-MEMBRANE; TINEA-PEDIS; METAL-IONS; VIRUS; INACTIVATION; HIV-1; RISK; TRANSMISSION; TRANSFUSION; MECHANISMS	Copper ions, either alone or in copper complexes, have been used for centuries to disinfect liquids, solids, and human tissue. Today copper is used as a water purifier, algaecide, fungicide, nematocide, molluscicide, and antibacterial and antifouling agent. Copper also displays potent antiviral activity. We hypothesized that introducing copper into clothing, bedding, and other articles would provide them with biocidal properties. A durable platform technology has been developed that introduces copper into cotton fibers, latex, and other polymeric materials. This study demonstrates the broad-spectrum antimicrobial ( antibacterial, antiviral, antifungal) and antimite activities of copper-impregnated fibers and polyester products. This technology enabled the production of antiviral gloves and filters (which deactivate HIV-1 and other viruses), antibacterial self-sterilizing fabrics (which kill antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci), antifungal socks (which alleviate symptoms of athlete's foot), and anti-dust mite mattress covers (which reduce mite-related allergies). These products did not have skin-sensitizing properties, as determined by guine pig maximization and rabbit skin irritation tests. Our study demonstrates the potential use of copper in new applications. These applications address medical issues of the greatest importance, such as viral transmissions; nosocomial, or healthcare-associated, infections; and the spread of antibiotic-resistant bacteria.	Cupron Inc, New York, NY 10165 USA		Borkow, G (corresponding author), Hameyasdim 44, IL-76910 Kfar Gibton, Israel.	gadi@cupron.com	Borkow, Gadi/W-4294-2019					[Anonymous], 1999, [No title captured], Patent No. 5871816; [Anonymous], DISINFECTION STERILI; AUGER P, 1993, MYCOSES, V36, P35, DOI 10.1111/j.1439-0507.1993.tb00685.x; Avery SV, 1995, BIOCHEM J, V312, P811, DOI 10.1042/bj3120811; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Bilian X, 2002, BEST PRACT RES CL OB, V16, P155, DOI 10.1053/beog.2002.0267; Borkow G, 1997, BIOCHEMISTRY-US, V36, P3179, DOI 10.1021/bi9624696; Brunton SA, 1999, HOSP PRACT, V34, P67, DOI 10.3810/hp.1999.09.15.165; CERVANTES C, 1994, FEMS MICROBIOL REV, V14, P121, DOI 10.1016/0168-6445(94)90002-7; Cooney JJ, 1999, METHOD ENZYMOL, V310, P637; COONEY TE, 1995, INFECT CONT HOSP EP, V16, P444; CORONEL D, 2000, REANIMATION, V9, P86; CORONEL D, 2001, REANIMATION S, V10, P43; DOLLWET HHA, 1985, TRACE ELEM MED, V2, P80; *FDA, 2003, MIN SAF EFF METH RED; Fowler MG, 2002, J ACQ IMMUN DEF SYND, V30, P230, DOI [10.1097/00042560-200206010-00012, 10.1097/01.QAI.0000018364.28828.14]; FRASER WD, 2001, 211 INCRA HUNT RES C, P43; Goodnough LT, 2003, LANCET, V361, P161, DOI 10.1016/S0140-6736(03)12195-2; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; Hellstern P, 2002, THROMB RES, V107, pS3, DOI 10.1016/S0049-3848(02)00145-7; Hess C, 2002, LANCET, V359, P2230, DOI 10.1016/S0140-6736(02)09291-7; Hostynek Jurij J, 2003, Rev Environ Health, V18, P153; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; International Diabetes Federation, 2000, DIAB ATL; JORDAN FTW, 1971, VET REC, V89, P609, DOI 10.1136/vr.89.23.609; KARLSTROM AR, 1991, P NATL ACAD SCI USA, V88, P5552, DOI 10.1073/pnas.88.13.5552; Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Lacroix C, 2002, J EUR ACAD DERMATOL, V16, P139, DOI 10.1046/j.1468-3083.2002.00400.x; Louder MK, 1999, METH MOLEC MED, V17, P23, DOI 10.1385/0-89603-369-4:23; MAGNUSSON B, 1980, CONTACT DERMATITIS, V6, P46, DOI 10.1111/j.1600-0536.1980.tb03894.x; Mascola Jr, 1999, METH MOLEC MED, V17, P317, DOI 10.1385/0-89603-369-4:317; OHSUMI Y, 1988, J BACTERIOL, V170, P2676, DOI 10.1128/jb.170.6.2676-2682.1988; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557, DOI 10.1289/ehp.02110s4557; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; RODRIGUEZMONTELONGO L, 1993, BIOCHIM BIOPHYS ACTA, V1144, P77, DOI 10.1016/0005-2728(93)90033-C; Sagripanti JL, 1996, AIDS RES HUM RETROV, V12, P333, DOI 10.1089/aid.1996.12.333; Sagripanti JL, 1997, ANTIMICROB AGENTS CH, V41, P812, DOI 10.1128/AAC.41.4.812; SAGRIPANTI JL, 1993, APPL ENVIRON MICROB, V59, P4374, DOI 10.1128/AEM.59.12.4374-4376.1993; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; Skoner D, 2000, J ALLERGY CLIN IMMUN, V105, pS16, DOI 10.1016/S0091-6749(00)90479-2; Snyder E L, 2001, Hematology Am Soc Hematol Educ Program, P433; SPENCER RC, 1994, INTENS CARE MED, V20, pS2, DOI 10.1007/BF01713975; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Stout JE, 1998, INFECT CONT HOSP EP, V19, P911; Strong DM, 2002, TRENDS MOL MED, V8, P355, DOI 10.1016/S1471-4914(02)02361-4; UEDA K, 1980, CHEM-BIOL INTERACT, V29, P145, DOI 10.1016/0009-2797(80)90029-0; YAHAYA MT, 2001, 48 INT COPP RES ASS; Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191; 2002, DRUG THER B, V40, P67	51	228	261	5	129	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1728	+		10.1096/fj.04-2029fje	http://dx.doi.org/10.1096/fj.04-2029fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15345689				2022-12-25	WOS:000224243200042
J	Berwin, B; Delneste, Y; Lovingood, RV; Post, SR; Pizzo, SV				Berwin, B; Delneste, Y; Lovingood, RV; Post, SR; Pizzo, SV			SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TUMOR-NECROSIS-FACTOR; MURINE MACROPHAGES; DENDRITIC CELLS; CUTTING EDGE; CROSS-PRESENTATION; GRP94(GP96)-ASSOCIATED PEPTIDES; ENDOTOXIN CONTAMINATION; ANTIGEN PRESENTATION; SURFACE EXPRESSION	Calreticulin and gp96 (GRP94) traffic associated peptides into the major histocompatibility complex class-I cross-presentation pathway of antigen-presenting cells (APCs). Efficient accession of the cross-presentation pathway requires APC receptor-mediated endocytosis of the chaperone/peptide complexes. Previously, scavenger receptor class-A (SRA) was shown to play a substantial role in trafficking gp96 and calreticulin into macrophages, accounting for half of total receptor-mediated uptake. However, the scavenger receptor ligand fucoidin competed the chaperone uptake beyond that accounted for by SRA, indicating that another scavenger receptor(s) may also contribute. Consistent with this hypothesis, we showed that the residual calreticulin uptake into SRA -/- macrophages is competed by the scavenger receptor ligand acetylated-low density lipoprotein (LDL). We now report that an additional scavenger receptor, SREC-I ( scavenger receptor expressed by endothelial cell-I), mediates the endocytosis of calreticulin and gp96. Ectopic expression of SREC-I in Chinese hamster ovary cells yielded chaperone recognition and uptake, and these processes were competed by the inhibitory ligands fucoidin and acetylated (Ac) LDL. Although AcLDL competes for the chaperone interactions with SRA and SREC, we showed that not all of the scavenger receptors, which bind AcLDL, bind calreticulin or gp96. The overexpression of SREC-I in macrophages increased chaperone endocytosis, indicating that SREC-I functions in APCs and that the cytosolic components necessary for the endocytosis of SREC-I and its cargo are present and not limiting in APCs. These data identify a novel class of ligands for SREC-I and provide insight into the mechanisms by which APCs and potentially endothelial cells traffic chaperone/antigen complexes.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Univ Hosp, INSERM, U564, F-49933 Angers, France; Univ Kentucky, Lexington, KY 40536 USA	Duke University; Duke University; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; University of Kentucky	Pizzo, SV (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	pizzo001@mc.duke.edu	Delneste, Yves/O-3956-2016; DELNESTE, Yves/K-7367-2015	DELNESTE, Yves/0000-0002-2142-596X; Post, Steven/0000-0002-4711-1723; Berwin, Brent/0000-0001-9196-3256	NCI NIH HHS [1F32CA9016901] Funding Source: Medline; NHLBI NIH HHS [HL-24066, HL-68072] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA090169] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068072, R37HL024066, R01HL024066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM R, 1995, J IMMUNOL, V154, P1; Adachi H, 2002, J BIOL CHEM, V277, P24014, DOI 10.1074/jbc.M201854200; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baker-LePain JC, 2004, J IMMUNOL, V172, P4195, DOI 10.4049/jimmunol.172.7.4195; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Bansal P, 1999, J IMMUNOL, V162, P4430; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Bausinger H, 2002, EUR J IMMUNOL, V32, P3708, DOI 10.1002/1521-4141(200212)32:12<3708::AID-IMMU3708>3.0.CO;2-C; Berwin B, 2003, EMBO J, V22, P6127, DOI 10.1093/emboj/cdg572; Berwin B, 2002, TRAFFIC, V3, P358, DOI 10.1034/j.1600-0854.2002.30505.x; Berwin B, 2002, J IMMUNOL, V168, P4282, DOI 10.4049/jimmunol.168.9.4282; Berwin B, 2001, J BIOL CHEM, V276, P21083, DOI 10.1074/jbc.M101836200; Binder RJ, 2000, J IMMUNOL, V165, P6029, DOI 10.4049/jimmunol.165.11.6029; Binder RJ, 2004, P NATL ACAD SCI USA, V101, P6128, DOI 10.1073/pnas.0308180101; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1453, DOI 10.1152/ajplung.2001.281.6.L1453; Castellino F, 2000, J EXP MED, V191, P1957, DOI 10.1084/jem.191.11.1957; Delneste Y, 2002, IMMUNITY, V17, P353, DOI 10.1016/S1074-7613(02)00388-6; Eggleton P, 1999, SCAND J IMMUNOL, V49, P466; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gao BC, 2003, J BIOL CHEM, V278, P22523, DOI 10.1074/jbc.M303161200; Gao BC, 2003, J BIOL CHEM, V278, P174, DOI 10.1074/jbc.M208742200; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Ishii J, 2002, J BIOL CHEM, V277, P39696, DOI 10.1074/jbc.M206140200; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Liu B, 2003, P NATL ACAD SCI USA, V100, P15824, DOI 10.1073/pnas.2635458100; MacAry PA, 2004, IMMUNITY, V20, P95, DOI 10.1016/S1074-7613(03)00357-1; Manjili MH, 2003, J IMMUNOL, V171, P4054, DOI 10.4049/jimmunol.171.8.4054; Manjili MH, 2002, CANCER RES, V62, P1737; Martin CA, 2003, J IMMUNOL, V171, P5736, DOI 10.4049/jimmunol.171.11.5736; Melcher A, 1998, NAT MED, V4, P581, DOI 10.1038/nm0598-581; Millar DG, 2003, NAT MED, V9, P1469, DOI 10.1038/nm962; Nair S, 1999, J IMMUNOL, V162, P6426; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; Peiser L, 2001, MICROBES INFECT, V3, P149, DOI 10.1016/S1286-4579(00)01362-9; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Platt N, 1998, CHEM BIOL, V5, pR193, DOI 10.1016/S1074-5521(98)90156-9; Post SR, 2002, J LIPID RES, V43, P1829, DOI 10.1194/jlr.M200231-JLR200; Radsak MP, 2003, BLOOD, V101, P2810, DOI 10.1182/blood-2002-07-2261; Reed RC, 2003, J BIOL CHEM, V278, P31853, DOI 10.1074/jbc.M305480200; Shen LJ, 2004, P NATL ACAD SCI USA, V101, P3035, DOI 10.1073/pnas.0308345101; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Singh-Jasuja H, 2000, CELL STRESS CHAPERON, V5, P462, DOI 10.1379/1466-1268(2000)005<0462:THSPGA>2.0.CO;2; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; SRIVASTAVA PK, 1994, CURR OPIN IMMUNOL, V6, P728, DOI 10.1016/0952-7915(94)90076-0; Strbo N, 2003, IMMUNITY, V18, P381, DOI 10.1016/S1074-7613(03)00056-6; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Tamura Y, 2004, J BIOL CHEM, V279, P30938, DOI 10.1074/jbc.M313088200; Todryk S, 1999, J IMMUNOL, V163, P1398; Todryk SM, 2000, IMMUNOLOGY, V99, P334, DOI 10.1046/j.1365-2567.2000.00002.x; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1993, J EXP MED, V178, P1391, DOI 10.1084/jem.178.4.1391; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; VABULAS RM, 2002, J BIOL CHEM, V23, P23; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015; Whitman SC, 2000, J LIPID RES, V41, P807; Xu QB, 2002, ARTERIOSCL THROM VAS, V22, P1547, DOI 10.1161/01.ATV.0000029720.59649.50; Yamazaki K, 1999, J IMMUNOL, V163, P5178; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	74	97	104	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51250	51257		10.1074/jbc.M406202200	http://dx.doi.org/10.1074/jbc.M406202200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15371419	hybrid			2022-12-25	WOS:000225355800073
J	Geiszt, M; Lekstrom, K; Leto, TL				Geiszt, M; Lekstrom, K; Leto, TL			Analysis of mRNA transcripts from the NAD(P)H oxidase 1 (Nox1) gene - Evidence against production of the NADPH oxidase homolog-1 short (NOH-1S) transcript variant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLON EPITHELIAL-CELLS; H+ CHANNEL; SUPEROXIDE; CLONING; PROTON; CONDUCTANCE; GP91-PHOX; COMPONENT; CYTOCHROME-B558; FLAVOPROTEIN	Recent reports indicate that NAD(P) H oxidase 1 (Nox1) mRNA undergoes alternative splicing, producing a short transcript (NOH-1S) encoding a novel H+ channel. Although the H+ transport properties of NOH-1S-transfected cells resemble those of many cells, the production of a NOH-1S protein was never documented. We characterized Nox1 transcripts in colon-derived cells and present evidence that mRNA splicing does not produce NOH-1S; rather, NOH-1S appears to be an artifact of template switching during cDNA synthesis. The NOH-1S transcript was not observed by Northern blotting, despite claims of its abundance based on RNase protection assays. The shortened cDNA was generated by avian myeloblastosis virus reverse transcriptase, but not by thermally stable reverse transcriptase under conditions that produce full-length Nox1. Analysis of shortened cDNAs detected NOH-1S sequence and other variants that differ at the alleged splice junction site. Although no appropriate RNA splicing sites were found within Nox1 to account for NOH-1S formation, we found repetitive sequence elements bordering the deleted region, which could promote intramolecular template switching during cDNA synthesis. Template switching was confirmed in vitro, where the deleted cDNA was generated by avian myeloblastosis virus reverse transcriptase from a synthetic, full-length Nox1 RNA template. A survey of the expressed sequence tags database suggests that similar switching phenomena occur between repetitive elements in other Nox family transcripts, indicating such cloning artifacts are common. In contrast, genuine RNA splicing does account for another Nox1 transcript lacking the entire exon 11, which is abundant in colon cells but encodes a protein incapable of supporting superoxide production.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Dept Physiol, Fac Med, H-1444 Budapest, Hungary	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Semmelweis University	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, 9000 Rockville Pike,Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.	tleto@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Banfi B, 1999, J EXP MED, V190, P183, DOI 10.1084/jem.190.2.183; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; CHANG MS, 1995, J BIOL CHEM, V270, P511, DOI 10.1074/jbc.270.2.511; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DeCoursey TE, 2002, J GEN PHYSIOL, V120, P773, DOI 10.1085/jgp.20028704; DeCoursey TE, 2001, J PHYSIOL-LONDON, V535, P767, DOI 10.1111/j.1469-7793.2001.00767.x; DeCoursey TE, 2001, J BIOL CHEM, V276, P36063, DOI 10.1074/jbc.C100352200; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Geiszt M, 2003, J IMMUNOL, V171, P299, DOI 10.4049/jimmunol.171.1.299; Geiszt M, 2003, J BIOL CHEM, V278, P20006, DOI 10.1074/jbc.M301289200; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Henderson LM, 1999, J GEN PHYSIOL, V114, P771, DOI 10.1085/jgp.114.6.771; Henderson LM, 2002, J GEN PHYSIOL, V120, P759, DOI 10.1085/jgp.20028708; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; Henderson LM, 1997, BIOCHEM J, V325, P701, DOI 10.1042/bj3250701; KAPLUS PA, 1991, SCIENCE, V251, P60; Leto TL., 1999, INFLAMMATION BASIC P, P769; LEWIN B, 1997, GENES, V6, P885; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; Mader RM, 2001, J LAB CLIN MED, V137, P422, DOI 10.1067/mlc.2001.115452; Maturana A, 2002, J GEN PHYSIOL, V120, P781, DOI 10.1085/jgp.20028713; Morgan D, 2002, J GEN PHYSIOL, V119, P571, DOI 10.1085/jgp.20018544; NANDA A, 1994, J BIOL CHEM, V269, P27280; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; Takeya R, 2003, J BIOL CHEM, V278, P25234, DOI 10.1074/jbc.M212856200; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; Touret N, 2002, J GEN PHYSIOL, V120, P767, DOI 10.1085/jgp.20028706; VIBEPEDERSEN K, 1986, FEBS LETT, V207, P287, DOI 10.1016/0014-5793(86)81506-X	36	36	37	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51661	51668		10.1074/jbc.M409325200	http://dx.doi.org/10.1074/jbc.M409325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15375166	hybrid			2022-12-25	WOS:000225355800122
J	Truscott, M; Raynal, L; Wang, YF; Berube, G; Leduy, L; Nepveu, A				Truscott, M; Raynal, L; Wang, YF; Berube, G; Leduy, L; Nepveu, A			The N-terminal region of the CCAAT displacement protein (CDP)/Cux transcription factor functions as an autoinhibitory domain that modulates DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUT HOMEODOMAIN PROTEIN; CELL TYPE SPECIFICATION; DROSOPHILA WING MARGIN; SENSORY ORGAN IDENTITY; GAMMA-GLOBIN GENE; FACTOR HINF-D; S-PHASE; REGULATORY ELEMENT; TUMOR SUPPRESSORS; AUTO-INHIBITION	The CCAAT displacement protein/Cut homeobox (CDP/Cux) transcription factor is expressed as multiple isoforms that may contain up to four DNA-binding domains: Cut repeats 1, 2, and 3 (CR1, CR2, CR3) and the Cut homeodomain (HD). The full-length protein, which contains all four DNA-binding domains, is surprisingly less efficient than the shorter isoforms in DNA binding. Using a panel of recombinant proteins expressed in mammalian or bacterial cells, we have identified a domain at the extreme N terminus of the protein that can inhibit DNA binding. This domain was able to inhibit the activity of full-length CDP/Cux and of proteins containing various combinations of DNA-binding domains: CR1CR2, CR3HD, or CR2CR3HD. Since inhibition of DNA binding was also observed with purified proteins obtained from bacteria, we conclude that autoinhibition does not require post-translational modification or interaction with an interacting protein but instead functions through an intramolecular mechanism. Antibodies directed against the N-terminal region were able to partially relieve inhibition. In vivo, the transition between the inactive and active states for DNA binding is likely to be governed by posttranslational modifications and/or interaction with one or more protein partners. In addition, we show that the relief of autoinhibition can be accomplished via the proteolytic processing of CDP/Cux. Altogether, these results reveal a novel mode of regulation that serves to modulate the DNA binding activity of CDP/Cux.	McGill Univ, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Nepveu, A (corresponding author), 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	alain.nepveu@mcgill.ca	/AAB-8315-2020	Truscott, Mary/0000-0002-2324-6383				ANDRES V, 1994, GENE DEV, V8, P245, DOI 10.1101/gad.8.2.245; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Banan M, 1997, J BIOL CHEM, V272, P18440, DOI 10.1074/jbc.272.29.18440; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BLANC R, 1942, U CALIF PUBL ZOOL, V49; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Catt D, 1999, CELL MOL BIOL, V45, P1149; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; Cowley DO, 2000, GENE DEV, V14, P366; ELHODIRI HM, 1995, MOL CELL BIOL, V15, P3587; Ellis T, 2001, GENE DEV, V15, P2307, DOI 10.1101/gad.200101; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Goulet B, 2004, MOL CELL, V14, P207, DOI 10.1016/S1097-2765(04)00209-6; Goulet B, 2002, CANCER RES, V62, P6625; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; Gupta S, 2003, J CELL PHYSIOL, V196, P541, DOI 10.1002/jcp.10335; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HARADA R, 1994, J BIOL CHEM, V269, P2062; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Hertweck H, 1931, Z WISS ZOOL ABT A, V139, P559; Hoppe T, 2001, CURR OPIN CELL BIOL, V13, P344, DOI 10.1016/S0955-0674(00)00218-0; Howcroft TK, 1997, ANAL BIOCHEM, V244, P22, DOI 10.1006/abio.1996.9868; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACK J, 1992, GENETICS, V131, P353; JACK J, 1991, DEVELOPMENT, V113, P735; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Ledford AW, 2002, DEV BIOL, V245, P157, DOI 10.1006/dbio.2002.0636; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; Li SD, 2000, P NATL ACAD SCI USA, V97, P7166, DOI 10.1073/pnas.130028697; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; Liu JQ, 1999, MOL CELL BIOL, V19, P4918; LIU S, 1992, DEV BIOL, V150, P133, DOI 10.1016/0012-1606(92)90013-7; LIU S, 1991, GENETICS, V127, P151; Luo W, 1996, J BIOL CHEM, V271, P18203, DOI 10.1074/jbc.271.30.18203; Luong MX, 2002, MOL CELL BIOL, V22, P1424, DOI 10.1128/MCB.22.5.1424-1437.2002; Mailly F, 1996, MOL CELL BIOL, V16, P5346; Martin-Soudant N, 2000, LEUKEMIA, V14, P863, DOI 10.1038/sj.leu.2401764; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; Moon NS, 2001, MOL CELL BIOL, V21, P6332, DOI 10.1128/MCB.21.18.6332-6345.2001; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; O'Connor MJ, 2000, J VIROL, V74, P401, DOI 10.1128/JVI.74.1.401-410.2000; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pattison S, 1997, J VIROL, V71, P2013, DOI 10.1128/JVI.71.3.2013-2022.1997; Pufall MA, 2002, ANNU REV CELL DEV BI, V18, P421, DOI 10.1146/annurev.cellbio.18.031502.133614; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sakai J, 1998, MOL CELL, V2, P505, DOI 10.1016/S1097-2765(00)80150-1; Santaguida M, 2001, J BIOL CHEM, V276, P45780, DOI 10.1074/jbc.M107978200; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Sinclair AM, 2001, BLOOD, V98, P3658, DOI 10.1182/blood.V98.13.3658; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; Skalnik DG, 2002, GENE, V284, P1, DOI 10.1016/S0378-1119(02)00387-6; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; Stunkel W, 2000, J VIROL, V74, P2489, DOI 10.1128/JVI.74.6.2489-2501.2000; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; Tian G, 1999, MOL CELL BIOL, V19, P2946; Truscott M, 2003, MOL CELL BIOL, V23, P3013, DOI 10.1128/MCB.23.8.3013-3028.2003; Tufarelli C, 1998, DEV BIOL, V200, P69, DOI 10.1006/dbio.1998.8950; VALARCHE I, 1993, DEVELOPMENT, V119, P881; van Gurp MF, 1999, CANCER RES, V59, P5980; VandenHeuvel GB, 1996, BIOL REPROD, V55, P731, DOI 10.1095/biolreprod55.4.731; VANWIJNEN AJ, 1989, J BIOL CHEM, V264, P15034; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973	87	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49787	49794		10.1074/jbc.M409484200	http://dx.doi.org/10.1074/jbc.M409484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15377665	hybrid			2022-12-25	WOS:000225229500031
J	Yoon-Robarts, M; Blouin, AG; Bleker, S; Kleinschmidt, JA; Aggarawal, AK; Escalante, CR; Linden, RM				Yoon-Robarts, M; Blouin, AG; Bleker, S; Kleinschmidt, JA; Aggarawal, AK; Escalante, CR; Linden, RM			Residues within the B ' motif are critical for DNA binding by the superfamily 3 helicase Rep40 of adeno-associated virus type 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; IN-VITRO; REPLICATIVE HELICASE; MUTATIONAL ANALYSIS; BIOCHEMICAL-CHARACTERIZATION; NUCLEASE DOMAIN; PROTEIN; REP68; SITE; AAV	We have recently published the crystal structure of the adeno-associated virus type 2 superfamily 3 (SF3) helicase Rep40. Although based on its biochemical properties it is unlikely that Rep40 plays a central role as a replicative helicase the involvement of this motor protein in DNA packaging has recently been demonstrated. Here we focused our attention on residues that fall within and adjacent to the B' motif of SF3 helicases that directly interact with single-stranded DNA during translocation of the motor protein. In vitro, alanine substitution at positions Lys-404 or Lys-406 abrogated the ability of the protein to interact with single-stranded DNA as demonstrated by electrophoretic mobility shift assay and fluorescence anisotropy, and accordingly these mutants could not unwind a partially duplex DNA substrate. Despite this loss of helicase activity, basal ATPase activity in these mutants remained intact. However, unlike the wild-type protein, K404A and K406A ATPase activity was not stimulated by DNA. As predicted, disruption of motor activity through interference with DNA binding resulted in an inability of Rep40 to package adeno-associated virus DNA in a tissue culture-based assay. Taken together, we characterized, for the first time in an SF3 helicase family member, residues that are directly involved in single-stranded DNA binding and that are critical for the Rep motor activity. Based on our findings we propose B' as the signature motif of SF3 helicases that is responsible for the complex interactions required for the coupling of DNA binding and ATP hydrolysis.	Mt Sinai Sch Med, Struct Biol Ctr, Dept Physiol & Biophys, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Gene & Cell Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; Deutsch Krebsforschungszentrum, Appl Tumor Virol Program, D-69120 Heidelberg, Germany	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Helmholtz Association; German Cancer Research Center (DKFZ)	Escalante, CR (corresponding author), Mt Sinai Sch Med, Struct Biol Ctr, Dept Physiol & Biophys, New York, NY 10029 USA.	escalant@inka.mssm.edu; Michael.Linden@mssm.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062234] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI41706] Funding Source: Medline; NIGMS NIH HHS [R01 GM/AI62234] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON RW, 1966, VIROLOGY, V29, P353, DOI 10.1016/0042-6822(66)90045-6; BERNS KI, 1995, BIOESSAYS, V17, P237, DOI 10.1002/bies.950170310; BOHENZKY RA, 1988, VIROLOGY, V166, P316, DOI 10.1016/0042-6822(88)90502-8; BULLER RML, 1981, J VIROL, V40, P241, DOI 10.1128/JVI.40.1.241-247.1981; Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cathomen T, 2000, J VIROL, V74, P2372, DOI 10.1128/JVI.74.5.2372-2382.2000; Collaco RF, 2003, J BIOL CHEM, V278, P34011, DOI 10.1074/jbc.M301537200; Davis MD, 2000, J VIROL, V74, P2936, DOI 10.1128/JVI.74.6.2936-2942.2000; Davis MD, 1999, J VIROL, V73, P2084, DOI 10.1128/JVI.73.3.2084-2093.1999; Dubielzig R, 1999, J VIROL, V73, P8989, DOI 10.1128/JVI.73.11.8989-8998.1999; GORBALENYA AE, 1990, FEBS LETT, V262, P145, DOI 10.1016/0014-5793(90)80175-I; Grimm D, 1999, GENE THER, V6, P1322, DOI 10.1038/sj.gt.3300946; Hickman AB, 2002, MOL CELL, V10, P327, DOI 10.1016/S1097-2765(02)00592-0; Hickman AB, 2004, MOL CELL, V13, P403, DOI 10.1016/S1097-2765(04)00023-1; HOGGAN MD, 1966, P NATL ACAD SCI USA, V55, P1467, DOI 10.1073/pnas.55.6.1467; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; IM DS, 1990, CELL, V61, P447, DOI 10.1016/0092-8674(90)90526-K; James JA, 2003, STRUCTURE, V11, P1025, DOI 10.1016/S0969-2126(03)00152-7; King JA, 2001, EMBO J, V20, P3282, DOI 10.1093/emboj/20.12.3282; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Li DW, 2003, NATURE, V423, P512, DOI 10.1038/nature01691; MCCARTY DM, 1992, J VIROL, V66, P4050, DOI 10.1128/JVI.66.7.4050-4057.1992; MENDELSON E, 1986, J VIROL, V60, P823, DOI 10.1128/JVI.60.3.823-832.1986; Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smith RH, 1998, J VIROL, V72, P4874, DOI 10.1128/JVI.72.6.4874-4881.1998; SRIVASTAVA A, 1983, J VIROL, V45, P555, DOI 10.1128/JVI.45.2.555-564.1983; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; Walker SL, 1997, J VIROL, V71, P6996, DOI 10.1128/JVI.71.9.6996-7004.1997; WARD P, 1995, VIROLOGY, V209, P692, DOI 10.1006/viro.1995.1306; WEINDLER FW, 1991, J VIROL, V65, P2476, DOI 10.1128/JVI.65.5.2476-2483.1991; WISTUBA A, 1995, J VIROL, V69, P5311, DOI 10.1128/JVI.69.9.5311-5319.1995; YANG QC, 1992, J VIROL, V66, P6058, DOI 10.1128/JVI.66.10.6058-6069.1992; Yoon M, 2001, J VIROL, V75, P3230, DOI 10.1128/JVI.75.7.3230-3239.2001; Yoon-Robarts M, 2003, J BIOL CHEM, V278, P4912, DOI 10.1074/jbc.M209750200; Zhou XH, 1999, J VIROL, V73, P1580, DOI 10.1128/JVI.73.2.1580-1590.1999	42	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50472	50481		10.1074/jbc.M403900200	http://dx.doi.org/10.1074/jbc.M403900200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371437	hybrid			2022-12-25	WOS:000225229500113
J	Ren, YG; Kirsebom, LA; Virtanen, A				Ren, YG; Kirsebom, LA; Virtanen, A			Coordination of divalent metal ions in the active site of poly(A)-specific ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; 3'-5' EXONUCLEASE ACTIVITY; MAMMALIAN MESSENGER-RNA; ESCHERICHIA-COLI; KLENOW FRAGMENT; DEADENYLATION; MECHANISM; STEREOCHEMISTRY; IDENTIFICATION; CATALYSIS	Poly(A)-specific ribonuclease (PARN) is a highly poly(A)-specific 3'-exoribonuclease that efficiently degrades mRNA poly( A) tails. PARN belongs to the DEDD family of nucleases, and four conserved residues are essential for PARN activity, i.e. Asp-28, Glu-30, Asp-292, and Asp-382. Here we have investigated how catalytically important divalent metal ions are coordinated in the active site of PARN. Each of the conserved amino acid residues was substituted with cysteines, and it was found that all four mutants were inactive in the presence of Mg2+. However, in the presence of Mn2+, Zn2+, Co2+, or Cd2+, PARN activity was rescued from the PARN(D28C), PARN(D292C), and PARN(D382C) variants, suggesting that these three amino acids interact with catalytically essential metal ions. It was found that the shortest sufficient substrate for PARN activity was adenosine trinucleotide (A(3)) in the presence of Mg2+ or Cd2+. Interestingly, adenosine dinucleotide (A(2)) was efficiently hydrolyzed in the presence of Mn2+, Zn2+, or Co2+, suggesting that the substrate length requirement for PARN can be modulated by the identity of the divalent metal ion. Finally, introduction of phosphorothioate modifications into the A(3) substrate demonstrated that the scissile bond non-bridging phosphate oxygen in the pro-R position plays an important role during cleavage, most likely by coordinating a catalytically important divalent metal ion. Based on our data we discuss binding and coordination of divalent metal ions in the active site of PARN.	Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, SE-75124 Uppsala, Sweden	Uppsala University	Virtanen, A (corresponding author), Uppsala Univ, Biomed Ctr, Dept Cell & Mol Biol, Box 596, SE-75124 Uppsala, Sweden.	anders.virtanen@icm.uu.se						ASTROM J, 1991, EMBO J, V10, P3067, DOI 10.1002/j.1460-2075.1991.tb07858.x; ASTROM J, 1992, J BIOL CHEM, V267, P18154; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brautigam CA, 1999, CHEM BIOL, V6, P901, DOI 10.1016/S1074-5521(00)80009-5; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; Brautigam CA, 1999, BIOCHEMISTRY-US, V38, P696, DOI 10.1021/bi981537g; BURGERS PMJ, 1978, P NATL ACAD SCI USA, V75, P4798, DOI 10.1073/pnas.75.10.4798; Copeland PR, 2001, RNA, V7, P875, DOI 10.1017/S1355838201010020; Dehlin E, 2000, EMBO J, V19, P1079, DOI 10.1093/emboj/19.5.1079; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; Gao M, 2000, MOL CELL, V5, P479, DOI 10.1016/S1097-2765(00)80442-6; JAFFE EK, 1978, J BIOL CHEM, V253, P4823; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Korner CG, 1997, J BIOL CHEM, V272, P10448; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Martinez J, 2001, J BIOL CHEM, V276, P27923, DOI 10.1074/jbc.M102270200; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Ren YG, 2002, J BIOL CHEM, V277, P5982, DOI 10.1074/jbc.M111515200; Shan S, 2001, BIOCHEMISTRY-US, V40, P5161, DOI 10.1021/bi002887h; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; Sontheimer EJ, 1999, GENE DEV, V13, P1729, DOI 10.1101/gad.13.13.1729; Sontheimer EJ, 1997, NATURE, V388, P801, DOI 10.1038/42068; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; Vortler LCS, 2000, METHOD ENZYMOL, V317, P74; Warnecke JM, 1999, J MOL BIOL, V290, P433, DOI 10.1006/jmbi.1999.2890; Warnecke JM, 2000, NUCLEIC ACIDS RES, V28, P720, DOI 10.1093/nar/28.3.720; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	33	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48702	48706		10.1074/jbc.M403858200	http://dx.doi.org/10.1074/jbc.M403858200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358788	hybrid			2022-12-25	WOS:000225098100027
J	Viggiani, A; Siani, L; Notomista, E; Birolo, L; Pucci, P; Di Donato, A				Viggiani, A; Siani, L; Notomista, E; Birolo, L; Pucci, P; Di Donato, A			The role of the conserved residues His-246, His-199, and Tyr-255 in the catalysis of catechol 2,3-dioxygenase from Pseudomonas stutzeri OX1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRADIOL CLEAVAGE MECHANISM; 2,3-DIHYDROXYBIPHENYL 1,2-DIOXYGENASE; MICROBIAL-DEGRADATION; SUBSTRATE-SPECIFICITY; OXIDATIVE CLEAVAGE; GLOBIFORMIS CM-2; ACTIVE-SITE; DIOXYGENASES; PUTIDA; ENZYMES	Catechol 2,3-dioxygenase (C2,3O) from Pseudomonas stutzeri OX1, which is able to grow on various aromatic substrates as the sole source of carbon and energy, has been expressed in Escherichia coli, purified, characterized, and found to be very similar to other dioxygenases from Pseudomonas species. Interestingly, the activity of the protein shows a rather unusual pH dependence when assayed on catechol. A model of the catalytic mechanism was developed that is able to reproduce the catalytic behavior of the protein as a function of the pH. The model includes multiple equilibria and four productive intermediates with different ionization states of the enzyme-substrate complex. The fitting of the theoretical curve to the experimental data suggests that a tyrosine and two histidine residues are involved in catalysis. Mutants (H246N)-, (H246A)-, (H199N)- and (Y255F)- C2,3O were produced to investigate the role of highly conserved His-199, His-246, and Tyr-255. The strongly reduced activity of the mutants suggests a primary catalytic role for each of these residues. Moreover, mutants at positions 199 and 246 display pH profiles different from that of the wild-type protein, thus indicating that residues His-246 and His-199 play a role in determining the unusual pH dependence of the enzyme. In addition, electron-withdrawing groups on catechol, which increase the acidity of the phenolic hydroxyl group, are able to counterbalance the effect of the mutation H246N in reducing catalytic activity but cause a further reduction of the activity of ( H199N)- C2,3O. This finding suggests that His-246 is involved in the initial catechol deprotonation, whereas His-199 promotes the reaction between oxygen and the aromatic ring.	Univ Naples Federico II, Dipartimento Chim Biol, I-80134 Naples, Italy; Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Di Donato, A (corresponding author), Univ Naples Federico II, Dipartimento Chim Biol, Via Mezzocannone 16, I-80134 Naples, Italy.	didonato@unina.it	Di Donato, Alberto/G-5494-2012	PUCCI, Pietro/0000-0002-5885-1495; DI DONATO, Alberto/0000-0001-9129-9850; NOTOMISTA, Eugenio/0000-0003-0097-6487; BIROLO, Leila/0000-0002-0915-7501				BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; Boldt YR, 1997, BIOCHEMISTRY-US, V36, P2147, DOI 10.1021/bi962362i; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugg TDH, 2001, CHEM COMMUN, P941, DOI 10.1039/b100484k; Bugg TDH, 1998, NAT PROD REP, V15, P513; CERDAN P, 1994, J BACTERIOL, V176, P6074, DOI 10.1128/jb.176.19.6074-6081.1994; CERDAN P, 1995, EUR J BIOCHEM, V229, P113, DOI 10.1111/j.1432-1033.1995.0113l.x; Deeth RJ, 2003, J BIOL INORG CHEM, V8, P409, DOI 10.1007/s00775-002-0430-7; Eltis LD, 1996, J BACTERIOL, V178, P5930, DOI 10.1128/jb.178.20.5930-5937.1996; Groce SL, 2003, J AM CHEM SOC, V125, P11780, DOI 10.1021/ja0368103; HARAYAMA S, 1993, MOL GEN GENET, V239, P81, DOI 10.1007/BF00281605; HARAYAMA S, 1989, J BIOL CHEM, V264, P15328; Holman CM, 1999, BIOCHEMISTRY-US, V38, P677, DOI 10.1021/bi9822170; Hugo N, 1998, J BIOL CHEM, V273, P9622, DOI 10.1074/jbc.273.16.9622; Hugo N, 2000, J BACTERIOL, V182, P5580, DOI 10.1128/JB.182.19.5580-5585.2000; Kang BS, 1998, BIOCHEM BIOPH RES CO, V245, P791, DOI 10.1006/bbrc.1998.8511; Kita A, 1999, STRUCTURE, V7, P25, DOI 10.1016/S0969-2126(99)80006-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin G, 2001, J AM CHEM SOC, V123, P5030, DOI 10.1021/ja004280u; Mars AE, 1997, J BACTERIOL, V179, P4530, DOI 10.1128/jb.179.14.4530-4537.1997; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; QUE L, 1983, ADV INORG BIOCHEM, V5, P167; REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403; Reynolds MF, 2003, J BIOL INORG CHEM, V8, P263, DOI 10.1007/s00775-002-0411-x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato N, 2002, J MOL BIOL, V321, P621, DOI 10.1016/S0022-2836(02)00673-3; Scognamiglio R, 2001, PROTEIN SCI, V10, P482, DOI 10.1110/ps.35701; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; Spence EL, 1996, J BACTERIOL, V178, P5249, DOI 10.1128/jb.178.17.5249-5256.1996; Timmis KN, 1999, TRENDS BIOTECHNOL, V17, P201, DOI 10.1016/S0167-7799(98)01295-5; Vaillancourt FH, 2002, J BIOL CHEM, V277, P2019, DOI 10.1074/jbc.M106890200; Vaillancourt FH, 2002, J AM CHEM SOC, V124, P2485, DOI 10.1021/ja0174682; Vetting MW, 2004, J BACTERIOL, V186, P1945, DOI 10.1128/JB.186.7.1945-1958.2004; VIGGIANI A, 2003, P 2 EUR BIOR C CHAN, P457; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; Winfield CJ, 2000, J CHEM SOC PERK T 1, P3277, DOI 10.1039/b004265j; Xia M, 1999, J BIOL CHEM, V274, P3323, DOI 10.1074/jbc.274.6.3323	39	45	45	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48630	48639		10.1074/jbc.M406243200	http://dx.doi.org/10.1074/jbc.M406243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347689	hybrid			2022-12-25	WOS:000225098100019
J	Yang, XL; Wang, WG; Fan, JS; Lal, A; Yang, DM; Cheng, HP; Gorospe, M				Yang, XL; Wang, WG; Fan, JS; Lal, A; Yang, DM; Cheng, HP; Gorospe, M			Prostaglandin A(2)-mediated stabilization of p21 mRNA through an ERK-dependent pathway requiring the RNA-binding protein HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTORS; GENE-EXPRESSION; CYCLOPENTENONE PROSTAGLANDIN; NUCLEAR IMPORT; ELEMENT; GROWTH; DEGRADATION; INDUCTION; TURNOVER; INHIBITION	Treatment with the stress agent prostaglandin A(2) (PGA(2)) induces expression of the cyclin-dependent kinase inhibitor p21. Here, we present evidence that p21 expression increases through PGA(2)-triggered stabilization of the p21 mRNA and further show that these events require the mitogen-activated protein (MAP) kinase ERK. Binding experiments using either endogenous p21 mRNA or in vitro-labeled p21 transcripts revealed a specific PGA(2)-dependent association of the p21 mRNA with the RNA-binding protein HuR. Interestingly, although inhibition of the ERK pathway did not prevent the PGA(2)-triggered increase in cytoplasmic HuR, it did impair the formation of endogenous and in vitro [HuR-p21 mRNA] complexes and further prevented the PGA(2)-mediated stabilization of the p21 mRNA, suggesting that ERK-mediated events were required for binding HuR to the p21 mRNA and preventing its decay. RNA interference-based knockdown of HuR abundance further served to demonstrate the contribution of HuR-mediated p21 mRNA stabilization toward enhancing p21 expression after PGA(2) treatment. Collectively, our results indicate that PGA(2) stabilizes the p21 mRNA through an ERK-independent increase in cytoplasmic HuR levels and an ERK-dependent association of HuR with the p21 mRNA.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; NIA, Cardiovasc Sci Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Gorospe, M (corresponding author), NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	myriam-gorospe@nih.gov	Heping, Cheng/AAE-2680-2019	Heping, Cheng/0000-0002-9604-6702	NATIONAL INSTITUTE ON AGING [Z01AG000511, Z01AG000852, ZIAAG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; AMICI C, 1993, EXP CELL RES, V207, P230, DOI 10.1006/excr.1993.1188; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brooks SA, 2004, J IMMUNOL, V172, P7263, DOI 10.4049/jimmunol.172.12.7263; CAGEN LM, 1975, BIOCHIM BIOPHYS ACTA, V398, P205, DOI 10.1016/0005-2760(75)90184-8; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOI AMK, 1994, FASEB J, V8, P1048, DOI 10.1096/fasebj.8.13.7926370; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUKUSHIMA M, 1994, ANN NY ACAD SCI, V744, P161, DOI 10.1111/j.1749-6632.1994.tb52733.x; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gherzi R, 2004, MOL CELL, V14, P571, DOI 10.1016/j.molcel.2004.05.002; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; GOROSPE M, 2003, HDB CELL SIGNALING, P283; Guttinger S, 2004, P NATL ACAD SCI USA, V101, P2918, DOI 10.1073/pnas.0400342101; HOLBROOK NJ, 1992, MOL CELL BIOL, V12, P1528, DOI 10.1128/MCB.12.4.1528; HUGHESFULFORD M, 1994, J CELL BIOCHEM, V54, P265, DOI 10.1002/jcb.240540302; Jain RG, 1997, MOL CELL BIOL, V17, P954, DOI 10.1128/MCB.17.2.954; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Joubert AM, 2003, CANCER LETT, V191, P203, DOI 10.1016/S0304-3835(02)00625-0; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; KIKUCHI Y, 1992, J CANCER RES CLIN, V118, P453, DOI 10.1007/BF01629429; KIKUCHI Y, 1992, INT J IMMUNOPHARMACO, V14, P105; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; NEGISHI M, 1995, BBA-LIPID LIPID MET, V1259, P109, DOI 10.1016/0005-2760(95)00146-4; OHNO K, 1986, BIOCHEM BIOPH RES CO, V139, P808, DOI 10.1016/S0006-291X(86)80062-6; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; Rebane A, 2004, RNA, V10, P590, DOI 10.1261/rna.5224304; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SASAKI H, 1994, ANTI-CANCER DRUG, V5, P131, DOI 10.1097/00001813-199404000-00002; SASAKI H, 1991, GYNECOL ONCOL, V41, P36, DOI 10.1016/0090-8258(91)90251-Y; Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Takahashi S, 1998, BIOCHEM J, V335, P35, DOI 10.1042/bj3350035; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tran H, 2003, MOL CELL BIOL, V23, P7177, DOI 10.1128/MCB.23.20.7177-7188.2003; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	68	63	65	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49298	49306		10.1074/jbc.M407535200	http://dx.doi.org/10.1074/jbc.M407535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15371446	hybrid			2022-12-25	WOS:000225098100098
J	Chytil, A; Waltner-Law, M; West, R; Friedman, D; Aakre, M; Barker, D; Law, B				Chytil, A; Waltner-Law, M; West, R; Friedman, D; Aakre, M; Barker, D; Law, B			Construction of a cyclin D1-Cdk2 fusion protein to model the biological functions of cyclin D1-Cdk2 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; INDUCED GROWTH ARREST; DEPENDENT KINASE; RETINOBLASTOMA PROTEIN; FARNESYLTRANSFERASE INHIBITOR; NUCLEAR ANTIGEN; DOWN-REGULATION; CDK INHIBITORS; BREAST-CANCER; DNA-SYNTHESIS	Cyclin D1 is frequently overexpressed in human breast cancers, and cyclin D1 overexpression correlates with poor prognosis. Cyclin D1-Cdk2 complexes were previously observed in human breast cancer cell lines, but their role in cell cycle regulation and transformation was not investigated. This report demonstrates that Cdk2 in cyclin D1-Cdk2 complexes from mammary epithelial cells is phosphorylated on the activating phosphorylation site, Thr(160). Furthermore, cyclin D1-Cdk2 complexes catalyze Rb phosphorylation on multiple sites in vitro. As a model to investigate the biological and biochemical functions of cyclin D1-Cdk2 complexes, and the mechanisms by which cyclin D1 activates Cdk2, a cyclin D1-Cdk2 fusion gene was constructed. The cyclin D1-Cdk2 fusion protein expressed in epithelial cells was phosphorylated on Thr160 and catalyzed the phosphorylation of Rb on multiple sites in vitro and in vivo. Kinase activity was not observed if either the cyclin D1 or Cdk2 domain was mutationally inactivated. Mutational inactivation of the cyclin D1 domain prevented activating phosphorylation of the Cdk2 domain on Thr160. These results indicate that the cyclin D1 domain of the fusion protein activated the Cdk2 domain through an intramolecular mechanism. Cells stably expressing the cyclin D1-Cdk2 fusion protein exhibited several hallmarks of transformation including hyperphosphorylation of Rb, resistance to TGFbeta-induced growth arrest, and anchorage-independent proliferation in soft agar. We propose that cyclin D1-Cdk2 complexes mediate some of the transforming effects of cyclin D1 and demonstrate that the cyclin D1-Cdk2 fusion protein is a useful model to investigate the biological functions of cyclin D1-Cdk2 complexes.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Mass Spectrometry Res Ctr, Vanderbilt Proteom Lab, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Law, B (corresponding author), Univ Florida, Shands Canc Ctr, Dept Pharmacol & Therapeut, Acad RSCH BLDG,Rm R5-126,1600 SW Archer Rd,POB 10, Gainesville, FL 32610 USA.	bklaw@pharmacology.ufl.edu	Barker, David JP/A-5671-2013		NATIONAL CANCER INSTITUTE [P30CA068485, R01CA093651] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485, R01-CA93651] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afshari CA, 1996, CELL GROWTH DIFFER, V7, P979; Bandyopadhyay A, 1998, CARCINOGENESIS, V19, P1907, DOI 10.1093/carcin/19.11.1907; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Brown KA, 2004, BREAST CANCER RES, V6, pR130, DOI 10.1186/bcr762; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Doebis C, 2002, TRANSPL IMMUNOL, V9, P323, DOI 10.1016/S0966-3274(02)00034-5; DOU QP, 1994, BIOCHEM BIOPH RES CO, V205, P1859, DOI 10.1006/bbrc.1994.2887; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Law BK, 2000, J BIOL CHEM, V275, P38261, DOI 10.1074/jbc.M005545200; Law BK, 1999, J BIOL CHEM, V274, P4743, DOI 10.1074/jbc.274.8.4743; Law BK, 2000, J BIOL CHEM, V275, P10796, DOI 10.1074/jbc.275.15.10796; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Pan WJ, 2001, CANCER RES, V61, P2885; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rao RN, 1999, ONCOGENE, V18, P6343, DOI 10.1038/sj.onc.1203009; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; Sasano H, 1997, ANTICANCER RES, V17, P3685; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sutherland RL, 2002, BREAST CANCER RES, V4, P14, DOI 10.1186/bcr411; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	45	40	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47688	47698		10.1074/jbc.M405938200	http://dx.doi.org/10.1074/jbc.M405938200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355984	hybrid			2022-12-25	WOS:000224957000034
J	Fukuchi, M; Tabuchi, A; Tsuda, M				Fukuchi, M; Tabuchi, A; Tsuda, M			Activity-dependent transcriptional activation and mRNA stabilization for cumulative expression of pituitary adenylate cyclase-activating polypeptide mRNA controlled by calcium and cAMP signals in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; GENE PROMOTER-I; PACAP GENE; MAP KINASE; MEMBRANE DEPOLARIZATION; SPLICE VARIANTS; C-FOS; CREB; RECEPTOR; BDNF	Although it has been established that an activity-dependent gene transcription is induced by the calcium (Ca2+) signals in neurons, it is unclear how the specific mRNA moieties are transiently accumulated in response to synaptic transmission which evokes multiple intracellular signals including Ca2+ and cAMP ones. The expression of pituitary adenylate cyclase activating polypeptide (PACAP), a neuropeptide, is controlled by Ca2+ signals evoked via membrane depolarization in neurons, and, in cultured rat cortical neuronal cells, we found that the Ca2+ signal-mediated activation of the PACAP gene promoter was critically controlled by a single cAMP-response element (CRE) located at around -200, to which the CRE-binding protein predominantly bound. The Ca2+ signal-induced expression of PACAP mRNA was enhanced by forskolin, which evokes cAMP signals. In support, the PACAP gene promoter was synergistically enhanced by Ca2+ and cAMP signals through the CRE, accompanying a prolonged activation of extracellular signal-related protein kinase 1/2 and CRE-binding protein. On the other hand, sole administration of forskolin markedly reduced the cellular content of PACAP mRNA, which was restored by the addition of Ca2+ signals. We found that the stability of PACAP mRNA was increased in response to Ca2+ signals but not that of activity-regulated cytoskeleton-associated protein (Arc) mRNA, indicating an activity-dependent stabilization of specific mRNA species in neurons, which can antagonize the regulation mediated by cAMP signals. Thus, the transcriptional activation and mRNA stabilization are coordinately regulated by Ca2+ and cAMP signals for the cumulative expression of PACAP mRNA in neurons.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9310194, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1500002, Japan	University of Toyama; Japan Science & Technology Agency (JST)	Tsuda, M (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sugitani 2630, Toyama 9310194, Japan.	tsuda@ms.toyama-mpu.ac.jp		Fukuchi, Mamoru/0000-0002-6807-8707				Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Brandenburg CA, 1997, J NEUROSCI, V17, P4045; Chen WG, 2003, J NEUROSCI, V23, P2572; Cummings KJ, 2002, MOL CELL ENDOCRINOL, V192, P133, DOI 10.1016/S0303-7207(02)00028-X; GHOSH A, 1994, J NEUROBIOL, V25, P294, DOI 10.1002/neu.480250309; Hansen TVO, 2004, J NEUROCHEM, V89, P15, DOI 10.1046/j.1471-4159.2003.02252.x; Harakall SA, 1998, ANN NY ACAD SCI, V865, P367, DOI 10.1111/j.1749-6632.1998.tb11197.x; Hashimoto H, 2000, J NEUROCHEM, V74, P501, DOI 10.1046/j.1471-4159.2000.740501.x; HASHIMOTO H, 1993, NEURON, V11, P333, DOI 10.1016/0896-6273(93)90188-W; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; Li M, 1999, NEUROENDOCRINOLOGY, V69, P217, DOI 10.1159/000054422; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Morozov A, 2003, NEURON, V39, P309, DOI 10.1016/S0896-6273(03)00404-5; Otto C, 2001, J NEUROSCI, V21, P5520, DOI 10.1523/JNEUROSCI.21-15-05520.2001; Park JI, 2000, MOL HUM REPROD, V6, P238, DOI 10.1093/molehr/6.3.238; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; Steward O, 2001, NEURON, V30, P227, DOI 10.1016/S0896-6273(01)00275-6; Tabuchi A, 2002, J BIOL CHEM, V277, P35920, DOI 10.1074/jbc.M204784200; Tabuchi A, 2001, NEUROSCI RES, V39, P85, DOI 10.1016/S0168-0102(00)00200-5; Tabuchi A, 2001, NEUROREPORT, V12, P1181, DOI 10.1097/00001756-200105080-00026; Tabuchi A, 2000, J BIOL CHEM, V275, P17269, DOI 10.1074/jbc.M909538199; Tabuchi A, 1998, BIOCHEM BIOPH RES CO, V253, P818, DOI 10.1006/bbrc.1998.9854; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Vaudry D, 2000, PHARMACOL REV, V52, P269; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White SL, 2000, ANN NY ACAD SCI, V921, P370; Yamamoto K, 1998, GENE, V211, P63, DOI 10.1016/S0378-1119(98)00110-3	40	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					47856	47865		10.1074/jbc.M409090200	http://dx.doi.org/10.1074/jbc.M409090200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15355970	hybrid			2022-12-25	WOS:000224957000055
J	Laederich, MB; Funes-Duran, M; Yen, LL; Ingalla, E; Wu, XL; Carraway, KL; Sweeney, C				Laederich, MB; Funes-Duran, M; Yen, LL; Ingalla, E; Wu, XL; Carraway, KL; Sweeney, C			The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CARCINOMA CELLS; EGF RECEPTOR; DROSOPHILA; DEGRADATION; ENDOCYTOSIS; DECORIN; CANCER; GENE; UBIQUITYLATION	The molecular mechanisms by which mammalian receptor tyrosine kinases are negatively regulated remain largely unexplored. Previous genetic and biochemical studies indicate that Kekkon-1, a transmembrane protein containing leucine-rich repeats and an immunoglobulin-like domain in its extracellular region, acts as a feedback negative regulator of epidermal growth factor (EGF) receptor signaling in Drosophila melanogaster development. Here we tested whether the related human LRIG1 ( also called Lig-1) protein can act as a negative regulator of EGF receptor and its relatives, ErbB2, ErbB3, and ErbB4. We observed that in co-transfected 293T cells, LRIG1 forms a complex with each of the ErbB receptors independent of growth factor binding. We further observed that co-expression of LRIG1 with EGF receptor suppresses cellular receptor levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination. Finally, we observed that co-expression of LRIG1 suppresses EGF-stimulated transformation of NIH3T3 fibroblasts and that the inducible expression of LRIG1 in PC3 prostate tumor cells suppresses EGF- and neuregulin-1-stimulated cell cycle progression. Our observations indicate that LRIG1 is a negative regulator of the ErbB family of receptor tyrosine kinases and suggest that LRIG1-mediated receptor ubiquitination and degradation may contribute to the suppression of ErbB receptor function.	Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis	Sweeney, C (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Rm 1400,4645 2nd Ave, Sacramento, CA 95817 USA.	casweeney@ucdavis.edu	高, 雨莉/HGU-8187-2022					Baulida J, 1997, EXP CELL RES, V232, P167, DOI 10.1006/excr.1997.3515; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bottcher RT, 2004, NAT CELL BIOL, V6, P38, DOI 10.1038/ncb1082; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Ghiglione C, 2003, DEVELOPMENT, V130, P4483, DOI 10.1242/dev.00617; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; HOFER DR, 1991, CANCER RES, V51, P2780; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Jin MH, 2000, MOL CELL BIOL, V20, P2098, DOI 10.1128/MCB.20.6.2098-2107.2000; Lacy SE, 1999, GENOMICS, V62, P417, DOI 10.1006/geno.1999.6033; Levkowitz G, 1996, ONCOGENE, V12, P1117; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; Vinos J, 2000, ONCOGENE, V19, P3560, DOI 10.1038/sj.onc.1203702; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084	32	187	201	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2004	279	45					47050	47056		10.1074/jbc.M409703200	http://dx.doi.org/10.1074/jbc.M409703200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	867HE	15345710	hybrid			2022-12-25	WOS:000224832400090
J	Plaks, V; Posen, Y; Mazor, O; Brandis, A; Scherz, A; Salomon, Y				Plaks, V; Posen, Y; Mazor, O; Brandis, A; Scherz, A; Salomon, Y			Homologous adaptation to oxidative stress induced by the photosensitized Pd-bacteriochlorophyll derivative (WST11) in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEAT-SHOCK PROTEINS; HUMAN U937 CELLS; NF-KAPPA-B; PHOTODYNAMIC THERAPY; HYDROGEN-PEROXIDE; NITRIC-OXIDE; MAP KINASES; P38 GROUP; IN-VIVO	Various forms of cellular stress induce adaptive responses through poorly understood mechanisms. In maintaining homeostasis, endothelial cells respond and adapt to changes in oxidative stress that prevail in the circulation. Endothelial cells are also the target of many oxidative stress-based vascular therapies. The objectives of this study were to determine whether endothelial cells adapt to oxidative stress induced upon the photosensitization of WST11 (a water-soluble Pd-bacteriochlorophyll derivative being developed as a photodynamic agent) and to study possible cellular mechanisms involved. The hallmark of WST11-based photodynamic therapy is the in situ generation of cytotoxic reactive oxygen species causing vascular shutdown, hypoxia, and tumor eradication. Here we demonstrated that photodynamic therapy also induces adaptive responses and tolerance following a sublethal preconditioning of endothelial cells with the same (homologous) or different (heterologous) stressor. A link among p38 MAPK activity, expression of hsp70 and hsp27, and homologous adaptation to reactive oxygen species induced by photosensitized WST11 was established. In addition to characterization of some key proteins involved, our observations provide a beneficial new working tool for the studies of mechanisms involved in oxidative stress and adaptation using light-controlled photosensitization.	Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Salomon, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yoram.salomon@weizmann.ac.il						Andoh T, 2003, J BIOL CHEM, V278, P885, DOI 10.1074/jbc.M209914200; Armstrong SC, 2000, J MOL CELL CARDIOL, V32, P1301, DOI 10.1006/jmcc.2000.1164; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; Calabrese V, 2002, J NEUROSCI RES, V68, P65, DOI 10.1002/jnr.10177; Carini R, 2003, FREE RADICAL BIO MED, V34, P1047, DOI 10.1016/S0891-5849(03)00039-X; Carmichael J, 2002, J BIOL CHEM, V277, P33791, DOI 10.1074/jbc.m204861200; Casas A, 2002, LASER MED SCI, V17, P42, DOI 10.1007/s10103-002-8265-6; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; Garmyn M, 2001, J INVEST DERMATOL, V117, P1290, DOI 10.1046/j.0022-202x.2001.01553.x; Gomer CJ, 1996, CANCER RES, V56, P2355; Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940; GROSS S, 2003, THESIS WEIZMANN I SC; Guo ZH, 2001, J NEUROCHEM, V79, P361, DOI 10.1046/j.1471-4159.2001.00564.x; Hanlon JG, 2001, J PHOTOCH PHOTOBIO B, V64, P55, DOI 10.1016/S1011-1344(01)00189-0; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kim DK, 2001, FREE RADICAL BIO MED, V30, P563, DOI 10.1016/S0891-5849(00)00504-9; Kim Y, 1997, J CELL BIOCHEM, V67, P43, DOI 10.1002/(SICI)1097-4644(19971001)67:1<43::AID-JCB5>3.0.CO;2-W; Klotz LO, 1998, CANCER RES, V58, P4297; Koudinova NV, 2003, INT J CANCER, V104, P782, DOI 10.1002/ijc.11002; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Lee BR, 1999, EXP CELL RES, V248, P430, DOI 10.1006/excr.1999.4409; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lin F, 1998, PHOTOCHEM PHOTOBIOL, V68, P211; MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328; Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2; MAZOR O, 2003, 9 INT PHOT ASS MIYAZ; Millar CGM, 1996, PHARMACOL THERAPEUT, V69, P143, DOI 10.1016/0163-7258(95)02055-1; Mitra S, 2003, PHOTOCHEM PHOTOBIOL, V78, P615, DOI 10.1562/0031-8655(2003)078<0615:AOHSPP>2.0.CO;2; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Plaks V, 2004, NEOPLASIA, V6, P224, DOI 10.1593/neo.03352; Pohlman TH, 2000, J SURG RES, V89, P85, DOI 10.1006/jsre.1999.5801; Preise D, 2003, NEOPLASIA, V5, P475, DOI 10.1016/S1476-5586(03)80031-3; Redaelli CA, 2002, NEPHRON, V90, P489, DOI 10.1159/000054739; SCHERZ A, 2002, Patent No. 04045492; Schreiber S, 2002, INT J CANCER, V99, P279, DOI 10.1002/ijc.10299; Seong JK, 2002, EXP MOL MED, V34, P374, DOI 10.1038/emm.2002.53; Sharma A, 2001, MOL CELL BIOCHEM, V219, P1, DOI 10.1023/A:1011038531656; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Tao JS, 1996, J BIOL CHEM, V271, P27107, DOI 10.1074/jbc.271.43.27107; Torres M, 2003, FRONT BIOSCI, V8, pD369, DOI 10.2741/999; VAKRATHAGLILI Y, 2002, THESIS WEIZMANN I SC; Varriale L, 2002, FEBS LETT, V512, P287, DOI 10.1016/S0014-5793(02)02239-1; Wang HP, 2002, PHOTOCHEM PHOTOBIOL, V76, P98, DOI 10.1562/0031-8655(2002)076<0098:UROHPA>2.0.CO;2; Yung Y, 2001, J BIOL CHEM, V276, P35280, DOI 10.1074/jbc.M105995200; Zilberstein J, 2001, PHOTOCHEM PHOTOBIOL, V73, P257, DOI 10.1562/0031-8655(2001)073<0257:ATOSMT>2.0.CO;2	54	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 29	2004	279	44					45713	45720		10.1074/jbc.M403515200	http://dx.doi.org/10.1074/jbc.M403515200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	865IC	15339936	hybrid			2022-12-25	WOS:000224694900053
J	Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM				Mazor, M; Kawano, Y; Zhu, HN; Waxman, J; Kypta, RM			Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth	ONCOGENE			English	Article						GSK-3; beta-catenin; androgen receptor; prostate cancer	ADENOMATOUS POLYPOSIS-COLI; SMALL-MOLECULE INHIBITORS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVITY; NEGATIVE REGULATOR; SIGNALING PATHWAY; GENE-EXPRESSION; AXIN; PHOSPHORYLATION; COMPLEX	The transcriptional activity of the androgen receptor (AR) is regulated by interaction with various coregulators, one of which is beta-catenin., Interest in the role of beta-catenin in prostate cancer has been stimulated by reports showing that it is aberrantly expressed in the cytoplasm and/or nucleus in up to 38% of hormone-refractory tumours and that overexpression of beta-catenin results in activation of AR transcriptional activity. We have examined the effect of depleting endogenous beta-catenin on AR activity using Axin and RNA interference. Axin, which promotes beta-catenin degradation, inhibited AR transcriptional activity. However, this did not require the beta-catenin-binding domain of Axin. Depletion of beta-catenin using RNA interference increased, rather than decreased, AR activity, suggesting that endogenous beta-catenin is not a transcriptional coactivator for the AR. The glycogen synthase kinase-3 (GSK-3)-binding domain of Axin prevented formation of a GSK-3-AR complex and was both necessary and sufficient for inhibition of AR-dependent transcription. A second GSK-3-binding protein, FRAT, also inhibited AR transcriptional activity, as did the GSK-3 inhibitors SB216763 and SB415286. Finally, inhibition of GSK-3 reduced the growth of AR-expressing prostate cancer cell lines. Our observations suggest a potential new therapeutic application for GSK-3 inhibitors in prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England	Imperial College London	Kypta, RM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Med, Dept Canc Cell Biol, Prostate Canc Res Grp, London W12 0NN, England.	r.kypta@imperial.ac.uk	Kypta, Robert/F-7699-2011	Kypta, Robert/0000-0002-2389-310X				Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Chesire DR, 2003, ENDOCR-RELAT CANCER, V10, P537, DOI 10.1677/erc.0.0100537; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cronauer MV, 2003, INT J ONCOL, V23, P1095; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franca-Koh J, 2002, J BIOL CHEM, V277, P43844, DOI 10.1074/jbc.M207265200; Fraser E, 2002, J BIOL CHEM, V277, P2176, DOI 10.1074/jbc.M109462200; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Giannini AL, 2000, J BIOL CHEM, V275, P21883, DOI 10.1074/jbc.M001929200; Gregory CW, 2001, CANCER RES, V61, P2892; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Salas TR, 2004, J BIOL CHEM, V279, P19191, DOI 10.1074/jbc.M309560200; Salas TR, 2003, J BIOL CHEM, V278, P41338, DOI 10.1074/jbc.M302972200; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Truica CI, 2000, CANCER RES, V60, P4709; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Wang L, 2004, J BIOL CHEM, V279, P32444, DOI 10.1074/jbc.M313963200; WOODGETT JR, 2001, SCI STKE, pRE12; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8	42	100	113	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7882	7892		10.1038/sj.onc.1208068	http://dx.doi.org/10.1038/sj.onc.1208068			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361837				2022-12-25	WOS:000224331600014
J	Tupling, AR; Gramolini, AO; Duhamel, TA; Kondo, H; Asahi, M; Tsuchiya, SC; Borrelli, MJ; Lepock, JR; Otsu, K; Hori, M; MacLennan, DH; Green, HJ				Tupling, AR; Gramolini, AO; Duhamel, TA; Kondo, H; Asahi, M; Tsuchiya, SC; Borrelli, MJ; Lepock, JR; Otsu, K; Hori, M; MacLennan, DH; Green, HJ			HSP70 binds to the fast-twitch skeletal muscle sarco(endo) plasmic reticulum Ca2+-ATPase (SERCA1a) and prevents thermal inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; SARCOPLASMIC-RETICULUM; OXIDATIVE STRESS; RAT MUSCLE; TRANSGENIC MICE; SR CA2+-ATPASE; CA-ATPASE; PHOSPHOLAMBAN; CA-2+-ATPASE; DENATURATION	This study examined whether HSP70 could bind to and protect against thermal inactivation of SERCA1a, the SERCA isoform expressed in adult fast-twitch skeletal muscle. Sarcoplasmic reticulum vesicles prepared from rat gastrocnemius muscle were incubated with purified HSP70 at both 37 and 41 degreesC for either 30, 60, or 120 min. Maximal SERCA1a activity (mumol/g protein/min) in the absence of HSP70 was reduced progressively with time, with greater reductions occurring at 41 degreesC compared with 37 degreesC. HSP70 protected against thermal inactivation of SERCA1a activity at 37 degreesC but not at 41 degreesC and only at 30 and 60 min but not at 120 min. HSP70 also protected against reductions in binding capacity for fluorescein isothiocyanate, a fluorescent probe that binds to Lys515 in the nucleotide binding domain of SERCA, at 30 and 60 min but not at 120 min, an effect that was independent of temperature. HEK-293 cells were cotransfected with cDNAs encoding rabbit SERCA1a and human HSP-EYFP and subjected to 40 degreesC for 1 h. Immunohistochemistry revealed nearly complete co-localization of SERCA1a with HSP70 under these conditions. Co-immunoprecipitation showed physical interaction between HSP70 and SERCA1a under all thermal conditions both in vitro and in HEK-293 cells. Modeling showed that the fluorescein isothiocyanate-binding site of intact SERCA1a in the E2 form lies in its close proximity to a potential interaction site between SERCA1a and HSP70. These results indicate that HSP70 can bind to SERCA1a and, depending on the severity of heat stress, protect SERCA1a function by stabilizing the nucleotide binding domain.	Univ Waterloo, Dept Kinesiol, Waterloo, ON N2L 3G1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Osaka Univ, Dept Internal Med & Therapeut, Grad Sch Med, Suita, Osaka 5650871, Japan; William Beaumont Hosp, Dept Radiat Oncol, Royal Oak, MI 48073 USA	University of Waterloo; University of Toronto; University of Toronto; Osaka University; Beaumont Health	Tupling, AR (corresponding author), Univ Waterloo, Dept Kinesiol, 200 Univ Ave, Waterloo, ON N2L 3G1, Canada.	rtupling@uwaterloo.ca	Duhamel, Todd/ABA-9623-2020; Duhamel, Todd A/F-4433-2017	Duhamel, Todd/0000-0001-8467-4800; Duhamel, Todd A/0000-0001-8467-4800; Tupling, A. Russell/0000-0002-3895-6767				Arnaud C, 2002, BRIT J PHARMACOL, V135, P1776, DOI 10.1038/sj.bjp.0704619; Asahi M, 1999, J BIOL CHEM, V274, P32855, DOI 10.1074/jbc.274.46.32855; Asahi M, 2003, P NATL ACAD SCI USA, V100, P5040, DOI 10.1073/pnas.0330962100; Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Bidmon B, 2000, KIDNEY INT, V58, P2400, DOI 10.1046/j.1523-1755.2000.00423.x; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; Bruskov VI, 2002, NUCLEIC ACIDS RES, V30, P1354, DOI 10.1093/nar/30.6.1354; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Callahan MK, 2002, J BIOL CHEM, V277, P33604, DOI 10.1074/jbc.M202890200; Choudhary Gaurav, 2002, Congest Heart Fail, V8, P148, DOI 10.1111/j.1527-5299.2002.00716.x; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Davidson GA, 1996, BBA-GEN SUBJECTS, V1289, P187, DOI 10.1016/0304-4165(95)00155-7; Dhalla NS, 2000, J HYPERTENS, V18, P655, DOI 10.1097/00004872-200018060-00002; Favero TG, 1998, J APPL PHYSIOL, V84, P425, DOI 10.1152/jappl.1998.84.2.425; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Javed MUH, 1999, BIOCHEM MOL BIOL INT, V47, P631; KAMPINGA HH, 1993, J CELL SCI, V104, P11; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Klebl BM, 1998, FEBS LETT, V422, P381, DOI 10.1016/S0014-5793(98)00053-2; KNOWLTON A, 1997, HEAT SHOCK PROTEINS, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1987, EUR J BIOCHEM, V162, P555, DOI 10.1111/j.1432-1033.1987.tb10675.x; LEPOCK JR, 1990, BIOCHEMISTRY-US, V29, P681, DOI 10.1021/bi00455a013; Lepore DA, 2000, MUSCLE NERVE, V23, P1847, DOI 10.1002/1097-4598(200012)23:12<1847::AID-MUS8>3.0.CO;2-U; LIU X, 2003, ANN REV PHARM TOXICO, V44, P349; LUCKIN KA, 1991, BIOCHEM MED METAB B, V46, P391, DOI 10.1016/0885-4505(91)90087-2; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; Maglara AA, 2003, J PHYSIOL-LONDON, V548, P837, DOI 10.1113/jphysiol.2002.034520; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Matsunaga S, 2001, J MUSCLE RES CELL M, V22, P685, DOI 10.1023/A:1016310607568; MATSUSHITA S, 1992, BIOCHEM J, V285, P303, DOI 10.1042/bj2850303; MCINTOSH DB, 1978, J BIOL CHEM, V253, P5140; Morris TE, 1997, FREE RADICAL BIO MED, V22, P37, DOI 10.1016/S0891-5849(96)00238-9; OBrien PJ, 1997, MOL CELL BIOCHEM, V173, P135, DOI 10.1023/A:1006840013439; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Reid MB, 2001, J APPL PHYSIOL, V90, P724, DOI 10.1152/jappl.2001.90.2.724; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Rubin BB, 1996, J APPL PHYSIOL, V80, P369, DOI 10.1152/jappl.1996.80.2.369; SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; Schertzer JD, 2002, AM J PHYSIOL-ENDOC M, V283, pE722, DOI 10.1152/ajpendo.00204.2002; Schertzer JD, 2003, AM J PHYSIOL-ENDOC M, V284, pE597, DOI 10.1152/ajpendo.00190.2002; Senisterra GA, 1997, BIOCHEMISTRY-US, V36, P11002, DOI 10.1021/bi9711590; Squier TC, 2000, FRONT BIOSCI-LANDMRK, V5, pD504, DOI 10.2741/Squier; Temsah RM, 1999, AM J PHYSIOL-HEART C, V277, pH584, DOI 10.1152/ajpheart.1999.277.2.H584; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tupling R, 2001, AM J PHYSIOL-ENDOC M, V281, pE224, DOI 10.1152/ajpendo.2001.281.2.E224; Tupling R, 2001, AM J PHYSIOL-REG I, V281, pR1681, DOI 10.1152/ajpregu.2001.281.5.R1681; Viner RI, 1997, BIOCHEMISTRY-US, V36, P7706, DOI 10.1021/bi970058z; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; Xu KY, 1997, CIRC RES, V80, P76, DOI 10.1161/01.RES.80.1.76; Zucchi R, 2001, PHARMACOL THERAPEUT, V89, P47, DOI 10.1016/S0163-7258(00)00103-0	61	64	65	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 10	2004	279	50					52382	52389		10.1074/jbc.M409336200	http://dx.doi.org/10.1074/jbc.M409336200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	876JT	15371420	hybrid			2022-12-25	WOS:000225493400082
J	Cilenti, L; Soundarapandian, MM; Kyriazis, GA; Stratico, V; Singh, S; Gupta, S; Bonventre, JV; Alnemri, ES; Zervos, AS				Cilenti, L; Soundarapandian, MM; Kyriazis, GA; Stratico, V; Singh, S; Gupta, S; Bonventre, JV; Alnemri, ES; Zervos, AS			Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE; INHIBITOR; INTERACTS; HTRA; MITOCHONDRIA; CHAPERONE; ASSAY; XIAP; MND2	Omi/HtrA2 is a nuclear-encoded mitochondrial serine protease that has a pro-apoptotic function in mammalian cells. Upon induction of apoptosis, Omi translocates to the cytoplasm and participates in caspase-dependent apoptosis by binding and degrading inhibitor of apoptosis proteins. Omi can also initiate caspase-independent apoptosis in a process that relies entirely on its ability to function as an active protease. To investigate the mechanism of Omi-induced apoptosis, we set out to isolate novel substrates that are cleaved by this protease. We identified HS1-associated protein X-1 (HAX-1), a mitochondrial anti-apoptotic protein, as a specific Omi interactor that is cleaved by Omi both in vitro and in vivo. HAX-1 degradation follows Omi activation in cells treated with various apoptotic stimuli. Using a specific inhibitor of Omi, HAX-1 degradation is prevented and cell death is reduced. Cleavage of HAX-1 was not observed in a cell line derived from motor neuron degeneration 2 mice that carry a mutated form of Omi that affects its proteolytic activity. Degradation of HAX-1 is an early event in the apoptotic process and occurs while Omi is still confined in the mitochondria. Our results suggest that Omi has a unique pro-apoptotic function in mitochondria that involves removal of the HAX-1 antiapoptotic protein. This function is distinct from its ability to activate caspase-dependent apoptosis in the cytoplasm by degrading inhibitor of apoptosis proteins.	Univ Cent Florida, Biomol Sci Ctr, Burnett Coll Biomed Sci, Orlando, FL 32826 USA; Thomas Jefferson Univ, Ctr Apoptosis Res, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Harvard Univ, Sch Med, Div Renal, Brigham & Womens Hosp, Boston, MA 02115 USA	State University System of Florida; University of Central Florida; Jefferson University; Jefferson University; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Zervos, AS (corresponding author), Univ Cent Florida, Biomol Sci Ctr, Burnett Coll Biomed Sci, 12722 Res Pkwy, Orlando, FL 32826 USA.	azervos@mail.ucf.edu	Alnemri, Emad S/B-4526-2010; Gupta, Sanjeev/AAG-9749-2020; gupta, sanjeev/B-2824-2008	Gupta, Sanjeev/0000-0002-4691-6853; gupta, sanjeev/0000-0002-4691-6853; Kyriazis, George/0000-0001-9514-3482	NIDDK NIH HHS [DK55734-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055734] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blink E, 2004, CELL DEATH DIFFER, V11, P937, DOI 10.1038/sj.cdd.4401409; Cilenti L, 2003, J BIOL CHEM, V278, P11489, DOI 10.1074/jbc.M212819200; Derby E, 2001, IMMUNOL LETT, V78, P35, DOI 10.1016/S0165-2478(01)00226-7; Dufva M, 2001, J GEN VIROL, V82, P1581, DOI 10.1099/0022-1317-82-7-1581; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Fantin VR, 2004, CANCER RES, V64, P329, DOI 10.1158/0008-5472.CAN-03-0899; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; GATEAU O, 1978, EUR J BIOCHEM, V88, P613, DOI 10.1111/j.1432-1033.1978.tb12488.x; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x; JONES JM, 1993, GENOMICS, V16, P669, DOI 10.1006/geno.1993.1246; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kim DY, 2002, ACTA CRYSTALLOGR D, V58, P170, DOI 10.1107/S0907444901018248; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Matsuda G, 2003, MICROBIOL IMMUNOL, V47, P91, DOI 10.1111/j.1348-0421.2003.tb02790.x; Mirmohammadsadegh A, 2003, J INVEST DERMATOL, V120, P1045, DOI 10.1046/j.1523-1747.2003.12247.x; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Sharp TV, 2002, J VIROL, V76, P802, DOI 10.1128/JVI.76.2.802-816.2002; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 1997, J IMMUNOL, V158, P2736; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Vaux DL, 2003, CELL, V115, P251, DOI 10.1016/S0092-8674(03)00851-1; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	32	150	156	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50295	50301		10.1074/jbc.M406006200	http://dx.doi.org/10.1074/jbc.M406006200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15371414	hybrid, Green Published			2022-12-25	WOS:000225229500092
J	Ralat, LA; Colman, RF				Ralat, LA; Colman, RF			Glutathione S-Transferase Pi has at least three distinguishable xenobiotic substrate sites close to its glutathione-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE RESIDUES; 3-DIMENSIONAL STRUCTURE; CHEMICAL-MODIFICATION; DIRECTED MUTAGENESIS; HUMAN PLACENTA; THIOL-GROUP; P1-1; A1-1; MONOBROMOBIMANE; ISOTHIOCYANATES	Benzyl isothiocyanate (BITC), present in cruciferous vegetables, is an efficient substrate of human glutathione S-transferase P1-1 (hGST P1-1). BITC also acts as an affinity label of hGST P1-1 in the absence of glutathione, yielding an enzyme inactive toward BITC as substrate. As monitored by using BITC as substrate, the dependence of k of inactivation (K-I) of hGST P1-1 on [ BITC] is hyperbolic, with K-I = 66 +/- 7 muM. The enzyme incorporates 2 mol of BITC/mol of enzyme subunit upon complete inactivation. S-Methylglutathione and 8-anilino-1-naphthalene sulfonate (ANS) each yield partial protection against inactivation and decrease reagent incorporation, whereas S-(N-benzylthiocarbamoyl) glutathione or S-methylglutathione + ANS protects completely. Mapping of proteolytic digests of modified enzyme by using mass spectrometry reveals that Tyr(103) and Cys(47) are modified equally. S- Methylglutathione reduces modification of Cys47, indicating this residue is at/near the glutathione binding region, whereas ANS decreases modification of Tyr(103), suggesting this residue is at/near the BITC substrate site, which is also near the binding site of ANS. The Y103F and Y103S mutant enzymes were generated, expressed, and purified. Both mutants handle substrate 1-chloro-2,4-dinitrobenzene normally; however, Y103S exhibits a 30-fold increase in Km for BITC and binds ANS poorly, whereas Y103F has a normal K-m for BITC and K-d for ANS. These results indicate that an aromatic residue at position 103 is essential for the binding of BITC and ANS. This study provides evidence for the existence of a novel xenobiotic substrate site in hGST P1-1, which can be occupied by benzyl isothiocyanate and is distinct from that of monobromobimane and 1-chloro-2,4 dinitrobenzene.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA	University of Delaware	Colman, RF (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	rfcolman@chem.udel.edu			NATIONAL CANCER INSTITUTE [R01CA066561] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA66561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACETO A, 1989, BIOCHEM PHARMACOL, V38, P3653, DOI 10.1016/0006-2952(89)90568-6; Ahn SY, 2003, B KOREAN CHEM SOC, V24, P1188; BICO P, 1994, BIOCHIM BIOPHYS ACTA, V1247, P225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACCURI AM, 1990, EUR J BIOCHEM, V189, P493, DOI 10.1111/j.1432-1033.1990.tb15514.x; CACCURI AM, 1992, ARCH BIOCHEM BIOPHYS, V297, P119, DOI 10.1016/0003-9861(92)90648-G; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CHEN WL, 1992, BIOCHEM J, V286, P205, DOI 10.1042/bj2860205; COLMAN RF, 1997, PROTEIN FUNCTION, P155; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; FAHEY RC, 1991, ADV ENZYMOL RAMB, V64, P1; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HONG KH, 1993, PROTEIN ENG, V6, P93; HSIEH JC, 1991, BIOCHEM J, V278, P293, DOI 10.1042/bj2780293; HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x; JI XH, 1995, BIOCHEMISTRY-US, V34, P5317, DOI 10.1021/bi00016a003; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; Ji XH, 1997, BIOCHEMISTRY-US, V36, P9690, DOI 10.1021/bi970805s; Kase H, 1998, ACTA CYTOL, V42, P1397, DOI 10.1159/000332174; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kolobe D, 2004, BIOCHEM J, V382, P703, DOI 10.1042/BJ20040056; KONG KH, 1992, BIOCHEM BIOPH RES CO, V184, P194, DOI 10.1016/0006-291X(92)91177-R; KONG KH, 1991, BIOCHEM BIOPH RES CO, V181, P748, DOI 10.1016/0006-291X(91)91254-A; KONG KH, 1992, BIOCHEM BIOPH RES CO, V182, P1122, DOI 10.1016/0006-291X(92)91848-K; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; Lyon RP, 2002, BIOCHEMISTRY-US, V41, P10920, DOI 10.1021/bi0262810; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANOHARAN TH, 1992, J BIOL CHEM, V267, P18940; Mao LS, 2004, J MOL BIOL, V336, P787, DOI 10.1016/j.jmb.2003.12.056; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Morrow CS, 1998, J BIOL CHEM, V273, P20114, DOI 10.1074/jbc.273.32.20114; Niitsu Y, 1998, CHEM-BIOL INTERACT, V112, P325; NISHIHIRA J, 1992, BIOCHEM BIOPH RES CO, V188, P424, DOI 10.1016/0006-291X(92)92402-J; Oakley AJ, 1999, J MOL BIOL, V291, P913, DOI 10.1006/jmbi.1999.3029; Oakley AJ, 1998, BIOCHEMISTRY-US, V37, P9912, DOI 10.1021/bi980323w; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Park HJ, 2001, B KOREAN CHEM SOC, V22, P77; Penefsky H S, 1979, Methods Enzymol, V56, P527; Ralat LA, 2004, FASEB J, V18, pC241; Ralat LA, 2003, PROTEIN SCI, V12, P2575, DOI 10.1110/ps.03249303; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; ZHANG YS, 1995, BIOCHEM BIOPH RES CO, V206, P748, DOI 10.1006/bbrc.1995.1106	48	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50204	50213		10.1074/jbc.M407445200	http://dx.doi.org/10.1074/jbc.M407445200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15347687	hybrid			2022-12-25	WOS:000225229500081
J	Dufner-Beattie, J; Kuo, YM; Gitschier, J; Andrews, GK				Dufner-Beattie, J; Kuo, YM; Gitschier, J; Andrews, GK			The adaptive response to dietary zinc in mice involves the differential cellular localization and zinc regulation of the zinc transporters ZIP4 and ZIP5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE METALLOTHIONEIN-I; LETHAL MILK; STIMULATED ENDOCYTOSIS; ANTIGEN RETRIEVAL; MOLECULAR-BIOLOGY; LIV-1 SUBFAMILY; GENE; EXPRESSION; FAMILY; DEFICIENCY	The ZIP5 gene encodes a protein closely related to ZIP4, a zinc transporter mutated in the human genetic disorder acrodermatitis enteropathica. Herein, we demonstrate that mouse ZIP5 and ZIP4 genes are co-expressed in several tissues involved in zinc homeostasis ( intestine, pancreas, embryonic yolk sac). However, unlike expression of the ZIP4 gene, which is induced during periods of zinc deficiency, ZIP5 gene expression is unaltered by dietary zinc. Immunohistochemistry localizes ZIP5 to the basolateral surfaces of enterocytes, acinar cells, and visceral endoderm cells in mice fed a zinc-adequate diet. However, this protein is removed from these cell surfaces and internalized during dietary zinc deficiency. In contrast, ZIP4 is induced and recruited to the apical surface of enterocytes and endoderm cells during zinc deficiency. In the pancreas, ZIP4 is expressed in beta-cells, whereas ZIP5 is expressed in acinar cells. These results suggest that the function of ZIP5 is antagonistic to that of ZIP4 in the control of zinc homeostasis; rather than functioning in the acquisition of dietary zinc, as does ZIP4, ZIP5 may function in the removal of zinc from the body. Thus, during periods when dietary zinc is replete, ZIP5 may function to remove zinc from the blood via the pancreas and intestine, the major sites of zinc excretion in mammals, whereas the acquisition of dietary zinc by intestinal ZIP4 would be minimal. In contrast, during periods of dietary zinc deficiency when secretion of zinc by the pancreas and intestine is minimized, ZIP5 is removed from the cell surface, and the intestinal uptake of zinc is augmented by induction of ZIP4.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of Kansas; University of Kansas Medical Center; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Andrews, GK (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Mail Stop 3030,39th & Rainbow Blvd, Kansas City, KS 66160 USA.	gandrews@kumc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063975, R01DK050181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50181, DK063975] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKLAND ML, 1992, J NUTR, V122, P1214, DOI 10.1093/jn/122.6.1214; Andrews GK, 2004, GENESIS, V40, P74, DOI 10.1002/gene.20067; Andrews GK, 1999, J NUTR, V129, P1643, DOI 10.1093/jn/129.9.1643; Andrews GK, 2001, EMBO J, V20, P1114, DOI 10.1093/emboj/20.5.1114; BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738; Chausmer AB, 1998, J AM COLL NUTR, V17, P109, DOI 10.1080/07315724.1998.10718735; Clifford KS, 2000, DIABETES RES CLIN PR, V49, P77, DOI 10.1016/S0168-8227(00)00141-8; Cragg RA, 2002, J BIOL CHEM, V277, P22789, DOI 10.1074/jbc.M200577200; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DANKS DM, 1985, CLIN ENDOCRINOL META, V14, P591, DOI 10.1016/S0300-595X(85)80008-6; DANKS DM, 1986, J MED GENET, V23, P99, DOI 10.1136/jmg.23.2.99; DeLisle RC, 1996, AM J PHYSIOL-CELL PH, V271, pC1103, DOI 10.1152/ajpcell.1996.271.4.C1103; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P33474, DOI 10.1074/jbc.M305000200; Dufner-Beattie J, 2003, J BIOL CHEM, V278, P50142, DOI 10.1074/jbc.M304163200; Eide D, 1997, CURR OPIN CELL BIOL, V9, P573, DOI 10.1016/S0955-0674(97)80036-1; Eng BH, 1998, J MEMBRANE BIOL, V166, P1, DOI 10.1007/s002329900442; FAIRWEATHERTAIT SJ, 1993, AM J CLIN NUTR, V57, P696, DOI 10.1093/ajcn/57.5.696a; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Gaither LA, 2001, J BIOL CHEM, V276, P22258, DOI 10.1074/jbc.M101772200; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; Guo Y, 2004, J BIOL CHEM, V279, P17428, DOI 10.1074/jbc.M401493200; Hambidge M, 2001, ANNU REV NUTR, V21, P429, DOI 10.1146/annurev.nutr.21.1.429; Harris ED, 2002, NUTR REV, V60, P121, DOI 10.1301/00296640260085877; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; HURLEY L, 1981, PHYSIOL REV, V61, P249, DOI 10.1152/physrev.1981.61.2.249; Inoue K, 2002, HUM MOL GENET, V11, P1775, DOI 10.1093/hmg/11.15.1775; Kambe T, 2004, CELL MOL LIFE SCI, V61, P49, DOI 10.1007/s00018-003-3148-y; Kambe T, 2002, J BIOL CHEM, V277, P19049, DOI 10.1074/jbc.M200910200; Kim BE, 2004, J BIOL CHEM, V279, P4523, DOI 10.1074/jbc.M310799200; King JC, 2000, J NUTR, V130, p1360S, DOI 10.1093/jn/130.5.1360S; Krotova KY, 2003, AM J PHYSIOL-LUNG C, V284, pL1037, DOI 10.1152/ajplung.00308.2002; Kury S, 2002, NAT GENET, V31, P239, DOI 10.1038/ng913; Laftah AH, 2004, BLOOD, V103, P3940, DOI 10.1182/blood-2003-03-0953; Langmade SJ, 2000, J BIOL CHEM, V275, P34803, DOI 10.1074/jbc.M007339200; Lee DK, 2003, J NUTR, V133, P45, DOI 10.1093/jn/133.1.45; MANNING DL, 1988, MOL CELL ENDOCRINOL, V59, P205, DOI 10.1016/0303-7207(88)90105-0; MCCLAIN CJ, 1990, J LAB CLIN MED, V116, P275; Miret S, 2003, ANNU REV NUTR, V23, P283, DOI 10.1146/annurev.nutr.23.011702.073139; Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7; PILETZ JE, 1978, SCIENCE, V199, P181, DOI 10.1126/science.619449; RECORD IR, 1987, NEUROTOXICOLOGY, V8, P369; Rodriguez E, 2004, ENDOCRINOLOGY, V145, P679, DOI 10.1210/en.2003-0755; Sagawa N, 2003, BRIT J CANCER, V88, P606, DOI 10.1038/sj.bjc.6600739; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHI SR, 1993, J HISTOCHEM CYTOCHEM, V41, P1599, DOI 10.1177/41.11.7691930; Taylor KM, 2004, BIOCHEM J, V377, P131, DOI 10.1042/BJ20031183; Taylor KM, 2003, BIOCHEM J, V375, P51, DOI 10.1042/BJ20030478; Taylor KM, 2003, BBA-BIOMEMBRANES, V1611, P16, DOI 10.1016/S0005-2736(03)00048-8; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Wang FD, 2004, J BIOL CHEM, V279, P51433, DOI 10.1074/jbc.M408361200; Wang FD, 2004, J BIOL CHEM, V279, P24631, DOI 10.1074/jbc.M400680200; Wang FD, 2004, HUM MOL GENET, V13, P563, DOI 10.1093/hmg/ddh049; Wang K, 2002, AM J HUM GENET, V71, P66, DOI 10.1086/341125; Yamashita S, 2004, NATURE, V429, P298, DOI 10.1038/nature02545	56	163	168	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49082	49090		10.1074/jbc.M409962200	http://dx.doi.org/10.1074/jbc.M409962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15358787	hybrid			2022-12-25	WOS:000225098100072
J	Grohmanova, K; Schlaepfer, D; Hess, D; Gutierrez, P; Beck, M; Kroschewski, R				Grohmanova, K; Schlaepfer, D; Hess, D; Gutierrez, P; Beck, M; Kroschewski, R			Phosphorylation of IQGAP1 modulates its binding to Cdc42, revealing a new type of Rho-GTPase regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE; E-CADHERIN; SEC7 DOMAIN; PROTEIN; RAC1; CALMODULIN; MEMBRANE; ORGANIZATION; GENTHREADER; ADHERENS	The Rho-GTPase Cdc42 is important for the establishment and maintenance of epithelial polarity. Signaling from Cdc42 is propagated via its effector molecules that specifically bind to Cdc42 in the GTP-bound form. The cell-cell contact regulator and actin-binding protein IQGAP1 is described as effector of Cdc42 and Rac. Unexpectedly, we show in this study that IQGAP1 bound also directly nucleotide-depleted Cdc42 (Cdc42-ND). This interaction was enhanced in the presence of phosphatase inhibitors and in epithelial cells without cell-cell contacts. Tandem mass spectrometry analysis and immunoprecipitation experiments revealed that IQGAP1 was Ser(1443)-phosphorylated in vivo, potentially by protein kinase Cepsilon and upon loss of cell-cell contacts. In addition, we identified two independent domains of the IQGAP1 C terminus that bound exclusively Cdc42-ND. These domains interacted with each other, favoring the binding to Cdc42-GTP. Moreover, phosphorylation on Ser(1443) strongly inhibited this intramolecular interaction. Thus, we unraveled a molecular mechanism that reveals a novel type of Rho-GTPase regulator. We propose that, depending on its phosphorylation state, IQGAP1 might serve as an effector or sequester nucleotide-free Cdc42 to prevent signaling.	ETH, Inst Biochem, CH-8093 Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Friedrich Miescher Institute for Biomedical Research	Kroschewski, R (corresponding author), ETH, Inst Biochem, Schafmattstr 18, CH-8093 Zurich, Switzerland.	kroschewski@bc.biol.ethz.ch		Kroschewski, Ruth/0000-0002-6032-2568				Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Beraud-Dufour S, 1999, J BIOL CHEM, V274, P37629, DOI 10.1074/jbc.274.53.37629; Briggs MW, 2003, EMBO REP, V4, P571, DOI 10.1038/sj.embor.embor867; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Cohen D, 2001, TRAFFIC, V2, P556, DOI 10.1034/j.1600-0854.2001.20805.x; Cote JF, 2002, J CELL SCI, V115, P4901, DOI 10.1242/jcs.00219; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Esters H, 2001, J MOL BIOL, V310, P141, DOI 10.1006/jmbi.2001.4735; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Fukuhara A, 2003, J BIOL CHEM, V278, P51885, DOI 10.1074/jbc.M308015200; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Hu PQ, 2001, J INVEST DERMATOL, V117, P1059, DOI 10.1046/j.0022-202x.2001.01523.x; Hussain NK, 2001, NAT CELL BIOL, V3, P927, DOI 10.1038/ncb1001-927; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Krendel M, 1999, P NATL ACAD SCI USA, V96, P9666, DOI 10.1073/pnas.96.17.9666; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; McGuffin LJ, 2003, BIOINFORMATICS, V19, P874, DOI 10.1093/bioinformatics/btg097; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Meller N, 2002, NAT CELL BIOL, V4, P639, DOI 10.1038/ncb835; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Noritake J, 2004, MOL BIOL CELL, V15, P1065, DOI 10.1091/mbc.E03-08-0582; Nuoffer C, 1997, MOL BIOL CELL, V8, P1305, DOI 10.1091/mbc.8.7.1305; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schlumberger MC, 2003, J BIOL CHEM, V278, P27149, DOI 10.1074/jbc.M302475200; Schrimpf SP, 2001, ELECTROPHORESIS, V22, P1224, DOI 10.1002/1522-2683()22:6&lt;1224::AID-ELPS1224&gt;3.0.CO;2-I; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; Zhou RH, 2003, MOL BIOL CELL, V14, P1097, DOI 10.1091/mbc.E02-07-0425	41	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48495	48504		10.1074/jbc.M408113200	http://dx.doi.org/10.1074/jbc.M408113200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15355962	hybrid			2022-12-25	WOS:000225098100004
J	Haller, K; Rambaldi, I; Daniels, E; Featherstone, M				Haller, K; Rambaldi, I; Daniels, E; Featherstone, M			Subcellular localization of multiple PREP2 isoforms is regulated by actin, tubulin, and nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEIN; HINDBRAIN FATES; DNA-BINDING; HOX GENES; PBX; TRANSCRIPTION; EXPRESSION; EXTRADENTICLE; ASSOCIATION; MEIS	The PREP, MEIS, and PBX families are mammalian members of the TALE (three amino acid loop extension) class of homeodomain-containing transcription factors. These factors have been implicated in cooperative DNA binding with the HOX class of homeoproteins, but PREP and MEIS interact with PBX in apparently non-HOX-dependent cooperative DNA binding as well. PREP, MEIS, and PBX have all been reported to reside in the cytoplasm in one or more tissues of the developing vertebrate embryo. In the case of PBX, cytoplasmic localization is due to the modulation of nuclear localization signals, nuclear export sequences, and interaction with a cytoplasmic anchoring factor, non-muscle myosin heavy chain II B. Here we report that murine PREP2 exists in multiple isoforms distinguished by interaction with affinity-purified antibodies raised to N- and C-terminal epitopes and by nuclear versus cytoplasmic localization. Alternative splicing gives rise to some of these PREP2 isoforms, including a 25-kDa variant lacking the C-terminal half of the protein and homeodomain and having the potential to act as dominant-negative. We further show that cytoplasmic localization is due to the concerted action of nuclear export, as evidenced by sensitivity to leptomycin B, and cytoplasmic retention by the actin and microtubule cytoskeletons. Cytoplasmic PREP2 colocalizes with both the actin and microtubule cytoskeletons and coimmunoprecipitates with actin and tubulin. Importantly, disruption of either cytoskeletal system redirects cytoplasmic PREP2 to the nucleus. We suggest that transcriptional regulation by PREP2 is modulated through the subcellular distribution of multiple isoforms and by interaction with two distinct cytoskeletal systems.	McGill Univ, Mcgill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University; McGill University	Featherstone, M (corresponding author), McGill Univ, Mcgill Canc Ctr, Mcintyre Med Sci Bldg,Rm 714,3655 Promenade Sir W, Montreal, PQ H3G 1Y6, Canada.	mark.featherstone@mcgill.ca	Featherstone, Mark/E-8057-2010	Featherstone, Mark/0000-0003-1576-046X				Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; AKNER G, 1995, J STEROID BIOCHEM, V52, P1, DOI 10.1016/0960-0760(94)00155-F; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Burglin TR, 1998, DEV GENES EVOL, V208, P113, DOI 10.1007/s004270050161; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Chan CK, 1998, GENE THER, V5, P1204, DOI 10.1038/sj.gt.3300708; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; Choe SK, 2004, DEV BIOL, V271, P350, DOI 10.1016/j.ydbio.2004.04.007; Choe SK, 2002, DEVELOPMENT, V129, P585; Dalpe G, 1998, MOL CELL NEUROSCI, V10, P243, DOI 10.1006/mcne.1997.0660; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Featherstone M, 2003, AD DEV BIOL, V13, P1; Ferretti E, 2000, DEVELOPMENT, V127, P155; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Fognani C, 2002, NUCLEIC ACIDS RES, V30, P2043, DOI 10.1093/nar/30.9.2043; Gebelein B, 2002, DEV CELL, V3, P487, DOI 10.1016/S1534-5807(02)00257-5; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; Haller K, 2002, DEV DYNAM, V225, P358, DOI 10.1002/dvdy.10167; Herzig S, 2000, J BIOL CHEM, V275, P27989; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; Huang H, 2003, MOL CELL BIOL, V23, P3636, DOI 10.1128/MCB.23.10.3636-3645.2003; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Imoto I, 2001, BIOCHEM BIOPH RES CO, V287, P270, DOI 10.1006/bbrc.2001.5578; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kilstrup-Nielsen C, 2003, EMBO J, V22, P89, DOI 10.1093/emboj/cdg010; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Komuves LG, 2000, DEV DYNAM, V218, P636; Komuves LG, 2003, DEV DYNAM, V227, P192, DOI 10.1002/dvdy.10290; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Mercader N, 1999, NATURE, V402, P425, DOI 10.1038/46580; Miralles F, 2003, CELL, V113, P329, DOI 10.1016/S0092-8674(03)00278-2; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Posern G, 2002, MOL BIOL CELL, V13, P4167, DOI 10.1091/mbc.02-05-0068; RAMBALDI I, 1994, NUCLEIC ACIDS RES, V22, P376, DOI 10.1093/nar/22.3.376; Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Saleh M, 2000, EXP CELL RES, V260, P105, DOI 10.1006/excr.2000.5010; Shanmugam K, 1999, MOL CELL BIOL, V19, P7577; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Vlachakis N, 2001, DEVELOPMENT, V128, P1299; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	47	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49384	49394		10.1074/jbc.M406046200	http://dx.doi.org/10.1074/jbc.M406046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15339927	hybrid			2022-12-25	WOS:000225098100107
J	Jenkins, CM; Mancuso, DJ; Yan, W; Sims, HF; Gibson, B; Gross, RW				Jenkins, CM; Mancuso, DJ; Yan, W; Sims, HF; Gibson, B; Gross, RW			Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A(2) family members possessing triacylglycerol lipase and acylglycerol transacylase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-SENSITIVE LIPASE; MESSENGER-RNA EXPRESSION; LIPID ACYL HYDROLASE; FATTY-ACID RELEASE; ADIPOSE-TISSUE; SUICIDE INHIBITION; GENE-EXPRESSION; OBESITY; PROTEIN; ADIPONUTRIN	Genetic knockout of hormone-sensitive lipase in mice has implicated the presence of other intracellular triacylglycerol (TAG) lipases mediating TAG hydrolysis in adipocytes. Despite intense interest in these TAG lipases, their molecular identities thus far are largely unknown. Sequence data base searches for proteins containing calcium-independent phospholipase A(2) ( iPLA(2)) dual signature nucleotide ((G/A) XGXXG) and lipase (GXSXG) consensus sequence motifs identified a novel subfamily of three putative iPLA(2)/lipase family members designated iPLA(2)epsilon, iPLA(2)zeta, and iPLA(2)eta (previously named adiponutrin, TTS-2.2, and GS2, respectively) of previously unknown catalytic function. Herein we describe the cloning, heterologous expression, and affinity purification of the three human isoforms of this iPLA(2) subfamily in Sf9 cells, and we demonstrate that each possesses abundant TAG lipase activity. Moreover, iPLA(2)epsilon, iPLA(2)zeta, and iPLA(2)eta also possess acylglycerol transacylase activity utilizing mono-olein as an acyl donor which, in the presence of mono-olein or diolein acceptors, results in the synthesis of diolein and triolein, respectively. (E)-6-(Bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2- one, a mechanism-based suicide substrate inhibitor of all known iPLA(2)s, inhibits the triglyceride lipase activity of each of the three isoforms similarly (IC50 = 0.1 - 0.5 muM). Quantitative PCR revealed dramatically increased expression of iPLA(2)epsilon and iPLA(2)zeta transcripts during the hormone-induced differentiation of 3T3-L1 cells into adipocytes and identified the presence of all three iPLA(2) isoforms in human SW872 liposarcoma cells. Collectively, these results identify three novel TAG lipases/acylglycerol transacylases that likely participate in TAG hydrolysis and the acyl-CoA independent transacylation of acylglycerols, thereby facilitating energy mobilization and storage in adipocytes.	Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Chem, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Gross, RW (corresponding author), Washington Univ, Sch Med, Div Bioorgan Chem & Mol Pharmacol, Dept Med, 660 S Euclid Ave,Campus Box 8020, St Louis, MO 63110 USA.				NHLBI NIH HHS [5RO1HL41250-12, 5PO1HL57278-08] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041250, P01HL057278] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS DL, 1988, BIOCHEM J, V252, P199, DOI 10.1042/bj2520199; Anthonsen MW, 1998, J BIOL CHEM, V273, P215, DOI 10.1074/jbc.273.1.215; Baulande S, 2001, J BIOL CHEM, V276, P33336, DOI 10.1074/jbc.M105193200; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Buhman KK, 2002, J BIOL CHEM, V277, P25474, DOI 10.1074/jbc.M202013200; Chen HC, 2002, J CLIN INVEST, V109, P1049, DOI [10.1172/JCI200214672, 10.1172/JCI0214672]; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; ELIA M, 1987, METABOLISM, V36, P251, DOI 10.1016/0026-0495(87)90184-3; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; FROST SC, 1985, J BIOL CHEM, V260, P2646; Gauthier A, 2003, J BIOL CHEM, V278, P11945, DOI 10.1074/jbc.M212989200; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Greenberg AS, 2001, J BIOL CHEM, V276, P45456, DOI 10.1074/jbc.M104436200; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HULSMANN WC, 1980, BIOCHIM BIOPHYS ACTA, V618, P364, DOI 10.1016/0005-2760(80)90043-0; Izem L, 2001, J BIOL CHEM, V276, P26534, DOI 10.1074/jbc.M103624200; James P T, 2001, Obes Res, V9 Suppl 4, p228S, DOI 10.1038/oby.2001.123; Jensen MD, 2001, AM J PHYSIOL-ENDOC M, V281, pE789; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Kraemer FB, 2002, J LIPID RES, V43, P1585, DOI 10.1194/jlr.R200009-JLR200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WC, 1994, GENOMICS, V22, P372, DOI 10.1006/geno.1994.1397; LEHNER R, 1993, J BIOL CHEM, V268, P8781; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; Liu PS, 2004, J BIOL CHEM, V279, P3787, DOI 10.1074/jbc.M311945200; Mancuso DJ, 2000, J BIOL CHEM, V275, P9937, DOI 10.1074/jbc.275.14.9937; McGarry JD, 1999, DIABETOLOGIA, V42, P128, DOI 10.1007/s001250051130; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Pi-Sunyer FX, 2002, OBES RES, V10, p97S, DOI 10.1038/oby.2002.202; Pinsirodom P, 2000, J AGR FOOD CHEM, V48, P155, DOI 10.1021/jf990338g; Polson D, 2003, HORM METAB RES, V35, P508; Polson DA, 2004, J NUTR BIOCHEM, V15, P242, DOI 10.1016/j.nutbio.2003.11.009; Polson DA, 2003, BIOCHEM BIOPH RES CO, V301, P261, DOI 10.1016/S0006-291X(02)03027-9; Raclot T, 2003, PROG LIPID RES, V42, P257, DOI 10.1016/S0163-7827(02)00066-8; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008; SHAPIRO LJ, 1989, P NATL ACAD SCI USA, V86, P8477, DOI 10.1073/pnas.86.21.8477; Shen WJ, 1998, BIOCHEMISTRY-US, V37, P8973, DOI 10.1021/bi980545u; Smith SJ, 2000, NAT GENET, V25, P87, DOI 10.1038/75651; Stone SJ, 2004, J BIOL CHEM, V279, P11767, DOI 10.1074/jbc.M311000200; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; van Tienhoven M, 2002, J BIOL CHEM, V277, P20942, DOI 10.1074/jbc.M200330200; Vassiliou G, 2001, J BIOL CHEM, V276, P48823, DOI 10.1074/jbc.M103954200; WAITE M, 1973, J BIOL CHEM, V248, P7985; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Yeaman SJ, 2004, BIOCHEM J, V379, P11, DOI 10.1042/BJ20031811; ZUPAN LA, 1993, J MED CHEM, V36, P95, DOI 10.1021/jm00053a012	57	657	711	2	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48968	48975		10.1074/jbc.M407841200	http://dx.doi.org/10.1074/jbc.M407841200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15364929	hybrid			2022-12-25	WOS:000225098100059
J	Saito-Nakano, Y; Yasuda, T; Nakada-Tsukui, K; Leippe, M; Nozaki, T				Saito-Nakano, Y; Yasuda, T; Nakada-Tsukui, K; Leippe, M; Nozaki, T			Rab5-associated Vacuoles play a unique role in phagocytosis of the enteric protozoan parasite Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; MYCOBACTERIAL PHAGOSOME MATURATION; RAB PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR CHARACTERIZATION; CYSTEINE PROTEINASES; ENDOCYTIC PATHWAY; MEMBRANE-FUSION; MACROPHAGES; YEAST	In mammals, Rab5 and Rab7 play a specific and coordinated role in a sequential process during phagosome maturation. Here, we report that Rab5 and Rab7 in the enteric protozoan parasite Entamoeba histolytica, EhRab5 and EhRab7A, are involved in steps that are distinct from those known for mammals. EhRab5 and EhRab7A were localized to independent small vesicular structures at steady state. Priming with red blood cells induced the formation of large vacuoles associated with both EhRab5 and EhRab7A ("prephagosomal vacuoles (PPV)") in the amoeba within an incubation period of 5-10 min. PPV emerged de novo physically and distinct from phagosomes. PPV were gradually acidified and matured by fusion with lysosomes containing a digestive hydrolase, cysteine proteinase, and a membrane-permeabilizing peptide amoebapore. After EhRab5 dissociated from PPV, 5-10 min later, the EhRab7A-PPV fused with phagosomes, and EhRab7A finally dissociated from the phagosomes. Immunoelectron and light micrographs showed that PPV contained small vesicle-like structures containing fluid-phase markers and amoebapores, which were not evenly distributed within PPV, suggesting that the mechanism was similar to multivesicular body formation in PPV generation. In contrast to Rab5 from other organisms, EhRab5 was involved exclusively in phagocytosis, but not in endocytosis. Overexpression of wild-type EhRab5 enhanced phagocytosis and the transport of amoebapore to phagosomes. Conversely, expression of an EhRab5Q67L GTP form mutant impaired the formation of PPV and phagocytosis. Altogether, we propose that the amoebic Rab5 plays an important role in the formation of unique vacuoles, which is essential for engulfment of erythrocytes and important for packaging of lysosomal hydrolases, prior to the targeting to phagosomes.	Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Kiel, Inst Zool, D-24118 Kiel, Germany; Japan Sci & Technol Agcy, Percursory Res Embryon Sci & Technol, Tokyo 1900012, Japan	National Institute of Infectious Diseases (NIID); University of Kiel; Japan Science & Technology Agency (JST)	Nozaki, T (corresponding author), Natl Inst Infect Dis, Dept Parasitol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	nozaki@nih.go.jp	Leippe, Matthias/AAP-1677-2020					Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Alvarez-Dominguez C, 1999, J BIOL CHEM, V274, P11459, DOI 10.1074/jbc.274.17.11459; [Anonymous], 1997, Epidemiol Bull, V18, P13; BAILEY GB, 1990, INFECT IMMUN, V58, P43, DOI 10.1128/IAI.58.1.43-47.1990; Batista EDO, 2000, PARASITOL RES, V86, P881, DOI 10.1007/s004360000269; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; Cheng XJ, 1998, PARASITOL RES, V84, P632, DOI 10.1007/s004360050462; Christoforidis S, 2000, METHODS, V20, P403, DOI 10.1006/meth.2000.0953; Damiani MT, 2003, EXP CELL RES, V289, P152, DOI 10.1016/S0014-4827(03)00253-2; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; DIAMOND LS, 1972, J VIROL, V9, P326, DOI 10.1128/JVI.9.2.326-341.1972; Duclos S, 2000, J CELL SCI, V113, P3531; Field H, 1998, J BIOL CHEM, V273, P32102, DOI 10.1074/jbc.273.48.32102; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Ghosh SK, 1997, INFECT IMMUN, V65, P4243, DOI 10.1128/IAI.65.10.4243-4249.1997; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Guillen N, 1998, J CELL SCI, V111, P1729; Hackam DJ, 1997, J BIOL CHEM, V272, P29810, DOI 10.1074/jbc.272.47.29810; Hamann L, 1997, MOL BIOCHEM PARASIT, V84, P83, DOI 10.1016/S0166-6851(96)02771-5; Harrison RE, 2003, MOL CELL BIOL, V23, P6494, DOI 10.1128/MCB.23.18.6494-6506.2003; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Hellberg A, 2000, MOL BIOCHEM PARASIT, V105, P305, DOI 10.1016/S0166-6851(99)00194-2; Henry RM, 2004, J CELL BIOL, V164, P185, DOI 10.1083/jcb.200307080; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; Jaunin F, 1998, EXP CELL RES, V243, P67, DOI 10.1006/excr.1998.4131; Jay DG, 1996, CELL, V86, P853, DOI 10.1016/S0092-8674(00)80160-9; Juarez P, 2001, MOL BIOCHEM PARASIT, V116, P223, DOI 10.1016/S0166-6851(01)00311-5; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Labruyere E, 2003, J CELL SCI, V116, P61, DOI 10.1242/jcs.00190; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEIPPE M, 1991, P NATL ACAD SCI USA, V88, P7659, DOI 10.1073/pnas.88.17.7659; Leippe M, 1999, DEV COMP IMMUNOL, V23, P267, DOI 10.1016/S0145-305X(99)00010-5; Mazzuco A, 1997, MICRON, V28, P241, DOI 10.1016/S0968-4328(97)00024-3; Nickel R, 1998, FEBS LETT, V437, P153, DOI 10.1016/S0014-5793(98)01220-4; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; NOVIKOFF AB, 1972, J HISTOCHEM CYTOCHEM, V20, P1006, DOI 10.1177/20.12.1006; Nozaki T, 1999, J BIOL CHEM, V274, P32445, DOI 10.1074/jbc.274.45.32445; Nozaki T, 1998, MOL BIOCHEM PARASIT, V97, P33, DOI 10.1016/S0166-6851(98)00129-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; OROZCO E, 1983, J EXP MED, V158, P1511, DOI 10.1084/jem.158.5.1511; Petri WA, 2002, CURR OPIN MICROBIOL, V5, P443, DOI 10.1016/S1369-5274(02)00335-1; POMMIER CG, 1983, J EXP MED, V157, P1844, DOI 10.1084/jem.157.6.1844; Que XC, 2000, CLIN MICROBIOL REV, V13, P196, DOI 10.1128/CMR.13.2.196-206.2000; Ramakrishnan G, 2001, PARASITOL INT, V50, P47, DOI 10.1016/S1383-5769(00)00067-2; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Rodriguez MA, 2000, MOL BIOCHEM PARASIT, V108, P199, DOI 10.1016/S0166-6851(00)00216-4; Rupper A, 2001, J CELL SCI, V114, P2449; Saito-Nakano Y, 2001, MOL BIOCHEM PARASIT, V116, P219, DOI 10.1016/S0166-6851(01)00318-8; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Silver LL, 2003, CURR OPIN MICROBIOL, V6, P431, DOI 10.1016/j.mib.2003.08.004; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SINGERKRUGER B, 1995, J CELL SCI, V108, P3509; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 2001, GENOME BIOL, V2; Tanaka T, 1997, BIOCHEM BIOPH RES CO, V236, P611, DOI 10.1006/bbrc.1997.7019; Temesvari LA, 1999, MOL BIOCHEM PARASIT, V103, P225, DOI 10.1016/S0166-6851(99)00133-4; Tjelle TE, 2000, BIOESSAYS, V22, P255, DOI 10.1002/(SICI)1521-1878(200003)22:3<255::AID-BIES7>3.0.CO;2-R; Tomishige M, 1998, J CELL BIOL, V142, P989, DOI 10.1083/jcb.142.4.989; Ueda T, 2002, CURR OPIN PLANT BIOL, V5, P513, DOI 10.1016/S1369-5266(02)00299-6; Vargas-Villarreal J, 1998, PARASITOL RES, V84, P310, DOI 10.1007/s004360050401; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Vieira OV, 2003, MOL CELL BIOL, V23, P2501, DOI 10.1128/MCB.23.7.2501-2514.2003; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Vines RR, 1998, MOL BIOL CELL, V9, P2069, DOI 10.1091/mbc.9.8.2069; Voigt H, 1999, J CELL SCI, V112, P1191; WICHMANN H, 1992, CELL, V71, P1131, DOI 10.1016/S0092-8674(05)80062-5	73	104	104	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					49497	49507		10.1074/jbc.M403987200	http://dx.doi.org/10.1074/jbc.M403987200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15347665	hybrid			2022-12-25	WOS:000225098100120
J	Hermann, A; Goyal, R; Jeltsch, A				Hermann, A; Goyal, R; Jeltsch, A			The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FOCI; MURINE DNA; METHYLTRANSFERASE; BINDING; DOMAINS; COMPLEX; ENZYME; ACTIVATION; COOPERATE; MECHANISM	In the cell, Dnmt1 is the major enzyme in maintenance of the pattern of DNA methylation after DNA replication. Evidence suggests that the protein is located at the replication fork, where it could directly modify nascent DNA immediately after replication. To elucidate the potential mechanism of this process, we investigate the processivity of DNA methylation and accuracy of copying an existing pattern of methylation in this study using purified Dnmt1 and hemimethylated substrate DNA. We demonstrate that Dnmt1 methylates a hemimethylated 958-mer substrate in a highly processive reaction. Fully methylated and unmethylated CG sites do not inhibit processive methylation of the DNA. Extending previous work, we show that unmethylated sites embedded in a hemimethylated context are modified at an approximately 24-fold reduced rate, which demonstrates that the enzyme accurately copies existing patterns of methylation. Completely unmodified DNA is methylated even more slowly due to an allosteric activation of Dnmt1 by methylcytosine-containing DNA. Interestingly, Dnmt1 is not able to methylate hemimethylated CG sites on different strands of the DNA in a processive manner, indicating that Dnmt1 keeps its orientation with respect to the DNA while methylating the CG sites on one strand of the DNA.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Int Jacobs Univ Bremen, Sch Sci & Engn, D-28759 Bremen, Germany	Justus Liebig University Giessen	Jeltsch, A (corresponding author), Univ Giessen, Inst Biochem, FB 08,Heinrich Buff Ring 58, D-35392 Giessen, Germany.	a.jeltsch@iu-bremen.de	Jeltsch, Albert/O-7404-2014	Jeltsch, Albert/0000-0001-6113-9290				Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bourc'his D, 2001, SCIENCE, V294, P2536, DOI 10.1126/science.1065848; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; Chuang LSH, 1996, J MOL BIOL, V257, P935, DOI 10.1006/jmbi.1996.0213; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Fatemi M, 2002, EUR J BIOCHEM, V269, P4981, DOI 10.1046/j.1432-1033.2002.03198.x; Fatemi M, 2001, J MOL BIOL, V309, P1189, DOI 10.1006/jmbi.2001.4709; Flynn J, 1998, J MOL BIOL, V279, P101, DOI 10.1006/jmbi.1998.1761; Friedhoff P, 2001, J BIOL CHEM, V276, P23581, DOI 10.1074/jbc.M101694200; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Gowher H, 2002, J BIOL CHEM, V277, P20409, DOI 10.1074/jbc.M202148200; Hermann A, 2003, J BIOL CHEM, V278, P31717, DOI 10.1074/jbc.M305448200; Hermann A, 2003, BIOTECHNIQUES, V34, P924, DOI 10.2144/03345bm05; Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S; Jeltsch Albert, 2002, Methods Mol Biol, V182, P85; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kim GD, 2002, EMBO J, V21, P4183, DOI 10.1093/emboj/cdf401; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; LIU Z, 2004, J BIOL CHEM; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Margot JB, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-7; OTTIGER HP, 1984, P NATL ACAD SCI-BIOL, V81, P3993, DOI 10.1073/pnas.81.13.3993; Reither S, 2003, J MOL BIOL, V329, P675, DOI 10.1016/S0022-2836(03)00509-6; RENBAUM P, 1992, FEBS LETT, V313, P243, DOI 10.1016/0014-5793(92)81201-V; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2201, DOI 10.1021/bi951883n; Thomas E, 2002, BIOL CHEM, V383, P1459, DOI 10.1515/BC.2002.166; Urig S, 2002, J MOL BIOL, V319, P1085, DOI 10.1016/S0022-2836(02)00371-6; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Zardo G, 2002, FASEB J, V16, P1319, DOI 10.1096/fj.01-0827fje; Zinoviev VV, 2003, J BIOL CHEM, V278, P7829, DOI 10.1074/jbc.M210769200	41	354	370	0	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 12	2004	279	46					48350	48359		10.1074/jbc.M403427200	http://dx.doi.org/10.1074/jbc.M403427200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	869BJ	15339928	hybrid			2022-12-25	WOS:000224957000110
J	Matsunaga, M; Jaehning, JA				Matsunaga, M; Jaehning, JA			Intrinsic promoter recognition by a "core" RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL TRANSCRIPTION FACTOR; SPECIFICITY FACTOR; STRUCTURAL BASIS; SACCHAROMYCES-CEREVISIAE; OPEN COMPLEX; T7 LYSOZYME; SC-MTTFB; INITIATION; DNA; PURIFICATION	Two classes of RNA polymerases transcribe RNA from promoters on DNA templates: promoter recognition-competent single polypeptides and multisubunit enzymes that require separable promoter recognition factors. Eukaryotic mitochondria utilize an unusual hybrid of these classes composed of a "core" RNA polymerase related to the single polypeptide enzymes plus a "specificity factor" necessary for promoter utilization. Using supercoiled or premelted templates, we have discovered that the yeast core mitochondrial RNA polymerase (Rpo41) has the intrinsic ability to initiate from promoters without its specificity factor (Mtf1). Rpo41 requires the mitochondrial promoter sequence (ATATAAGTA) for this activity. On premelted templates addition of Mtf1 actually inhibits the promoter selective activity of Rpo41. Mtf1 increases abortive relative to productive transcription by Rpo41, possibly by stabilizing the promoter complex and reducing escape into elongation. The requirement for Mtf1 on closed but not open templates indicates that Mtf1 facilitates melting but not recognition of promoters.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jaehning, JA (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, B121,4200 E 9th Ave, Denver, CO 80262 USA.	judith.jaehning@uchsc.edu						AIYAR SE, 1994, J BIOL CHEM, V269, P13179; Bendich AJ, 1996, J MOL BIOL, V255, P564, DOI 10.1006/jmbi.1996.0048; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; Cliften PF, 2000, MOL CELL BIOL, V20, P7013, DOI 10.1128/MCB.20.18.7013-7023.2000; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; JAEHNING JA, 1993, MOL MICROBIOL, V8, P1, DOI 10.1111/j.1365-2958.1993.tb01197.x; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Karlok MA, 2002, J BIOL CHEM, V277, P28143, DOI 10.1074/jbc.M204123200; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LEVENS D, 1981, J BIOL CHEM, V256, P1474; Mangus D A, 1996, Methods Enzymol, V264, P57, DOI 10.1016/S0076-6879(96)64009-9; MANGUS DA, 1994, J BIOL CHEM, V269, P26568; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; Matsunaga M, 2004, PROTEIN EXPRES PURIF, V35, P126, DOI 10.1016/j.pep.2003.12.022; Matsunaga M, 2004, J BIOL CHEM, V279, P2012, DOI 10.1074/jbc.M307819200; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002; Murakami KS, 2003, CURR OPIN STRUC BIOL, V13, P31, DOI 10.1016/S0959-440X(02)00005-2; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; RIEMEN G, 1993, MOL GEN GENET, V237, P49, DOI 10.1007/BF00282783; Schubot FD, 2001, PROTEIN SCI, V10, P1980, DOI 10.1110/ps.11201; SHADEL GS, 1995, MOL CELL BIOL, V15, P2101; Stano NM, 2004, J BIOL CHEM, V279, P16136, DOI 10.1074/jbc.M400139200; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Yin YW, 2002, SCIENCE, V298, P1387, DOI 10.1126/science.1077464	30	57	60	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 22	2004	279	43					44239	44242		10.1074/jbc.C400384200	http://dx.doi.org/10.1074/jbc.C400384200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	862QJ	15342628	hybrid			2022-12-25	WOS:000224505600003
J	Kleinau, G; Jaschke, H; Neumann, S; Lattig, J; Paschke, R; Krause, G				Kleinau, G; Jaschke, H; Neumann, S; Lattig, J; Paschke, R; Krause, G			Identification of a novel epitope in the thyroid-stimulating hormone receptor ectodomain acting as intramolecular signaling interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN TSH RECEPTOR; CHORIONIC-GONADOTROPIN RECEPTOR; LUTEINIZING-HORMONE; EXTRACELLULAR DOMAIN; BETA-SUBUNIT; HUMAN CHORIOGONADOTROPIN; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; BINDING; ACTIVATION	Glycoprotein hormone receptors (GPHRs) differ from the other seven transmembrane receptors mainly through a complex activation mechanism that requires the binding of a large hormone toward a large N-terminal ectodomain. The intramolecular mechanism of the signal transduction to the serpentine domain upon hormone binding at the ectodomain is not understood. To identify determinants at the GPHR ectodomain that may be involved in signal transduction, we first searched for homologous structural features. Based on high sequence similarity to the determined structures of the Nogo-receptor ectodomain and the intermolecular complex of the Interleukin-8 ligand (IL8) and the N-terminal peptide of the IL8 receptor (IL8RA), the hypothesis was developed that portions of the intramolecular components, Cysteine-box-2 and Cysteine-box-3, of the GPHR ectodomain interact and localize at the interface between ectodomain and serpentine domain. Indeed, point mutations within the (DEFN406)-E-403 motif at Cysteine-box-3 of the thyrotropin receptor resulted in increased basal cAMP levels, suggesting that this motif may be important for transduction of the signal from the ectodomain to the transmembrane domain. New indications are provided about the tight spatial cooperation and relative location of the new epitope and other determinants at the thyrotropin receptor ectodomain, such as the leucine-rich repeat motif Ser(281) and the cysteine boxes. According to the high sequence conservation, the results are of general relevance for the signal transduction mechanism of other glycoprotein hormone receptors such as choriogonadotrophic/luteinizing hormone receptor and follicle-stimulating hormone receptor.	Forsch Inst Mol Pharmacol, D-13125 Berlin, Germany; Univ Leipzig Klinikum, Dept Med 3, D-04103 Leipzig, Germany; NIDDK, NIH, CEB, Bethesda, MD 20892 USA	Leipzig University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Krause, G (corresponding author), Forsch Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	GKrause@FMP-Berlin.de	Kleinau, Gunnar/GPX-6330-2022; Neumann, Susanne/GPK-6035-2022					Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; Bozon W, 2002, PROTEIN EXPRES PURIF, V25, P114, DOI 10.1006/prep.2002.1617; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Case D. A., 2002, AMBER 7; Chen CR, 2003, ENDOCRINOLOGY, V144, P1324, DOI 10.1210/en.2002-0005; Ciullo I, 2003, ENDOCRINOLOGY, V144, P3176, DOI 10.1210/en.2002-220884; Duprez L, 1997, FEBS LETT, V409, P469, DOI 10.1016/S0014-5793(97)00532-2; Enkhbayar P., 2003, PROTEIN-STRUCT FUNCT, V54, P394, DOI [10.1002/prot.10605, DOI 10.1002/PR0T.10605]; Fox KM, 2001, MOL ENDOCRINOL, V15, P378, DOI 10.1210/me.15.3.378; Gromoll J, 2003, BIOL REPROD, V69, P75, DOI 10.1095/biolreprod.102.014902; Gromoll J, 2002, EUR J ENDOCRINOL, V147, P597, DOI 10.1530/eje.0.1470597; Grossmann M, 1997, J BIOL CHEM, V272, P15532, DOI 10.1074/jbc.272.24.15532; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Ho SC, 2001, ENDOCRINOLOGY, V142, P2760, DOI 10.1210/en.142.7.2760; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; Mishra AK, 2001, J PEPT RES, V58, P17, DOI 10.1034/j.1399-3011.2001.00866.x; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nakabayashi K, 2003, MOL CELL ENDOCRINOL, V202, P139, DOI 10.1016/S0303-7207(03)00075-3; Nechamen CA, 2000, MOL CELL ENDOCRINOL, V166, P101, DOI 10.1016/S0303-7207(00)00281-1; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Sangkuhl K, 2002, J BIOL CHEM, V277, P47748, DOI 10.1074/jbc.M203491200; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Smits G, 2002, MOL ENDOCRINOL, V16, P722, DOI 10.1210/me.16.4.722; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Sudo S, 2003, J BIOL CHEM, V278, P7855, DOI 10.1074/jbc.M212457200; SWILLENS S, 1995, MOL PHARMACOL, V47, P1197; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Tanaka K, 1998, J BIOL CHEM, V273, P1959, DOI 10.1074/jbc.273.4.1959; TAYAR NE, 1996, MOL CELL ENDOCRINOL, V125, P65; Themmen APN, 2000, ENDOCR REV, V21, P551, DOI 10.1210/er.21.5.551; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; YOO JK, 1993, J BIOL CHEM, V268, P13034; ZENG HW, 1995, ENDOCRINOLOGY, V136, P2948, DOI 10.1210/en.136.7.2948; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200; Zhang R, 1996, J BIOL CHEM, V271, P5755, DOI 10.1074/jbc.271.10.5755	52	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 3	2004	279	49					51590	51600		10.1074/jbc.M404748200	http://dx.doi.org/10.1074/jbc.M404748200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	874MZ	15345720	hybrid			2022-12-25	WOS:000225355800115
J	Kani, S; Oishi, I; Yamamoto, H; Yoda, A; Suzuki, H; Nomachi, A; Iozumi, K; Nishita, M; Kikuchi, A; Takumi, T; Minami, Y				Kani, S; Oishi, I; Yamamoto, H; Yoda, A; Suzuki, H; Nomachi, A; Iozumi, K; Nishita, M; Kikuchi, A; Takumi, T; Minami, Y			The receptor tyrosine kinase Ror2 associates with and is activated by casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE ROBINOW-SYNDROME; GROWTH-FACTOR RECEPTOR; BRACHYDACTYLY TYPE-B; CATENIN DEGRADATION COMPLEX; WNT SIGNALING PATHWAY; PROTEIN-KINASE; BETA-CATENIN; MOUSE DEVELOPMENT; INSULIN-RECEPTOR; DEPENDENT DEGRADATION	Ror2, a member of the mammalian Ror family of receptor tyrosine kinases, plays important roles in developmental morphogenesis, although the mechanism underlying activation of Ror2 remains largely elusive. We show that when expressed in mammalian cells, Ror2 associates with casein kinase Iepsilon (CKIepsilon), a crucial regulator of Wnt signaling. This association occurs primarily via the cytoplasmic C-terminal proline-rich domain of Ror2. We also show that Ror2 is phosphorylated by CKIepsilon on serine/threonine residues, in its C-terminal serine/ threonine-rich 2 domain, resulting in autophosphorylation of Ror2 on tyrosine residues. Furthermore, it was found that association of Ror2 with CKIepsilon is required for its serine/ threonine phosphorylation by CKIepsilon. Site-directed mutagenesis of tyrosine residues in Ror2 reveals that the sites of phosphorylation are contained among the five tyrosine residues in the proline-rich domain but not among the four tyrosine residues in the tyrosine kinase domain. Moreover, we show that in mammalian cells, CKIepsilon-mediated phosphorylation of Ror2 on serine/ threonine and tyrosine residues is followed by the tyrosine phosphorylation of G protein-coupled receptor kinase 2, a kinase with a developmental expression pattern that is remarkably similar to that of Ror2. Intriguingly, a mutant of Ror2 lacking five tyrosine residues, including the autophosphorylation sites, fails to tyrosine phosphorylate G protein-coupled receptor kinase 2. This indicates that autophosphorylation of Ror2 is required for full activation of its tyrosine kinase activity. These findings demonstrate a novel role for CKIepsilon in the regulation of Ror2 tyrosine kinase.	Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, Kobe, Hyogo 6500017, Japan; Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Hiroshima 7348551, Japan; Osaka Biosci Inst, Osaka 5650874, Japan	Kobe University; Hiroshima University	Kani, S (corresponding author), Kobe Univ, Grad Sch Med, Fac Med Sci, Dept Genome Sci,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	kani@med.kobe-u.ac.jp	Oishi, Isao/L-8639-2018	Oishi, Isao/0000-0003-3682-5349				Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Afzal AR, 2003, HUM MUTAT, V22, P1, DOI 10.1002/humu.10233; Al-Shawi R, 2001, DEV GENES EVOL, V211, P161, DOI 10.1007/s004270100140; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Barbier AJ, 1999, J BIOL CHEM, V274, P14067, DOI 10.1074/jbc.274.20.14067; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; Cunningham ME, 1997, J BIOL CHEM, V272, P10957; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Ding YN, 2002, TRENDS BIOCHEM SCI, V27, P327, DOI 10.1016/S0968-0004(02)02137-0; Elorza A, 2003, J BIOL CHEM, V278, P29164, DOI 10.1074/jbc.M304314200; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018-002-8407-9; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GRANDE J, 1988, FEBS LETT, V232, P130, DOI 10.1016/0014-5793(88)80401-0; Hikasa H, 2002, DEVELOPMENT, V129, P5227; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Matsuda T, 2003, J BIOL CHEM, V278, P29057, DOI 10.1074/jbc.M302199200; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Nomi M, 2001, MOL CELL BIOL, V21, P8329, DOI 10.1128/MCB.21.24.8329-8335.2001; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Patton MA, 2002, J MED GENET, V39, P305, DOI 10.1136/jmg.39.5.305; Penela P, 2001, EMBO J, V20, P5129, DOI 10.1093/emboj/20.18.5129; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; ROTH RA, 1987, DIABETES, V36, P123, DOI 10.2337/diabetes.36.1.123; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sarnago S, 1999, J BIOL CHEM, V274, P34411, DOI 10.1074/jbc.274.48.34411; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Sefton M, 2000, MECH DEVELOP, V98, P127, DOI 10.1016/S0925-4773(00)00441-X; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757	49	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					50102	50109		10.1074/jbc.M409039200	http://dx.doi.org/10.1074/jbc.M409039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15375164	hybrid			2022-12-25	WOS:000225229500069
J	Mesnier, D; Baneres, JL				Mesnier, D; Baneres, JL			Cooperative conformational changes in a G-protein-coupled receptor dimer, the leukotriene B-4 receptor BLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HORMONE RECEPTORS; SPLICE VARIANT; GPCR FUNCTION; CELL-SURFACE; GB2 SUBUNITS; OLIGOMERIZATION; AGONIST; ACTIVATION; HETERODIMERIZATION	We have used an isolated receptor, the leukotriene B-4 receptor BLT1, to analyze the mechanism of receptor activation in a G-protein-coupled receptor dimer. The isolated receptor is essentially a dimer whether the agonist is present or not, provided the detergent used stabilizes the inactive dimeric assembly. We have produced a receptor mutant where Cys(97) in the third transmembrane domain has been replaced by a serine. This mutation leads to an similar to100-fold decrease in the affinity for the agonist. 5-Hydroxytryptophan has then been introduced at position 234 in the C97A mutant sixth transmembrane domain. Agonist binding to the labeled receptor is associated with variations in the fluorescence properties of 5-hydroxytryptophan due to specific agonist-induced conformational changes. The C97A mutant labeled with 5-hydroxytryptophan has then been associated with a wild-type receptor in a dimeric complex that has been subsequently purified. The purified complex activates its G-protein partner in a similar manner as the wildtype homodimer. Due to the difference in the affinity for the agonist between the wild-type and mutant protomers in this dimer, we have been able to reach a state where one of the protomers, the mutant, is in its unliganded state, whereas the other, the wild type, is loaded with the agonist. We show that agonist binding to the wild-type receptor induces specific changes in the conformation of the unliganded protomer, as evidenced by the variations in the emission of the 5-hydroxytryptophan residue in the mutant receptor. These data provide a direct demonstration for agonist-induced cooperative conformational changes in a GPCR dimer.	Fac Pharm Montpellier, CNRS, UMR 5074, F-34093 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Baneres, JL (corresponding author), Fac Pharm Montpellier, CNRS, UMR 5074, 15 Av Ch Flahault,BP 14491, F-34093 Montpellier 5, France.	jean-louis.baneres@univ-montp1.fr		Baneres, jean-louis/0000-0001-7078-1285				Baneres JL, 2003, J MOL BIOL, V329, P815, DOI 10.1016/S0022-2836(03)00439-X; Baneres JL, 2003, J MOL BIOL, V329, P801, DOI 10.1016/S0022-2836(03)00438-8; Bockaert J, 2002, INT REV CYTOL, V212, P63; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Carrillo JJ, 2003, J BIOL CHEM, V278, P42578, DOI 10.1074/jbc.M306165200; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Grosse R, 1997, MOL ENDOCRINOL, V11, P1305, DOI 10.1210/me.11.9.1305; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Karpa KD, 2000, MOL PHARMACOL, V58, P677, DOI 10.1124/mol.58.4.677; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kobilka BK, 2002, J PEPT RES, V60, P317, DOI 10.1034/j.1399-3011.2002.21062.x; Lee CW, 2002, J BIOL CHEM, V277, P15795, DOI 10.1074/jbc.M111818200; Lee SP, 2000, MOL PHARMACOL, V58, P120, DOI 10.1124/mol.58.1.120; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Milligan G, 2001, J CELL SCI, V114, P1265; Parmentier ML, 2002, TRENDS PHARMACOL SCI, V23, P268, DOI 10.1016/S0165-6147(02)02016-3; Perron A, 2003, J BIOL CHEM, V278, P27956, DOI 10.1074/jbc.M212302200; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; Poudrel JM, 1999, J MED CHEM, V42, P5289, DOI 10.1021/jm9910573; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Sillen A, 2001, SPR S FLUOR, V1, P413; Stanasila L, 2003, J BIOL CHEM, V278, P40239, DOI 10.1074/jbc.M306085200; Terrillon S, 2004, P NATL ACAD SCI USA, V101, P1548, DOI 10.1073/pnas.0305322101; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; XIE YB, 1990, J BIOL CHEM, V265, P21411	35	62	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49664	49670		10.1074/jbc.M404941200	http://dx.doi.org/10.1074/jbc.M404941200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15358776	hybrid			2022-12-25	WOS:000225229500016
J	Patnaik, SK; Potvin, B; Stanley, P				Patnaik, SK; Potvin, B; Stanley, P			LEC12 and LEC29 gain-of-function Chinese hamster ovary mutants reveal mechanisms for regulating VIM-2 antigen synthesis and E-selectin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWIS-X EXPRESSION; CHO-CELLS; ALPHA-1,3-FUCOSYL-TRANSFERASE-IX FUT9; CARBOHYDRATE LIGANDS; MOLECULAR-CLONING; GDP-FUCOSE; ADHESION; DISTINCT; GENES; TIX	LEC12 and LEC29 are two gain-of-function Chinese hamster ovary glycosylation mutants that express the Fut9 gene encoding alpha(1,3) fucosyltransferase IX (alpha(1,3) Fuc-TIX). Both mutants express the Lewis X (Le(X)) determinant Galbeta(1,4)[Fucalpha(1,3)] GlcNAc, and LEC12, but not LEC29 cells, also express the VIM-2 antigen SAalpha(2,3) Galbeta(1,4) GlcNAcbeta(1,3) Galbeta(1,4)[Fucalpha(1,3)] GlcNAc. Here we show that LEC29 cells transfected with a Fut9 cDNA express VIM-2, and thus LEC29 cells synthesize appropriate acceptors to generate the VIM-2 epitope. Semiquantitative reverse transcription-PCR showed that LEC12 has 10- to 20-fold less Fut9 gene transcripts than LEC29. However, Western analysis revealed that LEC12 has similar to20 times more Fut9 protein than LEC29. The latter finding was consistent with our previous observation that LEC12 has similar to40 times more in vitro alpha(1,3) Fuc-T activity than LEC29. The basis for the difference in Fut9 protein levels was found to lie in sequence differences in the 5'-untranslated regions (5'-UTR) of LEC12 and LEC29 Fut9 gene transcripts. Whereas reporter assays with the respective 5'-UTR regions linked to luciferase did not indicate a reduced translation efficiency caused by the LEC29 5'-UTR, transfected full-length LEC29 Fut9 cDNA or in vitro-synthesized full-length LEC29 Fut9 RNA gave less Fut9 protein than similar constructs with a LEC12 5'-UTR. This difference appears to be largely responsible for the reduced alpha(1,3) Fuc-TIX activity and lack of VIM-2 expression of LEC29 cells. This could be of physiological relevance, because LEC29 and parent Chinese hamster ovary cells transiently expressing a Fut9 cDNA were able to bind mouse E-selectin, although they did not express sialyl-LeX.	Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Stanley, P (corresponding author), Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	stanley@aecom.yu.edu		Stanley, Pamela/0000-0001-5704-3747	NCI NIH HHS [P01 CA13330, R01 CA30645] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030645] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Becker DJ, 2003, GLYCOBIOLOGY, V13, p41R, DOI 10.1093/glycob/cwg054; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; DORNER AJ, 1991, J VIROL, V65, P4713, DOI 10.1128/JVI.65.9.4713-4719.1991; Favre D, 2001, J VIROL METHODS, V92, P177, DOI 10.1016/S0166-0934(00)00285-8; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Hiraiwa N, 2003, BLOOD, V101, P3615, DOI 10.1182/blood-2002-07-2301; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; Huang MC, 2002, J BIOL CHEM, V277, P47786, DOI 10.1074/jbc.M208283200; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; Kozak M, 2002, MAMM GENOME, V13, P401, DOI 10.1007/s00335-002-4002-5; Kudo T, 2004, MOL CELL BIOL, V24, P4221, DOI 10.1128/MCB.24.10.4221-4228.2004; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kudo T, 1998, LAB INVEST, V78, P797; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; Nakayama F, 2001, J BIOL CHEM, V276, P16100, DOI 10.1074/jbc.M007272200; Nishihara S, 2003, GLYCOBIOLOGY, V13, P445, DOI 10.1093/glycob/cwg048; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; Oulmouden A, 1997, J BIOL CHEM, V272, P8764, DOI 10.1074/jbc.272.13.8764; Patnaik SK, 2000, ARCH BIOCHEM BIOPHYS, V375, P322, DOI 10.1006/abbi.1999.1693; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POTVIN B, 1991, CELL REGUL, V2, P989, DOI 10.1091/mbc.2.12.989; POTVIN B, 1990, J BIOL CHEM, V265, P1615; Shimoda Y, 2002, J BIOL CHEM, V277, P2033, DOI 10.1074/jbc.M108495200; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; Stanley P, 1996, GLYCOBIOLOGY, V6, P695, DOI 10.1093/glycob/6.7.695; STANLEY P, 1983, SOMAT CELL GENET, V9, P593, DOI 10.1007/BF01574260; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; Toivonen S, 2002, GLYCOBIOLOGY, V12, P361, DOI 10.1093/glycob/12.6.361; Zerfaoui M, 2000, EUR J BIOCHEM, V267, P53, DOI 10.1046/j.1432-1327.2000.00958.x; Zhang AM, 1999, J BIOL CHEM, V274, P10439, DOI 10.1074/jbc.274.15.10439; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	42	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 26	2004	279	48					49716	49726		10.1074/jbc.M408755200	http://dx.doi.org/10.1074/jbc.M408755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	872SU	15364956	hybrid			2022-12-25	WOS:000225229500022
J	Morii, E; Oboki, K				Morii, E; Oboki, K			MITF is necessary for generation of prostaglandin D-2 in mouse mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; MUTANT MICE; EXPRESSION; GENE; MICROPHTHALMIA; SYNTHASE-2; ACTIVATION; PHENOTYPE; RASGRP4	Mast cells generate eicosanoids that are linked to asthma and other inflammatory diseases. A basic-helix-loop-helix leucine zipper transcription factor termed MITF is essential for the development of mast cells. Although other substances also linked to inflammatory reactions ( such as various proteases and serotonin) require MITF for their expression, the role of MITF in eicosanoid generation has not been studied. We examined eicosanoid generation in bone marrow-derived mast cells (BMMCs) of tg/tg mice that lack MITF. Most eicosanoids generated by BMMCs are either prostaglandin (PG) D-2 or leukotriene C-4. The former is synthesized via the cyclooxygenase pathway, whereas the latter is synthesized via the 5-lipoxygenase pathway. In response to stimulation with IgE and antigens, BMMCs of tg/tg mice synthesized leukotriene C-4 normally. However, neither immediate nor delayed PGD(2) production was detected in these BMMCs. This indicates that MITF is a transcription factor that specifically activates the cyclooxygenase pathway, but not the 5-lipoxygenase pathway. Significant decreases in expression of hematopoietic PGD(2) synthase (hPGDS, a terminal synthase for PGD(2)) were observed at both mRNA and protein levels in tg/tg BMMCs. MITF transactivated the hPGDS gene via a CACCTG motif located in the promoter region. MITF appeared to be essential for generation of PGD(2) by enhancing expression of the hPGDS gene in BMMCs.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan	Osaka University	Morii, E (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Rm C2,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morii@patho.med.osaka-u.ac.jp	Oboki, Keisuke/AAR-1813-2020					Diaz BL, 2002, J IMMUNOL, V168, P1397, DOI 10.4049/jimmunol.168.3.1397; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Inoue H, 2000, J BIOL CHEM, V275, P28028; Ito A, 1998, BLOOD, V91, P3210, DOI 10.1182/blood.V91.9.3210.3210_3210_3221; Jippo T, 1999, BLOOD, V93, P1942, DOI 10.1182/blood.V93.6.1942.406k08_1942_1950; Kanaoka Y, 2003, PROSTAG LEUKOTR ESS, V69, P163, DOI 10.1016/S0952-3278(03)00077-2; KAWATA R, 1995, J IMMUNOL, V155, P818; Kitamura Y, 2002, MOL IMMUNOL, V38, P1173, DOI 10.1016/S0161-5890(02)00058-5; Kitamura Y, 2002, INT ARCH ALLERGY IMM, V127, P106, DOI 10.1159/000048178; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; Li LX, 2003, J BIOL CHEM, V278, P4725, DOI 10.1074/jbc.C200635200; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Morii E, 2004, BLOOD, V104, P1656, DOI 10.1182/blood-2004-01-0247; Morii E, 2001, BIOCHEM BIOPH RES CO, V289, P1243, DOI 10.1006/bbrc.2001.6077; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morii E, 1997, BLOOD, V90, P3057, DOI 10.1182/blood.V90.8.3057; Morii E, 2001, BLOOD, V97, P2038, DOI 10.1182/blood.V97.7.2038; MURAKAMI M, 1994, ANN NY ACAD SCI, V744, P84, DOI 10.1111/j.1749-6632.1994.tb52726.x; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; OBOKI K, IN PRESS AM J PATHOL; Ogihara H, 2001, BLOOD, V97, P645, DOI 10.1182/blood.V97.3.645; RAZIN E, 1982, P NATL ACAD SCI-BIOL, V79, P4665, DOI 10.1073/pnas.79.15.4665; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; Yang Y, 2002, J BIOL CHEM, V277, P25756, DOI 10.1074/jbc.M202575200	29	27	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 19	2004	279	47					48923	48929		10.1074/jbc.M407026200	http://dx.doi.org/10.1074/jbc.M407026200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	870ZP	15375155	hybrid			2022-12-25	WOS:000225098100054
J	Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D				Buscemi, G; Perego, P; Carenini, N; Nakanishi, M; Chessa, L; Chen, JJ; Khanna, K; Delia, D			Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks	ONCOGENE			English	Article						ATM; Chk2; DNA double-strand breaks; checkpoints	ATAXIA-TELANGIECTASIA; CELL-CYCLE; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; CHECKPOINT KINASE-2; DAMAGE CHECKPOINT; TUMOR-SUPPRESSOR; PROTEIN-KINASE; IN-VIVO; REPAIR	The diverse checkpoint responses to DNA damage may reflect differential sensitivities by molecular components of the damage-signalling network to the type and amount of lesions. Here, we determined the kinetics of activation of the checkpoint kinases ATM and Chk2 ( the latter substrate of ATM) in relation to the initial yield of genomic DNA single-strand (SSBs) and double-strand breaks (DSBs). We show that doses of gamma-radiation (IR) as low as 0.25 Gy, which generate vast numbers of SSBs but only a few DSBs per cell (<8), promptly activate ATM kinase and induce the phosphorylation of the ATM substrates p53 - Ser15, Nbs1 - Ser343 and Chk2 - Thr68. The full activation of Chk2 kinase, however, is triggered by treatments inflicting >19 DSBs per cell (e.g. 1 Gy), which cause Chk2 autophosphorylation on Thr387, Chk2-dependent accumulation of p21(waf1) and checkpoint arrest in the S phase. Our results indicate that, in contrast to ATM, Chk2 activity is triggered by a greater number of DSBs, implying that, below a certain threshold level of lesions (<19 DSBs), DNA repair can occur through ATM, without enforcing Chk2-dependent checkpoints.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Osped S Andrea, I-00189 Rome, Italy; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Adolescent Med, Rochester, MN 55905 USA; Queensland Inst Med Res, Mol & Cellular Biol Div, Brisbane, Qld 4006, Australia	Fondazione IRCCS Istituto Nazionale Tumori Milan; Nagoya City University; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Mayo Clinic; Mayo Clinic; Mayo Clinic; QIMR Berghofer Medical Research Institute	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	delia@istitutotumori.mi.it	Buscemi, Giacomo/ABI-1170-2020; Perego, Paola/J-7647-2016	Buscemi, Giacomo/0000-0002-8404-7142; Perego, Paola/0000-0003-2806-7269; Khanna, Kum Kum/0000-0001-8650-5381	Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Birnboim HC, 1997, J CELL BIOCHEM, V66, P219, DOI 10.1002/(SICI)1097-4644(19970801)66:2<219::AID-JCB9>3.0.CO;2-T; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brosh RM, 1999, MOL BIOL CELL, V10, P3583, DOI 10.1091/mbc.10.11.3583; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Buscemi G, 2001, MOL CELL BIOL, V21, P5214, DOI 10.1128/MCB.21.15.5214-5222.2001; CAPRANICO G, 1987, CANCER RES, V47, P3752; Chehab NH, 2000, GENE DEV, V14, P278; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Delia D, 2000, BRIT J CANCER, V82, P1938; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Girard PM, 2002, ONCOGENE, V21, P4191, DOI 10.1038/sj.onc.1205596; GOLOS B, 1991, NEOPLASMA, V38, P559; Guidarelli A, 1997, FREE RADICAL RES, V26, P537, DOI 10.3109/10715769709097825; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; HUE YK, 1994, CANCER RES, V54, P2544; Jakob B, 2003, RADIAT RES, V159, P676, DOI 10.1667/0033-7587(2003)159[0676:BIOHCT]2.0.CO;2; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KOHN KW, 1981, MEASUREMENT DNA STRA, P370; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Leroy C, 2001, EMBO J, V20, P2896, DOI 10.1093/emboj/20.11.2896; MacQueen AJ, 2001, GENE DEV, V15, P1674, DOI 10.1101/gad.902601; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; Mirzayans R, 1999, CARCINOGENESIS, V20, P941, DOI 10.1093/carcin/20.6.941; Mochan TA, 2003, CANCER RES, V63, P8586; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Perego P, 2000, INT J CANCER, V87, P343, DOI 10.1002/1097-0215(20000801)87:3<343::AID-IJC6>3.0.CO;2-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Plumb MA, 1999, INT J RADIAT BIOL, V75, P553, DOI 10.1080/095530099140195; Prise KM, 2001, RADIAT RES, V156, P572, DOI 10.1667/0033-7587(2001)156[0572:AROSOI]2.0.CO;2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Taylor AMR, 2001, BEST PRACT RES CL HA, V14, P631, DOI 10.1053/beha.2001.0158; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	63	85	93	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7691	7700		10.1038/sj.onc.1207986	http://dx.doi.org/10.1038/sj.onc.1207986			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361830				2022-12-25	WOS:000224306700010
J	Unoki, M; Nishidate, T; Nakamura, Y				Unoki, M; Nishidate, T; Nakamura, Y			ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain	ONCOGENE			English	Article						ICBP90; methyl-CpG-binding protein; HDAC1; SRA domain; E2F-1; UHRF1BP1	CELL-CYCLE; UBIQUITIN LIGASE; DOWN-REGULATION; PARTNER KAISO; PROTEIN; NP95; GENE; NIRF; TRANSCRIPTION; EXPRESSION	ICBP90, invertedCCA AT box-binding protein of 90 kDa, has been reported as a regulator of topoisomerase IIalpha expression. We present evidence here that ICBP90 binds to methyl-CpG when at least one symmetrically methylated-CpG dinucleotides is presented as its recognition sequence. A SET and RING finger-associated(SRA) domain accounts for the high binding affinity of ICBP90 for methyl-CpG dinucleotides. This protein constitutes a complex with HDAC1 also via its SRA domain, and bound to methylated promoter regions of various tumor suppressor genes, including p16(INK4A) and p14(ARF), in cancer cells. It has been reported that expression of ICBP90 was upregulated by E2F-1, and we confirmed that the upregulation was caused by binding of E2F-1 to the intron1 of ICBP90, which contains two E2F-1-binding motifs. Our data also revealed accumulation of ICBP90 in breast-cancer cells, where it might suppress expression of tumor suppressor genes through deacetylation of histones after recruitment of HDAC1. The data reported here suggest that ICBP90 is involved in cell proliferation by way of methylation-mediated regulation of certain genes.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab,Minato Ku, 4-6-1 Shiorokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Unoki, Motoko/X-3285-2019	Unoki, Motoko/0000-0002-9629-3818				Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Fujimori A, 1998, MAMM GENOME, V9, P1032, DOI 10.1007/s003359900920; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Li YY, 2004, BIOCHEM BIOPH RES CO, V319, P464, DOI 10.1016/j.bbrc.2004.04.190; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783; Miura M, 2001, EXP CELL RES, V263, P202, DOI 10.1006/excr.2000.5115; Mori T, 2004, FEBS LETT, V557, P209, DOI 10.1016/S0014-5793(03)01495-9; Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; NISHIDATE T, 2004, IN PRESS INT J ONCOL; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Shimokawa T, 2003, CANCER RES, V63, P6116; Trotzier MA, 2004, BIOCHEM BIOPH RES CO, V319, P590, DOI 10.1016/j.bbrc.2004.05.028; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2003, FEBS LETT, V554, P67, DOI 10.1016/S0014-5793(03)01092-5; Unoki M, 2003, ONCOGENE, V22, P2172, DOI 10.1038/sj.onc.1206222; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008	27	224	244	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7601	7610		10.1038/sj.onc.1208053	http://dx.doi.org/10.1038/sj.onc.1208053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15361834				2022-12-25	WOS:000224306700001
J	Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M				Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M			5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking	FASEB JOURNAL			English	Article; Proceedings Paper	8th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases	SEP, 2003	Chicago, IL			eicosanoids; mesothelioma	CANCER-THERAPY; MALIGNANT MESOTHELIOMA; LEUKOTRIENE SYNTHESIS; CELL-SURVIVAL; EXPRESSION; PROTEIN; CYCLOOXYGENASE-2; OVEREXPRESSION; BIOSYNTHESIS; LINES	5-Lipoxygenase (5-LO) promotes cancer cell proliferation and survival by unclear mechanisms. Here, we show that 5-LO expression and activity were induced by genotoxic agents in a p53-independent manner and antagonized p53- or genotoxic drug-induced apoptosis in a variety of cancer cells. 5-LO inhibited p53- governed transactivation of the pro-apoptotic genes bax and pig3 but not of p21(WAF1/CIP1) or mdm2. This may be explained by 5-LO capability to inhibit the binding of p53 to promyelocytic leukemia protein (PML) and p53 subnuclear relocalization into PML-nuclear bodies in response to genotoxic stress. Interestingly, 5-LO activity appears to be involved in nuclear retention and inactivation of wild-type p53 in malignant mesothelioma cells. In these cells, genetic or pharmacological inhibition of 5-LO enabled suppression of in vitro tumorigenicity by low doses of chemotherapeutic drugs. Together, these results uncover novel functions of 5-LO and contribute to the understanding of 5-LO involvement in tumor progression. Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors.	Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, I-60131 Ancona, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Dept Biomed Sci, Chieti, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Aging Res Ctr, Chieti, Italy; NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Marche Polytechnic University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Catalano, A (corresponding author), Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, Via Ranieri, I-60131 Ancona, Italy.	catgfp@yahoo.it	Soddu, Silvia/K-2467-2018; Procopio, Antonio Domenico/AAB-2451-2021; Soddu, Silvia/ABH-6774-2020; Romano, Mario/I-7986-2012	Soddu, Silvia/0000-0001-8526-0044; Procopio, Antonio Domenico/0000-0001-6897-8724; Soddu, Silvia/0000-0001-8526-0044; Romano, Mario/0000-0001-8512-1458				Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Catalano A, 2004, CRIT REV ONCOL HEMAT, V50, P101, DOI 10.1016/j.critrevonc.2003.10.001; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; GIACCIA AJ, 1998, GENE DEV, V14, P2015; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Hong SH, 1999, CANCER RES, V59, P2223; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Prives C, 1999, J PATHOL, V187, P112; REID GK, 1990, J BIOL CHEM, V265, P19818; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	35	102	104	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1740	+		10.1096/fj.04-2258fje	http://dx.doi.org/10.1096/fj.04-2258fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375079	Green Published			2022-12-25	WOS:000224243200022
